0001561032-21-000004.txt : 20210330 0001561032-21-000004.hdr.sgml : 20210330 20210329182853 ACCESSION NUMBER: 0001561032-21-000004 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 112 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210330 DATE AS OF CHANGE: 20210329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Healthcare Trust, Inc. CENTRAL INDEX KEY: 0001561032 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383888962 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39153 FILM NUMBER: 21782961 BUSINESS ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 212-415-6500 MAIL ADDRESS: STREET 1: 650 FIFTH AVENUE STREET 2: 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: American Realty Capital Healthcare Trust II, Inc. DATE OF NAME CHANGE: 20121025 10-K 1 hct-20201231.htm 10-K hct-20201231
00015610322020FYFALSEus-gaap:AccountingStandardsUpdate201602MemberP6M00015610322020-01-012020-12-31iso4217:USD00015610322020-06-30xbrli:shares00015610322021-03-2300015610322020-12-3100015610322019-12-31xbrli:pure00015610322019-01-012019-12-31iso4217:USDxbrli:shares0001561032us-gaap:SubsequentEventMember2021-01-152021-01-1500015610322018-01-012018-12-310001561032us-gaap:PreferredStockMember2017-12-310001561032us-gaap:CommonStockMember2017-12-310001561032us-gaap:AdditionalPaidInCapitalMember2017-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310001561032us-gaap:RetainedEarningsMember2017-12-310001561032us-gaap:ParentMember2017-12-310001561032us-gaap:NoncontrollingInterestMember2017-12-3100015610322017-12-310001561032us-gaap:CommonStockMember2018-01-012018-12-310001561032us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001561032us-gaap:ParentMember2018-01-012018-12-310001561032us-gaap:NoncontrollingInterestMember2018-01-012018-12-310001561032us-gaap:RetainedEarningsMember2018-01-012018-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-12-310001561032us-gaap:PreferredStockMember2018-12-310001561032us-gaap:CommonStockMember2018-12-310001561032us-gaap:AdditionalPaidInCapitalMember2018-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001561032us-gaap:RetainedEarningsMember2018-12-310001561032us-gaap:ParentMember2018-12-310001561032us-gaap:NoncontrollingInterestMember2018-12-3100015610322018-12-310001561032us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001561032us-gaap:ParentMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001561032srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2018-12-310001561032us-gaap:PreferredStockMember2019-01-012019-12-310001561032us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001561032us-gaap:ParentMember2019-01-012019-12-310001561032us-gaap:CommonStockMember2019-01-012019-12-310001561032us-gaap:RetainedEarningsMember2019-01-012019-12-310001561032us-gaap:NoncontrollingInterestMember2019-01-012019-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-12-310001561032us-gaap:PreferredStockMember2019-12-310001561032us-gaap:CommonStockMember2019-12-310001561032us-gaap:AdditionalPaidInCapitalMember2019-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001561032us-gaap:RetainedEarningsMember2019-12-310001561032us-gaap:ParentMember2019-12-310001561032us-gaap:NoncontrollingInterestMember2019-12-310001561032us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001561032us-gaap:ParentMember2020-01-012020-12-310001561032us-gaap:CommonStockMember2020-01-012020-12-310001561032us-gaap:RetainedEarningsMember2020-01-012020-12-310001561032us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001561032us-gaap:PreferredStockMember2020-12-310001561032us-gaap:CommonStockMember2020-12-310001561032us-gaap:AdditionalPaidInCapitalMember2020-12-310001561032us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001561032us-gaap:RetainedEarningsMember2020-12-310001561032us-gaap:ParentMember2020-12-310001561032us-gaap:NoncontrollingInterestMember2020-12-31hct:propertyhct:stateutr:sqft00015610322020-10-012020-10-0100015610322020-10-012020-12-3100015610322017-01-012017-12-3100015610322016-01-012016-12-310001561032us-gaap:LineOfCreditMember2019-01-012019-12-310001561032srt:RestatementAdjustmentMemberus-gaap:LineOfCreditMember2019-01-012019-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-03-012020-03-310001561032hct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMember2019-01-012019-12-310001561032hct:SeniorsHousingCommunitiesMember2018-01-012018-12-310001561032srt:MinimumMember2020-01-012020-12-310001561032srt:MaximumMember2020-01-012020-12-31hct:segment0001561032us-gaap:BuildingMember2020-01-012020-12-310001561032us-gaap:LandImprovementsMember2020-01-012020-12-310001561032us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2020-01-012020-12-310001561032us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2020-01-012020-12-31hct:lease0001561032us-gaap:DomesticCountryMember2020-12-310001561032us-gaap:DomesticCountryMember2018-01-010001561032hct:COVID19PandemicMember2020-01-012020-12-310001561032us-gaap:SubsequentEventMember2021-01-012021-03-190001561032us-gaap:AccountingStandardsUpdate201602Member2019-01-010001561032us-gaap:AccountingStandardsUpdate201602Member2019-01-012019-01-010001561032us-gaap:LandAndBuildingMember2019-01-012019-01-0100015610322019-01-012019-01-010001561032hct:MultitenantMOBMember2020-01-012020-12-310001561032hct:SingleTenantMOBMember2020-01-012020-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-01-012020-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-01-012019-12-310001561032us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2018-01-012018-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-01-012019-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2018-01-012018-12-310001561032us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2020-01-012020-12-310001561032us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-01-012019-12-310001561032us-gaap:AboveMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2018-01-012018-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2020-01-012020-12-310001561032us-gaap:AboveMarketLeasesMember2020-01-012020-12-310001561032hct:BelowMarketLeasesMember2020-01-012020-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2019-01-012019-12-310001561032us-gaap:AboveMarketLeasesMember2019-01-012019-12-310001561032hct:BelowMarketLeasesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2019-01-012019-12-3100015610322015-08-310001561032us-gaap:LandMember2019-12-310001561032us-gaap:ConstructionInProgressMember2019-12-310001561032hct:JupiterFloridaMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-08-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:FLhct:SkilledNursingFacilitiesMember2020-08-310001561032hct:LutzFloridaMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-08-310001561032hct:WellingtonFloridaMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-08-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:FL2020-08-310001561032hct:LutzFloridaMemberhct:SkilledNursingFacilitiesMember2020-11-012020-11-300001561032stpr:FLus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001561032stpr:FLus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-12-310001561032stpr:FLus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2018-01-012018-12-310001561032stpr:GAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2018-01-012018-12-310001561032us-gaap:GeographicConcentrationRiskMemberstpr:MIus-gaap:SalesRevenueNetMember2019-01-012019-12-310001561032us-gaap:GeographicConcentrationRiskMemberstpr:MIus-gaap:SalesRevenueNetMember2018-01-012018-12-310001561032stpr:PAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-12-310001561032stpr:PAus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2018-01-012018-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2020-12-310001561032us-gaap:LeasesAcquiredInPlaceMember2019-12-310001561032hct:IntangibleMarketLeaseAssetsMember2020-12-310001561032hct:IntangibleMarketLeaseAssetsMember2019-12-310001561032us-gaap:OtherIntangibleAssetsMember2020-12-310001561032us-gaap:OtherIntangibleAssetsMember2019-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2020-01-012020-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2019-01-012019-12-310001561032hct:DepreciationandAmortizationExpenseMemberhct:InplaceLeasesandOtherIntangibleAssetsMember2018-01-012018-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2020-01-012020-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2019-01-012019-12-310001561032hct:RentalIncomeMemberhct:AboveandBelowMarketLeasesMember2018-01-012018-12-310001561032hct:PropertyOperatingandMaintenanceExpenseMemberhct:AboveMarketGroundLeaseMember2020-01-012020-12-310001561032hct:PropertyOperatingandMaintenanceExpenseMemberhct:AboveMarketGroundLeaseMember2019-01-012019-12-310001561032hct:PropertyOperatingandMaintenanceExpenseMemberhct:AboveMarketGroundLeaseMember2018-01-012018-12-310001561032us-gaap:LeasesAcquiredInPlaceMemberhct:AmortizationExpenseMember2020-12-310001561032us-gaap:OtherIntangibleAssetsMemberhct:AmortizationExpenseMember2020-12-310001561032hct:AmortizationExpenseMember2020-12-310001561032us-gaap:AboveMarketLeasesMemberhct:RentalIncomeMember2020-12-310001561032hct:RentalIncomeMemberhct:BelowMarketLeaseMember2020-12-310001561032hct:RentalIncomeMember2020-12-310001561032hct:LutzFloridaMemberhct:SkilledNursingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-12-160001561032hct:LutzFloridaMemberhct:SkilledNursingFacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-12-162020-12-160001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-11-022020-11-020001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-11-020001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-11-022020-11-020001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2020-03-190001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2020-03-192020-03-190001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2019-08-222019-08-220001561032hct:NewYorkSixMOBs1propertyMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-08-220001561032hct:NewYorkSixMOBs1propertyMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-08-222019-08-220001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:OceanParkCenterMember2019-08-010001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberhct:OceanParkCenterMember2019-08-012019-08-010001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2019-02-062019-02-060001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-02-060001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-02-062019-02-060001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-12-310001561032us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2019-01-012019-12-310001561032hct:SNFPropertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2018-12-050001561032hct:SNFPropertiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2018-12-052018-12-050001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-12-310001561032us-gaap:RevolvingCreditFacilityMember2020-12-162020-12-160001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-11-020001561032hct:SeniorsHousingCommunitiesMember2020-11-022020-11-020001561032us-gaap:LineOfCreditMember2020-11-020001561032hct:FannieMaeMasterCreditFacilityMember2020-11-020001561032hct:UnencumberedPropertiesMember2020-11-020001561032us-gaap:SubsequentEventMemberus-gaap:LineOfCreditMember2021-01-310001561032hct:UnencumberedPropertiesMemberus-gaap:SubsequentEventMember2021-01-310001561032hct:CapitalOneFacilityMemberus-gaap:LineOfCreditMemberhct:MasterCreditFacilityMember2020-01-012020-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2020-03-192020-03-190001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2018-07-260001561032hct:NewYorkSixMOBs5propertiesMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:MedicalOfficeBuildingsMember2018-09-250001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2019-03-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2019-03-210001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2019-04-010001561032hct:SeniorsHousingCommunitiesMember2019-04-012019-06-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2019-08-010001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SkilledNursingFacilitiesMemberhct:SNFPropertiesMember2018-11-062018-11-060001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SkilledNursingFacilitiesMemberhct:SNFPropertiesMember2019-01-012019-09-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-01-012020-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2019-01-012019-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2018-01-012018-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2020-01-012020-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2019-01-012019-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2018-01-012018-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2019-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2019-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-09-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-04-300001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMemberhct:SeniorsHousingCommunitiesMember2021-01-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-01-012020-09-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:SeniorsHousingCommunitiesMember2020-01-310001561032hct:JupiterFloridaMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2019-12-310001561032stpr:FLhct:SkilledNursingFacilitiesMember2019-12-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:JupiterFloridaMember2020-06-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:FLhct:SkilledNursingFacilitiesMember2020-06-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:LutzFloridaMemberhct:SkilledNursingFacilitiesMember2020-06-300001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhct:WellingtonFloridaMemberhct:SkilledNursingFacilitiesMember2020-06-300001561032hct:LutzFloridaMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:IncomeApproachValuationTechniqueMember2020-01-012020-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberhct:WellingtonFloridaMemberus-gaap:IncomeApproachValuationTechniqueMember2020-01-012020-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberhct:JupiterFloridaMemberus-gaap:IncomeApproachValuationTechniqueMember2020-01-012020-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2019-12-310001561032hct:LaSalleTenantMember2020-12-310001561032hct:LaSalleTenantMember2020-01-012020-12-310001561032hct:LaSalleTenantMember2019-01-012019-12-310001561032hct:LaSalleTenantMember2018-01-012018-12-310001561032us-gaap:SettledLitigationMemberhct:LaSalleGuarantorvsLaSalleTenantMember2019-08-272019-08-270001561032hct:NuVistaMember2020-12-310001561032hct:NuVistaMember2019-01-012019-12-310001561032hct:NuVistaMember2018-01-012018-12-310001561032hct:NuVistaMember2020-01-012020-12-310001561032hct:CountrysideMedicalArtsSafetyHarborFLMemberus-gaap:MortgagesMember2020-12-310001561032hct:CountrysideMedicalArtsSafetyHarborFLMemberus-gaap:MortgagesMember2019-12-310001561032hct:St.AndrewsMedicalParkVeniceFLMemberus-gaap:MortgagesMember2020-12-310001561032hct:St.AndrewsMedicalParkVeniceFLMemberus-gaap:MortgagesMember2019-12-310001561032hct:PalmValleyMedicalPlazaAZMemberus-gaap:MortgagesMember2020-12-310001561032hct:PalmValleyMedicalPlazaAZMemberus-gaap:MortgagesMember2019-12-310001561032us-gaap:MortgagesMemberhct:MedicalCenterVPeoriaAZMember2020-12-310001561032us-gaap:MortgagesMemberhct:MedicalCenterVPeoriaAZMember2019-12-310001561032us-gaap:MortgagesMemberhct:CourtyardFountainsGreshamORMember2020-12-310001561032us-gaap:MortgagesMemberhct:CourtyardFountainsGreshamORMember2019-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantMemberus-gaap:MortgagesMember2020-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantMemberus-gaap:MortgagesMember2019-12-310001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2020-12-310001561032us-gaap:MortgagesMemberhct:FoxRidgeSeniorLivingatChenalLittleRockMember2019-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2020-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMemberus-gaap:MortgagesMember2019-12-310001561032us-gaap:MortgagesMember2020-12-310001561032us-gaap:MortgagesMember2019-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2017-06-300001561032hct:MOBLoanMemberus-gaap:MortgagesMember2019-12-190001561032hct:MOBLoanMemberus-gaap:MortgagesMember2019-12-200001561032hct:MOBLoanMemberus-gaap:MortgagesMemberhct:MedicalOfficeBuildingsMember2019-12-200001561032hct:MOBLoanMemberus-gaap:MortgagesMemberhct:TripleNetLeasedHealthcareFacilitiesMember2019-12-200001561032us-gaap:RevolvingCreditFacilityMemberhct:MOBLoanMemberus-gaap:MortgagesMember2019-12-202019-12-200001561032us-gaap:RevolvingCreditFacilityMemberhct:MOBLoanMemberus-gaap:MortgagesMember2019-12-200001561032us-gaap:RevolvingCreditFacilityMemberhct:MOBLoanMember2019-12-202019-12-200001561032us-gaap:LondonInterbankOfferedRateLIBORMemberhct:MOBLoanMemberus-gaap:MortgagesMember2019-12-192019-12-190001561032us-gaap:LondonInterbankOfferedRateLIBORMemberhct:MOBLoanMemberus-gaap:MortgagesMember2019-12-202019-12-20hct:instrument0001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-12-310001561032hct:MOBLoanMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2020-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2020-01-012020-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:MOBLoanMemberus-gaap:MortgagesMember2020-12-310001561032hct:MOBLoanMemberus-gaap:MortgagesMember2019-12-310001561032hct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2018-04-100001561032us-gaap:RevolvingCreditFacilityMemberhct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2018-04-102018-04-100001561032us-gaap:RevolvingCreditFacilityMemberhct:MultiPropertyCMBSLoanMemberus-gaap:MortgagesMember2018-04-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-12-310001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-12-310001561032hct:TermLoanMemberus-gaap:LineOfCreditMember2020-12-310001561032hct:TermLoanMemberus-gaap:LineOfCreditMember2019-12-310001561032us-gaap:LineOfCreditMember2020-12-310001561032us-gaap:LineOfCreditMember2019-12-310001561032hct:CapitalOneFacilityMemberus-gaap:LineOfCreditMemberhct:MasterCreditFacilityMember2020-12-310001561032hct:CapitalOneFacilityMemberus-gaap:LineOfCreditMemberhct:MasterCreditFacilityMember2019-12-310001561032us-gaap:LineOfCreditMemberhct:KeyBankFacilityMemberhct:MasterCreditFacilityMember2020-12-310001561032us-gaap:LineOfCreditMemberhct:KeyBankFacilityMemberhct:MasterCreditFacilityMember2019-12-310001561032us-gaap:LineOfCreditMemberhct:MasterCreditFacilityMember2020-12-310001561032us-gaap:LineOfCreditMemberhct:MasterCreditFacilityMember2019-12-31hct:encumbered_property0001561032hct:MasterCreditFacilityMember2020-12-310001561032hct:NewCreditFacilitiesMember2020-12-310001561032hct:UnencumberedPropertiesMember2020-12-310001561032hct:TermLoanMember2019-03-132019-03-130001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-03-130001561032hct:TermLoanMember2019-03-130001561032us-gaap:SecuredDebtMembersrt:MinimumMember2019-03-130001561032srt:MaximumMemberus-gaap:SecuredDebtMember2019-03-130001561032us-gaap:SecuredDebtMember2020-12-3100015610322020-08-100001561032hct:NewCreditFacilitiesMemberhct:DayPriorToCommencementQuarterMember2020-08-100001561032hct:DayPriorToCommencementQuarterMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMemberhct:CovenantPeriodAugust102020Membersrt:MinimumMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMembersrt:MaximumMemberhct:CovenantPeriodAugust102020Member2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:CovenantPeriodAugust102020Membersrt:MinimumMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMemberhct:CovenantPeriodAugust102020Memberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMemberhct:CommencementQuarterMembersrt:MinimumMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:LineOfCreditMembersrt:MaximumMemberhct:CommencementQuarterMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberhct:CommencementQuarterMembersrt:MinimumMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMemberhct:CommencementQuarterMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032hct:TermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhct:CovenantPeriodAugust102020Membersrt:MinimumMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberhct:CovenantPeriodAugust102020Member2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMemberhct:CovenantPeriodAugust102020Membersrt:MinimumMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMembersrt:MaximumMemberhct:CovenantPeriodAugust102020Memberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhct:CommencementQuarterMembersrt:MinimumMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberhct:CommencementQuarterMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMemberhct:CommencementQuarterMembersrt:MinimumMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:RevolvingCreditFacilityMemberhct:TermLoanMembersrt:MaximumMemberhct:CommencementQuarterMemberus-gaap:BaseRateMember2020-08-102020-08-100001561032us-gaap:LondonInterbankOfferedRateLIBORMemberhct:CommencementQuarterMembersrt:MinimumMember2020-08-100001561032us-gaap:LondonInterbankOfferedRateLIBORMemberhct:CommencementQuarterMembersrt:MaximumMember2020-08-1000015610322020-08-102020-08-100001561032hct:NewCreditFacilitiesMemberhct:CommencementQuarterMember2020-08-100001561032hct:NewCreditFacilitiesMemberhct:CommencementQuarterMembersrt:MinimumMember2020-08-102020-08-100001561032hct:CovenantPeriodJuly12020ThroughJune302021Member2020-08-102020-08-100001561032hct:CovenantPeriodFromJune302021ThroughCommencementQuarterMember2020-08-102020-08-100001561032hct:CovenantPeriodAfterCommencementQuarterMember2020-08-102020-08-100001561032hct:CovenantPeriodJuly12020ThroughMarch312021Membersrt:MinimumMember2020-08-102020-08-100001561032hct:CovenantPeriodJuly12020ThroughMarch312021Member2020-08-102020-08-100001561032hct:CovenantPeriodFromApril12021ThroughJune302021Membersrt:MinimumMember2020-08-102020-08-100001561032hct:CovenantPeriodFromApril12021ThroughJune302021Member2020-08-102020-08-100001561032hct:CovenantPeriodAfterJune302021Membersrt:MinimumMember2020-08-102020-08-100001561032hct:CovenantPeriodAfterJune302021Member2020-08-102020-08-100001561032us-gaap:LineOfCreditMember2020-08-100001561032us-gaap:LineOfCreditMember2020-08-102020-08-100001561032us-gaap:InterestRateCapMemberhct:FannieCreditFacilityMember2016-10-3100015610322019-11-010001561032us-gaap:InterestRateCapMemberhct:FannieCreditFacilityMember2019-11-010001561032hct:MasterCreditFacilityMember2020-11-012020-11-300001561032us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001561032us-gaap:FairValueMeasurementsRecurringMember2020-12-310001561032us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001561032us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001561032us-gaap:FairValueMeasurementsRecurringMember2019-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MortgagesMember2020-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMember2020-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:MortgagesMember2019-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MortgagesMember2019-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2020-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMember2020-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2019-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMember2019-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberhct:FannieCreditFacilityMember2020-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberhct:FannieCreditFacilityMember2020-12-310001561032us-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberhct:FannieCreditFacilityMember2019-12-310001561032us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:LineOfCreditMemberhct:FannieCreditFacilityMember2019-12-310001561032us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-12-310001561032us-gaap:DerivativeFinancialInstrumentsAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310001561032us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-12-310001561032us-gaap:DerivativeFinancialInstrumentsLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMember2020-12-310001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:DerivativeFinancialInstrumentsAssetsMember2019-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-10-012020-12-310001561032us-gaap:InterestExpenseMemberhct:MOBLoanMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-10-012020-12-310001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-12-310001561032us-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-12-310001561032us-gaap:InterestExpenseMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-01-012020-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-01-012019-12-310001561032us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2018-01-012018-12-310001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2020-12-310001561032us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2019-12-310001561032hct:TenderOfferMember2020-01-090001561032hct:TenderOfferMember2020-01-092020-01-0900015610322020-01-092020-01-090001561032hct:TenderOfferMember2018-03-130001561032hct:TenderOfferMember2018-03-132018-03-130001561032hct:TenderOfferMember2018-04-042018-04-1600015610322018-05-012018-05-3100015610322019-10-302019-10-3000015610322020-02-262020-02-2600015610322012-10-152019-12-3100015610322012-10-152020-12-3100015610322017-02-172017-02-1700015610322020-05-310001561032srt:MaximumMember2019-12-310001561032hct:PublicStockOfferingMember2020-12-3100015610322020-09-300001561032hct:PublicStockOfferingMember2019-12-012019-12-3100015610322019-12-012019-12-310001561032hct:PreferredStockEquityLineMember2020-09-150001561032hct:PreferredStockEquityLineMember2020-01-012020-12-310001561032hct:DelistingMember2019-01-012019-12-3100015610322013-04-012013-04-3000015610322017-04-012017-04-0100015610322018-03-012018-03-010001561032hct:ReturnofCapitalMember2020-01-012020-12-310001561032hct:ReturnofCapitalMember2019-01-012019-12-310001561032hct:ReturnofCapitalMember2018-01-012018-12-310001561032hct:CapitalGainDividendIncomeMember2020-01-012020-12-310001561032hct:CapitalGainDividendIncomeMember2019-01-012019-12-310001561032hct:CapitalGainDividendIncomeMember2018-01-012018-12-310001561032hct:OrdinaryDividendIncomeMember2020-01-012020-12-310001561032hct:OrdinaryDividendIncomeMember2019-01-012019-12-310001561032hct:OrdinaryDividendIncomeMember2018-01-012018-12-310001561032hct:SpecialLimitedPartnerMemberhct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember2020-12-310001561032hct:SpecialLimitedPartnerMemberhct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember2019-12-310001561032hct:AdvisorMemberhct:TaxDepreciationDeductionMember2020-12-310001561032hct:SecondAmendedandRestatedAdvisoryAgreementMember2017-02-172017-02-170001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2017-02-172017-02-170001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:AdvanceOnLoanOrOtherInvestmentMember2020-12-310001561032hct:SpecialLimitedPartnerMemberhct:AnnualTargetedInvestorReturnMemberhct:PreTaxNonCompoundedReturnOnCapitalContributionMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMember2020-12-310001561032hct:AdvisorMemberhct:ContractPurchasePriceMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2020-12-310001561032hct:AdvisorMember2020-01-012020-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:MonthlyBaseManagementFeeMember2020-01-012020-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:QuarterlyVariableManagementFeeBenchmarkOneMember2020-01-012020-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:QuarterlyVariableManagementFeeBenchmarkTwoMember2020-01-012020-12-310001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember2020-12-310001561032hct:AdvisorMemberhct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember2020-12-310001561032hct:AdvisorMembersrt:MaximumMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:GrossRevenueManagedPropertiesMember2020-12-310001561032hct:AmendedandRestatedPropertyManagementandLeasingAgreementMember2017-02-172017-02-170001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2020-01-012020-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2019-01-012019-12-310001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsofAdministrativeServicesMember2018-01-012018-12-310001561032hct:ConsumerPriceIndexMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:CappedReimbursementAmountMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:RealEstateCostMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ThirdAmendedAndRestatedAdvisoryAgreementMemberhct:AdvisorAndCompanyMember2019-07-252019-07-250001561032hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMemberhct:ReimbursementsOfEmployeeBonusesOfTheAdvisorMember2019-01-012019-12-310001561032hct:A2019BonusAwardsMember2020-09-300001561032hct:A2019BonusAwardsMember2020-01-012020-09-300001561032hct:SeverancePaymentsMember2020-12-310001561032hct:AcquisitionCostsReimbursementsMember2020-01-012020-12-310001561032hct:AcquisitionCostsReimbursementsMember2019-01-012019-12-310001561032hct:AcquisitionCostsReimbursementsMember2018-01-012018-12-310001561032hct:AcquisitionCostsReimbursementsMember2020-12-310001561032hct:AcquisitionCostsReimbursementsMember2019-12-310001561032hct:AssetManagementFeesMember2020-01-012020-12-310001561032hct:AssetManagementFeesMember2019-01-012019-12-310001561032hct:AssetManagementFeesMember2018-01-012018-12-310001561032hct:AssetManagementFeesMember2020-12-310001561032hct:AssetManagementFeesMember2019-12-310001561032hct:PropertyManagementAndLeasingFeesMember2020-01-012020-12-310001561032hct:PropertyManagementAndLeasingFeesMember2019-01-012019-12-310001561032hct:PropertyManagementAndLeasingFeesMember2018-01-012018-12-310001561032hct:PropertyManagementAndLeasingFeesMember2020-12-310001561032hct:PropertyManagementAndLeasingFeesMember2019-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2020-01-012020-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2019-01-012019-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2018-01-012018-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2020-12-310001561032hct:TransferAgentandOtherProfessionalFeesMember2019-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2020-01-012020-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2019-01-012019-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2018-01-012018-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2020-12-310001561032hct:ProfessionalFeesCreditDueFromAdvisorMember2019-12-310001561032hct:DistributionsOnClassBUnitsMember2020-01-012020-12-310001561032hct:DistributionsOnClassBUnitsMember2019-01-012019-12-310001561032hct:DistributionsOnClassBUnitsMember2018-01-012018-12-310001561032hct:DistributionsOnClassBUnitsMember2020-12-310001561032hct:DistributionsOnClassBUnitsMember2019-12-310001561032hct:CappedReimbursementAmountMember2020-01-012020-12-310001561032hct:CappedReimbursementAmountMember2019-01-012019-12-310001561032hct:AdvisorMemberhct:A2019BonusAwardsMember2020-12-310001561032srt:RestatementAdjustmentMemberhct:TransferAgentandOtherProfessionalFeesMember2019-01-012019-12-310001561032hct:AdvisorMemberhct:ProfessionalFeesandReimbursementsMember2019-12-310001561032hct:PropertyManagementAndLeasingFeesMemberhct:PrepaidExpensesAndOtherAssetsMember2020-01-012020-12-310001561032hct:SpecialLimitedPartnerMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMemberhct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember2020-12-310001561032hct:SpecialLimitedPartnerMemberhct:HealthcareTrustSpecialLimitedPartnershipLLCMemberhct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember2020-12-310001561032hct:TransitionFeeMember2020-01-012020-12-310001561032hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember2020-01-012020-12-310001561032hct:SubjectFeesMember2020-01-012020-12-310001561032hct:ChangeinControlFeeMember2020-01-012020-12-310001561032hct:VariableManagementIncentiveFeeMember2020-01-012020-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2020-01-012020-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2020-12-310001561032us-gaap:RestrictedStockMemberhct:AmendedandRestatedRSPMember2017-08-310001561032srt:BoardOfDirectorsChairmanMemberus-gaap:RestrictedStockMemberhct:AmendedandRestatedRSPMember2017-08-012017-08-310001561032hct:IndependentDirectorsMemberus-gaap:RestrictedStockMemberhct:AmendedandRestatedRSPMember2017-08-012017-08-310001561032srt:DirectorMemberhct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2019-07-292019-07-290001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2017-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2018-01-012018-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2018-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2019-01-012019-12-310001561032hct:RestrictedSharePlanMemberus-gaap:RestrictedStockMember2019-12-310001561032srt:DirectorMember2019-01-012019-12-310001561032srt:DirectorMember2018-01-012018-12-310001561032srt:DirectorMember2020-01-012020-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2017-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-01-012018-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2018-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-01-012019-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2019-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-01-012020-12-310001561032us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember2020-12-310001561032us-gaap:NoncontrollingInterestMember2014-11-300001561032hct:UnityPointClinicPortfolioMember2020-11-042020-11-040001561032us-gaap:NoncontrollingInterestMemberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember2020-12-310001561032us-gaap:NoncontrollingInterestMemberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember2019-12-310001561032us-gaap:NoncontrollingInterestMemberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember2020-01-012020-12-310001561032us-gaap:NoncontrollingInterestMemberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember2019-01-012019-12-310001561032us-gaap:NoncontrollingInterestMemberhct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember2018-01-012018-12-310001561032us-gaap:NoncontrollingInterestMemberhct:UnityPointClinicPortfolioMember2020-12-310001561032us-gaap:NoncontrollingInterestMemberhct:UnityPointClinicPortfolioMember2019-12-310001561032us-gaap:NoncontrollingInterestMemberhct:UnityPointClinicPortfolioMember2020-01-012020-12-310001561032us-gaap:NoncontrollingInterestMemberhct:UnityPointClinicPortfolioMember2019-01-012019-12-310001561032us-gaap:NoncontrollingInterestMemberhct:UnityPointClinicPortfolioMember2018-01-012018-12-310001561032us-gaap:RestrictedStockMember2020-01-012020-12-310001561032us-gaap:RestrictedStockMember2019-01-012019-12-310001561032us-gaap:RestrictedStockMember2018-01-012018-12-310001561032hct:OpUnitsMember2020-01-012020-12-310001561032hct:OpUnitsMember2019-01-012019-12-310001561032hct:OpUnitsMember2018-01-012018-12-310001561032hct:ClassBUnitsMember2020-01-012020-12-310001561032hct:ClassBUnitsMember2019-01-012019-12-310001561032hct:ClassBUnitsMember2018-01-012018-12-310001561032us-gaap:RestrictedStockMember2020-12-310001561032us-gaap:RestrictedStockMember2019-12-310001561032us-gaap:RestrictedStockMember2018-12-310001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember2020-12-310001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember2019-12-310001561032hct:AdvisorMemberhct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember2018-12-310001561032hct:NuVistaMemberhct:TransitionPropertyMember2019-04-010001561032hct:LaSalleTenantMember2020-07-010001561032hct:MedicalOfficeBuildingsMember2020-01-012020-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMember2020-01-012020-12-310001561032hct:MedicalOfficeBuildingsMember2019-01-012019-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMember2019-01-012019-12-310001561032hct:SeniorsHousingCommunitiesMember2019-01-012019-12-310001561032hct:MedicalOfficeBuildingsMember2018-01-012018-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMember2018-01-012018-12-310001561032hct:SeniorsHousingCommunitiesMember2018-01-012018-12-310001561032hct:MedicalOfficeBuildingsMember2020-12-310001561032hct:MedicalOfficeBuildingsMember2019-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMember2020-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMember2019-12-310001561032hct:SeniorsHousingCommunitiesMember2020-12-310001561032hct:SeniorsHousingCommunitiesMember2019-12-310001561032hct:MedicalOfficeBuildingsMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001561032hct:MedicalOfficeBuildingsMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001561032hct:MedicalOfficeBuildingsMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001561032hct:TripleNetLeasedHealthcareFacilitiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:OperatingSegmentsMember2020-01-012020-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:OperatingSegmentsMember2019-01-012019-12-310001561032hct:SeniorsHousingCommunitiesMemberus-gaap:OperatingSegmentsMember2018-01-012018-12-310001561032us-gaap:OperatingSegmentsMember2020-01-012020-12-310001561032us-gaap:OperatingSegmentsMember2019-01-012019-12-310001561032us-gaap:OperatingSegmentsMember2018-01-012018-12-3100015610322020-01-012020-03-3100015610322020-04-012020-06-3000015610322020-07-012020-09-3000015610322019-01-012019-03-3100015610322019-04-012019-06-3000015610322019-07-012019-09-3000015610322019-10-012019-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2020-10-012020-12-310001561032hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember2019-10-012019-12-310001561032us-gaap:SubsequentEventMember2021-01-042021-01-040001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMemberstpr:MIhct:SeniorsHousingCommunitiesMember2021-03-310001561032us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberstpr:MIhct:SeniorsHousingCommunitiesMember2020-10-012020-12-310001561032hct:FreseniusMedicalCareWinfieldALMember2020-12-310001561032hct:AdenaHealthCenterJacksonOHMember2020-12-310001561032hct:OuachitaCommunityHospitalWestMonroeLAMember2020-12-310001561032hct:CareMeridianLittletonCO.Member2020-12-310001561032hct:OakLawnMedicalCenterOakLawnIL.Member2020-12-310001561032hct:SurgeryCenterofTempleTempleTX.Member2020-12-310001561032hct:GreenvilleHealthSystemGreenvilleSCMember2020-12-310001561032hct:StockbridgeFamilyMedicalStockbridgeMember2020-12-310001561032hct:ArrowheadMedicalPlazaIIGlendaleMember2020-12-310001561032hct:VillageCenterParkwayStockbridgeMember2020-12-310001561032hct:CreeksideMOBDouglasvilleMember2020-12-310001561032hct:BowieGatewayMedicalCenterBowieMember2020-12-310001561032hct:CampusatCrooksAuburnBuildingDRochesterHillsMember2020-12-310001561032hct:BerwynMedicalCenterBerwynMember2020-12-310001561032hct:CountrysideMedicalArtsSafetyHarborMember2020-12-310001561032hct:St.AndrewsMedicalParkVeniceMember2020-12-310001561032hct:CampusatCrooksAuburnBuildingCRochesterHillsJuneMember2020-12-310001561032hct:LagunaProfessionalCenterElkGroveMember2020-12-310001561032hct:UCDavisMOBElkGroveMember2020-12-310001561032hct:EstateatHydeParkTampaJulyMember2020-12-310001561032hct:AutumnRidgeOfClarkstonClarkstonAugustMember2020-12-310001561032hct:SunnybrookofBurlingtonBurlingtonMember2020-12-310001561032hct:SunnybrookofCarrollCarrollAugust26Member2020-12-310001561032hct:PrairieHillsatCedarRapidsCedarRapidsAugustMember2020-12-310001561032hct:PrairieHillsatClintonClintonAugustMember2020-12-310001561032hct:PrairieHillsatDesMoinesDesMoinesAugustMember2020-12-310001561032hct:SunnybrookofFairfieldFairfieldAugust26Member2020-12-310001561032hct:SunnybrookofFt.MadisonFt.MadisonAugust26Member2020-12-310001561032hct:PrairieHillsatIndependenceIndependenceMember2020-12-310001561032hct:SunnybrookofMT.PleasantMt.PleasantAugust26Member2020-12-310001561032hct:SunnybrookofMuscatineMuscatineAugust26Member2020-12-310001561032hct:PrairieHillsatOttumwaOttumwaAugustMember2020-12-310001561032hct:PrairieHillsatTiptonTiptonAugustMember2020-12-310001561032hct:LibertyCourtDixonMember2020-12-310001561032hct:LakesideVistaHollandMember2020-12-310001561032hct:TheAtriumRockfordMember2020-12-310001561032hct:ArrowheadMedicalPlazaIGlendaleMember2020-12-310001561032hct:SunnybrookofBurlingtonLandBurlingtonAugustMember2020-12-310001561032hct:CommunityHealthMOBHarrisburgMember2020-12-310001561032hct:BradyMOBHarrisburgMember2020-12-310001561032hct:LandisMemorialHarrisburgSeptemberMember2020-12-310001561032hct:FOCIIMechanicsburgMember2020-12-310001561032hct:FOCClinicalMechanicsburgMember2020-12-310001561032hct:FOCIMechanicsburgMember2020-12-310001561032hct:CopperSpringsSeniorLivingMeridianSeptemberMember2020-12-310001561032hct:AddingtonPlaceofBrunswickBrunswickSeptemberMember2020-12-310001561032hct:AddingtonPlaceofDublinDublinSeptemberMember2020-12-310001561032hct:AllegroatElizabethtownElizabethtownSeptemberMember2020-12-310001561032hct:AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember2020-12-310001561032hct:AllegroatJupiterJupiterSeptemberMember2020-12-310001561032hct:AddingtonPlaceofLeesSummitLeesSummitSeptemberMember2020-12-310001561032hct:AddingtonPlaceatMillsRosewellMember2020-12-310001561032hct:AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember2020-12-310001561032hct:AllegroatStuartStuartSeptemberMember2020-12-310001561032hct:AllegroatTarponTarponSpringsSeptemberMember2020-12-310001561032hct:AddingtonPlaceofTitusvilleTitusvilleMember2020-12-310001561032hct:AllegroatStPetersburgLandStPetersburgSeptemberMember2020-12-310001561032hct:GatewayMedicalOfficeBuildingClarksvilleOctoberMember2020-12-310001561032hct:AddingtonatWellingtonGreenWellingtonOctoberMember2020-12-310001561032hct:DyerBuildingDyerOctoberMember2020-12-310001561032hct:A757BuildingMunsterOctoberMember2020-12-310001561032hct:A761BuildingMunsterOctoberMember2020-12-310001561032hct:A759BuildingMunsterOctoberMember2020-12-310001561032hct:ScherervilleBuildingScherervilleMember2020-12-310001561032hct:MeadowbrookSeniorLivingAgouraHillsNovemberMember2020-12-310001561032hct:MountVernonMedicalOfficeBuildingMountVernonNovemberMember2020-12-310001561032hct:WellingtonatHersheysMillWestChesterMember2020-12-310001561032hct:CareplexWestMedicalOfficeBuildingHamptonMember2020-12-310001561032hct:HamptonRiverMedicalArtsBuildingHamptonDecemberMember2020-12-310001561032hct:EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember2020-12-310001561032hct:AddingtonPlaceofAlpharettaAlpharettaMember2020-12-310001561032hct:AddingtonPlaceofPrairieVillagePrairieVillageMember2020-12-310001561032hct:BloomMOBHarrisburgDecemberMember2020-12-310001561032hct:MedicalSciencesPavilionHarrisburgDecemberMember2020-12-310001561032hct:WoodGlenNursingandRehabCenterWestChicagoDecemberMember2020-12-310001561032hct:PinnacleCenterSouthavenDecemberMember2020-12-310001561032hct:ParadiseValleyMedicalPlazaPhoenixDecemberMember2020-12-310001561032hct:VictoryMedicalCenteratCraigRanchMcKinneyMember2020-12-310001561032hct:RivershoresHealthcareRehabCentreMarseillesDecemberMember2020-12-310001561032hct:MortonTerraceHealthcareRehabCentreMortonDecemberMember2020-12-310001561032hct:MortonVillaHealthcareRehabCentreMortonMember2020-12-310001561032hct:TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember2020-12-310001561032hct:ColonialHealthcareRehabCentrePrincetonDecemberMember2020-12-310001561032hct:CapitolHealthcareRehabCentreSpringfieldDecemberMember2020-12-310001561032hct:AcuitySpecialtyHospitalMesaMember2020-12-310001561032hct:AcuitySpecialtyHospitalSunCityMember2020-12-310001561032hct:AddingtonPlaceofShoalCreekKansasCityMember2020-12-310001561032hct:AuroraHealthCenterGreenBayMember2020-12-310001561032hct:AuroraHealthcareCenterGreenvilleWIMember2020-12-310001561032hct:AuraSheboyanClinicKielMarchMember2020-12-310001561032hct:AuroraHealthcareCenterPlymouthWIMember2020-12-310001561032hct:AuroraHealthcareCenterWaterfordWIMember2020-12-310001561032hct:AuroraHealthcareCenterWautomaWIMember2020-12-310001561032hct:ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember2020-12-310001561032hct:AdvancedOrthopaedicMedicalCenterRichmondAprilMember2020-12-310001561032hct:PalmValleyMedicalPlazaGoodyearAprilMember2020-12-310001561032hct:PhysiciansPlazaofRoaneCountyHarrimanMember2020-12-310001561032hct:AdventistHealthLaceyMedicalPlazaHanfordMember2020-12-310001561032hct:MedicalCenterIPeoriaMayMember2020-12-310001561032hct:MedicalCenterIIPeoriaMayMember2020-12-310001561032hct:CommercialCenterPeoriaMayMember2020-12-310001561032hct:MedicalCenterIIIPeoriaMember2020-12-310001561032hct:MorrowMedicalCenterMorrowJuneMember2020-12-310001561032hct:BelmarMedicalBuildingLakewoodJuneMember2020-12-310001561032hct:AddingtonPlaceNorthvilleMember2020-12-310001561032hct:ConroeMedicalArtsandSurgeryCenterConroeMember2020-12-310001561032hct:MedicalCenterVPeoriaAZMember2020-12-310001561032hct:LegacyMedicalVillagePlanoMember2020-12-310001561032hct:ScrippsCedarMedicalCenterVistaAugustMember2020-12-310001561032hct:NuVistaInstituteforHealthyLivingJupiterAugustMember2020-12-310001561032hct:RamseyWoodsCudahyMember2020-12-310001561032hct:EastCoastSquareWestCedarPointOctoberMember2020-12-310001561032hct:EastCoastSquareNorthMoreheadCityOctoberMember2020-12-310001561032hct:EastsideCancerinstituteGreenvilleOctoberMember2020-12-310001561032hct:SassafrasMedicalBuildingErieMember2020-12-310001561032hct:SkyLakesKlamathMedicalClinicKlamathFallsMember2020-12-310001561032hct:CourtyardFountainsGreshamORMember2020-12-310001561032hct:PresenceHealingArtsPavilionNewLenoxDecemberMember2020-12-310001561032hct:MainlandMedicalArtsPavilionTexasCityMember2020-12-310001561032hct:RenaissanceonPeachtreeAtlantaMember2020-12-310001561032hct:FoxRidgeSeniorLivingatBryantBryantDecemberMember2020-12-310001561032hct:FoxRidgeSeniorLivingatChenalLittleRockDecemberMember2020-12-310001561032hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember2020-12-310001561032hct:AutumnLeavesofCyFairHoustonDecemberMember2020-12-310001561032hct:AutumnLeavesofMeyerlandHoustonDecemberMember2020-12-310001561032hct:AutumnLeavesofClearLakeHoustonDecemberMember2020-12-310001561032hct:AutumnLeavesoftheWoodlandsTheWoodlandsMember2020-12-310001561032hct:HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember2020-12-310001561032hct:NorthsideHospitalMedicalOfficeBuildingCantonMember2020-12-310001561032hct:WestMichiganSurgeryCenterBigRapidsMember2020-12-310001561032hct:CamelliaWalkAssistedLivingAndMemoryCareEvansMember2020-12-310001561032hct:CedarhurstofCollinsvilleMember2020-12-310001561032hct:ArcadianCoveAssistedLivingMember2020-12-310001561032hct:BeaumontMedicalCenterWarrenMember2020-12-310001561032hct:DaVitaHudsonMember2020-12-310001561032hct:DaVitaBayBreezeMember2020-12-310001561032hct:GreenfieldMedicalPlazaGilbertMember2020-12-310001561032hct:RAIClearwaterMember2020-12-310001561032hct:IllinoisCancerCareGalesburgMember2020-12-310001561032hct:UnityPointClinicMuscatineMember2020-12-310001561032hct:LeeMemorialHealthSystemOutpatientCenterFortMeyersMember2020-12-310001561032hct:DecaturMedicalOfficeBuildingMember2020-12-310001561032hct:MadisonMedicalPlazaJolietMember2020-12-310001561032hct:WoodlakeOfficeCenterMember2020-12-310001561032hct:RockwallMedicalPlazaMember2020-12-310001561032hct:MetroHealthBuckeyeHealthCenterClevelandMember2020-12-310001561032hct:UnityPointClinicMolineMember2020-12-310001561032hct:VAOutpatientClinicGalesburgMember2020-12-310001561032hct:PhilipProfessionalCenterLawrencevilleGAMember2020-12-310001561032hct:TexasChildrensHospitalHoustonMember2020-12-310001561032hct:FloridaMedicalHeartcareMember2020-12-310001561032hct:FloridaMedicalSomersetMember2020-12-310001561032hct:FloridaMedicalTampaPalmsMember2020-12-310001561032hct:FloridaMedicalWesleyChapelMember2020-12-310001561032hct:AuroraHealthCenterMilwaukeeAprilMember2020-12-310001561032hct:VascularSurgeryAssociatesMember2020-12-310001561032hct:GlendaleMOBFarmingtonHillsMIMember2020-12-310001561032hct:CrittentonWashingtonMOBMember2020-12-310001561032hct:CrittentonSterlingHeightsMOBMember2020-12-310001561032hct:AdvocateAuroraMOBElkhornWIMember2020-12-310001561032hct:PulmonaryCriticalCareMedicineAccocLemoyneMember2020-12-310001561032hct:DignityEmerusBlueDiamondRoadLasVegasMember2020-12-310001561032hct:DignityEmerusCraigRoadNorthLasVegasMember2020-12-310001561032hct:GreenfieldMOBGreenfieldMember2020-12-310001561032hct:MilwaukeeMOBSouthMilwaukeeMember2020-12-310001561032hct:StFrancisWIMOBStFrancisMember2020-12-310001561032hct:LancasterMedicalArtsMOBLancasterMember2020-12-310001561032hct:WomensHealthcareGroupMOBYorkMember2020-12-310001561032hct:PioneerSpineSportsNorthamptonMember2020-12-310001561032hct:PioneerSpineSportsSpringfieldMember2020-12-310001561032hct:PioneerSpineSportsWestSpringfieldMember2020-12-310001561032hct:FelicitaVidaEscondidoMember2020-12-310001561032hct:CedarhurstOfEdwardsvilleEdwardsvilleMember2020-12-310001561032hct:UMPCSirThomasCourtHarrisburgMember2020-12-310001561032hct:UMPCFisherRoadMechanicsburgMember2020-12-310001561032hct:SwedishAmericanMOBRoscoeMember2020-12-310001561032hct:CedarhurstOfSpartaSpartaMember2020-12-310001561032hct:UMPCChambersHillHarrisburgMember2020-12-310001561032hct:CedarhurstOfShilohShilohMember2020-12-310001561032hct:BayshoreNaplesMemoryCareNaplesMember2020-12-310001561032hct:CirclevilleMOBCirclevilleMember2020-12-310001561032us-gaap:FurnitureAndFixturesMember2020-01-012020-12-310001561032us-gaap:RevolvingCreditFacilityMemberhct:UnencumberedPropertiesMember2020-12-310001561032hct:ReclassificationFromHeldForSaleToRealEstateInvestmentsMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2020-01-012020-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
 For the fiscal year ended December 31, 2020
 or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the transition period from _________ to __________
Commission file number: 001-39153
hct-20201231_g1.jpg
Healthcare Trust, Inc.
(Exact name of registrant as specified in its charter) 
Maryland38-3888962
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
650 Fifth Ave.30th Floor, New YorkNY                 10019
______________________________________________________________________________________ _________________________________________________________________________
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (212) 415-6500
Securities registered pursuant to section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share
HTIAThe Nasdaq Global Market
Securities registered pursuant to section 12 (g) of the Act:
Common stock, $0.01 par value per share
(Title of class)
Common Share Purchase Rights
(Title of class)
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act



Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes No
There is no established public market for the registrant’s shares of common stock.
As of March 23, 2021, the registrant had 95,040,732 shares of common stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end.


HEALTHCARE TRUST, INC.

FORM 10-K
Year Ended December 31, 2020


Page

2

Forward-Looking Statements
Certain statements included in this Annual Report on Form 10-K are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of Healthcare Trust, Inc. (“we,” “our” or “us”) and members of our management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,” “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Actual results may differ materially from those contemplated by such forward-looking statements. Further, forward-looking statements speak only as of the date they are made, and we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause our actual results to differ materially from those presented in our forward-looking statements are set forth in “Risk Factors” (Part I, Item 1A of this Annual Report on Form 10-K), “Quantitative and Qualitative Disclosures about Market Risk” (Part II, Item 7A), and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (Part II, Item 7).
3

PART I
Item 1. Business
We are an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate focused on medical office buildings (“MOBs,”), healthcare properties leased on a triple net basis (“NNN properties”) and senior housing operating properties (“SHOPs”). As of December 31, 2020, we owned 193 properties located in 31 states and comprised of 9.4 million rentable square feet.
The following table summarizes our portfolio of properties as of December 31, 2020:
Asset TypeNumber of PropertiesRentable Square Feet
Gross
Asset Value (1)
Gross Asset Value %
(In thousands)
Medical office and outpatient117 3,911,937 $1,087,266 41.8 %
Total Triple-Net Leased Healthcare (including Jupiter development property)15 1,104,423 279,484 10.8 %
Seniors Housing — Operating Properties (2)
61 4,367,124 1,232,953 47.4 %
Total193 9,383,484 $2,599,703 100.0 %
________
(1)    Gross asset value represents total real estate investments, at cost ($2.6 billion total at December 31, 2020) and assets held for sale at carrying value ($0.1 million total at December 31, 2020), net of gross market lease intangible liabilities ($22.1 million total at December 31, 2020). Impairment charges are already reflected within gross asset value.
(2) Includes two land parcels.
In constructing our portfolio, we are committed to diversifying our assets by geographic region. The following table details the geographic distribution, by region, of our portfolio as of December 31, 2020:
Geographic RegionNumber of Properties
Annualized Rental Income (1)
Rentable
Square Feet
(In thousands)
Northeast19 $34,425 1,465,977 
South70 138,177 3,703,006 
Midwest74 107,586 2,735,934 
West30 43,796 1,478,567 
Total193 $323,984 9,383,484 
___________
(1)    Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2020, which includes tenant concessions such as free rent, as applicable, as well as annualized gross revenue from our SHOPs (as defined below) for the fourth quarter of 2020.
Investment Strategy
Our investment strategy is guided by three core principles: (1) maintaining a balanced, well-diversified portfolio of high-quality assets; (2) pursuing accretive and opportunistic investment opportunities; and (3) maintaining a strong and flexible capital structure.
We have invested, and expect to continue investing, primarily in MOBs and seniors housing properties, primarily structured as SHOPs. In addition, we may invest in facilities leased to hospitals, including rehabilitation hospitals including long-term acute care centers, surgery centers, inpatient rehabilitation facilities, special medical and diagnostic service providers, laboratories, research firms, pharmaceutical and medical supply manufacturers and health insurance firms. While we may invest in facilities across the healthcare continuum, our primary investment focus going forward is MOBs and SHOPs. Our SHOP investments are held through a structure permitted under the REIT Investment Diversification and Empowerment Act of 2007 ("RIDEA"). We generally acquire a fee interest in any property we acquire (a “fee interest” is the absolute, legal possession and ownership of land, property, or rights), although we may also acquire a leasehold interest (a “leasehold interest” is a right to enjoy the exclusive possession and use of an asset or property for a stated definite period as created by a written lease). We have and may continue to acquire properties through a joint venture or the acquisition of substantially all of the interests of an entity which in turn owns the real property. We also may make preferred equity investments in an entity.
4

Healthcare is the single largest industry in the United States based on contribution to Gross Domestic Product (“GDP”). According to the National Health Expenditures Projections, 2018 - 2028 report by the Centers for Medicare and Medicaid Services (“CMS”): (i) national health expenditures are projected to grow 5.2% in 2020 and at an average annual growth rate of 5.4% per year for 2019 through 2028 and (ii) the healthcare industry is projected to increase from 17.7% of U.S. GDP in 2018 to 19.7% by 2028. This growth in expenditures is projected to lead to significant growth in healthcare employment. According to the U.S. Department of Labor’s Bureau of Labor Statistics, the healthcare industry was one of the largest industries in the United States, providing approximately 19.9 million seasonally adjusted jobs as of December 31, 2020. According to the Bureau of Labor Statistics, employment of healthcare occupations (healthcare practitioners and technical occupations and healthcare support) is projected to grow 15% from 2019 to 2029, adding approximately 2.4 million new jobs. This growth is expected due to an aging population and the projected increase in the number of individuals who have access to health insurance. We believe that the continued growth in employment in the healthcare industry will lead to growth in demand for MOBs and other facilities that serve the healthcare industry.
In addition to the growth in national health expenditures and corresponding increases in employment in the healthcare sector, the nature of healthcare delivery continues to evolve due to the COVID-19 pandemic, impact of government programs, regulatory changes and consumer preferences. We believe these changes have increased the need for capital among healthcare providers and increased incentives for these providers to develop more efficient real estate solutions in order to enhance the delivery of quality healthcare.
The aging of the U.S. population has a direct effect on the demand for healthcare as older persons generally utilize healthcare services at a rate well in excess of younger people. According to the Centers for Disease Control and Prevention (the “CDC”), 7.0% of all adults aged 65 years and over during 2018 needed help with personal care from another person. For both sexes combined, adults aged 85 years and over (21.1%) were nearly three times as likely as adults aged 75 to 84 (8.0%) to need help with personal care from other persons; adults aged 85 and over were nearly six times as likely as adults aged 65 to 74 (3.9%) to need help with personal care from other persons.
We believe that the aging population, improved chronic disease management, technological advances and healthcare reform will positively affect the demand for MOBs, seniors housing properties and other healthcare-related facilities and generate attractive investment opportunities. The first wave of Baby Boomers, the largest segment of the U.S. population, began turning 65 in 2011. According to the U.S. Census Bureau, the U.S. population over 65 will grow to 85 million in 2060, up from 49 million in 2016. This group will grow more rapidly than the overall population. Thus, its share of the population will increase to 22% in 2050, from 15.2% in 2016. Patients with diseases that were once life threatening are now being treated with specialized medical care and an arsenal of new pharmaceuticals. Advances in research, diagnostics, surgical procedures, pharmaceuticals and a focus on healthier lifestyles have led to people living longer. Finally, we believe that healthcare reform in the United States will continue to drive an increase in demand for medical services, and in particular, in the post-acute and long-term services which our tenants and operators provide. We may invest in healthcare assets through development and joint venture partnerships.
As of December 31, 2020, 2019 and 2018, none of our tenants (together with their affiliates) had annualized rental income on a straight-line basis representing 10% or greater of total annualized rental income on a straight-line basis for the portfolio.
The following table lists the states where we had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:
December 31,
State202020192018
Florida (1)
20.6%25.2%16.6%
Georgia**10.1%
Michigan (2)
*10.9%13.1%
Pennsylvania10.4%*10.2%
__________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income on a straight-line basis for all portfolio properties as of the period specified.
(1)We expect to sell the recently completed development project in Jupiter, Florida, in late March or second quarter 2021 pursuant to the definitive purchase and sale agreement (“PSA”) we entered into in August 2020. In addition, in August 2020 we entered into a PSA to sell a skilled nursing facility in Wellington, Florida, which is expected to close later in 2021. The PSAs are subject to conditions and there can be no assurance we will complete these transactions, or any future acquisitions or other investments, on a timely basis or on acceptable terms and conditions, if at all. If these sales had been completed prior to December 31, 2020, Florida would have represented 10.0% of our consolidated annualized rental income on a straight-line basis.
(2)During the year ended December 31, 2020, we sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020, and four of which remained classified as held for sale on our consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer during the first quarter of 2021. As of December 31 2019 we owned 14 SHOPs located in Michigan that were classified as assets held for sale on our consolidated balance sheet. Three of the 14 properties that are still owned by us after the aforementioned sale, were reclassified
5

from held for sale to held for use in 2020. For a complete description of the Michigan SHOP transaction, see Note 3 — Real Estate Investments, Net - “Assets Held for Sale and Related Impairments” below.
Medical Office Building and Outpatient Facilities
As of December 31, 2020, we owned 117 MOBs and outpatient facilities totaling 3.9 million square feet. These facilities typically contain physicians’ offices and examination rooms, and may also include pharmacies, hospital ancillary service space and outpatient services such as diagnostic imaging centers, rehabilitation clinics and ambulatory surgery centers. These facilities can be located on or near hospital campuses and require significant plumbing, electrical and mechanical systems to accommodate diagnostic imaging equipment such as x-rays or other imaging equipment, and may also have significant plumbing to accommodate physician exam rooms. In addition, MOBs are often built to accommodate higher structural loads for certain equipment and may contain specialized construction such as cancer radiation therapy vaults for cancer treatment.
There are a variety of types of MOBs: on campus, off campus, affiliated and non-affiliated. On campus MOBs are physically located on a hospital’s campus, often on land leased from the hospital. A hospital typically creates strong tenant demand which leads to high tenant retention. Off campus properties are located independent of a hospital’s location. Affiliated MOBs may be located on campus or off campus, but are affiliated with a hospital or health system. In some respects, affiliated MOBs are similar to on campus MOBs because the hospital relationship drives tenant demand and retention. Finally, non-affiliated MOBs are not affiliated with any hospital or health system, but may contain physician offices and other healthcare services. We favor affiliated MOBs versus non-affiliated MOBs because of the relationship and synergy with the sponsoring hospital or health system and buildings not affiliated with the hospital or health system but anchored or entirely occupied by a long-tenured physician practice.
The following table reflects the on campus, off campus, affiliated and non-affiliated MOB composition of our portfolio as of December 31, 2020:
MOB ClassificationNumber of PropertiesRentable Square Feet
On Campus20 1,212,405 
Off Campus97 2,699,532 
Total
117 3,911,937 
Affiliated78 2,874,174 
Non-affiliated39 1,037,763 
Total
117 3,911,937 
Seniors Housing Properties
As of December 31, 2020, we owned 59 seniors housing properties under the RIDEA structure in our SHOP segment. Under RIDEA, a REIT may lease qualified healthcare properties on an arm’s length basis to a taxable REIT subsidiary (“TRS”) if the property is operated on behalf of such subsidiary by a person who qualifies as an eligible independent contractor. Seniors housing properties primarily consist of independent living facilities, assisted living facilities and memory care facilities. These facilities cater to different segments of the elderly population based upon their personal needs and need for assistance with the activities of daily living. Services provided by our operators or tenants in these facilities are primarily paid for by the residents directly and are less reliant on government reimbursement programs such as Medicaid and Medicare.
6

Assisted living facilities are licensed care facilities that provide personal care services, support and housing for those who need help with activities of daily living, such as bathing, eating and dressing, yet require limited medical care. The programs and services may include transportation, social activities, exercise and fitness programs, beauty or barber shop access, hobby and craft activities, community excursions, meals in a dining room setting and other activities sought by residents. Assisted living facilities are often in apartment-like buildings with private residences ranging from single rooms to large apartments. Certain assisted living facilities may offer a separate facility that provides a higher level of care for residents requiring memory care as a result of Alzheimer’s disease or other forms of dementia. Levels of personal assistance are based in part on local regulations. As of December 31, 2020, our seniors housing properties included approximately 2,437 assisted living units and 1,307 memory care units.
Independent living facilities are designed to meet the needs of seniors who choose to live in an environment surrounded by their peers with services such as housekeeping, meals and activities. These residents generally do not need assistance with activities of daily living, however, in some of our facilities, residents have the option to contract for these services. As of December 31, 2020, our seniors housing properties included 967 independent living units. However, independent living facilities on their own are not treated as qualified health care properties eligible to be leased to a TRS.
Hospitals, Post-Acute Care, Skilled Nursing and Other Facilities
Our hospitals, post-acute care, skilled nursing and other facilities are leased to tenants that provide healthcare services. As of December 31, 2020, we owned 15 other healthcare-related assets, including hospitals, post-acute care, skilled nursing, and other facilities. Hospitals can include general acute care hospitals, inpatient rehabilitation hospitals, long-term acute care hospitals and surgical and specialty hospitals. These facilities provide inpatient diagnosis and treatment, both medical and surgical, and provide a broad array of inpatient and outpatient services including surgery, rehabilitation therapy as well as diagnostic and treatment services. Post-acute facilities offer restorative, rehabilitative and custodial care for people not requiring the more extensive and complex treatment available at acute care hospitals. Ancillary revenues and revenues from sub-acute care services are derived from providing services beyond room and board and include occupational, physical, speech, respiratory and intravenous therapy, wound care, oncology treatment, brain injury care and orthopedic therapy, as well as sales of pharmaceutical products and other services. Certain facilities provide some of the foregoing services on an outpatient basis. Our post-acute care services may be provided by SNFs. SNFs offer licensed therapy services, nutrition services, social services, activities, housekeeping and laundry services, medical services prescribed by physicians and rehabilitative services to residents in need of nursing care, but who do not require hospitalization. Inpatient rehabilitation services provided by our operators and tenants in these facilities are primarily paid for by private sources or through the Medicare and Medicaid programs.
7

Impact of COVID-19 Pandemic
Starting in early March 2020, we began to implement required and voluntary preventative actions at all our seniors housing properties in our SHOP segment, including restriction of visitation except in very limited and controlled circumstances, the practice of social distancing measures, increased infection control procedures and the immediate screening of individuals entering these facilities. Some of the additional steps we have taken to address the COVID-19 pandemic include, among other things, enhanced training for staff members, the implementation of telehealth to help residents remain safe while keeping appointments with important, but non-emergency, health providers, virtual tours for potential new residents, and agreements between some of our facilities and local lab partners to provide testing services. In the absence of visitors and outside vendors and in the observance of other precautionary measures, our on-site team members and caregivers have stepped in to provide care for our residents in addition to required medical care. As with almost all senior housing providers, there have been cases of coronavirus infection among the residents and staff of our seniors housing properties but we believe the actions our SHOP segment has taken has limited those infections.
In addition, pursuant to guidelines from the Centers for Disease Control (“CDC”), health care personnel and residents of long-term care facilities, including SNFs and assisted living facilities are the highest priority group to receive COVID-19 vaccines. Since its initial classification of the highest priority group, the CDC has expanded the recommended pool of eligible vaccine recipients to include frontline essential workers and people aged 75 years and older. While the CDC guidelines are only recommendations, most states have adopted similar guidelines or otherwise identified elderly individuals as a group that should receive the vaccines first. The COVID-19 stimulus bill (the “COVID-19 Stimulus”), which has been passed by Congress and signed into law by President Biden, provides, among other things, increased funding to improve vaccine distribution. Improvements in vaccine distribution could directly affect our operations by increasing the vaccination rate amongst personnel and residents of long-term care facilities, as members of the highest priority group. The extent to which the ongoing global COVID-19 pandemic, including the outbreaks that have occurred and may occur in markets where we own properties, impacts our operations and those of our tenants and third-party operators, will depend on future developments, including the scope, severity and duration of the pandemic, the willingness of residents to remain in and enter our facilities and remain able to pay for their stays, and the actions taken to contain COVID-19 or treat its impact, the effectiveness of the vaccines and the willingness of our healthcare personnel and residents to receive the vaccines and delays in distribution of the vaccines, among others, which are highly uncertain and cannot be predicted with confidence, but could be material.
The financial impact of the COVID-19 pandemic has been partially offset by funds received under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of our SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in our consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, we received an additional $5.1 million in funds through the CARES Act. In addition, the Company has applied for additional funds for other SHOP, assisted living or similar facilities. However, those applications have not yet been approved. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.
A smaller part of our business may involve originating or acquiring loans secured by or related to the same types of properties in which we may invest directly. Likewise, we may invest in commercial mortgage-backed securities (“CMBS”), securities of publicly-traded and private companies primarily engaged in real estate businesses, including REITs and other real estate operating companies, and securities issued by pass-through entities of which substantially all of the assets consist of qualifying assets or real estate-related assets. As of December 31, 2020, we do not own any assets of this type.
Organizational Structure
Substantially all of our business is conducted through Healthcare Trust Operating Partnership, L.P. (the “OP”), a Delaware limited partnership, and its wholly owned subsidiaries. Our Advisor manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”) (the “Property Manager”). Our Advisor and Property Manager are under common control with AR Global Investments LLC (“AR Global”) and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in us through ownership of interests in our OP.
We own our SHOPs through the RIDEA structure, pursuant to which, a REIT may lease “qualified healthcare properties” on an arm’s length basis to a TRS if the property is operated on behalf of such subsidiary by a person who qualifies as an “eligible independent contractor.” We view this as a structure primarily to be used on properties that present attractive valuation entry points with long term growth prospects or drive growth by: (i) transitioning the asset to a new third-party operator that can bring scale, operating efficiencies, or ancillary services; or (ii) investing capital to reposition the asset.
Financing Strategies and Policies
We utilize a combination of debt and equity to fund our investment activity. Our debt and equity levels are determined by management in consultation with the Board. For short-term purposes, we may borrow from our revolving credit facility (our
8

“Revolving Credit Facility”) and our Fannie Mae Master Credit Facilities, which include a secured credit facility (the “KeyBank Facility”) with KeyBank together with a secured credit facility (the “Capital One Facility”) with Capital One Multifamily Finance, LLC, an affiliate of Capital One, National Association (the Capital One Facility and the KeyBank Facility are referred to herein individually as a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Our senior secured credit facility (our “Credit Facility”) consists of two components, our Revolving Credit Facility and our term loan (our “Term Loan”). Our Credit Facility is secured by a pledged pool of the equity interests and related rights in wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base thereunder. As of December 31, 2020, the Fannie Mae Master Credit Facilities are secured by mortgages on 21 properties, in aggregate. We may seek and even replace current borrowings with longer-term capital such as senior secured or unsecured notes or other forms of long-term financing. We may invest in properties subject to existing mortgage indebtedness, which we assume as part of the acquisition. In addition, we may obtain financing secured by previously unencumbered properties in which we have invested or may refinance properties acquired on a leveraged basis. In our agreements with our lenders, we are subject to restrictions with respect to secured and unsecured indebtedness, including restrictions on permitted investments, distributions and maintenance of a maximum leverage ratio, among other things. As of December 31, 2020, our total debt leverage ratio (net debt divided by gross asset value) was approximately 44.5%. Net debt totaled $1.2 billion, which represents gross debt ($1.2 billion) less cash and cash equivalents ($72.4 million). Gross asset value totaled $2.6 billion, which represents total real estate investments, at cost ($2.6 billion) and assets held for sale at carrying value ($0.1 million), net of gross market lease intangible liabilities ($22.1 million). Impairment charges are already reflected within gross asset value.
Tax Status
We elected to be taxed as a REIT under Sections 856 through 860 of Internal Revenue Code of 1986, as amended (the “Code”), commencing with our taxable year ended December 31, 2013. Commencing with that taxable year, we have been organized and operated in a manner so that we qualify as a REIT under the Code. We intend to continue to operate in such a manner, but can provide no assurance be given that we will operate in a manner so as to remain qualified as a REIT. To continue to qualify as a REIT, we must, among other things, distribute at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with accounting principles generally accepted in the United States (“GAAP”)), determined without regard to the deduction for dividends paid and excluding net capital gains, and must comply with a number of other organizational and operational requirements. If we continue to qualify as a REIT, we generally will not be subject to U.S. federal corporate income tax on the portion of our REIT taxable income that we distribute to our stockholders. Even if we continue to qualify for taxation as a REIT, we may be subject to certain state and local taxes on our income and properties as well as U.S. federal income and excise taxes on our undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties. Generally, to qualify as a REIT, we cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS. Accordingly, we have formed a TRS that is wholly owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf. As of December 31, 2020, we owned 59 seniors housing properties, excluding two land parcels, which we lease to our TRS. The TRS is a wholly-owned subsidiary of the OP.
Competition
The market for MOBs, seniors housing and other healthcare-related real estate is highly competitive. We compete in all of our markets based on a number of factors that include location, rental rates, security, suitability of the property’s design to prospective tenants’ needs and the manner in which the property is operated and marketed. In addition, we compete with other entities engaged in real estate investment activities to locate suitable properties to acquire, tenants to occupy our properties and purchasers to buy our properties. These competitors include other REITs, private investment funds, specialty finance companies, institutional investors, pension funds and their advisors and other entities. There are also other REITs with asset acquisition objectives similar to ours, and others may be organized in the future. Some of these competitors, including larger REITs, have substantially greater marketing and financial resources than we have and generally may be able to accept more risk than we can prudently manage, including risks with respect to the creditworthiness of tenants. In addition, these same entities seek financing through similar channels.
Healthcare Regulation
Overview
The healthcare industry is one of the most regulated industries in the United States and is currently experiencing rapid regulatory change and uncertainty. The regulatory uncertainty and the potential impact on our tenants and operators could have an adverse material effect on their ability to satisfy their contractual obligations.    
9

Our tenants and operators must comply with a wide range of complex federal, state, and local laws and regulations, and the healthcare industry, in general, is the subject to increased enforcement and penalties in all areas. Fraud and abuse continues to be an enforcement priority at both the federal and state levels including, but not limited to, the Federal Anti-Kickback Statute, the Federal Physician Self-Referral Statute (commonly known as the “Stark Law”), the False Claims Act (“FCA”), the Civil Monetary Penalties Law (“CMPL”), and a range of other federal and state regulations relating to waste, cost control, and healthcare management. The business and operations of our tenants and therefore our business could be materially impacted by, among other things, a significant expansion of applicable federal, state or local laws and regulations, continued judicial and legislative changes to the ACA, future attempts to reform healthcare, new interpretations of existing laws and regulations, and changes or increased emphasis on certain enforcement priorities. Additionally, the ongoing political and legal challenges to the Patient Protection and Affordable Care Act (the “Affordable Care Act” or “ACA”) leave its future uncertain.
Our tenants and operators are subject to extensive federal, state, and local laws, regulations and industry standards which govern business operations, physical plant and structure, patient and employee health and safety, access to facilities, patient rights - including privacy, price transparency, fewer restrictions on access to care - and security of health information. Our tenants’ and operators’ failure to comply with any of these laws could result in loss of licensure, denial of reimbursement, imposition of fines or other penalties, suspension or exclusion from the government sponsored Medicare and Medicaid programs, loss of accreditation or certification, reputational damage or closure of a facility. In addition, both government and private third-party payors will likely continue their efforts to drive down reimbursement. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. Examples include, but are not limited to, changes in reimbursement rates and methodologies such as bundled payments, capitation payments, and discounted fee structures. Our tenants and operators may also face significant limits on the scope of services reimbursed and on reimbursement rates and fees. All of these changes could impact our operators’ and tenants’ ability to pay rent or other obligations to us.
Licensure, Certification and Certificate of Need
Our tenants operate hospitals, assisted living facilities, skilled nursing facilities and other healthcare facilities that receive reimbursement for services from third-party payors, including the government sponsored Medicare and Medicaid programs and private insurance carriers. To participate in the Medicare and Medicaid programs, operators of healthcare facilities must comply with the regulations previously referenced, as well as with licensing, certification and, in some states, with certificate of need (“CON”) requirements. Licensing and certification requirements also subject our tenants to compliance surveys and audits which are critical to the ongoing operations of the facilities.
In granting and renewing these licenses and certifications, the state regulatory agencies consider numerous factors relating to a facility’s operations, including, but not limited to, the plant and physical structure, admission and discharge standards, staffing, training, patient and consumer rights, medication guidelines and other rules. If an operator fails to maintain or renew any required license, certification or other regulatory approval, or to correct serious deficiencies identified in compliance surveys, the operator could be prohibited from continuing operations at a facility.
A loss of licensure or certification, as well as a change in participation status, could also adversely affect an operator’s ability to receive payments from the Medicare and Medicaid programs, which, in turn, could adversely affect the operator’s ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases with us. In addition, if we have to replace an operator, we may experience difficulties in finding a replacement because our ability to replace the operator may be affected by federal and state laws governing changes in control and ownership.
Similarly, in order to receive Medicare and Medicaid reimbursement, our healthcare facilities must meet the applicable conditions of participation established by the U.S. Department of Health and Human Services (“HHS”)relating to the type of facility and its equipment, personnel and standard of medical care, as well as comply with other federal, state and local laws and regulations. Healthcare facilities undergo periodic on-site licensure surveys, which generally are limited if the facility is accredited by The Joint Commission or other recognized accreditation organizations. A loss of licensure or certification could adversely affect a facility’s ability to receive payments from the Medicare and Medicaid programs, which, in turn, could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with, the terms of the operator’s or facility’s leases with us.
In some states, healthcare facilities are subject to various state CON laws requiring governmental approval prior to the development or expansion of healthcare facilities and services. The approval process in these states generally requires a facility to demonstrate the need for additional or expanded healthcare facilities or services. CONs, where applicable, can also be conditions to regulatory approval of changes in ownership or control of licensed facilities, addition of beds, investment in major capital equipment, introduction of new services, termination of services previously approved through the CON process and other control or operational changes.
10

CON laws and regulations may restrict an operator’s ability to expand properties and grow the operator’s business in certain circumstances, which could have an adverse effect on the operator’s or tenant’s revenues and, in turn, negatively impact their ability to make rental payments under, and otherwise comply with the terms of their leases with us.
Fraud and Abuse Enforcement
Various federal and state laws and regulations are aimed at actions that may constitute fraud and abuse by healthcare entities and providers who participate in, submit or cause to be submitted claims for payment to, or make or receive referrals in connection with government-funded healthcare programs, including Medicare and Medicaid. The federal laws include, for example, the following:
The Federal Anti-Kickback Statute (42 USC Section 1320a-7b(b) of the Social Security Act) which prohibits the knowing and willful solicitation, offer, payment or acceptance of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind in return for: (i) referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal health care program; or (ii) purchasing, leasing, ordering, or arranging for or recommending purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in party under a federal health care program;
The Stark Law (42 USC Section 1395nn), which prohibits referrals by physicians of Medicare patients to providers of a broad range of designated healthcare services in which the physicians (or their immediate family members) have ownership interests or certain other financial arrangements, unless an exception applies, and prohibits the designated health services entity from submitting claims to Medicare for those services resulting from a prohibited referral;
The FCA (13 USC Sections 3729-3733) creates liability for any person who submits a false claim to the government or causes another to submit a false claim to the government or knowingly makes a false record or statement to get a false claim paid by the government. In what is known as reverse false claims, the FCA imposes liability where a person acts improperly to avoid having to pay money to the government. The FCA also creates liability for people who conspire to violate the FCA; and
The CMPL (42 USC 1320a-7a for healthcare) authorizes HHS to impose civil penalties administratively for fraudulent acts. The scope of the Office of the Inspector General’s authority to enforce the CMPL was increased in 2016.
Courts have interpreted the fraud and abuse laws broadly. Sanctions for violating these federal laws include substantial criminal and civil penalties such as punitive sanctions, damage assessments, monetary penalties, imprisonment, denial of Medicare and Medicaid payments, and exclusion from the Medicare and Medicaid programs. These laws also impose an affirmative duty on operators to ensure that they do not employ or contract with persons excluded from the Medicare and other government programs. Many states have adopted laws similar to, or more expansive than, the federal fraud and abuse laws. States have also adopted and are enforcing laws that increase the regulatory burden and potential liability of healthcare entities including, but not limited to, patient protections, such as minimum staffing levels, criminal background checks, sanctions for employing excluded providers, restrictions on the use and disclosure of health information, and these state laws have their own penalties which may be in addition to federal penalties.
In the ordinary course of their business, the operators at our properties are regularly subject to inquiries, audits and investigations conducted by federal and state agencies that oversee applicable laws and regulations. Increased funding for investigation and enforcement efforts, accompanied by an increased pressure to eliminate government waste, has led to a significant increase in the number of investigations and enforcement actions over the past several years, a trend which is not anticipated to decrease considerably. Significant enforcement activity has been the result of actions brought by regulators, who file complaints in the name of the United States (and, if applicable, particular states) under the FCA or equivalent state statutes. Also, the qui tam and whistleblower provisions of the FCA allow private individuals to bring actions on behalf of the government alleging that the government was defrauded. Individuals have tremendous potential financial gain in bringing whistleblower claims as the statute provides that the individual will receive a portion of the money recouped. Additionally, violations of the FCA can result in treble damages.
Violations of federal or state law or FCA actions against an operator of our properties could have a material adverse effect on the operator’s liquidity, financial condition or results of operations. Such a negative impact on an operator’s financial health could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases and other agreements with us. Federal and state fraud and abuse laws may also restrict the terms of our rental agreements with our tenants.
Privacy and Security of Health Information
Various federal and state laws protect the privacy and security of health information. For example, the Health Insurance Portability and Accountability Act of 1996, its implementing regulations and related federal laws and regulations (commonly referred to as “HIPAA”) protect the privacy and security of individually identifiable health information by limiting its use and disclosure. Many states have implemented similar laws to limit the use and disclosure of patient specific health information.
11

The federal government has increased its HIPAA enforcement efforts over the past few years, which has increased the number of audits and enforcement actions, some of which have resulted in significant penalties to healthcare providers. For example, in October 2018, Anthem, Inc. agreed, in addition to implementing various corrective measures, to pay a record $16 million to HHS’s Office for Civil Rights in settlement of HIPAA violations stemming from the largest healthcare data breach in United States history. Violations of federal and state privacy and security laws could have a material adverse effect on the operator’s financial condition or operations, which could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, its leases and other agreements with us.
Reimbursement
We and our tenants derive a large portion of our revenues from insurance payments with the remainder coming from Medicare and Medicaid reimbursement and private pay. The reimbursement methodologies for healthcare facilities are constantly changing and federal and state authorities may implement new or modified reimbursement methodologies that may negatively impact healthcare operations. For example, the ACA enacted certain reductions in Medicare reimbursement rates for various healthcare providers, as well as certain other changes to Medicare payment methodologies.
The ACA has faced ongoing legal challenges, including litigation seeking to invalidate some or all of the law or the manner in which it has been interpreted. The uncertain status of the ACA and of the state Medicaid programs, among other things, affect our ability to plan for the future.
Federal and state budget pressures also continue to escalate and, in an effort to address actual or potential budget shortfalls, Congress and many state legislatures may continue to enact reductions to Medicare and Medicaid expenditures through cuts in rates paid to providers or restrictions in eligibility and benefits.
In addition to legislative and executive actions relating to the scope of the ACA, increased enforcement will likely continue to impact the financial framework for healthcare operators and facilities. For example, CMS is focused on reducing what it considers to be payment errors by identifying, reporting, and implementing actions to reduce payment error vulnerabilities. In November 2020, CMS announced its successes in reducing the 2020 Medicare improper payment rate and specifically called out the successes of its actions to address improper payments in home health and SNF claims.
In addition, CMS is currently in the midst of transitioning Medicare from a traditional fee for service reimbursement model to a capitated system, which means medical providers are given a set fee per patient regardless of treatment required, and value-based and bundled payment approaches, where the government pays a set amount for each beneficiary for a defined period of time, based on that person’s underlying medical needs, rather than based on the actual services provided. Providers and facilities are increasingly responsible to care for and be financially responsible for certain populations of patients under the population health models and this shift in patient management paradigm is creating and will continue to create unprecedented challenges for providers.
Another notable Medicare health care reform initiative, the Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”), permanently repealed the Sustainable Growth Rate formula, and provided for an annual rate increase of 0.5% for physicians through 2019, but imposed a six-year freeze on fee updates from 2020 through 2025. MACRA established a new payment framework, called the Quality Payment Program, which modified certain Medicare payments to “eligible clinicians,” including physicians, dentists, and other practitioners. MACRA represents a fundamental change in physician reimbursement. The implications of MACRA continue to be uncertain and will depend on future regulatory activity and physician activity in the marketplace. MACRA reporting requirements and quality metrics may encourage physicians to move from smaller practices to larger physician groups or hospital employment, leading to further consolidation of the industry. These and other shifts in payment and risk sharing within an outcome-based model are leading to, among other trends, increasing use of management tools to oversee individual providers and coordinate their services. The focus on utilization puts downward pressure on the number and expense of services provided as payors are moving away from a fee for service model. The continued trend toward capitated, value-based, and bundled payment approaches has the potential to diminish the market for certain healthcare providers, particularly specialist physicians and providers of particular diagnostic technologies. This could adversely impact the medical properties that house these physicians and medical technology providers.
In addition, on July 31, 2020, CMS announced a final rule that projects increased aggregate Medicare payments to SNF by 2.2 percent for fiscal year 2021. If payments under Medicare to our tenants do not continue or increase, our tenants may have difficulty making rent payments to us.
Under a program facilitated by the CMS known as the Skilled Nursing Facility Value-Based Purchasing Program, CMS began withholding 2% of SNF Medicare payments beginning October 1, 2018, to fund an incentive payment pool. CMS then redistributes 50-70% of the withheld payments back to high performing SNFs. The lowest ranked 40% of facilities receive payments that are less than what they otherwise would have received without the program. As a result, certain of our tenants could receive less in Medicare reimbursement payments, which could adversely affect their ability to make rent payments to us.
Effective October 1, 2019, CMS finalized a new case-mix classification system, the Patient-Driven Payment Model (“PDPM”). PDPM classifies SNF patients in Medicare Part A-covered stays into payment groups based on clinically relevant factors using diagnosis codes, rather than by the volume of services. This shifts the focus from the amount of care provided to
12

instead use the patient’s condition and resulting care needs to determine Medicare reimbursement. Future changes to payment rates or methodology under the PDPM system could reduce the reimbursement our tenants receive. For example, CMS has indicated that it is working toward a unified payment system for post-acute care services, including those provided by SNFs, home health agencies, and other long-term care providers.
Certain of our facilities are also subject to periodic pre- and post-payment reviews and other audits by governmental authorities, which could result in recoupments, denials, or delay of payments. Additionally, the introduction and explosion of new stakeholders competing with traditional providers in the health market, including companies such as Amazon.com Inc., JPMorgan Chase & Co., Apple Inc., CVS Health Corporation, as well as telemedicine, telehealth and mhealth, are disrupting the heath industry and could lead to new trends in payment. All of the factors discussed-recoupment of past payments or denial or delay of future payments-could adversely affect an operator’s ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of its leases and other agreements with us. Assisted and independent living services generally are not reimbursable under government reimbursement programs, such as Medicare and Medicaid. Most of the resident fee revenues generated by our SHOPs, therefore, are derived from private pay sources consisting of the income or assets of residents or their family members. The rates for these residents are set by the facilities based on local market conditions and operating costs.
We regularly assess the financial implications of reimbursement rule changes on our tenants, but we cannot assure you that current rules or future updates will not materially adversely affect our operators and tenants, which, in turn, could have a material adverse effect on their ability to pay rent and other obligations to us. See Item 1A. “Risk Factors — Risks Related to the Healthcare Industry — Reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid, or delays in receiving these reimbursements could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us” and “— A reduction in Medicare payment rates for skilled nursing facilities may have an adverse effect on the Medicare reimbursements received by certain of our tenants.”
Other Regulations
Our investments are subject to various federal, state and local laws, ordinances and regulations, including, among other things, the Americans with Disabilities Act of 1990, zoning regulations, land use controls, environmental controls relating to air and water quality, noise pollution and indirect environmental impacts such as increased motor vehicle activity. We believe that we have all permits and approvals necessary under current law to operate our investments.
Environmental Regulations
As an owner of real property, we are subject to various federal, state and local laws and regulations regarding environmental, health and safety matters. These laws and regulations address, among other things, asbestos, polychlorinated biphenyls, fuel, oil management, wastewater discharges, air emissions, radioactive materials, medical wastes, and hazardous wastes, and in certain cases, the costs of complying with these laws and regulations and the penalties for non-compliance can be substantial. Even with respect to properties that we do not operate or manage, we may be held primarily or jointly and severally liable for costs relating to the investigation and clean-up of any property from which there is or has been an actual or threatened release of a regulated material and any other affected properties, regardless of whether we knew of or caused the release. Such costs typically are not limited by law or regulation and could exceed the property’s value. In addition, we may be liable for certain other costs, such as governmental fines and injuries to persons, property or natural resources, as a result of any such actual or threatened release.
Under the terms of our lease and management agreements, we generally have a right to indemnification by the tenants, operators and managers of our properties for any contamination caused by them. However, we cannot assure you that our tenants, operators and managers will have the financial capability or willingness to satisfy their respective indemnification obligations to us, and any such inability or unwillingness to do so may require us to satisfy the underlying environmental claims.
We did not make any material capital expenditures in connection with environmental, health, and safety laws, ordinances and regulations in 2020 and do not expect that we will be required to make any such material capital expenditures during 2021.
Human Capital Resources
We are an externally managed company and thus have no employees. We have retained the Advisor pursuant to a long-term advisory contract to manage our affairs on a day-to-day basis. We have also entered into agreements with our Property Manager to manage and lease our properties. The employees of the Advisor, Property Manager, and their respective affiliates perform a full range of services for us, including acquisitions, property management, accounting, legal, asset management, investor relations and all general administrative services. We depend on the Advisor and the Property Manager for services that are essential to us. If the Advisor and the Property Manager were unable to provide these services to us, we would be required to provide these services ourselves or obtain them from other sources.
Estimate of Net Asset Value
On April 3, 2020, we published a new estimate of per share asset value (“Estimated Per-Share NAV”) equal to $15.75 as of December 31, 2019. Our previous Estimated Per-Share NAV was equal to $17.50 as of December 31, 2018. Unlike the per
13

share amounts in this Annual Report on Form 10-K, the Estimated Per-Share NAV has not been retroactively adjusted to reflect the payment of dividends in the form of common stock and will not be adjusted for stock dividends paid or that may be paid in the future until the Board determines a new Estimated Per-Share NAV which is expected in early April 2021. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, each stockholder will receive the same number of new shares, the total value of our common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of board of directors (the “Board”), provided that such estimates will be made at least once annually.
Available Information
We electronically file annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and all amendments to those filings with the Securities and Exchange Commission (“SEC”). You may read and copy any materials we file with the SEC at the SEC’s Internet address located at http://www.sec.gov. The website contains reports, proxy statements and information statements, and other information, which you may obtain free of charge. In addition, copies of our filings with the SEC may be obtained from our website www.healthcaretrustinc.com. Access to these filings is free of charge. We are not incorporating our website or any information from these websites into this Annual Report on Form 10-K.

14

Item 1A. Risk Factors
Set forth below are the risk factors that we believe are material to our investors and a summary thereof. The occurrence of any of the risks discussed in this Annual Report on Form 10-K could have a material adverse effect on our business, financial condition, results of operations and ability to pay dividends and they may also impact other distributions and the value of an investment in our common and preferred stock.
Summary Risk Factors
Our operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market in general.
Our property portfolio has a high concentration of properties located in Pennsylvania and Florida. Our properties may be adversely affected by economic cycles and risks inherent to those states.
Our Credit Facility restricts us from paying cash distributions on or repurchasing our common stock until at least the fiscal quarter ending June 30, 2021, and there can be no assurance we will be able to resume paying distributions on our common stock, and at what rate, or continue paying dividends on our 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (the “Series A Preferred Stock”) at the current rate.
Our Credit Facility restricts our ability to use cash that would otherwise be available to us, and there can be no assurance our available liquidity will be sufficient to meet our capital needs.
We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic, including negative impacts on our tenants and operators and their respective businesses.
No public market currently exists, or may ever exist, for shares of our common stock and our shares are, and may continue to be, illiquid.
In owning properties we may experience, among other things, unforeseen costs associated with complying with laws and regulations and other costs, potential difficulties selling properties and potential damages or losses resulting from climate change.
We focus on acquiring and owning a diversified portfolio of healthcare-related assets located in the United States and are subject to risks inherent in concentrating investments in the healthcare industry.
The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of tenants to make lease payments to us.
We depend on tenants for our rental revenue and, accordingly, our rental revenue is dependent upon the success and economic viability of our tenants. If a tenant or lease guarantor declares bankruptcy or becomes insolvent, we may be unable to collect balances due under relevant leases.
We assume additional operational risks and are subject to additional regulation and liability because we depend on eligible independent contractors to manage some of our facilities.
We have substantial indebtedness and may be unable to repay, refinance, restructure or extend our indebtedness as it becomes due. Increases in interest rates could increase the amount of our debt payments. We may incur additional indebtedness in the future.
We depend on the Advisor and Property Manager to provide us with executive officers, key personnel and all services required for us to conduct our operations.
All of our executive officers face conflicts of interest, such as conflicts created by the terms of our agreements with the Advisor and compensation payable thereunder, conflicts allocating investment opportunities to us, and conflicts in allocating their time and attention to our matters. Conflicts that arise may not be resolved in our favor and could result in actions that are adverse to us.
We have long-term agreements with our Advisor and its affiliates that may be terminated only in limited circumstances and may require us to pay a termination fee in some cases.
Estimated Per-Share NAV may not accurately reflect the value of our assets and may not represent what a stockholder may receive on a sale of the shares, what they may receive upon a liquidation of our assets and distribution of the net proceeds or what a third party may pay to acquire us.
The stockholder rights plan adopted by our board of directors, our classified board and other aspects of our corporate structure and Maryland law may discourage a third party from acquiring us in a manner that might result in a premium price to our stockholders.
Restrictions on share ownership contained in our charter may inhibit market activity in shares of our stock and restrict our business combination opportunities.
15

We may fail to continue to qualify as a REIT.

Risks Related to Our Properties and Operations

Our property portfolio has a high concentration of properties located in two states. Our properties may be adversely affected by economic cycles and risks inherent to those states.

The following two states represented 10% or more of our consolidated annualized rental income on a straight-line basis for the fiscal year ended December 31, 2020:
State
Percentage of Straight-Line Rental Income
Florida (1)
20.6%
Pennsylvania
10.4%
(1) During the fourth quarter of 2020, we completed the sale of our skilled nursing facility (“SNF”) in Lutz, Florida and we expect to sell the recently completed development project in Jupiter, Florida, in late March or second quarter 2021. In addition, in August 2020 we entered into an agreement to sell our skilled nursing facility in Wellington, Florida, which is expected to close later in 2021.

Any adverse situation that disproportionately affects the states listed above may have a magnified adverse effect on our portfolio. Real estate markets are subject to economic downturns, as they have been in the past, and we cannot predict how economic conditions will impact this market in both the short and long-term. Declines in the economy or a decline in the real estate market in these states could hurt our financial performance and the value of our properties. Factors that may negatively affect economic conditions include:
business layoffs or downsizing;
industry slowdowns;
relocations of businesses;
climate change;
changing demographics;
increased telecommuting and use of alternative workplaces;
infrastructure quality;
any oversupply of, or reduced demand for, real estate;
concessions or reduced rental rates under new leases for properties where tenants defaulted;
increased insurance premiums;
state budgets and payment to providers under Medicaid or other state healthcare programs; and
changes in reimbursement for healthcare services from commercial insurers.
We may be unable to enter into contracts for and complete property acquisitions on advantageous terms or our property acquisitions may not perform as we expect.
One of our goals is to grow through acquiring additional properties, and pursuing this investment objective exposes us to numerous risks, including:
competition from other real estate investors with significant capital resources;
we may acquire properties that are not accretive;
we may not successfully manage and lease the properties we acquire to meet our expectations or market conditions may result in future vacancies and lower-than expected rental rates;
we expect to finance future acquisitions primarily with additional borrowings under our Revolving Credit Facility, and there can be no assurance as to how much borrowing capacity will be available for this purpose
we may be unable to obtain property-level debt financing or raise equity required to fund acquisitions from other sources on favorable terms, or at all;
we may need to spend more than budgeted amounts to make necessary improvements or renovations to acquired properties;
agreements for the acquisition of properties are typically subject to customary conditions to closing that may or may not be completed, and we may spend significant time and money on potential acquisitions that we do not consummate;
the process of acquiring or pursuing the acquisition of a new property may divert the attention of our management team from our existing business operations; and
we may acquire properties without recourse, or with only limited recourse, for liabilities, whether known or unknown.
We rely upon our Advisor and the real estate professionals employed by affiliates of our Advisor to identify suitable investments, but there can be no assurance that our Advisor will be successful in doing so on financially attractive terms or that our objectives will be achieved
We have not paid our distributions on our common stock in cash since 2020, and there can be no assurance we will pay distributions on our common stock in cash in the future.
16

All distributions or dividends on our common stock are paid in the discretion of our board of directors. In August 2020, our board approved a change in our common stock distribution policy, pursuant to which, unless later revised, any future distributions authorized by our board on our shares of common stock, if and when declared, will be paid on a quarterly basis in arrears in shares of our common stock valued at the Estimated Per-Share NAV in effect on the applicable date. We issued a stock dividends on our common stock in October 2020 and January 2021 but there is no assurance we will continue to do so. The Estimated Per-Share NAV has not been adjusted to reflect the stock dividends we have paid and will not be adjusted for stock dividends paid or that may be paid in the future until our board determines a new Estimated Per-Share NAV. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, because each common stockholder will receive the same number of new shares, the total value of our common stockholders' investment, all things equal, will not change assuming no sales or other transfers. We will not be able to pay cash distributions on our common stock until we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million (giving effect to the aggregate amount of distributions projected to be paid by us during the quarter in which we have elected to commence paying cash distributions on common stock) and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%. As of December 31, 2020, our ratio of consolidated total indebtedness to
consolidated total asset value for these purposes was 61.7%.Thus, our ability to make future cash distributions on our common stock will depend on our future cash flows and indebtedness and may further depend on our ability to obtain additional liquidity, which may not be available on favorable terms, or at all. Further, if we do not pay dividends on our Series A Preferred Stock, any accrued and unpaid dividends payable with respect to the Series A Preferred Stock become part of the liquidation preference thereof, and, whenever dividends on the Series A Preferred Stock are in arrears, whether or not authorized or declared, for six or more quarterly periods, holders of Series A Preferred Stock will have the right to elect two additional directors to serve on our board.
We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic.
The COVID-19 pandemic has had, and another pandemic in the future could have, repercussions across many sectors and areas of the global economy and financial markets, leading to significant adverse impacts on economic activity as well as significant volatility and downward pressure in financial markets. The impact of the COVID-19 pandemic has evolved rapidly. In many states and cities where our properties are located, measures including “shelter-in-place” or “stay-at-home” orders issued by local, state and federal authorities and social distancing measures have resulted in closure and limitations on the operations of many businesses and organizations. Our tenants must interact with their patients and residents. Concern regarding the transmission of COVID-19 has impacted these interactions and has, and will likely continue to impact, the willingness of persons to has and may continue to live in or use facilities at our properties, and impact the revenues generated by our tenants which may further impact the ability of our tenants to pay their rent obligations to us when due.
The COVID-19 pandemic has triggered a slowdown in economic activity. Our ability to lease space and negotiate and maintain favorable rents and the results of operations at our SHOPs could also continue to be negatively impacted by a prolonged recession in the U.S. economy as could the rates charged to residents at our SHOPs. Moreover, the demand for leasing space at our MOB properties could decline further negatively impacting occupancy percentage, revenue and net income. Additionally, downturns or stagnation the U.S. housing market as a result of an economic downturn could adversely affect the ability, or perceived ability, of seniors to afford the resident fees and services at our seniors housing properties.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways. In our SHOP portfolio, occupancy trended lower as government policies and implementation of infection control best practices materially limited or closed communities to new resident move-ins which has affected and could continue to affect our ability to fill vacancies. We have also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. SHOP occupancy declined from 84.1% as of March 31, 2020, to 75.4% as of December 31, 2020. We could also incur more significant re-leasing costs and the re-leasing process with respect to both anticipated and unanticipated vacancies could take longer. In addition, starting in mid-March 2020, operating costs began to rise materially including for services, labor and personal protective equipment and other supplies, as our operators took actions to protect residents and caregivers. At our SHOP facilities, we bear these cost increases. These trends accelerated during the second, third and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact us in the future and have a material adverse effect on our revenues and income in the other quarters thereafter.
COVID-19 has proven to be particularly harmful to seniors and persons with other pre-existing health conditions. The pandemic raises the risk of an elevated level of resident illness and move-outs at our SHOPs, which has also adversely impacted occupancy and revenues as well as increase costs and could continue to do so. There have been some incidences of COVID-19 among the residents and staff at certain of our SHOPs. Further incidences, or the perception of that outbreaks may occur, could materially and adversely affect our revenues and net income, as well as cause significant reputational harm to us and our
17

tenants, managers and operators. Due to the contagious nature of COVID-19, residents at our SHOPSs may determine to leave the community and the workforce at these facilities may similarly shrink. The operators may be required, or may otherwise determine that it would be prudent, to impose a quarantine of an indeterminate duration. During any quarantine, new residents would not be permitted to move in and the risk of infection and death for their residents or members of the workforce could increase. We may also be required to incur additional costs to identify, contain and remedy the direct or indirect impacts of the COVID-19 pandemic, including costs related to implementing quarantines and vaccinations.Moreover, if seniors housing properties across the U.S. continue to experience high levels of residents infected with COVID-19 and related deaths, and news accounts emphasize these experiences, seniors may increasingly delay or forego moving into seniors housing properties. These trends could be realized across the senior living industry and not discriminate among owners and operators that have higher or lower levels of residents experiencing COVID-19 infections and related deaths. As a result, our operating results from our SHOPs, and the value of these properties, may be materially adversely affected.
Within our MOB portfolio, many physician practices temporarily discontinued nonessential surgeries and procedures due to “shelter-in-place” and other health and safety measures, which has negatively impacted their cash flows. Even now that prohibitions against performing elective procedures are generally no longer in place concern regarding the transmission of COVID-19 has impacted, and will likely continue to impact, the willingness of persons to seek medical care at healthcare facilities for non-urgent issues. Further, the COVID-19 pandemic might adversely impact the business of our MOB tenants by causing a decline in the number of patients seeking treatment, by disrupting or delaying production and delivery of medical supplies such as necessary pharmaceuticals (including due to a diversion of resources and priorities toward the treatment of COVID-19) or by causing staffing shortages, which would disrupt property operations. The complete or partial closures of, or other operational issues at, one or more of our properties resulting from government action or directives may intensify the risk of rent deferrals or non-payment of contractual obligations by our tenants or operators.
Further, certain of our tenants or our third-party operators may not be eligible for or may not be successful in securing stimulus funds under government stimulus programs which may impact their ability to pay their obligations including any obligations to us. We received $3.6 million under a government program during the year ended December 31, 2020 related to four of our properties. Subsequent to December 31, 2020, we received an additional $5.1 million in funding through the CARES Act. There can be no assurance that we will be able to qualify for, or receive, funds under this or any other governmental program established in response to COVID-19.
As a result of these and other factors, tenants or operators that experience deteriorating financial conditions as a result of the outbreak of COVID-19 have been, or may, in the future be, unwilling or unable to pay us in full or on a timely basis due to bankruptcy, lack of liquidity, lack of funding, operational failures, or for other reasons. We reported cash collections of nearly 100% for the MOB and triple-net leased healthcare facilities segments, respectively, for the year ended December 31, 2020 as of February 15, 2021. However, the impact of the COVID-19 pandemic on our tenants and operators and thus our ability to collect rents in future periods cannot be determined as present and the amount of cash rent collected during 2020 may not be indicative of any future period. In addition, there is no assurance that we will be able to collect the cash rent that is due in the future months including the deferred 2020 rent amounts due in 2021 under the deferral agreements we have entered into with our tenants.
The impact on our tenants and operators in our SHOP segment cannot be determined at present. We may face defaults and additional requests for rent deferrals or abatements or other allowances particularly if our tenants continue to experience financial distress and increased operating costs or if healthcare facilities and SHOPs continue to experience downward pressures on occupancy and increased costs. Furthermore, if we declare any tenants in default for non-payment of rent or other potential breaches of their leases with us, we might not be able to recover and may experience delays and additional costs in enforcing our rights as landlord to recover amounts due to us. Our ability to recover amounts under the terms of our leases may also be restricted or delayed as a result of any federal, state or local restrictions on tenant evictions for failure to make contractual rent payments, which may result in higher reserves for bad debt. If any of our tenants, any guarantor of a tenant’s lease obligations or an operator, files for bankruptcy, we could be further adversely affected due to loss of revenue and a decline in income produced by the property or properties operated by the third-party operator.
In addition to the impacts on us, our tenants and operators described above, the COVID-19 pandemic has also impacted us in other ways and enhanced certain risks that could have a significant adverse effect on our business, financial condition and results of operations and our ability to pay distributions (including dividends on our Series A Preferred Stock) and other distributions to our stockholders including:
difficulty accessing debt and equity capital on favorable terms, or at all, if global financial markets become disrupted or unstable or credit conditions deteriorate;
disruption and instability in financial markets or deteriorations in credit and financing conditions could have an impact on the overall amount of capital being invested in real estate and could result in price or value decreases for real estate assets, which could negatively impact the value of our assets and may result in future acquisitions generating lower overall economic returns;
18

the volatility in stock markets caused by the COVID-19 pandemic and its effects on the trading price of our Series A Preferred Stock and the value of our common stock and which could dilute our stockholders’ interest in us if we sell additional equity securities at prices less than the prices our stockholders paid for their shares;
limiting the number of properties we may seek to acquire due to capital availability;
that planned dispositions may not occur within the expected timeframe or at all because of buyer terminations or withdrawals related to the pandemic, capital constraints or other factors relating to the pandemic, including closing conditions that are dependent on the occurrence of events linked to the pandemic;
following an amendment to our Credit Facility in August 2020 as part of our efforts to continue addressing the adverse impacts of the COVID-19 pandemic, until at least the fiscal quarter ending June 30, 2021, our Credit Facility restricts us from paying cash distributions on, or repurchasing, shares of our common stock, and we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the revolving portion of the Credit Facility;
our ability to maintain sufficient availability under our Credit Facility to fund the purchase of properties and meet other capital requirements which may be adversely affected to the extent the decreases in cash rent collected from our tenants and income from our operators cause a decrease in availability of future borrowings under our Credit Facility;
if we are unable to comply with financial covenants and other obligations under our Credit Facility and other debt agreements we could default under those agreements which could potentially result in an acceleration of our indebtedness and foreclosure on our properties and could otherwise negatively impact our liquidity;
we have recognized impairment charges on our assets;
one or more counterparties to our derivative financial instruments could default on their obligations to us increasing the risk that we may not realize the benefits of utilizing these instruments;
we may be required to record reserves on previously accrued amounts in cases where it is subsequently concluded that collection is not probable
tenants and operators may be subject to lawsuits related to COVID-19 outbreaks that may occur at our properties and insurance coverage may not be sufficient to cover any potential losses further straining their financial condition;
difficulty in repositioning properties where we or our tenants or operators have terminated or do not renew the leases or management agreements with another tenant or operator may be exacerbated by the COVID-19 pandemic, as new operators or tenants may not be willing to take on the increased exposure, especially while active cases are occurring;
difficulties completing capital improvements at our properties on a timely basis, on budget or at all, could affect the value of our properties;
difficulty insuring business continuity in the event our Advisor’s continuity of operations plan is not effective or is improperly implemented or deployed during a disruption;
increased operating risks resulting from changes to our Advisor’s operations and remote work arrangements, including the potential effects on our financial reporting systems and internal controls and procedures, cybersecurity risks and increased vulnerability to security breaches, information technology disruptions and other similar events;
increased operating risks resulting from changes to operations of our third-party operators, including their personnel, which may adversely impact the service provided by our third-party operators with respect to our SHOPs; and
complying with REIT requirements during a period of reduced cash flow could cause us to liquidate otherwise attractive investments or borrow funds on unfavorable conditions.
The extent to which the COVID-19 pandemic, or a future pandemic, impacts our operations and those of our third-party operators will depend on future developments, including the scope, severity and duration of the pandemic, one or more resurgences of the virus which could result in further government restrictions, the efficacy of available vaccines or other remedies developed, the efficacy of on-going efforts to distribute and administer available vaccines, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others, which are highly uncertain and cannot be predicted with confidence but could be material. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. The rapid development and fluidity of this situation precludes any prediction as to the full adverse impact of the COVID-19 pandemic, but a prolonged or resurgent outbreak as well as related mitigation efforts could continue to have a material impact on our revenues and could materially and adversely affect our business, results of operations and financial condition. Moreover, many risk factors set forth in this Annual Report on Form 10-K should be interpreted as heightened risks as a result of the COVID-19 pandemic.
If a tenant or lease guarantor declares bankruptcy or becomes insolvent, we may be unable to collect balances due under relevant leases.
19

Any of our tenants, or any guarantor of a tenant’s lease obligations, could become insolvent or be subject to a bankruptcy proceeding pursuant to Title 11 of the United States Code. For example, during 2019, a guarantor of certain of the lease obligations of prior tenants (collectively, the “LaSalle Tenant”) at four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) filed for chapter 11 bankruptcy. As of December 31, 2020, the prior tenants at the LaSalle Properties remain in default of the forbearance agreement and owes us $12.7 million of rent, property taxes, late fees, and interest receivable thereunder. We have the entire receivable balance, including any monetary damages, and related income from the LaSalle Properties fully reserved as of December 31, 2020 and 2019. A bankruptcy filing of our tenants or any guarantor of a tenant’s lease obligations would result in a stay of all efforts by us to collect pre-bankruptcy debts from these entities or their assets, unless we receive an enabling order from the bankruptcy court. Post-bankruptcy debts would be required to be paid currently. If a lease is assumed by the tenant, all pre-bankruptcy balances owing under it must be paid in full. If a lease is rejected by a tenant in bankruptcy, we would only have a general unsecured claim for damages. If a lease is rejected, it is unlikely we would receive any payments from the tenant because our claim is capped at the rent reserved under the lease, without acceleration, for the greater of one year or 15% of the remaining term of the lease, but not greater than three years, plus rent already due but unpaid as of the date of the bankruptcy filing (post-bankruptcy rent would be payable in full). This claim could be paid only if funds were available, and then only in the same percentage as that realized on other unsecured claims.
A tenant or lease guarantor bankruptcy could delay efforts to collect past due balances under the relevant leases, and could ultimately preclude full collection of these sums. A tenant or lease guarantor bankruptcy could cause a decrease or cessation of rental payments that would mean a reduction in our cash flow and the amount available for dividends and other distributions to our stockholders. In the event of a bankruptcy, there is no assurance that the debtor in possession or the bankruptcy trustee will assume the lease.
A sale-leaseback transaction may be recharacterized in a tenant’s bankruptcy proceeding.
We may enter into sale-leaseback transactions, where we purchase a property and then lease the same property back to the seller, who becomes our tenant as part of the transaction. In the event of the bankruptcy of a tenant, a transaction structured as a sale-leaseback may be recharacterized as either a financing or a joint venture, and either type of recharacterization could adversely affect our business. If the sale-leaseback were recharacterized as a financing, we might not be considered the owner of the property, and as a result would have the status of a creditor. In that event, we would no longer have the right to sell or encumber our ownership interest in the property. Instead, we would have a claim against the tenant for the amounts owed under the lease. The tenant/debtor might have the ability to propose a plan restructuring the term, interest rate and amortization schedule of its outstanding balance. If this plan were confirmed by the bankruptcy court, we would be bound by the new terms. If the sale-leaseback were recharacterized as a joint venture, our lessee and we could be treated as co-venturers with regard to the property. As a result, we could be held liable, under some circumstances, for debts incurred by the lessee relating to the property. Either of these outcomes could adversely affect our cash flow.
Our results of operations have been, and may continue to be, adversely impacted by our inability to collect rent from tenants.
Tenants at certain properties in our triple-net leased healthcare facilities segment have been in default under their leases to us, and our results of operations have been adversely impacted by our inability to collect rent from these tenants. There can be no assurance that we will be able to collect rent from these or other tenants in the future. Further, we incurred $2.7 million of bad debt expense, including straight-line rent write-offs, related to tenants in default under their leases to us during the year ended December 31, 2020. These amounts primarily relate to former tenants at two of our properties in Florida (collectively the “NuVista Tenant” and the “LaSalle Tenant”).
Further, even if we replace tenants in default to us in a manner that will allow us to transition the properties leased to those tenants to our SHOP segment, there can be no assurance this strategy will be successful and we may be more exposed to changes in property operating expenses. There also can be no assurance that we will be able to replace these tenants on a timely basis, or at all, and our results of operations may therefore continue to be adversely impacted by bad debt expenses related to our inability to collect rent from defaulting tenants. Transitions will also increase our exposure to risks associated with operating in this structure.
Our tenants or operators that experience deteriorating financial conditions as a result of the outbreak of COVID-19 have been, or may, in the future be, unwilling or unable to pay us in full or on a timely basis due to bankruptcy, lack of liquidity, lack of funding, operational failures, or for other reasons. There is no assurance we will continue to collect at the current rates. The impact of the COVID-19 pandemic on our tenants and operators and thus our ability to collect rents in future periods cannot be determined as present and the amount of cash rent collected during 2020 may not be indicative of any future period. In addition, there is no assurance that we will be able to collect the cash rent that is due in the future months including the deferred 2020 rent amounts due in 2021 under the deferral agreements we have entered into with our tenants.
Our operating results are affected by economic and regulatory changes that have an adverse impact on the real estate market.
Our operating results and the value of our properties are subject to risks, including:
20

changes in national and market-specific economic conditions;
changes in supply of or demand for competing properties in the relevant market area;
changes in interest rates and availability of financing on favorable terms;
changes in tax, real estate, environmental and zoning laws;
periods of high interest rates and tight money supply; and
the possibility that one or more of our tenants will not pay their rental obligations
Properties may have vacancies for a significant period of time.
A property may have vacancies either due to the continued default of tenants under their leases or the expiration of leases. If vacancies continue for a long period of time, our revenues and net income will be adversely impacted. In addition, the value of a property depends principally upon the value of the cash flow generated by the properties. Prolonged vacancies reduce our cash flow.
We obtain only limited warranties when we purchase a property and therefore have only limited recourse if our due diligence did not identify any issues that lower the value of our property.
We have acquired and may continue to acquire properties in “as is” condition on a “where is” basis and “with all faults,” without any warranties of merchantability or fitness for a particular use or purpose. In addition, purchase agreements may contain only limited warranties, representations and indemnifications that will only survive for a limited period after the closing. The purchase of properties with limited warranties increases the risk that we may lose some or all our invested capital in the property as well as the loss of rental income from that property if a situation or loss occurs after the fact for which we have limited or no remedy.
Our properties and tenants may be unable to compete successfully.
The properties we have acquired and will acquire may face competition from nearby hospitals, senior housing properties and other medical office buildings and medical facilities that provide comparable services. Some of those competing facilities are owned by governmental agencies and supported by tax revenues, and others are owned by nonprofit corporations and may be supported to a large extent by endowments and charitable contributions. These types of support are not available to our properties. Similarly, our tenants face competition from other medical practices in nearby hospitals and other medical facilities. Additionally, the introduction and explosion of new stakeholders competing with traditional providers in the healthcare market, including companies such as telemedicine, telehealth and mhealth, are disrupting the healthcare industry. Our tenants’ failure to compete successfully with these other practices and providers could adversely affect their ability to make rental payments, which could adversely affect our rental revenues.
Further, from time to time and for reasons beyond our control, referral sources, including physicians and managed care organizations, may change their lists of hospitals or physicians to which they refer patients. This could adversely affect the ability of our tenants to make rental payments.
We may be unable to secure funds for future tenant improvements or capital needs.
To attract new replacement tenants, or in some cases to secure renewal of a lease, we may expend substantial funds for tenant improvements and refurbishments. In addition, we are typically responsible for any major structural repairs, such as repairs to the foundation, exterior walls and rooftops, even if our leases with tenants may require tenants to pay routine property maintenance costs. If we need additional capital in the future to improve or maintain our properties or for any other reason, we may have to obtain financing from sources beyond our cash flow from operations, such as borrowings, property sales or future equity offerings to fund these capital requirements. These sources of funding may not be available on attractive terms or at all. If we cannot procure additional funding for capital improvements, we may not be able to lease or re-lease space on attractive terms, if at all.
We have acquired or financed, and may continue to acquire or finance, properties with lock-out provisions which may prohibit us from selling a property, or may require us to maintain specified debt levels for a period of years on some properties.
Lock-out provisions, such as the provisions contained in certain mortgage loans we have entered into, could materially restrict our ability to sell or otherwise dispose of properties or refinance indebtedness, including by requiring the payment of a yield maintenance premium in connection with the required prepayment of principal upon a sale, disposition, or refinancing. Lock-out provisions may also prohibit us from reducing the outstanding indebtedness with respect to any properties, refinancing such indebtedness on a non-recourse basis at maturity, or increasing the amount of indebtedness with respect to such properties. Lock-out provisions could also impair our ability to take other actions during the lock-out period that may otherwise be in the best interests of our stockholders. In particular, lock-out provisions could preclude us from participating in major transactions that could result in a disposition of our assets or a change in control.
21

Rising expenses could reduce cash flow.
The properties that we own or may acquire are subject to operating risks, any or all of which may negatively affect us. If any property is not fully occupied or if rents are being paid in an amount that is insufficient to cover operating expenses, we could be required to expend funds with respect to that property for operating expenses. Properties may be subject to increases in tax rates, utility costs, operating expenses, insurance costs, repairs and maintenance and administrative expenses. We may not be able to negotiate leases on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, in which event we may have to pay those costs. If we are unable to lease properties on a triple-net basis or on a basis requiring the tenants to pay all or some of such expenses, or if tenants fail to pay required tax, utility and other impositions, we could be required to pay those costs.
Damage from catastrophic weather and other natural events and climate change could result in losses to us.
Certain of our properties are located in areas that may experience catastrophic weather and other natural events from time to time, including hurricanes or other severe weather, flooding, fires, snow or ice storms, windstorms or, earthquakes. These adverse weather and natural events could cause substantial damages or losses to our properties which could exceed our insurance coverage. In the event of a loss in excess of insured limits, we could lose our capital invested in the affected property, as well as anticipated future revenue from that property. We could also continue to be obligated to repay any mortgage indebtedness or other obligations related to the property.
To the extent that significant changes in the climate occur, we may experience extreme weather and changes in precipitation and temperature and rising sea levels, all of which may result in physical damage to or a decrease in demand for properties located in these areas or affected by these conditions. The impact of climate change may be material in nature, including destruction of our properties, or occur for lengthy periods of time.
In addition, changes in federal and state legislation and regulation on climate change could result in increased capital expenditures to improve the energy efficiency of our existing properties or to protect them from the consequence of climate change.
We may suffer uninsured losses relating to real property or have to pay expensive premiums for insurance coverage.
Our general liability coverage, property insurance coverage and umbrella liability coverage on all our properties may not be adequate to insure against liability claims and provide for the costs of defense. Similarly, we may not have adequate coverage against the risk of direct physical damage or to reimburse us on a replacement cost basis for costs incurred to repair or rebuild each property. Moreover, there are types of losses, generally catastrophic in nature, such as losses due to wars, acts of terrorism, earthquakes, floods, hurricanes, pollution or environmental matters that are uninsurable or not economically insurable, or may be insured subject to limitations, such as large deductibles or co-payments. Insurance risks associated with such catastrophic events could sharply increase the premiums we pay for coverage against property and casualty claims.
This risk is particularly relevant with respect to potential acts of terrorism. The Terrorism Risk Insurance Act of 2002 (the “TRIA”), under which the U.S. federal government bears a significant portion of insured losses caused by terrorism, will expire on December 31, 2027, and there can be no assurance that Congress will act to renew or replace the TRIA following its expiration. In the event that the TRIA is not renewed or replaced, terrorism insurance may become difficult or impossible to obtain at reasonable costs or at all, which may result in adverse impacts and additional costs to us.
Changes in the cost or availability of insurance due to the non-renewal of the TRIA or for other reasons could expose us to uninsured casualty losses. If any of our properties incurs a casualty loss that is not fully insured, the value of our assets will be reduced by any uninsured loss. In addition, other than any working capital reserve or other reserves we may establish, we have no source of funding to repair or reconstruct any uninsured property. Also, to the extent we must pay unexpectedly large amounts for insurance, we could suffer reduced earnings that would result in less cash flow.
Additionally, mortgage lenders insist in some cases that commercial property owners purchase coverage against terrorism as a condition for providing mortgage loans. Accordingly, to the extent terrorism risk insurance policies are not available at reasonable costs, if at all, our ability to finance or refinance indebtedness secured by our properties could be impaired. In such instances, we may be required to provide other financial support, either through financial assurances or self-insurance, to cover potential losses. We may not have adequate, or any, coverage for the losses.
Terrorist attacks and other acts of violence, civilian unrest or war may affect the markets in which we operate our business and our profitability.
We own properties in densely populated areas that are susceptible to terrorist attack. Because our properties are generally open to the public, they are exposed to a number of incidents that may take place within their premises and that are beyond our
22

control or ability to prevent, which may harm our tenants, operators or visitors. If an act of terror, a mass shooting or other violence were to occur, we may lose tenants or be forced to close one or more of our properties for some time. If any of these incidents were to occur, the relevant property could face material damage to its image and the revenue generated therefrom. In addition, we may be exposed to civil liability and be required to indemnify the victims, and our insurance premiums could rise, any of which could adversely affect us.
In addition, any kind of terrorist activity or violent criminal acts, including terrorist acts against public institutions or buildings or modes of public transportation (including airlines, trains or buses) could have a negative effect on our business and the value of our properties. More generally, any terrorist attack, other act of violence or war, including armed conflicts, could result in increased volatility in, or damage to, the worldwide financial markets and economy, including demand for properties and availability of financing. Increased economic volatility could adversely affect our tenants’ abilities to conduct their operations profitably or our ability to borrow money or issue capital stock at acceptable prices.
Real estate-related taxes may increase and these increases may not be passed on to tenants.
From time to time our property taxes increase as property values or assessment rates change or for other reasons. An increase in the assessed valuation of a property for real estate tax purposes will result in an increase in the related real estate taxes on that property. There is no assurance that leases will be negotiated on a basis that passes such taxes on to the tenant.
Properties may be subject to restrictions on their use that affect our ability to operate a property.
Some of our properties are contiguous to other parcels of real property, comprising part of the same commercial center. In connection with such properties, there are significant covenants, conditions and restrictions restricting the operation of such properties and any improvements on such properties, and related to granting easements on such properties. Moreover, the operation and management of the contiguous properties may impact such properties. Compliance with covenants, conditions and restrictions may adversely affect our operating costs and reduce the amount of cash flow that we generate.
Our operating results may be negatively affected by potential development and construction delays and resultant increased costs and risks.
We have acquired and developed, and may in the future acquire and develop, properties upon which we will construct improvements. In connection with our development activities, we are subject to uncertainties associated with re-zoning for development, environmental concerns of governmental entities or community groups and our builder or partner’s ability to build in conformity with plans, specifications, budgeted costs, and timetables. Performance also may be affected or delayed by conditions beyond our control. For example, we experienced substantial delays and incurred significant additional costs associated with our development property in Jupiter, Florida and would be exposed to the risks in connection with any other properties we develop. We may incur additional risks when we make periodic progress payments or other advances to builders before they complete construction. If a builder or development partner fails to perform, we may resort to legal action to rescind the purchase or the construction contract or to compel performance, but there can be no assurance any legal action would be successful. These and other factors can result in increased costs of a project or loss of our investment. In addition, we will be subject to normal lease-up risks relating to newly constructed projects. We also must rely on rental income and expense projections and estimates of the fair market value of property upon completion of construction when agreeing upon a price at the time we acquire the property. If our projections are inaccurate, we may pay too much for a property, and our return on our investment could suffer.
We compete with third parties in acquiring properties and other investments and attracting credit worthy tenants.
We compete with many other entities engaged in real estate investment activities, including individuals, corporations, private investment funds, bank and insurance company investment accounts, other REITs, real estate limited partnerships, and other entities engaged in real estate investment activities, many of which have greater resources than we do. These entities may enjoy significant competitive advantages that result from, among other things, a lower cost of capital and enhanced operating efficiencies. In addition, the number of entities and the amount of funds competing for suitable investments may increase. Increased demand for assets will likely increase acquisition prices.
We also compete with other comparable properties for tenants, which impacts our ability to rent space and the amount of rent charged. We could be adversely affected if additional competitive properties are built in locations near our properties, causing increased competition for creditworthy tenants. This could result in decreased cash flow from our properties and may require us to make capital improvements to properties that we would not have otherwise made, further impacting property cash flows.
Discovery of previously undetected environmentally hazardous conditions may adversely affect our operating results.
23

We are subject to various federal, state and local laws and regulations that (a) regulate certain activities and operations that may have environmental or health and safety effects, such as the management, generation, release or disposal of regulated materials, substances or wastes, (b) impose liability for the costs of cleaning up, and damages to natural resources from, past spills, waste disposals on and off-site, or other releases of hazardous materials or regulated substances, and (c) regulate workplace safety. Compliance with these laws and regulations could increase our operational costs. Violation of these laws may subject us to significant fines, penalties or disposal costs, which could negatively impact our results of operations, financial position and cash flows. Under various federal, state and local environmental laws (including those of foreign jurisdictions), a current or previous owner or operator of currently or formerly owned, leased or operated real property may be liable for the cost of removing or remediating hazardous or toxic substances on, under or in such property. The costs of removing or remediating could be substantial. These laws often impose liability whether or not the owner or operator knew of, or was responsible for, the presence of such hazardous or toxic substances. Certain environmental laws and common law principles could be used to impose liability for release of, and exposure to, hazardous substances, including asbestos-containing materials into the air, and third parties may seek recovery from owners or operators of real properties for personal injury or property damage associated with exposure to released hazardous substances. In addition, when excessive moisture accumulates in buildings or on building materials, mold growth may occur, particularly if the moisture problem remains undiscovered or is not addressed over a period of time. Some molds may produce airborne toxins or irritants. Concern about indoor exposure to mold has been increasing, as exposure to mold may cause a variety of adverse health effects and symptoms, including allergic or other reactions. As a result, the presence of significant mold at any of our properties could require us to undertake a costly remediation program to contain or remove the mold from the affected property or development project. Accordingly, we may incur significant costs to defend against claims of liability, to comply with environmental regulatory requirements, to remediate any contaminated property, or to pay personal injury claims.
Moreover, environmental laws also may impose liens on property or other restrictions on the manner in which property may be used or businesses may be operated, and these restrictions may require substantial expenditures or prevent us or our Property Manager and its assignees from operating such properties. Compliance with new or more stringent laws or regulations or stricter interpretation of existing laws may require us to incur material expenditures. Future laws, ordinances or regulations or the discovery of currently unknown conditions or non-compliances may impose material liability under environmental laws.
If we sell properties by providing financing to purchasers, defaults by the purchasers would adversely affect our cash flows.
In some instances, we may sell our properties by providing financing to purchasers. If we do so, we will bear the risk that the purchaser may default on its debt, requiring us to seek remedies, a process which may be time-consuming and costly. Further, the borrower may have defenses that could limit or eliminate our remedies. In addition, even in the absence of a purchaser default, the distribution of the proceeds of sales to our stockholders, or their reinvestment in other assets, will be delayed until the promissory notes or other property we may accept upon the sale are actually paid, sold, refinanced or otherwise disposed of. In some cases, we may receive initial down payments in cash and other property in the year of sale in an amount less than the selling price and subsequent payments will be spread over a number of years.
We assume additional operational risks and are subject to additional regulation and liability because we depend on eligible independent contractors to manage some of our facilities.
In our SHOP segment, we invest in SHOPs using the RIDEA structure which permits REITs such as us to lease certain types of healthcare facilities that we own or partially own to a TRS, provided that our TRS hires an independent qualifying management company to operate the facility. Under this structure, the independent qualifying management company, which we also refer to as an operator, receives a management fee from our TRS for operating the facility as an independent contractor. As the owner of the facility, we assume most of the operational risk because we lease our facility to our own partially- or wholly-owned subsidiary rather than a third-party operator. We are therefore responsible for any operating deficits incurred by the facility. As of December 31, 2020, we had seven eligible independent contractors operating 59 SHOPs (not including two land parcels). Some of these properties were recently transitioned from our triple-net leased facilities segment to our SHOP segment. We may in the future, transition other triple-net leased facilities, which may or may not be experiencing declining performance, to third-party managed facilities under this structure, in connection with which they would also transition from our triple-net leased healthcare facilities segment to our SHOP segment. There can be no assurance these transitions will improve performance of the properties, and they will also increase our exposure to risks associated with operating in this structure.
The income we generate from SHOPs is subject to a number of operational risks including fluctuations in occupancy levels and resident fee levels, increases in the cost of food, materials, energy, labor (as a result of unionization or otherwise) or other services, rent control regulations, national and regional economic conditions, the imposition of new or increased taxes, capital
24

expenditure requirements, professional and general liability claims, and the availability and cost of professional and general liability insurance. As noted herein, we have experienced declines in occupancy at our SHOPs during 2020 that may continue in 2021. Although we have various rights as the property owner under our management agreements, we rely on the personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment of our operators to set appropriate resident fees, provide accurate property-level financial results for our properties in a timely manner and to otherwise operate our SHOPs in compliance with the terms of our management agreements and all applicable laws and regulations. We also depend on our operators to attract and retain skilled management personnel who are responsible for the day-to-day operations of our SHOPs. A shortage of nurses or other trained personnel or general inflationary pressures may force the operator to enhance pay and benefit packages to compete effectively for personnel, but it may not be able to offset these added costs by increasing the rates charged to residents. Any increase in labor costs and other property operating expenses, any failure to attract and retain qualified personnel, or significant changes in the operator’s senior management or equity ownership could adversely affect the income we receive from our SHOPs.
The operator, which is our TRS when we use this type of lease structure, of a healthcare facility is generally required to be the holder of the applicable healthcare license. Any delay in obtaining the license, or failure to obtain one at all, could result in a delay or an inability to collect a significant portion of our revenue on the applicable property. Furthermore, this licensing requirement subjects us (through our ownership interest in our TRS) to various regulatory laws, including those described herein. Most states regulate and inspect healthcare facility operations, patient care, construction and the safety of the physical environment. If one or more of our healthcare real estate facilities fails to comply with applicable laws, our TRS, if it holds the healthcare license and is the entity enrolled in government health care programs, would be subject to penalties including loss or suspension of license, certification or accreditation, exclusion from government healthcare programs (i.e., Medicare, Medicaid), administrative sanctions, civil monetary penalties, and in certain instances, criminal penalties. Additionally, when we receive individually identifiable health information relating to residents of our TRS-operated healthcare facilities, we are subject to federal and state data privacy and confidentiality laws and rules, and could be subject to liability in the event of an audit, complaint, or data breach. Furthermore, to the extent our TRS holds the healthcare license, it could have exposure to professional liability claims arising out of an alleged breach of the applicable standard of care rules.
Joint venture investments could be adversely affected by our lack of sole decision-making authority, our reliance on the financial condition of co-venturers and disputes between us and our co-venturers.
We have made investments in certain assets through joint ventures and may continue to enter into joint ventures, partnerships and other co-ownership arrangements (including preferred equity investments) in the future. In such event, we may not be in a position to exercise sole decision-making authority regarding the joint venture. Investments in joint ventures may, under certain circumstances, involve risks not present were a third-party not involved, including the possibility that partners or co-venturers might become bankrupt or fail to fund their required capital contributions. Co-venturers may have economic or other business interests or goals which are inconsistent with our business interests or goals, and may be in a position to take actions contrary to our policies or objectives. These investments may also have the potential risk of impasses on decisions, such as a sale, because neither we nor the co-venturer would have full control over the joint venture. Disputes between us and co-venturers may result in litigation or arbitration that would increase our expenses and prevent our officers or directors from focusing their time and effort on our business. Consequently, actions by or disputes with co-venturers might result in subjecting properties owned by the joint venture to additional risk. In addition, we may in certain circumstances be liable for the actions of our co-venturers.
We may incur costs associated with complying with the Americans with Disabilities Act.
Our properties are subject to the Americans with Disabilities Act of 1990 (the “Disabilities Act”). Under the Disabilities Act, all places of public accommodation are required to comply with federal requirements related to access and use by disabled persons. The Disabilities Act has separate compliance requirements for “public accommodations” and “commercial facilities” that generally require that buildings and services, including restaurants and retail stores, be made accessible and available to people with disabilities. The Disabilities Act’s requirements could require removal of access barriers and could result in the imposition of injunctive relief, monetary penalties, or, in some cases, an award of damages. A determination that our properties do not comply with the Disabilities Act could result in liability for both governmental fines and damages. If we are required to make unanticipated major modifications to any of our properties to comply with the Disabilities Act which are determined not to be the responsibility of our tenants, we could incur unanticipated expenses that could have an adverse impact upon our cash flow.
Net leases may not result in fair market lease rates over time.
25

Some of our rental income is generated by net leases, which generally provide the tenant greater discretion in using the leased property than ordinary property leases, such as the right to freely sublease the property, to make alterations in the leased premises and to terminate the lease prior to its expiration under specified circumstances. Furthermore, net leases typically have longer lease terms and, thus, there is an increased risk that contractual rental increases in future years will fail to result in fair market rental rates during those years. Moreover, inflation could erode the value of long-term leases that do not contain indexed escalation provisions.
We may be unable to renew leases or re-lease space as leases expire.
We may be unable to renew expiring leases on terms and conditions that are as, or more, favorable as the terms and conditions of the expiring leases. In addition, vacancies may occur at one or more of our properties due to a default by a tenant on its lease or expiration of a lease. Healthcare facilities in general and MOBs in particular tend to be specifically suited for the particular needs of their tenants and major renovations and expenditures may be required in order for us to re-lease vacant space. Vacancies may reduce the value of a property as a result of reduced cash flow generated by the property.
Our properties have been and may continue to be subject to impairment charges.
We periodically evaluate our real estate investments for impairment indicators. The judgment regarding the existence of impairment indicators is based on factors such as market conditions, tenant performance and legal structure. For example, the early termination of, or default under, a lease by a major tenant may lead to an impairment charge. If we determine that an impairment has occurred, we would be required to make a downward adjustment to the net carrying value of the property. Impairment charges also indicate a potential permanent adverse change in the fundamental operating characteristics of the impaired property. There is no assurance that these adverse changes will be reversed in the future and the decline in the impaired property’s value could be permanent. We have incurred impairment charges, which have an immediate direct impact on our earnings, including $36.4 million, during the year ended December 31, 2020. There can be no assurance that we will not take additional charges in the future. Any future impairment could have a material adverse effect on our results in the period in which the charge is taken.
Our real estate investments are relatively illiquid, and therefore we may not be able to dispose of properties when we desire to do so or on favorable terms.
Investments in real properties are relatively illiquid. We may not be able to quickly alter our portfolio or generate capital by selling properties. The real estate market is affected by many factors, such as general economic conditions, availability of financing, interest rates and other factors, including supply and demand, that are beyond our control. If we need or desire to sell a property or properties, we cannot predict whether we will be able to do so at a price or on the terms and conditions acceptable to us. We cannot predict the length of time needed to find a willing purchaser and to close the sale of a property. Further, we may be required to invest monies to correct defects or to make improvements before a property can be sold. We can make no assurance that we will have funds available to correct these defects or to make these improvements. Moreover, in acquiring a property or incurring debt securing a property, we may agree to restrictions that prohibit the sale of that property for a period of time or impose other restrictions, such as a limitation on the amount of debt that can be placed or repaid on that property. These types of provisions restrict our ability to sell a property.
In addition, applicable provisions of the Code impose restrictions on the ability of a REIT to dispose of properties that are not applicable to other types of real estate companies. Thus, we may be unable to realize our investment objectives by selling or otherwise disposing of a property, or refinancing debt secured by the property, at attractive prices within any given period of time or may otherwise be unable to complete any exit strategy.

Risks Related to the Healthcare Industry

Our real estate investments are concentrated in healthcare-related facilities, and we may be negatively impacted by adverse trends in the healthcare industry.
We own and seek to acquire a diversified portfolio of healthcare-related assets including MOBs, SHOPs and other healthcare-related facilities. We are subject to risks inherent in concentrating investments in real estate and, in particular, healthcare-related assets. A downturn in the commercial real estate industry generally could significantly adversely affect the value of our properties. A downturn in the healthcare industry could particularly negatively affect our lessees’ ability to make lease payments to us and our ability to pay dividends and other distributions to our stockholders. These adverse effects could be more pronounced than if we diversified our investments outside of real estate or if our portfolio did not include a concentration in healthcare-related assets.
26

Furthermore, the healthcare industry currently is experiencing rapid regulatory changes and uncertainty; changes in the demand for and methods of delivering healthcare services; changes in third-party reimbursement policies; significant unused capacity in certain areas, which has created substantial competition for patients among healthcare providers in those areas; expansion of insurance providers into patient care; continuing pressure by private and governmental payors to reduce payments to providers of services; and increased scrutiny of billing, referral and other practices by federal and state authorities. These factors may adversely affect the economic performance of some or all of our tenants and, in turn, our revenues and cash flows.
Certain of our properties may not have efficient alternative uses, so the loss of a tenant may cause us to not be able to find a replacement or cause us to spend considerable capital to adapt the property to an alternative use.
Some of our properties and the properties we will seek to acquire are healthcare-related assets that may only be suitable for similar healthcare-related tenants. If we or our tenants terminate the leases for these properties or our tenants lose their regulatory authority to operate such properties, we may not be able to locate suitable replacement tenants to lease the properties for their specialized uses. Alternatively, we may be required to spend substantial amounts to adapt the properties to other uses.
The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure or failure to obtain licensure could result in the inability of our tenants to make rent payments to us.
The healthcare industry is heavily regulated by federal, state and local governmental bodies. Our tenants generally are subject to laws and regulations covering, among other things, licensure, certification for participation in government programs, relationships with physicians and other referral sources, and the privacy and security of patient health information. Changes in these laws and regulations could negatively affect the ability of our tenants to make lease payments to us. In some states, healthcare facilities are subject to various state CON laws requiring governmental approval prior to the development or expansion of healthcare facilities and services. The approval process in these states generally requires a facility to demonstrate the need for additional or expanded healthcare facilities or services. CONs, where applicable, can also be conditions to regulatory approval of changes in ownership or control of licensed facilities, addition of beds, investment in major capital equipment, introduction of new services, termination of services previously approved through the CON process and other control or operational changes. Many of our medical facilities and their tenants may require a license or CON to operate. Failure to obtain a license or CON, or loss of a required license or CON, would prevent a facility from operating in the manner intended by the tenant and may restrict an operator’s ability to expand properties and grow the operator’s business in certain circumstances, which could have an adverse effect on the operator’s or tenant’s revenues, and in turn, negatively impact their ability to make rental payments under, and otherwise comply with the terms of their leases with us. State CON laws are not uniform throughout the United States and are subject to change. We cannot predict the impact of state CON laws on our improvement of medical facilities or the operations of our tenants. In addition, state CON laws often materially impact the ability of competitors to enter into the marketplace of our facilities. The repeal of CON laws could allow competitors to freely operate in previously closed markets. This could negatively affect the ability of our tenants’ to make rental payments to us. In limited circumstances, loss of state licensure or certification or closure of a facility could ultimately result in loss of authority to operate the facility and require new CON authorization to re-institute operations.
Furthermore, uncertainty surrounding the implementation of the Affordable Care Act may adversely affect our operators. As the primary vehicle for comprehensive healthcare reform in the United States, the Affordable Care Act was designed to reduce the number of individuals in the United States without health insurance and change the ways in which healthcare is organized, delivered and reimbursed. The Affordable Care Act has faced ongoing legal challenges, including litigation seeking to invalidate some or all of the law or the manner in which it has been interpreted. The legal challenges and legislative initiatives to roll back the Affordable Care Act continues and the outcomes are uncertain. On March 2, 2020, the Supreme Court granted a petition of certiorari and heard arguments in November 2020. If an injunction or a final judgment is made which declares the Affordable Care Act unconstitutional, states may not have to comply with its requirements, which could impact health insurance coverage for individuals. The regulatory uncertainty and the potential impact on our tenants and operators could have an adverse material effect on their ability to satisfy their contractual obligations. Further, we are unable to predict the scope of future federal, state and local regulations and legislation, including Medicare and Medicaid statutes and regulations or judicial decisions, or the intensity of enforcement efforts with respect to such regulations and legislation, and any changes in the regulatory or judicial framework may have a material adverse effect on our tenants, which, in turn, could have a material adverse effect on us.
The expansion in health insurance coverage under the Affordable Care Act is likely going to continue to erode in 2020 as cuts in advertising and outreach during the marketplace open-enrollment periods, shorter open enrollment periods, and other changes have left many Americans uncertain about their ability to access and be eligible for coverage. Additionally, the repeal of the individual mandate penalty included in the TCJA, recent actions to increase the availability of insurance policies that do not include Affordable Care Act minimum benefit standards, and support for Medicaid work requirements will likely impact the market. Accordingly, current and future payments under federal and state healthcare programs may not be sufficient to sustain a facility’s operations, which could adversely affect its ability to satisfy its contractual obligations, including making rental payments under, and otherwise complying with the terms of, the facility’s leases and other agreements with us.
27

The Affordable Care Act includes program integrity provisions that both create new authorities and expand existing authorities for federal and state governments to address fraud, waste and abuse in federal health programs. In addition, the Affordable Care Act expands reporting requirements and responsibilities related to facility ownership and management, patient safety and care quality. In the ordinary course of their businesses, our operators may be regularly subjected to inquiries, investigations and audits by federal and state agencies that oversee these laws and regulations. If they do not comply with the additional reporting requirements and responsibilities, the ability of our operators’ to participate in federal health programs may be adversely affected. Moreover, there may be other aspects of the comprehensive healthcare reform legislation for which regulations have not yet been adopted, which, depending on how they are implemented, could materially and adversely affect our operators.
The Affordable Care Act also requires the reporting and return of overpayments. Healthcare providers that fail to report and return an overpayment could face potential liability under the FCA and the CMPL and exclusion from federal healthcare programs. Accordingly, if our operators fail to comply with the Affordable Care Act’s requirements, they may be subject to significant monetary penalties and excluded from participation in Medicare and Medicaid, which could materially and adversely affect their ability to pay rent and satisfy other financial obligations to us.
Reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid, or delays in receiving these reimbursements, could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us.
Our tenants may receive payments from the federal Medicare program, state Medicaid programs, private insurance carriers and health maintenance organizations, among others. Efforts by such payors to reduce healthcare costs have intensified in recent years and will likely continue, which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. Examples include, but are not limited to, changes in reimbursement rates and methodologies, such as bundled payments, capitation payments and discounted fee structures. As a result, our tenants and operators may face significant limits on the reimbursed and on reimbursement rates and fees. All of these changes could impact the ability our operators and tenants’ ability to pay rent or other obligations to us. In addition, operators and tenants in certain states have experienced delays; some of which are, have been, and may be late in receiving reimbursements, which have adversely affected their ability to make rent payments to us.Further, failure of any of our operators or tenants to comply with various laws and regulations could jeopardize their ability to continue participating in Medicare, Medicaid and other government-sponsored payment programs.
The healthcare industry continues to face various challenges, including increased government and private payor pressure on healthcare providers to control or reduce costs. Coverage expansions under the Affordable Care Act through the Medicaid expansion and health insurance exchanges may be scaled back or eliminated in the future due to ongoing legal challenges and the future status of the Affordable Care Act is unknown. We cannot ensure that of our operators or tenants who currently depend on governmental or private payer reimbursement will be adequately reimbursed for the services they provide.
Any slowdown in the United States economy can negatively affect state budgets, thereby putting pressure on states to decrease spending on state programs including Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in state Medicaid programs due to unemployment and declines in family incomes. Historically, some states have attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Potential reductions to Medicaid program spending in response to state budgetary pressures could negatively impact the ability of our tenants and operators to successfully operate their businesses.
Our tenants and operators may continue to experience a shift in payor mix away from fee-for-service payors, resulting in an increase in the percentage of revenues attributable to managed care payors, and general industry trends that include pressures to control healthcare costs. In addition, some of our tenants may be subject to value-based purchasing programs, which base reimbursement on the quality and efficiency of care provided by facilities and require the public reporting of quality data and preventable adverse events to receive full reimbursement. Pressures to control healthcare costs and a shift away from traditional health insurance reimbursement to managed care plans have resulted in an increase in the number of patients whose healthcare coverage is provided under managed care plans, such as health maintenance organizations and preferred provider organizations. Medicare Access and CHIP Reauthorization Act (“MACRA”) has also established a new payment framework, which modified certain Medicare payments to eligible clinicians, representing a fundamental change to physician reimbursement. These changes could have a material adverse effect on the financial condition of some or all of our tenants in our properties. The financial impact on our tenants and operators could restrict their ability to make rent payments to us.
Required regulatory approvals can delay or prohibit transfers of our healthcare facilities.
Transfers of healthcare facilities to successor tenants or operators are typically subject to regulatory approvals or ratifications, including, but not limited to, change of ownership approvals, zoning approvals, and Medicare and Medicaid provider arrangements that are either not required, or enjoy reduced requirements, in connection with transfers of other types of commercial operations and other types of real estate. The replacement of any tenant or operator could be delayed by the
28

regulatory approval process of any federal, state or local government agency necessary for the transfer of the facility or the replacement of the operator licensed to manage the facility. If we are unable to find a suitable replacement tenant or operator upon favorable terms, or at all, we may take possession of a facility, which could expose us to successor liability, require us to indemnify subsequent operators to whom we transfer the operating rights and licenses, or require us to spend substantial time and funds to preserve the value of the property and adapt the facility to other use. Furthermore, transitioning to a new tenant or operator could cause disruptions at the operations of the properties and, if there is a delay in the new tenant or operator obtaining its Medicare license, delays in our ability to receive reimbursements from Medicare.
A reduction in Medicare payment rates for skilled nursing facilities may have an adverse effect on the Medicare reimbursements received by certain of our tenants.
Several government initiatives have resulted in reductions in funding of the Medicare and Medicaid programs and additional changes in reimbursement regulations by the Centers for Medicare & Medicaid Services (“CMS”), contributing to enhanced pressure to contain healthcare costs and additional operational requirements, which has impacted the ability of our tenants’ and operators’ ability to make rent payments to us. The Medicare and Medicaid programs have adopted a variety of initiatives which have been incorporated and expanded by private insurance carriers, including health maintenance organizations and other health plans, to extract greater discounts and impose more stringent cost controls upon healthcare provider operations. As a result, our tenants and operators may face reductions in reimbursement rates and fees. Operators in certain states have experienced delays in receiving reimbursements, which has adversely affected their ability to make rent payments to us. Similar delays, or reductions in reimbursements, may continue to impose financial and operational challenges for our tenants and operators, which may affect their ability to make contractual payments to us.
There have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for and availability of healthcare services. We may own and acquire skilled nursing facility assets that rely on revenue from Medicaid or Medicare. Our tenants have and may experience limited increases or reductions in Medicare payments and aspects of certain of these government initiatives, such as further reductions in funding of the Medicare and Medicaid programs, additional changes in reimbursement regulations by CMS, enhanced pressure to contain healthcare costs by Medicare, Medicaid and other payors, and additional operational requirements may adversely affect their ability to make rental payments. For example, CMS is focused on reducing what it considers to be payment errors by identifying, reporting, and implementing actions to reduce payment error vulnerabilities.
In addition, CMS is currently in the midst of transitioning Medicare from traditional fee for service reimbursement models to a capitated system, which means medical providers are given a set fee per patient regardless of treatment required, and value-based and bundled payment approaches, where the government pays a set amount for each beneficiary for a defined period of time, based on that person’s underlying medical needs, rather than based on the actual services provided. Providers and facilities are increasing responsible to care for and be financially responsible for certain populations of patients under the population health models and this shift in patient management paradigm is creating and will continue to create unprecedented challenges for providers and impact their ability to pay rent to us.
Certain of our facilities may be subject to pre- and post-payment reviews and audits by governmental authorities, which could result in recoupments, denials or delay of payments and could adversely affect the profitability of our tenants.
Certain of our facilities may be subject to periodic pre- and post-payment reviews and audits by governmental authorities. If the review or audit shows a facility is not in compliance with federal and state requirements, previous payments to the facility may be recouped and future payments may be denied or delayed. Recoupments, denials or delay of payments could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us.
Events that adversely affect the ability of seniors and their families to afford daily resident fees at our SHOPs could cause our occupancy rates and resident fee revenues to decline.
Assisted and independent living services generally are not reimbursable under government reimbursement programs, such as Medicare and Medicaid. Most of the resident fee revenues generated by our SHOPs, therefore, are derived from private pay sources consisting of the income or assets of residents or their family members. The rates for these residents are set by the facilities based on local market conditions and operating costs. In light of the significant expense associated with building new properties and staffing and other costs of providing services, typically only seniors with income or assets that meet or exceed the comparable region median can afford the daily resident and care fees at our SHOPs. A weak economy, depressed housing market or changes in demographics could adversely affect their continued ability to do so. If the operators of our SHOPs are unable to attract and retain seniors that have sufficient income, assets or other resources to pay the fees associated with assisted and independent living services, the occupancy rates, resident fee revenues and results of operations of our SHOPs could decline.
29

Residents in our SHOPs may terminate leases.
State regulations generally require assisted living communities to have a written lease agreement with each resident that permits the resident to terminate his or her lease for any reason on reasonable notice, unlike typical apartment lease agreements that have initial terms of one year or longer. Due to these lease termination rights and the advanced age of the residents, the resident turnover rate in our SHOPs may be difficult to predict. A large number of resident lease agreements may terminate at or around the same time, and the affected units may remain unoccupied.
Some tenants of our healthcare-related assets must comply with fraud and abuse laws, the violation of which by a tenant may jeopardize the tenant’s ability to make rent payments to us.
There are various federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from or are in a position to make referrals in connection with government-sponsored healthcare programs, including the Medicare and Medicaid programs.
Our lease arrangements with certain tenants may also be subject to these fraud and abuse laws. These laws include the Federal Anti-Kickback Statute, which prohibits, among other things, the offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, the referral of any item or service reimbursed by Medicare or Medicaid; the Federal Physician Self-Referral Prohibition (commonly referred to as the “Stark Law”), which, subject to specific exceptions, restricts physicians from making referrals for specifically designated health services for which payment may be made under Medicare or Medicaid programs to an entity with which the physician, or an immediate family member, has a financial relationship; the FCA, which prohibits any person from knowingly presenting false or fraudulent claims for payment to the federal government, including claims paid by the Medicare and Medicaid programs; and the CMPL, which authorizes the U.S. Department of Health and Human Services to impose monetary penalties for certain fraudulent acts.
Each of these laws includes substantial criminal or civil penalties for violations that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments or exclusion from the Medicare and Medicaid programs. Certain laws, such as the FCA, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Individuals have tremendous potential financial gain in bringing whistleblower claims as the FCA statute provides that the individual will receive a portion of the money recouped. Additionally, violations of the FCA can result in treble damages. Significant enforcement activity has been the result of actions brought by these individuals. Additionally, certain states in which the facilities are located also have similar fraud and abuse laws. Federal and state adoption and enforcement of such laws increase the regulatory burden and costs, and potential liability, of healthcare providers. Investigation by a federal or state governmental body for violation of fraud and abuse laws, and these state laws have their own penalties which may be in additional to federal penalties.
Investigation by a federal or state governmental body for violation of fraud and abuse laws or imposition of any of these penalties upon one of our tenants could jeopardize that tenant’s business, its reputation, and its ability to operate or to make rent payments. Increased funding for investigation and enforcement efforts, accompanied by an increased pressure to eliminate government waste, has led to a significant increase in the number of investigations and enforcement actions over the past several years, a trend which is not anticipated to decrease considerably.
Tenants of our healthcare-related assets may be subject to significant legal actions that could subject them to increased operating costs and substantial uninsured liabilities, which may affect their ability to pay their rent payments to us.
As is typical in the healthcare industry, certain types of tenants of our healthcare-related assets may often become subject to claims that their services have resulted in patient injury or other adverse effects. The insurance coverage maintained by these tenants may not cover all claims made against them or continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation may not, in certain cases, be available to these tenants due to state law prohibitions or limitations of availability. As a result, these types of tenants operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits. Recently, there has been an increase in governmental investigations of certain healthcare providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance may not available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, whether currently asserted or arising in the future, could have a material adverse effect on a tenant’s financial condition. If a tenant is unable to obtain or maintain insurance coverage, if judgments are obtained in excess of the insurance coverage, if a tenant is required to pay uninsured punitive damages, or if a tenant is subject to an uninsurable government enforcement action, the tenant could be exposed to substantial additional liabilities, which may affect the tenant’s business, operations and ability to pay rent to us.
30

We may experience adverse effects as a result of potential financial and operational challenges faced by the operators of any seniors housing facilities and skilled nursing facilities we own or acquire.
Operators of any seniors housing facilities and skilled nursing facilities may face operational challenges from potentially reduced revenue streams and increased demands on their existing financial resources. The resources of our skilled nursing operators’ likely are primarily derived from governmentally funded reimbursement programs, such as Medicare and Medicaid. Accordingly, our facility operators are subject to the potential negative effects of decreased reimbursement rates or other changes in reimbursement policy or programs offered through such reimbursement programs. Their revenue may also be adversely affected as a result of falling occupancy rates or slow lease-ups for assisted and independent living facilities due to various factors, including the ongoing COVID-19 pandemic and its effects and turmoil in the capital debt and real estate markets. In addition, our facility operators may incur additional demands on their existing financial resources as a result of increases in seniors housing facility operator liability, insurance premiums and other operational expenses. The economic deterioration of an operator could cause such operator to file for bankruptcy protection. The bankruptcy or insolvency of an operator may adversely affect the income produced by the property or properties it operates.
The performance and economic condition of our operators may be negatively affected if they fail to comply with various complex federal and state laws that govern a wide array of referrals, relationships and licensure requirements in the senior healthcare industry. The violation of any of these laws or regulations by a seniors housing facility operator may result in the imposition of fines or other penalties that could jeopardize that operator’s ability to make payment obligations to us or to continue operating its facility. In addition, legislative proposals are commonly being introduced or proposed in federal and state legislatures that could affect major changes in the seniors housing sector, either nationally or at the state level. Any such legislation could materially impact our operators in an adverse fashion.
We may change our targeted investments without stockholder consent.
We have acquired and expect to continue to acquire a diversified portfolio of healthcare-related assets including MOBs, SHOPs and other healthcare-related facilities. However, the board may change our investment policies in its sole discretion. We may change our targeted investments and investment guidelines at any time without the consent of our stockholders, which could result in our making investments that are different from, and possibly riskier than, initially anticipated by among other things, increasing our exposure to interest rate risk, default risk and real estate market fluctuations.
If we internalize our management functions, we would be required to pay a transition fee and would not have the right to retain our management or personnel.
We may engage in an internalization transaction and become self-managed in the future. If we internalize our management functions, under the terms of our advisory agreement we would be required to pay a transition fee to our Advisor upon termination of the advisory agreement in connection with an internalization that could be up to 4.5 times the compensation paid to our Advisor in the previous year, plus expenses. We also would not have any right to retain our executive officers or other personnel of our Advisor who currently manage our day-to-day operations. An inability to manage an internalization transaction effectively could thus result in our incurring excess costs and suffering deficiencies in our disclosure controls and procedures or our internal control over financial reporting. These deficiencies could cause us to incur additional costs, and our management’s attention could be diverted from most effectively managing our investments, which could result in litigation and resulting associated costs in connection with the internalization transaction.
We may terminate our advisory agreement in only limited circumstances, which may require payment of a termination fee.
We have limited rights to terminate our Advisor. The initial term of our advisory agreement expires on February 16, 2027, but is automatically renewed upon expiration for consecutive ten-year terms unless notice of termination is provided by either party 365 days in advance of the expiration of the term. Further, we may terminate the agreement only under limited circumstances. In the event of a termination in connection with a change in control of us, we would be required to pay a termination fee that could be up to four times the compensation paid to our Advisor in the previous year, plus expenses. The limited termination rights will make it difficult for us to renegotiate the terms of the advisory agreement or replace our Advisor even if the terms of the advisory agreement are no longer consistent with the terms generally available to externally-managed REITs for similar services.
Our business and operations could suffer if our Advisor or any other party that provides us with services essential to our operations experiences system failures or cyber incidents or a deficiency in cybersecurity.
The internal information technology networks and related systems of our Advisor and other parties that provide us with services essential to our operations (including our tenant operators and other third-party operators of our healthcare facilities) are vulnerable to damage from any number of sources, including computer viruses, unauthorized access, energy blackouts, natural disasters, terrorism, war and telecommunication failures. Any system failure or accident that causes interruptions in our operations could result in a material disruption to our business. We may also incur additional costs to remedy damages caused by these disruptions.
31

As reliance on technology has increased, so have the risks posed to those systems. Our Advisor and other parties that provide us with services essential to our operations must continuously monitor and develop their networks and information technology to prevent, detect, address and mitigate the risk of unauthorized access, misuse, computer viruses, and social engineering, such as phishing. Our Advisor is continuously working, including with the aid of third-party service providers, to install new, and to upgrade existing, network and information technology systems, to create processes for risk assessment, testing, prioritization, remediation, risk acceptance, and reporting, and to provide awareness training around phishing, malware and other cyber risks to ensure that our Advisor and other parties that provide us with services essential to our operations are protected against cyber risks and security breaches and that we are also therefore so protected. However, these upgrades, processes, new technology and training may not be sufficient to protect us from all risks. Even the most well protected information, networks, systems and facilities remain potentially vulnerable because the techniques and technologies used in attempted attacks and intrusions evolve and generally are not recognized until launched against a target. In some cases, attempted attacks and intrusions are designed not to be detected and, in fact, may not be detected.
The remediation costs and lost revenues experienced by a subject of an intentional cyberattack or other event which results in unauthorized third-party access to systems to disrupt operations, corrupt data or steal confidential information may be significant and significant resources may be required to repair system damage, protect against the threat of future security breaches or to alleviate problems, including reputational harm, loss of revenues and litigation, caused by any breaches. Additionally, any failure to adequately protect against unauthorized or unlawful processing of personal data, or to take appropriate action in cases of infringement may result in significant penalties under privacy law.
Furthermore, a security breach or other significant disruption involving the information technology networks and related systems of our Advisor or any other party that provides us with services essential to our operations could:
result in misstated financial reports, violations of loan covenants, missed reporting deadlines or missed permitting deadlines;
affect our ability to properly monitor our compliance with the rules and regulations regarding our qualification as a REIT;
result in the unauthorized access to, and destruction, loss, theft, misappropriation or release of, proprietary, confidential, sensitive or otherwise valuable information (including information about our tenant operators and other third-party operators of our healthcare facilities, as well as the patients or residents at those facilities), which others could use to compete against us or for disruptive, destructive or otherwise harmful purposes and outcomes;
result in our inability to maintain the building systems relied upon by our tenants for the efficient use of their leased space;
require significant management attention and resources to remedy any damages that result;
subject us to claims for breach of contract, damages, credits, penalties or termination of leases or other agreements; or
adversely impact our reputation among our tenants, operators and investors generally.
Although our Advisor and other parties that provide us with services essential to our operations intend to continue to implement industry-standard security measures, there can be no assurance that those measures will be sufficient, and any material adverse effect experienced by our Advisor and other parties that provide us with services essential to our operations could, in turn, have an adverse impact on us.
We depend on our Advisor and Property Manager to provide us with executive officers, key personnel and all services required for us to conduct our operations and our operating performance may be impacted by any adverse changes in the financial health or reputation of our Advisor.
We have no employees. Personnel and services that we require are provided to us under contracts with our Advisor and its affiliates including our Property Manager. We depend on our Advisor and our Property Manager to manage our operations and acquire and manage certain of our real estate assets. Our Advisor makes all decisions with respect to the management of our company, subject to the supervision of, and any guidelines established by, the board.
Thus, our success depends to a significant degree upon the contributions of our executive officers and other key personnel of our Advisor and its affiliates, including Edward M. Weil, Jr., our chief executive officer. In February 2021 Katie P. Kurtz, resigned as our chief financial officer, treasurer and secretary effective April 9, 2021 and our board of directors unanimously elected Jason Doyle as assistant secretary, effective immediately, and as chief financial officer and secretary, effective upon Ms. Kurtz’s resignation. Neither our Advisor nor any of its affiliates has an employment agreement with these key personnel and we cannot guarantee that all, or any particular one, of these individuals will remain employed by our Advisor or one of its affiliates and otherwise available to continue to perform services for us. Further, we do not maintain key person life insurance on any person. We believe that our success depends, in large part, upon the ability of our Advisor to hire, retain or contract for services of highly skilled managerial, operational and marketing personnel. Competition for skilled personnel is intense, and there can be no assurance that our Advisor will be successful in attracting and retaining skilled personnel. If our Advisor loses
32

or is unable to obtain the services of key personnel, our Advisor’s ability to manage our business and implement our investment strategies could be delayed or hindered.
Any adverse changes in the financial condition or financial health of, or our relationship with, our Advisor or Property Manager, including any change resulting from an adverse outcome in any litigation could hinder their ability to successfully manage our operations and our portfolio of investments. Additionally, changes in ownership or management practices, the occurrence of adverse events affecting our Advisor or its affiliates or other companies advised by our Advisor or its affiliates could create adverse publicity and adversely affect us and our relationship with lenders, tenants, operators or counterparties.
We may in the future acquire or originate real estate debt or invest in real estate-related securities issued by real estate market participants, which would expose us to additional risks.
We may in the future acquire or originate first mortgage debt loans, mezzanine loans, preferred equity or securitized loans, CMBS, preferred equity and other higher-yielding structured debt and equity investments. Doing so would expose us not only to the risks and uncertainties we are currently exposed to through our direct investments in real estate but also to additional risks and uncertainties attendant to investing in and holding these types of investments, such as:
risk of defaults by borrowers in paying debt service on outstanding indebtedness and to other impairments of our loans and investments;
increased competition from entities engaged in mortgage lending and, or investing in our target assets;
deterioration in the performance of properties securing our investments may cause deterioration in the performance of our investments and, potentially, principal losses to us;
fluctuations in interest rates and credit spreads could reduce our ability to generate income on our loans and other investments;
difficulty in redeploying the proceeds from repayments of our existing loans and investments;
the illiquidity of certain of these investments;
lack of control over certain of our loans and investments;
the potential need to foreclose on certain of the loans we originate or acquire, which could result in losses;
additional risks, including the risks of the securitization process, posed by investments in CMBS and other similar structured finance investments, as well as those we structure, sponsor or arrange; use of leverage may create a mismatch with the duration and interest rate of the investments that we financing;
risks related to the operating performance or trading price volatility of any publicly-traded and private companies primarily engaged in real estate businesses we invest in; and
the need to structure, select and more closely monitor our investments such that we continue to maintain our qualification as a REIT and our exemption from registration under the Investment Company Act of 1940, as amended.

Risks Related to our Indebtedness

Our level of indebtedness may increase our business risks.
As of December 31, 2020, we had total outstanding indebtedness of $1.2 billion. We may incur additional indebtedness in the future for various purposes. The amount of our indebtedness could have material adverse consequences for us, including:
hindering our ability to adjust to changing market, industry or economic conditions;
limiting our ability to access the capital markets to raise additional equity or debt on favorable terms or at all, whether to refinance maturing debt, to fund acquisitions, to fund dividends and other distributions or for other corporate purposes;
limiting the amount of free cash flow available for future operations, acquisitions, dividends and other distributions, stock repurchases or other uses; and
making us more vulnerable to economic or industry downturns, including interest rate increases.
In most instances, we acquire real properties by using either existing financing or borrowing new funds. In addition, we may incur mortgage debt and pledge the underlying property as security for that debt to obtain funds to acquire additional real properties or for other corporate purposes. We may also borrow if we need funds to satisfy the REIT tax qualification requirement that we generally distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding any net capital gain. We also may borrow if we otherwise deem it necessary or advisable to assure that we maintain our qualification as a REIT.
33

If there is a shortfall between the cash flow from a property and the cash flow needed to service mortgage debt on that property, especially if we acquire the property when it is being developed or under construction, we may use additional borrowings to fund the shortfall. Using debt increases the risk of loss because defaults on indebtedness secured by a property may result in lenders initiating foreclosure actions. In that case, we could lose the property securing the loan that is in default. For U.S. federal income tax purposes, a foreclosure of any of our properties would be treated as a sale of the property for a purchase price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds. In this event, we may be unable to pay the amount of distributions required in order to maintain our REIT status. We may give full or partial guarantees to lenders of mortgage debt to the entities that own our properties. In those cases, we will be responsible to the lender for repaying the debt if it is not paid by the entity. If any mortgages contain cross-collateralization or cross-default provisions, a default on a single property could affect multiple properties.
Our Credit Facility contains various covenants that may restrict our ability to take certain actions and may restrict our ability to use our cash and make investments.
Our Credit Facility contains various covenants that may restrict our ability to take certain actions for example, may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of our common stock) on our common stock until no earlier than the fiscal quarter ending June 30, 2021. We may, however, pay dividends on the Series A Preferred Stock, or any other preferred stock we may issue and any cash distributions necessary to maintain our status as a REIT. The restrictions on paying cash distributions will no longer apply starting in the quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter, we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%. There can be no assurance as to if, or when, we will be able to satisfy these conditions. Moreover, we will only be permitted to pay cash distributions if the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after we make the election and begin paying distributions.
Covenants in the Credit Facility which restrict payment of distributions to a threshold based on Modified FFO, require maintenance of a minimum ratio of consolidated total indebtedness to consolidated total asset value and a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges did not apply for the fiscal quarter ended June 30, 2020. In addition, the lenders waived any defaults or event of defaults under those covenants that may have occurred during the fiscal quarter ended June 30, 2020 as well as any additional default or event of default resulting therefrom prior to August 10, 2020. There can be no assurance our lenders will consent to any amendments or waivers that may become necessary to comply with our Credit Facility in the future.
Covenants in our Credit Facility also require us to maintain a combination of cash, cash equivalents and availability for future borrowings under our Revolving Credit Facility totaling at least $50.0 million. As of December 31, 2020, we had $72.4 million of cash and cash equivalents, and $48.3 million was available for future borrowings under our Revolving Credit Facility. Following the amendment in August 2020, our Credit Facility also restricts our sources of liquidity. Pursuant to an amendment to our Credit Facility in August 2020, certain restrictions and conditions will no longer apply starting in a quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% (the “Commencement Quarter”). Until the first day of the Commencement Quarter, we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. We may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
Even if we are ultimately able to reborrow amounts generated by capital events that are required to be used to prepay the Revolving Credit Facility, there still can be no assurance as to the additional amount we will be able to generate from capital events and therefore availability under our Credit Facility giving effect to any required prepayment. Unencumbered real estate investments, at cost as of December 31, 2020 was $231.5 million, although our recently completed development property in Jupiter, Florida - representing $53.2 million in real estate investments, at cost is currently subject to a PSA. There can be no assurance as to the amount of liquidity we would be able to generate from adding any of the unencumbered assets we own to the borrowing base of our Credit Facility or pledging them as security for a new mortgage loan. Two of our assets, our recently completed development property in Jupiter, Florida and our skilled nursing facility in Wellington, Florida are under PSA to be sold, for an aggregate contract purchase price of $98.0 million, but these dispositions are subject to conditions. Due to the persistence of the COVID-19 pandemic and other factors beyond our control, there can be no assurance that we will be able to meet these conditions and that these dispositions will be completed on their contemplated terms, or at all. With respect to the
34

our skilled nursing facility in Wellington, Florida to be sold for $33.0 million, closing may not occur unless, among other conditions, certain occupancy and revenue levels have been maintained at each property for a period of time. In addition, any capital-raising transaction, to the extent we are able to access the debt or equity capital markets (which is not assured) could be on terms that would not be favorable to us or our stockholders, including high interest rates, in the case of debt, and substantial dilution, in the case of issuing equity or convertible debt securities. This includes any capital we may raise under our “Preferred Stock Equity Line” with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which we have right from time to time to sell up to an aggregate $15 million of shares of our Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement for the Preferred Stock Equity Line. Our ability to require purchaser under the Preferred Stock Equity Line to purchase shares of our Series A Preferred Stock and obtain funds when requested is limited by the terms and conditions of the preferred stock purchase agreement. There is no guarantee that we will receive all or any portion of the $15.0 million that is available to us under the Preferred Stock Equity Line.
The availability for future borrowings under the Credit Facility is calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and availability has been, and may continue to be, adversely affected by the decreases income from our operators that have resulted from the effects of the COVID-19 pandemic and may persist for some time. Our ability to increase the amount of cash we generate from property operations depends on a variety of factors, including the duration and scope of the COVID-19 pandemic and its impact on our tenants and properties, our ability to complete acquisitions of new properties on favorable terms and our ability to improve operations at our existing properties. There can be no assurance that we will complete acquisitions on a timely basis or on favorable terms and conditions, if at all, particularly if we do not have a source of capital available that will allow us to do so. Our ability to improve operations at our existing properties is also subject to a variety of risks and uncertainties, many of which are beyond our control, and there can be no assurance we will be successful in achieving this objective. Because shares of common stock are only offered and sold pursuant to the our distribution reinvestment plan (“DRIP”) in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as we pay distributions in stock instead of cash, so this source of capital will not be available unless and until we are able to resume paying cash distributions on our common stock. There is also no assurance that participation in the DRIP will be maintained at current or higher levels if the DRIP becomes a source of capital in the future.
Other financing arrangements have restrictive covenants.
Other financing arrangements contain provisions that affect or restrict our policies regarding dividends and other distributions and our operations, require us to satisfy financial coverage ratios, and may restrict our ability to, among other things, incur additional indebtedness, make certain investments, replace our Advisor, discontinue insurance coverage, merge with another company, and create, incur or assume liens. These or other limitations may adversely affect our flexibility and our ability to achieve our investment and operating objectives.
Changes in the debt markets could have a material adverse impact on our earnings and financial condition.
The commercial real estate debt markets are subject to volatility, resulting in, from time to time, the tightening of underwriting standards by lenders and credit rating agencies and reductions in the availability of financing. For example, the COVID-19 pandemic has adversely affected credit and capital market conditions resulting in volatility and a tightening of credit standards from time to time. This may impact our ability to access capital on favorable terms, in a timely manner, or at all, which could make obtaining funding for our capital needs more challenging or expensive.
If our overall cost of borrowings increases, either due to increases in the index rates or due to increases in lender spreads, we will need to factor such increases into the economics of future acquisitions. This may result in future acquisitions generating lower overall economic returns. Disruption or tightening of credit standards in the debt markets, may negatively impact our ability to borrow monies to finance the purchase of, or other activities related to, our real estate assets may be negatively impacted. If we are unable to borrow monies on terms and conditions that we find acceptable, our ability to purchase properties and meet other capital requirements may be limited, and the return on the properties we do purchase may be lower. In addition, we may find it difficult, costly or impossible to refinance maturing indebtedness.
Furthermore, the state of the debt markets could have an impact on the overall amount of capital being invested in real estate, which may result in price or value decreases of real estate assets and could negatively impact the value of our assets.
Increases in mortgage rates may make it difficult for us to finance or refinance indebtedness secured by our properties.
We have incurred, and may continue to incur, mortgage debt. We run the risk of being unable to refinance our mortgage loans when they come due or we otherwise desire to do so on favorable terms, or at all. If interest rates are higher when the indebtedness is refinanced, we may not be able to refinance indebtedness secured by the properties and we may be required to obtain equity to repay the mortgage or to increase the collateral for the loan.
Increasing interest rates could increase the amount of our debt payments and we may be adversely affected by uncertainty surrounding the LIBOR.
35

We have incurred, and may continue to incur, variable-rate debt. Increases in interest rates on our variable-rate debt would increase our interest cost.
If we need to repay existing debt during periods of rising interest rates, we may need to sell one or more of our investments in properties even though we would not otherwise choose to do so.
We have mortgages, credit facilities and derivative agreements that have terms that are based on the London Interbank Offered Rate (“LIBOR”). As of December 31, 2020, we have nine designated interest rate swaps with a notional amount of $578.5 million, which effectively fixes a portion of our variable-rate debt. In July 2017, the Financial Conduct Authority (the authority that regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline, announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. We are not able to predict when there will be sufficient liquidity in the SOFR market. We are monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. In some instances, transitioning to an alternative rate may require negotiation with lenders and other counterparties and could present challenges. Certain of our agreements that have terms that are based on LIBOR have alternative rates already contained in the agreements while others do not. We anticipate that we will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rate for LIBOR with the lenders and derivative counterparties. The consequences of these developments cannot be entirely predicted and could include an increase in the cost of our variable rate debt.
The consequences of these developments cannot be entirely predicted and could include an increase in the cost of our variable rate indebtedness. While we expect LIBOR to be available in substantially its current form until at least the end of 2021, it is possible that LIBOR will become unavailable prior to that time. This could occur, for example, if a sufficient number of banks decline to make submissions to the LIBOR administrator. In that case, the risks associated with the transition to an alternative reference rate would be accelerated or magnified. Any of these events, as well as the other uncertainty surrounding the transition to LIBOR, could adversely affect us.
Any hedging strategies we utilize may not be successful in mitigating our risks.
We have and may continue to enter into hedging transactions to manage risk of interest rate changes, price changes or currency fluctuations with respect to borrowings made or to be made to acquire or own real estate assets. To the extent that we use derivative financial instruments in connection with these risks, we will be exposed to credit, basis and legal enforceability risks. Derivative financial instruments may include interest rate swap contracts, interest rate cap or floor contracts, futures or forward contracts, options or repurchase agreements. In this context, credit risk is the failure of the counterparty to perform under the terms of the derivative contract. If the fair value of a derivative contract is positive, the counterparty owes us, which creates credit risk for us. Basis risk occurs when the index upon which the contract is based is more or less variable than the index upon which the hedged asset or liability is based, thereby making the hedge less effective. Finally, legal enforceability risks encompass general contractual risks, including the risk that the counterparty will breach the terms of, or fail to perform its obligations under, the derivative contract.

Risks Related to Conflicts of Interest

Our Advisor faces conflicts of interest relating to the purchase and leasing of properties and these conflicts may not be resolved in our favor, which could adversely affect our investment opportunities.
We rely on our Advisor and its executive officers and other key real estate professionals at our Advisor and our Property Manager to identify suitable investment opportunities for us. Several of these individuals are also executive officers or key real estate professionals at AR Global and other entities advised by affiliates of AR Global. Many investment opportunities that are suitable for us may also be suitable for other entities advised by affiliates of AR Global. We do not have any agreements with any of these entities that govern the allocation of investment opportunities. Thus, the executive officers and real estate professionals at our Advisor could direct attractive investment opportunities to other entities advised by affiliates of AR Global.
We and other entities advised by affiliates of AR Global also rely on these executive officers and other key real estate professionals to supervise the property management and leasing of properties. These individuals, as well as AR Global, as an entity are not prohibited from engaging, directly or indirectly, in any business or from possessing interests in other businesses and ventures, including businesses and ventures involved in the acquisition, development, ownership, leasing or sale of real estate investments.
36

In addition, we may acquire properties in geographic areas where other entities advised by affiliates of AR Global own properties, and if we may acquire properties from, or sell properties to, other entities advised by affiliates of AR Global. If one of the other entities advised by affiliates of AR Global attracts a tenant that we are competing for, we could suffer a loss of revenue due to delays in locating another suitable tenant.
Our Advisor faces conflicts of interest relating to joint ventures, which could result in a disproportionate benefit to the other venture partners at our expense.
We may enter into joint ventures with other entities advised by affiliates of AR Global for the acquisition, development or improvement of properties. Our Advisor may have conflicts of interest in determining which entities advised by affiliates of AR Global should enter into any particular joint venture agreement. The co-venturer may have economic or business interests or goals that are or may become inconsistent with our business interests or goals. In addition, our Advisor may face a conflict in structuring the terms of the relationship between our interests and the interest of the affiliated co-venturer and in managing the joint venture. Due to the role of our Advisor and its affiliates, agreements and transactions between the co-venturers with respect to any joint venture will not have the benefit of arm’s-length negotiation of the type normally conducted between unrelated co-venturers, which may result in the co‑venturer receiving benefits greater than the benefits that we receive. In addition, we may assume liabilities related to the joint venture that exceeds the percentage of our investment in the joint venture.
Our Advisor, AR Global and their officers and employees and certain of our executive officers and other key personnel face competing demands relating to their time, and this may cause our operating results to suffer.
Our Advisor, AR Global and their officers and employees and certain of our executive officers and other key personnel and their respective affiliates are key personnel, general partners, sponsors, managers, owners and advisors of other real estate investment programs, including entities advised by affiliates of AR Global, some of which have investment objectives and legal and financial obligations similar to ours and may have other business interests as well. Because these entities and individuals have competing demands on their time and resources, they may have conflicts of interest in allocating their time between our business and these other activities.
All of our executive officers, some of our directors and the key real estate and other professionals assembled by our Advisor and our Property Manager face conflicts of interest related to their positions or interests in entities related to AR Global, which could hinder our ability to implement our business strategy.
All of our executive officers, and the key real estate and other professionals assembled by our Advisor and Property Manager are also executive officers, directors, managers, key professionals or holders of a direct or indirect interests in our Advisor, our Property Manager or other AR Global-affiliated entities. Through AR Global’s affiliates, some of these persons work on behalf of entities advised by affiliates of AR Global. In addition, all of our executive officers and some of our directors serve in similar capacities for other entities advised by affiliates of our Advisor. As a result, they have duties to each of these entities, which duties could conflict with the duties they owe to us and could result in action or inaction detrimental to our business. Conflicts with our business and interests are most likely to arise from (a) allocation of investments and management time and services between us and the other entities; (b) compensation to our Advisor or Property Manager (c) our purchase of properties from, or sale of properties to, entities advised by affiliates of our Advisor; and (d) investments with entities advised by affiliates of our Advisor. Conflicts of interest may hinder our ability to implement our business strategy, and, if we do not successfully implement our business strategy.
Our Advisor faces conflicts of interest relating to the structure of the compensation it may receive.
Under our advisory agreement, the Advisor is entitled to substantial minimum compensation regardless of performance as well as incentive compensation. The variable base management fee payable to the Advisor under the advisory agreement increases proportionately with the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) raised by us. In addition, the limited partnership agreement of our OP requires it to pay a subordinated incentive listing distribution to the “Special Limited Partner,” an affiliate of our Advisor, in connection with a listing or other liquidity event, such as the sale of all or substantially all of our assets, or if we terminate the advisory agreement, even for “cause.” The Special Limited Partner is also entitled to participate in the distribution of net sales proceeds. These arrangements, coupled with the fact that the Advisor does not maintain a significant equity interest in us, may result in the Advisor taking actions or recommending investments that are riskier or more speculative than an advisor with a more significant investment in us might take or recommend. In addition, these fees reduce the cash available for investment or other
corporate purposes.

Risks Related to our Corporate Structure

Our common stock is not traded on a national securities exchange, and our SRP, which provides for repurchases only in the event of death or disability of a stockholder, is suspended. Stockholders may have to hold their shares for an indefinite period of time.
37

Our common stock is not listed on a national securities exchange and there is otherwise no active trading market for the shares and our SRP is suspended. Even if not suspended, our SRP includes numerous restrictions that limit a stockholder’s ability to sell shares of common stock to us, including limiting repurchases only to stockholders that have died or become disabled, limiting the total value of repurchases pursuant to our SRP to the amount of proceeds received from issuances of common stock pursuant to the DRIP and limiting repurchases in any fiscal semester to 2.5% of the average number of shares outstanding during the previous fiscal year. These limits are subject to the authority of the board to identify another source of funds for repurchases under the SRP. The board may also reject any request for repurchase of shares at its discretion or amend, suspend or terminate our SRP upon notice in its discretion. Shares that are repurchased will be repurchased at a price equal to the applicable Estimated Per-Share NAV and may be at a substantial discount to the price the stockholder paid for the shares. We are also restricted from making any share repurchases until the Commencement Quarter and, after that, to the extent they would be aggregated with dividends and other distributions to our stockholders under the covenant in our Credit Facility.
The Estimated Per-Share NAV of our common stock is based upon subjective judgments, assumptions and opinions about future events, and may not reflect the amount that our stockholders might receive for their shares.
We intend to publish an updated Estimated Per-Share NAV as of December 31, 2020 shortly after filing this Annual Report on Form 10-K. Our Advisor has engaged an independent valuer to perform appraisals of our real estate assets in accordance with valuation guidelines established by the board. As with any methodology used to estimate value, the valuation methodologies that will be used by any independent valuer to value our properties involve subjective judgments concerning factors such as comparable sales, rental and operating expense data, capitalization or discount rate, and projections of future rent and expenses.
Under our valuation guidelines, our independent valuer estimates the market value of our principal real estate and real estate-related assets, and our Advisor makes a recommendation as to the net value of our real estate and real estate-related assets and liabilities taking into consideration such estimate provided by the independent valuer. Our Advisor reviews the valuation provided by the independent valuer for consistency with our valuation guidelines and the reasonableness of the independent valuer’s conclusions. The independent directors of the board oversee and review the appraisals and valuations and make a final determination of the Estimated Per-Share NAV. The independent directors of the board rely on our Advisor’s input, including its view of the estimate and the appraisals performed by the independent valuer, but the independent directors of the board may, in their discretion, consider other factors. Although the valuations of our real estate assets by the independent valuer are reviewed by our Advisor and approved by the independent directors of the board, neither our Advisor nor the independent directors of the board will independently verify the appraised value of our properties and valuations do not necessarily represent the price at which we would be able to sell any asset. As a result, the appraised value of a particular property may be greater or less than its potential realizable value, which would cause our estimated per-share NAV to be greater or less than the potential realizable value of our assets.
The price at which shares of our common stock may be sold under the DRIP and the price at which shares of our common stock may be repurchased by us pursuant to the SRP are based on Estimated Per-Share NAV and may not reflect the price that our stockholders would receive for their shares in a market transaction, the proceeds that would be received upon our liquidation or the price that a third-party would pay to acquire us.
Because Estimated Per-Share NAV is only determined annually, it may differ significantly from our actual per‑share net asset value at any given time.
Our board estimates the per-share net asset value of our common stock only on an annual basis. In connection with any valuation, the board estimate of the value of our real estate and real estate-related assets will be partly based on appraisals of our properties. Because the process of making this estimate is conducted annually, this process may not account for material events that occur after the estimate has been completed for that year. Material events could include the appraised value of our properties substantially changing actual property operating results differing from what we originally budgeted or dividends and other distributions to stockholders exceeding cash flow generated by us. Any such material event could cause a change in the Estimated Per-Share NAV that would not be reflected until the next valuation. Also, dividends and other distributions in excess of our cash flows provided by operations could decrease our Estimated Per-Share NAV. Estimated Per-Share NAV will not be adjusted for stock dividends paid or that may be paid in the future until the board determines a new Estimated Per-Share NAV. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, each common stockholder will receive the same number of new shares, the total value of our common stockholders’ investment, all things equal, will not change assuming no sales or other transfers. As a result, the Estimated Per-Share NAV may not reflect the value of shares of our common stock at any given time, and our estimated per-share NAV may differ significantly from our actual per-share net asset value at any given time.
The trading price of our Series A Preferred Stock may fluctuate significantly.
The trading price of our Series A Preferred Stock may be volatile and subject to significant price and volume fluctuations in response to market and other factors, and is impacted by a number of factors, many of which are outside our control. Among the factors that could affect the trading price are:
38

our financial condition and performance;
our ability to grow through property acquisitions, the terms and pace of any acquisitions we may make and the availability and terms of financing for those acquisitions;
the financial condition of our tenants, including tenant bankruptcies or defaults;
actual or anticipated quarterly fluctuations in our operating results and financial condition;
the amount and frequency of our payment of dividends and other distributions;
additional sales of equity securities, including Series A Preferred Stock, common stock or any other equity interests, or the perception that additional sales may occur;
the reputation of REITs and real estate investments generally and the attractiveness of REIT equity securities in comparison to other equity securities, and fixed income debt securities;
our reputation and the reputation of AR Global and its affiliates or other entities advised by AR Global and its affiliates;
uncertainty and volatility in the equity and credit markets;
fluctuations in interest rates and exchange rates;
changes in revenue or earnings estimates, if any, or publication of research reports and recommendations by financial analysts or actions taken by rating agencies with respect to our securities or those of other REITs;
failure to meet analyst revenue or earnings estimates;
strategic actions by us or our competitors, such as acquisitions or restructurings;
the extent of investment in our Series A Preferred Stock by institutional investors;
the extent of short-selling of our Series A Preferred Stock;
general financial and economic market conditions and, in particular, developments related to market conditions for REITs and other real estate related companies;
failure to maintain our REIT status;
changes in tax laws;
domestic and international economic factors unrelated to our performance; and
all other risk factors addressed elsewhere in this Annual Report on Form 10-K.
Moreover, although shares of Series A Preferred Stock are listed on The Nasdaq Global Market, there can be no assurance that the trading volume for shares will provide sufficient liquidity for holders to sell their shares at the time of their choosing or that the trading price for shares will equal or exceed the price paid for the shares. Because the shares of Series A Preferred Stock carry a fixed dividend rate, the trading price in the secondary market will be influenced by changes in interest rates and will tend to move inversely to changes in interest rates. In particular, an increase in market interest rates may result in higher yields on other financial instruments and may lead purchasers of shares of Series A Preferred Stock to demand a higher yield on their purchase price, which could adversely affect the market price of those shares.
The limit on the number of shares a person may own may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
Our charter, with certain exceptions, authorizes our directors to take such actions as are necessary and desirable to preserve our qualification as a REIT. Unless exempted (prospectively or retroactively) by the board, no person may own more than 9.8% in value of the aggregate of our outstanding shares of our capital stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of shares of our capital stock. This restriction may have the effect of delaying, deferring or preventing a change in control of us, including an extraordinary transaction (such as a merger, tender offer or sale of all or substantially all our assets) that might provide a premium price for holders of our common stock.
The terms of our Series A Preferred Stock, and the terms of other preferred stock we may issue, may discourage a third- party from acquiring us in a manner that might result in a premium price to stockholders.
The change of control conversion and redemption features of the Series A Preferred Stock may make it more difficult for a party to acquire us or discourage a party from seeking to acquire us. Upon the occurrence of a change of control, holders of Series A Preferred Stock will, under certain circumstances, have the right to convert some of or all their shares of Series A Preferred Stock into shares of our common stock (or equivalent value of alternative consideration) and under these circumstances we will also have a change of control redemption right to redeem shares of Series A Preferred Stock. Upon exercise of this conversion right, the holders will be limited to a maximum number of shares of our common stock pursuant to a predetermined ratio. These features of the Series A Preferred Stock may have the effect of discouraging a third-party from seeking to acquire us or of delaying, deferring or preventing a change of control under circumstances that otherwise could provide the holders of our common stock with the opportunity to realize a premium over the then-current market price or that stockholders may otherwise believe is in their best interests. We may also issue other classes or series of preferred stock that could also have the same effect.
We may issue additional equity securities in the future.
Our stockholders do not have preemptive rights to any shares issued by us in the future. Our charter authorizes us to issue up to 350,000,000 shares of stock, consisting of 300,000,000 shares of common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of December 31, 2020, we had the following stock issued
39

and outstanding: (i) 93,775,746 shares of common stock; and (ii) 1,610,000 shares of Series A Preferred Stock. Subject to the approval rights of holders of our Series A Preferred Stock regarding authorization or issuance of equity securities ranking senior to the Series A Preferred Stock, the board, without approval of our common stockholders, may amend our charter from time to time to increase or decrease the aggregate number of authorized shares of stock, or the number of authorized shares of any class or series of stock or may classify or reclassify any unissued shares into other classes or series of stock without obtaining stockholder approval and establish the preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications or terms or conditions of redemption of the stock.
All of our authorized but unissued shares of stock may be issued in the discretion of the board. The issuance of additional shares of our common stock could dilute the interests of the holders of our common stock, and any issuance of shares of preferred stock senior to our common stock, such as our Series A Preferred Stock, or any incurrence of additional indebtedness, could affect our ability to pay distributions on our common stock. The issuance of additional shares of preferred stock ranking equal or senior to our Series A Preferred Stock, including preferred stock convertible into shares of our common stock, could dilute the interests of the holders of common stock, Series A Preferred Stock and any issuance of shares of preferred stock senior to our Series A Preferred Stock or incurrence of additional indebtedness could affect our ability to pay dividends on, redeem or pay the liquidation preference on our Series A Preferred Stock. These issuances could also adversely affect our Estimated Per-Share NAV or the trading price of our Series A Preferred Stock.
We may issue shares in public or private offerings in the future, including shares of our common stock issued as awards to our officers, directors and other eligible persons, pursuant to the advisory agreement in payment of fees thereunder and pursuant to the DRIP. We may also issue OP Units to sellers of properties we acquire which, subject to satisfying certain requirements, would give the holder of OP Units the option to redeem OP Units for shares of our common stock or cash at our option. We also may issue securities that are convertible into shares of our common stock.
Because our decision to issue equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings. The issuance of additional equity securities could adversely affect stockholders.
We have a classified board, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
The board is divided into three classes of directors. At each annual meeting, directors of one class are elected to serve until the annual meeting of stockholders held in the third year following the year of their election and until their successors are duly elected and qualify. The classification of our directors may have the effect of delaying, deferring or preventing a change in control of us, including an extraordinary transaction (such as a merger, tender offer or sale of all or substantially all our assets) that might result in a premium price for our stockholders.
Maryland law prohibits certain business combinations, which may make it more difficult for us to be acquired and may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
Under Maryland law, “business combinations” between a Maryland corporation and an interested stockholder or an affiliate of an interested stockholder are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. These business combinations include a merger, consolidation, share exchange or, in circumstances specified in the statute, an asset transfer or issuance or reclassification of equity securities. An interested stockholder is defined as:
any person who beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock; or
an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner of, directly or indirectly, 10% or more of the voting power of the then outstanding stock of the corporation.
A person is not an interested stockholder under the statute if the board of directors approved in advance the transaction by which he or she otherwise would have become an interested stockholder. However, in approving a transaction, the board of directors may provide that its approval is subject to compliance, at or after the time of approval, with any terms and conditions determined by the board of directors.
After the five-year prohibition, any business combination between the Maryland corporation and an interested stockholder generally must be recommended by the board of directors of the corporation and approved by the affirmative vote of at least:
80% of the votes entitled to be cast by holders of outstanding shares of voting stock of the corporation; and
two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom or with whose affiliate the business combination is to be effected or held by an affiliate or associate of the interested stockholder.
These super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price, as defined under Maryland law, for their shares in the form of cash or other consideration in the same form as previously paid by
40

the interested stockholder for its shares. The business combination statute permits various exemptions from its provisions, including business combinations that are exempted by the board of directors prior to the time that the interested stockholder becomes an interested stockholder. Pursuant to the statute, the board has exempted any business combination involving our Advisor or any affiliate of our Advisor. Consequently, the five-year prohibition and the super-majority vote requirements will not apply to business combinations between us and our Advisor or any affiliate of our Advisor. As a result, our Advisor and any affiliate of our Advisor may be able to enter into business combinations with us that may not be in the best interests of our stockholders, without compliance with the super-majority vote requirements and the other provisions of the statute. The business combination statute may discourage others from trying to acquire control of us and increase the difficulty of consummating any offer.
Our bylaws designate the Circuit Court for Baltimore City, Maryland as the sole and exclusive forum for certain actions and proceedings that may be initiated by our stockholders.
Our bylaws provide that, unless we consent to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Northern Division, is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, other than actions arising under federal securities laws; (b) any Internal Corporate Claim, as such term is defined in the Maryland General Corporation (the “MGCL”), or any successor provision thereof, including, without limitation, (i) any action asserting a claim of breach of any duty owed by any of our directors, officers or other employees to us or to our stockholders or (ii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the MGCL, our charter or our bylaws; or (c) any other action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine. Our bylaws also provide that unless we consent in writing, none of the foregoing actions, claims or proceedings may be brought in any court sitting outside the State of Maryland and the federal district courts are, to the fullest extent permitted by law, the sole and exclusive forum for the resolution of any complaint asserting a cause of action under the Securities Act. These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that the stockholder believes is favorable. Alternatively, if a court were to find these provisions of our bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving these matters in other jurisdictions.
Maryland law limits the ability of a third-party to buy a large stake in us and exercise voting power in electing directors, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
The Maryland Control Share Acquisition Act provides that holders of “control shares” of a Maryland corporation acquired in a “control share acquisition” have no voting rights except to the extent approved by the stockholders by the affirmative vote of two-thirds of all the votes entitled to be cast on the matter, excluding all shares of stock owned by the acquirer, by officers or by employees who are directors of the corporation. “Control shares” are voting shares of stock which, if aggregated with all other shares of stock owned by the acquirer or in respect of which the acquirer can exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquirer to exercise voting power in electing directors within specified ranges of voting power. Control shares do not include shares the acquiring person is then entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation. A “control share acquisition” means the acquisition of issued and outstanding control shares. The Maryland Control Share Acquisition Act does not apply (a) to shares acquired in a merger, consolidation or share exchange if the corporation is a party to the transaction, or (b) to acquisitions approved or exempted by the charter or bylaws of the corporation.
Our bylaws contain a provision exempting from the Maryland Control Share Acquisition Act any and all acquisitions of our stock by any person. There can be no assurance that this provision will not be amended or eliminated at any time in the future.
If our stockholders do not agree with the decisions of the board, our stockholders only have limited control over changes in our policies and operations and may not be able to change our policies and operations.
The board determines our major policies, including our policies regarding investments, financing, growth, debt capitalization, REIT qualification and dividends and other distributions. The board may amend or revise these and other policies without a vote of the stockholders except to the extent that the policies are set forth in our charter. Under Maryland General Corporation Law and our charter, our common stockholders have a right to vote only on the following:
the election or removal of directors;
amendment of our charter, except that the board may amend our charter without stockholder approval to (a) increase or decrease the aggregate number of our shares of stock or the number of shares of stock of any class or series that we have the authority to issue, (b) effect certain reverse stock splits, and (c) change our name or the name or other designation or the par value of any class or series of our stock and the aggregate par value of our stock;
our liquidation or dissolution;
certain reorganizations of our company; and
certain mergers, consolidations or sales or other dispositions of all or substantially all our assets
41

All other matters are subject to the discretion of the board. Holders of our Series A Preferred Stock have extremely limited voting rights.
The stockholder rights plan adopted by our board of directors may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
In May 2020, our board of directors adopted a stockholder rights plan that will expire in May 2023 or sooner under certain circumstances. In connection with the rights plan, in December 2020, we paid a dividend of one common share purchase right for each share of our common stock outstanding as authorized by our board in its discretion. If a person or entity, together with its affiliates and associates, acquires beneficial ownership of 2.0% or more of our then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than the acquirer, its affiliates and associates) to purchase additional shares of our common stock at a substantial discount to the then current per share estimated net asset value. In addition, under certain circumstances, we may exchange the rights (other than rights beneficially owned by the acquirer, its affiliates and associates), in whole or in part, for shares of common stock on a one-for-one basis. The stockholder rights plan could make it more difficult for a third-party to acquire the Company or a large block of our common stock without the approval of our board or directors, which may discourage a third-party from acquiring us in a manner that might result in a premium price to our stockholders.
We depend on our OP and its subsidiaries for cash flow and are structurally subordinated in right of payment to the obligations of our OP and its subsidiaries.
We conduct, and intend to continue conducting, all of our business operations through our OP, and, accordingly, we rely on distributions from our OP and its subsidiaries to provide cash to pay our obligations. There is no assurance that our OP or its subsidiaries will be able to, or be permitted to, pay distributions to us that will enable us to pay dividends and other distributions to our stockholders and meet our other obligations. Each of our OP’s subsidiaries is a distinct legal entity and, under certain circumstances, legal and contractual restrictions may limit our ability to obtain cash from these entities. In addition, any claims we may have will be structurally subordinated to all existing and future liabilities and obligations of our OP and its subsidiaries. Therefore, in the event of our bankruptcy, liquidation or reorganization, our assets and those of our OP and its subsidiaries will be available to satisfy the claims of our creditors or to pay dividends and other distributions to our stockholders only after all the liabilities and obligations of our OP and its subsidiaries have been paid in full.
We indemnify our officers, directors, our Advisor and its affiliates against claims or liability they may become subject to due to their service to us, and our rights and the rights of our stockholders to recover claims against our officers, directors, our Advisor and its affiliates are limited.
Maryland law provides that a director has no liability in that capacity if he or she performs his or her duties in good faith, in a manner he or she reasonably believes to be in the corporation’s best interests and with the care that an ordinarily prudent person in a like position would use under similar circumstances. In addition, subject to certain limitations set forth therein or under Maryland law, our charter provides that no director or officer will be liable to us or our stockholders for monetary damages and permits us to indemnify our directors and officers from liability and advance certain expenses to them in connection with claims or liability they may become subject to due to their service to us, and we are not restricted from indemnifying our Advisor or its affiliates on a similar basis. We have entered into indemnification agreements consistent with Maryland law and our charter with our directors and officers, certain former directors and officers, our Advisor and AR Global. We and our stockholders may have more limited rights against our directors, officers, employees and agents, and our Advisor and its affiliates, than might otherwise exist under common law, which could reduce the recovery of our stockholders and our recovery against them. In addition, we may be obligated to fund the defense costs incurred by our directors, officers, employees and agents or our Advisor and its affiliates in some cases. Subject to conditions and exceptions, we also indemnify our Advisor and its affiliates from losses arising in the performance of their duties under the advisory agreement and have agreed to advance certain expenses to them in connection with claims or liability they may become subject to due to their service to us.
U.S. Federal Income Tax Risks

Our failure to remain qualified as a REIT would subject us to U.S. federal income tax and potentially state and local tax.
We elected to be taxed as a REIT, commencing with our taxable year ended December 31, 2013 and intend to operate in a manner that would allow us to continue to qualify as a REIT for U.S. federal income tax purposes. However, we may terminate our REIT qualification inadvertently, or if the Board determines that doing so is in our best interests. Our qualification as a REIT depends upon our satisfaction of certain asset, income, organizational, distribution, stockholder ownership and other requirements on a continuing basis. We have structured and intend to continue structuring our activities in a manner designed to satisfy all the requirements to qualify as a REIT. However, the REIT qualification requirements are extremely complex and interpretation of the U.S. federal income tax laws governing qualification as a REIT is limited. Furthermore, any opinion of our counsel, including tax counsel, as to our eligibility to remain qualified as a REIT is not binding on the Internal Revenue Service (the “IRS”) and is not a guarantee that we will continue to qualify, as a REIT. Accordingly, we cannot be certain that we will be
42

successful in operating so we can remain qualified as a REIT. Our ability to satisfy the asset tests depends on our analysis of the characterization and fair market values of our assets, some of which are not susceptible to a precise determination, and for which we will not obtain independent appraisals. Our compliance with the REIT income or quarterly asset requirements also depends on our ability to successfully manage the composition of our income and assets on an ongoing basis. Accordingly, if certain of our operations were to be recharacterized by the IRS, such recharacterization would jeopardize our ability to satisfy all requirements for qualification as a REIT. Furthermore, future legislative, judicial or administrative changes to the U.S. federal income tax laws could be applied retroactively, which could result in our disqualification as a REIT.
If we fail to continue to qualify as a REIT for any taxable year, and we do not qualify for certain statutory relief provisions, we will be subject to U.S. federal income tax on our taxable income at the corporate rate. In addition, we would generally be disqualified from treatment as a REIT for the four taxable years following the year of losing our REIT qualification. Losing our REIT qualification would reduce our net earnings available for investment or distribution to stockholders because of the additional tax liability. In addition, amounts paid to stockholders that are treated as dividends for U.S. federal income tax purposes would no longer qualify for the dividends paid deduction, and we would no longer be required to make distributions. If this occurs, we might be required to borrow funds or liquidate some investments in order to pay the applicable tax.
Even as a REIT, in certain circumstances, we may incur tax liabilities that would reduce our cash available for distribution to our stockholders.
Even as a REIT, we may be subject to U.S. federal, state and local income taxes. For example, net income from the sale of properties that are “dealer” properties sold by a REIT and that do not meet a safe harbor available under the Code (a “prohibited transaction” under the Code) will be subject to a 100% tax. We may not make sufficient distributions to avoid excise taxes applicable to REITs. Similarly, if we were to fail an income test (and did not lose our REIT status because such failure was due to reasonable cause and not willful neglect) we would be subject to tax on the income that does not meet the income test requirements. We also may decide to retain net capital gains we earn from the sale or other disposition of our property and pay U.S. federal income tax directly on such income. In that event, our stockholders would be treated as if they earned that income and paid the tax on it directly. However, stockholders that are tax-exempt, such as charities or qualified pension plans, would have no benefit from their deemed payment of such tax liability unless they file U.S. federal income tax returns and seek a refund of such tax. We also will be subject to corporate tax on any undistributed REIT taxable income. We also may be subject to state and local taxes on our income or property, including franchise, payroll and transfer taxes, either directly or at the level of the OP or at the level of the other companies through which we indirectly own our assets, such as any TRSs, which are subject to full U.S. federal, state, local and foreign corporate-level income tax. Any taxes we pay directly or indirectly will reduce our cash flow.
To qualify as a REIT, we must meet annual distribution requirements, which may force us to forgo otherwise attractive opportunities or borrow funds during unfavorable market conditions. This could delay or hinder our ability to meet our investment objectives and reduce our stockholders’ overall return.
In order to qualify as a REIT, we must distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding net capital gain. We will be subject to U.S. federal income tax on our undistributed REIT taxable income and net capital gain and to a 4% nondeductible excise tax on any amount by which distributions we make with respect to any calendar year are less than the sum of (a) 85% of our ordinary income, (b) 95% of our capital gain net income and (c) 100% of our undistributed income from prior years. These requirements could cause us to distribute amounts that otherwise would be spent on investments in real estate assets and it is possible that we might be required to borrow funds, possibly at unfavorable rates, or sell assets to fund these distributions. Although we intend to make distributions sufficient to meet the annual distribution requirements and to avoid U.S. federal income and excise taxes on our earnings while we qualify as a REIT, it is possible that we might not always be able to do so.

43

Recharacterization of sale-leaseback transactions may cause us to lose our REIT status.
We will use commercially reasonable efforts to structure any sale-leaseback transaction we enter into so that the lease will be characterized as a “true lease” for U.S. federal income tax purposes, thereby allowing us to be treated as the owner of the property for U.S. federal income tax purposes. However, the IRS may challenge this characterization. In the event that any sale-leaseback transaction is challenged and recharacterized as a financing transaction or loan for U.S. federal income tax purposes, deductions for depreciation and cost recovery relating to the property would be disallowed. If a sale-leaseback transaction were so recharacterized, we might fail to continue to satisfy the REIT qualification “asset tests” or “income tests” and, consequently, lose our REIT status effective with the year of recharacterization. Alternatively, the amount of our REIT taxable income could be recalculated which might also cause us to fail to meet the distribution requirement for a taxable year.
Certain of our business activities are potentially subject to the prohibited transaction tax.
For so long as we qualify as a REIT, our ability to dispose of property during the first few years following acquisition may be restricted to a substantial extent as a result of our REIT qualification. Under applicable provisions of the Code regarding prohibited transactions by REITs, while we qualify as a REIT and provided we do not meet a safe harbor available under the Code, we will be subject to a 100% penalty tax on the net income from the sale or other disposition of any property (other than foreclosure property) that we own, directly or indirectly through any subsidiary entity, including the OP, but generally excluding TRSs, that is deemed to be inventory or property held primarily for sale to customers in the ordinary course of a trade or business. Whether property is inventory or otherwise held primarily for sale to customers in the ordinary course of a trade or business depends on the particular facts and circumstances surrounding each property. We intend to avoid the 100% prohibited transaction tax by (a) conducting activities that may otherwise be considered prohibited transactions through a TRS (but such TRS will incur corporate rate income taxes with respect to any income or gain recognized by it), (b) conducting our operations in such a manner so that no sale or other disposition of an asset we own, directly or indirectly through any subsidiary, will be treated as a prohibited transaction, or (c) structuring certain dispositions of our properties to comply with the requirements of the prohibited transaction safe harbor available under the Code for properties that, among other requirements, have been held for at least two years. Despite our present intention, no assurance can be given that any particular property we own, directly or through any subsidiary entity, including the OP, but generally excluding TRSs, will not be treated as inventory or property held primarily for sale to customers in the ordinary course of a trade or business.
TRSs are subject to corporate-level taxes and our dealings with TRSs may be subject to a 100% excise tax.
A REIT may own up to 100% of the stock of one or more TRSs. Both the subsidiary and the REIT must jointly elect to treat the subsidiary as a TRS. A corporation of which a TRS directly or indirectly owns more than 35% of the voting power or value of the stock will automatically be treated as a TRS. Overall, no more than 20% (25% for our taxable years beginning prior to January 1, 2018) of the gross value of a REIT’s assets may consist of stock or securities of one or more TRSs. A TRS may hold assets and earn income that would not be qualifying assets or income if held or earned directly by a REIT, including gross income from operations pursuant to management contracts. We may lease some of our seniors housing properties that are qualified health care properties to one or more TRSs which, in turn, contract with independent third-party management companies to operate those “qualified health care properties” on behalf of those TRSs. In addition, we may use one or more TRSs generally to hold properties for sale in the ordinary course of a trade or business or to hold assets or conduct activities that we cannot conduct directly as a REIT. A TRS is subject to applicable U.S. federal, state, local and foreign income tax on its taxable income, as well as limitations on the deductibility of its interest expenses. In addition, the Code imposes a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis.
If the OP failed to qualify as a partnership or is not otherwise disregarded for U.S. federal income tax purposes, we would cease to qualify as a REIT.
If the IRS were to successfully challenge the status of the OP as a partnership or disregarded entity for U.S. federal income tax purposes, the OP would be taxable as a corporation. In such event, this would reduce the amount of distributions that the OP could make to us. This also would result in our failing to qualify as a REIT, and becoming subject to a corporate-level tax on our income. This substantially would reduce our cash available to pay dividends and other distributions to our stockholders. In addition, if any of the partnerships or limited liability companies through which the OP owns its properties, in whole or in part, loses its characterization as a partnership and is otherwise not disregarded for U.S. federal income tax purposes, the partnership or limited liability company would be subject to taxation as a corporation, thereby reducing distributions to the OP. Such a recharacterization of an underlying property owner could also threaten our ability to maintain our REIT qualification.
If our “qualified health care properties” are not properly leased to a TRS or the managers of those “qualified health care properties” do not qualify as “eligible independent contractors,” we could fail to qualify as a REIT.
In general, under the REIT rules, we cannot directly operate any of our seniors housing properties that are “qualified health care properties” and can only indirectly participate in the operation of qualified health care properties on an after-tax basis by leasing those properties to independent health care facility operators or to TRSs. A qualified health care property is any real property, (and any personal property incident to that real property), which is, or is necessary or incidental to the use of, a hospital, nursing facility, assisted living facilities, congregate care facility, qualified continuing care facility, or other licensed
44

facility which extends medical or nursing or ancillary services to patients and is operated by a provider of those services that is eligible for participation in the Medicare program with respect to that facility. Furthermore, rent paid by a lessee of a qualified health care property that is a “related party tenant” of ours will not be qualifying income for purposes of the two gross income tests applicable to REITs. However, a TRS that leases qualified health care properties from us will not be treated as a “related party tenant” with respect to our “qualified health care properties” that are managed by an “eligible independent contractor.”
An “eligible independent contractor” is an independent contractor that, at the time such contractor enters into a management or other agreement with a TRS to operate a “qualified health care property,” is actively engaged in the trade or business of operating “qualified health care properties” for any person not related to us or the TRS. Among other requirements to qualify as an independent contractor, a manager must not own, directly or applying attribution provisions of the Code, more than 35% of the shares of our outstanding stock (by value), and no person or group of persons can own more than 35% of the shares of our outstanding stock and 35% of the ownership interests of the manager (taking into account only owners of more than 5% of our shares and, with respect to ownership interest in such managers that are publicly traded, only holders of more than 5% of such ownership interests). The ownership attribution rules that apply for purposes of the 35% thresholds are complex. There can be no assurance that the levels of ownership of our shares by our managers and their owners will not be exceeded.
If our leases with TRSs are not respected as true leases for U.S. federal income tax purposes, we likely would fail to qualify as a REIT.
To qualify as a REIT, we must satisfy two gross income tests, under which specified percentages of our gross income must be derived from certain sources, such as “rents from real property.” Rent paid by TRSs to the OP pursuant to the lease of our “qualified healthcare properties” will constitute a substantial portion of our gross income. For that rent to qualify as “rents from real property” for purposes of the REIT gross income tests, the leases must be respected as true leases for U.S. federal income tax purposes and not be treated as service contracts, joint ventures or some other type of arrangement. If our leases are not respected as true leases for U.S. federal income tax purposes, we may fail to qualify as a REIT.
We may choose to make distributions in shares of our common stock, in which case our stockholders may be required to pay U.S. federal income taxes in excess of the cash portion of distributions they receive.
In connection with our qualification as a REIT, we are required to distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard to the deduction for dividends paid and excluding net capital gain. In order to satisfy this requirement, we may make distributions with respect to our common stock that are payable in cash and/or shares of our common stock (which could account for up to 80% of the aggregate amount of such distributions) at the election of each stockholder. Taxable stockholders receiving such distributions will be required to include the full amount of such distributions as ordinary dividend income to the extent of our current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. As a result, U.S. stockholders may be required to pay U.S. federal income taxes with respect to such distributions in excess of the cash portion of the distribution received.
Accordingly, U.S. stockholders receiving a distribution of shares of our common stock may be required to sell shares received in such distribution or may be required to sell other stock or assets owned by them, at a time that may be disadvantageous, in order to satisfy any tax imposed on such distribution. If a U.S. stockholder sells the shares it receives as part of the distribution in order to pay this tax, the sales proceeds may be less than the amount included in income with respect to the distribution, depending on the value of the shares at the time of the sale. Furthermore, with respect to certain non-U.S. stockholders, we may be required to withhold U.S. tax with respect to such distribution, including in respect of all or a portion of such distribution that is payable in stock, by withholding or disposing of part of the shares included in such distribution and using the proceeds of such disposition to satisfy the withholding tax imposed. Because there is no established trading market for shares of our common stock, stockholders may not be able to sell shares of our common stock to pay taxes owed on dividend income.
The taxation of distributions can be complex; however, distributions to stockholders that are treated as dividends for U.S. federal income tax purposes generally will be taxable as ordinary income, which may reduce our stockholders’ after-tax anticipated return from an investment in us.
Amounts that we pay to our taxable stockholders out of current and accumulated earnings and profits (and not designated as capital gain dividends or qualified dividend income) generally will be treated as dividends for U.S. federal income tax purposes and will be taxable as ordinary income. Noncorporate stockholders are entitled to a 20% deduction with respect to these ordinary REIT dividends which would, if allowed in full, result in a maximum effective federal income tax rate on these ordinary REIT dividends of 29.6% (or 33.4% including the 3.8% surtax on net investment income); however, the 20% deduction will end after December 31, 2025.
45

However, a portion of the amounts that we pay to our stockholders generally may (a) be designated by us as capital gain dividends taxable as long-term capital gain to the extent that they are attributable to net capital gain recognized by us, (b) be designated by us as qualified dividend income, taxable at capital gains rates, to the extent they are attributable to dividends we receive from TRSs, or (c) constitute a return of capital to the extent that they exceed our accumulated earnings and profits as determined for U.S. federal income tax purposes. A return of capital is not taxable, but has the effect of reducing the tax basis of a stockholder’s investment in shares of our stock. Amounts paid to our stockholders that exceed our current and accumulated earnings and profits and a stockholder’s tax basis in shares of our stock generally will be taxable as capital gain.
Our stockholders may have tax liability on distributions that they elect to reinvest in shares of our common stock, but they would not receive the cash from such distributions to pay such tax liability.
Stockholders who participate in the DRIP will be deemed to have received, and for U.S. federal income tax purposes will be taxed on, the distributions reinvested in shares of our common stock to the extent the distributions were not a tax-free return of capital. In addition, our stockholders will be treated for tax purposes as having received an additional distribution to the extent the shares are purchased at a discount to fair market value. As a result, unless a stockholder is a tax-exempt entity, it may have to use funds from other sources to pay its tax liability on the distributions reinvested in shares of our common stock pursuant to the DRIP.
Dividends payable by REITs generally do not qualify for the reduced tax rates available for some dividends.
Currently, the maximum tax rate applicable to qualified dividend income payable to U.S. stockholders that are individuals, trusts and estates is 23.8%, including the 3.8% surtax on net investment income. Dividends payable by REITs, however, generally are not eligible for this reduced rate and, as described above, through December 31, 2025, will be subject to an effective rate of 33.4%, including the 3.8% surtax on net investment income. Although this does not adversely affect the taxation of REITs or dividends payable by REITs, the more favorable rates applicable to regular corporate qualified dividends could cause investors who are individuals, trusts and estates to perceive investments in REITs to be relatively less attractive than investments in the stock of non-REIT corporations that pay dividends, which could adversely affect the value of the stock of REITs, including shares of our stock. Tax rates could be changed in future legislation.
Complying with REIT requirements may limit our ability to hedge our liabilities effectively and may cause us to incur tax liabilities.
The REIT provisions of the Code may limit our ability to hedge our liabilities. Any income from a hedging transaction we enter into to manage risk of interest rate changes, price changes or currency fluctuations with respect to borrowings made or to be made to acquire or carry real estate assets, or in certain cases to hedge previously acquired hedges entered into to manage risks associated with property that has been disposed of or liabilities that have been extinguished, if properly identified under applicable Treasury Regulations, does not constitute “gross income” for purposes of the 75% or 95% gross income tests. To the extent that we enter into other types of hedging transactions, the income from those transactions will likely be treated as non-qualifying income for purposes of both of the gross income tests. As a result of these rules, we may need to limit our use of advantageous hedging techniques or implement those hedges through a TRS. This could increase the cost of our hedging activities because the TRS would be subject to tax on gains or expose us to greater risks associated with changes in interest rates than we would otherwise want to bear. In addition, losses in a TRS generally will not provide any tax benefit, except for being carried forward against future taxable income of the TRS.
Complying with REIT requirements may force us to forgo or liquidate otherwise attractive investment opportunities.
To maintain our qualification as a REIT, we must ensure that we meet the REIT gross income tests annually and that at the end of each calendar quarter, at least 75% of the value of our assets consists of cash, cash items, government securities and qualified REIT real estate assets, including certain mortgage loans and certain kinds of mortgage-related securities. The remainder of our investment in securities (other than securities that qualify for the 75% asset test and securities of qualified REIT subsidiaries and TRSs) generally cannot exceed 10% of the outstanding voting securities of any one issuer, 10% of the total value of the outstanding securities of any one issuer, or 5% of the value of our assets as to any one issuer. In addition, no more than 20% of the value of our total assets may consist of stock or securities of one or more TRSs and no more than 25% of our assets may consist of publicly offered REIT debt instruments that do not otherwise qualify under the 75% asset test. If we fail to comply with these requirements at the end of any calendar quarter, we must correct the failure within 30 days after the end of the calendar quarter or qualify for certain statutory relief provisions to avoid losing our REIT qualification and suffering adverse tax consequences. As a result, we may be required to liquidate assets from our portfolio or not make otherwise attractive investments in order to maintain our qualification as a REIT.
46

The ability of the Board to revoke our REIT qualification without stockholder approval may subject us to U.S. federal income tax and reduce distributions to our stockholders.
Our charter provides that the Board may revoke or otherwise terminate our REIT election, without the approval of our stockholders, if it determines that it is no longer in our best interests to continue to qualify as a REIT. While we intend to maintain our qualification as a REIT, we may terminate our REIT election if we determine that qualifying as a REIT is no longer in our best interests. If we cease to be a REIT, we would become subject to corporate-level U.S. federal income tax on our taxable income (as well as any applicable state and local corporate tax) and would no longer be required to distribute most of our taxable income to our stockholders, which may have adverse consequences on our total return to our stockholders and on the value of our stock.
We may be subject to adverse legislative or regulatory tax changes that could increase our tax liability, reduce our operating flexibility, and reduce the value of shares of our stock.
Changes to the tax laws may occur, and any such changes could have an adverse effect on an investment in shares of our stock or on the market value or the resale potential of our assets. Our stockholders are urged to consult with an independent tax advisor with respect to the status of legislative, regulatory or administrative developments and proposals and their potential effect on an investment in shares of our stock.
Although REITs generally receive better tax treatment than entities taxed as non-REIT “C corporations,” it is possible that future legislation would result in a REIT having fewer tax advantages, and it could become more advantageous for a company that invests in real estate to elect to be treated for U.S. federal income tax purposes as a non-REIT “C corporation.” As a result, our charter provides the Board with the power, under certain circumstances, to revoke or otherwise terminate our REIT election and cause us to be taxed as a non-REIT “C corporation”, without the vote of our stockholders. The Board has duties to us and could only cause such changes in our tax treatment if it determines that such changes are in our best interests.
The share ownership restrictions for REITs and the 9.8% share ownership limit in our charter may inhibit market activity in shares of our stock and restrict our business combination opportunities.
In order to qualify as a REIT, five or fewer individuals, as defined in the Code, may not own, actually or constructively, more than 50% in value of the issued and outstanding shares of our stock at any time during the last half of each taxable year, other than the first year for which a REIT election is made. Attribution rules in the Code determine if any individual or entity actually or constructively owns shares of our stock under this requirement. Additionally, at least 100 persons must beneficially own shares of our stock during at least 335 days of a taxable year for each taxable year, other than the first year for which a REIT election is made. To help ensure that we meet these tests, among other purposes, our charter restricts the acquisition and ownership of shares of our stock.
Our charter, with certain exceptions, authorizes our directors to take such actions as are necessary and desirable to preserve our qualification as a REIT while we so qualify. Unless exempted by the Board, for so long as we qualify as a REIT, our charter prohibits, among other limitations on ownership and transfer of shares of our stock, any person from beneficially or constructively owning (applying certain attribution rules under the Code) more than 9.8% in value of the aggregate outstanding shares of our stock and more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of the outstanding shares of our stock. The Board may not grant an exemption from these restrictions to any proposed transferee whose ownership in excess of the 9.8% ownership limit would result in the termination of our qualification as a REIT. These restrictions on transferability and ownership will not apply, however, if the Board determines that it is no longer in our best interests to continue to qualify as a REIT or that compliance with the restrictions is no longer required in order for us to continue to so qualify as a REIT.
These ownership limits could delay or prevent a transaction or a change in control that might involve a premium price for shares of our stock or otherwise be in the best interests of the stockholders.
Non-U.S. stockholders will be subject to U.S. federal withholding tax and may be subject to U.S. federal income tax on dividends and other distributions received from us and upon the disposition of shares of our stock.
Subject to certain exceptions, amounts paid to non-U.S. stockholders will be treated as dividends for U.S. federal income tax purposes to the extent of our current or accumulated earnings and profits. Such dividends ordinarily will be subject to U.S. withholding tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty, unless the dividends are treated as “effectively connected” with the conduct by the non-U.S. stockholder of a U.S. trade or business. Capital gain distributions attributable to sales or exchanges of “U.S. real property interests” (“USRPIs”), generally will be taxed to a non-U.S. stockholder (other than a “qualified foreign pension fund”, certain entities wholly owned by a “qualified foreign pension fund” and certain foreign publicly-traded entities) as if such gain were effectively connected with a U.S. trade or business. However, a capital gain distribution will not be treated as effectively connected income if (a) the distribution is received with respect to a class of stock that is regularly traded on an established securities market located in the U.S. and (b) the non-U.S. stockholder does not own more than 10% of any class of our stock at any time during the one-year period ending on the date the distribution is received.
47

Gain recognized by a non-U.S. stockholder upon the sale or exchange of shares of our stock generally will not be subject to U.S. federal income taxation unless such stock constitutes a USRPI . Shares of our stock will not constitute a USRPI so long as we are a “domestically-controlled qualified investment entity.” A domestically-controlled qualified investment entity includes a REIT if at all times during a specified testing period, less than 50% in value of such REIT’s stock is held directly or indirectly by non-U.S. stockholders. We believe, but there can be no assurance, that we will be a domestically-controlled qualified investment entity.
Even if we do not qualify as a domestically-controlled qualified investment entity at the time a non-U.S. stockholder sells or exchanges shares of our stock, gain arising from such a sale or exchange would not be subject to U.S. taxation as a sale of a USRPI if: (a) the shares are of a class of our stock that is “regularly traded,” as defined by applicable Treasury regulations, on an established securities market, and (b) such non-U.S. stockholder owned, actually and constructively, 10% or less of the outstanding shares of our stock of that class at any time during the five-year period ending on the date of the sale.
Potential characterization of dividends and other distributions or gain on sale may be treated as unrelated business taxable income to tax-exempt investors.
If (a) we are a “pension-held REIT,” (b) a tax-exempt stockholder has incurred (or is deemed to have incurred) debt to purchase or hold shares of our stock, or (c) a holder of shares of our stock is a certain type of tax-exempt stockholder, dividends on, and gains recognized on the sale of shares of our stock by such tax-exempt stockholder may be subject to U.S. federal income tax as unrelated business taxable income under the Code.
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties
The following table presents certain additional information about the properties we owned as of December 31, 2020:
PortfolioNumber
of Properties
Rentable
Square Feet
Percent Leased (1)
Weighted Average Remaining Lease Term (2)
Gross Asset Value (3)
(In thousands)
Medical Office Buildings1173,911,937 91.6%4.9$1,087,266 
Triple-Net Leased Healthcare Facilities:
Hospitals
6514,962 90.7%6.2133,580 
Post-Acute / Skilled Nursing (4)
8354,016 100.0%6.886,574 
Total Triple-Net Leased Healthcare Facilities14868,978 94.5%(6)6.5220,154 
Seniors Housing — Operating Properties(4)(7)
594,367,124 75.1%(5)N/A1,229,288 
Jupiter Property — Recently Developed1235,445 10.0%(6)9.959,330 
Land2N/AN/AN/A3,665 
Total Portfolio1939,383,484 $2,599,703 
_______________
(1)Inclusive of leases signed but not yet commenced as of December 31, 2020.
(2)Weighted-average remaining lease term in years is calculated based on square feet as of December 31, 2020.
(3)Gross asset value represents total real estate investments, at cost ($2.6 billion total as of December 31, 2020) and assets held for sale at carrying value ($0.1 million total as of December 31, 2020), net of gross market lease intangible liabilities ($22.1 million total as of December 31, 2020). Impairment charges are already reflected within gross asset value.
(4)Four properties were transitioned from Post-Acute / Skilled Nursing within our triple-net leased healthcare facilities segment to our SHOP segment during the period from January 1, 2020 through December 31, 2020 (the “Transition Properties”). The Transition Properties are presented within the SHOP segment as of December 31, 2020. See Results of Operations for more information on these properties.
(5)Weighted by unit count as of December 31, 2020.
(6)Our development property in Jupiter, Florida was substantially completed in the fourth quarter of 2019. See Note 3 — Real Estate Investments - “Development Property” to our consolidated financial statements included in this Annual Report on Form 10-K for additional information. Although a portion of the property has been leased as of December 31, 2020, the property is separately shown and excluded from combined occupancy numbers. Occupancy in the triple-net leased healthcare facilities segment would have been 76.5% had the development property been included. This property is expected to be sold in late March or second quarter of 2021.
(7)One skilled nursing facility in Wellington, Florida is expected to be sold in 2021. Subsequent to December 31, 2020, four MI SHOPs were transferred to their buyer pursuant to their sale in November, 2020. See Note 18 — Subsequent Events for more information.
N/A    Not applicable.

48

The following table details the geographic distribution, by state, of our portfolio as of December 31, 2020:
StateNumber of Properties
Annualized Rental Income (1)
Annualized Rental Income as a Percentage of the Total PortfolioRentable Square FeetPercentage of Portfolio
Rentable Square Feet
(In thousands)
Alabama1$159 — %5,564 0.1 %
Arizona148,289 2.6 %509,642 5.4 %
Arkansas313,655 4.2 %248,783 2.7 %
California816,532 5.1 %446,723 4.8 %
Colorado21,477 0.5 %59,366 0.6 %
Florida2366,601 20.6 %1,439,315 15.3 %
Georgia1529,104 9.0 %792,191 8.4 %
Idaho13,104 1.0 %55,846 0.6 %
Illinois2125,504 7.9 %857,836 9.1 %
Indiana53,613 1.1 %163,035 1.7 %
Iowa1431,842 9.8 %585,667 6.2 %
Kansas14,286 1.3 %49,360 0.5 %
Kentucky23,218 1.0 %92,875 1.0 %
Louisiana1621 0.2 %17,830 0.2 %
Maryland1944 0.3 %36,260 0.4 %
Massachusetts3890 0.3 %36,563 0.4 %
Michigan1422,885 7.1 %504,362 5.4 %
Minnesota11,096 0.3 %36,375 0.4 %
Mississippi31,644 0.5 %73,859 0.8 %
Missouri27,151 2.2 %96,016 1.0 %
Nevada23,260 1.0 %86,342 0.9 %
North Carolina2743 0.2 %68,122 0.7 %
Ohio31,190 0.4 %69,882 0.7 %
Oregon29,011 2.8 %267,748 2.9 %
Pennsylvania1633,535 10.4 %1,429,414 15.2 %
South Carolina2983 0.3 %52,527 0.6 %
Tennessee33,397 1.0 %177,489 1.9 %
Texas1112,871 4.0 %464,101 4.9 %
Virginia34,236 1.1 %234,090 2.5 %
Washington12,024 0.6 %52,900 0.6 %
Wisconsin1310,028 3.1 %373,401 4.0 %
Total193$323,893 100 %9,383,484 100 %
__________
(1)    Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2020, which includes tenant concessions such as free rent, as applicable, as well as annualized gross revenue from our SHOPs for the fourth quarter of 2020.
49

Future Minimum Lease Payments
The following table presents future minimum base rental cash payments due to us (excluding the SHOP segment) over the next ten years and thereafter as of December 31, 2020. The SHOP segment is excluded as the leases of units with residents are generally for annual periods or month to month. These amounts exclude contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to performance thresholds and increases in annual rent based on exceeding certain economic indexes, among other items.
(In thousands)Future Minimum
Base Rent Payments
2021$94,144 
202287,762 
202375,205 
202468,210 
202558,757 
202651,909 
202736,276 
202822,468 
202916,994 
203014,172 
Thereafter23,823 
$549,720 
Future Lease Expirations Table
The following is a summary of lease expirations for the next ten years at the properties we owned (excluding the SHOP segment) as of December 31, 2020:
Year of Expiration
Number of Leases Expiring
Annualized Rental Income (1)
Annualized Rental Income as a Percentage of the Total Portfolio
Leased Rentable Square Feet
Percent of Portfolio Rentable Square Feet Expiring
(In thousands)
202179$8,943 10.6%403.111 10.0%
20227614,889 17.6%610.95 15.2%
2023637,352 8.7%309.079 7.7%
20248911,294 13.3%536.423 13.3%
2025435,741 6.8%229.614 5.7%
20264414,484 17.1%867.029 21.4%
20276112,071 14.2%654.836 16.3%
2028175,121 6.0%205.147 5.1%
2029112,365 2.8%100.513 2.5%
2030162,499 2.9%111.269 2.8%
Total499$84,759 100.0%4,027.971 100.0%
_____________
(1)    Annualized rental income on a straight-line basis for the leases in place in the property portfolio as of December 31, 2020, excluding SHOPs, which includes tenant concessions such as free rent, as applicable.
Tenant Concentration
As of December 31, 2020, we did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or more of total annualized rental income on a straight-line basis for our portfolio.
Significant Portfolio Properties
As of December 31, 2020, the rentable square feet or annualized rental income on a straight-line basis of one property represented 5% or more of our total portfolio’s rentable square feet or annualized rental income on a straight-line basis:
50

Wellington at Hershey’s Mill - West Chester, PA
In December 2014, we purchased Wellington at Hershey’s Mill, a seniors housing property located in West Chester, Pennsylvania. Wellington at Hershey’s Mill, which is leased to our TRS and operated and managed on our behalf by a third-party operator in our SHOP segment, contains 491,710 rentable square feet and consists of 193 units dedicated to independent living patients, 64 units dedicated to assisted living patients and 36 units for patients requiring skilled nursing services. As of December 31, 2020, this property represented 5.2% of our total rentable square feet and 5.3% of our total annualized rental income on a straight-line basis.
Property Financings
See Note 4 — Mortgage Notes Payable, Net and Note 5 — Credit Facilities to our consolidated financial statements in this Annual Report on Form 10-K for property financings as of December 31, 2020 and 2019.

Item 3. Legal Proceedings.
We are not a party to, and none of our properties are subject to, any material pending legal proceedings.
Item 4. Mine Safety Disclosures.
Not applicable.
51

PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Market Information
No established public market currently exists for our shares of common stock. Until our shares are listed on a national exchange, if ever, our stockholders may not sell their shares unless the buyer meets the applicable suitability and minimum purchase requirements.
Our charter prohibits the ownership of more than 9.8% in value of the aggregate of our outstanding shares of stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of shares of our stock by a single investor, unless exempted by the Board. Consequently, there is the risk that our stockholders may not be able to sell their shares at a time or price acceptable to them.
On April 3, 2020, we published an Estimated Per-Share NAV equal to $15.75 as of December 31, 2019. We intend to publish an Estimated Per-Share NAV as of December 31, 2020 shortly after filing this Annual Report on Form 10-K for the year ended December 31, 2020.
Consistent with our valuation guidelines, we engaged Duff & Phelps, LLC (“Duff & Phelps”), an independent third-party real estate advisory firm, to perform appraisals of our real estate assets as of December 31, 2019 and provide a valuation range for each real estate asset. In addition, Duff & Phelps was engaged to review, and incorporate in its report our market value estimate regarding other assets, liabilities, and the liquidation value of our outstanding shares of Series A Preferred Stock as of December 31, 2019.
Duff & Phelps has extensive experience estimating the fair value of commercial real estate. The method used by Duff & Phelps to appraise our real estate assets in the report furnished to the Advisor and the Board by Duff & Phelps (the “Duff & Phelps Report”) complies with the Institute of Portfolio Alternatives (formerly known as the Investment Program Association) Practice Guideline 2013-01 titled “Valuations of Publicly Registered Non-Listed REITs,” issued April 29, 2013. Also, Duff & Phelps advised that the scope of work performed was conducted in conformity with the requirements of the Code of Professional Ethics and Standards of Professional Practice of the Appraisal Institute. Other than its engagement as described above and its engagements to provide certain purchase price allocation and other real estate valuation services, Duff & Phelps does not have any direct interests in any transaction with us.
Potential conflicts of interest between Duff & Phelps, on one hand and us or the Advisor, on the other hand, may arise as a result of (1) the impact of the findings of Duff & Phelps in relation to our real estate assets, or the assets of real estate investment programs sponsored by affiliates of the Advisor, on the value of ownership interests owned by, or incentive compensation payable to, our directors, officers or affiliates and those of the Advisor, or (2) Duff & Phelps performing valuation services for other programs sponsored by affiliates of the Advisor, as well as other services for us.
Duff & Phelps performed a full valuation of our real estate assets utilizing an income capitalization approach consisting of the Direct Capitalization Method or the Discounted Cash Flow Method and certain other approaches, including the acquisition price, disposition price, and sales comparison approach. These approaches are commonly used in the commercial real estate industry.
The Estimated Per-Share NAV is comprised of (i) the sum of (A) the estimated value of our real estate assets and (B) the estimated value of our other assets, minus (ii) the sum of (C) the estimated value of our debt and other liabilities, (D) the estimate of the aggregate incentive fees, participations and limited partnership interests held by or allocable to the Advisor, our management or any of their respective affiliates based on our aggregate net asset value based on Estimated Per-Share NAV and payable in our hypothetical liquidation as of December 31, 2019 (which was zero), divided by (iii) our number of shares of common stock outstanding on a fully-diluted basis as of December 31, 2019, which was 92,762,662 (this amount is not adjusted for dividends paid in the form of additional shares of common stock). Common shares outstanding on a fully-diluted basis is defined as the sum of shares of common stock, including vested and unvested restricted shares of common stock, (“restricted shares”) and OP Units outstanding, while excluding Class B units.
The Estimated Per-Share NAV does not represent: (i) the price that our shares may trade for on a national securities exchange or a third party may pay for us, (ii) the amount a stockholder would obtain if he or she tried to sell his or her shares of common stock, or (iii) the amount a stockholder would realize in per share distributions if we sold all of our assets and settled all of our liabilities in a plan of liquidation. Further, there is no assurance that the methodology used to establish the Estimated Per-Share NAV would be acceptable to the Financial Industry Regulatory Authority for use on customer account statements, or that the Estimated Per-Share NAV will satisfy the applicable annual valuation requirements under the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and the Code with respect to employee benefit plans subject to ERISA and other retirement plans or accounts subject to Section 4975 of the Code.
52

The Estimated Per-Share NAV as of December 31, 2019 of $15.75, a value within the range determined by Duff & Phelps, was unanimously adopted by the independent directors of the Board, who comprise a majority of the Board, with Mr. Weil abstaining, on March 31, 2020. The independent directors of the Board based their determination on the Advisor’s recommendation, which was based on the Advisor’s review of the Duff & Phelps Report and on the Advisor’s own analysis, estimates and calculations and the fundamentals of the real estate assets. As part of their determination to approve an Estimated Per-Share NAV, the independent directors considered the fundamentals of the real estate assets including geographic location, stabilization and credit quality of tenants. The Board is ultimately and solely responsible for the Estimated Per-Share NAV. Estimated Per-Share NAV was determined at a moment in time and will likely change over time as a result of changes to the value of individual assets as well as changes and developments in the real estate and capital markets, including changes in interest rates. As such, stockholders should not rely on the Estimated Per-Share NAV in making a decision to buy or sell shares of common stock pursuant to our DRIP or our SRP, respectively.
In connection with the independent directors of the Board’s determination of Estimated Per-Share NAV, the Advisor concluded that, in a hypothetical liquidation at such Estimated Per-Share NAV, it would not be entitled to any incentive fees or performance-based restricted partnership units of our operating partnership designated as “Class B Units.” The Advisor determined the Estimated Per-Share NAV in a manner consistent with the definition of fair value under GAAP set forth in FASB’s Topic ASC 820, Fair Value Measurements and Disclosures.
Holders
As of March 23, 2021 we had 95,040,732 shares of common stock outstanding held by a total of 44,089 stockholders of record.
Dividends and Other Distributions
We elected to be taxed as a REIT for U.S. federal income tax purposes commencing with our taxable year ended December 31, 2013. As a REIT, we are required to distribute annually to our stockholders at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP), determined without regard for the deduction for dividends paid and excluding net capital gains.
The amount of dividends and other distributions payable to our stockholders is determined by the Board and is dependent on a number of factors, including funds available for dividends and other distribution, financial condition, provisions in our Credit Facility or other agreements that may restrict our ability to pay dividends and other distributions, capital expenditure requirements, as applicable, and annual dividends and other distribution requirements needed to maintain our status as a REIT under the Code. Under our Credit Facility, we will not be able to pay cash distributions on our common stock until we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million (giving effect to the aggregate amount of distributions projected to be paid by us during the quarter in which we have elected to commence paying cash distributions on common stock) and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%. As of December 31, 2020, our ratio of consolidated total indebtedness to consolidated total asset value for these purposes was 61.7%. Thus, our ability to make future cash distributions on our common stock will depend on our future cash flows and indebtedness and may further depend on our ability to obtain additional liquidity, which may not be available on favorable terms, or at all. The Board may reduce the amount of dividends or other distributions paid or suspend dividends or other distribution payments at any time prior to declaration. Therefore, dividends and other distribution payments are not assured. Any accrued and unpaid dividends payable with respect to our Series A Preferred Stock must be paid upon redemption of those shares. For further information on provisions in our Credit Facility that restrict the payment of dividends and other distributions, see Note 5 — Credit Facility, Net to our consolidated financial statements included in this Annual Report on Form 10-K and Item 1A “Risk Factors. - We have not paid our distributions on our common stock in cash since 2020, and there can be no assurance we will pay distributions on our common stock in cash in the future.”
The following table details the tax treatment of the dividends and other distributions paid during the years ended December 31, 2020, 2019 and 2018, respectively, retroactively adjusted for the effects of the stock dividends:
Year Ended December 31,
202020192018
Return of capital(1)
100 %$0.42 100 %$0.83 100 %$0.92 
Capital gain dividend income— %— — %— — %— 
Ordinary dividend income— %— — %— — %— 
Total100.0 %$0.42 100.0 %$0.83 100.0 %$0.92 
53

________
(1) Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to our shareholders for U.S. federal income tax purposes.
Distributions to Common Stockholders
From March 1, 2018 until June 30, 2020, we generally paid distributions on our common stock on a monthly basis at a rate equivalent of $0.85 per annum, per share of common stock. Distributions were generally paid by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed our common stock distribution policy in order to preserve our liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility. Under the new policy, distributions authorized by the Board on our shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of our common stock valued at our estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. On October 1, 2020 and January 4, 2021, we declared a dividend payable entirely in stock equal to 0.01349 shares of our common stock on each share of our outstanding common stock. This amount was based on our prior cash distribution rate of $0.85 per share per annum. The Board may further change our common stock distribution policy at any time, further reduce the amount of distributions paid or suspend distribution payments at any time, and therefore distribution payments are not assured.
Dividends to Series A Preferred Stockholders
Dividends on our Series A Preferred Stock accrue in an amount equal to $1.84 per share each year ($0.46 per share per quarter) to Series A Preferred Stockholders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.

Sales of Unregistered Securities
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
In order to provide common stockholders with interim liquidity, the Board has adopted the SRP, which enables our common stockholders to sell their shares back to us after they have been held for at least one year, subject to significant conditions and limitations. For additional information on the SRP, see Note 8 — Stockholders’ Equity to our consolidated financial statements included in this Annual Report on Form 10-K.
In light of the amendment to the Credit Facility on August 10, 2020 which provides that we may not repurchase shares of our common stock until the Commencement Quarter, the Board suspended repurchases under the SRP effective August 14, 2020. The Board has also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated.
The following table summarizes our SRP activity for the periods presented. The cost of the repurchased common shares did not exceed DRIP proceeds during the periods presented. We funded common share repurchases from proceeds received from common stock issued under the DRIP. Repurchases are currently consummated using the most recently published Estimated Per-Share NAV at the time of the repurchase.
Number of Common Shares RepurchasedAverage Price per Share
Cumulative repurchases as of December 31, 20194,391,519 $20.95 
Year ended December 31, 2020 (1)
505,101 17.50 
Cumulative repurchases as of December 31, 2020
4,896,620 20.60 
________
(1) Consists of 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.
54

Item 6. Selected Financial Data.
The following selected financial data as of and for the years ended December 31, 2020, 2019, 2018, 2017 and 2016 should be read in conjunction with the accompanying consolidated financial statements and related notes thereto and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” below:
Balance sheet data (In thousands)
December 31,
20202019201820172016
Total real estate investments, at cost$2,621,723 $2,481,067 $2,553,079 $2,486,052 $2,355,262 
Total assets2,286,895 2,325,303 2,377,446 2,371,861 2,193,705 
Mortgage notes payable, net 542,698 528,284 462,839 406,630 142,754 
Credit facilities674,551 605,269 602,622 534,869 481,500 
Total liabilities1,325,523 1,218,559 1,136,512 1,015,802 689,379 
Total equity961,372 1,106,744 1,240,934 1,356,059 1,504,326 
Operating data (In thousands, except for share and per share data)
Year Ended December 31,
20202019201820172016
Revenue from tenants$381,612 $374,914 $362,406 $311,173 $302,566 
Total operating expenses(406,714)(415,492)(365,512)(323,827)(307,203)
Gain (loss) on dispositions of real estate investments5,230 8,790 (70)438 1,330 
Operating loss(19,872)(31,788)(3,176)(12,216)(3,307)
Total other expenses(51,577)(56,120)(49,605)(29,849)(19,747)
Loss before income taxes(71,449)(87,908)(52,781)(42,065)(23,054)
Income tax (expense) benefit(4,061)(399)(197)(647)2,084 
Net loss(75,510)(88,307)(52,978)(42,712)(20,970)
Net (income) loss attributable to non-controlling interests(303)393 216 164 96 
Allocation for preferred stock(2,968)(173)— — — 
Net loss attributable to common stockholders$(78,781)$(88,087)$(52,762)$(42,548)$(20,874)
Other data:
Cash flows provided by operations$41,807 $47,404 $54,151 $63,967 $78,725 
Cash flows used in investing activities(82,491)(46,249)(115,063)(194,409)(19,092)
Cash flows provided by (used in) financing activities19,431 19,086 49,682 199,843 (55,567)
Per share data:
Distributions declared in cash per common share (1) (2)
$0.42 $0.83 $0.92 $1.47 $1.66 
Preferred stock dividends declared per share$1.84 $0.11 $— $— $— 
Net loss per share attributable to common stockholders - Basic and Diluted (1)
$(0.83)$(0.93)$(0.56)$(0.46)$(0.23)
Weighted-average number of common shares outstanding:
Weighted-average shares outstanding - Basic and Diluted (1)
94,639,833 94,433,640 93,593,719 92,241,201 90,265,698 
______
(1) Retroactively adjusted for the effects of the stock dividends.
(2) In addition to the distributions declared in cash, distributions declared on common stock were paid in the form of additional shares of common stock equivalent to $0.42 per share for the year ended December 31, 2020 based on our most recent Estimated Per-Share NAV as of December 31, 2019.

55

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the accompanying consolidated financial statements. The following information contains forward-looking statements, which are subject to risks and uncertainties. Should one or more of these risks or uncertainties materialize, actual results may differ materially from those expressed or implied by the forward-looking statements. Please see “Forward-Looking Statements” elsewhere in this Annual Report on Form 10-K for a description of these risks and uncertainties.
Overview
We are an externally managed REIT that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate focused on MOBs, NNN properties, and SHOPs. As of December 31, 2020, we owned 193 properties located in 31 states and comprised of 9.4 million rentable square feet.
Substantially all of our business is conducted through the OP, a Delaware limited partnership, and its wholly owned subsidiaries. Our Advisor manages our day-to-day business with the assistance of our Property Manager. Our Advisor and Property Manager are under common control with AR Global and these related parties receive compensation and fees for providing services to us. We also reimburse these entities for certain expenses they incur in providing these services to us. The Special Limited Partner, which is also under common control with AR Global, also has an interest in us through ownership of interests in our OP.
We have declared quarterly dividends entirely in shares of our common stock equal to 0.01349 shares of our common stock on each share of our outstanding common stock on October 1, 2020 and January 4, 2021. These stock dividends were issued on October 15, 2020 and January 15, 2021 to holders of record of our common stock at the close of business on October 8, 2020 and January 11, 2021, respectively. Dividends payable entirely in shares of our common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. The aggregate impact of these stock dividends was an increase of 0.02716 shares, cumulatively, for every one share of common stock. No additional shares, except for the dividends paid in the form of additional shares of common stock, were issued during the three months ended December 31, 2020. Additionally, other references to weighted-average shares outstanding and per-share amounts have been retroactively adjusted for the stock dividends and are noted as such throughout the accompanying financial statements and footnotes.
On April 3, 2020, we published a new Estimated Per-Share NAV equal to $15.75 as of December 31, 2019. Our previous Estimated Per-Share NAV was equal to $17.50 as of December 31, 2018. Unlike the per share amounts in this Annual Report on Form 10-K, the Estimated Per-Share NAV has not been retroactively adjusted to reflect the payment of dividends in the form of common stock and will not be adjusted for stock dividends paid or that may be paid in the future until the Board determines a new Estimated Per-Share NAV. Dividends paid in the form of additional shares of common stock will, all things equal, cause the value of each share of common stock to decline because the number of shares outstanding will increase when dividends paid in stock are issued; however, each stockholder will receive the same number of new shares, the total value of our common stockholder’s investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually.
Management Update on the Impacts of the COVID-19 Pandemic
The economic uncertainty created by the COVID-19 global pandemic has created several risks and uncertainties that may impact our business, including our future results of operations and our liquidity. A pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global pandemic of COVID-19 affecting states or regions in which we or our tenants operate could have material and adverse effects on our business, financial condition, results of operations and cash flows. The ultimate impact on our results of operations, our liquidity and the ability of our tenants to continue to pay us rent will depend on numerous factors including the overall length and severity of the COVID-19 pandemic. Management is unable to predict the nature and scope of any of these factors. These factors include the following, among others:
The negative impacts of the COVID-19 pandemic has caused and may continue to cause certain of our tenants to be unable to make rent payments to us timely, or at all. However, we have taken proactive steps with regard to rent collections to mitigate the impact on our business (see “—Management Actions” below).
There may be a decline in the demand for tenants to lease real estate, as well as a negative impact on rental rates. As of December 31, 2020, our MOB segment had an occupancy of 91.6% with a weighted-average remaining lease term of 4.9 years, (based on annualized straight-line rent as of December 31, 2020) and our triple-net leased healthcare facilities segment had an occupancy of 94.5% with a weighted average remaining lease term of 6.5 years (based on annualized straight-line rent as of December 31, 2020) and our SHOP segment had an occupancy of 75.1%. During the year ended December 31, 2020, we experienced a decline in occupancy and an increase in costs at our SHOP portfolio, however, we received grants under the CARES Act of $3.6 million that helped offset the COVID-19 related operating
56

costs. Subsequent to December 31, 2020, we received an additional $5.1 million in funding through the CARES Act. For additional information on our SHOP portfolio, see the “Management Actions - Seniors Housing Properties” section below.
Capital market volatility and a tightening of credit standards could negatively impact our ability to obtain debt financing. We do not have any significant debt principal repayments due until 2024.
The volatility in the financial market could negatively impact our ability to raise capital through equity offerings, which as a result, could impact our decisions as to when and if we will seek additional equity funding.
The negative impact of the pandemic on our results of operations and cash flows could impact our ability to comply with covenants in our senior “Credit Facility” and the amount available for future borrowings thereunder.
The potential negative impact on the health of personnel of our Advisor and operators of our SHOP facilities, particularly if a significant number of the Advisor’s employees or operator’s employees are impacted, could result in a deterioration in our ability to ensure business continuity.
For additional information on the risks and uncertainties associated with the COVID-19 pandemic, please see Item 1A. “Risk Factors — We are subject to risks associated with a pandemic, epidemic or outbreak of a contagious disease, such as the ongoing global COVID-19 pandemic” included in this Annual Report on Form 10-K for the year ended December 31, 2020.
The Advisor has responded to the challenges resulting from the COVID-19 pandemic. Beginning in early March, the Advisor took proactive steps to prepare for and actively mitigate the inevitable disruption COVID-19 would cause, such as enacting safety measures, both required or recommended by local and federal authorities, including remote working policies, cooperation with localized closure or curfew directives, and social distancing measures at all of our properties. Additionally, there has been no material adverse impact on our financial reporting systems or internal controls and procedures and the Advisor’s ability to perform services for us. In light of the current COVID-19 pandemic, we are supplementing the historical discussion of our results of operations for the year ended December 31, 2020 with a current update on the measures we have taken to mitigate the negative impacts of the pandemic on our business and future results of operations.
Management’s Actions
Rent Collections
We have taken several steps to mitigate the impact of the pandemic on our business. For rent collections, we have been in direct contact with our tenants and operators since the crisis began, cultivating open dialogue and deepening the fundamental relationships that we have carefully developed through prior transactions and historic operations. Based on this approach and the overall financial strength and creditworthiness of our tenants, we believe that we have had positive results in our cash rent collections during this pandemic.
We have collected approximately 100% of the original cash rent due for the fourth quarter of 2020 in our MOB segment and 100% in our triple-net leased healthcare facilities segment. Cash rental payments for our 59 SHOPs is primarily paid for by the residents through private payer insurance or directly, and to a lesser extent, by government reimbursement programs such as Medicaid and Medicare. These cash rental payments are subject to timing differences, therefore we have not provided the amount of second, third or fourth quarter 2020 cash rent collected for our SHOP segment.
Rent collections in January and February 2021 were materially consistent with the fourth quarter 2020, and we expect this trend to continue. We have also granted rent concessions which serve to reduce revenue in our SHOP segment. The impact of the COVID-19 pandemic on our tenants and operators thus our ability to collect rents in future periods cannot be determined at present.
Seniors Housing Properties
In early March 2020, we implemented preventative actions at all our seniors housing properties in our SHOP segment, including restrictions on visitation except in very limited and controlled circumstances, social distancing measures, and the screening of all persons entering these facilities. Some of the additional steps we have taken to address the COVID-19 pandemic include, enhanced training for staff members, the implementation of Telehealth to help residents be safe while keeping appointments with important, but non-emergency, health providers, virtual tours for potential new residents, and agreements between some of our facilities and local lab partners to provide testing services.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect us in a number of ways. In our SHOP portfolio, occupancy has trended lower since the second half of March 2020 as government policies and implementation of infection control best practices and prospective residents’ concerns about communal-setting COVID-19 spread and prospective residents’ concerns about communal-setting COVID-19 spread limited resident move-ins. These and other impacts of the COVID-19 pandemic have affected and could continue to affect our ability to fill vacancies. We have also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. SHOP occupancy has continued to decline from 84.1% as of March 31, 2020, to 79.5% as of June 30, 2020, to 77.9%, as of September 30, 2020 and 75.1% as of December 31, 2020. The declines in revenue we experienced during the fourth quarter were primarily attributable
57

to this decline in occupancy which also represented a decline from December 31, 2019, when SHOP occupancy was 85.7%. In addition, starting in mid-March, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as our operators took appropriate actions to protect residents and caregivers. At our SHOP facilities, we bear these cost increases. These trends accelerated during the second, third and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact us in the and have a material adverse effect on our revenues and income in the other quarters thereafter. We believe that, as infections decline and more vaccinations are administered during 2021, our occupancy will stop declining, and may start to increase, but there can be no assurance as to when or if we will be able to approach pre-pandemic levels of occupancy.
The pandemic raises the risk of an elevated level of resident exposure to illness and restrictions on move-ins at our SHOPs, which has and could also continue to adversely impact occupancy and revenues as well as increase costs. We believe that the actions we have taken help reduce the incidences of COVID-19 at our properties, but there can be no assurance in this regard. There have been some incidences of COVID-19 among the residents and staff at certain of our seniors housing properties. Further incidences, or the perception that outbreaks may occur, could materially and adversely affect our revenues and income, as well as cause reputational harm to us and our tenants, managers and operators.
The extent to which the ongoing global COVID-19 pandemic, including the outbreaks that have occurred and may occur in markets where we own properties, impacts our operations and those of our tenants and third-party operators, will continue to depend on future developments, including the scope, severity and duration of the pandemic, and the actions taken to contain the COVID-19 or treat its impact, among others, which are highly uncertain and cannot be predicted with confidence, but could be material.
On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. As of December 31, 2020 we received $3.6 million in these funds related to four of our SHOPs and we considered the funds to be a grant contribution from the government. The full amount was recognized as a reduction of property operating expenses in our consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, we received an additional $5.1 million in CARES Act funding which will reduce property operating expenses incurred due to COVID-19 during the first quarter of 2021. There can be no assurance that the program will be extended or any further amounts received under currently effective or potential future government programs.

Significant Accounting Estimates and Critical Accounting Policies
Set forth below is a summary of the significant accounting estimates and critical accounting policies that management believes are important to the preparation of our consolidated financial statements. Certain of our accounting estimates are particularly important for an understanding of our financial position and results of operations and require the application of significant judgment by our management. As a result, these estimates are subject to a degree of uncertainty. These significant accounting estimates and critical accounting policies include:
Impacts of the COVID-19 Pandemic
As discussed above we have taken a proactive approach to achieve mutually agreeable solutions with its tenants and in some cases, in the second, third and fourth quarters of 2020, we executed lease amendments providing for deferral of rent.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, we would be required to apply modification accounting including assessing classification under ASC 842. Some, but not all of our lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, we elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that
58

accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, we applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
Revenue Recognition
Our revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020 and 2019, these leases had a weighted average remaining lease term of 4.9 years and 6.5 years, respectively. Rent from tenants in our MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires us to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that we will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When we acquire a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. We defer the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of our lease agreements, tenants are required to reimburse us for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, we have elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For comparative purposes, we have also elected to reflect prior revenue and reimbursements reported under ASC 842 also on a single line. For expenses paid directly by the tenant, under both ASC 842 and 840, we have reflected them on a net basis.
Our revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted by RIDEA and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in our SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the rent are short term in nature, primarily month-to-month. Fees for ancillary services are recorded in the period in which the services are performed.
We defer the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of our lease agreements, tenants are required to reimburse us for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.
Under ASC 842, we have elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, we have reflected them on a net basis.
We continually review receivables related to rent and unbilled rents receivable and determine collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under leasing standards, we are required to assess, based on credit risk only, if it is probable that we will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If we determine that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e. straight-line). However, if we determine it is not probable that we will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with accounting rules adopted after that date, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, we recorded such amounts as bad debt expense as part of property operating expenses. During the years ended December 31, 2020, 2019 and 2018 such amounts were $2.7 million, $6.5 million and $14.8 million, respectively, which include bad debt expense related to the NuVista and LaSalle Tenants (see Note 3Real Estate Investment, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
59

At the time an asset is acquired, we evaluate the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section below for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on our operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 or 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. We evaluate probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see Note 3Real Estate Investments, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
All of our leases as lessor prior to the adoption of new lease accounting rules on January 1, 2019, were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. We evaluate new leases originated after the adoption date (by us or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2020, we have no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
We are also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet and the rent expense is reflected on a straight-line basis over the lease term.
We generally determine the value of construction in progress based upon the replacement cost. During the construction period, we capitalize interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
In both a business combination and an asset acquisition, we allocate the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above-and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions.
For acquired properties with leases classified as operating leases, we allocate the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, we utilize a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. We also consider information obtained about each property as a result of our pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. We utilize various estimates, processes and information to determine the as-if vacant property value. We estimate fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates and land values per square foot.
60

Identifiable intangible assets include amounts allocated to acquired leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, we include real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. We also estimate costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on our evaluation of the specific characteristics of each tenant’s lease and our overall relationship with the tenant. Characteristics considered by us in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. We did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, we review the property for impairment. This review is based on an estimate of the future undiscounted cash flows expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, we would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above-and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
61

Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met.
CARES Act Grants
On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. We received $3.6 million in these funds during the year ended December 31, 2020, related to four of our SHOPs and we considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in our consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, we received an additional $5.1 million in funding through the CARES Act which will reduce property operating expenses incurred due to COVID-19 during the first quarter of 2021. There can be no assurance that the program will be extended or any further amounts received.
Recently Issued Accounting Pronouncements
See Note 2 — Summary of Significant Accounting Policies - Recently Issued Accounting Pronouncements to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion.
Results of Operations
We operate in three reportable business segments for management and internal financial reporting purposes: MOBs, triple-net leased healthcare facilities, and SHOPs. In our MOB operating segment, we own, manage and lease single and multi-tenant MOBs where tenants are required to pay their pro rata share of property operating expenses, which may be subject to expense exclusions and floors, in addition to base rent. In our triple-net leased healthcare facilities operating segment, we own, manage and lease seniors housing properties, hospitals, post-acute care and skilled nursing facilities throughout the United States under long-term triple-net leases, and tenants are generally directly responsible for all operating costs of the respective properties.Our Property Manager or third party managers manage our MOBs and our triple-net leased healthcare facilities. In our SHOP segment, we invest in seniors housing properties using the RIDEA structure. As of December 31, 2020, we had seven eligible independent contractors operating 59 SHOPs (not including two land parcels). All of our properties across all three business segments are located throughout the United States.

62

Same Store Properties
Information based on Same Store, Acquisitions and Dispositions (as each are defined below) allows us to evaluate the performance of our portfolio based on a consistent population of properties owned for the entire period of time covered. As of December 31, 2020, we owned 193 properties. There were 175 properties (our “Same Store” properties) owned for the entire years ended December 31, 2020 and 2019, including two vacant land parcels and one development property that was substantially completed in the fourth quarter of 2019. Since January 1, 2019 and through December 31, 2020, we acquired 18 properties (our “Acquisitions”) and disposed of 16 properties (our “Dispositions”). As described in more detail under “Results of OperationsComparison of the Years Ended December 31, 2020 and 2019 Transition Properties” below, our Same Store properties include four Transition Properties that were transitioned from Senior Housing - Triple Net Leased to our SHOP segment effective July 1, 2020, and another Transition Property which transitioned from our Triple Net Leased segment effective April 1, 2019. These five Transition Properties were owned for the entirety of 2019 and 2020 and merely moved between segments. We retroactively adjusted our Same Store reporting for those segments to include the Transition Properties as part of the Same Store reporting in our SHOP segment and excluded them from the Same Store reporting in our triple-net leased healthcare facilities segment (each segment as so retroactively adjusted, the “Segment Same Store”). See Note 3 Real Estate Investments, Net to our consolidated financial statements included in this Annual Report on Form 10-K for further information about the Transition Properties and the transition.
The following table presents a roll-forward of our properties owned from January 1, 2019 to December 31, 2020:

Number of Properties
Number of properties, December 31, 2018191 
Acquisition activity during the year ended December 31, 2019
Disposition activity during the year ended December 31, 2019(7)
Number of properties, December 31, 2019193 
Acquisition activity during the year ended December 31, 20209
Disposition activity during the year ended December 31, 2020(9)
Number of properties, December 31, 2020193 
Number of Same Store Properties (1)
175 
_______________
(1) Includes the acquisition of a land parcel adjacent to an existing property which is not considered an Acquisition.
63

In addition to the comparative period-over-period discussions below, please see the “Overview — Management Update on the Impacts of the COVID-19 Pandemic” section above for additional information on the risks and uncertainties associated with the COVID-19 pandemic and management’s responses.
Below is a discussion of our results of operations for the years ended December 31, 2020 and 2019. Please see the “Results of Operations” section located in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2019 for a comparison of our results of operations for the year ended December 31, 2019 and 2018.
Comparison of the Years Ended December 31, 2020 and 2019
Net loss attributable to common stockholders was $78.8 million and $88.1 million for the years ended December 31, 2020 and 2019, respectively. The following table shows our results of operations for the years ended December 31, 2020 and 2019 and the year to year change by line item of the consolidated statements of operations:
 Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20202019$%
Revenue from tenants
$381,612 $374,914 $6,698 1.8 %
Operating expenses:  
Property operating and maintenance243,548 234,185 9,363 4.0 %
Impairment charges36,446 55,969 (19,523)(34.9)%
Operating fees to related parties23,922 23,414 508 2.2 %
Acquisition and transaction related173 362 (189)(52.2)%
General and administrative21,572 20,530 1,042 5.1 %
Depreciation and amortization81,053 81,032 21 — %
Total expenses
406,714 415,492 (8,778)(2.1)%
Operating loss before gain (loss) on sale of real estate investments
(25,102)(40,578)15,476 38.1 %
Gain on sale of real estate investments5,230 8,790 (3,560)NM
Operating loss
(19,872)(31,788)11,916 37.5 %
Other income (expense):
Interest expense(51,519)(56,059)4,540 8.1 %
Interest and other income
44 37 528.6 %
Loss on non-designated derivatives
(102)(68)(34)(50.0)%
Total other expenses
(51,577)(56,120)4,543 8.1 %
Loss before income taxes(71,449)(87,908)16,459 18.7 %
Income tax expense(4,061)(399)(3,662)NM
Net loss(75,510)(88,307)12,797 14.5 %
Net income attributable to non-controlling interests(303)393 (696)(177.1)%
Allocation for preferred stock(2,968)(173)(2,795)NM
Net loss attributable to common stockholders$(78,781)$(88,087)$9,306 10.6 %
__________
NM — Not Meaningful
Transition Properties
Some of our properties move between our operating segments, for example if they are converted from being triple-net leased to third parties in our triple-net leased healthcare facilities segment to being leased to our TRS and operated and managed on our behalf by a third-party operator in our SHOP segment. When transfers between segments occur, we reclassify the operating results of the transferred properties to their current segment for both the current and all historical periods in order to present a consistent group of property results. See Note 3 — Real Estate Investments, Net - “Impairments” and “Held for Use Assets” and Note 15 — Segment Reporting to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.
64

Over the last three years, we have had properties transfer between operating segments. Upon such transfers the Company retroactively restates the historical operating results for the segment for all periods presented in that filing and, thereafter, the Company will restate other later prior periods when they are subsequently reported in later filings for comparative purposes. As a result, the Company provides transition disclosure adjustments only for properties that have transitioned since the prior numbers were previously reported. The Company had the following: (i) 2020 Transition Properties – the four LaSalle Properties (Effective July 1, 2020, reporting for the quarter ended September 30, 2020) – (ii) 2019 Transition Property – the Wellington Property (Effective in April, 2019, reporting for the quarter ended June 30, 2019). Collectively, these are referred generically as the “Transition Properties.”
During the year ended December 31, 2020, as shown in more detail in the table below, the Transition Properties contributed approximately $(0.1) million of net operating income (“NOI”). The results of operations of the Transition Properties are included in Segment Same Store with respect to the SHOP segment. The bad debt expense relating to the Transition Properties is included as a reduction to revenue from tenants on the consolidated statement of operations.
The previously reported Same Store results had already been retroactively adjusted to reflect the impact of Transition Properties during the applicable periods and require no further adjustments thereto.
The following table presents by segment Same Store properties’ NOI before and after adjusting for the 2020 Transition Properties as described above, to arrive at “Segment Same Store” results. Our MOB segment was not affected by the Transition Properties.
Year Ended December 31, 2020Year Ended December 31, 2019Increase (Decrease)
(Dollar amounts in thousands)Same Store PropertiesTransition PropertySegment Same StoreSame Store PropertiesTransition PropertySegment Same StoreSame Store PropertiesTransition PropertySegment Same Store
NNN Segment
Revenue from tenants$35,452 $(19,841)$15,611 $32,509 $(17,945)$14,564 $2,943 $(1,896)$1,047 
Less: Property operating and maintenance21,853 (19,892)1,961 18,180 (15,870)2,310 3,673 (4,022)(349)
NOI$13,599 $51 $13,650 $14,329 $(2,075)$12,254 $(730)$2,126 $1,396 
SHOP Segment
Revenue from tenants$198,864 $19,841 $218,705 $209,579 $17,945 $227,524 $(10,715)$1,896 $(8,819)
Less: Property operating and maintenance154,022 19,892 173,914 154,351 15,870 170,221 (329)4,022 3,693 
NOI$44,842 $(51)$44,791 $55,228 $2,075 $57,303 $(10,386)$(2,126)$(12,512)

Net Operating Income
NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate portfolio. NOI is equal to revenue from tenants less property operating and maintenance expenses. NOI excludes all other financial statement amounts included in net income (loss) attributable to common stockholders. We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property level and presents such items on an unlevered basis. See Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations — Non-GAAP Financial Measures included in this Annual Report on Form 10-K for additional disclosure and a reconciliation to our net income (loss) attributable to common stockholders.
Segment Results — Medical Office Buildings
The following table presents the components of NOI and the period to period change within our MOB segment for the years ended December 31, 2020 and 2019:
Segment Same Store(1)
Acquisitions(2)
Dispositions(3)
Segment Total(4)
 Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20202019$20202019$20202019$20202019$
Revenue from tenants
$95,500 $93,651 $1,849 $8,341 $5,372 $2,969 $372 $1,356 $(984)$104,213 $100,379 $3,834 
Less: Property operating and maintenance
28,380 29,218 (838)2,436 1,986 450 35 609 (574)30,851 31,813 (962)
NOI
$67,120 $64,433 $2,687 $5,905 $3,386 $2,519 $337 $747 $(410)$73,362 $68,566 $4,796 
_______________
(1)    Our MOB segment included 104 Same Store properties.
(2)    Our MOB segment included 13 Acquisition properties.
(3)    Our MOB segment included seven Disposition properties.
(4)    Our MOB segment consisted of 117 properties.
NM — Not Meaningful
65

Revenue from tenants is primarily related to contractual rent received from tenants in our MOBs. It also includes operating expense reimbursements which generally increase in proportion with the increase in property operating and maintenance expenses in our MOB segment. Pursuant to many of our lease agreements in our MOBs, tenants are required to pay their pro rata share of property operating and maintenance expenses, which may be subject to expense exclusions and floors, in addition to base rent.
Property operating and maintenance relates to the costs associated with our properties, including real estate taxes, utilities, repairs, maintenance, and unaffiliated third party property management fees.
During the year ended December 31, 2020, the MOB segment contributed a $4.8 million increase in NOI as compared to the year ended December 31, 2019. Of our 18 Acquisitions, during the period from January 1, 2019 through December 31, 2020, 13 were MOBs which contributed a $2.5 million increase in NOI, and our Disposition properties contributed a $0.4 million decrease in NOI, while NOI from our Same Store properties contributed a $2.7 million increase in NOI as compared to the year ended December 31, 2019.
Segment Results — Triple Net Leased Healthcare Facilities
The following table presents the revenue and property operating and maintenance expense and the period to period change within our triple net leased healthcare facilities segment for the years ended December 31, 2020 and 2019:
Segment Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total(4)
 Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20202019$20202019$20202019$20202019$
Revenue from tenants
$15,611 $14,564 $1,047 $— $— $— $— $— $— $15,611 $14,564 $1,047 
Less: Property operating and maintenance
1,961 2,310 (349)— — — — — — 1,961 2,310 (349)
NOI
$13,650 $12,254 $1,396 $— $— $— $— $— $— $13,650 $12,254 $1,396 
_________
(1)    Our triple-net leased healthcare facilities segment included 15 Same Store properties.
(2)    Our triple-net leased healthcare facilities segment did not have any Acquisitions properties.
(3)    Our triple-net leased healthcare facilities segment did not have any Dispositions properties.
(4)    Our triple-net leased healthcare facilities segment included 15 properties.
NM - Not Meaningful
Revenue from tenants for our triple-net leased healthcare facilities generally consist of fixed rental amounts (which may be subject to annual contractual escalations) received from our tenants in accordance with the applicable lease terms. These revenues are contractual rent received from tenants that does not vary based on the underlying operating performance of the properties. In addition, revenue from tenants also includes operating expense reimbursements in our triple-net leased healthcare facilities segment, which generally include reimbursement for property operating expenses that we pay on behalf of tenants in this segment. However, pursuant to many of our lease agreements in this segment, tenants are generally directly responsible for all operating costs of the respective properties in addition to base rent. Property operating and maintenance expense should typically include minimal activity in our triple-net leased healthcare facilities segment except for real estate taxes and insurance. Real estate taxes are typically paid directly by the tenants; however, they may be paid by us and reimbursed by the tenants.
During the year ended December 31, 2020, revenue from tenants in our triple-net leased healthcare facilities segment increased $1.0 million as compared to the year ended December 31, 2019. Property operating and maintenance expenses decreased $0.3 million during the year ended December 31, 2020 and December 31, 2019, respectively, primarily related to lower property taxes and operating expenses.
Segment Results — Seniors Housing Operating Properties
The following table presents the revenue and property operating and maintenance expense and the period to period change within our SHOP segment for the years ended December 31, 2020 and 2019:
Segment Same Store (1)
Acquisitions (2)
Dispositions (3)
Segment Total
 Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)Year Ended December 31,Increase (Decrease)
(Dollar amounts in thousands)20202019$20202019$20202019$20202019$
Revenue from tenants
$218,705 $227,524 $(8,819)$18,534 $2,052 $16,482 $24,549 $30,395 $(5,846)$261,788 $259,971 $1,817 
Less: Property operating and maintenance
173,914 170,221 3,693 15,330 1,760 13,570 21,492 28,081 (6,589)210,736 200,062 10,674 
NOI
$44,791 $57,303 $(12,512)$3,204 $292 $2,912 $3,057 $2,314 $743 $51,052 $59,909 $(8,857)
66

__________
(1)    Our SHOP segment included 56 Same Store properties, including two land parcels.
(2)    Our SHOP segment included five Acquisitions properties.
(3) Our SHOP segment included nine Dispositions properties.
(4) Our SHOP segment included 61 properties, including two land parcels.
NM — Not Meaningful
Revenues from tenants within our SHOP segment are generated in connection with rent and services offered to residents in our SHOPs depending on the level of care required, as well as fees associated with other ancillary services. Property operating and maintenance expenses relates to the costs associated with staffing to provide care for the residents in our SHOPs, as well as food, marketing, real estate taxes, management fees paid to our third party operators, and costs associated with maintaining the physical site
During the year ended December 31, 2020, revenue from tenants increased by $1.8 million in our SHOP segment as compared to the year ended December 31, 2019 which was primarily driven by an increase in revenue of $16.5 million due to our Acquisition properties, offset by decreases of $5.8 million due to our Disposition properties and $8.8 million due to our Same Store properties, which includes our Transition Properties.
Revenues declined in our Same Store SHOPs primarily due to a decrease in occupancy as a result of the impact of COVID-19 as discussed above. SHOP occupancy has declined from 84.1% as of March 31, 2020 to 79.5% as of June 30, 2020, to 77.9% as of September 30, 2020 and 75.1% as of December 31, 2020. This decline in occupancy trend is also represented in a decline from December 31, 2019, when SHOP occupancy was 85.7%. Regulatory and government-imposed restrictions and infectious disease protocols have hindered, and continue to hinder, our ability to accommodate and conduct in-person tours, process and attract new move-ins at our SHOPs and these and other impacts of the COVID-19 pandemic have affected, and could continue to affect, our ability to fill vacancies.
In addition, we also generated a portion of our SHOP revenue from skilled nursing facilities (which include ancillary revenue from non-residents) at four of our Same Store SHOPs. This revenue declined $2.1 million from $15.4 million during the year ended December 31, 2019 to $13.3 million during the year ended December 31, 2020 as a result of us limiting the services we offer at our skilled nursing facilities, during the COVID-19 pandemic, to protect our residents and on-site staff. We also offered COVID-related rent concessions of $0.4 million for the year ended December 31, 2020. These revenue decreases were partially offset by $1.3 million in COVID-19 surcharges we began billing residents for Personal Protective Equipment (“PPE”) during the quarter ended September 30, 2020, and less bad debt expense of $3.1 million relating to the LaSalle tenant, as described further below.
During the year ended December 31, 2020, property operating and maintenance expenses increased $10.7 million in our SHOP segment as compared to the year ended December 31, 2019, primarily due to an increase of $13.6 million due to our SHOP Acquisition properties and an increase of $3.7 million in our Same Store properties, which includes our Transition Properties. These increases were partially offset by a decrease in property operating and maintenance expenses from our Dispositions of $6.6 million.
The total increase in Same Store operating costs mainly related to costs incurred from the ongoing COVID-19 pandemic which totaled $7.6 million for the year ended December 31, 2020, which was partially offset by $3.6 million of funds received through the CARES Act. The full amount of the CARES Act funds was recognized as a reduction to our Same Store property operating expenses in the table above for the year ended December 31, 2020. As a result we experienced an increase in Same Store operating costs of $3.7 million year over year. Subsequent to December 31, 2020, we received an additional $5.1 million in funding through the CARES Act which will be recognized as a reduction to our Same Store property operating expenses in the quarter ending March 31, 2021. There can be no assurance that the program will be extended or any further amounts received. See the “Overview - Management Update on the Impacts of the COVID-19 Pandemic” section above for additional information on the risks and uncertainties associated with the COVID-19 pandemic and management’s actions taken in response.
The LaSalle Properties
On July 1, 2020, we transitioned the LaSalle Properties from our triple-net leased healthcare facilities segment to our SHOP segment, and the LaSalle Properties are now leased to our TRS and operated and managed on our behalf by a third-party operator. Beginning with our reporting for the period ended December 31, 2020 these properties are part of the “Transition Properties” and the resultant change has been applied retrospectively to historical periods.
As of December 31, 2020, the prior tenants at the LaSalle Properties remain in default of a forbearance agreement as described in more detail under “Note 3 Real Estate Investment, Net - The LaSalle Tenant” and owe us $12.7 million of rent, property taxes, late fees, and interest receivable thereunder.
We have the entire receivable balance, including any monetary damages, and related income from the LaSalle Properties fully reserved as of December 31, 2020 and 2019. We incurred bad debt expense, including straight-line rent write-offs of $0.4 million and $3.5 million, related to the LaSalle Properties during the years ended December 31, 2020 and 2019, respectively, which is included as a reduction in revenue from tenants on the consolidated statement of operations.
67

Now that the transition is complete, we have gained more control over the operations of the LaSalle Properties, and we believe this will allow us to improve performance and the cash flows generated by the LaSalle Properties. There can be no assurance, however, that completing this transition will result in us achieving our operational objectives.
Other Results of Operations
Impairment Charges
We incurred $36.4 million of impairment charges for the year ended December 31, 2020. We recorded $19.6 million of impairment charges related to the 11 Michigan SHOPs, which was recognized after an amendment to the PSA for the sale of these properties in April 2020 which reduced the number of properties under consideration as well as the contract purchase price. We recorded $16.9 million of impairment charges related to the two Florida properties in Jupiter and Wellington as a result of our marketing efforts during the COVID-19 pandemic which concluded with a PSA in August 2020, for which the contract purchase was less than the carrying values of the properties, as well as expected closing costs that were not previously anticipated, which reduced the net amount expected to be realized on the sale of properties.
We incurred $56.0 million of impairment charges for the year ended December 31, 2019. During the fourth quarter of 2019, we began to evaluate the properties in Lutz, Florida, Wellington, Florida and our recently completed development property in Jupiter, Florida for potential sale. As a result, we concluded these held for use assets were impaired and recognized impairment charges in the aggregate of $33.3 million. The other impairment charges for 2019 relate to the 14 Michigan SHOPs that were under contract to be sold.
See Note 3 — Real Estate Investments to our consolidated financial statements in this Annual Report on Form 10-K for additional information on impairment charges.
Operating Fees to Related Parties
Operating fees to related parties increased $0.5 million to $23.9 million for the year ended December 31, 2020 from $23.4 million for the year ended December 31, 2019.
Our Advisor and Property Manager are paid for asset management and property management services for managing our properties on a day-to-day basis. The fixed portion of the base management fee we pay for asset management services is equal to $1.6 million per month, while the variable portion of the base management fee is equal, per month, to one twelfth per month of 1.25% of the cumulative net proceeds of any equity the we raise. Asset management fees increased $0.5 million to $20.0 million for the year ended December 31, 2020, due to the increase in the variable portion of the base management fee related to the issuance and sale of Series A Preferred Stock in December 2019.
Property management fees increased $0.3 million to $4.2 million, inclusive of $0.3 million of leasing commissions paid, during the year ended December 31, 2020 from $3.9 million during the year ended December 31, 2019. Property management fees increase or decrease in direct correlation with gross revenues of the properties managed.
See Note 9 — Related Party Transactions and Arrangements to our consolidated financial statements found in this Annual Report on Form 10-K which provides detail on our fees and expense reimbursements.
Acquisition and Transaction Related Expenses
Acquisition and transaction related expenses were $0.2 million for the year ended December 31, 2020 and $0.4 million for the year ended December 31, 2019. The expenses in both periods primarily related to indirect costs associated with potential acquisitions.
General and Administrative Expenses
General and administrative expenses increased $1.0 million to $21.6 million for the year ended December 31, 2020 compared to $20.5 million for the year ended December 31, 2019, which includes a $0.8 million increase in expense reimbursements to related parties. The increase in expense reimbursements to related parties was primarily due to $2.2 million of severance payments and related to legal costs incurred by the Advisor relating to the termination in 2018 of our former chief executive officer, partially offset by a $1.2 million reduction in expenses as a result of revisions to previously accrued bonuses to reflect the ultimate amount paid (see Note 9 – Related Party Transactions and Arrangements to our consolidated financial statements included in this Annual Report on Form 10-K).
Depreciation and Amortization Expenses
Depreciation and amortization expense increased marginally to $81.1 million for the year ended December 31, 2020 from $81.0 million for the year ended December 31, 2019.
Gain on Sale of Real Estate Investments
During the year ended December 31, 2020, we disposed of nine properties. The properties were sold for an aggregate contract price of $40.4 million, which resulted in an aggregate gain on sale of $5.2 million. See Note 3 — Real Estate Investments, Net to our consolidated financial statements in this Annual Report on Form 10-K for additional information.
68

Interest Expense
Interest expense decreased by $4.6 million to $51.5 million for the year ended December 31, 2020 from $56.1 million for the year ended December 31, 2019. The decrease in interest expense resulted from lower interest rates, partially offset by the increase on average outstanding debt in 2020 compared to 2019, as well as $3.0 million of interest expense recorded in the year ended December 31, 2019 resulting from the write off of unamortized deferred financing costs from the refinancing of a $250.0 million mortgage loan originally entered into in 2017. As of December 31, 2020 our outstanding debt obligations were $1.2 billion at a weighted average interest rate of 3.58% per year. As of December 31, 2019, we had total borrowings of $1.1 billion, at a weighted average interest rate of 4.03% per year.
Our interest expense in future periods will vary based on our level of future borrowings, the cost of borrowings among other factors.
Interest and Other Income
Interest and other income includes income from our investment securities and interest income earned on cash and cash equivalents held during the period. Interest and other income was approximately $44,000 for the year ended December 31, 2020. Interest and other income was approximately $7,000 for the year ended December 31, 2019.
Loss on Non-Designated Derivatives
Loss on non-designated derivative instruments for the years ended December 31, 2020 and 2019 related to interest rate caps that are designed to protect us from adverse interest rate changes in connection with our Fannie Mae Master Credit Facilities, which have floating interest rates. Loss on derivative instruments for the years ended December 31, 2020, 2019 and 2018 were $0.1 million, $0.1 million and $0.2 million, respectively.
Income Tax Benefit (Expense)
We recorded income tax expense of $4.1 million and $0.4 million for the years ended December 31, 2020 and 2019, respectively, related to deferred tax assets generated by temporary differences and current period net operating income associated with our TRS. During the year ended December 31, 2020, we recorded a $4.6 million valuation allowance against our deferred tax asset. Income taxes generally relate to our SHOPs, which are leased by our TRS.
Because of our TRS recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of our SHOP assets, we are not able to conclude that it is more likely than not we will realize the future benefit of our deferred tax assets; thus we have recorded a 100% valuation allowance as of December 31, 2020 of $4.6 million. If and when we believe it is more likely than not that we will recover our deferred tax assets, we will reverse the valuation allowance as an income tax benefit in our consolidated statements of comprehensive income (loss). As of December 31, 2020, our consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date.
Net Income/Loss Attributable to Non-Controlling Interests
Net income attributable to non-controlling interests was approximately $0.3 million and net loss to non-controlling interests was $0.4 million for the years ended December 31, 2020 and 2019, respectively. These amounts represent the portion of our net loss that is related to the OP Units and non-controlling interest holders in our subsidiaries that own certain properties.
Cash Flows from Operating Activities
During the year ended December 31, 2020, net cash provided by operating activities was $41.8 million. The level of cash flows used in or provided by operating activities is affected by, among other things, the number of properties owned, the performance of those properties, the timing of interest payments and the amount of borrowings outstanding during the period, as well as the receipt of scheduled rent payments and the level of operating expenses. Cash inflows include non-cash items of $45.8 million (net loss of $75.5 million adjusted for non-cash items including depreciation and amortization of tangible and identifiable intangible real estate assets, deferred financing costs and mortgage premiums and discounts, bad debt expense, equity-based compensation, gain on non-designated derivatives and impairment charges). In addition, cash provided by operating activities was impacted by an increase in accounts payable and accrued expenses of $4.6 million related to higher accrued real estate taxes, property operating expenses and professional and legal fees. These cash inflows were partially offset by a net increase in prepaid expenses and other assets of $0.1 million and a net increase in unbilled receivables recorded in accordance with straight-line basis accounting of $2.4 million.
During the year ended December 31, 2019, net cash provided by operating activities was $47.4 million. The level of cash flows used in or provided by operating activities is affected by, among other things, the number of properties owned, the performance of those properties, the timing of interest payments and the amount of borrowings outstanding during the period, as well as the receipt of scheduled rent payments and the level of operating expenses. Cash inflows include non-cash items of $56.8 million (net loss of $88.3 million adjusted for non-cash items including depreciation and amortization of tangible and identifiable intangible real estate assets, deferred financing costs and mortgage premiums and discounts, bad debt expense, equity-based compensation, gain on non-
69

designated derivatives and impairment charges) and an increase in accounts payable and accrued expenses of $2.6 million related to higher accrued real estate taxes, property operating expenses and professional and legal fees. These cash inflows were partially offset by a net increase in prepaid expenses and other assets of $9.7 million and a net increase in unbilled receivables recorded in accordance with straight-line basis accounting of $3.8 million.
Cash Flows from Investing Activities
Net cash used in investing activities during the year ended December 31, 2020 was $82.5 million. The cash used in investing activities included $95.0 million for the acquisition of nine properties and $21.9 million in capital expenditures. These cash outflows were partially offset by proceeds from the sale of real estate of $34.4 million.
Net cash used in investing activities during the year ended December 31, 2019 was $46.2 million. The cash used in investing activities included $92.0 million for the acquisition of nine properties and to fund the cost of our ongoing development property in Jupiter, Florida during the period and $16.7 million in capital expenditures. These cash outflows were partially offset by proceeds from the sale of real estate of $62.5 million.
Cash Flows from Financing Activities
Net cash provided by financing activities of $19.4 million during the year ended December 31, 2020 included proceeds of $95.0 million from our Revolving Credit Facility. These cash inflows were partially offset by distributions to stockholders of $31.4 million, common stock repurchases of $10.5 million, payments for deferred financing costs of $2.2 million, the buyout of a non-controlling interest of $0.6 million and dividends paid to preferred stockholders $2.4 million.
Net cash provided by financing activities of $19.1 million during the year ended December 31, 2019 related to proceeds of $225.6 million from our Revolving Credit Facility, $150.0 million from our Term Loan, $136.5 million from the Multi-Property CMBS Loan and $37.6 million of net proceeds from the issuance of Series A Preferred Stock. These cash inflows were partially offset by payments on our Revolving Credit Facility of $368.3 million, mortgage principal repayments of $67.8 million, distributions to stockholders of $51.4 million, common stock repurchases of $21.1 million, payments for deferred financing costs of $19.5 million, and distributions to non-controlling interest holders of $0.3 million.
Liquidity and Capital Resources
The negative impacts of the COVID-19 pandemic has caused and may continue to cause certain of our tenants to be unable to make rent payments to us timely, or at all, which has, and could continue to have, an adverse effect on the amount of cash we receive from our operations. In addition to the discussion below, please see the “Overview — Management Update on the Impacts of the COVID-19 Pandemic” section above for additional information on the risks and uncertainties associated with the COVID-19 pandemic and management’s actions taken in response.
As of December 31, 2020, we had $72.4 million of cash and cash equivalents. Our ability to use this cash on hand is restricted. Under our Credit Facility, as amended on August 2020, we are required to maintain a combination of cash, cash equivalents and availability for future borrowings under our revolving credit facility under our Credit Facility (our “Revolving Credit Facility”) totaling at least $50.0 million. As of December 31, 2020, $48.3 million was available for future borrowings under our Revolving Credit Facility. Pursuant to an amendment to our Credit Facility in August 2020, certain other restrictions and conditions described below will no longer apply starting in the “Commencement Quarter” which is a quarter in which we make an election and, as of the day prior to the commencement of the applicable quarter we have a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by us during the applicable quarter, and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5%. As of December 31, 2020, our ratio of consolidated total indebtedness to consolidated total asset value for these purposes was 61.7%. The Commencement Quarter may be no earlier than the fiscal quarter ending June 30, 2021. There can be no assurance as to if, or when, we will be able to satisfy these conditions. We, for example, may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of our common stock) on our common stock until the Commencement Quarter. Moreover, beginning in the Commencement Quarter, we may only pay cash distributions provided that the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter.
Following the amendment in August 2020, our Credit Facility also restricts our sources of liquidity. Until the first day of the Commencement Quarter, we must use all of the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. We may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met. The availability for future borrowings under the Credit Facility is calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and availability has been, and may continue to be, adversely affected by the decreases in cash rent collected from our tenants and income from our operators that have resulted from the effects of the COVID-19 pandemic and may persist for some time. See “Item 1A. Risk Factors. Our Credit Facility restricts our ability to use cash
70

that would otherwise be available to us, and there can be no assurance our available liquidity will be sufficient to meet our capital needs.”
We expect to fund our future short-term operating liquidity requirements, including dividends to holders of Series A Preferred Stock, through a combination of current cash on hand, net cash provided by our property operations and proceeds from the Revolving Credit Facility. Our principal demands for cash are for acquisitions, capital expenditures, the payment of our operating and administrative expenses, debt service obligations (including principal repayment), and dividends to holders of our Series A Preferred Stock. We closely monitor our current and anticipated liquidity position relative to our current and anticipated demands for cash and believe that we have sufficient current liquidity and access to additional liquidity to meet our financial obligations for at least the next 12 months. Our future liquidity requirements, and available liquidity, however, depend on many factors, such as the on-going impact of COVID-19 on our tenants and operators and our ability to complete our pending dispositions on their contemplated terms, or at all.
Preferred Stock Equity Line with B. Riley Principal Capital, LLC
On September 15, 2020, we entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which we have the right from time to time to sell up to an aggregate of $15 million of shares of our Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” We control the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. We did not sell any shares under the Preferred Stock Equity Line during the year ended December 31, 2020.
Financings
As of December 31, 2020, our total debt leverage ratio (net debt divided by gross asset value) was approximately 44.5%. Net debt totaled $1.2 billion, which represents gross debt ($1.2 billion) less cash and cash equivalents ($72.4 million). Gross asset value totaled $2.6 billion, which represents total real estate investments, at cost ($2.6 billion) and assets held for sale at carrying value ($0.1 million), net of gross market lease intangible liabilities ($22.1 million). Impairment charges are already reflected within gross asset value.
As of December 31, 2020, we had total gross borrowings of $1.2 billion, at a weighted average interest rate of 3.6%. As of December 31, 2019, we had total gross borrowings of $1.1 billion at a weighted average interest rate of 4.0%. As of December 31, 2020, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, as applicable unless the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
We expect to utilize proceeds from our Credit Facility to fund future property acquisitions, as well as, subject to the terms of our Credit Facility, other sources of funds that may be available to us. These actions may require us to add some or all of our unencumbered properties as security for that debt or add them to the borrowing base under our Credit Facility. Unencumbered real estate investments, at cost as of December 31, 2020 was $0.2 billion. There can be no assurance as to the amount of liquidity we would be able to generate from adding any of the unencumbered assets we own to the borrowing base of our Credit Facility. Pursuant to the Credit Facility, any resulting net proceeds from these dispositions prior to the Commencement Quarter must be used to prepay amounts outstanding under the Revolving Credit Facility.
Mortgage Notes Payable
As of December 31, 2020, we had $550.4 million in gross mortgage notes payable outstanding. During the first quarter of 2020, we assumed one mortgage for $13.9 million in connection with one of our SHOP acquisitions.
Credit Facility
Our Credit Facility consists of two components, the Revolving Credit Facility and our Term Loan. The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to one one-year extension at our option. Our Term Loan is interest-only and matures on March 13, 2024. Loans under our Credit Facility may be prepaid at any time, in whole or in part, without premium or penalty, subject to customary breakage costs. Any amounts repaid under our Term Loan may not be re-borrowed.
In March 2020, we borrowed an additional $95.0 million under the Revolving Credit Facility a portion of which was used for general corporate purposes. Subsequently, we have not borrowed additional amount under the Revolving Credit Facility.
71

In the fourth quarter of 2020, we repaid $4.4 million of the Revolving Credit Facility from the proceeds of the Michigan SHOP disposition and $17.6 million from the disposition of the skilled nursing facility in Lutz, Florida. These amounts represented all the cash proceeds from these dispositions.
The total commitments under the Credit Facility are $630.0 million including $480.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion. As of December 31, 2020, $323.7 million was outstanding under the Credit Facility and the unused borrowing availability under the Credit Facility was $48.3 million. The amount available for future borrowings under the Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or a minimum debt service coverage ratio with respect to the borrowing base. Both of these amounts are calculated using the adjusted net operating income of the real estate assets comprising the borrowing base, and, therefore, availability under our Credit Facility has been adversely affected by the decreases in cash rent collected from our tenants and income from our operators due to the effects of the COVID-19 pandemic, and may continue to be adversely affected.
As of December 31, 2020, $150.0 million was outstanding under our Term Loan, and $173.7 million was outstanding under the Revolving Credit Facility. The equity interests and related rights in our wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility are pledged for the benefit of the lenders thereunder. The Credit Facility also contains a subfacility for letters of credit of up to $25.0 million. The applicable margin used to determine the interest rate under both the Term Loan and Revolving Credit Facility components of the Credit Facility varies based on our leverage. As of December 31, 2020, the Revolving Credit Facility and the Term Loan had an effective interest rate per annum equal to 3.21% and 4.95%, respectively. The Credit Facility prohibits us from exceeding a maximum ratio of consolidated total indebtedness to consolidated total asset value, and requires us to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges on a quarterly basis and a minimum consolidated tangible net worth. As of December 31, 2020, we were in compliance with the financial covenants under the Credit Facility. Based upon our current expectations, we believe our operating results during the next 12 months will allow us to comply with these covenants. Please see “Item 1A. Risk Factors. Risks Related to our Indebtedness.”
Fannie Mae Master Credit Facilities
As of December 31, 2020, $355.2 million was outstanding under the Fannie Mae Master Credit Facilities. We may request future advances under the Fannie Mae Master Credit Facilities by adding eligible properties to the collateral pool or by borrowing-up against the increased value of the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. Future advances based on the increased value of the collateral pool may only occur until November 2021 and not more than once annually for each of the Fannie Mae Master Credit Facilities. Borrowings under the Fannie Mae Master Credit facilities bear annual interest at a rate that varies on a monthly basis and is equal to the sum of the current LIBOR for one month U.S. dollar-denominated deposits and 2.62%, with a combined floor of 2.62%. The Fannie Mae Master Credit Facilities mature on November 1, 2026.
Capital Expenditures
During the year ended December 31, 2020, our capital expenditures were $21.9 million, of which approximately $4.6 million related our MOB segment, $4.0 million related to our NNN segment and $12.8 million related to our SHOP segment. All other capital expenditures were typical in nature for the other properties in our portfolio. We anticipate this rate of capital expenditures will be similar for the MOB, NNN and SHOP segments throughout 2021, however, the recent economic uncertainty created by the COVID-19 global pandemic will continue to impact our decisions on the amount and timing of future capital expenditures. Our capital expenditures in 2021 were funded using cash on hand, and we also expect to fund future capital expenditures using cash on hand.
Acquisitions — Year Ended December 31, 2020
During the year ended December 31, 2020, we completed the acquisitions of two multi-tenant MOBs, three single tenant MOBs and four SHOP for an aggregate contract purchase price of $109.6 million. The acquisition of one multi-tenant MOB for a contract purchase price of $5.7 million, was completed during the three months ended December 31, 2020. The properties acquired during the year ended December 31, 2020 are located in Illinois, Pennsylvania, Ohio and Florida and comprise approximately 340,783 square feet and were funded with proceeds from financings (including amounts borrowed under our Credit Facility), the assumption of the $13.9 million mortgage in an acquisition, and cash on hand.
Acquisitions — Subsequent to December 31, 2020 and Pending Transactions
We acquired one property subsequent to December 31, 2020 for $6.6 million. We have signed two PSAs to acquire two MOBs located in Ohio and Oklahoma for an aggregate contract purchase price of approximately $10.1 million. We anticipate using cash on hand to fund the consideration required to complete these acquisitions. The PSAs are subject to conditions and there can be no
72

assurance we will complete any of these acquisitions, or any future acquisitions or other investments, on a timely basis or on acceptable terms and conditions, if at all.
Acquisition of Non-Controlling Interest
In November 2020, we purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by us and added to the borrowing base under our Credit Facility.
Dispositions — Year Ended December 31, 2020
During the year ended December 31, 2020, we sold nine properties (one MOB, seven SHOPs and one skilled nursing facility in Lutz Florida) for an aggregate contract price of $40.4 million, which resulted in an aggregate gain on sale of $5.2 million. Eight of these properties (seven SHOPs in Michigan and one skilled nursing facility in Lutz Florida) were sold in the fourth quarter of 2020 and had an aggregate purchase price of $31.8 million, which resulted in an aggregate gain on sale of $2.9 million There were no mortgages on these properties, however the property in Lutz, Florida was part of the borrowing base under the Credit Facility, as well as four Michigan properties, and one of the Michigan properties was part of the Capital One Fannie Mae Credit Facility.
Which respect to the sale of the Michigan SHOPs, in November 2020, we received payment of the full $11.8 million sales price for all 11 of the Michigan SHOPs, less $0.8 million held in escrow, and transferred seven of the properties to the buyer. The remaining four properties were transferred to the buyer at a second closing in January 2021 when the $0.8 million held in escrow was released to the buyer. Of the properties transferred at the initial closing, four were part of the borrowing base under the Credit Facility, one was part of the collateral pool under the Fannie Mae Master Credit Facility with Capital One and two were unencumbered. Of the properties transferred at the second closing, three were part of the borrowing base under the Credit Facility until the initial closing and one was unencumbered. At the initial closing, $4.2 million of the net proceeds was used to repay amounts outstanding under the Fannie Mae Master Credit Facility with Capital One, $4.4 million of the net proceeds were used to repay amounts outstanding under the Revolving Credit Facility, with the remainder used for closing costs. Following the sale of the SHOP in Lutz, Florida, all $17.6 million of the net proceeds were used to repay amounts outstanding under the Credit Facility.
Dispositions — Subsequent to December 31, 2020
Subsequent to December 31, 2020, we did not dispose of any properties.
We have entered into two definitive PSAs to sell the property in Jupiter Florida for $65.0 million and a skilled nursing facility in Wellington, Florida for $33.0 million. The sales of these assets are subject to conditions, and, due to the persistence of the COVID-19 pandemic and other factors beyond our control, there can be no assurance that we will be able to meet these conditions and that these dispositions will be completed on their contemplated terms, or at all. With respect to the skilled nursing facility in Wellington, Florida, closing may not occur unless, among other conditions, certain occupancy and revenue levels have been maintained at the property for a period of time. The property in Jupiter, Florida is not currently encumbered by any mortgage debt or part of the borrowing base under our Credit Facility. The skilled nursing facility in Wellington Florida is part of the borrowing base under our Credit Facility. Pursuant to the terms of the amendment to our Credit Facility in August 2020, the net cash proceeds from any completed dispositions must be used to prepay amounts outstanding under the Revolving Credit Facility and will therefore not be available to us for any other purpose. We may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
Share Repurchase Program
Our Board has adopted the SRP, which enables our common stockholders to sell their shares of common stock to us under limited circumstances. At the time a common stockholder requests a repurchase, we may, subject to certain conditions, repurchase the shares presented for repurchase for cash. There are limits on the number of shares we may repurchase under this program during any calendar year. We are only authorized to repurchase shares using the proceeds secured from our DRIP in any given period, although the Board has the power, in its sole discretion, to determine the number of shares repurchased during any period as well as the amount of funds to be used for that purpose.
Under the currently effective amended and restated SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of our common stock or received their shares from us (directly or indirectly) through one or more non-cash transactions would be considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
The amendment to the Credit Facility on August 10, 2020 provides that we may not repurchase shares of our common stock until the Commencement Quarter. In light of this amendment, the Board suspended repurchases under the SRP effective August 14, 2020. The Board has also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. Prior to the Commencement Quarter, we may not repurchase shares of our common stock. Beginning in the Commencement Quarter, we will be permitted to repurchase up to $50.0 million of shares of our common stock (including amounts previously repurchased
73

during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, we maintain cash and cash equivalents of at least $30.0 million and our ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
No assurances can be made as to when or if our SRP will be reactivated.
Non-GAAP Financial Measures
This section discusses the non-GAAP financial measures we use to evaluate our performance including Funds from Operations (“FFO”), Modified Funds from Operations (“MFFO”) and NOI. While NOI is a property-level measure, MFFO is based on our total performance as a company and therefore reflects the impact of other items not specifically associated with NOI such as, interest expense, general and administrative expenses and operating fees to related parties. Additionally, NOI as defined here, includes straight-line rent which is excluded from MFFO. A description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP measure, which is net income, are provided below:
Funds from Operations and Modified Funds from Operations
The historical accounting convention used for real estate assets requires straight-line depreciation of buildings, improvements, and straight-line amortization of intangibles, which implies that the value of a real estate asset diminishes predictably over time. We believe that, because real estate values historically rise and fall with market conditions, including, but not limited to, inflation, interest rates, the business cycle, unemployment and consumer spending, presentations of operating results for a REIT using the historical accounting convention for depreciation and certain other items may be less informative.
Because of these factors, the National Association of Real Estate Investment Trusts (“NAREIT”), an industry trade group, has published a standardized measure of performance known as FFO, which is used in the REIT industry as a supplemental performance measure. We believe FFO, which excludes certain items such as real estate-related depreciation and amortization, is an appropriate supplemental measure of a REIT’s operating performance. FFO is not equivalent to our net income or loss as determined under GAAP.
We calculate FFO, a non-GAAP measure, consistent with the standards established over time by the Board of Governors of NAREIT, as restated in a White Paper approved by the Board of Governors of NAREIT effective in December 2018 (the “White Paper”). The White Paper defines FFO as net income or loss computed in accordance with GAAP, excluding depreciation and amortization related to real estate, gains and losses from the sale of certain real estate assets, gains and losses from change in control and impairment write-downs of certain real estate assets and investments in entities when the impairment is directly attributable to decreases in the value of depreciable real estate held by the entity. Adjustments for unconsolidated partnerships and joint ventures are calculated to reflect FFO. Our FFO calculation complies with NAREIT’s definition.
We believe that the use of FFO provides a more complete understanding of our operating performance to investors and to management, and reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income.
Changes in the accounting and reporting promulgations under GAAP that were put into effect in 2009 subsequent to the establishment of NAREIT’s definition of FFO, such as the change to expense as incurred rather than capitalize and depreciate acquisition fees and expenses incurred for business combinations, have prompted an increase in cash-settled expenses, specifically acquisition fees and expenses, as items that are expensed under GAAP across all industries. These changes had a particularly significant impact on publicly registered, non-listed REITs, which typically have a significant amount of acquisition activity in the early part of their existence, particularly during the period when they are raising capital through ongoing initial public offerings.
Because of these factors, the Institute of Portfolio Alternatives (“IPA”), an industry trade group, has published a standardized measure of performance known as MFFO, which the IPA has recommended as a supplemental measure for publicly registered, non-listed REITs. MFFO is designed to be reflective of the ongoing operating performance of publicly registered, non-listed REITs by adjusting for those costs that are more reflective of acquisitions and investment activity, along with other items the IPA believes are not indicative of the ongoing operating performance of a publicly registered, non-listed REIT, such as straight-lining of rents as required by GAAP. We believe it is appropriate to use MFFO as a supplemental measure of operating performance because we believe that, when compared year-over-year, both before and after we have deployed all of our offering proceeds and are no longer incurring a significant amount of acquisition fees or other related costs, it reflects the impact on our operations from trends in occupancy rates, rental rates, operating costs, general and administrative expenses, and interest costs, which may not be immediately apparent from net income. MFFO is not equivalent to our net income or loss as determined under GAAP.
We calculate MFFO, a non-GAAP measure, consistent with the IPA’s Guideline 2010-01, Supplemental Performance Measure for Publicly Registered, Non-Listed REITs: Modified Funds from Operations (the “Practice Guideline”) issued by the IPA in November 2010. The Practice Guideline defines MFFO as FFO further adjusted for acquisition fees and expenses and other items. In calculating MFFO, we follow the Practice Guideline and exclude acquisition fees and expenses, amortization of above and below market and other intangible lease assets and liabilities, amounts relating to straight-line rent adjustments (in order to reflect such payments from a GAAP accrual basis to a cash basis of disclosing the lease and rental payments), contingent purchase price
74

consideration, accretion of discounts and amortization of premiums on debt investments, mark-to-market adjustments included in net income, gains or losses included in net income from the extinguishment or sale of debt, hedges, foreign exchange, derivatives or securities holdings where trading of such holdings is not a fundamental attribute of the business plan, unrealized gains or losses resulting from consolidation from, or deconsolidation to, equity accounting, and adjustments for unconsolidated partnerships and joint ventures, with such adjustments calculated to reflect MFFO on the same basis. We also exclude other non-operating items in calculating MFFO, such as transaction-related fees and expenses and capitalized interest.
We believe that, because MFFO excludes costs that we consider more reflective of acquisition activities and other non-operating items, MFFO can provide, on a going-forward basis, an indication of the sustainability (that is, the capacity to continue to be maintained) of our operating performance once our portfolio is stabilized. Our Modified FFO (as defined in our Credit Facility) is similar but not identical to MFFO as discussed in this Quarterly Report on Form 10-Q. We also believe that MFFO is a recognized measure of sustainable operating performance by the non-listed REIT industry and allows for an evaluation of our performance against other publicly registered, non-listed REITs.
Not all REITs, including publicly registered, non-listed REITs, calculate FFO and MFFO the same way. Accordingly, comparisons with other REITs, including publicly registered, non-listed REITs, may not be meaningful. Furthermore, FFO and MFFO are not indicative of cash flow available to fund cash needs and should not be considered as an alternative to net income (loss) or income (loss) from continuing operations as determined under GAAP as an indication of our performance, as an alternative to cash flows from operations as an indication of our liquidity, or indicative of funds available to fund our cash needs including our ability to pay dividends and other distributions to our stockholders. FFO and MFFO should be reviewed in conjunction with GAAP measurements as an indication of our performance. The methods utilized to evaluate the performance of a publicly registered, non-listed REIT under GAAP should be construed as more relevant measures of operational performance and considered more prominently than the non-GAAP measures, FFO and MFFO, and the adjustments to GAAP in calculating FFO and MFFO.
Neither the SEC, NAREIT, the IPA nor any other regulatory body or industry trade group has passed judgment on the acceptability of the adjustments that we use to calculate FFO or MFFO. In the future, updates to the White Paper or the Practice Guideline may be published or the SEC or another regulatory body could standardize the allowable adjustments across the publicly registered, non-listed REIT industry and we would have to adjust our calculation and characterization of FFO or MFFO accordingly.
Accounting Treatment of Rent Deferrals
All of the concessions granted to our tenants as a result of the COVID-19 pandemic are rent deferrals with the original lease term unchanged and collection of deferred rent deemed probable (see the “Overview - Management Update on the Impacts of the COVID-19 Pandemic” section of this Management’s Discussion and Analysis of Financial Condition and Results of Operations for additional information). As a result of relief granted by the FASB and SEC related to lease modification accounting, rental revenue used to calculate Net Income and NAREIT FFO has not been, and we do not expect it to be, significantly impacted by these types of deferrals. In addition, since we currently believe that these deferral amounts are collectable, we have excluded from the increase in straight-line rent for MFFO purposes the amounts recognized under GAAP relating to these types of rent deferrals. For a detailed discussion of our revenue recognition policy, including details related to the relief granted by the FASB and SEC, see Note 2 — Significant Accounting Polices to our consolidated financial statements included in the Annual Report on Form 10-K.
75

The table below reflects the items deducted from or added to net loss attributable to stockholders in our calculation of FFO and MFFO for the periods indicated. In calculating our FFO and MFFO, we exclude the impact of amounts attributable to our non-controlling interests.
Year Ended December 31,
(In thousands)202020192018
Net loss attributable to common stockholders (in accordance with GAAP)
$(78,781)$(88,087)$(52,762)
Depreciation and amortization (1)
79,643 79,744 82,226 
Impairment charges
36,446 55,969 20,655 
(Gain) loss on sale of real estate investment
(5,230)(8,790)70 
Adjustments for non-controlling interests (2)
(526)(595)(484)
FFO (as defined by NAREIT) attributable to common stockholders
31,552 38,241 49,705 
Acquisition and transaction related
173 362 302 
(Accretion) amortization of market lease and other lease intangibles, net
(80)(4)255 
Straight-line rent adjustments
(2,405)(3,561)(1,863)
Straight-line rent (rent deferral agreements) (3)
280 — — 
Amortization of mortgage premiums and discounts, net
60 (162)(263)
Loss on non-designated derivatives
102 68 157 
Capitalized construction interest costs
— (2,756)(3,198)
Deferred tax asset valuation allowance (4)
4,641 — — 
Adjustments for non-controlling interests (2)
(9)31 24 
MFFO attributable to common stockholders
$34,314 $32,219 $45,119 
________
(1) Net of non-real estate depreciation and amortization.
(2) Represents the portion of the adjustments allocable to non-controlling interests.
(3) Represents the amount of deferred rent pursuant to lease negotiations which qualify for FASB relief for which rent was deferred but not reduced. These amounts are included in the straight-line rent receivable on our consolidated balance sheet but are considered to be earned revenue attributed to the current period for purposes of MFFO as they are expected to be collected.
(4) This is a non-cash item and is added back as it is not considered a part of operating performance.
Net Operating Income
NOI is a non-GAAP financial measure used by us to evaluate the operating performance of our real estate portfolio. NOI is equal to revenue from tenants less property operating and maintenance. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss).
We believe NOI provides useful and relevant information because it reflects only those income and expense items that are incurred at the property level and presents such items on an unlevered basis. We use NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. Further, we believe NOI is useful to investors as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by us may not be comparable to NOI reported by other REITs that define NOI differently. We believe that in order to facilitate a clear understanding of our operating results, NOI should be examined in conjunction with net income (loss) as presented in our consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of our performance or to cash flows as a measure of our liquidity or ability to pay distributions.
The following table reflects the items deducted from or added to net loss attributable to common stockholders in our calculation of NOI for the year ended December 31, 2020:
76

(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
Net income (loss) attributable to common stockholders (in accordance with GAAP)
$36,862 $2,492 $(15,690)$(102,445)$(78,781)
Impairment charges12,551 — 23,895 — 36,446 
Operating fees to related parties— — — 23,922 23,922 
Acquisition and transaction related— — — 173 173 
General and administrative95 — — 21,477 21,572 
Depreciation and amortization74,017 6,617 419 — 81,053 
Interest expense2,036 — — 49,483 51,519 
Interest and other income— — — (44)(44)
Loss on non-designated derivative instruments— 102 102 
Loss on sale of real estate investments— — (5,230)— (5,230)
Income tax expense— — — 4,061 4,061 
Net income attributable to non-controlling interests— — — 303 303 
Allocation for preferred stock— — — 2,968 2,968 
NOI$125,561 $9,109 $3,394 $— $138,064 
The following table reflects the items deducted from or added to net loss attributable to stockholders in our calculation of NOI for the year ended December 31, 2019:
(In thousands)Same StoreAcquisitionsDispositionsNon-Property SpecificTotal
Net income (loss) attributable to common stockholders (in accordance with GAAP)
$14,097 $1,552 $(3,519)$(100,217)$(88,087)
Impairment charges43,125 — 12,844 — 55,969 
Operating fees to related parties— — — 23,414 23,414 
Acquisition and transaction related28 — 327 362 
General and administrative93 11 11 20,415 20,530 
Depreciation and amortization76,430 2,087 2,515 — 81,032 
Interest expense213 — — 55,846 56,059 
Interest and other income— — (9)(7)
Loss on non-designated derivative instruments— — — 68 68 
Gain on sale of real estate investments— — (8,790)— (8,790)
Income tax expense— — — 399 399 
Net income (loss) attributable to non-controlling interests
23 — — (416)(393)
Allocation for preferred stock— — — 173 173 
NOI$133,990 $3,678 $3,061 $— $140,729 
Refer to Note 15 — Segment Reporting to our consolidated financial statements found in this Annual Report on Form 10-K for a reconciliation of NOI to net loss attributable to stockholders by reportable segment.
Dividends and Other Distributions
Dividends on our Series A Preferred Stock accrue in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to Series A Preferred Stock holders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us.
77

From March 1, 2018 until June 20, 2020, we paid distributions to our common stockholders, at a rate equivalent to $0.85 per annum, per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On June 29, 2020, the Board approved a change in our common stock distribution policy whereby we would no longer declare distributions based on daily record dates. Instead, any future distributions authorized by the Board on shares of our common stock were to be paid on a monthly basis in arrears based on a single record date during the applicable month.
As noted herein under our Credit Facility we may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying cash dividends on the Series A Preferred Stock or any other preferred stock we may issue and paying any cash distributions necessary to maintain our status as a REIT. We may not pay any cash distributions (including dividends on Series A Preferred Stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter we will be able to pay cash distributions to holders of common stock, subject to the restrictions described below. There can be no assurance as to if, or when, we will be able to satisfy these conditions. We may only pay cash distributions beginning in the Commencement Quarter and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. Until four full fiscal quarters have elapsed after the commencement of Commencement Quarter, the aggregate amount of permitted distributions and Modified FFO will be determined by using only the fiscal quarters that have elapsed from and after the Commencement Quarter and annualizing those amounts.
On August 13, 2020, the Board changed our common stock distribution policy in order to preserve our liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility described above. Under the new policy, distributions authorized by the Board on shares of our common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of our common stock valued at the Estimated Per-Share NAV in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. On October 1, 2020 and January 4, 2021, we declared dividends payable in 0.01349 shares of our common stock on each share of our outstanding common stock. This amount was based on our prior cash distribution rate of $0.85 per share per annum. The stock dividends were paid on October 15, 2020 and January 15, 2021 to holders of record of our common stock at the close of business on October 8, 2020 and January 11, 2021. See “— Overview” for additional information on the impact of the stock dividends.
Subject to the restrictions in our Credit Facility, the amount of dividends and other distributions payable to our stockholders is determined by the Board and is dependent on a number of factors, including funds available for distribution, our financial condition, capital expenditure requirements, as applicable, requirements of Maryland law and annual distribution requirements needed to maintain our status as a REIT under the Code. Distribution payments are dependent on the availability of funds. The Board may reduce the amount of dividends or distributions paid or suspend dividend or distribution payments at any time and therefore dividend and distribution payments are not assured. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock become part of the liquidation preference thereof.
78

The following table shows the sources for the payment of distributions to common stockholders preferred stockholders, including distributions on unvested restricted shares and OP Units, but excluding distributions related to Class B Units as these distributions are recorded as an expense in our consolidated statement of operations and comprehensive loss, for the periods indicated:
Three Months EndedYear Ended
March 31, 2020June 30, 2020September 30, 2020December 31, 2020December 31, 2020
(In thousands)Percentage of DistributionsPercentage of DistributionsPercentage of DistributionsPercentage of DistributionsPercentage of Distributions
Distributions:
Distributions to common stockholders not reinvested in common stock issued under the DRIP$13,225 $13,729 $4,400 $— $31,354 
Distributions reinvested in common stock issued under the DRIP6,322 6,267 2,015 — 14,604 
Dividends to preferred stockholders173 742 742 742 2,399 
Distributions on OP Units86 87 28 — 201 
Total distributions (1)
$19,806 $20,825 $7,185 $742 $48,558 
Source of distribution coverage:
Cash flows provided by operations (2)
$18,952 95.7 %$12,294 59.0 %$7,185 100.0 %$24 3.2 %$41,807 86.1 %
Proceeds received from common stock issued under the DRIP (2)
854 4.3 %6,267 30.1 %— — %718 96.8 %6,751 (3)13.9 %
Available cash on hand
— — %2,264 10.9 %— — %— — %— (3)— %
Total source of distribution coverage
$19,806 100.0 %$20,825 100.0 %$7,185 100.0 %$742 100.0 %$48,558 100.0 %
Cash flows provided by operations (in accordance with GAAP)
$18,952 $12,294 $10,537 $24 $41,807 
Net loss attributable to stockholders (in accordance with GAAP)
$(24,744)$(22.811)$(10,500)$(43,514)$(78,781)
_______
(1)    Excludes distributions related to Class B Units and distributions to non-controlling interest holders other than those paid on our OP Units.The decrease in total distributions was due to the change in the timing of our distributions to common stockholders and the change to declaring distributions in common stock (as opposed to cash) beginning in October 2020 (see disclosure above).
(2)    Assumes the use of available cash flows from operations before any other sources.
(3)    Year-to-date total does not equal the sum of the quarters. Each quarter and year-to-date period is evaluated separately for purposes of this table.
For the year ended December 31, 2020, cash flows provided by operations were $41.8 million. We had not historically generated sufficient cash flow from operations to fund the payment of dividends and other distributions at the current rate prior to switching from paying cash dividends to stock dividends on our common stock. As shown in the table above, we funded distributions with cash flows provided by operations, proceeds received from common stock issued under our DRIP and available cash on hand, comprised of proceeds from financings and dispositions. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as we pay distributions in stock instead of cash.
Our ability to pay dividends on our Series A Preferred Stock and starting with the Commencement Quarter, other distributions and maintain compliance with the restrictions on the payment of distributions in our Credit Facility depends on our ability to increase the amount of cash we generate from property operations which in turn depends on a variety of factors, including the duration and scope of the COVID-19 pandemic and its impact on our tenants and properties, our ability to complete acquisitions of new properties and our ability to improve operations at our existing properties. There can be no assurance that we will complete acquisitions on a timely basis or on acceptable terms and conditions, if at all. Our ability to improve operations at our existing properties is also subject to a variety of risks and uncertainties, many of which are beyond our control, and there can be no assurance we will be successful in achieving this objective.
We may still pay any cash distributions necessary to maintain its status as a REIT and may not pay any cash distributions (including dividends on Series A Preferred Stock) if a default or event of default exists or would result therefrom under the Credit
79

Facility. The amendment provided that the covenants restricting payment of distributions to a threshold based on Modified FFO and requiring maintenance of a minimum ratio of consolidated total indebtedness to consolidated total asset value and a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges did not apply for the fiscal quarter ended June 30, 2020. In addition, the lenders waived any defaults or event of defaults under those covenants that may have occurred during the fiscal quarter ended June 30, 2020 as well as any additional default or event of default resulting therefrom prior to August 10, 2020. There can be no assurance our lenders will consent to any amendments or waivers that may become necessary to comply with our Credit Facility in the future.
Loan Obligations
The payment terms of our mortgage notes payable generally require principal and interest amounts payable monthly with all unpaid principal and interest due at maturity. The payment terms of our Credit Facility require interest only amounts payable monthly with all unpaid principal and interest due at maturity. The payment terms of our Fannie Mae Master Credit Facilities require interest only payments through November 2021 and principal and interest payments thereafter. Our loan agreements require us to comply with specific reporting covenants. As of December 31, 2020, we were in compliance with the financial and reporting covenants under our loan agreements.
Following the amendment to our Credit Facility in August 2020, until the first day of the Commencement Quarter, we must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. We may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
Contractual Obligations
The following table reflects contractual debt obligations under our mortgage notes payable, Revolving Credit Facility and Fannie Mae Master Credit Facilities and minimum base rental cash payments due for leasehold interests over the next five years and thereafter as of December 31, 2020. The minimum base rental cash payments due for leasehold interests amounts exclude contingent rent payments, as applicable, that may be payable based on provisions related to increases in annual rent based on exceeding certain economic indexes, among other items. As of December 31, 2020, the outstanding mortgage notes payable and loans under the Revolving Credit Facility and Fannie Mae Master Credit Facilities had weighted-average effective interest rates of 3.9%, 3.2% and 2.6%, respectively.
  Years Ended December 31, 
(In thousands)Total20212022 - 20232024 -2025Thereafter
Principal on mortgage notes payable
$550,361 $1,191 $7,625 $2,237 $539,308 
Interest on mortgage notes payable
108,961 15,971 45,387 47,603 — 
Principal on Revolving Credit Facility173,674 — — 173,674 — 
Interest on Revolving Credit Facility27,875 5,575 11,150 11,150 — 
Principal on Term Loan150,000 — — 150,000 — 
Interest on Term Loan37,125 7,425 14,850 14,850 — 
Fannie Mae Master Credit Facilities355,175 130 7,316 8,993 338,736 
Interest on Fannie Mae Master Credit Facilities53,913 9,314 18,464 18,031 8,104 
Lease rental payments due (1)
39,944 747 1,540 1,560 36,097 
Total$1,497,028 $40,353 $106,332 $428,098 $922,245 
_________
(1) Includes all payments due on both operating leases and direct financing leases. See Note 16 — Commitments and Contingencies to our consolidated financial statements included in this Form 10-K for additional information.
80

Election as a REIT 
We elected to be taxed as a REIT under Sections 856 through 860 of the Code, effective for our taxable year ended December 31, 2013. Commencing with that taxable year, we have been organized and operated in a manner so that we qualify as a REIT under the Code. We intend to continue to operate in such a manner but can provide no assurances that we will operate in a manner so as to remain qualified for taxation as a REIT. To continue to qualify as a REIT, we must distribute annually at least 90% of our REIT taxable income (which does not equal net income as calculated in accordance with GAAP) determined without regard to the deduction for dividends paid and excluding net capital gains, and comply with a number of other organizational and operational requirements. If we continue to qualify as a REIT, we generally will not be subject to U.S. federal corporate income tax on the portion of our REIT taxable income that we distribute to our stockholders. Even if we continue to qualify for taxation as a REIT, we may be subject to certain state and local taxes on our income and properties as well as U.S. federal income and excise taxes on our undistributed income.
Inflation
We may be adversely impacted by inflation on any leases that do not contain indexed escalation provisions. In addition, we may be required to pay costs for maintenance and operation of properties, which may adversely impact our results of operations due to potential increases in costs and operating expenses resulting from inflation.
Related-Party Transactions and Agreements
Please see Note 9 — Related Party Transactions and Arrangements to our consolidated financial statements included in this Annual Report on Form 10-K for a discussion of the various related party transactions, agreements and fees.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
The market risk associated with financial instruments and derivative financial instruments is the risk of loss from adverse changes in market prices or interest rates. Our long-term debt, which consists of secured financings, our Credit Facility (which includes a Revolving Credit Facility and a Term Loan) and the Fannie Mae Master Credit Facilities, bear interest at fixed rates and variable rates. Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower our overall borrowing costs. To achieve these objectives, from time to time, we may enter into interest rate hedge contracts such as swaps, collars, and treasury lock agreements in order to mitigate our interest rate risk with respect to various debt instruments. We will not hold or issue these derivative contracts for trading or speculative purposes. As of December 31, 2020, we had entered into six non-designated interest rate caps with a notional amount of approximately $359.3 million and nine designated interest rate swaps with a notional amount of $578.5 million. We do not have any foreign operations and thus we are generally not directly exposed to foreign currency fluctuations.
Mortgage Notes Payable
As of December 31, 2020, all of our mortgages are either fixed-rate ($171.9 million) or variable-rate ($378.5 million), before consideration of interest rate swaps. Our mortgages had a gross aggregate carrying value of $550.4 million and a fair value of $549.6 million as of December 31, 2020.
Credit Facilities
Our Credit Facilities are variable-rate, before consideration of interest rate swaps, and are comprised of our Revolving Credit Facility, our Term Loan and our Fannie Mae Master Credit Facilities. Our Credit Facilities had a gross aggregate carrying amount of $678.8 million and a fair value of $673.6 million as of December 31, 2020.
Sensitivity Analysis - Interest Expense
Interest rate volatility associated with all of our variable-rate borrowings, which totaled $1.1 billion as of December 31, 2020, affects interest expense incurred and cash flow to the extent they are not fixed via interest rate swap. As noted above, we have nine designated interest rate swaps with a notional amount of $578.5 million, which effectively creates a fixed interest rate for a portion of our variable-rate debt. We also have six non-designated interest rate cap contracts, which are substantially out of the money and, therefore do not currently affect our near-term interest rate sensitivity. The sensitivity analysis related to the portion of our variable-rate debt that is not fixed via designated interest rate swaps assumes an immediate 100 basis point move in interest rates from their December 31, 2020 levels, with all other variables held constant. A 100 basis point increase and decrease in variable interest rates on the portion of our variable-rate debt that is not fixed via designated interest rate swaps would increase and decrease our interest expense by $4.8 million.

81

Sensitivity Analysis - Fair Value of Debt
Changes in market interest rates on our debt instruments impacts their fair value, even if it has no impact on interest due on them. For instance, if interest rates rise 100 basis points and the balances on our debt instruments remain constant, we expect the fair value of our obligations to decrease, the same way the price of a bond declines as interest rates rise. The sensitivity analysis related to our debt assumes an immediate 100 basis point move in interest rates from their December 31, 2020 levels, with all other variables held constant. A 100 basis point increase in market interest rates would result in a decrease in the fair value of our debt by $37.2 million. A 100 basis point decrease in market interest rates would result in an increase in the fair value of our debt by $35.2 million. A 100 basis point increase in market interest rates would result in an increase in the fair value of our nine designated interest rate swaps by $28.5 million. A 100 basis point decrease in market interest rates would result in a decrease in the fair value of our nine designated interest rate swaps by $30.2 million.
These amounts were determined by considering the impact of hypothetical interest rate changes on our borrowing costs, and assuming no other changes in our capital structure. The information presented above includes only those exposures that existed as of December 31, 2020 and does not consider exposures or positions arising after that date. The information represented herein has limited predictive value. Future actual realized gains or losses with respect to interest rate fluctuations will depend on cumulative exposures, hedging strategies employed and the magnitude of the fluctuations.
Item 8. Financial Statements and Supplementary Data.
The information required by this Item 8 is hereby incorporated by reference to our Consolidated Financial Statements beginning on page F-1 of this Annual Report on Form 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
In accordance with Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our disclosure controls and procedures include internal controls and other procedures designed to provide reasonable assurance that information required to be disclosed in this and other reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. It should be noted that no system of controls can provide complete assurance of achieving a company’s objectives and that future events may impact the effectiveness of a system of controls.
Our Chief Executive Officer and Chief Financial Officer, carried out an evaluation, together with other members of our management, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of December 31, 2020 at a reasonable level of assurance.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) or 15d-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.
Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making that assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway
82

Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on its assessment, our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective based on those criteria.
This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. The effectiveness of our internal control over financial reporting has not been audited by our independent registered public accounting firm because we are a “non-accelerated filer” as defined under SEC rules.
Changes in Internal Control Over Financial Reporting
During the three months ended December 31, 2020, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Information.
None.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
We have adopted a Code of Business Conduct and Ethics that applies to all of our executive officers and directors, including but not limited to, our principal executive officer and principal financial officer. A copy of our code of ethics may be obtained, free of charge, by sending a written request to our executive office: 650 Fifth Avenue - 30th Floor, New York, NY 10019, Attention: Chief Financial Officer. Our Code of Business Conduct and Ethics is also publicly available on our website at www.healthcaretrustinc.com. If we make any substantive amendments to the code of ethics or grant any waiver, including any implicit waiver, from a provision of the Code of Business Conduct and Ethics to our chief executive officer, chief financial officer, chief accounting officer or controller or persons performing similar functions, we will disclose the nature of the amendment or waiver on that website or in a report on Form 8-K.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2021 annual meeting of stockholders to be filed not later than 120 days after the end of the 2020 fiscal year, and is incorporated herein by reference.
Item 11. Executive Compensation.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2021 annual meeting of stockholders to be filed not later than 120 days after the end of the 2020 fiscal year, and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Securities Authorized for Issuance Under Equity Compensation Plans
Restricted Share Plan
We have an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides us with the ability to grant awards of restricted shares to our directors, officers and employees (if we ever have employees), and, among other eligible persons, employees of the Advisor and its affiliates who provide services to us. For additional information, see Note 11 — Equity-Based Compensation to our consolidated financial statements included in this Annual Report on Form 10-K.


83


The following table sets forth information regarding securities authorized for issuance under the RSP as of December 31, 2020:

Plan Category
Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights
Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights
Number of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a) )
(a)
(b)
(c)
Equity Compensation Plans approved by security holders
3,027,609 
(1)
Equity Compensation Plans not approved by security holders
Total
3,027,609 
(1)

________
(1) The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of our outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3,445,866 shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events). As of December 31, 2020, we had 93,775,746 shares of common stock issued and outstanding and 421,135 shares of common stock that were subject to awards granted under the RSP. For additional information on the RSP, please see Note 11 — Equity-Based Compensation to our consolidated financial statements included in this Annual Report on Form 10-K.
The other information required by this Item will be set forth in our definitive proxy statement with respect to our 2021 annual meeting of stockholders to be filed not later than 120 days after the end of the 2020 fiscal year, and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2021 annual meeting of stockholders to be filed not later than 120 days after the end of the 2020 fiscal year, and is incorporated herein by reference.
Item 14. Principal Accounting Fees and Services.
The information required by this Item will be set forth in our definitive proxy statement with respect to our 2021 annual meeting of stockholders to be filed not later than 120 days after the end of the 2020 fiscal year, and is incorporated herein by reference.
PART IV
Item 15. Exhibits and Financial Statement Schedules.
(a) Financial Statements and Financial Statement Schedules
1.    Financial Statements:
        See the Index to Consolidated Financial Statements at page F-1 of this Annual Report on Form 10-K.
2.    Financial Statement Schedules:
The following financial statement schedule is included herein at page F-42 of this Annual Report on Form 10-K: Schedule III — Real Estate and Accumulated Depreciation

(b) Exhibits
See Exhibit Index below.



EXHIBIT INDEX

The following exhibits are included, or incorporated by reference, in this Annual Report on Form 10-K for the year ended December 31, 2020 (and are numbered in accordance with Item 601 of Regulation S-K):
Exhibit No.  Description
 3.1 (1)
Articles of Amendment and Restatement for Healthcare Trust, Inc.
3.2 (2)
Articles Supplementary of Healthcare Trust, Inc. relating to election to be subject to Section 3-803 of the Maryland General Corporation Law, dated November 9, 2017.

3.3 (3)
Articles Supplementary relating to the designation of shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, dated December 6, 2019.

3.4 (4)
Amended and Restated Bylaws of Healthcare Trust, Inc.
3.5 (5)
Amendment to Amended and Restated Bylaws of Healthcare Trust, Inc.
3.6 (6)
Articles Supplementary designating additional shares of 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock
4.1 (7)
Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P. (f/k/a American Realty Capital Healthcare Trust II Operating Partnership, L.P.), dated as of February 14, 2013
4.2 (8)
First Amendment to the Agreement of Limited Partnership of American Realty Capital Healthcare Trust II, L.P., dated as of December 31, 2013
4.3 (9)
Second Amendment to the Agreement of Limited Partnership of American Realty Capital Healthcare Trust II, L.P., dated as of April 15, 2015
4.4 (10)
Third Amendment, dated December 6, 2019, to the Agreement of Limited Partnership of Healthcare Trust Operating Partnership, L.P., dated February 14, 2013

4.5 *
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

4.6 (11)
Rights Agreement, dated May 18, 2020, between Healthcare Trust, Inc.,and Computershare Trust Company, N.A., as Rights Agent.
10.1 (9)
Second Amended and Restated Advisory Agreement, dated as of February 17, 2017, by and among the Company, Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Advisors, LLC
10.2 (12)
Amendment No. 1, dated as of July 25, 2019, to the Second Amended and Restated Advisory Agreement, by and among Healthcare Trust, Inc., Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Advisors, LLC

10.3 (9)

Amended and Restated Property Management and Leasing Agreement, dated as of February 17, 2017, by and among the Company, Healthcare Trust Operating Partnership, L.P. and Healthcare Trust Properties, LLC
10.4 (13)
First Amendment, dated as of April 9, 2018, to Amended and Restated Property Management and Leasing Agreement, by and among Healthcare Trust, Inc., Healthcare Trust Operating Partnership, L.P., and Healthcare Trust Properties, LLC
10.5 (14)
Indemnification Agreement, dated as of December 31, 2014, with Directors, Officers, Advisor and Dealer Manager
10.6 (14)
Indemnification Agreement, dated April 14, 2015, with Mr. Randolph C. Read
10.7 (15)
Form of Restricted Stock Award Agreement Pursuant to the Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc.
10.8 (16)
Master Credit Facility Agreement, dated as of October 31, 2016, by and among the borrowers party thereto and KeyBank National Association.
10.9 (4)
First Amendment to Master Credit Facility, dated April 26, 2017, by among the borrowers party thereto and KeyBank National Association

10.10 (4)
Reaffirmation, Joinder and Second Amendment to Master Credit Facility, dated October 26, 2017, by among the borrowers party thereto and KeyBank National Association

10.11 (16)
Master Credit Facility Agreement, dated as of October 31, 2016, by and among the borrowers party thereto and Capital One Multifamily Finance, LLC.
10.12 (4)
Reaffirmation, Joinder and First Amendment to Master Credit Facility, dated March 30, 2017, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

10.13 (4)
Second Amendment to Master Credit Facility, dated October 26, 2017, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

10.14 (4)
Third Amendment to Master Credit Facility, dated March 2, 2018, by among the borrowers party thereto and Capital One Multifamily Finance, LLC

85

Exhibit No.  Description
10.15 (17)
Amended and Restated Loan Agreement, dated as of December 20, 2019, by and among the borrower entities party thereto, Capital One, National Association and the other lenders party thereto

10.16 (17)
Amended and Restated Guaranty of Recourse Obligations, dated as of December 20, 2019, by Healthcare Trust Operating Partnership, L.P. in favor of Capital One, National Association

10.17 (17)
Amended and Restated Hazardous Materials Indemnity Agreement, dated as of December 20, 2019, by Healthcare Trust Operating Partnership, L.P. and the borrower entities party thereto, for the benefit of Capital One, National Association

10.18 (2)
Amended and Restated Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc., effective as of August 31, 2017.
10.19 (2)
Form of Restricted Stock Award Agreement Pursuant to the Amended and Restated Employee and Director Incentive Restricted Share Plan of Healthcare Trust, Inc.
10.20 (18)
Loan Agreement, dated as of December 28, 2017, among the borrower entities party thereto and Capital One, National Association.
10.21 (18)
Guaranty of Recourse Obligation, dated as of December 28, 2017, by Healthcare Trust Operating Partnership, L.P. in favor of Capital One, National Association.
10.22 (18)
Hazardous Materials Indemnity Agreement, dated as of December 28, 2017, by Healthcare Trust Operating Partnership, L.P. and the borrower entities party thereto, for the benefit of Capital One, National Association.
10.23 (13)
 Loan Agreement, dated as of April 10, 2018, by and among the borrowers party thereto, and KeyBank National Association, as lender
10.24 (13)
Promissory Note A -1, dated as of April 10, 2018, by the borrowers party thereto in favor of KeyBank National
Association, as lender
10.25 (13)
 Promissory Note A-2, dated as of April 10, 2018, by the borrowers party thereto in favor of KeyBank National
Association, as lender
10.26 (13)
Guarantee Agreement, dated as of April 10, 2018, by Healthcare Trust Operating Partnership, L.P. in favor of KeyBank National Association, as lender
10.27 (13)
Environmental Indemnity Agreement, dated as of April 10, 2018, by the borrowers party thereto and Healthcare Trust Operating Partnership, L.P. in favor of KeyBank National Association, as indemnitee
10.28 (19)
Form of Indemnification Agreement
10.29 (20)
Amended and Restated Senior Secured Revolving Credit Agreement dated as of March 13, 2019 by and among Healthcare Trust Operating Partnership, L.P., KeyBank National Association and the other lender parties thereto

10.30 (21)
First Amendment, dated March 24, 2020, to Amended and Restated Senior Secured Revolving Credit Agreement dated as of March 13, 2019 by and among Healthcare Trust Operating Partnership, L.P., KeyBank National Association and the other lender parties thereto
10.31 (22)
Second Amendment to First Amended and Restated Senior Secured Credit Agreement, entered into as of August 10, 2020, among Healthcare Trust Operating Partnership, L.P., Healthcare Trust, Inc., the other guarantor parties thereto, Keybank National Association and the other lenders party thereto.
16.1 (23)
Letter from KPMG LLP to the Securities and Exchange Commission dated March 18, 2019
List of Subsidiaries of Healthcare Trust, Inc.
Consent of PricewaterhouseCoopers LLP
Consent of KPMG LLP
Certification of the Principal Executive Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Principal Financial Officer of the Company pursuant to Securities Exchange Act Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 *
Written statements of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
99.1 (24)
Second Amended and Restated Share Repurchase Program of Healthcare Trust, Inc.
99.2 (25)
Amendment to Second Amended and Restated Share Repurchase Program of Healthcare Trust, Inc.
99.3 (26)
Second Amendment to Second Amended and Restated Share Repurchase Program

99.4 (27)
Third Amendment to Second Amended and Restated Share Repurchase Program

99.5 (28)
Fourth Amendment to Second Amended and Restated Share Repurchase Program

99.6 (29)
Fifth Amendment to Second Amended and Restated Share Repurchase Program

86

Exhibit No.  Description
101.INS *
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL
tags are embedded within the Inline XBRL document.

101.SCH *XBRL Taxonomy Extension Schema Document.
101.CAL *XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF *XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB *XBRL Taxonomy Extension Label Linkbase Document.
101.PRE *XBRL Taxonomy Extension Presentation Linkbase Document.
104 *Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
________
*    Filed herewith

(1)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2016.
(2)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 filed with the Securities and Exchange Commission on November 14, 2017.
(3)Filed as an exhibit to the Company’s Registration Statement on Form 8-A filed with the Securities and Exchange Commission on December 6, 2019.
(4)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 20, 2018.
(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on May 19, 2020.
(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 15, 2020.
(7)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 filed with the Securities and Exchange Commission on May 13, 2013.
(8)Filed as an exhibit to the Company’s Quarterly Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission on March 7, 2014.
(9)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 17, 2017.
(10)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2019.
(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 19, 2020.
(12)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 25, 2019.
(13)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 16, 2018.
(14)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on April 15, 2015.
(15)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed with the Securities and Exchange Commission on August 15, 2016.
(16)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission on November 10, 2016.
(17)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 27, 2019.
(18)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2018.
(19)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 31, 2018 filed with the Securities and Exchange Commission on August 3, 2018.
(20)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 14, 2019.
(21)Filed as an exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 24, 2020.
(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 13, 2020.
(23)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2019.
(24)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 14, 2017.
(25)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019.
(26)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 27, 2019.
(27)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2019.
(28)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 21, 2019.
(29)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 9, 2020.
Item 16. Form 10-K Summary.
Not applicable.
87

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized this 29th day of March, 2021.
 HEALTHCARE TRUST, INC. 
 By/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
NameCapacityDate
/s/ Leslie D. MichelsonNon-Executive Chairman of the Board of Directors, Independent DirectorMarch 29, 2021
Leslie D. Michelson
/s/ Katie P. KurtzChief Financial Officer, Treasurer and SecretaryMarch 29, 2021
Katie P. Kurtz(Principal Financial Officer and Principal Accounting Officer)
/s/ Edward M. Weil, Jr.Chief Executive Officer, President and Director March 29, 2021
Edward M. Weil, Jr.(Principal Executive Officer)
/s/ Elizabeth K. TuppenyIndependent DirectorMarch 29, 2021
Elizabeth K. Tuppeny
/s/ Edward G. RendellIndependent DirectorMarch 29, 2021
Edward G. Rendell
/s/ Lee M. ElmanIndependent DirectorMarch 29, 2021
Lee M. Elman
/s/ B.J. PennIndependent DirectorMarch 29, 2021
B.J. Penn
88

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Healthcare Trust, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Healthcare Trust, Inc. and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations and comprehensive loss, of changes in equity and of cash flows for the years then ended, including the related notes and financial statement schedule as of December 31, 2020 and for the years ended December 31, 2020 and 2019 listed in the accompanying index (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

We also have audited the adjustments to the 2018 consolidated financial statements to retrospectively apply the stock dividends as described in Note 1. In our opinion, such adjustments are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the 2018 consolidated financial statements of the Company other than with respect to the adjustments and, accordingly, we do not express an opinion or any other form of assurance on the 2018 consolidated financial statements taken as a whole.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Purchase Price Allocations for Property Acquisitions

As described in Notes 2 and 3 to the consolidated financial statements, during the year ended December 31, 2020, the Company completed real estate acquisitions of $110.7 million. For acquired properties with leases classified as operating leases, management allocated the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed based on their respective fair values. Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. Management utilizes various estimates, processes and information to determine the as-if vacant property value. Management estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot. Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the
F-2

Report of Independent Registered Public Accounting Firm
leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.

The principal considerations for our determination that performing procedures relating to purchase price allocations for property acquisitions is a critical audit matter are (i) the significant judgment by management when developing the fair value estimates of tangible and intangible assets acquired and liabilities assumed; (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management’s significant assumptions related to capitalization rates, fair market lease rates, discount rates and land values per square foot; and (iii) the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included, among others (i) reading the purchase agreements and lease documents; (ii) testing the completeness and accuracy of underlying data used by management in the fair value estimates, and (iii) testing management’s process for estimating the fair value of tangible and intangible assets acquired and liabilities assumed, including testing management’s projected cash flows and evaluating the accuracy of valuation outputs. Testing management’s process included evaluating the appropriateness of the valuation methods and reasonableness of the significant assumptions related to capitalization rates, fair market lease rates, discount rates and land values per square foot. Evaluating the reasonableness of the significant assumptions included considering whether these assumptions were consistent with external market data, comparable transactions, and evidence obtained in other areas of the audit. In conjunction with certain purchase price allocations, professionals with specialized skill and knowledge were used to assist in evaluating the reasonableness of certain assumptions utilized by management related to capitalization rates, fair market lease rates, discount rates and land values per square foot.


/s/ PricewaterhouseCoopers LLP
New York, New York
March 29, 2021
We have served as the Company's auditor since 2019.

F-3

Report of Independent Registered Public Accounting Firm

To the Stockholders and Board of Directors
Healthcare Trust, Inc.:

Opinion on the Consolidated Financial Statements

We have audited, before the effects of the adjustments to retrospectively apply the effects of the stock dividend described in Note 1, the consolidated statements of operations and comprehensive loss, changes in equity, and cash flows of Healthcare Trust, Inc. and subsidiaries (the Company) for the year ended December 31, 2018, and the related notes and financial statement schedule III (collectively, the consolidated financial statements). The 2018 consolidated financial statements before the effects of the adjustments described in Note 1 are not presented herein. In our opinion, the consolidated financial statements, before the effects of the adjustments to retrospectively apply the effects of the stock dividend described in Note 1, present fairly, in all material respects, the results of the Company’s operations and its cash flows for the year ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.

We were not engaged to audit, review, or apply any procedures to the adjustments to retrospectively apply the effects of the stock dividend described in Note 1 and affecting per share amounts in the consolidated statements of operations and comprehensive loss, changes in equity, Note 2, Note 8 and Note 14, and accordingly, we do not express an opinion or any other form of assurance about whether such adjustments are appropriate and have been properly applied. Those adjustments were audited by other auditors.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.



/s/ KPMG LLP


We served as the Company’s auditor from 2014 to 2019.
Chicago, Illinois
March 13, 2019






F-4

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

December 31,
20202019
ASSETS 
Real estate investments, at cost:
Land
$212,651 $207,335 
Buildings, fixtures and improvements
2,133,057 2,004,116 
Acquired intangible assets
276,015 269,616 
Total real estate investments, at cost
2,621,723 2,481,067 
Less: accumulated depreciation and amortization
(512,775)(427,476)
Total real estate investments, net
2,108,948 2,053,591 
Assets held for sale90 70,839 
Cash and cash equivalents72,357 95,691 
Restricted cash17,989 15,908 
Derivative assets, at fair value13 392 
Straight-line rent receivable, net
23,322 21,182 
Operating lease right-of-use assets
13,912 14,351 
Prepaid expenses and other assets (including $1,278 and $394 due from related parties as of December 31, 2020 and 2019, respectively)
34,932 39,707 
Deferred costs, net15,332 13,642 
Total assets
$2,286,895 $2,325,303 
LIABILITIES AND EQUITY  
Mortgage notes payable, net$542,698 $528,284 
Credit facilities, net674,551 605,269 
Market lease intangible liabilities, net10,803 12,052 
Derivative liabilities, at fair value38,389 5,305 
Accounts payable and accrued expenses (including $299 due to related parties as of December 31, 2020)
42,271 43,094 
Operating lease liabilities9,155 9,133 
Deferred rent6,914 8,521 
Distributions payable
742 6,901 
Total liabilities
1,325,523 1,218,559 
Stockholders’ Equity
7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 2,210,000 and 1,610,000 authorized as of December 31, 2020 and 2019, respectively; 1,610,000 issued and outstanding as of December 31, 2020 and 2019
16 16 
Common stock, $0.01 par value, 300,000,000 shares authorized, 95,040,783 (including 1,265,037 shares paid as a stock dividend on January 15, 2021) and 92,356,664 shares of common stock issued and outstanding as of December 31, 2020 and 2019, respectively
938 923 
Additional paid-in capital2,104,261 2,078,628 
Accumulated other comprehensive loss(39,673)(7,043)
Distributions in excess of accumulated earnings(1,108,557)(971,190)
Total stockholders’ equity
956,985 1,101,334 
Non-controlling interests4,387 5,410 
Total equity
961,372 1,106,744 
Total liabilities and equity
$2,286,895 $2,325,303 


The accompanying notes are an integral part of these consolidated financial statements.
F-5

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
 Year Ended December 31,
202020192018
Revenue from tenants$381,612 $374,914 $362,406 
Operating expenses:  
Property operating and maintenance243,548 234,185 220,997 
Impairment charges36,446 55,969 20,655 
Operating fees to related parties23,922 23,414 23,071 
Acquisition and transaction related173 362 302 
General and administrative21,572 20,530 17,275 
Depreciation and amortization81,053 81,032 83,212 
Total expenses
406,714 415,492 365,512 
Operating loss before gain (loss) on sale of real estate investments(25,102)(40,578)(3,106)
Gain (loss) on sale of real estate investments
5,230 8,790 (70)
Operating loss
(19,872)(31,788)(3,176)
Other income (expense):
Interest expense(51,519)(56,059)(49,471)
Interest and other income
44 7 23 
Loss on non-designated derivatives
(102)(68)(157)
Total other expenses
(51,577)(56,120)(49,605)
Loss before income taxes(71,449)(87,908)(52,781)
Income tax expense(4,061)(399)(197)
Net loss(75,510)(88,307)(52,978)
Net (income) loss attributable to non-controlling interests(303)393 216 
Allocation for preferred stock(2,968)(173) 
Net loss attributable to common stockholders(78,781)(88,087)(52,762)
Other comprehensive income (loss):
Unrealized (loss) gain on designated derivatives(32,630)(11,625)2,109 
Comprehensive loss attributable to common stockholders$(111,411)$(99,712)$(50,653)
Weighted-average common shares outstanding — Basic and Diluted (1)
94,639,833 94,433,640 93,593,719 
Net loss per common share attributable to common stockholders — Basic and Diluted (1)
$(0.83)$(0.93)$(0.56)
_____
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1).



The accompanying notes are an integral part of these consolidated financial statements.
F-6

HEALTHCARE TRUST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Years Ended December 31, 2020, 2019 and 2018
(In thousands, except share data)
Preferred StockCommon StockAccumulated Other Comprehensive Income
Number of
Shares
Par ValueNumber of
Shares
Par ValueAdditional
Paid-in
Capital
Distributions in Excess of Accumulated EarningsTotal Stockholders’ EquityNon-controlling InterestsTotal Equity
Balance, December 31, 2017 $ 91,002,766 $910 $2,009,197 $2,473 $(665,026)$1,347,554 $8,505 $1,356,059 
Common stock issued through distribution reinvestment plan— — 1,720,633 17 35,720 — — 35,737 — 35,737 
Common stock repurchases— — (759,867)(8)(14,194)— — (14,202) (14,202)
Share-based compensation, net— —   1,244 — — 1,244 — 1,244 
Distributions declared on common stock, $0.92 per share (1)
— — — — — — (86,543)(86,543)— (86,543)
Distributions to non-controlling interest holders— — — — — — — — (492)(492)
Unrealized gain on designated derivative— — — — — 2,109 — 2,109 — 2,109 
Net loss— — — — — — (52,762)(52,762)(216)(52,978)
Balance, December 31, 2018  91,963,532 919 2,031,967 4,582 (804,331)1,233,137 7,797 1,240,934 
Impact of adoption of ASC 842— — — — — — (87)(87)— (87)
Issuance of Preferred Stock, net1,610,000 16 — — 37,601 — — 37,617 — 37,617 
Common stock issued through distribution reinvestment plan— — 1,481,395 15 27,195 — — 27,210 — 27,210 
Common stock repurchases— — (1,103,263)(11)(21,102)— — (21,113)— (21,113)
Share-based compensation, net— — 15,000 — 1,319 — — 1,319 — 1,319 
Distributions declared on common stock, $0.83 per share (1)
— — — — — — (78,685)(78,685)— (78,685)
Preferred stock dividends declared, $0.11 per share
— — — — — — (173)(173)— (173)
Distributions to non-controlling interest holders— — — — — — — — (346)(346)
Unrealized loss on designated derivative— — — — — (11,625)— (11,625)— (11,625)
Net loss— — — — — — (87,914)(87,914)(393)(88,307)
Rebalancing of ownership percentage— — — — 1,648 — — 1,648 (1,648)
Balance, December 31, 20191,610,000 16 92,356,664 923 2,078,628 (7,043)(971,190)1,101,334 5,410 1,106,744 
Issuance of Preferred Stock, net— — — — (59)— — (59)— (59)
Common stock issued through distribution reinvestment plan— — 875,986 9 14,595 — — 14,604 — 14,604 
Common stock repurchases— — (705,101)(7)(10,539)— — (10,546)— (10,546)
Share-based compensation, net— —  — 1,345 — — 1,345 — 1,345 
Distributions declared in common stock, $0.21 per share (1)
— — 1,248,197 13 19,646 — (19,659) —  
Distributions declared in cash on common stock, $0.42 per share (1)
— — — — — — (38,839)(38,839)— (38,839)
Preferred stock dividends declared, $1.84 per share
— — — — — — (2,968)(2,968)— (2,968)
Distributions to non-controlling interest holders— — — — — — — — (201)(201)
Unrealized loss on designated derivative— — — — — (32,615)— (32,615)— (32,615)
Buyout of NCI— — — — — (88)(88)(495)(583)
Net loss— — — — — — (75,813)(75,813)303 (75,510)
Rebalancing of ownership percentage— — — — 645 (15)630 (630) 
Balance, December 31, 20201,610,000 $16 93,775,746 $938 $2,104,261 $(39,673)$(1,108,557)$956,985 $4,387 $961,372 
______
(1) Per share amounts retroactively adjusted for the effects of the Stock Dividends.

The accompanying notes are an integral part of these consolidated financial statements.
F-7

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
202020192018
Cash flows from operating activities:  
Net loss$(75,510)$(88,307)$(52,978)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization81,053 81,032 83,212 
Amortization (including write-offs) of deferred financing costs4,059 9,171 8,633 
Amortization of terminated swap846   
Amortization of mortgage premiums and discounts, net60 (162)(263)
(Accretion) amortization of market lease and other intangibles, net
(80)(4)255 
Bad debt expense2,708 6,464 14,797 
Equity-based compensation1,345 1,319 1,244 
Loss (gain) on non-designated derivative instruments102 68 157 
(Gain) loss on sales of real estate investments, net(5,230)(8,790)70 
Impairment charges36,446 55,969 20,655 
Deferred tax valuation allowance4,641   
Changes in assets and liabilities:
Straight-line rent receivable(2,409)(3,831)(7,744)
Prepaid expenses and other assets(63)(9,667)(16,888)
Accounts payable, accrued expenses and other liabilities(4,554)2,632 2,191 
Deferred rent(1,607)1,510 810 
Net cash provided by operating activities41,807 47,404 54,151 
Cash flows from investing activities:
Property acquisitions and development costs(94,984)(91,998)(128,056)
Capital expenditures and other assets acquired(21,892)(16,719)(12,910)
Proceeds from sales of real estate investments34,385 62,468 25,903 
Net cash used in investing activities(82,491)(46,249)(115,063)
Cash flows from financing activities: 
Payments on credit facilities(26,091)(368,300)(80,000)
Proceeds from credit facilities95,000 225,618 147,753 
Proceeds from term loan 150,000  
Proceeds from mortgage notes payable 136,513 118,700 
Payments on mortgage notes payable(1,048)(67,797)(63,263)
Payments for derivative instruments(97)(2,147)(131)
Payments of deferred financing costs(2,241)(19,532)(3,354)
Proceeds from issuance of preferred stock, net(1,016)37,617  
Common stock repurchases(10,539)(21,113)(14,202)
Distributions paid on common stock(31,354)(51,427)(55,329)
Dividends paid on preferred stock(2,399)  
Buyout of non-controlling interest holders(583)  
Distributions to non-controlling interest holders(201)(346)(492)
Net cash, provided by financing activities19,431 19,086 49,682 
Net change in cash, cash equivalents and restricted cash(21,253)20,241 (11,230)
Cash, cash equivalents and restricted cash, beginning of year111,599 91,358 102,588 
Cash, cash equivalents and restricted cash, end of year$90,346 $111,599 $91,358 
F-8

HEALTHCARE TRUST, INC. AND SUBSIDIARIES
  
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Year Ended December 31,
202020192018
Cash, cash equivalents, end of period$72,357 $95,691 $77,264 
Restricted cash, end of period17,989 15,908 14,094 
Cash, cash equivalents and restricted cash, end of period$90,346 $111,599 $91,358 
Supplemental disclosures of cash flow information:
Cash paid for interest$47,878 $47,621 $43,266 
Cash paid for income taxes 315 447 407 
Non-cash investing and financing activities:
Common stock issued through distribution reinvestment plan
$14,604 $27,210 $35,737 
Common stock issued through stock dividends19,659   
Accrued capital expenditures (payable)1,287   
Mortgage assumed in acquisition 13,883   

The accompanying notes are an integral part of these consolidated financial statements.
F-9


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020

Note 1 — Organization
The Company is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office buildings (“MOBs”), healthcare properties leased on a triple-net basis (“NNN properties”) and senior housing operating properties (“SHOPs”). As of December 31, 2020, the Company owned 193 properties located in 31 states and comprised of 9.4 million rentable square feet.
Substantially all of the Company’s business is conducted through Healthcare Trust Operating Partnership, L.P. (the “OP”), a Delaware limited partnership, and its wholly owned subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to us. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP.
The Company has declared quarterly dividends entirely in shares of its common stock equal to 0.01349 shares of common stock on each share of outstanding common stock (“Stock Dividends”) on October 1, 2020 and January 4, 2021. These Stock Dividends were issued on October 15, 2020 and January 15, 2021 to holders of record of common stock at the close of business on October 8, 2020 and January 11, 2021, respectively. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. The aggregate impact of these Stock Dividends on the Company’s weighted-average share amounts used in its per-share calculations was an increase of 0.02716 shares, cumulatively, for every one share of common stock. No additional shares, except for the Stock Dividends, were issued during the three months ended December 31, 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the increase of 0.02716 shares for every share outstanding due to the Stock Dividends. Additionally, other references to weighted-average shares outstanding and per-share amounts have been retroactively adjusted for the Stock Dividends and are noted as such throughout the accompanying financial statements and footnotes.
On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019. The Company’s previous Estimated Per-Share NAV was as of December 31, 2018. Unlike the per share amounts in this Annual Report on Form 10-K, the Estimated Per-Share NAV has not been retroactively adjusted to reflect the payment of dividends in the form of common stock and will not be adjusted for Stock Dividends the Company pays in the future until the Board determines a new Estimated Per-Share NAV. Paying dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding will increase when Stock Dividends are paid; however, because each stockholder will receive the same number of new shares, the total value of our common stockholders’ investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of the board of directors (the “Board”), provided that such estimates will be made at least once annually.
Note 2 — Summary of Significant Accounting Policies
Basis of Accounting
    The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
F-10


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Out-of-Period Adjustments
During the year ended December 31, 2019, the Company identified certain historical errors in its tax provision and its net deferred taxes asset as well as its statements of operations and comprehensive income (loss), consolidated statements of changes in equity, and statements of cash flows since 2014, which impacted the quarterly financial statements and annual periods previously issued. Specifically, the Company had overstated intercompany rent on certain leases with the taxable REIT subsidiary (“TRS”) and reflected a portion of depreciation on REIT assets in the TRS’s tax provision, thereby overstating previously recorded tax benefits, deferred tax assets and net income by $0.8 million, $0.3 million and $0.2 million for the years ended December 31, 2018, 2017 and for Pre-2017 periods, respectively.  The intercompany rent and allocation of depreciation only affected the tax provision and did not affect the pre-tax consolidated financial results. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2019.
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The pandemic has had and could continue to have an adverse impact on economic and market conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The Company believes the estimates and assumptions underlying its consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ultimate impact COVID-19 will have on the global economy generally, and the Company’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways. In the Company’s SHOP portfolio, occupancy has trended lower since the second half of March as government policies and implementation of infection control best practices have materially limited or closed communities to new resident move-ins which affects the Company’s ability to fill vacancies. The Company has also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, the Company bears these cost increases. These trends accelerated during the second, third, and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact the Company in the future and have a material adverse effect on the Company’s revenues and income in the other quarters thereafter.
The financial stability and overall health of the Company’s tenants is critical to its business. The negative effects that the global pandemic has had on the economy includes the closure or reduction in activity of some of the Company’s MOBs and other healthcare-related facilities as well as restrictions on activity and access for many of the Company’s seniors housing properties. The economic impact of the pandemic has impacted the ability of some of the Company’s tenants to pay their monthly rent either temporarily or in the long term. The Company experienced delays in rent collections in the second, third and fourth quarters of 2020 although collections have been approximately 100%. The Company has taken a proactive approach
F-11


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
The Company has taken precautionary steps to increase liquidity and preserve financial flexibility in light of the uncertainty resulting from the COVID-19 pandemic. These steps include borrowing an additional $95.0 million under the Credit Facility (as defined below) in March 2020 to provide more cash on the Company’s balance sheet. A portion of the $95.0 million in borrowings was used for general corporate purposes and for acquisitions. The Company has not borrowed additional amounts subsequently. In August 2020, the Company amended the Credit Facility as part of its efforts to continue addressing the adverse impacts of the COVID-19 pandemic. For additional information on the Credit Facility amendment see Note 5 Credit Facilities.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020, these leases had a weighted average remaining lease term of 6.5 years. Rent from tenants in the Company’s MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted under the REIT Investment and Diversification and Empowerment Act of 2007 and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the rent are short term in nature, primarily month-to-month. Also included in revenue from tenants is fees
F-12


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
for ancillary revenue from non-residents of $13.3 million, $15.4 million and $8.1 million for the years ended December 31, 2020, 2019, and 2018, respectively. Fees for ancillary services are recorded in the period in which the services are performed.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2020 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2021$94,144 
202287,762 
202375,205 
202468,210 
202558,757 
Thereafter165,642 
Total$549,720 
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards (see the “Recently Issued Accounting Pronouncements” section below), the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, the Company recorded such amounts as bad debt expense as part of property operating expenses. During the years ended December 31, 2020, 2019 and 2018 such amounts were $2.7 million, $6.5 million and $14.8 million, respectively, which include bad debt expense related to the NuVista and LaSalle Tenants (see Note 3Real Estate Investment, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
F-13


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 and 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see Note 3Real Estate Investments, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
As more fully discussed in this Note under Recently Issued Accounting Pronouncements - ASU No. 2016-02 Leases, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2019, the Company has no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
The Company is also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet as of December 31, 2020 and 2019, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value
F-14


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate after January 1, 2018 are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Gain on sales of real estate prior to January 1, 2018 are recognized pursuant to the provisions included in ASC 360-20, Real Estate Sales (“ASC 360-20”). The specific timing of a sale was measured against various criteria in and ASC 360-20 related to the terms of the transaction and any continuing involvement in the form of management or financial assistance associated with the properties. If the sales criteria for the full accrual method are not met, depending on the circumstances, the Company may not record a sale or it may record a sale but may defer some or all of the gain recognition. If the criteria for full accrual are not met, the Company may account for the transaction by applying the finance, leasing, profit sharing, deposit, installment or cost recovery methods, as appropriate, until the sales criteria for the full accrual method are met.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has three reportable segments, with activities related to investing in MOBs, triple-net leased healthcare facilities, and seniors housing properties. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
F-15


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge.  The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.
The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests
The non-controlling interests represent the portion of the equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net loss based on their share of equity ownership. See Note 13 — Non-Controlling Interests for additional information.
F-16


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Cash and Cash Equivalents
Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2020 or 2019.
The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2020 and 2019, the Company had deposits of $72.4 million and $95.7 million, of which $57.0 million and $73.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.
Deferred Financing and Leasing Costs, Net
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to the mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing on our balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (See Note 11Equity-Based Compensation).
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2020, 2019 and 2018. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties.  Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS.  Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
F-17


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
As of December 31, 2020, the Company, owned 59 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2020 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic.
Because of the Company’s TRS's recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $4.6 million as of December 31, 2020. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. During the year ended December 31, 2020 the Company recorded a tax loss of $3.1 million. As of December 31, 2020, the Company had a deferred tax asset of $4.6 million with a full valuation allowance. As of December 31, 2019, the Company had a deferred tax asset of $3.9 million with no valuation allowance.
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202020192018
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $726 $ $ $(155)$(272)$399 
State (expense) benefit(196)50 (176)(68)(353)29 
Deferred tax asset valuation allowance— (4,641)—  —  
Total income tax benefit (expense)$530 $(4,591)$(176)$(223)$(625)$428 
As of December 31, 2020 and 2019, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2013 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to
F-18


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of its SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in the Company’s consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, the Company received an additional $5.1 million in funding from CARES Act grants. There can be no assurance that the program will be extended or any further amounts received.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2018
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), and has since issued several additional amendments thereto (collectively referred to herein as “ASC 606”). ASC 606 establishes a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Under ASC 606, an entity is required to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. A reporting entity may apply the amendments in ASC 606 using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or a full retrospective approach. The Company adopted this guidance effective January 1, 2018 under the modified retrospective approach and it did not have an impact on the Company’s consolidated financial statements. See above for further information on the Company’s Revenue Recognition Accounting Policies under ASC 606.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The revised guidance amends the recognition and measurement of financial instruments. The new guidance significantly revises an entity’s accounting related to equity investments and the presentation of certain fair value changes for financial liabilities measured at fair value. Among other things, it also amends the presentation and disclosure requirements associated with the fair value of financial instruments. The Company adopted this guidance effective January 1, 2018, using the modified retrospective transition method, and there was no impact to the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance on how certain transactions should be classified and presented in the statement of cash flows as either operating, investing or financing activities. Among other things, the update provides specific guidance on where to classify debt prepayment and extinguishment costs, payments for contingent consideration made after a business combination and distributions received from equity method investments. The Company adopted the new guidance on January 1, 2018 and it did not have an impact on its consolidated statement of cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which revises the definition of a business. This new guidance is applicable when evaluating whether an acquisition should be treated as either a business acquisition or an asset acquisition. Under the revised guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset or group of similar assets, the assets acquired would not be considered a business. The Company adopted this guidance effective January 1, 2018, and will apply the new rules prospectively. The Company expects, based on historical property acquisitions, that in most cases, a future property acquired after adoption will be treated as an asset acquisition rather than a business acquisition, which will result in the capitalization of related transaction costs. The Company has evaluated the impact of this new guidance beginning in the first quarter of 2018, and determined that it did not have a material impact on the Company’s consolidated financial statements. All acquisition costs incurred during the years ended December 31, 2020 and 2019 were capitalized since our acquisitions during the years were all classified as asset acquisitions.
In February 2017, the FASB issued ASU 2017-05, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Assets Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets, which provides guidance related to partial sales of non-financial assets, eliminates rules specifically addressing the sales of real estate, clarifies the definition of in substance non-financial assets, removes the exception to the financial asset derecognition model and clarifies the accounting for contributions of non-financial assets to joint ventures. The Company adopted this guidance effective January 1, 2018 using the modified transition method and it did not have an impact on its financial statements. The Company expects that any future sales of real estate in which the Company retains a non-controlling interest in the property would result in the full gain amount being recognized at the time of the partial sale. Historically, the Company has not retained any interest in properties it has sold.
F-19


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance that clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The update states that modification accounting should be used unless the fair value of the award, the vesting terms of the award, and the classification of the award as either equity or liability, all do not change as a result of the modification. The Company adopted this guidance effective January 1, 2018 using the modified retrospective transition method and it did not have an impact on its consolidated financial statements. The Company expects that any future modifications to the Company’s issued share-based awards will be accounted for using modification accounting, unless the modification meets all of the exception criteria noted above. As a result, the modification would be treated as an exchange of the original award for a new award, with any incremental fair value being treated as additional compensation cost.
Adopted as of January 1, 2019
ASU No. 2016-02 - Leases
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) which provides guidance related to the accounting for leases, as well as the related disclosures. For lessors of real estate, leases are accounted for using an approach substantially the same as previous accounting guidance for operating leases and direct financing leases. For lessees, the new standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction.
Upon adoption, lessors were allowed a practical expedient, which the Company has elected, by class of underlying assets to account for lease and non-lease components (such as tenant reimbursements of property operating expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under this new guidance, which is consistent with the Company’s existing policies. Also, upon adoption, companies were allowed a practical expedient package, which the Company has elected, that allowed the Company: (a) to not reassess whether any expired or existing contracts entered into prior to January 1, 2019 are or contain leases; (b) to not reassess the lease classification for any expired or existing leases entered into prior to January 1, 2019 (including assessing sale-leaseback transactions); and (c) to not reassess initial direct costs for any expired or existing leases entered into prior to January 1, 2019. As a result, all of the Company’s existing leases will continue to be classified as operating leases under the new standard. Further, any existing leases for which the property is the leased to a tenant in a transaction that at inception was a sale-leaseback transaction will continue to be treated (absent a modification) as operating leases. The Company did not have any leases that would be considered financing leases as of January 1, 2019.
The Company assessed the impact of adoption from both a lessor and lessee perspective, which is discussed in more detail below, and adopted the new guidance prospectively on January 1, 2019, using a prospective transition approach under which the Company elected to apply the guidance effective January 1, 2019 and not adjust prior comparative reporting periods (except for the Company’s presentation of lease revenue discussed below).
Lessor Accounting
As discussed above, the Company was not required to re-assess the classification of its leases, which are considered operating leases under ASU 2016-02. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessor:
Since the Company elected the practical expedient noted above to not separate non-lease component revenue from the associated lease component, the Company has aggregated revenue from its lease components and non-lease components (tenant operating expense reimbursements) into one line. The prior periods have been conformed to this new presentation.
Changes in the Company’s assessment of receivables that result in bad debt expense is now required to be recorded as an adjustment to revenue, rather than a charge to bad debt expense. This new classification applies for the first quarter of 2019 and reclassification of prior period amounts is not permitted. At transition on January 1, 2019, after assessing its reserve balances at December 31, 2018 under the new guidance, the Company wrote off accounts receivable of $0.1
F-20


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
million and straight-line rents receivable of $0.1 million as an adjustment to the opening balance of accumulated deficit, and accordingly rent for these tenants is currently recorded on a cash basis.
Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed. Under prior accounting guidance, the recognition would have been deferred.
Lessee Accounting
    The Company was a lessee under leases for 17 properties including capital leases of land and building as of January 1, 2019 and because the Company has elected the practical expedients described above, it determined that 11 of these leases would continue to be classified as operating leases under the new standard. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessee:
Upon adoption of the new standard, the Company recorded ROU assets and lease liabilities equal to $10.2 million for the present value of the lease payments related to its ground leases. These amounts are included in operating lease right-of-use assets and operating lease liabilities on the Company’s consolidated balance sheet as of December 31, 2019.
The Company also reclassified $0.5 million related to amounts previously reported as a straight-line rent liability and $4.8 million, net related to amounts previously reported as above and below market ground lease intangibles to the ROU assets. For additional information and disclosures related to these operating leases, see Note 16 — Commitments and Contingencies.
Other Accounting Pronouncements
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, to better align cash flow and fair value hedge accounting with the corresponding risk management activities. Among other things, the amendments expand which hedging strategies are eligible for hedge accounting, align the timing of recognition of hedge results with the earnings effect of the hedged item and allow companies to include the change in fair value of the derivative in the same income statement line item as the earnings effect of the hedged item. Additionally, for cash flow hedges that are highly effective, the update allows for all changes in fair value of the derivative to be recorded in other comprehensive income. The Company has adopted ASU 2017-12 on January 1, 2019, as required under the guidance, using a modified retrospective transition method and the adoption did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Not yet Adopted as of December 31, 2020
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition
F-21


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
methods. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period March 12, 2020 through December 31, 2022 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that our hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of our derivatives, which will be consistent with our past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
Note 3 — Real Estate Investments, Net
Property Acquisitions and Development Costs
The Company invests in MOBs, seniors housing properties and other healthcare-related facilities primarily to expand and diversify its portfolio and revenue base. The Company owned 193 properties as of December 31, 2020. During the year ended December 31, 2020, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of two multi-tenant MOBs, three single tenant MOBs and four SHOPs for an aggregate contract purchase price of $110.7 million, which includes other assets acquired as part of the acquisitions of $1.8 million and capitalized transaction costs. All acquisitions in 2020, 2019 and 2018 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of the assets acquired and liabilities assumed, as well as capitalized construction in progress during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Real estate investments, at cost:
Land$7,665 $6,356 $14,417 
Buildings, fixtures and improvements90,699 68,903 98,236 
Development costs 5,721 8,591 
Total tangible assets98,364 80,980 121,244 
Acquired intangibles:
In-place leases and other intangible assets (1)
10,369 11,777 6,823 
Market lease and other intangible assets (1)
496 724 275 
Market lease liabilities (1)
(362)(1,483)(286)
Total intangible assets and liabilities
10,503 11,018 6,812 
Mortgage notes payable, net(13,883)  
Cash paid for real estate investments, including acquisitions$94,984 $91,998 $128,056 
Number of properties purchased9 9 14 
_______________
(1) Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 8.1 years and 7.0 years, respectively, as of December 31, 2019. There were no below market leases acquired in the year ended December 31, 2019.
Development Project
In August 2015, the Company entered into an asset purchase agreement and development agreement to acquire land and construction in progress, and subsequently fund the remaining construction, of a development property in Jupiter, Florida for $82.0 million. As of December 31, 2019, the Company had funded $97.8 million, including $10.0 million for the land and $87.8 million for construction in progress.
The Company had been working for some time to obtain a certificate of occupancy for the facility (“CO”), which was ultimately obtained in December 2019. Historically, all construction costs, including capitalized interest, insurance and real
F-22


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
estate taxes were capitalized and classified in construction is progress on the Company’s consolidated balance sheet. In December 2019, when the development reached substantial completion and the Company reclassified the entire amount in construction in progress to its appropriate real estate investment components. During the years ended December 31, 2019, and 2018 the Company incurred an additional $5.7 million and $8.6 million in capitalized costs, including capitalized interest, related to this development project. No development costs were capitalized during the year ended December 31, 2020 as the property was considered substantially complete.    
Obtaining the CO was a necessary condition to leasing the property to any tenant other than a tenant associated with the developer of the property, which had been, and remains in, default under its agreements with the Company. The Company entered into a lease for 10% of the rentable square feet at the property (a portion of the non-assisted living component of the property) , but the tenant was not required to pay the Company cash rent until May 2021. As of December 31, 2020 the Company had not yet begun operating the assisted living component of the property.
During the fourth quarter of 2019, in connection with the substantial completion of the development property, the Company began to evaluate it for a potential sale. As a result of this potential change in plans, the Company concluded this held for use asset was impaired and recognized an impairment charge to its respective operating real estate components in 2019 (see Assets Held For Use and Related Impairments in this note for additional information). Further, as a result of COVID-19 and it impact on the ability to show the property to potential new tenants/residents, the launch of operations of the assisted living component of the property has been delayed.
In August 2020, the Company entered into definitive purchase and sale agreements (“PSA”) to sell the Company's recently completed development property in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. The buyer paid the Company $2.9 million in non-refundable deposits, In November 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida resulting in a gain on sale of real estate investments of $3.8 million, recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. See “Dispositions” below for more information. The sales of the properties in Wellington, Florida and Jupiter, Florida are expected to close later in 2021, but these dispositions are subject to conditions and there can be no assurance that they will be completed on their contemplated terms, or at all.
Significant Tenants
As of December 31, 2020, 2019 and 2018, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:
December 31,
State202020192018
Florida (1)
20.6%25.2%16.6%
Georgia**10.1%
Michigan (2)
*10.9%13.1%
Pennsylvania10.4 %*10.2%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)During the fourth quarter of 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida. In addition, in August 2020 the Company entered into an agreement to sell our skilled nursing facility in Wellington, Florida, and our development property in Jupiter, Florida.
(2)During the year ended December 31, 2020, the Company sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020 and four of which remained classified as held for sale on the Company’s consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer in the first quarter of 2021.
F-23


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Intangible Assets and Liabilities
Acquired intangible assets and liabilities consisted of the following as of the periods presented:
December 31, 2020December 31, 2019
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$241,097 $172,648 $68,449 $229,300 $156,428 $72,872 
Market lease assets14,116 10,845 3,271 13,616 9,501 4,115 
Other intangible assets20,802 1,171 19,631 26,700 1,144 25,556 
Total acquired intangible assets
$276,015 $184,664 $91,351 $269,616 $167,073 $102,543 
Intangible liabilities:
Market lease liabilities $22,109 $11,306 $10,803 $21,777 $9,725 $12,052 
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Amortization of in-place leases and other intangible assets(1)
$15,121 $15,559 $18,851 
Accretion of above-and below-market leases, net(2)
$(257)$(247)$(39)
Amortization of above-and below-market ground leases, net(3)
$178 $86 $147 
____________
(1)    Reflected within depreciation and amortization expense.
(2)    Reflected within revenue from tenants.
(3)    Reflected within property operating and maintenance expense. Upon adoption of ASC 842 effective January 1, 2019, intangible balances related to ground leases were reclassified to be included as part of the Operating lease right-of-use assets presented on the consolidated balance sheet with no change to placement of the amortization expense of such balances. Refer to Note 2 Summary of Significant Accounting Policies for additional details.
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20212022202320242025
In-place lease assets$10,904 $8,704 $6,830 $6,070 $4,896 
Other intangible assets613 613 613 613 588 
Total to be added to amortization expense$11,517 $9,317 $7,443 $6,683 $5,484 
Above-market lease assets$(1,299)$(993)$(645)$(307)$(260)
Below-market lease liabilities1,388 1,326 1,213 1,062 955 
Total to be added to revenue from tenants$89 $333 $568 $755 $695 






F-24


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020

Dispositions
The following table summarizes the properties sold during the years ended December 31, 2020, 2019, and 2018:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2020 Dispositions:
LutzDecember, 2020$20,000 $3,832 
Michigan SHOPs (11 properties) (1)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
2019 Dispositions:
New York Six MOBs (1 property)
August 22, 2019$13,600 $2,883 
Ocean Park (1)
August 1, 20193,600 (152)
New York Six MOBs (5 properties)
February 6, 201945,000 6,059 
Totals$62,200 $8,790 
2018 Dispositions:
Missouri SNF Properties (1)
December 5, 2018$27,500 $(70)
________
(1) These properties were previously impaired. See “Impairments” section below. Represents contract sales price for all 11 properties. Loss on sale relates to the seven properties that were transferred to the buyer in the fourth quarter of 2020 (see below for additional information).
The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.
2020 Dispositions
On December 16 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida for a contract purchase price of $20.0 million, resulting in a gain on sale of real estate investments of $3.8 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At closing, $17.6 million of net proceeds were used to repay amounts outstanding under the Revolving Credit Facility.
On November 2, 2020 the initial closing under the PSA pursuant to which the Company had agreed to sell 11 Michigan SHOPs occurred. The contract purchase price for the 11 Michigan SHOPs was $11.8 million, resulting in a loss on sale of $0.9 million on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At the initial closing, the Company received payment of the full $11.8 million sales price for all 11 of the Michigan SHOPs, less $0.8 million held in escrow, and transferred seven of the properties to the buyer. The remaining four properties were transferred to the buyer a second closing separate closings in the first quarter of 2021 when the $0.8 million held in escrow was released to the buyer. Of the properties transferred at the initial closing, four had been part of the borrowing base under the Credit Facility, one was part of the collateral pool under the Fannie Mae Master Credit Facility with Capital One and two were unencumbered. Of the properties transferred at the second closing, three were part of the borrowing base under the Credit Facility until the initial closing and one was unencumbered. At the initial closing, $4.2 million of the net proceeds was used to repay amounts outstanding under the Fannie Mae Master Credit Facility with Capital One, $4.4 million of the net proceeds were used to repay amounts outstanding under the Revolving Credit Facility, with the remainder used for closing costs. For the avoidance of any doubt, all impairments related to the disposal of the 11 Michigan SHOP assets were recognized in the year ended December 31, 2020.
On March 19, 2020 the Company disposed of one MOB property for a contract purchase price of $8.6 million, resulting in a gain on sale of $2.306 million.
2019 Dispositions
F-25


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
On February 6, 2019, the Company sold five of the MOB properties within the State of New York (the “New York Six MOBs”) for a contract sales price of $45.0 million, resulting in a gain on sale of real estate investments of $6.1 million which is included on the Consolidated Statement of Operations for the year ended December 31, 2019. The Company had reconsidered the intended holding period for all six of the New York Six MOBs due to various market conditions and the potential to reinvest in properties generating a higher yield. On July 26, 2018, the Company had originally entered into a PSA for the sale of the New York Six MOBs, for an aggregate contract sale price of approximately $68.0 million and subsequently, on September 25, 2018, the Company further amended the PSA to decrease the aggregate contract sale price to $58.8 million. The one remaining New York Six MOB was sold for a contract sales price of $13.6 million on August 22, 2019, resulting in a gain on sale of real estate investments of $2.9 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.
During the first quarter of 2019, the Company reconsidered the intended holding period for one of its SHOPs located in Brookings, OR (“Ocean Park”) due to various market conditions and the potential to reinvest in properties generating a higher yield. On March 21, 2019, the Company entered into a PSA for the sale of Ocean Park, for an aggregate contract sale price of approximately $3.6 million. On April 1, 2019, the Company amended the purchase and sale agreement to decrease the aggregate contract sale price to $3.5 million. In connection with this amendment, the Company recognized an impairment charge of approximately $19,000 on Ocean Park during the second quarter of 2019, which is included on the consolidated statement of operations and comprehensive loss. On August 1, 2019, the Company closed its disposition of Ocean Park resulting in a loss on sale of real estate investments of $0.2 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.
2018 Dispositions
On November 6, 2018, the Company entered into the final amendment to its January 2017 agreement (as amended to date, the “Amended Missouri SNF PSA”) to sell eight skilled nursing facility properties in Missouri (the “Missouri SNF Properties”) that were previously classified as held-for-sale, for an aggregate contract purchase price of $27.5 million. In connection with the Amended Missouri SNF PSA, the Company recognized an impairment charge of approximately $11.9 million on the Missouri SNF Properties in the third quarter of 2018 which is included on the consolidated statement of operations and comprehensive loss. The sale of these properties pursuant to the Amended Missouri SNF PSA, which occurred in the fourth quarter of 2018, resulted in a loss of $0.1 million for the year ended December 31, 2018, which is reflected within (loss) gain on sale of real estate investment in the consolidated statements of operations and comprehensive loss.
Impairments
The following is a summary of impairments taken during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Assets held for sale$19,570 $22,634 $18,255 
Assets held for use16,876 33,335 2,400 
Total$36,446 $55,969 $20,655 
For additional information on impairments related to assets held for sale and assets held for use, see the “Assets Held for Sale and Related Impairments” and “Assets Held for Use and Related Impairments” sections below.
Assets Held For Sale and Related Impairments
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.

F-26


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Balance Sheet Details - Assets Held for Sale
The following table details the major classes of assets associated with the properties that have been classified as held for sale as of December 31, 2020 and 2019:
December 31,
(In thousands)
2020 (1)
2019 (2)
   Land$145 $4,051 
   Buildings, fixtures and improvements(55)66,788 
Assets held for sale$90 $70,839 
_____
(1) Assets held for sale as of December 31, 2020 relates to four Michigan SHOPs.
(2) Assets held for sale as of December 31, 2019 relates to the original 14 Michigan SHOPs under the PSA entered into in January 2020 (see below for additional information).
In January 2020, the Company entered into a PSA for the sale of a portfolio of 14 SHOPs located in Michigan (the “Michigan SHOPs”) as a single portfolio for $71.8 million. Accordingly, all 14 of these SHOPs were classified as held for sale as of December 31, 2019.
During April, 2020, the PSA was amended so that only 11 of the Michigan SHOPs were to be sold pursuant to this PSA for $11.8 million. As a result of the amended PSA from April 2020, the three remaining Michigan SHOPs at that time no longer qualified as held for sale and were reclassified to assets held for use at their original carrying values as of March 31, 2020 and an additional $0.7 million in catch-up depreciation was recorded in the third quarter of 2020. In addition, the original deposit made by the buyer was reduced from $1.0 million to $0.3 million.
In October 2020, the PSA was amended to provide that the full $11.8 million sales price for all 11 Michigan SHOPs would be paid at an initial closing which occurred in November 2020, when seven of the properties were transferred to the buyer with the remaining four properties scheduled to be transferred to the buyer at a second closing, which occurred in the first quarter of 2021 (see Note 18 Subsequent Events). This amendment to the PSA also provided that $0.8 million of the sales price would be held in escrow and returned to the buyer at the second closing; provided that, if the PSA is terminated before the second closing closings due to a material default by the buyer, the Company will receive the escrowed amount. This amount was returned to the buyer at final closing. As a result, it represented an effective reduction in the sale price and the Company reflected an additional impairment loss to reflect this. The Company determined that the four Michigan SHOPs should be classified as held for sale as of December 31, 2020. As of December 31, 2020, for the four Michigan SHOPs that are classified as held for sale, three Michigan SHOPs were part of the borrowing base of the Credit Facility and one was unencumbered.
Held for Sale Impairments - 2020
As a result of the amendment to the PSA in April 2020, in which the number of properties under sale was reduced from 14 to 11, and in which the total consideration was reduced from $71.8 million to $11.8 million, the Company recorded an additional impairment charge of $19.6 million for the year ended December 31, 2020 related to the Michigan SHOP assets held for sale.
Held for Sale Impairments - 2019
During the year ended December 31, 2019 the Company recorded an impairment charge of $22.6 million related to assets held for sale, representing the amount by which the carrying amount of the Michigan SHOPs exceeded the Company’s estimate, at that time, of the net sales price of the Michigan SHOPs.
Held for Sale Impairments - 2018
During the year ended December 31, 2018, the Company recorded impairment charges of $18.3 million related to assets held for sale for the eight Missouri SNF Properties which were sold in 2018 and one of the New York Six MOBs which was sold in 2019.
Assets Held for Use and Related Impairments
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying
F-27


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
The Company owns held for use properties for which the Company may from time to time reconsider the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future.
As of December 31, 2019, the Company was actively considering plans to sell three assets in Florida including the recently completed development project in Jupiter, Florida and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida. The Company began marketing the properties in 2020 and, during the three months ended June 30, 2020, the Company received multiple bids and accepted a non-binding letter of intent from a prospective buyer to purchase the completed development project in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. During August 2020, the Company entered into PSAs with the buyer on the terms generally set forth in the letter of intent. The property in Lutz, Florida was sold in December 2020 (see “Dispositions” above) and the property in Jupiter, Florida and the property in Wellington, Florida are expected to be sold later in 2021 however, there can be no assurance that such transactions will actually close. If closed, the Company is required to use the proceeds of the sales to repay amounts outstanding under its Revolving Credit Facility.
Held for Use Impairments — 2020
During the year ended December 31, 2020, as a result of the Company’s marketing efforts during the COVID-19 pandemic which concluded with a PSA in August 2020, the Company recorded an additional impairment charge of $16.9 million on its completed development project in Jupiter, Florida and its skilled nursing facility in Wellington, Florida. The impairment charge represents the amount by which the carrying amount of the properties exceeded the Company’s estimate of the net sales price set forth in the PSA described above.
Held for Use Impairments — 2019
During the year ended December 31, 2019, the Company began to evaluate the properties in Lutz, Florida, Wellington, Florida and its completed development property in Jupiter, Florida for potential sales. As a result of these potential changes in plans, the Company concluded these held for use assets were impaired and recognized impairment charges in the aggregate of $33.3 million to reduce their carrying value to estimated fair value. The Company obtained third-party appraisals of all three properties (Lutz, Wellington, and Jupiter) which estimated fair value primarily applying an income approach using stabilized cash flows and capitalization rates of 9.0%, 9.0% and 7.0%, respectively.
Held for Use Impairments — 2018
During the year ended December 31, 2018, as a result of its consideration of impairment, the Company determined that the carrying value of one held for use property exceeded its estimated fair value and recognized an aggregate impairment charge of $2.4 million.
The LaSalle Tenant
On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. In January 2018, the Company entered into an agreement with the prior tenants at the LaSalle Properties (collectively, the “LaSalle Tenant”) in which the Company agreed to forbear from exercising legal remedies, including staying a lawsuit against the LaSalle Tenant, as long as the LaSalle Tenant paid the amounts due for rent and property taxes on an updated payment schedule pursuant to a forbearance agreement. As of December 31, 2020, the LaSalle Tenant remains in default of the forbearance agreement and owes the
F-28


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Company $12.7 million of rent, property taxes, late fees, and interest receivable thereunder and $7.7 million plus interest of unpaid monetary damages awarded to us by the court on our claims against the tenant.
The Company has the entire receivable balance, including any monetary damages, and related income from the LaSalle Tenant fully reserved as of December 31, 2020. The Company incurred $0.4 million, $3.5 million and $5.0 million of bad debt expense, including straight-line rent write-offs, related to the LaSalle Tenant during the years ended December 31, 2020, 2019 and 2018, respectively, which is included in revenue from tenants on the consolidated statement of operations.
On February 15, 2019, the Company filed an amended petition in Texas state court seeking the appointment of a receiver to manage the operations at these properties and for recovery of damages for the various breaches by the LaSalle Tenant. Subsequently, the LaSalle Group Inc., a guarantor of certain of the LaSalle Tenant’s lease obligations (the “LaSalle Guarantor”), filed for voluntarily relief under chapter 11 of the United States Bankruptcy Code. The Company severed its claims against the LaSalle Guarantor from the action against the LaSalle Tenant. On August 27, 2019, the court awarded the Company monetary damages on its claims against the LaSalle Tenant in an amount equal to $7.7 million plus interest. There can be no assurance the Company will receive any amounts with respect to these claims against the LaSalle Tenant.
On October 30, 2019, the court entered into an order appointing a receiver. This receiver was empowered to replace the LaSalle Tenant with a new tenant and operator at the properties, and, on February 15, 2020, the receiver took operational control of the properties. As noted above, the Company worked with the receiver and the Company’s designated third-party operator to transition the LaSalle Properties to its SHOP operating segment on July 1, 2020.
The NuVista Tenant
The Company had tenants at two of its Florida properties located in Lutz and Wellington Florida (collectively, the “NuVista Tenant”) that were in default under their leases beginning from July 2017. On January 1, 2018 the property was transitioned to the SHOP segment when the Company replaced the NuVista Tenant as tenant at the Lutz, Florida property with a TRS and engaged a third-party operator to operate the property. As a result, the property was transitioned to the SHOP segment as of January 1, 2018. The Company incurred bad debt expense of $1.1 million and $6.0 million related to the NuVista Tenant during the years ended December 31, 2019 and 2018, respectively which is included in revenue from tenants in the consolidated statement of operations and comprehensive loss.
At the property located in Wellington, Florida, the Company and the tenant entered into an operations transfer agreement (the “OTA”) pursuant to which the Company and the tenant agreed to cooperate in transitioning operations at the property to a third party operator selected by the Company. On February 19, 2019, in response to litigation commenced by the Company against the NuVista Tenant to enforce the OTA, the United States District Court for the Southern District of Florida entered into an agreed order (the “Order”) pursuant to which it found that the NuVista Tenant was in default under the lease for the property and that the OTA was valid, binding and in full force and effect, as modified by the Order. Subsequent to the entry into the Order, the Company, its designated third-party operator and the NuVista Tenant transitioned operations at the property to the Company’s designated third-party operator. The Company’s designated third-party operator received its license to operate the facility on April 1, 2019 and is in operational control of the property. On May 20, 2019, the court entered into a final order from the court terminating the existing lease with the NuVista Tenant. Following entry into the order, the property in Wellington, Florida transitioned to the SHOP segment as of April 1, 2019. In connection with this transition, the Company replaced the NuVista Tenant as a tenant with a TRS, and engaged a third-party operator to operate the property. During the year ended December 31, 2019 the company received $1.6 million under the OTA for periods prior to the lease termination, which amounts had previously been fully reserved. This payment under the OTA is included in revenue from tenants in consolidated statements of operations and comprehensive loss.
In August 2020, the Company entered into a PSA to sell the properties located in Lutz, Florida and Wellington Florida. The Company sold the property in Lutz, Florida in December 2020 (see “Dispositions” section above). The sale of the property in Jupiter, Florida and the sale of the property in Wellington, Florida are expected to be completed later in 2021.
F-29


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Note 4 — Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of December 31, 2020 and 2019:
Portfolio
Encumbered Properties (1)
Outstanding Loan Amount as of December 31,
Effective Interest Rate(2) as of December 31,
Interest Rate
2020201920202019Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ1$2,998 $3,112 4.15 %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ12,786 2,884 4.75 %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR17,133 7,283 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR116,390 16,695 3.98 %3.98%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR110,170 10,359 3.98 %3.98%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.71 %3.71%Fixed(3)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois (4)
113,684  4.34 %%FixedMarch 2026
Gross mortgage notes payable68550,361 537,533 3.94 %3.90%
Deferred financing costs, net of accumulated amortization (5)
(6,191)(7,718)
Mortgage premiums and discounts, net(1,472)(1,531)
Mortgage notes payable, net$542,698 $528,284 
__________
(1) Does not include real estate assets mortgaged to secure advances under the Fannie Mae Master Credit Facilities or eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below). The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 — Credit Facilities for additional details).
(2)    Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2020 and December 31, 2019. For the LIBOR based loans, LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(3) Variable rate loan, based on 30-day LIBOR, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. In connection with the amendment to this loan in December 2019 (see additional details below), the Company terminated the previous interest rate swap agreements and entered into new interest rate swap agreements (see Note 7 Derivatives and Hedging Activities for additional details).
(4)    The Company assumed this fixed rate mortgage when it acquired a property during the year ended December 31, 2020.
(5)    Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.

As of December 31, 2020, the Company had pledged $860.0 million in real estate investments, at cost, as collateral for its $550.4 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2020, the Company was in compliance with these financial covenants.
See Note 5 Credit Facilities for additional details - Future Principal Payment and LIBOR Transition for schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the expected cessation of LIBOR publication.
F-30


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Capital One MOB Loan
On June 30, 2017, Capital One, National Association (“Capital One”), as administrative agent and lender, and certain other lenders (collectively, the “MOB Lenders”), made a loan in the aggregate amount of $250.0 million (the “MOB Loan”) to certain subsidiaries of the OP. On December 20, 2019, the Company, through certain subsidiaries of the OP, entered into an amendment and restatement of the MOB Loan originally dated as of June 30, 2017 among the OP’s subsidiaries and Capital One, as administrative agent and lender, and certain other lenders. As a result, the principal amount outstanding increased from approximately $242.0 million to $378.5 million the number of properties mortgaged as collateral for the loan increased from 31 properties (all medical office buildings) to 41 properties (29 medical office buildings that continued to serve as collateral for the loan as well as an additional ten medical office buildings and two triple net leased hospitals).
At the closing of the amendment and restatement of the MOB Loan, after payment of closing costs and swap termination fees, the Company received $127.7 million in net refinancing proceeds in excess of the approximately $242.0 million principal amount outstanding prior to the closing. Of these excess proceeds, approximately $63.5 million were used to repay amounts outstanding under the Revolving Credit Facility (as defined below) in order to obtain a release of 12 of the mortgaged properties from the borrowing base thereunder, and approximately $61.5 million of the remaining proceeds were used to repay additional amounts outstanding under the Revolving Credit Facility.
Prior to the amendment and restatement of the MOB Loan, the MOB Loan bore interest at a variable rate equal to LIBOR plus 2.5% per annum. Subsequent to the amendment and restatement of the MOB Loan, the MOB Loan bears interest at a variable rate equal to LIBOR plus 2.0% per annum. The MOB Loan requires the Company to pay interest on a monthly basis with the principal balance due on the maturity date which was extended from June 30, 2022 to December 20, 2026 after the amendment and restatement of the MOB Loan. In connection with the amendment and restatement of the MOB Loan, the OP terminated two interest rate swaps and executed one interest rate swap on the new amount of the MOB Loan, fixing the interest rate exposure at 3.66%. See Note 7 — Derivatives and Hedging Activities for additional information on the Company’s outstanding derivatives.
The Company may pre-pay the MOB Loan, in whole or in part, at any time, with payment of a prepayment premium equal to (a) 3.0% for prepayments made prior to December 31, 2020, (b) 2.0% for prepayments made between January 1, 2021 and December 31, 2021, and (c) 1.0% for prepayments made between January 1, 2022 and December 31, 2022. Thereafter, no prepayment premium is required.
In addition, mortgaged properties may be released or replaced subject to certain conditions and limitations, including prepayment of not more than 110% of the principal amount allocated to the property together with any applicable prepayment premium and maintenance, giving effect to the release or replacement, of a minimum of either 25 mortgaged properties or $283.9 million principal amount outstanding, a minimum debt yield and a minimum debt service coverage ratio.
In connection with the amendment to the MOB Loan, the OP entered into an amended and restated guaranty of recourse obligations (the “Guaranty”) and an amended and restated hazardous materials indemnity agreement (the “Environmental Indemnity”) for the benefit of Capital One as administrative agent for the lenders on substantially identical terms to the guaranty and environmental indemnity entered into in connection with the original loan agreement entered into in June 2017. Pursuant to the Guaranty, the OP has guaranteed, among other things, specified losses arising from certain actions of any of the OP’s subsidiaries, including fraud, willful misrepresentation, certain intentional acts, misapplication of funds, physical waste, and failure to pay taxes. The Guaranty requires the Company to maintain a certain minimum of shareholders’ equity on its balance sheet. Pursuant to the Environmental Indemnity, the OP and the Company’s subsidiaries that directly own or lease the mortgaged properties have indemnified the MOB Lenders against losses, costs or liabilities related to certain environmental matters.
The amendment and restatement of the MOB Loan was considered an extinguishment of the old loan and a new loan agreement. Accordingly, fees and expense for the new loan have been capitalized and the unamortized fees relating to the old loan of approximately $3.0 million were written off as a charge to interest expense in the statement of operations for the year ended December 31, 2019.
Multi-Property CMBS Loan
On April 10, 2018, the Company, entered into a $118.7 million loan agreement (the “Multi-Property CMBS Loan”) with KeyBank National Association (“KeyBank”).
The Multi-Property CMBS Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The Multi-Property CMBS Loan permits KeyBank to securitize the entire Multi-Property CMBS Loan or any portion thereof.
F-31


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
At the closing of the Multi-Property CMBS Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $80.0 million of indebtedness under the Revolving Credit Facility, under which 14 of the properties were included as part of the borrowing base prior to the Multi-Property CMBS Loan, (ii) fund approximately $3.8 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $33.0 million net proceeds available to the Company to be used for general corporate purposes, including future acquisitions.
Note 5 — Credit Facilities, Net
The Company had the following credit facilities outstanding as of December 31, 2020 and 2019:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(10)
Credit Facility
Encumbered Properties(1)
2020201920202019Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$173,674 $100,618 3.21 %4.08 %Variable(8)Mar. 2023(9)
Term Loan
150,000 150,000 4.95 %4.05 %Variable(6)Mar. 2024
Deferred financing costs
(4,298)(4,671)
Term Loan, net
145,702 145,329 
Total Credit Facility
89(2)$319,376 $245,947 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$212,467 $216,614 2.60 %4.17 %Variable(7)Nov. 2026
KeyBank Facility10(4)142,708 142,708 2.65 %4.22 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$355,175 $359,322 
Total Credit Facilities110$674,551 $605,269 3.29 %(5)4.14 %(5)
__________
(1)Encumbered properties are as of December 31, 2020.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2020 with a carrying value of $344.0 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2020 with carrying value of $253.6 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2020 and 2019, respectively. For the LIBOR based loans that have not been fixed, the LIBOR rate in effect at the balance sheet date was utilized. For LIBOR based loans that have been fixed, the effective rate after consideration of the interest rate swap was utilized. See Note 7 — Derivatives and Hedging Activities for additional details.
(6)Variable rate loan, based on LIBOR, all of which was fixed as a result of entering into “pay-fixed” interest rate swap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(7)Variable rate loan which is capped as a result of entering into interest rate cap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(8)Variable rate loan with $50 million of principal amount fixed at a rate of 4.09% by an interest rate swap agreement.
(9)The company has the option to extend maturity one year to March 2024 subject to certain conditions.
(10)Effective interest rate below for variable rate debt gives effect to any “Pay-fixed” swap entered into by the Company. If not hedged, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2020. Interest rate caps are not considered unless the cap is currently in effect.
As of December 31, 2020, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
F-32


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Unencumbered real estate investments, at cost as of December 31, 2020 was $231.5 million, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of our Credit Facility. Pursuant to the August 10, 2020 amendment to the Credit Facility, any acquired properties must be pledged to the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be repaid to the Credit Facility.
Credit Facility
On March 13, 2019, the Company entered into an amended and restated senior secured credit facility (the “Credit Facility”), which consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). In both March and August 2020, the Credit Facility was further amended, and the terms of the Credit Facility giving effect to those amendments are generally described below.
The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $630.0 million, including $480.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.
The amount available for future borrowings under the Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.
As of December 31, 2020, $150.0 million was outstanding under the Term Loan, and $173.7 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $48.3 million.
The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Pursuant to the amendment in August 2020, certain other restrictions and conditions described below will no longer apply starting in a quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% (the “Commencement Quarter”). The Commencement Quarter may be no earlier than the fiscal quarter ending June 30, 2021.
During the period from August 10, 2020 until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. The Company may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
In addition, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.85% to 2.60%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.60% to 1.35%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2020 the Company had elected to use the LIBOR option for all of our borrowings under the Credit Facility.
Further, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.80% to 2.55%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.55% to 1.30%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%;
F-33


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the amendment to the Credit Facility in August 2020, the “floor” on LIBOR was increased from 0.00% to 0.25%.     
As of December 31, 2020, the Revolving Credit Facility and the Term Loan had an effective interest rate per annum equal to 3.21% and 4.95%, respectively.
Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”) or any other preferred stock the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below. The Company may pay cash distributions beginning in the Commencement Quarter and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
The Credit Facility prohibits the Company from exceeding a maximum ratio of consolidated total indebtedness to consolidated total asset value, and requires the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges and a minimum consolidated tangible net worth. The maximum ratio of consolidated total indebtedness to consolidated total asset value is 67.5% for the period from July 1, 2020 through June 30, 2021 and 65% thereafter unless and until the Commencement Quarter, following which it will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges is 1.50 to 1.00 for the period from July 1, 2020 through March 31, 2021, 1.55 to 1.00 for the period from April 1, 2021 through June 30, 2021, and 1.60 to 1.00 thereafter. The minimum consolidated tangible net worth is the sum of (i) approximately $1.2 million, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019.
As of December 31, 2020, the Company was in compliance with the financial covenants under the Credit Facility. Based upon the Company’s current expectations, the Company believes its operating results during the next 12 months will allow it to comply with these covenants.
Fannie Mae Master Credit Facilities
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Credit Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
Effective October 31, 2016, in conjunction with the execution of the Fannie Mae Master Credit Facilities, the OP entered into two interest rate cap agreements with an unrelated third party, which caps LIBOR interest paid (not giving effect to the applicable margin) on amounts outstanding under the Fannie Mae Master Credit Facilities at a maximum of 3.5%. On October 2019, the Company replaced two maturing interest rate cap agreements, effective November 1, 2019 for a total notional amount of $88.7 million. The two interest rate caps agreements extend three existing interest rate caps set to mature on the same date and are not designated as hedges (see Note 7 — Derivatives and Hedging Activities for additional disclosure regarding the Company’s derivatives).
In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.
F-34


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The Company may request future advances under the Fannie Mae Master Credit Facilities by borrowing against the value of the initial mortgaged properties, or by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests.
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2020 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2021$1,191 $130 $1,321 
20221,242 2,820 4,062 
20236,383 4,497 10,880 
20241,095 178,171 179,266 
20251,142 154,497 155,639 
Thereafter539,308 338,734 878,042 
Total$550,361 $678,849 $1,229,210 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. In some instances, transitioning to an alternative rate may require negotiation with lenders and other counterparties and could present challenges. To transition from LIBOR under the Credit Facility, the Company will either utilize the Base Rate (as defined in the Credit Facility) or an alternative benchmark established by the agent in accordance with the terms of the Credit Facility, which will be determined with due consideration to the then current market practices for determining and implementing a rate of interest for newly originated floating rate commercial real estate loans in the United States and loans converted from a LIBOR based rate to a replacement index-based rate.
The Company has mortgages, credit facilities and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rates for LIBOR with the lenders and derivative counterparties.
Note 6 — Fair Value of Financial Instruments
GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring financial instruments at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
F-35


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2020 and 2019, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020 and 2019, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2020
Derivative assets, at fair value$ $13 $ $13 
Derivative liabilities, at fair value (38,389) (38,389)
Total$ $(38,376)$ $(38,376)
December 31, 2019
Derivative assets, at fair value$ $392 $ $392 
Derivative liabilities, at fair value(5,305)(5,305)
Total$ $(4,913)$ $(4,913)
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2020.
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
F-36


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Real Estate Investments — Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2020 and 2019. As of December 31, 2020, the Company owned held for use properties for which the Company had reconsidered the projected cash flows due to various performance indicators. As a result, the Company evaluated the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company primarily uses a market approach to estimate the future cash flows expected to be generated. Impaired real estate investments held for use are generally classified in Level 3 of the fair value hierarchy. See Note 3 — Real Estate investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments — Held for Sale
The Company has impaired real estate investments held for sale, which are carried at net realizable value on a non-recurring basis on the consolidated balance sheets as of December 31, 2020 and 2019. Impaired real estate investments held for sale are generally classified in Level 3 of the fair value hierarchy. See Note 3 — Real Estate investments, Net - “Assets Held for Sale and Related Impairments” for additional details.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2020December 31, 2019
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$548,889 $549,553 $536,002 $545,414 
Credit Facility
3$323,674 $319,558 $250,618 $250,618 
Fannie Mae Master Credit Facilities
3$355,175 $354,073 $359,322 $370,122 
The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives. At December 31, 2020, the carrying values of the Credit Facility and Fannie Mae Master Credit Facilities do not approximate their fair values due to the widening of credit spreads during the period. At December 31, 2019, the carrying amounts approximated their fair values.
Note 7 — Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
F-37


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2020 and 2019:
December 31,
(In thousands)Balance Sheet Location20202019
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$ $377 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$38,389 $5,305 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$13 $15 
Cash Flow Hedges of Interest Rate Risk
The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2020 and 2019, such derivatives were used to hedge the variable cash flows associated with variable-rate debt.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
In connection with the refinancing of the MOB Loan during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and is being recorded as an adjustment to interest expense over the term of the two terminated swaps and the MOB Loan prior to its refinancing. Of the amount recorded in AOCI following these terminations, $0.9 million and $0.1 million was recorded as an increase to interest expense for the years ended December 31, 2020 and 2019, respectively, and approximately $1.3 million remained in AOCI as of December 31, 2020.
Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2021 through December 31, 2021, the Company estimates that $10.7 million will be reclassified from other comprehensive loss as an increase to interest expense.
As of December 31, 2020 and 2019, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2020December 31, 2019
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate “pay-fixed” swaps9 $578,500 9 $578,500 
F-38


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2020 and 2019:
Year Ended December 31,
(In thousands)202020192018
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$(40,614)$(10,753)$2,367 
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)$(7,999)$872 $258 
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,519 $56,059 $49,471 
Non-Designated Derivatives
These derivatives are used to manage the Company’s exposure to interest rate movements, but do not meet the strict hedge accounting requirements to be classified as hedging instruments. Changes in the fair value of derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and were a loss of $0.1 million, a loss of $0.1 million and a loss of $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2020 and 2019:
December 31, 2020December 31, 2019
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate caps6 $359,322 6 $359,322 
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2020 and 2019. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheet.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2020$13 —  $13   $13 
December 31, 2020$— (38,389) $(38,389)  $(38,389)
December 31, 2019$392 —  $392   $392 
December 31, 2019$— (5,305) $(5,305)  $(5,305)
Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of December 31, 2020 the fair value of derivatives in a net liability position, including accrued interest but excluding any adjustment for nonperformance risk related to these agreements, was $38.4 million. As of December 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the
F-39


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Company had breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value of $38.4 million at December 31, 2020.
Note 8 — Stockholders’ Equity
Common Stock
As of December 31, 2020 and 2019, the Company had 93,775,746 and 92,356,664 shares of common stock outstanding, respectively, including unvested restricted shares and shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases.
On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019, which was approved by the Board on September 30, 2020. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually.
Tender Offers
On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.
On March 13, 2018, the Company announced a tender offer (the “2018 Tender Offer”) to purchase up to 2.0 million shares of the Company’s common stock for cash at a purchase price equal to $13.15 per share with the proration period and withdrawal rights expiring on April 12, 2018. On April 4, 2018 and April 16, 2018, the 2018 Tender Offer was amended to reduce the number of shares the Company was offering to purchase to 230,000 shares and extend the expiration date to May 1, 2018. The 2018 Tender Offer expired in accordance with its terms on May 1, 2018. During May 2018, in accordance with the terms of the 2018 Tender Offer, the Company accepted for purchase 230,000 shares for a total cost of approximately $3.0 million.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
The Company suspended the SRP during the pendency of the 2018 Tender Offer. On June 29, 2018, the Company announced the Board unanimously determined to reactivate the SRP, effective June 30, 2018. In connection with reactivating the SRP, the Board approved all repurchase requests received during the period from January 1, 2018 through the suspension of the SRP on March 13, 2018 (see table below for additional details).
On January 29, 2019, the Company announced that the Board approved an amendment to the SRP changing the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than March 31, 2019, rather than on or before the 31st day following December 31, 2018. This SRP amendment became effective on January 30, 2019. Additionally, on March 27, 2019, the Company announced that the Board approved an amendment to the SRP further extending the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than April 30, 2019. This SRP amendment became effective on March 28, 2019 (see table below for details on cumulative shares repurchased pursuant to the SRP, including shares repurchased during 2019).
On July 23, 2019, the Company announced that the Board approved a third amendment to the SRP, effective July 24, 2019, extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than August 31, 2019, rather than on or before July 31, 2019.
F-40


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
On August 20, 2019, the Company announced that the Board approved a fourth amendment to the SRP, effective August 22, 2019 extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than October 31, 2019, rather than on or before August 31, 2019. The Company completed the repurchases on October 30, 2019 and repurchased 446,830 shares of common stock for approximately $7.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing January 1, 2019 up to and including June 30, 2019.
On January 9, 2020, the Company announced that the Board approved a fifth amendment to the SRP, effective January 10, 2020 extending the date on which repurchases are able to be made in respect of requests made during the period commencing July 1, 2019 up to and including December 31, 2019 to on or before March 16, 2020, rather than on or before January 31, 2020.
On January 9, 2020, the Company also announced that the Board had suspended the SRP, and that it would not accept any repurchase requests or make any repurchases under the SRP during the pendency of the 2020 Tender Offer or for 10 business days thereafter.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5, which restricts the Company from repurchasing shares until no earlier than the quarter ending June 30, 2021, on August 6, 2020, the Board determined that, effective on August 12, 2020, repurchases under the SRP would be suspended. The Board has also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2020:
Number of Shares Repurchased (2)
Average Price per Share (2)2
Cumulative repurchases as of December 31, 20194,391,519 $20.95 
Year ended December 31, 2020 (1)
505,101 17.50 
Cumulative repurchases as of December 31, 2020
4,896,620 20.60 
_________
(1) Includes 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.
F-41


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2020, 2019 and 2018, the Company issued 0.9 million, 1.5 million and 1.7 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million, $27.2 million and $35.7 million, respectively. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.
Preferred Stock
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2020. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below). The Company had 1,610,000 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2020 and 2019.
In December 2019, the Company issued and sold 1,610,000 shares of the Series A Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The gross proceeds from this offering were $40.3 million and net proceeds were $37.6 million after deducting the underwriting discount of $1.3 million and additional offering expenses of $1.4 million.
On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company did not sell any shares under the Preferred Stock Equity Line during the year ended December 31, 2020.
Series A Preferred Stock — Terms
Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate
F-42


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into Common Stock have not been met as of December 31, 2020. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2019.
The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.
Distributions and Dividends
Common Stock
In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock.
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5 which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The Company declared the Stock Dividends of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock on October 1, 2020 and January 4, 2021. This amount was based on the Company’s prior cash distribution rate of $0.85 per share per annum. The Board may further change the Company’s common stock distribution policy at any time, further reduce the amount of distributions paid or suspend distribution payments at any time, and therefore distribution payments are not assured.
The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the years ended December 31, 2020, 2019 and 2018, retroactively adjusted for the effect of the Stock Dividends:
Year Ended December 31,
202020192018
Return of capital (1)
100.0 %$0.42 100 %$0.83 100 %$0.92 
Capital gain dividend income %  %  % 
Ordinary dividend income %  %  % 
Total100.0 %$0.42 100.0 %$0.83 100.0 %$0.92 
________
(1) Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to the Company’s shareholders for U.S. federal income tax purposes.
F-43


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Series A Preferred Stock
Dividends on our Series A Preferred Stock accrue in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to Series A Preferred Stock holders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us. The first quarterly dividend for the Series A Preferred Stock sold in this offering was paid on January 15, 2020 and represented an accrual for less than a full quarter, covering the period from December 11, 2019 to December 31, 2019. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock become part of the liquidation preference thereof.
Note 9 — Related Party Transactions and Arrangements
As of December 31, 2020 and 2019, the Special Limited Partner owned 9,008 and 8,888 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2020 and 2019, the Advisor held 90 partnership units in the OP designated as “OP Units” (“OP Units”).
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
On February 17, 2017, the members of a special committee of the Board unanimously approved certain amendments to and a restatement of the then effective advisory agreement, by and among the Company, the OP and the Advisor (the “Second A&R Advisory Agreement”). The Second A&R Advisory Agreement, which superseded, amended and restated the previously effective advisory agreement (the “Original A&R Advisory Agreement”), took effect on February 17, 2017. The initial term of the Second A&R Advisory Agreement expires on February 17, 2027, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second Amended and Restated Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for third party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2020.
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the Original A&R Advisory Agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the
F-44


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
“Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2020, the Company cannot determine the probability of achieving the Performance Condition. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. These distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. The base management fee is payable to the Advisor or its assignees in cash, OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted number of shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2020, 2019 and 2018.
F-45


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by our Board of Directors (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2021.The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2020, 2019 and 2018, the Company incurred $10.8 million, $10.6 million and $8.9 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss).
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Second A&R Advisory Agreement, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), for each fiscal year is subject to a limit that is equal to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
F-46


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2019; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the advisory agreement requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the advisory agreement requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
As part of this reimbursement, for the year ended December 31, 2020, the Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original $2.5 million estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable is payable to the Company over a 10-month period from January 2021 through October 2021.
Reimbursements for the cash portion of 2020 bonuses to employees of the Advisor or its affiliates continue to be expensed and reimbursed on a monthly basis during 2020 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.
In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.
F-47


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Summary of fees, expenses and related payables
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202020192018December 31,
(In thousands)
Incurred
Incurred
Incurred20202019
One-time fees and reimbursements:
Acquisition cost reimbursements$81 $39 $176 $11 $ 
Ongoing fees and reimbursements:
Asset management fees 19,987 19,526 19,500  27 
Property management fees (6)
4,197 3,888 3,571 288 (44)
Professional fees and other reimbursements (1) (4)
12,102 

10,073 8,883 (61)(377)(5)
Professional fees credit due from Advisor(1,217)  (1,217)(3) 
Distributions on Class B Units (2)
178 305 340   
Total related party operation fees and reimbursements$35,328 $33,831 $32,470 $(979)$(394)
_________
(1)    Included in general and administrative expenses in the consolidated statements of operations. Includes $5.6 million and $7.2 million subject to the Capped Reimbursement Amount for the years ended December 31, 2020 and 2019, respectively.
(2)     Prior to April 1, 2015, the Company caused the OP to issue (subject to periodic approval by the Board) to the Advisor restricted performance-based Class B Units for asset management services. As of December 31, 2020, the Board had approved the issuance of, and the OP had issued, 359,250 Class B Units to the Advisor in connection with this arrangement. Effective April 1, 2015, the Company began paying an asset management fee to the Advisor or its assignees in cash, in shares, or a combination of both and no longer issues any Class B Units.
(3)     Balance includes a receivable of $1.2 million from the Advisor related to the overpayment of 2019 Bonus Awards as of December 31, 2020 which, pursuant to authorization by the independent members of the Company’s board of directors, is payable over a ten month period from January 2021 to October 2021.
(4)     During the year ended December 31, 2019, the Company recorded a reduction of general and administrative expenses in the amount of $0.5 million related to the reversal of a payable balance due to RCS Capital Corporation. During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(5) Balance includes a receivable of $0.5 million from the Advisor as of December 31, 2019, previously recorded in the fourth quarter of 2018, which, pursuant to authorization by the independent members of the Company’s board of directors, was fully paid during 2020.
(6)    Inclusive of $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2020.
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2020, 2019 and 2018. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2020, 2019 and 2018. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the
F-48


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to an annual 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Second A&R Advisory Agreement, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Second A&R Advisory Agreement.
Upon a termination by either party in connection with a change of control (as defined in the Second A&R Advisory Agreement), the Company would pay the Advisor a change of control fee equal to the product of four (4) and the “Subject Fees.”
Upon a termination by the Company in connection with a transition to self-management, the Company would pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
The right to termination of the Second A&R Advisory Agreement in connection with a change of control or transition to self-management is subject to a lockout period that requires the notice of any termination in connection with a change of control or transition to self-management to be delivered after February 14, 2019.
Note 10 — Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
F-49


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Note 11 — Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.5 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Prior to August 2017, the RSP provided for an automatic grant of 1,333 restricted shares to each of the independent directors, without any further approval by the Board or the stockholders, on the date of his or her initial election to the Board and thereafter on the date of each annual stockholder meeting. The restricted shares granted as annual automatic awards prior to August 2017 were subject to vesting over a five-year period following the date of grant.
In August 2017, the Board amended the RSP to provide that the number of restricted shares comprising the automatic annual award to each of the independent directors would be equal to the quotient of $30,000 divided by the then-current Estimated Per-Share NAV and subsequently amended and restated the RSP to eliminate the automatic annual awards and to make other revisions related to the implementation of a new independent director equity compensation program. As part of this independent director equity compensation program, the Board approved a one-time grant of restricted share awards to the independent directors as follows: (i) 300,000 restricted shares to the chairman, with one-seventh of the shares vesting annually in equal increments over a seven-year period with initial vesting on August 4, 2018; and (ii) 25,000 restricted shares to each of the three other independent directors, with one-fifth of the shares vesting annually in equal increments over a five-year period with initial vesting on August 4, 2018. In connection with these one-time grants, the restricted shares granted as automatic annual awards in connection with the Company’s 2017 annual meeting of stockholders on July 21, 2017 were forfeited.
On July 29, 2019, the Board elected B.J. Penn as a member of the Board to serve as a director effective immediately. Mr. Penn, like the Company’s other independent directors, participates in the Company’s independent director compensation program. During the year ended December 31, 2019, the Company paid to Mr. Penn an annual cash retainer effective as of July 29, 2019 pro-rated for the remaining portion of the current annual period, and he was awarded 15,000 restricted shares vesting annually in equal increments over a three-year period with initial vesting on August 4, 2020.
Restricted shares may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.

F-50


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The following table reflects the amount of shares outstanding as of December 31, 2020 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2017382,510 $21.47 
Granted  
Vested(60,268)21.78 
Forfeitures  
Unvested, December 31, 2018322,242 21.41 
Granted15,000 17.50 
Vested(60,001)21.48 
Forfeitures  
Unvested, December 31, 2019277,241 21.18 
Stock dividend2,878 15.75 
Granted  
Vested(64,735)21.18 
Forfeitures  
Unvested, December 31, 2020215,384 21.11 
As of December 31, 2020, the Company had $4.0 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 3.2 years. Compensation expense related to restricted shares was $1.3 million, $1.3 million and approximately $1.2 million during the years ended December 31, 2020, 2019 and 2018, respectively.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2020, 2019 and 2018.
F-51


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Note 12 — Accumulated Other Comprehensive (Loss) Income
The following table illustrates the changes in accumulated other comprehensive (loss) income as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 20172,473 
Other comprehensive income, before reclassifications2,367 
Amounts reclassified from accumulated other comprehensive (loss) income(258)
Balance, December 31, 20184,582 
Other comprehensive loss, before reclassifications(10,753)
Amounts reclassified from accumulated other comprehensive (loss) income(872)
Balance, December 31, 2019(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amounts reclassified from accumulated other comprehensive (loss) income7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020$(39,673)

Accumulated other comprehensive (loss) income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income is $1.3 million as of December 31, 2020.

F-52


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Note 13 — Non-Controlling Interests
Non-Controlling Interests in the Operating Partnership
The Company is the sole general partner and holds substantially all of the OP Units. As of December 31, 2020 and 2019, the Advisor held 90 OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the OP Units for a period of one year, a holder of OP Units has the right to redeem OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2020, 2019 and 2018, OP Unit non-controlling interest holders were paid distributions of $0.2 million, $0.3 million, and $0.5 million respectively.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
As of December 31,As of December 31,As of December 31,Year Ended December 31,
Property Name
(Dollar amounts in thousands)
Investment Date2020202020202019202020192018
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$371 2.2 %$12,790 $14,220 $ $ $87 
UnityPoint Clinic Portfolio (2)
December 2017$  %$ $8,842 $ $ $ 
_____________
(1)    One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
(2)    On November 4, 2020, the Company purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint portfolio. See details above for additional information.

F-53


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Note 14 — Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2020, 2019 and 2018 and has been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
Year Ended December 31,
202020192018
Net loss attributable to stockholders (in thousands)
$(78,781)$(88,087)$(52,762)
Basic and diluted weighted-average shares outstanding (1)
94,639,833 94,433,640 93,593,719 
Basic and diluted net loss per share (1)
$(0.83)$(0.93)$(0.56)
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for additional details)).

Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
December 31,
202020192018
Unvested restricted shares (1)
257,704 313,711 367,796 
OP Units (2)
417,025 417,025 417,025 
Class B Units (3)
369,007 369,007 369,007 
Total weighted average antidilutive common share equivalents1,043,736 1,099,743 1,153,828 
________
(1)    Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 215,373, 277,241 and 322,242 unvested restricted shares outstanding as of December 31, 2020, 2019 and 2018, respectively.
(2)    Weighted average number of antidilutive OP Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 405,998 OP Units outstanding as of December 31, 2020, 2019 and 2018.
(3)    Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 359,250 Class B Units outstanding as of December 31, 2020, 2019 and 2018.
Note 15 — Segment Reporting
During the years ended December 31, 2020, 2019 and 2018, the Company operated in three reportable business segments for management and internal financial reporting purposes: MOBs, triple-net leased healthcare facilities, and SHOPs.
The Company evaluates performance and makes resource allocations based on its three business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses. The triple-net leased healthcare facilities segment primarily consists of investments in seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
F-54


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Some of the Company’s properties move between its operating segments, for example if they are converted from being triple-net leased to third parties in the triple-net leased healthcare facilities segment to being leased to the TRS and operated and managed on the Company’s behalf by a third-party operator in the SHOP segment. When transfers between segments occur, the Company reclassifies the operating results of the transferred properties to their current segment for both the current and all historical periods in order to present a consistent group of property results. See Note 3 — Real Estate Investments, Net - “Impairments” and “Held for Use Assets” to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.
Over the last three years, the Company has had properties transfer between operating segments. Upon such transfers the Company retroactively restates the historical operating results for the segment for all periods presented in that filing and, thereafter, the Company will restate other later prior periods when they are subsequently reported in later filings for comparative purposes. As a result, the Company provides transition disclosure adjustments only for properties that have transitioned since the prior numbers were previously reported.
In 2018, the Company had also transitioned (i.e. this asset was operating as a SHOP asset and was not leased to a third party) a property located in Lutz, Florida from its triple-net leased healthcare facilities segment to its SHOP segment. The results of this property had previously been reclassified in the Same Store operating results in 2018 and 2019, and following its disposal in December 2020, it has been again reclassified from Same Store results to Disposals.
As described in more detail below, the Company transitioned one property located in Wellington, Florida and the four LaSalle Properties on April 1, 2019 and July 1, 2020, respectively, from its triple-net leased healthcare facilities segment to its SHOP segment (collectively, the “Transition Properties”). See Note 3 — Real Estate Investments for further information about this property and the transition. The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020, 2019 and 2018, respectively.
The previously reported same store results had already been retroactively adjusted to reflect the movement of the results Transition Property located in Wellington, Florida and the property located in Lutz, Florida and require no further adjustments thereto.
On July 1, 2020, the Company transitioned the LaSalle Properties from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. This segment has been applied retrospectively to historical periods starting with the quarter ended September 30, 2020.
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
F-55


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The following tables reconcile the segment activity, adjusted for the Transition Properties, to consolidated net loss for the years ended December 31, 2020 2019 and 2018:
Year Ended December 31, 2020
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$104,213 $15,611 $261,788 $381,612 
Property operating and maintenance30,851 1,961 210,736 243,548 
NOI$73,362 $13,650 $51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investments5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non designated derivatives(102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)
Year Ended December 31, 2019
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$100,379 $14,564 $259,971 $374,914 
Property operating and maintenance31,813 2,310 200,062 234,185 
NOI68,566 12,254 59,909 140,729 
Impairment charges(55,969)
Operating fees to related parties(23,414)
Acquisition and transaction related(362)
General and administrative(20,530)
Depreciation and amortization(81,032)
Interest expense(56,059)
Interest and other income7 
Gain on sale of real estate investments8,790 
Loss on sale of non-designated derivatives(68)
Income tax expense(399)
Net loss attributable to non-controlling interests393 
Allocation for preferred stock(173)
Net loss attributable to stockholders$(88,087)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020 and 2019, respectively.
F-56


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Year Ended December 31, 2018
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$99,103 $14,970 $248,333 $362,406 
Property operating and maintenance30,295 1,424 189,278 220,997 
NOI68,808 13,546 59,055 141,409 
Impairment charges(20,655)
Operating fees to related parties(23,071)
Acquisition and transaction related(302)
General and administrative(17,275)
Depreciation and amortization(83,212)
Gain on sale of real estate investment (70)
Interest expense(49,471)
Interest and other income 23 
Loss on non-designated derivatives (157)
Income tax expense(197)
Net loss attributable to non-controlling interests216 
Net loss attributable to common stockholders$(52,762)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the year ended December 31, 2018.
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20202019
ASSETS
Investments in real estate, net:
Medical office buildings
$883,471 $891,477 
Triple-net leased healthcare facilities (1)
238,427 256,661 
Seniors housing — operating properties (1)
987,050 905,453 
Total investments in real estate, net
2,108,948 2,053,591 
Cash and cash equivalents72,357 95,691 
Restricted cash17,989 15,908 
Assets held for sale90 70,839 
Derivative assets, at fair value13 392 
Straight-line rent receivable, net23,322 21,182 
Operating lease right-of-use asset13,912 14,351 
Prepaid expenses and other assets34,932 39,707 
Deferred costs, net15,332 13,642 
Total assets$2,286,895 $2,325,303 
__________________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020 and 2019.

F-57


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Medical office buildings$4,585 $5,309 $7,582 
Triple-net leased healthcare facilities (1)
3,976 396 1,152 
Seniors housing — operating properties (1)
12,833 11,014 4,176 
Total capital expenditures$21,394 $16,719 $12,910 
___________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020, 2019 and 2018.
Note 16 — Commitments and Contingencies
As of December 31, 2020, the Company has eight operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The eight operating leases have durations, including assumed renewals, ranging from 11.8 to 86.7 years as of December 31, 2020. On January 1, 2019, the Company adopted ASU 2016- 02 and recorded ROU assets and lease liabilities related to these ground operating leases (see Note 2Summary of Significant Accounting Policies for additional information). The Company did not enter into any additional ground leases during the year ended December 31, 2020.
As of December 31, 2020, the Company’s balance sheet includes ROU assets and operating lease liabilities of $13.9 million and $9.2 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the new lease guidance as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Since the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 41.3 years and a weighted-average discount rate of 7.35% as of December 31, 2020. For the years ended December 31, 2020 and 2019, the Company paid cash of $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $1.0 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2020, 2019 and 2018, respectively. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2021$663 $84 
2022682 86 
2023684 88 
2024686 90 
2025691 93 
Thereafter28,690 7,407 
Total minimum lease payments32,096 7,848 
Less: amounts representing interest(22,941)(3,011)
Total present value of minimum lease payments$9,155 $4,837 
_______
(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
F-58


HEALTHCARE TRUST, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2020
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2020, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
Note 17 — Quarterly Results (Unaudited)
Presented below is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019 which has been retroactively adjusted to reflect the Stock Dividends (see Note 1 — Organization for additional details):
Quarter Ended
(In thousands, except for share and per share data)March 31,
2020
June 30,
2020
September 30,
2020
December 31,
2020
Total revenues$100,235 $94,664 $95,835 $90,878 
Net loss attributable to stockholders$(24,744)$(22,811)$(10,500)$(20,726)
Basic and diluted weighted average shares outstanding (1)
94,458,620 94,479,156 94,796,190 94,821,653 
Basic and diluted net loss per share (1)
$(0.26)$(0.24)$(0.11)$(0.22)
Quarter Ended
(In thousands, except for share and per share data)March 31,
2019
June 30,
2019
September 30,
2019
December 31, 2019 (2)
Total revenues$88,718 $96,287 $95,440 $94,469 
Net loss attributable to stockholders$(5,111)$(6,054)$(28,789)$(48,133)
Basic and diluted weighted average shares outstanding (1)
95,417,626 94,276,398 94,419,591 94,592,579 
Basic and diluted net loss per share (1)
$(0.05)$(0.06)$(0.30)$(0.51)
__________
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization).
(2) During the quarter ended December 31, 2020 and 2019, the Company recorded $3.6 million and $33.3 million in impairment charges on real estate investments held for use. See Note 3 — Real Estate investments, Net - Impairments for additional details.
Note 18 — Subsequent Events
The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:
Stock Dividend
On January 4, 2021, the Company declared a quarterly stock dividend of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 15, 2021 to holders of record of the Company’s common stock at the close of business on January 11, 2021.
Michigan SHOP Transfer
During the first quarter of 2021, the Company completed the transfer of four properties to the buyer of its 11 Michigan properties sold in the fourth quarter of 2020. See Note 3 — Real Estate Investments, Net for additional information.
CARES Act Grants
On March 8, 2021, the Company received $5.1 million in grants from the CARES Act. Consistent with the Company’s policy on the accounting treatment of funds received through the CARES Act, these funds will be recorded as a reduction of property operating expenses to offset incurred COVID-19 costs. There can be no assurance that the program will be extended or any further amounts received.
F-59

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Fresenius Medical Care - Winfield, AL(5)AL5/10/2013$ $152 $1,568 $ $ $1,720 $353 
Adena Health Center - Jackson, OH(5)OH6/28/2013 242 4,494   4,736 873 
Ouachita Community Hospital - West Monroe, LA(5)LA7/12/2013 633 5,304   5,937 1,049 
CareMeridian - Littleton, CO(5)CO8/8/2013 976 8,900  111 9,987 2,560 
Oak Lawn Medical Center - Oak Lawn, ILIL8/21/20135,343 835 7,217   8,052 1,620 
Surgery Center of Temple - Temple, TX(5)TX8/30/2013 225 5,208  432 5,865 992 
Greenville Health System - Greenville, SC(5), (9)SC10/10/2013 720 3,045   3,765 569 
Stockbridge Family Medical - Stockbridge, GAGA2/21/20141,781 823 1,799  131 2,753 379 
Arrowhead Medical Plaza II - Glendale, AZAZ2/21/20147,540  9,758  1,867 11,625 2,458 
Village Center Parkway - Stockbridge, GAGA2/21/20142,434 1,135 2,299  156 3,590 633 
Creekside MOB - Douglasville, GAGA4/30/20148,814 2,709 5,320  637 8,666 1,472 
Bowie Gateway Medical Center - Bowie, MDMD5/7/20149,153 983 10,321  81 11,385 1,878 
Campus at Crooks & Auburn Building D - Rochester Mills, MIMI5/19/20143,627 640 4,166  118 4,924 831 
Berwyn Medical Center - Berwyn, IL(5)IL5/29/2014 1,305 7,559   8,864 1,298 
Countryside Medical Arts - Safety Harbor, FLFL5/30/20146,983 915 7,663  60 8,638 1,428 
St. Andrews Medical Park - Venice, FLFL5/30/201411,119 1,666 10,005 2 933 12,606 2,193 
Campus at Crooks & Auburn Building C - Rochester Mills, MIMI6/3/20143,831 609 3,893  130 4,632 810 
Laguna Professional Center - Elk Grove, CACA7/15/20148,887 1,811 14,598  311 16,720 2,748 
UC Davis MOB - Elk Grove, CACA7/15/20148,136 1,138 7,242  282 8,662 1,455 
Estate at Hyde Park - Tampa, FL(7)FL7/31/201420,116 1,777 20,308  660 22,745 3,950 
Autumn Ridge of Clarkston - Clarkston, MI(7)MI8/12/201419,245 655 19,967  38 20,660 3,809 
Sunnybrook of Burlington - Burlington, IA(6)IA8/26/201412,783 518 16,739  240 17,497 3,414 
Sunnybrook of Carroll - Carroll, IA(6)IA8/26/20146,144 473 11,263  36 11,772 2,086 
Prairie Hills at Cedar Rapids - Cedar Rapids, IA(7)IA8/26/20148,014 195 8,595  116 8,906 1,623 
Prairie Hills at Clinton - Clinton, IA(6)IA8/26/201410,759 890 18,882  47 19,819 3,653 
Prairie Hills at Des Moines - Des Moines, IA(6)IA8/26/20145,418 647 13,745  41 14,433 2,827 
Sunnybrook of Fairfield - Fairfield, IA(5)IA8/26/2014 340 14,115  233 14,688 2,871 
Sunnybrook of Ft. Madison - Ft. Madison, IA(5)IA8/26/2014 263 3,931  203 4,397 452 
Prairie Hills at Independence - Independence, IA(5)IA8/26/2014 473 10,600  176 11,249 1,949 
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA(5)IA8/26/2014 205 10,935  125 11,265 1,947 
Sunnybrook of Muscatine - Muscatine, IA(6)IA8/26/201411,989 302 13,840  145 14,287 2,614 
Prairie Hills at Ottumwa - Ottumwa, IA(5)IA8/26/2014 538 9,186  78 9,802 1,838 
Prairie Hills at Tipton - Tipton, IA(5)IA8/26/2014 306 10,409  33 10,748 1,812 
F-60

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Liberty Court - Dixon, IL(5)IL8/29/2014 119 1,998  37 2,154 423 
Lakeside Vista - Holland, MI(6)MI8/29/20146,128 378 12,196  420 12,994 2,324 
The Atrium - Rockford, IL(5)IL8/29/2014 164 1,746  237 2,147 213 
Arrowhead Medical Plaza I - Glendale, AZAZ9/10/20144,571  6,447  1,311 7,758 1,341 
Sunnybrook of Burlington - Land - Burlington, IAMO9/23/2014 620    620  
Community Health MOB - Harrisburg, PA(10)PA9/26/20145,424  6,170   6,170 996 
Brady MOB - Harrisburg, PA(10)PA9/26/201419,661  22,485   22,485 3,545 
Landis Memorial - Harrisburg, PA(5), (10)PA9/26/2014  32,484   32,484 5,138 
FOC II - Mechanicsburg, PA(10)PA9/26/201416,136  16,473  132 16,605 2,982 
FOC Clinical - Mechanicsburg, PA(10)PA9/26/201417,695  19,634   19,634 3,497 
FOC I - Mechanicsburg, PA(10)PA9/26/20148,204  8,923  155 9,078 1,713 
Copper Springs Senior Living - Meridian, ID(5)ID9/29/2014 498 7,130  101 7,729 1,771 
Addington Place of Brunswick - Brunswick, GA(5)GA9/30/2014 1,509 14,402  36 15,947 2,917 
Addington Place of Dublin - Dublin, GA(5)GA9/30/2014 403 9,281  115 9,799 2,036 
Allegro at Elizabethtown - Elizabethtown, KY(5)KY9/30/2014 317 7,290  232 7,839 1,719 
Addington Place of Johns Creek - Johns Creek, GA(7)GA9/30/201410,139 997 11,943  456 13,396 2,492 
Allegro at Jupiter - Jupiter, FL(6)FL9/30/201434,370 3,741 49,534  276 53,551 9,424 
Addington Place of Lee's Summit - Lee's Summit, MO(7)MO9/30/201417,187 2,734 25,008  309 28,051 4,772 
Addington Place at Mills - Roswell, GA(5)GA9/30/2014 1,000 8,611  2,205 11,816 2,139 
Addington Place of College Harbour - St Petersburg, FL(5)FL9/30/2014 3,791 8,684  1,392 13,867 2,657 
Allegro at Stuart - Stuart, FL(6)FL9/30/201449,069 5,018 60,575  625 66,218 11,807 
Allegro at Tarpon - Tarpon Springs, FL(7)FL9/30/20147,350 2,360 13,728  415 16,503 3,363 
Addington Place of Titusville - Titusville, FL(6)FL9/30/201412,423 1,379 13,976  414 15,769 3,112 
Allegro at St. Petersburg - Land - St. Petersburg, FLFL9/30/2014 3,045    3,045  
Gateway MOB - Clarksville, TN(9)TN10/3/201417,560  16,367  1,010 17,377 2,993 
Addington at Wellington Green - Wellington, FL(5) (11)FL10/17/2014 3,182 25,364  (2,131)26,415 1,002 
Dyer Building - Dyer, IN(5)IN10/17/2014 601 8,992  64 9,657 1,474 
757 Building - Munster, IN(5)IN10/17/2014 645 7,885   8,530 1,272 
761 Building - Munster, ININ10/17/20146,797 1,436 8,616  59 10,111 1,491 
759 Building - Munster, ININ10/17/20148,271 1,101 8,899   10,000 1,476 
Schererville Building - Schererville, ININ10/17/2014 1,260 935  29 2,224 278 
Meadowbrook Senior Living - Agoura Hills, CA(7)CA11/25/201419,167 8,821 48,682  1,840 59,343 8,703 
F-61

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Mount Vernon Medical Office Building - Mount Vernon, WA(9)WA11/25/201415,797  18,519  3 18,522 3,059 
Wellington at Hershey's Mill - West Chester, PA(5)PA12/3/2014 8,531 80,734  1,771 91,036 14,109 
Careplex West Medical Office Building - Hampton, VAVA12/3/20147,187 2,628 16,098  187 18,913 2,621 
Hampton River Medical Arts Building - Hampton, VA(9)PA12/3/2014  18,083  146 18,229 3,170 
Eye Specialty Group Medical Building - Memphis, TNTN12/5/20148,475 775 7,223   7,998 1,154 
Addington Place of Alpharetta - Alpharetta, GAGA12/10/2014 1,604 26,069  500 28,173 4,858 
Addington Place of Prairie Village - Prairie Village, KS(7)KS12/10/201414,812 1,782 21,869  356 24,007 4,240 
Bloom MOB - Harrisburg, PA(10)PA12/15/201415,322  15,928  175 16,103 2,605 
Medical Sciences Pavilion - Harrisburg, PA(10)PA12/15/201418,272  22,309   22,309 3,438 
Wood Glen Nursing and Rehab Center - West Chicago, IL(5)IL12/16/2014 1,896 16,107   18,003 3,647 
Pinnacle Center - Southaven, MSMS12/16/20147,085 1,378 6,547  573 8,498 1,344 
Paradise Valley Medical Plaza - Phoenix, AZAZ12/29/201413,085  25,194  1,178 26,372 4,404 
Victory Medical Center at Craig Ranch - McKinney, TXTX12/30/2014 1,596 40,475  1,340 43,411 6,488 
Rivershores Healthcare & Rehab Centre - Marseilles, IL(5)IL12/31/2014 1,276 6,868   8,144 1,653 
Morton Terrace Healthcare & Rehab Centre - Morton, IL(5)IL12/31/2014 709 5,649   6,358 1,610 
Morton Villa Healthcare & Rehab Centre - Morton, IL(5)IL12/31/2014 645 3,687  87 4,419 1,000 
The Heights Healthcare & Rehab Centre - Peoria Heights, IL(5)IL12/31/2014 214 7,952   8,166 2,007 
Colonial Healthcare & Rehab Centre - Princeton, IL(5)IL12/31/2014 173 5,871   6,044 1,656 
Capitol Healthcare & Rehab Centre - Springfield, IL(5)IL12/31/2014 603 21,699  26 22,328 4,792 
Acuity Specialty Hospital - Mesa, AZ(5)AZ1/14/2015 1,977 16,203  543 18,723 2,713 
Acuity Specialty Hospital - Sun City, AZAZ1/14/2015 2,329 15,795  279 18,403 2,602 
Addington Place of Shoal Creek - Kansas City, MO(7)MO2/2/201513,391 3,723 22,259  383 26,365 4,175 
Aurora Healthcare Center - Green Bay, WI(5)WI3/18/2015 1,130 1,678   2,808 311 
Aurora Healthcare Center - Greenville, WI(5)WI3/18/2015 259 958   1,217 188 
Aurora Healthcare Center - Kiel, WI(5)WI3/18/2015 676 2,214   2,890 367 
Aurora Healthcare Center - Plymouth, WIWI3/18/201517,038 2,891 24,224   27,115 4,029 
Aurora Healthcare Center - Waterford, WI(5)WI3/18/2015 590 6,452   7,042 1,035 
Aurora Healthcare Center - Wautoma, WI(5)WI3/18/2015 1,955 4,361   6,316 729 
Arbor View Assisted Living and Memory Care - Burlington, WI(5)WI3/31/2015 367 7,815  44 8,226 1,651 
Advanced Orthopedic Medical Center - Richmond, VAVA4/7/201515,390 1,523 19,229   20,752 2,934 
Palm Valley Medical Plaza - Goodyear, AZAZ4/7/20152,998 1,890 4,940  228 7,058 907 
Physicians Plaza of Roane County - Harriman, TNTN4/27/20156,293 1,746 7,842  32 9,620 1,276 
Adventist Health Lacey Medical Plaza - Hanford, CACA4/29/201511,526 328 13,302  44 13,674 1,925 
F-62

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Medical Center I - Peoria, AZAZ5/15/20153,085 807 1,115  513 2,435 741 
Medical Center II - Peoria, AZAZ5/15/2015 945 1,330  5,023 7,298 1,125 
Commercial Center - Peoria, AZAZ5/15/20153,254 959 1,110  635 2,704 375 
Medical Center III - Peoria, AZAZ5/15/20152,137 673 1,651  811 3,135 659 
Morrow Medical Center - Morrow, GAGA6/24/20154,334 1,155 5,674  270 7,099 909 
Belmar Medical Building -Lakewood, COCO6/29/20153,770 819 4,287  289 5,395 703 
Addington Place - Northville, MI(7)MI6/30/201513,287 440 14,975  303 15,718 2,569 
Conroe Medical Arts and Surgery Center - Conroe, TXTX7/10/201513,221 1,965 12,198  573 14,736 2,071 
Medical Center V - Peoria, AZAZ7/10/20152,786 1,089 3,200  370 4,659 562 
Legacy Medical Village - Plano, TXTX7/10/201523,662 3,755 31,097  639 35,491 4,788 
Scripps Cedar Medical Center - Vista, CACA8/6/201514,983 1,213 14,596  48 15,857 2,052 
Nuvista Institute for Healthy Living - Jupiter, FL(11)FL8/7/2015 8,586 54,051 (1,511)(7,939)53,187 1,284 
Ramsey Woods Memory Care - Cudahy, WI(5)WI10/2/2015 930 4,990  29 5,949 925 
East Coast Square West - Cedar Point, NCNC10/15/20155,254 1,535 4,803  6 6,344 696 
East Coast Square North - Morehead City, NCNC10/15/20153,933 899 4,761  6 5,666 679 
Eastside Cancer Institute - Greenville, SC(5)SC10/22/2015 1,498 6,637  32 8,167 960 
Sassafras Medical Building - Erie, PAPA10/22/20152,315 928 4,629  3 5,560 611 
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR(5)OR10/22/2015 433 2,623   3,056 366 
Courtyard Fountains - Gresham, OR(5)OR12/1/2015 2,476 50,601  881 53,958 8,037 
Presence Healing Arts Pavilion - New Lenox, IL(9)IL12/4/20155,966  6,768  76 6,844 991 
Mainland Medical Arts Pavilion - Texas City, TXTX12/4/20156,174 320 7,923  305 8,548 1,266 
Renaissance on Peachtree - Atlanta, GA(6)GA12/15/201550,821 4,535 68,895  1,751 75,181 10,102 
Fox Ridge Senior Living at Bryant - Bryant, ARAR12/29/20157,133 1,687 12,936  544 15,167 2,811 
Fox Ridge Senior Living at Chenal - Little Rock, ARAR12/29/201516,390 6,896 20,579  163 27,638 3,732 
Fox Ridge North Little Rock - North Little Rock, AR(9)AR12/29/201510,170  19,265  261 19,526 3,199 
Autumn Leaves of Cy-Fair - Houston, TXTX12/31/2015 1,225 11,335  59 12,619 1,880 
Autumn Leaves of Meyerland - Houston, TXTX12/31/2015 2,033 13,411  21 15,465 2,123 
Autumn Leaves of Clear Lake, Houston, TXTX12/31/2015 1,599 13,194  18 14,811 2,181 
Autumn Leaves of The Woodlands - The Woodlands, TXTX12/31/2015 2,413 9,141  20 11,574 1,619 
High Desert Medical Group Medical Office Building - Lancaster, CACA4/7/20177,480 1,459 9,300   10,759 1,141 
Northside Hospital - Canton, GAGA7/13/20178,014 3,408 8,191  40 11,639 784 
West Michigan Surgery Center - Big Rapids, MI(5)MI8/18/2017 258 5,677   5,935 502 
F-63

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Camellia Walk Assisted Living and Memory Care - Evans, GA(6)GA9/28/201712,563 1,854 17,372  822 20,048 2,001 
Cedarhurst of Collinsville - Collinsville, IL(5), (8)IL12/22/2017 1,228 8,652  113 9,993 819 
Arcadian Cove Assisted Living - Richmond, KY(5), (8)KY12/22/2017 481 3,923  63 4,467 420 
Beaumont Medical Center - Warren, MI(5), (8)MI12/22/2017 1,078 9,525  19 10,622 796 
DaVita Dialysis - Hudson, FL(5), (8)FL12/22/2017 226 1,979   2,205 160 
DaVita Bay Breeze Dialysis Center - Largo, FL(5), (8)FL12/22/2017 399 896   1,295 87 
Greenfield Medical Plaza - Gilbert, AZ(5), (8)AZ12/22/2017 1,476 4,144  48 5,668 357 
RAI Care Center - Clearwater, FL(5), (8)FL12/22/2017 624 3,156   3,780 252 
Illinois CancerCare - Galesburg, IL(5), (8)IL12/22/2017 290 2,457   2,747 221 
UnityPoint Clinic - Muscatine, IA(5), (8)IA12/22/2017 570 4,541  2 5,113 389 
Lee Memorial Health System Outpatient Center - Ft. Myers(5), (8)FL12/22/2017 439 4,374  363 5,176 369 
Decatur Medical Office Building - Decatur, GA(5), (8), (9)GA12/22/2017 695 3,273   3,968 295 
Madison Medical Plaza - Joliet, IL(5), (8), (9)IL12/22/2017  16,855  37 16,892 1,267 
Woodlake Office Center - Woodbury, MN(8)MN12/22/20178,638 1,017 10,688  1,297 13,002 873 
Rockwall Medical Plaza - Rockwall, TX(5), (8)MN12/22/2017 1,097 4,582  182 5,861 403 
MetroHealth Buckeye Health Center - Cleveland, OH(5), (8)OH12/22/2017 389 4,367  5 4,761 347 
UnityPoint Clinic - Moline, IL(5), (8)IL12/22/2017 396 2,880  1 3,277 246 
VA Outpatient Clinic - Galesberg, IL(5), (8)IL12/22/2017 359 1,852   2,211 181 
Philip Professional Center - Lawrenceville, GA(8)GA12/22/20175,780 1,285 6,714  169 8,168 577 
Texas Children’s Hospital - Houston, TX
(5)TX3/5/2018 1,368 4,428  116 5,912 484 
Florida Medical Heartcare - Tampa, FL
(5)FL3/29/2018 586 1,902   2,488 215 
Florida Medical Somerset - Tampa, FL
(5)FL3/29/2018 61 1,366   1,427 134 
Florida Medical Tampa Palms - Tampa, FL
(5)FL3/29/2018 141 1,402   1,543 143 
Florida Medical Wesley Chapel - Tampa, FL
(5)FL3/29/2018 485 1,987   2,472 228 
Aurora Health Center - Milwaukee, WI
(5)WI4/17/2018 1,014 4,041   5,055 528 
Vascular Surgery Associates - Tallahassee, FL
(5)FL5/11/2018 902 5,383   6,285 554 
Glendale MOB - Farmington Hills, MI
(5)MI8/28/2018 504 12,332   12,836 904 
Crittenton Washington MOB - Washington Township, MI
(5)MI9/12/2018 640 4,090  43 4,773 351 
Crittenton Sterling Heights MOB - Sterling Heights, MI
(5)MI9/12/2018 1,398 2,695  181 4,274 280 
Advocate Aurora MOB - Elkhorn, WI
(5)WI9/24/2018 181 9,452   9,633 762 
Pulmonary & Critical Care Med - Lemoyne, PA
PA11/13/20184,271 621 3,805   4,426 442 
Dignity Emerus Blue Diamond - Las Vegas, NV
NV11/15/201813,966 2,182 16,594   18,776 969 
F-64

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Dignity Emerus Craig Rd - North Las Vegas, NV
NV11/15/201818,780 3,807 22,803   26,610 1,344 
Greenfield MOB - Greenfield, WI
WI1/17/20197,526 1,552 8,333  225 10,110 757 
Milwaukee MOB - South Milwaukee, WI
WI1/17/20194,136 410 5,041   5,451 278 
St. Francis WI MOB - St. Francis, WI
WI1/17/20199,085 865 11,355  159 12,379 733 
Lancaster Medical Arts MOB - Lancaster, PA
(5)PA6/20/2019 85 4,417   4,502 346 
Women’s Healthcare Group MOB - York, PA
(5)PA6/21/2019 624 2,161   2,785 281 
Pioneer Spine Sports - Northampton, MA
(5)MA7/22/2019 435 1,858   2,293 75 
Pioneer Spine Sport - Springfield, MA
(5)MA7/22/2019 333 2,530   2,863 107 
Pioneer Spine Sports - West Springfield, MA
(5)MA7/22/2019 374 4,295   4,669 176 
Felicita Vida - Escondido, CA
(5)CA9/3/2019 1,677 28,953  17 30,647 1,098 
Cedarhurst of Edwardsville - Edwardsville, ILIL1/10/2020 321 9,032   9,353 262 
UMPC Sir Thomas Court - Harrisburg, PA(5)PA1/17/2020 745 6,272   7,017 157 
UMPC Fisher Road - Mechanicsburg, PA(5)PA1/17/2020 747 3,844   4,591 105 
Swedish American MOB - Roscoe, IL(5)IL1/22/2020 599 5,862   6,461 185 
Cedarhurst of Sparta - Sparta, IL(5)IL1/31/2020 381 13,807  22 14,210 405 
UMPC Chambers Hill - Harrisburg, PA(5)PA2/3/2020 498 4,238   4,736 103 
Cedarhurst of Shiloh - Shiloh, ILIL3/13/202013,684 376 28,299  14 28,689 612 
Bayshore Naples Memory Care - Naples, FL(5)FL3/20/2020 3,231 17,112   20,343 356 
Circleville MOB - Circleville, OH(5)OH12/7/2020 765 4,011   4,776 9 
Total
$905,536 $214,160 $2,098,361 $(1,509)$34,696 $2,345,708 $328,095 
______________
Note - The above schedule excludes properties that are reflected as part of Assets Held for Sale at December 31, 2020.
F-65

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

(1)Acquired intangible lease assets allocated to individual properties in the amount of $276.0 million are not reflected in the table above.
(2)The tax basis of aggregate land, buildings and improvements as of December 31, 2020 is $2.3 billion.
(3)The accumulated depreciation column excludes $184.7 million of accumulated amortization associated with acquired intangible lease assets.
(4)Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.
(5)These unencumbered properties were part of the borrowing base of the Credit Facility, which had $323.7 million of outstanding borrowings as of December 31, 2020. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 Credit Facilities, Net for additional details).
(6)These properties collateralize the Capital One Facility, which had $212.5 million of outstanding borrowings as of December 31, 2020.
(7)These properties collateralize the KeyBank Facility, which had $142.7 million of outstanding borrowings as of December 31, 2020.
(8)These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017. See Note 9 — Related Party Transactions and Arrangements for additional information.
(9)Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See Note 16 — Commitments and Contingencies for additional information.
(10)The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See Note 16 — Commitments and Contingencies for additional information.
(11)The property has been impaired as of December 31, 2020. See Note 3 — Real Estate Investments, Net “Assets Held for Use and Related Impairments” for additional information.

F-66

Healthcare Trust, Inc. and Subsidiaries

Real Estate and Accumulated Depreciation
Schedule III
December 31, 2020
(In thousands)

A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2020, 2019 and 2018:
December 31,
(In thousands)202020192018
Real estate investments, at cost (1):
 
Balance at beginning of year$2,211,451 $2,296,627 $2,229,374 
Additions-Acquisitions98,364 80,980 121,244 
Disposals, impairments and reclasses (2)
35,893 (166,156)(53,991)
Balance at end of the year$2,345,708 $2,211,451 $2,296,627 
  
Accumulated depreciation (1):
 
Balance at beginning of year$260,399 $226,167 $170,271 
Depreciation expense63,393 64,731 62,595 
Disposals, impairments and reclasses (2)
4,303 (30,499)(6,699)
Balance at end of the year$328,095 $260,399 $226,167 
__________
(1)Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.
(2)Includes amounts relating to dispositions and impairment charges on assets held for sale for the years ended December 31, 2020, 2019 and 2018. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see Note 3 — Real Estate Investments.

See accompanying report of independent registered public accounting firm.
F-67
EX-4.5 2 ex45descriptionofsecurities.htm EX-4.5 DESCRIPTION OF SECURITIES Document

EXHIBIT 4.5

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following is a description of securities of Healthcare Trust, Inc. registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of December 31, 2020 and certain provisions of the Maryland General Corporation Law (the “MGCL”) and our charter and our bylaws. The description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to Maryland law and to our charter (including any applicable articles supplementary classifying a class or series of preferred stock) and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and are incorporated by reference herein.

As used herein, the terms “Company,” “we,” “our” and “us” refer to Healthcare Trust, Inc., a Maryland corporation. Capitalized terms used but not defined herein shall have the meaning ascribed to such terms under our charter (including any applicable articles supplementary classifying a class or series of preferred stock).

General

Our charter authorizes us to issue up to 350,000,000 shares of stock, consisting of 300,000,000 shares of common stock, par value $0.01 per share, and 50,000,000 shares of preferred stock, par value $0.01 per share. As of December 31, 2020, we had the following stock issued and outstanding: (i) 93,775,746 shares of common stock; and (ii) 1,610,000 shares of our 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”).

Our board of directors, with the approval of a majority of the entire board of directors and without any action taken by our stockholders, may amend our charter from time to time to increase or decrease the aggregate number of our authorized shares of stock or the number of shares of stock of any class or series that we have authority to issue. Under Maryland law, stockholders are not generally liable for our debts or obligations solely as a result of their status as stockholders.

The transfer agent and registrar for our common stock and Series A Preferred Stock is Computershare Trust Company, N.A., which also serves as the rights agent for the rights to purchase from the Company one share of common stock that are attached to all shares of our common stock (the “Rights”).

Our Series A Preferred Stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “HTIA.” Our common stock and the Rights are registered under Section 12(g) of the Exchange Act but are not listed for trading on any national securities exchange.

Common Stock

Subject to the preferential rights, if any, of holders of any other class or series of our stock and to the provisions of our charter relating to the restrictions on ownership and transfer of our stock, the holders of our common stock:

have the right to receive ratably any distributions from funds legally available therefor, when, as and if authorized by our board of directors and declared by us; and

are entitled to share ratably in all of our assets available for distribution to holders of our common stock upon liquidation, dissolution or winding up of our affairs.

Subject to the provisions of our charter relating to the restrictions on ownership and transfer of our stock and except as may otherwise be provided in the charter, holders of our common stock are entitled to one vote per share on all matters on which holders of our common stock are entitled to vote at all meetings of our stockholders. The holders of our common stock do not have cumulative voting rights.




1


Preferred Stock

General

Under our charter, our board of directors, without stockholder approval, is authorized to cause us to issue shares of preferred stock in one or more classes or series, to establish the number of shares in each class or series and to fix the terms preferences, conversions or other rights, voting powers, restrictions, limitations as to dividends or other distributions, qualifications and terms and conditions of redemption for each class or series. Our board of directors could authorize the issuance of additional shares of preferred stock with terms and conditions that could have the effect of discouraging a takeover or other transaction that holders of common stock might believe to be in their best interests or in which holders of some, or a majority, of the shares of common stock might receive a premium for their shares over the then market price of such shares of common stock.

Some of the rights, preferences, privileges and restrictions of the shares of preferred stock of a class or series may include the following:

distribution rights;

conversion rights;

voting rights;

redemption rights and terms of redemptions; and

liquidation preferences.

Series A Preferred Stock

As of December 31, 2020, 2,210,000 shares of preferred stock were classified and designated as Series A Preferred Stock pursuant to our charter.

Ranking

The Series A Preferred Stock ranks, with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding-up:

senior to our common stock and to all other equity securities, the terms of which expressly provide that such securities rank junior to the Series A Preferred Stock;

on parity with all equity securities, the terms of which expressly provide that such securities rank on parity with the Series A Preferred Stock; and

junior to any class or series of equity securities, the terms of which expressly provide that such securities rank senior to the Series A Preferred Stock.

The authorization or issuance of equity securities ranking senior to the Series A Preferred Stock requires the affirmative vote of the holders of at least two-thirds of the outstanding shares of Series A Preferred Stock and of any other similarly-affected classes and series of preferred stock ranking on parity with the Series A Preferred Stock and upon which like voting rights have been conferred and are exercisable. Any convertible debt securities that we may issue will not be considered to be “equity securities” for these purposes prior to the time of conversion. The Series A Preferred Stock ranks junior to all our existing and future indebtedness. The terms of the Series A Preferred Stock do not limit our ability to (i) incur indebtedness or (ii) issue additional equity securities that rank junior to or on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up.

2



Dividends

Holders of Series A Preferred Stock are entitled to receive, when, as and if authorized by our board of directors and declared by us, out of funds legally available for the payment of dividends, cumulative cash dividends in the amount of  $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. Dividends are payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day. A dividend period is the respective quarterly period commencing on and including the 1st day of January, April, July and October of each year and ending on and including the day preceding the first day of the next succeeding dividend period to all holders of record on the applicable record date, when and as authorized by our board of directors and declared by us. Holders of record of all shares of Series A Preferred Stock issued and outstanding at the close of business on the record date fixed by our board of directors for any dividend will be entitled to receive the full dividend paid on the applicable dividend payment date even if such shares were not issued and outstanding for the full dividend period.

Any dividend, including any dividend payable on the Series A Preferred Stock for any partial dividend period, is computed on the basis of a 360-day year consisting of twelve 30-day months. Dividends are payable to holders of record of Series A Preferred Stock as they appear in the transfer agent’s records at the close of business on the applicable record date, which will be the date that our board of directors sets as the record date for the payment of a dividend that is not more than 30 nor fewer than 10 days prior to the applicable dividend payment date.

Our board of directors will not authorize, and we will not pay or declare and set apart for payment, any dividend on the Series A Preferred Stock at any time that:

the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, prohibit the authorization, payment or setting apart for payment;

the terms and conditions of any of our agreements, including our credit facility or any other agreement relating to our indebtedness, provide that the authorization, payment or setting apart for payment would constitute a breach of, or a default under, the agreement; or

the law restricts or prohibits the authorization, payment or setting apart for payment.

Notwithstanding the foregoing, dividends on the Series A Preferred Stock accrue whether or not the dividends are authorized by our board of directors and declared by us.

Accrued and unpaid dividends on the Series A Preferred Stock do not bear interest.

We will not pay or declare and set apart for payment any dividends (other than a dividend paid in common stock or other stock ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up) or declare and make any distribution of cash or other property on common stock or other stock that ranks junior to or on parity with the Series A Preferred Stock or redeem or otherwise acquire common stock or other stock that ranks junior to or on parity with the Series A Preferred Stock (except (i) by conversion into or exchange for common stock or other stock ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) for the redemption of shares of our stock pursuant to the provisions of our charter relating to the restrictions upon ownership and transfer of our stock and (iii) for a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up), unless we also have either paid or declared and set apart for payment full cumulative dividends on the Series A Preferred Stock for all past dividend periods.

Notwithstanding the foregoing, if we do not either pay or declare and set apart for payment full cumulative dividends on the Series A Preferred Stock and all stock that ranks on parity with the Series A Preferred Stock with respect to dividends, the amount which we have declared will be allocated pro rata to the holders of Series A
3



Preferred Stock and to each equally ranked class or series of stock, so that the amount declared for each share of Series A Preferred Stock and for each share of each equally ranked class or series of stock is proportionate to the accrued and unpaid dividends on those shares. Any dividend payment made on the Series A Preferred Stock will first be credited against the earliest accrued and unpaid dividend.

If, for any taxable year, we elect to designate as “capital gain dividends” (as defined in Section 857 of the Internal Revenue Code of 1986, as amended (the “Code”)) a portion (the “Capital Gains Amount”) of the dividends not in excess of our earnings and profits that are paid or made available for the year to the holders of all classes or series of shares (the “Total Dividends”), then the portion of the Capital Gains Amount that will be allocable to the holders of Series A Preferred Stock will be in the same proportion that the Total Dividends paid or made available to the holders of Series A Preferred Stock for the taxable year bears to the Total Dividends for the taxable year made with respect to all classes or series of stock outstanding.

Holders of shares of Series A Preferred Stock are not entitled to any dividend, whether payable in cash, property or shares of capital stock, in excess of full cumulative dividends on the Series A Preferred Stock as described above.

Liquidation Preference

Upon any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of  $25.00 per share, plus an amount equal to any accrued and unpaid dividends (whether or not authorized or declared) to, but not including, the date of payment, after payment of or provision for our debts and liabilities and any other class or series of our capital stock ranking senior to the Series A Preferred Stock with respect to liquidation rights before any distribution or payment may be made to holders of common stock or any other class or series of our equity stock ranking junior to the Series A Preferred Stock with respect to liquidation rights. If, upon our voluntary or involuntary liquidation, dissolution or winding up, our available assets are insufficient to pay the full amount of the liquidating distributions on all outstanding shares of Series A Preferred Stock and the corresponding amounts payable on all shares of each other class or series of stock ranking on parity with the Series A Preferred Stock with respect to liquidation rights, then the holders of Series A Preferred Stock and any other class or series of stock ranking on parity with the Series A Preferred Stock with respect to liquidation rights will share ratably in any distribution of assets in proportion to the full liquidating distributions to which they would otherwise be respectively entitled. Holders of Series A Preferred Stock are entitled to written notice of any voluntary or involuntary liquidation, dissolution or winding up at least 20 days before the payment date of the liquidating distribution. After the holders of Series A Preferred Stock have received the full amount of the liquidating distributions to which they are entitled, they will have no right or claim to any of our remaining assets.

In determining whether any distribution (other than upon voluntary or involuntary dissolution) by dividend, redemption or other acquisition of shares of stock of the Company or otherwise is permitted under the MGCL, amounts that would be needed, if the Company were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of the holders of Series A Preferred Stock will not be added to the Company’s total liabilities.

Our consolidation, conversion or merger with or into any other person or entity or the sale, lease, transfer or conveyance of all or substantially all of our property or business, whether in connection with a Change of Control (as defined below) or otherwise, will not be deemed to constitute our liquidation, dissolution or winding up.

Optional Redemption

The Series A Preferred Stock is not redeemable prior to December 11, 2024, except in the circumstances described in this section, in the section below titled “— Special Optional Redemption,” or pursuant to certain provisions of our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws — Restrictions on Transfer and Ownership of Stock” below.

4



Notwithstanding any other provision relating to redemption or repurchase of the Series A Preferred Stock, we may redeem any or all of the Series A Preferred Stock at any time, whether before or after December 11, 2024 at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), pursuant to the restrictions on ownership and transfer of our stock set forth in our charter or if our board of directors otherwise determines that redemption is necessary for us to preserve our status as a real estate investment trust for federal income tax purposes (“REIT”).

On and after December 11, 2024, the Series A Preferred Stock may be redeemed at our option, in whole or in part, at any time or from time to time, at a redemption price of  $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend will be included in the redemption price), without interest, upon the giving of notice, as provided below.

If less than all of the outstanding shares of Series A Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata (as nearly as may be practicable without creating fractional shares) or by lot. If the redemption is to be by lot, and if as a result of the redemption any holder of Series A Preferred Stock would own, or be deemed by virtue of certain attribution provisions of the Code to own, more than 9.8% in value of the aggregate of our outstanding shares of stock (which includes the Series A Preferred Stock) or 9.8% in value or in number of shares (whichever is more restrictive) of any class or series of our outstanding shares of stock or violate any of the other restrictions on ownership and transfer of our stock set forth in our charter, then, except in certain instances, we will redeem the requisite number of shares of Series A Preferred Stock of that holder so that the holder will not own or be deemed by virtue of certain attribution provisions of the Code to own, subsequent to the redemption, more than 9.8% in value of the aggregate of our outstanding shares of stock or 9.8% in value or in number of shares (whichever is more restrictive) of any class or series of our outstanding shares of stock or violate any of the other restrictions on ownership and transfer set forth in our charter.

We will mail to you, if you are a record holder of Series A Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to your address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing will not affect the validity of the redemption of any Series A Preferred Stock except as to shares held by any holder to whom notice was defective or not given. Each notice will state the following:

the redemption date;

the redemption price;

the total number of shares of Series A Preferred Stock to be redeemed (and, if less than all the shares held by any holder are to be redeemed, the number of shares to be redeemed from the holder);

the place or places where the shares of Series A Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with redemption; and

that dividends on the Series A Preferred Stock will cease to accrue on the redemption date.

We are not required to provide such notice in the event we redeem Series A Preferred Stock in order to maintain our status as a REIT.

Unless full cumulative dividends on all shares of Series A Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, no shares of Series A Preferred Stock may be redeemed unless all outstanding shares of Series A Preferred Stock are simultaneously redeemed. In addition, unless full cumulative dividends on all shares of Series A Preferred Stock have been or contemporaneously are declared and paid or declared and a sum sufficient for the payment thereof set apart for payment for all past dividend periods, we will not purchase or otherwise acquire
5



directly or indirectly any Series A Preferred Stock (except (i) by exchange for our equity securities ranking junior to the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up, (ii) pursuant to the provisions of our charter relating to restrictions on ownership and transfer of our stock and (iii) pursuant to a purchase or exchange offer made on the same terms to the holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up). So long as no dividends on Series A Preferred Stock for any past dividend period are in arrears, we are entitled at any time and from time to time to repurchase Series A Preferred Stock in open-market transactions duly authorized by our board of directors and effected in compliance with applicable laws and these requirements will not prevent our purchase or acquisition of Series A Preferred Stock pursuant to a purchase or exchange offer made on the same terms to holders of all outstanding shares of Series A Preferred Stock and any other stock that ranks on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up or our redemption of Series A Preferred Stock pursuant to the provisions of our charter relating to the restrictions on ownership and transfer of our stock.

Special Optional Redemption

During any period of time (whether before or after December 11, 2024) that the Series A Preferred Stock is not listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC (a “Delisting Event”), we have the option to redeem the outstanding shares of Series A Preferred Stock, in whole or in part, after the occurrence of the Delisting Event, for a redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price), upon the giving of notice, as provided below.

In addition to the foregoing, upon the occurrence of a Delisting Event, the dividend rate specified shall be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate of 9.375% of the
$25.00 per share stated liquidation preference per annum (equivalent to $2.34375 per annum per share) from and after the date of the Delisting Event. Following the cure of a Delisting Event, the dividend rate shall revert to the rate of 7.375% of the $25.00 per share stated liquidation preference per annum.

In addition, upon the occurrence of a Change of Control, we may, at our option, redeem the Series A Preferred Stock, in whole or in part, within 120 days after the first date on which the Change of Control occurred, by paying $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date (unless the redemption date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in the redemption price). If, prior to the Conversion Date (as defined below), we provide notice of redemption with respect to the Series A Preferred Stock (whether pursuant to our optional redemption right or our special optional redemption rights), you will not have the conversion right described below under “— Change of Control Conversion Right.”

We will mail to you, if you are the record holder of Series A Preferred Stock, a notice of redemption no less than 30 days nor more than 60 days prior to the redemption date. We will send the notice to your address, as shown on our share transfer books. A failure to give notice of redemption or any defect in the notice or in its mailing with not affect the validity of the redemption of any Series A Preferred Stock except as to the holder to whom notice was defective or not given. Each notice will state the following:

the redemption date;

the redemption price;

the total number of shares of Series A Preferred Stock to be redeemed;

6



the place or places where the shares of Series A Preferred Stock are to be surrendered for payment, together with the certificates, if any, representing the shares (duly endorsed for transfer) and any other documents we require in connection with the redemption;

that the Series A Preferred Stock is being redeemed pursuant to our special optional redemption right in connection with the occurrence of a Change of Control or a Delisting Event, as applicable, and a brief description of the transaction or transactions constituting the Change of Control or Delisting Event, as applicable;

that holders of Series A Preferred Stock to which the notice relates will not be able to tender the Series A Preferred Stock for conversion in connection with a Change of Control during a continuous Delisting Event, and each share of Series A Preferred Stock tendered for conversion that is selected, prior to the Conversion Date, for redemption will be redeemed on the related redemption date instead of converted on the Conversion Date; and

that dividends on the Series A Preferred Stock to be redeemed will cease to accrue on the redemption date.

A “Change of Control” occurs when, after the original issuance of the Series A Preferred Stock, the following has occurred and is continuing:

the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger, conversion or other acquisition transaction or series of purchases, mergers, conversions or other acquisition transactions, of shares of our stock entitling that person to exercise more than 50% of the total voting power of all outstanding shares of our stock entitled to vote generally in the election of directors (except that the person will be deemed to have beneficial ownership of all securities that the person has the right to acquire, whether the right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and

following the closing of any transaction referred to in the bullet point above, neither we nor the acquiring or surviving entity, including any parent of the Company or the acquiring or surviving entity, has a class of common equity securities listed on the Nasdaq Stock Market, the NYSE or the NYSE American LLC, or listed or quoted on an exchange or quotation system that is a successor to the Nasdaq Stock Market, the NYSE or the NYSE American LLC.

Additional Provisions Relating to Optional Redemption and Special Optional Redemption

If  (i) we have given a notice of redemption, (ii) we have set apart sufficient funds for the redemption of the shares of Series A Preferred Stock called for redemption and (iii) irrevocable instructions have been given to pay the redemption price and an amount equal to all accrued and unpaid dividends to, but not including, the redemption date, then from and after the redemption date, those shares of Series A Preferred Stock so called for redemption will no longer be outstanding, no further dividends will accrue and all other rights of the holders of those shares of Series A Preferred Stock will terminate, except the right to receive the redemption price, without interest. The holders of those shares of Series A Preferred Stock will retain their right to receive the redemption price for their shares and any accrued and unpaid dividends payable upon redemption, without interest.

The holders of Series A Preferred Stock at the close of business on a dividend record date will be entitled to receive the dividend payable with respect to the Series A Preferred Stock on the corresponding dividend payment date notwithstanding the redemption of the Series A Preferred Stock between such record date and the corresponding dividend payment date. There is no restriction on the redemption of shares of Series A Preferred Stock by us while there is any arrearage in the payment of dividends.

7



All shares of Series A Preferred Stock that we redeem or reacquire in any manner will return to the status of authorized but unissued shares of preferred stock, without further designation as to series or class and may thereafter be classified, reclassified or issued as any series or class of preferred stock.

Change of Control Conversion Right

Upon the occurrence of a Change of Control during a continuing Delisting Event, each holder of Series A Preferred Stock has the right, unless, prior to the Conversion Date, we have provided or provide notice of our election to redeem the shares of Series A Preferred Stock as described under “— Optional Redemption” or “— Special Optional Redemption,” to convert some of or all the shares of Series A Preferred Stock held by the holder (the “Change of Control Conversion Right”) on the Conversion Date into a number of shares of common stock per share of Series A Preferred Stock (the “Common Stock Conversion Consideration”), which is equal to the lesser of:

the quotient obtained by dividing (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared) on the Series A Preferred Stock to, but not including, the Conversion Date (unless the Conversion Date is after a dividend record date and prior to the corresponding dividend payment date, in which case no additional amount for the accrued and unpaid dividend payable on the payment date will be included in this sum), by (ii) the Common Stock Price; and

2.8571 (the “Share Cap”).

The Share Cap is subject to pro rata adjustments for any stock splits (including those effected pursuant to a common stock dividend), subdivisions or combinations (in each case, a “Stock Split”) with respect to shares of our common stock as follows: the adjusted Share Cap as the result of a Stock Split will be the number of shares of our common stock that is equivalent to the product of  (i) the Share Cap in effect immediately prior to the Stock Split, multiplied by (ii) a fraction, the numerator of which is the number of shares of our common stock outstanding after giving effect to the Stock Split and the denominator of which is the number of shares of our common stock outstanding immediately prior to the Stock Split.

If a Change of Control occurs during a continuing Delisting Event, pursuant to or in connection with which shares of our common stock will be converted into cash, securities or other property or assets (including any combination thereof) (the “Alternative Form Consideration”), a holder of shares of Series A Preferred Stock will receive upon conversion of the shares of Series A Preferred Stock the kind and amount of Alternative Form Consideration which the holder would have owned or been entitled to receive had the holder held a number of shares of our common stock equal to the Common Stock Conversion Consideration immediately prior to the effective time of the Change of Control (the “Alternative Conversion Consideration,” and the Common Stock Conversion Consideration or the Alternative Conversion Consideration, as may be applicable to a Change of Control during a continuing Delisting Event, is referred to as the “Conversion Consideration”).

If the holders of shares of our common stock have the opportunity to elect the form of consideration to be received in connection with the Change of Control during a continuing Delisting Event, the Conversion Consideration that holders of Series A Preferred Stock will receive will be the form of consideration elected by the holders of a plurality of the shares of common stock held by stockholders who participate in the election and will be subject to any limitations to which all holders of shares of common stock are subject, including, without limitation, pro rata reductions applicable to any portion of the consideration payable in connection with the Change of Control during a continuing Delisting Event.

We will not issue fractional shares of common stock upon the conversion of the Series A Preferred Stock.
Instead, we will pay the cash value of any fractional shares based on the Common Stock Price.

Within 15 days following the occurrence of a Change of Control during a continuing Delisting Event, unless we have provided notice of our election to redeem the shares of Series A Preferred Stock as described under “— Optional Redemption” or “— Special Optional Redemption,” we will provide to holders of record of outstanding shares of Series A Preferred Stock a notice of occurrence of both the Change of Control and Delisting
8



Event that describes the resulting Change of Control Conversion Right. A failure to give notice of conversion or any defect in the notice or in its mailing will not affect the validity of the proceedings for the conversion of any Series A Preferred Stock except as to the holder to whom this notice was defective or not given. This notice will state the following:

the events constituting the Change of Control during a continuing Delisting Event;

the date of the Change of Control during a continuing Delisting Event;

the last date on which the holders of shares of Series A Preferred Stock may exercise their Change of Control Conversion Right;

the method and period for calculating the Common Stock Price;

the “Conversion Date,” which will be a business day fixed by our board of directors that is not fewer than 20 and not more than 35 days following the date of the notice;

that if, prior to the Conversion Date we provide notice of our election to redeem all or any portion of the shares of Series A Preferred Stock, you will not be able to convert the shares of Series A Preferred Stock so called for redemption and the shares of Series A Preferred Stock will be redeemed on the related redemption date, even if they have already been tendered for conversion pursuant to the Change of Control Conversion Right;

if applicable, the type and amount of Alternative Conversion Consideration entitled to be received per share of Series A Preferred Stock;

the name and address of the paying agent and the conversion agent; and

the procedures that the holders of shares of Series A Preferred Stock must follow to exercise the Change of Control Conversion Right.

We will issue a press release for publication on the Dow Jones & Company, Inc., Business Wire, PR Newswire or Bloomberg Business News (or, if these organizations are not in existence at the time of issuance of the press release, another news or press organization as is reasonably calculated to broadly disseminate the relevant information to the public) containing the information stated in the notice, and post the notice on our website, in any event prior to the opening of business on the first business day following any date on which we provide the notice described above to the holders of record of Series A Preferred Stock.

To exercise the Change of Control Conversion Right, a holder of record of Series A Preferred Stock will be required to deliver, on or before the close of business on the Conversion Date, the certificates, if any, representing any certificated shares of Series A Preferred Stock to be converted, duly endorsed for transfer, together with a completed written conversion notice and any other documents we reasonably require in connection with the conversion, to our conversion agent. The conversion notice must state:

the Conversion Date; and

the number of shares of Series A Preferred Stock to be converted.

The “Common Stock Price” for any Change of Control will be (i) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is solely cash, the amount of cash consideration per share of common stock, and (ii) if the consideration to be received in the Change of Control during a continuing Delisting Event by holders of shares of our common stock is other than solely cash,
(x)the Non-traded Common Stock Price, if the common stock is not listed on a national exchange on the effective date of any Change in Control or (y) the Traded Common Stock Price, if the common stock is listed on a national securities exchange on the effective date of any Change in Control.
9



The “Non-traded Common Stock Price” is the currently applicable repurchase price for shares of common stock pursuant to our SRP immediately prior to the effective date of the Change of Control. The “Traded Common Stock Price” is the average of the closing price per share of our common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Change of Control.

Holders of Series A Preferred Stock may withdraw any notice of exercise of a Change of Control Conversion Right (in whole or in part) by a written notice of withdrawal delivered to our conversion agent prior to the close of business on the business day prior to the Conversion Date. The notice of withdrawal must state:

the number of withdrawn shares of Series A Preferred Stock;

if certificated shares of Series A Preferred Stock have been tendered for conversion and withdrawn, the certificate numbers of the withdrawn certificated shares of Series A Preferred Stock; and

the number of shares of Series A Preferred Stock, if any, which remain subject to the conversion notice.

Notwithstanding the foregoing, if the Series A Preferred Stock is held in global form, the conversion notice and/or the notice of withdrawal, as applicable, must comply with applicable procedures of DTC.

Shares of Series A Preferred Stock as to which the Change of Control Conversion Right have been properly exercised and for which the conversion notice has not been properly withdrawn will be converted into the applicable Conversion Consideration on the applicable Conversion Date, unless prior thereto we provide notice of our election to redeem those shares of Series A Preferred Stock, whether pursuant to our optional redemption right or our special optional redemption right. If we elect to redeem shares of Series A Preferred Stock that would otherwise be converted into the applicable Conversion Consideration on a Conversion Date, the shares of Series A Preferred Stock will not be so converted and the holders of the shares will be entitled to receive on the applicable redemption date the redemption price for the shares.

We will deliver amounts owing upon conversion no later than the third business day following the Conversion Date.

In connection with the exercise of any Change of Control Conversion Right, we will comply with all U.S. federal and state securities laws and stock exchange rules in connection with any conversion of shares of Series A Preferred Stock into shares of common stock. Notwithstanding any other provision of the Series A Preferred Stock, no holder of Series A Preferred Stock will be entitled to convert shares of Series A Preferred Stock for shares of our common stock to the extent that receipt of the shares of common stock would cause the holder (or any other person) to violate the restrictions on ownership and transfer of our stock contained in our charter. See “Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws—Restrictions on Transfer and Ownership of Stock” below.

These Change of Control conversion and redemption features may make it more difficult for or discourage a party from pursuing a takeover or other transaction that holders of common stock might believe to be in their best interests or in which holders of some, or a majority, of the shares of common stock might receive a premium for their shares over the then market price of such shares of common stock.

Except as provided above in connection with the occurrence of a Change of Control during a Delisting Event, the Series A Preferred Stock is not convertible into or exchangeable for any other property or securities.

Voting Rights

Except as described below, holders of Series A Preferred Stock generally have no voting rights. On any matter in which the Series A Preferred Stock may vote (as expressly provided in our charter), each share of Series A Preferred Stock entitles the holder thereof to cast one vote, except that, when voting together as a single class with

10



shares of any other class or series of voting preferred stock, shares of different classes or series will vote in proportion to the liquidation preference of the shares.

Whenever dividends on the Series A Preferred Stock are in arrears, whether or not authorized or declared, for six or more quarterly periods, whether or not these quarterly periods are consecutive, holders of Series A Preferred Stock and any other class or series of preferred stock ranking on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up and upon which like voting rights have been conferred and are exercisable, which we refer to as “voting preferred stock,” and with which the holders of Series A Preferred Stock are entitled to vote together as a single class, will have the exclusive power, voting together as a single class, to elect, at any special meeting called by our secretary at the written request of holders of record of at least 10% of the outstanding shares of Series A Preferred Stock and any other class or series of voting preferred stock (unless the request is received more than 45 days and less than 90 days before our next annual meeting of stockholders at which the vote would occur) and at each subsequent annual meeting of stockholders, two additional directors to serve on our board of directors. The right of holders of Series A Preferred Stock to vote in the election of directors will terminate when all dividends accrued and unpaid on the outstanding shares of Series A Preferred Stock for all past dividend periods have been fully paid. Unless the number of our directors has previously been increased pursuant to the terms of any other class or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote together as a single class in the election of directors, the number of our directors will automatically increase by two at the time as holders of Series A Preferred Stock become entitled to vote in the election of two additional directors. The term of office of these directors will terminate, and the number of our directors will automatically decrease by two, when all dividends accrued and unpaid for all past dividend periods on the Series A Preferred Stock have been fully paid, unless shares of voting preferred stock remain outstanding and entitled to vote in the election of directors. If the right of holders of Series A Preferred Stock to elect the two additional directors terminates after the record date for determining holders of shares of Series A Preferred Stock entitled to vote in any election of directors but before the closing of the polls in the election, holders of Series A Preferred Stock outstanding as of the applicable record date will not be entitled to vote in the election of directors. The right of the holders of Series A Preferred Stock to elect the additional directors will again vest if and whenever dividends are in arrears for six quarterly periods, as described above. In no event will the holders of Series A Preferred Stock be entitled to nominate or elect an individual as a director, and no individual will be qualified to be nominated for election or to serve as a director, if the individual’s service as a director would cause us to fail to satisfy a requirement relating to director independence of any national securities exchange on which any class or series of our stock is listed or otherwise conflict with our charter or bylaws.

The additional directors will be elected by a plurality of the votes cast in the election of preferred stock directors, and each of these directors will serve until the next annual meeting of our stockholders and until his or her successor is duly elected and qualifies, or until the director’s term of office terminates as described above. Any director elected by the holders of Series A Preferred Stock and any other class or series of voting preferred stock, voting together as a single class, may be removed, with or without cause, only by a vote of the holders of a majority of the outstanding shares of Series A Preferred Stock and all classes or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote together as a single class in the election of directors, voting together as a single class. At any time that the holders of Series A Preferred Stock are entitled to vote in the election of the two additional preferred stock directors, holders of Series A Preferred Stock will be entitled to vote in the election of a successor to fill any vacancy on our board of directors that results from the removal of the director.

At any time that holders of Series A Preferred Stock have the right to elect two additional preferred stock directors as described above but these directors have not been elected, our secretary must call a special meeting for the purpose of electing the additional directors upon the written request of the holders of record of 10% of the outstanding shares of Series A Preferred Stock and any other class or series of voting preferred stock with which the holders of Series A Preferred Stock are entitled to vote together as a single class with respect to the election of directors, unless the request is received more than 45 days and less than 90 days before the date fixed for the next annual meeting of our stockholders at which the vote would occur, in which case, the additional directors may be elected either at the annual meeting or at a separate special meeting of our stockholders at our discretion.

So long as any shares of Series A Preferred Stock are outstanding, the approval of the holders of at least two-thirds of the outstanding shares of Series A Preferred Stock and each other class or series of voting preferred
11



stock with which the holders of Series A Preferred Stock are entitled to vote as a single class on such matter (voting together as a single class), is required to authorize (a) any amendment, alteration, repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock (whether by merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or otherwise), that would materially and adversely affect the rights, preferences, privileges or voting powers of the Series A Preferred Stock, or (b) the creation, issuance or increase in the authorized number of shares of any class or series of stock ranking senior to the Series A Preferred Stock (or any equity securities convertible into or exchangeable for any such shares) with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up. Notwithstanding the foregoing, holders of voting preferred stock will not be entitled to vote together as a class with the holders of Series A Preferred Stock on any amendment, alteration, repeal or other change to any provision of our charter unless the action affects the holders of Series A Preferred Stock and the voting preferred stock equally.

The following actions will not be deemed to materially and adversely affect the rights, preferences, privileges or voting powers of the Series A Preferred Stock:

any increase or decrease in the number of authorized shares of common stock or preferred stock of any other class or series, any increase in the number of shares of Series A Preferred Stock or the classification or reclassification of any unissued shares, or the creation or issuance of equity securities, of any class or series ranking junior to or on parity with the Series A Preferred Stock with respect to dividend rights and rights upon our voluntary or involuntary liquidation, dissolution or winding up;

any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, whether or not we are the surviving entity, if the Series A Preferred Stock (or stock into which the Series A Preferred Stock has been converted in any successor person or entity to us) remains outstanding with the terms thereof unchanged in all material respects or is exchanged for stock of the successor person or entity with substantially identical rights; or

any amendment, alteration or repeal or other change to any provision of our charter, including the articles supplementary setting forth the terms of the Series A Preferred Stock, as a result of a merger, conversion, consolidation, transfer or conveyance of all or substantially all of our assets or other business combination, if the holders of Series A Preferred Stock receive the $25.00 liquidation preference per share of Series A Preferred Stock, plus an amount equal to accrued and unpaid dividends to, but not including, the date of the event.

The voting provisions above will not apply if, at or prior to the time when the act with respect to which the vote would otherwise be required would occur, we have redeemed or called for redemption all outstanding shares of Series A Preferred Stock.

No Maturity, Sinking Fund or Mandatory Redemption

The Series A Preferred Stock has no stated maturity date and is not subject to any sinking fund or mandatory redemption provisions.

Conversion

The Series A Preferred Stock is not convertible into any other property or securities, except as provided under “— Change of Control Conversion Rights.”

Information Rights

During any period in which we are not subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and any shares of Series A Preferred Stock are outstanding, we will (i) transmit by mail or other
12



permissible means under the Exchange Act to all holders of Series A Preferred Stock as their names and addresses appear in our record books and without cost to the holders, copies of the Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we would have been required to file with the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 or 15(d) of the Exchange Act if we were subject thereto (other than any exhibits that would have been required) within 15 days after the respective dates by which we would have been required to file these reports with the SEC if we were subject to Section 13 or 15(d) of the Exchange Act and (ii) within 15 days following written request, supply copies of these reports to any prospective holder of Series A Preferred Stock.

Preemptive Rights

No holders of Series A Preferred Stock shall, as a result of his, her or its status as such holder, have any preemptive rights to purchase or subscribe for shares of our common stock or any of our other securities.

Common Stock Purchase Rights

On December 8, 2020, following authorization by our board of directors, we declared a dividend of one Right for each share of our common stock outstanding on the close of business on December 18, 2020 to the stockholders of record on that date payable on that date. Initially, the Rights will be attached to all shares of common stock, and no separate certificates representing the Rights (“Right Certificates”) will be issued. Until the Distribution Date (as defined below), the Rights will be inseparable from the shares of common stock, and the Company will issue one Right with respect to each new share of common stock so that all shares of common stock will have Rights attached.

The Rights are in all respects subject to and governed by the provisions of the rights agreement (the “Rights Agreement”) the Company entered into with Computershare Trust Company, N.A., as rights agent, on May 18, 2020.

Distribution Date

On the Distribution Date, the Rights will separate from the shares of our common stock. As soon as practicable after the Distribution Date, unless the Rights are recorded in book-entry or another uncertificated form, the Company will prepare and cause the Right Certificates to be delivered to each record holder of shares of our common stock as of the Distribution Date (other than any Acquiring Person (as defined below), its affiliates and associates).

The “Distribution Date” generally means the close of business on the 10th business day after the date a majority of our board of directors becomes aware (pursuant to a public announcement or otherwise) that a person or entity has become an Acquiring Person (as defined below). Our board of directors may determine to delay the occurrence of the Distribution Date under certain limited circumstances, including, among other things, to preserve the Company’s status as a real estate investment trust for U.S. federal income tax purposes.

In addition, on the Distribution Date, proper provision will be made by the Company to provide each holder (other than the Company) of limited partnership units of the Company’s operating partnership, Healthcare Trust Operating Partnership, L.P. (the “OP”), designated as “OP Units” (“OP Units”) with the number of Rights that would have been issued to the holder as if the holder had redeemed all of its OP Units for an equal number of shares of our common stock pursuant to and subject to the terms and conditions of the agreement of limited partnership of the OP immediately prior to the Distribution Date.

Exercisability

The Rights will not be exercisable until the Distribution Date. After the Distribution Date, each Right will be exercisable to purchase one share of our common stock for $31.50 (the “Purchase Price”). Prior to exercising their Rights, holders of the Rights, in that capacity, have no rights as a stockholder of the Company.

13



Acquiring Person

An “Acquiring Person” generally means any person or entity that or which, together with its affiliates and associates, is or becomes on or after the date of the adoption of the Rights Agreement the Beneficial Owner (as described below) of 2.0% or more of the shares of our common stock then outstanding, but does not include:

the Company or any of its subsidiaries;

any employee benefit plan of the Company or any of its subsidiaries or the Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”);

any entity or trustee holding shares of our common stock for or pursuant to the terms of any plan or for the purpose of funding any plan or other benefits for employees of the Company or of any of its subsidiaries or the Advisor;

any passive investor, which generally means any person or entity Beneficially Owning shares of our common stock without a plan or an intent to seek control of or influence the control of the Company, but excluding any person or entity that makes a tender offer, mini or otherwise;

any person or entity that our board of directors has permitted to Beneficially Own a specified percentage of 2.0% or more of shares of our common stock but only for so long as the person or entity does not acquire, without the prior approval of our board of directors, Beneficial Ownership of any additional shares of our common stock above the specified percentage; and

any person or entity that would otherwise be deemed an Acquiring Person as of the date of the adoption of the Rights Agreement, but only for so long as the person or entity does not acquire, without the prior approval of our board of directors, Beneficial Ownership of any additional shares of our common stock.

The Rights Agreement also provides that our board of directors may exempt any person or entity from being an Acquiring Person prior to the person or entity becoming an Acquiring Person, subject to the right of our board of directors to revoke the exemption. In the event the shares of our common stock are listed on the New York Stock Exchange, Inc. or The NASDAQ Stock Market LLC, the 2.0% threshold will increase to a threshold of 4.9% effective upon the commencement of trading.

Securities “Beneficial Owned” by a person or entity, together with its affiliates and associates, include:

any securities beneficially owned, directly or indirectly, within the meaning of Rule 13d-3 of the Exchange Act;

except under limited circumstances, securities with respect to which the person or entity, or any of its affiliates or associates, has the right to acquire or vote pursuant to any agreement, arrangement or understanding;

any securities which are Beneficially Owned, directly or indirectly, by any other person or entity with which the person or entity, or any of its affiliates or associates, has any agreement, arrangement or understanding, whether or not in writing, for the purpose of acquiring, holding, voting or disposing of any voting securities of the Company, and which the person or entity, or any of its affiliates or associates, is acting in concert towards a common goal relating to (i) acquiring, holding, voting or disposing of voting securities of the Company or (ii) changing or influencing the control of the Company; and

any securities which are the subject of, or the reference securities for, or that underlie, any derivative securities (as defined under Rule 16a-1 under the Exchange Act) that increase in value as the value of the underlying equity increases.
14



From and after a person or entity becoming an Acquiring Person, all Rights that are, or, under certain circumstances specified in the Rights Agreement, were, Beneficially Owned by any Acquiring Person (or by certain related parties) will be null and void. In addition, on and after the Distribution Date, any Right, the exercise or exchange of which would cause a Person to become an Acquiring Person, will become null and void.

Consequences of Any Person or Entity Becoming an Acquiring Person

Flip In. If any person or entity becomes an Acquiring Person (other than pursuant to a Permitted Offer or a transaction described below under “—Flip Over”), each Right will entitle the holder thereof (other than Rights that have become null and void) to purchase at the Purchase Price a number of shares of our common stock having an estimated market value of twice the Purchase Price. However, these Rights will not be exercisable until the Rights are no longer redeemable by the Company as described below under “—Redemption” and are subject to the Company’s right to exchange described below under “—Exchange.” If shares of our common stock are not listed on a national securities exchange, the Company’s estimated net asset value per share of common stock in effect as of the applicable date, subject to adjustments and certain exceptions, will be deemed to be the market price of the shares of common stock.

A “Permitted Offer” is a tender or exchange offer for all outstanding shares of our common stock at a price and on terms which a majority of our board of directors has previously determined are fair to the Company’s stockholders and not inadequate and otherwise in the best interests of the Company.

Exchange. If any person or entity becomes an Acquiring Person (but before the completion of a transaction described below under “—Flip Over,”), the Company, upon the authorization and direction of our board of directors, may exchange the Rights (other than Rights that have become null and void), in whole or in part, for shares of our common stock on a one-for-one basis. To the extent prohibited by Maryland law, our board of directors will not authorize an exchange after an Acquiring Person becomes the Beneficial Owner of a majority of the outstanding shares of our common stock.

Flip Over. If, after the date a majority of our board of directors becomes aware (pursuant to a public announcement or otherwise) that a person or entity has become an Acquiring Person, (i) the Company completes a merger or other business combination in which the Company is not the surviving entity or in which the Company is the surviving entity and shares of our common stock are or will be exchanged for securities of any other person or entity or other assets, or (ii) 50% or more of the Company's assets or Earning Power (as defined in the Rights Agreement) is sold or transferred, each Right will entitle the holder thereof (other than Rights that have become null and void) to purchase at the Purchase Price a number of shares of common stock of the acquiring company having a market value of twice the Purchase Price.

Expiration

The Rights will expire, unless earlier exercised, exchanged, amended or redeemed, on the earlier of
May 18, 2023 or if shares of our common stock are listed on the New York Stock Exchange, Inc., or The NASDAQ Stock Market LLC, 364 days from the commencement of trading.

Redemption

At any time before the earlier of (i) the 5th business day following the Distribution Date, or (ii) the expiration of the Rights by their terms, the Company, upon the authorization and direction of our board of directors, may redeem the Rights in whole, but not in part, at a price of $0.000001 per Right. If Continuing Directors no longer comprise a majority of our board of directors, then, for a period of 180 days, the Rights cannot be redeemed unless there are Continuing Directors and a majority of the Continuing Directors concur with the decision of our board of directors to redeem the Rights. Immediately upon the action of our board of directors ordering redemption of the Rights (with, if required, the concurrence of a majority of the Continuing Directors), or at a later time as our
15



board of directors may establish for the effectiveness of the redemption, the Rights will terminate and the only right of the holders of Rights will be to receive the redemption price.

The “Continuing Directors” include any current member of our board of directors and any person subsequently elected to our board of directors upon recommendation or approval of a majority of those directors (or directors recommended or approved by them), and exclude an Acquiring Person, its affiliates and associates, or any of their respective representatives or nominees.

Amendment

The terms of the Rights may be amended by our board of directors without the consent of the holders of the Rights, except that from and after the Distribution Date no such amendment may adversely affect the interests of the holders of the Rights (other than the Acquiring Person and its affiliates and associates).

Adjustment

The Purchase Price payable, and the number of shares of common stock or other securities or property issuable, upon exercise of the Rights is subject to adjustment in connection with various events from time to time to prevent dilution, including:

if the Company declares a dividend on shares of our common stock payable in shares of common stock or effects a subdivision, combination or reclassification of shares of our common stock;

if the holders of shares of our common stock are granted rights, options or warrants to subscribe for or purchase shares of our common stock (or shares having the same rights, privileges and preferences as shares of our common stock) or convertible securities at a price less than the then current per share market price of shares of our common stock; or

upon the distribution to all holders of shares of our common stock of evidences of indebtedness or assets (excluding regular periodic cash dividends, if any, or dividends payable in shares of our common stock) or subscription rights or warrants (other than those referred to above).

With certain exceptions, no adjustment in the Purchase Price payable upon exercise of the Rights will be required until cumulative adjustments amount to at least 1% of the Purchase Price.

The number of outstanding Rights and the number of shares of our common stock issuable upon exercise of each Right are also subject to adjustment in the event of a stock split of our common stock or a stock dividend on our common stock payable in shares of our common stock or subdivisions, consolidations or combinations of shares of our common stock occurring, in any such case, prior to the Distribution Date.

Certain Provisions of the Maryland General Corporation Law and our Charter and Bylaws

Power to Reclassify Shares of Our Stock

Our board of directors may classify any unissued shares of preferred stock, and reclassify any unissued shares of common stock or any previously classified but unissued shares of preferred stock, into other classes or series of stock, including one or more classes or series of stock that have priority over our common stock with respect to voting rights, distributions or upon liquidation, and authorize us to issue the newly classified shares. Prior to the issuance of shares of each class or series, our board of directors is required by the MGCL and our charter to set, subject to the provisions of our charter regarding the restrictions on ownership and transfer of our stock, the preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications and terms and conditions of redemption for each such class or series. These actions can be taken without stockholder approval, unless stockholder approval is required by applicable law, the terms of any other class or series of our stock or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded.
16



Restrictions on Transfer and Ownership of Stock

In order for us to qualify as a REIT under the Code, shares of our stock must be owned by 100 or more persons during at least 335 days of a taxable year of 12 months (other than the first year for which an election to be taxed as a REIT has been made) or during a proportionate part of a shorter taxable year. Also, under Section 856(h) of the Code, a REIT cannot be “closely held.” In this regard, not more than 50% of the value of the outstanding shares of stock may be owned, directly or indirectly, by five or fewer individuals (as defined in the Code to include certain entities) during the last half of a taxable year (other than the first year for which an election to be a REIT has been made).

Our charter contains restrictions on the ownership and transfer of shares of our common stock and other outstanding shares of stock. The relevant sections of our charter provide that, subject to the exceptions described below, no person or entity may own, or be deemed to own, by virtue of the applicable constructive ownership provisions of the Code, more than 9.8% in value of the aggregate of our outstanding shares of stock or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of shares of our stock; we refer to these limitations as the “ownership limits.”

The constructive ownership rules under the Code are complex and may cause shares of stock owned actually or constructively by a group of related individuals or entities to be owned constructively by one individual or entity. As a result, the acquisition of less than 9.8% in value of the aggregate of our outstanding shares of stock or 9.8% (in value or in number of shares, whichever is more restrictive) of any class or series of shares of our stock (or the acquisition of an interest in an entity that owns, actually or constructively, shares of our stock by an individual or entity), could, nevertheless, cause that individual or entity, or another individual or entity, to violate the ownership limits.

Our board of directors may, upon receipt of certain representations, undertakings and agreements and in its sole discretion, exempt (prospectively or retroactively) any person from the ownership limits and establish a different limit, or excepted holder limit, for a particular person if the person’s ownership in excess of the ownership limits will not then or in the future result in our being “closely held” under Section 856(h) of the Code (without regard to whether the person’s interest is held during the last half of a taxable year) or otherwise cause us to fail to qualify as a REIT. In order to be considered by our board of directors for exemption, a person also must not own, actually or constructively, an interest in one of our tenants (or a tenant of any entity which we own or control) that would cause us to own, actually or constructively, more than a 9.9% interest in the tenant unless the revenue derived by us from such tenant is sufficiently small that, in the opinion of our board of directors, rent from such tenant would not adversely affect our ability to qualify as a REIT. The person seeking an exemption must provide such representations and undertakings to the satisfaction of our board of directors that it will not violate these two restrictions. The person also must agree that any violation or attempted violation of these restrictions will result in the automatic transfer to a charitable trust of the shares of stock causing the violation. As a condition of granting an exemption or creating an excepted holder limit, our board of directors may, but is not required to, obtain an opinion of counsel or Internal Revenue Service ruling satisfactory to our board of directors with respect to our qualification as a REIT and may impose such other conditions or restrictions as it deems appropriate.

Our board of directors may increase or decrease the ownership limits. Any decrease in the ownership limits will not be effective for any person whose percentage ownership of shares of our stock is in excess of such decreased limits until such person’s percentage ownership of shares of our stock equals or falls below such decreased limits (other than a decrease as a result of a retroactive change in existing law, which will be effective immediately), but any further acquisition of shares of our stock in excess of such percentage ownership will be in violation of the applicable decreased limits. Our board of directors may not increase or decrease the ownership limits if, after giving effect to such increase or decrease, five or fewer persons could beneficially own or constructively own in the aggregate more than 49.9% in value of the shares of our stock then outstanding. Prior to any modification of the ownership limits, our board of directors may require such opinions of counsel, affidavits, undertakings or agreements as it may deem necessary or advisable in order to determine or ensure our qualification as a REIT.

Our charter further prohibits:
17



any person from beneficially or constructively owning, applying certain attribution rules of the Code, shares of our stock that would result in our being “closely held” under Section 856(h) of the Code (without regard to whether the stockholder’s interest is held during the last half of a taxable year) or otherwise cause us to fail to qualify as a REIT; and

any person from transferring shares of our stock if such transfer would result in shares of our stock being beneficially owned by fewer than 100 persons (determined without reference to any rules of attribution).

Any person who acquires or attempts or intends to acquire beneficial or constructive ownership of shares of our stock that will or may violate the ownership limits or any of the other foregoing restrictions on ownership and transfer of our stock will be required to immediately give written notice to us or, in the case of a proposed or attempted transaction, give, at least 15 days’ prior written notice to us, and provide us with such other information as we may request in order to determine the effect of such transfer on our qualification as a REIT. The ownership limits and the other restrictions on ownership and transfer of our stock will not apply if our board of directors determines that it is no longer in our best interests to continue to qualify as a REIT or that compliance with the restrictions on ownership and transfer of our stock is no longer required in order for us to qualify as a REIT.

If any transfer of shares of our stock would result in shares of our stock being beneficially owned by fewer than 100 persons, such transfer will be void from the time of such purported transfer and the intended transferee will acquire no rights in such shares. In addition, if any purported transfer of shares of our stock or any other event would otherwise result in:

any person violating the ownership limits or such other limit established by our board of directors; or

us being “closely held” under Section 856(h) of the Code (without regard to whether the stockholder’s interest is held during the last half of a taxable year) or otherwise failing to qualify as a REIT,

then that number of shares (rounded up to the nearest whole share) that would cause us to violate such restrictions will automatically be transferred to, and held by, a charitable trust for the exclusive benefit of one or more charitable organizations selected by us, and the intended transferee will acquire no rights in such shares. The transfer will be deemed to be effective as of the close of business on the business day prior to the date of the violative transfer or other event that results in the transfer to the charitable trust. A person who, but for the transfer of the shares to the charitable trust, would have beneficially or constructively owned the shares so transferred is referred to as a “prohibited owner,” which, if appropriate in the context, also means any person who would have been the record owner of the shares that the prohibited owner would have so owned. If the transfer to the charitable trust as described above would not be effective, for any reason, to prevent violation of the applicable restriction on ownership and transfer contained in our charter, then our charter provides that the transfer of the shares will be void from the time of such purported transfer.

Shares of stock transferred to a charitable trust are deemed offered for sale to us, or our designee, at a price per share equal to the lesser of (1) the price paid per share in the transaction that resulted in such transfer to the charitable trust (or, if the event that resulted in the transfer to the charitable trust did not involve a purchase of such shares of stock at market price, defined generally as the last reported sales price reported on the principal national securities exchange on which the shares are listed and admitted to trading, the market price per share of such stock on the day of the event which resulted in the transfer of such shares of stock to the charitable trust) and (2) the market price on the date we, or our designee, accept such offer. We may reduce the amount payable to the charitable trust by the amount of dividends and other distributions which have been paid to the prohibited owner and are owed by the prohibited owner to the charitable trust as described below. We may pay the amount of such reduction to the charitable trust for the benefit of the charitable beneficiary. We have the right to accept such offer until the trustee of the charitable trust has sold the shares held in the charitable trust as discussed below. Upon a sale to us, the interest of the charitable beneficiary in the shares sold terminates, and the charitable trustee must distribute the net proceeds of the sale to the prohibited owner.

18



Within 20 days of receiving notice from us of the transfer of the shares to the charitable trust, the charitable trustee will sell the shares to a person or entity designated by the charitable trustee who could own the shares without violating the ownership limits or the other restrictions on ownership and transfer of our stock described above. After that, the charitable trustee must distribute to the prohibited owner an amount equal to the lesser of
(1)the price paid by the prohibited owner for the shares in the transaction that resulted in the transfer to the charitable trust (or, if the event that resulted in the transfer to the charitable trust did not involve a purchase of such shares at market price, the market price per share of such stock on the day of the event that resulted in the transfer to the charitable trust) and (2) the sales proceeds (net of commissions and other expenses of sale) received by the charitable trust for the shares. The charitable trustee may reduce the amount payable to the prohibited owner by the amount of dividends and other distributions which have been paid to the prohibited owner and are owed by the prohibited owner to the charitable trust. Any net sales proceeds in excess of the amount payable to the prohibited owner will be immediately paid to the charitable beneficiary, together with any dividends and other distributions thereon. In addition, if, prior to discovery by us that shares of stock have been transferred to a charitable trust, such shares of stock are sold by a prohibited owner, then such shares will be deemed to have been sold on behalf of the charitable trust and to the extent that the prohibited owner received an amount for or in respect of such shares that exceeds the amount that such prohibited owner was entitled to receive, such excess amount will be paid to the charitable trust upon demand by the charitable trustee. The prohibited owner will have no rights in the shares held by the charitable trust.

The charitable trustee will be designated by us and will be unaffiliated with us and with any prohibited owner. Prior to the sale of any shares by the charitable trust, the charitable trustee will receive, in trust for the charitable beneficiary, all distributions made by us with respect to such shares and may also exercise all voting rights with respect to such shares. Any dividend or other distribution paid prior to our discovery that shares of stock have been transferred to the charitable trust will be paid by the recipient to the charitable trust upon demand by the charitable trustee. These rights will be exercised for the exclusive benefit of the charitable beneficiary.

Subject to Maryland law, effective as of the date that the shares have been transferred to the charitable trust, the charitable trustee will have the authority, at the charitable trustee’s sole discretion:

to rescind as void any vote cast by a prohibited owner prior to our discovery that the shares have been transferred to the charitable trustee; and

to recast the vote in accordance with the desires of the charitable trustee acting for the benefit of the charitable beneficiary.

However, if we have already taken irreversible corporate action, then the charitable trustee may not rescind and recast the vote.

If our board of directors determines that a proposed transfer would violate the restrictions on ownership and transfer of our stock set forth in our charter, our board of directors may take such action as it deems advisable to refuse to give effect to or to prevent such transfer, including, but not limited to, causing us to redeem shares of stock, refusing to give effect to the transfer on our books or instituting proceedings to enjoin the transfer.

Every owner of more than 5% (or such lower percentage as required by the Code or the regulations promulgated thereunder) of the outstanding shares of all classes or series of our stock, including common stock, will be required to give written notice to us within 30 days after the end of each taxable year stating the name and address of such owner, the number of shares of each class and series of our stock that the person beneficially owns and a description of the manner in which such shares are held. Each such owner will be required to provide to us such additional information as we may request in order to determine the effect, if any, of such beneficial ownership on our qualification as a REIT and to ensure compliance with the ownership limits. In addition, each stockholder will, upon demand, be required to provide to us such information as we may request in order to determine our qualification as a REIT and to comply with the requirements of any taxing authority or governmental authority or to determine such compliance.

19



Any certificates representing shares of our stock, or any written statements of information delivered in lieu of certificates, will bear a legend referring to the restrictions described above.

Number of Directors; Vacancies; Removal

We presently have six directors. This number may be increased or decreased from time to time pursuant to the bylaws, but may never be less than one or more than fifteen. Our board of directors is divided into three classes of directors serving staggered three-year terms. At each annual meeting, directors of one class are elected to serve until the annual meeting of stockholders held in the third year following the year of their election and until their successors are duly elected and qualify.

We have elected by a provision of our charter to be subject to a provision of Maryland law requiring that, except as otherwise provided in the terms of any class or series of preferred stock, vacancies on our board of directors may be filled only by the remaining directors and that any individual elected to fill a vacancy will serve for the remainder of the full term of the directorship in which the vacancy occurred and until his or her successor is duly elected and qualifies. Any director may resign at any time by delivering his or her notice to the board of directors, the chairman of the board of directors or the Company’s secretary.

Our charter provides that, subject to the rights of holders of one or more classes or series of preferred stock, any or all directors may be removed from office only for “cause” by the affirmative vote of the stockholders, entitled to cast at least two-thirds of the votes entitled to be cast generally in the election of directors. For the purpose of this provision of our charter, “cause” means, with respect to any particular director, conviction of a felony or a final judgment of a court of competent jurisdiction holding that such director caused demonstrable, material harm to us through bad faith or active and deliberate dishonesty.

Action by Stockholders

Under the MGCL, common stockholder action can be taken only at an annual or special meeting of stockholders or by unanimous consent in lieu of a meeting (unless the charter provides for a lesser percentage, which our charter does not). These provisions, combined with the requirements of our charter and bylaws regarding the calling of a stockholder-requested special meeting of stockholders discussed below, may have the effect of delaying consideration of a stockholder proposal until the next annual meeting.

Meetings and Special Voting Requirements

Subject to our charter restrictions on ownership and transfer of our stock and the terms of each class or series of stock, including with respect to the vote by the stockholders for the election of the directors, each holder of common stock is entitled at each meeting of stockholders to one vote per share owned by such stockholder on all matters submitted to a vote of stockholders. There is no cumulative voting in the election of our board of directors, which means that the holders of a majority of shares of our outstanding common stock can elect all the directors then standing for election and the holders of the remaining shares of common stock will not be able to elect any directors.

Under Maryland law, a Maryland corporation generally cannot dissolve, amend its charter, merge, convert, sell all or substantially all of its assets, engage in a share exchange or engage in similar transactions outside the ordinary course of business, unless declared advisable by the board of directors and approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter. However, a Maryland corporation may provide in its charter for approval of these matters by a lesser percentage, but not less than a majority of all the votes entitled to be cast on the matter. Our charter provides for approval of these matters by the affirmative vote of stockholders entitled to cast a majority of all the votes entitled to be cast on the matter (except for certain charter amendments relating to director resignation and removal and the vote required for certain amendments). However, our operating assets are held by our subsidiaries and these subsidiaries may be able to merge or sell all or substantially all of their assets without the approval of our stockholders.

20



Pursuant to our charter and bylaws, an annual meeting of our stockholders for the purpose of the election of directors and the transaction of any business will be held annually on a date and at the time and place set by our board of directors. Special meetings of stockholders to act on any matter that may properly be considered at a meeting of stockholders may be called by the board of directors, the chairman of the board of directors, the president or the chief executive officer and, subject to the satisfaction of certain procedural requirements, must be called by our secretary to act on any matter that may properly be considered at a meeting of stockholders upon the written request of stockholders entitled to cast not less than a majority of all the votes entitled to be cast on the matter at the meeting. The presence of stockholders entitled to cast at least a majority of all the votes entitled to be cast at such meeting on any matter, either in person or by proxy, will constitute a quorum.

Our board of directors has the exclusive power to adopt, alter or repeal any provision of our bylaws and to make new bylaws.

No Appraisal Rights

As permitted by the MGCL, our charter provides that stockholders will not be entitled to exercise appraisal rights unless a majority of our board of directors determines that appraisal rights apply, with respect to all or any classes or series of stock, to one or more transactions occurring after the date of such determination in connection with which stockholders would otherwise be entitled to exercise appraisal rights.

Dissolution

Our dissolution must be declared advisable by a majority of our entire board of directors and approved by the affirmative vote of stockholders entitled to cast not less than a majority of the votes entitled to be cast on such matter.

Business Combinations

Under the MGCL, certain “business combinations,” including a merger, consolidation, share exchange or, in certain circumstances, an asset transfer or issuance or reclassification of equity securities, between a Maryland corporation and an “interested stockholder,” defined generally as any person who beneficially owns, directly or indirectly, 10% or more of the voting power of the corporation’s outstanding voting stock or an affiliate or associate of the corporation who, at any time within the two-year period prior to the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the voting power of the then outstanding stock of the corporation, or an affiliate of such an interested stockholder, are prohibited for five years after the most recent date on which the interested stockholder becomes an interested stockholder. Thereafter, any such business combination must be recommended by the board of directors of such corporation and approved by the affirmative vote of at least (1) 80% of the votes entitled to be cast by holders of outstanding voting stock of the corporation and (2) two-thirds of the votes entitled to be cast by holders of voting stock of the corporation other than shares held by the interested stockholder with whom (or with whose affiliate) the business combination is to be effected or held by an affiliate or associate of the interested stockholder. The super-majority vote requirements do not apply if the corporation’s common stockholders receive a minimum price (as defined in the MGCL) for their shares and the consideration is received in cash or in the same form as previously paid by the interested stockholder for its shares. Under the MGCL, a person is not an “interested stockholder” if the board of directors approved in advance the transaction by which the person otherwise would have become an interested stockholder. A corporation’s board of directors may provide that its approval is subject to compliance with any terms and conditions determined by it.

These provisions of the MGCL do not apply, however, to business combinations that are approved or exempted by a board of directors prior to the time that the interested stockholder becomes an interested stockholder. As permitted by the MGCL, our board of directors has by resolution exempted business combinations between us and our advisor or any affiliate of our advisor. Consequently, the five-year prohibition and the supermajority vote requirements will not apply to such business combinations. As a result, our advisor or any affiliate of our advisor may be able to enter into business combinations with us that may not be in the best interest of our stockholders without compliance by us with the supermajority vote requirements and other provisions of the statute. This resolution, however, may be altered or repealed in whole or in part at any time by our board of directors.
21



Control Share Acquisitions

The MGCL provides that “control shares” of a Maryland corporation acquired in a “control share acquisition” have no voting rights except to the extent approved by the affirmative vote of stockholders entitled to cast at least two-thirds of the votes entitled to be cast on the matter, excluding shares of stock in respect of which any of the following persons is entitled to exercise or direct the exercise of the voting power of such shares in the election of directors: (1) the person that has made or proposed to make the control share acquisition, (2) an officer of the corporation or (3) an employee of the corporation who is also a director of the corporation. “Control shares” are shares of voting stock which, if aggregated with all other such shares owned by the acquirer, or in respect of which the acquirer is able to exercise or direct the exercise of voting power (except solely by virtue of a revocable proxy), would entitle the acquirer to exercise voting power in electing directors within one of the following ranges of voting power: (A) one-tenth or more but less than one-third, (B) one-third or more but less than a majority or
(C)a majority or more of all voting power. Control shares do not include shares that the acquirer is then entitled to vote as a result of having previously obtained stockholder approval or shares acquired directly from the corporation. A “control share acquisition” means the acquisition of issued and outstanding control shares, subject to certain exceptions.

A person who has made or proposes to make a control share acquisition, upon satisfaction of certain conditions (including an undertaking to pay expenses and making an “acquiring person statement” as described in MGCL), may compel the board of directors to call a special meeting of stockholders to be held within 50 days of demand to consider the voting rights of the shares. If no request for a meeting is made, the corporation may itself present the question at any stockholders’ meeting.

If voting rights are not approved at the meeting or if the acquirer does not deliver an “acquiring person statement” as required by the statute, then, subject to certain conditions and limitations, the corporation may redeem any or all of the control shares (except those for which voting rights have previously been approved) for fair value determined, without regard to the absence of voting rights for the control shares, as of the date of any meeting of stockholders at which the voting rights of such shares are considered and not approved, or, if no such meeting is held, as of the date of the last control share acquisition by the acquirer. If voting rights for control shares are approved at a stockholders’ meeting and the acquirer becomes entitled to vote a majority of the shares entitled to vote, all other stockholders may exercise appraisal rights, unless the corporation’s charter provides otherwise. The fair value of the shares as determined for purposes of such appraisal rights may not be less than the highest price per share paid by the acquirer in the control share acquisition.

The control share acquisition statute does not apply to (1) shares acquired in a merger, consolidation or statutory share exchange if the corporation is a party to the transaction or (2) acquisitions approved or exempted by the charter or bylaws of the corporation.

Our bylaws contain a provision exempting from the control share acquisition statute any and all acquisitions by any person of our stock. This bylaw provision may be amended or eliminated at any time in the future.

Subtitle 8

Subtitle 8 of Title 3 of the MGCL permits the board of directors of a Maryland corporation with a class of equity securities registered under the Exchange Act and at least three independent directors to elect to be subject, by provision in its charter or bylaws or a resolution of its board of directors and notwithstanding any contrary provision in the charter or bylaws, to any or all of five provisions:

a classified board of directors;

a two-thirds vote requirement for removing a director;

a requirement that the number of directors be fixed only by vote of the directors;

22



a requirement that a vacancy on the board of directors be filled only by the remaining directors and, if the board of directors is classified, for the remainder of the full term of the class of directors in which the vacancy occurred; and

a majority requirement for the calling of a stockholder-requested special meeting of stockholders.

We have elected to be subject to the provisions of Subtitle 8 relating to a classified board of directors and the filling of vacancies on our board of directors. Through provisions in our charter and bylaws unrelated to Subtitle 8, we already (1) require a two-thirds vote for the removal of any director from the board of directors, which removal will be allowed only for cause, (2) vest in the board of directors the exclusive power to fix the number of directorships, and (3) require, unless called by the chairman of our board of directors, our president, our chief executive officer or our board of directors, the written request of stockholders entitled to cast not less than a majority of all votes entitled to be cast on any matter that may properly be considered at a meeting of stockholders in order to call a special meeting to act on such matter.

Advance Notice of Director Nominations and New Business

Our bylaws provide that nominations of individuals for election to the board of directors or proposals of other business may be made at an annual meeting (1) pursuant to our notice of meeting, (2) by or at the direction of our board of directors, or (3) by any stockholder of record both at the time of giving of notice pursuant to the bylaws and at the time of the annual meeting, who is entitled to vote at the meeting in the election of each individual so nominated or on any such other business and who has complied with the advance notice procedures set forth in our bylaws. Our bylaws currently require the stockholder to provide notice to the secretary containing the information required by our bylaws not earlier than the 150th day nor later than 5:00 p.m., Eastern Time, on the 120th day prior to the first anniversary of the date of our proxy statement for the preceding year’s annual meeting.

With respect to special meetings of stockholders, only the business specified in our notice of meeting may be brought before the meeting. Nominations of individuals for election to the board of directors may be made at a special meeting, (1) by or at the direction of the board of directors, or (2) provided that the special meeting has been called in accordance with our bylaws for the purpose of electing directors, by any stockholder who is a holder of record both at the time of giving of notice and at the time of the special meeting, who is entitled to vote at the meeting in the election of each individual so nominated and who complies with the notice procedures set forth in our bylaws. Such stockholder may nominate one or more individuals, as the case may be, for election as a director if the stockholder’s notice containing the information required by our bylaws is delivered to the secretary not earlier than the 120th day prior to such special meeting and not later than 5:00 p.m., Eastern Time, on the later of  (1) the 90th day prior to such special meeting or (2) the tenth day following the day on which public announcement is first made of the date of the special meeting and the proposed nominees of our board of directors to be elected at the meeting.

Indemnification and Limitation of Directors’ and Officers’ Liability

Maryland law permits a Maryland corporation to include in its charter a provision eliminating the liability of its directors and officers to the corporation and its stockholders for money damages except for liability resulting from (1) actual receipt of an improper benefit or profit in money, property or services or (2) active and deliberate dishonesty established by a final judgment as being material to the cause of action. Our charter contains a provision that eliminates such liability to the maximum extent permitted by Maryland law. This provision does not reduce the exposure of directors and officers to liability under federal or state securities laws, nor does it limit the stockholders’ ability to obtain injunctive relief or other equitable remedies for a violation of a director’s or an officer’s duties to us, although the equitable remedies may not be an effective remedy in some circumstances.

The MGCL requires a Maryland corporation (unless its charter provides otherwise, which our charter does not) to indemnify a director or officer who has been successful, on the merits or otherwise, in the defense of any proceeding to which he or she is made or threatened to be made a party by reason of his or her service in that capacity. The MGCL permits a Maryland corporation to indemnify its present and former directors and officers, among others, against judgments, penalties, fines, settlements and reasonable expenses actually incurred by them in connection with any proceeding to which they may be made or threatened to be made a party by reason of their
23




service in those or other capacities unless it is established that (1) the act or omission of the director or officer was material to the matter giving rise to the proceeding and (A) was committed in bad faith or (B) was the result of active and deliberate dishonesty, (2) the director or officer actually received an improper personal benefit in money, property or services, or (3) in the case of any criminal proceeding, the director or officer had reasonable cause to believe that the act or omission was unlawful. However, under the MGCL, a Maryland corporation may not indemnify a director or officer for an adverse judgment in a suit by or in the right of the corporation or for a judgment of liability on the basis that a personal benefit was improperly received. A court may order indemnification if it determines that the director or officer is fairly and reasonably entitled to indemnification, even though the director or officer did not meet the prescribed standard of conduct or was adjudged liable on the basis that personal benefit was improperly received. However, indemnification for an adverse judgment in a suit by us or in our right, or for a judgment of liability on the basis that personal benefit was improperly received, is limited to expenses. In addition, the MGCL permits a corporation to advance reasonable expenses to a director or officer upon the corporation’s receipt of  (1) a written affirmation by the director or officer of his or her good faith belief that he or she has met the standard of conduct necessary for indemnification by the corporation and (2) a written undertaking by him or her or on his or her behalf to repay the amount paid or reimbursed by the corporation if it is ultimately determined that the appropriate standard of conduct was not met.

Our charter authorizes us to obligate ourselves and our bylaws obligate us, to the maximum extent permitted by Maryland law in effect from time to time, to indemnify and, without requiring a preliminary determination of the ultimate entitlement to indemnification, pay or reimburse reasonable expenses in advance of final disposition of a proceeding to:

any present or former director or officer who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity; and

any individual who, while our director or officer and at our request, serves or has served as a director, officer, partner, member, manager or trustee of another corporation, real estate investment trust, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise and who is made or threatened to be made a party to or witness in the proceeding by reason of his or her service in that capacity.

Our charter and bylaws also permit us to indemnify and advance expenses to any person who served a predecessor of ours in any of the capacities described above and to any employee or agent of us or a predecessor of us.

We have entered into an indemnification agreement with each of our directors and officers, and certain former directors and officers, providing for indemnification of such directors and officers. The indemnification agreements provide that each indemnitee is entitled to indemnification unless it is established that (1) the act or omission of an indemnitee was material to the matter giving rise to the proceeding and (i) was committed in bad faith or (ii) was the result of active and deliberate dishonesty, (2) such indemnitee actually received an improper personal benefit in money, property or services or (3) in the case of any criminal proceeding, such indemnitee had reasonable cause to believe that his or her conduct was unlawful. The indemnification agreements further limit each indemnitee’s entitlement to indemnification in cases where (1) the proceeding was one by or in the right of us and such indemnitee was adjudged to be liable to us, (2) such indemnitee was adjudged to be liable on the basis that personal benefit was improperly received in any proceeding charging improper personal benefit to such indemnitee or (3) the proceeding was brought by such indemnitee, except in certain circumstances.

Insofar as indemnification for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Exclusive Forum

24



Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Northern Division, is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, other than actions arising under federal securities laws, (b) any Internal Corporate Claim, as such term is defined in the MGCL, or any successor provision thereof, including, without limitation, (i) any action asserting a claim of breach of any duty owed by any of our directors, officers or other employees to us or to our stockholders or (ii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the MGCL, our charter or our bylaws, or (c) any other action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.

Our bylaws also provide that, unless we consent in writing, none of the foregoing actions, claims or proceedings may be brought in any court sitting outside the State of Maryland and the federal district courts are, to the fullest extent permitted by law, the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
25

EX-21.1 3 ex211hti12312020.htm EX-21.1 SUBSIDIARY LISTING Document
Exhibit 21.1
Subsidiaries of Healthcare Trust, Inc.
NameJurisdiction of Formation/Incorporation
Advantage Senior Care, LLCDelaware
ARHC AAEKHWI01, LLCDelaware
ARHC ACRICKY01 TRS, LLCDelaware
ARHC ACRICKY01, LLCDelaware
ARHC AHGBYWI01, LLCDelaware
ARHC AHGVLWI01, LLCDelaware
ARHC AHHFDCA01, LLCDelaware
ARHC AHJACOH01, LLCDelaware
ARHC AHKIEWI01, LLCDelaware
ARHC AHMLWWI01, LLCDelaware
ARHC AHPLYWI01, LLCDelaware
ARHC AHWTFWI01, LLCDelaware
ARHC AHWTMWI01, LLCDelaware
ARHC ALALPGA01 TRS, LLCDelaware
ARHC ALALPGA01, LLCDelaware
ARHC ALCFBTX01, LLCDelaware
ARHC ALCLKTX01, LLCDelaware
ARHC ALELIKY01 TRS, LLCDelaware
ARHC ALELIKY01, LLCDelaware
ARHC ALJUPFL01 TRS, LLCDelaware
ARHC ALJUPFL01, LLCDelaware
ARHC ALMEYTX01, LLCDelaware
ARHC ALSPGFL01 TRS, LLCDelaware
ARHC ALSPGFL01, LLCDelaware
ARHC ALSTUFL01 TRS, LLCDelaware
ARHC ALSTUFL01, LLCDelaware
ARHC ALTSPFL01 TRS, LLCDelaware
ARHC ALTSPFL01, LLCDelaware
ARHC ALWOOTX01, LLCDelaware
ARHC AMGLNAZ01, LLCDelaware
ARHC AMGLNAZ02, LLCDelaware
ARHC AORMDVA01, LLCDelaware
ARHC APNVLMI01 TRS, LLCDelaware
ARHC APNVLMI01, LLCDelaware
ARHC ARCLRMI01 TRS, LLCDelaware
ARHC ARCLRMI01, LLCDelaware
ARHC ATROCIL01 TRS, LLCDelaware
ARHC ATROCIL01, LLCDelaware
ARHC AVBURWI01 TRS, LLCDelaware
ARHC AVBURWI01, LLCDelaware
ARHC BCKNGNY01, LLCDelaware
ARHC BGBOWMD01, LLCDelaware
ARHC BLHBGPA01, LLCDelaware
ARHC BMBUCMI01, LLC (f/k/a ARHC CO Borrower 5, LLC)Delaware
ARHC BMBWNIL01, LLCDelaware
ARHC BMLKWCO01, LLCDelaware



ARHC BMWRNMI01, LLCDelaware
ARHC BPBUFMO01, LLCDelaware
ARHC BRHBGPA01, LLCDelaware
ARHC BSHUMMO01, LLCDelaware
ARHC BSNPLFL01 TRS, LLCDelaware
ARHC BSNPLFL01, LLCDelaware
ARHC BWBRUGA01 TRS, LLCDelaware
ARHC BWBRUGA01, LLCDelaware
ARHC CALEWMO01, LLCDelaware
ARHC CAROCMI01, LLCDelaware
ARHC CAROCMI02, LLCDelaware
ARHC CCCGRMO01, LLCDelaware
ARHC CCGBGIL01, LLCDelaware
ARHC CCSCNNY01, LLCDelaware
ARHC CFGREOR01 TRS, LLCDelaware
ARHC CFGREOR01, LLCDelaware
ARHC CHCASMO01, LLCDelaware
ARHC CHCOLIL01 TRS, LLCDelaware
ARHC CHCOLIL01, LLCDelaware
ARHC CHEVLIL01 TRS, LLCDelaware
ARHC CHEVLIL01, LLCDelaware
ARHC CHHBGPA01, LLCDelaware
ARHC CHPTNIL01, LLCDelaware
ARHC CHSGDIL01, LLCDelaware
ARHC CHSLOIL01 TRS, LLCDelaware
ARHC CHSLOIL01, LLCDelaware
ARHC CHSLOIL02, LLCDelaware
ARHC CHSPTIL01 TRS, LLCDelaware
ARHC CHSPTIL01, LLCDelaware
ARHC CMCNRTX01, LLCDelaware
ARHC CMLITCO01, LLCDelaware
ARHC CMSHTMI001, LLCDelaware
ARHC CMWTSMI001, LLCDelaware
ARHC CO BORROWER 11, LLCDelaware
ARHC CO BORROWER 12, LLCDelaware
ARHC CO BORROWER 13, LLCDelaware
ARHC CO BORROWER 14, LLCDelaware
ARHC CO BORROWER 15, LLCDelaware
ARHC CO SPE Member, LLCDelaware
ARHC CPCIROH01, LLCDelaware
ARHC CPHAMVA01, LLCDelaware
ARHC CSCLWFL01, LLCDelaware
ARHC CSDOUGA01, LLCDelaware
ARHC CSKENMI01, LLCDelaware
ARHC CWEVAGA01 TRS, LLCDelaware
ARHC CWEVAGA01, LLC (f/k/a ARHC CO Borrower 6, LLC)Delaware
ARHC DBDUBGA01 TRS, LLCDelaware
ARHC DBDUBGA01, LLCDelaware
ARHC DDHUDFL01, LLCDelaware



ARHC DDLARFL01, LLCDelaware
ARHC DELVSNV01, LLCDelaware
ARHC DELVSNV02, LLCDelaware
ARHC DFDYRIN01, LLCDelaware
ARHC DMDCRGA01, LLCDelaware
ARHC DVMERID01 TRS, LLCDelaware
ARHC DVMERID01, LLCDelaware
ARHC ECCPTNC01, LLCDelaware
ARHC ECGVLSC01, LLCDelaware
ARHC ECMCYNC01, LLCDelaware
ARHC EMRAYMO01, LLCDelaware
ARHC ESMEMTN01, LLCDelaware
ARHC FMMUNIN01, LLCDelaware
ARHC FMMUNIN02, LLCDelaware
ARHC FMMUNIN03, LLCDelaware
ARHC FMWEDAL01, LLCDelaware
ARHC FOMBGPA01, LLCDelaware
ARHC FOMBGPA01, LLCDelaware
ARHC Fox Ridge MT, LLCDelaware
ARHC FRBRYAR01 TRS, LLCDelaware
ARHC FRBRYAR01, LLCDelaware
ARHC FRLTRAR01 TRS, LLCDelaware
ARHC FRLTRAR01, LLCDelaware
ARHC FRNLRAR01 TRS, LLCDelaware
ARHC FRNLRAR01, LLCDelaware
ARHC FVECOCA01 Trs, LLCDelaware
ARHC FVECOCA01, LLCDelaware
ARHC GDFMHMI01, LLCDelaware
ARHC GFGBTAZ01, LLCDelaware
ARHC GGPOTMO01, LLCDelaware
ARHC GHGVLSC01, LLCDelaware
ARHC GMCLKTN01, LLCDelaware
ARHC GOFENMI01, LLCDelaware
ARHC GYHSVMO01, LLCDelaware
ARHC HBTPAFL01 TRS, LLCDelaware
ARHC HBTPAFL01, LLCDelaware
ARHC HCTMPFL01, LLCDelaware
ARHC HDLANCA01, LLCDelaware
ARHC HHPEOIL01, LLCDelaware
ARHC HRHAMVA01, LLCDelaware
ARHC JCCRKGA01 TRS, LLCDelaware
ARHC JCCRKGA01, LLCDelaware
ARHC KB BORROWER 1, LLCDelaware
ARHC KB BORROWER 10, LLCDelaware
ARHC KB BORROWER 11, LLCDelaware
ARHC KB BORROWER 12, LLCDelaware
ARHC KB BORROWER 13, LLCDelaware
ARHC KB BORROWER 14, LLCDelaware
ARHC KB BORROWER 15, LLCDelaware



ARHC KB BORROWER 2, LLCDelaware
ARHC KB BORROWER 3, LLCDelaware
ARHC KB BORROWER 4, LLCDelaware
ARHC KB BORROWER 5, LLCDelaware
ARHC KB BORROWER 6, LLCDelaware
ARHC KB BORROWER 7, LLCDelaware
ARHC KB BORROWER 8, LLCDelaware
ARHC KB BORROWER 9, LLCDelaware
ARHC KB SPE Member, LLCDelaware
ARHC KEKWDTX01, LLCDelaware
ARHC LCDIXIL01 TRS, LLCDelaware
ARHC LCDIXIL01, LLCDelaware
ARHC LDSPGFL01, LLCDelaware
ARHC LHPTVPA01, LLCDelaware
ARHC LMFMYFL01, LLCDelaware
ARHC LMHBGPA01, LLCDelaware
ARHC LMLANPA01, LLCDelaware
ARHC LMPLNTX01, LLCDelaware
ARHC LPELKCA01, LLCDelaware
ARHC LSSMTMO01 TRS, LLCDelaware
ARHC LSSMTMO01, LLCDelaware
ARHC LVHLDMI01, LLC (f/k/a ARHC CO Borrower 7, LLC)Delaware
ARHC MBAGHCA01 TRS, LLCDelaware
ARHC MBAGHCA01, LLCDelaware
ARHC MCMSHMO01, LLCDelaware
ARHC MCNWDNY01, LLCDelaware
ARHC MHCLVOH01, LLCDelaware
ARHC MMJLTIL01, LLCDelaware
ARHC MMTCTTX01, LLCDelaware
ARHC MRMRWGA01, LLCDelaware
ARHC MSHBGPA01, LLCDelaware
ARHC MTMTNIL01, LLCDelaware
ARHC MVMTNIL01, LLCDelaware
ARHC MVMVNWA01, LLCDelaware
ARHC NHCANGA01, LLCDelaware
ARHC NVJUPFL01 TRS, LLCDelaware
ARHC NVJUPFL01, LLCDelaware
ARHC NVLTZFL01 TRS, LLCDelaware
ARHC NVLTZFL01, LLCDelaware
ARHC NVWELFL01 TRS, LLCDelaware
ARHC NVWELFL01, LLCDelaware
ARHC OCWMNLA01, LLCDelaware
ARHC OLOLNIL01, LLCDelaware
ARHC OOHLDOH001, LLCDelaware
ARHC OPBROOR01 TRS, LLCDelaware
ARHC OPBROOR01, LLCDelaware
ARHC PCCHEMI01, LLCDelaware
ARHC PCLMYPA01, LLCDelaware
ARHC PCPLSMI01, LLCDelaware



ARHC PCSHVMS01, LLCDelaware
ARHC PHCRPIA01 TRS, LLCDelaware
ARHC PHCRPIA01, LLCDelaware
ARHC PHCTNIA01 TRS, LLCDelaware
ARHC PHCTNIA01, LLC (f/k/a ARHC CO Borrower 8, LLC)Delaware
ARHC PHDESIA01 TRS, LLCDelaware
ARHC PHDESIA01, LLC (f/k/a ARHC CO BORROWER 2, LLC)Delaware
ARHC PHNLXIL01, LLCDelaware
ARHC PHOTTIA01 TRS, LLCDelaware
ARHC PHOTTIA01, LLCDelaware
ARHC PHTIPIA01 TRS, LLCDelaware
ARHC PHTIPIA01, LLCDelaware
ARHC Plaza Del Rio Medical Office Campus Member 1, LLCDelaware
ARHC Plaza Del Rio Medical Office Campus Member 2, LLCDelaware
ARHC PMCPKNY01, LLCDelaware
ARHC PMPEOAZ01, LLCDelaware
ARHC PPCLRMI01, LLCDelaware
ARHC PPDWTMI01 TRS, LLCDelaware
ARHC PPDWTMI01, LLCDelaware
ARHC PPDWTMI01, LLCDelaware
ARHC PPGBLMI01, LLCDelaware
ARHC PPHRNTN01, LLCDelaware
ARHC PPLVLGA01, LLCDelaware
ARHC PRPEOAZ01, LLCDelaware
ARHC PRPEOAZ02, LLCDelaware
ARHC PRPEOAZ03, LLCDelaware
ARHC PRPEOAZ04, LLCDelaware
ARHC PRPEOAZ05 TRS, LLCDelaware
ARHC PSINDIA01 TRS, LLCDelaware
ARHC PSINDIA01, LLCDelaware
ARHC PSNHTMA01, LLCDelaware
ARHC PSSGDMA01, LLCDelaware
ARHC PSWSGMA01, LLCDelaware
ARHC PVGYRAZ01, LLCDelaware
ARHC PVPHXAZ01, LLCDelaware
ARHC PVVLGKS01 TRS, LLCDelaware
ARHC PVVLGKS01, LLCDelaware
ARHC PWHLTMI01, LLCDelaware
ARHC Quad Cities Portfolio Member, LLCDelaware
ARHC RACLWFL01, LLCDelaware
ARHC RHMARIL01, LLCDelaware
ARHC RHMESAZ01, LLCDelaware
ARHC RHSUNAZ01, LLCDelaware
ARHC RMRWLTX01, LLCDelaware
ARHC RPATLGA01 TRS, LLCDelaware
ARHC RPATLGA01, LLC (f/k/a ARHC CO BORROWER 3, LLC)Delaware
ARHC RWCUDWI01 TRS, LLCDelaware
ARHC RWCUDWI01, LLCDelaware



ARHC RWROSGA01 TRS, LLCDelaware
ARHC RWROSGA01, LLCDelaware
ARHC SARCOIL01, LLCDelaware
ARHC SAVENFL01, LLCDelaware
ARHC SBBURIA01 TRS, LLCDelaware
ARHC SBBURIA01, LLC (f/k/a ARHC CO BORROWER 1, LLC)Delaware
ARHC SCBTHNY01, LLCDelaware
ARHC SCBTHNY02, LLCDelaware
ARHC SCCRLIA01 TRS, LLCDelaware
ARHC SCCRLIA01, LLC (f/k/a ARHC CO Borrower 9, LLC)Delaware
ARHC SCKCYMO01 TRS, LLCDelaware
ARHC SCKCYMO01, LLCDelaware
ARHC SCTEMTX01, LLCDelaware
ARHC SCVSTCA01, LLCDelaware
ARHC SFFLDIA01 TRS, LLCDelaware
ARHC SFFLDIA01, LLCDelaware
ARHC SFSCHIN01, LLCDelaware
ARHC SFSTOGA01, LLCDelaware
ARHC SLKLAOR01, LLCDelaware
ARHC SMERIPA01, LLCDelaware
ARHC SMMDSIA01 TRS, LLCDelaware
ARHC SMMDSIA01, LLCDelaware
ARHC SMMTEIA01 TRS, LLCDelaware
ARHC SMMTEIA01, LLC (f/k/a ARHC CO Borrower 10, LLC)Delaware
ARHC SPPLSIA01 TRS, LLCDelaware
ARHC SPPLSIA01, LLCDelaware
ARHC SSTMPFL01, LLCDelaware
ARHC TCHOUTX01, LLCDelaware
ARHC TPTMPFL01, LLCDelaware
ARHC TRS HOLDCO II, LLCDelaware
ARHC TVTITFL01 TRS, LLCDelaware
ARHC TVTITFL01, LLC (f/k/a ARHC CO BORROWER 4, LLC)Delaware
ARHC UCELKCA01, LLCDelaware
ARHC UPHBGPA01, LLCDelaware
ARHC UPHBGPA02, LLCDelaware
ARHC UPMOLIL01, LLCDelaware
ARHC UPMUSIA01, LLCDelaware
ARHC VAGBGIL01, LLCDelaware
ARHC VCSTOGA01, LLCDelaware
ARHC VSMCKTX01, LLCDelaware
ARHC VSTALFL01, LLCDelaware
ARHC WCWCHFL01, LLCDelaware
ARHC WGWCHIL01, LLCDelaware
ARHC WHWCHPA01 TRS, LLCDelaware
ARHC WHWCHPA01, LLCDelaware
ARHC WHYRKPA01, LLCDelaware
ARHC WIGNFWI01, LLCDelaware
ARHC WISMLWI01, LLCDelaware
ARHC WISTFWI01, LLCDelaware



ARHC WLWBYMN01, LLCDelaware
ARHC WMBRPMI01, LLCDelaware
ARHC WWGDRMI01, LLCDelaware
ARHC WWWYGMI01, LLCDelaware
Healthcare Trust Operating Partnership, L.P.Delaware
Healthcare Trust, Inc.Maryland
LEISURE LIVING MANAGEMENT OF BUCHANAN, LLCMichigan
LEISURE LIVING MANAGEMENT OF GRAND RAPIDS, INC.Michigan
LEISURE LIVING MANAGEMENT OF HOLLAND, INC.Michigan
LEISURE LIVING MANAGEMENT OF LANSING, INC.Michigan
LIFEHOUSE - CRYSTAL MANOR OPERATIONS, LLCMichigan
LIFEHOUSE - GOLDEN ACRES OPERATIONS, LLCMichigan
LIFEHOUSE - WALDON WOODS OPERATIONS, LLCMichigan
LIFEHOUSE CLARE OPERATIONS, LLCMichigan
LIFEHOUSE GRAND BLANC OPERATIONS, LLCMichigan
LIFEHOUSE MT. PLEASANT OPERATIONS, LLCMichigan
LIFEHOUSE PRESTIGE COMMONS OPERATIONS, LLCMichigan
LIFEHOUSE PRESTIGE WAY OPERATIONS, LLCMichigan
NuVista Living at Jupiter, LLCFlorida


EX-23.1 4 ex231hti12312020.htm EX-23.1 CONSENT OF PWC Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-197802) and S-11 (No. 333-248826) of Healthcare Trust, Inc. of our report dated March 29, 2021 relating to the financial statements and financial statement schedule, which appears in this Form 10‑K.


/s/ PricewaterhouseCoopers LLP
New York, New York
March 29, 2021










EX-23.2 5 ex232hti12312020.htm EX-23.2 CONSENT OF KPMG Document

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm


The Board of Directors
Healthcare Trust, Inc.:

We consent to the incorporation by reference in the registration statement (No. 333-197802) on Form S-3 and registration statement (No. 333-248826) on Form S-11 of Healthcare Trust, Inc. of our report dated March 13, 2019, with respect to the consolidated statements of operations and comprehensive loss, changes in equity, and cash flows of Healthcare Trust, Inc. for the year ended December 31, 2018, and the related notes and financial statement schedules III, before the effects of the retrospective adjustments for the effects of the stock dividends described in Note 1 and affecting per share amounts in the consolidated statements of operations and comprehensive loss, changes in equity, Note 2, Note 8 and Note 14, which report appears in the December 31, 2020 annual report on Form 10-K of Healthcare Trust, Inc.


/s/KPMG LLP

Chicago, Illinois 
March 29, 2021

EX-31.1 6 ex311hti12312020.htm EX-31.1 CEO 302 CERTIFICATION Document
Exhibit 31.1
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Edward M. Weil, Jr., certify that:
1.I have reviewed this Annual Report on Form 10-K of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated this 29th day of March, 2021/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)



EX-31.2 7 ex312hti12312020.htm EX-31.2 CFO 302 CERTIFICATION Document
Exhibit 31.2
CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a) UNDER
THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Katie P. Kurtz, certify that:
1.I have reviewed this Annual Report on Form 10-K of Healthcare Trust, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated this 29th day of March, 2021/s/ Katie P. Kurtz
Katie P. Kurtz
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)




EX-32 8 ex32hti12312020.htm EX-32 CEO AND CFO 906 CERTIFICATION Document

Exhibit 32
SECTION 1350 CERTIFICATIONS
This Certificate is being delivered pursuant to the requirements of Section 1350 of Chapter 63 (Mail Fraud) of Title 18 (Crimes and Criminal Procedures) of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
The undersigned, who are the Chief Executive Officer and Chief Financial Officer of Healthcare Trust, Inc. (the “Company”), each hereby certify as follows:
The Annual Report on Form 10-K of the Company, which accompanies this Certificate, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and all information contained in this annual report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of March, 2021
/s/ Edward M. Weil, Jr.
Edward M. Weil, Jr.
Chief Executive Officer and President
(Principal Executive Officer)
/s/ Katie P. Kurtz
Katie P. Kurtz
Chief Financial Officer, Treasurer and Secretary
(Principal Financial Officer and Principal Accounting Officer)


EX-101.SCH 9 hct-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details) link:presentationLink link:calculationLink link:definitionLink 2109103 - Disclosure - Real Estate Investments, Net link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Real Estate Investments, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Real Estate Investments, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details) link:presentationLink link:calculationLink link:definitionLink 2414408 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 2417411 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details) link:presentationLink link:calculationLink link:definitionLink 2418412 - Disclosure - Real Estate Investments, Net (Impairments) (Details) link:presentationLink link:calculationLink link:definitionLink 2419413 - Disclosure - Real Estate Investments, Net (Held for Sale) (Details) link:presentationLink link:calculationLink link:definitionLink 2120104 - Disclosure - Mortgage Notes Payable, Net link:presentationLink link:calculationLink link:definitionLink 2321303 - Disclosure - Mortgage Notes Payable, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422414 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details) link:presentationLink link:calculationLink link:definitionLink 2423415 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2124105 - Disclosure - Credit Facilities link:presentationLink link:calculationLink link:definitionLink 2325304 - Disclosure - Credit Facilities Credit Facilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2426416 - Disclosure - Credit Facilities (Summary of Credit Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 2427417 - Disclosure - Credit Facilities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2428418 - Disclosure - Credit Facilities (Future Principal Payments of Outstanding Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2129106 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2330305 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) link:presentationLink link:calculationLink link:definitionLink 2432420 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details) link:presentationLink link:calculationLink link:definitionLink 2133107 - Disclosure - Derivatives and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 2334306 - Disclosure - Derivatives and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 2435421 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2436422 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details) link:presentationLink link:calculationLink link:definitionLink 2437423 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2438424 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) link:presentationLink link:calculationLink link:definitionLink 2439425 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details) link:presentationLink link:calculationLink link:definitionLink 2140108 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2341307 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2442426 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2443427 - Disclosure - Stockholders' Equity (Stock Redemption) (Details) link:presentationLink link:calculationLink link:definitionLink 2444428 - Disclosure - Stockholders' Equity (Distributions) (Details) link:presentationLink link:calculationLink link:definitionLink 2145109 - Disclosure - Related Party Transactions and Arrangements link:presentationLink link:calculationLink link:definitionLink 2346308 - Disclosure - Related Party Transactions and Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2447429 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details) link:presentationLink link:calculationLink link:definitionLink 2448430 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details) link:presentationLink link:calculationLink link:definitionLink 2449431 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 2450432 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2151110 - Disclosure - Economic Dependency link:presentationLink link:calculationLink link:definitionLink 2152111 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2353309 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2454433 - Disclosure - Equity-Based Compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2455434 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) link:presentationLink link:calculationLink link:definitionLink 2156112 - Disclosure - Accumulated Other Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 2357310 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2458435 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) link:presentationLink link:calculationLink link:definitionLink 2159113 - Disclosure - Non-Controlling Interests link:presentationLink link:calculationLink link:definitionLink 2360311 - Disclosure - Non-Controlling Interests (Tables) link:presentationLink link:calculationLink link:definitionLink 2461436 - Disclosure - Non-Controlling Interests (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2462437 - Disclosure - Non-Controlling Interests (Summary of Non-Controlling Interests) (Details) link:presentationLink link:calculationLink link:definitionLink 2163114 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2364312 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2465438 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2166115 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2367313 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2468439 - Disclosure - Segment Reporting (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2469440 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2470441 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2471442 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) link:presentationLink link:calculationLink link:definitionLink 2172116 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2373314 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2474443 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2475444 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 2475444 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) link:presentationLink link:calculationLink link:definitionLink 2176117 - Disclosure - Quarterly Results (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2377315 - Disclosure - Quarterly Results (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2478445 - Disclosure - Quarterly Results (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2179118 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2480446 - Disclosure - Subsequent Events (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2181119 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III link:presentationLink link:calculationLink link:definitionLink 2482447 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details) link:presentationLink link:calculationLink link:definitionLink 2483448 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details) link:presentationLink link:calculationLink link:definitionLink 2484449 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 hct-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 hct-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 hct-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Area of real estate property Area of Real Estate Property FOC II - Mechanicsburg, PA FOC II - Mechanicsburg [Member] FOC II - Mechanicsburg [Member] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Revision of Prior Period [Axis] Revision of Prior Period [Axis] Related Party [Axis] Related Party [Axis] Tender Offer Tender Offer [Member] Tender Offer [Member] Amortization of mortgage premiums and discounts, net Amortization of Debt Discount (Premium) Real estate investments Real Estate Properties [Line Items] Common stock issued through distribution reinvestment plan (in shares) Stock Issued During Period, Shares, Dividend Reinvestment Plan Noncontrolling Interest [Table] Noncontrolling Interest [Table] Accumulated depreciation Real Estate Investment Property, Accumulated Depreciation, Period Increase (Decrease) Real Estate Investment Property, Accumulated Depreciation, Period Increase (Decrease) MetroHealth Buckeye Health Center - Cleveland, OH MetroHealthBuckeyeHealthCenterCleveland [Member] MetroHealthBuckeyeHealthCenterCleveland [Member] Aurora Healthcare Center - Green Bay, WI Aurora Health Center - Green Bay [Member] Aurora Health Center - Green Bay [Member] Aurora Healthcare Center - Wautoma, WI Aurora Healthcare Center, Wautoma, WI [Member] Aurora Healthcare Center, Wautoma, WI [Member] Economic Dependency [Abstract] Economic Dependency [Abstract] Economic Dependency [Abstract] Class B units (in shares) Common Share Equivalents, Shares Outstanding Common Share Equivalents, Shares Outstanding Campus at Crooks & Auburn Building D - Rochester Mills, MI Campus at Crooks & Auburn Building D - Rochester Hills [Member] Campus at Crooks & Auburn Building D - Rochester Hills [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND EQUITY Liabilities and Equity [Abstract] 2025 Lessor, Operating Lease, Payment to be Received, Year Five Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Distributions to non-controlling interest holders Distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Preferred Stock Preferred Stock [Member] Security Exchange Name Security Exchange Name CareMeridian - Littleton, CO CareMeridian - Littleton, CO. [Member] CareMeridian - Littleton, CO. [Member] Renaissance on Peachtree - Atlanta, GA Renaissance on Peachtree - Atlanta [Member] Renaissance on Peachtree - Atlanta [Member] Allegro at Elizabethtown - Elizabethtown, KY Allegro at Elizabethtown - Elizabethtown - September [Member] Allegro at Elizabethtown - Elizabethtown - September [Member] Below market leases Below Market Leases [Member] Below Market Leases Beginning Balance, Weighted-Average Issue Price (usd per share) Ending Balance, Weighted-Average Issue Price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Total minimum lease payments Finance Lease, Liability, Payment, Due ASSETS Assets [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Principal amount outstanding limitation to release or replace properties Long-term Debt, Outstanding, Limitation to Release or Replace Properties Long-term Debt, Outstanding, Limitation to Release or Replace Properties Share-based compensation, net Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Operating lease payments Operating Lease, Payments Intangible liabilities: Below Market Lease, Net [Abstract] Accumulated Other Comprehensive (Loss) Income Comprehensive Income (Loss) Note [Text Block] 2023 Long-Term Debt, Maturity, Year Three Change in Control Fee Change in Control Fee [Member] Change in Control Fee [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Adena Health Center - Jackson, OH Adena Health Center - Jackson, OH [Member] Adena Health Center - Jackson, OH [Member] Non-controlling Interests Non-controlling Interest Policy [Policy Text Block] Non-controlling Interest Policy [Policy Text Block] Overstatement of previously recorded tax benefits, deferred tax assets and net income Overstatement Of Previously Recorded Tax Benefits, Deferred Tax Assets and Net Income Overstatement Of Previously Recorded Tax Benefits, Deferred Tax Assets and Net Income 2021 Lessee, Operating Lease, Liability, to be Paid, Year One Number of shares repurchased (in shares) Treasury Stock, Shares, Acquired UMPC Chambers Hill - Harrisburg, PA UMPC Chambers Hill - Harrisburg [Member] UMPC Chambers Hill - Harrisburg NuVista NuVista [Member] NuVista [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Four Nonvested awards, compensation cost not yet recognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Shares approved for issuance (in shares) Common Share Equivalents, Shares Approved for Issuance Common Share Equivalents, Shares Approved for Issuance Other assets acquired and liabilities assumed in the asset acquisition, net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net Current state (expense) benefit Current State and Local Tax Expense (Benefit) Beginning Balance (in shares) Ending Balance (in shares) Common stock, shares outstanding (in shares) Shares, Outstanding Share price, net (in dollars per share) Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees 7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 2,210,000 and 1,610,000 authorized as of December 31, 2020 and 2019, respectively; 1,610,000 issued and outstanding as of December 31, 2020 and 2019 Preferred Stock, Value, Issued Gross Revenue, Stand-alone Single-tenant Net Leased Properties Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member] Total expenses Operating Expenses Building Building [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] New York Six MOBs (1 property) New York Six MOBs (1 property) [Member] New York Six MOBs (1 property) [Member] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Financing advance fees as a percentage of benchmark, expected third party costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs Common stock issued through distribution reinvestment plan Common stock issued through distribution reinvestment plan Stock Issued During Period, Value, Dividend Reinvestment Plan American Realty Capital Healthcare II Special Limited Partnership, LLC American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] American Realty Capital Healthcare II Special Limited Partnership, LLC [Member] Wellington at Hershey's Mill - West Chester, PA Wellington at Hershey's Mill - West Chester [Member] Wellington at Hershey's Mill - West Chester [Member] Amortization of terminated swap Amortization of Terminated Swap Payment Amortization of Terminated Swap Payment Transaction amount Related Party Transaction, Amounts of Transaction Variable Management - Incentive Fee Variable Management - Incentive Fee [Member] Variable Management - Incentive Fee [Member] Reduction of real estate cost percent Related Party Transaction Reduction of Real Estate Cost Percent Related Party Transaction Reduction of Real Estate Cost Percent Measurement Frequency [Domain] Measurement Frequency [Domain] Capped Reimbursement Amount Capped Reimbursement Amount [Member] Capped Reimbursement Amount [Member] SNF Properties SNF Properties [Member] SNF Properties [Member] Dividends Payable [Line Items] Dividends Payable [Line Items] Subordinated performance fee as a percentage of benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark Monthly Base Management Fee Monthly Base Management Fee [Member] Monthly Base Management Fee [Member] Concentration risk, percentage Concentration Risk, Percentage Board chairman Board of Directors Chairman [Member] Autumn Leaves of The Woodlands - The Woodlands, TX Autumn Leaves of the Woodlands - The Woodlands [Member] Autumn Leaves of the Woodlands - The Woodlands [Member] Statement [Line Items] Statement [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Disposals, impairments and reclasses Assets Other Real Estate, Disposals And Reclasses Other Real Estate, Disposals And Reclasses Addington Place of Brunswick - Brunswick, GA Addington Place of Brunswick - Brunswick - September [Member] Addington Place of Brunswick - Brunswick - September [Member] Number of properties transferred Disposal Group Including Discontinued Operation, Number Of Properties Transferred Disposal Group Including Discontinued Operation, Number Of Properties Transferred Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Cash in excess of FDIC limit Cash, Uninsured Amount Sale of stock, gross proceeds Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Entity Small Business Entity Small Business Principles of Consolidation and Basis of Presentation Consolidation, Policy [Policy Text Block] Encumbered properties Number of Real Estate Properties, Encumbered Number of Real Estate Properties, Encumbered Surgery Center of Temple - Temple, TX Surgery Center of Temple - Temple, TX. [Member] Surgery Center of Temple - Temple, TX. [Member] Impairment charges Impairment charges Impairment of Real Estate Preferred stock, number of shares issued in public offering Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Credit Facilities Debt Disclosure [Text Block] Eastside Cancer Institute - Greenville, SC Eastside Cancer institute - Greenville - October [Member] Eastside Cancer institute - Greenville - October [Member] American Realty Capital Healthcare Advisors, LLC American Realty Capital Healthcare Advisors, LLC [Member] American Realty Capital Healthcare Advisors, LLC [Member] Prairie Hills at Tipton - Tipton, IA Prairie Hills at Tipton - Tipton - August [Member] Prairie Hills at Tipton - Tipton - August [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Amendment Flag Amendment Flag Schedule of Restricted Share Award Activity Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized UMPC Fisher Road - Mechanicsburg, PA UMPC Fisher Road - Mechanicsburg [Member] UMPC Fisher Road - Mechanicsburg Below market leases, amortization income, 2022 Below Market Lease, Amortization Income, Year Two Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Below market leases, amortization income, 2023 Below Market Lease, Amortization Income, Year Three Addington Place of Alpharetta - Alpharetta, GA Addington Place of Alpharetta - Alpharetta [Member] Addington Place of Alpharetta - Alpharetta [Member] Distributions to non-controlling interest holders Distributions to non-controlling interest holders Payments of Ordinary Dividends, Noncontrolling Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Hampton River Medical Arts Building - Hampton, VA Hampton River Medical Arts Building - Hampton - December [Member] Hampton River Medical Arts Building - Hampton - December [Member] Line of credit, increase Line of Credit Facility, Accordion Feature, Increase Limit Line of Credit Facility, Accordion Feature, Increase Limit Covenant Period from June 30 2021 through Commencement Quarter Covenant Period from June 30 2021 through Commencement Quarter [Member] Covenant Period from June 30 2021 through Commencement Quarter Costs capitalized subsequent to acquisition, land SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Land Sunnybrook of Carroll - Carroll, IA Sunnybrook of Carroll - Carroll - August26 [Member] Sunnybrook of Carroll - Carroll - August26 [Member] Fair Value, by Balance Sheet Grouping Fair Value, by Balance Sheet Grouping [Table Text Block] Offsetting Assets Offsetting Assets [Table Text Block] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Acuity Specialty Hospital - Mesa, AZ AcuitySpecialtyHospitalMesa [Member] AcuitySpecialtyHospitalMesa [Member] Prepaid expenses and other assets, due from related parties Due from Related Parties Derivative Instruments Derivatives, Policy [Policy Text Block] Accrued capital expenditures (payable) Capital Expenditures Incurred but Not yet Paid Dividends [Domain] Dividends [Domain] Brady MOB - Harrisburg, PA Brady MOB - Harrisburg [Member] Brady MOB - Harrisburg [Member] Subsequent Events Subsequent Events [Text Block] Operating lease impairment loss Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal) Dignity Emerus Blue Diamond - Las Vegas, NV Dignity Emerus Blue Diamond Road - Las Vegas [Member] Dignity Emerus Blue Diamond Road - Las Vegas [Member] Straight-line rents receivable Proceeds from Lease Payment, Operating Activity Straight-line rent receivable, net Deferred Rent Receivables, Net, Noncurrent Day Prior to Commencement Quarter Day Prior to Commencement Quarter [Member] Day Prior to Commencement Quarter Additions-Acquisitions Real Estate Investment Property, at Cost, Acquisitions Real Estate Investment Property, at Cost, Acquisitions Covenant Period From April 1 2021 through June 30 2021 Covenant Period From April 1 2021 through June 30 2021 [Member] Covenant Period From April 1 2021 through June 30 2021 Professional Fees and Reimbursements Professional Fees and Reimbursements [Member] Professional Fees and Reimbursements [Member] Gross Carrying Amount Below Market Lease, Gross Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Real estate investments, at cost: Real Estate Investment Property, at Cost [Abstract] Florida Medical Somerset - Tampa, FL Florida Medical - Somerset [Member] Florida Medical - Somerset [Member] 2022 Lessee, Operating Lease, Liability, to be Paid, Year Two Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Minimum net worth required for compliance Minimum Net Worth Required for Compliance 2023 Lessee, Operating Lease, Liability, to be Paid, Year Three Stock issued during period, issued for services (in shares) Stock Issued During Period, Shares, Issued for Services Preferred Stock Equity Line Preferred Stock Equity Line [Member] Preferred Stock Equity Line Plan Name [Axis] Plan Name [Axis] Aggregate termination value Assets Needed for Immediate Settlement, Aggregate Fair Value Swedish American MOB - Roscoe, IL Swedish American MOB - Roscoe [Member] Swedish American MOB - Roscoe Concentration Risk [Table] Concentration Risk [Table] Commencement Quarter Commencement Quarter [Member] Commencement Quarter Real estate investments pledged as collateral Real Estate Investment, At Cost Relating to Notes Payable Real Estate Investment, At Cost Relating to Notes Payable Total assets Assets Reimbursed fees to related party, capped reimbursement amount Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount Related Party Transactions and Arrangements Related Party Transactions Disclosure [Text Block] UnityPoint Clinic - Moline, IL UnityPoint Clinic - Moline [Member] UnityPoint Clinic - Moline [Member] Multi-tenant MOB Multi-tenant MOB [Member] Multi-tenant MOB [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Felicita Vida - Escondido, CA FelicitaVidaEscondido [Member] FelicitaVidaEscondido [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Ouachita Community Hospital - West Monroe, LA Ouachita Community Hospital - West Monroe, LA [Member] Ouachita Community Hospital - West Monroe, LA [Member] Buildings, fixtures and improvements Buildings, Fixtures and Improvements Buildings, Fixtures and Improvements Quarterly asset management fee Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark Shares authorized for repurchase (in shares) Stock Repurchase Program, Number of Shares Authorized to be Repurchased Market lease assets Intangible Market Lease Assets [Member] Intangible Market Lease Assets [Member] Allegro at Tarpon - Tarpon Springs, FL Allegro at Tarpon - Tarpon Springs - September [Member] Allegro at Tarpon - Tarpon Springs - September [Member] Other intangible assets Other Intangible Assets [Member] Total liabilities Liabilities Long-term debt, percentage bearing fixed interest, amount Long-term Debt, Percentage Bearing Fixed Interest, Amount Land and Building Land and Building [Member] Net offering proceeds, percent Debt Instrument, Covenants, Percent Of Net Offering Proceeds Debt Instrument, Covenants, Percent Of Net Offering Proceeds Less: amounts representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule related to Investment Arrangements with Unaffiliated Third Party Redeemable Noncontrolling Interest [Table Text Block] 757 Building - Munster, IN 757 Building - Munster - October [Member] 757 Building - Munster - October [Member] Quoted Prices in Active Markets Level 1 Fair Value, Inputs, Level 1 [Member] Advance on Loan or Other Investment Advance on Loan or Other Investment [Member] Advance on Loan or Other Investment [Member] Amended and Restated RSP Amended and Restated RSP [Member] Amended and Restated RSP [Member] Real Estate [Abstract] Real Estate [Abstract] Number of states properties are located in Number of States in which Entity Operates Number of Common Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Fox Ridge Bryant - Bryant, AR Palm Valley Medical Plaza AZ [Member] Palm Valley Medical Plaza AZ [Member] Deferred tax valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Careplex West Medical Office Building - Hampton, VA Careplex West Medical Office Building- Hampton [Member] Careplex West Medical Office Building- Hampton [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Contract Purchase Price Contract Purchase Price [Member] Contract Purchase Price [Member] Circleville MOB - Circleville, OH Circleville MOB - Circleville [Member] Circleville MOB - Circleville Development costs Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Development in Process, Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Development in Process, Acquired in Period Rent collection percentage Rent Collection Percentage Rent Collection Percentage Reclassification From Held-For-Sale To Real Estate Investments Reclassification From Held-For-Sale To Real Estate Investments [Member] Reclassification From Held-For-Sale To Real Estate Investments Unencumbered properties Number of Real Estate Properties, Unencumbered Number of Real Estate Properties, Unencumbered KeyBank Facility KeyBank Facility [Member] KeyBank Facility [Member] Buyout of NCI Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Common stock, shares outstanding (in shares) Common stock held by related party (in shares) Common Stock, Shares, Outstanding Lancaster Medical Arts MOB - Lancaster, PA LancasterMedicalArtsMOBLancaster [Member] LancasterMedicalArtsMOBLancaster [Member] Sky Lakes Klamath Medical Clinic - Klamath Falls, OR Sky Lakes Klamath Medical Clinic - Klamath Falls [Member] Sky Lakes Klamath Medical Clinic - Klamath Falls [Member] Revolving Credit Facility Revolving Credit Facility [Member] Third Amended And Restated Advisory Agreement Third Amended And Restated Advisory Agreement [Member] Third Amended And Restated Advisory Agreement [Member] Return of capital (1) Return of Capital [Member] Return of Capital [Member] Debt Covenant Period [Domain] Debt Covenant Period [Domain] Debt Covenant Period Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Common stock, shares authorized (in shares) Common Stock, Shares Authorized RAI Care Center - Clearwater, FL RAI Clearwater [Member] RAI Clearwater [Member] Number of instruments terminated Derivative, Number of Instruments Terminated Derivative, Number of Instruments Terminated Deferred federal (expense) benefit Deferred Federal Income Tax Expense (Benefit) Mortgage Notes Payable, Net Mortgage Notes Payable Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Special allocation for tax purposes excess depreciation deductions maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Triple-net leased healthcare facilities Triple-Net Leased Healthcare Facilities [Member] Triple-Net Leased Healthcare Facilities [Member] Prepayment penalty, year two Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Two Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Two Fannie Mae Master Credit Facility Fannie Mae Master Credit Facility [Member] Fannie Mae Master Credit Facility [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Greenfield Medical Plaza - Gilbert, AZ Greenfield Medical Plaza - Gilbert [Member] Greenfield Medical Plaza - Gilbert [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Pioneer Spine Sports - Northampton, MA PioneerSpineSportsNorthampton [Member] PioneerSpineSportsNorthampton [Member] Name of Property [Domain] Name of Property [Domain] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Use of Estimates Use of Estimates, Policy [Policy Text Block] Lee Memorial Health System Outpatient Center - Ft. Myers Lee Memorial Health System Outpatient Center - Fort Meyers [Member] Lee Memorial Health System Outpatient Center - Fort Meyers [Member] Increase in preferred stock, dividend rate, percentage Increase (Decrease) Preferred Stock, Dividend Rate, Percentage Increase (Decrease) Preferred Stock, Dividend Rate, Percentage Income Tax Authority [Domain] Income Tax Authority [Domain] Distributions declared on common stock Dividends Shares granted automatically upon election to board of directors (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Automatic Grant Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Automatic Grant Economic Dependency Economic Dependency [Text Block] Matters related to services provided by affiliate. Interest rate caps Interest Rate Cap [Member] Capital expenditures Payments to Acquire Property, Plant, and Equipment Counterparty Name [Domain] Counterparty Name [Domain] Consolidation Items [Domain] Consolidation Items [Domain] Revision of Prior Period, Adjustment Revision of Prior Period, Adjustment [Member] Rental Income Rental Income [Member] Rental Income [Member] Addington Place of College Harbour - St Petersburg, FL AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member] AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member] Stock dividend (usd per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value Director Director [Member] Severance Payments Severance Payments [Member] Severance Payments Lease intangibles, lease-up period Lease Intangibles, Lease-up Period Lease Intangibles, Lease-up Period Illinois CancerCare - Galesburg, IL Illinois Cancer Care - Galesburg [Member] Illinois Cancer Care - Galesburg [Member] Real Estate Cost Real Estate Cost [Member] Real Estate Cost [Member] Acuity Specialty Hospital - Sun City, AZ AcuitySpecialtyHospitalSunCity [Member] AcuitySpecialtyHospitalSunCity [Member] Hedging Designation [Axis] Hedging Designation [Axis] Stock dividend (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend Schedule of Assets Held for Sale Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Transition Fee Transition Fee [Member] Transition Fee [Member] Entity [Domain] Entity [Domain] East Coast Square West - Cedar Point, NC East Coast Square West - Cedar Point - October [Member] East Coast Square West - Cedar Point - October [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Addington Place of Johns Creek - Johns Creek, GA Addington Place of Johns Creek - Johns Creek - September [Member] Addington Place of Johns Creek - Johns Creek - September [Member] Quarterly Results (Unaudited) Quarterly Financial Information [Text Block] MOB Loan MOB Loan [Member] MOB Loan [Member] Consumer Price Index Consumer Price Index [Member] Consumer Price Index [Member] Stock dividends (in shares) Stock Dividends, Shares Useful life Property, Plant and Equipment, Useful Life Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] In-place leases and other intangible assets In-place Leases and Other Intangible Assets [Member] In-place Leases and Other Intangible Assets [Member] Number of properties held-for-use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Disposal Group Including Discontinued Operation, Number Of Properties Held For Use Restricted cash Restricted Cash and Cash Equivalents Business acquisitions Series of Individually Immaterial Business Acquisitions [Member] Settled Litigation Settled Litigation [Member] VA Outpatient Clinic - Galesberg, IL VA Outpatient Clinic - Galesburg [Member] VA Outpatient Clinic - Galesburg [Member] Unvested restricted shares Restricted Stock [Member] Prepayment penalty, initial twelve months Debt Instrument, Prepayment Penalty, Percentage of Principal, Initial Twelve Months Debt Instrument, Prepayment Penalty, Percentage of Principal, Initial Twelve Months Deferred Financing and Leasing Costs, Net Deferred Charges, Policy [Policy Text Block] Above- and below-market leases, net Above and Below Market Leases [Member] Above and Below Market Leases [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Fannie Mae Master Credit Facilities Master Credit Facility Master Credit Facility [Member] Master Credit Facility [Member] Land Land [Member] Schererville Building - Schererville, IN Schererville Building - Schererville [Member] Schererville Building - Schererville [Member] Beginning Balance (in shares) Ending Balance (in shares) Unvested restricted stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number New Credit Facilities New Credit Facilities [Member] New Credit Facilities [Member] Forfeitures, Weighted-Average Issue Price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Contingent good faith negotiations of fixed component, term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Weighted-average remaining amortization periods Finite-Lived Intangible Assets, Remaining Amortization Period Capital One Facility Capital One Facility [Member] Capital One Facility [Member] Seniors Housing Communities Seniors Housing Communities [Member] Seniors Housing Communities [Member] Interest rate swaps Interest Rate Swap [Member] Customer [Domain] Customer [Domain] Second Amended and Restated Advisory Agreement Second Amended and Restated Advisory Agreement [Member] Second Amended and Restated Advisory Agreement [Member] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Land Improvements Land Improvements [Member] Preferred stock, additional shares authorized (in shares) Preferred Stock, Additional Shares Authorized Preferred Stock, Additional Shares Authorized Allegro at Jupiter - Jupiter, FL Allegro at Jupiter - Jupiter - September [Member] Allegro at Jupiter - Jupiter - September [Member] Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Concentration Risk [Line Items] Concentration Risk [Line Items] Deferred rent Increase (Decrease) in Other Operating Liabilities Total real estate investments, at cost Real estate investments, at cost Real Estate Investment Property, at Cost Impairment charges Asset Impairment Charges Autumn Leaves of Clear Lake, Houston, TX Autumn Leaves of Clear Lake - Houston - December [Member] Autumn Leaves of Clear Lake - Houston - December [Member] Deferred financing costs, net of accumulated amortization Deferred financing costs Debt Issuance Costs, Net Glendale MOB - Farmington Hills, MI Glendale MOB - Farmington Hills MI [Member] Glendale MOB - Farmington Hills MI [Member] Payments for underwriting expense Payments for Underwriting Expense Ocean Park Ocean Park Center [Member] Ocean Park Center [Member] Jupiter, Florida Jupiter, Florida [Member] Jupiter, Florida [Member] Less: amounts representing interest Finance Lease, Liability, Undiscounted Excess Amount Professional fees and other reimbursements Transfer Agent and Other Professional Fees [Member] Transfer Agent and other professional fees [Member] Distributions paid on common stock Payments of Ordinary Dividends, Common Stock Adventist Health Lacey Medical Plaza - Hanford, CA Adventist Health Lacey Medical Plaza - Hanford [Member] Adventist Health Lacey Medical Plaza - Hanford [Member] Fresenius Medical Care - Winfield, AL Fresenius Medical Care - Winfield, AL [Member] Fresenius Medical Care - Winfield, AL [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Assets held for sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Real Estate [Domain] Real Estate [Domain] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Period of notice of termination Related Party Transaction, Period of Notice for Termination Related Party Transaction, Period of Notice for Termination Percent distribution in excess of modified funds from operations Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Acquired intangibles Real Estate Investments, Acquired Intangible Assets, Total Real Estate Investments, Acquired Intangible Assets, Total Multi-Property CMBS Loan Fox Ridge Senior Living at Chenal - Little Rock [Member] Fox Ridge Senior Living at Chenal - Little Rock [Member] St. Andrews Medical Park - Venice, FL St. Andrews Medical Park - Venice [Member] St. Andrews Medical Park - Venice [Member] Sale of Stock [Axis] Sale of Stock [Axis] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Deferred tax asset, net Deferred Tax Assets, Net of Valuation Allowance Florida Medical Heartcare - Tampa, FL Florida Medical - Heartcare [Member] Florida Medical - Heartcare [Member] Proceeds from sale of interest rate cash flow hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Proceeds From Sale of Interest Rate Cash Flow Hedge Bowie Gateway Medical Center - Bowie, MD Bowie Gateway Medical Center - Bowie [Member] Bowie Gateway Medical Center - Bowie [Member] Real estate investments, at cost: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract] Lutz, Florida Lutz, Florida [Member] Lutz, Florida [Member] Scripps Cedar Medical Center - Vista, CA Scripps Cedar Medical Center - Vista - August [Member] Scripps Cedar Medical Center - Vista - August [Member] Distributions declared per share (in usd per share) Distributions declared in cash (in usd per share) Common Stock, Dividends, Per Share, Declared Debt instrument, face amount Debt Instrument, Face Amount Sassafras Medical Building - Erie, PA Sassafras Medical Building - Erie [Member] Sassafras Medical Building - Erie [Member] Prepaid Expenses and Other Assets Prepaid Expenses And Other Assets [Member] Prepaid Expenses And Other Assets Equity [Abstract] Equity [Abstract] Interest rate cap Derivative, Cap Interest Rate East Coast Square North - Morehead City, NC East Coast Square North - Morehead City - October [Member] East Coast Square North - Morehead City - October [Member] Federal income taxes SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Federal Income Tax Basis Maximum authorized amount as a percentage of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Arrowhead Medical Plaza I - Glendale, AZ Arrowhead Medical Plaza I - Glendale [Member] Arrowhead Medical Plaza I - Glendale [Member] Covenant Period July 1 2020 through June 30 2021 Covenant Period July 1 2020 through June 30 2021 [Member] Covenant Period July 1 2020 through June 30 2021 Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible List] Granted, Weighted-Average Issue Price (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Other income (expense): Other Income and Expenses [Abstract] Forfeitures (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] St. Francis WI MOB - St. Francis, WI StFrancisWIMOBStFrancis [Member] StFrancisWIMOBStFrancis [Member] Total intangible assets and liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net Pioneer Spine Sport - Springfield, MA PioneerSpineSportsSpringfield [Member] PioneerSpineSportsSpringfield [Member] Net cash, provided by financing activities Net Cash Provided by (Used in) Financing Activities Dividends paid on preferred stock Payments of Ordinary Dividends, Preferred Stock and Preference Stock Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.01 par value, 300,000,000 shares authorized, 95,040,783 (including 1,265,037 shares paid as a stock dividend on January 15, 2021) and 92,356,664 shares of common stock issued and outstanding as of December 31, 2020 and 2019, respectively Common Stock, Value, Issued Victory Medical Center at Craig Ranch - McKinney, TX VictoryMedicalCenteratCraigRanchMcKinney [Member] VictoryMedicalCenteratCraigRanchMcKinney [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] Palm Valley Medical Plaza - Goodyear, AZ Countryside Medical Arts - Safety Harbor, FL [Member] Countryside Medical Arts - Safety Harbor, FL [Member] Finite-lived intangible assets, amortization expense, 2022 Finite-Lived Intangible Asset, Expected Amortization, Year Two Proceeds from mortgage notes payable Proceeds from Issuance of Secured Debt Basis of core earnings, percent Related Party Transaction, Basis of Core Earnings, Percent Related Party Transaction, Basis of Core Earnings, Percent Crittenton Sterling Heights MOB - Sterling Heights, MI Crittenton Sterling Heights MOB [Member] Crittenton Sterling Heights MOB [Member] Entity Current Reporting Status Entity Current Reporting Status Schedule of Shares Repurchased [Table] Schedule of Shares Repurchased [Table] Schedule of Shares Repurchased [Table] Related Party Transaction [Axis] Related Party Transaction [Axis] Per Share Data Earnings Per Share, Policy [Policy Text Block] Aurora Health Center - Milwaukee, WI AuroraHealthCenterMilwaukeeApril [Member] AuroraHealthCenterMilwaukeeApril [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Addington Place of Titusville - Titusville, FL Addington Place of Titusville - Titusville [Member] Addington Place of Titusville - Titusville [Member] Mortgage notes payable, net Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds Operating lease liabilities Operating Lease, Liability Cash flow hedge reclassification current Unamortized portion remaining in accumulated other comprehensive (loss) income Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss Share Repurchase Program [Axis] Share Repurchase Program [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ equity Stockholders' Equity Attributable to Parent Cedarhurst of Edwardsville - Edwardsville, IL Cedarhurst Of Edwardsville - Edwardsville [Member] Cedarhurst Of Edwardsville - Edwardsville Business combination, consideration transferred Business Combination, Consideration Transferred COVID19 Pandemic COVID19 Pandemic [Member] COVID19 Pandemic Advanced Orthopedic Medical Center - Richmond, VA Advanced Orthopaedic Medical Center - Richmond - April [Member] Advanced Orthopaedic Medical Center - Richmond - April [Member] Entity Address, City or Town Entity Address, City or Town Northside Hospital - Canton, GA Northside Hospital Medical Office Building - Canton [Member] Northside Hospital Medical Office Building - Canton [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Total Stockholders’ Equity Parent [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Five Type of Adoption [Domain] Accounting Standards Update [Domain] Pulmonary & Critical Care Med - Lemoyne, PA Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member] Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member] Investments in Real Estate Real Estate, Policy [Policy Text Block] Schedule of Derivatives Included in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fox Ridge Senior Living at Chenal - Little Rock, AR Fox Ridge Senior Living at Chenal - Little Rock - December [Member] Fox Ridge Senior Living at Chenal - Little Rock - December [Member] Deferred tax asset valuation allowance Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Proceeds from government assistance Proceeds From Government Assistance, CARES Act Proceeds From Government Assistance, CARES Act Real Estate Investments, Net Real Estate Disclosure [Text Block] Finite-lived intangible assets, amortization expense, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year Three Construction in Progress Construction in Progress [Member] Assets held for sale Assets held for sale Disposal Group, Including Discontinued Operation, Assets Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Woodlake Office Center - Woodbury, MN Woodlake Office Center [Member] Woodlake Office Center [Member] Board of directors voting percentage Related Party Transaction, Voting Percentage Required to Alter Agreement Related Party Transaction, Voting Percentage Required to Alter Agreement Accumulated depreciation: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward] Below market leases, amortization income, 2024 Below Market Lease, Amortization Income, Year Four Skilled Nursing Facilities Skilled Nursing Facilities [Member] Skilled Nursing Facilities [Member] Number of senior housing communities Number of Senior Housing Communities Number of Senior Housing Communities Unrealized gain on designated derivative Other Comprehensive Income (Loss), Net of Tax Land Disposal Group, Including Discontinued Operation, Land Disposal Group, Including Discontinued Operation, Land Rivershores Healthcare & Rehab Centre - Marseilles, IL Rivershores Healthcare & Rehab Centre - Marseilles - December [Member] Rivershores Healthcare & Rehab Centre - Marseilles - December [Member] Leases [Abstract] Leases [Abstract] Number of properties receiving grants Number Of Properties For Which Grants Were Received Number Of Properties For Which Grants Were Received Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Operating loss carryforwards Operating Loss Carryforwards Dividends [Axis] Dividends [Axis] Market lease and other intangible assets Above-market lease assets Above Market Leases [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Floor interest rate Debt Instrument, Floor Interest Rate Debt Instrument, Floor Interest Rate Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Finite-lived intangible assets, amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Fiscal Period Focus Document Fiscal Period Focus Basis of core earnings (in usd per share) Related Party Transaction, Basis of Core Earnings, Per Share Basis Related Party Transaction, Basis of Core Earnings, Per Share Basis Authorized preferred stock offering, value Preferred Stock Offering, Authorized Value Preferred Stock Offering, Authorized Value Addington Place - Northville, MI Addington Place - Northville [Member] Addington Place - Northville Number of properties disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Disposal Group Including Discontinued Operation, Number Of Properties Disposed Disposals, impairments and reclasses Accumulated depreciation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold High Desert Medical Group Medical Office Building - Lancaster, CA High Desert Medical Group Medical Office Building - Lancaster [Member] High Desert Medical Group Medical Office Building - Lancaster [Member] Mount Vernon Medical Office Building - Mount Vernon, WA Mount Vernon Medical Office Building - Mount Vernon - November [Member] Mount Vernon Medical Office Building - Mount Vernon - November [Member] Operating fees to related parties Affiliate Costs Property management fees (6) Property Management and Leasing Fees [Member] Property Management and Leasing Fees [Member] Mortgage Notes Payable Mortgages [Member] Commercial Center - Peoria, AZ Commercial Center - Peoria - May [Member] Commercial Center - Peoria - May [Member] Addington Place of Lee's Summit - Lee's Summit, MO Addington Place of Lee's Summit - Lee's Summit - September [Member] Addington Place of Lee's Summit - Lee's Summit - September [Member] Entity Filer Category Entity Filer Category Renewal term Related Party Agreement, Term of Agreement, Renewal Period Related Party Agreement, Term of Agreement, Renewal Period Common Stock Common Stock [Member] Non-refundable deposits Disposal Group, Including Discontinued Operation, Consideration, Deposit Disposal Group, Including Discontinued Operation, Consideration, Deposit Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Mainland Medical Arts Pavilion - Texas City, TX Mainland Medical Arts Pavilion - Texas City [Member] Mainland Medical Arts Pavilion - Texas City [Member] Milwaukee MOB - South Milwaukee, WI MilwaukeeMOBSouthMilwaukee [Member] MilwaukeeMOBSouthMilwaukee [Member] Secured Debt Secured Debt [Member] 2021 Lessor, Operating Lease, Payment to be Received, Year One Mortgage assumed in acquisition Noncash, or Part Noncash, Mortgage Notes Payable Secured In Connection With The Acquisition Of Real Estate Noncash, or Part Noncash, Mortgage notes secured simultaneously with the acquisition of real estate assets, which includes land, buildings, fixtures, and land and building improvements. Derivative liabilities, at fair value Derivative Financial Instruments, Liabilities [Member] Sales Revenue, Net Revenue Benchmark [Member] Revision of Prior Period [Domain] Revision of Prior Period [Domain] Unusual or Infrequent Item, or Both [Domain] Unusual or Infrequent Item, or Both [Domain] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage American Realty Capital Healthcare III Advisors, LLC American Realty Capital Healthcare III Advisors, LLC [Member] American Realty Capital Healthcare III Advisors, LLC [Member] Land SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land Sunnybrook of Burlington - Burlington, IA Sunnybrook of Burlington - Burlington [Member] Sunnybrook of Burlington - Burlington [Member] Healthcare Trust Special Limited Partnership, LLC Healthcare Trust Special Limited Partnership, LLC [Member] Healthcare Trust Special Limited Partnership, LLC [Member] Name of Property [Axis] Name of Property [Axis] Paradise Valley Medical Plaza - Phoenix, AZ Paradise Valley Medical Plaza - Phoenix - December [Member] Paradise Valley Medical Plaza - Phoenix - December [Member] Limited partner units (in shares) Limited Partners' Capital Account, Units Outstanding Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other expenses Nonoperating Income (Expense) Number of finance lease contracts Lessee, Finance Lease, Number Of Contracts Lessee, Finance Lease, Number Of Contracts Allocation for preferred stock Dividends, Preferred Stock Remaining lease term Lease, Remaining Lease Term Lease, Remaining Lease Term Physicians Plaza of Roane County - Harriman, TN Physicians Plaza of Roane County - Harriman [Member] Physicians Plaza of Roane County - Harriman [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Reimbursements of Employee Bonuses of the Advisor Reimbursements of Employee Bonuses of the Advisor [Member] Reimbursements of Employee Bonuses of the Advisor Unrealized Gains (Losses) on Designated Derivative AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member] Colonial Healthcare & Rehab Centre - Princeton, IL Colonial Healthcare & Rehab Centre - Princeton - December [Member] Colonial Healthcare & Rehab Centre - Princeton - December [Member] Sale of Stock [Domain] Sale of Stock [Domain] Deferred state (expense) benefit Deferred State and Local Income Tax Expense (Benefit) Ownership [Domain] Ownership [Domain] 2025 Long-Term Debt, Maturity, Year Five DRIP, period of notice to alter agreement DRIP, Period of Notice to Alter Agreement DRIP, Period of Notice to Alter Agreement Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additional paid-in capital Additional Paid in Capital Finite-lived intangible assets, amortization expense, 2021 Finite-Lived Intangible Asset, Expected Amortization, Year One Total revenues Revenues Summary of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Landis Memorial - Harrisburg, PA Landis Memorial - Harrisburg - September [Member] Landis Memorial - Harrisburg - September [Member] Creekside MOB - Douglasville, GA Creekside MOB - Douglasville [Member] Creekside MOB - Douglasville [Member] Proceeds from issuance of preferred stock, net Proceeds from Issuance of Preferred Stock and Preference Stock Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Below market leases, amortization income, 2021 Below Market Lease, Amortization Income, Year One Encumbrances SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances Deferred rent Deferred Lease Income, before Accumulated Amortization Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Non-cash investing and financing activities: Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract] Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Prairie Hills at Clinton - Clinton, IA Prairie Hills at Clinton - Clinton - August [Member] Prairie Hills at Clinton - Clinton - August [Member] Covenant Period after June 30 2021 Covenant Period after June 30 2021 [Member] Covenant Period after June 30 2021 Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Reclassification, Type [Domain] Reclassification, Type [Domain] Deferred (expense) benefit Deferred Income Tax Expense (Benefit) Professional fees credit due from Advisor Related Party Transaction, Other Revenues from Transactions with Related Party Gross Amounts of Recognized (Liabilities) Derivative Liability, Fair Value, Gross Liability Market lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired Due from Affiliates Due from Affiliates Net Amount Derivative Liability, Fair Value, Amount Offset Against Collateral Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Non-controlling Interests Noncontrolling Interest [Member] Pioneer Spine Sports - West Springfield, MA PioneerSpineSportsWestSpringfield [Member] PioneerSpineSportsWestSpringfield [Member] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] Related Party Fees, by Benchmark [Axis] Gross Amount Balance at beginning of year Balance at end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross Plaza Del Rio Medical Office Campus Portfolio AZ Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Plaza Del Rio Medical Office Campus Portfolio AZ [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unamortized fees Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] 2023 Lessor, Operating Lease, Payment to be Received, Year Three Quarterly Variable Management Fee, Benchmark One Quarterly Variable Management Fee, Benchmark One [Member] Quarterly Variable Management Fee, Benchmark One [Member] Trading Symbol Trading Symbol Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Group Classification [Domain] Disposal Group Classification [Domain] The Heights Healthcare & Rehab Centre - Peoria Heights, IL The Heights Healthcare & rehab Centre - Peoria Heights - December [Member] The Heights Healthcare & rehab Centre - Peoria Heights - December [Member] Total Fair Value, Net Asset (Liability) Buildings, fixtures and improvements Disposal Group, Including Discontinued Operation, Buildings and Improvements, Gross Disposal Group, Including Discontinued Operation, Buildings and Improvements, Gross Sunnybrook of Muscatine - Muscatine, IA Sunnybrook of Muscatine - Muscatine - August26 [Member] Sunnybrook of Muscatine - Muscatine - August26 [Member] Special Limited Partner Special Limited Partner [Member] Special Limited Partner [Member] West Michigan Surgery Center - Big Rapids, MI West Michigan Surgery Center - Big Rapids [Member] West Michigan Surgery Center - Big Rapids [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Entity Shell Company Entity Shell Company Aurora Healthcare Center - Plymouth, WI Aurora Healthcare Center Plymouth, WI [Member] Aurora Healthcare Center Plymouth, WI [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Below-market lease liabilities Below Market Lease [Member] Below Market Lease [Member] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] 2022 Finance Lease, Liability, to be Paid, Year Two Reportable Segments Segment Reporting, Policy [Policy Text Block] Total real estate investments, net Net Real Estate Assets Subject to Investment Arrangement Investments in real estate, net Real Estate Investment Property, Net Entity Public Float Entity Public Float Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member] Morrow Medical Center - Morrow, GA Morrow Medical Center - Morrow - June [Member] Morrow Medical Center - Morrow - June [Member] UC Davis MOB - Elk Grove, CA UC Davis MOB - Elk Grove [Member] UC Davis MOB - Elk Grove [Member] Property acquisitions and development costs Payments to Acquire Real Estate Document Type Document Type ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Segments [Axis] Segments [Axis] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Vested, Weighted-Average Issue Price (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Units issued to purchase building Common Unit, Issuance Value Base management fee of net proceeds Related Party Transaction, Base Management Fee of Net Proceeds, Percent Related Party Transaction, Base Management Fee of Net Proceeds, Percent Significant Unobservable Inputs Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Common stock repurchases (in shares) Stock Repurchased During Period, Shares Expenses incurred Related Party Transaction, Expenses from Transactions with Related Party Subordinated participation fees as a percentage of benchmark Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark Derivative assets, at fair value Net Amounts of Assets presented in the Consolidated Balance Sheet Derivative Asset Credit Facilities Revolving Credit Facility Line of Credit [Member] Rockwall Medical Plaza - Rockwall, TX Rockwall Medical Plaza [Member] Rockwall Medical Plaza [Member] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Pinnacle Center - Southaven, MS Pinnacle Center - Southaven - December [Member] Pinnacle Center - Southaven - December [Member] Derivatives and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Net Carrying Amount Intangible Assets, Net (Excluding Goodwill) Operating loss Operating Income (Loss) Oversight fees earned by related party Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark Multi-Property CMBS Loan Multi-Property CMBS Loan [Member] Multi-Property CMBS Loan [Member] Gross Amounts Not Offset in Consolidated Balance Sheet, Cash Collateral Received Derivative, Collateral, Obligation to Return Cash Non-Controlling Interests Noncontrolling Interest Disclosure [Text Block] Units issued to fund purchase of A Building (in usd per share) Common Unit, Issuance Value Share Price Common Unit, Issuance Value Share Price Derivative liabilities, at fair value Derivative Liability, Fair Value, Amount Not Offset Against Collateral UnityPoint Clinic Portfolio UnityPoint Clinic Portfolio [Member] UnityPoint Clinic Portfolio [Member] Variable Rate [Axis] Variable Rate [Axis] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Aurora Healthcare Center - Kiel, WI Aura Sheboyan Clinic - Kiel - March [Member] Aura Sheboyan Clinic - Kiel - March [Member] Asset management fees Asset Management Fees [Member] Asset Management Fees [Member] Common stock repurchases Common stock repurchases Payments for Repurchase of Common Stock Beaumont Medical Center - Warren, MI Beaumont Medical Center - Warren [Member] Beaumont Medical Center - Warren [Member] Restricted share vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Fixtures and improvements Furniture and Fixtures [Member] Preferred stock, quarterly dividend rate (in usd per share) Preferred Stock, Quarterly Dividend Rate, Per-Dollar-Amount Preferred Stock, Quarterly Dividend Rate, Per-Dollar-Amount Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Decatur Medical Office Building - Decatur, GA Decatur Medical Office Building [Member] Decatur Medical Office Building [Member] (Accretion) amortization of market lease and other intangibles, net Accretion of above- and below-market leases, net Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition. Advisor And Company Advisor And Company [Member] Advisor And Company [Member] Income (loss), tax basis Income (Loss), Tax Basis Income (Loss), Tax Basis Distributions in excess of accumulated earnings Retained Earnings (Accumulated Deficit) Mortgage notes payable, net Secured debt Secured Debt Payments on credit facilities Repayments of credit facility borrowings Repayments of Lines of Credit Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Property Operating and Maintenance Expense Property Operating and Maintenance Expense [Member] Property Operating and Maintenance Expense [Member] Derivative assets, at fair value Derivative Financial Instruments, Assets [Member] Property management fees Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark Money market funds Money Market Funds, at Carrying Value Cash paid for income taxes Income Taxes Paid 2021 Finance Lease, Liability, to be Paid, Year One Pennsylvania PENNSYLVANIA Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member] Customer [Axis] Customer [Axis] Loss on non-designated derivatives Loss (gain) on non-designated derivative instruments Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income Taxes Income Tax, Policy [Policy Text Block] Hedging Designation [Domain] Hedging Designation [Domain] Number of intercompany leases modified Number Of Intercompany Leases Modified Number Of Intercompany Leases Modified Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Payments of deferred financing costs Payments of Financing Costs Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member] Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member] Thereafter Long-Term Debt, Maturity, after Year Five Lender Name [Axis] Lender Name [Axis] Maximum shares per preferred stock offering (in shares) Preferred Stock Offering, Maximum Shares per Offer Preferred Stock Offering, Maximum Shares per Offer Useful life SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation Business Acquisition [Axis] Business Acquisition [Axis] Geographical [Domain] Geographical [Domain] Reclassification, Type [Axis] Reclassification, Type [Axis] Cedarhurst of Shiloh - Shiloh, IL Cedarhurst Of Shiloh - Shiloh [Member] Cedarhurst Of Shiloh - Shiloh Proceeds from term loan Proceeds from Long-term Lines of Credit Entity Voluntary Filers Entity Voluntary Filers Acquisition and transaction related Acquisition and transaction related Business Combination, Acquisition Related Costs Credit Facility [Axis] Credit Facility [Axis] Operating fees to related parties Costs and Expenses, Related Party DaVita Dialysis - Hudson, FL DaVita Hudson [Member] DaVita Hudson [Member] Belmar Medical Building -Lakewood, CO Belmar Medical Building - Lakewood - June [Member] Belmar Medical Building - Lakewood - June [Member] Direct Financing Leases Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Debt, fair value disclosure Debt Instrument, Fair Value Disclosure Prepayment penalty, year three Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Three Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Three Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Land Land Bayshore Naples Memory Care - Naples, FL Bayshore Naples Memory Care - Naples [Member] Bayshore Naples Memory Care - Naples Legacy Medical Village - Plano, TX Legacy Medical Village - Plano [Member] Legacy Medical Village - Plano [Member] Total Lessor, Operating Lease, Payments to be Received Balance Sheet Location Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Florida Medical Wesley Chapel - Tampa, FL Florida Medical - Wesley Chapel [Member] Florida Medical - Wesley Chapel [Member] Fee multiplier Related Party Transaction, Fee Multiplier Related Party Transaction, Fee Multiplier Net loss per common share attributable to common stockholders - Basic and Diluted (in usd per share) Basic and diluted net loss per share (in usd per share) Earnings Per Share, Basic and Diluted Total tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Related Party Fees, Benchmark [Domain] Assets held for use Disposal Group, Held-for-use, Not Discontinued Operations [Member] Disposal Group, Held-for-use, Not Discontinued Operations [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Fixed charge coverage ratio Debt Instrument, Covenants, Fixed Charge Coverage Ratio Debt Instrument, Covenants, Fixed Charge Coverage Ratio Written off accounts receivable Accounts Receivable, before Allowance for Credit Loss Accumulated Depreciation Balance at beginning of year Balance at end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation Number of instruments Number of Instruments Derivative, Number of Instruments Held Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Financing advance fees as a percentage of benchmark, expected company portfolio cost Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs Class of Treasury Stock Class of Treasury Stock [Table Text Block] Tax Depreciation Deduction Tax Depreciation Deduction [Member] Tax Depreciation Deduction [Member] Credit facilities, net Outstanding balance Long-term Line of Credit Women’s Healthcare Group MOB - York, PA WomensHealthcareGroupMOBYork [Member] WomensHealthcareGroupMOBYork [Member] Repayments of debt Repayments of Debt Gateway MOB - Clarksville, TN Gateway Medical Office Building - Clarksville - October [Member] Gateway Medical Office Building - Clarksville - October [Member] Autumn Ridge of Clarkston - Clarkston, MI Autumn Ridge Of Clarkston - Clarkston - August [Member] Autumn Ridge Of Clarkston - Clarkston - August Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Proceeds from loans Proceeds from Loans Depreciation expense SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense Derivative Instrument [Axis] Derivative Instrument [Axis] Payable (receivable) Related Party Transaction, Due from (to) Related Party Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Capital gain dividend income Capital Gain Dividend Income [Member] Capital Gain Dividend Income [Member] FOC I - Mechanicsburg, PA FOC I - Mechanicsburg [Member] FOC I - Mechanicsburg [Member] Cedarhurst of Collinsville - Collinsville, IL Cedarhurst of Collinsville [Member] Cedarhurst of Collinsville [Member] Nuvista Institute for Healthy Living - Jupiter, FL NuVista Institute for Healthy Living - Jupiter - August [Member] NuVista Institute for Healthy Living - Jupiter - August [Member] Geographical [Axis] Geographical [Axis] Escrow deposits Escrow Deposits Related to Property Sales Buildings, fixtures and improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period Single Tenant MOB Single Tenant MOB [Member] Single Tenant MOB [Member] UnityPoint Clinic - Muscatine, IA UnityPoint Clinic - Muscatine [Member] UnityPoint Clinic - Muscatine [Member] Segments [Domain] Segments [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Fox Ridge Senior Living at Bryant - Bryant, AR Fox Ridge Senior Living at Bryant - Bryant - December [Member] Fox Ridge Senior Living at Bryant - Bryant - December [Member] 2024 Long-Term Debt, Maturity, Year Four Schedule of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Sunnybrook of Ft. Madison - Ft. Madison, IA Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member] Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member] Countryside Medical Arts - Safety Harbor, FL Countryside Medical Arts - Safety Harbor [Member] Countryside Medical Arts - Safety Harbor [Member] Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Restricted Share Plan Restricted Share Plan [Member] Restricted Share Plan [Member] Distributions on Class B Units Distributions On Class B Units [Member] Distributions On Class B Units [Member] Weighted-average price per share (in usd per share) Treasury Stock Acquired, Average Cost Per Share Dividends Payable [Table] Dividends Payable [Table] Cash flow hedge reclassification in next twelve months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Current federal (expense) benefit Current Federal Tax Expense (Benefit) Notional Amount Derivative, Notional Amount Amortization/accretion of market least intangibles Amortization of Intangible Assets Line of Credit Facility [Table] Line of Credit Facility [Table] Addington Place of Prairie Village - Prairie Village, KS Addington Place of Prairie Village - Prairie Village [Member] Addington Place of Prairie Village - Prairie Village [Member] Interest and other income Interest and Other Income Subject Fees (Transition Fee Not in Excess of the Product) Subject Fees (Transition Fee Not in Excess of the Product) [Member] Subject Fees (Transition Fee Not in Excess of the Product) [Member] Net Carrying Amount Below Market Lease, Net Segment Reporting Segment Reporting Disclosure [Text Block] Issuance of Preferred Stock, net Value of shares issued Stock Issued During Period, Value, New Issues Cost of living percent multiplier Related Party Transaction Basis Cost Of Living Percent Related Party Transaction Basis Cost Of Living Percent Capital expenditures and other assets acquired Payments to Acquire Other Property, Plant, and Equipment Fox Ridge Chenal - Little Rock, AR Medical Center V - Peoria, AZ Medical Center V - Peoria, AZ [Member] Medical Center V - Peoria, AZ [Member] Medical Center III - Peoria, AZ Medical Center III - Peoria [Member] Medical Center III - Peoria [Member] Prairie Hills at Des Moines - Des Moines, IA Prairie Hills at Des Moines - Des Moines - August [Member] Prairie Hills at Des Moines - Des Moines - August [Member] Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Fannie Credit Facility Fannie Credit Facility [Member] Fannie Credit Facility [Member] Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Florida Medical Tampa Palms - Tampa, FL Florida Medical - Tampa Palms [Member] Florida Medical - Tampa Palms [Member] Acquired intangible assets Finite-Lived Intangible Assets, Net Gross Revenue, Managed Properties Gross Revenue, Managed Properties [Member] Gross Revenue, Managed Properties [Member] Term of agreement Related Party Transaction, Term of Agreement Related Party Transaction, Term of Agreement Class B units Class B Units [Member] Class B Units [Member] 2022 Lessor, Operating Lease, Payment to be Received, Year Two Finance Lease, Liability, Maturity Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] Interest expense Interest expense Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss Interest Expense 759 Building - Munster, IN 759 Building - Munster - October [Member] 759 Building - Munster - October [Member] In-place and market leases Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period Depreciation and amortization Depreciation, Depletion and Amortization Non-Controlling Ownership Percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Preferred stock, liquidation preference (in usd per share) Preferred Stock, Liquidation Preference Per Share Schedule of Components of Income Tax Benefit (Expense) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Financial relief funds Revenue Not from Contract with Customer Aurora Healthcare Center - Greenville, WI Aurora Healthcare Center, Greenville,WI [Member] Aurora Healthcare Center, Greenville,WI [Member] 2025 Finance Lease, Liability, to be Paid, Year Five Nonvested awards, compensation cost not yet recognized, period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unencumbered Properties Unencumbered Properties [Member] Unencumbered Properties [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] 2022 Long-Term Debt, Maturity, Year Two Advocate Aurora MOB - Elkhorn, WI Advocate Aurora MOB - Elkhorn WI [Member] Advocate Aurora MOB - Elkhorn WI [Member] Net loss attributable to common stockholders Net loss attributable to stockholders Net Income (Loss) Available to Common Stockholders, Basic Property operating and maintenance Property operating and maintenance Operating Lease, Expense Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Sunnybrook of Fairfield - Fairfield, IA Sunnybrook of Fairfield - Fairfield - August26 [Member] Sunnybrook of Fairfield - Fairfield - August26 [Member] Dividends paid (in usd per share) Common Stock, Dividends, Per Share, Cash Paid Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Business Acquisitions, by Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Operating Segments Operating Segments [Member] Cedarhurst of Sparta - Sparta, IL Cedarhurst Of Sparta - Sparta [Member] Cedarhurst Of Sparta - Sparta Class of Stock [Line Items] Class of Stock [Line Items] Dividends, percent Dividends Payable, Percent Dividends Payable, Percent Stock repurchase, value Treasury Stock, Value, Acquired, Cost Method Development in progress Development in Process Benchmark basis for issuance Restricted Share Plan, Benchmark Basis for Issuance Restricted Share Plan, Benchmark Basis for Issuance Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Gain (loss) on sale of real estate investments (Gain) loss on sales of real estate investments, net Gains (Losses) on Sales of Investment Real Estate Derivative liabilities, at fair value Net Amounts of Assets presented in the Consolidated Balance Sheet Derivative Liability Litigation Case [Axis] Litigation Case [Axis] Distributions declared in common stock (in usd per share) Common Stock, Stock Dividends, Per Share, Declared Common Stock, Stock Dividends, Per Share, Declared Covenant Period August 10 2020 Covenant Period August 10 2020 [Member] Covenant Period August 10 2020 Below market leases, amortization income, 2025 Below Market Lease, Amortization Income, Year Five Arbor View Assisted Living and Memory Care - Burlington, WI Arbor View Assisted Living and Memory Care - Burlington - March [Member] Arbor View Assisted Living and Memory Care - Burlington - March [Member] Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Medical Center V - Peoria, AZ St. Andrews Medical Park, Venice, FL [Member] St. Andrews Medical Park, Venice, FL [Member] Subsequent Event Subsequent Event [Member] Domestic Tax Authority Domestic Tax Authority [Member] Morton Villa Healthcare & Rehab Centre - Morton, IL Morton Villa Healthcare & Rehab Centre - Morton [Member] Morton Villa Healthcare & Rehab Centre - Morton [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Campus at Crooks & Auburn Building C - Rochester Mills, MI Campus at Crooks & Auburn Building C - Rochester Hills - June [Member] Campus at Crooks & Auburn Building C - Rochester Hills - June [Member] CARES Act Grants Revenue [Policy Text Block] Fair Value Estimate of Fair Value Measurement [Member] Finite-lived intangible assets, amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Four Prairie Hills at Cedar Rapids - Cedar Rapids, IA Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member] Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member] Medical Center I - Peoria, AZ Medical Center I - Peoria - May [Member] Medical Center I - Peoria - May [Member] Valuation, Income Approach Valuation, Income Approach [Member] Autumn Leaves of Cy-Fair - Houston, TX Autumn Leaves of Cy-Fair - Houston - December [Member] Autumn Leaves of Cy-Fair - Houston - December [Member] Reduction in shares authorized for repurchase (in shares) Share Repurchase Program, Reduction In Authorized Shares For Repurchase Share Repurchase Program, Reduction In Authorized Shares For Repurchase Depreciation and Amortization Depreciation, Depletion, and Amortization [Policy Text Block] Depreciation and Amortization Expense Depreciation and Amortization Expense [Member] Depreciation and Amortization Expense [Member] Palm Valley Medical Plaza - Goodyear, AZ Palm Valley Medical Plaza - Goodyear - April [Member] Palm Valley Medical Plaza - Goodyear - April [Member] Transition Property Transition Property [Member] Transition Property [Member] Arcadian Cove Assisted Living - Richmond, KY Arcadian Cove Assisted Living [Member] Arcadian Cove Assisted Living [Member] Comprehensive loss attributable to common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2023 Finance Lease, Liability, to be Paid, Year Three Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Covenant Period July 1 2020 through March 31 2021 Covenant Period July 1 2020 through March 31 2021 [Member] Covenant Period July 1 2020 through March 31 2021 Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] 2021 Long-Term Debt, Maturity, Year One Term Loan Term Loan [Member] Term Loan [Member] Legal Entity [Axis] Legal Entity [Axis] City Area Code City Area Code Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Michigan MICHIGAN Vascular Surgery Associates - Tallahassee, FL Vascular Surgery Associates [Member] Vascular Surgery Associates [Member] Independent directors Independent Directors [Member] Independent Directors [Member] Dignity Emerus Craig Rd - North Las Vegas, NV Dignity Emerus Craig Road - North Las Vegas [Member] Dignity Emerus Craig Road - North Las Vegas [Member] Prairie Hills at Ottumwa - Ottumwa, IA Prairie Hills at Ottumwa - Ottumwa - August [Member] Prairie Hills at Ottumwa - Ottumwa - August [Member] Dividends Declared Dividends Declared [Table Text Block] Stock repurchased, authorized amount Stock Repurchase Program, Authorized Amount Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Ancillary revenue Ancillary Fee Income Generated by Servicing Financial Assets, Amount Amounts reclassified from accumulated other comprehensive (loss) income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Cash flows and capitalization rates Real Estate Investments, Measurement Input, Percent Real Estate Investments, Measurement Input, Percent Proceeds from common stock issued through distribution reinvestment plan Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan Subject Fees Subject Fees [Member] Subject Fees [Member] Quarterly Financial Information Disclosure [Abstract] Quarterly Financial Information Disclosure [Abstract] Real Estate and Accumulated Depreciation, Schedule III SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block] Medical Office Buildings Medical Office Buildings [Member] Medical Office Buildings [Member] Rebalancing of ownership percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Equity-based compensation Share-based Payment Arrangement, Noncash Expense Common stock repurchases Stock Repurchased During Period, Value Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period Cover [Abstract] Cover [Abstract] Base Rate Base Rate [Member] Number of operating lease contracts Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Distributions declared in common stock Stock Issued During Period, Value, Stock Dividend Other comprehensive income, before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Cash paid for real estate investments, including acquisitions Business Acquisition Cost Of Acquired Entity Cash Paid In Period Business Acquisition Cost Of Acquired Entity Cash Paid In Period Mortgage notes payable, net Long-term Debt The Atrium - Rockford, IL The Atrium - Rockford [Member] The Atrium - Rockford [Member] Commitments and Contingencies Lessee, Operating Leases [Text Block] Quarterly Variable Management Fee, Benchmark Two Quarterly Variable Management Fee, Benchmark Two [Member] Quarterly Variable Management Fee, Benchmark Two [Member] LaSalle Tenant LaSalle Tenant [Member] LaSalle Tenant [Member] Camellia Walk Assisted Living and Memory Care - Evans, GA Camellia Walk Assisted Living And Memory Care - Evans [Member] Camellia Walk Assisted Living And Memory Care - Evans [Member] In-place leases and other intangible assets In-place lease assets Leases, Acquired-in-Place [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Equity Components [Axis] Equity Components [Axis] Unrealized (loss) gain on designated derivatives Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Distributions declared in common stock (in shares) Common Stock Dividends, Shares Prairie Hills at Independence - Independence, IA Prairie Hills at Independence - Independence [Member] Prairie Hills at Independence - Independence [Member] Capital One MOB Loan Fox Ridge Senior Living at Bryant - Bryant [Member] Fox Ridge Senior Living at Bryant - Bryant [Member] Advisor Advisor [Member] Advisor [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Deferred costs, net Deferred Costs Minimum Minimum [Member] Medical Sciences Pavilion - Harrisburg, PA Medical Sciences Pavilion - Harrisburg - December [Member] Medical Sciences Pavilion - Harrisburg - December [Member] Conroe Medical Arts and Surgery Center - Conroe, TX Conroe Medical Arts and Surgery Center - Conroe [Member] Conroe Medical Arts and Surgery Center - Conroe [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Community Health MOB - Harrisburg, PA Community Health MOB - Harrisburg [Member] Community Health MOB - Harrisburg [Member] Sunnybrook of Burlington - Land - Burlington, IA Sunnybrook of Burlington - Land - Burlington - August [Member] Sunnybrook of Burlington - Land - Burlington - August [Member] Laguna Professional Center - Elk Grove, CA Laguna Professional Center - Elk Grove [Member] Laguna Professional Center - Elk Grove [Member] Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member] Term Loan, net Long-term Line of Credit, Including Financing Costs Long-term Line of Credit, Including Financing Costs Net (income) loss attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Entity Interactive Data Current Entity Interactive Data Current Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Purchase obligation Purchase Obligation Equity-Based Compensation Share-based Payment Arrangement [Policy Text Block] Pre-tax Non-compounded Return on Capital Contribution Pre-tax Non-compounded Return on Capital Contribution [Member] Pre-tax Non-compounded Return on Capital Contribution [Member] Unusual or Infrequent Item, or Both [Axis] Unusual or Infrequent Item, or Both [Axis] Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Professional fees credit due from Advisor Professional Fees Credit Due From Advisor [Member] Professional Fees Credit Due From Advisor Schedule of Acquired Finite-Lived Intangible Assets by Major Class Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Madison Medical Plaza - Joliet, IL Madison Medical Plaza - Joliet [Member] Madison Medical Plaza - Joliet [Member] Number of reportable segments Number of Reportable Segments Texas Children’s Hospital - Houston, TX Texas Children's Hospital - Houston [Member] Texas Children's Hospital - Houston [Member] Village Center Parkway - Stockbridge, GA Village Center Parkway - Stockbridge [Member] Village Center Parkway - Stockbridge [Member] Number of properties held for sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale Effective Interest Rate Effective interest rate Debt Instrument, Interest Rate, Effective Percentage Meadowbrook Senior Living - Agoura Hills, CA Meadowbrook Senior Living - Agoura Hills - November [Member] Meadowbrook Senior Living - Agoura Hills - November [Member] Consolidation Items [Axis] Consolidation Items [Axis] Greenfield MOB - Greenfield, WI GreenfieldMOBGreenfield [Member] GreenfieldMOBGreenfield [Member] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Total minimum lease payments Lessee, Operating Lease, Liability, to be Paid Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Shiloh - Illinois (4) Fox Ridge North Little Rock - North Little Rock, AR Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Fox Ridge Senior Living at Parkstone - North Little Rock [Member] Building and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] Weighted-average common shares outstanding - Basic and Diluted (in shares) Basic and diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Disposed by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Real estate cost percent multiplier Related Party Transaction Basis of Real Estate Cost Percent Related Party Transaction Basis of Real Estate Cost Percent 2019 Bonus Awards 2019 Bonus Awards [Member] 2019 Bonus Awards Addington Place at Mills - Roswell, GA AddingtonPlaceatMillsRosewell [Member] AddingtonPlaceatMillsRosewell [Member] Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Gross Amounts of Recognized Assets Derivative Asset, Fair Value, Gross Asset Above-market ground leases Above Market Ground Lease [Member] Above Market Ground Lease [Member] Significant Other Observable Inputs Level 2 Fair Value, Inputs, Level 2 [Member] Contract sale price Contract Sale Price Disposal Group, Including Discontinued Operation, Consideration Payments for derivative instruments Payments for Derivative Instrument, Financing Activities Net Amount Derivative Asset, Fair Value, Amount Offset Against Collateral Georgia GEORGIA Fixed rate Derivative, Fixed Interest Rate Subsequent Event [Line Items] Subsequent Event [Line Items] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Credit Facility [Domain] Credit Facility [Domain] Florida FLORIDA Proceeds from sales of real estate investments Proceeds from Sale of Real Estate Held-for-investment Mortgage premiums and discounts, net Debt Instrument, Unamortized Discount (Premium), Net Litigation Case [Domain] Litigation Case [Domain] Entity File Number Entity File Number Operating loss before gain (loss) on sale of real estate investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments Remaining lease term Operating Lease, Weighted Average Remaining Lease Term Line of credit facility Line of Credit Facility, Increase (Decrease), Net 2024 Lessor, Operating Lease, Payment to be Received, Year Four Presence Healing Arts Pavilion - New Lenox, IL Presence Healing Arts Pavilion - New Lenox - December [Member] Presence Healing Arts Pavilion - New Lenox - December [Member] Real Estate Sales Disposal Groups, Including Discontinued Operations [Table Text Block] Litigation settlement, amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Share-based compensation expense Share-based Payment Arrangement, Expense Debt instrument, collateral amount Debt Instrument, Collateral Amount Balance Sheet Location [Axis] Balance Sheet Location [Axis] Addington Place of Dublin - Dublin, GA Addington Place of Dublin - Dublin - September [Member] Addington Place of Dublin - Dublin - September [Member] Eye Specialty Group Medical Building - Memphis, TN Eye Specialty Group Medical Building - Memphis - December [Member] Eye Specialty Group Medical Building - Memphis - December [Member] Disposal Group Name [Axis] Disposal Group Name [Axis] Oak Lawn Medical Center - Oak Lawn, IL Oak Lawn Medical Center - Oak Lawn, IL. [Member] Oak Lawn Medical Center - Oak Lawn, IL. [Member] Delisting Delisting [Member] Delisting [Member] Document Annual Report Document Annual Report New York Six MOBs (5 properties) New York Six MOBs (5 properties) [Member] New York Six MOBs (5 properties) [Member] Liberty Court - Dixon, IL Liberty Court - Dixon [Member] Liberty Court - Dixon [Member] 2024 Finance Lease, Liability, to be Paid, Year Four Philip Professional Center - Lawrenceville, GA Philip Professional Center - Lawrenceville, GA [Member] Philip Professional Center - Lawrenceville, GA [Member] Estate at Hyde Park - Tampa, FL Estate at Hyde Park - Tampa - July [Member] Estate at Hyde Park - Tampa - July [Member] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] Subsequent Event [Table] Subsequent Event [Table] Share-based compensation, net (in shares) Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Non-controlling interests Third Party Net Investment Amount Stockholders' Equity Attributable to Noncontrolling Interest Preferred stock, dividend rate (in usd per share) Preferred Stock, Dividend Rate, Per-Dollar-Amount Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase obligation, amount funded Purchase Obligation, Amount Funded Purchase Obligation, Amount Funded Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Litigation Status [Axis] Litigation Status [Axis] Gross Amounts of Recognized Liabilities Gross Amounts Offset in the Consolidated Balance Sheet Derivative Asset, Fair Value, Gross Liability Autumn Leaves of Meyerland - Houston, TX Autumn Leaves of Meyerland - Houston - December [Member] Autumn Leaves of Meyerland - Houston - December [Member] Interest Expense Interest Expense [Member] Schedule of Shares Repurchased [Line Items] Schedule of Shares Repurchased [Line Items] [Line Items] for Schedule of Shares Repurchased [Table] Straight-line rent receivable Increase (Decrease) in Accounts Receivable Reimbursements of Administrative Services Reimbursements of Administrative Services [Member] Reimbursements of Administrative Services [Member] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block] Payments of additional offering expenses Payments of Stock Issuance Costs Concentration Risk Type [Domain] Concentration Risk Type [Domain] Current (expense) benefit Current Federal, State and Local, Tax Expense (Benefit) Total liabilities and equity Liabilities and Equity Number of real estate properties, released or replaced Number of Real Estate Properties, Released or Replaced Number of Real Estate Properties, Released or Replaced Number of properties purchased Number of Businesses Acquired Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Operating lease costs Operating Lease, Cost General and administrative Reduction of general and administrative expense General and administrative General and Administrative Expense Covenant Period After Commencement Quarter Covenant Period After Commencement Quarter [Member] Covenant Period After Commencement Quarter Market lease intangible liabilities, net Off-market Lease, Unfavorable Accumulated amortization Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 761 Building - Munster, IN 761 Building - Munster - October [Member] 761 Building - Munster - October [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Crittenton Washington MOB - Washington Township, MI Crittenton Washington MOB [Member] Crittenton Washington MOB [Member] Morton Terrace Healthcare & Rehab Centre - Morton, IL Morton Terrace Healthcare& Rehab Centre - Morton - December [Member] Morton Terrace Healthcare& Rehab Centre - Morton - December [Member] Equity Component [Domain] Equity Component [Domain] Current borrowing capacity, base percent Debt Instrument, Covenants, Current Borrowing Capacity Base Percent Debt Instrument, Covenants, Current Borrowing Capacity Base Percent Dyer Building - Dyer, IN Dyer Building - Dyer - October [Member] Dyer Building - Dyer - October [Member] NOI Gross Profit Minimum cash, cash equivalents, and borrowing capacity Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity Entity Tax Identification Number Entity Tax Identification Number Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Net loss attributable to stockholders Net Income (Loss) Attributable to Parent Equity-Based Compensation Share-based Payment Arrangement [Text Block] Interest rate contract Interest Rate Contract [Member] Arrowhead Medical Plaza II - Glendale, AZ Arrowhead Medical Plaza II - Glendale [Member] Arrowhead Medical Plaza II - Glendale [Member] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] DaVita Bay Breeze Dialysis Center - Largo, FL DaVita Bay Breeze [Member] DaVita Bay Breeze [Member] Berwyn Medical Center - Berwyn, IL Berwyn Medical Center - Berwyn [Member] Berwyn Medical Center - Berwyn [Member] Period of notice Related Party Transaction, Period of Notice to Alter Agreement Related Party Transaction, Period of Notice to Alter Agreement Buyout of non-controlling interest holders Buyout of non-controlling interest holders Payments to Noncontrolling Interests London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Prepayment percent of principal amount Debt Instrument, Prepayment, Maximum Percentage of Principal Debt Instrument, Prepayment, Maximum Percentage of Principal Total present value of minimum lease payments Finance Lease, Liability Interest and other income Other Nonoperating Income Addington Place of Shoal Creek - Kansas City, MO Addington Place of Shoal Creek - Kansas City [Member] Addington Place of Shoal Creek - Kansas City [Member] OP Units OP Units [Member] OP Units [Member] Costs capitalized subsequent to acquisition, buildings and improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Building and Improvements Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of real estate properties Number of properties Number of Real Estate Properties Thereafter Finance Lease, Liability, to be Paid, after Year Five Fox Ridge North Little Rock - North Little Rock, AR Courtyard Fountains - Gresham, OR Courtyard Fountains - Gresham, OR [Member] Courtyard Fountains - Gresham, OR [Member] Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Greenville Health System - Greenville, SC Greenville Health System - Greenville, SC [Member] Greenville Health System - Greenville, SC [Member] Accounts payable and accrued expenses, due to related parties Due to Related Parties Preferred stock, dividend rate, percentage Preferred Stock, Dividend Rate, Percentage Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period Accumulated Amortization Below Market Lease, Accumulated Amortization Purchase Price Allocation Purchase Price Allocation Policy [Policy Text Block] Purchase Price Allocation Policy [Policy Text Block] Operating Leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Issuance of preferred stock, net (in shares) Stock Issued During Period, Shares, New Issues Gross Carrying Amount Finite-Lived Intangible Assets, Gross Intangible assets: Finite-Lived Intangible Assets, Net [Abstract] FOC Clinical - Mechanicsburg, PA FOC Clinical - Mechanicsburg [Member] FOC Clinical - Mechanicsburg [Member] Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Lakeside Vista - Holland, MI Lakeside Vista - Holland [Member] Lakeside Vista - Holland Ordinary dividend income Ordinary Dividend Income [Member] Ordinary Dividend Income [Member] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Amended and Restated Property Management and Leasing Agreement Amended and Restated Property Management and Leasing Agreement [Member] Amended and Restated Property Management and Leasing Agreement [Member] Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Derivative assets, at fair value Derivative Asset, Fair Value, Amount Not Offset Against Collateral Basis of Accounting Basis of Accounting, Policy [Policy Text Block] Common stock issued through stock dividends Stock Issued Interest rate Debt Instrument, Basis Spread on Variable Rate Ownership [Axis] Ownership [Axis] Aurora Healthcare Center - Waterford, WI Aurora Healthcare Center, Waterford, WI [Member] Aurora Healthcare Center, Waterford, WI [Member] Carrying Amount  Reported Value Measurement [Member] Plan Name [Domain] Plan Name [Domain] Number of securities called by share purchase right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Distributions payable Dividends Payable Bloom MOB - Harrisburg, PA Bloom MOB - Harrisburg - December [Member] Bloom MOB - Harrisburg - December [Member] Wood Glen Nursing and Rehab Center - West Chicago, IL Wood Glen Nursing and Rehab Center - West Chicago - December [Member] Wood Glen Nursing and Rehab Center - West Chicago - December [Member] Preferred stock distributions declared per share (in usd per share) Preferred Stock, Dividends Per Share, Declared Revision of Prior Period, Reclassification, Adjustment Revision of Prior Period, Reclassification, Adjustment [Member] Allegro at Stuart - Stuart, FL Allegro at Stuart - Stuart - September [Member] Allegro at Stuart - Stuart - September [Member] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Acquisition cost reimbursements Acquisition Costs Reimbursements [Member] Acquisition Costs Reimbursements [Member] Income tax expense Income Tax Expense (Benefit) Cash, cash equivalents and restricted cash, beginning of year Cash, cash equivalents and restricted cash, end of year Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-term Debt [Table Text Block] Title of Individual [Domain] Title of Individual [Domain] Local Phone Number Local Phone Number UMPC Sir Thomas Court - Harrisburg, PA UMPC Sir Thomas Court - Harrisburg [Member] UMPC Sir Thomas Court - Harrisburg Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Derivative [Line Items] Derivative [Line Items] Payments for deposits Payments for Deposits on Real Estate Acquisitions Outstanding loan amount Mortgage notes payable, net Long-term Debt, Gross LaSalle Guarantor vs LaSalle Tenant LaSalle Guarantor vs LaSalle Tenant [Member] LaSalle Guarantor vs LaSalle Tenant [Member] Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Allegro at St. Petersburg - Land - St. Petersburg, FL Allegro at St Petersburg - Land - St Petersburg - September [Member] Allegro at St Petersburg - Land - St Petersburg - September [Member] Capitol Healthcare & Rehab Centre - Springfield, IL Capitol Healthcare & Rehab Centre - Springfield - December [Member] Capitol Healthcare & Rehab Centre - Springfield - December [Member] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Cumulative capital investment return to investors as a percentage of benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark Weighted-Average Issue Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Annual Targeted Investor Return Annual Targeted Investor Return [Member] Annual Targeted Investor Return [Member] Prepaid expenses and other assets (including $1,278 and $394 due from related parties as of December 31, 2020 and 2019, respectively) Prepaid expenses and other assets Prepaid Expense and Other Assets Copper Springs Senior Living - Meridian, ID Copper Springs Senior Living - Meridian - September [Member] Copper Springs Senior Living - Meridian - September [Member] Payments on mortgage notes payable Repayments of Secured Debt Renewal term Lessee, Lease, Renewal Term Lessee, Lease, Renewal Term Amortization (including write-offs) of deferred financing costs Amortization of Debt Issuance Costs Gross Amounts Not Offset in Consolidated Balance Sheet, Financial Instruments Derivative, Collateral, Obligation to Return Securities Restricted cash Restricted Cash Gain on Dispositions of Real Estate Investments Gain on Dispositions of Real Estate Investments Policy [Policy Text Block] Gain on Dispositions of Real Estate Investments Policy [Policy Text Block] Accounts payable and accrued expenses (including $299 due to related parties as of December 31, 2020) Accounts Payable and Accrued Liabilities Asset threshold for assignment of agreement Related Party Transaction, Asset Threshold Qualifying Management Related Party Transaction, Asset Threshold Qualifying Management Distributions in Excess of Accumulated Earnings Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Measurement Basis [Axis] Measurement Basis [Axis] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Wellington, Florida Wellington, Florida [Member] Wellington, Florida [Member] Award Type [Domain] Award Type [Domain] Lessor, Operating Lease, Payments to be Received, Maturity Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Derivative, net liability position, aggregate fair value Derivative, Net Liability Position, Aggregate Fair Value Litigation Status [Domain] Litigation Status [Domain] Addington at Wellington Green - Wellington, FL AddingtonatWellingtonGreenWellingtonOctober [Member] AddingtonatWellingtonGreenWellingtonOctober [Member] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Less: accumulated depreciation and amortization Real Estate Investment Property, Accumulated Depreciation Net Loss Per Share Earnings Per Share [Text Block] Ramsey Woods Memory Care - Cudahy, WI Ramsey Woods - Cudahy [Member] Ramsey Woods - Cudahy [Member] Extension period Line of Credit Facility, Extension Period Line of Credit Facility, Extension Period Stockbridge Family Medical - Stockbridge, GA Stockbridge Family Medical - Stockbridge [Member] Stockbridge Family Medical - Stockbridge [Member] Prospective consideration Disposal Group, Including Discontinued Operations, Prospective Consideration Disposal Group, Including Discontinued Operations, Prospective Consideration Medical Center II - Peoria, AZ Medical Center II - Peoria - May [Member] Medical Center II - Peoria - May [Member] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Proceeds from credit facilities Proceeds from Lines of Credit Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Amortization Expense Amortization Expense [Member] Amortization Expense [Member] EX-101.PRE 13 hct-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 hct-20201231_g1.jpg GRAPHIC begin 644 hct-20201231_g1.jpg M_]C_X 02D9)1@ ! 0$!+ $L #_X1""17AI9@ 34T *@ @ ! $[ ( M % (2H=I 0 ! (4)R= $ * 0<.H< < @, /@ M FMC.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z M;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \ M/WAP86-K970@96YD/2=W)S\^_]L 0P " 0$" 0$" @(" @(" @,% P,# P,& M! 0#!0<&!P<'!@<'" D+"0@("@@'!PH-"@H+# P,# <)#@\-# X+# P,_]L M0P$" @(# P,& P,&# @'" P,# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,_\ $0@$S0EM P$B (1 0,1 ?_$ !\ M $% 0$! 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ M !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?( MR;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! M 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ _?RBBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHSBC- !11FB@ HHHH **** M"BBC- !11FC- !11FB@ HHHH **** "BBB@ HHSBC.: "BC.*,T %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1106Q0 449XH!S0 4449H **,YHH **,T9 MH **,T;J "BC-&<4 %%,:XC3[SJ/J:Y[Q%\8O"7A#=_:WBCP_I>WK]KU"*'' M_?3"KC3G+X4V9RK4X_%)+YG29IK$YKQ_Q'_P4&^!?A1F%]\8/AK"Z]4'B*UD MD'_ %CZ>)_R:"W^17Q;K?\ P7^_9CTE6\CQEJNI8[6^@WBY^GF1I7%Z MY_P?Y=#XJT?O/T&! MSW_6C/%?F?JW_!SS\)X<_8? 7Q"N/3SQ:0Y^N)6KE]8_X.CO#,1/V'X2ZY<> MGGZU%#G\HGK:/#69O:D_P_S.>7%65K_E\G]Y^K/-+TK\@=1_X.FKF3<+7X*P MQ^AE\5;OT%H/YUAW_P#P=&>+&S]E^$^@0^GFZQ+)_P"@QK71'A3,VO@MZM'/ M+C#*U]N_R/V:HK\2K_\ X.?OB=(Q^S_#SP/#Z"22YD_DXK,N?^#G3XS-_J?! M7PTC/;?;7K?^W K1<'YE_*OO1C+C;*U]I_8]E]Y/^O66=Y?-<C8?:/ OPZD]?+CO$_G.:E\&YE_*O MO1:XXRM_:?W'[A4'FOQ4M/\ @Z$^(BG]_P##7P?)Z[+NX3/ZFM>P_P"#I#Q) M&ZFZ^$>BS#N(=6/_ &H?%(?]#:C^==-I/_!T3X*EQ]N^%OB>'U\C4H)+,K?_+U+[S]2R?Q_&C=CTK\V=)_X.;8.?P58_>CZ1S17 ME_AG]MGX.^, /[+^*OPZU!FZ+;^([21A[8$F?PKO-#\::/XFA\S3=5T_4(_[ MUM<)*/S4FN>5"K'XHO[F=4<51E\,U]Z-2BFK,K=&4_C3LUEL;*2>P449HS0, M**,T9H **,\T4 %%&<49H ***,T %%&:,YH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M***,T %%&ZC/- !11F@G% !11G%&: "BC.*-W- !37ZTV:[CMT+22*BJ,DDX MQ7DOQ1_;S^"_P8,J^)/B?X*TN>'A[9M5BDN0?^N*%I/_ !VM*=&I-VIQ;]$8 MU,12IK]Y)+U9ZYT'^--WX%?#OQ*_X.$_V;_ 9E73M:\1>+I$.-FDZ/(H)]FN M/)4_4$U\]_$K_@Z+TN R)X1^$]]==H[C5]76WV^YBBC?\@]>I0X?S"M\-)_/ M0\?$<39;1TE57RU/UH#?2C.1_A7X,_$;_@Y'^/?BL/'HNG^!_"\1/[LVFGR7 M,P^K3R,A^NP?2O"/B)_P5P_:0^)WF+J'Q:\46JOU72W33 /;_1UC/ZU[%'@G M'3_B.,?G<\:OQY@(.U-2E\K']*]YJ=OIUNTLUQ##&@RSR.%51[DUY?X[_;E^ M#?PRW_V]\4O .F21]89=F8[ MB^H:A+K1X#C_R]J_/^-O^#FGX+Z-N M31/"7Q!UJ9.C26UK:PM_P(S,W_CM?AK17IT>"/HWEE_P!:\Q\5?\%*OC_XR+?;?C!\0E5^ MJ6NMSVJG_@,;**\0HKT*>5X.GI&DON1Y]3-L94^.J_O9U'BGXV^,O'!?^VO% MGB75O,^]]LU.:?/_ 'TQ_G7,^:S=68_B3^/:FT5T1HTHZ15CDE6J2^*3?W@3 MGU_Q_*@-116JTV,OF%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH *,[EHHH 4$CIQ^/6I;?4)[257AFEBD7D,CL"/QS_ %J& MBH<8O=%1J26S.X\-?M-_$GP8RG1_B!XVTDI]TV6MW,&SZ;)%KTSPA_P5=_:, M\$;?L?Q?\8S>7P/M]W]N'_D=7_E7SW16$\#AI_%33^2.BGC\1#X:C^]GVKX/ M_P"#@/\ :8\,%?M7BK1M<5?X;[0[5=WU,*H?Y&O4_!__ HQ^6C/0I\19E3^&K+[S]A/!/_ M =(Z7<,B^(_A'?VN/OR:=KJSY^B/"GY;OQKV#P3_P ')7P!\2%%U+3_ !]X M>;^)KK3(IHU^AAF=B/\ @.>.E?@W17GU.#\MGM%KT9ZE'C3,X;S3]5^I_2+X M&_X+1_LS_$!E6U^*FDV4C_PZE:7-@%/NTT:K^.<5[9X _:;^'/Q3V?\ ",^/ M?!OB R?=&G:S;W+'\$I M1\0,0OXE)/T;1_7.)5D^ZV?H:=NQC^M?RG^ ?VH?B5\*@G_"-?$#QIH"Q\*F MGZS<6Z@>F%8#\Q7N'P]_X+7_ +3'PY=!!\2[[5((\ Q:I9VU[O\ J\B%_P 0 MU>76X%Q,=:51/UNCUJ/B!A7I5IM>FI_2 S8':@'(K\._AO\ \'-?Q!_$D*=7MUN-/GD]R=\B9^B"O?_AK_ ,'0'@'4UC3Q;\-?%FBL?OMI=Y!J M*@_1S#Q],UY%?A7,J>U/F]&>SA^,,KJ;U.7U5C]0\\4Z,Y6OCOX9?\%VOV:? MB6\<;^.9O#MS)C$.L:9<6^WZR*C1C_ONOHSX8_M+_#SXR(#X3\<>$_$A8;@N MFZM!=.![JCDC\0*\BM@,32TJ0:^1[-#,L+6UI5$_F=U134E5_NL#]#3LURG< MG?5!11G-&: "B@'(HH **,T4 %%&/=+^2U\?_ !G_ M .#E3X-^"#-#X/T#Q9XWNE)\N7RDTVSDZ_\ +20F4?C%_P#6[\-E.-Q#_7B\YP6'_BU$OF?HTG#4COM7)88_WNM?AE\:/^#E?XQ>.!-#X0\.>$O!=K M,?EE>-]2NXQ_OR;8R>G6'']/DWXP_P#!17XX_'AYO^$F^*'BZ\AF_P!9;07S M6=JX/8PP[(\>VVOHL+P3C:GO56H_BSYO%<=X"GI2BY?@C^CSXM_M_M32<^@]AT%>[A>!< M-'6O)R]'8^=Q7'V+EI0A&*[[L_6/XL_\'1&K77G0^!_A;I]IC_5W6N:F]QN_ MWH8E3'X2&OF3XK_\%Y/VDOB?YB0^+['PO:R]8-%TR&$ >TD@DE&/9A]:^-Z* M^@P_#V7T?AI)^;U?XGSN)XDS&N_?K-+LM$=Q\2_VF?B+\9W8^+O'?BWQ('.Y MEU/5I[E/H%9B!]!Q7$,S.P^8\?=))X_"DHKUJ=&%-6@DOD>14K5*CO.3?S#_ M "****T,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** _EZ&GPW#6[*T;-&5.5(8_+]/2F44I)-6 M8U)K5'K?PP_;T^-'P9,:^&_B?XUTVWAX6U_M666UXZ?N7+1_^.FOI+X3?\'$ MG[1'P]\M=8O/"_C2%>&_M72EAE(]FMC%S[D'_=KX2HKSJV4X.M_$I)_(]'#Y MQC*+_=U6OF?L9\)/^#HC0;ORXO'7POU?3^SW.B:C'>;_ '$4JQ;?^^S7T]\) M?^"Z7[-OQ5,<9\=/X9NY<8@URPFM-G^]* T(^OF=J_G5H/7_ #Q]*\/$\%Y? M5UC>/H_T/H,-QSF-*RE:2\U^J/ZQ/AS\9_"/Q=TO[9X5\4>'_$EGC=YVF:A% M=H![F-B*Z;=TK^2/P_XDU+PIJ<=]I=_>Z9>PG*3VL[0R1'U!4YS],5]%?!O_ M (+ _M%_!(Q)I_Q,UO5+.,8-MK>S54=1T4F<,ZC_ '6!YKP<1P)77\"HGZGT M6%\0*+TQ%-KT/Z4AS_\ KHW>]?BY\&O^#GKQKHAAA\>?#KP[KT> KW&CWDNG MR_[VV02J3[90?2OKGX*?\'"G[/?Q3\J/6-2U[P->28!36=.9H=W&<26YD&/= M]O3M7S^*X;S&AJZ=UW6I])A.*,MKZ1J6?9Z'W6M**XOX4_M#^!/CCIWVKP;X MP\->)X0H9CIFI0W)C&/X@C$K]" :[0,"*\6=.4':2L>Y3J0FKP:?H%%&: ..?NVZ9E;H?NJ:TIT9U'RTTV_ M(RJUZ=)GKG_2-3OH[6,GT!=@"?8_'C_@X0_9]^$AFM]%U#6O'U]&2NS1 MK(K;AAZS3F-2OO'OK\$_&?CW7?B-KLNJ>(M9U37M3N.9+O4;N2ZN&.3U>0LQ MZ^IK)_R3CK7U.#X%HQUQ$V_38^3QG'V(GIAX**\]S],OCI_PS*P^M?&OQN_X**_&_P#:':9?%GQ*\47U MK<$E[."Z-I9L#G@P0>7'[S?HF*6 M9SRQW*<@L<_4T@Z445ZJC;3\CR=]?S"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH"X4444 %%%% !1110 449HSF@+A11G)H MSS0 44'BCM0 44#D4#F@ HHS10 44=:* "BC-&>: "BC-&* "BBC.: "BC%% M !11T-&,4 %%&:* "BB@#)H **,8HS0 449YHH **** "BBB@ HHHHU"X444 M4 %%%% !1110 4#_ /5Z444>H;EK1M;O/#VH0W6GWEU8W5N=T4UO*T!+J'AR[:/ M'N+: M%[ACF0Z;?20)-_UT0,$<<=&##VK[4^ /_!Q[\:OAHT%OXRT_P_\ $*Q0J'DG MA_L^^<#KB6']V#]8CGUKY?&<$8JGK0DI>6S/K,%Q[A)Z8B+CY[H_>'S.?O"G M+TK\_P#]GS_@XL^!GQ5:"U\51Z[\/=2DP':_MC=V6X]A-#EL>[QH*^U_A;\: M_"'QI\/KJGA'Q/H/B73VY^T:9?1W,8SS@E"=IYZ'!KY?%9;B<,[5H->O]6/K M,)FF%Q*O1J)G5449S2!P>XKC/0%HHSFC- !11FB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BDW4N: "BC-(75>X]: %IK'#4[- M>./#_A^15+I:RW DO)1_L0)F5O\ @*FO@3]H[_@YK\(^''N++X7>"=2\37*Y M5-2UJ3[#:9[.L*YDD'3AC$:_&K5-5NMZ\,Z3-G&G>'%.G1J",8,JYF8$<$.["OEN^OIM2O);BXFDN+B4EWED)D M=V.,G1\CB,=7Q$N:M-R]0/7T_'-%%%=)RA1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 9'X9H MH **!R* <_AUH *.U+M.>AXK=\'?"WQ-\0;E8]!\.ZYK4C'&VPL);EC[8136 M_>!_^"6?[0_Q%$?]G_!_QM'OY4ZA8FP4 M_C<; /K7LG@7_@WH_:2\7E?MVB^&O#>_^+4]:B;;]?L_FG].U<%;-\!2^.JO MO.ZADN.J_!2?W'P[WHQ7ZC>"?^#7GQY?JO\ PD7Q.\*Z7W;^S]/GOL'V#F&O M5_!W_!KKX,M O]O_ !2\3:A_>_L_3(+//TWF7%>=4XKRV&CJ?82?O24 M?G<_F_ +=*>D$DA 6-V+= %ZU_4;X6_8,^"?@M%_LSX2_#FU9/NNOAVU:0?\ M"*%OUKO_ ]\-M \)KC2=#TC31V^RV<<'_H*BN*7'E/[%*_JST*?A[5?\2LO MDC^5KPY\"O&_C#;_ &3X.\4ZIO\ N_9-+GFW?3:IKOO#G_!.7X^>+2IL_@[\ M1F5NCS:!<0H?HTBJ*_I_6V4?PJ/P_P#K4JIY?_ZJXI\=5OL4DO5W.ZGX?45\ M=5OY'\W>A?\ !%?]ISQ&B^1\*=50-T^TZC96V/J))5KL-#_X-_OVF]6"_:/" M.DZ?G_GYUZT;;_W[D?\ 2OZ%B>* ,"N6?&^.E\*BOD=D. L OBE)_,_!;1O^ M#;/]H/5 /.OOAWIO?_2-5F('_?NW>NMT3_@V&^+5SM.I>/?A[:]S]G-U/CZ; MH4_I7[>8Y_\ K4NW-S2]$=$.!\LCJU)^K/QLT[_@UN\22A6O/BYHL M+'[WE:')+CZ9F%;EC_P:R9.ZZ^-A]UC\*?U-W_2OUVV4?=K&7%69/_EY^".F M/!^5K>G^+/RET_\ X-;_ Z@_P!*^+FM3>OE:'''G\Y6K:T[_@U\^'*/BK)_O:I9?TM*L1_P#!M/\ &(_-KGQ M,D^NJVO]+:OT.HJ?]8,Q_P"?TOO*_P!6\L_Y\Q/SW_XAL?V?2O\ R$OB-GU_ MM6W_ /D>HV_X-J/@ XXUCXD+]-5MOZVYK]#**7]OYC_S^E]X_P#5O+/^?,3\ M[9/^#9[X!O\ \S#\4%^FJ6?];4U5NO\ @V1^!*,R7_+W\%_D92X1RM_\ +K\6?C/JG_!KGXNA#?8?BQX>G/I-I$L( M/Y.]ZQT^T37D.?RMWK]PME!'^<5O'B[,E]N_R M1C+@S+']AKT9^">L?\&W7[0FF@^3<^ -0QT%OJ\JY^F^%?Z5Q_B+_@@)^T[H MV?L_@K2]4]K;7K/_ -J2+_*OZ&\X-+C=6\>-,P6KY7\O^"W,OF?S6 MZ[_P1R_:6\-!OM'PE\02;?\ GUEMKG_T6[9_"N)\0?\ !/;X[^& S7WP=^)4 M:+]YT\.W375#CK%+XH1_$Y)>'^$^Q4:^YG\G?B7X-^ M+O!F[^V/"WB+2]G4WFG30X_[Z45SK1,O56';D5_7(]LI'W%]^.M<_P"(_@]X M4\8AAJ_AG0=4#<,+O3XILC_@2FNVGQ[+:=)?)G%4\/>L*WWH_DYHQFOZ@_%7 M_!.KX$>-%;^T/A!\.I&;K)'H-O#+_P!]HH;]:\P\6_\ !#7]F/QAN:3X:PV$ MK='L=5O8-OT43;/_ !VNRGQWAK^_3:^YG#5X Q:^"HG^!_.7G-&*_>;Q;_P; M9_L_^(-S66H?$#1&/W1:ZI#(J_A+ Y_6O*/&O_!K?X>NB[>'?BUK.GC/RKJ& MBQ7>?J4DB_\ 0:[Z?&672W;7JO\ (\^IP5FD/ABGZ,_'"@\?RK],O&O_ ;" M_%/3BQ\/^/O ^JJOW1?1W-DS#Z(DF/SKR'QS_P &_P!^TOX.+&U\+:/X@5>K M:;K=NN1])FC8_EFO0I\09=/:JOZ]3RZO#N94_BI/[KGQ7C-&>?IUKV[QU_P3 M6^/OPXW'5OA#X\6&/(>6VTB2]B7ZO$K #WS7D?B+P=K'@VZ^SZQI>I:7<+P8 M[NW>%A^# &O2IXNA4UA)/YH\ZKA*\/C@U\F9M%#?*<'@^]%="UV.9IK<**", M49H **",44 %%%% !1110 4444 '7U'(P1V/J*VO 7Q&\0?"WQ!%JOAG7-6\ M.ZE 08[O3;N2UF3GLR'_ .M6+14RBI*TE=%0G*+YHNS/N;]G+_@X)^/7P5%O M:^(+[2_B'I<6$\O68-MTJ@]KB+8Q/^U+YAYZ=*^^/V;/^#C7X,_%EX+/QI8: MU\.=2DPK/<*;_3]Q[":-=X[\O$H [U^$- Z_K^/;VKY_'<+9?B-7#D?DSZ/ M\69AADH\_.O-']8GPO\ C'X3^-'AR/5_"'B30O$NER#Y;G3;R.XC^A*$@$>A MY%=*&^?M7\FWPV^*_B?X.^(HM7\)^(=:\-ZI"1MN]-NY+688:I:.*CR/NM4?O,'R?O#\*5#D5\4_LO?\%W?@)^T4;>T MU+6I_A[KTVT/9^( L-N6_P!FZ&8L=@7*$XZ5]F:#K=GXBTN&]T^[M[ZSN%\R M*>"421R*>A5AP0?45\EB,#7PTN6M!Q]3[/"X_#XE:A=);PQ_5G(&?09K\]_VM?^#CSX;?"S M[5IGPQTF[^(>L)N1;^;=9:5"?4,R^;+TZ!5!!&'].[!Y9B<7*U&#?Y?>>=CL MVPN#5Z\TOS^X_22658UW,V%')STKY;_:K_X+$? G]DZ2XM-4\60^(_$%OE3I M'A\+?7"L.JNP81Q$=Q(ZMZ U^)/[5G_!5_XX?M>O<6_B+Q==$T7-A M8[?[KJAWRCVF>0?2OG')/7K[]:^VR_@;[>+G\H_JSX/,N/OL82'S?^7^9^CW M[4O_ N-C$=F)Z? OQ0 M^,7BSXV>)IM9\8>(M8\2ZI,1NNM2O'N'QU !8G &3A1@#/3K7-T5]G@\IPF% MCRT()>?7[SX?&9QC,7+FKS;\N@'DY]?UHHHKT?0\P**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHS1GK_L]?:BX!11GF@#-&X!CBCK71> /A%X MK^*VIBS\+^&?$'B*\S@1:7I\MU)GZ1@G]*^E/A-_P0__ &E/BV8Y5\ 2^';. M;&;C7;R&RV_[T18S#_OV:XZ^/PU%7JU%'YG90R[%5OX5-OY'R2.:#P:_5+X2 M_P#!KUXJU,QR>./B=H>EKP7@T73Y+XGV#RF(+]=I^E?3WPK_ .#O6O$K\7Y=3T4G)^2_4][#<&YG55W% M17F_T/P/VDG&.?2NF^'_ ,%_&/Q9N5@\*^%?$GB28M@1Z7IT]TV?^V8)K^E; MX8_\$V_@1\'A&V@?"GP7;S18V7%QIJ7=PN/^FDP=_P!:]GT_2[?2;-8+6WAM MX8QM2.- J(/0 <"O$K<>17\*E][_ ,CWL/X>R>M:K;T5_P S^<;X8_\ !%'] MI3XI-#)#\-;[1[9^6GUFYM['R_?,!VHP2><_A7BUN-\_#W_@@A^S3X"\M MKCP;J'B2:/I+JVL7,G/J4C=(S_WS7V:>!_C1C->36S[,*OQU7\M/R/;P_#N7 M4?@I+YZ_F>4?#S]AGX-_"I(SX>^%_@72YH>%FAT2W\X?]M"FX_4DUZ?::7#8 M0+'##'#&HP$10J@?0<58/%*.E>;4Q%2;O*3?JSTJ>%HPTA%+T0P+AZ?0!BBL MSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M&"#[ M^U4M8\.V.OVK07UE;7D#C#1SQB16'T.:OTC4U)IZ.Q,J<9?$KGB?Q"_X)R_ MOXI"3^VOA/X&GDD^]-!I45K.W_;2(*_ZUX5\0_\ @WP_9M\;&0V7A_Q%X7DD MY+Z5K4S$'V6X\U1^5?<(&12,N6KKI9EBJ?P5)?>SSZV48*K_ !*47\C\J?B+ M_P &NWA:^5V\(_%37M+YRL>K:5#?9]BT3P_GBO /B3_P;3_&[PP)9/#_ (@\ M#^)K<'Y46[GL[EO^ R1E!_W\K]U0M!!%>OA^+,QI?;OZI'CXC@[*ZFO);T=C M^:GXD_\ !(']I'X5&1M0^$_B*\C4_?T<1ZEN'J!;.[?F,UX+XR^'/B'X=ZD; M/Q!H6L:'=@X,.H6SU73[/4K208>&Z MA6:-OJK @UZ]#CJLM*M-/S3:/%Q'A_1>M"JUY-)G\DHYHSFOZ9/BC_P2C_9Y M^,'F-K'PG\)1RS'=)+IMJ=,D8^I:V*$GW-?-OQ7_ .#:GX*^+5ED\,ZYXV\( MW#?ZN,74=]:I]4D3S#]/-'3ZU[6'XVP4M*D7%]]SP\1P'CXZTI*7SLS\+2<" M@G;UXK]./BO_ ,&Q'Q(\.-))X,^('A3Q)$I)$>HV\VF32#TPGFH3]6 KYD^* M_P#P1Q_:0^#@DDOOACK6J6T?W9]$>/4MX]=D#,X'L5%>]A\^P%;X*BOV>A\_ MBN'\PH/]Y3=NZU/F*BM+Q1X,UCP1JTECK6E:EI-]%_K+>]MGMY4[I?L M[_MK?%3]E/4EN/ /CC7= B5PS6:3^=8S?[]O(#&Q]V7CUZ5Y;16=:C2JJU2* M:\S:C7JT7S4Y-/R/UF_95_X.9[VS-OIOQ@\&QW4?"MK/AP[)!V)>VE(!)ZY2 M0 =EZ9_23]F?]O#X2_MI0WEC=7%G=6S>9%-#(T/X-PE9N5!\C\ MMOZ]#Z[+N.,90M&O[Z\]S^N(."M /%?SW_LH_P#!>KXY?LYO:V.N:G#\1] C MPK6VNDO>*H_N78_>;L#&9?-'L*_3O]DG_@NI\#_VGC:Z?JFK-\//$=QA#I^O MNL=L[GM'=#]TP/0;]C$]%Z5\/F'#&-PMW;FCW6OX;GW^6\58'%I+FY9=G_GL M?:B\]J>#D57L+R+4+6.:":.:&8!D>-@RN#T((ZBIE(%?/ZK1GTB::NF.HH#9 MHS0,**"<"@'- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4449H ** +M'\-6[ ^2EU-FXN2.T4*@R2' MV121Z5^8W[8'_!R[)-;U37M8O6W37E_ M#,+0M+$_O)?=U\=?VFO'W[3/B=M8\>>+-9\37P M;=']LG9X;?/.(H\A(QR>$51ST%<+T_S_ )_F:**^NIT8TTHQ5O):'QE2M.I) MRF[W[ZA1116AF%%%% !1110 4444 %%%% !1110 4444 %%% &30 448XSV/ M2CI^'7VH **W? /PP\2_%77%TSPOX?UKQ%J38(M=.LI;J7![[8P6_I7UK\#/ M^"!_[1?QG$,U]X=TWP3I\P#>?X@OEA?'_7&+S)5;V917'B,RPU!7J32]6=N' MRW%8AVI4W+T1\6DXHQ7[,_ W_@V#\*:,8;CXB?$+6M;D W/9Z):16,8/=3+( M)&8>X5#]*^Q_@=_P2A_9_P#V>Q#)H'PST"XOH<8O=5C;4K@,/XE:X+[#_N!: M^;QG&F!IZ4DY/R5E]Y]/@^!E"[%'/5F KZQ^#'_!NS^T%\2A#-KT'AKP/:GD_VIJ(GN # MCE4MQ(,^S,O3M7[XVFGPZ="D<$,<4<8"JJ#:H [ 581<#_ZW6OG<1QQC)_P8 MJ*\U=GTV%X!P<-:\G+T=D?ES\&/^#8;P+H!AF\=_$+Q)XBD49:VTBWCTV$^J MDN96(Z\C:?I7UE\&O^"1/[.WP,6%M*^%WA_4+F/_ )>-81M4D)_O?Z0753_N M@5]+ 8I",GK7SN*SS'5_XE1V[+1?@?387A_+\/\ PZ2OW>OYE#0O#FG^&-.C MM-.L+6PM8AM2&VA6*.,>@48 J]'P/QH(_P FE7I7EN3;O+<]:,5%6BA:***" M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8X^;\*?36&3_] M:@#!\#/"4*_7RS7R1 M\:/^"!G[1WPA,LEEX;TSQE90DYET'44D8K[12B.0GV5">>]?T-8^E-96)_SB MO>PO%^8TM&U)>:/G\7P7EM;5)Q?DS^3[XD_!3QC\&M4^P^+?"OB'PS=[BJQ: MGITUHSGV\P#/X5S!X-?UL>(_"&F^,-)FT_5M.LM4L+@;9;>[A6:&4>C*P(/X MBOF3XX?\$5?V=/CCYTEQ\/[3P[?2GB[\/2MIK1YZD11XA[]XS]*^BPO'4'_O M$&O-'S.*\/ZL=<-4379G\X6.: V:_7KXX_\ !KU"XFG^&_Q*DB'_ "RL/$5D M&!')PUQ!C_T3ZU\8_'G_ ((L_M%_ 0SR77@6\\4:?"3B\\.R#4E8>OE(?/ ^ ML8%?2X7B++\1;VA\OC.&\PPVM6%_-:GRG15O6_#]_X8U*:RU*RN]/O+ M=MLT%S"89(CZ,K $'Z\U4 R<=_2O:C.,E>+N>'*$HZ35F%% Y&:*9(4 [3G) M'&#R>?P__7]***EV>X]5L>[?LI_\%)?C%^QM=PKX-\87RZ1&PW:+?L;O39!Z M>4Y(CZ=8]C?[0K]2/V/?^#CWX?\ Q1%KI/Q6TJ7P#K4@"'5+4/=:3*W') !E MAR>Q5U Y+@5^(-'4_3WQC\>WY5XN9YEO$F-P6E.=X]GJ?U MH> ?B!H?Q.\+6NM>'-8TW7-(OEWP7MA=)<02CU5U)!_.MD_6OY7?V=?VM_B1 M^R?XG_M;X?>+M5\.S.ZM-#!,6M;L#M+ P\MQQ_$AQ^5?J'^QC_P:U)Z$S6V3(G3.Z,R9_N*!7P&9<'XK#WG1?/'\3]& MROC;"8BT:ZY)>>Q^L#'BE4Y%N:^4E"47RR5F?94ZD9KF@[KNAU% ;-&:DL** M"V#1F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T%@#36;)- !G' M?%&>>O;KFO/_ -H?]IWP#^RSX)D\0^/O$^E^'=-0%8S<2?OKEAR4BB7,DK=/ ME12?:OR5_;A_X.._%'CQ[S0?@QIA,47,4(]"Q=\8^ MXP('J9;DN+QLOW,=.[V/%S3/L)@(WK2U[+<_4O\ :L_;D^&/[&/AK^TO'WBB MQTR61"UMIZ-Y^H7G7'E0+EF&01N.%&.2*_)K]M/_ (.,?'OQ9^V:+\)M-_X0 M#07W1C4Y]EQK%POJO6*#/HN]O1P>!^=WC3QQK/Q(\3WFL^(-5U#6]8OG,D][ M>SM-/.QZEI&);T_#CM65^OX8K]&ROA#"X>TZW[R7X+Y'YGFO&6+Q/N8?]W#[ MV_F:/BSQ;JGCOQ#N9+F[NYVN)YV/4L[G)[>_;M6=G-%%?61C M&*M!61\?*3D^9N["BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****/( HHQ@T M8X'OT]Z>P!1G]*]<_9[_ &"_B_\ M3S0GP/X!\0:Q9S' U V_P!GL/QN)=L7 M'LQ//2OO+]G+_@V0\5^(1;WOQ0\ M1C,[P6%TJU-?O_(]C!9'C<7K2INW?8_+''S8[GM7J/P(_8I^*_[34T:^!_ / MB3Q!!(VT7<5F4LU/O/)B%>HZL*_>_P#9T_X(S_L__LW"":Q\#VOB35H0I_M' MQ"?[1E9A_$(W'DHPZY1%//TKZBLM.ATRVCAMH([>&)0J1QJ%50.@ '8>E?)X MSCJ-[8:%_-Z?@C[# >'\]\5.WDM?Q/Q*^ /_ ;/?$[QIY%W\0/%GA_P3:MA MFM;-3JE\OJIV[(E^HD?Z5]N_ '_@W[_9]^#/D7&K:/JWCW4H.1+KMWN@#=\0 M1!(V!]) _7Z5]OQ_\"_&E49%?*XOB7'XG>I9=EH?78/A;+L/JJ=WWEJ<_P" M/A;X;^%.A1Z7X9\/Z+X>TV+[EKIUE':PKP!PL8 [#MVKH(Q@4$8[4J]*\.4G M)WE=L^@A3C!6BDD+11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DSG^'\:?2 M%#?#GBB%5*Q_VCI\5PT.>I1F4LA]U(-?&/[0/_ M ;D_!#XI1SW'A.X\0?#W4)/F5+2X-]8[N?O0S$N1[+(HK]!NE-P=WM79A?BLIP>)7[ZFG\C\&?V@?^#%[LDA5U*PEMQ-UY1F #C@\ MJ2.*_JX[_=_2LWQ9X-TGQSHTVFZUI>GZQI]R-LUK>VR3PS#T9&!!_$5]3@^. M,5'2M%27W,^3QG >%G[V&DX>3U1_)3FC./PZ^U?T+?M%?\$%?V??CKY]QI_A MV\\!ZI+D_:/#MQ]GA)/K;N'B 'HB(3ZBO@W]HS_@VK^*7P^BFO/A_P"(M%\> M6\J9].U?68/B[+Z_P ;Y7YK^D?&X[@W,WK7T=*I"<>:#NN]SYFI1J0ERS5GVMJ%!YX]\_CV_*CH:*TU,SN/@-^TE MX[_9A\7QZ]X#\4:MX;U)2/,:TE*QW !SMEB.8Y%SGAP0.3CFOU*_8K_X.3[7 M5&M-#^-VAK83';&/$>BQ.\/8%I[;)9?7=$6]HP*_'VCK^?KC/X_Y%>3F&28/ M&K][#7NMSV,MS[&8*2]A/3L]C^L/X2_%_P +_&_P7:^(/"'B#2?$6BW@S'=Z M?FBYD@R>Z^8G4DH*_.\TX0Q6&7/0]^/XH_2LIXTPN):IUUR2_!GZ MD$;L4X5C^#/&>D>/_#-GJ^A:I8:SI.H)YUM>6=PD\$Z'NKJ2K#Z&M<-7R+33 MM+1]C[6,E)76PM%&>:,T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 449I"X'<4 *6Q3= MV:;,ZJ"Q/"@Y/H.]?#__ 4!_P""X_PU_8_^W>'O#( MKBZL8I"]GI%L/(TVPS_<@!(W#^^Y=SQES@ >,DY8G]?7_/O7Z+E'!M*G^\QO MO2[+;YGYAG''%6M^[P7NQZM[_P# .L^,OQT\8?M#>-KCQ%XV\1:IXDUJXZSW MLYD\D9)"H,%409.$3"C)P!7)]#_@,445]O3IPA%1@K)=CX6=24VY2=[]]0HH MHJS,**** "BBB@ HHHH **** "BBB@ HHSBB@-4!.*,9JQI.EW6M:C#:V5O/ M=W5TVR*&&,O).>R@+DD^@ YK[(_99_X(/?'C]HW[/>ZEHL/P^T&;:_VSQ"## M<,IYRELH,I.#T<1@_P!_J!R8K'X?#1YJ\U'\_N.S!Y?B<5+EH0#]>\476=L@L;1Y(X?^NCXV(.>KLH'K7[>?LM?\&] M7P5^!8M;_P 6+J'Q,UR##;M4_<:"&E ]*_ M0S]FS_@B]\ /V9?L]U9^#X?%6M0D$ZGXC8:A*6'1A&P$*$=BL8(]>E?5B&6Z3PRCT9&!!_$5\;_M*_P#! OX!_'C[1>:/H]Y\/=9FRWVC M0)=EN6/K;N&C"^T8C)]:^W&7CBD 8FNG#8_$8=WH3:^9PXK+L-B5:O!/\_O/ MP8_::_X-U?C1\'A<7W@NZTOXD:/'DA;1Q8ZB%'K;R'8WT21V)SQ7PU\0?AAX MD^$WB.71_%&@ZQX=U2#[]GJ-G):S)R1]UP#C@\@8K^LHY+8_I7*?%OX%>#OC MQX=DT?QIX7T/Q1IL@/[C4K)+A4R,97-L13]W$Q4O-:,^-Q M_ >'J7EA9.+[/5'\H>>/UH[?K7[@?M2_\&V'PW^(8N-0^&.O:IX"U-\LME=9 MU+36/H-["9/3.]P !A?7\WOVI?\ @CY\>/V4FN+K5O!MQK^A6Y)_M?P_G4+9 M5'5W50)HQ[R(![U]M@>),#BDN65I=GH?#YAPSF&$OS0O'NM3Y@H ^@/K_D&E MD&QL,-O)'/7CK25[?3R/ L[VZGM7[(7_ 4"^*7[$GB5;SP+XDN;73Y) ]WH MUT6N--NQP,-"Q !( &]-K@8Y S7[%_L)?\%[/AC^T^+'0?&GD_#?QE-B)8KR M<'2[V0\ 17!P%).?DDV^@9^M?@51W[8/!R,Y'TZ'\>E>%FG#N$QRYI1M+^9' MOY3Q)B\ U&G+FCU3U_X8_KDM[A)XE:-E96^Z0?E;W%3!\9[5_.K^P/\ \%G? MBE^Q0;/1;JX;QMX#A(1M$U*:#?D0:C:'O\F2)$'&7C++SR0<@?F>:\.XO N\U> M/='ZMD_$V$QZM%\L^J?Z/J?06:*:C*J]AW_QI0P/>O!/HA:*,T YH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M IK'!_"G;J@O;R*RMVFFD2*&-2S.[!54#J23Q@4+71";25V29P?Z^E>4_M5_ MMG_#O]C/P,WB#Q_X@M=+A8,+2R4B2]U%Q_!#"/F<^_09R2!S7Q+_ ,%&_P#@ MX'\-?!DWWA/X.?8?%_BI=T$^NO\ /I.F'H?+QG[1(, _+^['JY!2OQP^,?QN M\6?M!^.[SQ-XTU_4O$6MWQ_>7-[.7.W_ )YJ.B(,\(H"CD# X'U^2\)5L3^] MQ/N1_%_Y'Q&><94<+>EA;3GWZ+_,^P/^"@?_ 72^(W[64M[X?\ !\EW\/? MWY4BC _P#K?SI: M_3<%E^'PM/V="-OZZGY;CLPKXN?M*\FW^'R"BBBNPX0HHHH **** "BBB@ H MHHH **** "BC/Z=?:@#)Q0]-PUZ!_CC\:,=/]KI[U]$_LB?\$L_C-^VA-;W' MA?PO/8^'9B VNZL6LM/*]]CD;IOI&K8[^WZC_LE_\&X_PO\ A(+;4_B1J5Y\ M1]:3:[6I!L]*C8=C&A\R7'3YWVD=4[5X68\1X'!Z2ES2[(]_+.&<;C/>A!Q7 M=_Y'XV_ 3]EOXA?M0>)AI/@'PCK7B:Z! E:TMR8+8>LLK8CC'/5R*_27]DG_ M (-G-0U#[+JGQD\5KI\.56E%17EH+11169L% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %12Q[Y/PZ5+32,F@32>Y\W?M6?\$H M_@E^U[]INO$?@^TT_P 07&6_MS1L6-^7/\3LHV2G_KJC]*_,_P#:M_X-M?B- M\.!<:E\+]H:/.<;?7]P@,>E,>/-L8^92#[U^;_[7/_!M#H7B W6J?!OQ1+H%PX9UT/7'>XL\ M]ECN%S,@]G$A.>2!T^XR_C3#5;1Q,>1^6J/S_,N!<51O+"OGCVV?_!/QKZU? M\+^*M4\$>(;35M%U"^TG5-/E$UM=VD[0SV[CHZ.I!5AG\?P->C_M-_L2?%+] MD#7?L/Q!\'ZIHL?_!Q->:#]A\*?'B.34+/Y88?%EE!FXB'&#=PJ M/W@'>2,%N.4;)8?K;\-OB7H'Q:\(6.O^&-8T[7M#U*/S;6]LIUFAF7V921QT MQU!&*_DT.Y2/S_'L3W_*O:?V-OV_/B9^PWXP&I>!]>ECT^XD#WNCW9:73=1_ MZZ1$X#'&/,7:P&,$#.?C/O+S/X?O9AFX8#+-:R' F7J<8#@ MEE P3]=1L #SWK\WQ.%JX>?LZT>5GZE@\91Q5/VE"7,OZW'T49HS7.=04444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111N% 6VCFFL M^/\ ]=-E8+\WH.OM7P?_ ,%,_P#@MYX/_8XAOO"?@O[#XS^)$8:)X5D+Z?HC M],W#J07<<_ND(;@[BG&>K!X&MBJBI45=_P!;G'CLPH82DZM>5E_6Q]/?M9?M MB?#_ /8T^'$GB3Q]KL.EVV"+6UC(DO-1D'/EP19#.W3GA5R"Q4X\%_#MBR)H]I-BXU%3R&NY1@.#_P \Q^[&1G>1N/S9 M\??VB?&?[3WQ%N_%7CG7]0\0:S=D_O9Y,)"F3^ZB082)!DX5% Y/7-<3^7X" MOU+)>%><68C&OV>']R'XOU#.:***^LTW/C_ ""BBB@ MHHHH **** "BBB@ HHHH *,\_7I1_AFE5=S8Q]XA>>G/K]/ZT.RW"-W\(A.! M2HC2L%4;LD*!C.">,U]A_L4?\$2_C+^UV;/5+K3F\!>$9]K_ -K:U%)'+<1^ ML%MQ(YP<@G8G)^?/ _7;]BK_ ((W_!O]C-+/4+71?^$L\76X!_MW6XTGEA;C M)@CQYY^/_ .QW_P $ M5?C=^UJUGJ+:(?!'A>XPW]K:\CP-(GK% ,2R9'(. AS]\'-?JQ^QY_P0J^"W M[+:6NH:IIK?$3Q/;X;[?KD*O:Q..LZ=9ZMI ME[&8KBTNX%F@G0]5='!5@?0@BOS_ /VO_P#@W7^%OQH%UJGPYNIOAOKT@+BU MB0W&DS-SP83\T?U1MJXX0]*_1)1F@#-=F#S#$867-AYM'GX[*\+BX\N(@G^? MWG\R7[7_ /P3*^,'[%%],_C#PM/-H2OMBUW3(ICK@GK]WEO&T)6AC(V?=; M?-'Y[FG _R9^!VG:E&!"D M$8/''.,?I]_P3E_X.$-8\ QZ?X0^.37.OZ'A8(/%,<9EU"S7H/M*=;A!U+@^ M9UR)">/D+]LK_@EU\8/V'[V:;Q5X=:^\.A\1^(-*W7&G2#G&]]H>$MZ2!23T MR,$_/&0'_P!KKD<$GZ^V>]?4XC#8'-**U4E;=;H^3P^*S#*J_6,NJ>S/ZS_A MW\1-#^*G@W3]?\.:M8:WHVJ1":UO+.<313*>X8'GN/4$$8&,5MJ< U_,U^P= M_P %*OB1^P#XO%QX9OSJ7ANYD#ZCX>OI&:RO!P&91R89<# D3!^5=RNH*G]X M?V$O^"D7PW_;W\&+=>%M0^P:_9QA]2\/WKA+ZP/0G:.)(LD8=?EY&=IRH_,< MZX2S,Q '/7_]?#?M7?M=>!?V-_AC<^+/'.L1 M:?9Q*RVULA#W>HR@<0P19!=SQW 7.6*C)'X$_P#!1O\ X*K^._\ @H!XHDM9 MYI/#_@&SESI_A^WE)C?!XDN6P#+(<=P53L O6'P3X=F;28Y-ESK=]F MWTRU(QG,I!W,N<[(PS_,#CT_8?\ 87_X()_"W]E_[%K?C.)/B5XPA"R>;J$ M_LRSD&/]5;'(<@]'EW'@$!#7@YIQ)A,%[LGS2[+^M#Z'*N&<;CFI1CRQ[L_+ M+]AW_@CY\7OVVYK74K'2_P#A%/!DS!V\0:O&\<,B^L$?WIS@G!0!+[M1K,\+CDF"+_5PC/0@%P.-YKZVM(%M MX5CC18U3A55< < 8]JD P:_-LTXFQF,;C%\L>R_5]3]0RGA3!8).?#7:ZU9[KC3+P MCH%E ^4D#A'". !\N,$^6_#;XF^(/@[XWT_Q'X7UB^T+7-*D$MI>60< M*@&:^_ROC*E67LL=%*_7=/U70_.F/2 MOY5?VAOV8_'W[*OCF3P_X_\ #>I>'=43=Y)N(\PW2@@;H91N25<_Q(Q *C.# MP/NK_@EC_P %V=:^ T^G>!/B_>7NO>",I!8ZV^9K[14/ $O4S0#CG)=0#C<- MJ#CSCA:%2+Q>6M..[C_EY>1V9'Q94IR6$S--2V3_ ,_/S/W#!R/6EK(\$^,] M)^(/A2QUK0]2L]6T?4X5N+2\M)A-#<1L,JRL."#6L&S7P/*T[/<_1XR4ES1U M0M%!:B@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4UF^?KVZ4XMBHY&4'/6@ + =Z^8_ M^"D'_!3WP3_P3[\"%K^:/7/&FH1%M*\/P2@2R=0)ICSY4(((W$$L00H;!V^8 M?\%7O^"R>@_L0Z5<^$?![6?B+XH74>/))\RUT%".)9]O63NL7!(^9L#:'_"# MXG?$_P 0?&;QYJ'B;Q5JUYKFO:K,9[J\NGWN['TQP% P HP% %?8GYTJ*SNNWYFS\H/\ >Z#G\?Y5]_?\$\O^""OCS]J!+'Q)\0OMW@#P M--B1(Y(=NK:G&?\ GG$P_*_CWXYM/#7@WP_JGB+7+X_N[6Q@,DFT=7;H%5>[,R MJO.2 37ZV?L!_P#!N9I/A5;+Q+\N>E?FF<<7U\1^[PON1[]7_ )'ZEDO!=##?O,7[\OP1F^$/!NE^ M ?#MGI.BZ;9:3I=A&(;:TLX$MX($'1510%4#T Q6JM(!S2U\Y!+6]Y#NV/C ='X:-P"<.A##L17Y'_M]?\&Z& MN> EO?$OP1NI_$FEINFD\.WKJ-0MQR3]GDP%FP,X5MLF!@%V-?M(>M,E'.<= M!Z=:]++LXQ.!E>C+3MT9X^9Y'A,=%^VCKWZH_G5_X)^?\%.OB/\ \$S/B-/X M;UBSU*_\'_:C'K/A?40\4UC(<;I8 XS%,!U7[K#A@,*R_O5^S)^T_P""_P!K M?X46/C'P/K$.K:3>#9(OW;BRE !:":/K'(N1D'J"""5(8^<_MK_\$S/A;^W= MH+Q^+-$6S\01QE+3Q!IZK;ZA;=P&8#$R9YV29 ZC:W-?E?XE_9L_:(_X(1?& M-O''A>1O%7P]FD6.]N[:-CI^HP Y$5[",M;N 2%DR0"?E=LLI^BQ$L%G*YZ= MJ=?MTE_P3YO#+'Y(U"M>K0[K>*]#]U@VX_I3U.?SKPG]A3]OKP+^WM\+%U_P MK=F'4K4*FK:+FJM*7-%[,=11G(H!S69L%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.*<6%0R,,[NP') M]![4>@>H2^_/KZ5^:W_!7S_@MA;?L\+J7PS^%%Y;WWCI@UOJFL(5D@\/9R&C MCZA[D=#U6,]0S J.8_X+)?\ !; ?#EM5^%/P?U17\0KNM->\16TF5TL]&M[9 MAR9NH>1?]7C"_/EH_P ;+B=[F=Y)&:221B69CDL>Y)[Y]3UK[SAOA?VEL5C% MITC^K/SGBCBSV;>$P;U^U+MY(GUO6[SQ+K%UJ&H75Q?7U]*T]Q1CE MG9F))8DY)/)/-5:**_2XQ27*EL?EKDY.[^_N%%%%, HHHH **** "BBB@ HS MQ].OM0!D_B!^)Z?R-$?[UEV99F.%P>N>./\ ZW6AV6K'&[=D%>K?LG_L7?$7 M]M#QZNA> ?#]SJ4D;*UW?O\ NK+35/1YIB-J]R!RS8PH.2#]@?\ !-G_ ((( M^*OVB_[/\7?%1=0\&^"I-LT&G!?*U;5TX(X(!MXV_O,"Y'10"''[3?!GX'^% M/V>_ %EX7\&Z#IWAW0M/7$-K9Q;5SQEV)^9W/!+L2S'DDGFOC$.W5GR5_P3R_X(??#O]CA;+Q%XDCM?'?Q B4/]ONH/ M]"TR3O\ 9H6S@@Y_>/E_[OECBON* ;4Q[TB@[/Q]*D7I7YGB\;6Q53VM:5V? MJV!P%#"4U2H127];A1117*=@4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %5=4TZ'5+66WN(8[BWN$,4LL0_#GQ]8LTLNANVW1=8 M4D,\)7GRU?&"G,9XXC(#K]!?L;_MHQ_M&6UYX;\4Z'=>!/BKX;C']O>%[\;9 M8L':+JW).)K5V^[(I.,@$]"?=I!\W ^O^?SKB?BQ\ ] ^+=YINH7D$]AX@T- MS+I.MV!$.H:8^.?+DPT MPNB>\>GKY'=1-N7V-*HQ5+PW;WUIH\,>I2V]Q>1C;)-"AC28C^+8<[<]=N2! MZFKV:\_9GJ+;4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHH)Q0 4USBEW#-1S$%OPH 23!Y^HSZ?_7K\I_\ @M-_ MP6?_ .$+75OA#\(]45M:(>T\0>(+63/V#.0]K;./^6W4/)_ <@?/DIM?\%KO M^"Q@^#5EJ7PC^%VIY\77"-;^(-:MI<_V&A&#;PLO_+R>C-_RS&0/G.8_Q9EE M::1F=BS,26)ZD]S^/\J^^X7X:Y[8O%+3HOU/SCBOBI1O@L(]=I2[>2"20RR, MQ9F+$G+=3_G^>:;117Z4HV1^7ZO<****!!1110 4444 %%%!X&>W2BS */Z4 M'BOJ;_@G7_P2D^('_!0#Q#'>6D,GAWP':S;+WQ#=PDQG!^:.V3@S2]B 0J_Q M,,@'FQ6,I8:FZM9V7];'5A,'6Q-14J*;9XA^S_\ LY^,OVHOB1:>$_ ^AWFN M:S>9S'$N([>,$;I)G)"QQC(RS<-OLGC MCXAQ@2I+)'NT_2'Z_P"CQO\ ?D7H)7&00"JI7TO^R+^Q/X!_8E^&D?AKP)HZ MV2L%>]U&;$E]JDH!_>3RX!8\DA0 B9PJJ.*];A!$>,;<<8K\LSSBJMB_W6'] MV'XL_6LAX1HX2U;$VE/\%Z#DR%]/2G4TGFG U\F?:!1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %-?DTZD)Q]*0$;-@\X^GK7Y]?\%I_P#@K7#^R/X4N/AWX"OX9_B5 MKEOBYN8G#?\ ".6[C'F'MY[ _(I^Z/G(QM#>G?\ !6G_ (*7Z5^P#\'_ "=. MDMK_ .(WB2%X]$T]L.+8<@W/QIXSU;XB^+=1U[7-0N MM5UC5[A[N\O+ER\MS*YW,[$\DDFOM.%^'OK,EB:Z]Q;>;/@^+>)/JT?J>&?O MOXGV10O;Z;4[R6XN9I+BXG.@)^G6OVS_P""4W_!#+2_V>_[ M-^(7Q:MK/7?'B[;BPTA@LUGH#\$,Q^[+<#UY2,CY=Q <>/FV<8?+Z?-5=Y/9 M'LY+DN)S&IRTE:*W9\\?\$JO^"#%_P#%J'3OB!\:K.[T?PS(%N-.\-',-UJ8 M."LEP>&BBZ848=\Y)50-_P"S7@[PCIG@3PW9Z/H^GV6E:7IL2P6MI:0K%#;Q MJ,*B*H XP*O1Q_+TZ=JE6OR+-,XQ&/J^TK/Y+9'[/E&2X;+Z?)1CKU;W8H MHHHKS#V HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "C-%(W(H 0G'H*\=_;D_;)\-?L M.? /5/''B&996A0P:;IZ.%FU6[8$QPIGIG!);D*@9B#BO1OB'X]T?X7^#-6\ M1>(+^#2]%T6UDN[R[F.(X(D!+$]^W0#]%=[3P]I;M@6T&[YI9,''G2[0S$9Q\B9PF3[W#^2RQ]?7X([O]#YO MB3/(9?0M'XY;+]3RC]I+]HWQ1^U;\9-:\<>+[YK[6-9E+,JL5AMHNB0Q*3\D M:K@ =>N23R>$[>OT% Z#VXSZT5^S4Z,:4%3@K);(_#ZM6I4FZE1W@VXU'Q)J$:'6=?F M0"YU!Q_".OEQ*>%C!X')+,23\YGO$%++X\L/>J/IV\V?3\/\-U#H=2NUM?$/Q(U"'&H:VT>5MAK\BQ6*JXFHZM9W;/V?!X.CA:2HT(V2' M4445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 444$XH *BN/O?=W<=/7_/^>E2; MU]:^(_\ @MG_ ,%'H_V*?@+_ ,(_X$J8FLJ-):LY,=C*>%HRKU7I$^)/\ @OO_ ,%-&^+_ (RN/@KX M*O\ S/"_ARY_XJ&[B;Y-4OHSQ;@YR8X&!#9^](._EC/YED\]_P 33IYGN)FD MD+-(YRS,:;7[?EN7T\%0C1IK;=]WW/P+-,RJ8[$2Q%1[[+LNP44 M45Z!YX4444 %%%% !111_7B@-PKV#]BK]BOQK^W+\9+7PGX/M&&PK-J.I2 B MUTF#.#+*P'U"H/F<\#H(H8&'LJ6M1_AYL^LX:X:J8^7M*NE-?CY%3]B?\ 8B\& M?L,?!RS\)^$;,9^674M1F1?M.JW &#-(1Z=%4'" XY.:]GA.4Z$>QI"IV]>] M.48K\CK5IU9NI4=Y/<_9L/0IT8*E25HK86BBBLS8**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHS0 4U^M.W5'*I?L>?LA>+_VV_C7IW@KP=:^;2 _9M,M@0)+B4C^%=PP.K,0J MY) KG_V?_@'XH_:=^+.C^"O!^FR:IKFM2B.*/'[I%'+22MT2-5RS.>@'?-?T M;?\ !/#]@#PS_P $_?@C!X;T<+J.NWP2?7=:=,3:G<@8^JQKN8(F> 2>69C7 MS?$&?0P%/DIZU)+3R\SZCAOAVIF-7GJ:4UOY^1T'[$W[%G@_]AKX*6/@_P ) MVNYEQ+J6I2(/M6K7) WS2$>IZ*.%4 #IS[$@PM-"87NOH/2I!7X[4K3JS=2H M[R>Y^UT*$*--4J:M%;!1114FH4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'K M12'GB@!"?I7S9_P5/_;>:5BTDLC$LS,3R26)))[FJ]#')_B_&BOVM144HQV1 M^%N4G[T]WOZA1110(**** "BBB@ SBM#PKX3U/QWXFL=$T:QN-2U?59TM+.U M@CWRSRN0$10.22Q48'?%9Z@LZA?O]!\V,G\.1]??ZU^VW_!"'_@E8/@7X5M/ MC)X\TW;XOUNV#>']/GCPVC6Y_\$E_^"8>F_L"_"3[=JT=M>?$KQ)"K:S?+AA8J2&%G M">?W:M@L1P[ $Y"KC[ @.4[]<E?BN*Q57$U76K.[9^[8/! MTL+25&BK)"T445SG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36.*= M3)7VCZSR1^U?SL.6+G=U]?6OK_\ X+:?M@M^UA^VWK4.GWGVCPKX%8Z!I:HV8I#& MY^T3#LV^;< PZHB=J^/UX'OW/K7[)POEJPF#BY?'/5_HC\/XKS;Z[C6H_!#1 M?JPHHHKZ0^7"BBB@ HHHH *,]?S_ *?X4$[17N7_ 3X_8DUW]O/]HW2_!FE M^9:Z7'_I>MZCM^33;)6 D;W=LA$'=B,X7<1CB,13HTW5J.R6IOA\/4KU%1I* M\GL?4/\ P0I_X)>_\--_$"/XI>.-.6;P#X7N@NGVDZ9CUV^0@X*GAH8B 6SP MSX3D"0#]UH$V)W_&N<^$'PIT'X'_ TT7PCX9T^'3-#T&U2TL[>, !$4=3_> M8G+,QY9B22223TPK\3SG-)X[$NI+9:)=D?N^0Y/#+\*J2^)_$^["BBBO)/:" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQS11F@ )Q7S7_P5D_:S/[' MO[$OBKQ'97'V?Q#JD?\ 8NAE#^\6[G#*)$_VHD$DH_ZY8KZ2D/'\Z_#?_@Y$ M_:L/Q/\ VF='^&.GW&[2_A_:B:^4-\LE_M>UP_E_P!; MQL(/X5J_1'@\29C]3P,IKXGHO5GYORS-<2-(QW,Q))R3G\3S^?--HZ_YZ45^ MW?4**** "BBB@ HS10?F*C(!SQGH,]3^%'6P="YX?T*^\4 M:[9Z9IMK/>ZCJ-PEK:V\"%Y;B9SM1$ Y+$G Y)(]*_HX_X)1_\ !/RR_8)_ M9NM=-NH89/&WB/9?>(KM,-F7!V0*W>.($J.Q8NW\0KX+_P"#=O\ X)Y?\)IX MHD^.OBNQ9M+T:22T\+PS+D7-UC;+=X/\,0)5(/%6L3?9])\-Z=/J=V_I%$A=L>IPO [DU_*[\:/BIJ7QQ^+GB7QCK#[ M]3\3:E/J=QSD(TKE]H]EW8'H !VK]Q/^#BW]HL?"?]B*#PE:W CU+XB:G%8L MBMML]GBKXD0QRVOF+\]II8^:$9Q_P MCB4X_A\D?PFO%X@S18'" MNB]3WN'>:5ND:*"S$^P /-%F]$*4K*[/P?_P"# MB_X_-\4/VYX_"=O-OT[X>Z3#9F/=N3[5.!<2M]=CPJ?>,CM7P#C'I^%=I^T9 M\7+KX]_'SQEXTO-WG^)]8NM1*L>8A)*S*GT52%'L!7%U^\Y3A/JV$A1ZI(_G MC-L6\5BZE?NV%%%%=YYX4444 % &3]>!11C=\O7=Q@C@\@?UY_"@#Z(_X)K6IC\3?$X MQZFQD7]Y!8*"+5.G\09I3CC$J#^&OO=/NU^-\49H\7B^6/PPT7ZL_;>$EJ_3HA:**"VT9+J/HJ,W48_Y:+^='VR+_GHOYTNK=?JX%-1D]D'MJ?\R^\M45''>0S+E9$8$9!!ZTX MR*#U%39HN,D]AU%&[FC.:!A1110 4444 %%%% !1110 4444 %%%% !1106" M]30 45&]U'']Z15^IJ$:W9EMOVJWW>GF"J49/9&;JP3LVBU14(OX6'$L9_&G M?;(?^>B_G1ROL'MH=U]Y)14?VR+_ )Z+^='VF/\ OK^=+E8_:0[HDHIGVB/^ M^OYTOG+_ 'E_.BS'SQ[CJ*:)5/\ $*<&S2*N@HHS1F@ HHW49S0 449Q1F@ MHHW4TRJ#]Y?SH%S);CJ*;YZ?WE_.D^T1X^^OYT[,7M(]Q]%1_;(O^>B_G1]L MA_YZ+^=/E9/M8=U]Y)15>75K6 ?/<0I_O.!3HK^&< I-&P;H0V3,(8,@]5$LB,1Q\JGFM*-*56I&G'=NR,,36 MC1I2JRVBKGIUQ\3O#MCXI71)M>T:+6& 9;!KV,7)!Y!\O=NY^E;0D#D8-?R3 M^)_&&J>-O$=]K6L:A>:IJVJ3-OV:/^"J M_P =?V5#;6_AOQUJ-]HUN JZ1K#'4;'8/X%63YHA_P!E43 MEV9\%0\0*+J6JTW%=.I_2_T]*4/D=?SK\D?@=_P=!6C6T=O\1OAG=1R* )+S MP[>JX<^UO,1M[_\ +9J^G_A=_P %Z_V;?B48XY_%U_X7N),8AUK3)XL'T,D: MO$/J7Q7S>(R#,*/Q4V_-:_D?3X;B3+L0O3T9]HYHSFO%?"O_ 43^ WB MP*+'XP?#EV;[J2Z_;0R-]%=U/Z5Z)X9^,OA'Q@%_L?Q1X=U0-T^R:E#/G_OE MC7FRPM:/QQ:^3/5CBZ$OAFG\T=-14:7D4@^616^AIRRJW1E/XUERLV52+V8Z MB@-FC-(H***"<4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 M %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J-U !11NHW4 %%&ZC=0 44;J- MU !11NHW4 %%&ZC=0 449I"P% "TC4AG0?Q+^=4-:\5:7X?@\W4-2LK&,=7G MG6-?S)%5&,F[)&],A3:F/?BI!7B1V/>"BBBJ **** "BC-(7"]2!WH 6BF-<1IU=1]34/] MLV>_;]J@W>F\9JE&3V1#J06[19HJ(7L)_P"6B?G2_:XA_P M%_.CE8O:P[HD MHJ/[5&?XU_.E$Z'^)?SI697M(]Q]%-\Y/[R_G2JZL."*6HR%[:FMY+[RU1 M4<=U', 5D5@>F#UJ0L!4V:W+C)/5!10#FC.:!A1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?-?_!7?XR_\*._X)W_$ M_5(Y?)NM0TEM&MB#\^^[86V5]U65FX_NU]*9P:_,7_@YY^*G]@_LU^ ?"$S?\$^_V7;C]L3]KKP9X%6.1 MM/O[P7&JNO2*QBP]P2>Q* JN>K.!UKQD]?U]B>V?SS^%?LY_P;1_LE?\(Q\, M?$WQAU2U_P!,\32G1M%=UY6TA;,\B^SS )Z@VY]:\?/LP^J8*=1;[+U9[?#V M7/&XZ%'IN_1'ZC:3I5OHNEV]G:P1V]K:QK#%%&NU(D4 !5 Z 8 ]!5H<"H_ MN\8IP; ]*_#]6[L_>XV2LAU4]9U.WT2PN+V\FBM;2SA:>::5@J1(HRS$G@ # M)R> *MEU4>E? G_ <(?MB-^SY^R.G@O2+KR?$?Q,E?3SL;#Q:>@!N6 MXY&_='#[B9\(/!WQ&\=>%?"LEV;?1[#2M;NK&W2UB^2-S&CJ \@'F-D9W.1T QYE#_ M ,%%?CY ?E^-'Q//^]XEO&_G(:\:'0GR/<(/^"EW[04'W?C)\1C_ +VNW#?S:K'_ ]!_:&\ MO;_PN'Q]C_L*R9_]")KP>BK_ +/PW\D?N7^1G_:&)_Y^2^]GN$W_ 4O_:"F M!W?&3XC?\!URX7^3"JD__!13X^72X;XS_$\?[OB6\C_E)7C5%']GX5;4U]R# M^T,3UJ2^]GJTW[=WQONA^]^,7Q2D'??XJOC_ .U*H77[8OQJ-Q\<_&MY_K?%_BF3_ ']5F.?_ !XURM!.!1]7I;:]K4@[[[V1OYM5.7Q1J4W^LU"];/]Z9N?_'JH@9->P_!W_@G]\:OC MW'#-X3^&7B_5+6Y&8KPV#VMI*/:XEVQ?FV*QJ2PM)?O.6/K8TIQQ59VI-6C;5(?!_A&-N M6&HZMYTB#Z6R2 GV)Q7LV@_\&M_B:YA!U3XN:-9R8Y%KHCP_G%57C"7S9^7?A_QMK7A6[CN-+U?4M/GA8.DMM7PWX%T^XC2\<37]_>RF>\U&0#:&D; & .BJ%49) MQDDGY?B+/LMQ&&]E05Y=^6WXGU?#7#^9X?%*KB':/76_X'L:MN_K[4Y#34&$ MZ-4@&*_/S]*"BBB@ HHHH **** "BBB@ HHHH **** "OSB_X.'/VU?B!^R[ M\./ WA_P'JEYX9"^" VTD88,ISR#Q7H977 MHT<5"I75XIZH\W-\/7KX2=+#NTFM&?S#^*/B1X@\;W\ESK.O:SJUQ+R\MY>2 M3N^>>2Q+'J?3Z5C^>^/O-7[">+O^#6[1[JYD?0_C!J=E"S$I%>^'TN64=@66 M>,'C'11]!7/77_!K-J:QGR?C-92-V#^&60?F+DU^H4^)LH:T:2Z)H_)I<*YR MGJFWUU_(_)Y;J5#Q)(OH=YJ1-:O(FVK=72M_LRM_C7Z:^(_^#7WXD6D+'2?B M1X-OI.RW5K<6RGZE5D/Y"O'/BI_P;[_M(?#B!Y++0_#_ (NBC&3_ &-JR94< M]$N/*8GV4$UTT\[RJH[*:_KU.*KD.;T]90E^)\:P>+]5@.Z/4]00^JW#?T:K MD/Q/\2VW^K\0:U&>VR]E&/\ QZKWQ5^!OC/X&:W_ &;XR\*Z_P"%[XD[8M3L M);4R8ZE=X&X>XR/>N5)VCGCJ?RZUZ].G1FKQ2:[Z'D5*E>G+EDW%]G-K4_N_%_BB/_J[;_M*_$:U/[KQ]XRCQ_.FWQ#=_\ QRKUO^W)\:K3_5_%SXG1 MD=-OB>]'_M2O+:*7U2ANX+[D4L97V4Y?>SV&W_X*$_'JT^[\:/BG_P "\57K M?^U*N1?\%)_C_%]WXR_$K_@6OW+?S?M"W'WOC'\0E_P!W5Y5_DU>$T4?V M=A?^?Q/6I+[V>FW'[:GQCO/]=\ M5_B1+GKN\2WAS^#]YXT\62>N[5[@Y_-ZH7'Q6\478_?>(]>ESUWW\K?S M8U@9Q_.@#)QWSC%5]7I+517W(/K5;^=_>S0F\6:KA_!C]C?XJ?M$"-_!?P_P#%?B*UD)5;NUTYS:@].9F41+]2 MPKZ6^'7_ ;V?M)>.%C:^T;PYX55^K:IK4;X'N+?S3^@K@KX[+Z+_>SBON._ M#X',:^M&$G]Y\0I<,<_.WO@YJUI?B"^T>=9+.]O+5UY#0S%&_,'^5?IYX<_X M->?'=U;Q_P!K?$[PK92?Q+:Z?<72K]"YCS^0KM/#?_!K1;QRJVL?&6:50>8[ M3PRJ'_OIKEOT7\^E>=4XDRA/6:^Z_P"AZE/AG.)-6B_F['DO_!"+]OWXJW/[ M87A_X9:OXDUKQ5X1\3072/;:E=27;:8T-K+,DD3N2R+F+:5X4AR<%@N/W'@& MV/IBOF+]A'_@E-\,?^"?TMQJ7AFVU+6/$][ +6XUO591)A1XNNRXN': M9S[9B,'Y5]%PKA_;9E#^[=_?GAV_P _C11THK]E/P_3 M<*,^WXT44P#=@_3\?Z4[S74?>8?\#--HJ91B]RHRDNIIZ3XTUC0&S8ZIJ5GZ M&"Y:/'Y$5U&E_M1_$O0D"V/Q"\;V87IY.N7,?\GKA**S^K4GK9?SU2U_;I^-EC@0_&#XH1;>FSQ3>K^@E-:EK_P %&?C]9_<^,_Q./^_XDNW_ M )O7B]%9O!8>6\(_SWS_AZ5^T1_T6 M'QS_ .#-_P#Z]'_#TK]HC_HL7CG_ ,&3_P"%>!T4?V;A/^?:^Y#_ +0Q7_/R M7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^T1_T6+QS_P"#)_\ "O Z*/[-PG_/ MM?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_^#)_\*/^'I7[1'_18O'/_@R?_"O MZ*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I7[1'_18O'/\ X,G_ ,*/^'I7[1'_ M $6+QS_X,G_PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_P"'I7[1'_18O'/_ (,G M_P */^'I7[1'_18O'/\ X,G_ ,*\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7[ M1'_18O'/_@R?_"C_ (>E?M$?]%B\<_\ @R?_ KP.BC^S<)_S[7W(/[0Q7_/ MR7WL]\_X>E?M$?\ 18O'/_@R?_"C_AZ5^T1_T6+QS_X,G_PKP.BC^S<)_P ^ MU]R#^T,5_P _)?>SWS_AZ5^T1_T6+QS_ .#)_P#"C_AZ5^T1_P!%B\<_^#)_ M\*\#HH_LW"?\^U]R#^T,5_S\E][/?/\ AZ5^T1_T6+QS_P"#)_\ "C_AZ5^T M1_T6+QS_ .#)_P#"O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_T6+QS_X, MG_PH_P"'I7[1'_18O'/_ (,G_P *\#HH_LW"?\^U]R#^T,5_S\E][/?/^'I7 M[1'_ $6+QS_X,G_PH_X>E?M$?]%B\<_^#)_\*\#HH_LW"?\ /M?<@_M#%?\ M/R7WL]\_X>E?M$?]%B\<_P#@R?\ PH_X>E?M$?\ 18O'/_@R?_"O Z*/[-PG M_/M?<@_M#%?\_)?>SWS_ (>E?M$?]%B\<_\ @R?_ H_X>E?M$?]%B\<_P#@ MR?\ PKP.BC^S<)_S[7W(/[0Q7_/R7WL]\_X>E?M$?]%B\<_^#)_\*/\ AZ5^ MT1_T6+QS_P"#)_\ "O Z*/[-PG_/M?<@_M#%?\_)?>SWS_AZ5^T1_P!%B\<_ M^#)_\*/^'I7[1'_18O'/_@R?_"O Z*/[-PG_ #[7W(/[0Q7_ #\E][/?/^'I M7[1'_18O'/\ X,G_ ,*1O^"H_P"T0ZX_X7#XZ^HU)_\ $&O!**/[.PG_ #[7 MW(/[2Q2_Y>2^]GN%S_P4P_:"NC\WQD^(O_ -;G7^3"LS5/V__CIK*%+CXQ_$ MZ2,]5_X2:\"G\/,Q7D5%..7X9.ZIK[D+^T,2U_$E][.TU?\ :0^(?B(-_:'C MOQC>ANOVC6;B;=^!:N2OM5N=3N#+<7$\TC;_$.2V3AN<\_SZT#@8]***M66B,&V]PKZ;_X(W:U)H/\ P4O^$\T3M&TN MIR6S;3]Y9;>6,C\FKYDKZ2_X)!0?:/\ @I/\)%ZXU@O^4,A_I7#FBO@ZO^%G MH92VL;2M_,OS/Z6.@'UIPIIX-.'2OP8_H@**** "BBB@ ZU^6?\ P<._MT_% M#]G7Q'X-\%^!]>OO">E^(-/EOKW4=/;2]5T^18[O3W8 ,%+*RLC;5W(P(. MU3PRJP]+*<10H8J-3$QYH]CR-;J2XUC7]:U M6XE.Z26\O99GD)Y))+9)R2>?6L7SI.3YDGJ>:_7G7O\ @UGM9+AO[+^,MQ;P MY^6.Y\,K*P'NZW"Y_*N>UG_@UL\101;M.^+NCW,@Z"YT&2$?FLSG]*_3H\29 M0]I)?]NV/R>?"^<+[+?_ &]<_*N.]F3!2:9<]-K$5/'XDU"#'EW]XGIME(_D M:^^_B+_P;9_'CPLDDNC:GX&\31]1'!J$MO,W_ 98U7GW?%?+/QV_X)^_&C]F MJ&:?QG\.?$VCV4)P]Z+;[58Q_6>'=%VZ[J]'#YGE]?2G*+?RN>?B,KS+#O\ M>1DE\_T/-[;XC>(++B'7-8A(_N7DJX_\>%7H/C=XTM#^Z\7>)H\?W=3F_P#B MJY?;@8"D;>WI1G(KT?846K\J^Y'F_6*R=N9_>SMK?]I?XC6;?N?'WC2/_$?N17UW$+_ )>2^]GMT/\ P4H_: @^[\9/B/\ 0Z]<'_V:K<7_ 5 M_:&A7CXQ>/OQU:0_^S5X-14?V?AGO"/W+_(?]H8E?\O)?>SW6;_@IU^T) M^,7Q"'^[K$J_R:J=Q_P4<^/UQ][XS?$P?[OB.Z7^3BO%J*%E^%_Y]Q^Y#_M# M$_\ /R7WL];N/V^?CI= ^9\9OBHX/4'Q7?8_+S*H7'[9_P 8+P'SOBK\2)?7 M=XDO#G\Y*\SHK2.#H+10C]R,_KF)O?GE][_S.[N?VH_B9>_ZWXA^.)?7?KMR M?YR&J%Q\>O'-W_K?&7BJ3_>U:<_^S&N3H S5?5:*^PON0OK5:_Q2^]F]<_%# MQ)>?ZWQ#KDGKNOY6_K5"7Q5J=P,R:A?R>[3L?ZU0[X[^E>L?!K]A3XQ?M +! M+X/^&_B[6K2X_P!7>1Z=)%9O_P!O#A8OS;%8U'AJ2O4Y8^MC6G]:K:4N:7I< M\MEU&XF/SW$[?[SD_P S4?G/C.^3'NQK[K^&G_!NO^T7XY,;:I:^$_",;O1X>S>JE)0E\W;\S\Q/"?Q,\1> =0CO=#U_6M%NH3E+BQO9+>1 M/<,K _CGBOVA_P"#>/\ ;4^)/[3?A;QYX>\>:U>>*+?PA]ADL-2O&\VZ03^> M&BDEP&E'[D,&?+";6[\NZF^U7]]>2>;=ZC,%"[Y&P!PH "J HYP M,DD_+<1YYEN(PWLJ&LN_+;\3ZOAG(G*-M?GT;VU/TH6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ***1FQ0 UF^:OP[_ .#FKXF/XA_:\\'^&8Y-]OX;\-"Y89^Y M/_ M9?\ @A8_LV_L^^$? NF[6MO#&F0V)D"[?M$BJ/,E(]7D+.?=C7X7_P#!O_\ MLY+\V4FMR[ERC7'$5NI[;@[^8/\ K@?>OZ"H_N_C7YCQ MOCN>M'#1^SJ_5_\ /U;@'+_ &=">*EO+1>B'4UUS3J:YXKX4_0M]".=EC!/ MI\U?S??\%A_VM6_:Y_;B\3:A:W'G>'/"[C0-&7.4:*!B'D';$LQDD!_N%!VK M]N_^"JO[4/\ PR1^P]XT\46]Q]GUJZMCI.C%6P_VRY!C1E_VHU+2X](C7\T# MN7=B>6SSSGGO^M?H' ^7W<\7+T7ZGYKQ]F32C@X^K_03/']?7THHHK](\C\Q M"BBB@ HHHH **** #_#-=Q^SE^SSXH_:F^,FB^"/!]BU]KFM2[(^2L=N@Y>6 M1@/EC5O(SS,OJ6$=;KLO5GLY#E?U_%QH/;=^B/?OV$O M^",GPG_8Z\.V-Y?Z38^./'" -/K>K6PF2&0?\^T+%EA4=B,OZMC 'V)!$L:8 M4;0.GTIJ)_>Y/O4D??K7XMB<96Q$_:5Y7?X?(_=,'@J&&A[.A%17X_,G6G4UNM# P?'OPYT#XG^'[C2/$FB:7KVEW0_>VE_:)AZ_H\QANK.X3;(AZ@\$@JRX8,I(((()'-<[7[T?\%[_P!@.Q_: M*_9NO/B-HMBJ^-?A[:M=R21J/,O].7)FC?\ O&-=TBD\@!P,EJ_!?/\ L[<< M8]/\^_-?L.19M',,/[1;K==O^ S\5X@R>678GV?V7L^X4445[)X84444 %%% M% !1110 4449H#3J6] \/WWBO7;/3--M9[[4-0G2WMK>&+S)+B5V"HBJ.69F M( 'O[C_ /!-?_@@YX-^!/A'3O%'Q8TNP\8>.[I!/_9MTJW&F:)GD1>7 MC9/(/XF;*@C"# #-\?\ _!N9^R;:_&?]J;5OB!J]JUQIGPUMDDLU="8XXY6]F\L]0*_=:,;5XW#V]*_..+\\JQJ_4J$K"\@I3I/&X MF/-S;7[%?3]-ATFSBM[6&&WM[=!'''&NU44< #H!V XJU%]VC;2J,5^?7OK M<_2HQ25D+1110,**** "BBB@ HHHH *",BBFOTH ;(WEK[*,U_,7_P %,?BM M_P +J_;W^*GB!9/.@D\07%G;/G(:&V/V:,CV*1*?QK^DCX^?$:/X/_ _QAXL MGV^7X:T6\U1@YP&\F%Y,?CMQ^-?RDZC?2ZIJ$]U-(TTUQ(TKR-]Z1B_X(S0?:/\ @II\)U]-1G?_ +YM9C_2OF&OJS_@B':_:_\ M@J)\*U_NW%])_P!\Z?=-_2O.S?\ W*K_ (6>ED^N-I?XE^9_1]W_ !%*M)3A MTK\(/Z&"BBB@ HHHH **** "BBB@ J"[MUN%V,NY6&"",CFIZ:QYHU6PI)-6 M9\/_ +>O_!#KX6?M9:1?:MX8L++X>^.MK2Q7^G6XCLKV3D[;FW7"D,2"_&6FR:7KFDR;9$)W1RH>5EC;)#1L.01]."" M*_JR=&+K[O_ <*_L66WQK_ &7/^%E:79K_ ,)1\.<2RR(/GN-, M9@)E;U\IBLH)^ZHEQRU?9<,\15:-58?$/FB]->A\+Q5PS0K47B<.N6:[=>]S M\(Z*._I[>GX]_K17ZM8_(E\*"BBB@ HHHH **** "BBB@ Q74?!3X,^(OVA/ MBEHO@[PGITFJ:]KURMM:VZ 8)M+T_Q]X\"B6XU#4H/.L[ M.7KBV@?**%.?WC N3D_)G:/M>TMUMX0B(%51M"J, < 4X# Z-UZ8Z4]:_%< M5CJ^*FZM>3;?W?(_=L'@,/A::I4(I)??\Q11117,=@4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T_>IU-/WZ M &R\#\*_EI_;?\6?\)U^V5\5=8W^8NH>+=3FC.5 M9^2/S?Q"J?NZ,/-E&BBBOTH_+PHHHH *"=O/MG\1T_G13K>W>[NHHHU9Y)'" M(JC+,QX 'XXI2:2NPLWHC]R?^#;/]GP?#_\ 9&U[QW<0[;[Q_JS) ^.MG:%H M5P?^NQN3[X'I7Z/Q#"UYE^QG\%5_9W_94\ >"UC6.;P_H=M;76/X[C8&G;_@ M4I=OQKT]>E?A&:XJ6)QE2L^K/Z&R?!K#8.G171(*9)][\.GK3Z:XR?YUYYZ1 M^,__ TX/2ORM MP!]*]_\ ^"I_CK5/B%_P4.^+UYJ[;KBT\276FQ 9VK;VS_9X0!V_=QH2/4FO M *_I_/\ Q!C'BLPJ5.SM]V@4445ZQXX4444 %%%% !11 M11TU!;@%W,._;\_\FOZBO^"??PM'P8_8F^%_ASR1#-8^'+-KI=N/](DB668X M]Y7<_C7\P7AO2)/$'B/3[&+_ %M[<1P)Q_$[!1_.OZU="LH],T:UMXEVQ6\2 MQHH_A"@ #]*_/N/*S4:5+S;/TCP]HISJU?)(M4445^<'Z@%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-8X-.II&3 M0!4UW2;?7='NK&ZACN+6\A>&:*0925&!#*1W!!(_&OY5?VD/A:WP/_:!\;># M6+,/"^N7FEHQ_C2&=T5OQ4 _C7]6C]1_G%?S=?\ !:7PPOA+_@IO\5+:.,1I M/>VU[P,9,]G!,Q_%G-?<<"UFL1.EW7Y'Y_X@8=/#4ZO5,^6Z***_4#\G"BBB M@ HHHH **** "CKW_"BC^@S1U#;4_>__ (-R_A6O@?\ X)]C7&A"S>,]?O-0 M\S;AGBCVVRC/H&AD(]W-??<8PM?-?_!(3PQ_PB'_ 38^$=KMV^=HHO,8Z^? M+)-_[4-?2J=*_!\WK.ICJLW_ #,_H3):*HX&E272*%HHHKSSU HHHH **** M"BBB@ HHHH *1J6F2G H ^1_^"Y/Q3_X5=_P37\?&*3R[SQ MMHMO@_>\^9! M(/QA$M?SG?3IDX_.OV@_X.@OBC_9?P2^&G@V.3YM:UFXU>10V/EM8!&-WMF[ M)'NE?B_G/_ZJ_6N"Z')E_/\ S-_Y'XSQQB/:9C[/^5)??J%%'7^5 .?\_A7U MWJ?&[[!1G@_[/7VKZ(_9!_X):?&7]M9H;KPGX8>S\.R/M;7=7S::>,'#;7(+ MRX/&(E?!R#BOT6^ W_!L5X/T2WM[CXD>/M MO("'GM7BXWB+ X3W:E1-]DKL]S+^&L?BUS4J=EW;LC\83Q2A2QP 21UXK^D? MX9?\$9?V;?A=M^R_"[1M4D4#=)K$LVH^:?5DG9D_("O:O"'[,OPY\ 0)'H?@ M+P;HL%+X_KY5?U'^4 > M%6E$=9RX[K]*:^]FT?#VAUJO[D?R_P!K_P $W_C]=8V?!GXE+_O^';I/YH*T MK?\ X);_ +0]X1M^#WCH?[^F.G_H6*_INQCUHQ[FLY<=8I_\NX_B:+P_PO\ MS\?W(_FBMO\ @D?^TA=8V?"/Q5_P.-$_FPK1MO\ @C3^TU>M\OPGUH?[]W:K M_P"A2BOZ3<4AXJ/]>,7T@OQ*7A_A%O4E^!_.';_\$0/VH[O&WX67([?/K&G+ M_P"A7%:5I_P0?_:DN/O_ WBA_W_ !#IG])S7]%1HV\5$N.,<_LQ^[_@FL> M\#UE(_GEMO\ @@#^TY?]I.8_-HOAF'_ ']< MBX_+-?T$X(I:Q_UTS#M'[O\ @FBX#R]=9?>?@-:?\&YG[15Q]Z/P5#_OZR?Z M1FM&V_X-K_V@)\"34OAQ%W_>:K<-_*W;]*_>?RC_'WX+:M^SI\9/$7@?7IK*XUCPO>/874EI(TD#NO4H656Q]0 M*X^OH+_@JS_RD7^,'_8QW']*^?:_4L'6E5H0J3W:3T\S\CQE*-*O.G#9-K[F M%%%%=1RA1110 4444 %%%%&Z#7H>E_LC_LK>)/VT/CEIOP_\*W.DVFM:G%// M!+J4TD5NOE1M(V61'8?*IZ+Z5]=W'_!M;^T!']S5/AS(HZ!-6NS/P-F_X-P_VB(!\O\ P@LGLFKN,_G$*HW'_!NS^T? /ET_PE+_ +FM M*,_FHK^@#'^<4HR!7SW^NF8+M]W_ 3Z/_47+?[WWG\^$W_!O=^TM /E\.^' MY/9--\??51^[_@DO@+ =)2^\_F]F_X(H?M/6X^; MX4ZD?]W4K%OY3&J,_P#P1P_:7M1\WPEUYN_R36S?RDK^E T;# MHF;6/A?\0M+51DM=^'KR$ ?5HQ7!:GH=]HEP8;RSNK24<%)HF1A^!%?UO&$% MONCZU1USPMIWB*T:WU"PL]0@<8,=Q"LB,/<,#75#CRIM.DODSEJ>'M/>%5_< M?R2_Q;>_I1G]*_IT^)'_ 3+^ ?Q8W?VS\)O!;22??EM-.2RE8^I>#8Q/OFO ME_XX_P#!MC\&?'ZSS^#M8\5> [Q\F.%9QJ5C$?\ KG+^]/\ W^[5ZF&XVP"->NM)UK3K[2=4L9#%<6E["\,\#_ -UT M7G?^X5O\+/5R/7'TO\2/Z'!POZ4ZCM17X4NY_084444P"BBB@ MHHHH **** "BBB@ K!^)O@FQ^)?@#6_#NIQ"?3=>T^>PNHR,B2*5"CC\F-;U M1RC&3C/%5&3BTT34@IQ<'UT^\_DM\>^$;GP!XXUG0KP8O-%OI["<8Q^\BD:- MOU4_2LFO=_\ @I[X37P5_P %"/C!8H@C1O%%Y=JH'"B>0S#'_?RO"*_?L'5= M6A&H^J7Y'\XXJFJ=:=-=&U]S"BBBN@YPHHHH **** "BBBC2VHUN ..^W'(/ M^?K_ #K^F+_@DW\+%^#_ /P3O^%.E>3Y,MSH<6J3*1AO,N\W3;O<>;CGL!7\ MS\63(N.N:_K$^#'AH>#/A#X7T<+M&DZ3:V8&.GEPHG]*^"X[K-4:4.[;/T+P M]I*5:K4[*WXG34445^:'ZJ%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !2-V^M+2-_6DP.4^.VKGP]\%? M&&H [38Z+>7 /IL@=OZ5_*#(3X5U-\_2TE-?R ML-]XU^C\!1_=U7YH_+?$*7[VDO)_F)1117Z$?G(4444 %>Y?\$T/A#_PO7]O M3X6^&VA^T6\^O07MS&1E7M[;-S,"/0QQ,/QKPVOT2_X-K/A2OB_]MC7/$T\8 MDA\(^'9GA;'W+B>1(D_.(SBO+SK$.A@:M5=G^.AZF2X;ZQCZ5)]9(_=A!\BT MJC%(#\O'K2JNZ MYC']:_JRA&V,5_+C^P#I7]M_MS_!VUV[EE\::0&'JHO82?T!K^I =*_,^.Y7 MK4E_=?YGZIX>QM0JOS7Y!1117P9^B!1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0310>E)[ ,8\U_/)_P7YL/L?\ MP4Y\:28Q]JLM-EZ=<64*?^RU_0X1S^-?@!_P<36/V3_@H[?2=/M6@Z?+]<*Z M?^R5]?P5_P C%_X7^A\5QTKY1\*44&BOUH_' HHHH **** "BBB@ H(W M#\A^>:*='Q(OUSCUI2=DV-*[L?U&?L#Z-_PC_P"PY\'[/;M:W\&:2KC'\7V. M(M^N:]<0<5Q7[-FG#2OV>/ MJJX6V\/V$0'LMO&/Z5VXK^?L3*]:3\W^9_1^ M#C:A!>2_)!1116)T!1110 4444 %%%% !1110 4V3K]13J9+S\OYT">Q^%O_ M *^EO^"PGQ M*_X6G_P4D^*VH+)YD-CJPTB,9R$^R1);,![;HF/XU\TU^YY'1=' 4J=NE_O/ MY_S[$*MF%6H^]ON#&Y@,_>R!D9QZ_P#U_P *_63_ (([?\$0K7Q?H6D_%;XS M:6UQ9W2QW>@^&KI] #1VPR,%5!#R#G*E%(Q)D?O]:VZP6X51A5 MX48QM'85\IQ5Q!*F_J>&EK]I_H?7<'\-QJKZYBH^[]E=_,CT?2[?1M-@M;2" M.UM;9!%##$@2.) ,!54< < #BK6:0#%"C%?F^K=S]2BDE9"T444#"BBB@ H MHHH **** "BBB@ HHHH **** "FOUIU-?K0!_,O_ ,%6?^4B_P 8/^QCN/Z5 M\^U]!?\ !5G_ )2+_&#_ +&.X_I7S[7[UEO^Z4_\*_(_G7,O][J_XG^84445 MW'"%%%% !1110 4444 ?:'_! /\ Y2=>"_\ KQU/_P!(Y:_H;3[M?SR?\$ _ M^4G7@O\ Z\=3_P#2.6OZ&T^[7Y+QI_OZ_P */V+@/_D7/_$_T%HHHKY$^V"B MBB@ HHHH **** "BBB@ HHHH **** &NNX5XW^U?^P7\+OVT/#;6/CSPO9ZE M=1QF.VU.$>3J-EG.#'.N& !).QLH>ZFO9J:RUI1K5*4N>G*S75&-;#TZT>2J MDUYG\[__ 4F_P""-GCC]@V6?Q%IGZ5_6UXF\-6/C'0KS2=4LK74--U&![:ZMKF(213Q. MI5D93PRD$@@]037\[W_!8+_@G-+^P/\ M +_ &1'))X \8&6\T)V+,;(@YEL MV)ZM&74JVNU^T?\%*M ;_GCI&HO_Y *_\ LU?$!.2>^><^N>:^\/\ @W2M M/M'_ 47MW_Y]_#U^_T_U:_UKWL^_P"1?6_PL^>X?_Y&-'_$C]^C]RE7^E)U M2E']*_##]_ZBT444QA1110 4444 %%%% !1110 4UCAJ=36^]0!_-O\ \%H; M/[#_ ,%-_BLF,;KZVD_[ZLX&_K7R[7UM_P %S[?[-_P5,^**]F?37_/3+0_S M-?)-?NV42YL%2?\ =7Y'\\YQ'EQU5>;_ #"BBBO2/-"BBB@ HHHH **** -3 MP-HW_"1>-M'T_O?7T%N!Z[G"_P!17]:=D-MI'QCY17\J?[+NGC5OVEOA[:L- MRW'B33XB#W#7,8K^JVW&(U^@_E7YMQY+WZ*\I?FC]0\/5^[K/T_(DHHHKX _ M2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH ***#0!YO^V-;&\_9'^*$(Y,GA+5$&.^;.45_*XWWC]?SK M^K7]I.U^W_L\^/+?&?.\/7Z?G;2"OY2Y1B1O8XK](X#?[NJO-?D?EOB%'][2 M?D_S&T445^@'YR%%%%&K6@ #@&OV8_X->_AI]@^$?Q0\7-'_ ,A75[328W*] M/LT+2L ?^WI<_05^,^,G]:_H)_X-Z?!0\+?\$U]"OA'L/B+5M0U \8+XF^SY M/X6X_*OD^,JSAEW(NK1]AP30]IF7,]DF?<*#Y?H:<* 3_P4*MF_P">GA:Q?_R)<#^E?O?_ !?A7X.?\'*D/E_M_P"D M-C_6>#[)O_)F[']*^LX+_P"1C\F?&\<_\BQ_XD?GN**!17ZX?C(4444 %%%% M !1110 4Z'_7)_O"FTZ$XE7ZYJ*GP/T-*/QKU7YG]8WP?M?L/PE\,P]/)TJV M3'TB45TE97@B#[+X,TN/_GG:1+^2 5JU_/U;^(_5G]'X?^%'T7Y!11169J%% M%% !1110 4444 %%%% !5?5+B.RLIKB1ECCA0N[$X"@T^! MGC*2U!:YCT.\>(#^^('Q^N*NG'FFH]VC*O+EIREV3/Y9/BYXTD^)'Q5\3>(I MF9IM>U6ZU"0MU+2RLY_]"JK\/_!&I?$SQSH_AW1K>2[U;7+V&PLX4/S2S2NJ M1@>AW'K62X8R8ZMG''K7Z"?\&Z'[,J?&#]L>\\;W]OYVE?#>P^TQ,PRGVZXW M10\>R"9P>S(IK]SQV+6#PU'VVX1-OVV[?YIYCW^:0L0#R%VKVKUA!@4B#Y>!CF MGBOPRK5G5FZD]WJ_4_?L/1A2IJG3V2L@HHHJ#8**** "BBB@ HHHH **** " MBBB@ HHHH **** "FOUIU-?K0!_,O_P59_Y2+_&#_L8[C^E?/M?07_!5G_E( MO\8/^QCN/Z5\^U^]9;_NE/\ PK\C^=?A2^;_R+;C^M? MY"UM=R1NI5XW*,",$$'%?H-_P;40>;^W[K+?\\_!M MZW_DS:#^M?LF?2OEM62_E/P_A^+6:T4_YC]X/X6^M.'2F[LJ?K3ATK\/1^^! M1115 %%%% !1110 4444 %%%% !36^]^%.H-#V _G5_X+S0^5_P5'^(C?\]( M=+;_ ,IML/Z5\>U]F?\ !?6/9_P4\\<'^]9Z8?\ R1A']*^,Z_<\C_W"C_A1 M_/F>?[_5_P 3"BBBO5/*"BBB@ HHHH **** /3OV*;7[;^V-\)X?^>WC#24Q MZYO(A7]3J?=K^6_]@.'[1^W7\&(_[WCG11^=]"*_J04U^9\=R_?TEY/\S]4\ M/(VP]5_WE^0M%%%?!GZ(%%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !0>E%!Z4 9?B_1X_$/A74M/E_U= M]:R6[@],,I4_SK^2V_MGLKZ:&0;9(9&1ACH02#7]<5PNZ)O<8K^4O]I'PV?! MO[0_CS1RGEG2_$-_9E2,;3'_8IT#_A%?V//A7IFW:=/\):7;L,8Y6TB4_J*^%X\J6H4H>?Z'Z%X>T[XF MK4_NK\STZBBBOS$_5@II^]3J:?OT ?S>_P#!;)=O_!3_ .*O_7U9G_R0MJ^5 MZ^K?^"W:[/\ @J%\5/\ KXL?_3?;5\I5^\93_N=/T7Y'\\YQ_OM7U?YA1117 MH'FA1110 4444 %%%%'1AU/I/_@C_;_:O^"E/PD7TU@O^*PR'^E?TL@Y%?S6 M_P#!&\9_X*8?"7_L*2'_ ,EY:_I2'2ORSCC_ 'R'^$_6_#__ '*?^+] HHHK MXH^]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@!#P:_"C_@YFA\G]O3PRW_/3P/:-_P"3M^/Z5^Z[?TK\,/\ M@YRB_P",Y/"#?WO!%LO_ )/7W^-?5<&_\C)>C_(^0XX_Y%;_ ,43\X^]% .1 M17Z\?BP4444 %%%% !1110 4Z'_6K]<4VI+9=]S$O]Y@/Y5G6^!^C-:'\2/J MC^MSP^GE:':+_=A0?H*N5#IZ[+*(>BBIJ_GV;O)L_H^C_#CZ(****DT"BBB@ M HHHH **** "BBB@ JGK.FPZSI\]I^/'P]^-FJZ-X2\'S>+O#$UXW]DZI;WELD(KDZGKLT#; MHXY-H6.W0]UC08ST+LY'!%?4VSF@+D5[V8<18O%X>.'J6LM^[]3Y_+>&<)@\ M3+$T[MOOT] #=*=0!BBO!/H@HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "FOUIU-?K0!_,O_P %6?\ E(O\8/\ L8[C^E?/M?07_!5G_E(O\8/^ MQCN/Z5\^U^]9;_NE/_"OR/YUS+_>ZO\ B?YA1117<<(4444 %%%% !1110!] MH?\ ! /_ )2=>"_^O'4__2.6OZ&T^[7\\G_! /\ Y2=>"_\ KQU/_P!(Y:_H M;3[M?DO&G^_K_"C]BX#_ .1<_P#$_P!!:***^1/M@HHHH **** "BBB@ HHH MH **** "BBB@ HHHH *CG/R,/45)39!GW]L4 U=6/Y6_VO\ P%)\+/VJ_B1X M=DB\D:/XDO[6-2,?NUN'"$>Q4 CU!S7WA_P;#?#JXU+]I[X@>*O+D^RZ-X:7 M3&?'RA[JYCD7GUVVK?G7UY_P44_X(4^&?VX/B])X\T7Q5<^!?$FHQI'JA_LT M7UMJ!10BRE/,C*2;5"E@Q#!5X!R3[K_P3F_X)[>'?^"=OP:G\,Z-J%QKFI:K M=?;=5U6:W$#7DH4*H6,%MD:J.%+-RS'/.!^@9EQ-AZV5^PBWSR2B_EN?FN5\ M+XJAFWMYI>SBVUZL^@57C\M?NF1_P#(OH_X4?S_ )]_O]7_ !,****]0\<**** "BBB M@ HHHH ]E_X)V1>;^WM\&/;QMH[?E>1'^E?U"H,"OY@?^";<7G_M_?!M?^IP MTP_^3,=?T_K_ %K\OXZ_WFG_ (?U/U;P]_W6KZK\A:***^'/T(**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "FN:=37ZT !&!7\T/_!6_P-_PKS_@I!\7-/">6+C7&U$+C'_'U&ES^OFY M_&OZ73G%?@9_P<:_#MO!_P#P4,;5O+VQ>*_#]E?[\?>:/S+8_B! N?0$5]AP M16Y<$8,;?)T:S3'T@05_)_!Q,I[ Y^M?UH?#:-8?AYH*K]U=/@ ^@C6OS MWCS:DO7]#](\/(^]5?DC:HHHK\Y/U *0]:6D/6@#^P_]-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_/VTO!;_P![P; OY7MW_C7[D'I7X??\ M'/,>/VO_ *_][PBJ_E>7/\ C7U'!_\ R,H^C/D>-O\ D5OU1^:@^Z/I10:* M_8#\5"BBB@ HHHH **** "K&DKOU:U'_ $U7^8JO5K05WZY9C_ING\ZSK? _ M1FM#^)'U1_6Y:?\ 'FG^[4U16G_'G'_NU+7\]O<_H^C\"]$%%%%!H%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %-?K3J:_6@#^9?_ (*L_P#*1?XP?]C'LM_W2G_A7Y'\ZYE_O=7_$_P PHHHKN.$**** "BBB M@ HHHH ^T/\ @@'_ ,I.O!?_ %XZG_Z1RU_0VGW:_GD_X(!_\I.O!?\ UXZG M_P"DJ>2%%%% !1110 4 M444UN![E_P $S5W?\%!?@W_V-NGG_P CK7]/0Z5_,1_P3'7=_P %!_@Y_P!C M78?^CEK^G<=*_+N.O]ZI_P"%_F?K'A]_NU7_ !+\@HHHKX<_0 HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** FOR0_X.COAAOTGX5>-(8N8);[1KF3'W@ZQS1+GVV3D#W-?K?7Q7 M_P %^/@X?BQ_P3D\2WD49DNO!MY:Z_$ .R.89#G_ &89Y6_"O8X?Q'L'Q)AO;Y=5AY7^X_GG_S]:*#17[AY'X'YA1110]@6Z'1#]XOUQ7]8WP: MO/[1^$7A>X!W";2;60$=\Q*:_DX0X8>QS^5?U2?L>:P/$/[)?PPU -O%]X4T MN<-G.=]I$W]:_/\ CR/NTGYO]#]&\.Y?O*R\D>CT445^;GZD%(>M+2'K0!_. M'_P7!_Y2C?%/_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ MN5+T7Y'\\YQ_OU7U?YA1117H'FA1110 4444 %%%% =3ZB_X(O#=_P %-_A/ M_P!A"X/_ ))SU_22O"U_-O\ \$6O^4G/PI_Z_P"X_P#2.>OZ2$/RU^5\\-./_)F6OIN$?^1E'T?Y'R?&G_(KEZH_,?O1 M1G-%?L1^)] HHHH **** "BBB@ J]X:7=XCT_P#Z^8__ $(51K0\)#=XITT? M]/<7_H:UG6^!^C-:'\2/JC^M>T_X\X_]VI:BM/\ CSC_ -VI:_GM[G]'T?@7 MH@HHHH- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ IK]:=37ZT ?S+_\ !5G_ )2+_&#_ +&. MX_I7S[7T%_P59_Y2+_&#_L8[C^E?/M?O66_[I3_PK\C^=*O\ L&Z;_P"DJ5\4'K7[GD?^X4?\*/Y]S[_D85?\3"BB MBO5/)"BBB@ HHHH **** />/^"8(W?\ !0OX._\ 8U67_HT5_3FOW17\QW_! M+M=W_!0SX._]C39G_P B5_3BOW:_+>./]ZI_X?U/UCP__P!VJ>J_(6BBBOB3 M] "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH *Y/XZ?#BV^,GP;\5^$;S;]G\3:1X%=93)$YS^=5"3C)270BI!3@XOJC^2+Q#H=SX8UZ\TV\B:"[T^=[::- MNL;HQ5@??(/':J=?5W_!:SX ?\,__P#!1+QS;P0F'3?%$J^)+'C 9;G)EP/0 M7"SJ,=E%?*(.17[Y@<1[>A"M_,DS^=L?A7AL1.A+[+:"BBBNHXP_S^HK^FK_ M ()4^*?^$O\ ^"=GPANBV[R?#EM9YS_SP!@_3R\?A7\RH&2/Q_'I_C7]"W_! MOYXX_P"$M_X)G^$[1GWR>'[_ %#37.?^GEYU'_?,RC\*^)XXIWPD)]I?H?=\ M U.7&RAWC^I]K44 \4 YK\M/UT*0]:6D/6@#^P_] M-UK7RA7U?_P7!_Y2C?%/_KO8?^FZUKY0K]XRG_OVRK\3_\ @Z$7/[2?PX_[%N3_ -*F MKZ;A+_D91]'^1\KQG_R+)>J/S#/6BBBOV'J?B(4444P"BBB@ HHHH *T?!__ M "-VE_\ 7W%_Z&*SJT?!_P#R-VE_]?<7_H8K*M_#EZ&M#^)'U1_6O9_\>L?^ MZ*DJ.S_X]8_]T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.I MK]: /YE_^"K/_*1?XP?]C'.I M_P#I'+7]#:?=K^>3_@@'_P I.O!?_7CJ?_I'+7]#:?=K\EXT_P!_7^%'[%P' M_P BY_XG^@M%%%?(GVP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4UNHIU-;J* /Y[/\ @X'_ M .4F7BK_ +!NF_\ I*E?%!ZU]K_\' __ "DR\5?]@W3?_25*^*#UK]SR/_<* M/^%'\^Y]_P C"K_B84445ZIY(4444 %%%% !1111U ]\_P""6W_*0_X/?]C/ M9_\ HP5_3>O?ZU_,A_P2V_Y2'_![_L9[/_T8*_IO7O\ 6ORWCC_>X?X?U/UG MP_\ ]UJ?XE^0M%%%?$GWX4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !37.#^5.IKG!H _*/_@YW M_9Z;5O OP_\ BA9V^YM)N9= U.11\WE3#S8"?]E7249/>4#O7XXYR3ZYY'I7 M]1'[?G[.W[U$S[9'>OY>[NUDL; MJ2&:.2*:%BCHXPR,#@@CL%9)/+A\4>'#<1C_ )Z3VLR%1C_KG-,?P-?. M\54?:9;4\K/[F?2<)8CV6:4WWT^\_<8')^M.48IBC"?2I AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C M\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C M'3_ ((! M_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ M!+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+111 M7Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4V04ZD89- $3C.[_ &CBOYS?^"UG[+3_ ++G M[>7BA;6W\G0?&3?\)'IA PF)V8S(.PVSK* O9=A[BOZ-L<&OSW_X.)_V4A\: M?V0[;QUI]JTFM_#2Z-S(R#]X^GS[8[A?^ L(I,]%6-SQDU])PKF2PV/C?X9: M/]#Y3B[+7BLO;C\4-5^I^#IX8T4 Y';GGCH/I17[(?B5K.P5]#?\$HOC"OP. M_P""AGPLUR23R[:;6!I=P2<*L=VC6I+?[(\[=[; :^>:L:7J4VCZC;W=O(\- MQ:RK-%(IPT3J$_\ MD8Q]&?*\9_\ (LEZH_+P44#I17[&?B/0**** "BBB@ HHHH *T?!_P#R-VE_ M]?<7_H8K.K1\'_\ (W:7_P!?<7_H8K*M_#EZ&M#^)'U1_6O9_P#'K'_NBI*C ML_\ CUC_ -T5)7\^=3^CZ/P+T04444&@4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U^M.IK] M: /YE_\ @JS_ ,I%_C!_V,=Q_2OGVOH+_@JS_P I%_C!_P!C'3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^ M%'[%P'_R+G_B?Z"T445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X M.!_^4F7BK_L&Z;_Z2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ M '"C_A1_/N??\C"K_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V, M]G_Z,%?TWKW^M?S(?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6 M?#__ '6I_B7Y"T445\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61XY\)Z?X^\(ZI MH>K6L5YI>L6DME>02#*S0R(4=3[%216O4UL[L\6_;< M_>;_ (-S?CZOQ1_8;N/"-S,)-0^'^K2V@0MN86LY-Q"Q]M[3J/:.OT$B^[7X M(_\ !NS^T2/A+^V])X3O+CR=-^(FF26**S;5^V0_OH6/;)43(.^9 *_>Z/[M M?B_$^!>&S":Z2U^\_\?=?R'4AZTM(>M?/GTQ_.'_P7!_Y2C?%/ M_KO8?^FZUKY0KZO_ ."X/_*4;XI_]=[#_P!-UK7RA7[QE/\ N5+T7Y'\\YQ_ MOU7U?YA1117H'FA1110 4444 %%%% 'U'_P1;_Y2OZ1TX%? MS3_@@'_RDZ\%_P#7CJ?_ *1RU_0VGW:_)>-/]_7^%'[%P'_R+G_B?Z"T M445\B?;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH _GL_X.!_^4F7BK_L&Z;_Z M2I7Q0>M?:_\ P<#_ /*3+Q5_V#=-_P#25*^*#UK]SR/_ '"C_A1_/N??\C"K M_B84445ZIY(4444 %%%% !1111U ]\_X);?\I#_@]_V,]G_Z,%?TWKW^M?S( M?\$MO^4A_P 'O^QGL_\ T8*_IO7O]:_+>./][A_A_4_6?#__ '6I_B7Y"T44 M5\2??A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !0>1110!SOQ3^'FD_%SX>ZUX7UVS2^T M?7K*6PO+=QE9(I%*,/R.0>H(!'2OY@OVQ/V9M7_9 _:-\4> =861I="NRMM< ML,+>VK?-!,/]^,J2.S;AU!K^IN0?-QZ>G%?FS_P M(O ,/EZJL2G?=Z86)+G'),#,6]HWE/85]5PGFWU3%>RJ?#/3Y]#XWC+)_K>& M]M3^*'Y=3\/>A_2BC&SY>FW@CTH[U^O[R\C\9U:O8Z#X4_$;4OA!\3/#_BO1 MI/)U;PYJ$&I6DF?NRQ2*Z9]5R,$=QFOZI/@I\4]-^-OPC\->,-'D$FF>)M-M M]2M^ZF'CB8[Q?X,^^X M%S!4L5+#2VDOQ1^E5(>M /%!/-?ER/UH_G#_ ."X/_*4;XI_]=[#_P!-UK7R MA7U?_P %P?\ E*-\4_\ KO8?^FZUKY0K]YRG_C]ER[L(I9OB)<6OYU:*\G_ %&PG\\OP_R/8_U^ MQW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU: M*/\ 4;"?SR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+' M_13)/_"=U3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ MPG=4_P#D>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z M*O\ A_!^RQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"? MSR_#_(/]?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"= MU3_Y'K^=6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D M>C_A_!^RQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^ MRQ_T4R3_ ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/] M?L=_)'\3^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^= M6BC_ %&PG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^R MQ_T4R3_PG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ M ,)W5/\ Y'H_X?P?LL?]%,D_\)W5/_D>OYU:*/\ 4;"?SR_#_(/]?L=_)'\3 M^BK_ (?P?LL?]%,D_P#"=U3_ .1Z/^'\'[+'_13)/_"=U3_Y'K^=6BC_ %&P MG\\OP_R#_7['?R1_$_HJ_P"'\'[+'_13)/\ PG=4_P#D>C_A_!^RQ_T4R3_P MG=4_^1Z_G5HH_P!1L)_/+\/\@_U^QW\D?Q/Z*O\ A_!^RQ_T4R3_ ,)W5/\ MY'I1_P %X?V6!_S4QO\ PG=4_P#D:OYU**/]1L)_/+\/\@_U^QW\D?Q/Z*G_ M ."\/[+.>/B8WK_R+NJ?_(U?E'_P6S_;R\(_MU?M&Z'>>!6O+KPWX7TL6,5[ M<6[6_P!LE:1Y'=$;#A,% -P!R#QTKXQHKT,LX7PV"K>WIMM^9YN:<68O'4?J M]1)+?1=@'US]:***^F/EEH%%%% PHHHH **** "M'P?_ ,C=I?\ U]Q?^ABL MZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?UKV?_ !ZQ_P"Z*DJ.S_X]8_\ M=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?K3J:_6@#^9?_@JS M_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6W_*0_P"#W_8SV?\ Z,%? MTWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_UK\MXX_WN'^']3]9\/\ M_=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+7=*MM>TVXL; MRWANK6[B:&:&5-Z2HP*LI!X(()!!Z@D5=IK#.?I1JM4*235F?S3_ /!5#]AR MZ_82_:LU;P[;PS?\(GK1.I>')WRV^T=B/*+=WB;*'O@*Q^^*^;0<_P">M?TE M?\%7_P!@RS_;S_9COM&MX81XQT -J/AVXX[=!^Q\,9LL;AN63] M^.C_ ,S\0XJR=X'%>XO?EYR.WK^=>]BB"BBB@T"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "FOUIU-?K0!_,O\ \%6?^4B_Q@_[&.X_I7S[7T%_P59_Y2+_ !@_[&.X M_I7S[7[UEO\ NE/_ K\C^=_P"QGL__ $8*_IO7O]:_F0_X);?\I#_@]_V,]G_Z,%?TWKW^M?EO M''^]P_P_J?K/A_\ [K4_Q+\A:***^)/OPHHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *:V:=36&30!'.GF$?+NW#!R.W>OQG_ .#A?_@G%)X.\5M\=/"-B_\ 9.L2 M)!XI@@7;]DNFPB7F /NR<(Y_OX/_ "TK]G/SK%^('@+2?BAX,U3P]KEC#J>C MZU:O:7EK.NZ.>)QM8'\#U&".HYP:]'*3G65PQ^%=":UZ/S M/Y+\Y&?Y#C_(Z?AZ45]"_P#!2S]A#5OV!?VD=0\+SK<77AK4B;SP]J#@_P"E MVA. K'&/-C/R.!WPV '6OGK]:_<<+B(8FDJ]+:6Q^"8K#3PU5T:V\=SZN_X( MY_MJM^QC^V)I-SJ5T;?PCXOVZ+KFY\1PH[#RKDCI^YDP2>NQG ZU_1S&5,6X M$88D\=*_D8ZC&2,\5_01_P $*_VZO^&L_P!E&#P[K5YYGC/X=K%IE[YC?O+R MT(/V6XYY)**8V[[H\G[U? \;97>V.I+RE_F?HO >;-7P-7UC_D?E-_P7!_Y2 MC?%3_KO8?^FZUKY0KZN_X+?_ /*4/XI8Z":P ]M.M17RC7V>4O_ &.DO[J/ MAB>:%%%% !1110 4444 !.**]6_8?_9UA_:R_:O\ !/P] MNKZ;3;/Q)J'DW5Q 98X41I7V9XW%8V"D@@$@D$5^U&E_P#!NW^SA:V,<4VE M^*[J2,!6FDUIU:0^IVA1^0KP\TX@PN FJ=:[;UT/>RCAO%YA!SHV27<_ &BO MZ!O^(>']FS_H"^)O_!Y-1_Q#P_LV?] 7Q-_X/)J\O_7; =I?<>Q_J'F/>/WG M\_-%?T#?\0\/[-G_ $!?$W_@\FH_XAX?V;/^@+XF_P#!Y-1_KM@.TON#_4/, M>\?O/Y^:*_H&_P"(>']FS_H"^)O_ >34?\ $/#^S9_T!?$W_@\FH_UVP':7 MW!_J'F/>/WG\_-%?T#?\0\/[-G_0%\3?^#R:C_B'A_9L_P"@+XF_\'DU'^NV M [2^X/\ 4/,>\?O/Y^:*_H&_XAX?V;/^@+XF_P#!Y-1_Q#P_LV?] 7Q-_P"# MR:C_ %VP':7W!_J'F/>/WG\_-%?T#?\ $/#^S9_T!?$W_@\FH_XAX?V;/^@+ MXF_\'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_P"@+XF_\'DU'_$/#^S9 M_P! 7Q-_X/)J/]=L!VE]P?ZAYCWC]Y_/S17] W_$/#^S9_T!?$W_ (/)J/\ MB'A_9L_Z OB;_P 'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_B'A_9L_Z OB;_P> M34?\0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q#P_LV?\ 0%\3 M?^#R:C_B'A_9L_Z OB;_ ,'DU'^NV [2^X/]0\Q[Q^\_GYHK^@;_ (AX?V;/ M^@+XF_\ !Y-1_P 0\/[-G_0%\3?^#R:C_7; =I?<'^H>8]X_>?S\T5_0-_Q# MP_LV?] 7Q-_X/)J/^(>']FS_ * OB;_P>34?Z[8#M+[@_P!0\Q[Q^\_GYHK^ M@;_B'A_9L_Z OB;_ ,'DU'_$/#^S9_T!?$W_ (/)J/\ 7; =I?<'^H>8]X_> M?S\T5_0-_P 0\/[-G_0%\3?^#R:C_B'A_9L_Z OB;_P>34?Z[8#M+[A?ZAYC MWC]Y_/S1T_+-?T"-_P &\O[-P(VZ'XG_ !UN; _7\_PK\N/^"QW_ 3YT'_@ MG[^T#H^E^$[_ %&\\-^)M-_M&VBOW5Y[-U=HWB+J!N7A2"0#\V#D@L>_+>)L M)C:OL:5^;S78\[-.%<9@:/MZMN7R=SY"Z44#@?YYHKZ$^;"BBB@ HHHH *** M* "M'P?_ ,C=I?\ U]Q?^ABLZM'P?_R-VE_]?<7_ *&*RK?PY>AK0_B1]4?U MKV?_ !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/? M/^"6W_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^ MF]>_UK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4$X%%(_2@#P#_@HY^PGH/[?7[/M]X5U'R;/7+0-=Z#JC M+EM/NPO'3DQN!M<=PO:#=-:7EO(,% M67N#T92N"K#AE((R""?ZQ2-V>M?GQ_P7$_X)9?\ #5_@'_A9'@?3@WQ$\+VY M%S;0)\^OV:_,8\#EIX^2F,ELLO4J5^PX5S[ZK4^K5G[DMO)_\$^'XOX=^MP^ MM4%[\=_-?\ _![->Z?\ !.K]LW4OV&/VHM#\:6_G3:.Q-AKEFC<7EC(1YBXZ M%EP)$[;XP"0#7ALT3P2M'(&5U8J01@YS_/V]:;T_ETSG(_IP?PK]0Q&'A7HR MHSUC)'Y/AZU7#UHUJ>DHL^G/^"QOB_3O'_\ P47^(&N:1>0ZAI6KIIEY9W41 MW)<0R:9:.CJ?0J017S'4EQ=2WDF^:221PJH"[%B%4!5&3V"@ #L,#M4=&%H* MC2C27V5;_(6*Q'MZLJO=W"BBBN@P"BBB@ HHHH **** /J/_ ((M_P#*3CX4 M_P#7]<_^D<]?TCIP*_FX_P""+?\ RDX^%/\ U_7/_I'/7](Z=*_*^./]\C_A M1^N\ _[E/_$QU%%%?%GW84444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %?BS_P="_\E^^&?_8!G_\ 2BOVFK\6 M?^#H7_DOWPS_ .P#/_Z45]+PG_R,8^C/E>,_^19+U1^7(HH%%?L9^(] HHHH M **** "BBB@ K1\'_P#(W:7_ -?<7_H8K.K1\'_\C=I?_7W%_P"ABLJW\.7H M:T/XD?5']:]G_P >L?\ NBI*CL_^/6/_ '14E?SYU/Z/H_ O1!1110:!1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !37ZTZFOUH _F7_X*L_\ *1?XP?\ 8QW']*^?:^@O^"K/ M_*1?XP?]C'_P"Q MGL__ $8*_IO7O]:_+>./][A_A_4_6?#_ /W6I_B7Y"T445\2??A1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !44XRWMC'%2TC<]J/0/4_&[_@O/_P2 MB_X1.ZU#XY?#W3=NFW3&;Q;IEJG_ !YR'.;^-0/N-_RU &0S;\89ROY2D$'[ MNW'!&,8_S_G/6OZX-8TNWUK3KBTN[>*ZM;B-HIH94#QRHPVLK*//!%G+-\,=>N/FA5=Q\.W#'_ %#'D^2W.QS_ +C' M.PM^D\*<1AK0_B1]4?UKV?_ M !ZQ_P"Z*DJ.S_X]8_\ =%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %-?K3J:_6@#^9?_@JS_P I%_C!_P!C'3_ ((!_P#*3KP7_P!>.I_^DJ>2%%%% !1110 4444=0/?/^"6 MW_*0_P"#W_8SV?\ Z,%?TWKW^M?S(?\ !+;_ )2'_![_ +&>S_\ 1@K^F]>_ MUK\MXX_WN'^']3]9\/\ _=:G^)?D+1117Q)]^%%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !6'\1/A]H_Q5\&ZGX=U_3K75M&UFV>TO+2Y3=% M<1.,%6'XY&,$'D$5N4A^]3C)Q:E%V9,HJ2Y9*Z9_.?\ \%8/^"6NN?\ !/\ M^)SW^FQ76K?#37IV_L?42N]K-SEOL=P>@D7G:_ D"Y !#*OR(PVD\L<';D^M M?UA?&CX/>'?C[\-=6\(^+-)M]:T#6H&M[JUG3BN 6 &2J_JO M#/$<<7%8?$.U1=?YO^"?D'%7#,L)+ZSAU>F]_P"[_P ^7**"PQN^7;G&1PO MX?D:.]?9'Q 4444 %%%% !1110!]1_\ !%O_ )2L?^Z*DJ.S_ ./6/_=%25_/G4_H^C\"]$%%%%!H%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%-?K3J:_6@#^9?\ X*L_\I%_C!_V,=Q_2OGVOH+_ (*KG_C8M\8/^QDN/YBO MGVOWK+?]TI_X5^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** /M#_ ((! MG_C9UX+_ .O'4O\ TCEK^AM/NU_/%_P0$_Y2=^"_^O+4O_2.:OZ'5^[7Y+QI M_P C!?X4?L/ 7_(N?^)BT445\B?;A1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36ZBG4UNHH M_GL_X.!_^4F7BK_L&Z;_ .DJ5\4'K7VM_P ' QS_ ,%,_%G_ &#=-_\ 25*^ M*3UK]SR/_<*/^%'\^Y]_R,*O^)A1117JGDA1110 4444 %%%%'4#WS_@EL?^ M-A_P>_[&>S_]&"OZ;U[_ %K^8_\ X)5 =9D9=%UM5Y(//V:<@?),JCV5PI*X^8#Y;7]X&_C[\.M4\)^+M'M=(PJO3?3^7_ (!\@ Y%%#G!;GOC)^O%!&#B MOLM3X:(4444#"BBB@:W/J'_@B[_RDZ^$_P#U_P!Q_P"D=Q7])2?=K^;7_@B^ MOZ2D^[7Y7QQ_OL?\*/UO@#_%_^1DT_P#Z^(__ $(5G6^!^C-:'\2/JC^MFT_X\X_] MVI:BM/\ CSC_ -VI:_GM[G]'T?@7H@HHHH- HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK]? MPIU-?K^% '\RO_!5+_E(I\8/^QEN?_0J^?Z]^_X*GG/_ 42^,'_ &,MU_Z% M7@-?O66_[K3]%^1_.N9?[W5_Q/\ ,****[CA"BBB@ HHHH **** >Q]F?\$" M&V_\%/? _P#M6FI?^D,]?T0"OYV_^"!S[?\ @J!X#_VK74Q_Y(SU_1(*_)>- M/]_7^%'[#P%_R+W_ (F%%%%?(GVX4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=:6D(H _GH M_P"#@(_\;,O%G_8.TW_TECKXK/6OM/\ X. #G_@IIXN_[!^F_P#I)'7Q8>M? MN>1_[A1_PH_G_/?]_K?XF%%%%>J>.%%%% !1110 4444 >]_\$NCC_@H9\'? M^QHL_P#T,5_3C7\QG_!+XX_X*%_!W_L:;+_T8*_ISK\MXX_WJG_A_4_6?#__ M '6I_B7Y!1117Q)]^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1106Q0 44@8'N*7.: "L/XB?#_1?BKX.U'P[XBTRSUC1=7@:WO+.ZC$D5 MQ&W56!__ %CJ,$"MS-!&:(R:::)E%27+)71^!/\ P5E_X(Q:U^QCJ5[XX\!0 M7FN?#":0R2+_ *RY\.%C]R7^]!SA9>WW7.=I;X)^Z,#@+QCD;?3@]/IVZ5_7 M#JNEV^M6,]I=017-K=1M#-%(@=)$((*LI!# @XP>,$U^-_\ P5C_ ."#UUX& M;4OB-\$=-DO-%^>XU3PK"K236&>6DLQRS1=S$#E /D!7*K^D\/\ %:FEAL:] M=E+OY,_+>).#W3;Q6!6G6/8_*ZBG/&R.0593G&",$'_/T_+%-!R*^_NGHM3\ M[VT>C"BBBA[!U/I[_@C.^S_@IE\*#_U$I1^=M-7])PK^:S_@CB^S_@IA\)?? M59!_Y+RU_2F.E?EG''^^0_P_J?K?A_\ [E/_ !?H%%%%?%'WH4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? MBG_P="G_ (R,^&O_ &+LW_I2:_:ROQ1_X.@S_P 9(?#?_L79?_2EJ^FX2_Y& M4?1_D?*\9_\ (LEZH_,$=** ,"BOV'J?B(4444P"BBB@ HHHH *N^'#M\0V/ M_7Q'_P"A"J57- .-=LO^NZ?^A"LZWP/T9K0_B1]4?UM6?_'E'_NBIJALO^/- M/]T5-7\]O<_H^C\$?1!1110:!1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37Z_A3J;)W^E'4# M^9'_ (*E'_C8A\8/^QFNA_X]7@=>]_\ !4+5/_3;./]ZI_X?U/U MCP^_W:K_ (E^0M%%%?$GZ %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !49<:(YL;8--:YQ\O=XNAZ@AL@_J3\+OB;H'QB\ Z9XF\,ZM9ZUH> ML0BXM+RVDWQS(?Y$="#@@@@@$8K^=K_@M8?-_P""GGQ7]#>6HZ_].5L1].E2 M?\$T/^"J/C#_ ()\^-A;K]HU_P"'VJ3AM4T%I,>43@&>V)XCF X^[(!M8 A M67]$QW"\,5@J>(PJM/E5UWT_,_,8Y%R,JW/(/(()[T,*_ M/9TY0ER3T:/TNG4C4BIP=TQ:BF 9L>W?D5+NIIY/X5)9^<'_ 55_P""&>D? MM+-J'C[X5P6'A_QXX:XOM*VK%8Z\PR2W]V&=CDE@-LC'_$6EWVC:WI5R2I&2#]ED M?%53#6H8EWAWZH^#XBX0AB;XC!JT^JZ,_FV!R**]:_; _8G^('[$'Q(D\.^. MM(DM&D+M9:A#F2QU6,'F2&7&&Z@LI^=2?F )KR7&#COZ5^H8?$4ZT(U*3NF? ME.(HU*-5PJJS73M_F?2G_!'U_+_X*4_"5O\ J,,/_($M?TKKTK^:3_@D0VW_ M (*2?",_]1G_ -I25_2VIXK\SXX_WN'^']3]5\/_ /OVPK\3?^#H(Y_:8^'?\ V+,O M_I3)7TW"7_(RCZ/\CY7C/_D62]4?F+GFBC_&BOV'J?B(4444P"BBB@ HHHH M*M:*<:Q:G_ILG\ZJU8TIMNIVY_Z:+_,5G6^!^C-:'\2/JC^M^T_X]$_W:EJ* MTYM(_P#=J6OY[>Y_1]'X%Z(****#0**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)_2GTV3H? MI0!_,?\ \%1#G_@H;\8O^QIO/_1AKP6O>/\ @J <_P#!0SXQ?]C5>_\ HTUX M/7[YE_\ NM/_ K\D?SKF7^]U?\ $_S"BBBNPX0HHHH **** "BBB@:/K[_@ M@^^W_@J3\-_]I-4'_E,NJ_HN'2OYS?\ @A(V/^"IWPQ]QJG_ *:KROZ,A7Y/ MQM_O\?\ "OU/U_@/_<9?XF%%%%?'GW 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$44AH8'\ M\7_!?@Y_X*=>-/\ KRTW_P!(H:^,:^S/^"^QS_P4\\;?]>>F_P#I##7QG7[G MD?\ N%'_ H_GS//]_J_XF%%%%>J>4%%%% !1110 4444UN![G_P3+./^"@_ MP;_[&RP_]'+7]/(K^87_ ()G?\I!?@W_ -C=IW_H]:_IZ!S7Y=QU_O-/_"_S M/UCP^_W6K_B7Y!1117PY^@!1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4UCAA3J:WW@: /YLO^"R\_VC_@IE\6&]-1A7\K6 ?TKYB!P??J". M"#VKZ2_X*]S_ &C_ (*2_%MO36=OY11C^E?-M?O.5_[G2]%^1_.^;?[[5]7^ M9[A^PS^WWXZ_8(^**:]X3O/M&FW15-5T2X=OL6I1 ]&'\$@R=LB_,I)ZJS*? MZ"/V'/V^O 7[>?PN37O"-Z(M0M0JZKHUP5%YI'^)ZN7OVSJ01D\]17X8_P#!2W_@B9XT_8MN M+[Q/X3CO/&GPTW-+]KCC#7VCH>=MU&HP5' \]5*G&65,XK^@FJ][:K=1M&Z+ M)'(-K*PW*P/4$>F*]G)\\Q& G^[=X]4]F>#G7#V&SȄ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end XML 15 hct-20201231_htm.xml IDEA: XBRL DOCUMENT 0001561032 2020-01-01 2020-12-31 0001561032 2020-06-30 0001561032 2021-03-23 0001561032 2020-12-31 0001561032 2019-12-31 0001561032 2019-01-01 2019-12-31 0001561032 us-gaap:SubsequentEventMember 2021-01-15 2021-01-15 0001561032 2018-01-01 2018-12-31 0001561032 us-gaap:PreferredStockMember 2017-12-31 0001561032 us-gaap:CommonStockMember 2017-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001561032 us-gaap:RetainedEarningsMember 2017-12-31 0001561032 us-gaap:ParentMember 2017-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2017-12-31 0001561032 2017-12-31 0001561032 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001561032 us-gaap:ParentMember 2018-01-01 2018-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001561032 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001561032 us-gaap:PreferredStockMember 2018-12-31 0001561032 us-gaap:CommonStockMember 2018-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001561032 us-gaap:RetainedEarningsMember 2018-12-31 0001561032 us-gaap:ParentMember 2018-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2018-12-31 0001561032 2018-12-31 0001561032 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-12-31 0001561032 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2018-12-31 0001561032 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0001561032 us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001561032 us-gaap:ParentMember 2019-01-01 2019-12-31 0001561032 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001561032 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001561032 us-gaap:PreferredStockMember 2019-12-31 0001561032 us-gaap:CommonStockMember 2019-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001561032 us-gaap:RetainedEarningsMember 2019-12-31 0001561032 us-gaap:ParentMember 2019-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2019-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001561032 us-gaap:ParentMember 2020-01-01 2020-12-31 0001561032 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001561032 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001561032 us-gaap:PreferredStockMember 2020-12-31 0001561032 us-gaap:CommonStockMember 2020-12-31 0001561032 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001561032 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001561032 us-gaap:RetainedEarningsMember 2020-12-31 0001561032 us-gaap:ParentMember 2020-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2020-12-31 0001561032 2020-10-01 2020-10-01 0001561032 2020-10-01 2020-12-31 0001561032 2017-01-01 2017-12-31 0001561032 2016-01-01 2016-12-31 0001561032 us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001561032 srt:RestatementAdjustmentMember us-gaap:LineOfCreditMember 2019-01-01 2019-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-03-01 2020-03-31 0001561032 hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2019-01-01 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2018-01-01 2018-12-31 0001561032 srt:MinimumMember 2020-01-01 2020-12-31 0001561032 srt:MaximumMember 2020-01-01 2020-12-31 0001561032 us-gaap:BuildingMember 2020-01-01 2020-12-31 0001561032 us-gaap:LandImprovementsMember 2020-01-01 2020-12-31 0001561032 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001561032 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001561032 us-gaap:DomesticCountryMember 2020-12-31 0001561032 us-gaap:DomesticCountryMember 2018-01-01 0001561032 hct:COVID19PandemicMember 2020-01-01 2020-12-31 0001561032 us-gaap:SubsequentEventMember 2021-01-01 2021-03-19 0001561032 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001561032 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0001561032 us-gaap:LandAndBuildingMember 2019-01-01 2019-01-01 0001561032 2019-01-01 2019-01-01 0001561032 hct:MultitenantMOBMember 2020-01-01 2020-12-31 0001561032 hct:SingleTenantMOBMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2019-01-01 2019-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2018-01-01 2018-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2019-01-01 2019-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:LeasesAcquiredInPlaceMember 2018-01-01 2018-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2020-01-01 2020-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2019-01-01 2019-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember us-gaap:AboveMarketLeasesMember 2018-01-01 2018-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2020-01-01 2020-12-31 0001561032 us-gaap:AboveMarketLeasesMember 2020-01-01 2020-12-31 0001561032 hct:BelowMarketLeasesMember 2020-01-01 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2019-01-01 2019-12-31 0001561032 us-gaap:AboveMarketLeasesMember 2019-01-01 2019-12-31 0001561032 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hct:BelowMarketLeasesMember 2019-01-01 2019-12-31 0001561032 2015-08-31 0001561032 us-gaap:LandMember 2019-12-31 0001561032 us-gaap:ConstructionInProgressMember 2019-12-31 0001561032 hct:JupiterFloridaMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-08-31 0001561032 hct:SkilledNursingFacilitiesMember stpr:FL us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-08-31 0001561032 hct:SeniorsHousingCommunitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-08-31 0001561032 hct:SeniorsHousingCommunitiesMember hct:WellingtonFloridaMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-08-31 0001561032 stpr:FL us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-08-31 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember 2020-11-01 2020-11-30 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001561032 stpr:FL us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001561032 stpr:GA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001561032 stpr:MI us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001561032 stpr:MI us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001561032 stpr:PA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001561032 stpr:PA us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2020-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember 2019-12-31 0001561032 hct:IntangibleMarketLeaseAssetsMember 2020-12-31 0001561032 hct:IntangibleMarketLeaseAssetsMember 2019-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember 2020-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2020-01-01 2020-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2019-01-01 2019-12-31 0001561032 hct:InplaceLeasesandOtherIntangibleAssetsMember hct:DepreciationandAmortizationExpenseMember 2018-01-01 2018-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2020-01-01 2020-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2019-01-01 2019-12-31 0001561032 hct:AboveandBelowMarketLeasesMember hct:RentalIncomeMember 2018-01-01 2018-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2020-01-01 2020-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2019-01-01 2019-12-31 0001561032 hct:AboveMarketGroundLeaseMember hct:PropertyOperatingandMaintenanceExpenseMember 2018-01-01 2018-12-31 0001561032 us-gaap:LeasesAcquiredInPlaceMember hct:AmortizationExpenseMember 2020-12-31 0001561032 us-gaap:OtherIntangibleAssetsMember hct:AmortizationExpenseMember 2020-12-31 0001561032 hct:AmortizationExpenseMember 2020-12-31 0001561032 us-gaap:AboveMarketLeasesMember hct:RentalIncomeMember 2020-12-31 0001561032 hct:BelowMarketLeaseMember hct:RentalIncomeMember 2020-12-31 0001561032 hct:RentalIncomeMember 2020-12-31 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-16 0001561032 hct:SkilledNursingFacilitiesMember hct:LutzFloridaMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-16 2020-12-16 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-11-02 2020-11-02 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-11-02 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-11-02 2020-11-02 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-03-19 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-03-19 2020-03-19 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2019-08-22 2019-08-22 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs1propertyMember 2019-08-22 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs1propertyMember 2019-08-22 2019-08-22 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:OceanParkCenterMember 2019-08-01 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:OceanParkCenterMember 2019-08-01 2019-08-01 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2019-02-06 2019-02-06 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2019-02-06 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2019-02-06 2019-02-06 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember 2019-01-01 2019-12-31 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SNFPropertiesMember 2018-12-05 0001561032 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember hct:SNFPropertiesMember 2018-12-05 2018-12-05 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember 2020-12-16 2020-12-16 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-11-02 0001561032 hct:SeniorsHousingCommunitiesMember 2020-11-02 2020-11-02 0001561032 us-gaap:LineOfCreditMember 2020-11-02 0001561032 hct:FannieMaeMasterCreditFacilityMember 2020-11-02 0001561032 hct:UnencumberedPropertiesMember 2020-11-02 0001561032 us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2021-01-31 0001561032 hct:UnencumberedPropertiesMember us-gaap:SubsequentEventMember 2021-01-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2020-01-01 2020-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-01-01 2020-12-31 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-03-19 2020-03-19 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2018-07-26 0001561032 hct:MedicalOfficeBuildingsMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:NewYorkSixMOBs5propertiesMember 2018-09-25 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-03-31 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-03-21 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-04-01 0001561032 hct:SeniorsHousingCommunitiesMember 2019-04-01 2019-06-30 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-08-01 0001561032 hct:SkilledNursingFacilitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:SNFPropertiesMember 2018-11-06 2018-11-06 0001561032 hct:SkilledNursingFacilitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:SNFPropertiesMember 2019-01-01 2019-09-30 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-01-01 2019-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2018-01-01 2018-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2020-01-01 2020-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2019-01-01 2019-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2018-01-01 2018-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-09-30 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-04-30 0001561032 hct:SeniorsHousingCommunitiesMember hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember us-gaap:SubsequentEventMember 2021-01-31 0001561032 hct:SeniorsHousingCommunitiesMember hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2020-01-01 2020-09-30 0001561032 hct:SeniorsHousingCommunitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-01-31 0001561032 hct:JupiterFloridaMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2019-12-31 0001561032 hct:SkilledNursingFacilitiesMember stpr:FL 2019-12-31 0001561032 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember hct:JupiterFloridaMember 2020-06-30 0001561032 hct:SkilledNursingFacilitiesMember stpr:FL us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-06-30 0001561032 hct:LutzFloridaMember hct:SkilledNursingFacilitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-06-30 0001561032 hct:WellingtonFloridaMember hct:SkilledNursingFacilitiesMember us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-06-30 0001561032 hct:LutzFloridaMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:IncomeApproachValuationTechniqueMember 2020-01-01 2020-12-31 0001561032 hct:WellingtonFloridaMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:IncomeApproachValuationTechniqueMember 2020-01-01 2020-12-31 0001561032 hct:JupiterFloridaMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:IncomeApproachValuationTechniqueMember 2020-01-01 2020-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2019-12-31 0001561032 hct:LaSalleTenantMember 2020-12-31 0001561032 hct:LaSalleTenantMember 2020-01-01 2020-12-31 0001561032 hct:LaSalleTenantMember 2019-01-01 2019-12-31 0001561032 hct:LaSalleTenantMember 2018-01-01 2018-12-31 0001561032 hct:LaSalleGuarantorvsLaSalleTenantMember us-gaap:SettledLitigationMember 2019-08-27 2019-08-27 0001561032 hct:NuVistaMember 2020-12-31 0001561032 hct:NuVistaMember 2019-01-01 2019-12-31 0001561032 hct:NuVistaMember 2018-01-01 2018-12-31 0001561032 hct:NuVistaMember 2020-01-01 2020-12-31 0001561032 hct:CountrysideMedicalArtsSafetyHarborFLMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:CountrysideMedicalArtsSafetyHarborFLMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:St.AndrewsMedicalParkVeniceFLMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:St.AndrewsMedicalParkVeniceFLMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:PalmValleyMedicalPlazaAZMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:PalmValleyMedicalPlazaAZMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:CourtyardFountainsGreshamORMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:CourtyardFountainsGreshamORMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember us-gaap:MortgagesMember 2019-12-31 0001561032 us-gaap:MortgagesMember 2020-12-31 0001561032 us-gaap:MortgagesMember 2019-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2017-06-30 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-19 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-20 0001561032 hct:MedicalOfficeBuildingsMember hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-20 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-20 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-20 2019-12-20 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-20 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MOBLoanMember 2019-12-20 2019-12-20 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-19 2019-12-19 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-12-20 2019-12-20 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2020-01-01 2020-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MOBLoanMember us-gaap:MortgagesMember 2020-12-31 0001561032 hct:MOBLoanMember us-gaap:MortgagesMember 2019-12-31 0001561032 hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2018-04-10 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2018-04-10 2018-04-10 0001561032 us-gaap:RevolvingCreditFacilityMember hct:MultiPropertyCMBSLoanMember us-gaap:MortgagesMember 2018-04-10 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-12-31 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-12-31 0001561032 us-gaap:LineOfCreditMember hct:TermLoanMember 2020-12-31 0001561032 us-gaap:LineOfCreditMember hct:TermLoanMember 2019-12-31 0001561032 us-gaap:LineOfCreditMember 2020-12-31 0001561032 us-gaap:LineOfCreditMember 2019-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2020-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:CapitalOneFacilityMember 2019-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:KeyBankFacilityMember 2020-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember hct:KeyBankFacilityMember 2019-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember 2020-12-31 0001561032 us-gaap:LineOfCreditMember hct:MasterCreditFacilityMember 2019-12-31 0001561032 hct:MasterCreditFacilityMember 2020-12-31 0001561032 hct:NewCreditFacilitiesMember 2020-12-31 0001561032 hct:UnencumberedPropertiesMember 2020-12-31 0001561032 hct:TermLoanMember 2019-03-13 2019-03-13 0001561032 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-03-13 0001561032 hct:TermLoanMember 2019-03-13 0001561032 srt:MinimumMember us-gaap:SecuredDebtMember 2019-03-13 0001561032 srt:MaximumMember us-gaap:SecuredDebtMember 2019-03-13 0001561032 us-gaap:SecuredDebtMember 2020-12-31 0001561032 2020-08-10 0001561032 hct:NewCreditFacilitiesMember hct:DayPriorToCommencementQuarterMember 2020-08-10 0001561032 hct:DayPriorToCommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember hct:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:BaseRateMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:BaseRateMember hct:CovenantPeriodAugust102020Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember hct:TermLoanMember us-gaap:BaseRateMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 0001561032 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember hct:CommencementQuarterMember 2020-08-10 0001561032 2020-08-10 2020-08-10 0001561032 hct:NewCreditFacilitiesMember hct:CommencementQuarterMember 2020-08-10 0001561032 srt:MinimumMember hct:NewCreditFacilitiesMember hct:CommencementQuarterMember 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodJuly12020ThroughJune302021Member 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodFromJune302021ThroughCommencementQuarterMember 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodAfterCommencementQuarterMember 2020-08-10 2020-08-10 0001561032 srt:MinimumMember hct:CovenantPeriodJuly12020ThroughMarch312021Member 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodJuly12020ThroughMarch312021Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember hct:CovenantPeriodFromApril12021ThroughJune302021Member 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodFromApril12021ThroughJune302021Member 2020-08-10 2020-08-10 0001561032 srt:MinimumMember hct:CovenantPeriodAfterJune302021Member 2020-08-10 2020-08-10 0001561032 hct:CovenantPeriodAfterJune302021Member 2020-08-10 2020-08-10 0001561032 us-gaap:LineOfCreditMember 2020-08-10 0001561032 us-gaap:LineOfCreditMember 2020-08-10 2020-08-10 0001561032 hct:FannieCreditFacilityMember us-gaap:InterestRateCapMember 2016-10-31 0001561032 2019-11-01 0001561032 hct:FannieCreditFacilityMember us-gaap:InterestRateCapMember 2019-11-01 0001561032 hct:MasterCreditFacilityMember 2020-11-01 2020-11-30 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001561032 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:MortgagesMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MortgagesMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2020-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2019-12-31 0001561032 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2019-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2020-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2020-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2019-12-31 0001561032 hct:FannieCreditFacilityMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2019-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2020-12-31 0001561032 us-gaap:DerivativeFinancialInstrumentsAssetsMember us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2019-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-10-01 2020-12-31 0001561032 hct:MOBLoanMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-10-01 2020-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0001561032 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0001561032 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-12-31 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2020-12-31 0001561032 us-gaap:InterestRateCapMember us-gaap:NondesignatedMember 2019-12-31 0001561032 hct:TenderOfferMember 2020-01-09 0001561032 hct:TenderOfferMember 2020-01-09 2020-01-09 0001561032 2020-01-09 2020-01-09 0001561032 hct:TenderOfferMember 2018-03-13 0001561032 hct:TenderOfferMember 2018-03-13 2018-03-13 0001561032 hct:TenderOfferMember 2018-04-04 2018-04-16 0001561032 2018-05-01 2018-05-31 0001561032 2019-10-30 2019-10-30 0001561032 2020-02-26 2020-02-26 0001561032 2012-10-15 2019-12-31 0001561032 2012-10-15 2020-12-31 0001561032 2017-02-17 2017-02-17 0001561032 2020-05-31 0001561032 srt:MaximumMember 2019-12-31 0001561032 hct:PublicStockOfferingMember 2020-12-31 0001561032 2020-09-30 0001561032 hct:PublicStockOfferingMember 2019-12-01 2019-12-31 0001561032 2019-12-01 2019-12-31 0001561032 hct:PreferredStockEquityLineMember 2020-09-15 0001561032 hct:PreferredStockEquityLineMember 2020-01-01 2020-12-31 0001561032 hct:DelistingMember 2019-01-01 2019-12-31 0001561032 2013-04-01 2013-04-30 0001561032 2017-04-01 2017-04-01 0001561032 2018-03-01 2018-03-01 0001561032 hct:ReturnofCapitalMember 2020-01-01 2020-12-31 0001561032 hct:ReturnofCapitalMember 2019-01-01 2019-12-31 0001561032 hct:ReturnofCapitalMember 2018-01-01 2018-12-31 0001561032 hct:CapitalGainDividendIncomeMember 2020-01-01 2020-12-31 0001561032 hct:CapitalGainDividendIncomeMember 2019-01-01 2019-12-31 0001561032 hct:CapitalGainDividendIncomeMember 2018-01-01 2018-12-31 0001561032 hct:OrdinaryDividendIncomeMember 2020-01-01 2020-12-31 0001561032 hct:OrdinaryDividendIncomeMember 2019-01-01 2019-12-31 0001561032 hct:OrdinaryDividendIncomeMember 2018-01-01 2018-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2020-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember 2019-12-31 0001561032 hct:TaxDepreciationDeductionMember hct:AdvisorMember 2020-12-31 0001561032 hct:SecondAmendedandRestatedAdvisoryAgreementMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2017-02-17 2017-02-17 0001561032 hct:AdvisorMember hct:AdvanceOnLoanOrOtherInvestmentMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2020-12-31 0001561032 hct:AnnualTargetedInvestorReturnMember hct:SpecialLimitedPartnerMember hct:PreTaxNonCompoundedReturnOnCapitalContributionMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2020-12-31 0001561032 hct:AdvisorMember hct:ContractPurchasePriceMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2020-12-31 0001561032 hct:AdvisorMember 2020-01-01 2020-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:MonthlyBaseManagementFeeMember 2020-01-01 2020-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkOneMember 2020-01-01 2020-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:QuarterlyVariableManagementFeeBenchmarkTwoMember 2020-01-01 2020-12-31 0001561032 hct:AdvisorMember hct:GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2020-12-31 0001561032 hct:AdvisorMember hct:GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2020-12-31 0001561032 srt:MaximumMember hct:AdvisorMember hct:GrossRevenueManagedPropertiesMember hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember 2020-12-31 0001561032 hct:AmendedandRestatedPropertyManagementandLeasingAgreementMember 2017-02-17 2017-02-17 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2020-01-01 2020-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2019-01-01 2019-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsofAdministrativeServicesMember 2018-01-01 2018-12-31 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:ConsumerPriceIndexMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:CappedReimbursementAmountMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:RealEstateCostMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:AdvisorMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ThirdAmendedAndRestatedAdvisoryAgreementMember hct:AdvisorAndCompanyMember 2019-07-25 2019-07-25 0001561032 hct:AmericanRealtyCapitalHealthcareAdvisorsLLCMember hct:ReimbursementsOfEmployeeBonusesOfTheAdvisorMember 2019-01-01 2019-12-31 0001561032 hct:A2019BonusAwardsMember 2020-09-30 0001561032 hct:A2019BonusAwardsMember 2020-01-01 2020-09-30 0001561032 hct:SeverancePaymentsMember 2020-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2020-01-01 2020-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2019-01-01 2019-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2018-01-01 2018-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2020-12-31 0001561032 hct:AcquisitionCostsReimbursementsMember 2019-12-31 0001561032 hct:AssetManagementFeesMember 2020-01-01 2020-12-31 0001561032 hct:AssetManagementFeesMember 2019-01-01 2019-12-31 0001561032 hct:AssetManagementFeesMember 2018-01-01 2018-12-31 0001561032 hct:AssetManagementFeesMember 2020-12-31 0001561032 hct:AssetManagementFeesMember 2019-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2020-01-01 2020-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2019-01-01 2019-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2018-01-01 2018-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2020-12-31 0001561032 hct:PropertyManagementAndLeasingFeesMember 2019-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2020-01-01 2020-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2019-01-01 2019-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2018-01-01 2018-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2020-12-31 0001561032 hct:TransferAgentandOtherProfessionalFeesMember 2019-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2020-01-01 2020-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2019-01-01 2019-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2018-01-01 2018-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2020-12-31 0001561032 hct:ProfessionalFeesCreditDueFromAdvisorMember 2019-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2020-01-01 2020-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2019-01-01 2019-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2018-01-01 2018-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2020-12-31 0001561032 hct:DistributionsOnClassBUnitsMember 2019-12-31 0001561032 hct:CappedReimbursementAmountMember 2020-01-01 2020-12-31 0001561032 hct:CappedReimbursementAmountMember 2019-01-01 2019-12-31 0001561032 hct:A2019BonusAwardsMember hct:AdvisorMember 2020-12-31 0001561032 srt:RestatementAdjustmentMember hct:TransferAgentandOtherProfessionalFeesMember 2019-01-01 2019-12-31 0001561032 hct:ProfessionalFeesandReimbursementsMember hct:AdvisorMember 2019-12-31 0001561032 hct:PrepaidExpensesAndOtherAssetsMember hct:PropertyManagementAndLeasingFeesMember 2020-01-01 2020-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2020-12-31 0001561032 hct:SpecialLimitedPartnerMember hct:NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember hct:HealthcareTrustSpecialLimitedPartnershipLLCMember 2020-12-31 0001561032 hct:TransitionFeeMember 2020-01-01 2020-12-31 0001561032 hct:SubjectFeesTransitionFeeNotinExcessoftheProductMember 2020-01-01 2020-12-31 0001561032 hct:SubjectFeesMember 2020-01-01 2020-12-31 0001561032 hct:ChangeinControlFeeMember 2020-01-01 2020-12-31 0001561032 hct:VariableManagementIncentiveFeeMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2020-12-31 0001561032 us-gaap:RestrictedStockMember hct:AmendedandRestatedRSPMember 2017-08-31 0001561032 srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockMember hct:AmendedandRestatedRSPMember 2017-08-01 2017-08-31 0001561032 hct:IndependentDirectorsMember us-gaap:RestrictedStockMember hct:AmendedandRestatedRSPMember 2017-08-01 2017-08-31 0001561032 srt:DirectorMember us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2019-07-29 2019-07-29 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2017-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2018-01-01 2018-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2018-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2019-01-01 2019-12-31 0001561032 us-gaap:RestrictedStockMember hct:RestrictedSharePlanMember 2019-12-31 0001561032 srt:DirectorMember 2019-01-01 2019-12-31 0001561032 srt:DirectorMember 2018-01-01 2018-12-31 0001561032 srt:DirectorMember 2020-01-01 2020-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2017-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-01-01 2018-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2018-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-01-01 2019-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2019-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2020-12-31 0001561032 us-gaap:NoncontrollingInterestMember 2014-11-30 0001561032 hct:UnityPointClinicPortfolioMember 2020-11-04 2020-11-04 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2020-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001561032 hct:PlazaDelRioMedicalOfficeCampusPortfolioAZMember us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001561032 hct:UnityPointClinicPortfolioMember us-gaap:NoncontrollingInterestMember 2020-12-31 0001561032 hct:UnityPointClinicPortfolioMember us-gaap:NoncontrollingInterestMember 2019-12-31 0001561032 hct:UnityPointClinicPortfolioMember us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001561032 hct:UnityPointClinicPortfolioMember us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001561032 hct:UnityPointClinicPortfolioMember us-gaap:NoncontrollingInterestMember 2018-01-01 2018-12-31 0001561032 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001561032 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001561032 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001561032 hct:OpUnitsMember 2020-01-01 2020-12-31 0001561032 hct:OpUnitsMember 2019-01-01 2019-12-31 0001561032 hct:OpUnitsMember 2018-01-01 2018-12-31 0001561032 hct:ClassBUnitsMember 2020-01-01 2020-12-31 0001561032 hct:ClassBUnitsMember 2019-01-01 2019-12-31 0001561032 hct:ClassBUnitsMember 2018-01-01 2018-12-31 0001561032 us-gaap:RestrictedStockMember 2020-12-31 0001561032 us-gaap:RestrictedStockMember 2019-12-31 0001561032 us-gaap:RestrictedStockMember 2018-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2020-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2019-12-31 0001561032 hct:AdvisorMember hct:AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember 2018-12-31 0001561032 hct:NuVistaMember hct:TransitionPropertyMember 2019-04-01 0001561032 hct:LaSalleTenantMember 2020-07-01 0001561032 hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember 2020-01-01 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2019-01-01 2019-12-31 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember 2019-01-01 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2019-01-01 2019-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2018-01-01 2018-12-31 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember 2018-01-01 2018-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2018-01-01 2018-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2020-12-31 0001561032 hct:MedicalOfficeBuildingsMember 2019-12-31 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember 2020-12-31 0001561032 hct:TripleNetLeasedHealthcareFacilitiesMember 2019-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2020-12-31 0001561032 hct:SeniorsHousingCommunitiesMember 2019-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2019-01-01 2019-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:MedicalOfficeBuildingsMember 2018-01-01 2018-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:TripleNetLeasedHealthcareFacilitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:TripleNetLeasedHealthcareFacilitiesMember 2019-01-01 2019-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:TripleNetLeasedHealthcareFacilitiesMember 2018-01-01 2018-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2019-01-01 2019-12-31 0001561032 us-gaap:OperatingSegmentsMember hct:SeniorsHousingCommunitiesMember 2018-01-01 2018-12-31 0001561032 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0001561032 us-gaap:OperatingSegmentsMember 2019-01-01 2019-12-31 0001561032 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001561032 2020-01-01 2020-03-31 0001561032 2020-04-01 2020-06-30 0001561032 2020-07-01 2020-09-30 0001561032 2019-01-01 2019-03-31 0001561032 2019-04-01 2019-06-30 0001561032 2019-07-01 2019-09-30 0001561032 2019-10-01 2019-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2020-10-01 2020-12-31 0001561032 hct:DisposalGroupHeldforuseNotDiscontinuedOperationsMember 2019-10-01 2019-12-31 0001561032 us-gaap:SubsequentEventMember 2021-01-04 2021-01-04 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember us-gaap:SubsequentEventMember 2021-03-31 0001561032 hct:SeniorsHousingCommunitiesMember stpr:MI us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2020-10-01 2020-12-31 0001561032 hct:FreseniusMedicalCareWinfieldALMember 2020-12-31 0001561032 hct:AdenaHealthCenterJacksonOHMember 2020-12-31 0001561032 hct:OuachitaCommunityHospitalWestMonroeLAMember 2020-12-31 0001561032 hct:CareMeridianLittletonCO.Member 2020-12-31 0001561032 hct:OakLawnMedicalCenterOakLawnIL.Member 2020-12-31 0001561032 hct:SurgeryCenterofTempleTempleTX.Member 2020-12-31 0001561032 hct:GreenvilleHealthSystemGreenvilleSCMember 2020-12-31 0001561032 hct:StockbridgeFamilyMedicalStockbridgeMember 2020-12-31 0001561032 hct:ArrowheadMedicalPlazaIIGlendaleMember 2020-12-31 0001561032 hct:VillageCenterParkwayStockbridgeMember 2020-12-31 0001561032 hct:CreeksideMOBDouglasvilleMember 2020-12-31 0001561032 hct:BowieGatewayMedicalCenterBowieMember 2020-12-31 0001561032 hct:CampusatCrooksAuburnBuildingDRochesterHillsMember 2020-12-31 0001561032 hct:BerwynMedicalCenterBerwynMember 2020-12-31 0001561032 hct:CountrysideMedicalArtsSafetyHarborMember 2020-12-31 0001561032 hct:St.AndrewsMedicalParkVeniceMember 2020-12-31 0001561032 hct:CampusatCrooksAuburnBuildingCRochesterHillsJuneMember 2020-12-31 0001561032 hct:LagunaProfessionalCenterElkGroveMember 2020-12-31 0001561032 hct:UCDavisMOBElkGroveMember 2020-12-31 0001561032 hct:EstateatHydeParkTampaJulyMember 2020-12-31 0001561032 hct:AutumnRidgeOfClarkstonClarkstonAugustMember 2020-12-31 0001561032 hct:SunnybrookofBurlingtonBurlingtonMember 2020-12-31 0001561032 hct:SunnybrookofCarrollCarrollAugust26Member 2020-12-31 0001561032 hct:PrairieHillsatCedarRapidsCedarRapidsAugustMember 2020-12-31 0001561032 hct:PrairieHillsatClintonClintonAugustMember 2020-12-31 0001561032 hct:PrairieHillsatDesMoinesDesMoinesAugustMember 2020-12-31 0001561032 hct:SunnybrookofFairfieldFairfieldAugust26Member 2020-12-31 0001561032 hct:SunnybrookofFt.MadisonFt.MadisonAugust26Member 2020-12-31 0001561032 hct:PrairieHillsatIndependenceIndependenceMember 2020-12-31 0001561032 hct:SunnybrookofMT.PleasantMt.PleasantAugust26Member 2020-12-31 0001561032 hct:SunnybrookofMuscatineMuscatineAugust26Member 2020-12-31 0001561032 hct:PrairieHillsatOttumwaOttumwaAugustMember 2020-12-31 0001561032 hct:PrairieHillsatTiptonTiptonAugustMember 2020-12-31 0001561032 hct:LibertyCourtDixonMember 2020-12-31 0001561032 hct:LakesideVistaHollandMember 2020-12-31 0001561032 hct:TheAtriumRockfordMember 2020-12-31 0001561032 hct:ArrowheadMedicalPlazaIGlendaleMember 2020-12-31 0001561032 hct:SunnybrookofBurlingtonLandBurlingtonAugustMember 2020-12-31 0001561032 hct:CommunityHealthMOBHarrisburgMember 2020-12-31 0001561032 hct:BradyMOBHarrisburgMember 2020-12-31 0001561032 hct:LandisMemorialHarrisburgSeptemberMember 2020-12-31 0001561032 hct:FOCIIMechanicsburgMember 2020-12-31 0001561032 hct:FOCClinicalMechanicsburgMember 2020-12-31 0001561032 hct:FOCIMechanicsburgMember 2020-12-31 0001561032 hct:CopperSpringsSeniorLivingMeridianSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofBrunswickBrunswickSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofDublinDublinSeptemberMember 2020-12-31 0001561032 hct:AllegroatElizabethtownElizabethtownSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember 2020-12-31 0001561032 hct:AllegroatJupiterJupiterSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofLeesSummitLeesSummitSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceatMillsRosewellMember 2020-12-31 0001561032 hct:AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember 2020-12-31 0001561032 hct:AllegroatStuartStuartSeptemberMember 2020-12-31 0001561032 hct:AllegroatTarponTarponSpringsSeptemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofTitusvilleTitusvilleMember 2020-12-31 0001561032 hct:AllegroatStPetersburgLandStPetersburgSeptemberMember 2020-12-31 0001561032 hct:GatewayMedicalOfficeBuildingClarksvilleOctoberMember 2020-12-31 0001561032 hct:AddingtonatWellingtonGreenWellingtonOctoberMember 2020-12-31 0001561032 hct:DyerBuildingDyerOctoberMember 2020-12-31 0001561032 hct:A757BuildingMunsterOctoberMember 2020-12-31 0001561032 hct:A761BuildingMunsterOctoberMember 2020-12-31 0001561032 hct:A759BuildingMunsterOctoberMember 2020-12-31 0001561032 hct:ScherervilleBuildingScherervilleMember 2020-12-31 0001561032 hct:MeadowbrookSeniorLivingAgouraHillsNovemberMember 2020-12-31 0001561032 hct:MountVernonMedicalOfficeBuildingMountVernonNovemberMember 2020-12-31 0001561032 hct:WellingtonatHersheysMillWestChesterMember 2020-12-31 0001561032 hct:CareplexWestMedicalOfficeBuildingHamptonMember 2020-12-31 0001561032 hct:HamptonRiverMedicalArtsBuildingHamptonDecemberMember 2020-12-31 0001561032 hct:EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember 2020-12-31 0001561032 hct:AddingtonPlaceofAlpharettaAlpharettaMember 2020-12-31 0001561032 hct:AddingtonPlaceofPrairieVillagePrairieVillageMember 2020-12-31 0001561032 hct:BloomMOBHarrisburgDecemberMember 2020-12-31 0001561032 hct:MedicalSciencesPavilionHarrisburgDecemberMember 2020-12-31 0001561032 hct:WoodGlenNursingandRehabCenterWestChicagoDecemberMember 2020-12-31 0001561032 hct:PinnacleCenterSouthavenDecemberMember 2020-12-31 0001561032 hct:ParadiseValleyMedicalPlazaPhoenixDecemberMember 2020-12-31 0001561032 hct:VictoryMedicalCenteratCraigRanchMcKinneyMember 2020-12-31 0001561032 hct:RivershoresHealthcareRehabCentreMarseillesDecemberMember 2020-12-31 0001561032 hct:MortonTerraceHealthcareRehabCentreMortonDecemberMember 2020-12-31 0001561032 hct:MortonVillaHealthcareRehabCentreMortonMember 2020-12-31 0001561032 hct:TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember 2020-12-31 0001561032 hct:ColonialHealthcareRehabCentrePrincetonDecemberMember 2020-12-31 0001561032 hct:CapitolHealthcareRehabCentreSpringfieldDecemberMember 2020-12-31 0001561032 hct:AcuitySpecialtyHospitalMesaMember 2020-12-31 0001561032 hct:AcuitySpecialtyHospitalSunCityMember 2020-12-31 0001561032 hct:AddingtonPlaceofShoalCreekKansasCityMember 2020-12-31 0001561032 hct:AuroraHealthCenterGreenBayMember 2020-12-31 0001561032 hct:AuroraHealthcareCenterGreenvilleWIMember 2020-12-31 0001561032 hct:AuraSheboyanClinicKielMarchMember 2020-12-31 0001561032 hct:AuroraHealthcareCenterPlymouthWIMember 2020-12-31 0001561032 hct:AuroraHealthcareCenterWaterfordWIMember 2020-12-31 0001561032 hct:AuroraHealthcareCenterWautomaWIMember 2020-12-31 0001561032 hct:ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember 2020-12-31 0001561032 hct:AdvancedOrthopaedicMedicalCenterRichmondAprilMember 2020-12-31 0001561032 hct:PalmValleyMedicalPlazaGoodyearAprilMember 2020-12-31 0001561032 hct:PhysiciansPlazaofRoaneCountyHarrimanMember 2020-12-31 0001561032 hct:AdventistHealthLaceyMedicalPlazaHanfordMember 2020-12-31 0001561032 hct:MedicalCenterIPeoriaMayMember 2020-12-31 0001561032 hct:MedicalCenterIIPeoriaMayMember 2020-12-31 0001561032 hct:CommercialCenterPeoriaMayMember 2020-12-31 0001561032 hct:MedicalCenterIIIPeoriaMember 2020-12-31 0001561032 hct:MorrowMedicalCenterMorrowJuneMember 2020-12-31 0001561032 hct:BelmarMedicalBuildingLakewoodJuneMember 2020-12-31 0001561032 hct:AddingtonPlaceNorthvilleMember 2020-12-31 0001561032 hct:ConroeMedicalArtsandSurgeryCenterConroeMember 2020-12-31 0001561032 hct:MedicalCenterVPeoriaAZMember 2020-12-31 0001561032 hct:LegacyMedicalVillagePlanoMember 2020-12-31 0001561032 hct:ScrippsCedarMedicalCenterVistaAugustMember 2020-12-31 0001561032 hct:NuVistaInstituteforHealthyLivingJupiterAugustMember 2020-12-31 0001561032 hct:RamseyWoodsCudahyMember 2020-12-31 0001561032 hct:EastCoastSquareWestCedarPointOctoberMember 2020-12-31 0001561032 hct:EastCoastSquareNorthMoreheadCityOctoberMember 2020-12-31 0001561032 hct:EastsideCancerinstituteGreenvilleOctoberMember 2020-12-31 0001561032 hct:SassafrasMedicalBuildingErieMember 2020-12-31 0001561032 hct:SkyLakesKlamathMedicalClinicKlamathFallsMember 2020-12-31 0001561032 hct:CourtyardFountainsGreshamORMember 2020-12-31 0001561032 hct:PresenceHealingArtsPavilionNewLenoxDecemberMember 2020-12-31 0001561032 hct:MainlandMedicalArtsPavilionTexasCityMember 2020-12-31 0001561032 hct:RenaissanceonPeachtreeAtlantaMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatBryantBryantDecemberMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatChenalLittleRockDecemberMember 2020-12-31 0001561032 hct:FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember 2020-12-31 0001561032 hct:AutumnLeavesofCyFairHoustonDecemberMember 2020-12-31 0001561032 hct:AutumnLeavesofMeyerlandHoustonDecemberMember 2020-12-31 0001561032 hct:AutumnLeavesofClearLakeHoustonDecemberMember 2020-12-31 0001561032 hct:AutumnLeavesoftheWoodlandsTheWoodlandsMember 2020-12-31 0001561032 hct:HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember 2020-12-31 0001561032 hct:NorthsideHospitalMedicalOfficeBuildingCantonMember 2020-12-31 0001561032 hct:WestMichiganSurgeryCenterBigRapidsMember 2020-12-31 0001561032 hct:CamelliaWalkAssistedLivingAndMemoryCareEvansMember 2020-12-31 0001561032 hct:CedarhurstofCollinsvilleMember 2020-12-31 0001561032 hct:ArcadianCoveAssistedLivingMember 2020-12-31 0001561032 hct:BeaumontMedicalCenterWarrenMember 2020-12-31 0001561032 hct:DaVitaHudsonMember 2020-12-31 0001561032 hct:DaVitaBayBreezeMember 2020-12-31 0001561032 hct:GreenfieldMedicalPlazaGilbertMember 2020-12-31 0001561032 hct:RAIClearwaterMember 2020-12-31 0001561032 hct:IllinoisCancerCareGalesburgMember 2020-12-31 0001561032 hct:UnityPointClinicMuscatineMember 2020-12-31 0001561032 hct:LeeMemorialHealthSystemOutpatientCenterFortMeyersMember 2020-12-31 0001561032 hct:DecaturMedicalOfficeBuildingMember 2020-12-31 0001561032 hct:MadisonMedicalPlazaJolietMember 2020-12-31 0001561032 hct:WoodlakeOfficeCenterMember 2020-12-31 0001561032 hct:RockwallMedicalPlazaMember 2020-12-31 0001561032 hct:MetroHealthBuckeyeHealthCenterClevelandMember 2020-12-31 0001561032 hct:UnityPointClinicMolineMember 2020-12-31 0001561032 hct:VAOutpatientClinicGalesburgMember 2020-12-31 0001561032 hct:PhilipProfessionalCenterLawrencevilleGAMember 2020-12-31 0001561032 hct:TexasChildrensHospitalHoustonMember 2020-12-31 0001561032 hct:FloridaMedicalHeartcareMember 2020-12-31 0001561032 hct:FloridaMedicalSomersetMember 2020-12-31 0001561032 hct:FloridaMedicalTampaPalmsMember 2020-12-31 0001561032 hct:FloridaMedicalWesleyChapelMember 2020-12-31 0001561032 hct:AuroraHealthCenterMilwaukeeAprilMember 2020-12-31 0001561032 hct:VascularSurgeryAssociatesMember 2020-12-31 0001561032 hct:GlendaleMOBFarmingtonHillsMIMember 2020-12-31 0001561032 hct:CrittentonWashingtonMOBMember 2020-12-31 0001561032 hct:CrittentonSterlingHeightsMOBMember 2020-12-31 0001561032 hct:AdvocateAuroraMOBElkhornWIMember 2020-12-31 0001561032 hct:PulmonaryCriticalCareMedicineAccocLemoyneMember 2020-12-31 0001561032 hct:DignityEmerusBlueDiamondRoadLasVegasMember 2020-12-31 0001561032 hct:DignityEmerusCraigRoadNorthLasVegasMember 2020-12-31 0001561032 hct:GreenfieldMOBGreenfieldMember 2020-12-31 0001561032 hct:MilwaukeeMOBSouthMilwaukeeMember 2020-12-31 0001561032 hct:StFrancisWIMOBStFrancisMember 2020-12-31 0001561032 hct:LancasterMedicalArtsMOBLancasterMember 2020-12-31 0001561032 hct:WomensHealthcareGroupMOBYorkMember 2020-12-31 0001561032 hct:PioneerSpineSportsNorthamptonMember 2020-12-31 0001561032 hct:PioneerSpineSportsSpringfieldMember 2020-12-31 0001561032 hct:PioneerSpineSportsWestSpringfieldMember 2020-12-31 0001561032 hct:FelicitaVidaEscondidoMember 2020-12-31 0001561032 hct:CedarhurstOfEdwardsvilleEdwardsvilleMember 2020-12-31 0001561032 hct:UMPCSirThomasCourtHarrisburgMember 2020-12-31 0001561032 hct:UMPCFisherRoadMechanicsburgMember 2020-12-31 0001561032 hct:SwedishAmericanMOBRoscoeMember 2020-12-31 0001561032 hct:CedarhurstOfSpartaSpartaMember 2020-12-31 0001561032 hct:UMPCChambersHillHarrisburgMember 2020-12-31 0001561032 hct:CedarhurstOfShilohShilohMember 2020-12-31 0001561032 hct:BayshoreNaplesMemoryCareNaplesMember 2020-12-31 0001561032 hct:CirclevilleMOBCirclevilleMember 2020-12-31 0001561032 us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-12-31 0001561032 hct:UnencumberedPropertiesMember us-gaap:RevolvingCreditFacilityMember 2020-12-31 0001561032 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember hct:ReclassificationFromHeldForSaleToRealEstateInvestmentsMember 2020-01-01 2020-12-31 iso4217:USD shares pure iso4217:USD shares hct:property hct:state utr:sqft hct:segment hct:lease hct:instrument hct:encumbered_property 0001561032 2020 FY false us-gaap:AccountingStandardsUpdate201602Member P6M 10-K true 2020-12-31 --12-31 false 001-39153 Healthcare Trust, Inc. MD 38-3888962 650 Fifth Ave. 30th Floor New York NY 10019 212 415-6500 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share HTIA NASDAQ No No Yes Yes Non-accelerated Filer false false false false 0 95040732 Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end. 212651000 207335000 2133057000 2004116000 276015000 269616000 2621723000 2481067000 512775000 427476000 2108948000 2053591000 90000 70839000 72357000 95691000 17989000 15908000 13000 392000 23322000 21182000 13912000 14351000 1278000 394000 34932000 39707000 15332000 13642000 2286895000 2325303000 542698000 528284000 674551000 605269000 10803000 12052000 38389000 5305000 299000 42271000 43094000 9155000 9133000 6914000 8521000 742000 6901000 1325523000 1218559000 0.07375 0.07375 0.01 2210000 1610000 1610000 1610000 1610000 1610000 16000 16000 0.01 0.01 300000000 300000000 95040783 95040783 1265037 92356664 92356664 938000 923000 2104261000 2078628000 -39673000 -7043000 -1108557000 -971190000 956985000 1101334000 4387000 5410000 961372000 1106744000 2286895000 2325303000 381612000 374914000 362406000 243548000 234185000 220997000 36446000 55969000 20655000 23922000 23414000 23071000 173000 362000 302000 21572000 20530000 17275000 81053000 81032000 83212000 406714000 415492000 365512000 -25102000 -40578000 -3106000 5230000 8790000 -70000 -19872000 -31788000 -3176000 51519000 56059000 49471000 44000 7000 23000 -102000 -68000 -157000 -51577000 -56120000 -49605000 -71449000 -87908000 -52781000 4061000 399000 197000 -75510000 -88307000 -52978000 303000 -393000 -216000 2968000 173000 0 -78781000 -88087000 -52762000 -32630000 -11625000 2109000 -111411000 -99712000 -50653000 94639833 94433640 93593719 -0.83 -0.93 -0.56 0 0 91002766 910000 2009197000 2473000 -665026000 1347554000 8505000 1356059000 1720633 17000 35720000 35737000 35737000 759867 8000 14194000 14202000 0 14202000 0 0 1244000 1244000 1244000 0.92 86543000 86543000 86543000 492000 492000 2109000 2109000 2109000 -52762000 -52762000 -216000 -52978000 0 0 91963532 919000 2031967000 4582000 -804331000 1233137000 7797000 1240934000 -87000 -87000 -87000 1610000 16000 37601000 37617000 37617000 1481395 15000 27195000 27210000 27210000 1103263 11000 21102000 21113000 21113000 15000 1319000 1319000 1319000 0.83 78685000 78685000 78685000 0.11 173000 173000 173000 346000 346000 -11625000 -11625000 -11625000 -87914000 -87914000 -393000 -88307000 1648000 1648000 -1648000 1610000 16000 92356664 923000 2078628000 -7043000 -971190000 1101334000 5410000 1106744000 -59000 -59000 -59000 875986 9000 14595000 14604000 14604000 705101 7000 10539000 10546000 10546000 0 1345000 1345000 1345000 0.21 1248197 13000 19646000 -19659000 0 0 0.42 38839000 38839000 38839000 1.84 2968000 2968000 2968000 201000 201000 -32615000 -32615000 -32615000 88000 88000 495000 583000 -75813000 -75813000 303000 -75510000 645000 -15000 630000 -630000 0 1610000 16000 93775746 938000 2104261000 -39673000 -1108557000 956985000 4387000 961372000 -75510000 -88307000 -52978000 81053000 81032000 83212000 4059000 9171000 8633000 846000 0 0 60000 -162000 -263000 -80000 -4000 255000 2708000 6464000 14797000 1345000 1319000 1244000 -102000 -68000 -157000 5230000 8790000 -70000 36446000 55969000 20655000 -4641000 0 0 2409000 3831000 7744000 63000 9667000 16888000 -4554000 2632000 2191000 -1607000 1510000 810000 41807000 47404000 54151000 94984000 91998000 128056000 21892000 16719000 12910000 34385000 62468000 25903000 -82491000 -46249000 -115063000 26091000 368300000 80000000 95000000 225618000 147753000 0 150000000 0 0 136513000 118700000 1048000 67797000 63263000 97000 2147000 131000 2241000 19532000 3354000 -1016000 37617000 0 10539000 21113000 14202000 31354000 51427000 55329000 2399000 0 0 583000 0 0 201000 346000 492000 19431000 19086000 49682000 -21253000 20241000 -11230000 111599000 91358000 102588000 90346000 111599000 91358000 72357000 95691000 77264000 17989000 15908000 14094000 90346000 111599000 91358000 47878000 47621000 43266000 315000 447000 407000 14604000 27210000 35737000 19659000 0 0 1287000 0 0 13883000 0 0 — Organization <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office buildings (“MOBs”), healthcare properties leased on a triple-net basis (“NNN properties”) and senior housing operating properties (“SHOPs”). As of December 31, 2020, the Company owned 193 properties located in 31 states and comprised of 9.4 million rentable square feet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through Healthcare Trust Operating Partnership, L.P. (the “OP”), a Delaware limited partnership, and its wholly owned subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to us. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has declared quarterly dividends entirely in shares of its common stock equal to 0.01349 shares of common stock on each share of outstanding common stock (“Stock Dividends”) on October 1, 2020 and January 4, 2021. These Stock Dividends were issued on October 15, 2020 and January 15, 2021 to holders of record of common stock at the close of business on October 8, 2020 and January 11, 2021, respectively. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. The aggregate impact of these Stock Dividends on the Company’s weighted-average share amounts used in its per-share calculations was an increase of 0.02716 shares, cumulatively, for every one share of common stock. No additional shares, except for the Stock Dividends, were issued during the three months ended December 31, 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the increase of 0.02716 shares for every share outstanding due to the Stock Dividends. Additionally, other references to weighted-average shares outstanding and per-share amounts have been retroactively adjusted for the Stock Dividends and are noted as such throughout the accompanying financial statements and footnotes. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019. The Company’s previous Estimated Per-Share NAV was as of December 31, 2018. Unlike the per share amounts in this Annual Report on Form 10-K, the Estimated Per-Share NAV has not been retroactively adjusted to reflect the payment of dividends in the form of common stock and will not be adjusted for Stock Dividends the Company pays in the future until the Board determines a new Estimated Per-Share NAV. Paying dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding will increase when Stock Dividends are paid; however, because each stockholder will receive the same number of new shares, the total value of our common stockholders’ investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of the board of directors (the “Board”), provided that such estimates will be made at least once annually.</span></div> 193 31 9400000 0.01349 0.02716 0 0.02716 Summary of Significant Accounting Policies<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Accounting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Period Adjustments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company identified certain historical errors in its tax provision and its net deferred taxes asset as well as its statements of operations and comprehensive income (loss), consolidated statements of changes in equity, and statements of cash flows since 2014, which impacted the quarterly financial statements and annual periods previously issued. Specifically, the Company had overstated intercompany rent on certain leases with the taxable REIT subsidiary (“TRS”) and reflected a portion of depreciation on REIT assets in the TRS’s tax provision, thereby overstating previously recorded tax benefits, deferred tax assets and net incom</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e by $0.8 million, $0.3 million and $0.2 million for the years ended December 31, 2018, 2017 and for Pre-2017 periods, respectively.  The intercompany rent and allocation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depreciation only affected the tax provision and did not affect the pre-tax consolidated financial results. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2019.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2020.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impacts of the COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The pandemic has had and could continue to have an adverse impact on economic and market conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The Company believes the estimates and assumptions underlying its consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ultimate impact COVID-19 will have on the global economy generally, and the Company’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways. In the Company’s SHOP portfolio, occupancy has trended lower since the second half of March as government policies and implementation of infection control best practices have materially limited or closed communities to new resident move-ins which affects the Company’s ability to fill vacancies. The Company has also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, the Company bears these cost increases. These trends accelerated during the second, third, and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact the Company in the future and have a material adverse effect on the Company’s revenues and income in the other quarters thereafter. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial stability and overall health of the Company’s tenants is critical to its business. The negative effects that the global pandemic has had on the economy includes the closure or reduction in activity of some of the Company’s MOBs and other healthcare-related facilities as well as restrictions on activity and access for many of the Company’s seniors housing properties. The economic impact of the pandemic has impacted the ability of some of the Company’s tenants to pay their monthly rent either temporarily or in the long term. The Company experienced delays in rent collections in the second, third and fourth quarters of 2020 although collections have been approximately 100%. The Company has taken a proactive approach </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken precautionary steps to increase liquidity and preserve financial flexibility in light of the uncertainty resulting from the COVID-19 pandemic. These steps include borrowing an additional $95.0 million under the Credit Facility (as defined below) in March 2020 to provide more cash on the Company’s balance sheet. A portion of the $95.0 million in borrowings was used for general corporate purposes and for acquisitions. The Company has not borrowed additional amounts subsequently. In August 2020, the Company amended the Credit Facility as part of its efforts to continue addressing the adverse impacts of the COVID-19 pandemic. For additional information on the Credit Facility amendment see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Credit Facilities. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020, these leases had a weighted average remaining lease term of 6.5 years. Rent from tenants in the Company’s MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted under the REIT Investment and Diversification and Empowerment Act of 2007 and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the rent are short term in nature, primarily month-to-month. Also included in revenue from tenants is fees </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for ancillary revenue from non-residents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $13.3 million, $15.4 million and $8.1 million for the years ended December 31, 2020, 2019, and 2018, respectively. Fees for ancillary services are recorded in the period in which the services are performed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2020 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards (see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Recently Issued Accounting Pronouncements”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below), the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, the Company recorded such amounts as bad debt expense as part of property operating expenses. During the years ended December 31, 2020, 2019 and 2018 such amounts were $2.7 million, $6.5 million and $14.8 million, respectively, which include bad debt expense related to the NuVista and LaSalle Tenants (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 and 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in this Note under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements - ASU No. 2016-02 Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2019, the Company has no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet as of December 31, 2020 and 2019, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlYzZmNTFkYWVjYjQxM2FhODMzNTNlZTc3NmJhNjFjL3NlYzpiZWM2ZjUxZGFlY2I0MTNhYTgzMzUzZWU3NzZiYTYxY18xOTAvZnJhZzphMDA3NjZlM2VhNzE0YmQ5OTZhMGEyZDI3YzY1YzkwMS90ZXh0cmVnaW9uOmEwMDc2NmUzZWE3MTRiZDk5NmEwYTJkMjdjNjVjOTAxXzE3Mjkw_c986e26c-bb53-4216-a0af-68263bff1102">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Dispositions of Real Estate Investments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on sales of rental real estate after January 1, 2018 are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sales of real estate prior to January 1, 2018 are recognized pursuant to the provisions included in ASC 360-20, Real Estate Sales (“ASC 360-20”). The specific timing of a sale was measured against various criteria in and ASC 360-20 related to the terms of the transaction and any continuing involvement in the form of management or financial assistance associated with the properties. If the sales criteria for the full accrual method are not met, depending on the circumstances, the Company may not record a sale or it may record a sale but may defer some or all of the gain recognition. If the criteria for full accrual are not met, the Company may account for the transaction by applying the finance, leasing, profit sharing, deposit, installment or cost recovery methods, as appropriate, until the sales criteria for the full accrual method are met.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has three reportable segments, with activities related to investing in MOBs, triple-net leased healthcare facilities, and seniors housing properties. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Above and Below-Market Lease Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge.  The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-controlling interests represent the portion of the equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net loss based on their share of equity ownership. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_235" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-Controlling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2020 or 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2020 and 2019, the Company had deposits of $72.4 million and $95.7 million, of which $57.0 million and $73.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing and Leasing Costs, Net </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fannie Mae Master Credit Facilities (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and deferred leasing costs. Deferred financing costs relating to the mortgage notes payable (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are reflected net of the related financing on our balance sheet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2020, 2019 and 2018. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties.  Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS.  Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company, owned 59 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2020 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the Company’s TRS's recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $4.6 million as of December 31, 2020. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. During the year ended December 31, 2020 the Company recorded a tax loss of $3.1 million. As of December 31, 2020, the Company had a deferred tax asset of $4.6 million with a full valuation allowance. As of December 31, 2019, the Company had a deferred tax asset of $3.9 million with no valuation allowance. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2013 remain open to examination by the major taxing jurisdictions to which the Company is subject. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of its SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in the Company’s consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, the Company received an additional $5.1 million in funding from CARES Act grants. There can be no assurance that the program will be extended or any further amounts received.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2018</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has since issued several additional amendments thereto (collectively referred to herein as “ASC 606”). ASC 606 establishes a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Under ASC 606, an entity is required to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. A reporting entity may apply the amendments in ASC 606 using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or a full retrospective approach. The Company adopted this guidance effective January 1, 2018 under the modified retrospective approach and it did not have an impact on the Company’s consolidated financial statements. See above for further information on the Company’s Revenue Recognition Accounting Policies under ASC 606.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2016, the FASB issued ASU 2016-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The revised guidance amends the recognition and measurement of financial instruments. The new guidance significantly revises an entity’s accounting related to equity investments and the presentation of certain fair value changes for financial liabilities measured at fair value. Among other things, it also amends the presentation and disclosure requirements associated with the fair value of financial instruments. The Company adopted this guidance effective January 1, 2018, using the modified retrospective transition method, and there was no impact to the Company's consolidated financial statements.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the FASB issued ASU 2016-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides guidance on how certain transactions should be classified and presented in the statement of cash flows as either operating, investing or financing activities. Among other things, the update provides specific guidance on where to classify debt prepayment and extinguishment costs, payments for contingent consideration made after a business combination and distributions received from equity method investments. The Company adopted the new guidance on January 1, 2018 and it did not have an impact on its consolidated statement of cash flows.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which revises the definition of a business. This new guidance is applicable when evaluating whether an acquisition should be treated as either a business acquisition or an asset acquisition. Under the revised guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset or group of similar assets, the assets acquired would not be considered a business. The Company adopted this guidance effective January 1, 2018, and will apply the new rules prospectively. The Company expects, based on historical property acquisitions, that in most cases, a future property acquired after adoption will be treated as an asset acquisition rather than a business acquisition, which will result in the capitalization of related transaction costs. The Company has evaluated the impact of this new guidance beginning in the first quarter of 2018, and determined that it did not have a material impact on the Company’s consolidated financial statements. All acquisition costs incurred during the years ended December 31, 2020 and 2019 were capitalized since our acquisitions during the years were all classified as asset acquisitions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the FASB issued ASU 2017-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Assets Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides guidance related to partial sales of non-financial assets, eliminates rules specifically addressing the sales of real estate, clarifies the definition of in substance non-financial assets, removes the exception to the financial asset derecognition model and clarifies the accounting for contributions of non-financial assets to joint ventures. The Company adopted this guidance effective January 1, 2018 using the modified transition method and it did not have an impact on its financial statements. The Company expects that any future sales of real estate in which the Company retains a non-controlling interest in the property would result in the full gain amount being recognized at the time of the partial sale. Historically, the Company has not retained any interest in properties it has sold.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the FASB issued ASU 2017-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides guidance that clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The update states that modification accounting should be used unless the fair value of the award, the vesting terms of the award, and the classification of the award as either equity or liability, all do not change as a result of the modification. The Company adopted this guidance effective January 1, 2018 using the modified retrospective transition method and it did not have an impact on its consolidated financial statements. The Company expects that any future modifications to the Company’s issued share-based awards will be accounted for using modification accounting, unless the modification meets all of the exception criteria noted above. As a result, the modification would be treated as an exchange of the original award for a new award, with any incremental fair value being treated as additional compensation cost.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2019</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2016-02 - Leases</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) which provides guidance related to the accounting for leases, as well as the related disclosures. For lessors of real estate, leases are accounted for using an approach substantially the same as previous accounting guidance for operating leases and direct financing leases. For lessees, the new standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption, lessors were allowed a practical expedient, which the Company has elected, by class of underlying assets to account for lease and non-lease components (such as tenant reimbursements of property operating expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under this new guidance, which is consistent with the Company’s existing policies. Also, upon adoption, companies were allowed a practical expedient package, which the Company has elected, that allowed the Company: (a) to not reassess whether any expired or existing contracts entered into prior to January 1, 2019 are or contain leases; (b) to not reassess the lease classification for any expired or existing leases entered into prior to January 1, 2019 (including assessing sale-leaseback transactions); and (c) to not reassess initial direct costs for any expired or existing leases entered into prior to January 1, 2019. As a result, all of the Company’s existing leases will continue to be classified as operating leases under the new standard. Further, any existing leases for which the property is the leased to a tenant in a transaction that at inception was a sale-leaseback transaction will continue to be treated (absent a modification) as operating leases. The Company did not have any leases that would be considered financing leases as of January 1, 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the impact of adoption from both a lessor and lessee perspective, which is discussed in more detail below, and adopted the new guidance prospectively on January 1, 2019, using a prospective transition approach under which the Company elected to apply the guidance effective January 1, 2019 and not adjust prior comparative reporting periods (except for the Company’s presentation of lease revenue discussed below).</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company was not required to re-assess the classification of its leases, which are considered operating leases under ASU 2016-02. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessor:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Since the Company elected the practical expedient noted above to not separate non-lease component revenue from the associated lease component, the Company has aggregated revenue from its lease components and non-lease components (tenant operating expense reimbursements) into one line. The prior periods have been conformed to this new presentation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the Company’s assessment of receivables that result in bad debt expense is now required to be recorded as an adjustment to revenue, rather than a charge to bad debt expense. This new classification applies for the first quarter of 2019 and reclassification of prior period amounts is not permitted. At transition on January 1, 2019, after assessing its reserve balances at December 31, 2018 under the new guidance, the Company wrote off accounts receivable of $0.1 </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and straight-line rents receivable of $0.1 million as an adjustment to the opening balance of accumulated deficit, and accordingly rent for these tenants is currently recorded on a cash basis.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed. Under prior accounting guidance, the recognition would have been deferred. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company was a lessee under leases for 17 properties including capital leases of land and building as of January 1, 2019 and because the Company has elected the practical expedients described above, it determined that 11 of these leases would continue to be classified as operating leases under the new standard. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessee:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon adoption of the new standard, the Company recorded ROU assets and lease liabilities equal to $10.2 million for the present value of the lease payments related to its ground leases. These amounts are included in operating lease right-of-use assets and operating lease liabilities on the Company’s consolidated balance sheet as of December 31, 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company also reclassified $0.5 million related to amounts previously reported as a straight-line rent liability and $4.8 million, net related to amounts previously reported as above and below market ground lease intangibles to the ROU assets. For additional information and disclosures related to these operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_250" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Accounting Pronouncements</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the FASB issued ASU No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to better align cash flow and fair value hedge accounting with the corresponding risk management activities. Among other things, the amendments expand which hedging strategies are eligible for hedge accounting, align the timing of recognition of hedge results with the earnings effect of the hedged item and allow companies to include the change in fair value of the derivative in the same income statement line item as the earnings effect of the hedged item. Additionally, for cash flow hedges that are highly effective, the update allows for all changes in fair value of the derivative to be recorded in other comprehensive income. The Company has adopted ASU 2017-12 on January 1, 2019, as required under the guidance, using a modified retrospective transition method and the adoption did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Adopted as of December 31, 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methods. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period March 12, 2020 through December 31, 2022 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that our hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of our derivatives, which will be consistent with our past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.</span></div> Basis of Accounting     The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Period Adjustments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company identified certain historical errors in its tax provision and its net deferred taxes asset as well as its statements of operations and comprehensive income (loss), consolidated statements of changes in equity, and statements of cash flows since 2014, which impacted the quarterly financial statements and annual periods previously issued. Specifically, the Company had overstated intercompany rent on certain leases with the taxable REIT subsidiary (“TRS”) and reflected a portion of depreciation on REIT assets in the TRS’s tax provision, thereby overstating previously recorded tax benefits, deferred tax assets and net incom</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e by $0.8 million, $0.3 million and $0.2 million for the years ended December 31, 2018, 2017 and for Pre-2017 periods, respectively.  The intercompany rent and allocation of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depreciation only affected the tax provision and did not affect the pre-tax consolidated financial results. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2019.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2020.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impacts of the COVID-19 Pandemic</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The pandemic has had and could continue to have an adverse impact on economic and market conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The Company believes the estimates and assumptions underlying its consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ultimate impact COVID-19 will have on the global economy generally, and the Company’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways. In the Company’s SHOP portfolio, occupancy has trended lower since the second half of March as government policies and implementation of infection control best practices have materially limited or closed communities to new resident move-ins which affects the Company’s ability to fill vacancies. The Company has also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, the Company bears these cost increases. These trends accelerated during the second, third, and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact the Company in the future and have a material adverse effect on the Company’s revenues and income in the other quarters thereafter. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The financial stability and overall health of the Company’s tenants is critical to its business. The negative effects that the global pandemic has had on the economy includes the closure or reduction in activity of some of the Company’s MOBs and other healthcare-related facilities as well as restrictions on activity and access for many of the Company’s seniors housing properties. The economic impact of the pandemic has impacted the ability of some of the Company’s tenants to pay their monthly rent either temporarily or in the long term. The Company experienced delays in rent collections in the second, third and fourth quarters of 2020 although collections have been approximately 100%. The Company has taken a proactive approach </span></div>to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken precautionary steps to increase liquidity and preserve financial flexibility in light of the uncertainty resulting from the COVID-19 pandemic. These steps include borrowing an additional $95.0 million under the Credit Facility (as defined below) in March 2020 to provide more cash on the Company’s balance sheet. A portion of the $95.0 million in borrowings was used for general corporate purposes and for acquisitions. The Company has not borrowed additional amounts subsequently. In August 2020, the Company amended the Credit Facility as part of its efforts to continue addressing the adverse impacts of the COVID-19 pandemic. For additional information on the Credit Facility amendment see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span> Credit Facilities. <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation and Basis of Presentation </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.</span></div> <div style="margin-bottom:5pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.</span></div> 800000 300000 200000 0 300000 1 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.</span></div> 95000000.0 95000000.0 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020, these leases had a weighted average remaining lease term of 6.5 years. Rent from tenants in the Company’s MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted under the REIT Investment and Diversification and Empowerment Act of 2007 and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the rent are short term in nature, primarily month-to-month. Also included in revenue from tenants is fees </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for ancillary revenue from non-residents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $13.3 million, $15.4 million and $8.1 million for the years ended December 31, 2020, 2019, and 2018, respectively. Fees for ancillary services are recorded in the period in which the services are performed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2020 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards (see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Recently Issued Accounting Pronouncements”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below), the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.</span></div>Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, the Company recorded such amounts as bad debt expense as part of property operating expenses. P6Y6M 13300000 15400000 8100000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:78.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future <br/>Base Rent Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,720 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 94144000 87762000 75205000 68210000 58757000 165642000 549720000 2700000 6500000 14800000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Real Estate</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Price Allocation” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section in this Note for a discussion of the initial accounting for investments in real estate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 and 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in this Note under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements - ASU No. 2016-02 Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2019, the Company has no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet as of December 31, 2020 and 2019, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.</span></div> 100000 70800000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmJlYzZmNTFkYWVjYjQxM2FhODMzNTNlZTc3NmJhNjFjL3NlYzpiZWM2ZjUxZGFlY2I0MTNhYTgzMzUzZWU3NzZiYTYxY18xOTAvZnJhZzphMDA3NjZlM2VhNzE0YmQ5OTZhMGEyZDI3YzY1YzkwMS90ZXh0cmVnaW9uOmEwMDc2NmUzZWE3MTRiZDk5NmEwYTJkMjdjNjVjOTAxXzE3Mjkw_c986e26c-bb53-4216-a0af-68263bff1102">six</span> to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.</span></div> P24M <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Dispositions of Real Estate Investments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on sales of rental real estate after January 1, 2018 are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sales of real estate prior to January 1, 2018 are recognized pursuant to the provisions included in ASC 360-20, Real Estate Sales (“ASC 360-20”). The specific timing of a sale was measured against various criteria in and ASC 360-20 related to the terms of the transaction and any continuing involvement in the form of management or financial assistance associated with the properties. If the sales criteria for the full accrual method are not met, depending on the circumstances, the Company may not record a sale or it may record a sale but may defer some or all of the gain recognition. If the criteria for full accrual are not met, the Company may account for the transaction by applying the finance, leasing, profit sharing, deposit, installment or cost recovery methods, as appropriate, until the sales criteria for the full accrual method are met.</span></div> <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it has three reportable segments, with activities related to investing in MOBs, triple-net leased healthcare facilities, and seniors housing properties. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level.</span></div> 3 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Above and Below-Market Lease Amortization</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.</span></div> P40Y P15Y P7Y P10Y <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge.  The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.</span></div>The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss). Non-controlling Interests<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-controlling interests represent the portion of the equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net loss based on their share of equity ownership. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_235" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 13</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Non-Controlling Interests</span> for additional information. Cash and Cash EquivalentsCash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. 0 0 72400000 95700000 57000000.0 73200000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing and Leasing Costs, Net </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fannie Mae Master Credit Facilities (as defined in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Credit Facilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and deferred leasing costs. Deferred financing costs relating to the mortgage notes payable (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Mortgage Notes Payable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) are reflected net of the related financing on our balance sheet.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.</span></div> Equity-Based Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_226" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-Based Compensation</span>). <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2020, 2019 and 2018. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties.  Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS.  Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company, owned 59 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2020 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the Company’s TRS's recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $4.6 million as of December 31, 2020. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. During the year ended December 31, 2020 the Company recorded a tax loss of $3.1 million. As of December 31, 2020, the Company had a deferred tax asset of $4.6 million with a full valuation allowance. As of December 31, 2019, the Company had a deferred tax asset of $3.9 million with no valuation allowance. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.</span></div>The tax years subsequent to and including the fiscal year ended December 31, 2013 remain open to examination by the major taxing jurisdictions to which the Company is subject. 59 25 4600000 14000000 7600000 -3100000 4600000 3900000 0 The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:41.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,641)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,591)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -1.058 0.264 -726000 0 0 155000 272000 -399000 196000 -50000 176000 68000 353000 -29000 4641000 0 0 -530000 4591000 176000 223000 625000 -428000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Per Share Data</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to </span></div>reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of its SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in the Company’s consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, the Company received an additional $5.1 million in funding from CARES Act grants. There can be no assurance that the program will be extended or any further amounts received. 3600000 4 5100000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2018</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the FASB issued ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has since issued several additional amendments thereto (collectively referred to herein as “ASC 606”). ASC 606 establishes a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Under ASC 606, an entity is required to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. A reporting entity may apply the amendments in ASC 606 using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or a full retrospective approach. The Company adopted this guidance effective January 1, 2018 under the modified retrospective approach and it did not have an impact on the Company’s consolidated financial statements. See above for further information on the Company’s Revenue Recognition Accounting Policies under ASC 606.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2016, the FASB issued ASU 2016-01,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The revised guidance amends the recognition and measurement of financial instruments. The new guidance significantly revises an entity’s accounting related to equity investments and the presentation of certain fair value changes for financial liabilities measured at fair value. Among other things, it also amends the presentation and disclosure requirements associated with the fair value of financial instruments. The Company adopted this guidance effective January 1, 2018, using the modified retrospective transition method, and there was no impact to the Company's consolidated financial statements.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2016, the FASB issued ASU 2016-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides guidance on how certain transactions should be classified and presented in the statement of cash flows as either operating, investing or financing activities. Among other things, the update provides specific guidance on where to classify debt prepayment and extinguishment costs, payments for contingent consideration made after a business combination and distributions received from equity method investments. The Company adopted the new guidance on January 1, 2018 and it did not have an impact on its consolidated statement of cash flows.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which revises the definition of a business. This new guidance is applicable when evaluating whether an acquisition should be treated as either a business acquisition or an asset acquisition. Under the revised guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset or group of similar assets, the assets acquired would not be considered a business. The Company adopted this guidance effective January 1, 2018, and will apply the new rules prospectively. The Company expects, based on historical property acquisitions, that in most cases, a future property acquired after adoption will be treated as an asset acquisition rather than a business acquisition, which will result in the capitalization of related transaction costs. The Company has evaluated the impact of this new guidance beginning in the first quarter of 2018, and determined that it did not have a material impact on the Company’s consolidated financial statements. All acquisition costs incurred during the years ended December 31, 2020 and 2019 were capitalized since our acquisitions during the years were all classified as asset acquisitions.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, the FASB issued ASU 2017-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Assets Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides guidance related to partial sales of non-financial assets, eliminates rules specifically addressing the sales of real estate, clarifies the definition of in substance non-financial assets, removes the exception to the financial asset derecognition model and clarifies the accounting for contributions of non-financial assets to joint ventures. The Company adopted this guidance effective January 1, 2018 using the modified transition method and it did not have an impact on its financial statements. The Company expects that any future sales of real estate in which the Company retains a non-controlling interest in the property would result in the full gain amount being recognized at the time of the partial sale. Historically, the Company has not retained any interest in properties it has sold.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the FASB issued ASU 2017-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which provides guidance that clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The update states that modification accounting should be used unless the fair value of the award, the vesting terms of the award, and the classification of the award as either equity or liability, all do not change as a result of the modification. The Company adopted this guidance effective January 1, 2018 using the modified retrospective transition method and it did not have an impact on its consolidated financial statements. The Company expects that any future modifications to the Company’s issued share-based awards will be accounted for using modification accounting, unless the modification meets all of the exception criteria noted above. As a result, the modification would be treated as an exchange of the original award for a new award, with any incremental fair value being treated as additional compensation cost.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2019</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2016-02 - Leases</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) which provides guidance related to the accounting for leases, as well as the related disclosures. For lessors of real estate, leases are accounted for using an approach substantially the same as previous accounting guidance for operating leases and direct financing leases. For lessees, the new standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon adoption, lessors were allowed a practical expedient, which the Company has elected, by class of underlying assets to account for lease and non-lease components (such as tenant reimbursements of property operating expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under this new guidance, which is consistent with the Company’s existing policies. Also, upon adoption, companies were allowed a practical expedient package, which the Company has elected, that allowed the Company: (a) to not reassess whether any expired or existing contracts entered into prior to January 1, 2019 are or contain leases; (b) to not reassess the lease classification for any expired or existing leases entered into prior to January 1, 2019 (including assessing sale-leaseback transactions); and (c) to not reassess initial direct costs for any expired or existing leases entered into prior to January 1, 2019. As a result, all of the Company’s existing leases will continue to be classified as operating leases under the new standard. Further, any existing leases for which the property is the leased to a tenant in a transaction that at inception was a sale-leaseback transaction will continue to be treated (absent a modification) as operating leases. The Company did not have any leases that would be considered financing leases as of January 1, 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the impact of adoption from both a lessor and lessee perspective, which is discussed in more detail below, and adopted the new guidance prospectively on January 1, 2019, using a prospective transition approach under which the Company elected to apply the guidance effective January 1, 2019 and not adjust prior comparative reporting periods (except for the Company’s presentation of lease revenue discussed below).</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessor Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company was not required to re-assess the classification of its leases, which are considered operating leases under ASU 2016-02. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessor:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Since the Company elected the practical expedient noted above to not separate non-lease component revenue from the associated lease component, the Company has aggregated revenue from its lease components and non-lease components (tenant operating expense reimbursements) into one line. The prior periods have been conformed to this new presentation.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the Company’s assessment of receivables that result in bad debt expense is now required to be recorded as an adjustment to revenue, rather than a charge to bad debt expense. This new classification applies for the first quarter of 2019 and reclassification of prior period amounts is not permitted. At transition on January 1, 2019, after assessing its reserve balances at December 31, 2018 under the new guidance, the Company wrote off accounts receivable of $0.1 </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million and straight-line rents receivable of $0.1 million as an adjustment to the opening balance of accumulated deficit, and accordingly rent for these tenants is currently recorded on a cash basis.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed. Under prior accounting guidance, the recognition would have been deferred. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company was a lessee under leases for 17 properties including capital leases of land and building as of January 1, 2019 and because the Company has elected the practical expedients described above, it determined that 11 of these leases would continue to be classified as operating leases under the new standard. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessee:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Upon adoption of the new standard, the Company recorded ROU assets and lease liabilities equal to $10.2 million for the present value of the lease payments related to its ground leases. These amounts are included in operating lease right-of-use assets and operating lease liabilities on the Company’s consolidated balance sheet as of December 31, 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company also reclassified $0.5 million related to amounts previously reported as a straight-line rent liability and $4.8 million, net related to amounts previously reported as above and below market ground lease intangibles to the ROU assets. For additional information and disclosures related to these operating leases, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_250" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Accounting Pronouncements</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the FASB issued ASU No. 2017-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to better align cash flow and fair value hedge accounting with the corresponding risk management activities. Among other things, the amendments expand which hedging strategies are eligible for hedge accounting, align the timing of recognition of hedge results with the earnings effect of the hedged item and allow companies to include the change in fair value of the derivative in the same income statement line item as the earnings effect of the hedged item. Additionally, for cash flow hedges that are highly effective, the update allows for all changes in fair value of the derivative to be recorded in other comprehensive income. The Company has adopted ASU 2017-12 on January 1, 2019, as required under the guidance, using a modified retrospective transition method and the adoption did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adopted as of January 1, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not yet Adopted as of December 31, 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">methods. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period March 12, 2020 through December 31, 2022 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that our hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of our derivatives, which will be consistent with our past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.</span></div> 100000 100000 17 11 10200000 10200000 500000 4800000 Real Estate Investments, Net <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property Acquisitions and Development Costs</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in MOBs, seniors housing properties and other healthcare-related facilities primarily to expand and diversify its portfolio and revenue base. The Company owned 193 properties as of December 31, 2020. During the year ended December 31, 2020, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of two multi-tenant MOBs, three single tenant MOBs and four SHOPs for an aggregate contract purchase price of $110.7 million, which includes other assets acquired as part of the acquisitions of $1.8 million and capitalized transaction costs. All acquisitions in 2020, 2019 and 2018 were considered asset acquisitions for accounting purposes. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the allocation of the assets acquired and liabilities assumed, as well as capitalized construction in progress during the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,883)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,998 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">_______________</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 8.1 years and 7.0 years, respectively, as of December 31, 2019. There were no below market leases acquired in the year ended December 31, 2019. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Development Project</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, the Company entered into an asset purchase agreement and development agreement to acquire land and construction in progress, and subsequently fund the remaining construction, of a development property in Jupiter, Florida for $82.0 million. As of December 31, 2019, the Company had funded $97.8 million, including $10.0 million for the land and $87.8 million for construction in progress.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had been working for some time to obtain a certificate of occupancy for the facility (“CO”), which was ultimately obtained in December 2019. Historically, all construction costs, including capitalized interest, insurance and real </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estate taxes were capitalized and classified in construction is progress on the Company’s consolidated balance sheet. In December 2019, when the development reached substantial completion and the Company reclassified the entire amount in construction in progress to its appropriate real estate investment components. During the years ended December 31, 2019, and 2018 the Company incurred an additional $5.7 million and $8.6 million in capitalized costs, including capitalized interest, related to this development project. No development costs were capitalized during the year ended December 31, 2020 as the property was considered substantially complete.    </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining the CO was a necessary condition to leasing the property to any tenant other than a tenant associated with the developer of the property, which had been, and remains in, default under its agreements with the Company. The Company entered into a lease for 10% of the rentable square feet at the property (a portion of the non-assisted living component of the property) , but the tenant was not required to pay the Company cash rent until May 2021. As of December 31, 2020 the Company had not yet begun operating the assisted living component of the property. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2019, in connection with the substantial completion of the development property, the Company began to evaluate it for a potential sale. As a result of this potential change in plans, the Company concluded this held for use asset was impaired and recognized an impairment charge to its respective operating real estate components in 2019 (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Assets Held For Use and Related Impairments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this note for additional information). Further, as a result of COVID-19 and it impact on the ability to show the property to potential new tenants/residents, the launch of operations of the assisted living component of the property has been delayed. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2020, the Company entered into definitive purchase and sale agreements (“PSA”) to sell the Company's recently completed development property in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. The buyer paid the Company $2.9 million in non-refundable deposits, In November 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida resulting in a gain on sale of real estate investments of $3.8 million, recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. See “Dispositions” below for more information. The sales of the properties in Wellington, Florida and Jupiter, Florida are expected to close later in 2021, but these dispositions are subject to conditions and there can be no assurance that they will be completed on their contemplated terms, or at all. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant Tenants</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, 2019 and 2018, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">During the fourth quarter of 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida. In addition, in August 2020 the Company entered into an agreement to sell our skilled nursing facility in Wellington, Florida, and our development property in Jupiter, Florida. </span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">During the year ended December 31, 2020, the Company sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020 and four of which remained classified as held for sale on the Company’s consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer in the first quarter of 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intangible Assets and Liabilities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets and liabilities consisted of the following as of the periods presented:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,725 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,052 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:58.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above-and below-market leases, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above-and below-market ground leases, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within revenue from tenants.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within property operating and maintenance expense. Upon adoption of ASC 842 effective January 1, 2019, intangible balances related to ground leases were reclassified to be included as part of the Operating lease right-of-use assets presented on the consolidated balance sheet with no change to placement of the amortization expense of such balances. Refer to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization and adjustments to revenue from tenants for the next five years: </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dispositions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the properties sold during the years ended December 31, 2020, 2019, and 2018: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disposition Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Sale Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) <br/>on Sale, of Real Estate Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2020 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lutz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (11 properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Girardeau</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 19, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2019 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York Six MOBs (1 property)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 22, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ocean Park</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York Six MOBs (5 properties)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 6, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2018 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Missouri SNF Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 5, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> These properties were previously impaired. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> “Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section below. Represents contract sales price for all 11 properties. Loss on sale relates to the seven properties that were transferred to the buyer in the fourth quarter of 2020 (see below for additional information). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Dispositions</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida for a contract purchase price of $20.0 million, resulting in a gain on sale of real estate investments of $3.8 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At closing, $17.6 million of net proceeds were used to repay amounts outstanding under the Revolving Credit Facility.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2020 the initial closing under the PSA pursuant to which the Company had agreed to sell 11 Michigan SHOPs occurred. The contract purchase price for the 11 Michigan SHOPs was $11.8 million, resulting in a loss on sale of $0.9 million on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At the initial closing, the Company received payment of the full $11.8 million sales price for all 11 of the Michigan SHOPs, less $0.8 million held in escrow, and transferred seven of the properties to the buyer. The remaining four properties were transferred to the buyer a second closing separate closings in the first quarter of 2021 when the $0.8 million held in escrow was released to the buyer. Of the properties transferred at the initial closing, four had been part of the borrowing base under the Credit Facility, one was part of the collateral pool under the Fannie Mae Master Credit Facility with Capital One and two were unencumbered. Of the properties transferred at the second closing, three were part of the borrowing base under the Credit Facility until the initial </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">closing and one was unencumbered. At the initial closing, $4.2 million of the net proceeds was used to repay amounts outstanding under the Fannie Mae Master Credit Facility with Capital One, $4.4 million of the net proceeds were used to repay amounts outstanding under the Revolving Credit Facility, with the remainder used for closing costs. For the avoidance of any doubt, all impairments related to the disposal of the 11 Michigan SHOP assets were recognized in the year ended December 31, 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2020 the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disposed of one MOB property for a contract purchase price of $8.6 million, resulting in a gain on sale of $2.306 million.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Dispositions</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> February 6, 2019, the Company sold five of the MOB properties within the State of New York (the “New York Six MOBs”) for a contract sales price of $45.0 million, resulting in a gain on sale of real estate investments of $6.1 million which is included on the Consolidated Statement of Operations for the year ended December 31, 2019. The Company had reconsidered the intended holding period for all six of the New York Six MOBs due to various market conditions and the potential to reinvest in properties generating a higher yield. On July 26, 2018, the Company had originally entered into a PSA for the sale of the New York Six MOBs, for an aggregate contract sale price of approximately $68.0 million and subsequently, on September 25, 2018, the Company further amended the PSA to decrease the aggregate contract sale price to $58.8 million. The one remaining New York Six MOB was sold for a contract sales price of $13.6 million on August 22, 2019, resulting in a gain on sale of real estate investments of $2.9 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2019, the Company reconsidered the intended holding period for one of its SHOPs located in Brookings, OR (“Ocean Park”) due to various market conditions and the potential to reinvest in properties generating a higher yield. On March 21, 2019, the Company entered into a PSA for the sale of Ocean Park, for an aggregate contract sale price of approximately $3.6 million. On April 1, 2019, the Company amended the purchase and sale agreement to decrease the aggregate contract sale price to $3.5 million. In connection with this amendment, the Company recognized an impairment charge of approximately $19,000 on Ocean Park during the second quarter of 2019, which is included on the consolidated statement of operations and comprehensive loss. On August 1, 2019, the Company closed its disposition of Ocean Park resulting in a loss on sale of real estate investments of $0.2 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Dispositions</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2018, the Company entered into the final amendment to its January 2017 agreement (as amended to date, the “Amended Missouri SNF PSA”) to sell eight skilled nursing facility properties in Missouri (the “Missouri SNF Properties”) that were previously classified as held-for-sale, for an aggregate contract purchase price of $27.5 million. In connection with the Amended Missouri SNF PSA, the Company recognized an impairment charge of approximately $11.9 million on the Missouri SNF Properties in the third quarter of 2018 which is included on the consolidated statement of operations and comprehensive loss. The sale of these properties pursuant to the Amended Missouri SNF PSA, which occurred in the fourth quarter of 2018, resulted in a loss of $0.1 million for the year ended December 31, 2018, which is reflected within (loss) gain on sale of real estate investment in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairments</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of impairments taken during the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:243.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for use</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on impairments related to assets held for sale and assets held for use, see the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Assets Held for Sale and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sections below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale and Related Impairments </span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Details - Assets Held for Sale</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the major classes of assets associated with the properties that have been classified as held for sale as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,839 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Assets held for sale as of December 31, 2020 relates to four Michigan SHOPs. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Assets held for sale as of December 31, 2019 relates to the original 14 Michigan SHOPs under the PSA entered into in January 2020 (see below for additional information). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a PSA for the sale of a portfolio of 14 SHOPs located in Michigan (the “Michigan SHOPs”) as a single portfolio for $71.8 million. Accordingly, all 14 of these SHOPs were classified as held for sale as of December 31, 2019. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April, 2020, the PSA was amended so that only 11 of the Michigan SHOPs were to be sold pursuant to this PSA for $11.8 million. As a result of the amended PSA from April 2020, the three remaining Michigan SHOPs at that time no longer qualified as held for sale and were reclassified to assets held for use at their original carrying values as of March 31, 2020 and an additional $0.7 million in catch-up depreciation was recorded in the third quarter of 2020. In addition, the original deposit made by the buyer was reduced from $1.0 million to $0.3 million. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the PSA was amended to provide that the full $11.8 million sales price for all 11 Michigan SHOPs would be paid at an initial closing which occurred in November 2020, when seven of the properties were transferred to the buyer with the remaining four properties scheduled to be transferred to the buyer at a second closing, which occurred in the first quarter of 2021 (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_259" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Note 18</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">). This amendment to the PSA also provided that $0.8 million of the sales price would be held in escrow and returned to the buyer at the second closing; provided that, if the PSA is terminated before the second closing closings due to a material default by the buyer, the Company will receive the escrowed amount. This amount was returned to the buyer at final closing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, it represented an effective reduction in the sale price and the Company reflected an additional impairment loss to reflect this. The Company determined that the four Michigan SHOPs should be classified as held for sale as of December 31, 2020. As of December 31, 2020, for the four Michigan SHOPs that are classified as held for sale, three Michigan SHOPs were part of the borrowing base of the Credit Facility and one was unencumbered. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale Impairments - 2020</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the amendment to the PSA in April 2020, in which the number of properties under sale was reduced from 14 to 11, and in which the total consideration was reduced from $71.8 million to $11.8 million, the Company recorded an additional impairment charge of $19.6 million for the year ended December 31, 2020 related to the Michigan SHOP assets held for sale. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale Impairments - 2019</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019 the Company recorded an impairment charge of $22.6 million related to assets held for sale, representing the amount by which the carrying amount of the Michigan SHOPs exceeded the Company’s estimate, at that time, of the net sales price of the Michigan SHOPs. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale Impairments - 2018</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2018, the Company recorded impairment charges of $18.3 million related to assets held for sale for the eight Missouri SNF Properties which were sold in 2018 and one of the New York Six MOBs which was sold in 2019.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Use and Related Impairments </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns held for use properties for which the Company may from time to time reconsider the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company was actively considering plans to sell three assets in Florida including the recently completed development project in Jupiter, Florida and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida. The Company began marketing the properties in 2020 and, during the three months ended June 30, 2020, the Company received multiple bids and accepted a non-binding letter of intent from a prospective buyer to purchase the completed development project in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. During August 2020, the Company entered into PSAs with the buyer on the terms generally set forth in the letter of intent. The property in Lutz, Florida was sold in December 2020 (see “Dispositions” above) and the property in Jupiter, Florida and the property in Wellington, Florida are expected to be sold later in 2021 however, there can be no assurance that such transactions will actually close. If closed, the Company is required to use the proceeds of the sales to repay amounts outstanding under its Revolving Credit Facility.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Use Impairments — 2020</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, as a result of the Company’s marketing efforts during the COVID-19 pandemic which concluded with a PSA in August 2020, the Company recorded an additional impairment charge of $16.9 million on its completed development project in Jupiter, Florida and its skilled nursing facility in Wellington, Florida. The impairment charge represents the amount by which the carrying amount of the properties exceeded the Company’s estimate of the net sales price set forth in the PSA described above. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Use Impairments — 2019</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company began to evaluate the properties in Lutz, Florida, Wellington, Florida and its completed development property in Jupiter, Florida for potential sales. As a result of these potential changes in plans, the Company concluded these held for use assets were impaired and recognized impairment charges in the aggregate of $33.3 million to reduce their carrying value to estimated fair value. The Company obtained third-party appraisals of all three properties (Lutz, Wellington, and Jupiter) which estimated fair value primarily applying an income approach using stabilized cash flows and capitalization rates of 9.0%, 9.0% and 7.0%, respectively. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Use Impairments — 2018</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the year ended December 31, 2018, as a result of its consideration of impairment, the Company determined that the carrying value of one held for use property exceeded its estimated fair value and recognized an aggregate impairment charge of $2.4 million. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The LaSalle Tenant</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. In January 2018, the Company entered into an agreement with the prior tenants at the LaSalle Properties (collectively, the “LaSalle Tenant”) in which the Company agreed to forbear from exercising legal remedies, including staying a lawsuit against the LaSalle Tenant, as long as the LaSalle Tenant paid the amounts due for rent and property taxes on an updated payment schedule pursuant to a forbearance agreement. As of December 31, 2020, the LaSalle Tenant remains in default of the forbearance agreement and owes the </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company $12.7 million of rent, property taxes, late fees, and interest receivable thereunder and $7.7 million plus interest of unpaid monetary damages awarded to us by the court on our claims against the tenant. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the entire receivable balance, including any monetary damages, and related income from the LaSalle Tenant fully reserved as of December 31, 2020. The Company incurred $0.4 million, $3.5 million and $5.0 million of bad debt expense, including straight-line rent write-offs, related to the LaSalle Tenant during the years ended December 31, 2020, 2019 and 2018, respectively, which is included in revenue from tenants on the consolidated statement of operations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2019, the Company filed an amended petition in Texas state court seeking the appointment of a receiver to manage the operations at these properties and for recovery of damages for the various breaches by the LaSalle Tenant. Subsequently, the LaSalle Group Inc., a guarantor of certain of the LaSalle Tenant’s lease obligations (the “LaSalle Guarantor”), filed for voluntarily relief under chapter 11 of the United States Bankruptcy Code. The Company severed its claims against the LaSalle Guarantor from the action against the LaSalle Tenant. On August 27, 2019, the court awarded the Company monetary damages on its claims against the LaSalle Tenant in an amount equal to $7.7 million plus interest. There can be no assurance the Company will receive any amounts with respect to these claims against the LaSalle Tenant.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2019, the court entered into an order appointing a receiver. This receiver was empowered to replace the LaSalle Tenant with a new tenant and operator at the properties, and, on February 15, 2020, the receiver took operational control of the properties. As noted above, the Company worked with the receiver and the Company’s designated third-party operator to transition the LaSalle Properties to its SHOP operating segment on July 1, 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The NuVista Tenant</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had tenants at two of its Florida properties located in Lutz and Wellington Florida (collectively, the “NuVista Tenant”) that were in default under their leases beginning from July 2017. On January 1, 2018 the property was transitioned to the SHOP segment when the Company replaced the NuVista Tenant as tenant at the Lutz, Florida property with a TRS and engaged a third-party operator to operate the property. As a result, the property was transitioned to the SHOP segment as of January 1, 2018. The Company incurred bad debt expense of $1.1 million and $6.0 million related to the NuVista Tenant during the years ended December 31, 2019 and 2018, respectively which is included in revenue from tenants in the consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the property located in Wellington, Florida, the Company and the tenant entered into an operations transfer agreement (the “OTA”) pursuant to which the Company and the tenant agreed to cooperate in transitioning operations at the property to a third party operator selected by the Company. On February 19, 2019, in response to litigation commenced by the Company against the NuVista Tenant to enforce the OTA, the United States District Court for the Southern District of Florida entered into an agreed order (the “Order”) pursuant to which it found that the NuVista Tenant was in default under the lease for the property and that the OTA was valid, binding and in full force and effect, as modified by the Order. Subsequent to the entry into the Order, the Company, its designated third-party operator and the NuVista Tenant transitioned operations at the property to the Company’s designated third-party operator. The Company’s designated third-party operator received its license to operate the facility on April 1, 2019 and is in operational control of the property. On May 20, 2019, the court entered into a final order from the court terminating the existing lease with the NuVista Tenant. Following entry into the order, the property in Wellington, Florida transitioned to the SHOP segment as of April 1, 2019. In connection with this transition, the Company replaced the NuVista Tenant as a tenant with a TRS, and engaged a third-party operator to operate the property. During the year ended December 31, 2019 the company received $1.6 million under the OTA for periods prior to the lease termination, which amounts had previously been fully reserved. This payment under the OTA is included in revenue from tenants in consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a PSA to sell the properties located in Lutz, Florida and Wellington Florida. The Company sold the property in Lutz, Florida in December 2020 (see “Dispositions” section above). The sale of the property in Jupiter, Florida and the sale of the property in Wellington, Florida are expected to be completed later in 2021.</span></div> 193 2 3 4 110700000 1800000 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the allocation of the assets acquired and liabilities assumed, as well as capitalized construction in progress during the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate investments, at cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,665 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,699 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,903 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,236 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,591 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,980 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,244 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,777 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,823 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease and other intangible assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets and liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,503 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,018 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,812 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,883)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for real estate investments, including acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,998 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,056 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of properties purchased</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">_______________</span></div>(1) Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 8.1 years and 7.0 years, respectively, as of December 31, 2019. There were no below market leases acquired in the year ended December 31, 2019. 7665000 6356000 14417000 90699000 68903000 98236000 0 5721000 8591000 98364000 80980000 121244000 10369000 11777000 6823000 496000 724000 275000 362000 1483000 286000 10503000 11018000 6812000 13883000 0 0 94984000 91998000 128056000 9 9 14 P1Y8M12D P7Y8M12D P7Y4M24D P8Y1M6D P7Y 0 82000000.0 97800000 10000000.0 87800000 5700000 8600000 65000000.0 2 2 20000000.0 33000000.0 2900000 3800000 The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:<div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">During the fourth quarter of 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida. In addition, in August 2020 the Company entered into an agreement to sell our skilled nursing facility in Wellington, Florida, and our development property in Jupiter, Florida. </span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:11.94pt">During the year ended December 31, 2020, the Company sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020 and four of which remained classified as held for sale on the Company’s consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer in the first quarter of 2021.</span></div> 0.206 0.252 0.166 0.101 0.109 0.131 0.104 0.102 11 7 4 4 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired intangible assets and liabilities consisted of the following as of the periods presented:</span></div><div style="margin-bottom:10pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,648 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,845 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,015 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,664 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,543 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market lease liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,109 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,725 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,052 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 241097000 172648000 68449000 229300000 156428000 72872000 14116000 10845000 3271000 13616000 9501000 4115000 20802000 1171000 19631000 26700000 1144000 25556000 276015000 184664000 91351000 269616000 167073000 102543000 22109000 11306000 10803000 21777000 9725000 12052000 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:58.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of in-place leases and other intangible assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,851 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of above-and below-market leases, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of above-and below-market ground leases, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within depreciation and amortization expense.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within revenue from tenants.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Reflected within property operating and maintenance expense. Upon adoption of ASC 842 effective January 1, 2019, intangible balances related to ground leases were reclassified to be included as part of the Operating lease right-of-use assets presented on the consolidated balance sheet with no change to placement of the amortization expense of such balances. Refer to </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_190" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div> 15121000 15559000 18851000 -257000 -247000 -39000 178000 86000 147000 <div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the projected amortization and adjustments to revenue from tenants for the next five years: </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-place lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,070 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Above-market lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(993)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below-market lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total to be added to revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10904000 8704000 6830000 6070000 4896000 613000 613000 613000 613000 588000 11517000 9317000 7443000 6683000 5484000 -1299000 -993000 -645000 -307000 -260000 1388000 1326000 1213000 1062000 955000 89000 333000 568000 755000 695000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the properties sold during the years ended December 31, 2020, 2019, and 2018: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:39.749%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Disposition Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contract Sale Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) <br/>on Sale, of Real Estate Investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2020 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lutz</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan SHOPs (11 properties) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cape Girardeau</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 19, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,350 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2019 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York Six MOBs (1 property)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 22, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ocean Park</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York Six MOBs (5 properties)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 6, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">2018 Dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Missouri SNF Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 5, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,500 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> These properties were previously impaired. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> “Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section below. Represents contract sales price for all 11 properties. Loss on sale relates to the seven properties that were transferred to the buyer in the fourth quarter of 2020 (see below for additional information). </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of impairments taken during the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:510.00pt"><tr><td style="width:1.0pt"/><td style="width:243.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:82.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:84.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for use</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,446 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20000000 3832000 11 11750000 -908000 8600000 2306000 40350000 5230000 1 13600000 2883000 3600000 -152000 5 45000000 6059000 62200000 8790000 27500000 -70000 11 7 20000000.0 3800000 17600000 11 11 11800000 -900000 11800000 11 800000 7 4 800000 4 1 2 3 1 4200000 4400000 11 1 8600000 2306000 5 45000000.0 6100000 68000000.0 58800000 1 13600000 2900000 1 3600000 3500000 19000 200000 8 27500000 11900000 -100000 19570000 22634000 18255000 16876000 33335000 2400000 36446000 55969000 20655000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the major classes of assets associated with the properties that have been classified as held for sale as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   Buildings, fixtures and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,839 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Assets held for sale as of December 31, 2020 relates to four Michigan SHOPs. </span></div>(2) Assets held for sale as of December 31, 2019 relates to the original 14 Michigan SHOPs under the PSA entered into in January 2020 (see below for additional information). 145000 4051000 -55000 66788000 90000 70839000 4 14 14 71800000 14 11 11800000 3 700000 1000000.0 300000 11800000 11 7 4 800000 4 4 3 1 14 11 71800000 11800000 19600000 22600000 18300000 8 1 3 2 65000000.0 2 20000000.0 33000000.0 16900000 33300000 0.090 0.090 0.070 1 2400000 4 12700000 7700000 400000 3500000 5000000.0 7700000 2 1100000 6000000.0 1600000 Mortgage Notes Payable, Net<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:26.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.661%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> as of December 31, </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun. 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528,284 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Does not include real estate assets mortgaged to secure advances under the Fannie Mae Master Credit Facilities or eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details).</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2020 and December 31, 2019. For the LIBOR based loans, LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Variable rate loan, based on 30-day LIBOR, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. In connection with the amendment to this loan in December 2019 (see additional details below), the Company terminated the previous interest rate swap agreements and entered into new interest rate swap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details). </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    The Company assumed this fixed rate mortgage when it acquired a property during the year ended December 31, 2020.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had pledged $860.0 million in real estate investments, at cost, as collateral for its $550.4 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2020, the Company was in compliance with these financial covenants.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details - Future Principal Payment and LIBOR Transition for schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the expected cessation of LIBOR publication.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital One MOB Loan</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2017, Capital One, National Association (“Capital One”), as administrative agent and lender, and certain other lenders (collectively, the “MOB Lenders”), made a loan in the aggregate amount of $250.0 million (the “MOB Loan”) to certain subsidiaries of the OP. On December 20, 2019, the Company, through certain subsidiaries of the OP, entered into an amendment and restatement of the MOB Loan originally dated as of June 30, 2017 among the OP’s subsidiaries and Capital One, as administrative agent and lender, and certain other lenders. As a result, the principal amount outstanding increased from approximately $242.0 million to $378.5 million the number of properties mortgaged as collateral for the loan increased from 31 properties (all medical office buildings) to 41 properties (29 medical office buildings that continued to serve as collateral for the loan as well as an additional ten medical office buildings and two triple net leased hospitals).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the amendment and restatement of the MOB Loan, after payment of closing costs and swap termination fees, the Company received $127.7 million in net refinancing proceeds in excess of the approximately $242.0 million principal amount outstanding prior to the closing. Of these excess proceeds, approximately $63.5 million were used to repay amounts outstanding under the Revolving Credit Facility (as defined below) in order to obtain a release of 12 of the mortgaged properties from the borrowing base thereunder, and approximately $61.5 million of the remaining proceeds were used to repay additional amounts outstanding under the Revolving Credit Facility. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the amendment and restatement of the MOB Loan, the MOB Loan bore interest at a variable rate equal to LIBOR plus 2.5% per annum. Subsequent to the amendment and restatement of the MOB Loan, the MOB Loan bears interest at a variable rate equal to LIBOR plus 2.0% per annum. The MOB Loan requires the Company to pay interest on a monthly basis with the principal balance due on the maturity date which was extended from June 30, 2022 to December 20, 2026 after the amendment and restatement of the MOB Loan. In connection with the amendment and restatement of the MOB Loan, the OP terminated two interest rate swaps and executed one interest rate swap on the new amount of the MOB Loan, fixing the interest rate exposure at 3.66%. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the Company’s outstanding derivatives. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may pre-pay the MOB Loan, in whole or in part, at any time, with payment of a prepayment premium equal to (a) 3.0% for prepayments made prior to December 31, 2020, (b) 2.0% for prepayments made between January 1, 2021 and December 31, 2021, and (c) 1.0% for prepayments made between January 1, 2022 and December 31, 2022. Thereafter, no prepayment premium is required.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, mortgaged properties may be released or replaced subject to certain conditions and limitations, including prepayment of not more than 110% of the principal amount allocated to the property together with any applicable prepayment premium and maintenance, giving effect to the release or replacement, of a minimum of either 25 mortgaged properties or $283.9 million principal amount outstanding, a minimum debt yield and a minimum debt service coverage ratio.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the amendment to the MOB Loan, the OP entered into an amended and restated guaranty of recourse obligations (the “Guaranty”) and an amended and restated hazardous materials indemnity agreement (the “Environmental Indemnity”) for the benefit of Capital One as administrative agent for the lenders on substantially identical terms to the guaranty and environmental indemnity entered into in connection with the original loan agreement entered into in June 2017. Pursuant to the Guaranty, the OP has guaranteed, among other things, specified losses arising from certain actions of any of the OP’s subsidiaries, including fraud, willful misrepresentation, certain intentional acts, misapplication of funds, physical waste, and failure to pay taxes. The Guaranty requires the Company to maintain a certain minimum of shareholders’ equity on its balance sheet. Pursuant to the Environmental Indemnity, the OP and the Company’s subsidiaries that directly own or lease the mortgaged properties have indemnified the MOB Lenders against losses, costs or liabilities related to certain environmental matters.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendment and restatement of the MOB Loan was considered an extinguishment of the old loan and a new loan agreement. Accordingly, fees and expense for the new loan have been capitalized and the unamortized fees relating to the old loan of approximately $3.0 million were written off as a charge to interest expense in the statement of operations for the year ended December 31, 2019. </span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multi-Property CMBS Loan</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2018, the Company, entered into a $118.7 million loan agreement (the “Multi-Property CMBS Loan”) with KeyBank National Association (“KeyBank”).</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Multi-Property CMBS Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The Multi-Property CMBS Loan permits KeyBank to securitize the entire Multi-Property CMBS Loan or any portion thereof.</span></div>At the closing of the Multi-Property CMBS Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $80.0 million of indebtedness under the Revolving Credit Facility, under which 14 of the properties were included as part of the borrowing base prior to the Multi-Property CMBS Loan, (ii) fund approximately $3.8 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $33.0 million net proceeds available to the Company to be used for general corporate purposes, including future acquisitions. <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the Company’s mortgage notes payable as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:26.077%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.909%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.509%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.503%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.661%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbered Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Outstanding Loan Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Effective Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> as of December 31, </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun. 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2047</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One MOB Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.71%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multi-Property CMBS Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.60%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shiloh - Illinois </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fixed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross mortgage notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550,361 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537,533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs, net of accumulated amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage premiums and discounts, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,472)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">542,698 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528,284 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Does not include real estate assets mortgaged to secure advances under the Fannie Mae Master Credit Facilities or eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details).</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2020 and December 31, 2019. For the LIBOR based loans, LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Variable rate loan, based on 30-day LIBOR, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. In connection with the amendment to this loan in December 2019 (see additional details below), the Company terminated the previous interest rate swap agreements and entered into new interest rate swap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for additional details). </span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    The Company assumed this fixed rate mortgage when it acquired a property during the year ended December 31, 2020.</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">    Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.</span></div> 1 2998000 3112000 0.0415 0.0415 1 2786000 2884000 0.0475 0.0475 1 7133000 7283000 0.0398 0.0398 1 16390000 16695000 0.0398 0.0398 1 10170000 10359000 0.0398 0.0398 41 378500000 378500000 0.0371 0.0371 21 118700000 118700000 0.0460 0.0460 1 13684000 0 0.0434 0 68 550361000 537533000 0.0394 0.0390 6191000 7718000 1472000 1531000 542698000 528284000 860000000.0 550400000 250000000.0 242000000.0 378500000 31 41 29 10 2 127700000 242000000.0 63500000 12 61500000 0.025 0.020 2 1 0.0366 0.030 0.020 0.010 1.10 25 283900000 3000000.0 118700000 80000000.0 14 3800000 33000000.0 — Credit Facilities, Net <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following credit facilities outstanding as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate as of December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(9)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan, net </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,702 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facility </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">359,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">674,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of December 31, 2020.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2020 with a carrying value of $344.0 million.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2020 with carrying value of $253.6 million.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2020 and 2019, respectively. For the LIBOR based loans that have not been fixed, the LIBOR rate in effect at the balance sheet date was utilized. For LIBOR based loans that have been fixed, the effective rate after consideration of the interest rate swap was utilized. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on LIBOR, all of which was fixed as a result of entering into “pay-fixed” interest rate swap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan which is capped as a result of entering into interest rate cap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan with $50 million of principal amount fixed at a rate of 4.09% by an interest rate swap agreement.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The company has the option to extend maturity one year to March 2024 subject to certain conditions. </span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.34pt">Effective interest rate below for variable rate debt gives effect to any “Pay-fixed” swap entered into by the Company. If not hedged, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2020. Interest rate caps are not considered unless the cap is currently in effect.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unencumbered real estate investments, at cost as of December 31, 2020 was $231.5 million, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of our Credit Facility. Pursuant to the August 10, 2020 amendment to the Credit Facility, any acquired properties must be pledged to the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be repaid to the Credit Facility. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2019, the Company entered into an amended and restated senior secured credit facility (the “Credit Facility”), which consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). In both March and August 2020, the Credit Facility was further amended, and the terms of the Credit Facility giving effect to those amendments are generally described below.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $630.0 million, including $480.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount available for future borrowings under the Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, $150.0 million was outstanding under the Term Loan, and $173.7 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $48.3 million.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Pursuant to the amendment in August 2020, certain other restrictions and conditions described below will no longer apply starting in a quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% (the “Commencement Quarter”). The Commencement Quarter may be no earlier than the fiscal quarter ending June 30, 2021.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from August 10, 2020 until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. The Company may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.85% to 2.60%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.60% to 1.35%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2020 the Company had elected to use the LIBOR option for all of our borrowings under the Credit Facility.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.80% to 2.55%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.55% to 1.30%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%; </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the amendment to the Credit Facility in August 2020, the “floor” on LIBOR was increased from 0.00% to 0.25%.     </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Revolving Credit Facility and the Term Loan had an effective interest rate per annum equal to 3.21% and 4.95%, respectively. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”) or any other preferred stock the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below. The Company may pay cash distributions beginning in the Commencement Quarter and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility prohibits the Company from exceeding a maximum ratio of consolidated total indebtedness to consolidated total asset value, and requires the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges and a minimum consolidated tangible net worth. The maximum ratio of consolidated total indebtedness to consolidated total asset value is 67.5% for the period from July 1, 2020 through June 30, 2021 and 65% thereafter unless and until the Commencement Quarter, following which it will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges is 1.50 to 1.00 for the period from July 1, 2020 through March 31, 2021, 1.55 to 1.00 for the period from April 1, 2021 through June 30, 2021, and 1.60 to 1.00 thereafter. The minimum consolidated tangible net worth is the sum of (i) approximately $1.2 million, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company was in compliance with the financial covenants under the Credit Facility. Based upon the Company’s current expectations, the Company believes its operating results during the next 12 months will allow it to comply with these covenants.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fannie Mae Master Credit Facilities</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Credit Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 31, 2016, in conjunction with the execution of the Fannie Mae Master Credit Facilities, the OP entered into two interest rate cap agreements with an unrelated third party, which caps LIBOR interest paid (not giving effect to the applicable margin) on amounts outstanding under the Fannie Mae Master Credit Facilities at a maximum of 3.5%. On October 2019, the Company replaced two maturing interest rate cap agreements, effective November 1, 2019 for a total notional amount of $88.7 million. The two interest rate caps agreements extend three existing interest rate caps set to mature on the same date and are not designated as hedges (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional disclosure regarding the Company’s derivatives).</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may request future advances under the Fannie Mae Master Credit Facilities by borrowing against the value of the initial mortgaged properties, or by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Principal Payments </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2020 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities): </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229,210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LIBOR Transition</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. In some instances, transitioning to an alternative rate may require negotiation with lenders and other counterparties and could present challenges. To transition from LIBOR under the Credit Facility, the Company will either utilize the Base Rate (as defined in the Credit Facility) or an alternative benchmark established by the agent in accordance with the terms of the Credit Facility, which will be determined with due consideration to the then current market practices for determining and implementing a rate of interest for newly originated floating rate commercial real estate loans in the United States and loans converted from a LIBOR based rate to a replacement index-based rate.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has mortgages, credit facilities and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rates for LIBOR with the lenders and derivative counterparties.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following credit facilities outstanding as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding Facility Amount as of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Interest Rate as of December 31,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Encumbered Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Facility:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,618 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(9)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mar. 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred financing costs </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term Loan, net </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,702 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,329 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facility </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245,947 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fannie Mae Master Credit Facilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital One Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KeyBank Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nov. 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">355,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">359,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">674,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605,269</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.29</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Encumbered properties are as of December 31, 2020.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2020 with a carrying value of $344.0 million.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2020 with carrying value of $253.6 million.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2020 and 2019, respectively. For the LIBOR based loans that have not been fixed, the LIBOR rate in effect at the balance sheet date was utilized. For LIBOR based loans that have been fixed, the effective rate after consideration of the interest rate swap was utilized. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan, based on LIBOR, all of which was fixed as a result of entering into “pay-fixed” interest rate swap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan which is capped as a result of entering into interest rate cap agreements (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Variable rate loan with $50 million of principal amount fixed at a rate of 4.09% by an interest rate swap agreement.</span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The company has the option to extend maturity one year to March 2024 subject to certain conditions. </span></div><div style="margin-bottom:0.5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.34pt">Effective interest rate below for variable rate debt gives effect to any “Pay-fixed” swap entered into by the Company. If not hedged, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2020. Interest rate caps are not considered unless the cap is currently in effect.</span></div> 173674000 100618000 0.0321 0.0408 150000000 150000000 0.0495 0.0405 4298000 4671000 145702000 145329000 89 319376000 245947000 11 212467000 216614000 0.0260 0.0417 10 142708000 142708000 0.0265 0.0422 21 355175000 359322000 110 674551000 605269000 0.0329 0.0414 11 344000000.0 10 253600000 50000000 0.0409 2600000000 900000000 600000000 900000000 231500000 P1Y 630000000.0 480000000.0 370000000.0 1000000000.0 150000000.0 173700000 48300000 50000000.0 100000000.0 0.625 0.0185 0.0260 0.0060 0.0135 0.0160 0.0235 0.0035 0.0110 0.0180 0.0255 0.0055 0.0130 0.0155 0.0230 0.0030 0.0105 0.0000 0.0025 0.0321 0.0495 0.07375 0.01 0.95 50000000.0 30000000.0 0.550 0.675 0.65 0.625 1.50 1.00 1.55 1.00 1.60 1.00 1200000 0.75 2 0.035 2 88700000 2 4200000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2020 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities): </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Principal<br/>Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mortgage Notes Payable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Facilities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,820 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,062 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,361 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678,849 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,229,210 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1191000 130000 1321000 1242000 2820000 4062000 6383000 4497000 10880000 1095000 178171000 179266000 1142000 154497000 155639000 539308000 338734000 878042000 550361000 678849000 1229210000 — Fair Value of Financial Instruments GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring financial instruments at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below: <div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:63pt;text-align:justify;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2020 and 2019, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020 and 2019, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Investments Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments — Held for Use</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2020 and 2019. As of December 31, 2020, the Company owned held for use properties for which the Company had reconsidered the projected cash flows due to various performance indicators. As a result, the Company evaluated the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company primarily uses a market approach to estimate the future cash flows expected to be generated. Impaired real estate investments held for use are generally classified in Level 3 of the fair value hierarchy. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate investments, Net - “Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Investments — Held for Sale</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has impaired real estate investments held for sale, which are carried at net realizable value on a non-recurring basis on the consolidated balance sheets as of December 31, 2020 and 2019. Impaired real estate investments held for sale are generally classified in Level 3 of the fair value hierarchy. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate investments, Net - “Assets Held for Sale and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage <br/>premium and discounts, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,674 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,558 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,618 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,618 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives. At December 31, 2020, the carrying values of the Credit Facility and Fannie Mae Master Credit Facilities do not approximate their fair values due to the widening of credit spreads during the period. At December 31, 2019, the carrying amounts approximated their fair values.</span></div> <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020 and 2019, aggregated by the level in the fair value hierarchy within which those instruments fall.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:41.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets<br/>Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,913)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 13000 0 13000 0 38389000 0 38389000 0 -38376000 0 -38376000 0 392000 0 392000 5305000 5305000 0 -4913000 0 -4913000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:36.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.471%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross mortgage notes payable and mortgage <br/>premium and discounts, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,889 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,002 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545,414 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,674 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,558 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,618 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,618 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fannie Mae Master Credit Facilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,073 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 548889000 549553000 536002000 545414000 323674000 319558000 250618000 250618000 355175000 354073000 359322000 370122000 — Derivatives and Hedging Activities <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management Objective of Using Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,389 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Hedges of Interest Rate Risk</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2020 and 2019, such derivatives were used to hedge the variable cash flows associated with variable-rate debt. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the refinancing of the MOB Loan during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and is being recorded as an adjustment to interest expense over the term of the two terminated swaps and the MOB Loan prior to its refinancing. Of the amount recorded in AOCI following these terminations, $0.9 million and $0.1 million was recorded as an increase to interest expense for the years ended December 31, 2020 and 2019, respectively, and approximately $1.3 million remained in AOCI as of December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2021 through December 31, 2021, the Company estimates that $10.7 million will be reclassified from other comprehensive loss as an increase to interest expense.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the<br/>consolidated statements of operations and comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Designated Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These derivatives are used to manage the Company’s exposure to interest rate movements, but do not meet the strict hedge accounting requirements to be classified as hedging instruments. Changes in the fair value of derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and were a loss of $0.1 million, a loss of $0.1 million and a loss of $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Offsetting Derivatives</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2020 and 2019. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheet. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit-risk-related Contingent Features</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 the fair value of derivatives in a net liability position, including accrued interest but excluding any adjustment for nonperformance risk related to these agreements, was $38.4 million. As of December 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the </span></div>Company had breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value of $38.4 million at December 31, 2020. The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2020 and 2019:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.425%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,389 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 377000 38389000 5305000 13000 15000 9 2 250000000.0 2200000 -2200000 2 -900000 -100000 -1300000 -10700000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate “pay-fixed” swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578,500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rate Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate caps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9 578500000 9 578500000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2020 and 2019:</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,753)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,999)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total amount of interest expense presented in the<br/>consolidated statements of operations and comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,519 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,059 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,471 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -40614000 -10753000 2367000 -7999000 872000 258000 51519000 56059000 49471000 -100000 -100000 -200000 6 359322000 6 359322000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2020 and 2019. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheet. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:18.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Not Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts of Recognized (Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Amounts Offset in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amounts of Assets presented in the Consolidated Balance Sheet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instruments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Collateral Received</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38,389)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,305)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13000 0 13000 0 0 13000 38389000 0 38389000 0 0 38389000 392000 0 392000 0 0 392000 5305000 0 5305000 0 0 5305000 38400000 38400000 — Stockholders’ Equity <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Company had 93,775,746 and 92,356,664 shares of common stock outstanding, respectively, including unvested restricted shares and shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019, which was approved by the Board on September 30, 2020. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tender Offers</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 13, 2018, the Company announced a tender offer (the “2018 Tender Offer”) to purchase up to 2.0 million shares of the Company’s common stock for cash at a purchase price equal to $13.15 per share with the proration period and withdrawal rights expiring on April 12, 2018. On April 4, 2018 and April 16, 2018, the 2018 Tender Offer was amended to reduce the number of shares the Company was offering to purchase to 230,000 shares and extend the expiration date to May 1, 2018. The 2018 Tender Offer expired in accordance with its terms on May 1, 2018. During May 2018, in accordance with the terms of the 2018 Tender Offer, the Company accepted for purchase 230,000 shares for a total cost of approximately $3.0 million. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company suspended the SRP during the pendency of the 2018 Tender Offer. On June 29, 2018, the Company announced the Board unanimously determined to reactivate the SRP, effective June 30, 2018. In connection with reactivating the SRP, the Board approved all repurchase requests received during the period from January 1, 2018 through the suspension of the SRP on March 13, 2018 (see table below for additional details).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2019, the Company announced that the Board approved an amendment to the SRP changing the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than March 31, 2019, rather than on or before the 31st day following December 31, 2018. This SRP amendment became effective on January 30, 2019. Additionally, on March 27, 2019, the Company announced that the Board approved an amendment to the SRP further extending the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than April 30, 2019. This SRP amendment became effective on March 28, 2019 (see table below for details on cumulative shares repurchased pursuant to the SRP, including shares repurchased during 2019).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, the Company announced that the Board approved a third amendment to the SRP, effective July 24, 2019, extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than August 31, 2019, rather than on or before July 31, 2019. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 20, 2019, the Company announced that the Board approved a fourth amendment to the SRP, effective August 22, 2019 extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than October 31, 2019, rather than on or before August 31, 2019. The Company completed the repurchases on October 30, 2019 and repurchased 446,830 shares of common stock for approximately $7.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing January 1, 2019 up to and including June 30, 2019. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company announced that the Board approved a fifth amendment to the SRP, effective January 10, 2020 extending the date on which repurchases are able to be made in respect of requests made during the period commencing July 1, 2019 up to and including December 31, 2019 to on or before March 16, 2020, rather than on or before January 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2020, the Company also announced that the Board had suspended the SRP, and that it would not accept any repurchase requests or make any repurchases under the SRP during the pendency of the 2020 Tender Offer or for 10 business days thereafter.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the SRP, repurchases were to be ma</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">de in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5, which restricts the Company from repurchasing shares until no earlier than the quarter ending June 30, 2021, on August 6, 2020, the Board determined that, effective on August 12, 2020, repurchases under the SRP would be suspended. The Board has also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Repurchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price per Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Reinvestment Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2020, 2019 and 2018, the Company issued 0.9 million, 1.5 million and 1.7 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million, $27.2 million and $35.7 million, respectively. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Rights Plan</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2020. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below). The Company had 1,610,000 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued and sold 1,610,000 shares of the Series A Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The gross proceeds from this offering were $40.3 million and net proceeds were $37.6 million after deducting the underwriting discount of $1.3 million and additional offering expenses of $1.4 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company did not sell any shares under the Preferred Stock Equity Line during the year ended December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Stock — Terms</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into Common Stock have not been met as of December 31, 2020. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distributions and Dividends</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5 which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The Company declared the Stock Dividends of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock on October 1, 2020 and January 4, 2021. This amount was based on the Company’s prior cash distribution rate of $0.85 per share per annum. The Board may further change the Company’s common stock distribution policy at any time, further reduce the amount of distributions paid or suspend distribution payments at any time, and therefore distribution payments are not assured. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the years ended December 31, 2020, 2019 and 2018, retroactively adjusted for the effect of the Stock Dividends:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of capital </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital gain dividend income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary dividend income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to the Company’s shareholders for U.S. federal income tax purposes.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Preferred Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends on our Series A Preferred Stock accrue in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to Series A Preferred Stock holders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us. The first quarterly dividend for the Series A Preferred Stock sold in this offering was paid on January 15, 2020 and represented an accrual for less than a full quarter, covering the period from December 11, 2019 to December 31, 2019. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock become part of the liquidation preference thereof.</span></div> 93775746 92356664 200000 8.50 200000 1700000 2000000.0 13.15 230000 230000 3000000.0 446830 7800000 17.50 505101 8800000 17.50 <div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares Repurchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price per Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.95 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ended December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative repurchases as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896,620 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.</span></div> 4391519 20.95 505101 17.50 4896620 20.60 505101 8800000 17.50 P10D 900000 1500000 1700000 14600000 27200000 35700000 1 50000000 1610000 600000 1610000 1610000 1610000 25.00 40300000 37600000 1300000 1400000 15000000 3500 0 1.84375 0.07375 25.00 25.00 25.00 0.0200 0.09375 25.00 2.34375 0.07375 25.00 1.70 1.45 0.85 0.85 0.01349 0.85 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the years ended December 31, 2020, 2019 and 2018, retroactively adjusted for the effect of the Stock Dividends:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.813%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of capital </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital gain dividend income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ordinary dividend income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to the Company’s shareholders for U.S. federal income tax purposes.</span></div> 1.000 0.42 1 0.83 1 0.92 0 0 0 0 0 0 0 0 0 0 0 0 1.000 0.42 1.000 0.83 1.000 0.92 1.84375 0.460938 0.07375 25.00 Related Party Transactions and Arrangements <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the Special Limited Partner owned 9,008 and 8,888 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2020 and 2019, the Advisor held 90 partnership units in the OP designated as “OP Units” (“OP Units”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees Incurred in Connection with the Operations of the Company</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2017, the members of a special committee of the Board unanimously approved certain amendments to and a restatement of the then effective advisory agreement, by and among the Company, the OP and the Advisor (the “Second A&amp;R Advisory Agreement”). The Second A&amp;R Advisory Agreement, which superseded, amended and restated the previously effective advisory agreement (the “Original A&amp;R Advisory Agreement”), took effect on February 17, 2017. The initial term of the Second A&amp;R Advisory Agreement expires on February 17, 2027, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&amp;R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&amp;R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&amp;R Advisory Agreement or (b) any material breach of the Second A&amp;R Advisory Agreement of any nature whatsoever by the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into Amendment No. 1 to the Second Amended and Restated Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition Expense Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for third party acquisition expenses. Under the Second A&amp;R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Asset Management Fees and Variable Management/Incentive Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LPA and the advisory agreement that was superseded by the Original A&amp;R Advisory Agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2020, the Company cannot determine the probability of achieving the Performance Condition. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. These distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 17, 2017, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. The base management fee is payable to the Advisor or its assignees in cash, OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Second A&amp;R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted number of shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property Management Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by our Board of Directors (including a majority of the independent directors).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&amp;R Property Management Agreement”) with the OP and the Property Manager. The A&amp;R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&amp;R Property Management Agreement at least 90 days prior to the end of the term. Neither party provided notice of intent to terminate. The current term of the A&amp;R Property Management Agreement expires February 17, 2021.The Property Manager may assign the A&amp;R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&amp;R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&amp;R Property Management Agreement.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Professional Fees and Other Reimbursements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2020, 2019 and 2018, the Company incurred $10.8 million, $10.6 million and $8.9 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Second A&amp;R Advisory Agreement, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), for each fiscal year is subject to a limit that is equal to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2019; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the advisory agreement requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the advisory agreement requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this reimbursement, for the year ended December 31, 2020, the Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original $2.5 million estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable is payable to the Company over a 10-month period from January 2021 through October 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursements for the cash portion of 2020 bonuses to employees of the Advisor or its affiliates continue to be expensed and reimbursed on a monthly basis during 2020 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of fees, expenses and related payables</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payable (Receivable) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">One-time fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property management fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and other reimbursements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1) (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees credit due from Advisor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions on Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,328 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,831 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,470 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(979)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Included in general and administrative expenses in the consolidated statements of operations. Includes $5.6 million and $7.2 million subject to the Capped Reimbursement Amount for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Prior to April 1, 2015, the Company caused the OP to issue (subject to periodic approval by the Board) to the Advisor restricted performance-based Class B Units for asset management services. As of December 31, 2020, the Board had approved the issuance of, and the OP had issued, 359,250 Class B Units to the Advisor in connection with this arrangement. Effective April 1, 2015, the Company began paying an asset management fee to the Advisor or its assignees in cash, in shares, or a combination of both and no longer issues any Class B Units.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Balance includes a receivable of $1.2 million from the Advisor related to the overpayment of 2019 Bonus Awards as of December 31, 2020 which, pursuant to authorization by the independent members of the Company’s board of directors, is payable over a ten month period from January 2021 to October 2021. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     During the year ended December 31, 2019, the Company recorded a reduction of general and administrative expenses in the amount of $0.5 million related to the reversal of a payable balance due to RCS Capital Corporation. During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance includes a receivable of $0.5 million from the Advisor as of December 31, 2019, previously recorded in the fourth quarter of 2018, which, pursuant to authorization by the independent members of the Company’s board of directors, was fully paid during 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inclusive of $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fees Incurred in Connection with a Listing</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2020, 2019 and 2018. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Subordinated Participation in Net Sales Proceeds </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2020, 2019 and 2018. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination Fees</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, wi</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">th or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination dist</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to an annual 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Second A&amp;R Advisory Agreement, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Second A&amp;R Advisory Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by either party in connection with a change of control (as defined in the Second A&amp;R Advisory Agreement), the Company would pay the Advisor a change of control fee equal to the product of four (4) and the “Subject Fees.”</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a termination by the Company in connection with a transition to self-management, the Company would pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The right to termination of the Second A&amp;R Advisory Agreement in connection with a change of control or transition to self-management is subject to a lockout period that requires the notice of any termination in connection with a change of control or transition to self-management to be delivered after February 14, 2019.</span></div> 9008 8888 90 90 10000000.0 P10Y P365D 0.67 P45D P60D 0.005 0.005 0.045 0.045 0.060 0.001875 22.50 359250 1625000 0.0125 0.150 0.375 0.100 0.47 0.015 0.025 0.010 P1Y P90D 100000000.0 10800000 10600000 8900000 0.030 6800000 4 0.0029 0.250 P12M P90D 2500000 2500000 1200000 1200000 1200000 P10M 2200000 <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payable (Receivable) as of</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">One-time fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition cost reimbursements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ongoing fees and reimbursements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset management fees </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property management fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,888 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees and other reimbursements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1) (4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees credit due from Advisor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions on Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total related party operation fees and reimbursements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,328 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,831 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,470 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(979)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    Included in general and administrative expenses in the consolidated statements of operations. Includes $5.6 million and $7.2 million subject to the Capped Reimbursement Amount for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Prior to April 1, 2015, the Company caused the OP to issue (subject to periodic approval by the Board) to the Advisor restricted performance-based Class B Units for asset management services. As of December 31, 2020, the Board had approved the issuance of, and the OP had issued, 359,250 Class B Units to the Advisor in connection with this arrangement. Effective April 1, 2015, the Company began paying an asset management fee to the Advisor or its assignees in cash, in shares, or a combination of both and no longer issues any Class B Units.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     Balance includes a receivable of $1.2 million from the Advisor related to the overpayment of 2019 Bonus Awards as of December 31, 2020 which, pursuant to authorization by the independent members of the Company’s board of directors, is payable over a ten month period from January 2021 to October 2021. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">     During the year ended December 31, 2019, the Company recorded a reduction of general and administrative expenses in the amount of $0.5 million related to the reversal of a payable balance due to RCS Capital Corporation. During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance includes a receivable of $0.5 million from the Advisor as of December 31, 2019, previously recorded in the fourth quarter of 2018, which, pursuant to authorization by the independent members of the Company’s board of directors, was fully paid during 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inclusive of $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2020.</span></div> 81000 39000 176000 11000 0 19987000 19526000 19500000 0 27000 4197000 3888000 3571000 288000 -44000 12102000 10073000 8883000 -61000 -377000 1217000 0 0 -1217000 0 178000 305000 340000 0 0 35328000 33831000 32470000 -979000 -394000 5600000 7200000 359250 1200000 -500000 2200000 500000 300000 0.150 0.060 0.150 0.060 0.150 0.060 4 15000000.0 4 4.5 4 4 Economic Dependency<div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.</span></div> Equity-Based Compensation <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Plan</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.5 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to August 2017, the RSP provided for an automatic grant of 1,333 restricted shares to each of the independent directors, without any further approval by the Board or the stockholders, on the date of his or her initial election to the Board and thereafter on the date of each annual stockholder meeting. The restricted shares granted as annual automatic awards prior to August 2017 were subject to vesting over a five-year period following the date of grant.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Board amended the RSP to provide that the number of restricted shares comprising the automatic annual award to each of the independent directors would be equal to the quotient of $30,000 divided by the then-current Estimated Per-Share NAV and subsequently amended and restated the RSP to eliminate the automatic annual awards and to make other revisions related to the implementation of a new independent director equity compensation program. As part of this independent director equity compensation program, the Board approved a one-time grant of restricted share awards to the independent directors as follows: (i) 300,000 restricted shares to the chairman, with one-seventh of the shares vesting annually in equal increments over a seven-year period with initial vesting on August 4, 2018; and (ii) 25,000 restricted shares to each of the three other independent directors, with one-fifth of the shares vesting annually in equal increments over a five-year period with initial vesting on August 4, 2018. In connection with these one-time grants, the restricted shares granted as automatic annual awards in connection with the Company’s 2017 annual meeting of stockholders on July 21, 2017 were forfeited. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2019, the Board elected B.J. Penn as a member of the Board to serve as a director effective immediately. Mr. Penn, like the Company’s other independent directors, participates in the Company’s independent director compensation program. During the year ended December 31, 2019, the Company paid to Mr. Penn an annual cash retainer effective as of July 29, 2019 pro-rated for the remaining portion of the current annual period, and he was awarded 15,000 restricted shares vesting annually in equal increments over a three-year period with initial vesting on August 4, 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted shares may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of shares outstanding as of December 31, 2020 and activity for the period presented:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had $4.0 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 3.2 years. Compensation expense related to restricted shares was $1.3 million, $1.3 million and approximately $1.2 million during the years ended December 31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Share-Based Compensation</span></div>The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2020, 2019 and 2018. 0.050 3500000 1333 P5Y 30000 300000 P7Y 25000 P5Y 15000 P3Y <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the amount of shares outstanding as of December 31, 2020 and activity for the period presented:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Issue Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,510 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock dividend</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,384 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 382510 21.47 0 0 60268 21.78 0 0 322242 21.41 15000 17.50 60001 21.48 0 0 277241 21.18 2878 15.75 0 0 64735 21.18 0 0 215384 21.11 4000000.0 P3Y2M12D 1300000 1300000 1200000 0 0 0 Accumulated Other Comprehensive (Loss) Income<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in accumulated other comprehensive (loss) income as of and for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Designated Derivative</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39,673)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive (loss) income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_208" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income is $1.3 million as of December 31, 2020.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates the changes in accumulated other comprehensive (loss) income as of and for the periods presented: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.463%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Designated Derivative</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebalancing of ownership percentage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(39,673)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2473000 2367000 258000 4582000 -10753000 -872000 -7043000 -40614000 -7999000 -15000 -39673000 -1300000 Non-Controlling Interests <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in the Operating Partnership</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the sole general partner and holds substantially all of the OP Units. As of December 31, 2020 and 2019, the Advisor held 90 OP Units, which represents a nominal percentage of the aggregate ownership in the OP. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A holder of OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the OP Units for a period of one year, a holder of OP Units has the right to redeem OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2020, 2019 and 2018, OP Unit non-controlling interest holders were paid distributions of $0.2 million, $0.3 million, and $0.5 million respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interests in Property Owning Subsidiaries</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.</span></div><div style="margin-bottom:5pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with unaffiliated third parties. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic Portfolio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2017</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information.</span></div>(2)    On November 4, 2020, the Company purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint portfolio. See details above for additional information. 90 90 405908 10100000 25.00 200000 300000 500000 600000 <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to investment arrangements with unaffiliated third parties. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:16.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Third Party Net Investment Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Controlling Ownership Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Net Real Estate Assets Subject to Investment Arrangement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Distributions </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property Name </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Dollar amounts in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Investment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plaza Del Rio Medical Office Campus Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 10pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic Portfolio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 2017</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,842 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">    One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_199" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">- Mortgage Notes Payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information.</span></div>(2)    On November 4, 2020, the Company purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint portfolio. See details above for additional information. 371000 0.022 12790000 14220000 0 0 87000 0 0 0 8842000 0 0 0 Net Loss Per Share<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2020, 2019 and 2018 and has been retroactively adjusted to reflect the Stock Dividend (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,087)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,639,833 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433,640 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,593,719 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Retroactively adjusted for the effects of the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details)). </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the Stock Dividend (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common share equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 215,373, 277,241 and 322,242 unvested restricted shares outstanding as of December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive OP Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 405,998 OP Units outstanding as of December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 359,250 Class B Units outstanding as of December 31, 2020, 2019 and 2018.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2020, 2019 and 2018 and has been retroactively adjusted to reflect the Stock Dividend (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,781)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,087)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,762)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,639,833 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,433,640 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,593,719 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Retroactively adjusted for the effects of the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span> for additional details)). -78781000 -88087000 -52762000 94639833 94433640 93593719 -0.83 -0.93 -0.56 The amounts in the table below have been retroactively adjusted to reflect the Stock Dividend (see <span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OP Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total weighted average antidilutive common share equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,736 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099,743 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153,828 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 215,373, 277,241 and 322,242 unvested restricted shares outstanding as of December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive OP Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 405,998 OP Units outstanding as of December 31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">    Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 359,250 Class B Units outstanding as of December 31, 2020, 2019 and 2018.</span></div> 257704 313711 367796 417025 417025 417025 369007 369007 369007 1043736 1099743 1153828 215373 277241 322242 405998 405998 405998 359250 359250 359250 — Segment Reporting <div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2020, 2019 and 2018, the Company operated in three reportable business segments for management and internal financial reporting purposes: MOBs, triple-net leased healthcare facilities, and SHOPs.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates performance and makes resource allocations based on its three business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses. The triple-net leased healthcare facilities segment primarily consists of investments in seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s properties move between its operating segments, for example if they are converted from being triple-net leased to third parties in the triple-net leased healthcare facilities segment to being leased to the TRS and operated and managed on the Company’s behalf by a third-party operator in the SHOP segment. When transfers between segments occur, the Company reclassifies the operating results of the transferred properties to their current segment for both the current and all historical periods in order to present a consistent group of property results. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate Investments, Net - “Impairments” and “Held for Use Assets” </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last three years, the Company has had properties transfer between operating segments. Upon such transfers the Company retroactively restates the historical operating results for the segment for all periods presented in that filing and, thereafter, the Company will restate other later prior periods when they are subsequently reported in later filings for comparative purposes. As a result, the Company provides transition disclosure adjustments only for properties that have transitioned since the prior numbers were previously reported.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, the Company had also transitioned (i.e. this asset was operating as a SHOP asset and was not leased to a third party) a property located in Lutz, Florida from its triple-net leased healthcare facilities segment to its SHOP segment. The results of this property had previously been reclassified in the Same Store operating results in 2018 and 2019, and following its disposal in December 2020, it has been again reclassified from Same Store results to Disposals. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in more detail below, the Company transitioned one property located in Wellington, Florida and the four LaSalle Properties on April 1, 2019 and July 1, 2020, respectively, from its triple-net leased healthcare facilities segment to its SHOP segment (collectively, the “Transition Properties”). See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information about this property and the transition. The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020, 2019 and 2018, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The previously reported same store results had already been retroactively adjusted to reflect the movement of the results Transition Property located in Wellington, Florida and the property located in Lutz, Florida and require no further adjustments thereto.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, the Company transitioned the LaSalle Properties from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. This segment has been applied retrospectively to historical periods starting with the quarter ended September 30, 2020. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Income</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity, adjusted for the Transition Properties, to consolidated net loss for the years ended December 31, 2020 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,446)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(78,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of non-designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(88,087)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:45.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,655)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non-designated derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(52,762)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The results of operations from the Transition Properties are presented within the SHOP segment for the year ended December 31, 2018. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office buildings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Triple-net leased healthcare facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108,948 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,286,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,325,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">__________________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Transition Properties are presented within the SHOP segment as of December 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Triple-net leased healthcare facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,719 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Transition Properties are presented within the SHOP segment as of December 31, 2020, 2019 and 2018.</span></div> 3 3 3 3 3 3 1 4 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables reconcile the segment activity, adjusted for the Transition Properties, to consolidated net loss for the years ended December 31, 2020 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">381,612 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,064 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,446)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,053)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,230 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(78,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.385%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259,971 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,813 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,566 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,909 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,969)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,790 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on sale of non-designated derivatives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocation for preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(88,087)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:45.950%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.289%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical Office Buildings</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Triple-Net Leased Healthcare Facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Seniors Housing — Operating Properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from tenants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,970 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248,333 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property operating and maintenance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,055 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,409 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,655)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating fees to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition and transaction related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of real estate investment </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other income </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on non-designated derivatives </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(52,762)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The results of operations from the Transition Properties are presented within the SHOP segment for the year ended December 31, 2018. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the segment activity to consolidated total assets as of the periods presented:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in real estate, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office buildings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891,477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Triple-net leased healthcare facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,050 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments in real estate, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108,948 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,053,591 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,908 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,839 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative assets, at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line rent receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,932 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,707 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred costs, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,642 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,286,895</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,325,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">__________________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Transition Properties are presented within the SHOP segment as of December 31, 2020 and 2019.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical office buildings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,585 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,309 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,582 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Triple-net leased healthcare facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seniors housing — operating properties </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,833 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,394 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,719 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,910 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Transition Properties are presented within the SHOP segment as of December 31, 2020, 2019 and 2018.</span></div> 104213000 15611000 261788000 381612000 30851000 1961000 210736000 243548000 73362000 13650000 51052000 138064000 36446000 23922000 173000 21572000 81053000 5230000 51519000 44000 -102000 4061000 303000 2968000 -78781000 100379000 14564000 259971000 374914000 31813000 2310000 200062000 234185000 68566000 12254000 59909000 140729000 55969000 23414000 362000 20530000 81032000 56059000 7000 8790000 -68000 399000 -393000 173000 -88087000 99103000 14970000 248333000 362406000 30295000 1424000 189278000 220997000 68808000 13546000 59055000 141409000 20655000 23071000 302000 17275000 83212000 -70000 49471000 23000 -157000 197000 -216000 -52762000 883471000 891477000 238427000 256661000 987050000 905453000 2108948000 2053591000 72357000 95691000 17989000 15908000 90000 70839000 13000 392000 23322000 21182000 13912000 14351000 34932000 39707000 15332000 13642000 2286895000 2325303000 4585000 5309000 7582000 3976000 396000 1152000 12833000 11014000 4176000 21394000 16719000 12910000 Commitments and Contingencies <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2020, the Company has eight operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The eight operating leases have durations, including assumed renewals, ranging from 11.8 to 86.7 years as of December 31, 2020. On January 1, 2019, the Company adopted ASU 2016- 02 and recorded ROU assets and lease liabilities related to these ground operating leases (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information). The Company did not enter into any additional ground leases during the year ended December 31, 2020.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company’s balance sheet includes ROU assets and operating lease liabilities of $13.9 million and $9.2 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the new lease guidance as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Since the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 41.3 years and a weighted-average discount rate of 7.35% as of December 31, 2020. For the years ended December 31, 2020 and 2019, the Company paid cash of $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $1.0 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2020, 2019 and 2018, respectively. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,096 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2020, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.</span></div> 8 6 8 P11Y9M18D P86Y8M12D 13900000 9200000 P41Y3M18D 0.0735 800000 800000 900000 1000000.0 900000 <div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,096 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div>(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. <div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Base Rent Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Direct Financing Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,407 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,096 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,848 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts representing interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total present value of minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,155 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______</span></div>(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840. 663000 84000 682000 86000 684000 88000 686000 90000 691000 93000 28690000 7407000 32096000 7848000 22941000 3011000 9155000 4837000 Quarterly Results (Unaudited)<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019 which has been retroactively adjusted to reflect the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,235 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,744)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,811)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,500)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,726)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,458,620 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,479,156 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,796,190 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,821,653 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,718 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,469 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,111)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,789)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,133)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,417,626 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,276,398 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,419,591 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,592,579 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Retroactively adjusted for the effects of the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the quarter ended December 31, 2020 and 2019, the Company recorded $3.6 million and $33.3 million in impairment charges on real estate investments held for use. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate investments, Net - Impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details.</span></div> <div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented below is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019 which has been retroactively adjusted to reflect the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional details):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,235 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,664 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,835 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,878 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,744)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,811)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,500)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,726)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,458,620 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,479,156 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,796,190 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,821,653 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except for share and per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,718 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,287 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,440 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,469 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,111)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,054)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,789)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,133)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average shares outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,417,626 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,276,398 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,419,591 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,592,579 </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Retroactively adjusted for the effects of the Stock Dividends (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Organization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the quarter ended December 31, 2020 and 2019, the Company recorded $3.6 million and $33.3 million in impairment charges on real estate investments held for use. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> — Real Estate investments, Net - Impairments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional details.</span></div> 100235000 94664000 95835000 90878000 -24744000 -22811000 -10500000 -20726000 94458620 94479156 94796190 94821653 -0.26 -0.24 -0.11 -0.22 88718000 96287000 95440000 94469000 -5111000 -6054000 -28789000 -48133000 95417626 94276398 94419591 94592579 -0.05 -0.06 -0.30 -0.51 3600000 33300000 Subsequent Events<div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Dividend</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2021, the Company declared a quarterly stock dividend of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 15, 2021 to holders of record of the Company’s common stock at the close of business on January 11, 2021.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Michigan SHOP Transfer</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, the Company completed the transfer of four properties to the buyer of its 11 Michigan properties sold in the fourth quarter of 2020. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— Real Estate Investments, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Grants</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company received $5.1 million in grants from the CARES Act. Consistent with the Company’s policy on the accounting treatment of funds received through the CARES Act, these funds will be recorded as a reduction of property operating expenses to offset incurred COVID-19 costs. There can be no assurance that the program will be extended or any further amounts received.</span></div> 0.01349 4 11 5100000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fresenius Medical Care - Winfield, AL</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/10/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adena Health Center - Jackson, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/28/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,494 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ouachita Community Hospital - West Monroe, LA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/12/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CareMeridian - Littleton, CO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/8/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oak Lawn Medical Center - Oak Lawn, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/21/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">835 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgery Center of Temple - Temple, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/30/2013</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenville Health System - Greenville, SC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/10/2013</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockbridge Family Medical - Stockbridge, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,753 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Medical Plaza II - Glendale, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Village Center Parkway - Stockbridge, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/21/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Creekside MOB - Douglasville, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,814 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,709 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bowie Gateway Medical Center - Bowie, MD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/7/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Campus at Crooks &amp; Auburn Building D - Rochester Mills, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/19/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,627 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Berwyn Medical Center - Berwyn, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,864 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Countryside Medical Arts - Safety Harbor, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">915 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,663 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,638 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Andrews Medical Park - Venice, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,666 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Campus at Crooks &amp; Auburn Building C - Rochester Mills, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/3/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,632 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laguna Professional Center - Elk Grove, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/15/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,887 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,720 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UC Davis MOB - Elk Grove, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/15/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,242 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estate at Hyde Park - Tampa, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Ridge of Clarkston - Clarkston, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/12/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Burlington - Burlington, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,783 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,497 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Carroll - Carroll, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,263 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,086 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Cedar Rapids - Cedar Rapids, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,595 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Clinton - Clinton, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,819 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Des Moines - Des Moines, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,418 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Fairfield - Fairfield, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Ft. Madison - Ft. Madison, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,931 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Independence - Independence, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Muscatine - Muscatine, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,989 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,614 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Ottumwa - Ottumwa, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,802 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,838 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prairie Hills at Tipton - Tipton, IA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,812 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liberty Court - Dixon, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lakeside Vista - Holland, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,994 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Atrium - Rockford, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/29/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Medical Plaza I - Glendale, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/10/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,571 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,447 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunnybrook of Burlington - Land - Burlington, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/23/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Community Health MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,424 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brady MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,661 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Landis Memorial - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,138 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC II - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,982 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC Clinical - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,634 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FOC I - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/26/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,204 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,923 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,713 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Copper Springs Senior Living - Meridian, ID</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ID</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/29/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Brunswick - Brunswick, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,402 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,917 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Dublin - Dublin, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,799 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Elizabethtown - Elizabethtown, KY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,719 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Johns Creek - Johns Creek, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,943 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,492 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Jupiter - Jupiter, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,534 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Lee's Summit - Lee's Summit, MO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,008 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,051 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place at Mills - Roswell, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of College Harbour - St Petersburg, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,791 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Stuart - Stuart, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,069 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,018 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,575 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at Tarpon - Tarpon Springs, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,350 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,728 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,363 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Titusville - Titusville, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,769 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allegro at St. Petersburg - Land - St. Petersburg, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gateway MOB - Clarksville, TN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/3/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,377 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington at Wellington Green - Wellington, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5) (11)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,131)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,415 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,002 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dyer Building - Dyer, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,992 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757 Building - Munster, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,885 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">761 Building - Munster, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 Building - Munster, IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Schererville Building - Schererville, IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/17/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Meadowbrook Senior Living - Agoura Hills, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/25/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,343 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,703 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mount Vernon Medical Office Building - Mount Vernon, WA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/25/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wellington at Hershey's Mill - West Chester, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/3/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,734 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,771 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Careplex West Medical Office Building - Hampton, VA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/3/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hampton River Medical Arts Building - Hampton, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/3/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,083 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eye Specialty Group Medical Building - Memphis, TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/5/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Alpharetta - Alpharetta, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/10/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,069 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Prairie Village - Prairie Village, KS</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/10/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,812 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bloom MOB - Harrisburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,322 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,605 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Sciences Pavilion - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,438 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wood Glen Nursing and Rehab Center - West Chicago, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/16/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,896 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,003 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,647 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pinnacle Center - Southaven, MS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/16/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paradise Valley Medical Plaza - Phoenix, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,404 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Victory Medical Center at Craig Ranch - McKinney, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/30/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,596 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,475 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rivershores Healthcare &amp; Rehab Centre - Marseilles, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,868 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morton Terrace Healthcare &amp; Rehab Centre - Morton, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">709 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,649 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morton Villa Healthcare &amp; Rehab Centre - Morton, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The Heights Healthcare &amp; Rehab Centre - Peoria Heights, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Colonial Healthcare &amp; Rehab Centre - Princeton, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,044 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitol Healthcare &amp; Rehab Centre - Springfield, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acuity Specialty Hospital - Mesa, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/14/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acuity Specialty Hospital - Sun City, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/14/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place of Shoal Creek - Kansas City, MO</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/2/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,391 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,723 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,175 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Green Bay, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Greenville, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Kiel, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,214 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Plymouth, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,038 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,891 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Waterford, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Healthcare Center - Wautoma, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/18/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,955 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,361 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,316 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arbor View Assisted Living and Memory Care - Burlington, WI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/31/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,815 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advanced Orthopedic Medical Center - Richmond, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,752 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,934 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palm Valley Medical Plaza - Goodyear, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,940 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Physicians Plaza of Roane County - Harriman, TN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/27/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,276 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adventist Health Lacey Medical Plaza - Hanford, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/29/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,302 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center I - Peoria, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,085 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,115 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center II - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,023 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial Center - Peoria, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,254 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">959 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">635 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center III - Peoria, AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Morrow Medical Center - Morrow, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/24/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Belmar Medical Building -Lakewood, CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/29/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addington Place - Northville, MI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/30/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,718 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,569 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conroe Medical Arts and Surgery Center - Conroe, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,221 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical Center V - Peoria, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,200 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,659 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legacy Medical Village - Plano, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/10/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,097 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,788 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scripps Cedar Medical Center - Vista, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/6/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,983 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,596 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuvista Institute for Healthy Living - Jupiter, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/7/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ramsey Woods Memory Care - Cudahy, WI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/2/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">930 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">East Coast Square West - Cedar Point, NC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,344 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">East Coast Square North - Morehead City, NC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/15/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,933 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eastside Cancer Institute - Greenville, SC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sassafras Medical Building - Erie, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,315 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">928 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sky Lakes Klamath Medical Clinic - Klamath Falls, OR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10/22/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Courtyard Fountains - Gresham, OR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/1/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">881 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Presence Healing Arts Pavilion - New Lenox, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/4/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,768 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,844 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">991 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mainland Medical Arts Pavilion - Texas City, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/4/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Renaissance on Peachtree - Atlanta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/15/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,821 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,895 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,751 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Senior Living at Bryant - Bryant, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,687 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,811 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge Senior Living at Chenal - Little Rock, AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fox Ridge North Little Rock - North Little Rock, AR</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AR</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/29/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,265 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,526 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Leaves of Cy-Fair - Houston, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,335 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Leaves of Meyerland - Houston, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,465 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,123 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Leaves of Clear Lake, Houston, TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,811 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Autumn Leaves of The Woodlands - The Woodlands, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/31/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">High Desert Medical Group Medical Office Building - Lancaster, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/7/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,480 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,759 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Northside Hospital - Canton, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/13/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,408 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">784 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">West Michigan Surgery Center - Big Rapids, MI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/18/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,935 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Camellia Walk Assisted Living and Memory Care - Evans, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/28/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Collinsville - Collinsville, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcadian Cove Assisted Living - Richmond, KY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">KY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">481 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,923 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beaumont Medical Center - Warren, MI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,622 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DaVita Dialysis - Hudson, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DaVita Bay Breeze Dialysis Center - Largo, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenfield Medical Plaza - Gilbert, AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AZ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RAI Care Center - Clearwater, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,780 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Illinois CancerCare - Galesburg, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic - Muscatine, IA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,541 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lee Memorial Health System Outpatient Center - Ft. Myers</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decatur Medical Office Building - Decatur, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8), (9)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">695 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Madison Medical Plaza - Joliet, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8), (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,855 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,892 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Woodlake Office Center - Woodbury, MN</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,688 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,002 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">873 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rockwall Medical Plaza - Rockwall, TX</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MN</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,097 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MetroHealth Buckeye Health Center - Cleveland, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,367 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UnityPoint Clinic - Moline, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA Outpatient Clinic - Galesberg, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5), (8)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,211 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Philip Professional Center - Lawrenceville, GA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Texas Children’s Hospital - Houston, TX</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/5/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Heartcare - Tampa, FL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,488 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Somerset - Tampa, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Tampa Palms - Tampa, FL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,543 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida Medical Wesley Chapel - Tampa, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,987 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,472 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aurora Health Center - Milwaukee, WI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4/17/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,014 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,055 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vascular Surgery Associates - Tallahassee, FL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5/11/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Glendale MOB - Farmington Hills, MI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8/28/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crittenton Washington MOB - Washington Township, MI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/12/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Crittenton Sterling Heights MOB - Sterling Heights, MI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/12/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,695 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advocate Aurora MOB - Elkhorn, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/24/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,633 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pulmonary &amp; Critical Care Med - Lemoyne, PA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/13/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,805 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dignity Emerus Blue Diamond - Las Vegas, NV</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2018</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,966 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.924%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Subsequent to Acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition<br/>Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Encumbrances at <br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Land</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Building and<br/>Improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Amount at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Depreciation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3) (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dignity Emerus Craig Rd - North Las Vegas, NV</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11/15/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,780 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Greenfield MOB - Greenfield, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,526 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,552 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milwaukee MOB - South Milwaukee, WI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">St. Francis WI MOB - St. Francis, WI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">WI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,085 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,379 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lancaster Medical Arts MOB - Lancaster, PA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/20/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Women’s Healthcare Group MOB - York, PA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6/21/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,785 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sports - Northampton, MA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">435 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sport - Springfield, MA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,863 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pioneer Spine Sports - West Springfield, MA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7/22/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Felicita Vida - Escondido, CA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9/3/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,098 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Edwardsville - Edwardsville, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/10/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,353 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Sir Thomas Court - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,017 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Fisher Road - Mechanicsburg, PA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/17/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,844 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swedish American MOB - Roscoe, IL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/22/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,862 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,461 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Sparta - Sparta, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1/31/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">405 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMPC Chambers Hill - Harrisburg, PA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2/3/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cedarhurst of Shiloh - Shiloh, IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/13/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bayshore Naples Memory Care - Naples, FL</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3/20/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Circleville MOB - Circleville, OH</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12/7/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,776 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">905,536</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">214,160</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,098,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,509)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,345,708</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">328,095</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note - The above schedule excludes properties that are reflected as part of Assets Held for Sale at December 31, 2020. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Acquired intangible lease assets allocated to individual properties in the amount of $276.0 million are not reflected in the table above.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The tax basis of aggregate land, buildings and improvements as of December 31, 2020 is $2.3 billion.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The accumulated depreciation column excludes $184.7 million of accumulated amortization associated with acquired intangible lease assets.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These unencumbered properties were part of the borrowing base of the Credit Facility, which had $323.7 million of outstanding borrowings as of December 31, 2020. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_202" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Credit Facilities, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional details).</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties collateralize the Capital One Facility, which had $212.5 million of outstanding borrowings as of December 31, 2020.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties collateralize the KeyBank Facility, which had $142.7 million of outstanding borrowings as of December 31, 2020.</span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_217" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Related Party Transactions and Arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for additional information. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_250" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.28pt">The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_250" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> — Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information. </span></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:8.28pt">The property has been impaired as of December 31, 2020. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">— Real Estate Investments, Net “Assets Held for Use and Related Impairments”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2020, 2019 and 2018:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.891%"><tr><td style="width:1.0%"/><td style="width:55.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.663%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Real estate investments, at cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions-Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,364 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,980 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, impairments and reclasses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,893 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211,451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,296,627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated depreciation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,399 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,393 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, impairments and reclasses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,095 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,399 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,167 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes amounts relating to dispositions and impairment charges on assets held for sale for the years ended December 31, 2020, 2019 and 2018. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ibec6f51daecb413aa83353ee776ba61c_196" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">— Real Estate Investments</span>. 0 152000 1568000 0 0 1720000 353000 0 242000 4494000 0 0 4736000 873000 0 633000 5304000 0 0 5937000 1049000 0 976000 8900000 0 111000 9987000 2560000 5343000 835000 7217000 0 0 8052000 1620000 0 225000 5208000 0 432000 5865000 992000 0 720000 3045000 0 0 3765000 569000 1781000 823000 1799000 0 131000 2753000 379000 7540000 0 9758000 0 1867000 11625000 2458000 2434000 1135000 2299000 0 156000 3590000 633000 8814000 2709000 5320000 0 637000 8666000 1472000 9153000 983000 10321000 0 81000 11385000 1878000 3627000 640000 4166000 0 118000 4924000 831000 0 1305000 7559000 0 0 8864000 1298000 6983000 915000 7663000 0 60000 8638000 1428000 11119000 1666000 10005000 2000 933000 12606000 2193000 3831000 609000 3893000 0 130000 4632000 810000 8887000 1811000 14598000 0 311000 16720000 2748000 8136000 1138000 7242000 0 282000 8662000 1455000 20116000 1777000 20308000 0 660000 22745000 3950000 19245000 655000 19967000 0 38000 20660000 3809000 12783000 518000 16739000 0 240000 17497000 3414000 6144000 473000 11263000 0 36000 11772000 2086000 8014000 195000 8595000 0 116000 8906000 1623000 10759000 890000 18882000 0 47000 19819000 3653000 5418000 647000 13745000 0 41000 14433000 2827000 0 340000 14115000 0 233000 14688000 2871000 0 263000 3931000 0 203000 4397000 452000 0 473000 10600000 0 176000 11249000 1949000 0 205000 10935000 0 125000 11265000 1947000 11989000 302000 13840000 0 145000 14287000 2614000 0 538000 9186000 0 78000 9802000 1838000 0 306000 10409000 0 33000 10748000 1812000 0 119000 1998000 0 37000 2154000 423000 6128000 378000 12196000 0 420000 12994000 2324000 0 164000 1746000 0 237000 2147000 213000 4571000 0 6447000 0 1311000 7758000 1341000 0 620000 0 0 0 620000 0 5424000 0 6170000 0 0 6170000 996000 19661000 0 22485000 0 0 22485000 3545000 0 0 32484000 0 0 32484000 5138000 16136000 0 16473000 0 132000 16605000 2982000 17695000 0 19634000 0 0 19634000 3497000 8204000 0 8923000 0 155000 9078000 1713000 0 498000 7130000 0 101000 7729000 1771000 0 1509000 14402000 0 36000 15947000 2917000 0 403000 9281000 0 115000 9799000 2036000 0 317000 7290000 0 232000 7839000 1719000 10139000 997000 11943000 0 456000 13396000 2492000 34370000 3741000 49534000 0 276000 53551000 9424000 17187000 2734000 25008000 0 309000 28051000 4772000 0 1000000 8611000 0 2205000 11816000 2139000 0 3791000 8684000 0 1392000 13867000 2657000 49069000 5018000 60575000 0 625000 66218000 11807000 7350000 2360000 13728000 0 415000 16503000 3363000 12423000 1379000 13976000 0 414000 15769000 3112000 0 3045000 0 0 0 3045000 0 17560000 0 16367000 0 1010000 17377000 2993000 0 3182000 25364000 0 -2131000 26415000 1002000 0 601000 8992000 0 64000 9657000 1474000 0 645000 7885000 0 0 8530000 1272000 6797000 1436000 8616000 0 59000 10111000 1491000 8271000 1101000 8899000 0 0 10000000 1476000 0 1260000 935000 0 29000 2224000 278000 19167000 8821000 48682000 0 1840000 59343000 8703000 15797000 0 18519000 0 3000 18522000 3059000 0 8531000 80734000 0 1771000 91036000 14109000 7187000 2628000 16098000 0 187000 18913000 2621000 0 0 18083000 0 146000 18229000 3170000 8475000 775000 7223000 0 0 7998000 1154000 0 1604000 26069000 0 500000 28173000 4858000 14812000 1782000 21869000 0 356000 24007000 4240000 15322000 0 15928000 0 175000 16103000 2605000 18272000 0 22309000 0 0 22309000 3438000 0 1896000 16107000 0 0 18003000 3647000 7085000 1378000 6547000 0 573000 8498000 1344000 13085000 0 25194000 0 1178000 26372000 4404000 0 1596000 40475000 0 1340000 43411000 6488000 0 1276000 6868000 0 0 8144000 1653000 0 709000 5649000 0 0 6358000 1610000 0 645000 3687000 0 87000 4419000 1000000 0 214000 7952000 0 0 8166000 2007000 0 173000 5871000 0 0 6044000 1656000 0 603000 21699000 0 26000 22328000 4792000 0 1977000 16203000 0 543000 18723000 2713000 0 2329000 15795000 0 279000 18403000 2602000 13391000 3723000 22259000 0 383000 26365000 4175000 0 1130000 1678000 0 0 2808000 311000 0 259000 958000 0 0 1217000 188000 0 676000 2214000 0 0 2890000 367000 17038000 2891000 24224000 0 0 27115000 4029000 0 590000 6452000 0 0 7042000 1035000 0 1955000 4361000 0 0 6316000 729000 0 367000 7815000 0 44000 8226000 1651000 15390000 1523000 19229000 0 0 20752000 2934000 2998000 1890000 4940000 0 228000 7058000 907000 6293000 1746000 7842000 0 32000 9620000 1276000 11526000 328000 13302000 0 44000 13674000 1925000 3085000 807000 1115000 0 513000 2435000 741000 0 945000 1330000 0 5023000 7298000 1125000 3254000 959000 1110000 0 635000 2704000 375000 2137000 673000 1651000 0 811000 3135000 659000 4334000 1155000 5674000 0 270000 7099000 909000 3770000 819000 4287000 0 289000 5395000 703000 13287000 440000 14975000 0 303000 15718000 2569000 13221000 1965000 12198000 0 573000 14736000 2071000 2786000 1089000 3200000 0 370000 4659000 562000 23662000 3755000 31097000 0 639000 35491000 4788000 14983000 1213000 14596000 0 48000 15857000 2052000 0 8586000 54051000 -1511000 -7939000 53187000 1284000 0 930000 4990000 0 29000 5949000 925000 5254000 1535000 4803000 0 6000 6344000 696000 3933000 899000 4761000 0 6000 5666000 679000 0 1498000 6637000 0 32000 8167000 960000 2315000 928000 4629000 0 3000 5560000 611000 0 433000 2623000 0 0 3056000 366000 0 2476000 50601000 0 881000 53958000 8037000 5966000 0 6768000 0 76000 6844000 991000 6174000 320000 7923000 0 305000 8548000 1266000 50821000 4535000 68895000 0 1751000 75181000 10102000 7133000 1687000 12936000 0 544000 15167000 2811000 16390000 6896000 20579000 0 163000 27638000 3732000 10170000 0 19265000 0 261000 19526000 3199000 0 1225000 11335000 0 59000 12619000 1880000 0 2033000 13411000 0 21000 15465000 2123000 0 1599000 13194000 0 18000 14811000 2181000 0 2413000 9141000 0 20000 11574000 1619000 7480000 1459000 9300000 0 0 10759000 1141000 8014000 3408000 8191000 0 40000 11639000 784000 0 258000 5677000 0 0 5935000 502000 12563000 1854000 17372000 0 822000 20048000 2001000 0 1228000 8652000 0 113000 9993000 819000 0 481000 3923000 0 63000 4467000 420000 0 1078000 9525000 0 19000 10622000 796000 0 226000 1979000 0 0 2205000 160000 0 399000 896000 0 0 1295000 87000 0 1476000 4144000 0 48000 5668000 357000 0 624000 3156000 0 0 3780000 252000 0 290000 2457000 0 0 2747000 221000 0 570000 4541000 0 2000 5113000 389000 0 439000 4374000 0 363000 5176000 369000 0 695000 3273000 0 0 3968000 295000 0 0 16855000 0 37000 16892000 1267000 8638000 1017000 10688000 0 1297000 13002000 873000 0 1097000 4582000 0 182000 5861000 403000 0 389000 4367000 0 5000 4761000 347000 0 396000 2880000 0 1000 3277000 246000 0 359000 1852000 0 0 2211000 181000 5780000 1285000 6714000 0 169000 8168000 577000 0 1368000 4428000 0 116000 5912000 484000 0 586000 1902000 0 0 2488000 215000 0 61000 1366000 0 0 1427000 134000 0 141000 1402000 0 0 1543000 143000 0 485000 1987000 0 0 2472000 228000 0 1014000 4041000 0 0 5055000 528000 0 902000 5383000 0 0 6285000 554000 0 504000 12332000 0 0 12836000 904000 0 640000 4090000 0 43000 4773000 351000 0 1398000 2695000 0 181000 4274000 280000 0 181000 9452000 0 0 9633000 762000 4271000 621000 3805000 0 0 4426000 442000 13966000 2182000 16594000 0 0 18776000 969000 18780000 3807000 22803000 0 0 26610000 1344000 7526000 1552000 8333000 0 225000 10110000 757000 4136000 410000 5041000 0 0 5451000 278000 9085000 865000 11355000 0 159000 12379000 733000 0 85000 4417000 0 0 4502000 346000 0 624000 2161000 0 0 2785000 281000 0 435000 1858000 0 0 2293000 75000 0 333000 2530000 0 0 2863000 107000 0 374000 4295000 0 0 4669000 176000 0 1677000 28953000 0 17000 30647000 1098000 0 321000 9032000 0 0 9353000 262000 0 745000 6272000 0 0 7017000 157000 0 747000 3844000 0 0 4591000 105000 0 599000 5862000 0 0 6461000 185000 0 381000 13807000 0 22000 14210000 405000 0 498000 4238000 0 0 4736000 103000 13684000 376000 28299000 0 14000 28689000 612000 0 3231000 17112000 0 0 20343000 356000 0 765000 4011000 0 0 4776000 9000 905536000 214160000 2098361000 -1509000 34696000 2345708000 328095000 276000000.0 2300000000 184700000 P40Y P15Y P5Y 323700000 212500000 142700000 2211451000 2296627000 2229374000 98364000 80980000 121244000 -35893000 166156000 53991000 2345708000 2211451000 2296627000 260399000 226167000 170271000 63393000 64731000 62595000 -4303000 30499000 6699000 328095000 260399000 226167000 49400000 8700000 Retroactively adjusted for the effects of the Stock Dividends (see Note 1). Per share amounts retroactively adjusted for the effects of the Stock Dividends. XML 16 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 23, 2021
Jun. 30, 2020
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2020    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-39153    
Entity Registrant Name Healthcare Trust, Inc.    
Entity Incorporation, State or Country Code MD    
Entity Tax Identification Number 38-3888962    
Entity Address, Address Line One 650 Fifth Ave.    
Entity Address, Address Line Two 30th Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10019    
City Area Code 212    
Local Phone Number 415-6500    
Title of 12(b) Security 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share    
Trading Symbol HTIA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 0
Entity Common Stock, Shares Outstanding   95,040,732  
Documents Incorporated by Reference Portions of the registrant’s definitive proxy statement to be delivered to stockholders in connection with the registrant’s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. The registrant intends to file its proxy statement within 120 days after its fiscal year end.    
Entity Central Index Key 0001561032    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Real estate investments, at cost:    
Land $ 212,651 $ 207,335
Buildings, fixtures and improvements 2,133,057 2,004,116
Acquired intangible assets 276,015 269,616
Total real estate investments, at cost 2,621,723 2,481,067
Less: accumulated depreciation and amortization (512,775) (427,476)
Total real estate investments, net 2,108,948 2,053,591
Assets held for sale 90 70,839
Cash and cash equivalents 72,357 95,691
Restricted cash 17,989 15,908
Derivative assets, at fair value 13 392
Straight-line rent receivable, net 23,322 21,182
Operating lease right-of-use assets 13,912 14,351
Prepaid expenses and other assets (including $1,278 and $394 due from related parties as of December 31, 2020 and 2019, respectively) 34,932 39,707
Deferred costs, net 15,332 13,642
Total assets 2,286,895 2,325,303
LIABILITIES AND EQUITY    
Mortgage notes payable, net 542,698 528,284
Credit facilities, net 674,551 605,269
Market lease intangible liabilities, net 10,803 12,052
Derivative liabilities, at fair value 38,389 5,305
Accounts payable and accrued expenses (including $299 due to related parties as of December 31, 2020) 42,271 43,094
Operating lease liabilities 9,155 9,133
Deferred rent 6,914 8,521
Distributions payable 742 6,901
Total liabilities 1,325,523 1,218,559
Stockholders’ Equity    
7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 2,210,000 and 1,610,000 authorized as of December 31, 2020 and 2019, respectively; 1,610,000 issued and outstanding as of December 31, 2020 and 2019 16 16
Common stock, $0.01 par value, 300,000,000 shares authorized, 95,040,783 (including 1,265,037 shares paid as a stock dividend on January 15, 2021) and 92,356,664 shares of common stock issued and outstanding as of December 31, 2020 and 2019, respectively 938 923
Additional paid-in capital 2,104,261 2,078,628
Accumulated other comprehensive loss (39,673) (7,043)
Distributions in excess of accumulated earnings (1,108,557) (971,190)
Total stockholders’ equity 956,985 1,101,334
Non-controlling interests 4,387 5,410
Total equity 961,372 1,106,744
Total liabilities and equity $ 2,286,895 $ 2,325,303
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Jan. 15, 2021
Dec. 31, 2020
Dec. 31, 2019
Prepaid expenses and other assets, due from related parties   $ 1,278 $ 394
Accounts payable and accrued expenses, due to related parties   $ 299  
Preferred stock, dividend rate, percentage   7.375% 7.375%
Preferred stock, par value (in usd per share)   $ 0.01  
Preferred stock, shares authorized (in shares)   2,210,000 1,610,000
Preferred stock, shares issued (in shares)   1,610,000 1,610,000
Preferred stock, shares outstanding (in shares)   1,610,000 1,610,000
Common stock, par value (in usd per share)   $ 0.01 $ 0.01
Common stock, shares authorized (in shares)   300,000,000 300,000,000
Common stock, shares issued (in shares)   95,040,783 92,356,664
Common stock, shares outstanding (in shares)   95,040,783 92,356,664
Subsequent Event      
Distributions declared in common stock (in shares) 1,265,037    
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement [Abstract]      
Total revenues $ 381,612 $ 374,914 $ 362,406
Operating expenses:      
Property operating and maintenance 243,548 234,185 220,997
Impairment charges 36,446 55,969 20,655
Operating fees to related parties 23,922 23,414 23,071
Acquisition and transaction related 173 362 302
General and administrative 21,572 20,530 17,275
Depreciation and amortization 81,053 81,032 83,212
Total expenses 406,714 415,492 365,512
Operating loss before gain (loss) on sale of real estate investments (25,102) (40,578) (3,106)
Gain (loss) on sale of real estate investments 5,230 8,790 (70)
Operating loss (19,872) (31,788) (3,176)
Other income (expense):      
Interest expense (51,519) (56,059) (49,471)
Interest and other income 44 7 23
Loss on non-designated derivatives (102) (68) (157)
Total other expenses (51,577) (56,120) (49,605)
Loss before income taxes (71,449) (87,908) (52,781)
Income tax expense (4,061) (399) (197)
Net loss (75,510) (88,307) (52,978)
Net (income) loss attributable to non-controlling interests (303) 393 216
Allocation for preferred stock (2,968) (173) 0
Net loss attributable to common stockholders (78,781) (88,087) (52,762)
Other comprehensive income (loss):      
Unrealized (loss) gain on designated derivatives (32,630) (11,625) 2,109
Comprehensive loss attributable to common stockholders $ (111,411) $ (99,712) $ (50,653)
Weighted-average common shares outstanding - Basic and Diluted (in shares) [1] 94,639,833 94,433,640 93,593,719
Net loss per common share attributable to common stockholders - Basic and Diluted (in usd per share) [1] $ (0.83) $ (0.93) $ (0.56)
[1] Retroactively adjusted for the effects of the Stock Dividends (see Note 1).
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Total Stockholders’ Equity
Total Stockholders’ Equity
Cumulative Effect, Period of Adoption, Adjustment
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Distributions in Excess of Accumulated Earnings
Distributions in Excess of Accumulated Earnings
Cumulative Effect, Period of Adoption, Adjustment
Non-controlling Interests
Beginning Balance (in shares) at Dec. 31, 2017         0 91,002,766          
Beginning balance at Dec. 31, 2017 $ 1,356,059   $ 1,347,554   $ 0 $ 910 $ 2,009,197 $ 2,473 $ (665,026)   $ 8,505
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Accounting Standards Update [Extensible List] Accounting Standards Update 2016-02                    
Common stock issued through distribution reinvestment plan (in shares) 1,700,000         1,720,633          
Common stock issued through distribution reinvestment plan $ 35,737   35,737     $ 17 35,720        
Common stock repurchases (in shares)           (759,867)          
Common stock repurchases (14,202)   (14,202)     $ (8) (14,194)       0
Share-based compensation, net (in shares)           0          
Share-based compensation, net 1,244   1,244     $ 0 1,244        
Distributions declared on common stock [1] (86,543)   (86,543)           (86,543)    
Allocation for preferred stock 0                    
Distributions to non-controlling interest holders (492)                   (492)
Unrealized gain on designated derivative 2,109   2,109         2,109      
Net loss (52,978)   (52,762)           (52,762)   (216)
Ending Balance (in shares) at Dec. 31, 2018         0 91,963,532          
Ending balance at Dec. 31, 2018 1,240,934 $ (87) 1,233,137 $ (87) $ 0 $ 919 2,031,967 4,582 (804,331) $ (87) 7,797
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of preferred stock, net (in shares)         1,610,000            
Issuance of Preferred Stock, net $ 37,617   37,617   $ 16   37,601        
Common stock issued through distribution reinvestment plan (in shares) 1,500,000         1,481,395          
Common stock issued through distribution reinvestment plan $ 27,210   27,210     $ 15 27,195        
Common stock repurchases (in shares)           (1,103,263)          
Common stock repurchases (21,113)   (21,113)     $ (11) (21,102)        
Share-based compensation, net (in shares)           15,000          
Share-based compensation, net 1,319   1,319       1,319        
Distributions declared on common stock [1] (78,685)   (78,685)           (78,685)    
Allocation for preferred stock (173)   (173)           (173)    
Distributions to non-controlling interest holders (346)                   (346)
Unrealized gain on designated derivative (11,625)   (11,625)         (11,625)      
Net loss (88,307)   (87,914)           (87,914)   (393)
Rebalancing of ownership percentage     1,648       1,648       (1,648)
Ending Balance (in shares) at Dec. 31, 2019         1,610,000 92,356,664          
Ending balance at Dec. 31, 2019 1,106,744   1,101,334   $ 16 $ 923 2,078,628 (7,043) (971,190)   5,410
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Issuance of Preferred Stock, net $ (59)   (59)       (59)        
Common stock issued through distribution reinvestment plan (in shares) 900,000         875,986          
Common stock issued through distribution reinvestment plan $ 14,604   14,604     $ 9 14,595        
Common stock repurchases (in shares)           (705,101)          
Common stock repurchases (10,546)   (10,546)     $ (7) (10,539)        
Share-based compensation, net (in shares)           0          
Share-based compensation, net 1,345   1,345       1,345        
Distributions declared in common stock (in shares) [1]           1,248,197          
Distributions declared in common stock [1] 0   0     $ 13 19,646   (19,659)    
Distributions declared on common stock [1] (38,839)   (38,839)           (38,839)    
Allocation for preferred stock (2,968)   (2,968)           (2,968)    
Distributions to non-controlling interest holders (201)                   (201)
Unrealized gain on designated derivative (32,615)   (32,615)         (32,615)      
Buyout of NCI (583)   (88)           (88)   (495)
Net loss (75,510)   (75,813)           (75,813)   303
Rebalancing of ownership percentage 0   630       645 (15)     (630)
Ending Balance (in shares) at Dec. 31, 2020         1,610,000 93,775,746          
Ending balance at Dec. 31, 2020 $ 961,372   $ 956,985   $ 16 $ 938 $ 2,104,261 $ (39,673) $ (1,108,557)   $ 4,387
[1] Per share amounts retroactively adjusted for the effects of the Stock Dividends.
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]    
Distributions declared in common stock (in usd per share) $ 0.21  
Distributions declared per share (in usd per share) 0.42 $ 0.83
Preferred stock distributions declared per share (in usd per share) $ 1.84 $ 0.11
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net loss $ (75,510) $ (88,307) $ (52,978)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 81,053 81,032 83,212
Amortization (including write-offs) of deferred financing costs 4,059 9,171 8,633
Amortization of terminated swap 846 0 0
Amortization of mortgage premiums and discounts, net 60 (162) (263)
(Accretion) amortization of market lease and other intangibles, net (80) (4) 255
Bad debt expense 2,708 6,464 14,797
Equity-based compensation 1,345 1,319 1,244
Loss (gain) on non-designated derivative instruments 102 68 157
(Gain) loss on sales of real estate investments, net (5,230) (8,790) 70
Impairment charges 36,446 55,969 20,655
Deferred tax valuation allowance 4,641 0 0
Changes in assets and liabilities:      
Straight-line rent receivable (2,409) (3,831) (7,744)
Prepaid expenses and other assets (63) (9,667) (16,888)
Accounts payable, accrued expenses and other liabilities (4,554) 2,632 2,191
Deferred rent (1,607) 1,510 810
Net cash provided by operating activities 41,807 47,404 54,151
Cash flows from investing activities:      
Property acquisitions and development costs (94,984) (91,998) (128,056)
Capital expenditures and other assets acquired (21,892) (16,719) (12,910)
Proceeds from sales of real estate investments 34,385 62,468 25,903
Net cash used in investing activities (82,491) (46,249) (115,063)
Cash flows from financing activities:      
Payments on credit facilities (26,091) (368,300) (80,000)
Proceeds from credit facilities 95,000 225,618 147,753
Proceeds from term loan 0 150,000 0
Proceeds from mortgage notes payable 0 136,513 118,700
Payments on mortgage notes payable (1,048) (67,797) (63,263)
Payments for derivative instruments (97) (2,147) (131)
Payments of deferred financing costs (2,241) (19,532) (3,354)
Proceeds from issuance of preferred stock, net (1,016) 37,617 0
Common stock repurchases (10,539) (21,113) (14,202)
Distributions paid on common stock (31,354) (51,427) (55,329)
Dividends paid on preferred stock (2,399) 0 0
Buyout of non-controlling interest holders (583) 0 0
Distributions to non-controlling interest holders (201) (346) (492)
Net cash, provided by financing activities 19,431 19,086 49,682
Net change in cash, cash equivalents and restricted cash (21,253) 20,241 (11,230)
Cash, cash equivalents and restricted cash, beginning of year 111,599 91,358 102,588
Cash, cash equivalents and restricted cash, end of year 90,346 111,599 91,358
Cash, cash equivalents and restricted cash, end of period 111,599 91,358 91,358
Supplemental disclosures of cash flow information:      
Cash paid for interest 47,878 47,621 43,266
Cash paid for income taxes 315 447 407
Non-cash investing and financing activities:      
Common stock issued through distribution reinvestment plan 14,604 27,210 35,737
Common stock issued through stock dividends 19,659 0 0
Accrued capital expenditures (payable) 1,287 0 0
Mortgage assumed in acquisition $ 13,883 $ 0 $ 0
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Organization
12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization — Organization
The Company is an externally managed real estate investment trust for U.S. federal income tax purposes (“REIT”) that focuses on acquiring and managing a diversified portfolio of healthcare-related real estate, focused on medical office buildings (“MOBs”), healthcare properties leased on a triple-net basis (“NNN properties”) and senior housing operating properties (“SHOPs”). As of December 31, 2020, the Company owned 193 properties located in 31 states and comprised of 9.4 million rentable square feet.
Substantially all of the Company’s business is conducted through Healthcare Trust Operating Partnership, L.P. (the “OP”), a Delaware limited partnership, and its wholly owned subsidiaries. The Company’s advisor, Healthcare Trust Advisors, LLC (the “Advisor”) manages our day-to-day business with the assistance of our property manager, Healthcare Trust Properties, LLC (the “Property Manager”). The Company’s Advisor and Property Manager are under common control with AR Global Investments, LLC (“AR Global”), and these related parties receive compensation and fees for providing services to us. The Company also reimburses these entities for certain expenses they incur in providing these services to the Company. Healthcare Trust Special Limited Partnership, LLC (the “Special Limited Partner”), which is also under common control with AR Global, also has an interest in the Company through ownership of interests in the OP.
The Company has declared quarterly dividends entirely in shares of its common stock equal to 0.01349 shares of common stock on each share of outstanding common stock (“Stock Dividends”) on October 1, 2020 and January 4, 2021. These Stock Dividends were issued on October 15, 2020 and January 15, 2021 to holders of record of common stock at the close of business on October 8, 2020 and January 11, 2021, respectively. Dividends payable entirely in shares of common stock are treated in a fashion similar to a stock split for accounting purposes specifically related to per-share calculations for the current and prior periods. The aggregate impact of these Stock Dividends on the Company’s weighted-average share amounts used in its per-share calculations was an increase of 0.02716 shares, cumulatively, for every one share of common stock. No additional shares, except for the Stock Dividends, were issued during the three months ended December 31, 2020. References made to weighted-average shares and per-share amounts in the accompanying consolidated statements of operations and comprehensive income have been retroactively adjusted to reflect the increase of 0.02716 shares for every share outstanding due to the Stock Dividends. Additionally, other references to weighted-average shares outstanding and per-share amounts have been retroactively adjusted for the Stock Dividends and are noted as such throughout the accompanying financial statements and footnotes.
On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019. The Company’s previous Estimated Per-Share NAV was as of December 31, 2018. Unlike the per share amounts in this Annual Report on Form 10-K, the Estimated Per-Share NAV has not been retroactively adjusted to reflect the payment of dividends in the form of common stock and will not be adjusted for Stock Dividends the Company pays in the future until the Board determines a new Estimated Per-Share NAV. Paying dividends in additional shares of common stock will, all things equal, cause the value of each share to decline because the number of shares outstanding will increase when Stock Dividends are paid; however, because each stockholder will receive the same number of new shares, the total value of our common stockholders’ investment, all things equal, will not change assuming no sales or other transfers. We intend to publish Estimated Per-Share NAV periodically at the discretion of the board of directors (the “Board”), provided that such estimates will be made at least once annually.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Accounting
    The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Out-of-Period Adjustments
During the year ended December 31, 2019, the Company identified certain historical errors in its tax provision and its net deferred taxes asset as well as its statements of operations and comprehensive income (loss), consolidated statements of changes in equity, and statements of cash flows since 2014, which impacted the quarterly financial statements and annual periods previously issued. Specifically, the Company had overstated intercompany rent on certain leases with the taxable REIT subsidiary (“TRS”) and reflected a portion of depreciation on REIT assets in the TRS’s tax provision, thereby overstating previously recorded tax benefits, deferred tax assets and net income by $0.8 million, $0.3 million and $0.2 million for the years ended December 31, 2018, 2017 and for Pre-2017 periods, respectively.  The intercompany rent and allocation of depreciation only affected the tax provision and did not affect the pre-tax consolidated financial results. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2019.
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The pandemic has had and could continue to have an adverse impact on economic and market conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The Company believes the estimates and assumptions underlying its consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ultimate impact COVID-19 will have on the global economy generally, and the Company’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways. In the Company’s SHOP portfolio, occupancy has trended lower since the second half of March as government policies and implementation of infection control best practices have materially limited or closed communities to new resident move-ins which affects the Company’s ability to fill vacancies. The Company has also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, the Company bears these cost increases. These trends accelerated during the second, third, and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact the Company in the future and have a material adverse effect on the Company’s revenues and income in the other quarters thereafter.
The financial stability and overall health of the Company’s tenants is critical to its business. The negative effects that the global pandemic has had on the economy includes the closure or reduction in activity of some of the Company’s MOBs and other healthcare-related facilities as well as restrictions on activity and access for many of the Company’s seniors housing properties. The economic impact of the pandemic has impacted the ability of some of the Company’s tenants to pay their monthly rent either temporarily or in the long term. The Company experienced delays in rent collections in the second, third and fourth quarters of 2020 although collections have been approximately 100%. The Company has taken a proactive approach
to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent.
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
The Company has taken precautionary steps to increase liquidity and preserve financial flexibility in light of the uncertainty resulting from the COVID-19 pandemic. These steps include borrowing an additional $95.0 million under the Credit Facility (as defined below) in March 2020 to provide more cash on the Company’s balance sheet. A portion of the $95.0 million in borrowings was used for general corporate purposes and for acquisitions. The Company has not borrowed additional amounts subsequently. In August 2020, the Company amended the Credit Facility as part of its efforts to continue addressing the adverse impacts of the COVID-19 pandemic. For additional information on the Credit Facility amendment see Note 5 Credit Facilities.
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020, these leases had a weighted average remaining lease term of 6.5 years. Rent from tenants in the Company’s MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted under the REIT Investment and Diversification and Empowerment Act of 2007 and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the rent are short term in nature, primarily month-to-month. Also included in revenue from tenants is fees
for ancillary revenue from non-residents of $13.3 million, $15.4 million and $8.1 million for the years ended December 31, 2020, 2019, and 2018, respectively. Fees for ancillary services are recorded in the period in which the services are performed.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2020 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2021$94,144 
202287,762 
202375,205 
202468,210 
202558,757 
Thereafter165,642 
Total$549,720 
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards (see the “Recently Issued Accounting Pronouncements” section below), the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, the Company recorded such amounts as bad debt expense as part of property operating expenses. During the years ended December 31, 2020, 2019 and 2018 such amounts were $2.7 million, $6.5 million and $14.8 million, respectively, which include bad debt expense related to the NuVista and LaSalle Tenants (see Note 3Real Estate Investment, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 and 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see Note 3Real Estate Investments, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
As more fully discussed in this Note under Recently Issued Accounting Pronouncements - ASU No. 2016-02 Leases, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2019, the Company has no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
The Company is also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet as of December 31, 2020 and 2019, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value
estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate after January 1, 2018 are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Gain on sales of real estate prior to January 1, 2018 are recognized pursuant to the provisions included in ASC 360-20, Real Estate Sales (“ASC 360-20”). The specific timing of a sale was measured against various criteria in and ASC 360-20 related to the terms of the transaction and any continuing involvement in the form of management or financial assistance associated with the properties. If the sales criteria for the full accrual method are not met, depending on the circumstances, the Company may not record a sale or it may record a sale but may defer some or all of the gain recognition. If the criteria for full accrual are not met, the Company may account for the transaction by applying the finance, leasing, profit sharing, deposit, installment or cost recovery methods, as appropriate, until the sales criteria for the full accrual method are met.
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
The Company has determined that it has three reportable segments, with activities related to investing in MOBs, triple-net leased healthcare facilities, and seniors housing properties. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level.
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge.  The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.
The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests
The non-controlling interests represent the portion of the equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net loss based on their share of equity ownership. See Note 13 — Non-Controlling Interests for additional information.
Cash and Cash Equivalents
Cash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less. The Company did not have any cash invested in money market funds at December 31, 2020 or 2019.
The Company deposits cash with high quality financial institutions. These deposits are guaranteed by the Federal Deposit Insurance Company (“FDIC”) up to an insurance limit. At December 31, 2020 and 2019, the Company had deposits of $72.4 million and $95.7 million, of which $57.0 million and $73.2 million, respectively, were in excess of the amount insured by the FDIC. Although the Company bears risk to amounts in excess of those insured by the FDIC, it does not anticipate any losses as a result.
Deferred Financing and Leasing Costs, Net
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to the mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing on our balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
Equity-Based Compensation
The Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (See Note 11Equity-Based Compensation).
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2020, 2019 and 2018. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties.  Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS.  Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of December 31, 2020, the Company, owned 59 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2020 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic.
Because of the Company’s TRS's recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $4.6 million as of December 31, 2020. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. During the year ended December 31, 2020 the Company recorded a tax loss of $3.1 million. As of December 31, 2020, the Company had a deferred tax asset of $4.6 million with a full valuation allowance. As of December 31, 2019, the Company had a deferred tax asset of $3.9 million with no valuation allowance.
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202020192018
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $726 $— $— $(155)$(272)$399 
State (expense) benefit(196)50 (176)(68)(353)29 
Deferred tax asset valuation allowance— (4,641)— — — — 
Total income tax benefit (expense)$530 $(4,591)$(176)$(223)$(625)$428 
As of December 31, 2020 and 2019, the Company had no material uncertain income tax positions. The tax years subsequent to and including the fiscal year ended December 31, 2013 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to
reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of its SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in the Company’s consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, the Company received an additional $5.1 million in funding from CARES Act grants. There can be no assurance that the program will be extended or any further amounts received.
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2018
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), and has since issued several additional amendments thereto (collectively referred to herein as “ASC 606”). ASC 606 establishes a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Under ASC 606, an entity is required to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. A reporting entity may apply the amendments in ASC 606 using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or a full retrospective approach. The Company adopted this guidance effective January 1, 2018 under the modified retrospective approach and it did not have an impact on the Company’s consolidated financial statements. See above for further information on the Company’s Revenue Recognition Accounting Policies under ASC 606.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The revised guidance amends the recognition and measurement of financial instruments. The new guidance significantly revises an entity’s accounting related to equity investments and the presentation of certain fair value changes for financial liabilities measured at fair value. Among other things, it also amends the presentation and disclosure requirements associated with the fair value of financial instruments. The Company adopted this guidance effective January 1, 2018, using the modified retrospective transition method, and there was no impact to the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance on how certain transactions should be classified and presented in the statement of cash flows as either operating, investing or financing activities. Among other things, the update provides specific guidance on where to classify debt prepayment and extinguishment costs, payments for contingent consideration made after a business combination and distributions received from equity method investments. The Company adopted the new guidance on January 1, 2018 and it did not have an impact on its consolidated statement of cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which revises the definition of a business. This new guidance is applicable when evaluating whether an acquisition should be treated as either a business acquisition or an asset acquisition. Under the revised guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset or group of similar assets, the assets acquired would not be considered a business. The Company adopted this guidance effective January 1, 2018, and will apply the new rules prospectively. The Company expects, based on historical property acquisitions, that in most cases, a future property acquired after adoption will be treated as an asset acquisition rather than a business acquisition, which will result in the capitalization of related transaction costs. The Company has evaluated the impact of this new guidance beginning in the first quarter of 2018, and determined that it did not have a material impact on the Company’s consolidated financial statements. All acquisition costs incurred during the years ended December 31, 2020 and 2019 were capitalized since our acquisitions during the years were all classified as asset acquisitions.
In February 2017, the FASB issued ASU 2017-05, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Assets Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets, which provides guidance related to partial sales of non-financial assets, eliminates rules specifically addressing the sales of real estate, clarifies the definition of in substance non-financial assets, removes the exception to the financial asset derecognition model and clarifies the accounting for contributions of non-financial assets to joint ventures. The Company adopted this guidance effective January 1, 2018 using the modified transition method and it did not have an impact on its financial statements. The Company expects that any future sales of real estate in which the Company retains a non-controlling interest in the property would result in the full gain amount being recognized at the time of the partial sale. Historically, the Company has not retained any interest in properties it has sold.
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance that clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The update states that modification accounting should be used unless the fair value of the award, the vesting terms of the award, and the classification of the award as either equity or liability, all do not change as a result of the modification. The Company adopted this guidance effective January 1, 2018 using the modified retrospective transition method and it did not have an impact on its consolidated financial statements. The Company expects that any future modifications to the Company’s issued share-based awards will be accounted for using modification accounting, unless the modification meets all of the exception criteria noted above. As a result, the modification would be treated as an exchange of the original award for a new award, with any incremental fair value being treated as additional compensation cost.
Adopted as of January 1, 2019
ASU No. 2016-02 - Leases
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) which provides guidance related to the accounting for leases, as well as the related disclosures. For lessors of real estate, leases are accounted for using an approach substantially the same as previous accounting guidance for operating leases and direct financing leases. For lessees, the new standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction.
Upon adoption, lessors were allowed a practical expedient, which the Company has elected, by class of underlying assets to account for lease and non-lease components (such as tenant reimbursements of property operating expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under this new guidance, which is consistent with the Company’s existing policies. Also, upon adoption, companies were allowed a practical expedient package, which the Company has elected, that allowed the Company: (a) to not reassess whether any expired or existing contracts entered into prior to January 1, 2019 are or contain leases; (b) to not reassess the lease classification for any expired or existing leases entered into prior to January 1, 2019 (including assessing sale-leaseback transactions); and (c) to not reassess initial direct costs for any expired or existing leases entered into prior to January 1, 2019. As a result, all of the Company’s existing leases will continue to be classified as operating leases under the new standard. Further, any existing leases for which the property is the leased to a tenant in a transaction that at inception was a sale-leaseback transaction will continue to be treated (absent a modification) as operating leases. The Company did not have any leases that would be considered financing leases as of January 1, 2019.
The Company assessed the impact of adoption from both a lessor and lessee perspective, which is discussed in more detail below, and adopted the new guidance prospectively on January 1, 2019, using a prospective transition approach under which the Company elected to apply the guidance effective January 1, 2019 and not adjust prior comparative reporting periods (except for the Company’s presentation of lease revenue discussed below).
Lessor Accounting
As discussed above, the Company was not required to re-assess the classification of its leases, which are considered operating leases under ASU 2016-02. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessor:
Since the Company elected the practical expedient noted above to not separate non-lease component revenue from the associated lease component, the Company has aggregated revenue from its lease components and non-lease components (tenant operating expense reimbursements) into one line. The prior periods have been conformed to this new presentation.
Changes in the Company’s assessment of receivables that result in bad debt expense is now required to be recorded as an adjustment to revenue, rather than a charge to bad debt expense. This new classification applies for the first quarter of 2019 and reclassification of prior period amounts is not permitted. At transition on January 1, 2019, after assessing its reserve balances at December 31, 2018 under the new guidance, the Company wrote off accounts receivable of $0.1
million and straight-line rents receivable of $0.1 million as an adjustment to the opening balance of accumulated deficit, and accordingly rent for these tenants is currently recorded on a cash basis.
Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed. Under prior accounting guidance, the recognition would have been deferred.
Lessee Accounting
    The Company was a lessee under leases for 17 properties including capital leases of land and building as of January 1, 2019 and because the Company has elected the practical expedients described above, it determined that 11 of these leases would continue to be classified as operating leases under the new standard. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessee:
Upon adoption of the new standard, the Company recorded ROU assets and lease liabilities equal to $10.2 million for the present value of the lease payments related to its ground leases. These amounts are included in operating lease right-of-use assets and operating lease liabilities on the Company’s consolidated balance sheet as of December 31, 2019.
The Company also reclassified $0.5 million related to amounts previously reported as a straight-line rent liability and $4.8 million, net related to amounts previously reported as above and below market ground lease intangibles to the ROU assets. For additional information and disclosures related to these operating leases, see Note 16 — Commitments and Contingencies.
Other Accounting Pronouncements
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, to better align cash flow and fair value hedge accounting with the corresponding risk management activities. Among other things, the amendments expand which hedging strategies are eligible for hedge accounting, align the timing of recognition of hedge results with the earnings effect of the hedged item and allow companies to include the change in fair value of the derivative in the same income statement line item as the earnings effect of the hedged item. Additionally, for cash flow hedges that are highly effective, the update allows for all changes in fair value of the derivative to be recorded in other comprehensive income. The Company has adopted ASU 2017-12 on January 1, 2019, as required under the guidance, using a modified retrospective transition method and the adoption did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Not yet Adopted as of December 31, 2020
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition
methods. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period March 12, 2020 through December 31, 2022 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that our hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of our derivatives, which will be consistent with our past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net
12 Months Ended
Dec. 31, 2020
Real Estate [Abstract]  
Real Estate Investments, Net Real Estate Investments, Net
Property Acquisitions and Development Costs
The Company invests in MOBs, seniors housing properties and other healthcare-related facilities primarily to expand and diversify its portfolio and revenue base. The Company owned 193 properties as of December 31, 2020. During the year ended December 31, 2020, the Company, through wholly-owned subsidiaries of the OP, completed its acquisitions of two multi-tenant MOBs, three single tenant MOBs and four SHOPs for an aggregate contract purchase price of $110.7 million, which includes other assets acquired as part of the acquisitions of $1.8 million and capitalized transaction costs. All acquisitions in 2020, 2019 and 2018 were considered asset acquisitions for accounting purposes.
The following table presents the allocation of the assets acquired and liabilities assumed, as well as capitalized construction in progress during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Real estate investments, at cost:
Land$7,665 $6,356 $14,417 
Buildings, fixtures and improvements90,699 68,903 98,236 
Development costs— 5,721 8,591 
Total tangible assets98,364 80,980 121,244 
Acquired intangibles:
In-place leases and other intangible assets (1)
10,369 11,777 6,823 
Market lease and other intangible assets (1)
496 724 275 
Market lease liabilities (1)
(362)(1,483)(286)
Total intangible assets and liabilities
10,503 11,018 6,812 
Mortgage notes payable, net(13,883)— — 
Cash paid for real estate investments, including acquisitions$94,984 $91,998 $128,056 
Number of properties purchased14 
_______________
(1) Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 8.1 years and 7.0 years, respectively, as of December 31, 2019. There were no below market leases acquired in the year ended December 31, 2019.
Development Project
In August 2015, the Company entered into an asset purchase agreement and development agreement to acquire land and construction in progress, and subsequently fund the remaining construction, of a development property in Jupiter, Florida for $82.0 million. As of December 31, 2019, the Company had funded $97.8 million, including $10.0 million for the land and $87.8 million for construction in progress.
The Company had been working for some time to obtain a certificate of occupancy for the facility (“CO”), which was ultimately obtained in December 2019. Historically, all construction costs, including capitalized interest, insurance and real
estate taxes were capitalized and classified in construction is progress on the Company’s consolidated balance sheet. In December 2019, when the development reached substantial completion and the Company reclassified the entire amount in construction in progress to its appropriate real estate investment components. During the years ended December 31, 2019, and 2018 the Company incurred an additional $5.7 million and $8.6 million in capitalized costs, including capitalized interest, related to this development project. No development costs were capitalized during the year ended December 31, 2020 as the property was considered substantially complete.    
Obtaining the CO was a necessary condition to leasing the property to any tenant other than a tenant associated with the developer of the property, which had been, and remains in, default under its agreements with the Company. The Company entered into a lease for 10% of the rentable square feet at the property (a portion of the non-assisted living component of the property) , but the tenant was not required to pay the Company cash rent until May 2021. As of December 31, 2020 the Company had not yet begun operating the assisted living component of the property.
During the fourth quarter of 2019, in connection with the substantial completion of the development property, the Company began to evaluate it for a potential sale. As a result of this potential change in plans, the Company concluded this held for use asset was impaired and recognized an impairment charge to its respective operating real estate components in 2019 (see Assets Held For Use and Related Impairments in this note for additional information). Further, as a result of COVID-19 and it impact on the ability to show the property to potential new tenants/residents, the launch of operations of the assisted living component of the property has been delayed.
In August 2020, the Company entered into definitive purchase and sale agreements (“PSA”) to sell the Company's recently completed development property in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. The buyer paid the Company $2.9 million in non-refundable deposits, In November 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida resulting in a gain on sale of real estate investments of $3.8 million, recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. See “Dispositions” below for more information. The sales of the properties in Wellington, Florida and Jupiter, Florida are expected to close later in 2021, but these dispositions are subject to conditions and there can be no assurance that they will be completed on their contemplated terms, or at all.
Significant Tenants
As of December 31, 2020, 2019 and 2018, the Company did not have any tenants (including for this purpose, all affiliates of such tenants) whose annualized rental income on a straight-line basis represented 10% or greater of total annualized rental income on a straight-line basis for the portfolio. The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:
December 31,
State202020192018
Florida (1)
20.6%25.2%16.6%
Georgia**10.1%
Michigan (2)
*10.9%13.1%
Pennsylvania10.4 %*10.2%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)During the fourth quarter of 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida. In addition, in August 2020 the Company entered into an agreement to sell our skilled nursing facility in Wellington, Florida, and our development property in Jupiter, Florida.
(2)During the year ended December 31, 2020, the Company sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020 and four of which remained classified as held for sale on the Company’s consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer in the first quarter of 2021.
Intangible Assets and Liabilities
Acquired intangible assets and liabilities consisted of the following as of the periods presented:
December 31, 2020December 31, 2019
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$241,097 $172,648 $68,449 $229,300 $156,428 $72,872 
Market lease assets14,116 10,845 3,271 13,616 9,501 4,115 
Other intangible assets20,802 1,171 19,631 26,700 1,144 25,556 
Total acquired intangible assets
$276,015 $184,664 $91,351 $269,616 $167,073 $102,543 
Intangible liabilities:
Market lease liabilities $22,109 $11,306 $10,803 $21,777 $9,725 $12,052 
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Amortization of in-place leases and other intangible assets(1)
$15,121 $15,559 $18,851 
Accretion of above-and below-market leases, net(2)
$(257)$(247)$(39)
Amortization of above-and below-market ground leases, net(3)
$178 $86 $147 
____________
(1)    Reflected within depreciation and amortization expense.
(2)    Reflected within revenue from tenants.
(3)    Reflected within property operating and maintenance expense. Upon adoption of ASC 842 effective January 1, 2019, intangible balances related to ground leases were reclassified to be included as part of the Operating lease right-of-use assets presented on the consolidated balance sheet with no change to placement of the amortization expense of such balances. Refer to Note 2 Summary of Significant Accounting Policies for additional details.
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20212022202320242025
In-place lease assets$10,904 $8,704 $6,830 $6,070 $4,896 
Other intangible assets613 613 613 613 588 
Total to be added to amortization expense$11,517 $9,317 $7,443 $6,683 $5,484 
Above-market lease assets$(1,299)$(993)$(645)$(307)$(260)
Below-market lease liabilities1,388 1,326 1,213 1,062 955 
Total to be added to revenue from tenants$89 $333 $568 $755 $695 
Dispositions
The following table summarizes the properties sold during the years ended December 31, 2020, 2019, and 2018:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2020 Dispositions:
LutzDecember, 2020$20,000 $3,832 
Michigan SHOPs (11 properties) (1)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
2019 Dispositions:
New York Six MOBs (1 property)
August 22, 2019$13,600 $2,883 
Ocean Park (1)
August 1, 20193,600 (152)
New York Six MOBs (5 properties)
February 6, 201945,000 6,059 
Totals$62,200 $8,790 
2018 Dispositions:
Missouri SNF Properties (1)
December 5, 2018$27,500 $(70)
________
(1) These properties were previously impaired. See “Impairments” section below. Represents contract sales price for all 11 properties. Loss on sale relates to the seven properties that were transferred to the buyer in the fourth quarter of 2020 (see below for additional information).
The sales of the properties noted above did not represent a strategic shift that has a major effect on the Company’s operations and financial results. Accordingly, the results of operations of these properties remain classified within continuing operations for all periods presented until the respective sale dates.
2020 Dispositions
On December 16 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida for a contract purchase price of $20.0 million, resulting in a gain on sale of real estate investments of $3.8 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At closing, $17.6 million of net proceeds were used to repay amounts outstanding under the Revolving Credit Facility.
On November 2, 2020 the initial closing under the PSA pursuant to which the Company had agreed to sell 11 Michigan SHOPs occurred. The contract purchase price for the 11 Michigan SHOPs was $11.8 million, resulting in a loss on sale of $0.9 million on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020. At the initial closing, the Company received payment of the full $11.8 million sales price for all 11 of the Michigan SHOPs, less $0.8 million held in escrow, and transferred seven of the properties to the buyer. The remaining four properties were transferred to the buyer a second closing separate closings in the first quarter of 2021 when the $0.8 million held in escrow was released to the buyer. Of the properties transferred at the initial closing, four had been part of the borrowing base under the Credit Facility, one was part of the collateral pool under the Fannie Mae Master Credit Facility with Capital One and two were unencumbered. Of the properties transferred at the second closing, three were part of the borrowing base under the Credit Facility until the initial closing and one was unencumbered. At the initial closing, $4.2 million of the net proceeds was used to repay amounts outstanding under the Fannie Mae Master Credit Facility with Capital One, $4.4 million of the net proceeds were used to repay amounts outstanding under the Revolving Credit Facility, with the remainder used for closing costs. For the avoidance of any doubt, all impairments related to the disposal of the 11 Michigan SHOP assets were recognized in the year ended December 31, 2020.
On March 19, 2020 the Company disposed of one MOB property for a contract purchase price of $8.6 million, resulting in a gain on sale of $2.306 million.
2019 Dispositions
On February 6, 2019, the Company sold five of the MOB properties within the State of New York (the “New York Six MOBs”) for a contract sales price of $45.0 million, resulting in a gain on sale of real estate investments of $6.1 million which is included on the Consolidated Statement of Operations for the year ended December 31, 2019. The Company had reconsidered the intended holding period for all six of the New York Six MOBs due to various market conditions and the potential to reinvest in properties generating a higher yield. On July 26, 2018, the Company had originally entered into a PSA for the sale of the New York Six MOBs, for an aggregate contract sale price of approximately $68.0 million and subsequently, on September 25, 2018, the Company further amended the PSA to decrease the aggregate contract sale price to $58.8 million. The one remaining New York Six MOB was sold for a contract sales price of $13.6 million on August 22, 2019, resulting in a gain on sale of real estate investments of $2.9 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.
During the first quarter of 2019, the Company reconsidered the intended holding period for one of its SHOPs located in Brookings, OR (“Ocean Park”) due to various market conditions and the potential to reinvest in properties generating a higher yield. On March 21, 2019, the Company entered into a PSA for the sale of Ocean Park, for an aggregate contract sale price of approximately $3.6 million. On April 1, 2019, the Company amended the purchase and sale agreement to decrease the aggregate contract sale price to $3.5 million. In connection with this amendment, the Company recognized an impairment charge of approximately $19,000 on Ocean Park during the second quarter of 2019, which is included on the consolidated statement of operations and comprehensive loss. On August 1, 2019, the Company closed its disposition of Ocean Park resulting in a loss on sale of real estate investments of $0.2 million recorded in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019.
2018 Dispositions
On November 6, 2018, the Company entered into the final amendment to its January 2017 agreement (as amended to date, the “Amended Missouri SNF PSA”) to sell eight skilled nursing facility properties in Missouri (the “Missouri SNF Properties”) that were previously classified as held-for-sale, for an aggregate contract purchase price of $27.5 million. In connection with the Amended Missouri SNF PSA, the Company recognized an impairment charge of approximately $11.9 million on the Missouri SNF Properties in the third quarter of 2018 which is included on the consolidated statement of operations and comprehensive loss. The sale of these properties pursuant to the Amended Missouri SNF PSA, which occurred in the fourth quarter of 2018, resulted in a loss of $0.1 million for the year ended December 31, 2018, which is reflected within (loss) gain on sale of real estate investment in the consolidated statements of operations and comprehensive loss.
Impairments
The following is a summary of impairments taken during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Assets held for sale$19,570 $22,634 $18,255 
Assets held for use16,876 33,335 2,400 
Total$36,446 $55,969 $20,655 
For additional information on impairments related to assets held for sale and assets held for use, see the “Assets Held for Sale and Related Impairments” and “Assets Held for Use and Related Impairments” sections below.
Assets Held For Sale and Related Impairments
When assets are identified by management as held for sale, the Company reflects them separately on its balance sheet and stops recognizing depreciation and amortization expense on the identified assets and estimates the sales price, net of costs to sell, of those assets. If the carrying amount of the assets classified as held for sale exceeds the estimated net sales price, the Company records an impairment charge equal to the amount by which the carrying amount of the assets exceeds the Company’s estimate of the net sales price of the assets. For held-for-sale properties, the Company predominately uses the contract sale price as fair market value.
Balance Sheet Details - Assets Held for Sale
The following table details the major classes of assets associated with the properties that have been classified as held for sale as of December 31, 2020 and 2019:
December 31,
(In thousands)
2020 (1)
2019 (2)
   Land$145 $4,051 
   Buildings, fixtures and improvements(55)66,788 
Assets held for sale$90 $70,839 
_____
(1) Assets held for sale as of December 31, 2020 relates to four Michigan SHOPs.
(2) Assets held for sale as of December 31, 2019 relates to the original 14 Michigan SHOPs under the PSA entered into in January 2020 (see below for additional information).
In January 2020, the Company entered into a PSA for the sale of a portfolio of 14 SHOPs located in Michigan (the “Michigan SHOPs”) as a single portfolio for $71.8 million. Accordingly, all 14 of these SHOPs were classified as held for sale as of December 31, 2019.
During April, 2020, the PSA was amended so that only 11 of the Michigan SHOPs were to be sold pursuant to this PSA for $11.8 million. As a result of the amended PSA from April 2020, the three remaining Michigan SHOPs at that time no longer qualified as held for sale and were reclassified to assets held for use at their original carrying values as of March 31, 2020 and an additional $0.7 million in catch-up depreciation was recorded in the third quarter of 2020. In addition, the original deposit made by the buyer was reduced from $1.0 million to $0.3 million.
In October 2020, the PSA was amended to provide that the full $11.8 million sales price for all 11 Michigan SHOPs would be paid at an initial closing which occurred in November 2020, when seven of the properties were transferred to the buyer with the remaining four properties scheduled to be transferred to the buyer at a second closing, which occurred in the first quarter of 2021 (see Note 18 Subsequent Events). This amendment to the PSA also provided that $0.8 million of the sales price would be held in escrow and returned to the buyer at the second closing; provided that, if the PSA is terminated before the second closing closings due to a material default by the buyer, the Company will receive the escrowed amount. This amount was returned to the buyer at final closing. As a result, it represented an effective reduction in the sale price and the Company reflected an additional impairment loss to reflect this. The Company determined that the four Michigan SHOPs should be classified as held for sale as of December 31, 2020. As of December 31, 2020, for the four Michigan SHOPs that are classified as held for sale, three Michigan SHOPs were part of the borrowing base of the Credit Facility and one was unencumbered.
Held for Sale Impairments - 2020
As a result of the amendment to the PSA in April 2020, in which the number of properties under sale was reduced from 14 to 11, and in which the total consideration was reduced from $71.8 million to $11.8 million, the Company recorded an additional impairment charge of $19.6 million for the year ended December 31, 2020 related to the Michigan SHOP assets held for sale.
Held for Sale Impairments - 2019
During the year ended December 31, 2019 the Company recorded an impairment charge of $22.6 million related to assets held for sale, representing the amount by which the carrying amount of the Michigan SHOPs exceeded the Company’s estimate, at that time, of the net sales price of the Michigan SHOPs.
Held for Sale Impairments - 2018
During the year ended December 31, 2018, the Company recorded impairment charges of $18.3 million related to assets held for sale for the eight Missouri SNF Properties which were sold in 2018 and one of the New York Six MOBs which was sold in 2019.
Assets Held for Use and Related Impairments
When circumstances indicate the carrying value of a property classified as held for use may not be recoverable, the Company reviews the property for impairment. For the Company, the most common triggering events are (i) concerns regarding the tenant (i.e., credit or expirations) in the Company’s single tenant properties or significant vacancy in the Company’s multi-tenant properties and (ii) changes to the Company’s expected holding period as a result of business decisions or non-recourse debt maturities. If a triggering event is identified, the Company considers the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying
value of the properties based on the expected cash flows on an undiscounted basis over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach in estimating cash flows. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future. If the undiscounted cash flows over the expected hold period are less than the carrying value, the Company reflects an impairment charge to write the asset down to its fair value.
The Company owns held for use properties for which the Company may from time to time reconsider the projected cash flows due to various performance indicators, and where appropriate, the Company evaluates the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company makes certain assumptions in this approach including, among others, the market and economic conditions, expected cash flow projections, intended holding periods and assessments of terminal values. Where more than one possible scenario exists, the Company uses a probability weighted approach. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in its impairment analysis may not be achieved, and actual losses for impairment may be realized in the future.
As of December 31, 2019, the Company was actively considering plans to sell three assets in Florida including the recently completed development project in Jupiter, Florida and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida. The Company began marketing the properties in 2020 and, during the three months ended June 30, 2020, the Company received multiple bids and accepted a non-binding letter of intent from a prospective buyer to purchase the completed development project in Jupiter, Florida for $65.0 million and the Company’s two skilled nursing facilities in Lutz, Florida and Wellington, Florida for $20.0 million and $33.0 million, respectively. During August 2020, the Company entered into PSAs with the buyer on the terms generally set forth in the letter of intent. The property in Lutz, Florida was sold in December 2020 (see “Dispositions” above) and the property in Jupiter, Florida and the property in Wellington, Florida are expected to be sold later in 2021 however, there can be no assurance that such transactions will actually close. If closed, the Company is required to use the proceeds of the sales to repay amounts outstanding under its Revolving Credit Facility.
Held for Use Impairments — 2020
During the year ended December 31, 2020, as a result of the Company’s marketing efforts during the COVID-19 pandemic which concluded with a PSA in August 2020, the Company recorded an additional impairment charge of $16.9 million on its completed development project in Jupiter, Florida and its skilled nursing facility in Wellington, Florida. The impairment charge represents the amount by which the carrying amount of the properties exceeded the Company’s estimate of the net sales price set forth in the PSA described above.
Held for Use Impairments — 2019
During the year ended December 31, 2019, the Company began to evaluate the properties in Lutz, Florida, Wellington, Florida and its completed development property in Jupiter, Florida for potential sales. As a result of these potential changes in plans, the Company concluded these held for use assets were impaired and recognized impairment charges in the aggregate of $33.3 million to reduce their carrying value to estimated fair value. The Company obtained third-party appraisals of all three properties (Lutz, Wellington, and Jupiter) which estimated fair value primarily applying an income approach using stabilized cash flows and capitalization rates of 9.0%, 9.0% and 7.0%, respectively.
Held for Use Impairments — 2018
During the year ended December 31, 2018, as a result of its consideration of impairment, the Company determined that the carrying value of one held for use property exceeded its estimated fair value and recognized an aggregate impairment charge of $2.4 million.
The LaSalle Tenant
On July 1, 2020, the Company transitioned four triple-net leased properties in Texas (collectively, the “LaSalle Properties”) from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. In January 2018, the Company entered into an agreement with the prior tenants at the LaSalle Properties (collectively, the “LaSalle Tenant”) in which the Company agreed to forbear from exercising legal remedies, including staying a lawsuit against the LaSalle Tenant, as long as the LaSalle Tenant paid the amounts due for rent and property taxes on an updated payment schedule pursuant to a forbearance agreement. As of December 31, 2020, the LaSalle Tenant remains in default of the forbearance agreement and owes the
Company $12.7 million of rent, property taxes, late fees, and interest receivable thereunder and $7.7 million plus interest of unpaid monetary damages awarded to us by the court on our claims against the tenant.
The Company has the entire receivable balance, including any monetary damages, and related income from the LaSalle Tenant fully reserved as of December 31, 2020. The Company incurred $0.4 million, $3.5 million and $5.0 million of bad debt expense, including straight-line rent write-offs, related to the LaSalle Tenant during the years ended December 31, 2020, 2019 and 2018, respectively, which is included in revenue from tenants on the consolidated statement of operations.
On February 15, 2019, the Company filed an amended petition in Texas state court seeking the appointment of a receiver to manage the operations at these properties and for recovery of damages for the various breaches by the LaSalle Tenant. Subsequently, the LaSalle Group Inc., a guarantor of certain of the LaSalle Tenant’s lease obligations (the “LaSalle Guarantor”), filed for voluntarily relief under chapter 11 of the United States Bankruptcy Code. The Company severed its claims against the LaSalle Guarantor from the action against the LaSalle Tenant. On August 27, 2019, the court awarded the Company monetary damages on its claims against the LaSalle Tenant in an amount equal to $7.7 million plus interest. There can be no assurance the Company will receive any amounts with respect to these claims against the LaSalle Tenant.
On October 30, 2019, the court entered into an order appointing a receiver. This receiver was empowered to replace the LaSalle Tenant with a new tenant and operator at the properties, and, on February 15, 2020, the receiver took operational control of the properties. As noted above, the Company worked with the receiver and the Company’s designated third-party operator to transition the LaSalle Properties to its SHOP operating segment on July 1, 2020.
The NuVista Tenant
The Company had tenants at two of its Florida properties located in Lutz and Wellington Florida (collectively, the “NuVista Tenant”) that were in default under their leases beginning from July 2017. On January 1, 2018 the property was transitioned to the SHOP segment when the Company replaced the NuVista Tenant as tenant at the Lutz, Florida property with a TRS and engaged a third-party operator to operate the property. As a result, the property was transitioned to the SHOP segment as of January 1, 2018. The Company incurred bad debt expense of $1.1 million and $6.0 million related to the NuVista Tenant during the years ended December 31, 2019 and 2018, respectively which is included in revenue from tenants in the consolidated statement of operations and comprehensive loss.
At the property located in Wellington, Florida, the Company and the tenant entered into an operations transfer agreement (the “OTA”) pursuant to which the Company and the tenant agreed to cooperate in transitioning operations at the property to a third party operator selected by the Company. On February 19, 2019, in response to litigation commenced by the Company against the NuVista Tenant to enforce the OTA, the United States District Court for the Southern District of Florida entered into an agreed order (the “Order”) pursuant to which it found that the NuVista Tenant was in default under the lease for the property and that the OTA was valid, binding and in full force and effect, as modified by the Order. Subsequent to the entry into the Order, the Company, its designated third-party operator and the NuVista Tenant transitioned operations at the property to the Company’s designated third-party operator. The Company’s designated third-party operator received its license to operate the facility on April 1, 2019 and is in operational control of the property. On May 20, 2019, the court entered into a final order from the court terminating the existing lease with the NuVista Tenant. Following entry into the order, the property in Wellington, Florida transitioned to the SHOP segment as of April 1, 2019. In connection with this transition, the Company replaced the NuVista Tenant as a tenant with a TRS, and engaged a third-party operator to operate the property. During the year ended December 31, 2019 the company received $1.6 million under the OTA for periods prior to the lease termination, which amounts had previously been fully reserved. This payment under the OTA is included in revenue from tenants in consolidated statements of operations and comprehensive loss.
In August 2020, the Company entered into a PSA to sell the properties located in Lutz, Florida and Wellington Florida. The Company sold the property in Lutz, Florida in December 2020 (see “Dispositions” section above). The sale of the property in Jupiter, Florida and the sale of the property in Wellington, Florida are expected to be completed later in 2021.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Mortgage Notes Payable, Net
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Mortgage Notes Payable, Net Mortgage Notes Payable, Net
The following table reflects the Company’s mortgage notes payable as of December 31, 2020 and 2019:
Portfolio
Encumbered Properties (1)
Outstanding Loan Amount as of December 31,
Effective Interest Rate(2) as of December 31,
Interest Rate
2020201920202019Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ1$2,998 $3,112 4.15 %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ12,786 2,884 4.75 %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR17,133 7,283 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR116,390 16,695 3.98 %3.98%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR110,170 10,359 3.98 %3.98%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.71 %3.71%Fixed(3)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois (4)
113,684 — 4.34 %—%FixedMarch 2026
Gross mortgage notes payable68550,361 537,533 3.94 %3.90%
Deferred financing costs, net of accumulated amortization (5)
(6,191)(7,718)
Mortgage premiums and discounts, net(1,472)(1,531)
Mortgage notes payable, net$542,698 $528,284 
__________
(1) Does not include real estate assets mortgaged to secure advances under the Fannie Mae Master Credit Facilities or eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below). The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 — Credit Facilities for additional details).
(2)    Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2020 and December 31, 2019. For the LIBOR based loans, LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(3) Variable rate loan, based on 30-day LIBOR, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. In connection with the amendment to this loan in December 2019 (see additional details below), the Company terminated the previous interest rate swap agreements and entered into new interest rate swap agreements (see Note 7 Derivatives and Hedging Activities for additional details).
(4)    The Company assumed this fixed rate mortgage when it acquired a property during the year ended December 31, 2020.
(5)    Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.

As of December 31, 2020, the Company had pledged $860.0 million in real estate investments, at cost, as collateral for its $550.4 million of gross mortgage notes payable. This real estate is not available to satisfy other debts and obligations unless first satisfying the mortgage notes payable secured by these properties. The Company makes payments of principal and interest, or interest only, depending upon the specific requirements of each mortgage note, on a monthly basis.
Some of the Company’s mortgage note agreements require compliance with certain property-level financial covenants including debt service coverage ratios. As of December 31, 2020, the Company was in compliance with these financial covenants.
See Note 5 Credit Facilities for additional details - Future Principal Payment and LIBOR Transition for schedule of principal payment requirements of the Company’s Mortgage Notes and Credit Facilities and discussion of the expected cessation of LIBOR publication.
Capital One MOB Loan
On June 30, 2017, Capital One, National Association (“Capital One”), as administrative agent and lender, and certain other lenders (collectively, the “MOB Lenders”), made a loan in the aggregate amount of $250.0 million (the “MOB Loan”) to certain subsidiaries of the OP. On December 20, 2019, the Company, through certain subsidiaries of the OP, entered into an amendment and restatement of the MOB Loan originally dated as of June 30, 2017 among the OP’s subsidiaries and Capital One, as administrative agent and lender, and certain other lenders. As a result, the principal amount outstanding increased from approximately $242.0 million to $378.5 million the number of properties mortgaged as collateral for the loan increased from 31 properties (all medical office buildings) to 41 properties (29 medical office buildings that continued to serve as collateral for the loan as well as an additional ten medical office buildings and two triple net leased hospitals).
At the closing of the amendment and restatement of the MOB Loan, after payment of closing costs and swap termination fees, the Company received $127.7 million in net refinancing proceeds in excess of the approximately $242.0 million principal amount outstanding prior to the closing. Of these excess proceeds, approximately $63.5 million were used to repay amounts outstanding under the Revolving Credit Facility (as defined below) in order to obtain a release of 12 of the mortgaged properties from the borrowing base thereunder, and approximately $61.5 million of the remaining proceeds were used to repay additional amounts outstanding under the Revolving Credit Facility.
Prior to the amendment and restatement of the MOB Loan, the MOB Loan bore interest at a variable rate equal to LIBOR plus 2.5% per annum. Subsequent to the amendment and restatement of the MOB Loan, the MOB Loan bears interest at a variable rate equal to LIBOR plus 2.0% per annum. The MOB Loan requires the Company to pay interest on a monthly basis with the principal balance due on the maturity date which was extended from June 30, 2022 to December 20, 2026 after the amendment and restatement of the MOB Loan. In connection with the amendment and restatement of the MOB Loan, the OP terminated two interest rate swaps and executed one interest rate swap on the new amount of the MOB Loan, fixing the interest rate exposure at 3.66%. See Note 7 — Derivatives and Hedging Activities for additional information on the Company’s outstanding derivatives.
The Company may pre-pay the MOB Loan, in whole or in part, at any time, with payment of a prepayment premium equal to (a) 3.0% for prepayments made prior to December 31, 2020, (b) 2.0% for prepayments made between January 1, 2021 and December 31, 2021, and (c) 1.0% for prepayments made between January 1, 2022 and December 31, 2022. Thereafter, no prepayment premium is required.
In addition, mortgaged properties may be released or replaced subject to certain conditions and limitations, including prepayment of not more than 110% of the principal amount allocated to the property together with any applicable prepayment premium and maintenance, giving effect to the release or replacement, of a minimum of either 25 mortgaged properties or $283.9 million principal amount outstanding, a minimum debt yield and a minimum debt service coverage ratio.
In connection with the amendment to the MOB Loan, the OP entered into an amended and restated guaranty of recourse obligations (the “Guaranty”) and an amended and restated hazardous materials indemnity agreement (the “Environmental Indemnity”) for the benefit of Capital One as administrative agent for the lenders on substantially identical terms to the guaranty and environmental indemnity entered into in connection with the original loan agreement entered into in June 2017. Pursuant to the Guaranty, the OP has guaranteed, among other things, specified losses arising from certain actions of any of the OP’s subsidiaries, including fraud, willful misrepresentation, certain intentional acts, misapplication of funds, physical waste, and failure to pay taxes. The Guaranty requires the Company to maintain a certain minimum of shareholders’ equity on its balance sheet. Pursuant to the Environmental Indemnity, the OP and the Company’s subsidiaries that directly own or lease the mortgaged properties have indemnified the MOB Lenders against losses, costs or liabilities related to certain environmental matters.
The amendment and restatement of the MOB Loan was considered an extinguishment of the old loan and a new loan agreement. Accordingly, fees and expense for the new loan have been capitalized and the unamortized fees relating to the old loan of approximately $3.0 million were written off as a charge to interest expense in the statement of operations for the year ended December 31, 2019.
Multi-Property CMBS Loan
On April 10, 2018, the Company, entered into a $118.7 million loan agreement (the “Multi-Property CMBS Loan”) with KeyBank National Association (“KeyBank”).
The Multi-Property CMBS Loan requires monthly interest-only payments, with the principal balance due on the maturity date. The Multi-Property CMBS Loan permits KeyBank to securitize the entire Multi-Property CMBS Loan or any portion thereof.
At the closing of the Multi-Property CMBS Loan, the net proceeds after accrued interest and closing costs were used to (i) repay approximately $80.0 million of indebtedness under the Revolving Credit Facility, under which 14 of the properties were included as part of the borrowing base prior to the Multi-Property CMBS Loan, (ii) fund approximately $3.8 million in deposits required to be made at closing into reserve accounts required under the loan agreement. The remaining $33.0 million net proceeds available to the Company to be used for general corporate purposes, including future acquisitions.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Facilities
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Credit Facilities — Credit Facilities, Net
The Company had the following credit facilities outstanding as of December 31, 2020 and 2019:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(10)
Credit Facility
Encumbered Properties(1)
2020201920202019Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$173,674 $100,618 3.21 %4.08 %Variable(8)Mar. 2023(9)
Term Loan
150,000 150,000 4.95 %4.05 %Variable(6)Mar. 2024
Deferred financing costs
(4,298)(4,671)
Term Loan, net
145,702 145,329 
Total Credit Facility
89(2)$319,376 $245,947 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$212,467 $216,614 2.60 %4.17 %Variable(7)Nov. 2026
KeyBank Facility10(4)142,708 142,708 2.65 %4.22 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$355,175 $359,322 
Total Credit Facilities110$674,551 $605,269 3.29 %(5)4.14 %(5)
__________
(1)Encumbered properties are as of December 31, 2020.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2020 with a carrying value of $344.0 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2020 with carrying value of $253.6 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2020 and 2019, respectively. For the LIBOR based loans that have not been fixed, the LIBOR rate in effect at the balance sheet date was utilized. For LIBOR based loans that have been fixed, the effective rate after consideration of the interest rate swap was utilized. See Note 7 — Derivatives and Hedging Activities for additional details.
(6)Variable rate loan, based on LIBOR, all of which was fixed as a result of entering into “pay-fixed” interest rate swap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(7)Variable rate loan which is capped as a result of entering into interest rate cap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(8)Variable rate loan with $50 million of principal amount fixed at a rate of 4.09% by an interest rate swap agreement.
(9)The company has the option to extend maturity one year to March 2024 subject to certain conditions.
(10)Effective interest rate below for variable rate debt gives effect to any “Pay-fixed” swap entered into by the Company. If not hedged, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2020. Interest rate caps are not considered unless the cap is currently in effect.
As of December 31, 2020, the carrying value of our real estate investments, at cost was $2.6 billion, with $0.9 billion of this amount pledged as collateral for mortgage notes payable, $0.6 billion of this amount pledged to secure advances under the Fannie Mae Master Credit Facilities and $0.9 billion of this amount comprising the borrowing base of the Credit Facility. These real estate assets are not available to satisfy other debts and obligations, or to serve as collateral with respect to new indebtedness, unless, as applicable, the existing indebtedness associated with the property is satisfied or the property is removed from the borrowing base of the Credit Facility, which would impact availability thereunder.
Unencumbered real estate investments, at cost as of December 31, 2020 was $231.5 million, although there can be no assurance as to the amount of liquidity the Company would be able to generate from using these unencumbered assets as collateral for mortgage loans or adding them to the borrowing base of our Credit Facility. Pursuant to the August 10, 2020 amendment to the Credit Facility, any acquired properties must be pledged to the Credit Facility, and any net proceeds from the dispositions of any unencumbered properties must be repaid to the Credit Facility.
Credit Facility
On March 13, 2019, the Company entered into an amended and restated senior secured credit facility (the “Credit Facility”), which consists of two components, a revolving credit facility (the “Revolving Credit Facility”) and a term loan (the “Term Loan”). In both March and August 2020, the Credit Facility was further amended, and the terms of the Credit Facility giving effect to those amendments are generally described below.
The Revolving Credit Facility is interest-only and matures on March 13, 2023, subject to a one-year extension at the Company’s option. The Term Loan is interest-only and matures on March 13, 2024. The total commitments under the Credit Facility are $630.0 million, including $480.0 million under the Revolving Credit Facility. The Credit Facility includes an uncommitted “accordion feature” that may be used to increase the commitments under either component of the Credit Facility by up to an additional $370.0 million to a total of $1.0 billion.
The amount available for future borrowings under the Credit Facility is based on either the value of the pool of eligible unencumbered real estate assets comprising the borrowing base, or a minimum debt service coverage ratio with respect to the borrowing base. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Revolving Credit Facility have been pledged for the benefit of the lenders thereunder.
As of December 31, 2020, $150.0 million was outstanding under the Term Loan, and $173.7 million was outstanding under the Revolving Credit Facility. The unused borrowing availability under the Revolving Credit Facility was $48.3 million.
The Company is required to maintain a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $50.0 million. Pursuant to the amendment in August 2020, certain other restrictions and conditions described below will no longer apply starting in a quarter in which the Company makes an election and, as of the day prior to the commencement of the applicable quarter, the Company has a combination of cash, cash equivalents and availability for future borrowings under the Revolving Credit Facility totaling at least $100.0 million, giving effect to the aggregate amount of distributions projected to be paid by the Company during the applicable quarter, and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 62.5% (the “Commencement Quarter”). The Commencement Quarter may be no earlier than the fiscal quarter ending June 30, 2021.
During the period from August 10, 2020 until the first day of the Commencement Quarter, the Company must use all the net cash proceeds from any capital event (such as an asset sale, financing or equity issuance) to prepay amounts outstanding under the Revolving Credit Facility. The Company may reborrow any amounts so repaid if all relevant conditions are met, including sufficient availability for future borrowings. There can be no assurance these conditions will be met.
In addition, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.85% to 2.60%; or (ii) the Base Rate (as defined in the Credit Facility), plus an applicable margin that ranges, depending on the Company’s leverage, from 0.60% to 1.35%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Revolving Credit Facility bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.60% to 2.35%; or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.35% to 1.10%. As of December 31, 2020 the Company had elected to use the LIBOR option for all of our borrowings under the Credit Facility.
Further, commencing on August 10, 2020 and until the Commencement Quarter, the Company has the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (i) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.80% to 2.55%; or (ii) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.55% to 1.30%. Commencing on the first day of the Commencement Quarter, the Company will have the option to have amounts outstanding under the Term Loan bear interest at an annual rate equal to either: (a) LIBOR, plus an applicable margin that ranges, depending on the Company’s leverage, from 1.55% to 2.30%;
or (b) the Base Rate, plus an applicable margin that ranges, depending on the Company’s leverage, from 0.30% to 1.05%. Pursuant to the amendment to the Credit Facility in August 2020, the “floor” on LIBOR was increased from 0.00% to 0.25%.     
As of December 31, 2020, the Revolving Credit Facility and the Term Loan had an effective interest rate per annum equal to 3.21% and 4.95%, respectively.
Until the Commencement Quarter, the Company may not pay distributions to holders of common stock in cash or any other cash distributions (including repurchases of shares of the Company’s common stock), subject to certain exceptions. These exceptions include paying dividends on the 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share (“Series A Preferred Stock”) or any other preferred stock the Company may issue and paying any cash distributions necessary to maintain its status as a REIT. The Company may not pay any cash distributions (including dividends on Series A Preferred Stock) if a default or event of default exists or would result therefrom. Beginning in the Commencement Quarter, the Company will be able to pay cash distributions to holders of common stock, subject to the restrictions described below. The Company may pay cash distributions beginning in the Commencement Quarter and the aggregate distributions (as defined in the Credit Facility and including dividends on Series A Preferred Stock) for any period of four fiscal quarters do not exceed 95% of Modified FFO (as defined in the Credit Facility) for the same period based only on fiscal quarters after the Commencement Quarter. In addition, beginning in the Commencement Quarter, the Company will be permitted to repurchase up to $50.0 million of shares of its common stock (including amounts previously repurchased during the term of the Revolving Credit Facility) if, after giving effect to the repurchases, the Company maintains cash and cash equivalents of at least $30.0 million and the Company’s ratio of consolidated total indebtedness to consolidated total asset value (expressed as a percentage) is less than 55.0%.
The Credit Facility prohibits the Company from exceeding a maximum ratio of consolidated total indebtedness to consolidated total asset value, and requires the Company to maintain a minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges and a minimum consolidated tangible net worth. The maximum ratio of consolidated total indebtedness to consolidated total asset value is 67.5% for the period from July 1, 2020 through June 30, 2021 and 65% thereafter unless and until the Commencement Quarter, following which it will be 62.5%. The minimum ratio of adjusted consolidated EBITDA to consolidated fixed charges is 1.50 to 1.00 for the period from July 1, 2020 through March 31, 2021, 1.55 to 1.00 for the period from April 1, 2021 through June 30, 2021, and 1.60 to 1.00 thereafter. The minimum consolidated tangible net worth is the sum of (i) approximately $1.2 million, plus (ii) 75% of any net offering proceeds (as defined in the Credit Facility) since the Credit Facility closed in March 2019.
As of December 31, 2020, the Company was in compliance with the financial covenants under the Credit Facility. Based upon the Company’s current expectations, the Company believes its operating results during the next 12 months will allow it to comply with these covenants.
Fannie Mae Master Credit Facilities
On October 31, 2016, the Company, through wholly-owned subsidiaries of the OP, entered into a master credit facility agreement relating to a secured credit facility with KeyBank (the “KeyBank Facility”) and a master credit facility agreement with Capital One for a secured credit facility with Capital One Multifamily Finance LLC, an affiliate of Capital One (the “Capital One Credit Facility”; the Capital One Facility and the KeyBank Facility are referred to herein individually a “Fannie Mae Master Credit Facility” and together as the “Fannie Mae Master Credit Facilities”). Advances made under these agreements are assigned by Capital One and KeyBank to Fannie Mae at closing for inclusion in Fannie Mae’s Multifamily MBS program.
Effective October 31, 2016, in conjunction with the execution of the Fannie Mae Master Credit Facilities, the OP entered into two interest rate cap agreements with an unrelated third party, which caps LIBOR interest paid (not giving effect to the applicable margin) on amounts outstanding under the Fannie Mae Master Credit Facilities at a maximum of 3.5%. On October 2019, the Company replaced two maturing interest rate cap agreements, effective November 1, 2019 for a total notional amount of $88.7 million. The two interest rate caps agreements extend three existing interest rate caps set to mature on the same date and are not designated as hedges (see Note 7 — Derivatives and Hedging Activities for additional disclosure regarding the Company’s derivatives).
In November 2020, in conjunction with the sale and transfer of four of the Michigan SHOPs, one of which was encumbered under the Fannie Mae Master Credit Facility with Capital One, $4.2 million was repaid to Capitol One upon the release of the property.
The Company may request future advances under the Fannie Mae Master Credit Facilities by borrowing against the value of the initial mortgaged properties, or by adding eligible properties to the collateral pool, subject to customary conditions, including satisfaction of minimum debt service coverage and maximum loan-to-value tests.
Future Principal Payments
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2020 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2021$1,191 $130 $1,321 
20221,242 2,820 4,062 
20236,383 4,497 10,880 
20241,095 178,171 179,266 
20251,142 154,497 155,639 
Thereafter539,308 338,734 878,042 
Total$550,361 $678,849 $1,229,210 
LIBOR Transition
In July 2017, the Financial Conduct Authority (which regulates LIBOR) announced it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. As a result, the Federal Reserve Board and the Federal Reserve Bank of New York organized the Alternative Reference Rates Committee, which identified the Secured Overnight Financing Rate (“SOFR”) as its preferred alternative to LIBOR in derivatives and other financial contracts. On March 5, 2021, the Financial Conduct Authority confirmed a partial extension of this deadline announcing that it will cease the publication of the one-week and two-month USD LIBOR settings immediately following December 31, 2021. The remaining USD LIBOR settings will continue to be published through June 30, 2023. The Company is not able to predict when there will be sufficient liquidity in the SOFR market. The Company is monitoring and evaluating the risks related to changes in LIBOR availability, which include potential changes in interest paid on debt and amounts received and paid on interest rate swaps. In addition, the value of debt or derivative instruments tied to LIBOR will also be impacted as LIBOR is limited and discontinued and contracts must be transitioned to a new alternative rate. In some instances, transitioning to an alternative rate may require negotiation with lenders and other counterparties and could present challenges. To transition from LIBOR under the Credit Facility, the Company will either utilize the Base Rate (as defined in the Credit Facility) or an alternative benchmark established by the agent in accordance with the terms of the Credit Facility, which will be determined with due consideration to the then current market practices for determining and implementing a rate of interest for newly originated floating rate commercial real estate loans in the United States and loans converted from a LIBOR based rate to a replacement index-based rate.
The Company has mortgages, credit facilities and derivative agreements that have terms that are based on LIBOR. Certain of those agreements have alternative rates already contained in the agreements while others do not. The Company anticipates that it will either utilize the alternative rates contained in the agreements or negotiate a replacement reference rates for LIBOR with the lenders and derivative counterparties.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments — Fair Value of Financial Instruments GAAP establishes a hierarchy of valuation techniques based on the observability of inputs used in measuring financial instruments at fair value. GAAP establishes market-based or observable inputs as the preferred source of values, followed by valuation models using management assumptions in the absence of market inputs. The three levels of the hierarchy are described below:
Level 1 — Quoted prices in active markets for identical assets and liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset and liability or can be corroborated with observable market data for substantially the entire contractual term of the asset or liability.
Level 3 — Unobservable inputs that reflect the entity’s own assumptions that market participants would use in the pricing of the asset or liability and are consequently not based on market activity, but rather through particular valuation techniques.
The determination of where an asset or liability falls in the hierarchy requires significant judgment and considers factors specific to the asset or liability. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company evaluates its hierarchy disclosures each quarter and depending on various factors, it is possible that an asset or liability may be classified differently from quarter to quarter. However, the Company expects that changes in classifications between levels will be rare.
Financial Instruments Measured at Fair Value on a Recurring Basis
Derivative Instruments
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with those derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. However, as of December 31, 2020 and 2019, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the Company’s derivatives. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.
The valuation of derivative instruments is determined using a discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, as well as observable market-based inputs, including interest rate curves and implied volatilities. In addition, credit valuation adjustments, are incorporated into the fair values to account for the Company’s potential nonperformance risk and the performance risk of the counterparties.
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020 and 2019, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2020
Derivative assets, at fair value$— $13 $— $13 
Derivative liabilities, at fair value— (38,389)— (38,389)
Total$— $(38,376)$— $(38,376)
December 31, 2019
Derivative assets, at fair value$— $392 $— $392 
Derivative liabilities, at fair value(5,305)(5,305)
Total$— $(4,913)$— $(4,913)
A review of the fair value hierarchy classification is conducted on a quarterly basis. Changes in the type of inputs may result in a reclassification for certain assets. There were no transfers between Level 1 and Level 2 of the fair value hierarchy during the year ended December 31, 2020.
Real Estate Investments Measured at Fair Value on a Non-Recurring Basis
Real Estate Investments — Held for Use
The Company also had impaired real estate investments held for use, which were carried at fair value on a non-recurring basis on the consolidated balance sheet as of December 31, 2020 and 2019. As of December 31, 2020, the Company owned held for use properties for which the Company had reconsidered the projected cash flows due to various performance indicators. As a result, the Company evaluated the impact on its ability to recover the carrying value of such properties based on the expected cash flows over its intended holding period. The Company primarily uses a market approach to estimate the future cash flows expected to be generated. Impaired real estate investments held for use are generally classified in Level 3 of the fair value hierarchy. See Note 3 — Real Estate investments, Net - “Assets Held for Use and Related Impairments” for additional details.
Real Estate Investments — Held for Sale
The Company has impaired real estate investments held for sale, which are carried at net realizable value on a non-recurring basis on the consolidated balance sheets as of December 31, 2020 and 2019. Impaired real estate investments held for sale are generally classified in Level 3 of the fair value hierarchy. See Note 3 — Real Estate investments, Net - “Assets Held for Sale and Related Impairments” for additional details.
Financial Instruments Not Measured at Fair Value
The Company is required to disclose the fair value of financial instruments for which it is practicable to estimate that value. The fair values of short-term financial instruments such as cash and cash equivalents, restricted cash, straight-line rent receivable, net, prepaid expenses and other assets, deferred costs, net, accounts payable and accrued expenses, deferred rent and distributions payable approximate their carrying value on the consolidated balance sheets due to their short-term nature.
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2020December 31, 2019
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$548,889 $549,553 $536,002 $545,414 
Credit Facility
3$323,674 $319,558 $250,618 $250,618 
Fannie Mae Master Credit Facilities
3$355,175 $354,073 $359,322 $370,122 
The fair value of the mortgage notes payable is estimated using a discounted cash flow analysis, based on the Advisor’s experience with similar types of borrowing arrangements, excluding the value of derivatives. At December 31, 2020, the carrying values of the Credit Facility and Fannie Mae Master Credit Facilities do not approximate their fair values due to the widening of credit spreads during the period. At December 31, 2019, the carrying amounts approximated their fair values.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities
12 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives and Hedging Activities — Derivatives and Hedging Activities
Risk Management Objective of Using Derivatives
The Company may use derivative financial instruments, including interest rate swaps, caps, collars, options, floors and other interest rate derivative contracts, to hedge all or a portion of the interest rate risk associated with its borrowings.
The principal objective of such arrangements is to minimize the risks and/or costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions. Additionally, in using interest rate derivatives, the Company aims to add stability to interest expense and to manage its exposure to interest rate movements. The Company does not intend to utilize derivatives for speculative purposes or purposes other than interest rate risk management. The use of derivative financial instruments carries certain risks, including the risk that the counterparties to these contractual arrangements are not able to perform under the agreements. To mitigate this risk, the Company only enters into derivative financial instruments with counterparties with high credit ratings and with major financial institutions with which the Company, and its affiliates, may also have other financial relationships. The Company does not anticipate that any of its counterparties will fail to meet their obligations.
    The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2020 and 2019:
December 31,
(In thousands)Balance Sheet Location20202019
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$— $377 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$38,389 $5,305 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$13 $15 
Cash Flow Hedges of Interest Rate Risk
The Company currently has nine interest rate swaps that are designated as cash flow hedges. The interest rate swaps are used as part of the Company’s interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. During 2020 and 2019, such derivatives were used to hedge the variable cash flows associated with variable-rate debt.
The changes in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive (loss) income and is subsequently reclassified into earnings in the period that the hedged forecasted transaction affects earnings.
In connection with the refinancing of the MOB Loan during the fourth quarter of 2019, the Company terminated two interest rate swaps with an aggregate notional amount of $250.0 million for a payment of approximately $2.2 million. Following these terminations, $2.2 million was recorded in AOCI and is being recorded as an adjustment to interest expense over the term of the two terminated swaps and the MOB Loan prior to its refinancing. Of the amount recorded in AOCI following these terminations, $0.9 million and $0.1 million was recorded as an increase to interest expense for the years ended December 31, 2020 and 2019, respectively, and approximately $1.3 million remained in AOCI as of December 31, 2020.
Amounts reported in accumulated other comprehensive (loss) income related to derivatives will be reclassified to interest expense as interest payments are made on the Company’s variable-rate debt. During the next 12 months, from January 1, 2021 through December 31, 2021, the Company estimates that $10.7 million will be reclassified from other comprehensive loss as an increase to interest expense.
As of December 31, 2020 and 2019, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2020December 31, 2019
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate “pay-fixed” swaps$578,500 $578,500 
The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2020 and 2019:
Year Ended December 31,
(In thousands)202020192018
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$(40,614)$(10,753)$2,367 
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)$(7,999)$872 $258 
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,519 $56,059 $49,471 
Non-Designated Derivatives
These derivatives are used to manage the Company’s exposure to interest rate movements, but do not meet the strict hedge accounting requirements to be classified as hedging instruments. Changes in the fair value of derivatives not designated as hedges under a qualifying hedging relationship are recorded directly to net income (loss) and were a loss of $0.1 million, a loss of $0.1 million and a loss of $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2020 and 2019:
December 31, 2020December 31, 2019
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate caps$359,322 $359,322 
Offsetting Derivatives
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2020 and 2019. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheet.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2020$13 — — $13 — — $13 
December 31, 2020$— (38,389)— $(38,389)— — $(38,389)
December 31, 2019$392 — — $392 — — $392 
December 31, 2019$— (5,305)— $(5,305)— — $(5,305)
Credit-risk-related Contingent Features
The Company has agreements in place with each of its derivative counterparties that contain a provision where if the Company either defaults or is capable of being declared in default on any of its indebtedness, then the Company could also be declared in default on its derivative obligations.
As of December 31, 2020 the fair value of derivatives in a net liability position, including accrued interest but excluding any adjustment for nonperformance risk related to these agreements, was $38.4 million. As of December 31, 2020, the Company has not posted any collateral related to these agreements and was not in breach of any agreement provisions. If the
Company had breached any of these provisions, it could have been required to settle its obligations under the agreements at their aggregate termination value of $38.4 million at December 31, 2020.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Stockholders' Equity — Stockholders’ Equity
Common Stock
As of December 31, 2020 and 2019, the Company had 93,775,746 and 92,356,664 shares of common stock outstanding, respectively, including unvested restricted shares and shares issued pursuant to the Company’s distribution reinvestment plan (“DRIP”), net of share repurchases.
On April 3, 2020, the Company published a new estimate of per-share net asset value (“Estimated Per-Share NAV”) as of December 31, 2019, which was approved by the Board on September 30, 2020. The Company intends to publish Estimated Per-Share NAV periodically at the discretion of the Board, provided that such estimates will be made at least once annually.
Tender Offers
On January 9, 2020, the Company announced a tender offer (the “2020 Tender Offer”) to purchase up to 200,000 shares of its common stock for cash at a purchase price equal to $8.50 per share with the proration period and withdrawal rights expiring February 7, 2020. The Company made the 2020 Tender Offer in response to an unsolicited offer to stockholders commenced on December 31, 2019. The 2020 Tender Offer expired in accordance with the terms on February 7, 2020. In accordance with the 2020 Tender Offer, the Company accepted for purchase 200,000 shares for a total cost of approximately $1.7 million, which was funded with available cash.
On March 13, 2018, the Company announced a tender offer (the “2018 Tender Offer”) to purchase up to 2.0 million shares of the Company’s common stock for cash at a purchase price equal to $13.15 per share with the proration period and withdrawal rights expiring on April 12, 2018. On April 4, 2018 and April 16, 2018, the 2018 Tender Offer was amended to reduce the number of shares the Company was offering to purchase to 230,000 shares and extend the expiration date to May 1, 2018. The 2018 Tender Offer expired in accordance with its terms on May 1, 2018. During May 2018, in accordance with the terms of the 2018 Tender Offer, the Company accepted for purchase 230,000 shares for a total cost of approximately $3.0 million.
Share Repurchase Program
Under the Company’s share repurchase program (the “SRP”), as amended from time to time, qualifying stockholders are able to sell their shares to the Company in limited circumstances. The SRP permits investors to sell their shares back to the Company after they have held them for at least one year, subject to significant conditions and limitations. Repurchases of shares of the Company’s common stock, when requested, are at the sole discretion of the Board.
Under the SRP, subject to certain conditions, only repurchase requests made following the death or qualifying disability of stockholders that purchased shares of the Company’s common stock or received their shares from the Company (directly or indirectly) through one or more non-cash transactions are considered for repurchase. Additionally, pursuant to the SRP, the repurchase price per share equals 100% of the Estimated Per-Share NAV in effect on the last day of the fiscal semester, or the six-month period ending June 30 or December 31.
The Company suspended the SRP during the pendency of the 2018 Tender Offer. On June 29, 2018, the Company announced the Board unanimously determined to reactivate the SRP, effective June 30, 2018. In connection with reactivating the SRP, the Board approved all repurchase requests received during the period from January 1, 2018 through the suspension of the SRP on March 13, 2018 (see table below for additional details).
On January 29, 2019, the Company announced that the Board approved an amendment to the SRP changing the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than March 31, 2019, rather than on or before the 31st day following December 31, 2018. This SRP amendment became effective on January 30, 2019. Additionally, on March 27, 2019, the Company announced that the Board approved an amendment to the SRP further extending the date on which any repurchases are to be made in respect of requests made during the period commencing March 13, 2018 up to and including December 31, 2018 to no later than April 30, 2019. This SRP amendment became effective on March 28, 2019 (see table below for details on cumulative shares repurchased pursuant to the SRP, including shares repurchased during 2019).
On July 23, 2019, the Company announced that the Board approved a third amendment to the SRP, effective July 24, 2019, extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than August 31, 2019, rather than on or before July 31, 2019.
On August 20, 2019, the Company announced that the Board approved a fourth amendment to the SRP, effective August 22, 2019 extending the date on which repurchases are able to be made in respect of requests made during the period commencing January 1, 2019 up to and including June 30, 2019 to no later than October 31, 2019, rather than on or before August 31, 2019. The Company completed the repurchases on October 30, 2019 and repurchased 446,830 shares of common stock for approximately $7.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing January 1, 2019 up to and including June 30, 2019.
On January 9, 2020, the Company announced that the Board approved a fifth amendment to the SRP, effective January 10, 2020 extending the date on which repurchases are able to be made in respect of requests made during the period commencing July 1, 2019 up to and including December 31, 2019 to on or before March 16, 2020, rather than on or before January 31, 2020.
On January 9, 2020, the Company also announced that the Board had suspended the SRP, and that it would not accept any repurchase requests or make any repurchases under the SRP during the pendency of the 2020 Tender Offer or for 10 business days thereafter.
On February 26, 2020, the Company repurchased 505,101 shares of common stock for approximately $8.8 million, at an average price per share of $17.50 pursuant to the SRP. The repurchases reflect all repurchase requests made in good order following the death or qualifying disability of stockholders during the period commencing July 1, 2019 up to and including December 31, 2019.
Pursuant to the SRP, repurchases were to be made in respect of requests made during the periods when the SRP was active during the active periods under the SRP during the six months ending June 30, 2020 - the period from January 1, 2020 to January 8, 2020 and the period from February 26, 2020 up to and including June 30, 2020 - no later than July 31, 2020.
On August 13, 2020, in order to strategically maintain the Company’s liquidity in light of the continued impact of COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5, which restricts the Company from repurchasing shares until no earlier than the quarter ending June 30, 2021, on August 6, 2020, the Board determined that, effective on August 12, 2020, repurchases under the SRP would be suspended. The Board has also rejected all repurchase requests made during the period from January 1, 2020 until the effectiveness of the suspension of the SRP. No further repurchase requests under the SRP may be made unless and until the SRP is reactivated. No assurances can be made as to when or if the SRP will be reactivated.
When a stockholder requests redemption and redemption is approved by the Board, the Company will reclassify such obligation from equity to a liability based on the settlement value of the obligation. Shares repurchased under the SRP have the status of authorized but unissued shares.
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2020:
Number of Shares Repurchased (2)
Average Price per Share (2)2
Cumulative repurchases as of December 31, 20194,391,519 $20.95 
Year ended December 31, 2020 (1)
505,101 17.50 
Cumulative repurchases as of December 31, 2020
4,896,620 20.60 
_________
(1) Includes 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.
Distribution Reinvestment Plan
Pursuant to the DRIP, stockholders may elect to reinvest distributions paid in cash by the Company into shares of common stock. No dealer manager fees or selling commissions are paid with respect to shares purchased under the DRIP. The shares purchased pursuant to the DRIP have the same rights and are treated in the same manner as all of the other shares of outstanding common stock. The Board may designate that certain cash or other distributions be excluded from reinvestment pursuant to the DRIP. The Company has the right to amend the DRIP or terminate the DRIP with ten days’ notice to participants. Shares issued under the DRIP are recorded as equity in the accompanying consolidated balance sheet in the period distributions are declared. During the years ended December 31, 2020, 2019 and 2018, the Company issued 0.9 million, 1.5 million and 1.7 million shares of common stock pursuant to the DRIP, generating aggregate proceeds of $14.6 million, $27.2 million and $35.7 million, respectively. Because shares of common stock are only offered and sold pursuant to the DRIP in connection with the reinvestment of distributions paid in cash, participants in the DRIP will not be able to reinvest in shares thereunder for so long as the Company pays distributions in stock instead of cash.
Stockholder Rights Plan
In May 2020, the Company announced that the Board had approved a stockholder rights plan. In December 2020, the Company issued a dividend of one common share purchase right for each share of its common stock outstanding as authorized by its board of directors in its discretion.
Preferred Stock
The Company is authorized to issue up to 50,000,000 shares of preferred stock. In connection with an underwritten offering in December 2019 (see details below), the Company classified and designated 1,610,000 shares of its authorized preferred stock as authorized shares of its Series A Preferred Stock as of December 31, 2020. In September 2020, the Board authorized the classification of 600,000 additional shares of the Company’s preferred stock as Series A Preferred Stock in connection with the Preferred Stock Equity Line (as defined below). The Company had 1,610,000 shares of Series A Preferred Stock issued and outstanding, as of December 31, 2020 and 2019.
In December 2019, the Company issued and sold 1,610,000 shares of the Series A Preferred Stock in an underwritten public offering at a public offering price equal to the liquidation preference of $25.00 per share. The gross proceeds from this offering were $40.3 million and net proceeds were $37.6 million after deducting the underwriting discount of $1.3 million and additional offering expenses of $1.4 million.
On September 15, 2020, the Company entered into a preferred stock purchase agreement and registration rights agreement with B. Riley Principal Capital, LLC (“B. Riley”), pursuant to which the Company has the right from time to time to sell up to an aggregate of $15 million of shares of its Series A Preferred Stock to B. Riley until December 31, 2023, on the terms and subject to the conditions set forth in the purchase agreement. This arrangement is also referred to as the “Preferred Stock Equity Line.” The Company controls the timing and amount of any sales to B. Riley under the Preferred Stock Equity Line, and B. Riley is obligated to make purchases of up to 3,500 shares of Series A Preferred Stock each time (as may be increased by mutual agreement by the parties) in accordance with the purchase agreement, upon certain terms and conditions being met. The Company did not sell any shares under the Preferred Stock Equity Line during the year ended December 31, 2020.
Series A Preferred Stock — Terms
Holders of Series A Preferred Stock are entitled to cumulative dividends in the amount of $1.84375 per share each year, which is equivalent to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The Series A Preferred Stock has no stated maturity and will remain outstanding indefinitely unless redeemed, converted or otherwise repurchased. On and after December 11, 2024, at any time and from time to time, the Series A Preferred Stock will be redeemable in whole or in part, at the Company’s option, at a cash redemption price of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. In addition, upon the occurrence of a Delisting Event or a Change of Control (each as defined in the articles supplementary governing the terms of the Series A Preferred Stock (the “Articles Supplementary”)), the Company may, subject to certain conditions, at its option, redeem the Series A Preferred Stock, in whole or in part, after the first date on which the Delisting Event occurred or within 120 days after the first date on which the Change of Control occurred, as applicable, by paying the liquidation preference of $25.00 per share, plus an amount equal to all dividends accrued and unpaid (whether or not authorized or declared), if any, to, but not including, the redemption date. Upon the occurrence of a Change of Control during a continuing Delisting Event, unless the Company has elected to exercise its redemption right, holders of the Series A Preferred Stock will have certain rights to convert Series A Preferred Stock into shares of Company’s common stock. In addition, upon the occurrence of a Delisting Event, the dividend rate will be increased on the day after the occurrence of the Delisting Event by 2.00% per annum to the rate
of 9.375% of the $25.00 liquidation preference per share per annum (equivalent to $2.34375 per share each year) from and after the date of the Delisting Event. Following the cure of such Delisting Event, the dividend rate will revert to the rate of 7.375% of the $25.00 liquidation preference per share per annum. The necessary conditions to convert the Series A Preferred Stock into Common Stock have not been met as of December 31, 2020. Therefore, Series A Preferred Stock did not impact Company’s earnings per share calculations for the year ended December 31, 2019.
The Series A Preferred Stock ranks senior to common stock, with respect to dividend rights and rights upon the Company’s voluntary or involuntary liquidation, dissolution or winding up.
Voting rights for holders of Series A Preferred Stock exist primarily with respect to the ability to elect two additional directors to the board of directors if six or more quarterly dividends (whether or not authorized or declared or consecutive) payable on the Series A Preferred Stock are in arrears, and with respect to voting on amendments to the Company’s charter (which includes the Articles Supplementary) that materially and adversely affect the rights of the Series A Preferred Stock or create additional classes or series of shares of the Company’s capital stock that are senior to the Series A Preferred Stock. Other than the limited circumstances described above and in the Articles Supplementary, holders of Series A Preferred Stock do not have any voting rights.
Distributions and Dividends
Common Stock
In April 2013, the Board authorized, and the Company began paying distributions on a monthly basis at a rate equivalent to $1.70 per annum, per share of common stock, which began in May 2013. In March 2017, the Board authorized a decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of April 1, 2017, to a rate equivalent to $1.45 per annum per share of common stock. On February 20, 2018, the Board authorized a further decrease in the rate at which the Company pays monthly distributions to stockholders, effective as of March 1, 2018, to a rate equivalent to $0.85 per annum per share of common stock.
From March 1, 2018 until June 30, 2020, the Company paid monthly distributions to stockholders at a rate equivalent to $0.85 per annum per share of common stock. Distributions were payable by the 5th day following each month end to stockholders of record at the close of business each day during the prior month.
On August 13, 2020, the Board changed the Company’s common stock distribution policy in order to preserve the Company’s liquidity and maintain additional financial flexibility in light of the continued COVID-19 pandemic and to comply with an amendment to the Credit Facility described in Note 5 which restricts the Company from paying distributions on common stock until no earlier than the quarter ending June 30, 2021. Under the new policy, distributions authorized by the Board on the Company’s shares of common stock, if and when declared, are now paid on a quarterly basis in arrears in shares of the Company’s common stock valued at the Company’s estimated per share net asset value of common stock in effect on the applicable date, based on a single record date to be specified at the beginning of each quarter. The Company declared the Stock Dividends of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock on October 1, 2020 and January 4, 2021. This amount was based on the Company’s prior cash distribution rate of $0.85 per share per annum. The Board may further change the Company’s common stock distribution policy at any time, further reduce the amount of distributions paid or suspend distribution payments at any time, and therefore distribution payments are not assured.
The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the years ended December 31, 2020, 2019 and 2018, retroactively adjusted for the effect of the Stock Dividends:
Year Ended December 31,
202020192018
Return of capital (1)
100.0 %$0.42 100 %$0.83 100 %$0.92 
Capital gain dividend income— %— — %— — %— 
Ordinary dividend income— %— — %— — %— 
Total100.0 %$0.42 100.0 %$0.83 100.0 %$0.92 
________
(1) Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to the Company’s shareholders for U.S. federal income tax purposes.
Series A Preferred Stock
Dividends on our Series A Preferred Stock accrue in an amount equal to $1.84375 per share each year ($0.460938 per share per quarter) to Series A Preferred Stock holders, which is equivalent to 7.375% per annum on the $25.00 liquidation preference per share of Series A Preferred Stock. Dividends on the Series A Preferred Stock are cumulative and payable quarterly in arrears on the 15th day of January, April, July and October of each year or, if not a business day, the next succeeding business day to holders of record on the close of business on the record date set by our board of directors and declared by us. The first quarterly dividend for the Series A Preferred Stock sold in this offering was paid on January 15, 2020 and represented an accrual for less than a full quarter, covering the period from December 11, 2019 to December 31, 2019. Any accrued and unpaid dividends payable with respect to the Series A Preferred Stock become part of the liquidation preference thereof.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements
12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]  
Related Party Transactions and Arrangements Related Party Transactions and Arrangements
As of December 31, 2020 and 2019, the Special Limited Partner owned 9,008 and 8,888 shares, respectively, of the Company’s outstanding common stock. The Advisor and its affiliates may incur and pay costs and fees on behalf of the Company. As of December 31, 2020 and 2019, the Advisor held 90 partnership units in the OP designated as “OP Units” (“OP Units”).
The limited partnership agreement of the OP (as amended from time to time, the “LPA”) allows for the special allocation, solely for tax purposes, of excess depreciation deductions of up to $10.0 million to the Advisor, a limited partner of the OP.  In connection with this special allocation, the Advisor has agreed to restore a deficit balance in its capital account in the event of a liquidation of the OP and has agreed to provide a guaranty or indemnity of indebtedness of the OP.
Fees Incurred in Connection with the Operations of the Company
On February 17, 2017, the members of a special committee of the Board unanimously approved certain amendments to and a restatement of the then effective advisory agreement, by and among the Company, the OP and the Advisor (the “Second A&R Advisory Agreement”). The Second A&R Advisory Agreement, which superseded, amended and restated the previously effective advisory agreement (the “Original A&R Advisory Agreement”), took effect on February 17, 2017. The initial term of the Second A&R Advisory Agreement expires on February 17, 2027, and is automatically renewable for another ten-year term upon each ten-year anniversary unless the Second A&R Advisory Agreement is terminated (i) with notice of an election not to renew at least 365 days prior to the applicable tenth anniversary, (ii) in accordance with a change of control (as defined in the Second A&R Advisory Agreement) or a transition to self-management, (iii) by 67% of the independent directors of the Board for cause, without penalty, with 45 days’ notice or (iv) with 60 days prior written notice by the Advisor for (a) a failure to obtain a satisfactory agreement for any successor to the Company to assume and agree to perform obligations under the Second A&R Advisory Agreement or (b) any material breach of the Second A&R Advisory Agreement of any nature whatsoever by the Company.
On July 25, 2019, the Company entered into Amendment No. 1 to the Second Amended and Restated Advisory Agreement (the “Advisory Agreement Amendment”) among the Company, the OP, and the Advisor. The Advisory Agreement Amendment was unanimously approved by the Company’s independent directors. Additional information on the Advisory Agreement Amendment is included later in this footnote under “—Professional Fees and Other Reimbursements.”
Acquisition Expense Reimbursements
The Advisor may be reimbursed for services provided for which it incurs investment-related expenses, or insourced expenses. The amount reimbursed for insourced expenses may not exceed 0.5% of the contract purchase price of each acquired property or 0.5% of the amount advanced for a loan or other investment. Additionally, the Company reimburses the Advisor for third party acquisition expenses. Under the Second A&R Advisory Agreement, total acquisition expenses may not exceed 4.5% of the contract purchase price of the Company’s portfolio or 4.5% of the amount advanced for all loans or other investments. This threshold has not been exceeded through December 31, 2020.
Asset Management Fees and Variable Management/Incentive Fees
Under the LPA and the advisory agreement that was superseded by the Original A&R Advisory Agreement and until March 31, 2015, for its asset management services, the Company issued the Advisor an asset management subordinated participation by causing the OP to issue (subject to periodic approval by the Board) to the Advisor partnership units of the OP designated as “Class B Units” (“Class B Units”). The Class B Units were intended to be profit interests and vest, and no longer are subject to forfeiture, at such time as: (x) the value of the OP’s assets plus all distributions made equals or exceeds the total amount of capital contributed by investors plus a 6.0% cumulative, pre-tax, non-compounded annual return thereon (the
“Economic Hurdle”); (y) any one of the following occurs: (1) a listing; (2) another liquidity event or (3) the termination of the advisory agreement by an affirmative vote of a majority of the Company’s independent directors without cause; and (z) the Advisor is still providing advisory services to the Company (the “Performance Condition”).
Unvested Class B Units will be forfeited immediately if: (a) the advisory agreement is terminated for any reason other than a termination without cause; or (b) the advisory agreement is terminated by an affirmative vote of a majority of the Company’s independent directors without cause before the Economic Hurdle has been met.
Subject to approval by the Board, the Class B Units were issued to the Advisor quarterly in arrears pursuant to the terms of the LPA. The number of Class B Units issued in any quarter was equal to: (i) the excess of (A) the product of (y) the cost of assets multiplied by (z) 0.1875% over (B) any amounts payable as an oversight fee (as described below) for such calendar quarter; divided by (ii) the value of one share of common stock as of the last day of such calendar quarter, which was initially equal to $22.50 (the price in the Company’s initial public offering of common stock minus the selling commissions and dealer manager fees). The value of issued Class B Units will be determined and expensed when the Company deems the achievement of the Performance Condition to be probable. As of December 31, 2020, the Company cannot determine the probability of achieving the Performance Condition. The Advisor receives cash distributions on each issued Class B Unit equivalent to the cash distribution paid, if any on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. These distributions on Class B Units are included in general and administrative expenses in the consolidated statement of operations and comprehensive loss until the Performance Condition is considered probable to occur. The Board has previously approved the issuance of 359,250 Class B Units to the Advisor in connection with this arrangement. The Board determined in February 2018 that Economic Hurdle had been satisfied, however none of the events have occurred, including a listing of the Company’s common stock on a national securities exchange, which would have satisfied the other vesting requirement of the Class B Units. Therefore, no expense has ever been recognized in connection with the Class B Units.
On May 12, 2015, the Company, the OP and the Advisor entered into an amendment to the then-current advisory agreement, which, among other things, provided that the Company would cease causing the OP to issue Class B Units to the Advisor with respect to any period ending after March 31, 2015.
Effective February 17, 2017, the Second A&R Advisory Agreement requires the Company to pay the Advisor a base management fee, which is payable on the first business day of each month. The fixed portion of the base management fee is equal to $1.625 million per month, while the variable portion of the base management fee is equal to one-twelfth of 1.25% of the cumulative net proceeds of any equity (including convertible equity and certain convertible debt but excluding proceeds from the DRIP) issued by the Company and its subsidiaries subsequent to February 17, 2017 per month. The base management fee is payable to the Advisor or its assignees in cash, OP Units or shares, or a combination thereof, the form of payment to be determined at the discretion of the Advisor and the value of any OP Unit or share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate.
In addition, the Second A&R Advisory Agreement requires the Company to pay the Advisor a variable management/incentive fee quarterly in arrears equal to (1) the product of fully diluted number of shares of common stock outstanding multiplied by (2) (x) 15.0% of the applicable prior quarter’s Core Earnings (as defined below) per share in excess of $0.375 per share plus (y) 10.0% of the applicable prior quarter’s Core Earnings per share in excess of $0.47 per share. Core Earnings is defined as, for the applicable period, net income or loss, computed in accordance with GAAP, excluding non-cash equity compensation expense, the variable management/incentive fee, acquisition and transaction related fees and expenses, financing related fees and expenses, depreciation and amortization, realized gains and losses on the sale of assets, any unrealized gains or losses or other non-cash items recorded in net income or loss for the applicable period, regardless of whether such items are included in other comprehensive income or loss, or in net income, one-time events pursuant to changes in GAAP and certain non-cash charges, impairment losses on real estate related investments and other than temporary impairments of securities, amortization of deferred financing costs, amortization of tenant inducements, amortization of straight-line rent and any associated bad debt reserves, amortization of market lease intangibles, provision for loss loans, and other non-recurring revenue and expenses (in each case after discussions between the Advisor and the independent directors and approved by a majority of the independent directors). The variable management/incentive fee is payable to the Advisor or its assignees in cash or shares, or a combination of both, the form of payment to be determined in the sole discretion of the Advisor and the value of any share to be determined by the Advisor acting in good faith on the basis of such quotations and other information as it considers, in its reasonable judgment, appropriate. No variable management incentive fee was incurred for the years ended December 31, 2020, 2019 and 2018.
Property Management Fees
Unless the Company contracts with a third party, the Company pays the Property Manager a property management fee on a monthly basis, equal to 1.5% of gross revenues from the Company’s stand-alone single-tenant net leased properties managed and 2.5% of gross revenues from all other types of properties managed, plus market-based leasing commissions applicable to the geographic location of the property. The Company also reimburses the Property Manager for property level expenses incurred by the Property Manager. The Property Manager may charge a separate fee for the one-time initial rent-up or leasing-up of newly constructed properties in an amount not to exceed the fee customarily charged in arm’s length transactions by others rendering similar services in the same geographic area for similar properties, and the Property Manager is allowed to receive a higher property management fee in certain cases if approved by our Board of Directors (including a majority of the independent directors).
If the Company contracts directly with third parties for such services, the Company will pay the third party customary market fees and will pay the Property Manager an oversight fee of 1.0% of the gross revenues of the property managed by the third party. In no event will the Company pay the Property Manager or any affiliate of the Property Manager both a property management fee and an oversight fee with respect to any particular property. If the Property Manager provides services other than those specified in the Property Management Agreement, the Company will pay the Property Manager a monthly fee equal to no more than that which the Company would pay to a third party that is not an affiliate of the Company or the Property Manager to provide the services.
On February 17, 2017, the Company entered into the Amended and Restated Property Management and Leasing Agreement (the “A&R Property Management Agreement”) with the OP and the Property Manager. The A&R Property Management Agreement automatically renews for successive one-year terms unless any party provides written notice of its intention to terminate the A&R Property Management Agreement at least 90 days prior to the end of the term. Neither party provided notice of intent to terminate. The current term of the A&R Property Management Agreement expires February 17, 2021.The Property Manager may assign the A&R Property Management Agreement to any party with expertise in commercial real estate which has, together with its affiliates, over $100.0 million in assets under management.
On April 10, 2018, in connection with the Multi-Property CMBS Loan, the Company and the OP entered into a further amendment to the A&R Property Management Agreement confirming, consistent with the intent of the parties, that the borrowers under the Multi-Property CMBS Loan and other subsidiaries of the OP that own or lease the Company’s properties are the direct obligors under the arrangements pursuant to which the Company’s properties are managed by either the Property Manager or a third party overseen by the Property Manager pursuant to the A&R Property Management Agreement.
Professional Fees and Other Reimbursements
The Company reimburses the Advisor’s costs of providing administrative services including personnel costs, except for costs to the extent that the employees perform services for which the Advisor receives a separate fee. This reimbursement includes reasonable overhead expenses for employees of the Advisor or its affiliates directly involved in the performance of services on behalf of the Company, including the reimbursement of rent expense at certain properties that are both occupied by employees of the Advisor or its affiliates and owned by affiliates of the Advisor. During the year ended December 31, 2020, 2019 and 2018, the Company incurred $10.8 million, $10.6 million and $8.9 million, respectively, of reimbursement expenses from the Advisor for providing administrative services. These reimbursement expenses are included in general and administrative expense on the consolidated statements of operations and comprehensive income (loss).
On July 25, 2019, the Company entered into the Advisory Agreement Amendment. Under the Second A&R Advisory Agreement, including prior to the Advisory Agreement Amendment, the Company has been required to reimburse the Advisor for, among other things, reasonable salaries and wages, benefits and overhead of all employees of the Advisor or its affiliates, except for costs of employees to the extent that the employees perform services for which the Advisor receives a separate fee.
The Advisory Agreement Amendment clarifies that, with respect to executive officers of the Advisor, the Company is required to reimburse the Advisor or its affiliates for the reasonable salaries and wages, benefits and overhead of the Company’s executive officers, other than for any executive officer that is also a partner, member or equity owner of AR Global, an affiliate of the Advisor.
Further, under the Advisory Agreement Amendment, the aggregate amount of expenses relating to salaries, wages and benefits, including for executive officers and all other employees of the Advisor or its affiliates (the “Capped Reimbursement Amount”), for each fiscal year is subject to a limit that is equal to the greater of: (a) a fixed component (the “Fixed Component”) and (b) a variable component (the “Variable Component”).
Both the Fixed Component and the Variable Component increase by an annual cost of living adjustment equal to the greater of (x) 3.0% and (y) the CPI, as defined in the amendment for the prior year ended December 31st. Initially, for the year ended December 31, 2019; (a) the Fixed Component was equal to $6.8 million and (b) the Variable Component was equal to (i) the sum of the total real estate investments, at cost as recorded on the balance sheet dated as of the last day of each fiscal quarter (the “Real Estate Cost”) in the year divided by four, which amount is then (ii) multiplied by 0.29%.
If the Company sells real estate investments aggregating an amount equal to or more than 25.0% of Real Estate Cost, in one or a series of related dispositions in which the proceeds of the disposition(s) are not reinvested in Investments (as defined in the Advisory Agreement Amendment), then within 12 months following the disposition(s), the advisory agreement requires the Advisor and the Company to negotiate in good faith to reset the Fixed Component; provided that if the proceeds of the disposition(s) are paid to shareholders of the Company as a special distribution or used to repay loans with no intent of subsequently re-financing and re-investing the proceeds thereof in Investments, the advisory agreement requires these negotiations within 90 days thereof, in each case taking into account reasonable projections of reimbursable costs in light of the Company’s reduced assets.
As part of this reimbursement, for the year ended December 31, 2020, the Company paid approximately $2.5 million in 2019 to the Advisor or its affiliates as reimbursement for bonuses of employees of the Advisor or its affiliates who provided administrative services during such calendar year, prorated for the time spent working on matters relating to the Company. The Company does not reimburse the Advisor or its affiliates for any bonus amounts relating to time dedicated to the Company by Edward M. Weil, Jr., the Company’s Chief Executive Officer. The Advisor formally awarded 2019 bonuses to employees of the Advisor or its affiliates in September 2020 (the “2019 Bonus Awards”). The original $2.5 million estimate for bonuses recorded and paid to the Advisor in 2019 exceeded the cash portion of the 2019 Bonus Awards to be paid to employees of the Advisor or its affiliates and to be reimbursed by the Company by $1.2 million. As a result, during the three months ended September 30, 2020, the Company recorded a receivable from the Advisor of $1.2 million in prepaid expenses and other assets on the consolidated balance sheet and a corresponding reduction in general and administrative expenses. Pursuant to authorization by the independent members of the Company’s board of directors, the $1.2 million receivable is payable to the Company over a 10-month period from January 2021 through October 2021.
Reimbursements for the cash portion of 2020 bonuses to employees of the Advisor or its affiliates continue to be expensed and reimbursed on a monthly basis during 2020 in accordance with estimates provided by the Advisor. Generally, prior to the 2019 Bonus Awards, employee bonuses have been formally awarded to employees of the Advisor or its affiliates in March as an all - cash award and paid out by the Advisor in the year subsequent to the year in which services were rendered to the Company.
In December 2020, after mediation on October 27, 2020, the Advisor agreed to a settlement with the Company’s former chief executive officer for severance claims related to his termination in 2018. Pursuant to the settlement, among other parties, the Advisor advised the Company that the Company and its directors and officers were released from any and all actions or claims the former chief executive officer now has or may ever have against them. Prior to the agreement, the Advisor did not believe any settlement was probable. In consideration of the release, among other things, and upon the recommendation of its nominating and corporate governance committee, which determined that the reimbursement was advisable and fair to, and in the best interest of, the Company, the Company’s board of directors approved the reimbursement by the Company to the Advisor of severance payments and legal costs relating to this settlement and determined that the reimbursement for those payments and costs would not be subject to (and therefore would not be aggregated with other reimbursements that are subject to) the Capped Reimbursement Amount. The Company recorded approximately $2.2 million of expenses for the reimbursement which is included in general and administrative expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.
Summary of fees, expenses and related payables
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202020192018December 31,
(In thousands)
Incurred
Incurred
Incurred20202019
One-time fees and reimbursements:
Acquisition cost reimbursements$81 $39 $176 $11 $— 
Ongoing fees and reimbursements:
Asset management fees 19,987 19,526 19,500 — 27 
Property management fees (6)
4,197 3,888 3,571 288 (44)
Professional fees and other reimbursements (1) (4)
12,102 

10,073 8,883 (61)(377)(5)
Professional fees credit due from Advisor(1,217)— — (1,217)(3)— 
Distributions on Class B Units (2)
178 305 340 — — 
Total related party operation fees and reimbursements$35,328 $33,831 $32,470 $(979)$(394)
_________
(1)    Included in general and administrative expenses in the consolidated statements of operations. Includes $5.6 million and $7.2 million subject to the Capped Reimbursement Amount for the years ended December 31, 2020 and 2019, respectively.
(2)     Prior to April 1, 2015, the Company caused the OP to issue (subject to periodic approval by the Board) to the Advisor restricted performance-based Class B Units for asset management services. As of December 31, 2020, the Board had approved the issuance of, and the OP had issued, 359,250 Class B Units to the Advisor in connection with this arrangement. Effective April 1, 2015, the Company began paying an asset management fee to the Advisor or its assignees in cash, in shares, or a combination of both and no longer issues any Class B Units.
(3)     Balance includes a receivable of $1.2 million from the Advisor related to the overpayment of 2019 Bonus Awards as of December 31, 2020 which, pursuant to authorization by the independent members of the Company’s board of directors, is payable over a ten month period from January 2021 to October 2021.
(4)     During the year ended December 31, 2019, the Company recorded a reduction of general and administrative expenses in the amount of $0.5 million related to the reversal of a payable balance due to RCS Capital Corporation. During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(5) Balance includes a receivable of $0.5 million from the Advisor as of December 31, 2019, previously recorded in the fourth quarter of 2018, which, pursuant to authorization by the independent members of the Company’s board of directors, was fully paid during 2020.
(6)    Inclusive of $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2020.
Fees and Participations Incurred in Connection with a Listing or the Liquidation of the Company’s Real Estate Assets
Fees Incurred in Connection with a Listing
If the common stock of the Company is listed on a national exchange, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive a subordinated incentive listing distribution from the OP equal to 15.0% of the amount by which the market value of all issued and outstanding shares of common stock plus distributions exceeds the aggregate capital contributed plus an amount equal to a 6.0% cumulative, pre-tax non-compounded annual return to investors in the Company’s initial public offering of common stock. No such distribution was incurred during the years ended December 31, 2020, 2019 and 2018. If the Special Limited Partner or any of its affiliates receives the subordinated incentive listing distribution the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive termination distribution described below.
Subordinated Participation in Net Sales Proceeds
Upon a liquidation or sale of all or substantially all of the Company’s assets, including through a merger or sale of stock, the Special Limited Partner will be entitled to receive a subordinated participation in the net sales proceeds of the sale of real estate assets from the OP equal to 15.0% of remaining net sale proceeds after return of capital contributions to investors in the Company’s initial public offering of common stock plus payment to investors of a 6.0% cumulative, pre-tax non-compounded annual return on the capital contributed by investors. No such participation in net sales proceeds became due and payable during the years ended December 31, 2020, 2019 and 2018. Any amount of net sales proceeds paid to the Special Limited Partner or any of its affiliates prior to the Company’s listing or termination or non-renewal of the advisory agreement with the
Advisor, as applicable, will reduce dollar for dollar the amount of the subordinated incentive listing distribution described above and subordinated incentive termination distribution described below.
Termination Fees
Under the operating partnership agreement of the OP, upon termination or non-renewal of the advisory agreement with the Advisor, with or without cause, the Special Limited Partner will be entitled to receive a promissory note as evidence of its right to receive subordinated termination distributions from the OP equal to 15.0% of the amount by which the sum of the Company’s market value plus distributions exceeds the sum of the aggregate capital contributed plus an amount equal to an annual 6.0% cumulative, pre-tax, non-compounded annual return to investors in the Company’s initial public offering of common stock. The Special Limited Partner is able to elect to defer its right to receive a subordinated distribution upon termination until either a listing on a national securities exchange or other liquidity event occurs. If the Special Limited Partner or any of its affiliates receives the subordinated incentive termination distribution, the Special Limited Partner and its affiliates will no longer be entitled to receive the subordinated participation in net sales proceeds or the subordinated incentive listing distribution described above.
Under the Second A&R Advisory Agreement, upon the termination or non-renewal of the agreement, the Advisor will be entitled to receive from the Company all amounts due to the Advisor, including any change of control fee and transition fee (both described below), as well as the then-present fair market value of the Advisor’s interest in the Company. All fees will be due within 30 days after the effective date of the termination of the Second A&R Advisory Agreement.
Upon a termination by either party in connection with a change of control (as defined in the Second A&R Advisory Agreement), the Company would pay the Advisor a change of control fee equal to the product of four (4) and the “Subject Fees.”
Upon a termination by the Company in connection with a transition to self-management, the Company would pay the Advisor a transition fee equal to (i) $15.0 million plus (ii) the product of four multiplied by the Subject Fees, provided that the transition fee shall not exceed an amount equal to 4.5 multiplied by the Subject Fees.
The Subject Fees are equal to (i) the product of four multiplied by the actual base management fee plus (ii) the product of four multiplied by the actual variable management/incentive fee, in each of clauses (i) and (ii), payable for the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated, plus (iii) without duplication, the annual increase in the base management fee resulting from the cumulative net proceeds of any equity raised (but excluding proceeds from the DRIP) in respect to the fiscal quarter immediately prior to the fiscal quarter in which the change of control occurs or the transition to self-management, as applicable, is consummated.
The right to termination of the Second A&R Advisory Agreement in connection with a change of control or transition to self-management is subject to a lockout period that requires the notice of any termination in connection with a change of control or transition to self-management to be delivered after February 14, 2019.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Economic Dependency
12 Months Ended
Dec. 31, 2020
Economic Dependency [Abstract]  
Economic Dependency Economic Dependency
Under various agreements, the Company has engaged or will engage the Advisor, its affiliates and entities under common control with the Advisor to provide certain services that are essential to the Company, including asset management services, supervision of the management and leasing of properties owned by the Company and asset acquisition and disposition decisions, as well as other administrative responsibilities for the Company including accounting services and investor relations.
As a result of these relationships, the Company is dependent upon the Advisor and its affiliates. In the event that the Advisor and its affiliates are unable to provide the Company with the respective services, the Company will be required to find alternative providers of these services.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-Based Compensation
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Equity-Based Compensation Equity-Based Compensation
Restricted Share Plan
The Company has adopted an employee and director incentive restricted share plan (as amended from time to time, the “RSP”), which provides the Company with the ability to grant awards of restricted shares of common stock (“restricted shares”) to the Company’s directors, officers and employees (if the Company ever has employees), employees of the Advisor and its affiliates, employees of entities that provide services to the Company, directors of the Advisor or of entities that provide services to the Company, certain consultants to the Company and the Advisor and its affiliates or to entities that provide services to the Company. The total number of shares of common stock that may be subject to awards granted under the RSP may not exceed 5.0% of the Company’s outstanding shares of common stock on a fully diluted basis at any time and in any event will not exceed 3.5 million shares (as such number may be further adjusted for stock splits, stock dividends, combinations and similar events).
Prior to August 2017, the RSP provided for an automatic grant of 1,333 restricted shares to each of the independent directors, without any further approval by the Board or the stockholders, on the date of his or her initial election to the Board and thereafter on the date of each annual stockholder meeting. The restricted shares granted as annual automatic awards prior to August 2017 were subject to vesting over a five-year period following the date of grant.
In August 2017, the Board amended the RSP to provide that the number of restricted shares comprising the automatic annual award to each of the independent directors would be equal to the quotient of $30,000 divided by the then-current Estimated Per-Share NAV and subsequently amended and restated the RSP to eliminate the automatic annual awards and to make other revisions related to the implementation of a new independent director equity compensation program. As part of this independent director equity compensation program, the Board approved a one-time grant of restricted share awards to the independent directors as follows: (i) 300,000 restricted shares to the chairman, with one-seventh of the shares vesting annually in equal increments over a seven-year period with initial vesting on August 4, 2018; and (ii) 25,000 restricted shares to each of the three other independent directors, with one-fifth of the shares vesting annually in equal increments over a five-year period with initial vesting on August 4, 2018. In connection with these one-time grants, the restricted shares granted as automatic annual awards in connection with the Company’s 2017 annual meeting of stockholders on July 21, 2017 were forfeited.
On July 29, 2019, the Board elected B.J. Penn as a member of the Board to serve as a director effective immediately. Mr. Penn, like the Company’s other independent directors, participates in the Company’s independent director compensation program. During the year ended December 31, 2019, the Company paid to Mr. Penn an annual cash retainer effective as of July 29, 2019 pro-rated for the remaining portion of the current annual period, and he was awarded 15,000 restricted shares vesting annually in equal increments over a three-year period with initial vesting on August 4, 2020.
Restricted shares may not, in general, be sold or otherwise transferred until restrictions are removed and the shares have vested. Holders of restricted shares may receive cash distributions prior to the time that the restrictions on the restricted shares have lapsed. Any distributions payable in shares of common stock are subject to the same restrictions as the underlying restricted shares.
The following table reflects the amount of shares outstanding as of December 31, 2020 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2017382,510 $21.47 
Granted— — 
Vested(60,268)21.78 
Forfeitures— — 
Unvested, December 31, 2018322,242 21.41 
Granted15,000 17.50 
Vested(60,001)21.48 
Forfeitures— — 
Unvested, December 31, 2019277,241 21.18 
Stock dividend2,878 15.75 
Granted— — 
Vested(64,735)21.18 
Forfeitures— — 
Unvested, December 31, 2020215,384 21.11 
As of December 31, 2020, the Company had $4.0 million of unrecognized compensation cost related to unvested restricted share awards granted under the RSP. That cost is expected to be recognized over a weighted-average period of 3.2 years. Compensation expense related to restricted shares was $1.3 million, $1.3 million and approximately $1.2 million during the years ended December 31, 2020, 2019 and 2018, respectively.
Other Share-Based Compensation
The Company may issue common stock in lieu of cash to pay fees earned by the Company’s directors at the respective director’s election. There are no restrictions on shares issued in lieu of cash compensation since these payments in lieu of cash relate to fees earned for services performed. No such shares were issued during the years ended December 31, 2020, 2019 and 2018.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive (Loss) Income
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Accumulated Other Comprehensive (Loss) Income Accumulated Other Comprehensive (Loss) Income
The following table illustrates the changes in accumulated other comprehensive (loss) income as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 20172,473 
Other comprehensive income, before reclassifications2,367 
Amounts reclassified from accumulated other comprehensive (loss) income(258)
Balance, December 31, 20184,582 
Other comprehensive loss, before reclassifications(10,753)
Amounts reclassified from accumulated other comprehensive (loss) income(872)
Balance, December 31, 2019(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amounts reclassified from accumulated other comprehensive (loss) income7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020$(39,673)

Accumulated other comprehensive (loss) income predominately relates to the unrealized gains (losses) on designated derivatives, however, as previously discussed in Note 7 — Derivatives and Hedging, a previously designated hedge was terminated and the termination costs are being amortized over the term of the hedged item. The unamortized portion of the terminated swap still remaining in accumulated other comprehensive (loss) income is $1.3 million as of December 31, 2020.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Non-Controlling Interests
12 Months Ended
Dec. 31, 2020
Noncontrolling Interest [Abstract]  
Non-Controlling Interests Non-Controlling Interests
Non-Controlling Interests in the Operating Partnership
The Company is the sole general partner and holds substantially all of the OP Units. As of December 31, 2020 and 2019, the Advisor held 90 OP Units, which represents a nominal percentage of the aggregate ownership in the OP.
In November 2014, the Company partially funded the purchase of an MOB from an unaffiliated third party by causing the OP to issue 405,908 OP Units, with a value of $10.1 million, or $25.00 per unit, to the unaffiliated third party.
A holder of OP Units has the right to receive cash distributions equivalent to the cash distributions, if any, on the Company’s common stock in an amount retroactively adjusted to reflect the Stock Dividends, other stock dividends and other similar events. After holding the OP Units for a period of one year, a holder of OP Units has the right to redeem OP Units for, at the option of the OP, the corresponding number of shares of the Company’s common stock as retroactively adjusted for the Stock Dividends, other stock dividends and other similar events, or the cash equivalent. The remaining rights of the limited partners in the OP are limited, however, and do not include the ability to replace the general partner or to approve the sale, purchase or refinancing of the OP’s assets. During the years ended December 31, 2020, 2019 and 2018, OP Unit non-controlling interest holders were paid distributions of $0.2 million, $0.3 million, and $0.5 million respectively.
Non-Controlling Interests in Property Owning Subsidiaries
The Company also has investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Upon disposition of a property subject to non-controlling interest, the investor will receive a proportionate share of the net proceeds from the sale of the property. The investor has no recourse to any other assets of the Company. Due to the nature of the Company’s involvement with these arrangements and the significance of its investment in relation to the investment of the third party, the Company has determined that it controls each entity in these arrangements and therefore the entities related to these arrangements are consolidated within the Company’s financial statements. A non-controlling interest is recorded for the investor’s ownership interest in the properties.
On November 4, 2020, the Company purchased all of the outstanding the membership interests in the joint venture that owns the UnityPoint Clinics in Muscatine, Iowa and Moline, Illinois for approximately $0.6 million, funded with cash on hand. Following this transaction, the properties were wholly owned by the Company and added to the borrowing base under the Credit Facility.
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
As of December 31,As of December 31,As of December 31,Year Ended December 31,
Property Name
(Dollar amounts in thousands)
Investment Date2020202020202019202020192018
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$371 2.2 %$12,790 $14,220 $— $— $87 
UnityPoint Clinic Portfolio (2)
December 2017$— — %$— $8,842 $— $— $— 
_____________
(1)    One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
(2)    On November 4, 2020, the Company purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint portfolio. See details above for additional information.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2020, 2019 and 2018 and has been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
Year Ended December 31,
202020192018
Net loss attributable to stockholders (in thousands)
$(78,781)$(88,087)$(52,762)
Basic and diluted weighted-average shares outstanding (1)
94,639,833 94,433,640 93,593,719 
Basic and diluted net loss per share (1)
$(0.83)$(0.93)$(0.56)
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for additional details)).

Diluted net loss per share assumes the conversion of all common stock equivalents into an equivalent number of shares of common stock, unless the effect is antidilutive. The Company considers unvested restricted shares, OP Units and Class B Units to be common share equivalents. The Company had the following common stock equivalents on a weighted-average basis that were excluded from the calculation of diluted net loss per share attributable to stockholders as their effect would have been antidilutive. The amounts in the table below have been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
December 31,
202020192018
Unvested restricted shares (1)
257,704 313,711 367,796 
OP Units (2)
417,025 417,025 417,025 
Class B Units (3)
369,007 369,007 369,007 
Total weighted average antidilutive common share equivalents1,043,736 1,099,743 1,153,828 
________
(1)    Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 215,373, 277,241 and 322,242 unvested restricted shares outstanding as of December 31, 2020, 2019 and 2018, respectively.
(2)    Weighted average number of antidilutive OP Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 405,998 OP Units outstanding as of December 31, 2020, 2019 and 2018.
(3)    Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 359,250 Class B Units outstanding as of December 31, 2020, 2019 and 2018.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Segment Reporting — Segment Reporting
During the years ended December 31, 2020, 2019 and 2018, the Company operated in three reportable business segments for management and internal financial reporting purposes: MOBs, triple-net leased healthcare facilities, and SHOPs.
The Company evaluates performance and makes resource allocations based on its three business segments. The medical office building segment primarily consists of MOBs leased to healthcare-related tenants under long-term leases, which may require such tenants to pay a pro rata share of property-related expenses. The triple-net leased healthcare facilities segment primarily consists of investments in seniors housing properties, hospitals, inpatient rehabilitation facilities and skilled nursing facilities under long-term leases, under which tenants are generally responsible to directly pay property-related expenses. The SHOP segment consists of direct investments in seniors housing properties, primarily providing assisted living, independent living and memory care services, which are operated through engaging independent third-party operators.
Some of the Company’s properties move between its operating segments, for example if they are converted from being triple-net leased to third parties in the triple-net leased healthcare facilities segment to being leased to the TRS and operated and managed on the Company’s behalf by a third-party operator in the SHOP segment. When transfers between segments occur, the Company reclassifies the operating results of the transferred properties to their current segment for both the current and all historical periods in order to present a consistent group of property results. See Note 3 — Real Estate Investments, Net - “Impairments” and “Held for Use Assets” to our consolidated financial statements included in this Annual Report on Form 10-K for additional information.
Over the last three years, the Company has had properties transfer between operating segments. Upon such transfers the Company retroactively restates the historical operating results for the segment for all periods presented in that filing and, thereafter, the Company will restate other later prior periods when they are subsequently reported in later filings for comparative purposes. As a result, the Company provides transition disclosure adjustments only for properties that have transitioned since the prior numbers were previously reported.
In 2018, the Company had also transitioned (i.e. this asset was operating as a SHOP asset and was not leased to a third party) a property located in Lutz, Florida from its triple-net leased healthcare facilities segment to its SHOP segment. The results of this property had previously been reclassified in the Same Store operating results in 2018 and 2019, and following its disposal in December 2020, it has been again reclassified from Same Store results to Disposals.
As described in more detail below, the Company transitioned one property located in Wellington, Florida and the four LaSalle Properties on April 1, 2019 and July 1, 2020, respectively, from its triple-net leased healthcare facilities segment to its SHOP segment (collectively, the “Transition Properties”). See Note 3 — Real Estate Investments for further information about this property and the transition. The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020, 2019 and 2018, respectively.
The previously reported same store results had already been retroactively adjusted to reflect the movement of the results Transition Property located in Wellington, Florida and the property located in Lutz, Florida and require no further adjustments thereto.
On July 1, 2020, the Company transitioned the LaSalle Properties from the triple-net leased healthcare facilities segment to the SHOP segment, and the LaSalle Properties are now leased to the Company’s TRS and operated and managed on the Company’s behalf by a third-party operator. This segment has been applied retrospectively to historical periods starting with the quarter ended September 30, 2020.
Net Operating Income
The Company evaluates the performance of the combined properties in each segment based on net operating income (“NOI”). NOI is defined as total revenues from tenants, less property operating and maintenance expense. NOI excludes all other items of expense and income included in the financial statements in calculating net income (loss). The Company uses NOI to assess and compare property level performance and to make decisions concerning the operation of the properties. The Company believes that NOI is useful as a performance measure because, when compared across periods, NOI reflects the impact on operations from trends in occupancy rates, rental rates, operating expenses and acquisition activity on an unleveraged basis, providing perspective not immediately apparent from net income (loss).
NOI excludes certain components from net income (loss) in order to provide results that are more closely related to a property’s results of operations. For example, interest expense is not necessarily linked to the operating performance of a real estate asset and is often incurred at the corporate level. In addition, depreciation and amortization, because of historical cost accounting and useful life estimates, may distort operating performance at the property level. NOI presented by the Company may not be comparable to NOI reported by other REITs that define NOI differently. The Company believes that in order to facilitate a clear understanding of the Company’s operating results, NOI should be examined in conjunction with net income (loss) as presented in the Company’s consolidated financial statements. NOI should not be considered as an alternative to net income (loss) as an indication of the Company’s performance or to cash flows as a measure of the Company’s liquidity or ability to pay distributions.
The following tables reconcile the segment activity, adjusted for the Transition Properties, to consolidated net loss for the years ended December 31, 2020 2019 and 2018:
Year Ended December 31, 2020
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$104,213 $15,611 $261,788 $381,612 
Property operating and maintenance30,851 1,961 210,736 243,548 
NOI$73,362 $13,650 $51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investments5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non designated derivatives(102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)
Year Ended December 31, 2019
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$100,379 $14,564 $259,971 $374,914 
Property operating and maintenance31,813 2,310 200,062 234,185 
NOI68,566 12,254 59,909 140,729 
Impairment charges(55,969)
Operating fees to related parties(23,414)
Acquisition and transaction related(362)
General and administrative(20,530)
Depreciation and amortization(81,032)
Interest expense(56,059)
Interest and other income
Gain on sale of real estate investments8,790 
Loss on sale of non-designated derivatives(68)
Income tax expense(399)
Net loss attributable to non-controlling interests393 
Allocation for preferred stock(173)
Net loss attributable to stockholders$(88,087)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020 and 2019, respectively.
Year Ended December 31, 2018
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$99,103 $14,970 $248,333 $362,406 
Property operating and maintenance30,295 1,424 189,278 220,997 
NOI68,808 13,546 59,055 141,409 
Impairment charges(20,655)
Operating fees to related parties(23,071)
Acquisition and transaction related(302)
General and administrative(17,275)
Depreciation and amortization(83,212)
Gain on sale of real estate investment (70)
Interest expense(49,471)
Interest and other income 23 
Loss on non-designated derivatives (157)
Income tax expense(197)
Net loss attributable to non-controlling interests216 
Net loss attributable to common stockholders$(52,762)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the year ended December 31, 2018.
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20202019
ASSETS
Investments in real estate, net:
Medical office buildings
$883,471 $891,477 
Triple-net leased healthcare facilities (1)
238,427 256,661 
Seniors housing — operating properties (1)
987,050 905,453 
Total investments in real estate, net
2,108,948 2,053,591 
Cash and cash equivalents72,357 95,691 
Restricted cash17,989 15,908 
Assets held for sale90 70,839 
Derivative assets, at fair value13 392 
Straight-line rent receivable, net23,322 21,182 
Operating lease right-of-use asset13,912 14,351 
Prepaid expenses and other assets34,932 39,707 
Deferred costs, net15,332 13,642 
Total assets$2,286,895 $2,325,303 
__________________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020 and 2019.
The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Medical office buildings$4,585 $5,309 $7,582 
Triple-net leased healthcare facilities (1)
3,976 396 1,152 
Seniors housing — operating properties (1)
12,833 11,014 4,176 
Total capital expenditures$21,394 $16,719 $12,910 
___________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020, 2019 and 2018.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Commitments and Contingencies Commitments and Contingencies
As of December 31, 2020, the Company has eight operating and six direct financing lease agreements related to certain acquisitions under leasehold interests arrangements. The eight operating leases have durations, including assumed renewals, ranging from 11.8 to 86.7 years as of December 31, 2020. On January 1, 2019, the Company adopted ASU 2016- 02 and recorded ROU assets and lease liabilities related to these ground operating leases (see Note 2Summary of Significant Accounting Policies for additional information). The Company did not enter into any additional ground leases during the year ended December 31, 2020.
As of December 31, 2020, the Company’s balance sheet includes ROU assets and operating lease liabilities of $13.9 million and $9.2 million, respectively, which are included in operating lease right-of-use assets and operating lease liabilities, respectively, on the Company’s consolidated balance sheet. In determining operating ROU assets and lease liabilities for the Company’s existing operating leases upon the adoption of the new lease guidance as well as for new operating leases in the current period, the Company was required to estimate an appropriate incremental borrowing rate on a fully-collateralized basis for the terms of the leases. Since the terms of the Company’s ground leases are significantly longer than the terms of borrowings available to the Company on a fully-collateralized basis, the Company’s estimate of this rate required significant judgment.
The Company’s ground operating leases have a weighted-average remaining lease term, including assumed renewals, of 41.3 years and a weighted-average discount rate of 7.35% as of December 31, 2020. For the years ended December 31, 2020 and 2019, the Company paid cash of $0.8 million and $0.8 million for amounts included in the measurement of lease liabilities and recorded total rental expense from operating leases of $0.9 million, $1.0 million and $0.9 million, on a straight-line basis in accordance with the standard, during the years ended December 31, 2020, 2019 and 2018, respectively. The lease expense is recorded in property operating expenses in the consolidated statements of operations and comprehensive loss.
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2021$663 $84 
2022682 86 
2023684 88 
2024686 90 
2025691 93 
Thereafter28,690 7,407 
Total minimum lease payments32,096 7,848 
Less: amounts representing interest(22,941)(3,011)
Total present value of minimum lease payments$9,155 $4,837 
_______
(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Litigation and Regulatory Matters
In the ordinary course of business, the Company may become subject to litigation, claims and regulatory matters. There are no material legal or regulatory proceedings pending or known to be contemplated against the Company or its properties.
Environmental Matters
In connection with the ownership and operation of real estate, the Company may potentially be liable for costs and damages related to environmental matters. As of December 31, 2020, the Company had not been notified by any governmental authority of any non-compliance, liability or other claim, and is not aware of any other environmental condition that it believes will have a material adverse effect on the results of operations.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Quarterly Results (Unaudited)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Results (Unaudited) Quarterly Results (Unaudited)
Presented below is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019 which has been retroactively adjusted to reflect the Stock Dividends (see Note 1 — Organization for additional details):
Quarter Ended
(In thousands, except for share and per share data)March 31,
2020
June 30,
2020
September 30,
2020
December 31,
2020
Total revenues$100,235 $94,664 $95,835 $90,878 
Net loss attributable to stockholders$(24,744)$(22,811)$(10,500)$(20,726)
Basic and diluted weighted average shares outstanding (1)
94,458,620 94,479,156 94,796,190 94,821,653 
Basic and diluted net loss per share (1)
$(0.26)$(0.24)$(0.11)$(0.22)
Quarter Ended
(In thousands, except for share and per share data)March 31,
2019
June 30,
2019
September 30,
2019
December 31, 2019 (2)
Total revenues$88,718 $96,287 $95,440 $94,469 
Net loss attributable to stockholders$(5,111)$(6,054)$(28,789)$(48,133)
Basic and diluted weighted average shares outstanding (1)
95,417,626 94,276,398 94,419,591 94,592,579 
Basic and diluted net loss per share (1)
$(0.05)$(0.06)$(0.30)$(0.51)
__________
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization).
(2) During the quarter ended December 31, 2020 and 2019, the Company recorded $3.6 million and $33.3 million in impairment charges on real estate investments held for use. See Note 3 — Real Estate investments, Net - Impairments for additional details.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and determined that there have not been any events that have occurred that would require adjustments to disclosures in the consolidated financial statements except the following disclosures:
Stock Dividend
On January 4, 2021, the Company declared a quarterly stock dividend of 0.01349 shares of the Company’s common stock on each share of the Company’s outstanding common stock. The stock dividend was payable on January 15, 2021 to holders of record of the Company’s common stock at the close of business on January 11, 2021.
Michigan SHOP Transfer
During the first quarter of 2021, the Company completed the transfer of four properties to the buyer of its 11 Michigan properties sold in the fourth quarter of 2020. See Note 3 — Real Estate Investments, Net for additional information.
CARES Act Grants
On March 8, 2021, the Company received $5.1 million in grants from the CARES Act. Consistent with the Company’s policy on the accounting treatment of funds received through the CARES Act, these funds will be recorded as a reduction of property operating expenses to offset incurred COVID-19 costs. There can be no assurance that the program will be extended or any further amounts received.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate and Accumulated Depreciation - Schedule III
12 Months Ended
Dec. 31, 2020
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]  
Real Estate and Accumulated Depreciation, Schedule III
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Fresenius Medical Care - Winfield, AL(5)AL5/10/2013$— $152 $1,568 $— $— $1,720 $353 
Adena Health Center - Jackson, OH(5)OH6/28/2013— 242 4,494 — — 4,736 873 
Ouachita Community Hospital - West Monroe, LA(5)LA7/12/2013— 633 5,304 — — 5,937 1,049 
CareMeridian - Littleton, CO(5)CO8/8/2013— 976 8,900 — 111 9,987 2,560 
Oak Lawn Medical Center - Oak Lawn, ILIL8/21/20135,343 835 7,217 — — 8,052 1,620 
Surgery Center of Temple - Temple, TX(5)TX8/30/2013— 225 5,208 — 432 5,865 992 
Greenville Health System - Greenville, SC(5), (9)SC10/10/2013— 720 3,045 — — 3,765 569 
Stockbridge Family Medical - Stockbridge, GAGA2/21/20141,781 823 1,799 — 131 2,753 379 
Arrowhead Medical Plaza II - Glendale, AZAZ2/21/20147,540 — 9,758 — 1,867 11,625 2,458 
Village Center Parkway - Stockbridge, GAGA2/21/20142,434 1,135 2,299 — 156 3,590 633 
Creekside MOB - Douglasville, GAGA4/30/20148,814 2,709 5,320 — 637 8,666 1,472 
Bowie Gateway Medical Center - Bowie, MDMD5/7/20149,153 983 10,321 — 81 11,385 1,878 
Campus at Crooks & Auburn Building D - Rochester Mills, MIMI5/19/20143,627 640 4,166 — 118 4,924 831 
Berwyn Medical Center - Berwyn, IL(5)IL5/29/2014— 1,305 7,559 — — 8,864 1,298 
Countryside Medical Arts - Safety Harbor, FLFL5/30/20146,983 915 7,663 — 60 8,638 1,428 
St. Andrews Medical Park - Venice, FLFL5/30/201411,119 1,666 10,005 933 12,606 2,193 
Campus at Crooks & Auburn Building C - Rochester Mills, MIMI6/3/20143,831 609 3,893 — 130 4,632 810 
Laguna Professional Center - Elk Grove, CACA7/15/20148,887 1,811 14,598 — 311 16,720 2,748 
UC Davis MOB - Elk Grove, CACA7/15/20148,136 1,138 7,242 — 282 8,662 1,455 
Estate at Hyde Park - Tampa, FL(7)FL7/31/201420,116 1,777 20,308 — 660 22,745 3,950 
Autumn Ridge of Clarkston - Clarkston, MI(7)MI8/12/201419,245 655 19,967 — 38 20,660 3,809 
Sunnybrook of Burlington - Burlington, IA(6)IA8/26/201412,783 518 16,739 — 240 17,497 3,414 
Sunnybrook of Carroll - Carroll, IA(6)IA8/26/20146,144 473 11,263 — 36 11,772 2,086 
Prairie Hills at Cedar Rapids - Cedar Rapids, IA(7)IA8/26/20148,014 195 8,595 — 116 8,906 1,623 
Prairie Hills at Clinton - Clinton, IA(6)IA8/26/201410,759 890 18,882 — 47 19,819 3,653 
Prairie Hills at Des Moines - Des Moines, IA(6)IA8/26/20145,418 647 13,745 — 41 14,433 2,827 
Sunnybrook of Fairfield - Fairfield, IA(5)IA8/26/2014— 340 14,115 — 233 14,688 2,871 
Sunnybrook of Ft. Madison - Ft. Madison, IA(5)IA8/26/2014— 263 3,931 — 203 4,397 452 
Prairie Hills at Independence - Independence, IA(5)IA8/26/2014— 473 10,600 — 176 11,249 1,949 
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA(5)IA8/26/2014— 205 10,935 — 125 11,265 1,947 
Sunnybrook of Muscatine - Muscatine, IA(6)IA8/26/201411,989 302 13,840 — 145 14,287 2,614 
Prairie Hills at Ottumwa - Ottumwa, IA(5)IA8/26/2014— 538 9,186 — 78 9,802 1,838 
Prairie Hills at Tipton - Tipton, IA(5)IA8/26/2014— 306 10,409 — 33 10,748 1,812 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Liberty Court - Dixon, IL(5)IL8/29/2014— 119 1,998 — 37 2,154 423 
Lakeside Vista - Holland, MI(6)MI8/29/20146,128 378 12,196 — 420 12,994 2,324 
The Atrium - Rockford, IL(5)IL8/29/2014— 164 1,746 — 237 2,147 213 
Arrowhead Medical Plaza I - Glendale, AZAZ9/10/20144,571 — 6,447 — 1,311 7,758 1,341 
Sunnybrook of Burlington - Land - Burlington, IAMO9/23/2014— 620 — — — 620 — 
Community Health MOB - Harrisburg, PA(10)PA9/26/20145,424 — 6,170 — — 6,170 996 
Brady MOB - Harrisburg, PA(10)PA9/26/201419,661 — 22,485 — — 22,485 3,545 
Landis Memorial - Harrisburg, PA(5), (10)PA9/26/2014— — 32,484 — — 32,484 5,138 
FOC II - Mechanicsburg, PA(10)PA9/26/201416,136 — 16,473 — 132 16,605 2,982 
FOC Clinical - Mechanicsburg, PA(10)PA9/26/201417,695 — 19,634 — — 19,634 3,497 
FOC I - Mechanicsburg, PA(10)PA9/26/20148,204 — 8,923 — 155 9,078 1,713 
Copper Springs Senior Living - Meridian, ID(5)ID9/29/2014— 498 7,130 — 101 7,729 1,771 
Addington Place of Brunswick - Brunswick, GA(5)GA9/30/2014— 1,509 14,402 — 36 15,947 2,917 
Addington Place of Dublin - Dublin, GA(5)GA9/30/2014— 403 9,281 — 115 9,799 2,036 
Allegro at Elizabethtown - Elizabethtown, KY(5)KY9/30/2014— 317 7,290 — 232 7,839 1,719 
Addington Place of Johns Creek - Johns Creek, GA(7)GA9/30/201410,139 997 11,943 — 456 13,396 2,492 
Allegro at Jupiter - Jupiter, FL(6)FL9/30/201434,370 3,741 49,534 — 276 53,551 9,424 
Addington Place of Lee's Summit - Lee's Summit, MO(7)MO9/30/201417,187 2,734 25,008 — 309 28,051 4,772 
Addington Place at Mills - Roswell, GA(5)GA9/30/2014— 1,000 8,611 — 2,205 11,816 2,139 
Addington Place of College Harbour - St Petersburg, FL(5)FL9/30/2014— 3,791 8,684 — 1,392 13,867 2,657 
Allegro at Stuart - Stuart, FL(6)FL9/30/201449,069 5,018 60,575 — 625 66,218 11,807 
Allegro at Tarpon - Tarpon Springs, FL(7)FL9/30/20147,350 2,360 13,728 — 415 16,503 3,363 
Addington Place of Titusville - Titusville, FL(6)FL9/30/201412,423 1,379 13,976 — 414 15,769 3,112 
Allegro at St. Petersburg - Land - St. Petersburg, FLFL9/30/2014— 3,045 — — — 3,045 — 
Gateway MOB - Clarksville, TN(9)TN10/3/201417,560 — 16,367 — 1,010 17,377 2,993 
Addington at Wellington Green - Wellington, FL(5) (11)FL10/17/2014— 3,182 25,364 — (2,131)26,415 1,002 
Dyer Building - Dyer, IN(5)IN10/17/2014— 601 8,992 — 64 9,657 1,474 
757 Building - Munster, IN(5)IN10/17/2014— 645 7,885 — — 8,530 1,272 
761 Building - Munster, ININ10/17/20146,797 1,436 8,616 — 59 10,111 1,491 
759 Building - Munster, ININ10/17/20148,271 1,101 8,899 — — 10,000 1,476 
Schererville Building - Schererville, ININ10/17/2014— 1,260 935 — 29 2,224 278 
Meadowbrook Senior Living - Agoura Hills, CA(7)CA11/25/201419,167 8,821 48,682 — 1,840 59,343 8,703 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Mount Vernon Medical Office Building - Mount Vernon, WA(9)WA11/25/201415,797 — 18,519 — 18,522 3,059 
Wellington at Hershey's Mill - West Chester, PA(5)PA12/3/2014— 8,531 80,734 — 1,771 91,036 14,109 
Careplex West Medical Office Building - Hampton, VAVA12/3/20147,187 2,628 16,098 — 187 18,913 2,621 
Hampton River Medical Arts Building - Hampton, VA(9)PA12/3/2014— — 18,083 — 146 18,229 3,170 
Eye Specialty Group Medical Building - Memphis, TNTN12/5/20148,475 775 7,223 — — 7,998 1,154 
Addington Place of Alpharetta - Alpharetta, GAGA12/10/2014— 1,604 26,069 — 500 28,173 4,858 
Addington Place of Prairie Village - Prairie Village, KS(7)KS12/10/201414,812 1,782 21,869 — 356 24,007 4,240 
Bloom MOB - Harrisburg, PA(10)PA12/15/201415,322 — 15,928 — 175 16,103 2,605 
Medical Sciences Pavilion - Harrisburg, PA(10)PA12/15/201418,272 — 22,309 — — 22,309 3,438 
Wood Glen Nursing and Rehab Center - West Chicago, IL(5)IL12/16/2014— 1,896 16,107 — — 18,003 3,647 
Pinnacle Center - Southaven, MSMS12/16/20147,085 1,378 6,547 — 573 8,498 1,344 
Paradise Valley Medical Plaza - Phoenix, AZAZ12/29/201413,085 — 25,194 — 1,178 26,372 4,404 
Victory Medical Center at Craig Ranch - McKinney, TXTX12/30/2014— 1,596 40,475 — 1,340 43,411 6,488 
Rivershores Healthcare & Rehab Centre - Marseilles, IL(5)IL12/31/2014— 1,276 6,868 — — 8,144 1,653 
Morton Terrace Healthcare & Rehab Centre - Morton, IL(5)IL12/31/2014— 709 5,649 — — 6,358 1,610 
Morton Villa Healthcare & Rehab Centre - Morton, IL(5)IL12/31/2014— 645 3,687 — 87 4,419 1,000 
The Heights Healthcare & Rehab Centre - Peoria Heights, IL(5)IL12/31/2014— 214 7,952 — — 8,166 2,007 
Colonial Healthcare & Rehab Centre - Princeton, IL(5)IL12/31/2014— 173 5,871 — — 6,044 1,656 
Capitol Healthcare & Rehab Centre - Springfield, IL(5)IL12/31/2014— 603 21,699 — 26 22,328 4,792 
Acuity Specialty Hospital - Mesa, AZ(5)AZ1/14/2015— 1,977 16,203 — 543 18,723 2,713 
Acuity Specialty Hospital - Sun City, AZAZ1/14/2015— 2,329 15,795 — 279 18,403 2,602 
Addington Place of Shoal Creek - Kansas City, MO(7)MO2/2/201513,391 3,723 22,259 — 383 26,365 4,175 
Aurora Healthcare Center - Green Bay, WI(5)WI3/18/2015— 1,130 1,678 — — 2,808 311 
Aurora Healthcare Center - Greenville, WI(5)WI3/18/2015— 259 958 — — 1,217 188 
Aurora Healthcare Center - Kiel, WI(5)WI3/18/2015— 676 2,214 — — 2,890 367 
Aurora Healthcare Center - Plymouth, WIWI3/18/201517,038 2,891 24,224 — — 27,115 4,029 
Aurora Healthcare Center - Waterford, WI(5)WI3/18/2015— 590 6,452 — — 7,042 1,035 
Aurora Healthcare Center - Wautoma, WI(5)WI3/18/2015— 1,955 4,361 — — 6,316 729 
Arbor View Assisted Living and Memory Care - Burlington, WI(5)WI3/31/2015— 367 7,815 — 44 8,226 1,651 
Advanced Orthopedic Medical Center - Richmond, VAVA4/7/201515,390 1,523 19,229 — — 20,752 2,934 
Palm Valley Medical Plaza - Goodyear, AZAZ4/7/20152,998 1,890 4,940 — 228 7,058 907 
Physicians Plaza of Roane County - Harriman, TNTN4/27/20156,293 1,746 7,842 — 32 9,620 1,276 
Adventist Health Lacey Medical Plaza - Hanford, CACA4/29/201511,526 328 13,302 — 44 13,674 1,925 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Medical Center I - Peoria, AZAZ5/15/20153,085 807 1,115 — 513 2,435 741 
Medical Center II - Peoria, AZAZ5/15/2015— 945 1,330 — 5,023 7,298 1,125 
Commercial Center - Peoria, AZAZ5/15/20153,254 959 1,110 — 635 2,704 375 
Medical Center III - Peoria, AZAZ5/15/20152,137 673 1,651 — 811 3,135 659 
Morrow Medical Center - Morrow, GAGA6/24/20154,334 1,155 5,674 — 270 7,099 909 
Belmar Medical Building -Lakewood, COCO6/29/20153,770 819 4,287 — 289 5,395 703 
Addington Place - Northville, MI(7)MI6/30/201513,287 440 14,975 — 303 15,718 2,569 
Conroe Medical Arts and Surgery Center - Conroe, TXTX7/10/201513,221 1,965 12,198 — 573 14,736 2,071 
Medical Center V - Peoria, AZAZ7/10/20152,786 1,089 3,200 — 370 4,659 562 
Legacy Medical Village - Plano, TXTX7/10/201523,662 3,755 31,097 — 639 35,491 4,788 
Scripps Cedar Medical Center - Vista, CACA8/6/201514,983 1,213 14,596 — 48 15,857 2,052 
Nuvista Institute for Healthy Living - Jupiter, FL(11)FL8/7/2015— 8,586 54,051 (1,511)(7,939)53,187 1,284 
Ramsey Woods Memory Care - Cudahy, WI(5)WI10/2/2015— 930 4,990 — 29 5,949 925 
East Coast Square West - Cedar Point, NCNC10/15/20155,254 1,535 4,803 — 6,344 696 
East Coast Square North - Morehead City, NCNC10/15/20153,933 899 4,761 — 5,666 679 
Eastside Cancer Institute - Greenville, SC(5)SC10/22/2015— 1,498 6,637 — 32 8,167 960 
Sassafras Medical Building - Erie, PAPA10/22/20152,315 928 4,629 — 5,560 611 
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR(5)OR10/22/2015— 433 2,623 — — 3,056 366 
Courtyard Fountains - Gresham, OR(5)OR12/1/2015— 2,476 50,601 — 881 53,958 8,037 
Presence Healing Arts Pavilion - New Lenox, IL(9)IL12/4/20155,966 — 6,768 — 76 6,844 991 
Mainland Medical Arts Pavilion - Texas City, TXTX12/4/20156,174 320 7,923 — 305 8,548 1,266 
Renaissance on Peachtree - Atlanta, GA(6)GA12/15/201550,821 4,535 68,895 — 1,751 75,181 10,102 
Fox Ridge Senior Living at Bryant - Bryant, ARAR12/29/20157,133 1,687 12,936 — 544 15,167 2,811 
Fox Ridge Senior Living at Chenal - Little Rock, ARAR12/29/201516,390 6,896 20,579 — 163 27,638 3,732 
Fox Ridge North Little Rock - North Little Rock, AR(9)AR12/29/201510,170 — 19,265 — 261 19,526 3,199 
Autumn Leaves of Cy-Fair - Houston, TXTX12/31/2015— 1,225 11,335 — 59 12,619 1,880 
Autumn Leaves of Meyerland - Houston, TXTX12/31/2015— 2,033 13,411 — 21 15,465 2,123 
Autumn Leaves of Clear Lake, Houston, TXTX12/31/2015— 1,599 13,194 — 18 14,811 2,181 
Autumn Leaves of The Woodlands - The Woodlands, TXTX12/31/2015— 2,413 9,141 — 20 11,574 1,619 
High Desert Medical Group Medical Office Building - Lancaster, CACA4/7/20177,480 1,459 9,300 — — 10,759 1,141 
Northside Hospital - Canton, GAGA7/13/20178,014 3,408 8,191 — 40 11,639 784 
West Michigan Surgery Center - Big Rapids, MI(5)MI8/18/2017— 258 5,677 — — 5,935 502 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Camellia Walk Assisted Living and Memory Care - Evans, GA(6)GA9/28/201712,563 1,854 17,372 — 822 20,048 2,001 
Cedarhurst of Collinsville - Collinsville, IL(5), (8)IL12/22/2017— 1,228 8,652 — 113 9,993 819 
Arcadian Cove Assisted Living - Richmond, KY(5), (8)KY12/22/2017— 481 3,923 — 63 4,467 420 
Beaumont Medical Center - Warren, MI(5), (8)MI12/22/2017— 1,078 9,525 — 19 10,622 796 
DaVita Dialysis - Hudson, FL(5), (8)FL12/22/2017— 226 1,979 — — 2,205 160 
DaVita Bay Breeze Dialysis Center - Largo, FL(5), (8)FL12/22/2017— 399 896 — — 1,295 87 
Greenfield Medical Plaza - Gilbert, AZ(5), (8)AZ12/22/2017— 1,476 4,144 — 48 5,668 357 
RAI Care Center - Clearwater, FL(5), (8)FL12/22/2017— 624 3,156 — — 3,780 252 
Illinois CancerCare - Galesburg, IL(5), (8)IL12/22/2017— 290 2,457 — — 2,747 221 
UnityPoint Clinic - Muscatine, IA(5), (8)IA12/22/2017— 570 4,541 — 5,113 389 
Lee Memorial Health System Outpatient Center - Ft. Myers(5), (8)FL12/22/2017— 439 4,374 — 363 5,176 369 
Decatur Medical Office Building - Decatur, GA(5), (8), (9)GA12/22/2017— 695 3,273 — — 3,968 295 
Madison Medical Plaza - Joliet, IL(5), (8), (9)IL12/22/2017— — 16,855 — 37 16,892 1,267 
Woodlake Office Center - Woodbury, MN(8)MN12/22/20178,638 1,017 10,688 — 1,297 13,002 873 
Rockwall Medical Plaza - Rockwall, TX(5), (8)MN12/22/2017— 1,097 4,582 — 182 5,861 403 
MetroHealth Buckeye Health Center - Cleveland, OH(5), (8)OH12/22/2017— 389 4,367 — 4,761 347 
UnityPoint Clinic - Moline, IL(5), (8)IL12/22/2017— 396 2,880 — 3,277 246 
VA Outpatient Clinic - Galesberg, IL(5), (8)IL12/22/2017— 359 1,852 — — 2,211 181 
Philip Professional Center - Lawrenceville, GA(8)GA12/22/20175,780 1,285 6,714 — 169 8,168 577 
Texas Children’s Hospital - Houston, TX
(5)TX3/5/2018— 1,368 4,428 — 116 5,912 484 
Florida Medical Heartcare - Tampa, FL
(5)FL3/29/2018— 586 1,902 — — 2,488 215 
Florida Medical Somerset - Tampa, FL
(5)FL3/29/2018— 61 1,366 — — 1,427 134 
Florida Medical Tampa Palms - Tampa, FL
(5)FL3/29/2018— 141 1,402 — — 1,543 143 
Florida Medical Wesley Chapel - Tampa, FL
(5)FL3/29/2018— 485 1,987 — — 2,472 228 
Aurora Health Center - Milwaukee, WI
(5)WI4/17/2018— 1,014 4,041 — — 5,055 528 
Vascular Surgery Associates - Tallahassee, FL
(5)FL5/11/2018— 902 5,383 — — 6,285 554 
Glendale MOB - Farmington Hills, MI
(5)MI8/28/2018— 504 12,332 — — 12,836 904 
Crittenton Washington MOB - Washington Township, MI
(5)MI9/12/2018— 640 4,090 — 43 4,773 351 
Crittenton Sterling Heights MOB - Sterling Heights, MI
(5)MI9/12/2018— 1,398 2,695 — 181 4,274 280 
Advocate Aurora MOB - Elkhorn, WI
(5)WI9/24/2018— 181 9,452 — — 9,633 762 
Pulmonary & Critical Care Med - Lemoyne, PA
PA11/13/20184,271 621 3,805 — — 4,426 442 
Dignity Emerus Blue Diamond - Las Vegas, NV
NV11/15/201813,966 2,182 16,594 — — 18,776 969 
   Initial CostsSubsequent to Acquisition  
Property StateAcquisition
Date
Encumbrances at 
December 31, 2020
LandBuilding and
Improvements
LandBuilding and
Improvements
Gross Amount at
December 31,2020(1) (2)
Accumulated
Depreciation(3) (4)
Dignity Emerus Craig Rd - North Las Vegas, NV
NV11/15/201818,780 3,807 22,803 — — 26,610 1,344 
Greenfield MOB - Greenfield, WI
WI1/17/20197,526 1,552 8,333 — 225 10,110 757 
Milwaukee MOB - South Milwaukee, WI
WI1/17/20194,136 410 5,041 — — 5,451 278 
St. Francis WI MOB - St. Francis, WI
WI1/17/20199,085 865 11,355 — 159 12,379 733 
Lancaster Medical Arts MOB - Lancaster, PA
(5)PA6/20/2019— 85 4,417 — — 4,502 346 
Women’s Healthcare Group MOB - York, PA
(5)PA6/21/2019— 624 2,161 — — 2,785 281 
Pioneer Spine Sports - Northampton, MA
(5)MA7/22/2019— 435 1,858 — — 2,293 75 
Pioneer Spine Sport - Springfield, MA
(5)MA7/22/2019— 333 2,530 — — 2,863 107 
Pioneer Spine Sports - West Springfield, MA
(5)MA7/22/2019— 374 4,295 — — 4,669 176 
Felicita Vida - Escondido, CA
(5)CA9/3/2019— 1,677 28,953 — 17 30,647 1,098 
Cedarhurst of Edwardsville - Edwardsville, ILIL1/10/2020— 321 9,032 — — 9,353 262 
UMPC Sir Thomas Court - Harrisburg, PA(5)PA1/17/2020— 745 6,272 — — 7,017 157 
UMPC Fisher Road - Mechanicsburg, PA(5)PA1/17/2020— 747 3,844 — — 4,591 105 
Swedish American MOB - Roscoe, IL(5)IL1/22/2020— 599 5,862 — — 6,461 185 
Cedarhurst of Sparta - Sparta, IL(5)IL1/31/2020— 381 13,807 — 22 14,210 405 
UMPC Chambers Hill - Harrisburg, PA(5)PA2/3/2020— 498 4,238 — — 4,736 103 
Cedarhurst of Shiloh - Shiloh, ILIL3/13/202013,684 376 28,299 — 14 28,689 612 
Bayshore Naples Memory Care - Naples, FL(5)FL3/20/2020— 3,231 17,112 — — 20,343 356 
Circleville MOB - Circleville, OH(5)OH12/7/2020— 765 4,011 — — 4,776 
Total
$905,536 $214,160 $2,098,361 $(1,509)$34,696 $2,345,708 $328,095 
______________
Note - The above schedule excludes properties that are reflected as part of Assets Held for Sale at December 31, 2020.
(1)Acquired intangible lease assets allocated to individual properties in the amount of $276.0 million are not reflected in the table above.
(2)The tax basis of aggregate land, buildings and improvements as of December 31, 2020 is $2.3 billion.
(3)The accumulated depreciation column excludes $184.7 million of accumulated amortization associated with acquired intangible lease assets.
(4)Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements and 5 years for fixtures.
(5)These unencumbered properties were part of the borrowing base of the Credit Facility, which had $323.7 million of outstanding borrowings as of December 31, 2020. The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 Credit Facilities, Net for additional details).
(6)These properties collateralize the Capital One Facility, which had $212.5 million of outstanding borrowings as of December 31, 2020.
(7)These properties collateralize the KeyBank Facility, which had $142.7 million of outstanding borrowings as of December 31, 2020.
(8)These properties were acquired from American Realty Capital Healthcare Trust III, Inc. in 2017. See Note 9 — Related Party Transactions and Arrangements for additional information.
(9)Some or all of the land underlying this property is subject to an operating land lease. The related right-of-use assets are separately recorded. See Note 16 — Commitments and Contingencies for additional information.
(10)The building amount represents combined direct financing lease for the total asset as the land element was not required to be bifurcated under ASU 840. See Note 16 — Commitments and Contingencies for additional information.
(11)The property has been impaired as of December 31, 2020. See Note 3 — Real Estate Investments, Net “Assets Held for Use and Related Impairments” for additional information.
A summary of activity for real estate and accumulated depreciation for the years ended December 31, 2020, 2019 and 2018:
December 31,
(In thousands)202020192018
Real estate investments, at cost (1):
 
Balance at beginning of year$2,211,451 $2,296,627 $2,229,374 
Additions-Acquisitions98,364 80,980 121,244 
Disposals, impairments and reclasses (2)
35,893 (166,156)(53,991)
Balance at end of the year$2,345,708 $2,211,451 $2,296,627 
  
Accumulated depreciation (1):
 
Balance at beginning of year$260,399 $226,167 $170,271 
Depreciation expense63,393 64,731 62,595 
Disposals, impairments and reclasses (2)
4,303 (30,499)(6,699)
Balance at end of the year$328,095 $260,399 $226,167 
__________
(1)Acquired intangible lease assets and related accumulated depreciation are not reflected in the table above.
(2)Includes amounts relating to dispositions and impairment charges on assets held for sale for the years ended December 31, 2020, 2019 and 2018. Amounts for the year ended December 31, 2020 include the reclassification of approximately $49.4 million and $8.7 million of assets and accumulated depreciation, respectively, that were previously classified as held-for-sale as of December 31, 2019 to real estate investments, at cost and accumulated depreciation during the year ended December 31, 2020. For additional information on this reclassification during the year ended December 31, 2020, see Note 3 — Real Estate Investments.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Basis of Accounting Basis of Accounting     The accompanying consolidated financial statements of the Company are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States (“GAAP”).
Out-of-Period Adjustments
During the year ended December 31, 2019, the Company identified certain historical errors in its tax provision and its net deferred taxes asset as well as its statements of operations and comprehensive income (loss), consolidated statements of changes in equity, and statements of cash flows since 2014, which impacted the quarterly financial statements and annual periods previously issued. Specifically, the Company had overstated intercompany rent on certain leases with the taxable REIT subsidiary (“TRS”) and reflected a portion of depreciation on REIT assets in the TRS’s tax provision, thereby overstating previously recorded tax benefits, deferred tax assets and net income by $0.8 million, $0.3 million and $0.2 million for the years ended December 31, 2018, 2017 and for Pre-2017 periods, respectively.  The intercompany rent and allocation of depreciation only affected the tax provision and did not affect the pre-tax consolidated financial results. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2019.
During the year ended December 31, 2019, the Company did not record quarterly interest expense related to borrowings under the Revolving Credit Facility (as defined below) that were borrowed and repaid during the fourth quarter of 2019. The amount of interest expense and related payable that should have been recorded was $0.3 million. In 2020, the Company identified that the cumulative interest payable balance was understated, and as a result a true up entry was recorded to record the payable and related expense, resulting in an out of period adjustment. The Company concluded that the errors noted above were not material for the period ended December 31, 2019 or any prior periods and has adjusted the amounts on a cumulative basis in 2020.
Impacts of the COVID-19 Pandemic
During the first quarter of 2020, the global COVID-19 pandemic that has spread around the world and to every state in the United States commenced. The pandemic has had and could continue to have an adverse impact on economic and market conditions, including a global economic slowdown and recession that may continue for some time. The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact of COVID-19 on economic and market conditions. The Company believes the estimates and assumptions underlying its consolidated financial statements are reasonable and supportable based on the information available as of December 31, 2020, however uncertainty over the ultimate impact COVID-19 will have on the global economy generally, and the Company’s business in particular, makes any estimates and assumptions as of December 31, 2020 inherently less certain than they would be absent the current and potential impacts of COVID-19. Actual results may ultimately differ from those estimates.
Starting in March 2020, the COVID-19 pandemic and measures to prevent its spread began to affect the Company in a number of ways. In the Company’s SHOP portfolio, occupancy has trended lower since the second half of March as government policies and implementation of infection control best practices have materially limited or closed communities to new resident move-ins which affects the Company’s ability to fill vacancies. The Company has also continued to experience lower inquiry volumes and reduced in-person tours during the pandemic. In addition, starting in mid-March 2020, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as the Company’s operators took appropriate actions to protect residents and caregivers. At the SHOP facilities, the Company bears these cost increases. These trends accelerated during the second, third, and fourth quarters of 2020 and into the beginning of the first quarter of 2021 as the surge of new COVID-19 cases that started in late 2020 crested, and may continue to impact the Company in the future and have a material adverse effect on the Company’s revenues and income in the other quarters thereafter.
The financial stability and overall health of the Company’s tenants is critical to its business. The negative effects that the global pandemic has had on the economy includes the closure or reduction in activity of some of the Company’s MOBs and other healthcare-related facilities as well as restrictions on activity and access for many of the Company’s seniors housing properties. The economic impact of the pandemic has impacted the ability of some of the Company’s tenants to pay their monthly rent either temporarily or in the long term. The Company experienced delays in rent collections in the second, third and fourth quarters of 2020 although collections have been approximately 100%. The Company has taken a proactive approach
to achieve mutually agreeable solutions with its tenants and in some cases, during the year ended December 31, 2020, the Company executed lease amendments providing for deferral of rent.The Company has taken precautionary steps to increase liquidity and preserve financial flexibility in light of the uncertainty resulting from the COVID-19 pandemic. These steps include borrowing an additional $95.0 million under the Credit Facility (as defined below) in March 2020 to provide more cash on the Company’s balance sheet. A portion of the $95.0 million in borrowings was used for general corporate purposes and for acquisitions. The Company has not borrowed additional amounts subsequently. In August 2020, the Company amended the Credit Facility as part of its efforts to continue addressing the adverse impacts of the COVID-19 pandemic. For additional information on the Credit Facility amendment see Note 5 Credit Facilities.
Principles of Consolidation and Basis of Presentation
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of the Company, the OP and its subsidiaries. All inter-company accounts and transactions are eliminated in consolidation. In determining whether the Company has a controlling financial interest in a joint venture and the requirement to consolidate the accounts of that entity, management considers factors such as ownership interest, authority to make decisions and contractual and substantive participating rights of the other partners or members as well as whether the entity is a variable interest entity (“VIE”) for which the Company is the primary beneficiary. The Company has determined the OP is a VIE of which the Company is the primary beneficiary. Substantially all of the Company’s assets and liabilities are held by the OP.
Use of Estimates
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management makes significant estimates regarding revenue recognition, purchase price allocations to record investments in real estate, impairments, fair value measurements and income taxes, as applicable.
Leases
For accounting purposes, in accordance with ASC 842: Leases, normally a company would be required to assess a lease modification to determine if the lease modification should be treated as a separate lease and if not, modification accounting would be applied which would require a company to reassess the classification of the lease (including leases for which the prior classification under ASC 840 was retained as part of the election to apply the package of practical expedients allowed upon the adoption of ASC 842, which doesn’t apply to leases subsequently modified). However, in light of the COVID-19 pandemic in which many leases are being modified, the FASB and SEC have provided relief that allows companies to make a policy election as to whether they treat COVID-19 related lease amendments as a provision included in the pre-concession arrangement, and therefore, not a lease modification, or to treat the lease amendment as a modification. In order to be considered COVID-19 related, cash flows must be substantially the same or less than those prior to the concession. For COVID-19 relief qualified changes, there are two methods to potentially account for such rent deferrals or abatements under the relief, (1) as if the changes were originally contemplated in the lease contract or (2) as if the deferred payments are variable lease payments contained in the lease contract.
For all other lease changes that did not qualify for FASB relief, the Company is required to apply modification accounting including assessing classification under ASC 842. Some, but not all of the Company’s lease modifications qualify for the FASB relief. In accordance with the relief provisions, instead of treating these qualifying leases as modifications, the Company has elected to treat the modifications as if previously contained in the lease and recast rents receivable prospectively (if necessary). Under that accounting, for modifications that were deferrals only, there would be no impact on overall rental revenue and for any abatement amounts that reduced total rent to be received, the impact would be recognized ratably over the remaining life of the lease. For leases not qualifying for this relief, the Company has applied modification accounting and determined that there were no changes in the current classification of its leases impacted by negotiations with its tenants.
Revenue Recognition
Revenue Recognition
The Company’s revenues, which are derived primarily from lease contracts, include rent received from tenants in MOBs and triple-net leased healthcare facilities. As of December 31, 2020, these leases had a weighted average remaining lease term of 6.5 years. Rent from tenants in the Company’s MOB and triple-net leased healthcare facilities operating segments (as discussed below) is recorded in accordance with the terms of each lease on a straight-line basis over the initial term of the lease. Because many of the leases provide for rental increases at specified intervals, straight-line basis accounting requires the Company to record a receivable for, and include in revenue from tenants on a straight-line basis, unbilled rent receivables that the Company will only receive if the tenant makes all rent payments required through the expiration of the initial term of the lease. When the Company acquires a property, the acquisition date is considered to be the commencement date for purposes of this calculation. For new leases after acquisition, the commencement date is considered to be the date the tenant takes control of the space. For lease modifications, the commencement date is considered to be the date the lease modification is executed. The Company defers the revenue related to lease payments received from tenants in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses, in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties. Under ASC 842, the Company has elected to report combined lease and non-lease components in a single line “Revenue from tenants.” For expenses paid directly by the tenant, under both ASC 842 and 840, the Company has reflected them on a net basis.
The Company’s revenues also include resident services and fee income primarily related to rent derived from lease contracts with residents in the Company’s SHOPs held using a structure permitted under the REIT Investment and Diversification and Empowerment Act of 2007 and to fees for ancillary services performed for SHOP residents, which are generally variable in nature. Rental income from residents in the Company’s SHOP segment is recognized as earned. Residents pay monthly rent that covers occupancy of their unit and basic services, including utilities, meals and some housekeeping services. The terms of the rent are short term in nature, primarily month-to-month. Also included in revenue from tenants is fees
for ancillary revenue from non-residents of $13.3 million, $15.4 million and $8.1 million for the years ended December 31, 2020, 2019, and 2018, respectively. Fees for ancillary services are recorded in the period in which the services are performed.
The Company defers the revenue related to lease payments received from tenants and residents in advance of their due dates. Pursuant to certain of the Company’s lease agreements, tenants are required to reimburse the Company for certain property operating expenses related to non-SHOP assets (recorded in revenue from tenants), in addition to paying base rent, whereas under certain other lease agreements, the tenants are directly responsible for all operating costs of the respective properties.
The following table presents future base rent payments on a cash basis due to the Company as of December 31, 2020 over the next five years and thereafter. These amounts exclude tenant reimbursements and contingent rent payments, as applicable, that may be collected from certain tenants based on provisions related to sales thresholds and increases in annual rent based on exceeding certain economic indexes, among other items. These amounts also exclude SHOP leases which are short-term in nature.
(In thousands)Future 
Base Rent Payments
2021$94,144 
202287,762 
202375,205 
202468,210 
202558,757 
Thereafter165,642 
Total$549,720 
The Company continually reviews receivables related to rent and unbilled rents receivable and determines collectability by taking into consideration the tenant’s payment history, the financial condition of the tenant, business conditions in the industry in which the tenant operates and economic conditions in the area in which the property is located. Under the leasing standards (see the “Recently Issued Accounting Pronouncements” section below), the Company is required to assess, based on credit risk only, if it is probable that the Company will collect virtually all of the lease payments at lease commencement date and it must continue to reassess collectability periodically thereafter based on new facts and circumstances affecting the credit risk of the tenant. Partial reserves, or the ability to assume partial recovery are no longer permitted. If the Company determines that it is probable it will collect virtually all of the lease payments (rent and common area maintenance), the lease will continue to be accounted for on an accrual basis (i.e., straight-line). However, if the Company determines it is not probable that it will collect virtually all of the lease payments, the lease will be accounted for on a cash basis and a full reserve would be recorded on previously accrued amounts in cases where it was subsequently concluded that collection was not probable. Cost recoveries from tenants are included in operating revenue from tenants beginning on January 1, 2019, in accordance with new accounting rules, on the accompanying consolidated statements of operations and comprehensive income (loss) in the period the related costs are incurred, as applicable.
Under ASC 842, which was adopted effective on January 1, 2019, uncollectable amounts are reflected as reductions in revenue. Under ASC 840, the Company recorded such amounts as bad debt expense as part of property operating expenses.
Investments in Real Estate
Investments in Real Estate
Investments in real estate are recorded at cost. Improvements and replacements are capitalized when they extend the useful life or improve the productive capacity of the asset. Costs of repairs and maintenance are expensed as incurred.
At the time an asset is acquired, the Company evaluates the inputs, processes and outputs of the asset acquired to determine if the transaction is a business combination or asset acquisition. If an acquisition qualifies as a business combination, the related transaction costs are recorded as an expense in the consolidated statements of operations and comprehensive loss. If an acquisition qualifies as an asset acquisition, the related transaction costs are generally capitalized and subsequently amortized over the useful life of the acquired assets. See the “Purchase Price Allocation” section in this Note for a discussion of the initial accounting for investments in real estate.
Disposal of real estate investments that represent a strategic shift in operations that will have a major effect on the Company's operations and financial results are required to be presented as discontinued operations in the consolidated statements of operations. No properties were presented as discontinued operations during the years ended December 31, 2020, 2019 and 2018. Properties that are intended to be sold are to be designated as “held for sale” on the consolidated balance sheets at the lesser of carrying amount or fair value less estimated selling costs when they meet specific criteria to be presented as held for sale, most significantly that the sale is probable within one year. The Company evaluates probability of sale based on specific facts including whether a sales agreement is in place and the buyer has made significant non-refundable deposits. Properties are no longer depreciated when they are classified as held for sale. There were $0.1 million and $70.8 million in real estate investments held for sale as of December 31, 2020 and 2019, respectively (see Note 3Real Estate Investments, Net to the consolidated financial statements included in this Annual Report on Form 10-K for additional information).
As more fully discussed in this Note under Recently Issued Accounting Pronouncements - ASU No. 2016-02 Leases, all of the Company’s leases as lessor prior to adoption were accounted for as operating leases and they continue to be accounted for as operating leases under the transition guidance. The Company evaluates new leases originated after the adoption date (by the Company or by a predecessor lessor/owner) pursuant to the new guidance where a lease for some or all of a building is classified by a lessor as a sales-type lease if the significant risks and rewards of ownership reside with the tenant. This situation is met if, among other things, there is an automatic transfer of title during the lease, a bargain purchase option, the non-cancelable lease term is for more than major part of remaining economic useful life of the asset (e.g., equal to or greater than 75%), if the present value of the minimum lease payments represents substantially all (e.g., equal to or greater than 90%) of the leased property’s fair value at lease inception, or if the asset so specialized in nature that it provides no alternative use to the lessor (and therefore would not provide any future value to the lessor) after the lease term. Further, such new leases would be evaluated to consider whether they would be failed sale-leaseback transactions and accounted for as financing transactions by the lessor. For the three-year period ended December 31, 2019, the Company has no leases as a lessor that would be considered as sales-type leases or financings under sale-leaseback rules.
The Company is also the lessee under certain land leases which were previously classified prior to adoption of lease accounting and will continue to be classified as operating leases under transition elections unless subsequently modified. These leases are reflected on the balance sheet as of December 31, 2020 and 2019, and the rent expense is reflected on a straight-line basis over the lease term in the consolidated statements of operations for the years ended December 31, 2020, 2019, and 2018.
The Company generally determines the value of construction in progress based upon the replacement cost. During the construction period, the Company capitalizes interest, insurance and real estate taxes until the development has reached substantial completion.
Purchase Price Allocation
Purchase Price Allocation
In both a business combination and an asset acquisition, the Company allocates the purchase price of acquired properties to tangible and identifiable intangible assets or liabilities based on their respective fair values. Tangible assets may include land, land improvements, buildings, fixtures and tenant improvements on an as if vacant basis. Intangible assets may include the value of in-place leases and above- and below-market leases and other identifiable assets or liabilities based on lease or property specific characteristics. In addition, any assumed mortgages receivable or payable and any assumed or issued non-controlling interests (in a business combination) are recorded at their estimated fair values. In allocating the fair value to assumed mortgages, amounts are recorded to debt premiums or discounts based on the present value of the estimated cash flows, which is calculated to account for either above or below-market interest rates. In a business combination, the difference between the purchase price and the fair value of identifiable net assets acquired is either recorded as goodwill or as a bargain purchase gain. In an asset acquisition, the difference between the acquisition price (including capitalized transaction costs) and the fair value of identifiable net assets acquired is allocated to the non-current assets. All acquisitions during the years ended December 31, 2020, 2019 and 2018 were accounted for as asset acquisitions.
For acquired properties with leases classified as operating leases, the Company allocates the purchase price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their respective fair values. In making estimates of fair values for purposes of allocating purchase price, the Company utilizes a number of sources, including independent appraisals that may be obtained in connection with the acquisition or financing of the respective property and other market data. The Company also considers information obtained about each property as a result of the Company’s pre-acquisition due diligence in estimating the fair value of the tangible and intangible assets acquired and intangible liabilities assumed.
Tangible assets include land, land improvements, buildings, fixtures and tenant improvements on an as-if vacant basis. The Company utilizes various estimates, processes and information to determine the as-if vacant property value. The Company estimates fair value using data from appraisals, comparable sales, discounted cash flow analysis and other methods. Fair value
estimates are also made using significant assumptions such as capitalization rates, fair market lease rates, discount rates and land values per square foot.
Identifiable intangible assets include amounts allocated to acquire leases for above- and below-market lease rates and the value of in-place leases. Factors considered in the analysis of the in-place lease intangibles include an estimate of carrying costs during the expected lease-up period for each property, taking into account current market conditions and costs to execute similar leases. In estimating carrying costs, the Company includes real estate taxes, insurance and other operating expenses and estimates of lost rentals at contract rates during the expected lease-up period, which typically ranges from six to 24 months. The Company also estimates costs to execute similar leases including leasing commissions, legal and other related expenses.
Above-market and below-market lease values for acquired properties are initially recorded based on the present value (using a discount rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to each in-place lease and (ii) management’s estimate of fair market lease rates for each corresponding in-place lease, measured over a period equal to the remaining initial term of the lease for above-market leases and the remaining initial term plus the term of any below-market fixed rate renewal options for below-market leases.
The aggregate value of intangible assets related to customer relationship, as applicable, is measured based on the Company’s evaluation of the specific characteristics of each tenant’s lease and the Company’s overall relationship with the tenant. Characteristics considered by the Company in determining these values include the nature and extent of its existing business relationships with the tenant, growth prospects for developing new business with the tenant, the tenant’s credit quality and expectations of lease renewals, among other factors. The Company did not record any intangible asset amounts related to customer relationships during the years ended December 31, 2020 and 2019.
Gain on Dispositions of Real Estate Investments
Gain on Dispositions of Real Estate Investments
Gains on sales of rental real estate after January 1, 2018 are not considered sales to customers and will generally be recognized pursuant to the provisions included in ASC 610-20, Gains and Losses from the Derecognition of Nonfinancial Assets (“ASC 610-20”).
Gain on sales of real estate prior to January 1, 2018 are recognized pursuant to the provisions included in ASC 360-20, Real Estate Sales (“ASC 360-20”). The specific timing of a sale was measured against various criteria in and ASC 360-20 related to the terms of the transaction and any continuing involvement in the form of management or financial assistance associated with the properties. If the sales criteria for the full accrual method are not met, depending on the circumstances, the Company may not record a sale or it may record a sale but may defer some or all of the gain recognition. If the criteria for full accrual are not met, the Company may account for the transaction by applying the finance, leasing, profit sharing, deposit, installment or cost recovery methods, as appropriate, until the sales criteria for the full accrual method are met.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
When circumstances indicate the carrying value of a property may not be recoverable, the Company reviews the property for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. These estimates consider factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If an impairment exists, due to the inability to recover the carrying value of a property, the Company would recognize an impairment loss in the consolidated statement of operations and comprehensive (loss) to the extent that the carrying value exceeds the estimated fair value of the property for properties to be held and used. For properties held for sale, the impairment loss recorded would equal the adjustment to fair value less estimated cost to dispose of the asset. These assessments have a direct impact on net income because recording an impairment loss results in an immediate negative adjustment to net earnings.
Reportable Segments
Reportable Segments
The Company has determined that it has three reportable segments, with activities related to investing in MOBs, triple-net leased healthcare facilities, and seniors housing properties. Management evaluates the operating performance of the Company’s investments in real estate and seniors housing properties on an individual property level.
Depreciation and Amortization
Depreciation and Amortization
Depreciation is computed using the straight-line method over the estimated useful lives of up to 40 years for buildings, 15 years for land improvements, 7 to 10 years for fixtures and improvements, and the shorter of the useful life or the remaining lease term for tenant improvements and leasehold interests.
Construction in progress, including capitalized interest, insurance and real estate taxes, is not depreciated until the development has reached substantial completion. The value of certain other intangibles such as certificates of need in certain jurisdictions are amortized over the expected period of benefit (generally the life of the related building).
The value of in-place leases, exclusive of the value of above-market and below-market in-place leases, is amortized to expense over the remaining periods of the respective leases.
The value of customer relationship intangibles, if any, is amortized to expense over the initial term and any renewal periods in the respective leases, but in no event does the amortization period for intangible assets exceed the remaining depreciable life of the building. If a tenant terminates its lease, the unamortized portion of the in-place lease value and customer relationship intangibles is charged to expense.
Assumed mortgage premiums or discounts are amortized as an increase or reduction to interest expense over the remaining terms of the respective mortgages.
Above and Below-Market Lease Amortization
Capitalized above-market lease values are amortized as a reduction of revenue from tenants over the remaining terms of the respective leases and the capitalized below-market lease values are amortized as an increase to revenue from tenants over the remaining initial terms plus the terms of any below-market fixed rate renewal options of the respective leases. If a tenant with a below-market rent renewal does not renew, any remaining unamortized amount will be taken into income at that time.
Capitalized above-market ground lease values are amortized as a reduction of property operating expense over the remaining terms of the respective leases. Capitalized below-market ground lease values are amortized as an increase to property operating expense over the remaining terms of the respective leases and expected below-market renewal option periods.
Derivative Instruments
Derivative Instruments
The Company may use derivative financial instruments to hedge all or a portion of the interest rate risk associated with its borrowings. Certain of the techniques used to hedge exposure to interest rate fluctuations may also be used to protect against declines in the market value of assets that result from general trends in debt markets. The principal objective of such agreements is to minimize the risks and costs associated with the Company’s operating and financial structure as well as to hedge specific anticipated transactions.
The Company records all derivatives on the balance sheet at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair value of the hedged asset or liability that are attributable to the hedged risk in a fair value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge.  The Company may enter into derivative contracts that are intended to economically hedge certain of its risk, even though hedge accounting does not apply, or the Company elects not to apply hedge accounting.
The accounting for subsequent changes in the fair value of these derivatives depends on whether each has been designated and qualifies for hedge accounting treatment. If the Company elects not to apply hedge accounting treatment, any change in the fair value of these derivative instruments is recognized immediately in gains (losses) on derivative instruments in the accompanying consolidated statements of operations and comprehensive loss prior to the adoption of ASU 2017-2 on January 1, 2019. If the derivative is designated and qualifies for hedge accounting treatment, the change in the estimated fair value of the derivative is recorded in other comprehensive income (loss) to the extent that it is effective, with any ineffective portion of a derivative’s change in fair value immediately recognized in earnings. After the adoption of ASU 2017-2, if the derivative qualifies for hedge accounting, all of the change in value is recorded in other comprehensive income (loss).
Non-controlling Interests Non-controlling InterestsThe non-controlling interests represent the portion of the equity in the OP that is not owned by the Company as well as certain investment arrangements with other unaffiliated third parties whereby such investors receive an ownership interest in certain of the Company’s property-owning subsidiaries and are entitled to receive a proportionate share of the net operating cash flow derived from the subsidiaries’ property. Non-controlling interests are presented as a separate component of equity on the consolidated balance sheets and presented as net loss attributable to non-controlling interests on the consolidated statements of operations and comprehensive loss. Non-controlling interests are allocated a share of net loss based on their share of equity ownership. See Note 13 — Non-Controlling Interests for additional information.
Cash and Cash Equivalents Cash and Cash EquivalentsCash and cash equivalents includes cash in bank accounts as well as investments in highly-liquid money market funds with original maturities of three months or less.
Deferred Financing and Leasing Costs, Net
Deferred Financing and Leasing Costs, Net
Deferred costs, net, consists of deferred financing costs related to the Credit Facility (as defined in Note 5 — Credit Facilities) Fannie Mae Master Credit Facilities (as defined in Note 5 — Credit Facilities), and deferred leasing costs. Deferred financing costs relating to the mortgage notes payable (see Note 4 — Mortgage Notes Payable, Net) are reflected net of the related financing on our balance sheet.
Deferred financing costs associated with the Credit Facility and Fannie Mae Master Credit Facilities and mortgage notes payable represent commitment fees, legal fees, and other costs associated with obtaining commitments for financing. These costs are amortized over the term of the financing agreement using the effective interest method for the Credit Facility and Fannie Mae Master Credit Facilities and using the effective interest method over the expected term for the mortgage notes payable.
Unamortized deferred financing costs are expensed if the associated debt is refinanced or paid down before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
Deferred leasing costs, consisting primarily of lease commissions and professional fees incurred in connection with new leases, are deferred and amortized over the term of the lease.
Equity-Based Compensation Equity-Based CompensationThe Company has a stock-based incentive award program for its directors, which is accounted for under the guidance of share- based payments. The cost of services received in exchange for these stock awards is measured at the grant date fair value of the award and the expense for such awards is included in general and administrative expenses and is recognized over the service period (i.e., vesting) required or when the requirements for exercise of the award have been met (See Note 11Equity-Based Compensation).
Income Taxes
Income Taxes
The Company elected to be taxed as a REIT under Sections 856 through 860 of the Internal Revenue Code of 1986 (the “Code”), as amended, commencing with the taxable year ended December 31, 2013. If the Company continues to qualify for taxation as a REIT, it generally will not be subject to U.S. federal corporate income tax to the extent it distributes all of its REIT taxable income (which does not equal net income as calculated in accordance with GAAP) to its stockholders. REITs are subject to a number of organizational and operational requirements, including a requirement that the Company distribute annually at least 90% of the Company’s REIT taxable income to the Company’s stockholders.
If the Company fails to continue to qualify as a REIT in any taxable year and does not qualify for certain statutory relief provisions, the Company will be subject to U.S. federal, state and income taxes at regular corporate rates beginning with the year in which it fails to qualify and may be precluded from being able to elect to be treated as a REIT for the Company’s four subsequent taxable years. The Company distributed to its stockholders 100% of its REIT taxable income for each of the years ended December 31, 2020, 2019 and 2018. Accordingly, no provision for U.S. federal or state income taxes related to such REIT taxable income was recorded in the Company’s financial statements. Even if the Company continues to qualify as a REIT, it may be subject to certain state and local taxes on its income and property, and U.S. federal income and excise taxes on its undistributed income.
Certain limitations are imposed on REITs with respect to the ownership and operation of seniors housing properties.  Generally, to qualify as a REIT, the Company cannot directly or indirectly operate seniors housing properties. Instead, such facilities may be either leased to a third-party operator or leased to a TRS and operated by a third party on behalf of the TRS.  Accordingly, the Company has formed a TRS that is wholly-owned by the OP to lease its SHOPs and the TRS has entered into management contracts with unaffiliated third-party operators to operate the facilities on its behalf.
As of December 31, 2020, the Company, owned 59 seniors housing properties which are leased and operated through its TRS. The TRS is a wholly-owned subsidiary of the OP. A TRS is subject to U.S. federal, state and local income taxes. The Company records net deferred tax assets to the extent the Company believes these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies (including modifying intercompany leases with the TRS) and recent financial operations. In the event the Company determines that it would not be able to realize the deferred income tax assets in the future in excess of the net recorded amount, the Company establishes a valuation allowance which offsets the previously recognized income tax asset. Deferred income taxes result from temporary differences between the carrying amounts of the TRS’s assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes as well as net operating loss carryforwards. Significant components of the deferred tax assets and liabilities as of December 31, 2020 consisted of deferred rent and net operating loss carryforwards. During the year ended December 31, 2020, the Company modified 25 intercompany leases with the TRS which abated intercompany rent due to the ongoing COVID-19 pandemic.
Because of the Company’s TRS's recent operating history of losses and the on-going impacts of the COVID-19 pandemic on the results of operations of the Company’s SHOP assets, the Company is not able to conclude that it is more likely than not it will realize the future benefit of its deferred tax assets; thus the Company has provided a 100% valuation allowance of $4.6 million as of December 31, 2020. If and when the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in its consolidated statements of comprehensive income (loss). As of December 31, 2020, the Company’s consolidated TRS had net operating loss carryforwards for federal income tax purposes of approximately $14 million at December 31, 2020 (of which $7.6 million were incurred prior to January 1, 2018). For losses incurred prior to January 1, 2018, if unused, these will begin to expire in 2035. For net operating losses incurred subsequent to December 31, 2017, there is no expiration date. During the year ended December 31, 2020 the Company recorded a tax loss of $3.1 million. As of December 31, 2020, the Company had a deferred tax asset of $4.6 million with a full valuation allowance. As of December 31, 2019, the Company had a deferred tax asset of $3.9 million with no valuation allowance.
The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
The tax years subsequent to and including the fiscal year ended December 31, 2013 remain open to examination by the major taxing jurisdictions to which the Company is subject.
Per Share Data
Per Share Data
Net income (loss) per basic share of common stock is calculated by dividing net income (loss) by the weighted-average number of shares (retroactively adjusted for the Stock Dividends) of common stock issued and outstanding during such period. Diluted net income (loss) per share of common stock considers the effect of potentially dilutive shares of common stock outstanding during the period.
CARES Act Grants
CARES Act Grants
On March 27, 2020, Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law and it provides funding to Medicare providers in order to provide financial relief during the COVID-19 pandemic. Funds provided under the program were to be used for the preparation, prevention, and medical response to COVID-19, and were designated to
reimburse providers for healthcare related expenses and lost revenues attributable to COVID-19. The Company received $3.6 million in these funds during the year ended December 31, 2020, related to four of its SHOPs and considered the funds to be a grant contribution from the government. The full amounts received were recognized as a reduction of property operating expenses in the Company’s consolidated statement of operations for the year ended December 31, 2020 to offset the incurred COVID-19 expenses. Subsequent to December 31, 2020, the Company received an additional $5.1 million in funding from CARES Act grants. There can be no assurance that the program will be extended or any further amounts received.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Adopted as of January 1, 2018
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), and has since issued several additional amendments thereto (collectively referred to herein as “ASC 606”). ASC 606 establishes a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. Under ASC 606, an entity is required to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASC 606 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. A reporting entity may apply the amendments in ASC 606 using either a modified retrospective approach, by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption or a full retrospective approach. The Company adopted this guidance effective January 1, 2018 under the modified retrospective approach and it did not have an impact on the Company’s consolidated financial statements. See above for further information on the Company’s Revenue Recognition Accounting Policies under ASC 606.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The revised guidance amends the recognition and measurement of financial instruments. The new guidance significantly revises an entity’s accounting related to equity investments and the presentation of certain fair value changes for financial liabilities measured at fair value. Among other things, it also amends the presentation and disclosure requirements associated with the fair value of financial instruments. The Company adopted this guidance effective January 1, 2018, using the modified retrospective transition method, and there was no impact to the Company's consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which provides guidance on how certain transactions should be classified and presented in the statement of cash flows as either operating, investing or financing activities. Among other things, the update provides specific guidance on where to classify debt prepayment and extinguishment costs, payments for contingent consideration made after a business combination and distributions received from equity method investments. The Company adopted the new guidance on January 1, 2018 and it did not have an impact on its consolidated statement of cash flows.
In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business (“ASU 2017-01”), which revises the definition of a business. This new guidance is applicable when evaluating whether an acquisition should be treated as either a business acquisition or an asset acquisition. Under the revised guidance, when substantially all of the fair value of gross assets acquired is concentrated in a single asset or group of similar assets, the assets acquired would not be considered a business. The Company adopted this guidance effective January 1, 2018, and will apply the new rules prospectively. The Company expects, based on historical property acquisitions, that in most cases, a future property acquired after adoption will be treated as an asset acquisition rather than a business acquisition, which will result in the capitalization of related transaction costs. The Company has evaluated the impact of this new guidance beginning in the first quarter of 2018, and determined that it did not have a material impact on the Company’s consolidated financial statements. All acquisition costs incurred during the years ended December 31, 2020 and 2019 were capitalized since our acquisitions during the years were all classified as asset acquisitions.
In February 2017, the FASB issued ASU 2017-05, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Assets Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets, which provides guidance related to partial sales of non-financial assets, eliminates rules specifically addressing the sales of real estate, clarifies the definition of in substance non-financial assets, removes the exception to the financial asset derecognition model and clarifies the accounting for contributions of non-financial assets to joint ventures. The Company adopted this guidance effective January 1, 2018 using the modified transition method and it did not have an impact on its financial statements. The Company expects that any future sales of real estate in which the Company retains a non-controlling interest in the property would result in the full gain amount being recognized at the time of the partial sale. Historically, the Company has not retained any interest in properties it has sold.
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance that clarifies which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The update states that modification accounting should be used unless the fair value of the award, the vesting terms of the award, and the classification of the award as either equity or liability, all do not change as a result of the modification. The Company adopted this guidance effective January 1, 2018 using the modified retrospective transition method and it did not have an impact on its consolidated financial statements. The Company expects that any future modifications to the Company’s issued share-based awards will be accounted for using modification accounting, unless the modification meets all of the exception criteria noted above. As a result, the modification would be treated as an exchange of the original award for a new award, with any incremental fair value being treated as additional compensation cost.
Adopted as of January 1, 2019
ASU No. 2016-02 - Leases
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) which provides guidance related to the accounting for leases, as well as the related disclosures. For lessors of real estate, leases are accounted for using an approach substantially the same as previous accounting guidance for operating leases and direct financing leases. For lessees, the new standard requires the application of a dual lease classification approach, classifying leases as either operating or finance leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. Lease expense for operating leases is recognized on a straight-line basis over the term of the lease, while lease expense for finance leases is recognized based on an effective interest method over the term of the lease. Also, lessees must recognize a right-of-use asset (“ROU”) and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Further, certain transactions where at inception of the lease the buyer-lessor accounted for the transaction as a purchase of real estate and a new lease, may now be required to have symmetrical accounting to the seller-lessee if the transaction was not a qualified sale-leaseback and accounted for as a financing transaction.
Upon adoption, lessors were allowed a practical expedient, which the Company has elected, by class of underlying assets to account for lease and non-lease components (such as tenant reimbursements of property operating expenses) as a single lease component as an operating lease because (a) the non-lease components have the same timing and pattern of transfer as the associated lease component; and (b) the lease component, if accounted for separately, would be classified as an operating lease. Additionally, only incremental direct leasing costs may be capitalized under this new guidance, which is consistent with the Company’s existing policies. Also, upon adoption, companies were allowed a practical expedient package, which the Company has elected, that allowed the Company: (a) to not reassess whether any expired or existing contracts entered into prior to January 1, 2019 are or contain leases; (b) to not reassess the lease classification for any expired or existing leases entered into prior to January 1, 2019 (including assessing sale-leaseback transactions); and (c) to not reassess initial direct costs for any expired or existing leases entered into prior to January 1, 2019. As a result, all of the Company’s existing leases will continue to be classified as operating leases under the new standard. Further, any existing leases for which the property is the leased to a tenant in a transaction that at inception was a sale-leaseback transaction will continue to be treated (absent a modification) as operating leases. The Company did not have any leases that would be considered financing leases as of January 1, 2019.
The Company assessed the impact of adoption from both a lessor and lessee perspective, which is discussed in more detail below, and adopted the new guidance prospectively on January 1, 2019, using a prospective transition approach under which the Company elected to apply the guidance effective January 1, 2019 and not adjust prior comparative reporting periods (except for the Company’s presentation of lease revenue discussed below).
Lessor Accounting
As discussed above, the Company was not required to re-assess the classification of its leases, which are considered operating leases under ASU 2016-02. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessor:
Since the Company elected the practical expedient noted above to not separate non-lease component revenue from the associated lease component, the Company has aggregated revenue from its lease components and non-lease components (tenant operating expense reimbursements) into one line. The prior periods have been conformed to this new presentation.
Changes in the Company’s assessment of receivables that result in bad debt expense is now required to be recorded as an adjustment to revenue, rather than a charge to bad debt expense. This new classification applies for the first quarter of 2019 and reclassification of prior period amounts is not permitted. At transition on January 1, 2019, after assessing its reserve balances at December 31, 2018 under the new guidance, the Company wrote off accounts receivable of $0.1
million and straight-line rents receivable of $0.1 million as an adjustment to the opening balance of accumulated deficit, and accordingly rent for these tenants is currently recorded on a cash basis.
Indirect leasing costs in connection with new or extended tenant leases, if any, are being expensed. Under prior accounting guidance, the recognition would have been deferred.
Lessee Accounting
    The Company was a lessee under leases for 17 properties including capital leases of land and building as of January 1, 2019 and because the Company has elected the practical expedients described above, it determined that 11 of these leases would continue to be classified as operating leases under the new standard. The following is a summary of the most significant impacts to the Company of the new accounting guidance, as lessee:
Upon adoption of the new standard, the Company recorded ROU assets and lease liabilities equal to $10.2 million for the present value of the lease payments related to its ground leases. These amounts are included in operating lease right-of-use assets and operating lease liabilities on the Company’s consolidated balance sheet as of December 31, 2019.
The Company also reclassified $0.5 million related to amounts previously reported as a straight-line rent liability and $4.8 million, net related to amounts previously reported as above and below market ground lease intangibles to the ROU assets. For additional information and disclosures related to these operating leases, see Note 16 — Commitments and Contingencies.
Other Accounting Pronouncements
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, to better align cash flow and fair value hedge accounting with the corresponding risk management activities. Among other things, the amendments expand which hedging strategies are eligible for hedge accounting, align the timing of recognition of hedge results with the earnings effect of the hedged item and allow companies to include the change in fair value of the derivative in the same income statement line item as the earnings effect of the hedged item. Additionally, for cash flow hedges that are highly effective, the update allows for all changes in fair value of the derivative to be recorded in other comprehensive income. The Company has adopted ASU 2017-12 on January 1, 2019, as required under the guidance, using a modified retrospective transition method and the adoption did not have a material impact on its consolidated financial statements.
Adopted as of January 1, 2020:
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The objective of ASU 2018-13 is to improve the effectiveness of disclosures in the notes to the financial statements by removing, modifying, and adding certain fair value disclosure requirements to facilitate clear communication of the information required by generally accepted accounting principles. The amended guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which changes how entities measure credit losses for financial assets carried at amortized cost. The update eliminates the requirement that a credit loss must be probable before it can be recognized and instead requires an entity to recognize the current estimate of all expected credit losses. Additionally, the amended standard requires credit losses on available-for-sale debt securities to be carried as an allowance rather than as a direct write-down of the asset. On July 25, 2018, the FASB proposed an amendment to ASU 2016-13 to clarify that operating lease receivables recorded by lessors (including unbilled straight-line rent) are explicitly excluded from the scope of ASU 2016-13. The new guidance is effective for the Company beginning on January 1, 2020. The Company adopted the new guidance on January 1, 2020 and determined it did not have a material impact on its consolidated financial statements.
Not yet Adopted as of December 31, 2020
In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Topic 470) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Topic 815). The new standard reduces the number of accounting models for convertible debt instruments and convertible preferred stock, and amends the guidance for the derivatives scope exception for contracts in an entity's own equity. The standard also amends and makes targeted improvements to the related earnings per share guidance. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The standard allows for either modified or full retrospective transition
methods. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848). Topic 848 contains practical expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in Topic 848 is optional and may be elected over the period March 12, 2020 through December 31, 2022 as reference rate reform activities occur. During the year ended December 31, 2020, the Company elected to apply the hedge accounting expedients related to (i) the assertion that our hedged forecasted transactions remain probable and (ii) the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. Application of these expedients preserves the presentation of our derivatives, which will be consistent with our past presentation. The Company will continue to evaluate the impact of the guidance and may apply other elections, as applicable, as additional changes in the market occur.
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Lessor, Operating Lease, Payments to be Received, Maturity
(In thousands)Future 
Base Rent Payments
2021$94,144 
202287,762 
202375,205 
202468,210 
202558,757 
Thereafter165,642 
Total$549,720 
Schedule of Components of Income Tax Benefit (Expense) The following table details the composition of the Company’s tax (expense) benefit for the years ended December 31, 2020, 2019 and 2018, which includes U.S. federal and state income taxes incurred by the Company’s TRS. The Company estimated its income tax (expense) benefit relating to its TRS using a combined federal and state rate of approximately (105.8)% and 26.4% for the years ended December 31, 2020 and 2019, respectively. These income taxes are reflected in income tax (expense) benefit on the accompanying consolidated statements of operations and comprehensive loss.
Year Ended December 31,
202020192018
(In thousands)CurrentDeferredCurrentDeferredCurrentDeferred
Federal (expense) benefit $726 $— $— $(155)$(272)$399 
State (expense) benefit(196)50 (176)(68)(353)29 
Deferred tax asset valuation allowance— (4,641)— — — — 
Total income tax benefit (expense)$530 $(4,591)$(176)$(223)$(625)$428 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Tables)
12 Months Ended
Dec. 31, 2020
Real Estate [Abstract]  
Schedule of Business Acquisitions, by Acquisition
The following table presents the allocation of the assets acquired and liabilities assumed, as well as capitalized construction in progress during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Real estate investments, at cost:
Land$7,665 $6,356 $14,417 
Buildings, fixtures and improvements90,699 68,903 98,236 
Development costs— 5,721 8,591 
Total tangible assets98,364 80,980 121,244 
Acquired intangibles:
In-place leases and other intangible assets (1)
10,369 11,777 6,823 
Market lease and other intangible assets (1)
496 724 275 
Market lease liabilities (1)
(362)(1,483)(286)
Total intangible assets and liabilities
10,503 11,018 6,812 
Mortgage notes payable, net(13,883)— — 
Cash paid for real estate investments, including acquisitions$94,984 $91,998 $128,056 
Number of properties purchased14 
_______________
(1) Weighted-average remaining amortization periods for in-place leases, above-market leases and below market leases acquired were 1.7 years, 7.7 years and 7.4 years, respectively, as of December 31, 2020. Weighted-average remaining amortization periods for in-place leases and above-market leases acquired were 8.1 years and 7.0 years, respectively, as of December 31, 2019. There were no below market leases acquired in the year ended December 31, 2019.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas The following table lists the states where the Company had concentrations of properties where annualized rental income on a straight-line basis represented 10% or more of consolidated annualized rental income on a straight-line basis for all properties as of December 31, 2020, 2019 and 2018:
December 31,
State202020192018
Florida (1)
20.6%25.2%16.6%
Georgia**10.1%
Michigan (2)
*10.9%13.1%
Pennsylvania10.4 %*10.2%
_______________
*    State’s annualized rental income on a straight-line basis was not greater than 10% of total annualized rental income for all portfolio properties as of the period specified.
(1)During the fourth quarter of 2020, the Company completed the sale of its skilled nursing facility in Lutz, Florida. In addition, in August 2020 the Company entered into an agreement to sell our skilled nursing facility in Wellington, Florida, and our development property in Jupiter, Florida.
(2)During the year ended December 31, 2020, the Company sold 11 SHOPs located in Michigan, seven of which were transferred to the buyer during the fourth quarter of 2020 and four of which remained classified as held for sale on the Company’s consolidated balance sheet as of December 31, 2020. The remaining four properties were transferred to the buyer in the first quarter of 2021.
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
Acquired intangible assets and liabilities consisted of the following as of the periods presented:
December 31, 2020December 31, 2019
(In thousands)Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Intangible assets:
In-place leases$241,097 $172,648 $68,449 $229,300 $156,428 $72,872 
Market lease assets14,116 10,845 3,271 13,616 9,501 4,115 
Other intangible assets20,802 1,171 19,631 26,700 1,144 25,556 
Total acquired intangible assets
$276,015 $184,664 $91,351 $269,616 $167,073 $102,543 
Intangible liabilities:
Market lease liabilities $22,109 $11,306 $10,803 $21,777 $9,725 $12,052 
Schedule of Finite-Lived Intangible Assets
The following table discloses amounts recognized within the consolidated statements of operations and comprehensive loss related to amortization of in-place leases and other intangible assets, amortization and accretion of above-and below-market lease assets and liabilities, net and the amortization of above-and below-market ground leases, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Amortization of in-place leases and other intangible assets(1)
$15,121 $15,559 $18,851 
Accretion of above-and below-market leases, net(2)
$(257)$(247)$(39)
Amortization of above-and below-market ground leases, net(3)
$178 $86 $147 
____________
(1)    Reflected within depreciation and amortization expense.
(2)    Reflected within revenue from tenants.
(3)    Reflected within property operating and maintenance expense. Upon adoption of ASC 842 effective January 1, 2019, intangible balances related to ground leases were reclassified to be included as part of the Operating lease right-of-use assets presented on the consolidated balance sheet with no change to placement of the amortization expense of such balances. Refer to Note 2 Summary of Significant Accounting Policies for additional details.
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The following table provides the projected amortization and adjustments to revenue from tenants for the next five years:
(In thousands)20212022202320242025
In-place lease assets$10,904 $8,704 $6,830 $6,070 $4,896 
Other intangible assets613 613 613 613 588 
Total to be added to amortization expense$11,517 $9,317 $7,443 $6,683 $5,484 
Above-market lease assets$(1,299)$(993)$(645)$(307)$(260)
Below-market lease liabilities1,388 1,326 1,213 1,062 955 
Total to be added to revenue from tenants$89 $333 $568 $755 $695 
Real Estate Sales
The following table summarizes the properties sold during the years ended December 31, 2020, 2019, and 2018:
(In thousands)Disposition DateContract Sale PriceGain (Loss)
on Sale, of Real Estate Investments
2020 Dispositions:
LutzDecember, 2020$20,000 $3,832 
Michigan SHOPs (11 properties) (1)
November 2, 202011,750 (908)
Cape GirardeauMarch 19, 20208,600 2,306 
Totals$40,350 $5,230 
2019 Dispositions:
New York Six MOBs (1 property)
August 22, 2019$13,600 $2,883 
Ocean Park (1)
August 1, 20193,600 (152)
New York Six MOBs (5 properties)
February 6, 201945,000 6,059 
Totals$62,200 $8,790 
2018 Dispositions:
Missouri SNF Properties (1)
December 5, 2018$27,500 $(70)
________
(1) These properties were previously impaired. See “Impairments” section below. Represents contract sales price for all 11 properties. Loss on sale relates to the seven properties that were transferred to the buyer in the fourth quarter of 2020 (see below for additional information).
The following is a summary of impairments taken during the years ended December 31, 2020, 2019 and 2018:
Year Ended December 31,
(In thousands)202020192018
Assets held for sale$19,570 $22,634 $18,255 
Assets held for use16,876 33,335 2,400 
Total$36,446 $55,969 $20,655 
Schedule of Assets Held for Sale
The following table details the major classes of assets associated with the properties that have been classified as held for sale as of December 31, 2020 and 2019:
December 31,
(In thousands)
2020 (1)
2019 (2)
   Land$145 $4,051 
   Buildings, fixtures and improvements(55)66,788 
Assets held for sale$90 $70,839 
_____
(1) Assets held for sale as of December 31, 2020 relates to four Michigan SHOPs.
(2) Assets held for sale as of December 31, 2019 relates to the original 14 Michigan SHOPs under the PSA entered into in January 2020 (see below for additional information).
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Mortgage Notes Payable, Net (Tables)
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
The following table reflects the Company’s mortgage notes payable as of December 31, 2020 and 2019:
Portfolio
Encumbered Properties (1)
Outstanding Loan Amount as of December 31,
Effective Interest Rate(2) as of December 31,
Interest Rate
2020201920202019Maturity
(In thousands)(In thousands)
Palm Valley Medical Plaza - Goodyear, AZ1$2,998 $3,112 4.15 %4.15%FixedJun. 2023
Medical Center V - Peoria, AZ12,786 2,884 4.75 %4.75%FixedSep. 2023
Fox Ridge Bryant - Bryant, AR17,133 7,283 3.98 %3.98%FixedMay 2047
Fox Ridge Chenal - Little Rock, AR116,390 16,695 3.98 %3.98%FixedMay 2049
Fox Ridge North Little Rock - North Little Rock, AR110,170 10,359 3.98 %3.98%FixedMay 2049
Capital One MOB Loan41378,500 378,500 3.71 %3.71%Fixed(3)Dec. 2026
Multi-Property CMBS Loan21118,700 118,700 4.60 %4.60%FixedMay 2028
Shiloh - Illinois (4)
113,684 — 4.34 %—%FixedMarch 2026
Gross mortgage notes payable68550,361 537,533 3.94 %3.90%
Deferred financing costs, net of accumulated amortization (5)
(6,191)(7,718)
Mortgage premiums and discounts, net(1,472)(1,531)
Mortgage notes payable, net$542,698 $528,284 
__________
(1) Does not include real estate assets mortgaged to secure advances under the Fannie Mae Master Credit Facilities or eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below). The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the real estate assets comprising the borrowing base have been pledged for the benefit of the lenders thereunder (see Note 5 — Credit Facilities for additional details).
(2)    Calculated on a weighted average basis for all mortgages outstanding as of December 31, 2020 and December 31, 2019. For the LIBOR based loans, LIBOR in effect at the balance sheet date was utilized. For the Capital One MOB Loan, the effective rate does not include the effect of amortizing the amount paid to terminate the previous pay-fixed swap. See Note 7 — Derivatives and Hedging Activities for additional details.
(3) Variable rate loan, based on 30-day LIBOR, which is fixed as a result of entering into “pay-fixed” interest rate swap agreements. In connection with the amendment to this loan in December 2019 (see additional details below), the Company terminated the previous interest rate swap agreements and entered into new interest rate swap agreements (see Note 7 Derivatives and Hedging Activities for additional details).
(4)    The Company assumed this fixed rate mortgage when it acquired a property during the year ended December 31, 2020.
(5)    Deferred financing costs represent commitment fees, legal fees and other costs associated with obtaining financing. These costs are amortized to interest expense over the terms of the respective financing agreements using the effective interest method. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financial transactions that do not close are expensed in the period in which it is determined that the financing will not close.
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Facilities Credit Facilities (Tables)
12 Months Ended
Dec. 31, 2020
Debt Disclosure [Abstract]  
Schedule of Credit Facilities
The Company had the following credit facilities outstanding as of December 31, 2020 and 2019:
Outstanding Facility Amount as of December 31,
Effective Interest Rate as of December 31,(10)
Credit Facility
Encumbered Properties(1)
2020201920202019Interest RateMaturity
(In thousands)(In thousands)
Credit Facility:
Revolving Credit Facility
$173,674 $100,618 3.21 %4.08 %Variable(8)Mar. 2023(9)
Term Loan
150,000 150,000 4.95 %4.05 %Variable(6)Mar. 2024
Deferred financing costs
(4,298)(4,671)
Term Loan, net
145,702 145,329 
Total Credit Facility
89(2)$319,376 $245,947 
Fannie Mae Master Credit Facilities:
Capital One Facility11(3)$212,467 $216,614 2.60 %4.17 %Variable(7)Nov. 2026
KeyBank Facility10(4)142,708 142,708 2.65 %4.22 %Variable(7)Nov. 2026
Total Fannie Mae Master Credit Facilities
21$355,175 $359,322 
Total Credit Facilities110$674,551 $605,269 3.29 %(5)4.14 %(5)
__________
(1)Encumbered properties are as of December 31, 2020.
(2)The equity interests and related rights in the Company’s wholly owned subsidiaries that directly own or lease the eligible unencumbered real estate assets comprising the borrowing base of the Credit Facility (as defined below) have been pledged for the benefit of the lenders thereunder.
(3)Secured by first-priority mortgages on 11 of the Company’s seniors housing properties located in Florida, Georgia, Iowa and Michigan as of December 31, 2020 with a carrying value of $344.0 million.
(4)Secured by first-priority mortgages on ten of the Company’s seniors housing properties located in, Missouri, Kansas, California, Florida, Georgia and Iowa as of December 31, 2020 with carrying value of $253.6 million.
(5)Calculated on a weighted average basis for all credit facilities outstanding as of December 31, 2020 and 2019, respectively. For the LIBOR based loans that have not been fixed, the LIBOR rate in effect at the balance sheet date was utilized. For LIBOR based loans that have been fixed, the effective rate after consideration of the interest rate swap was utilized. See Note 7 — Derivatives and Hedging Activities for additional details.
(6)Variable rate loan, based on LIBOR, all of which was fixed as a result of entering into “pay-fixed” interest rate swap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(7)Variable rate loan which is capped as a result of entering into interest rate cap agreements (see Note 7 — Derivatives and Hedging Activities for additional details).
(8)Variable rate loan with $50 million of principal amount fixed at a rate of 4.09% by an interest rate swap agreement.
(9)The company has the option to extend maturity one year to March 2024 subject to certain conditions.
(10)Effective interest rate below for variable rate debt gives effect to any “Pay-fixed” swap entered into by the Company. If not hedged, the effective interest rate below represents the variable rate (or contractual floor if appropriate) and the applicable margin in effect as of December 31, 2020. Interest rate caps are not considered unless the cap is currently in effect.
Schedule of Maturities of Long-term Debt
The following table summarizes the scheduled aggregate principal payments for the five years subsequent to December 31, 2020 and thereafter, on all of the Company’s outstanding debt (mortgage notes payable and credit facilities):
Future Principal
Payments
(In thousands)Mortgage Notes PayableCredit FacilitiesTotal
2021$1,191 $130 $1,321 
20221,242 2,820 4,062 
20236,383 4,497 10,880 
20241,095 178,171 179,266 
20251,142 154,497 155,639 
Thereafter539,308 338,734 878,042 
Total$550,361 $678,849 $1,229,210 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements, Recurring and Nonrecurring
The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020 and 2019, aggregated by the level in the fair value hierarchy within which those instruments fall.
(In thousands)Quoted Prices in Active Markets
Level 1
Significant
Other Observable Inputs
Level 2
Significant Unobservable Inputs
Level 3
Total
December 31, 2020
Derivative assets, at fair value$— $13 $— $13 
Derivative liabilities, at fair value— (38,389)— (38,389)
Total$— $(38,376)$— $(38,376)
December 31, 2019
Derivative assets, at fair value$— $392 $— $392 
Derivative liabilities, at fair value(5,305)(5,305)
Total$— $(4,913)$— $(4,913)
Fair Value, by Balance Sheet Grouping
The fair values of the Company’s remaining financial instruments that are not reported at fair value on the consolidated balance sheets are reported below:
December 31, 2020December 31, 2019
(In thousands)Level
Carrying Amount 
Fair Value
Carrying Amount 
Fair Value
Gross mortgage notes payable and mortgage
premium and discounts, net
3$548,889 $549,553 $536,002 $545,414 
Credit Facility
3$323,674 $319,558 $250,618 $250,618 
Fannie Mae Master Credit Facilities
3$355,175 $354,073 $359,322 $370,122 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Tables)
12 Months Ended
Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Balance Sheet Location The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the consolidated balance sheets as of December 31, 2020 and 2019:
December 31,
(In thousands)Balance Sheet Location20202019
Derivatives designated as hedging instruments:
Interest rate “pay-fixed” swapsDerivative assets, at fair value$— $377 
Interest rate “pay-fixed” swapsDerivative liabilities, at fair value$38,389 $5,305 
Derivatives not designated as hedging instruments:
Interest rate capsDerivative assets, at fair value$13 $15 
Summary of Derivative Instruments
As of December 31, 2020 and 2019, the Company had the following derivatives that were designated as cash flow hedges of interest rate risk:
December 31, 2020December 31, 2019
Interest Rate DerivativeNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate “pay-fixed” swaps$578,500 $578,500 
The Company had the following outstanding interest rate derivatives that were not designated as a hedges in qualifying hedging relationships as of as of December 31, 2020 and 2019:
December 31, 2020December 31, 2019
Interest Rate DerivativesNumber of InstrumentsNotional AmountNumber of InstrumentsNotional Amount
(In thousands)(In thousands)
Interest rate caps$359,322 $359,322 
Schedule of Derivatives Included in AOCI
The table below details the location in the financial statements of the loss recognized on interest rate derivatives designated as cash flow hedges for the periods ended December 31, 2020 and 2019:
Year Ended December 31,
(In thousands)202020192018
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives$(40,614)$(10,753)$2,367 
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)$(7,999)$872 $258 
Total amount of interest expense presented in the
consolidated statements of operations and comprehensive loss
$51,519 $56,059 $49,471 
Offsetting Assets
The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2020 and 2019. The net amounts of derivative assets or liabilities can be reconciled to the tabular disclosure of fair value. The tabular disclosure of fair value provides the location that derivative assets and liabilities are presented on the consolidated balance sheet.
Gross Amounts Not Offset in the Consolidated Balance Sheet
(In thousands)Gross Amounts of Recognized AssetsGross Amounts of Recognized (Liabilities)Gross Amounts Offset in the Consolidated Balance SheetNet Amounts of Assets presented in the Consolidated Balance SheetFinancial InstrumentsCash Collateral ReceivedNet Amount
December 31, 2020$13 — — $13 — — $13 
December 31, 2020$— (38,389)— $(38,389)— — $(38,389)
December 31, 2019$392 — — $392 — — $392 
December 31, 2019$— (5,305)— $(5,305)— — $(5,305)
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Class of Treasury Stock
The table below reflects the number of shares repurchased and the average price per share (retroactively adjusted for the Stock Dividends), under the SRP and does not include any repurchases under tender offers (see above), cumulatively through December 31, 2020:
Number of Shares Repurchased (2)
Average Price per Share (2)2
Cumulative repurchases as of December 31, 20194,391,519 $20.95 
Year ended December 31, 2020 (1)
505,101 17.50 
Cumulative repurchases as of December 31, 2020
4,896,620 20.60 
_________
(1) Includes 505,101 shares of common stock repurchased on February 26, 2020 with respect to requests received during the period commencing July 1, 2019 up to and including December 31, 2019 for $8.8 million at an average price per share of $17.50.
Dividends Declared
The following table details from a tax perspective the portion of distributions classified as a return of capital, capital gain dividend income and ordinary dividend income, per share per annum, for the years ended December 31, 2020, 2019 and 2018, retroactively adjusted for the effect of the Stock Dividends:
Year Ended December 31,
202020192018
Return of capital (1)
100.0 %$0.42 100 %$0.83 100 %$0.92 
Capital gain dividend income— %— — %— — %— 
Ordinary dividend income— %— — %— — %— 
Total100.0 %$0.42 100.0 %$0.83 100.0 %$0.92 
________
(1) Amount for December 31, 2020 represents actual cash distributions paid to common shareholders during the year ended 2020, but excludes the stock dividends which do not represent taxable dividends to the Company’s shareholders for U.S. federal income tax purposes.
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements (Tables)
12 Months Ended
Dec. 31, 2020
Related Party Transactions [Abstract]  
Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services
The following table details amounts incurred, forgiven and payable in connection with the Company’s operations-related services described above as of and for the periods presented:
Year Ended December 31,Payable (Receivable) as of
 202020192018December 31,
(In thousands)
Incurred
Incurred
Incurred20202019
One-time fees and reimbursements:
Acquisition cost reimbursements$81 $39 $176 $11 $— 
Ongoing fees and reimbursements:
Asset management fees 19,987 19,526 19,500 — 27 
Property management fees (6)
4,197 3,888 3,571 288 (44)
Professional fees and other reimbursements (1) (4)
12,102 

10,073 8,883 (61)(377)(5)
Professional fees credit due from Advisor(1,217)— — (1,217)(3)— 
Distributions on Class B Units (2)
178 305 340 — — 
Total related party operation fees and reimbursements$35,328 $33,831 $32,470 $(979)$(394)
_________
(1)    Included in general and administrative expenses in the consolidated statements of operations. Includes $5.6 million and $7.2 million subject to the Capped Reimbursement Amount for the years ended December 31, 2020 and 2019, respectively.
(2)     Prior to April 1, 2015, the Company caused the OP to issue (subject to periodic approval by the Board) to the Advisor restricted performance-based Class B Units for asset management services. As of December 31, 2020, the Board had approved the issuance of, and the OP had issued, 359,250 Class B Units to the Advisor in connection with this arrangement. Effective April 1, 2015, the Company began paying an asset management fee to the Advisor or its assignees in cash, in shares, or a combination of both and no longer issues any Class B Units.
(3)     Balance includes a receivable of $1.2 million from the Advisor related to the overpayment of 2019 Bonus Awards as of December 31, 2020 which, pursuant to authorization by the independent members of the Company’s board of directors, is payable over a ten month period from January 2021 to October 2021.
(4)     During the year ended December 31, 2019, the Company recorded a reduction of general and administrative expenses in the amount of $0.5 million related to the reversal of a payable balance due to RCS Capital Corporation. During the year ended December 31, 2020 the Company recorded approximately $2.2 million of expense reimbursements to the Advisor for severance payments and related legal costs relating to the termination of its former Chief Executive Officer.
(5) Balance includes a receivable of $0.5 million from the Advisor as of December 31, 2019, previously recorded in the fourth quarter of 2018, which, pursuant to authorization by the independent members of the Company’s board of directors, was fully paid during 2020.
(6)    Inclusive of $0.3 million of leasing commissions which are included in prepaid expenses and other assets on the consolidated balance sheet as of December 31, 2020.
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Restricted Share Award Activity
The following table reflects the amount of shares outstanding as of December 31, 2020 and activity for the period presented:
Number of Common Shares Weighted-Average Issue Price
Unvested, December 31, 2017382,510 $21.47 
Granted— — 
Vested(60,268)21.78 
Forfeitures— — 
Unvested, December 31, 2018322,242 21.41 
Granted15,000 17.50 
Vested(60,001)21.48 
Forfeitures— — 
Unvested, December 31, 2019277,241 21.18 
Stock dividend2,878 15.75 
Granted— — 
Vested(64,735)21.18 
Forfeitures— — 
Unvested, December 31, 2020215,384 21.11 
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive (Loss) Income (Tables)
12 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table illustrates the changes in accumulated other comprehensive (loss) income as of and for the periods presented:
(In thousands)Unrealized Gains (Losses) on Designated Derivative
Balance, December 31, 20172,473 
Other comprehensive income, before reclassifications2,367 
Amounts reclassified from accumulated other comprehensive (loss) income(258)
Balance, December 31, 20184,582 
Other comprehensive loss, before reclassifications(10,753)
Amounts reclassified from accumulated other comprehensive (loss) income(872)
Balance, December 31, 2019(7,043)
Other comprehensive loss, before reclassifications(40,614)
Amounts reclassified from accumulated other comprehensive (loss) income7,999 
Rebalancing of ownership percentage(15)
Balance, December 31, 2020$(39,673)
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Non-Controlling Interests (Tables)
12 Months Ended
Dec. 31, 2020
Noncontrolling Interest [Abstract]  
Schedule related to Investment Arrangements with Unaffiliated Third Party
The following table summarizes the activity related to investment arrangements with unaffiliated third parties.
Third Party Net Investment AmountNon-Controlling Ownership PercentageNet Real Estate Assets Subject to Investment ArrangementDistributions
As of December 31,As of December 31,As of December 31,Year Ended December 31,
Property Name
(Dollar amounts in thousands)
Investment Date2020202020202019202020192018
Plaza Del Rio Medical Office Campus Portfolio(1)
May 2015$371 2.2 %$12,790 $14,220 $— $— $87 
UnityPoint Clinic Portfolio (2)
December 2017$— — %$— $8,842 $— $— $— 
_____________
(1)    One property within the Plaza Del Rio Medical Office Campus Portfolio was mortgaged as part of the Multi-Property CMBS Loan. See Note 4 - Mortgage Notes Payable for additional information.
(2)    On November 4, 2020, the Company purchased all of the outstanding membership interests in the joint venture that owns the UnityPoint portfolio. See details above for additional information.
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2020
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following is a summary of the basic and diluted net loss per share computation for the years ended December 31, 2020, 2019 and 2018 and has been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
Year Ended December 31,
202020192018
Net loss attributable to stockholders (in thousands)
$(78,781)$(88,087)$(52,762)
Basic and diluted weighted-average shares outstanding (1)
94,639,833 94,433,640 93,593,719 
Basic and diluted net loss per share (1)
$(0.83)$(0.93)$(0.56)
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization for additional details)).
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The amounts in the table below have been retroactively adjusted to reflect the Stock Dividend (see Note 1 — Organization for additional details):
December 31,
202020192018
Unvested restricted shares (1)
257,704 313,711 367,796 
OP Units (2)
417,025 417,025 417,025 
Class B Units (3)
369,007 369,007 369,007 
Total weighted average antidilutive common share equivalents1,043,736 1,099,743 1,153,828 
________
(1)    Weighted average number of antidilutive unvested restricted shares outstanding for the periods presented. There were 215,373, 277,241 and 322,242 unvested restricted shares outstanding as of December 31, 2020, 2019 and 2018, respectively.
(2)    Weighted average number of antidilutive OP Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 405,998 OP Units outstanding as of December 31, 2020, 2019 and 2018.
(3)    Weighted average number of antidilutive Class B Units presented as shares outstanding for the periods presented, at the current conversion rate as adjusted for the effect of the Stock Dividends. There were 359,250 Class B Units outstanding as of December 31, 2020, 2019 and 2018.
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables reconcile the segment activity, adjusted for the Transition Properties, to consolidated net loss for the years ended December 31, 2020 2019 and 2018:
Year Ended December 31, 2020
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$104,213 $15,611 $261,788 $381,612 
Property operating and maintenance30,851 1,961 210,736 243,548 
NOI$73,362 $13,650 $51,052 138,064 
Impairment charges(36,446)
Operating fees to related parties(23,922)
Acquisition and transaction related(173)
General and administrative(21,572)
Depreciation and amortization(81,053)
Gain on sale of real estate investments5,230 
Interest expense(51,519)
Interest and other income 44 
Loss on non designated derivatives(102)
Income tax expense(4,061)
Net income attributable to non-controlling interests(303)
Allocation for preferred stock(2,968)
Net loss attributable to common stockholders$(78,781)
Year Ended December 31, 2019
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$100,379 $14,564 $259,971 $374,914 
Property operating and maintenance31,813 2,310 200,062 234,185 
NOI68,566 12,254 59,909 140,729 
Impairment charges(55,969)
Operating fees to related parties(23,414)
Acquisition and transaction related(362)
General and administrative(20,530)
Depreciation and amortization(81,032)
Interest expense(56,059)
Interest and other income
Gain on sale of real estate investments8,790 
Loss on sale of non-designated derivatives(68)
Income tax expense(399)
Net loss attributable to non-controlling interests393 
Allocation for preferred stock(173)
Net loss attributable to stockholders$(88,087)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the years ended December 31, 2020 and 2019, respectively.
Year Ended December 31, 2018
(In thousands)Medical Office Buildings
Triple-Net Leased Healthcare Facilities (1)
Seniors Housing — Operating Properties (1)
Consolidated
Revenue from tenants$99,103 $14,970 $248,333 $362,406 
Property operating and maintenance30,295 1,424 189,278 220,997 
NOI68,808 13,546 59,055 141,409 
Impairment charges(20,655)
Operating fees to related parties(23,071)
Acquisition and transaction related(302)
General and administrative(17,275)
Depreciation and amortization(83,212)
Gain on sale of real estate investment (70)
Interest expense(49,471)
Interest and other income 23 
Loss on non-designated derivatives (157)
Income tax expense(197)
Net loss attributable to non-controlling interests216 
Net loss attributable to common stockholders$(52,762)
______________
(1) The results of operations from the Transition Properties are presented within the SHOP segment for the year ended December 31, 2018.
The following table reconciles the segment activity to consolidated total assets as of the periods presented:
December 31,
(In thousands)20202019
ASSETS
Investments in real estate, net:
Medical office buildings
$883,471 $891,477 
Triple-net leased healthcare facilities (1)
238,427 256,661 
Seniors housing — operating properties (1)
987,050 905,453 
Total investments in real estate, net
2,108,948 2,053,591 
Cash and cash equivalents72,357 95,691 
Restricted cash17,989 15,908 
Assets held for sale90 70,839 
Derivative assets, at fair value13 392 
Straight-line rent receivable, net23,322 21,182 
Operating lease right-of-use asset13,912 14,351 
Prepaid expenses and other assets34,932 39,707 
Deferred costs, net15,332 13,642 
Total assets$2,286,895 $2,325,303 
__________________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020 and 2019.
The following table reconciles capital expenditures by reportable business segments, excluding corporate non-real estate expenditures, for the periods presented:
Year Ended December 31,
(In thousands)202020192018
Medical office buildings$4,585 $5,309 $7,582 
Triple-net leased healthcare facilities (1)
3,976 396 1,152 
Seniors housing — operating properties (1)
12,833 11,014 4,176 
Total capital expenditures$21,394 $16,719 $12,910 
___________
(1) The Transition Properties are presented within the SHOP segment as of December 31, 2020, 2019 and 2018.
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2020
Leases [Abstract]  
Operating Lease, Liability, Maturity
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2021$663 $84 
2022682 86 
2023684 88 
2024686 90 
2025691 93 
Thereafter28,690 7,407 
Total minimum lease payments32,096 7,848 
Less: amounts representing interest(22,941)(3,011)
Total present value of minimum lease payments$9,155 $4,837 
_______
(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
Finance Lease, Liability, Maturity
Future Base Rent Payments
(In thousands)Operating Leases
Direct Financing Leases (1)
2021$663 $84 
2022682 86 
2023684 88 
2024686 90 
2025691 93 
Thereafter28,690 7,407 
Total minimum lease payments32,096 7,848 
Less: amounts representing interest(22,941)(3,011)
Total present value of minimum lease payments$9,155 $4,837 
_______
(1) The Direct Finance Lease liability is included in Accounts Payable and accrued expenses on the balance sheet as of December 31, 2020. The Direct Financing lease asset is included as part of building and improvements as the land component was not required to be bifurcated under ASU 840.
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Quarterly Results (Unaudited) (Tables)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
Presented below is a summary of the unaudited quarterly financial information for the years ended December 31, 2020 and 2019 which has been retroactively adjusted to reflect the Stock Dividends (see Note 1 — Organization for additional details):
Quarter Ended
(In thousands, except for share and per share data)March 31,
2020
June 30,
2020
September 30,
2020
December 31,
2020
Total revenues$100,235 $94,664 $95,835 $90,878 
Net loss attributable to stockholders$(24,744)$(22,811)$(10,500)$(20,726)
Basic and diluted weighted average shares outstanding (1)
94,458,620 94,479,156 94,796,190 94,821,653 
Basic and diluted net loss per share (1)
$(0.26)$(0.24)$(0.11)$(0.22)
Quarter Ended
(In thousands, except for share and per share data)March 31,
2019
June 30,
2019
September 30,
2019
December 31, 2019 (2)
Total revenues$88,718 $96,287 $95,440 $94,469 
Net loss attributable to stockholders$(5,111)$(6,054)$(28,789)$(48,133)
Basic and diluted weighted average shares outstanding (1)
95,417,626 94,276,398 94,419,591 94,592,579 
Basic and diluted net loss per share (1)
$(0.05)$(0.06)$(0.30)$(0.51)
__________
(1) Retroactively adjusted for the effects of the Stock Dividends (see Note 1 — Organization).
(2) During the quarter ended December 31, 2020 and 2019, the Company recorded $3.6 million and $33.3 million in impairment charges on real estate investments held for use. See Note 3 — Real Estate investments, Net - Impairments for additional details.
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Organization (Details)
ft² in Millions
3 Months Ended 12 Months Ended
Oct. 01, 2020
shares
Dec. 31, 2020
property
shares
Dec. 31, 2020
property
shares
Dec. 31, 2020
state
Dec. 31, 2020
ft²
Dec. 31, 2020
encumbered_property
Organization, Consolidation and Presentation of Financial Statements [Abstract]            
Number of real estate properties   193 193     110
Number of states properties are located in | state       31    
Area of real estate property | ft²         9.4  
Stock dividends (in shares) 0.01349   0.02716      
Issuance of preferred stock, net (in shares)   0        
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Narrative) (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 01, 2019
USD ($)
lease
property
Mar. 31, 2020
USD ($)
Mar. 19, 2021
USD ($)
Dec. 31, 2020
USD ($)
lease
property
segment
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
segment
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Jan. 01, 2018
USD ($)
Schedule of Shares Repurchased [Line Items]                  
Overstatement of previously recorded tax benefits, deferred tax assets and net income           $ 800,000 $ 300,000 $ 200,000  
Interest expense       $ 51,519,000 $ 56,059,000 49,471,000      
Rent collection percentage       100.00%          
Remaining lease term       6 years 6 months          
Operating lease impairment loss       $ 2,700,000 6,500,000        
Bad debt expense       2,708,000 6,464,000 $ 14,797,000      
Assets held for sale       $ 90,000 $ 70,839,000        
Number of reportable segments | segment       3 3 3      
Money market funds       $ 0 $ 0        
Cash and cash equivalents       72,357,000 95,691,000 $ 77,264,000      
Cash in excess of FDIC limit       $ 57,000,000.0 73,200,000        
Number of senior housing communities | property       59          
Number of intercompany leases modified | lease       25          
Deferred tax asset, net       $ 4,600,000 3,900,000        
Income (loss), tax basis       $ (3,100,000)          
Deferred tax assets, valuation allowance         $ 0        
Effective income tax rate       (105.80%) 26.40%        
Number of properties receiving grants | property       4          
Number of operating lease contracts | lease 11     8          
Operating lease right-of-use assets       $ 13,912,000 $ 14,351,000        
Operating lease liabilities       9,155,000 9,133,000        
Operating lease costs       900,000 1,000,000.0 900,000      
Total present value of minimum lease payments       4,837,000 4,800,000        
Domestic Tax Authority                  
Schedule of Shares Repurchased [Line Items]                  
Operating loss carryforwards       14,000,000         $ 7,600,000
Subsequent Event                  
Schedule of Shares Repurchased [Line Items]                  
Proceeds from government assistance     $ 5,100,000            
COVID19 Pandemic                  
Schedule of Shares Repurchased [Line Items]                  
Financial relief funds       $ 3,600,000          
Credit Facilities                  
Schedule of Shares Repurchased [Line Items]                  
Interest expense         0        
Credit Facilities | Revision of Prior Period, Adjustment                  
Schedule of Shares Repurchased [Line Items]                  
Interest expense         300,000        
Revolving Credit Facility | Credit Facilities                  
Schedule of Shares Repurchased [Line Items]                  
Line of credit facility   $ 95,000,000.0              
Minimum                  
Schedule of Shares Repurchased [Line Items]                  
Lease intangibles, lease-up period       6 months          
Maximum                  
Schedule of Shares Repurchased [Line Items]                  
Lease intangibles, lease-up period       24 months          
Building                  
Schedule of Shares Repurchased [Line Items]                  
Useful life       40 years          
Land Improvements                  
Schedule of Shares Repurchased [Line Items]                  
Useful life       15 years          
Fixtures and improvements | Minimum                  
Schedule of Shares Repurchased [Line Items]                  
Useful life       7 years          
Fixtures and improvements | Maximum                  
Schedule of Shares Repurchased [Line Items]                  
Useful life       10 years          
Land and Building                  
Schedule of Shares Repurchased [Line Items]                  
Number of operating lease contracts | property 17                
Accounting Standards Update 2016-02                  
Schedule of Shares Repurchased [Line Items]                  
Written off accounts receivable $ 100,000                
Straight-line rents receivable 100,000                
Operating lease right-of-use assets 10,200,000                
Operating lease liabilities 10,200,000                
Operating lease costs $ 500,000                
Seniors Housing Communities                  
Schedule of Shares Repurchased [Line Items]                  
Ancillary revenue       $ 13,300,000 $ 15,400,000 $ 8,100,000      
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Accounting Policies [Abstract]  
2021 $ 94,144
2022 87,762
2023 75,205
2024 68,210
2025 58,757
Thereafter 165,642
Total $ 549,720
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Income Taxes) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accounting Policies [Abstract]      
Current federal (expense) benefit $ 726 $ 0 $ (272)
Current state (expense) benefit (196) (176) (353)
Current (expense) benefit 530 (176) (625)
Deferred federal (expense) benefit 0 (155) 399
Deferred state (expense) benefit 50 (68) 29
Deferred tax asset valuation allowance (4,641) 0 0
Deferred (expense) benefit $ (4,591) $ (223) $ 428
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Narrative) (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 16, 2020
USD ($)
Nov. 02, 2020
USD ($)
property
Mar. 19, 2020
USD ($)
property
Aug. 27, 2019
USD ($)
Aug. 22, 2019
USD ($)
property
Feb. 06, 2019
USD ($)
property
Dec. 05, 2018
USD ($)
Nov. 06, 2018
property
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
property
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
property
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
property
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
property
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2020
USD ($)
property
Dec. 31, 2019
USD ($)
property
Dec. 31, 2018
USD ($)
property
Mar. 31, 2021
property
Jan. 31, 2021
property
Dec. 31, 2020
property
Dec. 31, 2020
encumbered_property
Aug. 31, 2020
USD ($)
property
Jul. 01, 2020
property
Apr. 30, 2020
USD ($)
property
Jan. 31, 2020
USD ($)
Aug. 01, 2019
USD ($)
Apr. 01, 2019
USD ($)
Mar. 21, 2019
USD ($)
Sep. 25, 2018
USD ($)
Jul. 26, 2018
USD ($)
Aug. 31, 2015
USD ($)
Business Acquisition [Line Items]                                                                        
Number of properties purchased | property                                       193                                
Purchase obligation                                                                       $ 82,000,000.0
Purchase obligation, amount funded                           $ 97,800,000             $ 97,800,000                              
Development costs                                         5,700,000 $ 8,600,000                            
Gain (loss) on sale of real estate investments                                       $ 5,230,000 8,790,000 (70,000)                            
Repayments of credit facility borrowings                                       26,091,000 368,300,000 80,000,000                            
Number of properties transferred | property                                                 7                      
Number of real estate properties                                                 193 110                    
Impairment charges                                       36,446,000 55,969,000 20,655,000                            
Bad debt expense                                       2,708,000 6,464,000 14,797,000                            
Total revenues                   $ 90,878,000 $ 95,835,000 $ 94,664,000 $ 100,235,000 94,469,000 $ 95,440,000 $ 96,287,000 $ 88,718,000     $ 381,612,000 $ 374,914,000 $ 362,406,000                            
Business acquisitions                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties purchased | property                                       9 9 14                            
Other assets acquired and liabilities assumed in the asset acquisition, net                                       $ 1,800,000                                
Development costs                                       0 $ 5,721,000 $ 8,591,000                            
Fannie Mae Master Credit Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Repayments of credit facility borrowings                 $ 4,200,000                                                      
Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                                                 11                      
Impairment charges                                       19,570,000 22,634,000 18,255,000                            
Disposed by sale                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments                                       5,230,000 8,790,000                              
Contract sale price                   40,350,000       62,200,000           40,350,000 62,200,000                              
Disposed by sale | New York Six MOBs (5 properties)                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments           $ 6,059,000                                                            
Contract sale price           $ 45,000,000.0                                                            
Disposed by sale | SNF Properties                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments             $ (70,000)                                                          
Contract sale price             $ 27,500,000                                                          
Disposed by sale | New York Six MOBs (1 property)                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments         $ 2,883,000                                                              
Contract sale price         $ 13,600,000                                                              
Assets held for use                                                                        
Business Acquisition [Line Items]                                                                        
Impairment charges                   3,600,000       $ 33,300,000           $ 16,876,000 33,335,000 2,400,000                            
Seniors Housing Communities                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties purchased | property                                       4                                
Escrow deposits   $ 800,000                                                                    
Impairment charges                               $ 19,000                                        
Seniors Housing Communities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                                 1                       11              
Non-refundable deposits                                                         $ 300,000 $ 1,000,000.0            
Contract sale price                     $ 71,800,000             $ 71,800,000                         $ 200,000 $ 3,500,000 $ 3,600,000      
Seniors Housing Communities | Assets held for use                                                                        
Business Acquisition [Line Items]                                                                        
Accumulated depreciation                                   $ 700,000                                    
Skilled Nursing Facilities | Assets held for sale | SNF Properties                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties disposed | property               8                                                        
Impairment charges                                     $ 11,900,000                                  
Medical Office Buildings | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties disposed | property     1                                                                  
Medical Office Buildings | Assets held for sale | New York Six MOBs (5 properties)                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties disposed | property         1 5                                                            
Contract sale price                                                                   $ 58,800,000 $ 68,000,000.0  
Medical Office Buildings | Disposed by sale                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments     $ 2,306,000                                                                  
Contract sale price     $ 8,600,000                                                                  
Multi-tenant MOB                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties purchased | property                                       2                                
Single Tenant MOB                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties purchased | property                                       3                                
Business combination, consideration transferred                                       $ 110,700,000                                
Subsequent Event | Seniors Housing Communities | Assets held for use                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                                               3                        
LaSalle Tenant                                                                        
Business Acquisition [Line Items]                                                                        
Number of real estate properties | property                                                 4     4                
Accounts receivable, net                   $ 12,700,000                   12,700,000                                
Litigation settlement, amount awarded from other party                                       7,700,000                                
Bad debt expense                                       400,000 3,500,000 5,000,000.0                            
NuVista                                                                        
Business Acquisition [Line Items]                                                                        
Number of real estate properties | property                                                 2                      
Bad debt expense                                         $ 1,100,000 $ 6,000,000.0                            
Total revenues                                       $ 1,600,000                                
LaSalle Guarantor vs LaSalle Tenant | Settled Litigation                                                                        
Business Acquisition [Line Items]                                                                        
Litigation settlement, amount awarded from other party       $ 7,700,000                                                                
Jupiter, Florida | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                                                     $ 65,000,000.0                  
Number of properties held for sale | property                           3             3                              
Jupiter, Florida | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                       $ 65,000,000.0                                                
Florida | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Non-refundable deposits                                                     $ 2,900,000                  
Florida | Skilled Nursing Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                           2             2                              
Florida | Skilled Nursing Facilities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                       2                             2                  
Lutz, Florida | Seniors Housing Communities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                                                     $ 20,000,000.0                  
Lutz, Florida | Skilled Nursing Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments                 $ 3,800,000                                                      
Lutz, Florida | Skilled Nursing Facilities | Disposed by sale                                                                        
Business Acquisition [Line Items]                                                                        
Gain (loss) on sale of real estate investments $ 3,832,000                                                                      
Contract sale price 20,000,000                                                                      
Wellington, Florida | Seniors Housing Communities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                                                     $ 33,000,000.0                  
Michigan | Seniors Housing Communities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                           14             14       4                      
Number of properties disposed | property   11               11                                                    
Contract sale price   $ 11,800,000                                                                    
Number of properties transferred   7                                             7                      
Michigan | Seniors Housing Communities | Disposed by sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                                                 11                      
Gain (loss) on sale of real estate investments   $ (908,000)                                                                    
Contract sale price   $ 11,750,000                                                                    
Michigan | Subsequent Event | Seniors Housing Communities | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties held for sale | property                                             4                          
Skilled Nursing Facilities | Lutz, Florida | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                       $ 20,000,000.0                                                
Skilled Nursing Facilities | Wellington, Florida | Assets held for sale                                                                        
Business Acquisition [Line Items]                                                                        
Prospective consideration                       $ 33,000,000.0                                                
Fair Value | Valuation, Income Approach | Jupiter, Florida                                                                        
Business Acquisition [Line Items]                                                                        
Cash flows and capitalization rates                                       7.00%                                
Fair Value | Valuation, Income Approach | Lutz, Florida                                                                        
Business Acquisition [Line Items]                                                                        
Cash flows and capitalization rates                                       9.00%                                
Fair Value | Valuation, Income Approach | Wellington, Florida                                                                        
Business Acquisition [Line Items]                                                                        
Cash flows and capitalization rates                                       9.00%                                
Land                                                                        
Business Acquisition [Line Items]                                                                        
Development in progress                           $ 10,000,000.0             $ 10,000,000.0                              
Construction in Progress                                                                        
Business Acquisition [Line Items]                                                                        
Development in progress                           $ 87,800,000             $ 87,800,000                              
Credit Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties transferred | property   4                                                                    
Credit Facilities | Fannie Mae Master Credit Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Number of real estate properties | property                                                 21                      
Credit Facilities | Fannie Mae Master Credit Facilities | Capital One Facility                                                                        
Business Acquisition [Line Items]                                                                        
Number of real estate properties | property                                                 11                      
Repayments of debt                                       $ 4,200,000                                
Credit Facilities | Subsequent Event                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties transferred | property                                               3                        
Fannie Mae Master Credit Facility                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties transferred | property   1                                                                    
Unencumbered Properties                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties transferred | property   2                                                                    
Unencumbered Properties | Subsequent Event                                                                        
Business Acquisition [Line Items]                                                                        
Number of properties transferred | property                                               1                        
Revolving Credit Facility                                                                        
Business Acquisition [Line Items]                                                                        
Repayments of credit facility borrowings $ 17,600,000                                                                      
Revolving Credit Facility | Credit Facilities                                                                        
Business Acquisition [Line Items]                                                                        
Number of real estate properties | property                                                 89                      
Repayments of debt                                       $ 4,400,000                                
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Acquired Assets) (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
property
Dec. 31, 2019
USD ($)
property
Dec. 31, 2018
USD ($)
property
Real estate investments, at cost:      
Development costs   $ 5,700,000 $ 8,600,000
Number of properties purchased | property 193    
In-place leases and other intangible assets      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 1 year 8 months 12 days 8 years 1 month 6 days  
Market lease and other intangible assets      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 7 years 8 months 12 days 7 years  
Below market leases      
Real estate investments, at cost:      
Weighted-average remaining amortization periods 7 years 4 months 24 days    
Business acquisitions      
Real estate investments, at cost:      
Land $ 7,665,000 $ 6,356,000 14,417,000
Buildings, fixtures and improvements 90,699,000 68,903,000 98,236,000
Development costs 0 5,721,000 8,591,000
Total tangible assets 98,364,000 80,980,000 121,244,000
Market lease liabilities (362,000) (1,483,000) (286,000)
Total intangible assets and liabilities 10,503,000 11,018,000 6,812,000
Mortgage notes payable, net (13,883,000) 0 0
Cash paid for real estate investments, including acquisitions $ 94,984,000 $ 91,998,000 $ 128,056,000
Number of properties purchased | property 9 9 14
Business acquisitions | In-place leases and other intangible assets      
Real estate investments, at cost:      
In-place and market leases $ 10,369,000 $ 11,777,000 $ 6,823,000
Business acquisitions | Market lease and other intangible assets      
Real estate investments, at cost:      
In-place and market leases $ 496,000 724,000 $ 275,000
Business acquisitions | Below market leases      
Real estate investments, at cost:      
In-place and market leases   $ 0  
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Geographic Concentrations) (Details)
12 Months Ended
Dec. 31, 2020
property
Dec. 31, 2019
property
Dec. 31, 2018
Nov. 02, 2020
property
Nov. 02, 2020
USD ($)
Apr. 30, 2020
property
Mar. 31, 2019
property
Concentration Risk [Line Items]              
Number of properties transferred 7            
Geographic Concentration Risk | Sales Revenue, Net | Florida              
Concentration Risk [Line Items]              
Concentration risk, percentage 20.60% 25.20% 16.60%        
Geographic Concentration Risk | Sales Revenue, Net | Georgia              
Concentration Risk [Line Items]              
Concentration risk, percentage     10.10%        
Geographic Concentration Risk | Sales Revenue, Net | Michigan              
Concentration Risk [Line Items]              
Concentration risk, percentage   10.90% 13.10%        
Geographic Concentration Risk | Sales Revenue, Net | Pennsylvania              
Concentration Risk [Line Items]              
Concentration risk, percentage 10.40%   10.20%        
Assets held for sale              
Concentration Risk [Line Items]              
Number of properties held for sale 11            
Assets held for use              
Concentration Risk [Line Items]              
Number of properties held-for-use   1          
Seniors Housing Communities | Assets held for sale              
Concentration Risk [Line Items]              
Number of properties held for sale           11 1
Seniors Housing Communities | Assets held for sale | Michigan              
Concentration Risk [Line Items]              
Number of properties held for sale 4 14          
Number of properties transferred 7     7 7    
Seniors Housing Communities | Disposed by sale | Michigan              
Concentration Risk [Line Items]              
Number of properties held for sale 11            
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Intangible assets:    
Gross Carrying Amount $ 276,015 $ 269,616
Accumulated Amortization 184,664 167,073
Net Carrying Amount 91,351 102,543
Intangible liabilities:    
Gross Carrying Amount 22,109 21,777
Accumulated Amortization 11,306 9,725
Net Carrying Amount 10,803 12,052
In-place leases and other intangible assets    
Intangible assets:    
Gross Carrying Amount 241,097 229,300
Accumulated Amortization 172,648 156,428
Net Carrying Amount 68,449 72,872
Market lease assets    
Intangible assets:    
Gross Carrying Amount 14,116 13,616
Accumulated Amortization 10,845 9,501
Net Carrying Amount 3,271 4,115
Other intangible assets    
Intangible assets:    
Gross Carrying Amount 20,802 26,700
Accumulated Amortization 1,171 1,144
Net Carrying Amount $ 19,631 $ 25,556
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]      
Accretion of above- and below-market leases, net $ (80) $ (4) $ 255
Depreciation and Amortization Expense | In-place leases and other intangible assets      
Finite-Lived Intangible Assets [Line Items]      
Amortization/accretion of market least intangibles 15,121 15,559 18,851
Rental Income | Above- and below-market leases, net      
Finite-Lived Intangible Assets [Line Items]      
Accretion of above- and below-market leases, net (257) (247) (39)
Property Operating and Maintenance Expense | Above-market ground leases      
Finite-Lived Intangible Assets [Line Items]      
Amortization/accretion of market least intangibles $ 178 $ 86 $ 147
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible assets, amortization expense, 2021 $ 11,517
Finite-lived intangible assets, amortization expense, 2022 9,317
Finite-lived intangible assets, amortization expense, 2023 7,443
Finite-lived intangible assets, amortization expense, 2024 6,683
Finite-lived intangible assets, amortization expense, 2025 5,484
Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, 2021 89
Below market leases, amortization income, 2022 333
Below market leases, amortization income, 2023 568
Below market leases, amortization income, 2024 755
Below market leases, amortization income, 2025 695
In-place lease assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible assets, amortization expense, 2021 10,904
Finite-lived intangible assets, amortization expense, 2022 8,704
Finite-lived intangible assets, amortization expense, 2023 6,830
Finite-lived intangible assets, amortization expense, 2024 6,070
Finite-lived intangible assets, amortization expense, 2025 4,896
Other intangible assets | Amortization Expense  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible assets, amortization expense, 2021 613
Finite-lived intangible assets, amortization expense, 2022 613
Finite-lived intangible assets, amortization expense, 2023 613
Finite-lived intangible assets, amortization expense, 2024 613
Finite-lived intangible assets, amortization expense, 2025 588
Above-market lease assets | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Finite-lived intangible assets, amortization expense, 2021 (1,299)
Finite-lived intangible assets, amortization expense, 2022 (993)
Finite-lived intangible assets, amortization expense, 2023 (645)
Finite-lived intangible assets, amortization expense, 2024 (307)
Finite-lived intangible assets, amortization expense, 2025 (260)
Below-market lease liabilities | Rental Income  
Finite-Lived Intangible Assets [Line Items]  
Below market leases, amortization income, 2021 1,388
Below market leases, amortization income, 2022 1,326
Below market leases, amortization income, 2023 1,213
Below market leases, amortization income, 2024 1,062
Below market leases, amortization income, 2025 $ 955
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Real Estate Sales) (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 16, 2020
USD ($)
Nov. 02, 2020
USD ($)
property
Mar. 19, 2020
USD ($)
property
Aug. 22, 2019
USD ($)
property
Aug. 01, 2019
USD ($)
Feb. 06, 2019
USD ($)
property
Dec. 05, 2018
USD ($)
Nov. 06, 2018
property
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
property
Dec. 31, 2020
USD ($)
property
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Apr. 01, 2019
USD ($)
Mar. 21, 2019
USD ($)
Sep. 25, 2018
USD ($)
Jul. 26, 2018
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Gain (loss) on sale of real estate investments                     $ 5,230,000 $ 8,790,000 $ (70,000)          
Number of properties transferred | property                   7 7              
Skilled Nursing Facilities | Lutz, Florida                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Gain (loss) on sale of real estate investments                 $ 3,800,000                  
Disposed by sale                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price                   $ 40,350,000 $ 40,350,000 62,200,000            
Gain (loss) on sale of real estate investments                     $ 5,230,000 $ 8,790,000            
Disposed by sale | Skilled Nursing Facilities | Lutz, Florida                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price $ 20,000,000                                  
Gain (loss) on sale of real estate investments $ 3,832,000                                  
Disposed by sale | Seniors Housing Communities | Michigan                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price   $ 11,750,000                                
Gain (loss) on sale of real estate investments   (908,000)                                
Disposed by sale | Medical Office Buildings                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price     $ 8,600,000                              
Gain (loss) on sale of real estate investments     $ 2,306,000                              
Disposed by sale | New York Six MOBs (1 property)                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price       $ 13,600,000                            
Gain (loss) on sale of real estate investments       $ 2,883,000                            
Disposed by sale | Ocean Park                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price         $ 3,600,000                          
Gain (loss) on sale of real estate investments         (152,000)                          
Disposed by sale | New York Six MOBs (5 properties)                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price           $ 45,000,000.0                        
Gain (loss) on sale of real estate investments           $ 6,059,000                        
Disposed by sale | SNF Properties                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price             $ 27,500,000                      
Gain (loss) on sale of real estate investments             $ (70,000)                      
Assets held for sale | Seniors Housing Communities                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price         $ 200,000                 $ 71,800,000 $ 3,500,000 $ 3,600,000    
Assets held for sale | Seniors Housing Communities | Michigan                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price   $ 11,800,000                                
Number of properties disposed | property   11               11                
Number of properties transferred   7               7 7              
Assets held for sale | Medical Office Buildings                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Number of properties disposed | property     1                              
Assets held for sale | New York Six MOBs (5 properties) | Medical Office Buildings                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Contract Sale Price                                 $ 58,800,000 $ 68,000,000.0
Number of properties disposed | property       1   5                        
Assets held for sale | SNF Properties | Skilled Nursing Facilities                                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                                    
Number of properties disposed | property               8                    
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Impairments) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Impairment charges     $ 36,446 $ 55,969 $ 20,655
Assets held for sale          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Impairment charges     19,570 22,634 18,255
Assets held for use          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Impairment charges $ 3,600 $ 33,300 $ 16,876 $ 33,335 $ 2,400
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate Investments, Net (Held for Sale) (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
property
Apr. 30, 2020
property
Dec. 31, 2019
USD ($)
property
Mar. 31, 2019
property
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Assets held for sale $ 90   $ 70,839  
Assets held for sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Land 145   4,051  
Buildings, fixtures and improvements (55)   66,788  
Assets held for sale $ 90   $ 70,839  
Number of properties held for sale | property 11      
Seniors Housing Communities | Assets held for sale        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of properties held for sale | property   11   1
Seniors Housing Communities | Assets held for sale | Michigan        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Number of properties held for sale | property 4   14  
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Mortgage Notes Payable, Net (Mortgage Notes) (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
property
Dec. 31, 2019
USD ($)
Debt Instrument [Line Items]    
Outstanding loan amount $ 1,229,210  
Effective Interest Rate 3.29% 4.14%
Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 68  
Outstanding loan amount $ 550,361 $ 537,533
Effective Interest Rate 3.94% 3.90%
Deferred financing costs, net of accumulated amortization $ (6,191) $ (7,718)
Mortgage premiums and discounts, net (1,472) (1,531)
Mortgage notes payable, net $ 542,698 528,284
Palm Valley Medical Plaza - Goodyear, AZ | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 2,998 $ 3,112
Effective Interest Rate 4.15% 4.15%
Medical Center V - Peoria, AZ | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 2,786 $ 2,884
Effective Interest Rate 4.75% 4.75%
Fox Ridge Bryant - Bryant, AR | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 7,133 $ 7,283
Effective Interest Rate 3.98% 3.98%
Fox Ridge Chenal - Little Rock, AR | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 16,390 $ 16,695
Effective Interest Rate 3.98% 3.98%
Fox Ridge North Little Rock - North Little Rock, AR | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 10,170 $ 10,359
Effective Interest Rate 3.98% 3.98%
Capital One MOB Loan | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 41  
Outstanding loan amount $ 378,500 $ 378,500
Effective Interest Rate 3.71% 3.71%
Multi-Property CMBS Loan | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 21  
Outstanding loan amount $ 118,700 $ 118,700
Effective Interest Rate 4.60% 4.60%
Shiloh - Illinois (4) | Mortgage Notes Payable    
Debt Instrument [Line Items]    
Encumbered properties | property 1  
Outstanding loan amount $ 13,684 $ 0
Effective Interest Rate 4.34% 0.00%
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Mortgage Notes Payable, Net (Narrative) (Details)
12 Months Ended
Dec. 16, 2020
USD ($)
Dec. 20, 2019
USD ($)
property
Dec. 19, 2019
USD ($)
property
Apr. 10, 2018
USD ($)
property
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
instrument
Dec. 31, 2018
USD ($)
Dec. 31, 2020
property
Dec. 31, 2020
Dec. 31, 2020
instrument
Dec. 31, 2020
encumbered_property
Jun. 30, 2017
USD ($)
Debt Instrument [Line Items]                        
Outstanding loan amount         $ 1,229,210,000              
Repayments of credit facility borrowings         26,091,000 $ 368,300,000 $ 80,000,000          
Number of real estate properties               193     110  
Mortgage Notes Payable                        
Debt Instrument [Line Items]                        
Real estate investments pledged as collateral         860,000,000.0              
Outstanding loan amount         $ 550,361,000 537,533,000            
Encumbered properties | property               68        
Mortgage Notes Payable | MOB Loan                        
Debt Instrument [Line Items]                        
Outstanding loan amount   $ 378,500,000 $ 242,000,000.0                 $ 250,000,000.0
Encumbered properties | property   41 31                  
Fixed rate                 3.66%      
Prepayment penalty, initial twelve months         3.00%              
Prepayment penalty, year two         2.00%              
Prepayment penalty, year three         1.00%              
Prepayment percent of principal amount         110.00%              
Principal amount outstanding limitation to release or replace properties   $ 283,900,000                    
Unamortized fees           $ 3,000,000.0            
Mortgage Notes Payable | MOB Loan | London Interbank Offered Rate (LIBOR)                        
Debt Instrument [Line Items]                        
Interest rate   2.00% 2.50%                  
Mortgage Notes Payable | Multi-Property CMBS Loan                        
Debt Instrument [Line Items]                        
Debt instrument, face amount       $ 118,700,000                
Revolving Credit Facility                        
Debt Instrument [Line Items]                        
Repayments of credit facility borrowings $ 17,600,000                      
Revolving Credit Facility | MOB Loan                        
Debt Instrument [Line Items]                        
Repayments of credit facility borrowings   $ 61,500,000                    
Revolving Credit Facility | Mortgage Notes Payable | MOB Loan                        
Debt Instrument [Line Items]                        
Proceeds from loans   127,700,000                    
Repayments of credit facility borrowings   $ 63,500,000                    
Number of real estate properties | property   12                    
Number of real estate properties, released or replaced | property               25        
Revolving Credit Facility | Mortgage Notes Payable | Multi-Property CMBS Loan                        
Debt Instrument [Line Items]                        
Proceeds from loans       33,000,000.0                
Repayments of credit facility borrowings       $ 80,000,000.0                
Number of real estate properties | property       14                
Payments for deposits       $ 3,800,000                
Medical Office Buildings | Mortgage Notes Payable | MOB Loan                        
Debt Instrument [Line Items]                        
Encumbered properties | property   29                    
Unencumbered properties | property   10                    
Triple-net leased healthcare facilities | Mortgage Notes Payable | MOB Loan                        
Debt Instrument [Line Items]                        
Encumbered properties | property   2                    
Designated as Hedging Instrument | Interest rate swaps                        
Debt Instrument [Line Items]                        
Number of instruments terminated | instrument                   2    
Number of instruments | instrument           9       9    
Designated as Hedging Instrument | Interest rate swaps | MOB Loan                        
Debt Instrument [Line Items]                        
Number of instruments | instrument                   1    
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Facilities (Summary of Credit Facilities) (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Dec. 31, 2020
property
Dec. 31, 2020
Dec. 31, 2020
encumbered_property
Dec. 31, 2019
USD ($)
Line of Credit Facility [Line Items]          
Number of properties   193   110  
Outstanding balance $ 674,551       $ 605,269
Effective interest rate     3.29%   4.14%
Credit Facilities          
Line of Credit Facility [Line Items]          
Outstanding balance 319,376       $ 245,947
Fannie Mae Master Credit Facilities | Credit Facilities          
Line of Credit Facility [Line Items]          
Number of properties | property   21      
Outstanding balance 355,175       359,322
Fannie Mae Master Credit Facilities | Capital One Facility | Credit Facilities          
Line of Credit Facility [Line Items]          
Number of properties | property   11      
Outstanding balance 212,467       $ 216,614
Effective interest rate     2.60%   4.17%
Debt instrument, collateral amount 344,000        
Fannie Mae Master Credit Facilities | KeyBank Facility | Credit Facilities          
Line of Credit Facility [Line Items]          
Number of properties | property   10      
Outstanding balance 142,708       $ 142,708
Effective interest rate     2.65%   4.22%
Debt instrument, collateral amount 253,600        
Credit Facilities | Revolving Credit Facility          
Line of Credit Facility [Line Items]          
Number of properties | property   89      
Outstanding balance 173,674       $ 100,618
Effective interest rate     3.21%   4.08%
Long-term debt, percentage bearing fixed interest, amount 50,000        
Stated interest rate     4.09%    
Term Loan | Credit Facilities          
Line of Credit Facility [Line Items]          
Outstanding balance 150,000       $ 150,000
Deferred financing costs (4,298)       (4,671)
Term Loan, net $ 145,702       $ 145,329
Effective interest rate     4.95%   4.05%
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Facilities (Narrative) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Dec. 16, 2020
USD ($)
Aug. 10, 2020
USD ($)
Mar. 13, 2019
USD ($)
Nov. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Nov. 01, 2019
USD ($)
property
Oct. 31, 2016
property
Line of Credit Facility [Line Items]                  
Real estate investments, at cost         $ 2,621,723 $ 2,481,067      
Outstanding balance         $ 674,551 $ 605,269      
Minimum cash, cash equivalents, and borrowing capacity   $ 50,000              
Effective interest rate         3.29% 4.14%      
Preferred stock, dividend rate, percentage         7.375% 7.375%      
Preferred stock, par value (in usd per share) | $ / shares         $ 0.01        
Percent distribution in excess of modified funds from operations   95.00%              
Stock repurchased, authorized amount   $ 50,000              
Notional Amount               $ 88,700  
Repayments of credit facility borrowings         $ 26,091 $ 368,300 $ 80,000    
Day Prior to Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Current borrowing capacity, base percent   62.50%              
Covenant Period July 1 2020 through June 30 2021                  
Line of Credit Facility [Line Items]                  
Current borrowing capacity, base percent   67.50%              
Covenant Period from June 30 2021 through Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Current borrowing capacity, base percent   65.00%              
Covenant Period After Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Current borrowing capacity, base percent   62.50%              
Covenant Period July 1 2020 through March 31 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.00              
Covenant Period From April 1 2021 through June 30 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.00              
Covenant Period after June 30 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.00              
Mortgage Notes Payable                  
Line of Credit Facility [Line Items]                  
Real estate investments pledged as collateral         $ 860,000        
Effective interest rate         3.94% 3.90%      
Term Loan                  
Line of Credit Facility [Line Items]                  
Extension period     1 year            
Maximum borrowing capacity     $ 480,000            
Fannie Mae Master Credit Facilities                  
Line of Credit Facility [Line Items]                  
Real estate investments, at cost         $ 600,000        
Repayments of credit facility borrowings       $ 4,200          
New Credit Facilities                  
Line of Credit Facility [Line Items]                  
Real estate investments, at cost         900,000        
New Credit Facilities | Day Prior to Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Minimum cash, cash equivalents, and borrowing capacity   $ 100,000              
New Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Minimum cash, cash equivalents, and borrowing capacity   $ 30,000              
Fannie Credit Facility | Interest rate caps                  
Line of Credit Facility [Line Items]                  
Number of instruments | property               2 2
Interest rate cap                 3.50%
Minimum | Covenant Period July 1 2020 through March 31 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.50              
Minimum | Covenant Period From April 1 2021 through June 30 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.55              
Minimum | Covenant Period after June 30 2021                  
Line of Credit Facility [Line Items]                  
Fixed charge coverage ratio   1.60              
Minimum | New Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Current borrowing capacity, base percent   55.00%              
London Interbank Offered Rate (LIBOR) | Minimum | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Floor interest rate   0.00%              
London Interbank Offered Rate (LIBOR) | Minimum | Term Loan | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   1.80%              
London Interbank Offered Rate (LIBOR) | Maximum | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Floor interest rate   0.25%              
Unencumbered Properties                  
Line of Credit Facility [Line Items]                  
Real estate investments, at cost         231,500        
Revolving Credit Facility                  
Line of Credit Facility [Line Items]                  
Repayments of credit facility borrowings $ 17,600                
Revolving Credit Facility | Credit Facilities                  
Line of Credit Facility [Line Items]                  
Maximum borrowing capacity     630,000            
Outstanding balance         $ 173,674 $ 100,618      
Effective interest rate         3.21% 4.08%      
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Term Loan | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   1.55%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Credit Facilities | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   1.85%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   1.60%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Term Loan | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   2.55%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Term Loan | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   2.30%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Credit Facilities | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   2.60%              
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   2.35%              
Revolving Credit Facility | Base Rate | Minimum | Term Loan | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   0.55%              
Revolving Credit Facility | Base Rate | Minimum | Term Loan | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   0.30%              
Revolving Credit Facility | Base Rate | Minimum | Credit Facilities | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   0.60%              
Revolving Credit Facility | Base Rate | Minimum | Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   0.35%              
Revolving Credit Facility | Base Rate | Maximum | Term Loan | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   1.30%              
Revolving Credit Facility | Base Rate | Maximum | Term Loan | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   1.05%              
Revolving Credit Facility | Base Rate | Maximum | Credit Facilities | Covenant Period August 10 2020                  
Line of Credit Facility [Line Items]                  
Interest rate   1.35%              
Revolving Credit Facility | Base Rate | Maximum | Credit Facilities | Commencement Quarter                  
Line of Credit Facility [Line Items]                  
Interest rate   1.10%              
Secured Debt                  
Line of Credit Facility [Line Items]                  
Remaining borrowing capacity         $ 48,300        
Secured Debt | Minimum                  
Line of Credit Facility [Line Items]                  
Line of credit, increase     370,000            
Secured Debt | Maximum                  
Line of Credit Facility [Line Items]                  
Line of credit, increase     $ 1,000,000            
Credit Facilities                  
Line of Credit Facility [Line Items]                  
Outstanding balance         319,376 $ 245,947      
Minimum net worth required for compliance   $ 1,200              
Net offering proceeds, percent   75.00%              
Credit Facilities | Term Loan                  
Line of Credit Facility [Line Items]                  
Outstanding balance         $ 150,000 $ 150,000      
Effective interest rate         4.95% 4.05%      
Credit Facilities | Fannie Mae Master Credit Facilities                  
Line of Credit Facility [Line Items]                  
Outstanding balance         $ 355,175 $ 359,322      
Capital One Facility | Credit Facilities | Fannie Mae Master Credit Facilities                  
Line of Credit Facility [Line Items]                  
Outstanding balance         $ 212,467 $ 216,614      
Effective interest rate         2.60% 4.17%      
KeyBank Facility | Credit Facilities | Fannie Mae Master Credit Facilities                  
Line of Credit Facility [Line Items]                  
Outstanding balance         $ 142,708 $ 142,708      
Effective interest rate         2.65% 4.22%      
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Facilities (Future Principal Payments of Outstanding Debt) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Debt Instrument [Line Items]    
2021 $ 1,321  
2022 4,062  
2023 10,880  
2024 179,266  
2025 155,639  
Thereafter 878,042  
Mortgage notes payable, net 1,229,210  
Credit Facilities    
Debt Instrument [Line Items]    
2021 130  
2022 2,820  
2023 4,497  
2024 178,171  
2025 154,497  
Thereafter 338,734  
Mortgage notes payable, net 678,849  
Mortgage Notes Payable    
Debt Instrument [Line Items]    
2021 1,191  
2022 1,242  
2023 6,383  
2024 1,095  
2025 1,142  
Thereafter 539,308  
Mortgage notes payable, net $ 550,361 $ 537,533
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value $ 13 $ 392
Derivative liabilities, at fair value (38,389) (5,305)
Total (38,376) (4,913)
Quoted Prices in Active Markets Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 0 0
Derivative liabilities, at fair value 0
Total 0 0
Significant Other Observable Inputs Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 13 392
Derivative liabilities, at fair value (38,389) (5,305)
Total (38,376) (4,913)
Significant Unobservable Inputs Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets, at fair value 0 0
Derivative liabilities, at fair value 0
Total $ 0 $ 0
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value of Financial Instruments (Level 3 Inputs) (Details) - Significant Unobservable Inputs Level 3 - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Mortgage Notes Payable | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure $ 548,889 $ 536,002
Mortgage Notes Payable | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 549,553 545,414
Revolving Credit Facility | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 323,674 250,618
Revolving Credit Facility | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 319,558 250,618
Fannie Credit Facility | Revolving Credit Facility | Carrying Amount     
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure 355,175 359,322
Fannie Credit Facility | Revolving Credit Facility | Fair Value    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Debt, fair value disclosure $ 354,073 $ 370,122
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Narrative) (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
instrument
Dec. 31, 2020
USD ($)
instrument
Dec. 31, 2019
USD ($)
instrument
Dec. 31, 2018
USD ($)
Nov. 01, 2019
USD ($)
Derivative [Line Items]          
Notional Amount         $ 88,700,000
Loss on non-designated derivatives   $ (102,000) $ (68,000) $ (157,000)  
Derivative, net liability position, aggregate fair value $ 38,400,000 38,400,000      
Aggregate termination value $ 38,400,000 $ 38,400,000      
Designated as Hedging Instrument | Interest rate swaps          
Derivative [Line Items]          
Number of instruments | instrument 9 9 9    
Number of instruments terminated | instrument 2 2      
Notional Amount $ 578,500,000 $ 578,500,000 $ 578,500,000    
Proceeds from sale of interest rate cash flow hedge 2,200,000        
Designated as Hedging Instrument | Interest rate contract          
Derivative [Line Items]          
Cash flow hedge reclassification current   1,300,000      
Interest Expense | Designated as Hedging Instrument | Interest rate contract          
Derivative [Line Items]          
Cash flow hedge reclassification current   900,000 $ 100,000    
Cash flow hedge reclassification in next twelve months $ 10,700,000 $ 10,700,000      
MOB Loan | Designated as Hedging Instrument | Interest rate swaps          
Derivative [Line Items]          
Number of instruments | instrument 1 1      
Notional Amount $ 250,000,000.0 $ 250,000,000.0      
MOB Loan | Interest Expense | Designated as Hedging Instrument | Interest rate contract          
Derivative [Line Items]          
Cash flow hedge reclassification current $ 2,200,000        
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Balance Sheet Location) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Derivative [Line Items]    
Gross Amounts of Recognized Assets $ 13 $ 392
Gross Amounts of Recognized Liabilities 0 0
Derivative assets, at fair value | Designated as Hedging Instrument | Interest rate swaps    
Derivative [Line Items]    
Gross Amounts of Recognized Assets 0 377
Derivative assets, at fair value | Not Designated as Hedging Instrument | Interest rate caps    
Derivative [Line Items]    
Gross Amounts of Recognized Assets 13 15
Derivative liabilities, at fair value | Designated as Hedging Instrument | Interest rate swaps    
Derivative [Line Items]    
Gross Amounts of Recognized Liabilities $ 38,389 $ 5,305
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)
Dec. 31, 2020
USD ($)
instrument
Dec. 31, 2019
USD ($)
instrument
Nov. 01, 2019
USD ($)
Derivative [Line Items]      
Notional Amount     $ 88,700,000
Designated as Hedging Instrument | Interest rate swaps      
Derivative [Line Items]      
Number of Instruments | instrument 9 9  
Notional Amount $ 578,500,000 $ 578,500,000  
Not Designated as Hedging Instrument | Interest rate caps      
Derivative [Line Items]      
Number of Instruments | instrument 6 6  
Notional Amount $ 359,322,000 $ 359,322,000  
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Derivative [Line Items]      
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives $ (32,630) $ (11,625) $ 2,109
Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss 51,519 56,059 49,471
Designated as Hedging Instrument | Interest rate swaps      
Derivative [Line Items]      
Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives (40,614) (10,753) 2,367
Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion) $ (7,999) $ 872 $ 258
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Derivatives and Hedging Activities (Offsetting Derivatives) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross Amounts of Recognized Assets $ 13 $ 392
Gross Amounts of Recognized (Liabilities) (38,389) (5,305)
Gross Amounts Offset in the Consolidated Balance Sheet 0 0
Net Amounts of Assets presented in the Consolidated Balance Sheet 13 392
Net Amounts of Assets presented in the Consolidated Balance Sheet (38,389) (5,305)
Gross Amounts Not Offset in Consolidated Balance Sheet, Financial Instruments 0 0
Gross Amounts Not Offset in Consolidated Balance Sheet, Cash Collateral Received 0 0
Net Amount 13 392
Net Amount $ (38,389) $ (5,305)
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended 87 Months Ended 99 Months Ended
Oct. 01, 2020
Feb. 26, 2020
Jan. 09, 2020
Oct. 30, 2019
Apr. 16, 2018
Mar. 13, 2018
Mar. 01, 2018
Apr. 01, 2017
Feb. 17, 2017
Dec. 31, 2019
May 31, 2018
Apr. 30, 2013
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2020
Sep. 30, 2020
Sep. 15, 2020
May 31, 2020
Dec. 31, 2017
Class of Stock [Line Items]                                            
Weighted-average price per share (in usd per share)   $ 17.50   $ 17.50                   $ 17.50     $ 20.95 $ 20.60        
Stock repurchase, value   $ 8,800 $ 1,700               $ 3,000                      
Number of shares repurchased (in shares)   505,101   446,830                   505,101     4,391,519 4,896,620        
Common stock repurchases       $ 7,800                   $ 10,539 $ 21,113 $ 14,202            
DRIP, period of notice to alter agreement                 10 days                          
Common stock issued through distribution reinvestment plan (in shares)                           900,000 1,500,000 1,700,000            
Proceeds from common stock issued through distribution reinvestment plan                           $ 14,600 $ 27,200 $ 35,700            
Number of securities called by share purchase right (in shares)                                         1  
Preferred stock, shares authorized (in shares)                   1,610,000     2,210,000 2,210,000 1,610,000   1,610,000 2,210,000        
Preferred stock, additional shares authorized (in shares)                                     600,000      
Preferred stock, shares issued (in shares)                   1,610,000     1,610,000 1,610,000 1,610,000   1,610,000 1,610,000        
Preferred stock, liquidation preference (in usd per share)                   $ 25.00         $ 25.00   $ 25.00          
Value of shares issued                           $ (59) $ 37,617              
Payments for underwriting expense                   $ (1,300)                        
Payments of additional offering expenses                   $ (1,400)                        
Issuance of preferred stock, net (in shares)                         0                  
Preferred stock, dividend rate (in usd per share)                           $ 1.84375                
Preferred stock, dividend rate, percentage                           7.375% 7.375%              
Distributions declared in cash (in usd per share) $ 0.85           $ 0.85 $ 1.45       $ 1.70   $ 0.42 $ 0.83 $ 0.92            
Stock dividends (in shares) 0.01349                         0.02716                
Preferred stock, quarterly dividend rate (in usd per share)                           0.460938                
Common Stock                                            
Class of Stock [Line Items]                                            
Common stock, shares outstanding (in shares)                   92,356,664     93,775,746 93,775,746 92,356,664 91,963,532 92,356,664 93,775,746       91,002,766
Common stock issued through distribution reinvestment plan (in shares)                           875,986 1,481,395 1,720,633            
Tender Offer                                            
Class of Stock [Line Items]                                            
Shares authorized for repurchase (in shares)     200,000     2,000,000.0                                
Weighted-average price per share (in usd per share)     $ 8.50     $ 13.15                                
Reduction in shares authorized for repurchase (in shares)         230,000                                  
Public Stock Offering                                            
Class of Stock [Line Items]                                            
Preferred stock, shares authorized (in shares)                         1,610,000 1,610,000       1,610,000        
Preferred stock, number of shares issued in public offering                   1,610,000                        
Preferred stock, liquidation preference (in usd per share)                         $ 25.00 $ 25.00       $ 25.00        
Sale of stock, gross proceeds                   $ 40,300                        
Delisting                                            
Class of Stock [Line Items]                                            
Preferred stock, dividend rate (in usd per share)                             $ 2.34375              
Preferred stock, dividend rate, percentage                             9.375%              
Increase in preferred stock, dividend rate, percentage                             2.00%              
Preferred Stock Equity Line                                            
Class of Stock [Line Items]                                            
Authorized preferred stock offering, value                                       $ 15,000    
Maximum shares per preferred stock offering (in shares)                                       3,500    
Issuance of preferred stock, net (in shares)                           0                
Maximum                                            
Class of Stock [Line Items]                                            
Preferred stock, shares authorized (in shares)                   50,000,000         50,000,000   50,000,000          
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Stock Redemption) (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended 87 Months Ended 99 Months Ended
Feb. 26, 2020
Jan. 09, 2020
Oct. 30, 2019
May 31, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Accounting Policies [Abstract]              
Number of shares repurchased (in shares) 505,101   446,830   505,101 4,391,519 4,896,620
Weighted-average price per share (in usd per share) $ 17.50   $ 17.50   $ 17.50 $ 20.95 $ 20.60
Stock repurchase, value $ 8.8 $ 1.7   $ 3.0      
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholders' Equity (Distributions) (Details) - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dividends Payable [Line Items]      
Dividends, percent 100.00% 100.00% 100.00%
Dividends paid (in usd per share) $ 0.42 $ 0.83 $ 0.92
Return of capital (1)      
Dividends Payable [Line Items]      
Dividends, percent 100.00% 100.00% 100.00%
Dividends paid (in usd per share) $ 0.42 $ 0.83 $ 0.92
Capital gain dividend income      
Dividends Payable [Line Items]      
Dividends, percent 0.00% 0.00% 0.00%
Dividends paid (in usd per share) $ 0 $ 0 $ 0
Ordinary dividend income      
Dividends Payable [Line Items]      
Dividends, percent 0.00% 0.00% 0.00%
Dividends paid (in usd per share) $ 0 $ 0 $ 0
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements (Ownership) (Details) - USD ($)
$ in Millions
Dec. 31, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]    
Common stock held by related party (in shares) 95,040,783 92,356,664
Limited partner units (in shares) 90 90
Tax Depreciation Deduction | Advisor    
Related Party Transaction [Line Items]    
Special allocation for tax purposes excess depreciation deductions maximum $ 10.0  
American Realty Capital Healthcare II Special Limited Partnership, LLC | Special Limited Partner    
Related Party Transaction [Line Items]    
Common stock held by related party (in shares) 9,008 8,888
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Jul. 25, 2019
USD ($)
Feb. 17, 2017
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Related Party Transaction [Line Items]            
Renewal term   10 years        
Board of directors voting percentage   67.00%        
Period of notice   45 days        
Share price, net (in dollars per share) | $ / shares       $ 22.50    
Asset threshold for assignment of agreement       $ 100,000    
Payable (receivable)       $ (979) $ (394)  
Advisor            
Related Party Transaction [Line Items]            
Shares approved for issuance (in shares) | shares       359,250    
Capped Reimbursement Amount            
Related Party Transaction [Line Items]            
Reimbursed fees to related party, capped reimbursement amount       $ 5,600 7,200  
American Realty Capital Healthcare Advisors, LLC | Advance on Loan or Other Investment | Advisor            
Related Party Transaction [Line Items]            
Financing advance fees as a percentage of benchmark, expected third party costs       0.50%    
Financing advance fees as a percentage of benchmark, expected company portfolio cost       4.50%    
American Realty Capital Healthcare Advisors, LLC | Contract Purchase Price | Advisor            
Related Party Transaction [Line Items]            
Quarterly asset management fee       0.1875%    
American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Stand-alone Single-tenant Net Leased Properties | Advisor            
Related Party Transaction [Line Items]            
Property management fees       1.50%    
American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties | Advisor            
Related Party Transaction [Line Items]            
Property management fees       2.50%    
American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Period of notice   60 days        
Second Amended and Restated Advisory Agreement            
Related Party Transaction [Line Items]            
Period of notice of termination   365 days        
Monthly Base Management Fee | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Base management fee of net proceeds       1.25%    
Transaction amount       $ 1,625    
Quarterly Variable Management Fee, Benchmark One | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Basis of core earnings, percent       15.00%    
Basis of core earnings (in usd per share) | $ / shares       $ 0.375    
Quarterly Variable Management Fee, Benchmark Two | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Basis of core earnings, percent       10.00%    
Basis of core earnings (in usd per share) | $ / shares       $ 0.47    
Amended and Restated Property Management and Leasing Agreement            
Related Party Transaction [Line Items]            
Renewal term   1 year        
Period of notice of termination   90 days        
Reimbursements of Administrative Services | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Transaction amount       $ 10,800 10,600 $ 8,900
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Advisor            
Related Party Transaction [Line Items]            
Contingent good faith negotiations of fixed component, term 12 months          
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Advisor And Company            
Related Party Transaction [Line Items]            
Contingent good faith negotiations of fixed component, term 90 days          
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Capped Reimbursement Amount            
Related Party Transaction [Line Items]            
Reimbursed fees to related party, capped reimbursement amount $ 6,800          
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Real Estate Cost            
Related Party Transaction [Line Items]            
Fee multiplier 4          
Real estate cost percent multiplier 0.0029          
Reduction of real estate cost percent 0.250          
Third Amended And Restated Advisory Agreement | American Realty Capital Healthcare Advisors, LLC | Consumer Price Index            
Related Party Transaction [Line Items]            
Cost of living percent multiplier 0.030          
Reimbursements of Employee Bonuses of the Advisor | American Realty Capital Healthcare Advisors, LLC            
Related Party Transaction [Line Items]            
Transaction amount         $ 2,500  
2019 Bonus Awards            
Related Party Transaction [Line Items]            
Payable (receivable)     $ 1,200      
Term of agreement     10 months      
Severance Payments            
Related Party Transaction [Line Items]            
Payable (receivable)       $ 2,200    
Maximum | American Realty Capital Healthcare Advisors, LLC | Gross Revenue, Managed Properties | Advisor            
Related Party Transaction [Line Items]            
Oversight fees earned by related party       1.00%    
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Sep. 30, 2020
Related Party Transaction [Line Items]        
Expenses incurred $ 35,328 $ 33,831 $ 32,470  
Payable (receivable) (979) (394)    
Reduction of general and administrative expense (21,572) (20,530) (17,275)  
Acquisition cost reimbursements        
Related Party Transaction [Line Items]        
Expenses incurred 81 39 176  
Payable (receivable) 11 0    
Asset management fees        
Related Party Transaction [Line Items]        
Expenses incurred 19,987 19,526 19,500  
Payable (receivable) 0 27    
Property management fees (6)        
Related Party Transaction [Line Items]        
Expenses incurred 4,197 3,888 3,571  
Payable (receivable) 288 (44)    
Property management fees (6) | Prepaid Expenses and Other Assets        
Related Party Transaction [Line Items]        
Expenses incurred 300      
Professional fees and other reimbursements        
Related Party Transaction [Line Items]        
Expenses incurred 12,102 10,073 8,883  
Payable (receivable) (61) (377)    
Professional fees and other reimbursements | Revision of Prior Period, Adjustment        
Related Party Transaction [Line Items]        
Reduction of general and administrative expense   500    
Professional fees credit due from Advisor        
Related Party Transaction [Line Items]        
Payable (receivable) (1,217) 0    
Professional fees credit due from Advisor (1,217) 0 0  
Distributions on Class B Units        
Related Party Transaction [Line Items]        
Expenses incurred 178 305 $ 340  
Payable (receivable) 0 0    
2019 Bonus Awards        
Related Party Transaction [Line Items]        
Payable (receivable)       $ 1,200
Severance Payments        
Related Party Transaction [Line Items]        
Payable (receivable) $ 2,200      
Advisor        
Related Party Transaction [Line Items]        
Shares approved for issuance (in shares) 359,250      
Advisor | 2019 Bonus Awards        
Related Party Transaction [Line Items]        
Due from Affiliates $ 1,200      
Advisor | Professional Fees and Reimbursements        
Related Party Transaction [Line Items]        
Due from Affiliates   500    
Capped Reimbursement Amount        
Related Party Transaction [Line Items]        
Reimbursed fees to related party, capped reimbursement amount $ 5,600 $ 7,200    
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details)
$ in Millions
12 Months Ended
Dec. 31, 2020
USD ($)
Healthcare Trust Special Limited Partnership, LLC | Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated participation fees as a percentage of benchmark 15.00%
Healthcare Trust Special Limited Partnership, LLC | Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return | Special Limited Partner  
Related Party Transaction [Line Items]  
Subordinated performance fee as a percentage of benchmark 15.00%
Annual Targeted Investor Return | Healthcare Trust Special Limited Partnership, LLC | Pre-tax Non-compounded Return on Capital Contribution | Special Limited Partner  
Related Party Transaction [Line Items]  
Cumulative capital investment return to investors as a percentage of benchmark 6.00%
Asset management fees  
Related Party Transaction [Line Items]  
Fee multiplier 4
Transition Fee  
Related Party Transaction [Line Items]  
Transaction amount $ 15.0
Subject Fees (Transition Fee Not in Excess of the Product)  
Related Party Transaction [Line Items]  
Fee multiplier 4
Subject Fees  
Related Party Transaction [Line Items]  
Fee multiplier 4.5
Change in Control Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
Variable Management - Incentive Fee  
Related Party Transaction [Line Items]  
Fee multiplier 4
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-Based Compensation (Narrative) (Details) - USD ($)
1 Months Ended 12 Months Ended
Jul. 29, 2019
Aug. 31, 2017
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Restricted Share Plan | Unvested restricted shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Maximum authorized amount as a percentage of shares authorized     5.00%    
Number of shares authorized (in shares)     3,500,000    
Shares granted automatically upon election to board of directors (in shares)     1,333    
Restricted share vesting period     5 years    
Granted (in shares)     0 15,000 0
Nonvested awards, compensation cost not yet recognized     $ 4,000,000.0    
Nonvested awards, compensation cost not yet recognized, period for recognition     3 years 2 months 12 days    
Share-based compensation expense     $ 1,300,000 $ 1,300,000 $ 1,200,000
Amended and Restated RSP | Unvested restricted shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Benchmark basis for issuance   $ 30,000      
Board chairman | Amended and Restated RSP | Unvested restricted shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted share vesting period   7 years      
Granted (in shares)   300,000      
Independent directors | Amended and Restated RSP | Unvested restricted shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted share vesting period   5 years      
Granted (in shares)   25,000      
Director          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Stock issued during period, issued for services (in shares)     0 0 0
Director | Restricted Share Plan | Unvested restricted shares          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Restricted share vesting period 3 years        
Granted (in shares) 15,000        
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.21.1
Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) - Unvested restricted shares - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Number of Common Shares      
Beginning Balance (in shares) 277,241 322,242  
Ending Balance (in shares) 215,373 277,241 322,242
Restricted Share Plan      
Number of Common Shares      
Beginning Balance (in shares) 277,241 322,242 382,510
Stock dividend (in shares) 2,878    
Granted (in shares) 0 15,000 0
Vested (in shares) (64,735) (60,001) (60,268)
Forfeitures (in shares) 0 0 0
Ending Balance (in shares) 215,384 277,241 322,242
Weighted-Average Issue Price      
Beginning Balance, Weighted-Average Issue Price (usd per share) $ 21.18 $ 21.41 $ 21.47
Stock dividend (usd per share) 15.75    
Granted, Weighted-Average Issue Price (usd per share) 0 17.50 0
Vested, Weighted-Average Issue Price (usd per share) 21.18 21.48 21.78
Forfeitures, Weighted-Average Issue Price (usd per share) 0 0 0
Ending Balance, Weighted-Average Issue Price (usd per share) $ 21.11 $ 21.18 $ 21.41
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Beginning balance $ 1,106,744 $ 1,240,934 $ 1,356,059
Rebalancing of ownership percentage 0    
Ending balance 961,372 1,106,744 1,240,934
Interest rate contract | Designated as Hedging Instrument      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Unamortized portion remaining in accumulated other comprehensive (loss) income 1,300    
Unrealized Gains (Losses) on Designated Derivative      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Beginning balance (7,043) 4,582 2,473
Other comprehensive income, before reclassifications (40,614) (10,753) 2,367
Amounts reclassified from accumulated other comprehensive (loss) income 7,999 872 (258)
Ending balance (39,673) (7,043) 4,582
Accumulated Other Comprehensive Income      
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]      
Beginning balance (7,043) 4,582 2,473
Rebalancing of ownership percentage (15)    
Ending balance $ (39,673) $ (7,043) $ 4,582
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.21.1
Non-Controlling Interests (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 04, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Nov. 30, 2014
Noncontrolling Interest [Line Items]          
Limited partner units (in shares)   90 90    
Distributions to non-controlling interest holders   $ 201 $ 346 $ 492  
Buyout of non-controlling interest holders   $ 583 $ 0 $ 0  
UnityPoint Clinic Portfolio          
Noncontrolling Interest [Line Items]          
Buyout of non-controlling interest holders $ 600        
Non-controlling Interests          
Noncontrolling Interest [Line Items]          
Limited partner units (in shares)         405,908
Units issued to purchase building         $ 10,100
Units issued to fund purchase of A Building (in usd per share)         $ 25.00
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.21.1
Non-Controlling Interests (Summary of Non-Controlling Interests) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Noncontrolling Interest [Line Items]      
Third Party Net Investment Amount $ 4,387 $ 5,410  
Net Real Estate Assets Subject to Investment Arrangement 2,108,948 2,053,591  
Distributions 201 346 $ 492
Non-controlling Interests      
Noncontrolling Interest [Line Items]      
Distributions 201 346 492
Plaza Del Rio Medical Office Campus Portfolio AZ | Non-controlling Interests      
Noncontrolling Interest [Line Items]      
Third Party Net Investment Amount $ 371    
Non-Controlling Ownership Percentage 2.20%    
Net Real Estate Assets Subject to Investment Arrangement $ 12,790 14,220  
Distributions 0 0 87
UnityPoint Clinic Portfolio | Non-controlling Interests      
Noncontrolling Interest [Line Items]      
Third Party Net Investment Amount $ 0    
Non-Controlling Ownership Percentage 0.00%    
Net Real Estate Assets Subject to Investment Arrangement $ 0 8,842  
Distributions $ 0 $ 0 $ 0
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Earnings Per Share [Abstract]                      
Net loss attributable to stockholders                 $ (78,781) $ (88,087) $ (52,762)
Basic and diluted weighted average shares outstanding (in shares) 94,821,653 94,796,190 94,479,156 94,458,620 94,592,579 94,419,591 94,276,398 95,417,626 94,639,833 [1] 94,433,640 [1] 93,593,719 [1]
Basic and diluted net loss per share (in usd per share) $ (0.22) $ (0.11) $ (0.24) $ (0.26) $ (0.51) $ (0.30) $ (0.06) $ (0.05) $ (0.83) [1] $ (0.93) [1] $ (0.56) [1]
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Antidilutive securities excluded from computation of earnings per share (in shares)                 1,043,736 1,099,743 1,153,828
Limited partner units (in shares) 90       90       90 90  
Class B units (in shares) 359,250       359,250       359,250 359,250 359,250
Unvested restricted shares                      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Antidilutive securities excluded from computation of earnings per share (in shares)                 257,704 313,711 367,796
OP Units                      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Antidilutive securities excluded from computation of earnings per share (in shares)                 417,025 417,025 417,025
Class B units                      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Antidilutive securities excluded from computation of earnings per share (in shares)                 369,007 369,007 369,007
Unvested restricted shares                      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Unvested restricted stock (in shares) 215,373       277,241       215,373 277,241 322,242
American Realty Capital Healthcare III Advisors, LLC | Advisor                      
Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]                      
Limited partner units (in shares) 405,998       405,998       405,998 405,998 405,998
[1] Retroactively adjusted for the effects of the Stock Dividends (see Note 1).
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Narrative) (Details)
12 Months Ended
Dec. 31, 2020
property
segment
Dec. 31, 2019
segment
Dec. 31, 2018
segment
Dec. 31, 2020
encumbered_property
Jul. 01, 2020
property
Apr. 01, 2019
property
Segment Reporting Information [Line Items]            
Number of reportable segments | segment 3 3 3      
Number of real estate properties 193     110    
NuVista            
Segment Reporting Information [Line Items]            
Number of real estate properties 2          
NuVista | Transition Property            
Segment Reporting Information [Line Items]            
Number of real estate properties           1
LaSalle Tenant            
Segment Reporting Information [Line Items]            
Number of real estate properties 4       4  
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Reconciliation of Segment Activity) (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]                      
Total revenues $ 90,878 $ 95,835 $ 94,664 $ 100,235 $ 94,469 $ 95,440 $ 96,287 $ 88,718 $ 381,612 $ 374,914 $ 362,406
Property operating and maintenance                 243,548 234,185 220,997
NOI                 138,064 140,729 141,409
Impairment charges                 (36,446) (55,969) (20,655)
Operating fees to related parties                 (23,922) (23,414) (23,071)
Acquisition and transaction related                 (173) (362) (302)
General and administrative                 (21,572) (20,530) (17,275)
Depreciation and amortization                 (81,053) (81,032) (83,212)
Gain (loss) on sale of real estate investments                 5,230 8,790 (70)
Interest expense                 (51,519) (56,059) (49,471)
Interest and other income                 44 7 23
Loss on non-designated derivatives                 (102) (68) (157)
Income tax expense                 (4,061) (399) (197)
Net (income) loss attributable to non-controlling interests                 (303) 393 216
Allocation for preferred stock                 (2,968) (173) 0
Net loss attributable to common stockholders                 (78,781) (88,087) (52,762)
Medical Office Buildings                      
Segment Reporting Information [Line Items]                      
Total revenues                 104,213 100,379 99,103
Property operating and maintenance                 30,851 31,813 30,295
NOI                 73,362 68,566 68,808
Triple-net leased healthcare facilities                      
Segment Reporting Information [Line Items]                      
Total revenues                 15,611 14,564 14,970
Property operating and maintenance                 1,961 2,310 1,424
NOI                 13,650 12,254 13,546
Seniors Housing Communities                      
Segment Reporting Information [Line Items]                      
Total revenues                 261,788 259,971 248,333
Property operating and maintenance                 210,736 200,062 189,278
NOI                 $ 51,052 $ 59,909 $ 59,055
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Real estate investments, at cost:      
Investments in real estate, net $ 2,108,948 $ 2,053,591  
Cash and cash equivalents 72,357 95,691 $ 77,264
Restricted cash 17,989 15,908  
Assets held for sale 90 70,839  
Derivative assets, at fair value 13 392  
Straight-line rent receivable, net 23,322 21,182  
Operating lease right-of-use assets 13,912 14,351  
Prepaid expenses and other assets 34,932 39,707  
Deferred costs, net 15,332 13,642  
Total assets 2,286,895 2,325,303  
Medical Office Buildings      
Real estate investments, at cost:      
Investments in real estate, net 883,471 891,477  
Triple-net leased healthcare facilities      
Real estate investments, at cost:      
Investments in real estate, net 238,427 256,661  
Seniors Housing Communities      
Real estate investments, at cost:      
Investments in real estate, net $ 987,050 $ 905,453  
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.21.1
Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) - Operating Segments - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Segment Reporting Information [Line Items]      
Capital expenditures $ 21,394 $ 16,719 $ 12,910
Medical Office Buildings      
Segment Reporting Information [Line Items]      
Capital expenditures 4,585 5,309 7,582
Triple-net leased healthcare facilities      
Segment Reporting Information [Line Items]      
Capital expenditures 3,976 396 1,152
Seniors Housing Communities      
Segment Reporting Information [Line Items]      
Capital expenditures $ 12,833 $ 11,014 $ 4,176
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Narrative) (Details)
$ in Thousands
12 Months Ended
Jan. 01, 2019
lease
Dec. 31, 2020
USD ($)
lease
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Lessee, Lease, Description [Line Items]        
Number of operating lease contracts | lease 11 8    
Number of finance lease contracts | lease   6    
Operating lease right-of-use assets   $ 13,912 $ 14,351  
Operating lease liabilities   $ 9,155 9,133  
Remaining lease term   41 years 3 months 18 days    
Weighted average discount rate, percent   7.35%    
Operating lease payments   $ 800 800  
Operating lease costs   $ 900 $ 1,000 $ 900
Minimum        
Lessee, Lease, Description [Line Items]        
Renewal term   11 years 9 months 18 days    
Maximum        
Lessee, Lease, Description [Line Items]        
Renewal term   86 years 8 months 12 days    
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Operating Leases    
2021 $ 663  
2022 682  
2023 684  
2024 686  
2025 691  
Thereafter 28,690  
Total minimum lease payments 32,096  
Less: amounts representing interest (22,941)  
Operating lease liabilities 9,155 $ 9,133
Direct Financing Leases    
2021 84  
2022 86  
2023 88  
2024 90  
2025 93  
Thereafter 7,407  
Total minimum lease payments 7,848  
Less: amounts representing interest (3,011)  
Total present value of minimum lease payments $ 4,837 $ 4,800
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.21.1
Quarterly Results (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]                      
Total revenues $ 90,878 $ 95,835 $ 94,664 $ 100,235 $ 94,469 $ 95,440 $ 96,287 $ 88,718 $ 381,612 $ 374,914 $ 362,406
Net loss attributable to stockholders $ (20,726) $ (10,500) $ (22,811) $ (24,744) $ (48,133) $ (28,789) $ (6,054) $ (5,111)      
Basic and diluted weighted average shares outstanding (in shares) 94,821,653 94,796,190 94,479,156 94,458,620 94,592,579 94,419,591 94,276,398 95,417,626 94,639,833 [1] 94,433,640 [1] 93,593,719 [1]
Basic and diluted net loss per share (in usd per share) $ (0.22) $ (0.11) $ (0.24) $ (0.26) $ (0.51) $ (0.30) $ (0.06) $ (0.05) $ (0.83) [1] $ (0.93) [1] $ (0.56) [1]
Business Acquisition [Line Items]                      
Impairment charges                 $ 36,446 $ 55,969 $ 20,655
Assets held for use                      
Business Acquisition [Line Items]                      
Impairment charges $ 3,600       $ 33,300       $ 16,876 $ 33,335 $ 2,400
[1] Retroactively adjusted for the effects of the Stock Dividends (see Note 1).
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Narrative) (Details)
$ in Millions
3 Months Ended 12 Months Ended
Jan. 04, 2021
shares
Nov. 02, 2020
property
Oct. 01, 2020
shares
Mar. 19, 2021
USD ($)
Dec. 31, 2020
property
Dec. 31, 2020
property
shares
Mar. 31, 2021
property
Apr. 30, 2020
property
Dec. 31, 2019
property
Mar. 31, 2019
property
Subsequent Event [Line Items]                    
Stock dividends (in shares) | shares     0.01349     0.02716        
Assets held for sale                    
Subsequent Event [Line Items]                    
Number of properties held for sale         11 11        
Seniors Housing Communities | Assets held for sale                    
Subsequent Event [Line Items]                    
Number of properties held for sale               11   1
Seniors Housing Communities | Michigan | Assets held for sale                    
Subsequent Event [Line Items]                    
Number of properties held for sale         4 4     14  
Number of properties disposed   11     11          
Subsequent Event                    
Subsequent Event [Line Items]                    
Stock dividends (in shares) | shares 0.01349                  
Proceeds from government assistance | $       $ 5.1            
Subsequent Event | Seniors Housing Communities | Michigan | Assets held for sale                    
Subsequent Event [Line Items]                    
Number of properties held for sale             4      
XML 104 R89.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances $ 905,536      
Land 214,160      
Building and Improvements 2,098,361      
Costs capitalized subsequent to acquisition, land (1,509)      
Costs capitalized subsequent to acquisition, buildings and improvements 34,696      
Gross Amount 2,345,708 $ 2,211,451 $ 2,296,627 $ 2,229,374
Accumulated Depreciation 328,095 260,399 $ 226,167 $ 170,271
Acquired intangibles 276,000      
Federal income taxes 2,300,000      
Accumulated amortization 184,700      
Secured debt $ 542,698 $ 528,284    
Building        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 40 years      
Land Improvements        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 15 years      
Fixtures and improvements        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Useful life 5 years      
Fresenius Medical Care - Winfield, AL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances $ 0      
Land 152      
Building and Improvements 1,568      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,720      
Accumulated Depreciation 353      
Adena Health Center - Jackson, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 242      
Building and Improvements 4,494      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,736      
Accumulated Depreciation 873      
Ouachita Community Hospital - West Monroe, LA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 633      
Building and Improvements 5,304      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,937      
Accumulated Depreciation 1,049      
CareMeridian - Littleton, CO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 976      
Building and Improvements 8,900      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 111      
Gross Amount 9,987      
Accumulated Depreciation 2,560      
Oak Lawn Medical Center - Oak Lawn, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,343      
Land 835      
Building and Improvements 7,217      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,052      
Accumulated Depreciation 1,620      
Surgery Center of Temple - Temple, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 225      
Building and Improvements 5,208      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 432      
Gross Amount 5,865      
Accumulated Depreciation 992      
Greenville Health System - Greenville, SC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 720      
Building and Improvements 3,045      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,765      
Accumulated Depreciation 569      
Stockbridge Family Medical - Stockbridge, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 1,781      
Land 823      
Building and Improvements 1,799      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 131      
Gross Amount 2,753      
Accumulated Depreciation 379      
Arrowhead Medical Plaza II - Glendale, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,540      
Land 0      
Building and Improvements 9,758      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,867      
Gross Amount 11,625      
Accumulated Depreciation 2,458      
Village Center Parkway - Stockbridge, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,434      
Land 1,135      
Building and Improvements 2,299      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 156      
Gross Amount 3,590      
Accumulated Depreciation 633      
Creekside MOB - Douglasville, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,814      
Land 2,709      
Building and Improvements 5,320      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 637      
Gross Amount 8,666      
Accumulated Depreciation 1,472      
Bowie Gateway Medical Center - Bowie, MD        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 9,153      
Land 983      
Building and Improvements 10,321      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 81      
Gross Amount 11,385      
Accumulated Depreciation 1,878      
Campus at Crooks & Auburn Building D - Rochester Mills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,627      
Land 640      
Building and Improvements 4,166      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 118      
Gross Amount 4,924      
Accumulated Depreciation 831      
Berwyn Medical Center - Berwyn, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,305      
Building and Improvements 7,559      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,864      
Accumulated Depreciation 1,298      
Countryside Medical Arts - Safety Harbor, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,983      
Land 915      
Building and Improvements 7,663      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 60      
Gross Amount 8,638      
Accumulated Depreciation 1,428      
St. Andrews Medical Park - Venice, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 11,119      
Land 1,666      
Building and Improvements 10,005      
Costs capitalized subsequent to acquisition, land 2      
Costs capitalized subsequent to acquisition, buildings and improvements 933      
Gross Amount 12,606      
Accumulated Depreciation 2,193      
Campus at Crooks & Auburn Building C - Rochester Mills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,831      
Land 609      
Building and Improvements 3,893      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 130      
Gross Amount 4,632      
Accumulated Depreciation 810      
Laguna Professional Center - Elk Grove, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,887      
Land 1,811      
Building and Improvements 14,598      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 311      
Gross Amount 16,720      
Accumulated Depreciation 2,748      
UC Davis MOB - Elk Grove, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,136      
Land 1,138      
Building and Improvements 7,242      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 282      
Gross Amount 8,662      
Accumulated Depreciation 1,455      
Estate at Hyde Park - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 20,116      
Land 1,777      
Building and Improvements 20,308      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 660      
Gross Amount 22,745      
Accumulated Depreciation 3,950      
Autumn Ridge of Clarkston - Clarkston, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 19,245      
Land 655      
Building and Improvements 19,967      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 38      
Gross Amount 20,660      
Accumulated Depreciation 3,809      
Sunnybrook of Burlington - Burlington, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 12,783      
Land 518      
Building and Improvements 16,739      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 240      
Gross Amount 17,497      
Accumulated Depreciation 3,414      
Sunnybrook of Carroll - Carroll, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,144      
Land 473      
Building and Improvements 11,263      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 36      
Gross Amount 11,772      
Accumulated Depreciation 2,086      
Prairie Hills at Cedar Rapids - Cedar Rapids, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,014      
Land 195      
Building and Improvements 8,595      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 116      
Gross Amount 8,906      
Accumulated Depreciation 1,623      
Prairie Hills at Clinton - Clinton, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 10,759      
Land 890      
Building and Improvements 18,882      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 47      
Gross Amount 19,819      
Accumulated Depreciation 3,653      
Prairie Hills at Des Moines - Des Moines, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,418      
Land 647      
Building and Improvements 13,745      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 41      
Gross Amount 14,433      
Accumulated Depreciation 2,827      
Sunnybrook of Fairfield - Fairfield, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 340      
Building and Improvements 14,115      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 233      
Gross Amount 14,688      
Accumulated Depreciation 2,871      
Sunnybrook of Ft. Madison - Ft. Madison, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 263      
Building and Improvements 3,931      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 203      
Gross Amount 4,397      
Accumulated Depreciation 452      
Prairie Hills at Independence - Independence, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 473      
Building and Improvements 10,600      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 176      
Gross Amount 11,249      
Accumulated Depreciation 1,949      
Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 205      
Building and Improvements 10,935      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 125      
Gross Amount 11,265      
Accumulated Depreciation 1,947      
Sunnybrook of Muscatine - Muscatine, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 11,989      
Land 302      
Building and Improvements 13,840      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 145      
Gross Amount 14,287      
Accumulated Depreciation 2,614      
Prairie Hills at Ottumwa - Ottumwa, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 538      
Building and Improvements 9,186      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 78      
Gross Amount 9,802      
Accumulated Depreciation 1,838      
Prairie Hills at Tipton - Tipton, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 306      
Building and Improvements 10,409      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 33      
Gross Amount 10,748      
Accumulated Depreciation 1,812      
Liberty Court - Dixon, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 119      
Building and Improvements 1,998      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 37      
Gross Amount 2,154      
Accumulated Depreciation 423      
Lakeside Vista - Holland, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,128      
Land 378      
Building and Improvements 12,196      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 420      
Gross Amount 12,994      
Accumulated Depreciation 2,324      
The Atrium - Rockford, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 164      
Building and Improvements 1,746      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 237      
Gross Amount 2,147      
Accumulated Depreciation 213      
Arrowhead Medical Plaza I - Glendale, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,571      
Land 0      
Building and Improvements 6,447      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,311      
Gross Amount 7,758      
Accumulated Depreciation 1,341      
Sunnybrook of Burlington - Land - Burlington, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 620      
Building and Improvements 0      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 620      
Accumulated Depreciation 0      
Community Health MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,424      
Land 0      
Building and Improvements 6,170      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,170      
Accumulated Depreciation 996      
Brady MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 19,661      
Land 0      
Building and Improvements 22,485      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 22,485      
Accumulated Depreciation 3,545      
Landis Memorial - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 0      
Building and Improvements 32,484      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 32,484      
Accumulated Depreciation 5,138      
FOC II - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 16,136      
Land 0      
Building and Improvements 16,473      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 132      
Gross Amount 16,605      
Accumulated Depreciation 2,982      
FOC Clinical - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,695      
Land 0      
Building and Improvements 19,634      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 19,634      
Accumulated Depreciation 3,497      
FOC I - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,204      
Land 0      
Building and Improvements 8,923      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 155      
Gross Amount 9,078      
Accumulated Depreciation 1,713      
Copper Springs Senior Living - Meridian, ID        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 498      
Building and Improvements 7,130      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 101      
Gross Amount 7,729      
Accumulated Depreciation 1,771      
Addington Place of Brunswick - Brunswick, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,509      
Building and Improvements 14,402      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 36      
Gross Amount 15,947      
Accumulated Depreciation 2,917      
Addington Place of Dublin - Dublin, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 403      
Building and Improvements 9,281      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 115      
Gross Amount 9,799      
Accumulated Depreciation 2,036      
Allegro at Elizabethtown - Elizabethtown, KY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 317      
Building and Improvements 7,290      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 232      
Gross Amount 7,839      
Accumulated Depreciation 1,719      
Addington Place of Johns Creek - Johns Creek, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 10,139      
Land 997      
Building and Improvements 11,943      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 456      
Gross Amount 13,396      
Accumulated Depreciation 2,492      
Allegro at Jupiter - Jupiter, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 34,370      
Land 3,741      
Building and Improvements 49,534      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 276      
Gross Amount 53,551      
Accumulated Depreciation 9,424      
Addington Place of Lee's Summit - Lee's Summit, MO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,187      
Land 2,734      
Building and Improvements 25,008      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 309      
Gross Amount 28,051      
Accumulated Depreciation 4,772      
Addington Place at Mills - Roswell, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,000      
Building and Improvements 8,611      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2,205      
Gross Amount 11,816      
Accumulated Depreciation 2,139      
Addington Place of College Harbour - St Petersburg, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,791      
Building and Improvements 8,684      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,392      
Gross Amount 13,867      
Accumulated Depreciation 2,657      
Allegro at Stuart - Stuart, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 49,069      
Land 5,018      
Building and Improvements 60,575      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 625      
Gross Amount 66,218      
Accumulated Depreciation 11,807      
Allegro at Tarpon - Tarpon Springs, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,350      
Land 2,360      
Building and Improvements 13,728      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 415      
Gross Amount 16,503      
Accumulated Depreciation 3,363      
Addington Place of Titusville - Titusville, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 12,423      
Land 1,379      
Building and Improvements 13,976      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 414      
Gross Amount 15,769      
Accumulated Depreciation 3,112      
Allegro at St. Petersburg - Land - St. Petersburg, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,045      
Building and Improvements 0      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,045      
Accumulated Depreciation 0      
Gateway MOB - Clarksville, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,560      
Land 0      
Building and Improvements 16,367      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,010      
Gross Amount 17,377      
Accumulated Depreciation 2,993      
Addington at Wellington Green - Wellington, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,182      
Building and Improvements 25,364      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements (2,131)      
Gross Amount 26,415      
Accumulated Depreciation 1,002      
Dyer Building - Dyer, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 601      
Building and Improvements 8,992      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 64      
Gross Amount 9,657      
Accumulated Depreciation 1,474      
757 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 645      
Building and Improvements 7,885      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,530      
Accumulated Depreciation 1,272      
761 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,797      
Land 1,436      
Building and Improvements 8,616      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 59      
Gross Amount 10,111      
Accumulated Depreciation 1,491      
759 Building - Munster, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,271      
Land 1,101      
Building and Improvements 8,899      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 10,000      
Accumulated Depreciation 1,476      
Schererville Building - Schererville, IN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,260      
Building and Improvements 935      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 29      
Gross Amount 2,224      
Accumulated Depreciation 278      
Meadowbrook Senior Living - Agoura Hills, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 19,167      
Land 8,821      
Building and Improvements 48,682      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,840      
Gross Amount 59,343      
Accumulated Depreciation 8,703      
Mount Vernon Medical Office Building - Mount Vernon, WA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,797      
Land 0      
Building and Improvements 18,519      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 3      
Gross Amount 18,522      
Accumulated Depreciation 3,059      
Wellington at Hershey's Mill - West Chester, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 8,531      
Building and Improvements 80,734      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,771      
Gross Amount 91,036      
Accumulated Depreciation 14,109      
Careplex West Medical Office Building - Hampton, VA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,187      
Land 2,628      
Building and Improvements 16,098      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 187      
Gross Amount 18,913      
Accumulated Depreciation 2,621      
Hampton River Medical Arts Building - Hampton, VA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 0      
Building and Improvements 18,083      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 146      
Gross Amount 18,229      
Accumulated Depreciation 3,170      
Eye Specialty Group Medical Building - Memphis, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,475      
Land 775      
Building and Improvements 7,223      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,998      
Accumulated Depreciation 1,154      
Addington Place of Alpharetta - Alpharetta, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,604      
Building and Improvements 26,069      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 500      
Gross Amount 28,173      
Accumulated Depreciation 4,858      
Addington Place of Prairie Village - Prairie Village, KS        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 14,812      
Land 1,782      
Building and Improvements 21,869      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 356      
Gross Amount 24,007      
Accumulated Depreciation 4,240      
Bloom MOB - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,322      
Land 0      
Building and Improvements 15,928      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 175      
Gross Amount 16,103      
Accumulated Depreciation 2,605      
Medical Sciences Pavilion - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 18,272      
Land 0      
Building and Improvements 22,309      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 22,309      
Accumulated Depreciation 3,438      
Wood Glen Nursing and Rehab Center - West Chicago, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,896      
Building and Improvements 16,107      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 18,003      
Accumulated Depreciation 3,647      
Pinnacle Center - Southaven, MS        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,085      
Land 1,378      
Building and Improvements 6,547      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 573      
Gross Amount 8,498      
Accumulated Depreciation 1,344      
Paradise Valley Medical Plaza - Phoenix, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,085      
Land 0      
Building and Improvements 25,194      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,178      
Gross Amount 26,372      
Accumulated Depreciation 4,404      
Victory Medical Center at Craig Ranch - McKinney, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,596      
Building and Improvements 40,475      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,340      
Gross Amount 43,411      
Accumulated Depreciation 6,488      
Rivershores Healthcare & Rehab Centre - Marseilles, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,276      
Building and Improvements 6,868      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,144      
Accumulated Depreciation 1,653      
Morton Terrace Healthcare & Rehab Centre - Morton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 709      
Building and Improvements 5,649      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,358      
Accumulated Depreciation 1,610      
Morton Villa Healthcare & Rehab Centre - Morton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 645      
Building and Improvements 3,687      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 87      
Gross Amount 4,419      
Accumulated Depreciation 1,000      
The Heights Healthcare & Rehab Centre - Peoria Heights, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 214      
Building and Improvements 7,952      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 8,166      
Accumulated Depreciation 2,007      
Colonial Healthcare & Rehab Centre - Princeton, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 173      
Building and Improvements 5,871      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,044      
Accumulated Depreciation 1,656      
Capitol Healthcare & Rehab Centre - Springfield, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 603      
Building and Improvements 21,699      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 26      
Gross Amount 22,328      
Accumulated Depreciation 4,792      
Acuity Specialty Hospital - Mesa, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,977      
Building and Improvements 16,203      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 543      
Gross Amount 18,723      
Accumulated Depreciation 2,713      
Acuity Specialty Hospital - Sun City, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,329      
Building and Improvements 15,795      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 279      
Gross Amount 18,403      
Accumulated Depreciation 2,602      
Addington Place of Shoal Creek - Kansas City, MO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,391      
Land 3,723      
Building and Improvements 22,259      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 383      
Gross Amount 26,365      
Accumulated Depreciation 4,175      
Aurora Healthcare Center - Green Bay, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,130      
Building and Improvements 1,678      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,808      
Accumulated Depreciation 311      
Aurora Healthcare Center - Greenville, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 259      
Building and Improvements 958      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,217      
Accumulated Depreciation 188      
Aurora Healthcare Center - Kiel, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 676      
Building and Improvements 2,214      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,890      
Accumulated Depreciation 367      
Aurora Healthcare Center - Plymouth, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 17,038      
Land 2,891      
Building and Improvements 24,224      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 27,115      
Accumulated Depreciation 4,029      
Aurora Healthcare Center - Waterford, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 590      
Building and Improvements 6,452      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,042      
Accumulated Depreciation 1,035      
Aurora Healthcare Center - Wautoma, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,955      
Building and Improvements 4,361      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,316      
Accumulated Depreciation 729      
Arbor View Assisted Living and Memory Care - Burlington, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 367      
Building and Improvements 7,815      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 44      
Gross Amount 8,226      
Accumulated Depreciation 1,651      
Advanced Orthopedic Medical Center - Richmond, VA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 15,390      
Land 1,523      
Building and Improvements 19,229      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 20,752      
Accumulated Depreciation 2,934      
Palm Valley Medical Plaza - Goodyear, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,998      
Land 1,890      
Building and Improvements 4,940      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 228      
Gross Amount 7,058      
Accumulated Depreciation 907      
Physicians Plaza of Roane County - Harriman, TN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,293      
Land 1,746      
Building and Improvements 7,842      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 32      
Gross Amount 9,620      
Accumulated Depreciation 1,276      
Adventist Health Lacey Medical Plaza - Hanford, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 11,526      
Land 328      
Building and Improvements 13,302      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 44      
Gross Amount 13,674      
Accumulated Depreciation 1,925      
Medical Center I - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,085      
Land 807      
Building and Improvements 1,115      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 513      
Gross Amount 2,435      
Accumulated Depreciation 741      
Medical Center II - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 945      
Building and Improvements 1,330      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 5,023      
Gross Amount 7,298      
Accumulated Depreciation 1,125      
Commercial Center - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,254      
Land 959      
Building and Improvements 1,110      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 635      
Gross Amount 2,704      
Accumulated Depreciation 375      
Medical Center III - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,137      
Land 673      
Building and Improvements 1,651      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 811      
Gross Amount 3,135      
Accumulated Depreciation 659      
Morrow Medical Center - Morrow, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,334      
Land 1,155      
Building and Improvements 5,674      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 270      
Gross Amount 7,099      
Accumulated Depreciation 909      
Belmar Medical Building -Lakewood, CO        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,770      
Land 819      
Building and Improvements 4,287      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 289      
Gross Amount 5,395      
Accumulated Depreciation 703      
Addington Place - Northville, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,287      
Land 440      
Building and Improvements 14,975      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 303      
Gross Amount 15,718      
Accumulated Depreciation 2,569      
Conroe Medical Arts and Surgery Center - Conroe, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,221      
Land 1,965      
Building and Improvements 12,198      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 573      
Gross Amount 14,736      
Accumulated Depreciation 2,071      
Medical Center V - Peoria, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,786      
Land 1,089      
Building and Improvements 3,200      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 370      
Gross Amount 4,659      
Accumulated Depreciation 562      
Legacy Medical Village - Plano, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 23,662      
Land 3,755      
Building and Improvements 31,097      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 639      
Gross Amount 35,491      
Accumulated Depreciation 4,788      
Scripps Cedar Medical Center - Vista, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 14,983      
Land 1,213      
Building and Improvements 14,596      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 48      
Gross Amount 15,857      
Accumulated Depreciation 2,052      
Nuvista Institute for Healthy Living - Jupiter, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 8,586      
Building and Improvements 54,051      
Costs capitalized subsequent to acquisition, land (1,511)      
Costs capitalized subsequent to acquisition, buildings and improvements (7,939)      
Gross Amount 53,187      
Accumulated Depreciation 1,284      
Ramsey Woods Memory Care - Cudahy, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 930      
Building and Improvements 4,990      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 29      
Gross Amount 5,949      
Accumulated Depreciation 925      
East Coast Square West - Cedar Point, NC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,254      
Land 1,535      
Building and Improvements 4,803      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 6      
Gross Amount 6,344      
Accumulated Depreciation 696      
East Coast Square North - Morehead City, NC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 3,933      
Land 899      
Building and Improvements 4,761      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 6      
Gross Amount 5,666      
Accumulated Depreciation 679      
Eastside Cancer Institute - Greenville, SC        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,498      
Building and Improvements 6,637      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 32      
Gross Amount 8,167      
Accumulated Depreciation 960      
Sassafras Medical Building - Erie, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 2,315      
Land 928      
Building and Improvements 4,629      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 3      
Gross Amount 5,560      
Accumulated Depreciation 611      
Sky Lakes Klamath Medical Clinic - Klamath Falls, OR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 433      
Building and Improvements 2,623      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,056      
Accumulated Depreciation 366      
Courtyard Fountains - Gresham, OR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,476      
Building and Improvements 50,601      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 881      
Gross Amount 53,958      
Accumulated Depreciation 8,037      
Presence Healing Arts Pavilion - New Lenox, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,966      
Land 0      
Building and Improvements 6,768      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 76      
Gross Amount 6,844      
Accumulated Depreciation 991      
Mainland Medical Arts Pavilion - Texas City, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 6,174      
Land 320      
Building and Improvements 7,923      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 305      
Gross Amount 8,548      
Accumulated Depreciation 1,266      
Renaissance on Peachtree - Atlanta, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 50,821      
Land 4,535      
Building and Improvements 68,895      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,751      
Gross Amount 75,181      
Accumulated Depreciation 10,102      
Fox Ridge Senior Living at Bryant - Bryant, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,133      
Land 1,687      
Building and Improvements 12,936      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 544      
Gross Amount 15,167      
Accumulated Depreciation 2,811      
Fox Ridge Senior Living at Chenal - Little Rock, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 16,390      
Land 6,896      
Building and Improvements 20,579      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 163      
Gross Amount 27,638      
Accumulated Depreciation 3,732      
Fox Ridge North Little Rock - North Little Rock, AR        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 10,170      
Land 0      
Building and Improvements 19,265      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 261      
Gross Amount 19,526      
Accumulated Depreciation 3,199      
Autumn Leaves of Cy-Fair - Houston, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,225      
Building and Improvements 11,335      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 59      
Gross Amount 12,619      
Accumulated Depreciation 1,880      
Autumn Leaves of Meyerland - Houston, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,033      
Building and Improvements 13,411      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 21      
Gross Amount 15,465      
Accumulated Depreciation 2,123      
Autumn Leaves of Clear Lake, Houston, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,599      
Building and Improvements 13,194      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 18      
Gross Amount 14,811      
Accumulated Depreciation 2,181      
Autumn Leaves of The Woodlands - The Woodlands, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 2,413      
Building and Improvements 9,141      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 20      
Gross Amount 11,574      
Accumulated Depreciation 1,619      
High Desert Medical Group Medical Office Building - Lancaster, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,480      
Land 1,459      
Building and Improvements 9,300      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 10,759      
Accumulated Depreciation 1,141      
Northside Hospital - Canton, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,014      
Land 3,408      
Building and Improvements 8,191      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 40      
Gross Amount 11,639      
Accumulated Depreciation 784      
West Michigan Surgery Center - Big Rapids, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 258      
Building and Improvements 5,677      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,935      
Accumulated Depreciation 502      
Camellia Walk Assisted Living and Memory Care - Evans, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 12,563      
Land 1,854      
Building and Improvements 17,372      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 822      
Gross Amount 20,048      
Accumulated Depreciation 2,001      
Cedarhurst of Collinsville - Collinsville, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,228      
Building and Improvements 8,652      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 113      
Gross Amount 9,993      
Accumulated Depreciation 819      
Arcadian Cove Assisted Living - Richmond, KY        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 481      
Building and Improvements 3,923      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 63      
Gross Amount 4,467      
Accumulated Depreciation 420      
Beaumont Medical Center - Warren, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,078      
Building and Improvements 9,525      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 19      
Gross Amount 10,622      
Accumulated Depreciation 796      
DaVita Dialysis - Hudson, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 226      
Building and Improvements 1,979      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,205      
Accumulated Depreciation 160      
DaVita Bay Breeze Dialysis Center - Largo, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 399      
Building and Improvements 896      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,295      
Accumulated Depreciation 87      
Greenfield Medical Plaza - Gilbert, AZ        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,476      
Building and Improvements 4,144      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 48      
Gross Amount 5,668      
Accumulated Depreciation 357      
RAI Care Center - Clearwater, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 624      
Building and Improvements 3,156      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,780      
Accumulated Depreciation 252      
Illinois CancerCare - Galesburg, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 290      
Building and Improvements 2,457      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,747      
Accumulated Depreciation 221      
UnityPoint Clinic - Muscatine, IA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 570      
Building and Improvements 4,541      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 2      
Gross Amount 5,113      
Accumulated Depreciation 389      
Lee Memorial Health System Outpatient Center - Ft. Myers        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 439      
Building and Improvements 4,374      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 363      
Gross Amount 5,176      
Accumulated Depreciation 369      
Decatur Medical Office Building - Decatur, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 695      
Building and Improvements 3,273      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 3,968      
Accumulated Depreciation 295      
Madison Medical Plaza - Joliet, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 0      
Building and Improvements 16,855      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 37      
Gross Amount 16,892      
Accumulated Depreciation 1,267      
Woodlake Office Center - Woodbury, MN        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 8,638      
Land 1,017      
Building and Improvements 10,688      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1,297      
Gross Amount 13,002      
Accumulated Depreciation 873      
Rockwall Medical Plaza - Rockwall, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,097      
Building and Improvements 4,582      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 182      
Gross Amount 5,861      
Accumulated Depreciation 403      
MetroHealth Buckeye Health Center - Cleveland, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 389      
Building and Improvements 4,367      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 5      
Gross Amount 4,761      
Accumulated Depreciation 347      
UnityPoint Clinic - Moline, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 396      
Building and Improvements 2,880      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 1      
Gross Amount 3,277      
Accumulated Depreciation 246      
VA Outpatient Clinic - Galesberg, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 359      
Building and Improvements 1,852      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,211      
Accumulated Depreciation 181      
Philip Professional Center - Lawrenceville, GA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 5,780      
Land 1,285      
Building and Improvements 6,714      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 169      
Gross Amount 8,168      
Accumulated Depreciation 577      
Texas Children’s Hospital - Houston, TX        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,368      
Building and Improvements 4,428      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 116      
Gross Amount 5,912      
Accumulated Depreciation 484      
Florida Medical Heartcare - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 586      
Building and Improvements 1,902      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,488      
Accumulated Depreciation 215      
Florida Medical Somerset - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 61      
Building and Improvements 1,366      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,427      
Accumulated Depreciation 134      
Florida Medical Tampa Palms - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 141      
Building and Improvements 1,402      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 1,543      
Accumulated Depreciation 143      
Florida Medical Wesley Chapel - Tampa, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 485      
Building and Improvements 1,987      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,472      
Accumulated Depreciation 228      
Aurora Health Center - Milwaukee, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,014      
Building and Improvements 4,041      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,055      
Accumulated Depreciation 528      
Vascular Surgery Associates - Tallahassee, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 902      
Building and Improvements 5,383      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,285      
Accumulated Depreciation 554      
Glendale MOB - Farmington Hills, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 504      
Building and Improvements 12,332      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 12,836      
Accumulated Depreciation 904      
Crittenton Washington MOB - Washington Township, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 640      
Building and Improvements 4,090      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 43      
Gross Amount 4,773      
Accumulated Depreciation 351      
Crittenton Sterling Heights MOB - Sterling Heights, MI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,398      
Building and Improvements 2,695      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 181      
Gross Amount 4,274      
Accumulated Depreciation 280      
Advocate Aurora MOB - Elkhorn, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 181      
Building and Improvements 9,452      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 9,633      
Accumulated Depreciation 762      
Pulmonary & Critical Care Med - Lemoyne, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,271      
Land 621      
Building and Improvements 3,805      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,426      
Accumulated Depreciation 442      
Dignity Emerus Blue Diamond - Las Vegas, NV        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,966      
Land 2,182      
Building and Improvements 16,594      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 18,776      
Accumulated Depreciation 969      
Dignity Emerus Craig Rd - North Las Vegas, NV        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 18,780      
Land 3,807      
Building and Improvements 22,803      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 26,610      
Accumulated Depreciation 1,344      
Greenfield MOB - Greenfield, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 7,526      
Land 1,552      
Building and Improvements 8,333      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 225      
Gross Amount 10,110      
Accumulated Depreciation 757      
Milwaukee MOB - South Milwaukee, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 4,136      
Land 410      
Building and Improvements 5,041      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 5,451      
Accumulated Depreciation 278      
St. Francis WI MOB - St. Francis, WI        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 9,085      
Land 865      
Building and Improvements 11,355      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 159      
Gross Amount 12,379      
Accumulated Depreciation 733      
Lancaster Medical Arts MOB - Lancaster, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 85      
Building and Improvements 4,417      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,502      
Accumulated Depreciation 346      
Women’s Healthcare Group MOB - York, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 624      
Building and Improvements 2,161      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,785      
Accumulated Depreciation 281      
Pioneer Spine Sports - Northampton, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 435      
Building and Improvements 1,858      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,293      
Accumulated Depreciation 75      
Pioneer Spine Sport - Springfield, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 333      
Building and Improvements 2,530      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 2,863      
Accumulated Depreciation 107      
Pioneer Spine Sports - West Springfield, MA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 374      
Building and Improvements 4,295      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,669      
Accumulated Depreciation 176      
Felicita Vida - Escondido, CA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 1,677      
Building and Improvements 28,953      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 17      
Gross Amount 30,647      
Accumulated Depreciation 1,098      
Cedarhurst of Edwardsville - Edwardsville, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 321      
Building and Improvements 9,032      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 9,353      
Accumulated Depreciation 262      
UMPC Sir Thomas Court - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 745      
Building and Improvements 6,272      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 7,017      
Accumulated Depreciation 157      
UMPC Fisher Road - Mechanicsburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 747      
Building and Improvements 3,844      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,591      
Accumulated Depreciation 105      
Swedish American MOB - Roscoe, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 599      
Building and Improvements 5,862      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 6,461      
Accumulated Depreciation 185      
Cedarhurst of Sparta - Sparta, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 381      
Building and Improvements 13,807      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 22      
Gross Amount 14,210      
Accumulated Depreciation 405      
UMPC Chambers Hill - Harrisburg, PA        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 498      
Building and Improvements 4,238      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,736      
Accumulated Depreciation 103      
Cedarhurst of Shiloh - Shiloh, IL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 13,684      
Land 376      
Building and Improvements 28,299      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 14      
Gross Amount 28,689      
Accumulated Depreciation 612      
Bayshore Naples Memory Care - Naples, FL        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 3,231      
Building and Improvements 17,112      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 20,343      
Accumulated Depreciation 356      
Circleville MOB - Circleville, OH        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Encumbrances 0      
Land 765      
Building and Improvements 4,011      
Costs capitalized subsequent to acquisition, land 0      
Costs capitalized subsequent to acquisition, buildings and improvements 0      
Gross Amount 4,776      
Accumulated Depreciation 9      
Revolving Credit Facility | Unencumbered Properties        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Maximum borrowing capacity 323,700      
Capital One Facility | Credit Facilities | Master Credit Facility        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Secured debt 212,500      
KeyBank Facility | Credit Facilities | Master Credit Facility        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]        
Secured debt $ 142,700      
XML 105 R90.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Real estate investments, at cost:      
Balance at beginning of year $ 2,211,451 $ 2,296,627 $ 2,229,374
Additions-Acquisitions 98,364 80,980 121,244
Disposals, impairments and reclasses (35,893) 166,156 53,991
Balance at end of the year 2,345,708 2,211,451 2,296,627
Accumulated depreciation:      
Balance at beginning of year 260,399 226,167 170,271
Depreciation expense 63,393 64,731 62,595
Disposals, impairments and reclasses (4,303) 30,499 6,699
Balance at end of the year $ 328,095 $ 260,399 $ 226,167
XML 106 R91.htm IDEA: XBRL DOCUMENT v3.21.1
Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]      
Assets $ (35,893) $ 166,156 $ 53,991
Accumulated depreciation (4,303) $ 30,499 $ 6,699
Reclassification From Held-For-Sale To Real Estate Investments | Revision of Prior Period, Reclassification, Adjustment      
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]      
Assets 49,400    
Accumulated depreciation $ 8,700    
EXCEL 107 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$0-:%,'<$[N)H, MX?#@" Z R/'%3Z8'OHW-'(PT9NK['N:X9(X=<^T1Y@]2* 7]3.1<*Q S MN,1$S#G]A2GTE4*],WD;SKKCM"=TU0OCCK^J)NAA2-R.RI@[6FNEUMJ+M8XI MF5+F=LHNP1OB1D5-<$_OOH@[:NNEVOI>M17/B$OD,1 -,T(EK C+$7[#$!6= M1L3-YFZ#6J74UK\:]$GHOS]1NY37?F6/PF!;;8,W<*D@;>P[]KMB MZKM]"BL_A_"Y3K'M.?\/YRG<%NCPM2MTN"W1X&PO=V]R:W-H965TPFL29;4@G[XW/O/<295(S? MB0VBA/L\*\34V4A9GKFN2#:8$]%C)19J9\5X3J2:\K4K2HXD-: \

,55/'=QX6;NAZ(_6".YN49(T+E+?E M-5OAM2Q9VI@>_S _LDDKY)9$H$7+/M.4[F9.B,'4ER1;29O M6'6)34*1YDM8)LPW5$VLYT"R%9+E#5@IR&E1_Y+[IA M0.@? 0-(#@6$#: M\ D@. 3H-X"^J4R=BJE#3"2933BK@.MHQ:8'II@&K=*GA>[[0G*U2Q5.SF+D M=$=T[060(H5+3->T6,.Y[@>55"V?+&I/ %O!8SA<%4+RK;* %*=P$J,D-!.G M$U?GQ6>W E,1<_.YA#RQP:YOY!P?H?13(X MS]GVY8QK@L@0Z"?#;C8:#3W]F;B[%X[NVZ/[G4?'*.BZ(!)3(,)ZZ=$I\$=- M)'(4$K@* U&14G3D'-F#HW>NYL R#[JKN71::EYS#EH%'MO* MUB;NBM@3.K1"AV]L^WSXK.W1"\API;!>;ZA(>'U3UQ/)2G-W+9E4-Z$9;M3;#7(=H/97C,F' MB;X.[?O2["]02P,$% @ E)-]4H9W69.( P <0H !D !X;"]W;W)K M&ULS59-;]LX$/TKA-!# C31MVP5M@$GZJ(&6FS0 MM+N'H@=&&DE$)=)+4G%VL3]^AY2L=6S%S6$/>['Y,>]QY@TYFL5.R!^J!M#D MJ6VX6CJUUMMWKJOR&EJJKL46..Z40K94XU16KMI*H(4%M8T;>%[BMI1Q9[6P M:W=RM1"=;AB'.TE4U[94_GD#C=@M'=_9+WQF5:W-@KM:;&D%]Z"_;N\DSMR1 MI6 M<,4$)Q+*I;/VWV6IL;<&OS'8J8,Q,9$\"/'#3#;%TO&,0]! K@T#Q;]' MN(6F,43HQA\#IS,>:8"'XSW[+S9VC.6!*K@5S>^LT/72F3ND@))VC?XL=A]@ MB"*2W: 8P>M(SW__1IT.$ X"E#L3ID5-/50HH=D<8:V92#9(S7: M*T)Y03Y 43%>D;7)!],,ER\.;38\;[H""L(X6?]ZN[DTVYJR1EV2*_+U/B,7 M;R[)&[/]I1:=0DZU<#5Z:LYS\\&KF]ZKX 6O_(!\$ES7BKSG>-AS A=#'.,, M]G'>!&<9,\BO2>B_)8$7>!,.W;X:[J<3\.SU\/F9:,(Q:Z'E"W^:-?+M(^Z1 MC896?3_#'(W,D66.7F!>MZ+CFHB25%@SR$4C%&960BXJSO[J\T[SO&N[AFJ< M"EV#)+EHL>C4IAJ@2P.(<5P&@H^;<0T2E"82,?@JQ^LT=3-Z_V+KGRE:CZNK M,$A"3-KC8;XFS'P_">+G9MFI6>![Z6CT3*-XU"@^J]$7H6E#Z*C4&!X\8356 M0% +!5SW:J% J ]7HF&%E4QI_,/*J94!8P%'5; $]N_ON9)&R"F->O^2@ZAB M/_;3(XDFK!(O/K+*3JVB-)KYTQ(EHT3)68DR4*SB-ERJQJ*RX4K+SH1._L;) MX:50.[I59^[O;#QX]A^_C/G(//^?OXSY2::N(B_QHZ.T3YCYWBP.C_)^:A:$ MR6PZ[>FH4?I*C89(K52H44.58B5#64HIVI_J- B$ZHC]&*_1R3N[@+($VSB0 MK9#F$5U.Z9:>EHI9FAZ_EE.K^2PXTNS4)HCG1Y*Y!Q_C%F1EFQJ% :(R_?=J M7!W[IK5M%X[6;["?ZMN??VGZ9NP3E?B>%&F@1$KO>H8>R;[!Z2=:;.TG_T%H M;"#LL,:>$*0QP/U2"+V?F /&+G/U#U!+ P04 " "4DWU2(^7UUA8# "Q M"@ &0 'AL+W=OG',Y MMN]PP\6CC E1Z"EAJ1Q9L5*K"]N604P2+,_YBJ3P)N(BP0JF8FG+E2 X-$$) MLSW'Z=H)IJDU'IJU.S$>\DPQFI([@626)%C\O"2,;T:6:STOW--EK/2"/1ZN M\)+,B7I8W0F8V666D"8DE92G2)!H9$WW(0C MR]&,"".!TBDP/-9D2AC3F8#'CR*I57Y3!U;'S]FOC'@0L\"23#G[2D,5CZR^ MA4(2X8RI>[ZY)H6@CLX7<";-+]H46,="02853XI@8)#0-'_BIZ(0E0"WW1#@ M%0'>L0%^$> ;H3DS(VN&%1X/!=\@H=&030],;4PTJ*&I_AOG2L!;"G%J/"." MKK$NI40X#=$U"9(INASS#,)V>305L!1?\D."CZ7.1^OD4]PCGSW#'F.Y]2$3X\.=P?;X394 MIBR/5Y;',_G\@^5!-ZE4(@,'J\9*S:@,&)>9(.C;9 %P,.GW/2S\DH5O6+0; M6+P77$HT27BF/\XC=$\"ODSI+Q*BB83_IK;0>"5FBVN[Y-I^,]?6!XH7E)EBG=91SE-W*WS>^7V_/WA!NP;6\9U./?%.2;SS M"N*YY[6954S0E*>2,QIB!2HN,<-I0-!<;[HZ%9T=>LX+ ?L06^2[)?GN7O*W MP+52\]P4" YV"7X%SF_2T=UAN6.@74BC@7JEE-[_E]([SE@UL&9C]4M!_5<8 MZY:KBKF:59RA*YK"E&)6/7KJQ/4/^FT?8DO3H-0T^">:IEC& & ,7@I0!H<# M@<,UK),U."AK'V)+ENO\N0Z=(]U7>WZ^\Z M7(W![4H_H9NYCUC 52<1(Q'$.><]2"#R_BB?*+XR+<:"*VA8S#"&GI((#8#W M$>?J>:*[EK)+'?\&4$L#!!0 ( )23?5+[R-L+[@@ "

&PO M=V]R:W-H965T.G#599M_AR-4G]%UR0=)AL:\V]N$[8F&7_+[D;IAE$2%*1U-$*6 MY8[6)(P'QX?%9W-V?)CD613&=,Y FJ_7A#U^H%'R<#2 @_J#17BWRL0'H^/# M#;FC2YI=;>:,OQMM5PG"-8W3,(D!H[='@_?PSVNG(!2([R%]2!NO@5#E)DE^ MB#>GP=' $A+1B/J96(+P/_?TA$:16(G+\;-:=+#=4Q";K^O5/Q7*PBH(B!3 JX(V)1@5P3;E.!4!,>4X%8$UY3@503/E#"N"&-3 MPJ0B3$P)T*H]9QE3ML[N>!OW46IW0V-_P]KAT-CCL'8Y-/8YK)T.C;T.:[=# M8[_#VO'0V/.P=CTT]CVLG0^-O8]J[R-C[Z/:^\C8^VA[V(V]CVKOH\+[HS(3 M%6EL2C)R?,B2!\ $GJ\G7A2YL.#S[!7&(FTO,\:_#3DO.UYFB?]CE40!9>D? MX.///,P>P9L+PA@1^?0M>#.E&0FC]"UX!ZZ64_#FM[?@-S "Z8HPFH(P!E=Q MF*4'_$/^^MLJR5,2!^GA*./2B3U&?B7)AU(2U"/)S,^&P((' %G(4M!/]/1/ M]&8(D-M+G^KI?Y&8[S[II7\T$!Y;@@XG"OHG/?W]A@T!+(2'8P7]LYY^3@0= M]]*_&-!+RROIIP;"5W1/0?_+P''0ZZ6?Z>E3ZG/+PU[+?]VG^V/-5JE^;J!Z MY7:LH%\8RZX,NMG+Z/.76>[2G*XRW>)ENR]?IOLW/7U)-[7CE/0K SIT>NG? M38-.R;XVMUSKP(QX]M^6 +0M :A8#_>L=Q*1- 7)+2AJ ?C[*_\>G&9TG?ZC M61UO5\?%ZG;/ZM=%XTR#=^2>,CX(@ T+??XO964) 6]XV]E;>]E:>Y5.8'23 M,W_%YY$#<$^BG*IL4B[D-+8?CRUK5\9I%P2]-NAK%X2M!FA'$6>KB*-5Y")? MWW"7\KBJ6@6I4U XO?Q8Z>UR9; (= MD9UVO*[ C2>NBWKLY6[MY6KM=9*LUWR.35O^5W52']V.O[R.YV==$+0+T_F!./=A$H@XB9-,I(8L 23*>.B0 M.T;IFL:9JJG0+PTM$)#'5)._QELAQ^9N"=,TY]&;K5B2WZU $*89"V_RK+S# M".-[FF9"8+")2+PGR&?C3AQ-+,MJNW'>A4%'@;M4X+Q=W([^DZW^$ZW^6:1:C?L["+.29 MS"=1Q!6_>:Q*6'U6 1.U;H_?OU<[[GBJ1\S&% ?W>(G>4L:X4(5K#NJ<2_)L ME;#PW[TI]ZS:8$R6(GF9H$@2A MB'@2/=GFWZJ]FF*ZFB,+9<\%]4U77SA4)W9?*"# $SDR!ZX89I1BR@X*ZENH.7D4]8;7JH2!/ XH M>Q 9.[X#]->&QJFJBSZ#W=[F'<2]X2&;&ZAO0;;"<+,UDD1RR^.B(9*JOSNK MEMZ5R>Z52?8R4-_,G'*_$1&37*9-.WQCNJ]T7'IFU1X0-H_Y<&QCKR?VD>P D+X#T,M7]*\^]S,?;56"[5G<&W() M?U?=W3R#N*N@[!V0OG>8-OJV% 34CXC0EMO=)^G*S $?JCV:L[ U'+>2TQGW5ZJ]T@VG63:TWP MN$=46:61ODI7\UMA9=UQD;40.:]P789D$4/F]P#;QBW)LS0C<2 *QY[NK5I^ M9ZY$V'%=UVZU;RHD]CS'L]UV*)DBY\:[7ZJ0<.)B![>.Y\)XS:6QG-?*W2U^ M.-R^PR$+/](7_M>[,:@V;@H]]IS)N..$+@[:8XC;%YB7*B"?K5V,>XP@.PVD M[S2^4=%^@9GH=G3'0K8):/(:M]2RS&-]05UVAC?11,I[N#V^F>+N5(\4US2? M>W$]C126=1SKZ_C_<],^Q=TR-V[?CW]6@" >PIYF"\MBB/7%<$&#O/P]S];: MSW;))]P=KQ'66+KQ2&-/^6R>&'](/?B>Z(+ MW+W^5L_\IL"E 7!76UE*\9YYL#/BM)])5.F9J[PI?9HHO5E65MRM&7I!9V;%__,JX0)WI\?V-<', +/48W95E84!ZPO#DD3E34*IZ!U+>,!OJDMFI=7' M'2ELJW<^Q[*@8/W<.:41+\;Z@VO+\F%;KW!P;9G<[2=>\#ZCSYY7>^Q,R6B( M^Z=D6R9N^XGWHD^9DN=[%I_L&W9MF;IM?>H^C7U&1>T(X^X-R--DUF^$AI:E M%;GQ0-CTGK&,K>I'6B+"=.O+FF"_QD!CRRQLZ[/P>UE;6A;?9MO^A]Q7MN+1 MH].;+QDZOA#)3VJ]Z63>SC2_K M;)DT;7W2K*RFB0M'IDSG-5*F(U.F\]K/Q)SN8Z3RT6OGN84Q-7[5 M*7Y"?T[871BG(**WG&H-/7XF6/FK]/)-EFR*'WK>)%F6K(N7*TKX&"8 _/O; M),GJ-^*WH]O_&W#\'U!+ P04 " "4DWU2<3F UA # !/"0 &0 'AL M+W=OBS#+,WRZ!LLW8\JQWPSU9I5(;G,FHP"MX /E8W'$U<[9> M$I)!+@C+$8?EV+KPSN>AUAO!;P(;T1@CO9(%8\]Z\CT96ZY.""C$4GO ZF\- M5T"I=J32>*E]6MN0&FR.W[W/S-K56A98P!6C3R21Z=@:6"B!)2ZIO&>;.=3K M,0G&C KS1)M:ZUHH+H5D60VK##*25__XM:Y# _!Z>P"_!ORN0% #05>@5P.] M72#8 X0U$':-$-5 U!7HUT"_*S"H@8'9W6H[S%Y.L<23$6<;Q+5:>=,#TQ"& M5EM(8@$,G18TZD.%5&-;XEE"I,C!RIL 6_/HS?XC<4 M>(8>M-"SP_048KO&6W._Z8RWYC[_[^B.ZJEM8_G;QO*-OV"/OXLX9F4N2;Y" M=XR2F*@N^7.Q$)*KX^KO@0#!-D!@ O3V!/A99@O@B"W?>Y!#4?(X50=9@HY5 M$U;FD[8>K#Q'QK,^W->3T T]UQLYZV:S?)7U>M$@<#_+9MV\W;1X"X9>J#>K MJ9NWZ ;#*/(_PGZJ5V];K][!>CV98QR2,[P&KFXE5' 2JZ>JH:F4J5DID@]+ M:^FJ(/U&=E[?#G<*UT4TZR*Z^2KR77NXHYJWJJ+V>H7;>H4'ZU6=@1]-=8K6 MF);05I/*D1&PO=V]R:W-H965TW"3V\8BL8/M M4/CWLYV0M"Q-2P4OK>W<<^X]SE'L.UEQ<2=C (4>TX3)J1,KE9VZK@QC2(GL M\ R8?K+@(B5*3\72E9D $EE0FKB^YPWS ^ZT2^BG5.#6[53R\BWD2@9"?T)?[G*HG=!10 MJ02=Y^;5R&,]!T5HHD>?T0?D(AD3 7+B*EV H7'#,MEYD2+S!-"?[SH$72I(Y=^6!+TJ0<\FZ.U*<((R$"$PU?02 MVSFPYW4\[V/39A\*# X ;NCO5_K[^^E'&:$1.J(,Y3(R>U%X^KAI.PK*H:4T MG]&'F=?I^1/W85UZ4]"HNQD4- 6-:Z8-28-*TJ!5T@VH7##$%R@D&54D04?X MN&6KAA7O\'V\.*H2C-[ B^T<+5X\%!@< -S0/Z[TC]_>B^-]O-@4])\7FX*V M>1%[]6GBM8JZ*#VXU#<.%)4*$64A3Z%ES_#:<87?QY;8KU/X;V#,'21;?7D@ M+G@];E-^?0;A[MO[LN3LK]OIA2MWAP2M(9MRZA,/MQ\>/T1$F;[1OL:-]7&" M^^_DQOKSCMN_[WNZL9UDNQL/PP6OQVW*KT\A/'P'-PYWNW%G2- :4LAQUR[> M*8BE;6 D"GG.5'&)K5:K)NG,M@8OUL]-\V0O]#5-T7E=$;&D3*($%IK2ZPQU M/:)H9HJ)XIF]WL^YTLV"'<:Z 01A O3S!>?J>6(25"WE[!]02P,$% @ ME)-]4MQNP?@$ P J @ !D !X;"]W;W)K&UL MM5;?;]HP$/Y73E$?6JEK0OA1J "I!4VKU&JH/[:':0]N)$481U$OE(SGP7CHUV9Z/%1+*WB.,PUF*273KU"T>,%)RB$\T0\?E5.@SJF VZ/-]X_>_$D MYHD9G"CQG::,G,RYHRR\9#K5:@G35Y0,VJU3 MB*,XV@.?O!O>&NS"0TI*G9FXSDSL_;7_-S/PXX9,X=JB-#\; K7K0&T?J',@ MT$1)25ZIU,DS9"A2>'JE'5)&+WST8TJLR9A&<[(OKZ7_GO?O]NW+>-"-.M%Y MOST,7[8SN,COX1M]\-:O NQND:C_9A_ML>K3[TTIPZUK MQ-WAMTPO.#6(P#G!HK-S:@1=7HOEQ*K"WRQ/RM(]Y8<9?4J@=@;T?JZ4W4S< M955_G(S_ %!+ P04 " "4DWU22HU,=S4) !<,@ &0 'AL+W=O'K,YJQQ^.1.WK^X#:=+Z3Z8')RM"1S M>D?E]^4-AW>3C90DS6DA4E8@3A^.1Z?N;Y^F6#703_R9TD?1>(W44.X9^Z'> M?$Z.1X[2B&8TEDH$@5\K>DZS3$D"/?Y7"QUM^E0-FZ^?I5_IP<-@[HF@YRS[ M*TWDXG@T':&$/I RD[?L\7=:#RA0\F*6"?T3/=;/.B,4ET*RO&X,&N1I4?TF M3_5$-!I@MZ,!KAO@%PU#H&X0[-I#6#<(=VT0 MU0TB;:QJ=K5I+H@D)T>D6'] !Q=4DC03'] O:(+$@G"0!6*^%ZD4A_ AO/ZV M8*6 ;L711,+8E(:3N!['634.W#&.?Y79&.'@$&''G7V_NT 'OWQHD7)NEW)% M[\?(C;24J*7YA;WY'5V.D>>HYMCI5N+2+N6"QB#%W9)BYJSZV2+U:F>IM@GZ MM+N4::N4"3C@Q@OQQ@NQ%NN]U0O1?Z[A4?19TES\U]*1M^G(TQWYG1T5])%D M2%*>M[F'O;7KH#4E7%@4\3>*^%919XSP1"V2).6PBA@7:,5D6LP1+*$8EAO$ M@38%[5+#:.PXOUK4"S;J!59!-Y2G3.M7@%9QJRIV"7Z $K*V356XT26T2KI3 M'H^6'-0X1 5$YP- 1<*R#"RA9JM:&!_0WPVRM*VZJI=(]Z(B].H$XW%P-%FU MZ!9M=(NLNIT* 0K)!72Y8%F"(#= 1(AT7BADJODCV.V% M=1]A8T*]8(:##IN[!J$NMFIW#GJ!4K]++K3/H=.#Y5N#)2V#K2?=?^7%0=A89G4 ]5^9 M)L)=B]$U*'7M)#S- :8Q*< T)(.I T.E$F+0[^KM(E9PJQ<$Y$'7U^?@/O!> M.Q5,[C6#EN!H7R&;XNASL:)"ZM'^C7981H:Q;CBP=0TR73LSK]("!J="':F' MJ8U,X'\C^"EVWM,B7L .Z<970-G'%BCI&M( MZ]I1^\_&$E?),5HR+A]8EC(]HM8!V=7P^P9DR.SVH/GMS@H; ,% M; O1C8K5.SDH-IS' W,>&\YC.^?_**$/RK.U"N40WG-2D&H/I*S;9IX>@<[8 MG4:!S4"XD2G;,?\. WWB3 AX?D6+$E*H.PE;K(\D8S!K=^"Z&?TH*;BQ1/^& MP5Y3HKA[PQGXKTS!F7>RHPDC>. P@DT8P?8P4H]A_<* K<3H$>7V+#!LH@'> M>S1X8;_+IS@K$\6<02QI0@8>.&1@$S*P'=AOLJ1=%.ZSI&$_MD/WK9:T=6KX MC&<#[Y0-<3WG'^\!>T2$3M\FT#-4]GJR;QHS59$"XR

I[7 MZ+1]M[7=I6&M-W19HE&7L)<67DZVKI]1GD-^H3ILG7N[1"_LW8%[!J6>G7]? M(,8O("">J?#^Q2S"*ZKC_/Y6@F= Z@4#&\>0SK-7(/2HM]&C+060A:U@3&EK MQ?*R1ZH[QM:Q/DM50;0MQ1 /$,!CT[!DVV]"?AJ2X\;#O( M(3I[SGW1UV+?_F+(Z0U,3M^0T[=C#_PEU17PF,%0*.$%!&<82KTC:#-.CT0W MZ"GL^8:COIVC[TY[IM[Y!*^8;0?#>PKALB^GJ>A)=:J&P:E\>GVSK;6)(.'!F'QK^A_8\7)50\C*3Z3)+ M*6^US>MSR8X#^-"$@M .9SUKE2GTH=/S1J)/E4JJ&VPEZ(Z#9QT*-2YYV/E^ M2Y.RFF$ %._0KE6E2JX;;JG45=<(#;7#GJ+*3P 2\+B$9O6!V6?HZN[17;1 M(\-U^O/PJ''AS8[%.[JB7-]T@*G1R\PFUA K&IA8D2%6U%.4V/%Z7"UF:TET MFG1JU,^H+>4KS,G]?Q'AQ%%Q5KMY\QCLUG)H.S*FIX=34SJFOX%="?7&@ MRFA5%1$ZOE]O)[:M]QCM@MVN.N>D<6U>?>_B"^'S%'9(&7T 0?96A M>B/94M^DOV=2LER_7%"24*X>@+\_,":?WZC+^9LOE)S\'U!+ P04 " "4 MDWU2[)>:0HH& "%( &0 'AL+W=O'Q1X8B[:YE427I)T&V(]? M4E)$6Z)H%8TOL27/##DS;QZ'9"Z?N/@NUY0J\#-+3\Q&LJ-H"0IE+)TB()@-,P(RP?7E\6[N;B^Y%N5LIS.!9#; M+"/B^9:F_.EJ +^]Q?K'PKGM3./1-(I3[^Q1*VO!N,!2.B2;%-USY_^H)5#D;&W MX*DL_H*G2C88@,56*IY5RGH&& AQU**!* 345P@X%7"G@O@IA MI1#V58@JA<+U8>E[$;@94>3Z4O G((RTMF:^%-$OM'6\6&Z \J"$_I5I/75] M3U.B: +F1*AG\$607)(BA1*0/ $W0K]948T,)<'9!TJEEF0)8#F8\CROLOV- MJ350:PH^;Z@@I39?%F^F/-N0_/D"?,P76R%H<@%T@E<:''DQP)P\D\>4GH.S M&56$I?(&/&^;+F6ZE%Y>50:8?-M(>+RKG;TCG4X1Q$X!// MU5J"NSRAR:&!H8Y4'2[T$JY;Y+4XHXMW ,,+@ (4."8T[:T.)P[U67_UL4/] MSJ_^0#=:/7!-_B 8N,8.+NSA7\4.^/M/+0H^*IK)?SP#A?5 83%0V#'0W4_- MBU)CCU4@1 MUXL*ZN!,T 5ENP+V+D=**Z.]P=].XDG##X<0GH3N"8[J"8Z\$[RGR;;,GR[> M%+'EDE6.+K@4NGUCF6/6R%+FO/@=5R/,#YM84SJ@2:_7QB35A3' M#;Q/VR*X ;A96P3&(W'3$?!PKW%$?JA(J7NU3*2 MDW(-!$N] GKR!I&UC$X+$6A9&N+?!TEEXR#"D\DX;@;9)1:A40,L;K&@*Q]V M'8#^A: W7D(/%BI/VB(H[IB?97AXA.*%[N!-0AN0 6>C"\8%F%/]H??"-\F_>H]OY'P8L)R-XA/#S=(J\M/J[V\6 MIJA-IIT] K)DBHZ2:2,S"UT,3(%D2\%2\$P'7:>#"]\.V+(F/C%K8LN:V,^: M?Q0);!L?AB;%D*1;[*;;78H';U GC9D?D$,)! MU$Q(U#Y0";M28CD8'^'@O@71/D=H[@:\(H?3LV2,_0VT.>,#MSS?2G#S1$3S M //0JN5=?.*S!6R9%!]ATG[QO:O,1 =-11>1AY9:0__AP /=Z44E7U!S2'RL M)0LMC8;PQ*>6E@[#(W38$Z"5F?T HNX 6LH*_91U?)T+]TY@3\Q-H>6FT,]- M#VLB3#^UV0B^TT,N=;_$I-P64#AC.9"%@#N2#C:*)BCJBJ7EFM#/-54L=3/W M*V4=6K((3]RYA99!0G_G-JO7XN62I4P/Z[Q:J:STK&I+*J&?5&P@#YJ%#R\M M]'W?35ADB20Z<8\667*)_#U:O]A.HW;OU=GY1I9N(C_=3'7)T$8$P4W&M][= M163Y)#KQ9C:R=!/Y-[.U#TG91BJN=U7EZ!LS^@58E,X>[+4 <3A;7:JTKW2B M4=!L QQ2<1OSP[WKUHR*57'/K5M=,W9YE5B_K>_2;XH;Y,;[6_A^5MZ(6S/E M!?TG(E9,]YDI76J3P;M83TF4=][E@^*;XE+WD2O%L^+KFI*$"B.@?U]RKEX> MS #U?QY<_P]02P,$% @ E)-]4L1IEX*@! S!$ !D !X;"]W;W)K M&ULM5AK3^,X%/TK5C6K920@B:&%CDJE4F8T2#!; MT1GVPVH_N,EMXR&Q,[9#09H?/]=.FI1=Z@*[E1"-7_=Q?')\G<%2JCN= ACR MD&="GW528XH/0:#C%'*F#V4! D?F4N7,8%,M ETH8(E;E&D#,N.L.! MZYNHX4"6)N,")HKH,L^9>CR'3"[/.E%GU7'#%ZFQ'<%P4+ %3,%\*R8*6T%C M)>$Y",VE( KF9YU1].&<]NT"-^.6PU*O/1.;RDS*.]NX3,XZH8T(,HB--<'P MYQ[&D&76$L;QHS;::7S:A>O/*^N?7/*8S(QI&,OL3YZ8]*QSVB$)S%F9F1NY M_ QU0EUK+Y:9=O_)LIX;=DA<:B/S>C%&D'-1_;*'&HBU!33:L(#6"ZB+NW+D MHKQ@A@T'2BZ)LK/1FGUPJ;K5&!P7=E>F1N$HQW5F> ,9,Y"0"5/FD7Q53&CF M\-*$B82,%/8L +?!:++W"4#C3)X0+LA8"E%#N^0F)28%2C-NB:C+0&H]^3O0LPC&?X],Z:O^999L,8! ;3 MM,$&<9W2>942W9!21,FU%";5Y*-(('EJ($!\&I#H"J1SZK5X ?$A.8KV"0UI M^&UZ0?;>O?>8/6JP/W)FCS>8_8PHF#1F"A!XW&HR+2#FB,P5S_EJ4P0HG?)B MGUQ=C'K>\NR$NS O\$EDZS4Y )W0_%96>WN M'_>@R&BQ4+"P$W$WJT$T>"GN 8FGR)@5W*"QGYLB\X!PW(!P[$ X>BT!R5]7 M.)5<&LCUWQY'W<91UXOVM)Q)E7#AO!7HC<>\J*@ZM[QF^$<*4#%R'?7((CD# M$:H>AN%OGK![3=B]_YTD7Y .4Y8!F2@9 R1ZG["YP?V^ 5,J M85-;;6VS[^TK+T2) U^96L 3-M2+WT*&DR;9D]V2X;1Q=/H*,H!RQYN(P5+A MU4SPN]K*A'X3<]]K:/O&O(4K$P4'ACV0+U(#P([I_SVAX-D5^M74K<980!^!)I93OJ[1BS5C2CD^W1U\99CB^P M>1:WRDAW#;>HNP&X5D:CK3KZ'8M XBK#O:%XW9XB!UAHV+/.'I%;@&QE@Y[N&,A6(JB_:GH!D/VM0 9K M%^PK3 M0=4PLG#7]9DT>/EWCRFP!)2=@.-S*&ULS5A1 M;^(X$/XK%KJ36JEM8H= 65&D MO;GFY7J*B[#Z=[,(D!JTG,VDXII_OQ-TY" MDB[!X58]J7THB3/?S-C?>#XGPZV03VK-F$8O<92HF\Y:Z\T'QU'!FL5478D- M2^#)4LB8:KB5*T=M)*-A!HHCA[ANSXDI3SJC838VDZ.A2'7$$S:32*5Q3.5N MS"*QO>G@SG[@@:_6V@PXH^&&KMB=&[QASLR M,(#,XBMG6U6[1F8J"R&>S,U]>--Q348L8H$V+BC\/+,)BR+C"?+X7CCME#$- ML'Z]]WZ731XFLZ"*343TC8=Z?=.Y[J"0+6D:Z0>Q_<2*"?G&7R BE?U'V]RV M/^B@(%5:Q 48,HAYDO_2EV(A:@#$I!YP>??R> M:"!MOJ:2H5E$$_0/>DR>X0F, MRLI &0-E">J50;TLJ'BTD_QOBT5BD$(XJ1-&&R0!B0X-$ M8EDL0\VVJ8;L\?PKU_W5DK=?YNU;_7Q)XP63C4FA,YX4HTU;;)H[[F6.C6H\ MCSS?-7]#Y[DAHUZ94<^:T3S/8P4\FI*!? 1T;1[0*-JA= ,ZB5$ M_*,51*K&3#QK^&E1-;:Y5"V5=-\)^55W)?;N.M,KZ.L0*4UGQ?K$?-8U? M,?G, ]9ZHB:';P(_ZGR[R9W5Y/5$J]Y-[.\2>R)AB[_I:RJI6C7IOQ/VJ_Y, M[/WYOV_]<8M'KWWK5]V;V+OW:5M_7'@Y_CJ2AW=JGZ/,Y\G/5*YXHE#$EH!S MK_I0=#+_XI??:+')OE MA(;WSNQRS6C(I#& YTLA]/[&?/0JO[N._@502P,$ M% @ E9-]4MD2OM07! 91$ !D !X;"]W;W)K&ULK5A1CYLX$/XK%KJ'K=0-V)# KI)(FZ5WUX>>5ANU?7; 2= "3FV3 MM/_^;& A@'%2-2^)#=]\GF_&S&#F)\K>^)X0 7YF:6=+68:%G+*=S0^,X+@TRE(;.<[,SG"26\MY>>V%+>>T$&F2DQ<&>)%E MF/U:D92>%A:TWB^\)KN]4!?LY?R =V1-Q-?#"Y,SNV&)DXSD/*$Y8&2[L)[@ M8X@<95 BOB7DQ,_&0$G94/JF)I_CA>4HCTA*(J$HL/P[DF>2IHI)^O&C)K6: M-97A^?B=_>]2O!2SP9P\T_1[$HO]P@HL$),M+E+Q2D__DEK05/%%-.7E+SC5 M6,<"4<$%S6ICZ4&6Y-4__ED'XLP SD8,4&V ^@;>B(%;&[C7&GBU@5=&II)2 MQB'$ B_GC)X 4VC)I@9E,$MK*3_)5=[7@LF[B;03RT\_BD3\NE_)T,7@F69R M/W%<9N1N76T%0+=@O<>,W&^&H*<39C'_ .Y"(G"2RM$]^)H?"1<2R>0?2R(U MY(J RYM_ ;N>S&TA_5=>V%'MZZKR%8WX"A'X0G.QY^!3'I.X2V!+X8UZ]*Y^ MA8R,(8DFP(4? 7*0HW'H^6IS^* Q#Z\W#PQJW":7;LGGCO#]5V0;PE2^9(XR MF9VU)M =9J]A]DIF;X1Y179)GB?Y#JQPBO.(@+LDK_/X09?(BFY6TJG2G-O'\_ .82Y"R$,-K./MM/%V:O16[H[?<'4Z=!5.7=_MN:J!:12%0YA) MT:Q1-#,J>FV?I#*GX$5*,^35;WC]&^^8H&$.;KMC@NMVS!#6BV^5!@TL0%/H MZ-/PT(AZ,(I:"QJ]@3@Y)C')XTN*'H:* C_0>P"=MEX[1A_^83A7^^#"XC7+ M^>I.+Y0:")PZ3@\6&IFZ(LZ:#C2*^%8UB$L:X&#E^YGGN].^$!U."ND_FWH< MFHWE!+5RD%&.? /9DD04JL5=TH0NY^4B)#1"NB+:Y@'=&U;-FJQ?-@.O+T:# MT]5-#%+*"RG!)#G8-MLX'F;C.H M=!^!:4UP5_ 8'&35+:.K#VZUHM\)[@0&_=AJ80.1 MP4"!=G=I85[05ZJ%C?:YMM5"BA/N1LJY)FY'.X) MC@E3 'E_2ZEXGZ@%FB\KR_\!4$L#!!0 ( )63?5*!K=P?2 0 (X0 9 M >&PO=V]R:W-H965T-G H1.ELNS+T;OERPK2P)Q3<%JY;11P"OD\]5SL8BZ\$[T3O&F@J#XQ] MTXOK_'SF:D2XQ)G4(9#Z><17N"QU)(7C[R;HK'VG=NQ?/T?_U9!79!Z0P%>L M_(/DLCB?S6<@QRNT+>4MVWW #:%0Q\M8*X^ -'8(##G[CX+_4(6@< I.9FHK)0XHD6BXXVP&NK54T?6&2 M:;P5?4+UOM])KIX2Y2>7%UFVK;8EDC@'GV6!.;ABE:J@0F_M(P9O/S(AWH%K MFK%*K5(L$2G5C5-P?Y>"MV_>@3> 4/"E8%N!:"X6CE2H=&PG:Q!>QO@L7."]S$']BE M%CL_C-PP:>WVN(0MEW"2RRVN.6@V*E]L1S$7!=F #>89IE(-/1N[.FC40^/: M<40MCF@2ARKZ(PF-1J],(NC'WB"?8S-KWE.+W2#O>SSBED<\R>.:2LRQD("K M2@69ZFBN9CKX#Z18D#4UY8L$^(#SM>9[387D6R4@.2_*N@;/2%D4]#HSW\^.M MB='/_VGL!OZ@&RUF03@?]&QJL?*"V#^PF9UB0'^2R&=+7=4%=0(>L/I8Q*HF MLQ()058D0[I([<+MC[D&;@2'H]QF!]TX](=TQW:>'\4'Z':J!*=EZ:)B6RI% MCY.JIA5GU<\W6_/F/N(X29(A_['5?#B?4XO1J1?.#Y#O9 Q.Z]AQ_8!CS3KU MDR@>E:S%;ES9J<5LK[+W>70R"*=U\&638*K/.Z6"\:L/G4ZZX/Q_&#KSEPV= ML9EMZ(RM)H9.)WQP6OE^\(,*CO7L%(9V,%XG9]ZTG!WOBB9 >*PK;':6KK"8 M6;K"Z1W4*LS7YL KU%!2\ZL^W[1WVT/UA3E*#NY?JL-V?33NPM0G]4^(K[5^ MEWBE0KIGL8+$Z\-OO9!L8XZ##TRJPZ6Y+##*,=<&ZOF*,?F\T"]H_P6Q_ Y0 M2P,$% @ E9-]4EM>@"]/ P ?@L !D !X;"]W;W)K&ULM59M;]HP$/XKIV@?6FEKWBE4@%2@U2IU%5K7[<.T#R8QQ%IB M,]LIZ[_?V:1I"B%#T_J%^.6>N^=>.-]P(^1/E5&JX7>15XLQ2R(!JW33A.9B,W)\Y_G@,UMEVARXX^&:K.@]U0_KN<2=6VM)64&Y8H*#I,N1<^E? M7/NA 5B)KXQN5&,-QI6%$#_-YB8=.9YA1'.::*."X.>13FF>&TW(XU>EU*EM M&F!S_:S]VCJ/SBR(HE.1?V.ISD9.WX&4+DF9Z\]B\Y%6#L5&7R)R97]A4\EZ M#B2ETJ*HP,B@8'S[);^K0#0 ?G0 $%2 X%A 6 '"8P%1!8B.!<05(#X6T*L M/1O[;;!LI&=$D_%0B@U((XW:S,*FRZ(QP(R;RKK7$F\9XO3X3O /4\&U%#E> MK>"&:RJIT@I.[HB4Q.3]%$YF5!.6JU/X _W,SAY=PKOP 65$10&QN&!,ZW> MXR&NOV2B5(2G:NAJI&@,N4E%9[*E$QRD\W@&7O0> B_P6N#3;OB,)F<0^@?A MLZ/A_J %?G4\O-\"OS["]]"S\.@UW,6LUJD-ZM0&5E]X.+5)2V;A^RT*PHVF MA?K182:LS8363'3 S"TKF*8IK(G4G$HH327 "=;!MCI.V]*X5=FS*DWS>QP/ M,%^/S51UBKQB&M5,HTZF,Z:T9(O2M#0%6@#'XF^&B#V'*!-Y2F5;_4ZW)N(& M+4S7#O5]F3#JO9:YVI>)!D&[?W'M7]SIWZ1\PK<#Q/*?'(OW",7]<,>Q?9F= MK%UU2;QRJE<[U>MTRC26I[E #V"*=RR!N9!Z*7(F.HKWO-9^_I;_D7YMIO]V MF9GT]V+:\PY$=5 3&G02NMNA4;?]#F=][^5-\=XRJG[C\?+_>^^YKG0V.TOD MQ0.OWQY2_Z7?^L%?2Q4?0Z5*I(3M95W*),.I!Q8ERU.,1"N;8"^[ON:<>N<=_ M %!+ P04 " "5DWU26QQ=\_D# #^#P &0 'AL+W=O.=X]TTR,7WV1(J8+O<93(F1$J MM?]@FM(/:4SD@.]IHD^V7,1$Z:W8F7(O* DRI3@RL66-S)BPQ)A/LVU^)?3.+*T$+*:) M9#P!0;#A3R"1^9_0H:VM(0]EP_BW=7 4SPTH1T8CZ*C5!]-\=7=(H M2BUI'/\61HW29ZI87S]8_S4+7@>S(9(N>?0'"U0X,UP# KHEATC=\.-OM AH MF-KS>22S7S@6LI8!_D$J'A?*&D',DOR??"\245- HPX%7"C@O8?;M0<7;][!&V )? WY M09(DD%-3::"I.],O0%WFH' '*(3A6GL+)7Q, AJ<&C!UA&68^"',2]QKT:/^ M &ST"V +6RV ED]61Y,6=>_IZFY/-'9Y:79FS^Z^-+_E-N"O3UH0KA2-Y=\] M;IS2C9.Y<3K]:%.$-Y1$\%$JHB@LI*2ZC->'S3^:8T#Q M$_Q"D&1'TW5;$+FG40T?1I8[<=RS.%KDK*$]G*#V4$9E**/>4#PFE6";0\J, MK>TS:O&+SK U96QG="KCC9J7-<'MV,61/E_\"?_#<^X,U=XPZ#5O#>'*$7YYOBILUGO 'G?T+ZH(&MF/ M=D']A?GEF% A0[:'%16^1J2_J5K1])O% VR][VHG]M?DBU1D\X1'D^L MLXXHQ.KECAR,.V@?5;R/^HG_T79%39IN8'M4Q&L1J;W73K%71(_ZF?XV8>I^ MQ9E.\E*?,;_6FL_LRXJHT?A5^[)B;>2^0E^ZC:+JJI2*UU$_L3^[*_O-6@.K MMRMQQ=VXG[M?LBL+5^T)+#YZK69)NT['&PA7A(_1SS5DH=\+[5$1KUSYI1YN\U&T,I-/QM=$[%@B(:);;=(: MC#4>D0^;^4;Q?39^;;C2PURV#/6 3D4JH,^WG*N'3>J@'/GG/P!02P,$% M @ E9-]4N@U7(N!!@ KA\ !D !X;"]W;W)K&ULS5EM3]LZ%/XK5K4/0V(D=MX1( &%T:X4!./>#],^A,:EN4OBWMAM-^G^ M^&LG:=*XKAN8-+$/(W&?Y]CGQ><@\QV%4D-+$0*;I&FD89[VSDV+L/C\[(0N6Q!F^ MSP%=I&F8_[K "5F=]F!O/? 0O\R8&##.3N;A"W[$[&E^G_,WHY82Q2G.:$PR MD./I:>\<'M\A3Q *Q%\Q7M&-9R!4>2;DAW@91*<]4ZP()WC"A(B0_UGB2YPD M0A)?Q[^5T%X]IR!N/J^E7Q?*0XHO2?)W'+'9:<_O@0A/PT7"'LCJ!E<* M.4+>A"2T^!^L*JS9 Y,%922MR'P%:9R5?\.?E2$V")ZW@X J I((T-Y!L"J" MU95@5P2[*\&I"$Y7@EL1W*X$KR)X70E^1?"[$H**$,@$=Y?CS+7G3)EB[:+4 MSI:]O7-9<.UNN.7OG;.L'0X[>QRN70ZW?+YSEK73RX WRH@OMDL_9.'924Y6 M(!=X+D\\%'NNX/-=$F;.^E]/7VXR+3T*SW]-LRUB[_NK#L,%/3/G757TF\ZZZZD#SKK MKJ0/?\_OH]\SW;@[W==$L57O::N09^V0=Q7F69R];.[I;^?/E.6\%G_7R+=K M^78AW];DC$3DC)"Q/'Y>L/ YP8 1P//5Y,>,)!'.5>E@6(IU"K&B;UF>??)\ MSX2ZJ82WEG%HY1ZO<14CC"> )#41QLF X JNB MQ> /X1+GO&5:)T+>;%'&@=S4X"//A.7P@2H/EE.Z&TL-;!]!U[':.EVJ@%[@ MPL!L _LJ($="QVT#KY1 QW>1)/%:!70"Y'A!&_A9*1$&3B#Y\48%Y ZR K\- M'"B C@VY*R5EABJ)0IXEV?&+WL??X'?5)E_=*Z:TH=^LH=U\9Y=EZ4\]YTJ!E(\"#>D&C9D09V^5$WN8V-(\0D@);B8)2 MQ/35LFPII-4H*5:NE2A'FO&S$B5%TXT29$H3#M0H1PIA) M)B'EK>L@FR2+(G-_79%R$-QB-B,1^#;B:P T M+1G45\0_%0#NEL-XKVTB1PZ ;KCQ?ES;'DUIAU[WS*FS<%.*H?]>HZ ID%!? M(?]4%&S7.LL-3-.3HZ ;;KP?U_X@U]1/I*^?;ZH,J"D\"+[3D$!-]4+H]280 MGUKVM1.5W%:NYUV<)S5[URJ6-%3@+(63O^(2#FEJ*]M32 M%',[A1EXP&'"N._">4+ MV>\UL)JJB/3?$M[4C:/M#QFVZ03R1YWKCKAA1]RH(VZ\']>VEJC/[9&F0B%] MA5(?EB_VL!XPRTEY+9K\ F'TSZ+8W%.2 S;# $^G>,+=P-.Z>'TL-GH_7L81 MSB+N'8HQ&!.& 00'1ZHP,#9N@_@^>"DN7RDO&8N,E>?6>K2^X#TOKKFD\0MX M/("*\2$\OE..H^,O*CDC='RK&A^CXSO5^#ER^0^N:D7(6]]%&XUJY4WV;9B_ MQ!D%"9YR-&PO=V]R:W-H965T MAC21.$EOJ*U$*3 F0!5E[&&:)CP4(4ET1VDC,LH6:!/MX1SH@OD"'T:@R01%4=]6RIC&F(' M.?$H(W8KB+&+;E@BEP*=)R&$^P2V4EE(=3=21VXMXQB"8^3AS\AU7"?EZFWD M\D5D^DOTG35FP[UJEG%SEFXUR_D_> 9)L(IGP"'\M7&RA/&BGO'KBAXCYR!6 M)327]32G*=_0X%XYS5XJO:+J/,/K-:ZZJR1KJ[H]_;A6U]&5A%C\K#'F%\9\ M8\RO,'9KPHG87+5.;8[,** \5P+]0=5I&V7$;4.LF_K3T.O;3[M%]N:-<=V- M/7]:A3^MQOX0BD!((@'EV8E E#G2>B4"]PZ$GI?'6ZK@F4T)5"[B'A!R^]ON4VW:&_T,_P]N& MAIMWM*;UB5_W(7^_ 5S47LFDVCN31@Q\889(@0*V2F3V)2].BT'UU(QG!^="V2 $G3 MBQ/W@J;;'H8],#)M"Y5$3Z*3=K]^I*Q(-GG$&BVVE\16OD.>3^?R'4HY>Y3U MEV8MA$)?RZ)JSB=KI38OIM,F6XN2-\_E1E3Z+TM9EUSIK_5JVFQJP1>M45E, M*<;1M.1Y-;DX:Z]]K"_.Y%85>24^UJC9EB6OOUV)0CZ>3\CDZ<*G?+56YL+T MXFS#5^).J-\V'VO];=JOLLA+436YK% MEN>32_)BS@)CT")^S\5CL_<9&2KW M4GXQ7V:+\PDV'HE"9,HLP?6O!_%2%(592?OQ=[?HI-_3&.Y_?EK]=4M>D[GG MC7@IBS_RA5J?3Y()6H@EWQ;JDWQ\*SI"H5DODT73_D2/'19/4+9ME"P[8^U! MF5>[W_QK=R/V#/0ZL 'M#*AM$(P8L,Z '6L0= ;!L09A9Q >:Q!U!M&Q!G%G M$!]KD'0&R;$&:6>0V@;16.#P4^3PL7N0/MA.M$=-GL)-VGA/=XG59N4U5_SB MK):/J#9XO9[YT*9V:Z^3,:],%=ZI6O\UUW;JXDZL=$TI]$EL9*WR:H5./HE, M5EE>Y+RM$[E$3Z!+4S*Y^O8,G5P+Q?.B>89.T6]WU^CDEV?H%Y17Z/-:;AM> M+9JSJ=+NF4VF6>?*UE4MQ *PO_';$^I98*KO2W]SZ-/- MN:+>%:]%]APQ\BNBF&+ H9=^\SNQT>9XU/S:;WZSK;SFK_SF[WCM=?[UT=Q) M"IB_.9H[:/[V:.Z@^>QH[J#YS<_%_?;G;MW\>//$D\6L+W'6KL>.+O%9M9-O M4]Y_SC4I>*'E^4%46P$V@9U]V-J;&>'A(L5) MK(D^[%<6@ H3%AZBK@%4$$7!(>J5BR(84WNQU]!B090>HMY C@4!/D2]!5 1 M3>)#U,Q%)4E,K%MQXZ)80B)"#V&W "P.4F+=C#D BVB HQYV$/:P#WOH#?O' M6L^%M?J&S"_>)ID6 63&0"4J7F4"JL+=FM&>+S1@86#=@%L Q@*26/&; S"* MTS2&F44]L\C+[/V'&>1ZY&Q&6(+MU+L%8 &.J954MR['GM=GY4; MGM=M[6=K7J_ >KR)G;U/6:03WV("P,(PM *2ZE=-R L<.H&A.&8P,32GECJ)7:9_;W-FWQW M(-$%HVI>-7QW0.DH0M12UQD2,XL8 -*E;M&"0)C"I @>ADKLI?5&5#I@14N) M+_3@FC?*!/ !; /=8H?WEH2Q'2D0AT-F-=\YA",QC4>2D.S-RL1+ZUKHDV[6 MS<4MM](HZC_M!9 9<3U)B';99@;CF!TM$,!+92 9C8)N-"*!LA,@P.Q#\YS'7.F92K9'6Z$$V^ MJMJ^OA!U_M!V##C;7+$_)=AI& J2FQ6T%+AR-1 AK&!^.>&61L-I/A7;[ZY MRG^JAS%B$P%@+'62#4"1L?F'#%,$\8\1[X5")[OD>H9,BT!BJ@V,&C FQ/K0Y>0K@D@3;!Y\YA MI'(WH&!T&#^H?/-Z)19YI MS?JP7.:90%?;O%CHC&Q\#X,&^:?DOS](TT&3J5^3OWN4OJ&N3A(<4&(7$XC# M++8;"(!+4X)'>CP=E)?ZE??'3H?4U4Z&D]#..0A&$OL>S,'5:#HR$])!B*E? MB$?.AQ204^:,W[< +$K"*+*=AV"ZKD:<'\27^L7W*-[W%I/ M?&J=\5J@)3%>@R#2Z'^HGD&UJ%^UCJ@>5SU(&!$GOP!8$-HG_3D( M2\>F5CJH$?6KT0_6CBLB)'7&"@!%&;&G<6BM@ 8CQ 9-HM_1I)'"<:6!L"BT M#Q(0C-+0B0JT6AB,S ALT!GFUYD[4>6R;M!;N6U,2%YJ'=U6WRL6-D@-^Q^D MA@U2PWY6:I@K#30B<6+/.! N3-/82KTYA L2QD:TANT][/XOM(:YZD )CIG] M% S"88R=QRH CB0IC4*;>5VKV>Z*_V+^POV]>6UO4K\F)&@.LWY,5\]SI^6'[WWP'O M>+W*JT:KUE)OA9_'VM=Z]\)]]T7)3?O2\UXJ)&PO=V]R:W-H M965T2A+*GX+_UBF=M>+>($RR.FA4!M^_ *M M0X&QE_)"UK_HV,JZ"Y0>I.)EJZP)2E8U__1W&X@3!>Q/*)!6@;Q5P6L5O+F<:6.PYHJNEH*?D3"2&MK9E 'L];6[K/*Y/U!"?V5:3VU>H"MSJ)" M&]ASH5BU16<;2'F5LH+1.C,\1R]"-R9)3/U!BJ,;*4')S^AL#8JR0H\NT(^' M-3K[]!E]0JQ"CSM^D+3*Y-)1&M1,YZ0MU&T#12:@UI!>(@^?(^(2UZ)^]V9U MG%C4UV]7CU^K.SJZ78A)%V)2V_,F[&V %@BDH@IT7)[UR 13GB.J4,JENIJ9 MP^OF\.HY_(DYOO9V3>Q%/^4YJD#94M 8#&J#ICH\KPAVX\37+C^?QMHBYP9> MD.!.[A6QWQ'[L\1W5.Z07AXH-0/X=6#/M##\-M;&5'C"$!$OB :D8ZDD"$\X MF^3[(W^BB(2^W9N@\R:8]6:C@RU8JJ#QQ^9#,*+#41(G Q\L4D'BQG:ZL*,+ M9^F:O8IV4&1(MPHD=:1MB.$X@.Z ;RP2N;&7V/FBCB^:Y5N#T-DW#0#1&K7> M&SEE NE%<;"R1N- >0/6L8B7$#MIW)'&LZ1Z3$TGN3 ?]#;315% "IK^J9C> M:O$(A'@>(0-YQ<'^1)L&W%BB6Z" MA\06*=\+)@H#=ON6Y,XRWPO84Y8A^*U/-Q)D72:XVH&8(6YMOLJVGWA#9)M8 M$KG1!/-)&\5_6<(Y"&&VOZ[H[V]O3&D1\T)_8BW@OA-A,DOYR)5N M##-!).,U2.(P3H(AH$70(X'G>A.(?2/#\YWL&V0LU9#?\YRE@&X/K,CT\I4S M31+W/0?[']:*<=\+\'PS>$>'^%AW"UR"?:CJ?7;=P@\WR(>!=L7 M<*'QFD*1Z6Y!"[5+J0!=B+]7OR8*M4,<^&1XT M;')!&(93E:\OUGB^6C] Q;B0Z(L^.IN:??D1F3NK]^HV+)*ZK6=:T7W,M(61',E M;!X4W]>7I">N])6K'NH-D($P OI[SKEZ>3#WKNYBOOH?4$L#!!0 ( )63 M?5*#DAJ]0@, ,$* 9 >&PO=V]R:W-H965TF_7Y*2 M%461O3FD>[%%:MZ;>?,D:A8'(7^H D"CQY)QM?0*K:L/OJ_2 DJBKD0%W-S) MA2R)-DNY]U4E@60.5#(_#(*)7Q+*O=7"[=W*U4+4FE$.MQ*INBR)_+D&)@Y+ M#WO'C3NZ+[3=\%>+BNQA!_I[=2O-RN]8,EH"5U1P)"%?>A_QARV.+,!%_$'A MH'K7R$JY%^*'75QG2R^P%0%L*8OX>8 .,6293QS\MJ=?EM,#^]9']=R?> MB+DG"C:"_4DS72R]F8IP>G5#O;&18WNH!)24[Y'%W>0"IY21HES1N1H0RJJ M"4.?'LWCEE%=2U#H_B=JP9?H8@N:4*8NT7OTM0))'%-[6YG-[[LMNGAWB=XA MRM&W0M2*\$PM?&TDV$+\M"UWW90;GB@7A^A&<%TH](EGD#TG\(WVK@'AL0'K M\"SC%M(K%.'?4!B$P4A!FU?#\7P$OGT]?'9&3=39&3F^Z-5V7O/F<+!6_O7% MA*-K#:7Z^TRRN$L6NV3QB63'QP)ZC\68I0U+XECL.?2P"G$TCQ?^0[_/+Z/P M9&I[VH_:CD2%37 M&S+MDDW?Q)"&9=)K8IS,DH$?+X.2*!C:\3)HFLS"<3=FG8K9617?)*T8O.?F MH\? '.D9*H P7:1$ LJ)/9DT'0I[EFG>99K_>G-P\'34!F]B3TO3[VHTGTX& M_HQ*V(T$8)R<,PKV/!CZK9 ><"JG09W.0V[9M1%G6_+]LP>$3?_@_&/-T M:.+H;8R)1DZ?610-G1D)PP&.A]Z\#(MQS^9&C-_[MI<@]VY&4B@5-=?-5Z[; M[>:PCV[Z&.RO[7SF9H8GFF:XNR%R3[DR;UMN*(.KJ2E)-O-2L]"B2<4)L!\_DE;D+TEQ'OIBB](] MAX?GZEY2PXV0/]0*0*-G5G U\E9:KS_YOLI7P(CJB35P\V0A)"/:#.725VL) M9.Y K/##($A\1BCWQD-W[UZ.AZ+4!>5P+Y$J&2/RY1H*L1EYV'N]\4"7*VUO M^./AFBSA$?2W];TT([]FF5,&7%'!D83%R/L5?[K!B06XB+\H;-3>-;)+F0GQ MPPX^ST=>8!5! ;FV%,3\/<$$BL(R&1W_5J1>/:<%[E^_LO_F%F\6,R,*)J+X M3N=Z-?)2#\UA0*BU8!38*&.7;?_)< M&;$'P%D+(*P X1$@3%H 406(C@&X!="O /US 7$%<$OWMVMWQDV))N.A%!LD M;;1ALQ?.?8YRBBP^7;533LZEP5E$UL-RNQOZ^-;'HLP:F_NF8*:IGBMQ,_9:9 MOI9L!A*)!3)=R":=+Y%S%.7FG9"FHA7Z#[5Y?+TE3QRY[4Y/8XR'_M-^1D]# MTCKB0'*_EMP_4_*"(?@2?]$3=*L)J[5Q)UJ_CBR3=H>]5$L/I9F0$P: M=5.M3+:D\;YQ48;#0^^F#5']*,;-BI-:M('-[M /AG;P%XMP?@[DW@ 3AL2-%: M86_ \6N)9>>7&-YU>]S=[N_(\UNF[GHUCG^VJ;LNB[O;[)NF=L/3I#(UK4T- M6TWU]XZ"]J1_1^22Y,A\<(&V M>;X00K\.[(&S_H09_P]02P,$% @ E9-]4I3@VWY\ P _PP !D !X M;"]W;W)K&ULM9=A;Z,X$(;_BH7V0U>Z+8PA!*HD MTFVBZD[:U57M[MUG-YDDU@+.V:;9_?=K&PJY8M(J=_RJ-0\V&M]N E#M=YCR=2U.&!ESFR%+)DV4[D+U4$BVSA1680TBM*P M9+P*%C-W[$XN9J+6!:_P3A)5ER63/SYB(8[S (+G _=\M]?V0+B8'=@.'U!_ M/=Q),PN[*!M>8J6XJ(C$[3SX%6Z6U G<%7]R/*J3,;%+>13BFYW\OID'D=IA:?CY^BW;O%F,8],X5(4?_&-WL^#+" ; MW+*ZT/?B^!NV"YK8>&M1*/=+CNVU44#6M=*B;,4F@Y)7S3_[WA;B1 #)B("V M OI60=P*8K?0)C.WK!73;#&3XDBDO=I$LP-7&Z$5^;(7M3+!U2S4)F5K'*[;]#XVZ=&1 M]%:XOB8Q_$)H1"./?/EF.>3_E(>F4%VU:%LXI]5A./5>*W2CNK]#6KQ&>5>JQ2O]6TLYJ^9C7Q64V'5CGXK;+.*CMK M]66/ALI;C=)GF T,:9;FD=\R[RSS\Y;"]G/9MG=A'W!R:+O;ET0^2"*F43Y2 M8HAZ($5GT_B$2MT05HK:,DFB>3LI=% R+#'U0*6]'(D&Z7R@-$]&[@.< !+. MYM/W?%.2@K-'7G#-7[9_FP<,\LAA,NFR:+$%@_;.(1[I;^CQ!.?YM.+2O![) M+:^8 ?A;, 4]I^ R4+6RTP6/M33TI(++4 5#5HTU-?2L@LM@!4-:9=F(64\K MN Q7,.356$-#SRNX#%@P)%8^]O#UQ()_@RP8,FN:1-,1TYY9\-]""X;4FF;) MR%VE/;3H_P(MZH%6',$(LVC/+'J>64U5VB3($RMJMX-[>YGHD$])%D]?4,Q[ M5?3RJ0U/=J?VT^ SDSM>*9/%ULBBZZG1RV:WW4RT.+@-ZZ/09OOKAGOSA8+2 M7F#.;X70SQ.[!^Z^>18_ 5!+ P04 " "5DWU2K .)\*@% @%P &0 M 'AL+W=OW:ME<[6 M//\JEHQ)]#U-,G$^6$JY.C4,$2Y92L4)7[%,_;+@>4JE>LV?#;'*&8TJ4IH8 MQ#1=(Z5Q-AB>56,?\^$9+V029^QCCD21IC3_,6()7Y\/\& SCM1+%*2*J_]&ZP9H#%!9"\K0AJQFD<5;_ MI=^;0&P1/&\/@30$HA%49&""U1"L0PEV0[ /)3@-P3F4X#8$]U""UQ"\0PE^ M0_ /)00-(= )[C[AS(URIDZQ]E%:L76U]TX+;^3&.WKO];(1'!^L.-Y(CGXI6]\J&JN8JOJB3.RL_#@\S5K['BR>%? M!!MDS#0O=\DPN!;K*(A8! M_%D_'Y,> X:*21L8L@G,B/1:'+/P!%GX+2(F,8$)7?;3']A*TO#:0?KLSW2_^;/0S0^G^SU9 M;+7E;57VK)^6]R3.:!;&-$'3K.XJRMUY'(LPX:+(&?I\\21DKK;K+SU^[=:O M7?FU]_C]Q*7RE+,7EA4,_![4?*?BESW,RS P?4^M^66[R "4XUM.%S4&4+;K MVEW4U2X*FR;1C4T@8[8;=%'OH8G9MME%70,HE_A>%S7=1?F^A[50S'91EH]= M3+JP&P#FV0'6@C$'8"ZQ3;>%=61W6MF=7MGGJI]5Z200E3*/GPI)GQ*&)$=J M)PN_+GD2L1S,!F=G.N^(Z1%72P< ADW'U,(^AJP1'V,M(2"8[=E:J"8 S/:Q M96D9 5E3":TESC4 6D!'';=5Q^U59T1%'"*U0:,H3@JUP:-U MU3VK!_K"[=#OEXA/L.EI\+B&@%[@X MT-6#@ J)'2T;KD"@X[M$LSB!@$Y '$^O:M B#IQ 2YUK"$@\UPJTJIT"0,?& MGJNG]@RR6-K3\^Q#O\:?\1=HTP(79EFN_L6Z_1WK<\"ZY026A[7XWOVB]4Z6 M>VV6>[^8Y=GFJ[1B>9W*55(7(GH= 7.[=N1M5Z%Y0K0O[B6(TC\V8]B6OD?! M*"U7)B#*T3R^!U%:-EV#(%-S.(51VLXY U&^GK_]ZNW)7]!TH)F^_1W3CS$;0^ M@MZ93M,5C?.491*%J@J>P59M%@"]@FJ)M,9C%^4X@=XWS7=1Q'0=!][8L/EZ MBC5[%W(A!%-GUR5+(J2Z6U7;K"<\>.MTC/\W$3!Y]4+^7(918Z2K@][[3""4 M9>FP&0##KN_IHL+6])YY#L!4,VGN4;4\O'1'7H\5N/]< =?PZ">L>R9S7E]$ MJI,0C?XM1+DOE(DBEPRQQ8*%*GOXHGI]*'M5=3)ZB2.610(="<;0G$N&,#H^ M@00WMNY?4J;T*Z\[!0IYD04+C9/3#Y"= M&W)Z"XW/R>D=-'Z!+>7 F=D;VY_C=>EU7?'ZJ3]'&<")6RAEFF>>$K_O+Z. MK5\D7U4W3T]<2IY6CTM&U1F@!*C?%UQ%M7DI';27XL/_ %!+ P04 " "5 MDWU2=(%_@M4# #N$ &0 'AL+W=O!Y#I-B?AU 0G? MCCWLO5SX2A=+92[XD]&*+. )U+?5H]!G?L$2TQ28I)PA ?.Q=XX_WH6! 606 M?U/8RIUC9$*9L:8"[QR_L M5UGP.I@9D7#)DW]HK)9C;^"A&.9DG:BO?'L--J"NX8MX(K-?M+6V@8>BM50\ MM6#M04I9_D]^VD3L ,(Z0&@!X3X@K &T+:#==(6.!73V ;@&T+6 ;E.7>A;0 MVP<,:@!]"^@W76%@ 8.F@*$%#)L"YR)<):Y:Y):R%@LX'% 8AEDLBH(KD MTDWRP#>:),Q(@I70LB+4KPJ:J9OFKTAI&IS3U/KRR4UR3T0+X6$>T+>G*3H] M.:M@N7*S3"%JH38^&-'G=]#41G;=(#)+AAT^W;AISE>&)C@8VFWCT/#007/7 M.*@Z&E]/3C$^83$^8<;;;C@^Z/L7;8%N%*3R7P=_N^!O9_R=.G[%HV<4TPV- M@<5Z./44YH4]0[]1;8FG.:O1%TUKMM7-)&@%N-T9COS-;F-5&X9]W"L,7SG> M*1SO.!T_EQ*TF"PAB9'>^)$D"3CRT2UHNT?)=Z_@[SG=?EBG,Q"(SY%M$@K. M(/(ASSE[.SG$>"_/3I-7KO8+5_ONU@!&N9#HFJ\E90MTR=-TS6CF\6_TQOP/ MBD4'1\G_L. ?_O_YOQD>S/]=A4EU^G%0[IS!'Q3@GD9+NB#L[;7 .WLW/DHU M<"EO.#S"/%C2W6QW]N;AL,EMA0GNU!2MU%/L%M3*@&(J5UQ"7/E(TC[87%=N MF]>>E@**W0JZ7UQ7/4OYQ,?13UP**'8KZ#MWK M+Z]RR7KM4"B5V*^6CX!& M]F4N>(H6? ."I29X(B65BK (M&LGE0^!.3-N[WC5;=75ME11/'A3;?7R1U.3 M4GKQ\"B]$9:*&;H5\UUJ0$R7P+TX]Z",HD2F&M,T.KKJ1#Y MRW5^HO@J>R>:<:7?L;+#)9 8A#'0]^>&UL MU=UKD]M&FJ[KO\+P6C%K5H3<9AZ1F.GI"*E\D*>EMD)RVS.S8W^ JB 50ZRB M!F1)KH[]XS=0)SXEOB\>))W3'?C2++WR[6 ME]M_^^I\M_OX+]]\LST];R^:[1\V']O+_K^\VW07S:[_;??^F^W'KFW.;G[H M8OV-72[C-Q?-ZO*K/_WQYL]>=7_ZX^9JMUY=MJ^ZQ?;JXJ+IKI^UZ\WG?_O* M?'7_!Z]7[\]WPQ]\\Z<_?FS>MV_:W5\_ONKZWWWS\+>\W6P^#+_Y\>S?OEH.V]2NV]/=\)^[O_:KAV<=?A!_??^W?W_SS^__.6^;;7NR6?^Z.MN= M_]M7Z:O%6?NNN5KO7F\^/V_O_DEA^/M.-^OMS?\N/M\]=OG5XO1JN]MW__:;%^[;9M?\Z8_=YO.B&Q[=_VW#+VY>_9N?[E^OU>7P5GFSZ_K_NNI_ M;O>GUVVS7GRWW36[=M%GIY>75RM^]^>+;YM^W??Z:JYV:-?+][T;].S MJW6[^/'''Q?__.;VO;78O%O@W_&JZ]_%W6[5;O_OXI^_;7?-:MW_ZNO%7]]\ MN_CG__U_%_][L;I<_'R^N=KVS[;]XS>[_M\P;,DWIW?;^^QV>ZVRO<8N7FXN M=^?;Q7>79^W9X[_@F_X?__ *V/M7X)D=_1N_;4__L'#FR<(N[5+8H)/)/VYJ MX<>_G?[C2?CQ[Z;_>#7R8KB'MX.[^?N<\O>]^>[D83\_61C[M4U/'NW?D\W% MQ^:RW[U/%C]>?FJWNSX;NV&?3GXC_3\O^N=<_+AK+[;_[\@6^XKR_?_]+_ZO^I?AU?WQXN/W>93.[SX MXK\Z'F['LDXN&GE#JH<-J48WY&2SW6T7I\W'U:Y9K_[6[]KMU=MM^]]7PYM@ MM^FS_]]7J^UJV,]/%FOE-:H.MNUK$Y:UO&7I8_=Z;F_>J2OR6J:# M[74^ULH;J'[8WGIT>W_H-MOMXNG%YNIR)SUI?;@#G0_5,CT\[6V/^Y;Z7%UC+9Z_+COI,?9VE5>_N>:Y?Y[9CGZ#]9Z('X%+ ]?E'OAC-_EO#Q)E\F9O]%XP9 M_X;YZ[9]=[5>K%?O6G$'C?^T7RZNVZ;;CFW*_AO%C'^EO!C_HGW\M^Z[;^J9 M[!2[;[<=;S?9*>2G3: [Q>Y+:L=+^OWJMUW_$6;?W(__]GTFK9W+SMF'U8Z' ME>V<\9^>L&_V=;7C=?V^WR_MY>IJNWC9GJU.^Q?DI.G:_N3OU]7ENU6[/GNR M>/IB[)GVF;1A+OMI7V,[?A#/3E3N?AR_4Y3O.[NOJ1WOH7::8@^/P4VPRK/M M@VG'@YE_FF(/CZU-B$G9D'UC[?C!=9'3%'MX"*[L#[6W:2X@X/5TUEM:?=5]B-'ZSFG"JXPP-6%YRR!7 5A!RLGK67S>)Y MWXK=^>*D?\G;KL_8OS>G'[;#GOGI^=BEEGTOG9])Q=R^O&[\ )55S!U> ='> M#_MRNO%R:A5SPE4.KU3,[9OIQIN97S%W6%/O:^5TM JY@X+J^V/ M?5Y=P;QF5FQR=/T^NGX\NJQB_K",7\8TE0I%?/[COKQ MCOYTU9R>]_MHZ,C%U>5J=[UXOMG>[+7AH*SOR7 MO=OT\7GQ=.Q2[+Z;?C:7 MC^'Z\>^\@.PGOR7W%?7'73[VA_6,3GL?[/OI2U\^]H=E#6ZI%,WOT^K_#I>/ M_6%MM?VQ3ZW_AUT]]I,#[/-1'4XH7[;=ZFS5#+#E5>0N&?37#>#75&V"'M:PK[68;W&V;=EET>L'"84E3K5U #ON4AO&4 M%BE8.*RKMF'[M(:":,)Y>4@*>XC&L8C[ MLL;QLA8)6IQ\TA]AR$/!TN8%+4[N;]SW-X[WE^4L'D8T+;5+KG%?T3A>T9R< M1>%B:]2NUL5]4>-X4=]<=>_;[OJ^8IMWBY_;BX_KX;K_[2^>+'[^CY$R5/MP M5LN9U*S:%[@:/V!E-:L.S_R5/5+M"UJ-%U1+627RZK"\WBE5J?;MK<;;RV)6"9<' M4M3>23"X;+RA.3&K#GM:U]H_?)_3BAV4MNWEI]6ZK]?=Q?\WU]L^!GW+]O_I MR>+-R5@;]N6LYC(4(.T;G,8/7EG/TN3;4&G?T#3>4*UGZ;"=ZMVGM*]G&J]G M?L^2< ]JZ96/0]J'-8V'M4C/TN1S_[0/;2H8VLRQEI/SF_;Y3>/Y935+APUU ME5:SM(]H&H]H3LV2$-2HC8C=]S2-]_3-;G/ZX6VW.GO?+KYO+E;KZX=3SJ\7 M\!^?+'X8N_R?8 QNFDO0]A%.XX>O-&B'%P%,E93+'_6^H_5X1[6FU8?]3%8Y MN:WW!:W'"YK?M%JZM5\K;\EZ']=Z/*Y%FE8?]E:)1+V/;5TPMGE-JX71K$Y[ M ^TC7(]'F X@/RRIK;21$?4^IO5X3'.J5DMAU=Y"^Z[6I*M=_R/G;7/V$+-7 MZ^9OS>+''X>CM'5[>=8,]7GZ7R-YJ/<-K:N9)*W>9[@>/XIE2:L/+P14P6L? M(1 -XR55DS;YGKY9(B<8#VA^TN[_QL?W)H)RWFF6,+I_2>Y*E:C:_9-,>IU@ MX/^R8''SPG;_U(_'Z4?EFJ19@A58CM>8Q>W^YQ_?DXC:Q0RS!"&P'.]JGE,1 M(NOU=Q0P@.5X9G_I3S2;_K#M[J+:JZ;[\+FYSCIL,TN LO92($E4('E^/$M MZ]S]SS_>/4ZE3" #EIP&R,\H7&,UVNT"LP0UL!R/ZS&Y$VY?6>T0SJ#D(I2K M3.X$O*7E[A&T*ICBS-P).LL$Y=ZV09M%W>M;;QQ**O,7,R 0<)E?I\: MN/_Y1R>,R6B-0XA%+)7:."-4M=+\KD%O1<#5$8TSA[T-3KL&:%!IF;\#(;A_ MDBF- XUE"*CZGVR)] MI=Q7,("T#'%6SS:?5^WBAWXKAN.X@Y$?-__YR>+EMV/9 (EE[%QH@0'59>SO MPP7W/__H#,YH%S4,V"Q#<)8:.WN8USJI3PAU)3+KB-9):&OIK(;3P6T9 K?* MQ$[ 7&KL(,0E+5=N[ [SK%W9-8"\#%%>M'6"U>J/KI)VF@!@RQ"QE14[B6^E M2CM[!;]E". Z:2X^7O7[8+)A>7UOMM 6PER':*ZN OU*VJT9 _3+$/OUK.T^7PL#?&__ MG SO-2"\C)\+5S"@Q(S_?6#A_N>G?) \3OYRG%DP O'JOZ.UKV-@7H8XKR,2 M)Q"P*@3M[!H0F"$*K$SB!!FF[AG(;TD8EIFXZ5[, !@S1(S1P GN*Z6H!@[2 M2O!77N"$T0NVU@(/%,P0"W8R_,.[Z]O+=G>9>]KU._'KQ9OF73M0TZ9[N^F> M++X?;1W0+Q/F@AD,>#(3?A]GN/_Y1X=7^BDFJ#!#6)B:.\&#]6?1VA-"7XD) M.Z)V A>K8E3_\3B/UM_!-1A!D6GM $-F2B*RS-H)MDP32P9TF2&\C.9.0&(I M.C4T$%KBQ+)R)Z"Q_@A*W0J(+F%C;W9_6#R]/.O:S_O)C8:;LGWN?FDO5Z9 (E,\22E4F=X,NTR]Z@RTQ)7I:9.D&=U>K]R(BS)OX^_6 $/V9L M7*KO*\@L4619L1-(F36U^@) <@DJFWCY[B3_\AVH,A/G@B,,"#53_3X>I950,&A):/^\W$.6C;T MX?W593.L9?"NW0Z+8N UO._6'Q8_#+OER>)D=&P*L#-3S05.&.!KIOI]=.+^ MYQ]? ]'F<#" T Q1:&KL!'YFDC99A0&"9HA!.Z)V D\S/J@77T"H&4+4RN1. M8&O:9P?0FBFIUC)S)V VI^]<2#0!;31W DOK#[_4<49@TPS!:5F]$Z2:K;SZ MAH+J$JOVUY/%M\VGU?9N!-[DQ(%%,VDND,(DG +\]U&*^Y]__!6D31YH@*49 MXM+TQ F7=(UZI05$FB$D[8C$"5JM4J?@-.#5# %K90HG(#;M(PN$S90T;)F% M$VB;3>KK"54FO(T63D!J*4;UF:&MQ*EE!4Y :_U7IG:-!-2:(6SM/A^[Q?/K ML_;^TMW/_7EMPZ[<@4PS]6P8!0@W4_].1E$+%QJ6QFB1 ZAFB%13(R<0M?Z@ M73MRK''UA>*.0O!K=NFT^4KL$I=5^#M "BNP-FWB>#!MMJ1IRZN<%:1;U.Y2 M6+!NEE@W5CDK@#7;'T$I@;$@UBP1:SF9LX)>_@UN4AG@:G9Y5Q,A07M9I>_SU3<__RC^M16?YO >@R$ MK*D+,@A4+6I??!:DFB52[8@U&23#5M<:Z[2 V"Q!;(5Z-QE56$!MMB1JR^R= MM)Z9]O5A<"F7E]=OA M'L40NV=77?^ ][>UV_^F+\_8.:P%J6;-7%2%!?AFR9IB-'?F\+*"L94V!,6" M7K-$KZFY$]1:T,:=6D!KEJ"U(W(G<#83*Z>^/:&]Q+.5R9U W-0/,*2XI&_+ MS9UPP*P-&+>X"AEQ;[1W EXSE:^U;RY<=8SPM:S>"93->8UDVD>KDXU7]W'O M3IJNVZR'N9SN?L5*AVN*V;G@"8OKCY$%R&CI[.'UA6B\NF>@L42NJ:$3Q)K7 M5O:PN)@8 6M'A$Z@;,98;;"=Q57&"&8K$SK!MZG1@ B7M&V9H1/$FW;IU^+J M982\\0MLS1*VEM4Z@;"YJ,VV88&P64+8#EKW;;M=O-STCQJ.[O:_8<4#KV;#7%"% M!?)FR7)GM'CA\%)#\.J%-&!KEK U-7@25U,_%*#5+-%J1P1/<&S&Z7?S0+)9 M(MG*!$_ ;5KP BY]_@\C%5;P;EX97V M@-ALTN;6L(#8+$%LCR_G MCW, MV:)6U-#)W@UIU[%!JUFB58[(G228_-&([L6()LED*U,Z 3;IKY0$.&2 MKBTS=))V4W,#WLT2[T9+)Z UXV/2OK&!K5G"UK)*)Q VFRHM]2#8+!%L7Y1N M]X?%R^9LM;TYCX7?L=J!5K-Q+G;" F^S9-4T7KOIHQS IUGBT]3:"2Y-OS4 M+,T2EG9$[02PYFJ-R%D0:Y:(M3*Q$Q";NF,@Q"4%6V;L!-=FE^J^A4 3V49C M)_ T[]3;L>#3+/%I6:V3K)JV\J(%JF8)53LXB_WQ\JS]V/;_TW^H^]SA;UGO M *?9:BZ0PH)PLV1E-=J[:OHP!R!JEA UO7?"_&/J?5F0:9;(M"-Z)YFU9=36 MJK: UBQ!:V6")S@V==L@QB4-6V;P!-EFM$7(+=@V2VP;#9X U(RQVK+W%HB: M)40MJW@25ZOUK8#N$JWV^.CN97\\]VK=-MNFWV5?/_HMZQW8-)OF@BHL<#=+ MUEZCO4O31SN 5[/$JZF]$YR:U28?L<#4+&%JQ_1.N(6VK+5%,BP(-DL$6YG> M":A-VS,@VFQ)T9;9.VFQ-FTM' O2S1+I1GLG<+5A2)'ZU)!: M:R>B>ML%:K M%Z4!KUF"U[[HW=7VM-^(R^'@[N'7K'2 U&P]&TT!Z,V2]=AHZ6IIW%F=M*\C MD&N6R#6U=H)8[8C:29+-)?5"(E V2RA;H=I-OL[@0+:YDK(M MKW9.\&Y&N^GC0+PY(MY8[9S UH;9Y93..(!KCL"UG-HY";%%;3R7 \/FB&$[ M.*']:;>[NOC<]+F[^Q6)G0.JYI9SL10.P)LCZ[*QV-W__*2/4X2G/:.4&KU4G[]G3@U1SQ:EF5DQ9;2^I;&^B:(W3MH'(_KS[>CK.[_05K M'/@T9^:B*!PH-T?68Z.-,Y/'-3A@:HXP-;5Q D]SVKA/!SC-$9QV1.,$MF:6 M7J.,#N":(W"M3.0$RZ;N&0AP2<>6&3E!MVGW81WP-D=X&X^<=!%"G4O)@5)S M1*EE54X2:\EHK06PY@A8>[%ZVW:[Z[XP5]UP<>[;U6\;MO"$ XKF[%RLA /6 MYL@J;#1M=O)(!@-&12$P?ZS+FYX @'>,V1-==HVIPP M<-=H<^,[ &B. #2U;@(\<^H9#+@S1]S9$7631)HUM784"2;-$9-6)F\"4]/R M!D;-E31JF7F3EF+3)L1T8-<S3EO S %' M+I[NNM75Q>W\ZA_>;;HS=N0&T,SYN4@(!V+-D175:-[\Y%$*#LB9 M(^1,;9M$S;35G1Q ,T>@V1%M$PB:J;R6-C!HCABT,FD36)JZ8R"[)4E:9MH$ MJ&;50S>@:HY0-9HVP9M9H]W'="#.'!%G6643])DUVJ$;V#/'[%G7_]!YVYSM M5]!9-W]K%C_VG?MAW5Z>-4.0GO[7:#&@HWXN"L*!4W-D737:N7!XQ< ';>2V M VOFB#534R<8,^T##,#,$6!V1.A$>J9^/,">.6+/RH1.X&CJZP01+DG1,D,G M #6C3JCNP*@Y8M1HZ01H5E5!.S< :N8(-'*@S1]39R,1TP\RV8 T:L[\G%U>5J6.VU#\CN_&[]B.=-UZVV;Z^Z]T\6KT;C!K+,Q;FX!P.K(I& M$Y>F#TH .N8('5/S-IV,.2!CCI"Q(_(F8#+7?RJT@U;@9(YPLD)YFWZ$"[K, ME=1EF7F;;LXTF!HW08FI MGP!H*1%B1\1-L&,FJG,#.-!CCNBQ,G$30)GZ0D%X2V*RW+@)8VVUM:(](#-/ MD!G+FY>D6(P:>_9@Q3RQ8CEY\X(;L[4V+ZL'-N8)&QOR-DP.?',S-2]R'ER8 M7\Z%,7@ 9IZLA<8B=__S7\P2H:+$M,CYZ3K,@P[S1(?E1\Z+*YQ% MIWSQ>Y!CGLBQ(I'S B937Z@$V_8/@PQ^NB_SX,L\\64\<4);1W8D.#%/G%A6 MXJ05SM2%=SR8,4_,V,T17&[;0(-Y,Q?'X &6>;+P&6V;$:8EMTOU70%5)3A, M3=MT%.8!A7F"PHY(F\#%4JT-/??@Q3SQ8F7*)A R]76"ZI;D8YEEDQ9(TY:F M],#*/&%EM&V"#:N7V@!R#SK,$QV6ES:AL)4V'LX#%/,$BIUL/GYLN\6;C]W- MOGC37JXVW>+%ZE/_VYOB=:NS53.,#_EV+!N PKR=BVSP0,T\6?6,QLY.ONWE MP8IY8L74T@E&S&M0RH,2\T2)'=$ZP8_U;TWU'P_=)8"L3.L$4Z9N&W2X)"C+ M;)VT1MI2N67E 9IY LUHZP0M5E56H8 >O)@G7BRK=8(=,Y4VN-2#'?/,CIV= MW8V >[5N3F_6IG[675UN/Z]./PRCX>Y__63QP^B1'4@Q[^;B'#S@,T^6/J.Q M2+*RN1.0&;J MKH$4EP1FF;D3V)EVD=>#._/$G=':"7C,!'7&-@]\S!,^EI4[@9+9VJA; =%E MDNPP=]]>O>T?-4C\FU_0T$%;W5R@@P>&YLEZ9S1T?O(M,0^.S!-'IH9.\&-> MFR3;@R#S1) =T3G!EM4V:=_"@,L\P65E,B=X,W7'0()+8K/,S$DKHVFK9WA M:)X@--HY09+55:U]>P(E\X22965.8F5+M?/ RCQC9>MU^[[;#),H?=?OL^9M MNSO?;3X/E7OT^R>+/__G:#:@K'XNQ,?-DP3,>N\DC%CQ@,D\PF1H[ 9$Y M]7L/#)DGANR(V FZK#_O4?_Q$%X"S,K$3C!GZK9!B$N"L\S8"0S-JG=; :)Y M M%H[ 1-5B6GQ0XTF2>:+"MV@BPSE3:GC@=9YIDL.SRF^_?-^>5V<=*U[7 2 M"[]C1W= R7R8"WOP(-$\6?",!B\(5QJ61G^W0&L))].C=]C86KU%!9#,$TAV M1/0$8F9,[;7#34!FGB"S,M6;[LX\N#-?TIUE5D_0:/T'6MMF*#7Q:+1Z BHS MSFGPP ,L\P26965/6M#,UUKV09EYILSVQWC_?M7ON;8;4G?[JR>+[\=F)?$@ MR7R<"X+P8-(\6>V,9BX*DX!YI]D8#[#,$UBF9DX 9:[24+,'4.8)*#NF<\(L M8'501R< -_.$FY7IG"#0M%T#_,R7Y&>9G1-0FM66MO' TCQA:;1S@BT++@3M M?06^S!-?EM4YP9K5*I?T8,T\LV:'AWLU.9P&<^307 M,.'!KWFR[AFM79H^T@$ FB< 32V= ,_,4ELQT(,]\\2>'5$Z0:6EJ$TBY &F M>0+3RH1.L&KJZP01+NG4@"AYHE04\LGR#17U5IM *9Y M..*)] UE+4\*0'M>:) M6BM3/@&RJ7L&JEP2L6663UPK3;V(!;K-$]W&RR<1M125LY4 2"T0I)93OB" M-1N#NA4&MH+T=W\5[\WNJKE9$N+V%Z1P 3A:6,[%4@30;8&L>L8*=__SCR]B M+:/R?12 J 5"U+3*!8&F]7M8.7D,(-,"D6GYE0N"68O+4"G'(P'<6B!NK4CF M@D#9E,P%8&RA)&/+RUP0<%O4EFL-P-L"X6VL@U MM7J"6NM+HQU5 EP+!*X=43V!M/4G7MI]Q0"H+1#45J9Z@G/3J@?(+91$;IG5 M$^B;U]9H#H#? L%OM'J28 N5>K8"ABT0PY95/6GU,Z,M;!C LP7FV?!,]@]P MJ6X_M_KC/Z?Q@^+:N4B+ ! ND"73:/S#9PO$LY5IFT#< MU!<*NEO2MV6V35IE;6G4C88@$_A&\R;IM8-MM_*6OG7*#: E%M99(W?1FU ,HM ME%1NF41# *L6B%53 MZR88M:A-!A1 J 4BU(Z)VV%H4ZV-C B UP+!:V7:)G@V;<> 90LE+5MFVP3A MIGY5 '$+A+C1L E.K=9'> !4"P2J975-0FN^4O_]4%=BUJI08=9>7EUN=[QL MP-%"G(N6"*#; EDGC98M3K]X #PM$)ZFEDU@:5&]8 (H+1"4=D39!*Y6)6V! ME0!<+1"N5JALDYU$ +T62NJUS+)--VT!3%L@IHV&38!I*6A3$0:0:8'(M*RP M"4K-6 U)!$!J@2"U*IHCP@;^+%1S@1$!\%H@BZ/1L%7"Z+%*4_&WT>P")%HA$JT)]1-X F84T M%_T00*L%LCP:S5LZO$"0K#9A:@!Q%H@X4_,F2#.C3E$; )L%@LV.R)O T%+2 MIC<+P- "86AE\C9]O;0 +"V49&F9>9N.U0)@M4"P&J^;<*=LJ7K" .0L$'*6 M53>)GWEU$!+HLT#TV1">KNUN!\9!YO#/6>N F85Z-@X"?%H@:Z71UM73QR, M, L$F*FA$V"9L>K=6[!E@=BR(T(GJ+/::>>H@,X"06=E.C=]Z;0 ""V41&B9 MG1-HFC;7>0";%HA-HZ$3@)FUVNPA 8!9(, LKW,"\-66M8A S2*A9B_;YFSS M^6VWV7PX6$WBZ?O-5=+A)OE-"\*]"Q5 MFL6((,\BD6VN^Q;\;(]NUD+\:=W[U:GCP[U\&%/%K^.]@_ 631S MX1 1Y%HDBZK1_AGA.D-0+]M%X&>1\#.U?P([TSX>8,XB,6='Q$_0:"8%;0;9 M"!PM$HY6)G[3%UJ+H--B29V6&3_!K&D??#!KD9@U6CX!GO4[TFK?8D#/(J%G M6>43&)I;:A+DO+V]D#>Z M8&($=1;-7 Q$!+86R5IKM'AV\EVS".XL$G>FUD[P9BEH(ZLB<+-(N-D1P1,@ M6EJJ\^9%D&B12+0RP1-PFKIK(,8E85IF\ 2NIB^C%4&L12+6:/,$=E8;=:V' M"/ L$GB6U3P)H7FCS=87 :%%@M!.FJ[]N&Y_N\V;?KSWO+GX>#-B^)?1\ $\ MBW8N2B("68MDX34>OL.+$?HTG1'8623L3&V?P,ULU(1]!'$6B3@[HGV"1>M_ M5EO-,0)&BP2CE6G?=)\6P:?%DCXMLWW2(FWZVPEZ3=P:39^ STRJM85:(P"T M2 !:5OH$C-:_N[7V T:+!*/=%6WQ>O6I[1[*][3K]V1^]T"@13<7*1'!M$6R M AOMGIM\JRT"2HL$I>G1FSR.+ )$BP2B'5$\@:B9M$S:QP286B1,K4SQ!+FF MOE!0XY)J+;-X@F4S7COB LT6B6:CQ9-(6K+:C90()BT2DY95/,&G.:,M<1"! MIT7"T[Z[;A=O/@[/O=Y=+_J7X^KC0_?PTEY[\?%\M24@-H)(BWXN?"(":8MD M-3::/"^,1O/:1&X16%HD+$VMGL#1*OT)(;,$I!W3/>$XUVH3O$2@:I%0M3+9 M$_2:]@D"N19+RK7,[$WW;!$\6R2>C49/0&E5K1ZP@TF+Q*1E-4_P:<8$[9() M\+3(>-KAI$Y/UQ_/^[/>W:X9[N,^_(9,RAY!H\4P%U01 ;E%LB ;[5V8/"XB M@E*+1*FIL1-T6E\G]3T!>25 [8C:"73-1G7.T@AX+1*\5BAWTP^' ;/%DI@M M,W<"<0O:"+D(R"T2Y$:#)T@UFTRE?7,!5HL$JV453X!K/@6MNP#7(H-KA\5[ MU36K;M4N?EFMU\W[82Z[+_[DR>+/;\8J F(MQKFXBP@,+I)5V6C[HC!,V"=M M JX(EBT2RZ;V3S!LIE('C0!CBX2Q'=$_ ;A9D]3^ 7&+A+B5Z9^@WM260)M+ MDK?<_@E3/6@++$:@<)%0.-H_P;-9O]1F"XY@VB(Q;5G]$WR;M^H('O!MD?BV M9^O-YN)N?J?G3=>M[F:M&[]C"W0M5G.A%Q$\7"3KL='"5<+UWN#4V_N VB)! M;6KA!,RFO@$@J$2R'9$WR;B%6KV' L@M$N16)F^">U-?*$AO2?26F3>!PAGU M2@5@N$@P',^;8"^B44?& 6J+!+5EY4T ;OT)@_8"@&^+Q+?=7[![<[IJA\_R MXE7S:;5>W4S-/CUW0-EBFHN^B.#C(EF$C>8NB1=[-=H< ;E%@MS4W FX3?L4 M@VR+1+8=D3O!O%FK+OX7 ;U%@M[*Y$YP<.H+!2DNB> R=QD6@<9'0.!H[ MP;>-[DCH+#%N>;$3CF6]T[X]@;M%PMU^W6S.%C^LV\O%7ZZZ[7![8M@;K]OS MYNWBI-\9-XMGWPW,ZZOX?M,G:&Q&NPC(+=:SH1A@Y2)9DHUVKYX^ @*P6R38 M36V>@-Q,TE9SC^#<(G%N1V1/$G#]H8%VY@,$+A("5R9[@HI3=PTDN:2)R\S> M="D70,O*GJ#?7/3JVPGB2_3;J]7E97.Z;O>- M>[.YVITWG]I^%[TPM!NT]60%[JPA[*Y*X2I!P2C J4'!52067 ME[A*L'%!NUE0@8ZKB(YCD:L$XI:\=F.V N)6$>*6T[A*X&[&>>4F7 7:K2+: M[573-6>K;;OXI5FOV^N'@2BOULW?AANSK\XW[>7JMR>+I_\U6HX:GG$NTJ(" M$5>1)=AH[XPP ,WIP0/65A'6I@9/X&S:IQ@H6T4HVQ&U$Y";#:;6WIX W2H" MW":K/1:1=D*I!M%9%M6<&3 MEE?SVJB#"I!;19#;+ZO3W:;;A^[NV*[ISUV[9O5^\;K_B)\/P^]._]P?_K77 M3Q8__\=H0Z"U9B[4H@(95Y'UV'CY)@]ZJ("V582VJ=432)L)VJEL!:JM(JKM MB/ )WJU_DVH7V"L ;Q4!;V7")Q@X=== E$OZM\SPB4NV:?)YWY/=^6G3M8M_ M:BX^_BM0MYBB]EX%\E81\E:F?H*"T_8,"+BJI(#+ MK-]T%U>!BZN(BZ/I$W!;,NK9)>BVBNBVK/))TBT&[1P?H%M%H-O+33>,P_NY M[;IA)!Z-W\W#6?B N%5N+NZB B!7D27::/CL#<*C\7?5&!D:O( MJFVT>G[RO;8*D%M%D)M:/0&WJ4M:5&#;*F+;CJB>H-YRM(NRM4/6F M7X8 !E>59'"9U1-PG/IR@HZKB(ZCV1.(F_?:3& 5*+>**+>L[ GBS:B3,U<@ MWBHBWGX^'X[Q5N_/=_Q$]U6[Z5;-_<-9_0"\56$N_J(",5>1]=MH_<+DL1$5 MD+>*D#>U?@)UL]IR\Q5@MXI@MR/J)S"XJ@[:97%@\U6+F*6#D:/P&\)1.UZR<@WBHBWK+B)^DW%7]4@-\J@M].-NO-Y:HO M""U?M^H_Y1,.^<"\57$N)*,"*E>1Q=UH].+TT1)@W2IBW=3H2<9-'>H PJTB MPNV(Z GV+21MQK<*[%M%[%N9Z D<3MTQ$.22%"XS>M.!7 5 KB) CD?OL+5Q MJ5[@ ^96$>:6%3V!O)FH8;L*Q%M%Q-O)L*\VO'EO/O;1>_]NU:[/6/5 NE75 M7&1&!7RN(BN_T>I5TP=-@'^KB']3JR>XMZ@-):U O55$O1U1/<'#61.U!8 J M,'$5,7%ELBR@UD7.T>P)_L]9IH+ " %<1 )<7 MOL/\^DI;YK@""U=1"W>UVEW#;%+/-]N;_7*L+>U,I)W*VNM.-^T&X5T6Y'9$YP<"9:M;E@X2IBXD<9F9$\!*4#>U=0)Q MZ[][M:,H4&X546Y'M$[R;Z&JM1LI . J N#*M$XP<>JN@0Z7]'"9K1.4G*W4 MG0M])DZ.MD[ ;L.:0UIE +Q5!+QEM4Y:ZRTNM6,ZL&\5LV^'$T>].=\,(Y6[ MMOW0!^_/S>6VV=XU[^5/H_6 Q-9S81D)\%PB:\.QYMW__./QI$Y;6SB!@$M$ MP&G=2X)\<^IW<0+YEHA\R^]>$DR=U+ IUSVC33"?!<(GB.=2\) LY&%Y6OL 0&+A$#E].])'@XKTXID\##)>;A MKKI-]VBHS0ET)>CNB==+J;E$S4PE$7"(BKDSJIJ\$EP#(I9) +C-UT]E< M C:7")NCH1/LF^T_S=HS0V*)?"+;FY6(H$ M[BV1I=UHY)QP*;=::C,6)L!KB> U-70"6NO?E=IQ/;BU1-S:$:431)OUUJJI M@^P2TU8H==.O)8!Q2R6-6V;JILNW!/(M$?E&4R?P-5L9HUT4 \*6"&'+:IW MV?Q2N^&6@+,EQMGTV/W:;UKW;M.=L=J!6TM^+G8B@7=+;%DW5CL_>3Q# K"6 M"%A32R= M:!^_0)52X2J'1$Z&;$I]\H2*+9$%%N9S@FP37V=H,$E55MNYZ:7 M&:Q;(M:-=DX :]72:_L1R%HB9"TK^B=F@) M6BT1K5:F<@)@4_<,%+BD7LNLW'33EL"T)6+:>.4$+.&,=C$$;%HB-BVKO8#8BT1L58F? )B4W<,1+FD8,L,G^#:-*R5 +8E MMH^02=EJP&-1( MM42 6E[YI*6#@O8]"E@M,:QV]FGX^)XM?NIVYYN/PP2@7TX#^O7B]>KT_&)S MV9_/_C*V=$\"GI:JN=")!*PMD07<:/ J80*'X-133+!IB=@T-7J"23-!'5H' M+"T1EG9$]:2%VFIUF?H$9"T1LE8F>]-7=4L@V%))P9:9O>FN+8%K2\2UT>I) M.&U9J9JE@A5>]6L+[3IW7_8;,ZNVZ8C>"*!24MI M+G@B 6]+9#TW6KLD7.-5%VA/0-02(6IJ[ 2:9O0;:*#3$M%I1\1.<&N^UJ;E M3>#6$G%K95HW?4FW!(PME61LF:T3UWY3WTW09\+;:.T$HU8MU?%#@-0206I9 ML1/ 6JU-?Y* JR7"U5Z=7V]7_1-?;N\2MWFW>+UI+H?J]*_(]?WJC!=-O\M^ M_LMH/*"P:39V I1;(JNZT>35PO2^_5>2LI= JB4BU=3D"4+-5%X[ 0&DE@A2 M.R)Y E^KDGJQ&_A:(GRM3/($T:8E#S1;*JG9,I,G&#>GOIQ0:8+<:/$$J59' MJ[Y8T%I"U;**)[$U==[N!&HM,;5V]JE_R5?;W=V-B\6+YE0XTGO>7-[>ICT9 M/:T%J);JV0@*<&Z)+.K&JR=[4 U8R+E?K4 9ZZG*.H!;9F:JM<'*Y!K=5$K7UQY>['A]D\R;EL#2:M7LX% M3]1 VVJRIAM+W/W//^J-NE19#3RM)CQ-+]QA5)-VO%\#3*L)3#NB<")9T^Y6 MU$#6:D+6R@1N^J)N-1"VNB1ARPR< -N"-NE'#;2M)K2-%D[P:=9K T%J(&HU M(6I9@1.X6N65NQ4U:+6::+4O^S8]<*#1:C,7/5&#::O)&FXT<&;R6(<:4%I- M4)I:-P&CU=HD[35PM)IPM&/J)AR].@WDUB#5:B+5RM1-P&OJMD%Y2]*US+H) MH"TLM5M.-9BVFI@VFC=,0)*JPE*4PLG8+2H3;M> T6K"44[HG "4M-'0-6 U&J"U,H4 M3G!K:N&@OB7-6F[AA,L/VF0>-5BVFE@V6C@!I#FCMA5,6DU,6E;A!)\6U2]O MT&DUT6DO-]WP4P=CZ&[__,GBA[%;#34 M-K/!4O4X-AJLOX:C9P_O'3@G3;D MIP:+5A.+ID9.,&C&:%ZB!H96$X9V1.4DH*9?GP:A5A.A5J9R EK3*@=BK2XI MUC(K)SBV_G!*VV8H,Y%LO'*'>:V6VGSY-8BTFHBTK,H).JW6%@BM :?5!*<] M:]<73?=0N?MW^N+K%\V']O-F,]Q3'9N%LP:"5H>YV(@:+%M-5ERCH0O"+ R5 M^M8$CU83CZ:&3G!H25OBK@:)5A.)=D3G!*/FK;;07PU&K29&K4SG!+:F[AAH M<$FSEMDY0;+9I.Y;:#.Q;+1S D@+3IM$N@:35A.3EM10&/5A./5B9R E%37R@(<$F?EADY0:TY M_5,.829NC49.P&[1]Y<=>_;@;[>G\7>/O#)XN?_&&L(^+.ZFHN,J$&OU61Q-5J^2AHR9JUV M>04(6DT(FEH^B9[5VE38-[8L+ M=;],OA\!VJRNYF(A:D!K-5E(C48N'5Y#,+-73' !G M-0%G1S1.H&C.:FNUUT#1:D+1RB1.T&GJMD%^2]*TS,0)8,VIUT. K-6$K-'$ M">[,Z_<" )[5!)YE%4Y:*"UJ8\S!H-7$H+UHWS>G>_OP2W_JVKR_6>VZ?^]L MV*$<.+,ZS<4^U.#4:K*,&J^<,/>NB^J> 6Q6$VRF9DY 9JY2[T@ ,JL),CLB MLOJ[XP MQ'K5@,SJ>C80 H1:3992H[VKA:%DOM:6F]$P;H6FVXO%D"+[OY M3=GB/?R5CU^!4"L'MOWC#6[/WP%$/#S+A.KUC[6X>?\P$_'PW(\^^,K'OG^P MPZW^?2KBX2]X? $O!>5;K'^\QV_K+')[+:Q"K]PP-NR'B%_W+U:4A< M'YOM;K6[ZN/R;M/="=CK^PGMOE[\^U6_=]ONR>+[%R--Z9\MXE//Q4STFUKA M=O\^-?'P%TS[I"5\YN/@Q,,//KI-&[33ZO[A-3YI:3SQ\%<^.B_Q2VWDG5D: MK#.A:H5J*/"UKTW0!K/UC\=@EQ1LN4448-O75:T=#/:/QY03WL:C*"$U9[3; M<_WC,[WX=;,YVWXQD^?)U5ESSM9/ M[)\ $VSF8BOZ3<5^DQ78> ?-Y"$1_6.QP,2MZ1T4P%JMJ:W^T=A>@M:.R:#@ MV7RMS3S5/QRK3$A;J0I.1A9F:3'2)95;;@$%_*9-%]@_&+M-_!O/GZ38:J\_ M.;:7.+:\^@FH39T-H'\T5IBHMN^:[:Y/SO"_;_[[:JC>KWURAO3=G"*_VJPN M=T\6?SD9[8C%VMJYR(M^4[';9&TVWC\KW(!3>5G_<(POH6UZ @739H(V5+Y_ M.':7J+9C&BB -Y^T 1C]PS')Q+P5:J#@X/0&8J)+,KCL!@J3JVL;[3#UYVYPM3E:[:UI! MA]EU,ZI-[ M+#"Q<'D1%&!+K> (%)9>,MG)*_W#L+X%RF0D\ M;'$=U5T7,,6$S;UIMMOF7==L!;2V^*Y;]9%Z-79GN'\"#&Z8"^CH-Q6K399[ MX_4+PA+&3ILJKG\XII>0.3V @I6KM:YI*[+[9^ [M03BX#1)NR.YT_ K0J$=L; MYX(\^DW%BI-UX7@-8\8XC(@=)K1.3Z%@ZKQ^ AXQO\34'9-"@=O9J,T$US\< MRTS$7:$4"@I/WT-8ZI(&+S>%TVE>_UCL-\%Y/(4BL0OJR7#$#A-EEY="@=PY M_:0\8I()N3O97'6[ZZ8[6WP_O [-ZG)[>QJ\/6\N>/O<$46>]ME9 _W",+2%UQX1/T':A_QI4OZLK##$!=X7* M)R \?1]AF$L2O-SR"3(O)?U5Q6 3G>O+UXB_MY\6+]G+S6]^D\0&" M%4:WF@L.Z3<5$TX6BIN00N'R<:U_4R7L,!%X>@T%>J=^MA/VE\B[8U(HH+Q8 M1?53D[#,A.45*J% ]?17"T-=4NKEEE ?/K77<)^$\/'0RA(O)CTV\()*TPP M7EX'!9E7:UZE?S3VF-"\E_UAW_IV<6^8\P R^'/[6[.]NS4\2N3ZI\+\IKF@ MD7Y3L=]D$3G>P21=N]"FKAO4+C[Y<7#DX0>_0+C:<];87H+SCBFAX/:J6C\; MKC',1.X5*J&@^?17"T-=TO+EEE @?OTYJ;K9&'#"_'@*!:R7@JY6:NPP\7IY M*13PGK'Z84:-329Z[W5[V:RVV^&SO1AFNFJ;T_-=UPXWAY_N^O?2H.9&IRWM MGP'36\_'BM28;K*H'$]@+5Q'[@\^U"^L&@-,W)[>0 'L^9%!@C6&EXB]HR(H MC&9+29L1SAC4?(9HOC(5- +PTRIH$/>9DK@OLX)&6H6N4AF.0?5GB/JC&30" MW>N?6STQ-ZCW#-%[61TTDN1;&FTQOO[Q'K=DO,C?;WY;O%Z=O6\7;]K+U::[ M-W/-;O&LN^Y#V!?Q]A=/%D]'+Q,:='MF.1LT8A#]&;+:' WB_5_PZ&UCU+L5 M!N6>(7)/[:$1Q)Z)JFHRB/8,07M']- (G,_86IM J7]\C=OS]Y C1B!^:@^1 M]YF2O"^WAP+Z"^HYJD'R9PCYXSD4W)X)^H 9@V[/$+>7ET/!\%EU&O_^X=AE M0OA&:GARWA\RKOL:OECM=NMV\7IS^H$F$=6>,;-Q) ;]GR$+U/$D&F&V^>A4 M2&90\1FB^/0F"GHO)G6 O4' 9PC@.Z:) NVSRZ".=36(^PS!?86:*'@_?1]A MLDMBO^PF"A-I1/7K%A&@(0B0-U&2?%5TVJFR0_CL1[(2 M(X@^_1FQPH3S'1-$"?K55IN]M7\\!II(OT)!%/"?_G)AKTO*O]P@"A[0JE;' MH @T1 1."*(0XSI8]4L7:9\AM"\OB +S-$V?7 6 MFW>+D^NOOV]6PWQ;SS=7V]VPT\9OGQC4?,;-1I48%(&&K'O'&^BFC]8P:/H, M,7UZ_P3+UW_]J(Y3LF@8+R&UX5?7LPR<3Y%4J@0/_T?82%+NG^!Z[;I;L#)D\D-1,UGPFQ$B4$7 M:,BZ>;R!8?H(#8.RSQ#9IS=0$'TFZ&<'*/H,$7W'-%"P?OU)2*U>V4?M9XCV M*]1 0#J^P@375+_Y390,(': D;]@[' UCQD@- ME'V&R#Z]AH+HLUZ=B]H@ZC,$]1U30X'[U?T)@KHY&&?B_0K%4"" ^B["5I?T M?[DQ%%2@.FS4( LTA 7R& JV;^B2^OV&OL\0WY<70\'ZF9&S<[1^AEB_YZOW MY_T6;-MN]S#"NG]IKCX^_.ZG=^]6IRU.PM!_)D^;[13@WS WOOJDV&1B_X[)HZ ":Z1T%_S? //T-AFTF C"OCH(& M-"/?O(@!#<& -_>);^;C>K[9WNS 84K6YO+F+'E\I+5!ZV>JV6 3@UC0D#7Y M>/LJ8<*BI5&_0U'\&2+^1MHG8!._5,^A4/H9(OV.:9]@ )-1=91!!F@( RS4 M/D$&JAE!%FA*LL#<]@E84%M NG\P%IMH01X_@?P-Q]=J_%#]&:+^\N(G",!* MG8_?( T! #>3$#]F2(Y,_4\R$G M: <-6>*/][ 6+FK8H ^"10%HB #4FRC(O_Z+4/W"1/AG"/P[)HK2&GZ5J_0W M+T::F,!259QN3BP205N2"&96T0IP,%GM5;5(!RVA@[2+5O!__?:H%-DB +0$ M &:%T0H8L-\2[<3#H@6TQ +>K$MR?M7UQXC#7>1-7\G+[ #]5U4X^;]XZ")%<2@46^2632#EIA!'D(!_M5UK3\Y M5IC(O[P."@HPJ;=/+!I RPQ@=]J-V?/U]L+L^>+/[\ MGZ,U0>]GS6Q\B44K:,D*?[R"9OIX#8O:SQ+MIU=04'Y>'69@T?A98OR.B:"@ M_YP^+XU%_6>)_BL400$$ZGL(&UT2 ^9&4"""ZGF&12-HB1&?5.ND7S9XGY>]8V5WWC=H<+N?_:=%U[R:X/6G1]UL[&E5@T M@98M\$?;9Z??RK.H^BQ1?7K[1,U7J4> B/DLP7S'Q$]@?G50F8M%Z6>)]"L4 M/P'_Z;L(VUP2_N7&3^" ^K$/>D!+/""/GX#ZAGG1U8-Z9'V6L+[,^@E#,%15 M;Q'X60+\OFU^Z??:XMM5L[[NC_X&2G)UMAUVU/BJ[1;QGG6SD206%:!E:_K1 MZKGIHRXL.CY+')]>/<'O6=5Z6A1\E@B^8Z(GV;Y:G5_!HNVSQ/85BI[ _?0] MA$TN2?URHYH/CZ8R_U6PP=GR6.+R]YDNE3ETJQ*/HL$7UW MR7O67"^>=6W[MW9?OX=#OQ=-]WY#&XA\S_K92!*+"M"R)?UH _WT6W@6'9\E MCD]OH.#WG I)+ H^2P3?,0T4;)\^Y8U%VF<)[2N40$'[Z3L("UU2^N4F,,/_ M6?1_EO@_GD !\1FKSBMID?%9POCR$BB0/G5Z.8N>S]*%^MKV\MVJ7>^GI7ZU M;O[6#,N3K-9OVVZ8=_"_QA."P?6S82,6\9\E2_GQ](7I0RXL\CU+^)Z>/H'M M&7UY$HMRSQ*Y=TS[!-/GC3H[GD739XGI*Q0_@?GINPC;7)+XY<9/6OE/O;"! M\L\2^M&JH4&C9XG1.Z9[ M@MYS1EV^S*+>LT3O%>J> /KT/819+JGYU9?1P!HCU+T-Z/PZB6S7"6>[,X^]V8OQ^:=;M]>]6]IR-=T.79 M.!L18E'Q6;)F'R]?S!A&@0[/$H+_,X2?G=,^028UY^KJ=_+ M"/,L@7F%RB=8/?W5PC"7A'JYYQ;YGB5\CY=/,'BV\OH.Q>P2AI=7/H'D M677V'(L@SQ*0]]?+U>[ZU6;5[Z>'58A?7FU/^XVY'$;XC8YWMBCN;#4;_V%1 M\%FR6A_O7I4Q<@(-GB4&3^^>8.^".E>K17IG";T[JGO"2(B@,DV+*,\2E%>H M>QEK]5E$>K8DTLOMGD#WU(,=I'N6T#W>/<'?A9&QA2CP+!%X>=T3-)Y+ZM5L MM'B66+P7;7LK/%9]6X9U.'?GBS?7VSX=BY^N=A_[;1IVX<-9\/>[/RQ>7K?= M=C0KB/!LF@W_L,CX+%FUC^9; O&_;_ICOJAN9'.;N$0S!661XMIX/^T"\9\EZ?;R" M=<9-.N1WEO [O8("NXOZO3E$=Y:@NV,J*' \UY]0J9N#428EV:/8<,7NT@4Z =ZY6[WXXE'>.R+NL!CI)X:GO$W1'9PN^%V@[HAF&#"[FYG1?W0WA_W[:5'_Q_> M7G773Q8O_S):$<1USLS&>CCT>8ZLQ\?K9X01;_H*7 Z1G2/(3@^@@.N&Q9O4 M)\7J$E]W3 .E]?66,>DO C:9V+M"#10XGMI M'BNI,7+;: @](;C;'6[L=T$ MZ?$*"M)N.";4*X@-)M@NLX*'/4[JB85#=^>(NQO6B_OU0 MUSD[&_KA$.HYL@ ?CZ"=?L?.(;5SA-KI!12(W; 6O/JDF%VB[(XIH.#O?$CJ M9P7]G2/^KE ,U;><^CQ7$F/EQM :8F^D5<5NTV<'N^?@.U"4M>Q<\CM'.%V M>?D3Z)U?ZOG##!-X][+==9N[>R'/KDX_M-?M_:T1' [XJ1W>5D\6/ST?30I2 M.^=F(T .^#L]A8*[T^^9.91WCLB[8THHF#SO]%,6 M1'F.H+Q")12V F/%+@(CMG)N-_7#(]1Q9;8]'ST\?;N$0W#D" M[O3H"=#.J=#,(;5SA-H=$ST!X5E]J4.'"L\1A5@+,TS5&3UJ: M3]UH+#7!>CQZ@KCK#PC5V""Z6F+X/J.:1ZCE ]GC[!VUFKKAOG4-PY M(N[RTB[Z8\'1_[ MXM#:N3 ;".*0[CFRRAZ/8)"&)^O'/^CO'/%W(QT4;M/9I)X5(;USA-X=$T() MY57J\B@.59XC*J]0" 6HI^XB5'JNI-++#:%@]XPZ ,ZAWG-$[_$4"@0O&7T$ M#"H\1Q1>7@H%D1?THU$$>8Z O)_;WYKMXJ0/XEE?O7_Z7\F:ZE^WN$;2Q*6$ M'?([%V=#0QQ2/D>6V.,EC!EC+1#C.8+Q] P*"&_X0_5)L;W$X1V506F63'4N M:H=$SQ&B5RB#@MI3=Q&2/5>2[.5F4(!\QJCG@4CY'*%\/(."QPNU40_QD>0Y M0O+R,BCP/*^ND.10YSFB\[Y?;[K56?-P'_AYVW2[TUL5_'/3MXC-A>#0X+EJ M-A3$H>AS9 T]GK\J8Y@%FCQ'3)Z>/\'BA:1_,#"Y1.,=4S_!Z9E:'S.!4,\1 MJ%>J?AG7*Q#NN9)P+[=^&9S/(>=SA//Q]DDFS^LCFY#E.<+R\MHG$#UKU),= M%'J."+TOV_=F<]%VVW8W.7W(\%R:C?]PJ/<<64*/IR]E#+! ?^>(O]/3)[@[ M_;XOH,PS"6-7G;Y,G*-(9IQ[U(<5SA.)]6;Z;W"U>->N+[>3X(;ES]7P, M"*(]1];.X_&K,\94(+MSA-WI\1.XG;Y2M$-PYPBX.Z9^T@IX7C_N0XOGB,4K M5#^!Y^E[".-XZ(O0GU$RXN!Z^-NO,H[SR1=UGU\X+",R/; M87 [QBO\9?U^;;?K]GIQ1V_GE;!2(1[OGR0IYM'_W?\&4-ZI' M?>>)OE/[YP5UY]6;'Q[=G2?N[HC^>4'DF5J=H-0+P,OLGS/BF7D[V2/$\HWA7W:9K M#@8\OURM/S=7']J^4+^.+G;DD=MY,QO[X1'N>;(J'D^?F3Z\PB.]\X3>Z>D3 MR)U9JG=:/9([3\C=,>T3,%Y?9^U0U"/&\P3C%6J?X//T781I+FGSTWHUN\N>K>M]WU ML-[E9MB6]O;,=[UNSIOM=H@@.?Y#;N?M;-2'1[CGR;)X/()V^M *C_3.$WJG M1U @=_J-!H_HSA-T=TP#!8X77%)/4Y#C><+Q"C50$'KZ'L)$E^1YN0W,0'L> MT9XG:(\W4)!W41]>4+O\AHH,;R@?M>CPO-LT;MU>WG6K-O%RY^>#3/^ M-=U%OVMV?42>K];K+5OKTJ.T\W8V],.CT_-D23Q>/C?]UIQ':>>)M-/+)PB[ ML%3?$6CL/#%VQY1/T'?#PG1JB='?>>+O"J5/('GZ+L(RE_1XN>G+4'H>E9XG M2H^G3Z!VP\2DVJTLC]S.$VZ7USZ!WM4C[W1L,)%W)]UJM^M?_+X;OS;;\[ON MW880_N#GS>?+_C]YLE;>A!9.OUGG$>!Y O#T%@KP+GK] M.;&_A-X=TT(!Y?FE.CV_1Y7GB M;Z$@\'RESKWB$>%Y@O#R4BB!O*!>8T&/YXG'@Q2^V;7=>IC[]'F[>G_>[]#; M('[YQ[2&R/"\GPT*\2CZ/%DWC]?03[]YY]'D>6+R1FHHW+1SM7K!!#F>)QSO MF!P*4,_J$[1ZE'J>2+U".13PGKJ+4.[YDG(O-X>"Y]-=F$?1YXGHXST46%Y_ MAJH>DJ',\T3FY?504GHJN/*(]#Q#>F>?-J=#4^[NC]PV\+OUA_--=TGOB2## M\V$V"L2CX_-DS3R>OI!QWPXEGB<23T^?(/#&/A286P+PCBK?88AKKZ)@CS3/ M$YI7J'R"UE/W$%(]7Y+JY98O _!Y!'R> #[>/4'AU=&IQX'(\#QA>'G=$TA> M%?4W%O:7B+Q75^N+S67372_^J;GX^*^+X;CP9ES,S>)P+_NM^WKQHKW87 ^S MPKP:5<$>!9Z/L\$@'@V?)TOH\0I&8>8@6ZE10HCG"<330R@ O*BNG.61X'E" M\(X)H8#S7%JJAX"(\SS!>:5"F''- K&>+XGU#PO+?J MM4&$>)Y O+P0"BBOWQ!U.S#(Q.1]NWH_S(>U^.ZB[:ZVBV?KJW;Q[:KIXWB3 MP&:[^*5]W_0U^LLOHS%!?^>KV; 0CY+/D]7T> 0KX6JRJU48X='C>>+Q] H* M#L_J,V=ZI'B>4+QC,B@@/1-#K9XW(=/SA.D5ZJ @]_2D8*9+LKWL#F;$&S&? M)YB/=U 0>295Z@I)'E6>)RHO+X2"T*O5"2(\ CU/@-X7(3SIFM7[Q>LA@G_9 M=+OSC!0BQ_-I-DC$H^SS9($]GL)T>,VB?\_H5RW0YWGB\_04"BZO/P13AR8C MS?.$YAV30@'M69O4^7P]NCU/W%ZA% J43]]'6.J2CB\WA1FZSZ/N\T3W34BA M,$(Y1J,^.S(]3YA>7@HELN>\^BV+9,_3)?/:]O+=JEV?W5T0W/\!O2:(),_7 M\R$B2/L\64V/UZ\6KEP$_TEIU]& M0K7GB=HKU#X!\ND?9$QS2<67VS[!]EFK7F1 W>>)[N/U$XB>69J1^F%["=/+ MK-]AAZN@?<\'%'N!B+T'$G)_0WASU1_^388B 55>6,X&B@2T?8$LI4<#>/\7 M/+IB8=1A50&!7B! 3PU@$&">5]^< 6E>(#3OB/X% >T%G8H$5'N!J+TR_0L9 M2^L%5'RAI.++[%_(L'T!;5\@MH_6+PA +WAU7$I HQ>(TF]V?UA\/WRN5]N^T-T_RJVX,U)G"O4/X$RZ>6!"%?* GY M$/@% OQX 6E9ZRK]&?'_!*IEU= 0>U5ZJE%0+07"-KK/U^G MS7;0P?=3)3SM'@8'/OQ'=E,XH,\+9C9>)*#P"V1!/=Y!._W674"C%XC1TR,H MV#R]NXCS L%YQS108'O>JRMW!G1[@;B]0@D4*)^^@[#0)1U?;@(S=%] W1>( M[N,!%(B>#RK$#*CT E%Z>?T3Q)Y35PH)"/8" 7N_;BYP:NB;^1)NYD;M7YVK MCW<=_,]-]X$F$'E>L+-A(@&I7R"+ZDU(X/2[=@&Q7B!83T^@@/2BU:X+!V1Z M@3"]8QHH #YKU)D+ PJ^0 1?H08*J$_?0YCHDJ OMX$9S"\@\PN$^?$&"E:O M/_E4OV.1ZP7"]?(:*- ]JXZ"#0CW H%[K_KG;/LCP#/K\]'$5 2E>(!1/3Y] \/3;K0$17B ([ZCT"0,E^D-3;7.0YP7"\PJE M3Q![^N9AF4MRO=ST92"^@(@O$,3'TR=(/)NB^OY"BA<(Q,Z#% M"\3B'5- 0>EYJXK@@$PO$*97JH 9UR:0[862;"^W@!F8+R#F"P3S\0(*(L]' M=?1Q0)07",K+*Z ](PZ&CN@SPO$YWW?KE>G_5Y;_#),%OUUGY?3S>79ZFSS M9'$RWCS4=R'.!H $U'N!K)_'FQIR@0'=72#N[ICH M"2+/ICJHAPEH\@(Q>86J)S ]?1]AE$L:O>SJ";-=J#L9Z5X@=(]G3_!W;AF] M_NP876+P\KHGK8NW5*?\".CQ O%X)^U9TYU?=?V1WN;=XKNSSTUWMKU9%7BH M(/R6K90>4-^%:C;\(Z#@"V0%/1["*N,>'1J\0 R>'D+!WCG5 @>4=X'(NV,Z M*)B\>JE.%!C0Y 5B\@IE4&!Z^A["2IKD9S(![ >%>('!O0@6%62Z<_KV& M "\0@)<700'C6752A( 4+Q"*]]>7K_H;BV&AX,W5S<6_YTW7K;9O MK[KW])XOBKN09J,_ IJ]0);0X_%+&3?G4-T%HN[T^ G:KO+JJ29:NT"LW3'Q M$Q1>M.IZ$@$57B *KU#\!)BG[R%L- /\?=F>GO?].9V6/@1VH9Z/ M^T"P%\@:>CQ]=<:M.21W@9 [/7T2M=-/3E#:!2+MCDF?8/!<4E5F0(,7B,$K ME#Z!Y>E[",MH%(/9X^@=OY_N.M/CEVEWB[O/2)]D[]BD=Y M%XB\>_.Y/>O#U[\,;;ZGAGZ]V9YNZ/EN1%L7E[,1'Q&=7B2KY]'NW?\% M4]Z@$:5=)-).[5X4A%V_H]7G=/B1V+LRW8L"Q]/W M4,#-^\=ICY@A]"(*O4B$'NU>%)A=].JXS8C2+A)IE]6]**@[HPXWC(CN(D%W MCZ_YO?G8=+OF9JS+\ O>O1J?:3;"(Z+0BV35/-X],_UN7$1C%XFQT[LGV#JG M#ON,2.LBH77'=$] =V9DQIF(["X2=E5%LFS>A/A-'S\1$=9% NOT^ F@SJLWP"*2NDA(W3'Q$["= MMT[?'&PQX7:%VB<(/'T/89I+\KO<]F6@O(@H+Q*4Q],GR#I?J;-V1,1UD>"Z MO/()T,ZHTZ9%=':1.+LO#OK.5^O-^7#0=_,+>M"'DB[:V;".B!8ODJ7R>/>L M<"G"Q:1=Y8HHZB(1=2/M.ZRM4T<]1;1TD5BZ8]HG*#N;K'X"CLXN$F=7*'X" MO5,[@NXNEG1WN?&3EMA3WUC(\2+A>+Q^@JFS*29]EV)[B:O+RY]@[/HS#74[ M,,.$V#UKKK?GFZY=_*7YN&ZWBY?MQ::[OIWV_NN[/V3+ $>T=-'-1GA$1'F1 M+)K'*^BFWXZ+R.HB875Z 05.YZQ3SWU1U$4BZHY*H#0FS>CO4]1VD6B[0@D4 M )ZZCU#?Q9+Z+C>!&28OHLF+Q.3Q @JPSBZ=NOY<1%P7":[+*Z [5Q0O^S1 MV47B[$Y6W>FZO1W:=WNC _[DR>*GYZ,)04H7_6QH1T24%\DB>3Q]?OKMN(BL M+A)6IZ=/X'25.KE51% 7":@[IGP"M?-+HX88K5TDUJY4^#(N3:"]BR7M76[X M,D1>1)$7BOR)Q"X28O>Z_;19?QK6M3SI MVK/5;O%]<[I:#Q/>_W^+OUZV-Y_XMO\OBU?=YF/;[59??O2_?&XL;I@-]XA( M\R)9'.]E\]OJXNIB\7;3]3\_O';]^[Y_V7;7RKZ31B"[:JF_AS'*Q-N=W'[D M%C_U_T[8=X_W9O\2]G_V\G;^LB]V]/C+@I$.\[FN@88O$L/WICV]&M[A9^U; MK0+"O)K&AI$=B&$G9N_/[?6SYO+#_\#.0YH7XWQ&8*#.BT3G\9UW]Q>$Q[=M M#C]]WVS/VW;W;;-K_O3'B[9[WYZTZW7_E39\.?1;]17\Z:)KWPT;]R]/[5?? M]#^Y?_B?_OBQ>=^^;+KWJ\OM8MV^ZW]T^8>!('3#JL'WO]EM/@Y_95^0W6YS M560$5E==B#UQ_V8JZHDI/ MZYTK]S70W)*JTB6>%[D59=Q9+^W:0[U>BD:5C,-#C6135;3^=0NE.*P<[+PM M/+)=H0'W;/]1ZYO96 M_M+7[B &!!R=()".0,:$X 3![PC^1PE!1PCLR;12[#FD5-'ULA8'5!NTMF8& M]C M6\MGW,3]2=7Z*],\M7X$6J(O4E$%B/(<;;*LJ9I23W.4@DZEC%$;H"OT MI',N;TI ]_?WZ.*NH'P'$C%^DG.)+E)0E)7R4M._/:7HXM,E^F0H_Q6BD7H_ MN7255F%\<;/.X]O68W+"8TS05\%5(=$7GD-^;,#5\OLS(&]G<$O.6DPANT8^ M_HR(1[P9A^X^3,?)##W].'UQ1HW?1]2W]OQS$84VHHR_Z)$N4R4_(ZI0)J2Z M.;-'T.\1V#V"$WO.F^# ]Z#I=$$8F/<>D\IJFP6V MQG6!EE1*F%463;RY\L-%XH^D36$XBG 8C;1-8:&?)'A>6MQ+BS^:?:#EZ+Q3 M!9S,O7CB O&#,/86(T4SN+D<3>=PQSEZ)&K1BUJ<+=OA)9H/+M%SY9KTMI,_ M6J[)5&+DZ;B-3FP&1B(8?Q7ZK4S>U2P@>]-U$UAOA>,0YK.P*)H M@#H61][%D3]8L9VQX?7N$WUSAF--4]Q&PO=V]R:W-H965T3X@F#1 ME[Y8O,P9GC,SYG"T%_*'R@$T^5D67(V=7.OM>]=5:0XE53=B"QQWUD*65.-4 M;ERUE4 S"RH+-_"\V"TIX\YD9->6C,#&TR+ M1OF,F[2OM,1=AC@]>0!:D'NEJ09">4:F:5J558'3C,P!*REEU":H3U98L2Q=DUN9J#IJQ0U^CU<34G5^^NR3OC MZ4LN*H4TU,C5*,Y0=--&R%TM)#@CQ _(9\%UKL@]SR [=.!B5-K0!,^AN0LN M>IQ#>D-"OT<"+_!.$)J]&>XG)^#SM\.'%]2$;:)#ZR\\XV]U/VLSV"-^T ^& M/=+-_DR46\H9J!XF:P=*XY];FZ2\N42^?\(SR4)#J?ZZP#AJ&4>6<72&\50I MT"X*R<*O==J!DN>WAG_%W5R LE=-LRO_U#BG[8,A[^SZ(?'E5)E$2>=SJU27M<\MO*-#DJ MK>'MT?ENIQ65(#>VI2N2BHKK^NIM5]M7P]0VRU?K=_B:J)O_BYOZ*?*9R@WC MBA2P1I?>S2U2DG5[KR=:;&W#>Q(:VZ<=YO@B FD,<'\MA'Z>F /:-];D%U!+ M P04 " "5DWU2;=L+HF@# "G%P #0 'AL+W-T>6QE* )F_!1%U73."EI=J9))Z\F5 M+JBQ73V+JE(SFE4 *D34[722J*!!NU^\O[CHW+^[WK=?UHYW8>0E_7@$Z54'Y[4^ MC#K9I6Z&6Z8U$@/VO$"XML!P803]XY+J',[K0( 45;@O$:/H=8[2>$ ?1AP? MF?S!U#'R+I;X;MH8G"#P'70-CII-,1KD2F[V!@F=P;+3@@4/5 S#,15\HCF@ MN!_NUX2FX5+J.[2*X[TDS?,^Q[H% M+D0KL!LZPVA04F.8EC>V4P^NC4]<0=.^6Y56X4S35=S]&&X ]YNV]R+>H.0/RGQ9V'1DW8=*93\UR_FR[B_S M5@#&'N/LM"S%ZK/@,UDPE_S1 4<#NL8%D:1W M^AJ; \]IBR3IZ6MLCG>G+O(L2K)_#B+/H29[K_9D?X[(^!Q$=L]!)#E)D5%S M\-TZ7>^0-$FOI7&XL#"&P5L-J!^/XX4%-^#"&PJI@V M; ?CGC3%/%"+_AI-$F1V$OCXUP?;)82DJ=\#/K\"0C /[$;<@RD #9B'D/H] MN/<^BM;OJ6CSK_G17U!+ P04 " "5DWU2EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( )63?5*0.*<>8 8 #H\ M / >&PO=V]R:V)O;VLN>&ULQ9M=<]I&%(;_R@XWI3-M,4)?SL29(0;' MS#C@@IO;SEI:8"?2KK.2G#J_OBL8-T<&O].;8ZXP HN'LVB?<_:LWG^W[NN] MM5_%/V5AJHO>MJX?W@T&5;95I:S^L _*^%?6UI6R]D_=9E ]."7S:JM471:# MX.PL'I12F]Z']\_GNG4#^L36*JNU-?Y@>^"+5M^KGZ^W3\6CKO2]+G3]=-'; M_5VHGBBUT:7^H?*+WEE/5%O[_=HZ_<.:6A:KS-FBN.@-]R]\4:[6V<'A50MY M)^^KW9%:WB^E![GHQ6?^A&OMJGKWCMWYI6=\5/[-^V=-;:]T42LWD;7ZY&SS MH,VF/8W_%@/R-79Q>'[L+( M4EWT+NVCZ?]"VZ6[Q@9>1;SU>)F-AG?32?B MX_AF/+^#O+P>SPED!""C$T+^'1#(&$#&IX,8E635E*]R3L6JSTQFC_;]+48IQEMC&U)I#G /*<%W*I9"&FNT\7,_.H MJKK]A^HW,5<2K7M;B2 M69L(:%51,*23(;-/KJ1VXHLL&M7^#J^TD2;3?LAGIJI=4U),))0ALU$FRNE' MV28QE9 F%]HG<>>DJ>0N==U'E&(BEPR993+-K+&ESL1$^;/DRF2=""*# M#)D5LA_/WS_*RH?QTI;^5-5+GPR14(;,1O'J:,IF/\R+>NLSZY;2J:T']9<. MQ41*&3([96[-[Y>^TFG+F?8BGAE?BGBST$DQ0$()F(7BQ2%N;.55XD.XVDI' M0Q<@CP3,'EFI3?L.L50/7GH^>!0,EB7<=8DM2[W/#7;323N^'L]?OEW9!<@B M ;-%_FS\W*=<\>3C5S6%1^W_963CS:SR7RDDE"" M+OH4$ZDG9%8/3-&[F$@](;-ZZ&JRZ$]4+771'6MDG)#;.#"W#"DF;,"P5SH( M,Z*8R#DALW,P9DPQD7-"9N?@3)WVLT+DG)#9.1AS3#&1<\*3UCV?*";R3GC" M]HSHTYYUA.03,R5#\*DW>L(;@1@MA!&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/- MVDUNXD 0AN&K(!\@IJN[J\JCD-5LLHUR 8LT/PI@9'N4Y/:#R (^:Q:SB?RM M4-NB_,J+1ZCIQY=R:,=]=QIV^_.P^#P>3L.JVHWC^5==#^M=.;;#0W/TZE_^9V&TV^W7YW:W_',MI M_,?@^J/KWX==*6.U>&W[;1E75?UYN%T>ZNM'>+A,KA;/;ZNJ?WX+53UWD$"0 MS!\4(2C.'Y0@*,T?E"$HSQ^D$*3S!QD$V?Q!#D$^?U #0@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z M"^HM!'I'U#L2Z!U1[TB@=T2](X'><;)90J!W1+TC@=X1]8X$>D?4.Q+H'5'O M2*!W1+TC@=X1]8X$>B?4.Q'HG5#O1*!W0KT3@=X)]4X$>J?)9C>!W@GU3@1Z M)]0[$>B=4.]$H'="O1.!W@GU3@1Z9]0[$^B=4>],H'=&O3.!WAGUS@1Z9]0[ M$^B=)W]6$NB=4>],H'=&O3.!WAGUS@1Z9]0[$^BMJ+<2Z*VHMQ+HK:BW$NBM MJ+<2Z*VHMQ+HK:BW$NBMD\,F!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z M&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>MODL""!WH9Z&X'>AGH;@=Z.>CN! MWHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>/CGL3:"WH]Y. MH'>#>C<$>C>H=_.3>@_CUZ$,MY[O-3[_)ZD>+]\MM\=?E]\7)R_ABG-]7S$\ M_0502P,$% @ E9-]4GLV%NT] @ \3, !, !;0V]N=&5N=%]4>7!E M&ULS=O?;MHP%,?Q5T&YK4B(X]AA*KUI=[OU8B_@):9$Y)]LMZ-O/Q/: M2ILZM(I)^]X0@>WS._&1/G=K%\<^F[PFV07PO0IRWR]L[WQZ3C9(:YL M1]>;$+^ZAVPR]=X\V$RL5BJKQR'8(2S#L49R]IXS-HD9IJZMC8AKF=/0_-;RO(E(8TGYSU^UT[^*FY(LG<3CBM_#G@Y M]_7).MGY$N_T.&ZW;6V;L7[LXY'43\Z:QN^L M#7V7GHI>G4\.\8;MZ3._.'\N-SK2(ZGEU,L9%UHS[_B M6V(L??'[V>.T&]O\97:\WA^CV\_S\-G\N/R.?YWQ6_T/]B$@?120/B2DCQ+2 MAX+TH2%]5) ^UI ^\A6E$8JH.874G&)J3D$UIZB:4UC-*:[F%%ASBJR"(JN@ MR"HHL@J*K((BJZ#(*BBR"HJL@B*KH,A:4&0M*+(6%%D+BJP%1=:"(FM!D;6@ MR%I09"THLDJ*K)(BJZ3(*BFR2HJLDB*KI,@J*;)*BJR2(FM)D;6DR%I29"TI MLI8464N*K"5%UI(B:TF1M:3(JBBR*HJLBB*KHLBJ*+(JBJR*(JNBR*HHLBJ* MK)HBJZ;(JBFR:HJLFB*KILBJ*;)JBJR:(JNFR%I19*THLE8462N*K!5%UHHB M:T61M:+(6E%DK2BRKBFRKO^GK-_',W/YG_ZW/P$4$L! A0# M% @ E)-]4@=!36*! L0 ! ( ! &1O8U!R M;W!S+V%P<"YX;6Q02P$"% ,4 " "4DWU2F78WU.\ K @ $0 M @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 " "4DWU2 MF5R<(Q & "<)P $P @ '- 0 >&PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 ( )23?5(=Z/YNL 8 -H: 8 " M@0X( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4E T_SFH P ]@P !@ M ("!UA8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ E)-]4L0QF_6N @ NP8 !@ ("!,"T 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4OD^]3DT M* MX4 !@ ("! 4, 'AL+W=O&UL4$L! A0#% @ E)-] M4MRQF5S.#@ )BH !D ("!VH\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4M[S3) J"P DB( M !D ("!*\$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4EDI:#0H P 8P< !D M ("!/04! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ E)-]4KTR?2&6!P 9Q, !D ("!(!4! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4M3= M;(]W!P E1( !D ("!%#$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4@ ]AEPM(@ &PO M=V]R:W-H965T&UL4$L! A0#% @ E)-]4E%2!P\+# A2$ !D ("! M/:T! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ E)-]4A'/U\P5! Z@D !D ("!2&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4MVLX+:% P [P< !D M ("!X.4! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ E)-]4OW(N-C5 @ F < !D ("!#_8! M 'AL+W=O&PO=V]R:W-H965T!@, "() 9 M " @:7] 0!X;"]W;W)K&UL4$L! A0#% @ ME)-]4O#L"45,"0 ?BX !D ("!X@ " 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4N14/0D.$0 MFG@ !D ("![:EX% "\& &0 @(&X M(0( >&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4C?7_87? P 0A !D M ("!^BL" 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ E)-]4@VLE>D)!P $2X !D ("!QC@" 'AL M+W=O&PO=V]R:W-H965T@, %L- 9 " M@8!# @!X;"]W;W)K&UL4$L! A0#% @ E)-] M4E@M6.?7!0 [R !D ("!,4<" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4BG5:6_^# H%P M !D ("!)UH" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4@Y0!R., P 1 X !D M ("!'6\" 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ E)-]4DCA9E^_ @ .PD !D ("!SGH" 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4OO( MVPON" )S !D ("!T(0" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E)-]4MQNP?@$ P J @ !D M ("!N90" 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ E)-]4L1IEX*@! S!$ !D ("! M(:@" 'AL+W=O&PO=V]R:W-H965TVQ @!X;"]W;W)K&UL4$L! A0#% M @ E9-]4H&MW!](! CA !D ("!.[8" 'AL+W=O&UL4$L! A0#% @ E9-]4N@U7(N! M!@ KA\ !D ("!<,(" 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ E9-]4OL2.)M)! I \ !D M ("!$=0" 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ E9-]4I3@VWY\ P _PP !D ("!X-\" M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ ME9-]4L#_S#7;80 X98# !D ("!?NT" 'AL+W=O6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ E9-]4E].Z@JF @ F#4 M !H ( !VF$# 'AL+U]R96QS+W=O XML 108 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 109 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 727 570 1 true 363 0 false 11 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.thehealthcarereit2.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY Statements 5 false false R6.htm 1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Organization Sheet http://www.thehealthcarereit2.com/role/Organization Organization Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2109103 - Disclosure - Real Estate Investments, Net Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet Real Estate Investments, Net Notes 10 false false R11.htm 2120104 - Disclosure - Mortgage Notes Payable, Net Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet Mortgage Notes Payable, Net Notes 11 false false R12.htm 2124105 - Disclosure - Credit Facilities Sheet http://www.thehealthcarereit2.com/role/CreditFacilities Credit Facilities Notes 12 false false R13.htm 2129106 - Disclosure - Fair Value of Financial Instruments Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 13 false false R14.htm 2133107 - Disclosure - Derivatives and Hedging Activities Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities Derivatives and Hedging Activities Notes 14 false false R15.htm 2140108 - Disclosure - Stockholders' Equity Sheet http://www.thehealthcarereit2.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2145109 - Disclosure - Related Party Transactions and Arrangements Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements Related Party Transactions and Arrangements Notes 16 false false R17.htm 2151110 - Disclosure - Economic Dependency Sheet http://www.thehealthcarereit2.com/role/EconomicDependency Economic Dependency Notes 17 false false R18.htm 2152111 - Disclosure - Equity-Based Compensation Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensation Equity-Based Compensation Notes 18 false false R19.htm 2156112 - Disclosure - Accumulated Other Comprehensive (Loss) Income Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncome Accumulated Other Comprehensive (Loss) Income Notes 19 false false R20.htm 2159113 - Disclosure - Non-Controlling Interests Sheet http://www.thehealthcarereit2.com/role/NonControllingInterests Non-Controlling Interests Notes 20 false false R21.htm 2163114 - Disclosure - Net Loss Per Share Sheet http://www.thehealthcarereit2.com/role/NetLossPerShare Net Loss Per Share Notes 21 false false R22.htm 2166115 - Disclosure - Segment Reporting Sheet http://www.thehealthcarereit2.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 2172116 - Disclosure - Commitments and Contingencies Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 2176117 - Disclosure - Quarterly Results (Unaudited) Sheet http://www.thehealthcarereit2.com/role/QuarterlyResultsUnaudited Quarterly Results (Unaudited) Notes 24 false false R25.htm 2179118 - Disclosure - Subsequent Events Sheet http://www.thehealthcarereit2.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 2181119 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII Real Estate and Accumulated Depreciation - Schedule III Notes 26 false false R27.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 27 false false R28.htm 2305301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 2310302 - Disclosure - Real Estate Investments, Net (Tables) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables Real Estate Investments, Net (Tables) Tables http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet 29 false false R30.htm 2321303 - Disclosure - Mortgage Notes Payable, Net (Tables) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables Mortgage Notes Payable, Net (Tables) Tables http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet 30 false false R31.htm 2325304 - Disclosure - Credit Facilities Credit Facilities (Tables) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables Credit Facilities Credit Facilities (Tables) Tables 31 false false R32.htm 2330305 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments 32 false false R33.htm 2334306 - Disclosure - Derivatives and Hedging Activities (Tables) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables Derivatives and Hedging Activities (Tables) Tables http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities 33 false false R34.htm 2341307 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.thehealthcarereit2.com/role/StockholdersEquity 34 false false R35.htm 2346308 - Disclosure - Related Party Transactions and Arrangements (Tables) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables Related Party Transactions and Arrangements (Tables) Tables http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements 35 false false R36.htm 2353309 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.thehealthcarereit2.com/role/EquityBasedCompensation 36 false false R37.htm 2357310 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeTables Accumulated Other Comprehensive (Loss) Income (Tables) Tables http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncome 37 false false R38.htm 2360311 - Disclosure - Non-Controlling Interests (Tables) Sheet http://www.thehealthcarereit2.com/role/NonControllingInterestsTables Non-Controlling Interests (Tables) Tables http://www.thehealthcarereit2.com/role/NonControllingInterests 38 false false R39.htm 2364312 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.thehealthcarereit2.com/role/NetLossPerShare 39 false false R40.htm 2367313 - Disclosure - Segment Reporting (Tables) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.thehealthcarereit2.com/role/SegmentReporting 40 false false R41.htm 2373314 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables Commitments and Contingencies (Tables) Tables http://www.thehealthcarereit2.com/role/CommitmentsandContingencies 41 false false R42.htm 2377315 - Disclosure - Quarterly Results (Unaudited) (Tables) Sheet http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedTables Quarterly Results (Unaudited) (Tables) Tables http://www.thehealthcarereit2.com/role/QuarterlyResultsUnaudited 42 false false R43.htm 2402401 - Disclosure - Organization (Details) Sheet http://www.thehealthcarereit2.com/role/OrganizationDetails Organization (Details) Details http://www.thehealthcarereit2.com/role/Organization 43 false false R44.htm 2406402 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 44 false false R45.htm 2407403 - Disclosure - Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 45 false false R46.htm 2408404 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details) Sheet http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails Summary of Significant Accounting Policies (Income Taxes) (Details) Details http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables 46 false false R47.htm 2411405 - Disclosure - Real Estate Investments, Net (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails Real Estate Investments, Net (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 47 false false R48.htm 2412406 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails Real Estate Investments, Net (Acquired Assets) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 48 false false R49.htm 2413407 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails Real Estate Investments, Net (Geographic Concentrations) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 49 false false R50.htm 2414408 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 50 false false R51.htm 2415409 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 51 false false R52.htm 2416410 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 52 false false R53.htm 2417411 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails Real Estate Investments, Net (Real Estate Sales) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 53 false false R54.htm 2418412 - Disclosure - Real Estate Investments, Net (Impairments) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails Real Estate Investments, Net (Impairments) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 54 false false R55.htm 2419413 - Disclosure - Real Estate Investments, Net (Held for Sale) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails Real Estate Investments, Net (Held for Sale) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables 55 false false R56.htm 2422414 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails Mortgage Notes Payable, Net (Mortgage Notes) (Details) Details http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables 56 false false R57.htm 2423415 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details) Notes http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails Mortgage Notes Payable, Net (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables 57 false false R58.htm 2426416 - Disclosure - Credit Facilities (Summary of Credit Facilities) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails Credit Facilities (Summary of Credit Facilities) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables 58 false false R59.htm 2427417 - Disclosure - Credit Facilities (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails Credit Facilities (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables 59 false false R60.htm 2428418 - Disclosure - Credit Facilities (Future Principal Payments of Outstanding Debt) (Details) Sheet http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails Credit Facilities (Future Principal Payments of Outstanding Debt) (Details) Details http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables 60 false false R61.htm 2431419 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details) Details http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables 61 false false R62.htm 2432420 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details) Sheet http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails Fair Value of Financial Instruments (Level 3 Inputs) (Details) Details http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables 62 false false R63.htm 2435421 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails Derivatives and Hedging Activities (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 63 false false R64.htm 2436422 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails Derivatives and Hedging Activities (Balance Sheet Location) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 64 false false R65.htm 2437423 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 65 false false R66.htm 2438424 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 66 false false R67.htm 2439425 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details) Sheet http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails Derivatives and Hedging Activities (Offsetting Derivatives) (Details) Details http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables 67 false false R68.htm 2442426 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 68 false false R69.htm 2443427 - Disclosure - Stockholders' Equity (Stock Redemption) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails Stockholders' Equity (Stock Redemption) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 69 false false R70.htm 2444428 - Disclosure - Stockholders' Equity (Distributions) (Details) Sheet http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails Stockholders' Equity (Distributions) (Details) Details http://www.thehealthcarereit2.com/role/StockholdersEquityTables 70 false false R71.htm 2447429 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails Related Party Transactions and Arrangements (Ownership) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 71 false false R72.htm 2448430 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 72 false false R73.htm 2449431 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 73 false false R74.htm 2450432 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details) Details http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables 74 false false R75.htm 2454433 - Disclosure - Equity-Based Compensation (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables 75 false false R76.htm 2455434 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) Sheet http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details) Details http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables 76 false false R77.htm 2458435 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details) Sheet http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails Accumulated Other Comprehensive (Loss) Income (Details) Details http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeTables 77 false false R78.htm 2461436 - Disclosure - Non-Controlling Interests (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails Non-Controlling Interests (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/NonControllingInterestsTables 78 false false R79.htm 2462437 - Disclosure - Non-Controlling Interests (Summary of Non-Controlling Interests) (Details) Sheet http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails Non-Controlling Interests (Summary of Non-Controlling Interests) (Details) Details http://www.thehealthcarereit2.com/role/NonControllingInterestsTables 79 false false R80.htm 2465438 - Disclosure - Net Loss Per Share (Details) Sheet http://www.thehealthcarereit2.com/role/NetLossPerShareDetails Net Loss Per Share (Details) Details http://www.thehealthcarereit2.com/role/NetLossPerShareTables 80 false false R81.htm 2468439 - Disclosure - Segment Reporting (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails Segment Reporting (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 81 false false R82.htm 2469440 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails Segment Reporting (Reconciliation of Segment Activity) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 82 false false R83.htm 2470441 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails Segment Reporting (Reconciliation of Segment Activity to Assets) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 83 false false R84.htm 2471442 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) Sheet http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details) Details http://www.thehealthcarereit2.com/role/SegmentReportingTables 84 false false R85.htm 2474443 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables 85 false false R86.htm 2475444 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) Sheet http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details) Details http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables 86 false false R87.htm 2478445 - Disclosure - Quarterly Results (Unaudited) (Details) Sheet http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails Quarterly Results (Unaudited) (Details) Details http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedTables 87 false false R88.htm 2480446 - Disclosure - Subsequent Events (Narrative) (Details) Sheet http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails Subsequent Events (Narrative) (Details) Details http://www.thehealthcarereit2.com/role/SubsequentEvents 88 false false R89.htm 2482447 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 89 false false R90.htm 2483448 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 90 false false R91.htm 2484449 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) Sheet http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details) Details http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII 91 false false All Reports Book All Reports hct-20201231.htm ex211hti12312020.htm ex231hti12312020.htm ex232hti12312020.htm ex311hti12312020.htm ex312hti12312020.htm ex32hti12312020.htm ex45descriptionofsecurities.htm hct-20201231.xsd hct-20201231_cal.xml hct-20201231_def.xml hct-20201231_lab.xml hct-20201231_pre.xml hct-20201231_g1.jpg http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 113 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hct-20201231.htm": { "axisCustom": 2, "axisStandard": 49, "contextCount": 727, "dts": { "calculationLink": { "local": [ "hct-20201231_cal.xml" ] }, "definitionLink": { "local": [ "hct-20201231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "hct-20201231.htm" ] }, "labelLink": { "local": [ "hct-20201231_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "hct-20201231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml" ] }, "schema": { "local": [ "hct-20201231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 1056, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 1, "http://www.thehealthcarereit2.com/20201231": 1, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 6 }, "keyCustom": 111, "keyStandard": 459, "memberCustom": 292, "memberStandard": 60, "nsprefix": "hct", "nsuri": "http://www.thehealthcarereit2.com/20201231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.thehealthcarereit2.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109103 - Disclosure - Real Estate Investments, Net", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet", "shortName": "Real Estate Investments, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RealEstateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120104 - Disclosure - Mortgage Notes Payable, Net", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet", "shortName": "Mortgage Notes Payable, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124105 - Disclosure - Credit Facilities", "role": "http://www.thehealthcarereit2.com/role/CreditFacilities", "shortName": "Credit Facilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129106 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133107 - Disclosure - Derivatives and Hedging Activities", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities", "shortName": "Derivatives and Hedging Activities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140108 - Disclosure - Stockholders' Equity", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2145109 - Disclosure - Related Party Transactions and Arrangements", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements", "shortName": "Related Party Transactions and Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:EconomicDependencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151110 - Disclosure - Economic Dependency", "role": "http://www.thehealthcarereit2.com/role/EconomicDependency", "shortName": "Economic Dependency", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:EconomicDependencyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152111 - Disclosure - Equity-Based Compensation", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensation", "shortName": "Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156112 - Disclosure - Accumulated Other Comprehensive (Loss) Income", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncome", "shortName": "Accumulated Other Comprehensive (Loss) Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2159113 - Disclosure - Non-Controlling Interests", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterests", "shortName": "Non-Controlling Interests", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163114 - Disclosure - Net Loss Per Share", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2166115 - Disclosure - Segment Reporting", "role": "http://www.thehealthcarereit2.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172116 - Disclosure - Commitments and Contingencies", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2176117 - Disclosure - Quarterly Results (Unaudited)", "role": "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnaudited", "shortName": "Quarterly Results (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2179118 - Disclosure - Subsequent Events", "role": "http://www.thehealthcarereit2.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2181119 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII", "shortName": "Real Estate and Accumulated Depreciation - Schedule III", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Real Estate Investments, Net (Tables)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables", "shortName": "Real Estate Investments, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321303 - Disclosure - Mortgage Notes Payable, Net (Tables)", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables", "shortName": "Mortgage Notes Payable, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325304 - Disclosure - Credit Facilities Credit Facilities (Tables)", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables", "shortName": "Credit Facilities Credit Facilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330305 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334306 - Disclosure - Derivatives and Hedging Activities (Tables)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables", "shortName": "Derivatives and Hedging Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341307 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2346308 - Disclosure - Related Party Transactions and Arrangements (Tables)", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables", "shortName": "Related Party Transactions and Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353309 - Disclosure - Equity-Based Compensation (Tables)", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables", "shortName": "Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2357310 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeTables", "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2360311 - Disclosure - Non-Controlling Interests (Tables)", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterestsTables", "shortName": "Non-Controlling Interests (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2364312 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostsAndExpensesRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2367313 - Disclosure - Segment Reporting (Tables)", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2373314 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2377315 - Disclosure - Quarterly Results (Unaudited) (Tables)", "role": "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedTables", "shortName": "Quarterly Results (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Organization (Details)", "role": "http://www.thehealthcarereit2.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ia840ee0279a34a79907b83aa01509ee9_D20180101-20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "hct:OverstatementOfPreviouslyRecordedTaxBenefitsDeferredTaxAssetsandNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ia840ee0279a34a79907b83aa01509ee9_D20180101-20181231", "decimals": "-5", "first": true, "lang": "en-US", "name": "hct:OverstatementOfPreviouslyRecordedTaxBenefitsDeferredTaxAssetsandNetIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details)", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails", "shortName": "Summary of Significant Accounting Policies (Lessor Maturity Schedule) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies (Income Taxes) (Details)", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "Summary of Significant Accounting Policies (Income Taxes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Real Estate Investments, Net (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "shortName": "Real Estate Investments, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ifcab330961a24184a1c1d5c8c39f8538_I20150831", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i3fb4a93ea00a410881f907790bee148a_D20190101-20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "hct:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopmentinProcessAcquiredinPeriod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Real Estate Investments, Net (Acquired Assets) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "shortName": "Real Estate Investments, Net (Acquired Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ibf3006d9625a45e7a3d1b06e87f1e1d1_D20200101-20201231", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesTransferred", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Real Estate Investments, Net (Geographic Concentrations) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "shortName": "Real Estate Investments, Net (Geographic Concentrations) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7393e1d74dde4ae69b9aa8e38893caa1_D20200101-20201231", "decimals": "3", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "icc5dbc6f37b04a93bd48e47f84ed86e5_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "icc5dbc6f37b04a93bd48e47f84ed86e5_I20171231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414408 - Disclosure - Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails", "shortName": "Real Estate Investments, Net (Summary of Intangible Lease Assets and Liabilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "shortName": "Real Estate Investments, Net (Summary of Amortization and Accretion Recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i258e3e26ea294ce8872ff672e7597cba_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ie7f461cac12443bdac05bfdabe7872d5_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "shortName": "Real Estate Investments, Net (Summary of Intangible Assets and Liabilities Future Amortization Expense) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ie7f461cac12443bdac05bfdabe7872d5_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnSalesOfInvestmentRealEstate", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417411 - Disclosure - Real Estate Investments, Net (Real Estate Sales) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "shortName": "Real Estate Investments, Net (Real Estate Sales) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i07187d62de1940599bafeae20b5e8c14_I20190801", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfRealEstate", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418412 - Disclosure - Real Estate Investments, Net (Impairments) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "shortName": "Real Estate Investments, Net (Impairments) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419413 - Disclosure - Real Estate Investments, Net (Held for Sale) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "shortName": "Real Estate Investments, Net (Held for Sale) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i87b1796a34e64356a39a20799871c874_I20201231", "decimals": "-3", "lang": "en-US", "name": "hct:DisposalGroupIncludingDiscontinuedOperationLand", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422414 - Disclosure - Mortgage Notes Payable, Net (Mortgage Notes) (Details)", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "shortName": "Mortgage Notes Payable, Net (Mortgage Notes) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i15025cb6d9dd4db3b733b9f24f11ca31_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423415 - Disclosure - Mortgage Notes Payable, Net (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "shortName": "Mortgage Notes Payable, Net (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i0b242181567c45639a5bb61756bdc428_I20191220", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "property", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426416 - Disclosure - Credit Facilities (Summary of Credit Facilities) (Details)", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "shortName": "Credit Facilities (Summary of Credit Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "idcd90ce68d8541f389c76f3378cc2170_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DebtInstrumentCollateralAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427417 - Disclosure - Credit Facilities (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "shortName": "Credit Facilities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i0c6c9cb2eb9e4e0cb226c90df88cae4c_I20200810", "decimals": "-5", "lang": "en-US", "name": "hct:DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "hct:CommonStockStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "2", "first": true, "lang": "en-US", "name": "hct:CommonStockStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428418 - Disclosure - Credit Facilities (Future Principal Payments of Outstanding Debt) (Details)", "role": "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "shortName": "Credit Facilities (Future Principal Payments of Outstanding Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ia4fe7dece96749a6b7c42be3fdb0f5cf_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431419 - Disclosure - Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details)", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "shortName": "Fair Value of Financial Instruments (Assets Measured at Fair Value) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ia4fe7dece96749a6b7c42be3fdb0f5cf_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ibe21e5b3e42442049c649b73281aecf9_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432420 - Disclosure - Fair Value of Financial Instruments (Level 3 Inputs) (Details)", "role": "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "shortName": "Fair Value of Financial Instruments (Level 3 Inputs) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ibe21e5b3e42442049c649b73281aecf9_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i1fedcc6e405e42519eaeb65908fbaf57_I20191101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435421 - Disclosure - Derivatives and Hedging Activities (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "shortName": "Derivatives and Hedging Activities (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i5d6d01fac9644a6e9b9e788015c6a27c_D20201001-20201231", "decimals": "-5", "lang": "en-US", "name": "hct:ProceedsFromSaleofInterestRateCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436422 - Disclosure - Derivatives and Hedging Activities (Balance Sheet Location) (Details)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "shortName": "Derivatives and Hedging Activities (Balance Sheet Location) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i726ab01449354ee1b893f62e112faf92_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i1fedcc6e405e42519eaeb65908fbaf57_I20191101", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437423 - Disclosure - Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "shortName": "Derivatives and Hedging Activities (Summary of Derivative Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i3d4e1030f94d4624a75ad441d8d88148_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "reportCount": 1, "unique": true, "unitRef": "instrument", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438424 - Disclosure - Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "shortName": "Derivatives and Hedging Activities (Derivatives Included in AOCI) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ifdecbe99b1ca435e82c13a636f7f351f_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439425 - Disclosure - Derivatives and Hedging Activities (Offsetting Derivatives) (Details)", "role": "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "shortName": "Derivatives and Hedging Activities (Offsetting Derivatives) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfTreasuryStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ib902c9be3bb44d35bf05fa74b242653c_D20200226-20200226", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442426 - Disclosure - Stockholders' Equity (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "shortName": "Stockholders' Equity (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ibc15bbe4ba1845e9abd376464d662d9e_D20191030-20191030", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ib902c9be3bb44d35bf05fa74b242653c_D20200226-20200226", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443427 - Disclosure - Stockholders' Equity (Stock Redemption) (Details)", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails", "shortName": "Stockholders' Equity (Stock Redemption) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "hct:DividendsPayablePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444428 - Disclosure - Stockholders' Equity (Distributions) (Details)", "role": "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails", "shortName": "Stockholders' Equity (Distributions) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DividendsDeclaredTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "3", "first": true, "lang": "en-US", "name": "hct:DividendsPayablePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447429 - Disclosure - Related Party Transactions and Arrangements (Ownership) (Details)", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails", "shortName": "Related Party Transactions and Arrangements (Ownership) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i6ffc99e150bf4ad99c18999886dc30d7_I20201231", "decimals": "-5", "lang": "en-US", "name": "hct:RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i8c13214a0d1e4d96890e63516ba1ca76_D20170217-20170217", "decimals": null, "first": true, "lang": "en-US", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448430 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details)", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "shortName": "Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i8c13214a0d1e4d96890e63516ba1ca76_D20170217-20170217", "decimals": null, "first": true, "lang": "en-US", "name": "hct:RelatedPartyAgreementTermofAgreementRenewalPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449431 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details)", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "shortName": "Related Party Transactions and Arrangements (Fees Paid in Connection With the Operations of the Company, Incurred, Forgiven and Payable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "hct:ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i8123ece4d9394d2d9938c3bb749bc9f7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450432 - Disclosure - Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details)", "role": "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "shortName": "Related Party Transactions and Arrangements (Fees Paid in Connection with the Liquidation or Listing of the Company's Real Estate Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i8123ece4d9394d2d9938c3bb749bc9f7_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i455891a046574e64bcb53c055db592e4_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454433 - Disclosure - Equity-Based Compensation (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "shortName": "Equity-Based Compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i455891a046574e64bcb53c055db592e4_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i161a9036153c4fa4aff6da330de2b4e5_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455434 - Disclosure - Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details)", "role": "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "shortName": "Equity-Based Compensation (Summary of Share-based Compensation Awards) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i91279aab0d554b3da7276399e73d5470_I20171231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i86dc51592d0742738ef2ad96e40932db_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458435 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)", "role": "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i511a051d61aa4e328939a4ac9974b563_I20171231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461436 - Disclosure - Non-Controlling Interests (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "shortName": "Non-Controlling Interests (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i32f4388574c94edbb9092d4f5b5827be_D20201104-20201104", "decimals": "-5", "lang": "en-US", "name": "us-gaap:PaymentsToMinorityShareholders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462437 - Disclosure - Non-Controlling Interests (Summary of Non-Controlling Interests) (Details)", "role": "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails", "shortName": "Non-Controlling Interests (Summary of Non-Controlling Interests) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RedeemableNoncontrollingInterestTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "idbdeded1dc364beb9d3572d5f25a0563_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MinorityInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.thehealthcarereit2.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465438 - Disclosure - Net Loss Per Share (Details)", "role": "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "shortName": "Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "0", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468439 - Disclosure - Segment Reporting (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i3ab4f61e20ac41ad85d34d4a2139bf7e_I20190401", "decimals": "INF", "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "property", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ief676d903bcb4aeba86c193c432e6c91_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469440 - Disclosure - Segment Reporting (Reconciliation of Segment Activity) (Details)", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "shortName": "Segment Reporting (Reconciliation of Segment Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateInvestmentPropertyNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470441 - Disclosure - Segment Reporting (Reconciliation of Segment Activity to Assets) (Details)", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "shortName": "Segment Reporting (Reconciliation of Segment Activity to Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i59ea93dafc9f42daa0115fb4359e6250_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471442 - Disclosure - Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details)", "role": "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "shortName": "Segment Reporting (Reconciliation of Capital Expenditures by Segment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i59ea93dafc9f42daa0115fb4359e6250_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ib912277b15284b1887cf627270d78799_D20190101-20190101", "decimals": "INF", "first": true, "lang": "en-US", "name": "hct:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unitRef": "lease", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474443 - Disclosure - Commitments and Contingencies (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "hct:LesseeFinanceLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475444 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details)", "role": "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails", "shortName": "Commitments and Contingencies (Schedule of Future Minimum Rental Payments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ief676d903bcb4aeba86c193c432e6c91_D20201001-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478445 - Disclosure - Quarterly Results (Unaudited) (Details)", "role": "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "shortName": "Quarterly Results (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ief676d903bcb4aeba86c193c432e6c91_D20201001-20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i3082d01098d740e5ae26310ce36bffa6_D20201001-20201001", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockDividendsShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2480446 - Disclosure - Subsequent Events (Narrative) (Details)", "role": "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "shortName": "Subsequent Events (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ie5a7179fbaf04cd286c0642e4a1ae106_D20210104-20210104", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockDividendsShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2482447 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "shortName": "Real Estate and Accumulated Depreciation - Schedule III (Summary of Real Estate Properties) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "id62c52988f3949b09084ab8831754ec8_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i86dc51592d0742738ef2ad96e40932db_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RealEstateGrossAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483448 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "shortName": "Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "hct:RealEstateInvestmentPropertyAtCostAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "i7016ed62543e41b2a69e99ba5f18b2b1_D20200101-20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "hct:OtherRealEstateDisposalsAndReclasses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2484449 - Disclosure - Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details)", "role": "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "shortName": "Real Estate and Accumulated Depreciation - Schedule III (Changes in Accumulated Depreciation Additional Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "hct-20201231.htm", "contextRef": "ie8baf65bb2f84f4f9ab9c100df5c8b68_D20200101-20201231", "decimals": "-5", "lang": "en-US", "name": "hct:OtherRealEstateDisposalsAndReclasses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 363, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r618" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r610" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hct_A2019BonusAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Bonus Awards", "label": "2019 Bonus Awards [Member]", "terseLabel": "2019 Bonus Awards" } } }, "localname": "A2019BonusAwardsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_A757BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "757 Building - Munster - October [Member]", "label": "757 Building - Munster - October [Member]", "terseLabel": "757 Building - Munster, IN" } } }, "localname": "A757BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_A759BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "759 Building - Munster - October [Member]", "label": "759 Building - Munster - October [Member]", "terseLabel": "759 Building - Munster, IN" } } }, "localname": "A759BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_A761BuildingMunsterOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "761 Building - Munster - October [Member]", "label": "761 Building - Munster - October [Member]", "terseLabel": "761 Building - Munster, IN" } } }, "localname": "A761BuildingMunsterOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AboveMarketGroundLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Above Market Ground Lease [Member]", "label": "Above Market Ground Lease [Member]", "verboseLabel": "Above-market ground leases" } } }, "localname": "AboveMarketGroundLeaseMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_AboveandBelowMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Above and Below Market Leases [Member]", "label": "Above and Below Market Leases [Member]", "terseLabel": "Above- and below-market leases, net" } } }, "localname": "AboveandBelowMarketLeasesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment for noncash decrease (increase) in rental revenue related to assets (liabilities) associated with the acquisition of an off-market lease when the terms of the lease are favorable (unfavorable) to the market terms for the lease at the date of acquisition.", "label": "Accretion of Below-Market Lease Liabilities and Amortization of Above-Market Lease Assets, Net", "terseLabel": "(Accretion) amortization of market lease and other intangibles, net", "verboseLabel": "Accretion of above- and below-market leases, net" } } }, "localname": "AccretionOfBelowMarketLeaseLiabilitiesAndAmortizationOfAboveMarketLeaseAssetsNet", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "hct_AcquisitionCostsReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition Costs Reimbursements [Member]", "label": "Acquisition Costs Reimbursements [Member]", "terseLabel": "Acquisition cost reimbursements" } } }, "localname": "AcquisitionCostsReimbursementsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_AcuitySpecialtyHospitalMesaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AcuitySpecialtyHospitalMesa [Member]", "label": "AcuitySpecialtyHospitalMesa [Member]", "terseLabel": "Acuity Specialty Hospital - Mesa, AZ" } } }, "localname": "AcuitySpecialtyHospitalMesaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AcuitySpecialtyHospitalSunCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AcuitySpecialtyHospitalSunCity [Member]", "label": "AcuitySpecialtyHospitalSunCity [Member]", "terseLabel": "Acuity Specialty Hospital - Sun City, AZ" } } }, "localname": "AcuitySpecialtyHospitalSunCityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceNorthvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place - Northville", "label": "Addington Place - Northville [Member]", "terseLabel": "Addington Place - Northville, MI" } } }, "localname": "AddingtonPlaceNorthvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceatMillsRosewellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AddingtonPlaceatMillsRosewell [Member]", "label": "AddingtonPlaceatMillsRosewell [Member]", "terseLabel": "Addington Place at Mills - Roswell, GA" } } }, "localname": "AddingtonPlaceatMillsRosewellMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofAlpharettaAlpharettaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Alpharetta - Alpharetta [Member]", "label": "Addington Place of Alpharetta - Alpharetta [Member]", "terseLabel": "Addington Place of Alpharetta - Alpharetta, GA" } } }, "localname": "AddingtonPlaceofAlpharettaAlpharettaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofBrunswickBrunswickSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Brunswick - Brunswick - September [Member]", "label": "Addington Place of Brunswick - Brunswick - September [Member]", "terseLabel": "Addington Place of Brunswick - Brunswick, GA" } } }, "localname": "AddingtonPlaceofBrunswickBrunswickSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member]", "label": "AddingtonPlaceofCollegeHarbourStPetersburgSeptember [Member]", "terseLabel": "Addington Place of College Harbour - St Petersburg, FL" } } }, "localname": "AddingtonPlaceofCollegeHarbourStPetersburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofDublinDublinSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Dublin - Dublin - September [Member]", "label": "Addington Place of Dublin - Dublin - September [Member]", "terseLabel": "Addington Place of Dublin - Dublin, GA" } } }, "localname": "AddingtonPlaceofDublinDublinSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Johns Creek - Johns Creek - September [Member]", "label": "Addington Place of Johns Creek - Johns Creek - September [Member]", "terseLabel": "Addington Place of Johns Creek - Johns Creek, GA" } } }, "localname": "AddingtonPlaceofJohnsCreekJohnsCreekSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofLeesSummitLeesSummitSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Lee's Summit - Lee's Summit - September [Member]", "label": "Addington Place of Lee's Summit - Lee's Summit - September [Member]", "terseLabel": "Addington Place of Lee's Summit - Lee's Summit, MO" } } }, "localname": "AddingtonPlaceofLeesSummitLeesSummitSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofPrairieVillagePrairieVillageMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Prairie Village - Prairie Village [Member]", "label": "Addington Place of Prairie Village - Prairie Village [Member]", "terseLabel": "Addington Place of Prairie Village - Prairie Village, KS" } } }, "localname": "AddingtonPlaceofPrairieVillagePrairieVillageMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofShoalCreekKansasCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Shoal Creek - Kansas City [Member]", "label": "Addington Place of Shoal Creek - Kansas City [Member]", "terseLabel": "Addington Place of Shoal Creek - Kansas City, MO" } } }, "localname": "AddingtonPlaceofShoalCreekKansasCityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonPlaceofTitusvilleTitusvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Addington Place of Titusville - Titusville [Member]", "label": "Addington Place of Titusville - Titusville [Member]", "terseLabel": "Addington Place of Titusville - Titusville, FL" } } }, "localname": "AddingtonPlaceofTitusvilleTitusvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AddingtonatWellingtonGreenWellingtonOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AddingtonatWellingtonGreenWellingtonOctober [Member]", "label": "AddingtonatWellingtonGreenWellingtonOctober [Member]", "terseLabel": "Addington at Wellington Green - Wellington, FL" } } }, "localname": "AddingtonatWellingtonGreenWellingtonOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdenaHealthCenterJacksonOHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adena Health Center - Jackson, OH [Member]", "label": "Adena Health Center - Jackson, OH [Member]", "terseLabel": "Adena Health Center - Jackson, OH" } } }, "localname": "AdenaHealthCenterJacksonOHMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage", "label": "Adjustments to Additional Paid in Capital, Rebalancing Of Ownership Percentage", "terseLabel": "Rebalancing of ownership percentage" } } }, "localname": "AdjustmentstoAdditionalPaidinCapitalRebalancingOfOwnershipPercentage", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "hct_AdvanceOnLoanOrOtherInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advance on Loan or Other Investment [Member]", "label": "Advance on Loan or Other Investment [Member]", "terseLabel": "Advance on Loan or Other Investment" } } }, "localname": "AdvanceOnLoanOrOtherInvestmentMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AdvancedOrthopaedicMedicalCenterRichmondAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Orthopaedic Medical Center - Richmond - April [Member]", "label": "Advanced Orthopaedic Medical Center - Richmond - April [Member]", "terseLabel": "Advanced Orthopedic Medical Center - Richmond, VA" } } }, "localname": "AdvancedOrthopaedicMedicalCenterRichmondAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdventistHealthLaceyMedicalPlazaHanfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adventist Health Lacey Medical Plaza - Hanford [Member]", "label": "Adventist Health Lacey Medical Plaza - Hanford [Member]", "terseLabel": "Adventist Health Lacey Medical Plaza - Hanford, CA" } } }, "localname": "AdventistHealthLaceyMedicalPlazaHanfordMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AdvisorAndCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor And Company [Member]", "label": "Advisor And Company [Member]", "terseLabel": "Advisor And Company" } } }, "localname": "AdvisorAndCompanyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor [Member]", "label": "Advisor [Member]", "terseLabel": "Advisor" } } }, "localname": "AdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_AdvocateAuroraMOBElkhornWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advocate Aurora MOB - Elkhorn WI [Member]", "label": "Advocate Aurora MOB - Elkhorn WI [Member]", "terseLabel": "Advocate Aurora MOB - Elkhorn, WI" } } }, "localname": "AdvocateAuroraMOBElkhornWIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatElizabethtownElizabethtownSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Elizabethtown - Elizabethtown - September [Member]", "label": "Allegro at Elizabethtown - Elizabethtown - September [Member]", "terseLabel": "Allegro at Elizabethtown - Elizabethtown, KY" } } }, "localname": "AllegroatElizabethtownElizabethtownSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatJupiterJupiterSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Jupiter - Jupiter - September [Member]", "label": "Allegro at Jupiter - Jupiter - September [Member]", "terseLabel": "Allegro at Jupiter - Jupiter, FL" } } }, "localname": "AllegroatJupiterJupiterSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatStPetersburgLandStPetersburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at St Petersburg - Land - St Petersburg - September [Member]", "label": "Allegro at St Petersburg - Land - St Petersburg - September [Member]", "terseLabel": "Allegro at St. Petersburg - Land - St. Petersburg, FL" } } }, "localname": "AllegroatStPetersburgLandStPetersburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatStuartStuartSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Stuart - Stuart - September [Member]", "label": "Allegro at Stuart - Stuart - September [Member]", "terseLabel": "Allegro at Stuart - Stuart, FL" } } }, "localname": "AllegroatStuartStuartSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AllegroatTarponTarponSpringsSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Allegro at Tarpon - Tarpon Springs - September [Member]", "label": "Allegro at Tarpon - Tarpon Springs - September [Member]", "terseLabel": "Allegro at Tarpon - Tarpon Springs, FL" } } }, "localname": "AllegroatTarponTarponSpringsSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AmendedandRestatedPropertyManagementandLeasingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Property Management and Leasing Agreement [Member]", "label": "Amended and Restated Property Management and Leasing Agreement [Member]", "terseLabel": "Amended and Restated Property Management and Leasing Agreement" } } }, "localname": "AmendedandRestatedPropertyManagementandLeasingAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AmendedandRestatedRSPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated RSP [Member]", "label": "Amended and Restated RSP [Member]", "terseLabel": "Amended and Restated RSP" } } }, "localname": "AmendedandRestatedRSPMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare Advisors, LLC [Member]", "label": "American Realty Capital Healthcare Advisors, LLC [Member]", "terseLabel": "American Realty Capital Healthcare Advisors, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareAdvisorsLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare III Advisors, LLC [Member]", "label": "American Realty Capital Healthcare III Advisors, LLC [Member]", "terseLabel": "American Realty Capital Healthcare III Advisors, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareIIIAdvisorsLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "hct_AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]", "label": "American Realty Capital Healthcare II Special Limited Partnership, LLC [Member]", "terseLabel": "American Realty Capital Healthcare II Special Limited Partnership, LLC" } } }, "localname": "AmericanRealtyCapitalHealthcareIISpecialLimitedPartnershipLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_AmortizationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization Expense [Member]", "label": "Amortization Expense [Member]", "terseLabel": "Amortization Expense" } } }, "localname": "AmortizationExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_AmortizationOfTerminatedSwapPayment": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Terminated Swap Payment", "label": "Amortization of Terminated Swap Payment", "terseLabel": "Amortization of terminated swap" } } }, "localname": "AmortizationOfTerminatedSwapPayment", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_AnnualTargetedInvestorReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Targeted Investor Return [Member]", "label": "Annual Targeted Investor Return [Member]", "terseLabel": "Annual Targeted Investor Return" } } }, "localname": "AnnualTargetedInvestorReturnMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arbor View Assisted Living and Memory Care - Burlington - March [Member]", "label": "Arbor View Assisted Living and Memory Care - Burlington - March [Member]", "terseLabel": "Arbor View Assisted Living and Memory Care - Burlington, WI" } } }, "localname": "ArborViewAssistedLivingandMemoryCareBurlingtonMarchMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArcadianCoveAssistedLivingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arcadian Cove Assisted Living [Member]", "label": "Arcadian Cove Assisted Living [Member]", "terseLabel": "Arcadian Cove Assisted Living - Richmond, KY" } } }, "localname": "ArcadianCoveAssistedLivingMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArrowheadMedicalPlazaIGlendaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrowhead Medical Plaza I - Glendale [Member]", "label": "Arrowhead Medical Plaza I - Glendale [Member]", "terseLabel": "Arrowhead Medical Plaza I - Glendale, AZ" } } }, "localname": "ArrowheadMedicalPlazaIGlendaleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ArrowheadMedicalPlazaIIGlendaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrowhead Medical Plaza II - Glendale [Member]", "label": "Arrowhead Medical Plaza II - Glendale [Member]", "terseLabel": "Arrowhead Medical Plaza II - Glendale, AZ" } } }, "localname": "ArrowheadMedicalPlazaIIGlendaleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AssetManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Management Fees [Member]", "label": "Asset Management Fees [Member]", "terseLabel": "Asset management fees" } } }, "localname": "AssetManagementFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_AuraSheboyanClinicKielMarchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aura Sheboyan Clinic - Kiel - March [Member]", "label": "Aura Sheboyan Clinic - Kiel - March [Member]", "terseLabel": "Aurora Healthcare Center - Kiel, WI" } } }, "localname": "AuraSheboyanClinicKielMarchMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthCenterGreenBayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Health Center - Green Bay [Member]", "label": "Aurora Health Center - Green Bay [Member]", "terseLabel": "Aurora Healthcare Center - Green Bay, WI" } } }, "localname": "AuroraHealthCenterGreenBayMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthCenterMilwaukeeAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AuroraHealthCenterMilwaukeeApril [Member]", "label": "AuroraHealthCenterMilwaukeeApril [Member]", "terseLabel": "Aurora Health Center - Milwaukee, WI" } } }, "localname": "AuroraHealthCenterMilwaukeeAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterGreenvilleWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Greenville,WI [Member]", "label": "Aurora Healthcare Center, Greenville,WI [Member]", "terseLabel": "Aurora Healthcare Center - Greenville, WI" } } }, "localname": "AuroraHealthcareCenterGreenvilleWIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterPlymouthWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center Plymouth, WI [Member]", "label": "Aurora Healthcare Center Plymouth, WI [Member]", "terseLabel": "Aurora Healthcare Center - Plymouth, WI" } } }, "localname": "AuroraHealthcareCenterPlymouthWIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterWaterfordWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Waterford, WI [Member]", "label": "Aurora Healthcare Center, Waterford, WI [Member]", "terseLabel": "Aurora Healthcare Center - Waterford, WI" } } }, "localname": "AuroraHealthcareCenterWaterfordWIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AuroraHealthcareCenterWautomaWIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aurora Healthcare Center, Wautoma, WI [Member]", "label": "Aurora Healthcare Center, Wautoma, WI [Member]", "terseLabel": "Aurora Healthcare Center - Wautoma, WI" } } }, "localname": "AuroraHealthcareCenterWautomaWIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnLeavesofClearLakeHoustonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Leaves of Clear Lake - Houston - December [Member]", "label": "Autumn Leaves of Clear Lake - Houston - December [Member]", "terseLabel": "Autumn Leaves of Clear Lake, Houston, TX" } } }, "localname": "AutumnLeavesofClearLakeHoustonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnLeavesofCyFairHoustonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Leaves of Cy-Fair - Houston - December [Member]", "label": "Autumn Leaves of Cy-Fair - Houston - December [Member]", "terseLabel": "Autumn Leaves of Cy-Fair - Houston, TX" } } }, "localname": "AutumnLeavesofCyFairHoustonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnLeavesofMeyerlandHoustonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Leaves of Meyerland - Houston - December [Member]", "label": "Autumn Leaves of Meyerland - Houston - December [Member]", "terseLabel": "Autumn Leaves of Meyerland - Houston, TX" } } }, "localname": "AutumnLeavesofMeyerlandHoustonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnLeavesoftheWoodlandsTheWoodlandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Leaves of the Woodlands - The Woodlands [Member]", "label": "Autumn Leaves of the Woodlands - The Woodlands [Member]", "terseLabel": "Autumn Leaves of The Woodlands - The Woodlands, TX" } } }, "localname": "AutumnLeavesoftheWoodlandsTheWoodlandsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_AutumnRidgeOfClarkstonClarkstonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Autumn Ridge Of Clarkston - Clarkston - August", "label": "Autumn Ridge Of Clarkston - Clarkston - August [Member]", "terseLabel": "Autumn Ridge of Clarkston - Clarkston, MI" } } }, "localname": "AutumnRidgeOfClarkstonClarkstonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BayshoreNaplesMemoryCareNaplesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayshore Naples Memory Care - Naples", "label": "Bayshore Naples Memory Care - Naples [Member]", "terseLabel": "Bayshore Naples Memory Care - Naples, FL" } } }, "localname": "BayshoreNaplesMemoryCareNaplesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BeaumontMedicalCenterWarrenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beaumont Medical Center - Warren [Member]", "label": "Beaumont Medical Center - Warren [Member]", "terseLabel": "Beaumont Medical Center - Warren, MI" } } }, "localname": "BeaumontMedicalCenterWarrenMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BelmarMedicalBuildingLakewoodJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belmar Medical Building - Lakewood - June [Member]", "label": "Belmar Medical Building - Lakewood - June [Member]", "terseLabel": "Belmar Medical Building -Lakewood, CO" } } }, "localname": "BelmarMedicalBuildingLakewoodJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BelowMarketLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Below Market Lease [Member]", "label": "Below Market Lease [Member]", "terseLabel": "Below-market lease liabilities" } } }, "localname": "BelowMarketLeaseMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_BelowMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Below Market Leases", "label": "Below Market Leases [Member]", "terseLabel": "Below market leases" } } }, "localname": "BelowMarketLeasesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_BerwynMedicalCenterBerwynMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Berwyn Medical Center - Berwyn [Member]", "label": "Berwyn Medical Center - Berwyn [Member]", "terseLabel": "Berwyn Medical Center - Berwyn, IL" } } }, "localname": "BerwynMedicalCenterBerwynMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BloomMOBHarrisburgDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bloom MOB - Harrisburg - December [Member]", "label": "Bloom MOB - Harrisburg - December [Member]", "terseLabel": "Bloom MOB - Harrisburg, PA" } } }, "localname": "BloomMOBHarrisburgDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BowieGatewayMedicalCenterBowieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bowie Gateway Medical Center - Bowie [Member]", "label": "Bowie Gateway Medical Center - Bowie [Member]", "terseLabel": "Bowie Gateway Medical Center - Bowie, MD" } } }, "localname": "BowieGatewayMedicalCenterBowieMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BradyMOBHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brady MOB - Harrisburg [Member]", "label": "Brady MOB - Harrisburg [Member]", "terseLabel": "Brady MOB - Harrisburg, PA" } } }, "localname": "BradyMOBHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_BuildingsFixturesandImprovements": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Buildings, Fixtures and Improvements", "label": "Buildings, Fixtures and Improvements", "terseLabel": "Buildings, fixtures and improvements" } } }, "localname": "BuildingsFixturesandImprovements", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period", "label": "Business Acquisition Cost Of Acquired Entity Cash Paid In Period", "totalLabel": "Cash paid for real estate investments, including acquisitions" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationAssetsandLiabilitiesAssumedMortgageProceeds": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds", "label": "Business Combination, Assets and Liabilities Assumed, Mortgage Proceeds", "negatedTerseLabel": "Mortgage notes payable, net" } } }, "localname": "BusinessCombinationAssetsandLiabilitiesAssumedMortgageProceeds", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other, Net", "verboseLabel": "Other assets acquired and liabilities assumed in the asset acquisition, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNet", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Acquired in Period, Net", "totalLabel": "Total intangible assets and liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed Building, Fixtures and Improvements, Capital Leases, Acquired in Period", "terseLabel": "Buildings, fixtures and improvements" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedBuildingFixturesandImprovementsCapitalLeasesAcquiredinPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopmentinProcessAcquiredinPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 3.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Development in Process, Acquired in Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Development in Process, Acquired in Period", "terseLabel": "Development costs" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopmentinProcessAcquiredinPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Acquired During The Period", "terseLabel": "In-place and market leases" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedFiniteLivedIntangiblesAcquiredDuringThePeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 1.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Acquired in Period", "verboseLabel": "Land" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLandAcquiredinPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 2.0, "parentTag": "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAssetsAcquiredinPeriodNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Lease Liabilities Acquired", "negatedTerseLabel": "Market lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedLeaseLiabilitiesAcquired", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails": { "order": 3.0, "parentTag": "hct_BusinessAcquisitionCostOfAcquiredEntityCashPaidInPeriod", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired During Period", "totalLabel": "Total tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTangibleAssetsAcquiredDuringPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "monetaryItemType" }, "hct_COVID19PandemicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID19 Pandemic", "label": "COVID19 Pandemic [Member]", "terseLabel": "COVID19 Pandemic" } } }, "localname": "COVID19PandemicMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CamelliaWalkAssistedLivingAndMemoryCareEvansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Camellia Walk Assisted Living And Memory Care - Evans [Member]", "label": "Camellia Walk Assisted Living And Memory Care - Evans [Member]", "terseLabel": "Camellia Walk Assisted Living and Memory Care - Evans, GA" } } }, "localname": "CamelliaWalkAssistedLivingAndMemoryCareEvansMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CampusatCrooksAuburnBuildingCRochesterHillsJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus at Crooks & Auburn Building C - Rochester Hills - June [Member]", "label": "Campus at Crooks & Auburn Building C - Rochester Hills - June [Member]", "terseLabel": "Campus at Crooks & Auburn Building C - Rochester Mills, MI" } } }, "localname": "CampusatCrooksAuburnBuildingCRochesterHillsJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CampusatCrooksAuburnBuildingDRochesterHillsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus at Crooks & Auburn Building D - Rochester Hills [Member]", "label": "Campus at Crooks & Auburn Building D - Rochester Hills [Member]", "terseLabel": "Campus at Crooks & Auburn Building D - Rochester Mills, MI" } } }, "localname": "CampusatCrooksAuburnBuildingDRochesterHillsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CapitalGainDividendIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Gain Dividend Income [Member]", "label": "Capital Gain Dividend Income [Member]", "verboseLabel": "Capital gain dividend income" } } }, "localname": "CapitalGainDividendIncomeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "domainItemType" }, "hct_CapitalOneFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital One Facility [Member]", "label": "Capital One Facility [Member]", "terseLabel": "Capital One Facility" } } }, "localname": "CapitalOneFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CapitolHealthcareRehabCentreSpringfieldDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitol Healthcare & Rehab Centre - Springfield - December [Member]", "label": "Capitol Healthcare & Rehab Centre - Springfield - December [Member]", "terseLabel": "Capitol Healthcare & Rehab Centre - Springfield, IL" } } }, "localname": "CapitolHealthcareRehabCentreSpringfieldDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CappedReimbursementAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capped Reimbursement Amount [Member]", "label": "Capped Reimbursement Amount [Member]", "terseLabel": "Capped Reimbursement Amount" } } }, "localname": "CappedReimbursementAmountMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_CareMeridianLittletonCO.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareMeridian - Littleton, CO. [Member]", "label": "CareMeridian - Littleton, CO. [Member]", "terseLabel": "CareMeridian - Littleton, CO" } } }, "localname": "CareMeridianLittletonCO.Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CareplexWestMedicalOfficeBuildingHamptonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Careplex West Medical Office Building- Hampton [Member]", "label": "Careplex West Medical Office Building- Hampton [Member]", "terseLabel": "Careplex West Medical Office Building - Hampton, VA" } } }, "localname": "CareplexWestMedicalOfficeBuildingHamptonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfEdwardsvilleEdwardsvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Edwardsville - Edwardsville", "label": "Cedarhurst Of Edwardsville - Edwardsville [Member]", "terseLabel": "Cedarhurst of Edwardsville - Edwardsville, IL" } } }, "localname": "CedarhurstOfEdwardsvilleEdwardsvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfShilohShilohMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Shiloh - Shiloh", "label": "Cedarhurst Of Shiloh - Shiloh [Member]", "terseLabel": "Cedarhurst of Shiloh - Shiloh, IL" } } }, "localname": "CedarhurstOfShilohShilohMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstOfSpartaSpartaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst Of Sparta - Sparta", "label": "Cedarhurst Of Sparta - Sparta [Member]", "terseLabel": "Cedarhurst of Sparta - Sparta, IL" } } }, "localname": "CedarhurstOfSpartaSpartaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CedarhurstofCollinsvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cedarhurst of Collinsville [Member]", "label": "Cedarhurst of Collinsville [Member]", "terseLabel": "Cedarhurst of Collinsville - Collinsville, IL" } } }, "localname": "CedarhurstofCollinsvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ChangeinControlFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in Control Fee [Member]", "label": "Change in Control Fee [Member]", "terseLabel": "Change in Control Fee" } } }, "localname": "ChangeinControlFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_CirclevilleMOBCirclevilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Circleville MOB - Circleville", "label": "Circleville MOB - Circleville [Member]", "terseLabel": "Circleville MOB - Circleville, OH" } } }, "localname": "CirclevilleMOBCirclevilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ClassBUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B Units [Member]", "label": "Class B Units [Member]", "terseLabel": "Class B units" } } }, "localname": "ClassBUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "hct_ColonialHealthcareRehabCentrePrincetonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Colonial Healthcare & Rehab Centre - Princeton - December [Member]", "label": "Colonial Healthcare & Rehab Centre - Princeton - December [Member]", "terseLabel": "Colonial Healthcare & Rehab Centre - Princeton, IL" } } }, "localname": "ColonialHealthcareRehabCentrePrincetonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commencement Quarter", "label": "Commencement Quarter [Member]", "terseLabel": "Commencement Quarter" } } }, "localname": "CommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CommercialCenterPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial Center - Peoria - May [Member]", "label": "Commercial Center - Peoria - May [Member]", "terseLabel": "Commercial Center - Peoria, AZ" } } }, "localname": "CommercialCenterPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CommonShareEquivalentsSharesApprovedforIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Share Equivalents, Shares Approved for Issuance", "label": "Common Share Equivalents, Shares Approved for Issuance", "terseLabel": "Shares approved for issuance (in shares)" } } }, "localname": "CommonShareEquivalentsSharesApprovedforIssuance", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "sharesItemType" }, "hct_CommonShareEquivalentsSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Share Equivalents, Shares Outstanding", "label": "Common Share Equivalents, Shares Outstanding", "terseLabel": "Class B units (in shares)" } } }, "localname": "CommonShareEquivalentsSharesOutstanding", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "hct_CommonStockStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Stock Dividends, Per Share, Declared", "label": "Common Stock, Stock Dividends, Per Share, Declared", "terseLabel": "Distributions declared in common stock (in usd per share)" } } }, "localname": "CommonStockStockDividendsPerShareDeclared", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "hct_CommonUnitIssuanceValueSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Unit, Issuance Value Share Price", "label": "Common Unit, Issuance Value Share Price", "terseLabel": "Units issued to fund purchase of A Building (in usd per share)" } } }, "localname": "CommonUnitIssuanceValueSharePrice", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "hct_CommunityHealthMOBHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Community Health MOB - Harrisburg [Member]", "label": "Community Health MOB - Harrisburg [Member]", "terseLabel": "Community Health MOB - Harrisburg, PA" } } }, "localname": "CommunityHealthMOBHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ConroeMedicalArtsandSurgeryCenterConroeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conroe Medical Arts and Surgery Center - Conroe [Member]", "label": "Conroe Medical Arts and Surgery Center - Conroe [Member]", "terseLabel": "Conroe Medical Arts and Surgery Center - Conroe, TX" } } }, "localname": "ConroeMedicalArtsandSurgeryCenterConroeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ConsumerPriceIndexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consumer Price Index [Member]", "label": "Consumer Price Index [Member]", "terseLabel": "Consumer Price Index" } } }, "localname": "ConsumerPriceIndexMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_ContractPurchasePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Purchase Price [Member]", "label": "Contract Purchase Price [Member]", "terseLabel": "Contract Purchase Price" } } }, "localname": "ContractPurchasePriceMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_CopperSpringsSeniorLivingMeridianSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Copper Springs Senior Living - Meridian - September [Member]", "label": "Copper Springs Senior Living - Meridian - September [Member]", "terseLabel": "Copper Springs Senior Living - Meridian, ID" } } }, "localname": "CopperSpringsSeniorLivingMeridianSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CountrysideMedicalArtsSafetyHarborFLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countryside Medical Arts - Safety Harbor, FL [Member]", "label": "Countryside Medical Arts - Safety Harbor, FL [Member]", "terseLabel": "Palm Valley Medical Plaza - Goodyear, AZ" } } }, "localname": "CountrysideMedicalArtsSafetyHarborFLMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_CountrysideMedicalArtsSafetyHarborMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countryside Medical Arts - Safety Harbor [Member]", "label": "Countryside Medical Arts - Safety Harbor [Member]", "terseLabel": "Countryside Medical Arts - Safety Harbor, FL" } } }, "localname": "CountrysideMedicalArtsSafetyHarborMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CourtyardFountainsGreshamORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Courtyard Fountains - Gresham, OR [Member]", "label": "Courtyard Fountains - Gresham, OR [Member]", "terseLabel": "Fox Ridge North Little Rock - North Little Rock, AR", "verboseLabel": "Courtyard Fountains - Gresham, OR" } } }, "localname": "CourtyardFountainsGreshamORMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAfterCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period After Commencement Quarter", "label": "Covenant Period After Commencement Quarter [Member]", "terseLabel": "Covenant Period After Commencement Quarter" } } }, "localname": "CovenantPeriodAfterCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAfterJune302021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period after June 30 2021", "label": "Covenant Period after June 30 2021 [Member]", "terseLabel": "Covenant Period after June 30 2021" } } }, "localname": "CovenantPeriodAfterJune302021Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodAugust102020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period August 10 2020", "label": "Covenant Period August 10 2020 [Member]", "terseLabel": "Covenant Period August 10 2020" } } }, "localname": "CovenantPeriodAugust102020Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodFromApril12021ThroughJune302021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period From April 1 2021 through June 30 2021", "label": "Covenant Period From April 1 2021 through June 30 2021 [Member]", "terseLabel": "Covenant Period From April 1 2021 through June 30 2021" } } }, "localname": "CovenantPeriodFromApril12021ThroughJune302021Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodFromJune302021ThroughCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period from June 30 2021 through Commencement Quarter", "label": "Covenant Period from June 30 2021 through Commencement Quarter [Member]", "terseLabel": "Covenant Period from June 30 2021 through Commencement Quarter" } } }, "localname": "CovenantPeriodFromJune302021ThroughCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodJuly12020ThroughJune302021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period July 1 2020 through June 30 2021", "label": "Covenant Period July 1 2020 through June 30 2021 [Member]", "terseLabel": "Covenant Period July 1 2020 through June 30 2021" } } }, "localname": "CovenantPeriodJuly12020ThroughJune302021Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CovenantPeriodJuly12020ThroughMarch312021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period July 1 2020 through March 31 2021", "label": "Covenant Period July 1 2020 through March 31 2021 [Member]", "terseLabel": "Covenant Period July 1 2020 through March 31 2021" } } }, "localname": "CovenantPeriodJuly12020ThroughMarch312021Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_CreeksideMOBDouglasvilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creekside MOB - Douglasville [Member]", "label": "Creekside MOB - Douglasville [Member]", "terseLabel": "Creekside MOB - Douglasville, GA" } } }, "localname": "CreeksideMOBDouglasvilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CrittentonSterlingHeightsMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crittenton Sterling Heights MOB [Member]", "label": "Crittenton Sterling Heights MOB [Member]", "terseLabel": "Crittenton Sterling Heights MOB - Sterling Heights, MI" } } }, "localname": "CrittentonSterlingHeightsMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_CrittentonWashingtonMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crittenton Washington MOB [Member]", "label": "Crittenton Washington MOB [Member]", "terseLabel": "Crittenton Washington MOB - Washington Township, MI" } } }, "localname": "CrittentonWashingtonMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DRIPPeriodofNoticetoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DRIP, Period of Notice to Alter Agreement", "label": "DRIP, Period of Notice to Alter Agreement", "terseLabel": "DRIP, period of notice to alter agreement" } } }, "localname": "DRIPPeriodofNoticetoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_DaVitaBayBreezeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DaVita Bay Breeze [Member]", "label": "DaVita Bay Breeze [Member]", "terseLabel": "DaVita Bay Breeze Dialysis Center - Largo, FL" } } }, "localname": "DaVitaBayBreezeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DaVitaHudsonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DaVita Hudson [Member]", "label": "DaVita Hudson [Member]", "terseLabel": "DaVita Dialysis - Hudson, FL" } } }, "localname": "DaVitaHudsonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DayPriorToCommencementQuarterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Day Prior to Commencement Quarter", "label": "Day Prior to Commencement Quarter [Member]", "terseLabel": "Day Prior to Commencement Quarter" } } }, "localname": "DayPriorToCommencementQuarterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DebtInstrumentCovenantsCurrentBorrowingCapacityBasePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Current Borrowing Capacity Base Percent", "label": "Debt Instrument, Covenants, Current Borrowing Capacity Base Percent", "terseLabel": "Current borrowing capacity, base percent" } } }, "localname": "DebtInstrumentCovenantsCurrentBorrowingCapacityBasePercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentCovenantsDistributionInExcessOfModifiedFundsFromOperationsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent", "label": "Debt Instrument, Covenants, Distribution In Excess Of Modified Funds From Operations, Percent", "terseLabel": "Percent distribution in excess of modified funds from operations" } } }, "localname": "DebtInstrumentCovenantsDistributionInExcessOfModifiedFundsFromOperationsPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentCovenantsFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Fixed Charge Coverage Ratio", "label": "Debt Instrument, Covenants, Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage ratio" } } }, "localname": "DebtInstrumentCovenantsFixedChargeCoverageRatio", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "pureItemType" }, "hct_DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity", "label": "Debt Instrument, Covenants, Minimum Cash, Cash Equivalents, and Borrowing Capacity", "terseLabel": "Minimum cash, cash equivalents, and borrowing capacity" } } }, "localname": "DebtInstrumentCovenantsMinimumCashCashEquivalentsAndBorrowingCapacity", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_DebtInstrumentCovenantsPercentOfNetOfferingProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Percent Of Net Offering Proceeds", "label": "Debt Instrument, Covenants, Percent Of Net Offering Proceeds", "terseLabel": "Net offering proceeds, percent" } } }, "localname": "DebtInstrumentCovenantsPercentOfNetOfferingProceeds", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentFloorInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Floor interest rate" } } }, "localname": "DebtInstrumentFloorInterestRate", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentPrepaymentMaximumPercentageofPrincipal": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment, Maximum Percentage of Principal", "label": "Debt Instrument, Prepayment, Maximum Percentage of Principal", "terseLabel": "Prepayment percent of principal amount" } } }, "localname": "DebtInstrumentPrepaymentMaximumPercentageofPrincipal", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentPrepaymentPenaltyPercentageofPrincipalInitialTwelveMonths": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Initial Twelve Months", "label": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Initial Twelve Months", "terseLabel": "Prepayment penalty, initial twelve months" } } }, "localname": "DebtInstrumentPrepaymentPenaltyPercentageofPrincipalInitialTwelveMonths", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentPrepaymentPenaltyPercentageofPrincipalYearThree": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Three", "label": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Three", "terseLabel": "Prepayment penalty, year three" } } }, "localname": "DebtInstrumentPrepaymentPenaltyPercentageofPrincipalYearThree", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DebtInstrumentPrepaymentPenaltyPercentageofPrincipalYearTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Two", "label": "Debt Instrument, Prepayment Penalty, Percentage of Principal, Year Two", "terseLabel": "Prepayment penalty, year two" } } }, "localname": "DebtInstrumentPrepaymentPenaltyPercentageofPrincipalYearTwo", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_DecaturMedicalOfficeBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decatur Medical Office Building [Member]", "label": "Decatur Medical Office Building [Member]", "terseLabel": "Decatur Medical Office Building - Decatur, GA" } } }, "localname": "DecaturMedicalOfficeBuildingMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DelistingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delisting [Member]", "label": "Delisting [Member]", "terseLabel": "Delisting" } } }, "localname": "DelistingMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DepreciationandAmortizationExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation and Amortization Expense [Member]", "label": "Depreciation and Amortization Expense [Member]", "terseLabel": "Depreciation and Amortization Expense" } } }, "localname": "DepreciationandAmortizationExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_DerivativeNumberofInstrumentsTerminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative, Number of Instruments Terminated", "label": "Derivative, Number of Instruments Terminated", "terseLabel": "Number of instruments terminated" } } }, "localname": "DerivativeNumberofInstrumentsTerminated", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DignityEmerusBlueDiamondRoadLasVegasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dignity Emerus Blue Diamond Road - Las Vegas [Member]", "label": "Dignity Emerus Blue Diamond Road - Las Vegas [Member]", "terseLabel": "Dignity Emerus Blue Diamond - Las Vegas, NV" } } }, "localname": "DignityEmerusBlueDiamondRoadLasVegasMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DignityEmerusCraigRoadNorthLasVegasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dignity Emerus Craig Road - North Las Vegas [Member]", "label": "Dignity Emerus Craig Road - North Las Vegas [Member]", "terseLabel": "Dignity Emerus Craig Rd - North Las Vegas, NV" } } }, "localname": "DignityEmerusCraigRoadNorthLasVegasMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_DisposalGroupHeldforuseNotDiscontinuedOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]", "label": "Disposal Group, Held-for-use, Not Discontinued Operations [Member]", "terseLabel": "Assets held for use" } } }, "localname": "DisposalGroupHeldforuseNotDiscontinuedOperationsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationBuildingsandImprovementsGross": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Buildings and Improvements, Gross", "label": "Disposal Group, Including Discontinued Operation, Buildings and Improvements, Gross", "verboseLabel": "Buildings, fixtures and improvements" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationBuildingsandImprovementsGross", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationConsiderationDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Deposit", "label": "Disposal Group, Including Discontinued Operation, Consideration, Deposit", "terseLabel": "Non-refundable deposits" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationDeposit", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationLand": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Land", "label": "Disposal Group, Including Discontinued Operation, Land", "terseLabel": "Land" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLand", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Disposed", "terseLabel": "Number of properties disposed" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesDisposed", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Sale", "terseLabel": "Number of properties held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForSale", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Held For Use", "terseLabel": "Number of properties held-for-use" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesHeldForUse", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operation, Number Of Properties Transferred", "label": "Disposal Group Including Discontinued Operation, Number Of Properties Transferred", "terseLabel": "Number of properties transferred" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfPropertiesTransferred", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "integerItemType" }, "hct_DisposalGroupIncludingDiscontinuedOperationsProspectiveConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Prospective Consideration", "label": "Disposal Group, Including Discontinued Operations, Prospective Consideration", "terseLabel": "Prospective consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsProspectiveConsideration", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_DistributionsOnClassBUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions On Class B Units [Member]", "label": "Distributions On Class B Units [Member]", "terseLabel": "Distributions on Class B Units" } } }, "localname": "DistributionsOnClassBUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_DividendsPayablePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends Payable, Percent", "label": "Dividends Payable, Percent", "terseLabel": "Dividends, percent" } } }, "localname": "DividendsPayablePercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "percentItemType" }, "hct_DyerBuildingDyerOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dyer Building - Dyer - October [Member]", "label": "Dyer Building - Dyer - October [Member]", "verboseLabel": "Dyer Building - Dyer, IN" } } }, "localname": "DyerBuildingDyerOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Line Items]" } } }, "localname": "EarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodLineItems", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "hct_EastCoastSquareNorthMoreheadCityOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "East Coast Square North - Morehead City - October [Member]", "label": "East Coast Square North - Morehead City - October [Member]", "terseLabel": "East Coast Square North - Morehead City, NC" } } }, "localname": "EastCoastSquareNorthMoreheadCityOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EastCoastSquareWestCedarPointOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "East Coast Square West - Cedar Point - October [Member]", "label": "East Coast Square West - Cedar Point - October [Member]", "terseLabel": "East Coast Square West - Cedar Point, NC" } } }, "localname": "EastCoastSquareWestCedarPointOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EastsideCancerinstituteGreenvilleOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eastside Cancer institute - Greenville - October [Member]", "label": "Eastside Cancer institute - Greenville - October [Member]", "terseLabel": "Eastside Cancer Institute - Greenville, SC" } } }, "localname": "EastsideCancerinstituteGreenvilleOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_EconomicDependencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Economic Dependency [Abstract]", "label": "Economic Dependency [Abstract]", "terseLabel": "Economic Dependency [Abstract]" } } }, "localname": "EconomicDependencyAbstract", "nsuri": "http://www.thehealthcarereit2.com/20201231", "xbrltype": "stringItemType" }, "hct_EconomicDependencyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Matters related to services provided by affiliate.", "label": "Economic Dependency [Text Block]", "terseLabel": "Economic Dependency" } } }, "localname": "EconomicDependencyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EconomicDependency" ], "xbrltype": "textBlockItemType" }, "hct_EstateatHydeParkTampaJulyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estate at Hyde Park - Tampa - July [Member]", "label": "Estate at Hyde Park - Tampa - July [Member]", "terseLabel": "Estate at Hyde Park - Tampa, FL" } } }, "localname": "EstateatHydeParkTampaJulyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]", "label": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital [Member]", "terseLabel": "Excess of Adjusted Market Value of Real Estate Assets Plus Distributions Over Aggregate Contributed Investor Capital" } } }, "localname": "ExcessOfAdjustedMarketValueOfRealEstateAssetsPlusDistributionsOverAggregateContributedInvestorCapitalMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eye Specialty Group Medical Building - Memphis - December [Member]", "label": "Eye Specialty Group Medical Building - Memphis - December [Member]", "terseLabel": "Eye Specialty Group Medical Building - Memphis, TN" } } }, "localname": "EyeSpecialtyGroupMedicalBuildingMemphisDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCClinicalMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC Clinical - Mechanicsburg [Member]", "label": "FOC Clinical - Mechanicsburg [Member]", "terseLabel": "FOC Clinical - Mechanicsburg, PA" } } }, "localname": "FOCClinicalMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCIIMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC II - Mechanicsburg [Member]", "label": "FOC II - Mechanicsburg [Member]", "terseLabel": "FOC II - Mechanicsburg, PA" } } }, "localname": "FOCIIMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FOCIMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FOC I - Mechanicsburg [Member]", "label": "FOC I - Mechanicsburg [Member]", "terseLabel": "FOC I - Mechanicsburg, PA" } } }, "localname": "FOCIMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FannieCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fannie Credit Facility [Member]", "label": "Fannie Credit Facility [Member]", "terseLabel": "Fannie Credit Facility" } } }, "localname": "FannieCreditFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "hct_FannieMaeMasterCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fannie Mae Master Credit Facility [Member]", "label": "Fannie Mae Master Credit Facility [Member]", "terseLabel": "Fannie Mae Master Credit Facility" } } }, "localname": "FannieMaeMasterCreditFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_FelicitaVidaEscondidoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FelicitaVidaEscondido [Member]", "label": "FelicitaVidaEscondido [Member]", "terseLabel": "Felicita Vida - Escondido, CA" } } }, "localname": "FelicitaVidaEscondidoMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FiniteLivedIntangibleAssetsandLiabilitiesAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization", "label": "Finite-Lived Intangible Assets and Liabilities, Accumulated Amortization", "terseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsandLiabilitiesAccumulatedAmortization", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_FloridaMedicalHeartcareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Heartcare [Member]", "label": "Florida Medical - Heartcare [Member]", "terseLabel": "Florida Medical Heartcare - Tampa, FL" } } }, "localname": "FloridaMedicalHeartcareMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalSomersetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Somerset [Member]", "label": "Florida Medical - Somerset [Member]", "terseLabel": "Florida Medical Somerset - Tampa, FL" } } }, "localname": "FloridaMedicalSomersetMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalTampaPalmsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Tampa Palms [Member]", "label": "Florida Medical - Tampa Palms [Member]", "terseLabel": "Florida Medical Tampa Palms - Tampa, FL" } } }, "localname": "FloridaMedicalTampaPalmsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FloridaMedicalWesleyChapelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Florida Medical - Wesley Chapel [Member]", "label": "Florida Medical - Wesley Chapel [Member]", "terseLabel": "Florida Medical Wesley Chapel - Tampa, FL" } } }, "localname": "FloridaMedicalWesleyChapelMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatBryantBryantDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Bryant - Bryant - December [Member]", "label": "Fox Ridge Senior Living at Bryant - Bryant - December [Member]", "terseLabel": "Fox Ridge Senior Living at Bryant - Bryant, AR" } } }, "localname": "FoxRidgeSeniorLivingatBryantBryantDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatBryantBryantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Bryant - Bryant [Member]", "label": "Fox Ridge Senior Living at Bryant - Bryant [Member]", "terseLabel": "Capital One MOB Loan" } } }, "localname": "FoxRidgeSeniorLivingatBryantBryantMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatChenalLittleRockDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Chenal - Little Rock - December [Member]", "label": "Fox Ridge Senior Living at Chenal - Little Rock - December [Member]", "terseLabel": "Fox Ridge Senior Living at Chenal - Little Rock, AR" } } }, "localname": "FoxRidgeSeniorLivingatChenalLittleRockDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatChenalLittleRockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Chenal - Little Rock [Member]", "label": "Fox Ridge Senior Living at Chenal - Little Rock [Member]", "terseLabel": "Multi-Property CMBS Loan" } } }, "localname": "FoxRidgeSeniorLivingatChenalLittleRockMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]", "label": "Fox Ridge Senior Living at Parkstone - North Little Rock [Member]", "terseLabel": "Shiloh - Illinois (4)", "verboseLabel": "Fox Ridge North Little Rock - North Little Rock, AR" } } }, "localname": "FoxRidgeSeniorLivingatParkstoneNorthLittleRockMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_FreseniusMedicalCareWinfieldALMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fresenius Medical Care - Winfield, AL [Member]", "label": "Fresenius Medical Care - Winfield, AL [Member]", "terseLabel": "Fresenius Medical Care - Winfield, AL" } } }, "localname": "FreseniusMedicalCareWinfieldALMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GainonDispositionsofRealEstateInvestmentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gain on Dispositions of Real Estate Investments Policy [Policy Text Block]", "label": "Gain on Dispositions of Real Estate Investments Policy [Policy Text Block]", "terseLabel": "Gain on Dispositions of Real Estate Investments" } } }, "localname": "GainonDispositionsofRealEstateInvestmentsPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_GatewayMedicalOfficeBuildingClarksvilleOctoberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gateway Medical Office Building - Clarksville - October [Member]", "label": "Gateway Medical Office Building - Clarksville - October [Member]", "terseLabel": "Gateway MOB - Clarksville, TN" } } }, "localname": "GatewayMedicalOfficeBuildingClarksvilleOctoberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GlendaleMOBFarmingtonHillsMIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glendale MOB - Farmington Hills MI [Member]", "label": "Glendale MOB - Farmington Hills MI [Member]", "terseLabel": "Glendale MOB - Farmington Hills, MI" } } }, "localname": "GlendaleMOBFarmingtonHillsMIMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenfieldMOBGreenfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GreenfieldMOBGreenfield [Member]", "label": "GreenfieldMOBGreenfield [Member]", "terseLabel": "Greenfield MOB - Greenfield, WI" } } }, "localname": "GreenfieldMOBGreenfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenfieldMedicalPlazaGilbertMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greenfield Medical Plaza - Gilbert [Member]", "label": "Greenfield Medical Plaza - Gilbert [Member]", "terseLabel": "Greenfield Medical Plaza - Gilbert, AZ" } } }, "localname": "GreenfieldMedicalPlazaGilbertMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GreenvilleHealthSystemGreenvilleSCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Greenville Health System - Greenville, SC [Member]", "label": "Greenville Health System - Greenville, SC [Member]", "terseLabel": "Greenville Health System - Greenville, SC" } } }, "localname": "GreenvilleHealthSystemGreenvilleSCMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]", "label": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties [Member]", "terseLabel": "Gross Revenue, Excluding Stand-alone Single-tenant Net Leased Properties" } } }, "localname": "GrossRevenueExcludingStandAloneSingleTenantNetLeasedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueManagedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Managed Properties [Member]", "label": "Gross Revenue, Managed Properties [Member]", "terseLabel": "Gross Revenue, Managed Properties" } } }, "localname": "GrossRevenueManagedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]", "label": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties [Member]", "terseLabel": "Gross Revenue, Stand-alone Single-tenant Net Leased Properties" } } }, "localname": "GrossRevenueStandAloneSingleTenantNetLeasedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_HamptonRiverMedicalArtsBuildingHamptonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hampton River Medical Arts Building - Hampton - December [Member]", "label": "Hampton River Medical Arts Building - Hampton - December [Member]", "terseLabel": "Hampton River Medical Arts Building - Hampton, VA" } } }, "localname": "HamptonRiverMedicalArtsBuildingHamptonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_HealthcareTrustSpecialLimitedPartnershipLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Trust Special Limited Partnership, LLC [Member]", "label": "Healthcare Trust Special Limited Partnership, LLC [Member]", "terseLabel": "Healthcare Trust Special Limited Partnership, LLC" } } }, "localname": "HealthcareTrustSpecialLimitedPartnershipLLCMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "High Desert Medical Group Medical Office Building - Lancaster [Member]", "label": "High Desert Medical Group Medical Office Building - Lancaster [Member]", "terseLabel": "High Desert Medical Group Medical Office Building - Lancaster, CA" } } }, "localname": "HighDesertMedicalGroupMedicalOfficeBuildingLancasterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_IllinoisCancerCareGalesburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Illinois Cancer Care - Galesburg [Member]", "label": "Illinois Cancer Care - Galesburg [Member]", "terseLabel": "Illinois CancerCare - Galesburg, IL" } } }, "localname": "IllinoisCancerCareGalesburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_IncomeLossTaxBasis": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income (Loss), Tax Basis", "label": "Income (Loss), Tax Basis", "terseLabel": "Income (loss), tax basis" } } }, "localname": "IncomeLossTaxBasis", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_IncreaseDecreasePreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Preferred Stock, Dividend Rate, Percentage", "label": "Increase (Decrease) Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Increase in preferred stock, dividend rate, percentage" } } }, "localname": "IncreaseDecreasePreferredStockDividendRatePercentage", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_IndependentDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Independent Directors [Member]", "label": "Independent Directors [Member]", "terseLabel": "Independent directors" } } }, "localname": "IndependentDirectorsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_InplaceLeasesandOtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In-place Leases and Other Intangible Assets [Member]", "label": "In-place Leases and Other Intangible Assets [Member]", "terseLabel": "In-place leases and other intangible assets" } } }, "localname": "InplaceLeasesandOtherIntangibleAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_IntangibleMarketLeaseAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Market Lease Assets [Member]", "label": "Intangible Market Lease Assets [Member]", "terseLabel": "Market lease assets" } } }, "localname": "IntangibleMarketLeaseAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "hct_JupiterFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jupiter, Florida [Member]", "label": "Jupiter, Florida [Member]", "terseLabel": "Jupiter, Florida" } } }, "localname": "JupiterFloridaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_KeyBankFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KeyBank Facility [Member]", "label": "KeyBank Facility [Member]", "terseLabel": "KeyBank Facility" } } }, "localname": "KeyBankFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LaSalleGuarantorvsLaSalleTenantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LaSalle Guarantor vs LaSalle Tenant [Member]", "label": "LaSalle Guarantor vs LaSalle Tenant [Member]", "terseLabel": "LaSalle Guarantor vs LaSalle Tenant" } } }, "localname": "LaSalleGuarantorvsLaSalleTenantMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_LaSalleTenantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LaSalle Tenant [Member]", "label": "LaSalle Tenant [Member]", "terseLabel": "LaSalle Tenant" } } }, "localname": "LaSalleTenantMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_LagunaProfessionalCenterElkGroveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laguna Professional Center - Elk Grove [Member]", "label": "Laguna Professional Center - Elk Grove [Member]", "terseLabel": "Laguna Professional Center - Elk Grove, CA" } } }, "localname": "LagunaProfessionalCenterElkGroveMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LakesideVistaHollandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lakeside Vista - Holland", "label": "Lakeside Vista - Holland [Member]", "terseLabel": "Lakeside Vista - Holland, MI" } } }, "localname": "LakesideVistaHollandMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LancasterMedicalArtsMOBLancasterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LancasterMedicalArtsMOBLancaster [Member]", "label": "LancasterMedicalArtsMOBLancaster [Member]", "terseLabel": "Lancaster Medical Arts MOB - Lancaster, PA" } } }, "localname": "LancasterMedicalArtsMOBLancasterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LandisMemorialHarrisburgSeptemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Landis Memorial - Harrisburg - September [Member]", "label": "Landis Memorial - Harrisburg - September [Member]", "terseLabel": "Landis Memorial - Harrisburg, PA" } } }, "localname": "LandisMemorialHarrisburgSeptemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LeaseIntangiblesLeaseupPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Intangibles, Lease-up Period", "label": "Lease Intangibles, Lease-up Period", "terseLabel": "Lease intangibles, lease-up period" } } }, "localname": "LeaseIntangiblesLeaseupPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Remaining Lease Term", "label": "Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LeaseRemainingLeaseTerm", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LeeMemorialHealthSystemOutpatientCenterFortMeyersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lee Memorial Health System Outpatient Center - Fort Meyers [Member]", "label": "Lee Memorial Health System Outpatient Center - Fort Meyers [Member]", "terseLabel": "Lee Memorial Health System Outpatient Center - Ft. Myers" } } }, "localname": "LeeMemorialHealthSystemOutpatientCenterFortMeyersMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LegacyMedicalVillagePlanoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legacy Medical Village - Plano [Member]", "label": "Legacy Medical Village - Plano [Member]", "terseLabel": "Legacy Medical Village - Plano, TX" } } }, "localname": "LegacyMedicalVillagePlanoMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LesseeFinanceLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Finance Lease, Number Of Contracts", "label": "Lessee, Finance Lease, Number Of Contracts", "terseLabel": "Number of finance lease contracts" } } }, "localname": "LesseeFinanceLeaseNumberOfContracts", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_LesseeLeaseRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease, Renewal Term", "label": "Lessee, Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeLeaseRenewalTerm", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LesseeOperatingLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Contracts", "label": "Lessee, Operating Lease, Number Of Contracts", "terseLabel": "Number of operating lease contracts" } } }, "localname": "LesseeOperatingLeaseNumberOfContracts", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_LibertyCourtDixonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liberty Court - Dixon [Member]", "label": "Liberty Court - Dixon [Member]", "terseLabel": "Liberty Court - Dixon, IL" } } }, "localname": "LibertyCourtDixonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_LineOfCreditFacilityExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Extension Period", "label": "Line of Credit Facility, Extension Period", "terseLabel": "Extension period" } } }, "localname": "LineOfCreditFacilityExtensionPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hct_LineofCreditFacilityAccordionFeatureIncreaseLimit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Accordion Feature, Increase Limit", "label": "Line of Credit Facility, Accordion Feature, Increase Limit", "verboseLabel": "Line of credit, increase" } } }, "localname": "LineofCreditFacilityAccordionFeatureIncreaseLimit", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_LongtermDebtOutstandingLimitationtoReleaseorReplaceProperties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Outstanding, Limitation to Release or Replace Properties", "label": "Long-term Debt, Outstanding, Limitation to Release or Replace Properties", "terseLabel": "Principal amount outstanding limitation to release or replace properties" } } }, "localname": "LongtermDebtOutstandingLimitationtoReleaseorReplaceProperties", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_LongtermLineofCreditIncludingFinancingCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Line of Credit, Including Financing Costs", "label": "Long-term Line of Credit, Including Financing Costs", "terseLabel": "Term Loan, net" } } }, "localname": "LongtermLineofCreditIncludingFinancingCosts", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_LutzFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lutz, Florida [Member]", "label": "Lutz, Florida [Member]", "terseLabel": "Lutz, Florida" } } }, "localname": "LutzFloridaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_MOBLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MOB Loan [Member]", "label": "MOB Loan [Member]", "terseLabel": "MOB Loan" } } }, "localname": "MOBLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_MadisonMedicalPlazaJolietMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Madison Medical Plaza - Joliet [Member]", "label": "Madison Medical Plaza - Joliet [Member]", "terseLabel": "Madison Medical Plaza - Joliet, IL" } } }, "localname": "MadisonMedicalPlazaJolietMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MainlandMedicalArtsPavilionTexasCityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mainland Medical Arts Pavilion - Texas City [Member]", "label": "Mainland Medical Arts Pavilion - Texas City [Member]", "terseLabel": "Mainland Medical Arts Pavilion - Texas City, TX" } } }, "localname": "MainlandMedicalArtsPavilionTexasCityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MasterCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Credit Facility [Member]", "label": "Master Credit Facility [Member]", "terseLabel": "Fannie Mae Master Credit Facilities", "verboseLabel": "Master Credit Facility" } } }, "localname": "MasterCreditFacilityMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MeadowbrookSeniorLivingAgouraHillsNovemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Meadowbrook Senior Living - Agoura Hills - November [Member]", "label": "Meadowbrook Senior Living - Agoura Hills - November [Member]", "terseLabel": "Meadowbrook Senior Living - Agoura Hills, CA" } } }, "localname": "MeadowbrookSeniorLivingAgouraHillsNovemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIIIPeoriaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center III - Peoria [Member]", "label": "Medical Center III - Peoria [Member]", "terseLabel": "Medical Center III - Peoria, AZ" } } }, "localname": "MedicalCenterIIIPeoriaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIIPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center II - Peoria - May [Member]", "label": "Medical Center II - Peoria - May [Member]", "terseLabel": "Medical Center II - Peoria, AZ" } } }, "localname": "MedicalCenterIIPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterIPeoriaMayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center I - Peoria - May [Member]", "label": "Medical Center I - Peoria - May [Member]", "terseLabel": "Medical Center I - Peoria, AZ" } } }, "localname": "MedicalCenterIPeoriaMayMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalCenterVPeoriaAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Center V - Peoria, AZ [Member]", "label": "Medical Center V - Peoria, AZ [Member]", "terseLabel": "Fox Ridge Chenal - Little Rock, AR", "verboseLabel": "Medical Center V - Peoria, AZ" } } }, "localname": "MedicalCenterVPeoriaAZMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalOfficeBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Office Buildings [Member]", "label": "Medical Office Buildings [Member]", "terseLabel": "Medical Office Buildings" } } }, "localname": "MedicalOfficeBuildingsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_MedicalSciencesPavilionHarrisburgDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical Sciences Pavilion - Harrisburg - December [Member]", "label": "Medical Sciences Pavilion - Harrisburg - December [Member]", "terseLabel": "Medical Sciences Pavilion - Harrisburg, PA" } } }, "localname": "MedicalSciencesPavilionHarrisburgDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MetroHealthBuckeyeHealthCenterClevelandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MetroHealthBuckeyeHealthCenterCleveland [Member]", "label": "MetroHealthBuckeyeHealthCenterCleveland [Member]", "terseLabel": "MetroHealth Buckeye Health Center - Cleveland, OH" } } }, "localname": "MetroHealthBuckeyeHealthCenterClevelandMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MilwaukeeMOBSouthMilwaukeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MilwaukeeMOBSouthMilwaukee [Member]", "label": "MilwaukeeMOBSouthMilwaukee [Member]", "terseLabel": "Milwaukee MOB - South Milwaukee, WI" } } }, "localname": "MilwaukeeMOBSouthMilwaukeeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MonthlyBaseManagementFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monthly Base Management Fee [Member]", "label": "Monthly Base Management Fee [Member]", "terseLabel": "Monthly Base Management Fee" } } }, "localname": "MonthlyBaseManagementFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_MorrowMedicalCenterMorrowJuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morrow Medical Center - Morrow - June [Member]", "label": "Morrow Medical Center - Morrow - June [Member]", "terseLabel": "Morrow Medical Center - Morrow, GA" } } }, "localname": "MorrowMedicalCenterMorrowJuneMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MortonTerraceHealthcareRehabCentreMortonDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morton Terrace Healthcare& Rehab Centre - Morton - December [Member]", "label": "Morton Terrace Healthcare& Rehab Centre - Morton - December [Member]", "terseLabel": "Morton Terrace Healthcare & Rehab Centre - Morton, IL" } } }, "localname": "MortonTerraceHealthcareRehabCentreMortonDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MortonVillaHealthcareRehabCentreMortonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morton Villa Healthcare & Rehab Centre - Morton [Member]", "label": "Morton Villa Healthcare & Rehab Centre - Morton [Member]", "terseLabel": "Morton Villa Healthcare & Rehab Centre - Morton, IL" } } }, "localname": "MortonVillaHealthcareRehabCentreMortonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MountVernonMedicalOfficeBuildingMountVernonNovemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mount Vernon Medical Office Building - Mount Vernon - November [Member]", "label": "Mount Vernon Medical Office Building - Mount Vernon - November [Member]", "terseLabel": "Mount Vernon Medical Office Building - Mount Vernon, WA" } } }, "localname": "MountVernonMedicalOfficeBuildingMountVernonNovemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_MultiPropertyCMBSLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-Property CMBS Loan [Member]", "label": "Multi-Property CMBS Loan [Member]", "verboseLabel": "Multi-Property CMBS Loan" } } }, "localname": "MultiPropertyCMBSLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_MultitenantMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multi-tenant MOB [Member]", "label": "Multi-tenant MOB [Member]", "terseLabel": "Multi-tenant MOB" } } }, "localname": "MultitenantMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]", "label": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return [Member]", "terseLabel": "Net Sale Proceeds, after Return of Capital Contributions and Annual Targeted Investor Return" } } }, "localname": "NetSaleProceedsAfterReturnOfCapitalContributionsAndAnnualTargetedInvestorReturnMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_NewCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Credit Facilities [Member]", "label": "New Credit Facilities [Member]", "terseLabel": "New Credit Facilities" } } }, "localname": "NewCreditFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_NewYorkSixMOBs1propertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Six MOBs (1 property) [Member]", "label": "New York Six MOBs (1 property) [Member]", "terseLabel": "New York Six MOBs (1 property)" } } }, "localname": "NewYorkSixMOBs1propertyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_NewYorkSixMOBs5propertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New York Six MOBs (5 properties) [Member]", "label": "New York Six MOBs (5 properties) [Member]", "terseLabel": "New York Six MOBs (5 properties)" } } }, "localname": "NewYorkSixMOBs5propertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_NoncashorPartNoncashMortgageNotesPayableSecuredInConnectionWithTheAcquisitionOfRealEstate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash, or Part Noncash, Mortgage notes secured simultaneously with the acquisition of real estate assets, which includes land, buildings, fixtures, and land and building improvements.", "label": "Noncash, or Part Noncash, Mortgage Notes Payable Secured In Connection With The Acquisition Of Real Estate", "terseLabel": "Mortgage assumed in acquisition" } } }, "localname": "NoncashorPartNoncashMortgageNotesPayableSecuredInConnectionWithTheAcquisitionOfRealEstate", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "hct_NoncontrollingInterestPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-controlling Interest Policy [Policy Text Block]", "label": "Non-controlling Interest Policy [Policy Text Block]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_NorthsideHospitalMedicalOfficeBuildingCantonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Northside Hospital Medical Office Building - Canton [Member]", "label": "Northside Hospital Medical Office Building - Canton [Member]", "terseLabel": "Northside Hospital - Canton, GA" } } }, "localname": "NorthsideHospitalMedicalOfficeBuildingCantonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_NuVistaInstituteforHealthyLivingJupiterAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NuVista Institute for Healthy Living - Jupiter - August [Member]", "label": "NuVista Institute for Healthy Living - Jupiter - August [Member]", "terseLabel": "Nuvista Institute for Healthy Living - Jupiter, FL" } } }, "localname": "NuVistaInstituteforHealthyLivingJupiterAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_NuVistaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NuVista [Member]", "label": "NuVista [Member]", "terseLabel": "NuVista" } } }, "localname": "NuVistaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_NumberOfIntercompanyLeasesModified": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Intercompany Leases Modified", "label": "Number Of Intercompany Leases Modified", "terseLabel": "Number of intercompany leases modified" } } }, "localname": "NumberOfIntercompanyLeasesModified", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfPropertiesForWhichGrantsWereReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties For Which Grants Were Received", "label": "Number Of Properties For Which Grants Were Received", "terseLabel": "Number of properties receiving grants" } } }, "localname": "NumberOfPropertiesForWhichGrantsWereReceived", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberOfRealEstatePropertiesEncumbered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties, Encumbered", "label": "Number of Real Estate Properties, Encumbered", "terseLabel": "Encumbered properties" } } }, "localname": "NumberOfRealEstatePropertiesEncumbered", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberofRealEstatePropertiesReleasedorReplaced": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties, Released or Replaced", "label": "Number of Real Estate Properties, Released or Replaced", "terseLabel": "Number of real estate properties, released or replaced" } } }, "localname": "NumberofRealEstatePropertiesReleasedorReplaced", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberofRealEstatePropertiesUnencumbered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties, Unencumbered", "label": "Number of Real Estate Properties, Unencumbered", "terseLabel": "Unencumbered properties" } } }, "localname": "NumberofRealEstatePropertiesUnencumbered", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_NumberofSeniorHousingCommunities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Senior Housing Communities", "label": "Number of Senior Housing Communities", "terseLabel": "Number of senior housing communities" } } }, "localname": "NumberofSeniorHousingCommunities", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hct_OakLawnMedicalCenterOakLawnIL.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oak Lawn Medical Center - Oak Lawn, IL. [Member]", "label": "Oak Lawn Medical Center - Oak Lawn, IL. [Member]", "terseLabel": "Oak Lawn Medical Center - Oak Lawn, IL" } } }, "localname": "OakLawnMedicalCenterOakLawnIL.Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_OceanParkCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ocean Park Center [Member]", "label": "Ocean Park Center [Member]", "terseLabel": "Ocean Park" } } }, "localname": "OceanParkCenterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_OpUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OP Units [Member]", "label": "OP Units [Member]", "terseLabel": "OP Units" } } }, "localname": "OpUnitsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments", "label": "Operating Income (Loss) Before Gain (Loss) on Sale of Real Estate Investments", "totalLabel": "Operating loss before gain (loss) on sale of real estate investments" } } }, "localname": "OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "hct_OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "label": "Operating Lease, Net Investment in Lease, Credit Loss Expense (Reversal)", "terseLabel": "Operating lease impairment loss" } } }, "localname": "OperatingLeaseNetInvestmentinLeaseCreditLossExpenseReversal", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_OrdinaryDividendIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary Dividend Income [Member]", "label": "Ordinary Dividend Income [Member]", "verboseLabel": "Ordinary dividend income" } } }, "localname": "OrdinaryDividendIncomeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "domainItemType" }, "hct_OtherRealEstateDisposalsAndReclasses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Real Estate, Disposals And Reclasses", "label": "Other Real Estate, Disposals And Reclasses", "terseLabel": "Assets", "verboseLabel": "Disposals, impairments and reclasses" } } }, "localname": "OtherRealEstateDisposalsAndReclasses", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "hct_OuachitaCommunityHospitalWestMonroeLAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ouachita Community Hospital - West Monroe, LA [Member]", "label": "Ouachita Community Hospital - West Monroe, LA [Member]", "terseLabel": "Ouachita Community Hospital - West Monroe, LA" } } }, "localname": "OuachitaCommunityHospitalWestMonroeLAMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_OverstatementOfPreviouslyRecordedTaxBenefitsDeferredTaxAssetsandNetIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Overstatement Of Previously Recorded Tax Benefits, Deferred Tax Assets and Net Income", "label": "Overstatement Of Previously Recorded Tax Benefits, Deferred Tax Assets and Net Income", "terseLabel": "Overstatement of previously recorded tax benefits, deferred tax assets and net income" } } }, "localname": "OverstatementOfPreviouslyRecordedTaxBenefitsDeferredTaxAssetsandNetIncome", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_PalmValleyMedicalPlazaAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palm Valley Medical Plaza AZ [Member]", "label": "Palm Valley Medical Plaza AZ [Member]", "terseLabel": "Fox Ridge Bryant - Bryant, AR" } } }, "localname": "PalmValleyMedicalPlazaAZMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_PalmValleyMedicalPlazaGoodyearAprilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Palm Valley Medical Plaza - Goodyear - April [Member]", "label": "Palm Valley Medical Plaza - Goodyear - April [Member]", "terseLabel": "Palm Valley Medical Plaza - Goodyear, AZ" } } }, "localname": "PalmValleyMedicalPlazaGoodyearAprilMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ParadiseValleyMedicalPlazaPhoenixDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paradise Valley Medical Plaza - Phoenix - December [Member]", "label": "Paradise Valley Medical Plaza - Phoenix - December [Member]", "terseLabel": "Paradise Valley Medical Plaza - Phoenix, AZ" } } }, "localname": "ParadiseValleyMedicalPlazaPhoenixDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PhilipProfessionalCenterLawrencevilleGAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Philip Professional Center - Lawrenceville, GA [Member]", "label": "Philip Professional Center - Lawrenceville, GA [Member]", "verboseLabel": "Philip Professional Center - Lawrenceville, GA" } } }, "localname": "PhilipProfessionalCenterLawrencevilleGAMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PhysiciansPlazaofRoaneCountyHarrimanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physicians Plaza of Roane County - Harriman [Member]", "label": "Physicians Plaza of Roane County - Harriman [Member]", "terseLabel": "Physicians Plaza of Roane County - Harriman, TN" } } }, "localname": "PhysiciansPlazaofRoaneCountyHarrimanMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PinnacleCenterSouthavenDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pinnacle Center - Southaven - December [Member]", "label": "Pinnacle Center - Southaven - December [Member]", "terseLabel": "Pinnacle Center - Southaven, MS" } } }, "localname": "PinnacleCenterSouthavenDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsNorthamptonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsNorthampton [Member]", "label": "PioneerSpineSportsNorthampton [Member]", "terseLabel": "Pioneer Spine Sports - Northampton, MA" } } }, "localname": "PioneerSpineSportsNorthamptonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsSpringfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsSpringfield [Member]", "label": "PioneerSpineSportsSpringfield [Member]", "terseLabel": "Pioneer Spine Sport - Springfield, MA" } } }, "localname": "PioneerSpineSportsSpringfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PioneerSpineSportsWestSpringfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PioneerSpineSportsWestSpringfield [Member]", "label": "PioneerSpineSportsWestSpringfield [Member]", "terseLabel": "Pioneer Spine Sports - West Springfield, MA" } } }, "localname": "PioneerSpineSportsWestSpringfieldMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PlazaDelRioMedicalOfficeCampusPortfolioAZMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]", "label": "Plaza Del Rio Medical Office Campus Portfolio AZ [Member]", "terseLabel": "Plaza Del Rio Medical Office Campus Portfolio AZ" } } }, "localname": "PlazaDelRioMedicalOfficeCampusPortfolioAZMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatCedarRapidsCedarRapidsAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member]", "label": "Prairie Hills at Cedar Rapids - Cedar Rapids - August [Member]", "terseLabel": "Prairie Hills at Cedar Rapids - Cedar Rapids, IA" } } }, "localname": "PrairieHillsatCedarRapidsCedarRapidsAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatClintonClintonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Clinton - Clinton - August [Member]", "label": "Prairie Hills at Clinton - Clinton - August [Member]", "terseLabel": "Prairie Hills at Clinton - Clinton, IA" } } }, "localname": "PrairieHillsatClintonClintonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatDesMoinesDesMoinesAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Des Moines - Des Moines - August [Member]", "label": "Prairie Hills at Des Moines - Des Moines - August [Member]", "terseLabel": "Prairie Hills at Des Moines - Des Moines, IA" } } }, "localname": "PrairieHillsatDesMoinesDesMoinesAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatIndependenceIndependenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Independence - Independence [Member]", "label": "Prairie Hills at Independence - Independence [Member]", "terseLabel": "Prairie Hills at Independence - Independence, IA" } } }, "localname": "PrairieHillsatIndependenceIndependenceMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatOttumwaOttumwaAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Ottumwa - Ottumwa - August [Member]", "label": "Prairie Hills at Ottumwa - Ottumwa - August [Member]", "terseLabel": "Prairie Hills at Ottumwa - Ottumwa, IA" } } }, "localname": "PrairieHillsatOttumwaOttumwaAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PrairieHillsatTiptonTiptonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prairie Hills at Tipton - Tipton - August [Member]", "label": "Prairie Hills at Tipton - Tipton - August [Member]", "terseLabel": "Prairie Hills at Tipton - Tipton, IA" } } }, "localname": "PrairieHillsatTiptonTiptonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PreTaxNonCompoundedReturnOnCapitalContributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-tax Non-compounded Return on Capital Contribution [Member]", "label": "Pre-tax Non-compounded Return on Capital Contribution [Member]", "terseLabel": "Pre-tax Non-compounded Return on Capital Contribution" } } }, "localname": "PreTaxNonCompoundedReturnOnCapitalContributionMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_PreferredStockAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Additional Shares Authorized", "label": "Preferred Stock, Additional Shares Authorized", "terseLabel": "Preferred stock, additional shares authorized (in shares)" } } }, "localname": "PreferredStockAdditionalSharesAuthorized", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_PreferredStockEquityLineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Equity Line", "label": "Preferred Stock Equity Line [Member]", "terseLabel": "Preferred Stock Equity Line" } } }, "localname": "PreferredStockEquityLineMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_PreferredStockOfferingAuthorizedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred Stock Offering, Authorized Value", "label": "Preferred Stock Offering, Authorized Value", "terseLabel": "Authorized preferred stock offering, value" } } }, "localname": "PreferredStockOfferingAuthorizedValue", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_PreferredStockOfferingMaximumSharesPerOffer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock Offering, Maximum Shares per Offer", "label": "Preferred Stock Offering, Maximum Shares per Offer", "terseLabel": "Maximum shares per preferred stock offering (in shares)" } } }, "localname": "PreferredStockOfferingMaximumSharesPerOffer", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_PreferredStockQuarterlyDividendRatePerDollarAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock, Quarterly Dividend Rate, Per-Dollar-Amount", "label": "Preferred Stock, Quarterly Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock, quarterly dividend rate (in usd per share)" } } }, "localname": "PreferredStockQuarterlyDividendRatePerDollarAmount", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "decimalItemType" }, "hct_PrepaidExpensesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Expenses And Other Assets", "label": "Prepaid Expenses And Other Assets [Member]", "terseLabel": "Prepaid Expenses and Other Assets" } } }, "localname": "PrepaidExpensesAndOtherAssetsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_PresenceHealingArtsPavilionNewLenoxDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Presence Healing Arts Pavilion - New Lenox - December [Member]", "label": "Presence Healing Arts Pavilion - New Lenox - December [Member]", "terseLabel": "Presence Healing Arts Pavilion - New Lenox, IL" } } }, "localname": "PresenceHealingArtsPavilionNewLenoxDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ProceedsFromGovernmentAssistanceCARESAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Government Assistance, CARES Act", "label": "Proceeds From Government Assistance, CARES Act", "terseLabel": "Proceeds from government assistance" } } }, "localname": "ProceedsFromGovernmentAssistanceCARESAct", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_ProceedsFromSaleofInterestRateCashFlowHedge": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale of Interest Rate Cash Flow Hedge", "label": "Proceeds From Sale of Interest Rate Cash Flow Hedge", "terseLabel": "Proceeds from sale of interest rate cash flow hedge" } } }, "localname": "ProceedsFromSaleofInterestRateCashFlowHedge", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_ProfessionalFeesCreditDueFromAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional Fees Credit Due From Advisor", "label": "Professional Fees Credit Due From Advisor [Member]", "terseLabel": "Professional fees credit due from Advisor" } } }, "localname": "ProfessionalFeesCreditDueFromAdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_ProfessionalFeesandReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional Fees and Reimbursements [Member]", "label": "Professional Fees and Reimbursements [Member]", "terseLabel": "Professional Fees and Reimbursements" } } }, "localname": "ProfessionalFeesandReimbursementsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_PropertyManagementAndLeasingFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management and Leasing Fees [Member]", "label": "Property Management and Leasing Fees [Member]", "terseLabel": "Property management fees (6)" } } }, "localname": "PropertyManagementAndLeasingFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_PropertyOperatingandMaintenanceExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Operating and Maintenance Expense [Member]", "label": "Property Operating and Maintenance Expense [Member]", "terseLabel": "Property Operating and Maintenance Expense" } } }, "localname": "PropertyOperatingandMaintenanceExpenseMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "domainItemType" }, "hct_PublicStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Stock Offering [Member]", "label": "Public Stock Offering [Member]", "terseLabel": "Public Stock Offering" } } }, "localname": "PublicStockOfferingMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_PulmonaryCriticalCareMedicineAccocLemoyneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member]", "label": "Pulmonary & Critical Care Medicine Accoc - Lemoyne [Member]", "terseLabel": "Pulmonary & Critical Care Med - Lemoyne, PA" } } }, "localname": "PulmonaryCriticalCareMedicineAccocLemoyneMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_PurchaseObligationAmountFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase Obligation, Amount Funded", "label": "Purchase Obligation, Amount Funded", "terseLabel": "Purchase obligation, amount funded" } } }, "localname": "PurchaseObligationAmountFunded", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_PurchasePriceAllocationPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Price Allocation Policy [Policy Text Block]", "label": "Purchase Price Allocation Policy [Policy Text Block]", "terseLabel": "Purchase Price Allocation" } } }, "localname": "PurchasePriceAllocationPolicyPolicyTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hct_QuarterlyVariableManagementFeeBenchmarkOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quarterly Variable Management Fee, Benchmark One [Member]", "label": "Quarterly Variable Management Fee, Benchmark One [Member]", "terseLabel": "Quarterly Variable Management Fee, Benchmark One" } } }, "localname": "QuarterlyVariableManagementFeeBenchmarkOneMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_QuarterlyVariableManagementFeeBenchmarkTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Quarterly Variable Management Fee, Benchmark Two [Member]", "label": "Quarterly Variable Management Fee, Benchmark Two [Member]", "terseLabel": "Quarterly Variable Management Fee, Benchmark Two" } } }, "localname": "QuarterlyVariableManagementFeeBenchmarkTwoMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RAIClearwaterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RAI Clearwater [Member]", "label": "RAI Clearwater [Member]", "terseLabel": "RAI Care Center - Clearwater, FL" } } }, "localname": "RAIClearwaterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RamseyWoodsCudahyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ramsey Woods - Cudahy [Member]", "label": "Ramsey Woods - Cudahy [Member]", "terseLabel": "Ramsey Woods Memory Care - Cudahy, WI" } } }, "localname": "RamseyWoodsCudahyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RealEstateCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Cost [Member]", "label": "Real Estate Cost [Member]", "terseLabel": "Real Estate Cost" } } }, "localname": "RealEstateCostMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RealEstateInvestmentAtCostRelatingtoNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investment, At Cost Relating to Notes Payable", "label": "Real Estate Investment, At Cost Relating to Notes Payable", "terseLabel": "Real estate investments pledged as collateral" } } }, "localname": "RealEstateInvestmentAtCostRelatingtoNotesPayable", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentPropertyAccumulatedDepreciationPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investment Property, Accumulated Depreciation, Period Increase (Decrease)", "label": "Real Estate Investment Property, Accumulated Depreciation, Period Increase (Decrease)", "terseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciationPeriodIncreaseDecrease", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentPropertyAtCostAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investment Property, at Cost, Acquisitions", "label": "Real Estate Investment Property, at Cost, Acquisitions", "verboseLabel": "Additions-Acquisitions" } } }, "localname": "RealEstateInvestmentPropertyAtCostAcquisitions", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentsAcquiredIntangibleAssetsTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Real Estate Investments, Acquired Intangible Assets, Total", "label": "Real Estate Investments, Acquired Intangible Assets, Total", "terseLabel": "Acquired intangibles" } } }, "localname": "RealEstateInvestmentsAcquiredIntangibleAssetsTotal", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "hct_RealEstateInvestmentsMeasurementInputPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Investments, Measurement Input, Percent", "label": "Real Estate Investments, Measurement Input, Percent", "terseLabel": "Cash flows and capitalization rates" } } }, "localname": "RealEstateInvestmentsMeasurementInputPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_ReclassificationFromHeldForSaleToRealEstateInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassification From Held-For-Sale To Real Estate Investments", "label": "Reclassification From Held-For-Sale To Real Estate Investments [Member]", "terseLabel": "Reclassification From Held-For-Sale To Real Estate Investments" } } }, "localname": "ReclassificationFromHeldForSaleToRealEstateInvestmentsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "hct_ReimbursementsOfEmployeeBonusesOfTheAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursements of Employee Bonuses of the Advisor", "label": "Reimbursements of Employee Bonuses of the Advisor [Member]", "terseLabel": "Reimbursements of Employee Bonuses of the Advisor" } } }, "localname": "ReimbursementsOfEmployeeBonusesOfTheAdvisorMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_ReimbursementsofAdministrativeServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reimbursements of Administrative Services [Member]", "label": "Reimbursements of Administrative Services [Member]", "terseLabel": "Reimbursements of Administrative Services" } } }, "localname": "ReimbursementsofAdministrativeServicesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_RelatedPartyAgreementTermofAgreementRenewalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Agreement, Term of Agreement, Renewal Period", "label": "Related Party Agreement, Term of Agreement, Renewal Period", "terseLabel": "Renewal term" } } }, "localname": "RelatedPartyAgreementTermofAgreementRenewalPeriod", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyFeesBenchmarkDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Fees, Benchmark [Domain]", "label": "Related Party Fees, Benchmark [Domain]", "terseLabel": "Related Party Fees, Benchmark [Domain]" } } }, "localname": "RelatedPartyFeesBenchmarkDomain", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_RelatedPartyFeesByBenchmarkAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Fees, by Benchmark [Axis]", "label": "Related Party Fees, by Benchmark [Axis]", "terseLabel": "Related Party Fees, by Benchmark [Axis]" } } }, "localname": "RelatedPartyFeesByBenchmarkAxis", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "stringItemType" }, "hct_RelatedPartyTransactionAssetThresholdQualifyingManagement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Asset Threshold Qualifying Management", "label": "Related Party Transaction, Asset Threshold Qualifying Management", "terseLabel": "Asset threshold for assignment of agreement" } } }, "localname": "RelatedPartyTransactionAssetThresholdQualifyingManagement", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent", "label": "Related Party Transaction, Base Management Fee of Net Proceeds, Percent", "terseLabel": "Base management fee of net proceeds" } } }, "localname": "RelatedPartyTransactionBaseManagementFeeofNetProceedsPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionBasisCostOfLivingPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Basis Cost Of Living Percent", "label": "Related Party Transaction Basis Cost Of Living Percent", "terseLabel": "Cost of living percent multiplier" } } }, "localname": "RelatedPartyTransactionBasisCostOfLivingPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionBasisofCoreEarningsPerShareBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Basis of Core Earnings, Per Share Basis", "label": "Related Party Transaction, Basis of Core Earnings, Per Share Basis", "terseLabel": "Basis of core earnings (in usd per share)" } } }, "localname": "RelatedPartyTransactionBasisofCoreEarningsPerShareBasis", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "perShareItemType" }, "hct_RelatedPartyTransactionBasisofCoreEarningsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Basis of Core Earnings, Percent", "label": "Related Party Transaction, Basis of Core Earnings, Percent", "terseLabel": "Basis of core earnings, percent" } } }, "localname": "RelatedPartyTransactionBasisofCoreEarningsPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionBasisofRealEstateCostPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Basis of Real Estate Cost Percent", "label": "Related Party Transaction Basis of Real Estate Cost Percent", "terseLabel": "Real estate cost percent multiplier" } } }, "localname": "RelatedPartyTransactionBasisofRealEstateCostPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term", "label": "Related Party Transaction, Contingent Good Faith Negotiations Of Fixed Component, Term", "terseLabel": "Contingent good faith negotiations of fixed component, term" } } }, "localname": "RelatedPartyTransactionContingentGoodFaithNegotiationsOfFixedComponentTerm", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark", "label": "Related Party Transaction, Cumulative Capital Investment Return, as a Percentage of Benchmark", "terseLabel": "Cumulative capital investment return to investors as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionCumulativeCapitalInvestmentReturnAsPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionFeeMultiplier": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Fee Multiplier", "label": "Related Party Transaction, Fee Multiplier", "terseLabel": "Fee multiplier" } } }, "localname": "RelatedPartyTransactionFeeMultiplier", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Oversight Fees Earned by Related Party, Percentage of Benchmark", "terseLabel": "Oversight fees earned by related party" } } }, "localname": "RelatedPartyTransactionOversightFeesEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionPeriodofNoticeforTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Period of Notice for Termination", "label": "Related Party Transaction, Period of Notice for Termination", "terseLabel": "Period of notice of termination" } } }, "localname": "RelatedPartyTransactionPeriodofNoticeforTermination", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionPeriodofNoticetoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Period of Notice to Alter Agreement", "label": "Related Party Transaction, Period of Notice to Alter Agreement", "terseLabel": "Period of notice" } } }, "localname": "RelatedPartyTransactionPeriodofNoticetoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Property Management Fees Earned by Related Party, Percentage of Benchmark", "terseLabel": "Property management fees" } } }, "localname": "RelatedPartyTransactionPropertyManagementFeesEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Quarterly Asset Management Fee Earned By Related Party, Percentage of Benchmark", "terseLabel": "Quarterly asset management fee" } } }, "localname": "RelatedPartyTransactionQuarterlyAssetManagementFeeEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionReductionofRealEstateCostPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction Reduction of Real Estate Cost Percent", "label": "Related Party Transaction Reduction of Real Estate Cost Percent", "terseLabel": "Reduction of real estate cost percent" } } }, "localname": "RelatedPartyTransactionReductionofRealEstateCostPercent", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "pureItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Capped Reimbursement Amount", "terseLabel": "Reimbursed fees to related party, capped reimbursement amount" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyCappedReimbursementAmount", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Company's Portfolio Costs", "terseLabel": "Financing advance fees as a percentage of benchmark, expected company portfolio cost" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedCompanysPortfolioCosts", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs", "label": "Related Party Transaction, Reimbursed Fees to Related Party, Percentage of Benchmark, Expected Third Party Acquisition Costs", "terseLabel": "Financing advance fees as a percentage of benchmark, expected third party costs" } } }, "localname": "RelatedPartyTransactionReimbursedFeestoRelatedPartyPercentageofBenchmarkExpectedThirdPartyAcquisitionCosts", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum", "label": "Related Party Transaction, Special Allocation for Tax Purposes, Excess Depreciation Deductions Maximum", "terseLabel": "Special allocation for tax purposes excess depreciation deductions maximum" } } }, "localname": "RelatedPartyTransactionSpecialAllocationforTaxPurposesExcessDepreciationDeductionsMaximum", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "monetaryItemType" }, "hct_RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark", "label": "Related Party Transaction, Subordinated Incentive Listing Distribution, Percentage of Benchmark", "terseLabel": "Subordinated participation fees as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionSubordinatedIncentiveListingDistributionPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark", "label": "Related Party Transaction, Subordinated Performance Fee Earned by Related Party, Percentage of Benchmark", "terseLabel": "Subordinated performance fee as a percentage of benchmark" } } }, "localname": "RelatedPartyTransactionSubordinatedPerformanceFeeEarnedByRelatedPartyPercentageOfBenchmark", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "percentItemType" }, "hct_RelatedPartyTransactionTermofAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Term of Agreement", "label": "Related Party Transaction, Term of Agreement", "terseLabel": "Term of agreement" } } }, "localname": "RelatedPartyTransactionTermofAgreement", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "durationItemType" }, "hct_RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Voting Percentage Required to Alter Agreement", "label": "Related Party Transaction, Voting Percentage Required to Alter Agreement", "terseLabel": "Board of directors voting percentage" } } }, "localname": "RelatedPartyTransactionVotingPercentageRequiredtoAlterAgreement", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "percentItemType" }, "hct_RenaissanceonPeachtreeAtlantaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renaissance on Peachtree - Atlanta [Member]", "label": "Renaissance on Peachtree - Atlanta [Member]", "terseLabel": "Renaissance on Peachtree - Atlanta, GA" } } }, "localname": "RenaissanceonPeachtreeAtlantaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RentCollectionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rent Collection Percentage", "label": "Rent Collection Percentage", "terseLabel": "Rent collection percentage" } } }, "localname": "RentCollectionPercentage", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "hct_RentalIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental Income [Member]", "label": "Rental Income [Member]", "terseLabel": "Rental Income" } } }, "localname": "RentalIncomeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "hct_RestrictedSharePlanBenchmarkBasisforIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted Share Plan, Benchmark Basis for Issuance", "label": "Restricted Share Plan, Benchmark Basis for Issuance", "terseLabel": "Benchmark basis for issuance" } } }, "localname": "RestrictedSharePlanBenchmarkBasisforIssuance", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_RestrictedSharePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Share Plan [Member]", "label": "Restricted Share Plan [Member]", "terseLabel": "Restricted Share Plan" } } }, "localname": "RestrictedSharePlanMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "domainItemType" }, "hct_ReturnofCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Return of Capital [Member]", "label": "Return of Capital [Member]", "verboseLabel": "Return of capital (1)" } } }, "localname": "ReturnofCapitalMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "domainItemType" }, "hct_RivershoresHealthcareRehabCentreMarseillesDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rivershores Healthcare & Rehab Centre - Marseilles - December [Member]", "label": "Rivershores Healthcare & Rehab Centre - Marseilles - December [Member]", "terseLabel": "Rivershores Healthcare & Rehab Centre - Marseilles, IL" } } }, "localname": "RivershoresHealthcareRehabCentreMarseillesDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_RockwallMedicalPlazaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockwall Medical Plaza [Member]", "label": "Rockwall Medical Plaza [Member]", "terseLabel": "Rockwall Medical Plaza - Rockwall, TX" } } }, "localname": "RockwallMedicalPlazaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SNFPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SNF Properties [Member]", "label": "SNF Properties [Member]", "terseLabel": "SNF Properties" } } }, "localname": "SNFPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_SaleofStockConsiderationReceivedonTransactionGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Consideration Received on Transaction, Gross", "label": "Sale of Stock, Consideration Received on Transaction, Gross", "terseLabel": "Sale of stock, gross proceeds" } } }, "localname": "SaleofStockConsiderationReceivedonTransactionGross", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hct_SassafrasMedicalBuildingErieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sassafras Medical Building - Erie [Member]", "label": "Sassafras Medical Building - Erie [Member]", "terseLabel": "Sassafras Medical Building - Erie, PA" } } }, "localname": "SassafrasMedicalBuildingErieMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]", "label": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services [Table Text Block]", "terseLabel": "Schedule of Amount Contractually Due and Forgiven in Connection With Operation Related Services" } } }, "localname": "ScheduleOfAmountContractuallyDueAndForgivenInConnectionWithOperationRelatedServicesTableTextBlock", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsTables" ], "xbrltype": "textBlockItemType" }, "hct_ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic and Diluted, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedByCommonClassIncludingTwoClassMethodTable", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "hct_ScheduleOfSharesRepurchasedLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Schedule of Shares Repurchased [Table]", "label": "Schedule of Shares Repurchased [Line Items]", "terseLabel": "Schedule of Shares Repurchased [Line Items]" } } }, "localname": "ScheduleOfSharesRepurchasedLineItems", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_ScheduleOfSharesRepurchasedTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Shares Repurchased [Table]", "label": "Schedule of Shares Repurchased [Table]", "terseLabel": "Schedule of Shares Repurchased [Table]" } } }, "localname": "ScheduleOfSharesRepurchasedTable", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "hct_ScherervilleBuildingScherervilleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schererville Building - Schererville [Member]", "label": "Schererville Building - Schererville [Member]", "terseLabel": "Schererville Building - Schererville, IN" } } }, "localname": "ScherervilleBuildingScherervilleMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ScrippsCedarMedicalCenterVistaAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scripps Cedar Medical Center - Vista - August [Member]", "label": "Scripps Cedar Medical Center - Vista - August [Member]", "terseLabel": "Scripps Cedar Medical Center - Vista, CA" } } }, "localname": "ScrippsCedarMedicalCenterVistaAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SecondAmendedandRestatedAdvisoryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Amended and Restated Advisory Agreement [Member]", "label": "Second Amended and Restated Advisory Agreement [Member]", "terseLabel": "Second Amended and Restated Advisory Agreement" } } }, "localname": "SecondAmendedandRestatedAdvisoryAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_SeniorsHousingCommunitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seniors Housing Communities [Member]", "label": "Seniors Housing Communities [Member]", "terseLabel": "Seniors Housing Communities" } } }, "localname": "SeniorsHousingCommunitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SeverancePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Severance Payments", "label": "Severance Payments [Member]", "terseLabel": "Severance Payments" } } }, "localname": "SeverancePaymentsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAutomaticGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Automatic Grant", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Automatic Grant", "terseLabel": "Shares granted automatically upon election to board of directors (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAutomaticGrant", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend", "terseLabel": "Stock dividend (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividend", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "hct_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Stock Dividend, Weighted Average Grant Date Fair Value", "terseLabel": "Stock dividend (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsStockDividendWeightedAverageGrantDateFairValue", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "hct_SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees", "label": "Share Price, Equity Instruments, Net of Selling Commissions and Dealer Fees", "terseLabel": "Share price, net (in dollars per share)" } } }, "localname": "SharePriceEquityInstrumentsNetofSellingCommissionsandDealerFees", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "perShareItemType" }, "hct_ShareRepurchaseProgramReductionInAuthorizedSharesForRepurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program, Reduction In Authorized Shares For Repurchase", "label": "Share Repurchase Program, Reduction In Authorized Shares For Repurchase", "terseLabel": "Reduction in shares authorized for repurchase (in shares)" } } }, "localname": "ShareRepurchaseProgramReductionInAuthorizedSharesForRepurchase", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "hct_SingleTenantMOBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Single Tenant MOB [Member]", "label": "Single Tenant MOB [Member]", "terseLabel": "Single Tenant MOB" } } }, "localname": "SingleTenantMOBMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_SkilledNursingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Facilities [Member]", "label": "Skilled Nursing Facilities [Member]", "terseLabel": "Skilled Nursing Facilities" } } }, "localname": "SkilledNursingFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "hct_SkyLakesKlamathMedicalClinicKlamathFallsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sky Lakes Klamath Medical Clinic - Klamath Falls [Member]", "label": "Sky Lakes Klamath Medical Clinic - Klamath Falls [Member]", "terseLabel": "Sky Lakes Klamath Medical Clinic - Klamath Falls, OR" } } }, "localname": "SkyLakesKlamathMedicalClinicKlamathFallsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SpecialLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special Limited Partner [Member]", "label": "Special Limited Partner [Member]", "terseLabel": "Special Limited Partner" } } }, "localname": "SpecialLimitedPartnerMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_St.AndrewsMedicalParkVeniceFLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Andrews Medical Park, Venice, FL [Member]", "label": "St. Andrews Medical Park, Venice, FL [Member]", "terseLabel": "Medical Center V - Peoria, AZ" } } }, "localname": "St.AndrewsMedicalParkVeniceFLMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "domainItemType" }, "hct_St.AndrewsMedicalParkVeniceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "St. Andrews Medical Park - Venice [Member]", "label": "St. Andrews Medical Park - Venice [Member]", "terseLabel": "St. Andrews Medical Park - Venice, FL" } } }, "localname": "St.AndrewsMedicalParkVeniceMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StFrancisWIMOBStFrancisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "StFrancisWIMOBStFrancis [Member]", "label": "StFrancisWIMOBStFrancis [Member]", "terseLabel": "St. Francis WI MOB - St. Francis, WI" } } }, "localname": "StFrancisWIMOBStFrancisMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_StockbridgeFamilyMedicalStockbridgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockbridge Family Medical - Stockbridge [Member]", "label": "Stockbridge Family Medical - Stockbridge [Member]", "terseLabel": "Stockbridge Family Medical - Stockbridge, GA" } } }, "localname": "StockbridgeFamilyMedicalStockbridgeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SubjectFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject Fees [Member]", "label": "Subject Fees [Member]", "terseLabel": "Subject Fees" } } }, "localname": "SubjectFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_SubjectFeesTransitionFeeNotinExcessoftheProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]", "label": "Subject Fees (Transition Fee Not in Excess of the Product) [Member]", "terseLabel": "Subject Fees (Transition Fee Not in Excess of the Product)" } } }, "localname": "SubjectFeesTransitionFeeNotinExcessoftheProductMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofBurlingtonBurlingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Burlington - Burlington [Member]", "label": "Sunnybrook of Burlington - Burlington [Member]", "terseLabel": "Sunnybrook of Burlington - Burlington, IA" } } }, "localname": "SunnybrookofBurlingtonBurlingtonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofBurlingtonLandBurlingtonAugustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Burlington - Land - Burlington - August [Member]", "label": "Sunnybrook of Burlington - Land - Burlington - August [Member]", "terseLabel": "Sunnybrook of Burlington - Land - Burlington, IA" } } }, "localname": "SunnybrookofBurlingtonLandBurlingtonAugustMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofCarrollCarrollAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Carroll - Carroll - August26 [Member]", "label": "Sunnybrook of Carroll - Carroll - August26 [Member]", "terseLabel": "Sunnybrook of Carroll - Carroll, IA" } } }, "localname": "SunnybrookofCarrollCarrollAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofFairfieldFairfieldAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Fairfield - Fairfield - August26 [Member]", "label": "Sunnybrook of Fairfield - Fairfield - August26 [Member]", "terseLabel": "Sunnybrook of Fairfield - Fairfield, IA" } } }, "localname": "SunnybrookofFairfieldFairfieldAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofFt.MadisonFt.MadisonAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member]", "label": "Sunnybrook of Ft. Madison - Ft. Madison - August26 [Member]", "terseLabel": "Sunnybrook of Ft. Madison - Ft. Madison, IA" } } }, "localname": "SunnybrookofFt.MadisonFt.MadisonAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofMT.PleasantMt.PleasantAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member]", "label": "Sunnybrook of MT. Pleasant - Mt. Pleasant - August26 [Member]", "terseLabel": "Sunnybrook of Mt. Pleasant - Mt. Pleasant, IA" } } }, "localname": "SunnybrookofMT.PleasantMt.PleasantAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SunnybrookofMuscatineMuscatineAugust26Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sunnybrook of Muscatine - Muscatine - August26 [Member]", "label": "Sunnybrook of Muscatine - Muscatine - August26 [Member]", "terseLabel": "Sunnybrook of Muscatine - Muscatine, IA" } } }, "localname": "SunnybrookofMuscatineMuscatineAugust26Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SurgeryCenterofTempleTempleTX.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Surgery Center of Temple - Temple, TX. [Member]", "label": "Surgery Center of Temple - Temple, TX. [Member]", "terseLabel": "Surgery Center of Temple - Temple, TX" } } }, "localname": "SurgeryCenterofTempleTempleTX.Member", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_SwedishAmericanMOBRoscoeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swedish American MOB - Roscoe", "label": "Swedish American MOB - Roscoe [Member]", "terseLabel": "Swedish American MOB - Roscoe, IL" } } }, "localname": "SwedishAmericanMOBRoscoeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TaxDepreciationDeductionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax Depreciation Deduction [Member]", "label": "Tax Depreciation Deduction [Member]", "terseLabel": "Tax Depreciation Deduction" } } }, "localname": "TaxDepreciationDeductionMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "hct_TenderOfferMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tender Offer [Member]", "label": "Tender Offer [Member]", "terseLabel": "Tender Offer" } } }, "localname": "TenderOfferMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "hct_TexasChildrensHospitalHoustonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Texas Children's Hospital - Houston [Member]", "label": "Texas Children's Hospital - Houston [Member]", "terseLabel": "Texas Children\u2019s Hospital - Houston, TX" } } }, "localname": "TexasChildrensHospitalHoustonMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TheAtriumRockfordMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Atrium - Rockford [Member]", "label": "The Atrium - Rockford [Member]", "terseLabel": "The Atrium - Rockford, IL" } } }, "localname": "TheAtriumRockfordMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Heights Healthcare & rehab Centre - Peoria Heights - December [Member]", "label": "The Heights Healthcare & rehab Centre - Peoria Heights - December [Member]", "terseLabel": "The Heights Healthcare & Rehab Centre - Peoria Heights, IL" } } }, "localname": "TheHeightsHealthcarerehabCentrePeoriaHeightsDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_ThirdAmendedAndRestatedAdvisoryAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Amended And Restated Advisory Agreement [Member]", "label": "Third Amended And Restated Advisory Agreement [Member]", "terseLabel": "Third Amended And Restated Advisory Agreement" } } }, "localname": "ThirdAmendedAndRestatedAdvisoryAgreementMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "hct_TransferAgentandOtherProfessionalFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transfer Agent and other professional fees [Member]", "label": "Transfer Agent and Other Professional Fees [Member]", "terseLabel": "Professional fees and other reimbursements" } } }, "localname": "TransferAgentandOtherProfessionalFeesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "hct_TransitionFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Fee [Member]", "label": "Transition Fee [Member]", "terseLabel": "Transition Fee" } } }, "localname": "TransitionFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_TransitionPropertyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Property [Member]", "label": "Transition Property [Member]", "terseLabel": "Transition Property" } } }, "localname": "TransitionPropertyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_TripleNetLeasedHealthcareFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triple-Net Leased Healthcare Facilities [Member]", "label": "Triple-Net Leased Healthcare Facilities [Member]", "terseLabel": "Triple-net leased healthcare facilities" } } }, "localname": "TripleNetLeasedHealthcareFacilitiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_UCDavisMOBElkGroveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UC Davis MOB - Elk Grove [Member]", "label": "UC Davis MOB - Elk Grove [Member]", "terseLabel": "UC Davis MOB - Elk Grove, CA" } } }, "localname": "UCDavisMOBElkGroveMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCChambersHillHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Chambers Hill - Harrisburg", "label": "UMPC Chambers Hill - Harrisburg [Member]", "terseLabel": "UMPC Chambers Hill - Harrisburg, PA" } } }, "localname": "UMPCChambersHillHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCFisherRoadMechanicsburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Fisher Road - Mechanicsburg", "label": "UMPC Fisher Road - Mechanicsburg [Member]", "terseLabel": "UMPC Fisher Road - Mechanicsburg, PA" } } }, "localname": "UMPCFisherRoadMechanicsburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UMPCSirThomasCourtHarrisburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UMPC Sir Thomas Court - Harrisburg", "label": "UMPC Sir Thomas Court - Harrisburg [Member]", "terseLabel": "UMPC Sir Thomas Court - Harrisburg, PA" } } }, "localname": "UMPCSirThomasCourtHarrisburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnencumberedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unencumbered Properties [Member]", "label": "Unencumbered Properties [Member]", "terseLabel": "Unencumbered Properties" } } }, "localname": "UnencumberedPropertiesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicMolineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic - Moline [Member]", "label": "UnityPoint Clinic - Moline [Member]", "terseLabel": "UnityPoint Clinic - Moline, IL" } } }, "localname": "UnityPointClinicMolineMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicMuscatineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic - Muscatine [Member]", "label": "UnityPoint Clinic - Muscatine [Member]", "terseLabel": "UnityPoint Clinic - Muscatine, IA" } } }, "localname": "UnityPointClinicMuscatineMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_UnityPointClinicPortfolioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UnityPoint Clinic Portfolio [Member]", "label": "UnityPoint Clinic Portfolio [Member]", "terseLabel": "UnityPoint Clinic Portfolio" } } }, "localname": "UnityPointClinicPortfolioMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "hct_VAOutpatientClinicGalesburgMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VA Outpatient Clinic - Galesburg [Member]", "label": "VA Outpatient Clinic - Galesburg [Member]", "terseLabel": "VA Outpatient Clinic - Galesberg, IL" } } }, "localname": "VAOutpatientClinicGalesburgMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VariableManagementIncentiveFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Management - Incentive Fee [Member]", "label": "Variable Management - Incentive Fee [Member]", "terseLabel": "Variable Management - Incentive Fee" } } }, "localname": "VariableManagementIncentiveFeeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "domainItemType" }, "hct_VascularSurgeryAssociatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vascular Surgery Associates [Member]", "label": "Vascular Surgery Associates [Member]", "terseLabel": "Vascular Surgery Associates - Tallahassee, FL" } } }, "localname": "VascularSurgeryAssociatesMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VictoryMedicalCenteratCraigRanchMcKinneyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VictoryMedicalCenteratCraigRanchMcKinney [Member]", "label": "VictoryMedicalCenteratCraigRanchMcKinney [Member]", "terseLabel": "Victory Medical Center at Craig Ranch - McKinney, TX" } } }, "localname": "VictoryMedicalCenteratCraigRanchMcKinneyMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_VillageCenterParkwayStockbridgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Village Center Parkway - Stockbridge [Member]", "label": "Village Center Parkway - Stockbridge [Member]", "terseLabel": "Village Center Parkway - Stockbridge, GA" } } }, "localname": "VillageCenterParkwayStockbridgeMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WellingtonFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wellington, Florida [Member]", "label": "Wellington, Florida [Member]", "terseLabel": "Wellington, Florida" } } }, "localname": "WellingtonFloridaMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "hct_WellingtonatHersheysMillWestChesterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wellington at Hershey's Mill - West Chester [Member]", "label": "Wellington at Hershey's Mill - West Chester [Member]", "verboseLabel": "Wellington at Hershey's Mill - West Chester, PA" } } }, "localname": "WellingtonatHersheysMillWestChesterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WestMichiganSurgeryCenterBigRapidsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "West Michigan Surgery Center - Big Rapids [Member]", "label": "West Michigan Surgery Center - Big Rapids [Member]", "terseLabel": "West Michigan Surgery Center - Big Rapids, MI" } } }, "localname": "WestMichiganSurgeryCenterBigRapidsMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WomensHealthcareGroupMOBYorkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WomensHealthcareGroupMOBYork [Member]", "label": "WomensHealthcareGroupMOBYork [Member]", "terseLabel": "Women\u2019s Healthcare Group MOB - York, PA" } } }, "localname": "WomensHealthcareGroupMOBYorkMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WoodGlenNursingandRehabCenterWestChicagoDecemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wood Glen Nursing and Rehab Center - West Chicago - December [Member]", "label": "Wood Glen Nursing and Rehab Center - West Chicago - December [Member]", "terseLabel": "Wood Glen Nursing and Rehab Center - West Chicago, IL" } } }, "localname": "WoodGlenNursingandRehabCenterWestChicagoDecemberMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "hct_WoodlakeOfficeCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Woodlake Office Center [Member]", "label": "Woodlake Office Center [Member]", "terseLabel": "Woodlake Office Center - Woodbury, MN" } } }, "localname": "WoodlakeOfficeCenterMember", "nsuri": "http://www.thehealthcarereit2.com/20201231", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board chairman" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r191", "r210", "r211", "r212", "r213", "r215", "r217", "r221" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r191", "r210", "r211", "r212", "r213", "r215", "r217", "r221" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r56", "r133", "r624" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r144", "r151", "r237", "r341", "r342", "r343", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r144", "r151", "r237", "r341", "r342", "r343", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r144", "r151", "r237", "r341", "r342", "r343", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.", "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Person serving on board of directors.", "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r227", "r299", "r302", "r573" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r315", "r317", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r571", "r574" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r315", "r317", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r571", "r574" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by type of real estate property.", "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Land and any structures permanently fixed to it.", "label": "Real Estate [Domain]", "terseLabel": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r227", "r299", "r302", "r573" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r304", "r315", "r317", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r571", "r574" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r304", "r315", "r317", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r571", "r574" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationAmountOfEncumbrances": { "auth_ref": [ "r593", "r622" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lien or mortgage outstanding on real estate investment properties for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances", "terseLabel": "Encumbrances" } } }, "localname": "RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_RealEstateAndAccumulatedDepreciationByPropertyTable": { "auth_ref": [ "r604", "r623" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about real estate investments and accompanying accumulated depreciation for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]" } } }, "localname": "RealEstateAndAccumulatedDepreciationByPropertyTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r623", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by name of property.", "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDisclosureAbstract", "nsuri": "http://fasb.org/srt/2020-01-31", "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationDisclosureTextBlock": { "auth_ref": [ "r604", "r623" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of real estate investments and associated accumulated depreciation for entities with a significant portion of their business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block]", "terseLabel": "Real Estate and Accumulated Depreciation, Schedule III" } } }, "localname": "RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIII" ], "xbrltype": "textBlockItemType" }, "srt_RealEstateAndAccumulatedDepreciationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]", "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]" } } }, "localname": "RealEstateAndAccumulatedDepreciationLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.", "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateFederalIncomeTaxBasis": { "auth_ref": [ "r603", "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost basis of real estate investments for federal income tax purposes for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Federal Income Tax Basis", "terseLabel": "Federal income taxes" } } }, "localname": "RealEstateFederalIncomeTaxBasis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r140", "r141", "r142", "r143", "r145", "r146", "r149", "r150", "r151", "r153", "r154", "r156", "r157", "r167" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r140", "r141", "r142", "r143", "r145", "r146", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r167", "r238", "r239", "r344", "r365", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Axis]", "terseLabel": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r140", "r141", "r142", "r143", "r145", "r146", "r149", "r150", "r151", "r153", "r154", "r155", "r156", "r157", "r167", "r238", "r239", "r344", "r365", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.", "label": "Revision of Prior Period [Domain]", "terseLabel": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards.", "label": "Revision of Prior Period, Reclassification, Adjustment [Member]", "terseLabel": "Revision of Prior Period, Reclassification, Adjustment" } } }, "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r224", "r225", "r299", "r301", "r572", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r224", "r225", "r299", "r301", "r572", "r590", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r229", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_FL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FLORIDA", "terseLabel": "Florida" } } }, "localname": "FL", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GEORGIA", "terseLabel": "Georgia" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "stpr_MI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MICHIGAN", "terseLabel": "Michigan" } } }, "localname": "MI", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "stpr_PA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania" } } }, "localname": "PA", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AboveMarketLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases acquired as part of a real property acquisition at above market lease rate.", "label": "Above Market Leases [Member]", "terseLabel": "Above-market lease assets", "verboseLabel": "Market lease and other intangible assets" } } }, "localname": "AboveMarketLeasesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r145", "r146", "r147", "r148", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r364", "r365", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible List]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r533", "r558" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses (including $299 due to related parties as of December\u00a031, 2020)" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Written off accounts receivable" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r27", "r546" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "auth_ref": [ "r61", "r62", "r63", "r67", "r69" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]", "terseLabel": "Unrealized Gains (Losses) on Designated Derivative" } } }, "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r65", "r66", "r67", "r551", "r582", "r586" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r448", "r449", "r450", "r451", "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r67", "r69", "r140", "r141", "r143", "r388", "r577", "r578" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r28", "r344" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r140", "r141", "r143", "r341", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r145", "r146", "r147", "r148", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r362", "r363", "r364", "r365", "r508", "r509", "r510", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash\u00a0provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AffiliateCosts": { "auth_ref": [ "r92", "r136" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership.", "label": "Affiliate Costs", "negatedTerseLabel": "Operating fees to related parties" } } }, "localname": "AffiliateCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r319", "r334", "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r95", "r116", "r458" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of mortgage premiums and discounts, net" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r86", "r116", "r460" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization (including write-offs) of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r116", "r243", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization/accretion of market least intangibles" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AncillaryFeeIncomeGeneratedByServicingFinancialAssetsAmount": { "auth_ref": [ "r504" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "All amounts that are due to the servicer of a financial asset, excluding contractually specified servicing fees and late fees.", "label": "Ancillary Fee Income Generated by Servicing Financial Assets, Amount", "terseLabel": "Ancillary revenue" } } }, "localname": "AncillaryFeeIncomeGeneratedByServicingFinancialAssetsAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r116", "r254" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r130", "r199", "r212", "r219", "r233", "r382", "r390", "r446", "r526", "r547" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNeededForImmediateSettlementAggregateFairValue": { "auth_ref": [ "r418" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value of assets needed to immediately settle the derivative instruments with credit-risk-related contingent features if the credit-risk-related contingent features were triggered at the end of the reporting period.", "label": "Assets Needed for Immediate Settlement, Aggregate Fair Value", "terseLabel": "Aggregate termination value" } } }, "localname": "AssetsNeededForImmediateSettlementAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r1", "r2", "r10", "r12", "r15", "r261" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Assets held for sale", "totalLabel": "Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r321", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r402", "r407" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Accounting" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BelowMarketLeaseAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "BelowMarketLeaseAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year One", "terseLabel": "Below market leases, amortization income, 2021" } } }, "localname": "BelowMarketLeaseAmortizationIncomeNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Five", "terseLabel": "Below market leases, amortization income, 2025" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Four", "terseLabel": "Below market leases, amortization income, 2024" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Three", "terseLabel": "Below market leases, amortization income, 2023" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Below Market Lease, Amortization Income, Year Two", "terseLabel": "Below market leases, amortization income, 2022" } } }, "localname": "BelowMarketLeaseAmortizationIncomeYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseGross": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "BelowMarketLeaseGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseNet": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life.", "label": "Below Market Lease, Net", "totalLabel": "Net Carrying Amount" } } }, "localname": "BelowMarketLeaseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BelowMarketLeaseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Below Market Lease, Net [Abstract]", "terseLabel": "Intangible liabilities:" } } }, "localname": "BelowMarketLeaseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r314", "r316", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r371" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedTerseLabel": "Acquisition and transaction related", "terseLabel": "Acquisition and transaction related" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r374", "r375", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business combination, consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r121", "r122", "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures (payable)" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Direct Financing Leases" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r34", "r118" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r19", "r119", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r109", "r118", "r124" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year", "totalLabel": "Cash, cash equivalents and restricted cash, end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r109", "r447" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash in excess of FDIC limit" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of securities called by share purchase right (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Distributions declared per share (in usd per share)", "verboseLabel": "Distributions declared in cash (in usd per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Distributions declared in common stock (in shares)" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock held by related party (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value, 300,000,000 shares authorized, 95,040,783 (including 1,265,037 shares paid as a stock dividend on January 15, 2021) and 92,356,664 shares of common stock issued and outstanding as of December\u00a031, 2020 and 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Units issued to purchase building" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r72", "r74", "r75", "r83", "r539", "r563" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to common stockholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r82", "r97", "r538", "r562" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r180", "r181", "r227", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r180", "r181", "r227", "r443", "r444", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r180", "r181", "r227", "r443", "r444", "r587" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r180", "r181", "r227", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r178", "r180", "r181", "r182", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r180", "r181", "r227", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r125", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation and Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r92" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and Expenses, Related Party", "terseLabel": "Operating fees to related parties" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "negatedTotalLabel": "Current (expense) benefit" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r131", "r358", "r367" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "negatedTerseLabel": "Current federal (expense) benefit" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r131", "r358", "r367" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "negatedTerseLabel": "Current state (expense) benefit" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Credit Facilities" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r527", "r529", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r23", "r270", "r529", "r545" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Outstanding loan amount", "totalLabel": "Mortgage notes payable, net" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCollateralAmount": { "auth_ref": [ "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets pledged to secure a debt instrument.", "label": "Debt Instrument, Collateral Amount", "terseLabel": "Debt instrument, collateral amount" } } }, "localname": "DebtInstrumentCollateralAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r459", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt, fair value disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r272", "r459" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate", "verboseLabel": "Effective Interest Rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r134", "r278", "r281", "r282", "r283", "r458", "r459", "r462", "r544" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r458", "r459", "r460", "r461", "r462" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedTerseLabel": "Mortgage premiums and discounts, net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r37", "r125" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]", "terseLabel": "Deferred Financing and Leasing Costs, Net" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of deferred costs.", "label": "Deferred Costs", "terseLabel": "Deferred costs, net" } } }, "localname": "DeferredCostsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r359", "r367" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "negatedTerseLabel": "Deferred federal (expense) benefit" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r37", "r460" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Deferred financing costs", "negatedTerseLabel": "Deferred financing costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r116", "r131", "r359", "r367", "r368", "r369" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "negatedTotalLabel": "Deferred (expense) benefit" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentReceivablesNetNoncurrent": { "auth_ref": [ "r45", "r463" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date. Such receivable is reduced by allowances attributable to, for instance, credit risk associated with a lessee.", "label": "Deferred Rent Receivables, Net, Noncurrent", "terseLabel": "Straight-line rent receivable, net" } } }, "localname": "DeferredRentReceivablesNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueLeasesGross": { "auth_ref": [ "r464" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of deferred lease income. Includes, but is not limited to, amount paid in advance by lessee.", "label": "Deferred Lease Income, before Accumulated Amortization", "terseLabel": "Deferred rent" } } }, "localname": "DeferredRevenueLeasesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r359", "r367" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "negatedTerseLabel": "Deferred state (expense) benefit" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred tax asset, net" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r116", "r256" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "negatedTerseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r116", "r194" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r48", "r58", "r405" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Offset in the Consolidated Balance Sheet", "terseLabel": "Gross Amounts of Recognized Liabilities" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r49", "r54", "r440" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets, at fair value", "totalLabel": "Net Amounts of Assets presented in the Consolidated Balance Sheet" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCapInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract.", "label": "Derivative, Cap Interest Rate", "terseLabel": "Interest rate cap" } } }, "localname": "DerivativeCapInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r50", "r55", "r422" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Cash", "negatedTerseLabel": "Gross Amounts Not Offset in Consolidated Balance Sheet, Cash Collateral Received" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "auth_ref": [ "r50", "r55" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Securities", "negatedTerseLabel": "Gross Amounts Not Offset in Consolidated Balance Sheet, Financial Instruments" } } }, "localname": "DerivativeCollateralObligationToReturnSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r47", "r57", "r405", "r503" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts of Recognized Assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r49", "r54", "r59", "r423" ], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after offset of derivative liability, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, before offset against an obligation to return collateral under a master netting arrangement. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Amount Not Offset Against Collateral", "terseLabel": "Derivative assets, at fair value" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "auth_ref": [ "r51", "r55", "r421" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against an obligation to return collateral. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Fair Value, Amount Offset Against Collateral", "totalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r47", "r57", "r405", "r503" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts of Recognized (Liabilities)" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral": { "auth_ref": [ "r49", "r54", "r59", "r423" ], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after offset of derivative asset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be and before offset against a right to receive collateral under a master netting arrangement. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Amount Not Offset Against Collateral", "negatedTerseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "auth_ref": [ "r51", "r55", "r421" ], "calculation": { "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset offset against the right to receive collateral. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Fair Value, Amount Offset Against Collateral", "negatedTotalLabel": "Net Amount" } } }, "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).", "label": "Derivative Financial Instruments, Assets [Member]", "terseLabel": "Derivative assets, at fair value" } } }, "localname": "DerivativeFinancialInstrumentsAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r403", "r406", "r411", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivatives and Hedging Activities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r410", "r412" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Loss (gain) on non-designated derivative instruments", "terseLabel": "Loss on non-designated derivatives" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r49", "r54", "r440" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Net Amounts of Assets presented in the Consolidated Balance Sheet", "terseLabel": "Derivative liabilities, at fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": { "auth_ref": [ "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.", "label": "Derivative, Net Liability Position, Aggregate Fair Value", "terseLabel": "Derivative, net liability position, aggregate fair value" } } }, "localname": "DerivativeNetLiabilityPositionAggregateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r397", "r399" ], "lang": { "en-us": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative, Number of Instruments Held", "terseLabel": "Number of instruments", "verboseLabel": "Number of Instruments" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r396", "r398", "r399", "r400", "r401", "r408", "r411", "r419", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r125", "r137", "r396", "r398", "r400", "r401", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopmentInProcess": { "auth_ref": [ "r557" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.", "label": "Development in Process", "terseLabel": "Development in progress" } } }, "localname": "DevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Schedule of Assets Held for Sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r321", "r336" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Schedule of Restricted Share Award Activity" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r255", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r12", "r253", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Assets held for sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Contract Sale Price", "verboseLabel": "Contract sale price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r284", "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Distributions declared on common stock" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]", "terseLabel": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Dividends Declared" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock.", "label": "Dividends [Domain]", "terseLabel": "Dividends [Domain]" } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r22", "r24", "r528", "r548" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Distributions payable" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Dividends Payable [Line Items]", "terseLabel": "Dividends Payable [Line Items]" } } }, "localname": "DividendsPayableLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPayableTable": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.", "label": "Dividends Payable [Table]", "terseLabel": "Dividends Payable [Table]" } } }, "localname": "DividendsPayableTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityDistributionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r284", "r542" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedTerseLabel": "Allocation for preferred stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromAffiliates": { "auth_ref": [ "r136", "r485", "r487", "r560" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Due from Affiliates", "terseLabel": "Due from Affiliates" } } }, "localname": "DueFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r136", "r485", "r532", "r560" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Prepaid expenses and other assets, due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r136", "r485", "r534", "r559" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Accounts payable and accrued expenses, due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share (in usd per share)", "verboseLabel": "Net loss per common share attributable to common stockholders - Basic and Diluted (in usd per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r125", "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Per Share Data" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r164", "r165", "r166", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r335" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Nonvested awards, compensation cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Nonvested awards, compensation cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r140", "r141", "r143", "r146", "r154", "r157", "r171", "r237", "r277", "r284", "r341", "r342", "r343", "r364", "r365", "r448", "r449", "r450", "r451", "r452", "r454", "r577", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDepositsRelatedToPropertySales": { "auth_ref": [ "r121", "r122", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Escrow deposits related to property sales in noncash investing and financing activities.", "label": "Escrow Deposits Related to Property Sales", "terseLabel": "Escrow deposits" } } }, "localname": "EscrowDepositsRelatedToPropertySales", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair\u00a0Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r428", "r429", "r430", "r436" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r428", "r429", "r430", "r435", "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r428", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r428", "r441" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Fair Value, by Balance Sheet Grouping" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r429", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r428", "r437" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r428", "r429", "r432", "r433", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r305", "r306", "r311", "r313", "r429", "r494" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r305", "r306", "r311", "r313", "r429", "r495" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r429", "r496" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r313", "r494", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r434", "r438" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "totalLabel": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsAssetsMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r467", "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total present value of minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Finance Lease, Liability, Maturity" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r248" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Finite-lived intangible assets, amortization expense, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Finite-lived intangible assets, amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Finite-lived intangible assets, amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Finite-lived intangible assets, amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Finite-lived intangible assets, amortization expense, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r244", "r245", "r248", "r251", "r507", "r511" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r248", "r511" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r244", "r247" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r248", "r507" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Acquired intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible assets:" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-average remaining amortization periods" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Fixtures and improvements" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "auth_ref": [ "r87", "r88", "r116", "r535", "r564", "r567", "r568", "r569" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes.", "label": "Gains (Losses) on Sales of Investment Real Estate", "negatedTerseLabel": "(Gain) loss on sales of real estate investments, net", "terseLabel": "Gain (loss) on sale of real estate investments" } } }, "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "Reduction of general and administrative expense", "negatedTerseLabel": "General and administrative", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r90", "r130", "r199", "r211", "r215", "r218", "r221", "r233", "r446" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "NOI" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r400", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfRealEstate": { "auth_ref": [ "r116", "r259" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value.", "label": "Impairment of Real Estate", "negatedLabel": "Impairment charges", "terseLabel": "Impairment charges" } } }, "localname": "ImpairmentOfRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r125", "r252", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeApproachValuationTechniqueMember": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach converting future amounts to single current discounted amount.", "label": "Valuation, Income Approach [Member]", "terseLabel": "Valuation, Income Approach" } } }, "localname": "IncomeApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r80", "r199", "r211", "r215", "r218", "r221", "r524", "r536", "r541", "r565" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r314", "r316" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetHeldforSaleDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetImpairmentsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetRealEstateSalesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r156", "r157", "r197", "r349", "r366", "r370", "r566" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": { "auth_ref": [ "r360" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.", "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability", "negatedTerseLabel": "Deferred tax asset valuation allowance" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r76", "r125", "r347", "r348", "r352", "r353", "r356", "r361", "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r112", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r115" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r115" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Straight-line rent receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r115" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Deferred rent" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r115" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r242", "r246" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "totalLabel": "Net Carrying Amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest and Other Income", "terseLabel": "Interest and other income" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r78", "r193", "r457", "r460", "r540" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 8.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Total amount of interest expense presented in the consolidated statements of operations and comprehensive loss", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r106", "r111", "r120" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest rate caps" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet": { "auth_ref": [ "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net gains or losses on interest rate cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "negatedLabel": "Cash flow hedge reclassification current", "negatedTerseLabel": "Unamortized portion remaining in accumulated other comprehensive (loss) income" } } }, "localname": "InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedLabel": "Cash flow hedge reclassification in next twelve months" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r305", "r413" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate contract" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Land": { "auth_ref": [ "r18", "r35" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held for productive use and structures used in the conduct of business, including but not limited to, office, production, storage and distribution facilities.", "label": "Land and Building [Member]", "terseLabel": "Land and Building" } } }, "localname": "LandAndBuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land Improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesAcquiredInPlaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired.", "label": "Leases, Acquired-in-Place [Member]", "terseLabel": "In-place leases and other intangible assets", "verboseLabel": "In-place lease assets" } } }, "localname": "LeasesAcquiredInPlaceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r476" ], "calculation": { "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: amounts representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Lessor, Operating Lease, Payments to be Received, Maturity" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2021" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r481" ], "calculation": { "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesLessorMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r39", "r130", "r213", "r233", "r383", "r390", "r391", "r446" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r130", "r233", "r446", "r531", "r554" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of limited partner units outstanding.", "label": "Limited Partners' Capital Account, Units Outstanding", "terseLabel": "Limited partner units (in shares)" } } }, "localname": "LimitedPartnersCapitalAccountUnitsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r23", "r529", "r545" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Credit facilities, net", "verboseLabel": "Outstanding balance" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r38", "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Line of credit facility" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r38", "r134" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facilities", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Litigation settlement, amount awarded from other party" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r23", "r271", "r529", "r549" ], "calculation": { "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Mortgage notes payable, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 6.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, after Year Five", "verboseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r138", "r268" ], "calculation": { "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtPercentageBearingFixedInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.", "label": "Long-term Debt, Percentage Bearing Fixed Interest, Amount", "terseLabel": "Long-term debt, percentage bearing fixed interest, amount" } } }, "localname": "LongtermDebtPercentageBearingFixedInterestAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r269" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinimumNetWorthRequiredForCompliance": { "auth_ref": [ "r588", "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The lowest amount of net worth (total assets minus total liabilities) required by secondary market investors or state-imposed regulatory mandates.", "label": "Minimum Net Worth Required for Compliance", "terseLabel": "Minimum net worth required for compliance" } } }, "localname": "MinimumNetWorthRequiredForCompliance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r130", "r233", "r446", "r530", "r553" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "verboseLabel": "Third Party Net Investment Amount" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r284", "r380", "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Buyout of NCI" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest Disclosure [Text Block]", "terseLabel": "Non-Controlling Interests" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterests" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Noncontrolling Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Non-Controlling Ownership Percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r46", "r91", "r378", "r389" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Noncontrolling Interest [Table]", "terseLabel": "Noncontrolling Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageNotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for mortgage notes payable.", "label": "Mortgage Notes Payable Disclosure [Text Block]", "terseLabel": "Mortgage Notes Payable, Net" } } }, "localname": "MortgageNotesPayableDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgage Notes Payable" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesFuturePrincipalPaymentsofOutstandingDebtDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetMortgageNotesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash, provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r109", "r114", "r117" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r70", "r73", "r81", "r117", "r130", "r145", "r149", "r150", "r151", "r152", "r156", "r157", "r160", "r199", "r211", "r215", "r218", "r221", "r233", "r446", "r537", "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss attributable to stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r70", "r73", "r156", "r157", "r386", "r393" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Net (income) loss attributable to non-controlling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r149", "r150", "r151", "r152", "r158", "r159", "r161", "r163", "r199", "r211", "r215", "r218", "r221" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to stockholders", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]", "terseLabel": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r140", "r141", "r143", "r284", "r377" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesBalanceSheetLocationDetails", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesSummaryofDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r94" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expenses" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of properties purchased" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of real estate properties", "verboseLabel": "Number of properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states properties are located in" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffMarketLeaseUnfavorable": { "auth_ref": [ "r42" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.", "label": "Off-market Lease, Unfavorable", "terseLabel": "Market lease intangible liabilities, net" } } }, "localname": "OffMarketLeaseUnfavorable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r52", "r53" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r199", "r211", "r215", "r218", "r221" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r472", "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r468" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Property operating and maintenance", "verboseLabel": "Property operating and maintenance" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r467" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r469", "r473" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r466" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r475", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r474", "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CommitmentsandContingenciesScheduleofFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r357" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r210", "r211", "r212", "r213", "r215", "r221" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r16", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r67", "r77", "r448", "r450", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income, before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r60", "r65" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized (loss) gain on designated derivatives", "verboseLabel": "Amount of gain (loss) recognized in accumulated other comprehensive (loss) income on interest rate derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r65", "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Amount of (loss) gain reclassified from accumulated other comprehensive income into income as interest expense (effective portion)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesDerivativesIncludedinAOCIDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r71", "r74", "r77", "r82", "r277", "r448", "r453", "r454", "r538", "r562" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Unrealized gain on designated derivative" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r85" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Interest and other income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "Payments for Deposits on Real Estate Acquisitions", "terseLabel": "Payments for deposits" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "auth_ref": [ "r104", "r108" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for Derivative Instrument, Financing Activities", "negatedTerseLabel": "Payments for derivative instruments" } } }, "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r102" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Common stock repurchases", "verboseLabel": "Common stock repurchases" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "negatedLabel": "Payments for underwriting expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r102" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedTerseLabel": "Distributions paid on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "auth_ref": [ "r102" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.", "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedTerseLabel": "Distributions to non-controlling interest holders", "terseLabel": "Distributions to non-controlling interest holders" } } }, "localname": "PaymentsOfDividendsMinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r102" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock", "negatedTerseLabel": "Dividends paid on preferred stock" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r105" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payments of additional offering expenses" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from the acquisition of or improvements to long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.", "label": "Payments to Acquire Other Property, Plant, and Equipment", "negatedTerseLabel": "Capital expenditures and other assets acquired" } } }, "localname": "PaymentsToAcquireOtherPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireRealEstate": { "auth_ref": [ "r99" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.", "label": "Payments to Acquire Real Estate", "negatedTerseLabel": "Property acquisitions and development costs" } } }, "localname": "PaymentsToAcquireRealEstate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r105" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Buyout of non-controlling interest holders", "terseLabel": "Buyout of non-controlling interest holders" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r321", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/FairValueofFinancialInstrumentsLevel3InputsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendRatePerDollarAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount per share used to calculated dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount", "terseLabel": "Preferred stock, dividend rate (in usd per share)" } } }, "localname": "PreferredStockDividendRatePerDollarAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Preferred stock, dividend rate, percentage" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.", "label": "Preferred Stock, Dividends Per Share, Declared", "terseLabel": "Preferred stock distributions declared per share (in usd per share)" } } }, "localname": "PreferredStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r25", "r128", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Preferred stock, liquidation preference (in usd per share)" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "7.375% Series A cumulative redeemable perpetual preferred stock, $0.01 par value, 2,210,000 and 1,610,000 authorized as of December\u00a031, 2020 and 2019, respectively; 1,610,000 issued and outstanding as of December\u00a031, 2020 and 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets (including $1,278 and $394 due from related parties as of December\u00a031, 2020 and 2019, respectively)", "verboseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan": { "auth_ref": [ "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from capital contributions to an entity associated with a dividend reinvestment plan.", "label": "Proceeds from Issuance of Common Stock, Dividend Reinvestment Plan", "terseLabel": "Proceeds from common stock issued through distribution reinvestment plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r100" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of preferred stock, net" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r101" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from mortgage notes payable" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePayments": { "auth_ref": [ "r479", "r480" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from lease payment, classified as operating activity.", "label": "Proceeds from Lease Payment, Operating Activity", "terseLabel": "Straight-line rents receivable" } } }, "localname": "ProceedsFromLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r101", "r135" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from credit facilities" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r110" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans", "terseLabel": "Proceeds from loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r101" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from term loan" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r98" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds from Sale of Real Estate Held-for-investment", "terseLabel": "Proceeds from sales of real estate investments" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r15", "r70", "r73", "r107", "r130", "r145", "r156", "r157", "r199", "r211", "r215", "r218", "r221", "r233", "r379", "r385", "r387", "r393", "r394", "r446", "r541" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r258" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r20", "r257" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r84", "r240" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]", "terseLabel": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Results (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]", "terseLabel": "Real Estate [Abstract]" } } }, "localname": "RealEstateAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RealEstateAccumulatedDepreciation": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation", "periodEndLabel": "Balance at end of the year", "periodStartLabel": "Balance at beginning of year", "terseLabel": "Accumulated Depreciation" } } }, "localname": "RealEstateAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAccumulatedDepreciationRealEstateSold": { "auth_ref": [ "r602" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to accumulated depreciation for real estate investments sold for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold", "terseLabel": "Disposals, impairments and reclasses", "verboseLabel": "Accumulated depreciation" } } }, "localname": "RealEstateAccumulatedDepreciationRealEstateSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract]", "terseLabel": "Real estate investments, at cost:" } } }, "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements": { "auth_ref": [ "r594" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 2.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial cost of buildings and improvements for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements", "terseLabel": "Building\u00a0and Improvements" } } }, "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfLand": { "auth_ref": [ "r594" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 1.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Initial cost of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land", "terseLabel": "Land" } } }, "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1": { "auth_ref": [ "r600" ], "lang": { "en-us": { "role": { "documentation": "Useful life on which depreciation was computed for entities with a substantial portion of business acquiring and holding investment real estate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation", "terseLabel": "Useful life" } } }, "localname": "RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RealEstateDisclosureTextBlock": { "auth_ref": [ "r605", "r606", "r607", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.", "label": "Real Estate Disclosure [Text Block]", "terseLabel": "Real Estate Investments, Net" } } }, "localname": "RealEstateDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstateGrossAtCarryingValue": { "auth_ref": [ "r596" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation, of real estate investment by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Excludes real estate not held as investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross", "periodEndLabel": "Balance at end of the year", "periodStartLabel": "Balance at beginning of year", "totalLabel": "Gross Amount" } } }, "localname": "RealEstateGrossAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r555" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property, Accumulated Depreciation", "negatedTerseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r556" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, at Cost", "terseLabel": "Real estate investments, at cost", "totalLabel": "Total real estate investments, at cost" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate Investment Property, at Cost [Abstract]", "terseLabel": "Real estate investments, at cost:" } } }, "localname": "RealEstateInvestmentPropertyAtCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r556" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property, Net", "terseLabel": "Net Real Estate Assets Subject to Investment Arrangement", "totalLabel": "Total real estate investments, net", "verboseLabel": "Investments in real estate, net" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePolicyTextBlock": { "auth_ref": [ "r125", "r456", "r592" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise.", "label": "Real Estate, Policy [Policy Text Block]", "terseLabel": "Investments in Real Estate" } } }, "localname": "RealEstatePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real estate investments" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r67", "r69", "r77", "r448", "r452", "r454" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive (loss) income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationTypeAxis": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Type [Axis]", "terseLabel": "Reclassification, Type [Axis]" } } }, "localname": "ReclassificationTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationTypeDomain": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Type [Domain]", "terseLabel": "Reclassification, Type [Domain]" } } }, "localname": "ReclassificationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfRealEstateAccumulatedDepreciationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]", "terseLabel": "Accumulated depreciation:" } } }, "localname": "ReconciliationOfRealEstateAccumulatedDepreciationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.", "label": "Redeemable Noncontrolling Interest [Table Text Block]", "terseLabel": "Schedule related to Investment Arrangements with Unaffiliated Third Party" } } }, "localname": "RedeemableNoncontrollingInterestTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NonControllingInterestsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r312", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r484", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Transaction amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r312", "r484", "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r136", "r485" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Payable (receivable)" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses incurred" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.", "label": "Related Party Transaction, Other Revenues from Transactions with Related Party", "negatedTerseLabel": "Professional fees credit due from Advisor" } } }, "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r312", "r484", "r488", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r482", "r483", "r485", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions and Arrangements" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r103", "r135" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Payments on credit facilities", "terseLabel": "Repayments of credit facility borrowings" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r103" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments of Secured Debt", "negatedTerseLabel": "Payments on mortgage notes payable" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r124", "r525", "r550" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r19", "r118", "r124", "r525", "r550" ], "calculation": { "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted shares" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r284", "r344", "r552", "r581", "r586" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Distributions in excess of accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r140", "r141", "r143", "r146", "r154", "r157", "r237", "r341", "r342", "r343", "r364", "r365", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Distributions in Excess of Accumulated Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r126", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r303" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomer": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606.", "label": "Revenue Not from Contract with Customer", "terseLabel": "Financial relief funds" } } }, "localname": "RevenueNotFromContractWithCustomer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "CARES Act Grants" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r79", "r130", "r190", "r191", "r210", "r216", "r217", "r223", "r224", "r227", "r233", "r446", "r541" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "hct_OperatingIncomeLossBeforeGainLossonSaleofRealEstateInvestments", "weight": 1.0 }, "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/CreditFacilitiesSummaryofCreditFacilitiesDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense": { "auth_ref": [ "r602" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of depreciation expense of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense", "terseLabel": "Depreciation expense" } } }, "localname": "SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIIChangesinAccumulatedDepreciationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionBuildingsAndImprovements": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 3.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of building and improvement costs capitalized since acquisition for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Building and Improvements", "terseLabel": "Costs capitalized subsequent to acquisition, buildings and improvements" } } }, "localname": "SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionBuildingsAndImprovements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionLand": { "auth_ref": [ "r595" ], "calculation": { "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails": { "order": 4.0, "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of land costs capitalized since acquisition for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest.", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Land", "terseLabel": "Costs capitalized subsequent to acquisition, land" } } }, "localname": "SECScheduleIIIRealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Preferred stock, number of shares issued in public offering" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r180", "r227" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue, Net" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetGeographicConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r67", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Derivatives Included in AOCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Benefit (Expense)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r41", "r134", "r278", "r281", "r282", "r283", "r458", "r459", "r462", "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "auth_ref": [ "r396", "r398", "r399", "r400", "r401", "r408", "r411", "r419", "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Summary of Derivative Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Balance Sheet Location" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/DerivativesandHedgingActivitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Real Estate Sales" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r244", "r247", "r507" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofAmortizationandAccretionRecognizedDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleAssetsandLiabilitiesFutureAmortizationExpenseDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetSummaryofIntangibleLeaseAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r244", "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r38", "r134" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of Credit Facilities" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesCreditFacilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Schedule of Quarterly Financial Information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r132", "r486", "r488" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionWiththeOperationsoftheCompanyIncurredForgivenandPayableDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsFeesPaidinConnectionwiththeLiquidationorListingoftheCompanysRealEstateAssetsDetails", "http://www.thehealthcarereit2.com/role/RelatedPartyTransactionsandArrangementsOwnershipDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r89", "r226" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r199", "r202", "r214", "r241" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r199", "r202", "r214", "r241" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r321", "r336" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r128", "r172", "r173", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": { "auth_ref": [ "r286", "r287", "r288", "r289" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table Text Block]", "terseLabel": "Class of Treasury Stock" } } }, "localname": "ScheduleOfTreasuryStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r23", "r529", "r549" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "netLabel": "Secured debt", "terseLabel": "Mortgage notes payable, net" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/RealEstateandAccumulatedDepreciationScheduleIIISummaryofRealEstatePropertiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r186", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r210", "r211", "r212", "r213", "r215", "r216", "r217", "r218", "r219", "r221", "r227", "r570" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r186", "r188", "r189", "r199", "r203", "r215", "r219", "r220", "r221", "r222", "r223", "r226", "r227", "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingNarrativeDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r125", "r204", "r205", "r206", "r207", "r208", "r209", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Reportable Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Business acquisitions" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetAcquiredAssetsDetails", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r115" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Restricted share vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeitures (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeitures, Weighted-Average Issue Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Common Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending Balance, Weighted-Average Issue Price (usd per share)", "periodStartLabel": "Beginning Balance, Weighted-Average Issue Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Issue Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted-Average Issue Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r326", "r327" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Unvested restricted stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Maximum authorized amount as a percentage of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r318", "r324" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails", "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted, Weighted-Average Issue Price (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationSummaryofSharebasedCompensationAwardsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r125", "r321", "r325" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r3", "r186", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r210", "r211", "r212", "r213", "r215", "r216", "r217", "r218", "r219", "r221", "r227", "r241", "r262", "r266", "r267", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofCapitalExpendituresbySegmentDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivityDetails", "http://www.thehealthcarereit2.com/role/SegmentReportingReconciliationofSegmentActivitytoAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r140", "r141", "r143", "r146", "r154", "r157", "r171", "r237", "r277", "r284", "r341", "r342", "r343", "r364", "r365", "r448", "r449", "r450", "r451", "r452", "r454", "r577", "r578", "r579" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/NonControllingInterestsNarrativeDetails", "http://www.thehealthcarereit2.com/role/NonControllingInterestsSummaryofNonControllingInterestsDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r140", "r141", "r143", "r171", "r506" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockDividendsShares": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits.", "label": "Stock Dividends, Shares", "terseLabel": "Stock dividends (in shares)" } } }, "localname": "StockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r121", "r122", "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Common stock issued through stock dividends" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesDividendReinvestmentPlan": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the shareholders to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Shares, Dividend Reinvestment Plan", "terseLabel": "Common stock issued through distribution reinvestment plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued during period, issued for services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/EquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r277", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of preferred stock, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/OrganizationDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r277", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueDividendReinvestmentPlan": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period from a dividend reinvestment plan (DRIP). A dividend reinvestment plan allows the holder of the stock to reinvest dividends paid to them by the entity on new issues of stock by the entity.", "label": "Stock Issued During Period, Value, Dividend Reinvestment Plan", "terseLabel": "Common stock issued through distribution reinvestment plan", "verboseLabel": "Common stock issued through distribution reinvestment plan" } } }, "localname": "StockIssuedDuringPeriodValueDividendReinvestmentPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r25", "r26", "r277", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Preferred Stock, net", "verboseLabel": "Value of shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY", "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r284", "r320", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation, net" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockDividend": { "auth_ref": [ "r44", "r277", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued to shareholders as a dividend during the period.", "label": "Stock Issued During Period, Value, Stock Dividend", "verboseLabel": "Distributions declared in common stock" } } }, "localname": "StockIssuedDuringPeriodValueStockDividend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchased, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.", "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased", "terseLabel": "Shares authorized for repurchase (in shares)" } } }, "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r25", "r26", "r277", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Common stock repurchases (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r25", "r26", "r277", "r284" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Common stock repurchases" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r130", "r231", "r233", "r446" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r130", "r140", "r141", "r143", "r146", "r154", "r233", "r237", "r284", "r341", "r342", "r343", "r364", "r365", "r377", "r378", "r392", "r446", "r448", "r449", "r454", "r578", "r579" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/AccumulatedOtherComprehensiveLossIncomeDetails", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r129", "r284", "r290" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r455", "r492" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r455", "r492" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r455", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r455", "r492" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails", "http://www.thehealthcarereit2.com/role/SubsequentEventsNarrativeDetails", "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r491", "r493" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "verboseLabel": "Weighted-average price per share (in usd per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r26", "r277", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "verboseLabel": "Number of shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r277", "r284", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Stock repurchase, value" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/StockholdersEquityNarrativeDetails", "http://www.thehealthcarereit2.com/role/StockholdersEquityStockRedemptionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r234", "r235", "r236", "r237", "r238", "r239", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r362", "r363", "r364", "r365", "r508", "r509", "r510", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred fees paid by borrowers and unamortized costs incurred to originate loans and leases, unamortized loan commitments and loan syndication fees, and premiums over or discounts from face amounts of loans that are being amortized into income as an adjustment to yield. Excludes amounts for loans and leases covered under loss sharing agreements.", "label": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums", "terseLabel": "Unamortized fees" } } }, "localname": "UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnusualOrInfrequentItemAxis": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Axis]", "terseLabel": "Unusual or Infrequent Item, or Both [Axis]" } } }, "localname": "UnusualOrInfrequentItemAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnusualOrInfrequentItemDomain": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Item, or Both [Domain]", "terseLabel": "Unusual or Infrequent Item, or Both [Domain]" } } }, "localname": "UnusualOrInfrequentItemDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r174", "r175", "r176", "r177", "r183", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r355" ], "calculation": { "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Deferred tax valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/RealEstateInvestmentsNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CreditFacilitiesNarrativeDetails", "http://www.thehealthcarereit2.com/role/MortgageNotesPayableNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted average shares outstanding (in shares)", "verboseLabel": "Weighted-average common shares outstanding - Basic and Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.thehealthcarereit2.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.thehealthcarereit2.com/role/NetLossPerShareDetails", "http://www.thehealthcarereit2.com/role/QuarterlyResultsUnauditedDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3505-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=6378536&loc=d3e10092-111533" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r346": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624258-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r427": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "15", "SubTopic": "20", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450852&loc=d3e24871-108386" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(4)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121568338&loc=d3e45377-112738" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919320-209978" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919327-209978" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r490": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r493": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122596-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(14)(d))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(d)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23415-158514" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337397&loc=d3e23439-158514" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117337411&loc=d3e23528-158515" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(a)", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226006-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=121604013&loc=d3e24546-110282" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 6))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r605": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "970", "URI": "http://asc.fasb.org/topic&trid=2156125" }, "r606": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "972", "URI": "http://asc.fasb.org/topic&trid=2134617" }, "r607": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "974", "URI": "http://asc.fasb.org/topic&trid=2156429" }, "r608": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "976", "URI": "http://asc.fasb.org/topic&trid=2134846" }, "r609": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "978", "URI": "http://asc.fasb.org/topic&trid=2134977" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r610": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r611": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r612": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r613": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r614": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r615": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r616": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r617": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r618": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r619": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r620": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r621": { "Footnote": "6", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r622": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r623": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r624": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r625": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "c", "Publisher": "SEC", "Section": "5", "Subparagraph": "Schedule III", "Subsection": "04" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" } }, "version": "2.1" } ZIP 114 0001561032-21-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001561032-21-000004-xbrl.zip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

"*!9>K*VXQX9GU=6-OT+KN M>U5A4"$[W+($:X1P%0B)' >%5[;[!]W8YR5KVX\L\UV-G53 MB 4VK3!L?;"JC78'G)7V$5C]W*)M$3]HAQ+GNG&,1LQI!SK(3>CRY6.S>QVR M&C5W*QJC]2JZL6N[_K@QT8("EC@6D5@&,'GP&.\;AM$I3^@$/*&@:+)&@6 SL,E86F2EDBB1F,].$[-6K6WB#;7@X+2" MTNQN@]_MC]'@?+(18^9U98/"TBG/$ K&N1NRU'?[(/T@D%DP-AH[US*X/AEY MA2OF0'GCS(:8NQ?F-]W@$CY<7CX,/%R]@.ME1-*^E8$U%&T_=]OY,C"(N]:A#]G.$/0E21D-P= M:]!:SMK7[M$J:L.X>_3Q8G=[]R'OL61U3UBG'4T9B4EY&KK!Z(QTV&8 MS@!\$!<;Y[89L@^2^U"#6#2S_]'JY$.5JMUT!VAZMSS8:^SE6J-KP+K(?<27 M%:[[@=%3N=8'74#T%/,-OV'!FS#4.!MJF0_'OX8O,M6*5;N!D'+N)<'7'3:88AZZW-@KR!=S6ZO/^7^DC(_Y);[N+=&I !G8Z_1C@^CQ5NC/WI6Q8/6/TSI.WW,UQ=@' M^NOJ#,(I5O5YX'KQ?P=YX,7[;^/]*)[##?MYHW&0SYT*CZL8PE%!1';%P"J, M'+!0>F#+.%XF4I:2#Q2'Q$5@EBO.C!EFS5P'_; ']K[GNYV+*LC0 MJP;7''2&T=9L:WJUMS4T-E?O#Z5F1DL>D0:(09SJA S7X&T1)T40BF+/K(C;C/M>(6!=!?C >L7@N1;R^&_N#;GN.$2HN,F&&?IV4NO5&,XV$$H05 M;% Y:B5_%8A(G'.)X;^]1A@41ZZVD0>_=)M%;#;9?'XV'I:=3.>[@%O,,>#8 M_!:KN3;Y/F*H1LZ,M*:8/U-&=!?<72I/-5)6]]B&1KO5P'Z4?YD-3JG'>;-8(K3AT%C,X5@WXNT MZ.I/BU/V_/2N+Q)B*4]#B+O/B6E-N%+04X?L!BDT3L>(M_=4Z0IUQMA24RB1'$K7?(8!,0US%1'8W%FB[,$9F7 MRW9NNZ,\)-?I=LNY);GL:_CJ.W@&8.\_6-]L-?N7Y632)87-BY ,"2YQ*;F- MP0AEM10L6:%@Z;06MA43-KR[?72HN$@F*(Z(,QYQXP+2VA#D%8LJ>L%<3EGO MM.>(6F;4@W9L^V*S8WC8Y.)5&&)1SGN;&"<\/F85S1D:]CHRJAT5&]LO^CX/6R'? XFO0[_1RA&4_,^+$DO;JF;N6%B.QO?WV(FKIEL_/J M9*07(!H'#Y*,-&_B^4V1RFKZ.9":I=(]O8A>$A-LB!RLE0Z - X.0^:!S&= MRS[3*6P9R;HFJ/OI.K?]#9)$ MSEN'L$U&^A"$,=DNF0VY&%*&D;[+:+N-,A%RP23.LNW'Z,QAPD&?*;?(S/A- M^E'$O$8_JJI,O8.@$+,0B7X8?H#8$(.]T#[D?(7D'( ;PX1%K:)0+,,/_$$) M/W,:%=;P\U#P0^$[#H%:&!>E1DY8BCC8!*056#$EG&1"R?GUT-Y2_ZAC478Z1ZE$95_7F_'K8^-W'6![SC@2TR-I0O\*;H&_YS'9] MH@AM?7BI=NQ/G#W/_8:W"7CZ[0'>L ^!7D"[9I"NMRS4>:J8U-A[K 0/FAEO MPZ:%*6C.O/(HFE[LFI9 64B(91;!" MX1A,!*:EYU3/W!7J[GWFZC3F+$F;P)OD0CEKM212"V4XUIK;4E3 RY-H^,-S M'%R4'W[3IQ83)E3L7NT>2LK@:46!7! \GUHPE'TL!-X5 09/0G3 X M@FG=$ MUNMU *<:G_<^-/X:R_@N[&)Q8E;T?6BV"ZRZWV&8 S$"P6>.@VDGWBK%/"'C B-L0R(>7@\7$:&#/44>?@]P<,$N<,+ MCL0J>I.-Z==.][3QN?F]L;O_VTBV;&];(-[M^< :,H.WARK"H9NX?-\FZB^8)5=?!"D86Y7_D-@QG M]K+1[O1S_E)F3-] JUVF^I-4ZELS7O3&BUDNBPM<4ZN-QH?*8E8?*J]PUND! MZ^J5X:;=Y=!0+)A>+[.6GYL\9Y'SLMG/<_<@67WL_#5,%I#Z+JCE==8NRL,!MX>+RP&3Z_\\W"/_YR MT67.!JU^$\U>)4O>3\V\]&/;/KINOSKCR'P_+[,4CSO%[*K&>='EH>S@=WT4 MZ@:PWMCK%6#=RS>6UPD@@/(S&73A.8'QR2T%^F!B\@HV&COY"4_O:\>-U.I'5+"<^M\AJ-/-C=V4^2)&;68C> M;.D[IM"5BO#<@'BV/?%%,_2/AY,7QCY5Z3^^_HAU@*"#_N*/C &#+SI^/A,, M?$!43>W/V'^/N\/UG-NCB%PWVE-D$RSW%]NZL)>]M7]-XB% 7W5YD[]_^NX? MK;;GIC;33UW)<[^UW+UN1ZUM'F1,S8K^+M.YHO#CNG[GIM+]"5G;_&_7_=?R M'WL\$9UOJ?_]?NO/@W^_V_KTOG'PZ_AZPR,^-@_W&N_V]S_M_[FQO';S?;GS8V=O:>[>S]6?C\P&\L/M^ M[V#Y'7CJ6YF9FC />>9V.9=:8A.WG@.W<+T.K"U;^X+'V>YI[!>&/]?:=,Z:/C_!\C 3_F;V M%H8$HWQ_P6)+(I4#,+U>2=WS5I4U/JVJ#=A&X^^":IR5U3ZP*^ D-V5/-@-24?YN#(1OK[Q8;RY*!X:/8,B+;_LCYJ MO0#S*0AK:";@CIFX%3U*@)3ZVW":D+)W^".!K#'N4@&]FB2S!>?*AP"T*&KL5K@8D4%]*='7V:)V7-/AMGOET=^$>S>&.?FEZU.::X2X+-.7GH+J^XL MC!"V-X [6PIB:R1]6"2M 7,!8+Y&[-F:WPM\JI@VQSF*XL[6=?RA$-H6?'5^ MZ+UXCSY-3#EML1/* EL,7%LC@D_<:A.HB5C <&$-W?72AJ=+B$;XL*Y5*):&2#3+H+)7),&DP M\SIZ;>$]7$OEZDGEZ:$@45"O$TH^Y7,9+)#%1"/MK8HZ.,F= ZF\Z,S*9.^T MVGV28[B8LU=*AC 4 M[#%&4YSOE"V0UX%]C7(B"I4!J][N'_?*W(B2"/XQ:,Q&%=IG0P;>!8E5=@ H:TB^98T$+>N=5%7_9_B";^D$7 M:'JO.IY86BU!)\K%+Y.I(:0(BOE()(M<"6J\%(00J1)1.$E7Y=_+QV^!VOOK M>D_J9.NI]FJ7<&V>IRQHA94E6B.9N /M2Q)I0Q42+D8!3U%SX]Y# M@;AG6F;Q"!1+(!;)2$H !K@A@3#MY'P!JD'\*<7H]&IO^PO?VSX2>P?OZ?[! MUB'V.=$]$,0"R!+G*B#'24+4)8&5LUQH]7@@OOS8#NE!M)7U(-\\^&B8QD&E MA%VT25M?H]0*H=35UJ&)(JG(,0H.2\2%"0B@02#"..4.)^N\7-ND^$XHM90Y M YD.%H2;),H5=B8Q@T5T+!$-YBW4@K(Z@K*__>40)P,"D0@2.&'$M>;(*0,> M#S&@[ F+P.W:)F.W"4K.M![N=NMRHS&<134X&O3ZM\V@_.LS^.:C5J(E':O" M8#D@U&L<" M*&C9]JL(%[7S'[:+1-!!MXA?%L&G(J!8M- L'U&O[ U6QH&RI]GJ].)&(T?# MBQ^GTBV:.9WE?P?-JOGFH"+"< \Y\;TWV4.MB&Z>YVA7D3,/[P[Z.7L.6'V*WSJM;_FUJ=X:+SWGZY9<]YSL-9[@-6SO^%H[)=PIX3V#@)UMJ3"3 MPC1R)V/*NMX;=QW?[?]G9QL1TX"/A)ACT>4)0<[( FL 7UH B1WU95B$0(]5 MY"BL!<,;) [$YG;+Q@GC8G"<@Q8Q[.LBQR=,O=\YI%[&2+1"SAJ*N*<)B':B MR M*M,%4,ILGF\@-TJ'!IQOYF-0NYXV3395W*-O*UUS$MQO:W6+VYX""EC P"2Q@>E]JR^'B0:A='0H!A74.K=S:93C!J#R>=Y,&8@?T\J?2IT<5\4LPY5R_5P9FGG?GPT$0!K 3_Z>5FF#8'(5V5N7K=(LH#5+E2)LK_6=+PJ"4D= M]LY'PYT.UCN1HO26!VL8E[>0L*FN2/-F(_9VHP7GJSB=WVF?#_I_Q6X^T!MI M Z)O3QWXWHF_.HQ"XQ1Q0$9+F:L=<^$0A9VVV 8//$,GM[9IYH04_N\-O3WG M/N=$G&5*<6$5X4)Y'84T!KZ'$\5$JI_SXSUG=FB282DECICF&($%TL@X;)$, M,D2LF:-2+'C.-Q<3SGW40GC'&*?9K0*GBCAXXL0P(I)W/(;;_*KZ4=_[41_A MPP!&+$66D*"1@UGC ADK]G\RF7;@MM8Q)82L[V_O\$,J$\6"T)QYI1#/U-HF$Y P@6$KJ8_$+RA%GI=;?'D= M \EB.)?-3GEN.4@X/8G?[]#"IW*H^6&2PC&#B0D(..P/2!IYT#AYJ!FR&;LSIUGK[;-N78=OF MUU1EM_)/^QG.^*32\B+:/-X M\X0L%0JI8)2*)+J@V*()%?UN3C1$.1#>BD6%QF00\R!^!VKS$\AI:TAR2^&I MCI*'JG/]/*H#Y9^K*I9\RCWS'.OQHG5B]=KZZ,QY M]@N+8^9VYV)X\06E_P>?/A<7Z12DI(I>EC4(H[*4Z<^X>&Q;*1]!V(E04WF- M3G>CL0.*9=L#V[VA )[>< 37G'N\_0F4 MX#7:_8F^RL,%%0LH=@ATSV5"6SRD^!UUED,\+7K8UG=H'9E MU*O1LA>]0;,/5[/-=F]RR>4J"C[V]@:V%!T[O+NBJIJJFR;1^:OY07O^6+VO7>IZ(,)H/-7NS73GS1L^[KQ=Z)/Z11&Z(]091ZF8]? M ]+.>L25$)H*$HD&HD_HAKHE[QE O%NPZDF:M5YD9C92C+WA<(Y,8'O]JC2I M, !%EF:9 KEL^K0"3\58(['VFA,J'&.,:D933($X9Q\R>>Q/X$1'A3)_COU^ MJV!H6P7;W+JP.3/N S#?_7PS?]G"JZWE+,O9Y>[VQ\.$K18A,.1DGDB,(\@9 MAXR/>$-3!>RN+"'_E M0=:YF=^'3G>[,W!]N-6AS7G#ZI^K)H[8H151)RP((M;F>91!Y%()BJ1A8%>8 MQUH44\@7!XC7EWKRQ @B-6: +KX8BQL 7:3.W0.8)4D\9&97_>07U\O@0T^= M8BD$E)DML KAD9$6(Y('K@4>&.9^;9-MB,4Y7P5]=ICE8=S"<9M3%B3 MF.?= \-)Z2$/A^J'?^L1T='5WLG.H4B22R9RKVJ)P>JG@(SP.1^":1^ 8.)< M57=[Z6_NGVI#V2 U5_^T>W$RCMBUV=*A;/7*@%_1,PIU4NJM3P_2F;).8?(\ MOG?C4)YJXDH6SC(V.YZJL5Z%1W.#UF'>:S/WH?\6VX.A>:S"LE5T.!_H=UK- M,@99G$(483^XW\ZH+.]5]I;9;S<^1-_-]!T7_/KSP,)R_ M7NUPOI-OG19@5YF+"MK2C*FJ2//']CP7UA$R7,07@&#XU.=^D6?ZFVV?=@?G M?7\)SRU,I=3V<@U>E3(PAVS/K.R:0%9PO_@T8*.Q?UVII,;%IY2&$?L?;^\U M[2(,JU06+ZV"B&:[E,.B/@2>HFTM.QF0,X>]R+TR ?YHD$XH'0R826D-"YR, MVOJK85M_5;NIC\]6=BUC5[W;C>?SHR5&YX+CEFDSNFU(2I'U?:[G=9L'5IQW-CN M](=58U-]V#K=TV$MY\07+&J;$F)NDE\2HSGGT(7I39W>\X@6[VK_P.-#@;4)*@BD)3<(MC]/$A0!;)\)5 B?<)Y4 M,[>93I6)/*P9'*/+K8ZOHH%%G>)4*YW1)Q:GG4QJT2CMI$A@+JL$K[,F2GI: MEGL5!#AGUH JM8MJX]Q:&9&=VJ(%H=AI/WS9\DMJI5&2*^Z5X=J#RG.N="0V6*4DR&8=I'MT$,![ M!^^O#ET(D4EOD1.&(RZ-1H:RB+!5VDFOE&!Y"O8&>;@@72X9T-@'Y1GCB0AM M;*")6:^II]ZH.DCWI$&ZTXO=J_<@!S&EH"2R&H,)T,XCZP5&,4JJX.F 6M*U M37EKD&XJS#:%B+>$V49%\0MB:TN$UIIW#ZV5!;0 <=T(Z-[+?EAN_OPJ':FM M_J1E&#/7<_H(3#H70Q^BLFDS3M?UAA:V)F6W8Y3#.!Z-VC_8&MGU\0S+.7FE MDU]YG6;J.T,;F!_TR+1EX9J)YXTE(W2&1K4Q951[L55VDZHB=]4""M9P[;R9 MH>M92%WOO)--'URT-0JV%#/08MO/7&G"8Y_2BER:W@9(J[Q.V)[U.5&V;?A( M-[=4?U?XO,/8X^?.($=QVM?O@W /*<;<1.%0^<<3CR2_8O'+3'"LFF M[B%3C'G,K I,#E<[>A1V_%IPQ\4%OH'.@,,\[$);9HH4)\>-I02/*HB M$_BL$\IA=]5>%W.HH0X([M9YM]EJC.-O ;-WB$J46K)K M,]&^+3;32,6<@E( 1Y'>\B^K*0:CCLC%>((R=SR+T"BH,;GY>2!AJ]6Y*!I? M33[FSO53OJVCW!W9\<0F%4GZL"7MAE*ERC0 ZL5"][S",PQ>,LX#DY8YXU)#YEN\:DT]V^9ONW0 MW*?K,%+"'?!CQ%T>-:ND1([BA#PSW$N?#+R>N;M']H9]%JYC5%L3V7\5('788G%Y!??D='-9W.] MMTOG=F[HU#<%O+GCV' .QV1(>3IFLZ@/\OQ>]D7CS6F(G;S,TCU#>Q6BEKU# MR^\KIK5/&9ZY#:Q&1GK1)^[84?2Z=]9$6]&-N@#GQ@(] MS+B0N[4 ZQITXP%\U6_ ,$Z?G:6?#EDZW]L.S7].CH%Q Y,^R)\[NM@_V(/7 M6O#YW>_[?W\Z_7KE+[\VIUGZ$=ZC?YSM__[/Z>[)5[(+:]S?WA*[^;6_/QSO M7KT7__S^Z63OZH]F'E\![/\0"RZ5P1Q)KX&D"VF!I'N%" ]4X1AE"FIZ2JZ* MRE#AG+8:PR>P];GIKJ$N4A&5,VN-"+[/>=:J[@!,R/ )-(I'T*B>P3H(5G]( M_:N'/P4U<\O3;O_VR=5:IAW'*BGK-'?*:DY2]%R#%\(5U7YM\Y$%\'-5KKV? MMJ/K[[1[L"N%8_"696]O>^LPI[\;IC1B)''$::3(:,.1#9HGPK'QD4_+TASL M6XQTJ^(''12U\\,P4+]@)J.)LO-";F=#C6D7&G->:LR-52G#,PGSRQT]R;O: MBG*Y(_*?@U8H'X_;\U[\9?C#KP'\I):]_*79+FZ_^-"OW[('YVVKNB9\345W MC=I@4F?&V^_"_X?AY2LRO%&0X7_UP^Q[5&Y@I1:^C3?(/=\38O&7WO3)FQ:K M-@"87LA:]884+V>MXL7LJ]@PXN'EE6Q(?-]/+EZKW*"/LE8E'GZM:H,(_>!7 MI2!9[!'6RN^YUIO>HQM2WNV3_RI0=A2HJ&P3)85![.=P9"N;C/^WQM8:WGS[@;CRELWFWS7K?]D4&8@SCZ;+#G7O0!7' UCNL:4X8 M,G,31#V),.X/WO ; MV[BQV4NU4-5"M9I"=8\_?1$[M6O[@VZS?WG?W:I,R6.+YD-+\1LV8PO+"F?B MVH6 _+23T]@[ [AHZ/W\AI'ZI>W;V]"JU?S*Y:]S&XY:?WK4S>GOJ))H[V-, MZ28M>;JXG;[MA*R,V]G66>,_N7+[LK$;0UY5XZ^6O;(-U/B]TPDY/WB]L?7/ M71C/;=MQEV=TCRU]2N"YVZ8N6_1L R?$ZT"\$YPZ[;Q21*<0F15.6W=#T?/U M>)R;BIJO XXK5-Y\O[/OKW__T?OGH'.QOWU\NOO[#OEZ]:F9LZ?W_MX[WL^= MI>C'[WM_[_"O!Q^__W-PRKY>5I_YGS^.W5EH[9]L\?W?/UY\/?G/R=[O.U>[ M)Q_)5_I>P'VQ?[;?DZ\GQ\=[VQ]:^P?AY'^N=ON[3?S]SX/W_=VM0^>YP5I+ MY'BNA>-2Y&F4'%FJ,?7>,)\G\C=#!,P?/R^9\FI#G M-ZJ(C!0>6:4H%?"3D0F;+. MDK5-MDX(?7UP-+H&7!YT[ZO1^EX#?KZ? <+1^CC4YOJP&_]NAZ M%.(*S/A]&9J[?TTD@N-:46)1-%CD_L@":>Y ?<'_P)I(F;Q?V^0;9+9!\K,H M[C-HP/^MPQ&/AA?WL_DU7CQQ6.)@J[_[.6/&UJ&EAFE/-+*:><0-SEV;)$,J M"I8\,5I9NP P:D5:1I$^-+_'4._8$COVQZ"]D:LDV(/OVM*Q^53\[R7%YH?Q M^'?%8VW\IX$:?\5.MVGO'9"?VH-[B>'M^[AZ8KAT0#X)&8@*0O#(O;/:)FE( M8-[S)!2V=4#^N2S?Q_& /%!AC(G4B%AI$/>9*5-J$<,\:N\B%MH\6$#^KKIS MD\LY1W=>N,LY)X1]+]VI8T;/I4]C(6P<66*$8X0=IH@'@9&-,J*( R7<&V(8 MSR%LI6=;!RWI>LZW(H\:,ZH5^&X*+)B*AO(\&\US+*)S/D43$I%!N\12'?1= M,06^-HC,1TVX34@$YQ"W.!].>X.BLE0P[ D)."NPUK-CU6H%?ID*/#_H>R\C M7 =QGE9SQX.^WE'#=4 ARH X<009R01*\- ,9IK://^9;Z@?#OH^C.*^F*!O M[?+>!2_N9_-KO'ABUW M)NC[5G?LF/K4WWV\(A! M7Z;SK!DFO9; DJVRWCII-0;RK"/'I [Z/I?E^S*1A6UBM,(G)*DBB"LO$#PA MB2*569YH\$(^51;V&\TSFHT9W4]WZIC1<^G36-!7!&PM$Q$E*2/BCGGDL*?( M])4XIMY*3K55PLJH,56F#OJN MF )?&T1M#)<^4D1,T4G61.14=$BIJ+D#.*9)9P6FNE;@UZ+ "OEKA2"T+B#BE$3?>(N.U1TK(* SQW(2T #!J1:HS?1\U6;68 M\\=5G>C[(S'?=\)&]].=.F[T7/HTWK#")M H+1 /!OYC(T-:,XF((DX22I@G O1)KC.S M:+I[G2WX\C782T/RX^;24P2]DDE:[>MTWU73X#&+&$V0,1F4HDZ( M)VJ0QCX@DQCFTFG.I2\T6)H521NL-?AQ0CGW,\-U*.=I57=__-25!*\C1I:) MD+M%462I<<@X9RT/RG*B'R;T6^?[OFVG=RY>W,_HUWCQQ,[O6.@7("%*Y0Q2 M.#'$X?$@$T1"!@M!#(N8QT5G1;4BU?F^3Q#ZO4MS_SK==V'H=Z_3[1^/QWT; M:/:U.@GXL3L_8*%$"#818KD(V 41HR3<:$:!4M,Z%OQ"0]4 L.7,1 MN1@94BY)&9("X5K5'8L%2ZV<(]*C:(5 7#F)G+,2B<08H=0&SG"=!EP[O8^$%_ M/+'S.Q8+3M)*,/ 4$1$2XE[3W/:!(:=D(DHI F_6:,=A+'6$V4D6)YMQC[&*@1BG/+ Z*Y_+ MWAU-!'M9(D9;C612X-I**Y --J#HN0J>\*B\6=OD=>;OD\:*[J<\=:SHN11J MO,\OY=80K1&34B/N0)U M"K\N%9X;O[F?(:[C-T^KNV/Q7B^M\DIQ)!P-B&NBD&-$("$4\5$:D_)A*]M0 MLXRVSOVM_=X?Q8O[6?T:+Y[8_QV+]PH1:4P>(\\) $9T!&FO'&):42PUD8#[ M"P"C5J1GR?V]8[2QWSE_GAO]B?W\2+>Y>@]U._JB';&L\Y/O$<\?M/I-5$4T M+QOO=G_[?/^X]%L]%%DV+FV,5$P8AQ4//&FKF1,L>A$8-0$K7<>EG\LNGX[' MI973PCK),X6WB$LARJ1)+3S7T;(@7%C;I'46\I,&M>ZG/'50Z[D4:BPN'9/] M_]E[\Z8VDFQ]^*LH?._\PAU!TKDOW?,Z@C;V#',;\$)/C_L?(E>0+21&BS'^ M]._)K-(&8A%F$5".MANDJJRLS+,\9TV)52YOLTDC[ET PSARI#Q.AF@>%,T= M*8A>4S_NU&J2&%>6A2EASC,1O*&$BT1=TLHH:JDE6.LH&K_TBK'PC%_:$1&M MS5V9M$<\.Z]]J U7LM;G8U8I]>8SZ_'O4$["XY?^K%CLPS_==@[_@71 M]?PV9]?.#F(>X,6KEWP:YB@+V43![L!=+0#@)^ 1\#WU6C*1F ^L M2:-^,'7]YN3WO:VINF8&;#*C$4T>U'7(/>>85,CZF+B-1CNCF@;*]^SKNAGS M-+ZNAV.H]Q.&BL9&Y;G,*=0&<:XUTL)BQ'0R/E@IL$S 4&Q-:KX:J5P-"]]% MQ"E$R8D0-GK,20J6N4BE<\%YK[CGUW-7?X_]7K"#PX9[[Y1[/TVY5PD1DY!( M2NL0]]F.%8PARTD0TA$2%:C#__<_FA+Z:\.^3X1]%[J>;J:$&]?3?3/OP13+ M4DN2\A9)(Q0P+\!8#0R-5,+>[[PR9W^8:K]X]^;S!H'?7ZPP,0E*UN;PA#']M3ZSKQH8,IKM2Q#M9$GC.?7[R2Y_M+/71J\_7XZI';L.==4#?C MJ\:+_'"\-O4B$^NHQI2BQ'C,IBQ'EDJ":+1*6QN V?"+5T+@-29_N")X6?7S M6)(IGRG?2]A\!;8*UXIS8Z16DE(=# M14.9PDRF]:GP_]3\'1WP00B%K%4&< M@NEIDY)()453M%:'PO=,K0G&&KY_GDG4-U/LC6?ZOMEZZIE.6FNK%$-!)H/<*T8+$B:<$S<)R!Y@Z]D>O$ MUGC9;C/<\;RR/UZNFNNLXJVWA;7BZ\Q7.[&QGI?4FG36:\9M((HRB037H#2Y M\:[W49.V]0@9]UY\7PWCW@[C3MU>2GL; M"09XFW1$W&&3&=>CQ*WDP@CBN'CQ2JTI MYW <]^-1>W0T:-EN:(7VP..C8P4,B\[GLZIL#\L=@<%W#[U";QM7.++*.+TS$N5;*VJI1P?\N MZY>YQ?59:32T6I;-[[WNP5[L'V50U*"=Y= .GS5=%#4F4$&14!@P3DP>V4 $ M"HD'#GC6),U?O!*QL9.?C2X-N9.HW>6M><)R,[FS&:,2X/!/T\S ;8.+$) M_AF/-4.OGT>#83N=WK98)_@JN4ZS7-^?_)E/PIJ9:_UZ*.OJ7XB>5^#U[*N/ MVMT0N\-?4+[H8=14J_RYYJNP=7&=ERF7W?;KW&U*'?GI3O( K[L'FST8K-L; MMMI=WQF%V.I'VVG%4AWY S*O/PH&KZO9/\6UZ]G%F9/YU_Q&GKI1T 4DGPIJ'E8J=W'^G70.CGL=3JGK=Y)7MO!R W:H6W[>5>'AQ:00;L?_;"Z(.]S)^9MR@,M MO;>']BM\%F.W==R)(1,>P,WJPMB%S1V.=[\3,_7E"<#;5)3X26A !SW^B7M]Y<,&LU8X+%J)1T M5A*_+_2+5SL]V%OQ]Y_MJY5BMU;=@.:\)'I(H9N).6NWO.+ &2$.;;LS^&G] MV>M"^I"ZL+*0SO_[VG9\G;X/QK1M58/D9'YXD>S!AQ=H#ZI-[70FRA)TW6@( M,J^;=P[$7A99F]''K.^J@1E9RRUJ M9R9J[79!6>_^5HZF7"O?Q'&94JN?;P]G\<'TFE+<4(6%QW+RGAT2XK=:_ 9%F0[Z27ITBUBK)"<*;813L M:24\UP#/MOUA*XON(HM 3EJ JH-1ITBV4LZ:Z0V@K5IRE=_)KQ,< M73TNB[.6/>C'F)-F!NNMK6[VMW9CY8@]:0\/:S$)N#5?4H3D(4PA3S2+\XD: MR"J@PK+GJ:PV;-9F4?I4UH9Y87OI# MCE3>%V\J+=F$?+K^E =B-N)[AN =% M;)6F6*D%>8QJZZ?UQ@_'5]'VV)L1\'8P&!T5Z3Y1644^3_HTGAQ&T"%@"_C_ MCMI9H-O6N)M@*XSZ8XQ^&FV_E?TFYXP.BAO\(E:1#"ZJ,0>X GI^D(&$[QT= MM8<%4Z08P4+LQ -@\/QS$4.]["*K[P)*ZOEV@0H%DO0<2(%N'G4R_GH+2&\0 MQS?T8VN2 )PQRP0AQ&_'L9N]L5]K)W"&(8.Q>PXN.:Z-R>G,9Z#$:.( G%J= MDZ&/XO"P!R;K3.YQ]NPN7H@\PX/8!8,\NRCK686*)0KBFKYRB&Z845\_5H-D M:-C/*YF-5A=!0@)/V2$PS/!TO55*%[/Q.^I7&*D%\.?+S%K!(@_[L.55G'7L M"^T5F]EW>K V>6Z3&=6^5>#*=J_\5J/0,B40QP7%%2ZO3?KIFYZT.YWIL&=8 MM8[W[H"(Z+?][;+NJ[^[_L^O+A0-1[8/&FX<),ZCUY]DAKO&P^XB!'7-D-K& M)6Z9>7A]:,/$&?V_=Y^=)JZ189%;NDY;N6YU 7$4 ; QS$3[H8B][L&PEY'C MX%V58#K)P)"/- /CK_\<8G_T[Z[]TXQV/Q_@'?JOH]U__/5E^_,GL@USW-W< M$-OYLS_?'FY_?R/^^L>'SSO?_]7.#>^!A6?C&^W)-H ,ML,BGM:R M;0DDG9V(_2R40=ZT0:JL"!TMU;#P^='-%MO=_++/M#?*$(42UAQQ["RR)@7$ M-56*,!P(I:79Z/KYW)L)K8"L.;BDMW96ND4QS9!3Y7RU7P&F%[=&CL "7P_2 M::W2LSJK5;P#$6LK+33J=N(@P\0^:-+ZAK&N7?SP.K +*O T7S6(8_ (%DM! M Q-1>&2_5+=52AQ>ZAC I6\?P[3S/,8:?"WKU8DZ[W4[IVLP6]"#Q2,^.NY5 MJC!#A'9J>WCO@ELGHT8+BG%NLFN5!_X(&.,0U'QQO%\,61^Q7OK8.YI&N,^$ M8>=69!9-U>M78JN==HD#%'CG81,!WTV, 0 "7V-G!K]X0&_PR_MGTL%Y101W%B #E<7V_F\$.[>VY.%84MF,+3W,Z[\IA-GW]]+P6]-Y?9 M[<]N&9\9O?.H] W?[\Z=9DO.9G)(RYTNT0,LR(WWYWZR!:Z[-HM]=BW4>CL: MYE2L=Q/M^Z[2R44+5Q'BO6R:ECO+, -_&,.H$^>5=JW*SRG@1=IG4K=6K(KR MI/-97N,F$Z/!H(8]Q<;_EIT!@# \0).J!1Y\4\WS> 3@Q9)9_)]W^)RTP_!PG!0_M0O#T%NL&O/$MYQJ=/I F>8L8 M/K,^,_\>]J]? F/__LV]^9MEHE MW737FDB]>+57 #80^^MLT@%WS:JDRQ*.YVCM"C?,_9.H6DBB_WRS\?O>/U]O M?'C3VOOPQ\>]M=;6SFN C#N;K8]__/9Q:W-KX\/6FX]/]?5W=O?>?&SM[;9> M[^Y\W/U]:W-C[\UFZ^W6SL;.ZZV-WUL?]^"#[3<[>\NOP'V_RKGPP"+)9.6"%T*+Q6NZ*/'JFB;/M5YT54R>W6[K7R-X M1X9+.IM:FTTY6VOMV!K-;-2.^4PZ+^LLBYDKZSR+GXH+S0906.W!L%_4.YB^ M8ZQ3I0&OE9_'UF[E'1DG"+_,[K[ M#KQMOOU]>]\KS*+3"GD9!.(^$J2)%X@("AL0)281OWA%Q:7.WI=G"0<(9$PU MV34W)KZY[/@:_NZ^6P>*GLWPJ1(]Y_PE^9=^;W1P>,50:_-9.T"FTYRB*J._ M^ _+[_5-X_FV>OTVR) 2* M55^HR\!R[9B*OW86[[R;@?VXN!?K/\O0/<6CQ M*8WSK];J%*:)5['FN)F$6OBJ'TM>5^KWCEKV^+C?^P9,,03^7HHOM7%)&JD< MCY);+EQBD1BA05E%1>VD!):8AB]OER_?GVY_W]C7VF,CDD$QQH2X8!I9V!$D MN;$Z*!4]2<"7G%[&E\ "R^PY=C >T41(Y;F0S%CAG"1*2!<\IWJ\Y[21Q7>P MYY_V0XC),:*1,2$'WJB!/:<2)>$ ';)(320O7C&EU\4E>PXBHCK)H_)FC(,5 M,^5JY\-NI6BHTNIS\F/9\SAO)C6>YWFWP]R_[S%,KN%'(4%#^/":!M*(<42*T,I8[ M(F"'J5F@#RY@ZBJ%:N)GJ&J7^QF57JP5X*N3"((B0]GNK-/]'DEG!F* \>TS MS#CI]<,@=L^356\A6?TQ4UC]G D+P]SWB<"<>1L13PDCCG5$ACF*@E-<1A E MB;D7KX:QNP1E92MF:<1 "!" ,#BFP)T@(+]TTI+1R' P,=X2132"YF)Z(-M[ M?^P''1CLO$)2 IH8GO3.T\.PWS[NQ'*N4Z?"CH>] M03& +RO>?<1.O(TJ!37GFV:;NW8D7-O3 .9^CCU-XHOP]7BH.FNW6Y6 3HJ7 M2IRRI"_/YI#THX_MKTLF7HIHF63,FF@D]Y;K0$)@3!-F,4TA[&^.^0W]L+$' MC.9C#(.W8$KD%Q\\9PN/[NYM[?/(DA=:(\4$J',&@,TF(1"V,H&>IYHZL.H) M5>OJTM3*S&OC1.U,-\?U2I?2YV\YD#RARL8#]/AHA>WLO;\=#]"ESD+X,J.\ MWJPT6V_MICH-K2:D,6VM_0 MW:?4^1#'.9B[Z7>0W?"_*A7C.5,4/.=@GQF/ MA2;EA 0P%R6FR'#J$(D&,QV-=@$PGV27N9=. "VU1H/*<,C5(:M?1D4=AQ,3RJ(S0<\".2X"$@D1W#4S@3J02J1RZ32 MI+#NJ*[8FP"B1?)JZK^XH>BZI"[X$9LU[V;AP!+6S%P4U>4ZP4EU@X7_6E_G M>D_$_XYR;6!OG.'8&0TN%NL+CR0/-.+HI,"2:X"ERGI&L>+)10;LZ]F8;8E! M5T0;%N/0WW+]Q,?C?K1AMSMNG)&/*B>/_V#R'V#6[]N;;_:QP(I*E],% )ER M!::,"X!,J:2*.$V$]A9 Z0)>_5LN[@1B@BU=;WT:,4,#('(3+$O"7*$G&H*[&<'AG-!@[FIAEE#,275 B2"V8"]PR2Q>792[AU9VV M$QE[_*?L--B;3/T90_/\_/?[(:@0I TH"I40CUXA:X) 0@/$]8QA+^@%;MWS M[8[JODC?HA_=D"S 3L!!N,BMX4GE)%@#6H,G8 L68_HALIC*UGG2V)TEC7_& MSK,F"KZ]M[$OF<18:Y<32\!>HX8@!Z8;TMY$Y4/0)(H7KWK=>!VB&(N]W"%K MF@(Z+U)2^]NXRG9^@/CMN#7E>^SUKTB-P*(/'E" A"&,1'EL" RWCAD;3ZP1BC!%5AF M;%W*\\KW#MM7-M6=#]D1[>;5G0_]!F+[7JKMSK )!U?UCZ?A2D#=-9JZ#I3 @T=^4:^\C& MYW)/;;>7]JQER9UIULPO[;M[)W$SM>XG2V)P7/6*9^^[6Q^ MV>[F^_W28(% M]C@B%2@!0\<)L'Y-0F [!&> M]*<)3S)5:FN:+KJV.,R7,82+XR#ON.E@Q_KJ-)7/N:/^3 D9,%LU7(4=.^TC M *#E][69-CTS*PW0(K>*.LIQB>$AK, J\O.V_=8^&ATMY.=GS<8D8P9GJ'+9 M^J2**\2Q!#9V3B'"N+3<1J.% S8FB]BX]D6_45=4_88>\@ MEA*\@E!+B]GCX]R%(T<4%K!P)L,<=AS&TC9SK770+C'#^C2(>OA)$L.$O/,@ M:Q7RS=6!L/VENU>[/'O91 =BF&>)) ZV.3>29UE1;9:0+&%_B6;M>\O2' MFC][_0\U=SYC-QJ\W?<_]HT-..JHD!'<(\YER"FS$BD30U2>^U 2M!:%K1<) M0J",%2G6R[20SR<=UN>3[D[MV]\G\G;8JTEB0A$+,F*>7T[#)Y9S&ABA/#E) M0:DRD%B$ FDXDM,^E3 RSL;+0.@#$9[N@($!*]Z/OC?I9G,\TEYRM@O]' M??&D"K[LS 4C']KOMA_RJ10YB:G?!DYMY=4\ZN8PXJ25X=P#WG2_MON];OX< M"&1K?/7D>0M.AIOML7%14?JD[*=N$-&K*NV!ZK(KHW,*[ R7E?*/JJ5UO:23 MQ:E.SIB=V_1-YI:YO7BSQE7X=>'1Y-W/WEOBI[DD?[WU#G9B9*?;.U[[R?8> MPMO6$XPQK-5%_%6=_? PEZZLC=MMEJ.D!H/LF:S/X2O1VC'Z''>SSEJ[>SKM M.["P%< L($U].PIKI5=U&G6 0P>3'N6V L?C1Q0@,4Y/\KE=+EQ<(Y!Q<[ T MZN9\W./#TT'9BI-\KF1EL2;;[N2 2AW.'MIOXSZEXV6Y,/Q=0$R5S PP M&1S:?CSL=<8=0>!UQZHF3= M6R:%H&0[ &_#KA66M;DF(??<'K4'A[,W #'5;%[45HX@SG/]>FO#^UX_OTPVZ4SS_[SBKR>G'&QTPVXE0?,LW\)+ MPBGN05.SA_DQ"AD Q.(2\.1MCHB&Y66F,@$ M=N9BE_1\5OQ)OPT2(!-/JD[-\B R#^+"@R'J[DES/)0%5@TEQH1]\:$D^23$ M&TN:E6G[M3WJ#-OHW=CT?KW]V\>GW/IK R!]IT6J9D+Z3(>C>1"Z7*D6LXY: M'CC6!FQ!;R1AC%M%J!'>RJJL6F-.+BVB7:96ZRW8>\^^3NL ;W_V^YZIR!.5 MR!"K,[GRQ4N6C)IM!WG-@Y%LPH]^&?-.]?NTFJ9YUD>M&CCW-2(L#*\4:- MSXQO9[U<-0(&V-^_9(2D+W/0% M;OH"/QDEN[B]\=7MBA=WSKA(XZW5QOUP6LY7U418[_NC&&;*?G+_S+D>&G-U M?R_;/XUK_VYLU1,3HN/1,YF;H5!AF3/88VR4(I(G68J "L9&B\!V4RSZHV!; MY-1U @8Y-=XC+7-*,O<)N10-$LH$FXC0 K,7K_2EW6J!ZC('N6$,W=S@X!H% MGVOU154US[+!V2B!'7 *+AG+F9$:IDRDCL(:)KFXS#QKJM"O11H[WP_V 3]P M'A5&,KE3>^ZI?9DY@'5]W MIAY]KHO&Q:+L91N$4';Q"_ M?-O>_+1/A>+.:XH(%OD4/,:0LTRC**6C&CB=!)P]B/K2ICZA7N9)1E@F*A?K MKNO#B8(K#J(<.RI=^WSESYW>-!5G9YWI>W,E\BM+>$W7J"EYG6Y_WMZ/23*C M(T8D@K[C+CGD#%/($6&%]%AAJH&\+O50SZ.HV7,3ST0!70V;L@NZ/CH8:*%_ MW"L%6\S#T;YV> M__*PC'.ZO;DU9ARQ\^<;O/OG'R= X%]V]H 9-@\$/(?\M1F^?/K\6V?GSYW# M[___O+#OW0WO[''^03?7.R ML_F)_.?[F]RM@.UK;A2@18*BRJ<;4*)0KC% 6FDFDL: R\C90U>X#I+@R&&! M'4\I.IW=NXI[&QQQ0;]H19!'Q]GP!"-D MQ+A!]VT0 /:51=Z:OV8H R%*/"<^9NHK7<>4N'O;A;QB/ M7W^]7K[Z>1@6?*?7L: 7?HW7R0V_$^SBAUYVYV63->M4WVS4R[ZC,*IX)'-] M3.OZF.9Z-S2@UZF0=S!7H=2MSU6N8\D>R;JJ=L!?3J%_(&N87W")%,X['6YU+S;E+Z?&W?/&OYX(>9[5.I?!N6]_K MJRR>HMUF"@:F[3XWZL*;.76>8R43U7W7"]6):7CA,MUG0.EZJ_BF%!#EW.QQ M6Y+6AW+0WH4K>*N3%.OT&M-0<16BZ_DESRZV'<0J-/V2X)_.A,=6COEN M[])KRJ%E2?8!:/),7.0V6/?'U^&RU(L[9=#)\1&M:1SF,?+BG;!B;3,5*^MX MV!KT.NW0&J_!HU)G<['\'WSA9[9PQ-RNB'A*:],0U8H0U:-Z_3DL^(S78;O. MO;WI$ER!R6Z+[VZ;11_@D:M"#A?6EISS.1<">;F5WKD#S_O*CEI_9>#?F_4#:BF6.]C3.DR+KBN'Z8> N7K?R%L?1+CJ@-: MJ/IL)2SA7ZYM0EVY8M?9[F:,9HQFC!4>8VFQF;%*_3!Y*;B^'%A3G6 M/R! SZS=C3;S'L989N]Q:Z6\P8OW\G_/HL.EWG#VS?IYU%5ZM2628UV(2B;% M>9*41\ZT=U@R3!4F@ED6%O=>0VR)G-C9C*I).BQ[I(E4G_[\U^"OO>/#W7_\ MU=[]\SW]:P_&WMS"GX[^RI\=_O7YP^=/1_\Z^K3W[R]_[1U^^:M=W_.??QVZ MH]#9/7K#_SK:$G]M_M6!]_BR_?E#^Z_RV=NCG7_LM/,X.W]^Z.S^X\/1?[Y_ M&NZ\QM]^WWLSW-[8=]1&[I-'EKF(>!"YZ8/EB N:9&)<"9]K!!1;D^I\H4"= MP?D#-)^Q^9*TWPB@1@!=U?[!ZX29$X8%QV/B)N5C=XQSC'AADKN@X4PC@.Y+ M +4G H@SZ9W##D66CU[1\).3! ,B?0":#(&70X) M+Q1&CX=E%W86OAEL6'""S6Q?EMD#;";Y(].VPBO32_C1\.[N%#Q(KR,(68TX M4P 90+PB*Q5##+ #X F";2C'X5"R&HS[ !SPM^M$-!NA<7.A<3-5WPB-^Q4: MVWL;P^V/67" U- 8LR 58MPHQ)-VR.HH 0!$ 3J?6$W-BU=\':^(NG]R4N/' MG&X/&?A>O%KC V)O8]&N_<+#WO%MOZV\UMN^U-<)0=ZZ._4!]G7;]M=S41-[ M)AMKYC>V=IB/9S$I'RM,O2I>_4!?(['[)=]:5\ M^H&[9VJ!GOQ" M/^_-%&WCY[U?WIT)#H&2]5YSCJBW"G$=+')2&)0\ES8Q)E60VH$ MV&*<<01;B)%/+D9I%&76 JI:H^9\SLTYA;*D(+Q3!TK#MZOC]&SX]I;X=NK_ M)$Y@055$*4:/N$P":<4]PHDYJ:2U-(3,MU*=S[!]$GS;C-&,T20@+)N L%8. MMVBR$&;'N':#FL>A^U<#LA_ZX2^_][H'0Z"\'//LU3'/K?%1*&_'IF)! PT4 M6 H*O#GY?>_]Q#,:J(@V*(,";!OBRI)RD!<" $\\X;"9WN33O,2:PO26G*/+ M='5Z+('2YRL([M &: 3!70N"3Q-!8$&0RR0E(I@FQ+WBR#$0"32EP 630HI4 M"0)&S7,5!,T8S1BKZME?M<9M>[VA[9QM/K1B7OU'$6M<]AC42),-Y)0%$FO'BESZO9&X4E;TKS#Q=N MIDM[&7\,?J]:B>+UV^TL_?I/Q>K .E*+H^0VY_;$9/-)DYXEC)EB-+JF0N*A MQ=W4QT ]L\*F@!@V!G$36<[95$C+**-@^>M\;#,Q:TS)'S4MEN6(!XY)-(*M M$6QS@HT&D[#"/&G">')12ZX$9T)AHV6R31W)@PNVJ<\$D>_&*G$\2?29N:O9#R;!/TV'S M)'TR-Q-5C4_F_H363$(;IHE;C!&52B >24+:1H&"4([*%*5SZ<4K2N@:E[?E MDUDAMTLC@9ZD!.+2:V>\9)8!=7MIHW/8\$!M\%RYV'B%'UH"S7B%(&V\B]DY[2;($DFN2_/#A-ZLG@:Z5-?MHJ^.6ZQ1R,^#0= JY M;^8]F# OE]9XPC3BG,,_'IA7>^Q13()R&XUCE@+SKLL?;@QV.YS[:#J%-%+C M^DW);J3L&ZEQWU(C)]"_R9+C9-\8R1-L#Q+<@<[7EB++>$(2:TPC%LFDE!L, MD14Q.9Z=>0 M@F=#-5'#5D0G 7]8AG@B"1E..5)6DTATS)EJ^;S+VPG5W)3F'T[#\(LUS/-J M:'K>M7@SYFY8H\L1%215)1.3#!CA=4ZMR MSEW3A/@N3J+.I=DQ<6:,YE8*;9.UR07&)+"N%$TXX*%Y=AH.8,E)D:1%PL2$ MN H4 6DZ)"RWQB3KH[(-SSXUGEWHV+N9JFT<>_?-O--P@-'&&I8BJ-G@$2>$ M(B,]1HY[X2@A1*I0P@%-X_!&:MS56=0W4O:-U+AOJ3$3#E V6!X(2(R8F^EP M[9$V5*.0 N,!>Q)T"0?0VVJIU8B-I^VQN^/S!IY$.. Q[NN/A0/NH7KCR978 M56V)KE%HMQJ=BI8I]UT54E^\\,L&'53DA@=O9,22&QU,HF F,2TD8!_E3!-T M> "80^;J0X*TL!\1>9;[B(>$D9::(8 XT0BG&8DB)SK>27W(@<0L!:.:03T8@[91&@-8^H2$8%'F-(,LM4L\86N*$:F=KT16K&>*"^ M2..;QVQ!RQ6KTA?D27:W:6:Y6E33C/&(QKAO7_.#N8TO=A(_K'NX6IE%,N$9 M^(]CUQ+">62X8@BK$ 3FC&B;\]=O*X']=OP>M\!U3]HQ<<<#,C)@Q V51##'(HXO7DG%UX2X.+CUV#PGMX,A M'H&[NA';C=B^=J&%#%X086C BE/%=$S4!B,CQX;1X!J']T.+[:G#FW).0S[* M5&$B$2?.(*,\1L2)(&#SO,O%41*+-2HO/EJI$=NKW##JCD7XXQ%5B]M-W0AD M-IGB]RVSIO4E)"6/61(()R, 8#*#M /C-WH5E8,M=#0'Z=87'+G:"*P5AQFW MTO#F$=36BYO5UC<2_3JU/S?"GXU$OV^)/E/[8Y/77"6/'.$.\2 $LLPJE'S* MS0.925:65F#G>W\V(KT1Z:LNTA][BL6MI6G\/,P%6>/ZD)GRER/;/VAWQTR1 MBU_J3S(7G&FK]7DT&+;3Z6UO,\%7[3/-^[P_^3-?['+AR^!2RS-?WZ,7OM&9 M@A]]^^4^8IU>XR5_/>X-VEFX_M*/'9L5W:]Y&Q!=S_,^*UKL(.8!@ /(3P\C MC,N4Y]:7K!N>5^_-),S9.IX$'5NV'UMVT.JEUF;T,7]?27)&UG)=&5YO=O;, MSM*5V]F]P]B*_QVUAZ>M=@W-8&.[H55>#/:[Z,$!?-D:PJ6O>TT>OU6)\):E(%@ M10[:65N/NM,8.CS4=EJQ!+>!L@81'NSAB?WV &9>[@.EWN^=Y-_RLF;:*].: MRXTX;;T$L@PQM?.L7.ST3GYJ'=JO<'>,W=9Q)X8#^"+!A,J0L0N7#L=C=2*0 M5S^_ $QIE']NZ/@L';.5H^./T8\R!;G35FKW!T,$1-/K9UHXZO6'!V!:@*#J MMIJ#HN["YOGK/X?8'_V[:_\TH]W/7\BGO??BK[T-MGWTGNQNOL>[FU_X]O=_ M?]FA']K;__B#?*)O3G8V/Y'_?'\OM@]N?M;3A/W/2*5![,+F#UJ'O5$1'#,Z MJ]/S1:R!/'L+U-H.=JWUC]@#-H8?MGHGM@B_[;8_;!\ 95^FWEHG[>%AR[:\ M[?=/\V.^VLZHB*3_O?OS?<0249YY"_PU2&Q8@K[M;!P!Z)S&?>2SH[Y/I]OY M(.4D@F,!&8MSUWW&D T4Z) JD0@CG.'TXA7C?/U\ E +I%L'?F@TQ%D-P9^+ MAOB!_K0S# POZC,3G_3Z :17HSVNQ[]T^^2:[6>'L7N>>W](?ZR!EA@,>J-^ M>ZWU?T"K=K#6>@U\ +O:SL#)\4_M;#&LSU_>S MG0U(.)9 3 MN*/:P[=BNCZW!88Q@PN=K3F!RHR',^GL,U4,O>^#9A\5QG*=Z MH$VYYPU(K$$;C&M;I%DMB,]QR_%7U#1Z]_MZDZN==C/FN)_VBYZF00)-GK'";-6,R98C I, M+BN)WZ=8YTY1L!OJ[S_;.XX2+?5Z+UZUBL*FOP+3]-M?BR2I?%?_C.$@L]1& MIKJY6IE[EQPPR\+^(#[R'M@.:-RA;7<&C7P_*]_ERLGW<>>[2AQE,;=6BSP0 M644"KA7!#M+KY+#M#XNP*H(O2W.;9?6H4QR+)<:621(D7*_0+H633CT*R91_<,AXW%Z*227&>).61,^T=E@Q3A8E@ MEH5;\+C]WNL>@ @]RIZW:;[D;]%F&?LVH\AQ:N6S]\%M?=O=^W*R_7G[=.?S MEV\[FQO[&F.;#+>(D$ 0U]0@391!/%'"(Z')$/'BE;CH7.7:)9>UVC$LMV\? M \/;LLQCN#_,NB\3$%RS7)KMS6AGB33;CSE>$)Y2CNVMD<;>EWU)!/>"6"2U MBHA++)#&&B-LM632ID"CRRFS^'P5Q-]R+ G$Q65F6V/FG]4 9N4T0,Z!\E4( MJ'5H2^9/JW=<6!>0*ZQV!/ !4GI4HH6];FR=@MC-WVW;/D!@X$^>DY\^9R#]59#!F>3'/&JT(%99U62X\1-/<_0)8&LP+VO\S#=7NG7=GW3M%,A2SJ 00X6J0'S/QQ_765BK>^L.2H';6>;YH M5OUX#!\5(RI?/#_!E[WB9A]F>34"C94Z/?BDG5I@K_5[H,G@HI\*LL[WPH> MS\O=%4W.1@;F8A.M28)G:^NL65=EA>:7&#OXX5U'W4X<5#/,EE\V&4?]/LRZ MG.0\QRUWP2S7S'K>N"3(LU8OT-G0;V_4GTN, M;'>!Y(;%-M^&G_>I]0)[XP":,HEXM!;9D!3RA)L ?Z1.KISW=0%* M=15*75O>?"$"4^&=#/ <'AQSBC%G$N6)$&\9^0%B./3#A810$<"'HC+ L.EE M7\0 )&:6/\^9+$X GY+MO3=TY_O[4_ALGU 2O4@<62' ="&:(A="1-89')S5 MFF;3!:^?AZN,VIU-S^&YWW<^>[S]?6,_,1XTR'80 M)-Z!R:L44! -*!_^20W' N1-IJ %N2A74! @F$')JFO9\#7G# Q:Q1E9%-DU MCKDIV&,I/XL+F'J/@PR."Z<,6/4!LV2QIP[8I"&N>R6NS8-][!EA&AN49/:L M")%/F-4).<6=XXE9P]QRXNDF!1_K+;#AX-L%]2-C.&J_VG:GH-M,M:!U!@EL MN5SD48!\18L]!Z"Q>-4!6O7Z%8'WO\8SLK(HV#H1)U_3!7"8L:4;QM %I+M6 M(]ZU$A.9X.H:T']K#X957&1Z1YYMS[=+*E$9/5\YSCC-@+F:<3N'GOOGONS' MH][77-'2[QU=?]'6QD'KWJ@#]@B8('ZR3%49S84E,'DO,V.VNR-;50_/P/,: M\/)BR9XS#D_:87@XKD>?N6ML $]OL6[0ZXR&%]]RKHCU@4#]6\3HF?69^?=P MTE+[&%0K#%S_/6#1@R]? F/__LV]]RA.Q:[WA/ ;$? MG_5WU_]Y^=ONCD3/%8\7$OWG MFXW?]_[Y>N/#F];>AS\^[JVUMG9>K[/6YM;&AZTW'Y_JZ^_L M[KWYV-K;;;W>W?FX^_O6YL;>F\W6VZV=C9W76QN_MS[NP0?;;W;VEE^!^WZ5 MAIN3Q[?TDWC.4,@X%D@V"!*V*, MP,G&*(7"(*JJ'BL_&#A< M ^OU#A'*!E<-V^(2)RRR-2/F+$?0S(@>V*P.(@ M3J4HL,H'"S*R?OXPL''N?LX*'![V1@>'%81J>2!JEW%HQGFC?DFOSH&&7N5Y MK8 O4%6G_=]1.]30:^P6K@$:W#^&KP>Q&XO#M0"^T1@K#\Y44X\1\,5V?I6Y M72C&%YR# MH?D=K8<'\H8W3C,-_N8PR#*18.[<$84A;.S5?.+=." M)_;CL6U?],!K!W,6I'C<9_N-"]-N%BN6,V]YLW=<;4&_VZTC=H2MU>44LWPV M%YK)Q;^9< Z '1F1>LPT$]CNZL$2'*[ MA6R>G?2*X=OKULH&'OBUU_F:V>^R1WR87'7!PRKF:.7,D2JW9?;NO?SI[_#I M^.HEYU"^F=+UD:Y.H4G[PX*(V#0?M,O5I M] R$YB!.)49EO5?2+K>9"''@^P#NZZ8.-TRU6FT:S<'H"W9.#Z@,0R>]@*KWP['#' =O=^W2R MN[=]DG''SN?M?1UM/AA/HA@H0=Q$BC0W%E$/Z#P *N0$OW@%\@'EY(.SX=$J M2R$OZ+B*ZVQ-:Y704!QEK0G?+T=/O+I[6(ZC 6EUU*ZP\8S3]RR]9OY=!@]K MC:V7GHLH%SQ893S.E=COP$A< MT"AA+H]N#6C.=T8%<2Y#',GQJ!-107C%-9:.<: 2DQ)VB26E&^)X(.+XO+&O MG:3>^(2844 AA#BD85N0C3P*JCE+.KYX!;MV%7',"),+U6 EA\[IQD)4):H$ M@U3R*2.V&NQ8[T$WY2>D6 3<."VG%*X>V=,,_$>#RLZ L?J37E7G15UL%[0S M06P7 1P'IL9QJT:3TUSQ98B>&ZRE%Q8+*3BCH)8]89XSI7E4)/@?(/JQ?L+)BG^IV]C7WL #%IFI ,.3@??40YZ 7(T#LM M&#= ]R]>,74UU1> 5FG6);L]Y :O+A E90C<)N(XYHY+DJA*RAMZ 8%<-WGC MY@3R_,*C9\3B]T_[%-C6DJ00@UU!G$J9FPL%!.S,&'&>F0BHCEQ('FZY9A"/ MSM*I75_3X&QV3Z51)JJI ^HR@ D =E*16TOE*A&R3IXKH=)>KW#5[?0<+(%A MVSIJ=S,JJ+) ;+'>0]_%1T7UEV> M+H4,E&!"&YD22=Q:EX,(EAIA/18$]-)='>OV_!3_7)0 _O_'?O(X<;!&D-(, M%'^* 1E-!'+."RDQ32X(D.MBD>(?1PF*XVRV \Q4RDT,]+7E4Z3NH12MH8H% MN9I[6_L9INO@#(*U!FT?E$7:,8&(\BPH3_/W0!6*K:N;4,45]M"H6ZR7J8"> MR^6YQC!+1R^%CE$&+D%B&@ZT96+R0CM G6"4.W*1!/I1@_Q#/+*@?;L'C4E^ MH8S:V]['C L7'4:.)J!&;04RL#=@EQ/FE+(YE)E-\G7VPTW('I4&WIL)^93D MN3KR" MTU4IW;(9]KAV=]*=RMO!X5KYMZ UP)=5?")'5V;9["K\>C'S%>.O ML.VPP+3A4JR(O?3&.QJ=B3QB^(G"!S@DK;V-O&9%K F^D9O@;+^_K[%KX?VW M*Q#\&I8E_WTS79F-;FBX<[%E^ ?;_OS'/ACK*C+'4'0^@*[P!FD6&*+2<$>P MP<;(7))\E>=@_5P ?AIP!T*>B]Z-"Q.KM-=L:O3;O@J,9T*>UBN>C;2!)=/I MY/2%3J][D,-\Q\=@4X"*ZM>9K, P_QW!;_!=>]P99#:T>F2_5(ZYV(D5+<,# MU^IMTI!U_!;9Z0:&22FB'5\T4Z)6/VT^@'M86I \,LYET8;(@"P+@0.4'!_UX4"SP26)0:&=>=:.*.X_[O1S5K7163I#)R2KSM:2M M,.J/3?9%;#..SY_U)U2.B\PV\*!\8I*M'I,=DW,)Z[G.^?PEQ6=0>U]>QF^Y M.'4P;@UT/.E \%/6NW5)J+VDY?+"?@DIT40891(3SFE*EN?S"A,'[)E3$WF. M5%?\@A8Q#KL&<[RNJE//L<%O=C ^JZQIHC!AB>]^'W-I*/<.42\CX@IL'B.3 M02#+,.R!\Q*'%Z\D79 S][?YE)E9J?^^(M9I@(**MM]I%XEM M*X=9:N>-FFBG6!E5_QIU8XM5*6KD2:+J/Y@ M6/3PM"OVN96>U[2^/QG+=G-_A9*2"T0+/^:^(24:\4OK9?NG<:_0X\ZH MHOASK1:*LQ[V_B .UD!9'==BJK?8Z0_$6,(,:Q5[+:D_G74F\<"H(%P290W7 M7MEDC636/U1^!2&W:[X]9:N0L1:31FI3&WZ>[FIWUOJ1!< M,&09VOW_9UPXL.^E\SJ"TB+OHD0XV(JFE-Y%3 MEX@N#1[.VPU_^S4KQ)=MD"59(&0@VOI0>KS,G'0V#A'.2ZR?5D3N>$RELH(R M%R,G7AN.N1#64<&\,EPT-'CG%84*M]T"I'*#'WWKEFS^]XS]GVYIM]V +"0-P@ MF1@'ZXR07-(4D 00P!FW2I3SU=;9 EVS/D98,V+A!I9"P:\%=STH%+.K!<4D M=4PK YQ()7?,9(<2#DH!&F/4:=JPQ]VSQ\&^H91'">S!HP'V8$H@ZQP'9!:I ME]X;SEAFC]L1B9Q@G9P'.1@XP&]JO! <"H)4($UNSYG>_YWA_[)AIK>6FN MQ4 -$@- 7,!/S%GC1)):>).AV"*16$$Q=P:)K8A("2(ZA0/5FDBN"YHT:N?L]!Y$"1CMA*2N/D-4(P2D;\PFQ MP$T$N<*<)%F-D 5J9+VUL;C#YAE/5JCBIU7@9U1GBDUQY 4]3:BHAQ M!$F3"-$7_'Z.5- M1C#[G"OE+*?(>9D[A8+]KJ/,F5W1!T.X5SFSBZSK6T<F.+0Q+8*<^S_\;K MF"P)A'A,!3/-GM_YGN_Y?14M5M%;I%,^III(BK1F'DD+2,^J($DHW6'%A8CU MG/-P162*T)'KX(C24G,?F.8XJTPC8M)!R0:^W -];>SGI!:5;$+>,9--88=< M8A8!J,1661 I%&?(NHB^EI!R, 5C=9HXE( H>:$\J31(W>]Y]]S M17>2+'DA/"(A]SK*Z8>.28V2$?G@[!0Q3<4QN!"R/K1C\$=@U8HY CU-T5/B M%(F@8AVQ)B46I)#,,.EI(P+OG!UV-D'%"A<<#181H2S8ZA9@%>@?Q$!88>Z\ M R4V>&61""U3 8=<(SY!!ILO- R>I6\(\:IJ_+8FCW_\3W?>[]O& @\(AW* M#4=@SP%@&:L%DEICG;N_&4J*(W!A3+;IBGMI5US6=,5=@;DT77&;KKA-5]R+ MNN)>V>7V3%=<)SDS06LC;.ZRX2SC% N #WSTZ_OQF'T!"2-PR)+&- MV>F8D-5!H<29AL4&(G"RM*]9F#ET<6'BXL:ZY^H59PI#RMEUXXY=0#U5T"L7 MK(];=86;B!;"F!54"WA/RS4A#CN@,!IM M'O,5Y.XP4$; M0R215IK <;JH*)HWNWLC<7&PKUW2FE"#0#53Q(WQR A#45 >3&D'XCR6Y%*Z M4%Q4M9'G_WV*X>D+POUK5V0\CJLVIZ[/G!-@NQ>>$GJH \PNB-VHJU2SX;>TX9\_[6M&O->BHE]^DY[]D M&%J*6',J57=\2%SY9'Z(E]/*SWX\'O7](<#0,MS@T/;C8"8*-F<,SS[LI[5% M)X?';SX>UR>'[Y5:T.DGXSZW^9WRHV%3V[ E83"VO9?C=Y89OV&XQ<< M_?OY#=[7P:N(/2 E:PC*A@C21'O$0?D,>'%*[7.U*+0T\=8&CYNM%Z/ MCD950 $P1(CQJ#AL8-6/8SD ?+(SK;(U5[0;A/L^9CJ^E9.CKZ23=[:_V_]8 MSMCX=VX?,7UZ32GXV1/*UND^UA1;A2TBW O$O0S(14%1HC%JDX^,DJ;83^?! M ,B+?MV9(Z/"(J):+VOS>D)"9TAD"/6H9534 M."= NX!_!P/;/YWKO=7.%?A "*-!U3?DPYNMO?.%^V.I?L'0,[)Y3D!>]*(_ ME5+_7$II1YUAZ3[PM>X\-/ZL'-Q93DNJ#F0""9\_+OU*L^MAO?5;! W:K3LB M+9'_,'.T4WZE!:]SL;::TQ]YY+FV3F=/3#FWC!<\SUWG32;FR+1CS9E-N+(X MM0RQ]%:EFAKKQA:P(BDG.\^W^H!']PJ59-49EX7!@I&@B5!:2\Z#\59*R8*/ MB2@"DEE?X7^DU^@RLSFS5EO=-]\R+^RF[5YHYW->WXY@&=X"6>T>QRJD-VA: MS\SX'':^?V$Y%U8DZE,0&EG*0&%B[)'6@B/-54J),OA6OWBU""MGNAFO=NOM MV]WKU%)/FA-CK@RD0-DKF%VGZCDTH/3L" M@@C<"81=/FJ;X(A,% F10"5ER1-N['4Z!LX;*.WAO$$RJSG'^7>@[[^V>Z-! MYW2&L,)LB[%ROMA5O<"SCEVK^6%AY[,9*^JL&5=A@T&EJTJSPK,-_?+1?C?I MOV>(<5(2S$WV"GL'U*Y3M%+D\YAH9$W_O=7A [Z=,Y4)ME8ZB:+3@(&--,CP MZ!#H:HQ-HHDG,):N/H;H$?? 4\$[2UC$-CI.0W)"10H" -[<^'1E/Y>F!]YM MDR4 $!8+R/)O3[($;]$93NU6=JE%[/\T^?[_L\/M=C\F@;\KK&,/^ M-[]M[6UNG'MN:G_+5X)V/8AUC]G)B/,3M-WJ^(W<,N^DUQ\>5K;9[;]YEC/+ M21<*@,)[;D0RGBMKG&)$.&45BT3H=%4V>B-=;E6Z^&_;FW[?*T=]9!;A4D>> MRW,,-O"KEA$V"TP@ZEZ\DFIAA\VQT3+;"/)?(T!STRKC?CFM>JXMY@V"1YY2 M)V,.ZPO'DP_:!8^!?C35(NBD;L%J;BAG">58)B=&6!>5R=0HW*GHOK 32 MR*E:5_5%:0CFEI3*QCX5P1'*@4RPM#DR4DC'@YP 4J$@17P,%W1PO(&<"#2H M1&1V\W%#K.$$Y!"8YD82"3JBV?9[D1/?W^\'8R5AFB,,@AIQ:RDR%* %MPYS MED\DJ=3#(CDQ-6WGK9(KG'39XBCAWU$)=^7V7/;XN-_[!KL[C !%EHD\26NC M"#QB)30/05D/ADD 8$Q%TD#0MQ!GK<-,.W'X9Y[^A_JLN[>]?O9^=MKYM(DF MN#0V2SYO['MOM8DR(IQ8R<1SR,GD4*"@AD"<1%:9)?2JHYU*Y63IN;2DJ:(E MU\XK3:SC@7N'0;50X:FDGAMZ&XDGM6-C-P%9[*84< ,JE#V.2:1V4ULC%9)!6A%$C%A!QR7YB4F1T;W=,B.7KU&D]/Q;E.ILF@ M79\$CDO-PG&4&ZM$IFDO]2:@#+,>65/*N.7:_Z$973A&RG M',Q>:/^2-IBE[CFT1L<7U##[RE?8BM]R@GV5DC4_%1<[[?@U^Z5R/D*5MU62 MPW.BX& V7Z(+"]PBM'4$:W!8'^]CL]LT>TN+S^LHG[ X?I-!G+[!#7>:W7.Q M>1GQEWSD4]M?HX#_K>UVVQ$(.O\=9(_S_/:TX^ VWWM5*'RWV]KUP]Z4NHF< M(ZFUB;ER]?@R\.OZ8+!=,,=*8N?E\YB]?!O8JEWM2^MMX?78^OWWUVNE8T%*<%?. M2Y<,=[952@G@TU25G/F+NQ)SFONEO36 M$? Y7#.>PE6$/YY(];C>02P9V'4;VFN. 50R/41O(WS-"S6 [0EQ*@[S*6[C MC:D.-[.# 7!,+"=+SBY GLCXG>'M9AYNAT4W98+*.UD2R0:ETT9WYK*)0)W= MONW?/F;UF+, GV;5TJ3L;0'#%_75_3SJ5@!QHK_B-^"$\3FV^8-K;/1:+0SF M9<&%&!36'/14SC";0Z%:42>S.S8D#AC4: .FB6=821$Q4:7LDTB"%Q1YS-@F ML%8^VR=@.H5![)ZO$>RWOY9RE9V"A'?3%*P._AD[X1E;N_-E@=ES'EDR1@N' MF,@U0L889 E62'KM1$YS%HF^>#4\Z9TW=N=K@KT]GF7U0FTVDT31!EED';;[ MN70#R&*MCN'"/8.ZY\)DL') XLN<8;_X&-NS+6-^RMG1E[=TO 9]E_:.DS09 MX(OES*N;$3:[F'1!,C8- <[3[!\G.P4;9PYJ%V/QYWK+^LK*.1;(^#2C; RG8AVA01P40@3IU!VD6! MI&2$)IT4%>("R0;[41E5EXFXM9GV"#M@1A5CLE*^IH:<5=8 M7L:?1X"LO9>18Q$Y%<1$&W/E=C[PQR:A"FD9 F]Y8W_>#&'5N$>:YBQQ00WFQA&NS8M76J^KRYUXE6=X60%C$U9. M41(5SE&@Z))-%"2=)%IKS_1B*F@$S%U!I[WMW)@TF,5.L.FQ6('P254?NE 6#5HY&[?D&9=#H&L'4ZDARY&&RE[N MQU*N&&(VNPH0 ROO,(:[&K18G""$_MJ:RL0J3_6?P#J9'3>RYI_S M(#X(S1:@41=Z L0([4'VE8R*K^C ]L/8-7S6[1RFK_73D_3R;W6GJ*QR[U_D M#QF 1JO\8'UX7H+KQZ7?M7]D&VS5]@&\PL=_[KX#W-?K%O=?9<_C%9TSSF;%JZ"(50!D5>*.:\<#5D0RA@4+@M:91:1JL9)_8#IEGC!#/6!R?LUUJ;#+$(:(!%W(I C)6<40##3CW M.?.>YQ9+5T1Y"TF!)9H=(:#="X'T*B?I)(K4C[DD-8XI= P:UYO6\9>VCN=- MZ_@5F$O3.KYI'=^TCK^H=?R=MX)?%81VMFE0+J/-]FT:%7/6CB.*RSGRW>GT M>%(PJG-[A])-J2Y;K15F&W!5SN XZO6'!R#OPUB%EE@78&H8)L/J''^ M2OI M>M,KQL$(6*D]7F>^Z1XL-JQ1_S2CM@J?#]9FFA(-8,L'J89Y,*MQ MJF NP@7#OO^U[:OTC)RE6>#I.#K1Z=F\O:AZH2$LV>"FP1$T>M--$89T4BVE$W[FDP0(7SA0 ,+C7/<@-_#,WSH]_^7Y(>'OVYL; M;#\JRZ@.*?=I]H@G3Y$ST:/$-:3F6@=E/").%J93YEW8X<[DR0/<__7)= M2:/G]T]?)&GJQ1I;%WV0]:C(U>-!_&7\PZ^A/3CNV--?VMVR^.6F7[]F:0SF M9STF/*9&X<:L:\$R$!_VX6\8#U]C]/6"T7\>AO/?2;E.,+OP:[Q.;OB=8/1& M=UXV6;..\9Z^5RI4=<:]>="7Q6- :UFQBAA_8DE62#$+[A%BF@:CW>3 M2XDX=RT]_I:O_O4#%%QHI\(DR66,T%K]V):7C?+WU] MAW)9AI=;V7/3&\&H8?#3W'O_,/'48C/+6;BV54I-6N.7?%S4LCU61CM%&;VK ME-$UENM::_"\UO+B7.=F&9=8QKVW7H>8+EJ(BPCIUA80MQ[#,O[OV36\O?>??>]^?N1*O?@RZ4\"4^&= M#"8$'AQSBC%G$LW--[QE9'%C>,26B&[-FO)3$W\VYC4!+UO='9C9WDGL?(W; MI=S M!Y[KOW_Z\_VWR3W_^?_9^]*F-I+D[Z_2X?_S8C>"8NKLKO)L.((Q>):)D5C; M\LSB-T2=("PD5BT9PZ=_LJIUM(2P 7,(Z(A=CY#ZJ"/SEV=E_G%D3EQO[_@3 M_/V)1W] Z_B0MCKO1>NDW?U\LG/^^>0]W?O[W5'[HGWT>7LGYE6-6EW\[<_. MSJBU=2 -+SR5!:+$2\1#D$AJ[)&5/FB%59!!OWI#-HBZ7'A^J8O373-0_/6& MC-0 80.$]PB$6'H*S)%S;02/#%)()BP+&+."46^N!L(&[1X/[=IO9VA'92#< M%!@I+$C5I5 5&B/-K-",4NH* VBWHM-I@W4-UKTHK+M=-Z!&Z5M?&)PK?=21 M0G*5(\)B+RKE-=)@3B+AO2@8D8Z06%]E@ZUH/;BF0'AC?X"UWM<0\2G %C < MO97)OS37*WU']&;KM1+LGS3HK9NEN^_UL',V:+#N1EC7JANXGA4J6*J1@_\B M;@-!,M<%*@3EN9$>D]A4@FQ0?E5.Z+6Q;C6DW*M>UW#VO9MN#6>O$V?7C#D7 MJ,%!,L1CWWGN T/*Q +65A(P[[3S10"AN2'I3YMS#6>O+V>OFZ'2-+Y#WN0G2@WYF]*LW? /GZR2S;QN2?&(F"+N/J..U MX&S%>CT_.%M+$R0>@VX [4: ]KYNA&C%>' A1MFP!T"C!9)4*42U*C@!ZX1S M^>I-OL$DNR.'RQHYEQO>7FLCI.'M6_!VS0P)Q&,9W0JYQ*"LY"Q'6L@^%@*B6]P=555DH:WGP%OKZ49TO#V;7A[+K<)5BH$CY%71B#.-44FT!P% M)K14)#@I_*LW!&](>5IRY<;&9_IL6'L=#9&&M6_!VC4[1$KN M--,861N;YN0T=DT2L1:>T-[%BG@AZBJ%W"#%3Z=U-,R]OLR]CI9(P]RW8>Z: MW.;>D\ HDDY;Q(4"0T18C%A1Y 0@W'+#(W.K#9KG:\3<+R0F(IJ8R(NS1+I? M&]?*S1!M?\$2*5BAN)&(>H\1P!M'"M07A)UE3DI#K;;IX-'/YV4U;M/U9>VU MM$0:UKXY:]N=BT55 >65LT,9%GSMQK:8DT MS'T+YI[+[8"I*E(/!A)[,##GD**&@&%B@;\9X\[+R-QB(V=JC9C[)<1$.K,2 M9$UDY.78(UMQPQMHNQ6TV063A%.&W(" X(]C6@0N9"NT(H5H#J MPIC<*&*9^H:_GRM_KY==TO#W3_%W[:AGX0DV5*""D6B:*(\,I1QQ13V1W.9: ML%=O9"$W\%H=]GP)09++%?P>MG3)O*1UY@;C6.]X.N>FMLF=+="S$1 /8.!% MP3!O[?A6#X?GL(Y+33\;(7 =(7"X<-2&2"5]'I"3L:"=X 4R1N7(,AFL\B'* M C#B!-Y@^1U7-[D#%GH:=: :,&W =*VLZ09,[Q!,:Q:SH"$(GTN$XXDFKJD% MB]D'Y!D J-;>>(=?OS;- MTO[<_6WO0]:)/8Q3M[EGVM3YCW'O/ .0*3:JEH#=ON[;V,KO[:#OQG:4;8U' M1X-A[*_\CZI#\] ?CF.;OC)+2_3/3/?[0*O6NZP[RKJQJZA++?U*6 O)-3 MW^O%]EA&][]4/XS-"5PZ3 ^9=N@"BK/QN9/^?=7RI_AW;,M%-K.M,M/P\G+< M&TW&ZEWJ%?C!Q_Y^/OMMH(=NVK[K\J_P]OC@N'3[@R%\'A[J/BQ6=?E6#][4 M3\UZX9;@AQYFE'U(0WP[.('QCKS?F#2I[L:-ZX;NY-Z/WHYCL^H]8)U^7-[I M,L*DXQ.R?\1V813_^G'OW8?TD?P*RU;">I79Z3"^+=ZN:T. 5:I6H-NO]Q9/ MLQO$[F19F.U4E"D15\K-;*^?M?001BA2,S/RXTV%FT-W>!)?GYWJ8>KB",3I M@>JKC1@==6-[<^TB^633S:[ZH.M1W/*S;@\&D?HGI^;)@$B 'Z/9_3YV^ 9" M]%^JS3D;H)-8]C7[]'%[,LO2CT;P2%B1$QA*%]8,J'+> 6ZY21M00R=U;3[1 MW7Z\8,63JE$-4CO0M)YF,K3R*&T;X.OA$9 _3(KA]%16/77:0Q.FW1^,LM1/ M#6X_C=U?8.G.CGR_Z@]7O<+$UG0A=&TW=I3K=?\W[KJXL-VJLW3<\@P X8L? M77H\K$)W!-L0.VO"POC8@5*/IBWFA]WR2VQ<'7DM=:ZV1[I_"#0 3YYPQU?= M[6F3NI_/2#-UQ(2I#F)WWT0>\]LBBAP]9QNL^Y,!0$ Z%;3J>:0UA#T MFK0_75@:&V>KRRGYE["DP'R3$;EN.=W2ZHL9[6OT5D?.+[. M6W$6:?SEX*0:6FJ,NE&[->T!W-N_=..LM6H7"*#O#P>PQHG44_?YGH_-5>ML M:N.Z^F%BK0G_PE>]V" 5@ DH!K:G![?!#@%]#&ICR,)P<#)9AGG/UJ6F]QOU MIH358OIN>O%X!!=<5"SY6^3-"HET9&; CHC6_55/_&?@N6,FI6=")3IHZ:L!835\Y'\TA?51L*@ M9H0=[P$R = !=@39G5@N] 85-Z;+09"!@I-0=.@C2,)*P->Q>VPY7_S.:7=(UW.V@<#+UYJE5GQ_QQ2].'0^PFB1$%TI+].R2W]K8$_J^4;3/!R M,WL+FP 2HZ+'0;GPD'3_,K?#6WNPVR[)R7CKG&UJMP(9QY[JD>V NP91;"QB MO0;"B^'AD2\7I>8*7KT\A.^].M%M!4)^B8*&,RUFKFA-,7?"G76XJBWM(F8M M4=XO2UVV*UJL6FW_J/\\Q>+5#RE87$>#?OC>955'=9"JE>F69_?<)OF=[@[_ MBB)U&V1>;U""AEFN3T_D3Q.#_?2D=;%_MMJ)?+)_T3[>$NW.A^.]SGO4__>[%_T=JV!X0*KUG@R!DADL)IC[@G'@HN":!:]GH&2X)@EQ"^W4$Z=?>FO65S_[*^I3C-7H7=K MJLPEV_<'&+W^%N&_EKB[HK,?K^'BFOO" __D/FWO4[\96]G,X3S:%B7;=1/NMA/GI M&/9D7%9 >0(&R3CIUG-+J:Z&ZBA<8(N3VKJ971I0I5=,)#! Y_1]/3]]DZXZ M4<\-N'(P'EH_'7Z48I4)4^E*\RF=#)SOQ9'&T<&6@<1+B*W+ MWMJOGCE1=*J75_)E%&M" 8I_C8^;*%GS98P2T %Q#P&8800>1O(Z6X'?5Q'M MA#!XI-C30:64OD[V" B)26OHB<^S=M<$Q?'\%IC#H#<>77W+I7Z5CT3\[Q 3 M2\*N]N_1<#J>4]@P9$ O^(*2@^*U[IWI\_+5+XL\#PP_>;R*[U^>_95S#.'> MYEC!C/.@J*?-?YT,BW@5C$FOS5@RH&L0H__W8XVB "4R\210_]LH@5,39'TU M45]%:V]2'^4;W_;0"LB_=[;^[/S[[=:'G:SSX=/'SD:VVWZ[F6VUM[./GW[[ MN+N]N_5A=^?CZ^S\S'K[&5O]]H?]_[#R1G)01DM C8\ MC\<@;J2,3\((*,8D7^?7,#!1E"#KT#B\\NM':9G-VNT^AIS)ICKF^_$@.@5. MA\EQD5PHR0"K1'UELE6^9@O:"Z@'\#A3X(JDYWZ/FJXZ#:\DXEF@G>CKRBP\W$2+?S@E' RN9#-.(4E*DZI8CK5*,8] M/5QI1OX,[:VOX1[-P:G7>Q9[.TMA*MU?M=8!N'=F9LZ-QDEHH\Q*F&0W@. ! MV7 \=H>5A5J%7))+OHS.V=$ _EN>>ALOG?KG5_'[;G\>:9F,:[1JR/'+N5V^ M(*&Z-0_ A%B3.]UU0_)TCI8LX=IC9O/;F/@](P].YK[JLBFR5@&*&L1=,;3) M8BZY**+I7XYF;X,13[R_BZL[6;6K9MU/8>+J_7$EZX[E28 M>0U3^-\8F,(/)Y[>4]]WB1/[\,)A=S">[>5&BN&7&1CO93=%/I-,64E!,1(6 M94GVL5UFKA2RW)@NW/=L8JMU=\Y M#7!-E)_)0#= E01L@LD!3'9/$H[!2*:1W# M@:N2#H(>]T;3H/0\\N;2 BR%M.8@I.,KJY#.U"*O_IJ:Y>D1%!.U<6E+(B:6 MY20):([HE;LV[4?*9YC^]=TUG'JUO\:DI5[MHNC97MC!;.I8K4S!JVCC^SL6 MDQ= KUHAAE:.H#;SF2)8V]\5R5G?(]VE^-%5'@ BGXJY2!^<2YGHT>Z>B M8)TTO(5-N2*_IKNPX%6005>9,Y$'0('3Y5%,;C@#^M&]E]4?]&'B*9,[!>F[Y9=9\N*E'Z80\KW( M_ /%H[>2&VJK[_Z<.Z&F^LA>?Z9]P 7M07\X_3/I(LE5_X*#V.=[G2\'-&>: M8J-BFW:%.+86*8\#(@5F)I@@QOSK5D'C/#,:C ME?QSA1/TI*80UR1"DN[9#P6[/CP<^L/$UQ/]X<86XJ!<1.&H95U7#*75JVUB M^GNE1EHMV2S2FI+]8?-Z^K3TKZN71"H?J-DTV!\RM_QIODEK\)1F]UY_<&2^BF$J(9 M[$L?+-D$GK_68W]0RF/-*G9W/= MO(I:U9:+-LM56=8+899+RW2='LS/=IDNEQ*Z;6W7FQQ]?&RL_NZ27)T8H4?+OQPX'1Y=+GFPY149SZ[O3#_,OGOJ@H0[<%H+X3X MYZ&.SHNWT8,PBO[_-:H-<3LO754;XO1H_V3W&SQ;?.X[]_PI^W M80PPU_;ON]_^>[%;KUHFI%2YLQ@%')OW"<^1D2Q'0>9%/#E!N16S#3H^-3O1"8=TK"5J*< M6HV + JDJ3+(8R.#*%0>8E5%PAIH:J#IB4 39U9CQDQPEG)=8(-SQ[V1Q#FM M<_$=:&H4JG4%K+E"A4E!K*<2V< -XD%)9*RWR"A/1$X-Q['6?Z-0-:BU!G.[ M 6II'GP!<.157G"E@J-KFI]VWF#?G6)?J^[L M8M855.<6J<)AQ!T/2'NNP:+,N<'>N!#(G>EF31^F!V;U?SR(>^@&U8P;AG\4 MAJ]YCP)U6JG"H,)B@KBV$FD3&S/EP06&"RZ+_-4;)C>8O%Q%_E*B4! :*9Q+9 OI%=?<2>O62ZJ_A*2CQVZT^-*[ MU;RD9C3WZZJ9(7L;@#OZHV>HWJ#VC5#[?=WY0AS/-66 U:"5(6YR@K0G A'- MI0I,$6+]70?&GEG'K@;BGCC$/8R+*A9*@$\WT&H;Q+LSQ*MYG[@*,>JO$ ;@ M0]P5 >F"8D2=L+(@DAI#*SVUR']"3VVPKL&Z-<2ZM?'1->!V=^ V5^=HKJ4& M#1R%@$V,I5FDI<\15R"-*CG'B"># : M26(#G1\JL69K RY-%P@1JA&/'IAI28,>< GHV0NM)2OWC!%&VQJL.F)8),*F'!6 MY$0%PQG(V1Q3&T+A#'>*!-EH5$\/L6H'L6#C!,4,<2H+Q M%D2(LH!QCXQ@K MK+2JT:@:U%J+N=T M0B5WN:J\($S;J0VS -H<:R SH/CN-&HUAB?:J$>EA<% M5D0AQ81%G'N)E%02,4JI(: <:TO63:-Z6A7 '^0P_"TJ$4\OO1_?SRR4^ZWL MONYW>Y.6&OL\4.B82%QEO?%%8!4*T\%'=%TAQ#.(4 M\%(+CDG*@14;#(MKYTSPL"0W/BL%*(JH(ASBQ%RBN'-'7: MK$9TW>_0.LM$]8FZ:+)H;YS ML[JU=: *8[S3 A68@4U .$6:2XFD"RJGBA6$H0%Y0BR4V!& U!\$)J5>A7;_B&6E'5]\;E@I@Q$K=/13.XV4H#DJF/<46PFFQ=V=9&Y0 MM$'1EXFB#^/M;732-7#DQMHWA!&'7:P,@2WBC%FD03@B9IW@RA:YCQDTST8G M3=[A7T:Q:3;\UW6_SN(\[?$)\(M]\R_X9[>FR3"W%$ZMWR\C?;FQC\WKX6V?_&^OAR ][YYG19;?Z?YAU=,^ M/G5T?NKC&[JI WEVHL_AM>6X-XH7:/B\] 9@]\S"#NGX3S_2[DW+C(=!)^OW\?*TY[_\'K7K93CO0H]H;_ZLO1 M"=!CF;6\+L=#6 P]RB*>9@E0JYUN#_KH@[?C85J\W^)N+ZY-9)2(_MW^6%<1 MT=IJ35[/X\*<#LINO.#UT/=22.[7LZX;'4VU]-I=D\7%\UNT :8?CZZ^Y5+K M^4=BKW>(Y4OK4_OW:%:OX50?>F2&7G]!.L!P7^O>F3XO7_VR2&Q 5Y/'J_C^ MY=E?.<<0[FV.%8&#-!X,TWZ_!D ')("K8$QZ;<:2'0VC+O)_70.J2!#$:6\- MB#6M)6,";(.BR(W.B3TH7KWI1.2/X/$VJC' $O_Z1;^Y$@*NHK4W_S+#7VY^ MVP,6%T@D^N^=K3\[_WZ[]6$GZWSX]+&SD>VVWVYF6^WM[..GWS[N;N]N?=C= M^?AZ^Q\S#I[V=N]]L>]/W>WMSH[V]F[W?96^^WNUI_9QPY\T=II=VZ^ M @\]E:4R$12O0IXE>*Y4X8)Z8:2DECK+G0PF9R171AGTM^ET%_0^(A\-'T/M"A M1-X\WD&9M8@.](NZ\+?W2CP MAW%U?+4ZW=KJ'$U795SZC>SLJ&N/*DW,:E $*DVAIF0E30&T932<:0I)+XP_ M1'T+"# I[3HJD$;W=-_ZK#SR?@3:'N!NI7RM5L62?A?M18"H'UV[D=XVG>[@ MK ^OJT\E.QT.3J,A .L;OZHF5K\GK@Y, L;;!4D"M\Z[.#H?ERXM2/PV[H@= MQ?7JPO)/+-CX_#@8L%VJ983%/X^+.UGUD)5C&']M4K#JE8H>+_??3B^-.CTK MOJ(;!5U4@(\&O6@_Q0ET!RZIW;,QG@[!Y!X"4<;%BQ.!O[[$33N%=^JX=(-( M/7 1T$]2O,>C<:*2V0MG@X!+C<\.?1_TCB]N=>;&RAP=W=J M";#O:?^;V4?OLRF#WY/6="-H>G ]ZJY&=WW-BJ@X@O][S=+\_N3C$Z!B) M>P?3P(E,!KQ?E>Q_(/][?O4C6 MT<]*^K(2]5#G?I1AUL,=)@HZD&D;,&@/'.F2:=)/ M=@T\>P!+,)S5$G0^^&%<)#LHX]_I/FUM/#H"L];G:<;Q/OAR./;SA]7N36^/ MU\ RPRC-.+)<[>YH1'V;V4ZP0,OVW8]%ZL0(K6Z?KVK6U]$.6V;JA9#68LBV MP"3W+J>",\^)H3I77BFC12#24$,.MJ.4Q@03-"]T?44D]K?SWZI1?HR#_'TX M&)_"I#KPKM]Z _OEB49C/__W"-N3O_KZ;S7>.]F_:!]OB7;GP_%>YSUN7[P7 M^Q>_==M_?[IH__['%_B-[_V]RSYWWM/_7NQ?P#L/"/9$XYC<)UR!N(9_=.X9 M\D;D%A89BT*\ @ZR^M1/S@D^)P1:0H":)R2)V^+7B$PGNMN/]+\:#Q*HZ!0. MC%Q]"M2^RA/U0S5TZ.=W&]\;G+V^8]F7 LGS8%8*7MMXP.RT]*^G'WX%5#CM MZ?/7W7Y:L733_L7R327+E MSWCSMK\)1F]UY_<&RS=))Z [IFD9=; MG%]_H$O5=0K25#&QA\E>4[>IIUX+E+WXM5BJ+?^TRA!=W[*OUN6.=)T$#RB]WM_&^2HW=MLGG(F/OU5N[MU$2KR@CDK'^)2RGN5*O"3&WN/!+)^W!,-W6H1_[K[2F8-'S5\ MU/#1K>MUW#?[3!Z!XO6O"=N<^0 F7A94??=(AS1^'P[*,CL9#$>'^C#Y2?RB MMW+V4\K5.QWZD^[X9.JCK+R;R=EY+_R8;RZSXZI97,V.W^7&[/J,^$ -K=:6 M.Z])3.P12\F\]/-D3_ZXV U.BQE/B1>&>4XYIY@KFW-E"D8ET=X&=;WVP3^H M#69&\P#@+%#Q3$Z(#7#KXI#M_?Y'#^YC[]M'Y*];?MM_Z1]TMI^ MS_>/M_C^\@FQX_<7< W?/_DDVAU+VMOO1>MBE^]M?^+MBW?=?;I_UMX^ZK:V MCX[^>[%;KUI@K#%4Y 8%J3SBTA9($5V@PCI!A76F*&)E2"XWI%1W>^SVN9RJ MO3R/%XUPSQ3>L">YX3*$D'MN#9%&8^X)-BPGVE'?P-OZP%NMQ84T3DKL$14$ MX"TO-%(T)TC!!A;>\]SJ6,>0JPTA+A^!O6-X>Q;8]M+A[?DBG 4\\UPS10-H M<%)+Y71@0O)".:49OY/BK@W"W07"U8[X!VV5+ J/O'8<%#AJD9:Y0KG7C&HG ME&<8$([E&QC?5:.,9Z_ -2#W7$&N ([ SDBN6 [J ):!6*L(+GB.I=>A ;FU M ;E69VO4^AB!;NM 6^D*RC"R0A+$-2%(6Z^0$B"U, 4!5;"HQXD-3OA30;D; M.\>7NH4_6__WVZ%WW9C/;=/YR9]P"=]#C_;G[/7]P7+]Z+X:QZPH__.K- M%^#92%3&C =P#ECXG$N>:T&5];$> 15*!MPX1M9$HK;J?E]LM%!$6N2DR!$' MLP\9HPWRMH#=E+IPP0**4+:1%S\M4&_,'?=M-S0XU^#! M*B6D*CPW7A'OO&AP;GUP;NX QA(K2AT &V82<5HPI(M"(DNUQ=H1EGL/.$>B M U@V.-?@W(O'.6^Y55AA'PSE"A/C#,YY$,SRP M\-TTA&YR["YS;J\?Q@Q." M&P VYQ!7U""M@T76Y+B01#EB\:LW5."-G#0XU^!<@W-@FEK"&+.&@Q)'O5&: M!4HPPX5ATC?AKO7!N05/<,Z(]E0@7@0 .FQRI(FDB N;%T$]?L%!S.AW& :D,V6!HH;:#T$9*8.:&68BRDY1Q3K@37-GA: M!"^494T2\QI!Z=R';0CC#CN')O[V _-6:8(-\$09VA.!>&Z<1^M#936W>0T..R51D1Q MC7C(#9*Y=8@YV$20B)[;$*%4;3!ZQ]G2#90V4-I Z4I//%7!YT89+ -8^$YS MB7,+D%I(XW+7Y&2O#Y0N>N*U%33GB()% 1:^Y$@Q42!'@M5,.-!*)6!I@3?( M<\+2AVTRN3;E7J?57J^H2M(M9U6C738N8TD@/2M&4N]=D^F^[IV7W7)CUN6F M(H7X\"WWM5L.AK-2LK$:\[#K8]77L^[H*"N[,$\]3'TIR^HV&!;L^7!PEEXY M',;^E9/Z[OZ;[8W=M%GD;!9 ']VOJ2))[.LSNJ*3P<:*5CWSDK>+">JI\LHU M(A5 CJGH[>62T?6RNO-BT#!I((+X>GBOK9Y6G@Z]=F6]#>:TY4]M+K.J@$O3 MT"=5Z>O:"-SE(2RUS5S=&C+AY0];!% L7ZU[,?KO]YF+[0V*[)Z+;F_/:+)6 MX'ZK[_[M':S*X19@YM=$0MM5J??QT*]/(>[#B>@:G'_>_M"#^T0+Q :(-+Q_ M_$7L=0[A^\\@OO[XTCKYZVB?[ERTE@MQ'__QI?W[7S#&+Q>?C[?.VIT/W;T. MW+L-WY]\NFB=O#___/>[XWT0:_^]^$1;%U\./.&%=BQ'/.<$<<,9DEY8% KJ M. ':H]97B@;0K7=;44W( [6:.E:0PO""6FE\<$Z0@@4.WX7EPMW3%A+S[:FJ MS$^V)9OO2W9)""R7;+__'HUD8MOEV#MM+KA6 M5U;?@#^F$B_VA8M=%;+8I2TKS_0I_&RK?V/E\B%\&)RF3@8;42X/AO7^"8MW MU]X;"3)J<' 3B*@C8 .?Z5XOB\U(LEB+/1+W1$@N/F08MU27Y0!&'85.DN>Q M@]U,>M]Q\Y)UVLE3D-6V>PK;-:A3ZG.]E>0KV4P ! MIP%XXHB3?A![=E=J>]289DUG>N>1XB;:WE4D4RZV2]3=D_0Z4,1A*+4&B;/[ M)QTXTK#C6B042)0"OR3)MW!Y>MW)X&NU@(M]#]T MC$J7%67Q'C?> 1OO%@8 M8-6#"B8^KNK49:?C(;PH:GO#VN?$&*,C(* 5A'TRPZIJ!)%=%U3-*WHA5'VZ MREG3]+39=3Z>4D#5-:'JB1 UZN&IKEI%5IIB.6?-,;QB@::FK1:FW5TF+2ZS MU/$I/5(?#OUL_2+YC;J'E6X:&\W VY<:V1JW4ZX'I MQ45-/-1T7K\:+M\A5C2=U]=@+$WG]:;S^FJ+N.F\?@U;;,EV*ZQUBGDF%<7< M26$*0HM"$^:$5$&O[M3^B,Z0U>!2?OK;Z;?SV1B'\.;-K.A%POV9?2WOYR( PAGNN #)8XAD4] M4I[GR(1@<^U8R(5:INA0D,+;@DAF*<^MU'GN*99<*N% H.!E7TK4JZJ.6JE9 M5VS?5T[Z@:WR,R_;,S_4,>OF3-6&;])#MMKG.^ML^_K[GI[K&JV)XU8R]DJ\ M^>%JKUN[,DXWU9-I 4;S34[%$QDLH9N4LJH9=9&ZYOY/VKQFJ<]K-E6,UJ,?SAHNUS4;S[VD1C'77KF;M:F[SH',NVL/ M\SC0.W=#.U_">))>"HKHT23$6%-Q7]_JT-X=EL"[,Y)^TH-C>70C 1!.1QH4Y1Z'[S;OT-_FU"GK>QSG7ASB@_1C+.@>C&&'T M,9U%O07!M,.%=,<.^)D8J%/![=I4$'1:]WU.S"#P=. MET=7YTO-)+GWO/7W)_[YI(4_=_[J[7=V<(M^$OO' M?QVU_O[KI+V]*Z*7KW6\]6V6$#Q+[MW]]KES=+)_\:'7_ANN[[R_^-SI==M_ M[WS[_/<^;AWW3EK;6S"^';I4'M)YR;7C 4FO)>):YDCB8%%N)2NTQEY).4N/ MNJ/// M_,AK'J21(1@D><"(,^*1%IX@:G$A0M"6J'A.JRC6"'ONJ)Q[HX0_9.GVM5O6 MFA+>ZU;Y<5U_)YIX4R2O*9)W4WGI<"R9FXN"%Y9C;J0PVA0X2,!G0AR_DX(1 M"U)S)D]3$^0_)RQPW@C3&PG3A5(\Q A96"E0R(5 G J%-%,:%04ETL<8/XNU MWN4&^_D6GTUIT ;UGCSJ22UE87CP*L26GT*I8%60/F=*&6[5G1Q(;E#O/E!O M;D($[*C@L:FQ(1IQ83@8$P""6##05&E1%#ZVC-I@^*?+CSW;,J&/'1*+J??W M%!:[!Q__8S_C>O3W!$?YHBUKVQC0CQ_%NALM\NJR%2]'D;SF&CP;79(&+7+/ MJ#:^ %M:2:QBD:F<.>V#9]]IC]9XG.]97=RO&\DF2&M%( @3BV.118=T4A>I M$R9GFF*E7[TA/UU?\3;<\#1LY ;=7AZZ,57D.>>:."6X,T8[KX-S7!&CX4O; MQ-,>$]WFQG!!N*.:$F3S(D><68$4]CEB.;6%\)+D6@"ZW;$E?+_HMEB(Z](A MZO6N.71ELOKJ@XIO8_FL=_'85"P]4Q6BFID)'Z*9$$NF/-?R&=/C^'8\',)P M>N?9D2ZS*V%J[AM8CO[G"F-# ].,QIBR<85PN13,.*Y!Q*_6Q7;;[Q8<>S 3 M&YU[9T#DI>]?#67M<3Q5L1=J)Q7_[7MNAF/XB>+8[4\;[M#6\?L#IKSP@DG$ MM&:Q<4^!C),,&8]#;G/0C0.H6GT@A4MPE*TJ;#,IR3#T2[ZB>.RNBL6]KY.2+][Z[FD: MQ5<][$:$0^E)T_)M83@XR72]],1YK,3BO]FC6/K]'EBC>+R^*\&3W?XD'5ND<*67%4 MMKZ>=0J+U6XB5_QO#/,*YZM)KHR4%D6UBP_7UHY/8@T>$ Y-J7_W[A"97C:Y,QM>B+LJM?#?BKJ,AE\5:IP M7LPFC<1%>O4V%DU<*#84:[AX&PO_3)YR[3UFBWO,UGJ/=_M12O5]->=90:>A MGYQSKLH_QJ]:>[]E?PY@A+7BCV$P'L(=L,_#6',2KIR7?9RR/_QPTJT(8\V$ MYI$=71*8@[K [,R&_H+%YBYI71P>**ZPQM@A)JP!'9Y1I'(%LE,+#097;)%D M7KT9G0TN2\U5,B\1&M"2/@2P3^6>EG \TM+_NTEN)2X"=L)XKA4/A9'<@!DH M>0!\8=Z'ZQ'*=<.F[:"FM+@)%.=ASB!MM0)UR!A%B M/!&<&FM5:HNXB2^3!X!:+VYNJ,KX5:I!W/Y:F5B ]QL1@\L=)D%;%=T#N5=& M^4)*3(3--2UL5?6#X(6J'S4/@;@&443P^,]P8+UWY3O0B#X"!43PJ&@]6D71 M;(I64S*:7C*-T-;%[D%0VF+B% J%H(C;' -V\!P)0[D0DIJ\D$ CFY>+=4\I M9#-[-^CUJEK+5=6YJ6BI"DG>A$(*2['F8 'DRL4&&E(5G'ON ORK=$ZN02%1 MW8%/-\"/*XGC=]WM_PGZS8>:"M,9[$P4C[9_T0A#V\?[!UH8[8T$FK'21JN- M(VF=0!@SGU-')*8_H)[L3"]JG%M[;W>GBJ3QD:AFO^HRR287=;6$1JM*1,YL METB%4R6IT7">(HG!^[<.SIJ=05XDPYN0",&2V,)@8@GE!2\D\3AH1S61A2&NB"1"U(1$5D16&A)Y M.%]F>_O+>?O8QB8M\'GG@%-"A+($%9X!:$D&LM)AC8*W0A!N3:%X)!=R191E MI9BL!&&W;X=>EWZE&)QZ^\Z]'I:9[\?;?E#$; ->$$L>1YG4FU3-O;VRCVDA M!/5@G0;+-95*:,:"C@<&! C6!M?6AFA;\.S# Q"G1ML@4%X0(%20/R@F/R#F MA2URX0CF_M4;LGDYV6&&:T-_ LM<5^.^4SMO\SFZ9KBT@,?/GQU#&B79^6N]P.82QRG.^/71@JAH''[ '4KTB:^I^@*0S^,W7P:1:KC8,EM!66J<7#BHP[MV# MG 0E"ZF1HZ"WO'QF=VX@KB+]1(*KN"DRTS7D MXQ+Z/'RIV@5C[R47FFT=!$= 5] Y8H4I$'>:(QWKSF(3"D]XSIRYU+0GFGW2 M895K0(%@P# GW#%>*"8,I7FQ7&CVN)K=M>KV]3#O=523A,N*E]"0W(-R3TFR?WHF.T=K>9=+_PCO')M]OK* M8P0/7_.^V:L'VZOG509BO6L\TYLMZ\KCC4_HB-]]),F\M/,QTW-^^Q>'WUJ= MG6^MF$'U]R[>O]AE>]L?NOL7G[[M7_QQ!+^?[Q__UMU[NWS.[X_CO>V=>.]% MZWB?[!]_.&X=6][^_8]CF.MQZ^0=_/Y'M_7[+H]U,UOS.'PJ):O44.#,F2,*0%$$C[JU#6@$FY=A3$W)9 MJ)R\>B,*N2'PY93T)X]'C?ZPG/M(XX&0@B@C,1>2:A9$($IR2KG.\14U]1K] MX2&X=JX_&$N(PT5 6A"'N*06:9Y3%(*2DBOE)&[TAT9_>.RYW23G^O:XT^@/ M#XU$>[6BQ:&PEDJ'#-4%Z ^!@OX0//*%LDPP8KSDZZ@_+%8EJ=J(+_<+OE2K MI)9-,:%S'I-33B>]JE^G3$$@KTF6PX0):G=-DB_P_!9MRD%O/+KZEH?OP;XZ MS^4=8G)5V_7JWZ/AW"]XZ)$9>OT%Z0##?:U[9_J\?/7+8C)*MS]]O(KO7Y[] ME7,,X=[F6%&0BQG=:;]?5[43X"H8DUZ;L61'PXB8_]WLXZ??/NYN[VY]V-WY^%RGW][K M['S,.GO9V[WVQ[T_=[>W.CO;V;O=]E;[[>[6G]G'#GS1VFEW;KX"#SV5JW,\ M:IBSL@$[2".GF&=24&2 MB&@7.^=>/5PFZD)2<[G;M[VQ\VZWOS7/5M^+Z;5OZ]FUNRE'/:4_1U9_R8FK MK0M[(!PCQ!<3$D-AMOD1;F9*]&,]5[& MJM8M)Y2()YH'N>_U,-M90)>H.SSA;,BGEC+R-.CDFOG"34;:BI5;2BYN5N[Z M*R?O)"_HMFNR=C[OK5GALD,-&NGDN&U-Y[SQ&=WO*:F/T0_]VEOU3(,4UY__ M>D4DN8SED>BL $"3\JK\!NQZ!E:>DMZ)3 M=GY,NK(+M_JNH[\]DSC(:7?_8E?L=[Z(UN^MB_U."[>W#R_VCWM?]B]:WUH7 M1\=[VU_8WO;AMTMQD),_CEO'O:.]SI>S_8OV4>OB/=[;;G?W_OYPW+K8N=C[ MO<7W.I;O;>_P_U[LUC.Z',NU+W*!I'(><4HQTKDRR$@:N).4,45>O>%X(R?\ M4ACDDKYVEY)@G<.U#4R^/)CT!;,Y,Y0'([A@4EMA,!?":VF#<.%'I9,:F'QJ M,%E+-U-$6LD91GF12\2M!IBD(B!C0=_S4E.>I^H3&X6X7-6F@RN-Q8X:>:2(4D M]AXYI7*P2G60*K6ODD\& U]"C9;.8+30+>Z22P%XJHQY,VZ2'YS..P [)W]0 MU:QE(4UX<.JK8RE5_Y;+Y9X?,>7BZF;6+U<.W<,*/1M!=:LC'+=TM$^+)>U4 M?-=(HAM)HO<+^18YMX%XT,:%\8A[89$VG"+AB"ZXAHT4^M4;038$N:MC\'?( M/D\CWMA :0.E-]+Y@^%:,:\QUIQ@*4E0N"@4-MX3+O4U_!X-E#X0E-8<&Z&@ M'K;*()T3@[BB.5+8,Q2$T@1,N-R: J TW\"B@=(&2ALH?0 HU9*#78UIH33C MNE" HT8RK3$16'E_I^D?#93^))3.M5).E):6>*2T(XA+89 BCB%)&'?4AM7&[RXJKO@$X32:]12^;DCUH]PRNZ*$@N#/MJ>'WG>7G'(Y!FUSNND/KKU MX]ZQ:]VXK/K

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�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